,id,ticker,title,category,content,date,provider,url,article_id
104148,325663,AGN,AbbVie Allergan  63 billion deal aided by Nestle  AstraZeneca buys,news,"By John Miller ZURICH  Reuters    U S  drugmaker AbbVie s  N ABBV   63 billion tie up with Allergan  N AGN  is getting help from Nestle  S NESN  and AstraZeneca  L AZN  buying up products the Irish domiciled company is shedding to placate regulators  AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its  19 billion per year arthritis drug Humira  the world s best selling medicine that is advancing toward U S  patent expiration  Swiss food group Nestle bulked up its medical nutrition business with Allergan s Zenpep  a product with 2018 sales of  237 million which treats people whose pancreases do not provide enough enzymes to digest fats  proteins and sugars  Nestle did not give financial details  but analysts from Zuercher Kantonalbank estimated the takeover could have cost the Vevey  Switzerland based company more than  1 billion  Meanwhile  AstraZeneca is regaining rights to brazikumab  Allergan s experimental drug against Crohn s Disease and ulcerative colitis  The European Commission said this month the immunology medicine must be divested because of the risk its development would be halted after AbbVie s takeover because of competing medicines   These definitive agreements represent significant progress toward the completion of our acquisition of Allergan   Richard Gonzalez  AbbVie s chairman and chief executive  said  With regulators wary of the deal s anti competitive potential  rivals are getting a chance to stock their own product shelves  Nestle Chief Executive Mark Schneider  who also gets Allergan s Viokace  another pancreatic enzyme product  in Monday s deal  is bulking up on nutrition products that combine properties of medicine and food as the Swiss company expands in areas where growth may outpace its mainstream food business   This is a significant opportunity for our business in the United States   Greg Behar  head of Nestle Health Science  said in a statement   AstraZeneca s pact for brazikumab marks a return of the inflammation medicine to the British drugmaker s portfolio  In 2016  Astra had struck a licensing deal with Allergan worth up to  1 5 billion for the medicine  With its return to AstraZeneca  Allergan has agreed to fund development costs for brazikumab in Crohn s disease and ulcerative colitis  including the creation of a companion diagnostic  AstraZeneca said in a separate statement   This agreement creates an opportunity for us to complete the full development program and bring this potential new treatment option to patients as quickly as possible   Mene Pangalos  Astra s biopharmaceuticals research head  Even if Allergan must foot the development bill  analysts appeared underwhelmed  in part because AbbVie s Skyrizi  or risankizumab  a similar medicine  has a head start  
 This could be another autoimmune product to add to Astra s portfolio  although it will be somewhat late to the market   Liberum s Alistair Campbell wrote in a note to investors ",2020-01-27,Reuters,https://www.investing.com/news/stock-market-news/abbvieallergan-63-billion-deal-aided-by-nestle-astrazeneca-buys-2068141,2068141
104149,325664,AGN,AbbVie and Allergan to divest Brazikumab and Zenpep,news,"AbbVie  NYSE ABBV  and Allergan  NYSE AGN  announce that the latter has entered into definitive agreements to divest brazikumab  IL 23 inhibitor  and Zenpep  pancrelipase   These agreements are in conjunction with the ongoing merger process of both the companies  AstraZeneca  NYSE AZN  will acquire brazikumab  an investigational IL 23 inhibitor and Nestle  OTCPK NSRGF  will acquire Zenpep  Nestle also will be acquiring Viokace  as part of the same transaction  The closings of the acquisitions are contingent upon receipt of U S  Federal Trade Commission and European Commission approval  AbbVie and Allergan expect to close their pending transaction in Q1 
ABBV and AGN shares are up 1  premarket 
AZN is down 1  premarket ",2020-01-27,Seeking Alpha,https://invst.ly/pnc2k,2068217
104150,325665,AGN,AbbVie s Acquisition of Allergan Gets Help From Nestle and AstraZeneca,news,"Some unlikely good Samaritans are going out of their way to help AbbVie  NYSE ABBV  and Allergan  NYSE AGN  complete the  63 billion merger deal the giant drugmakers announced last June  To appease antitrust regulators  AstraZeneca  NYSE AZN  will take back control of an experimental psoriasis drug  and Nestle will acquire a gastrointestinal medication from Allergan    
Hello again 
Allergan was developing a monoclonal antibody that inhibits interleukin 23  IL 23  called brazikumab for the treatment of Crohn s disease and ulcerative colitis  AbbVie recently launched its own IL 23 inhibitor  risankizumab  under the brand name Skyrizi for the treatment of psoriasis 

Allergan had licensed brazikumab from AstraZeneca  now  it will return the antibody to the big British pharmaceutical company  At the moment  brazikumab and Skyrizi are both in late stage clinical trials for the treatment of Crohn s disease and ulcerative colitis 
More than just cocoa 
You re probably more familiar with the Swiss food conglomerate s packaged food brands  but Nestle is also a leading player in the growing medical nutrition space 
Nestle will acquire Zenpep from Allergan for an undisclosed sum  adding it to its growing line of nutritional therapies designed for specific medical conditions  Zenprep is a collection of pancreatic enzymes that is especially useful for cystic fibrosis  CF  patients  Since Nestle already markets nutritional therapies for CF and a wide range of other disorders  Zenprep should fit comfortably in its portfolio ",2020-01-27,The Motley Fool,https://invst.ly/pnh9f,2068590
104151,325666,AGN,What to Expect From Pfizer  Biogen and Allergan Earnings Tuesday Morning,news,"This is already a huge week for earnings  as nearly half of the Dow Jones industrial average is reporting  and roughly 150 companies in the S P 500 as well  Needless to say  this will be a huge week for companies in the health care sector  with a few big names coming out The Chinese coronavirus is already bringing a lot of attention to the sector  and quite a few companies stand to gain from this  While this coronavirus scare may be over relatively quickly  earnings and fundamentals will be a driving force for companies in the sector in the months to come All three of the following companies included are reporting earnings on Tuesday morning  but there will be even more coming out later this week  We have included what analysts are calling for  as well as a recent trading history and consensus targets div connatix margin bottom  1 5em   div connatix img  margin  unset  Pfizer Inc   NYSE  PFE  shares are up about 8  over the past quarter  but the stock is actually down nearly 3  in the past 52 weeks  If Pfizer wants to break out from here  it will have to top the consensus estimates of  0 57 in earnings per share  EPS  and  12 61 billion in revenue  The same period of last year reportedly had  0 64 in EPS and  13 98 billion in revenue Here s what a few analysts have said about Pfizer 
RBC has an Outperform rating and a  46 price target 
Credit Suisse has a Hold rating 
JPMorgan has a Neutral rating 
Merrill Lynch has a Neutral rating and a  37 price target 
Pfizer stock was last seen trading at  39 92  in a 52 week range of  33 97 to  44 56  The consensus price target is  42 33 Allergan PLC  NYSE  AGN  is in the process of being acquired by AbbVie  but before then it will report its fourth quarter results  The consensus estimates are  4 57 in EPS and  4 09 billion in revenue  In the same period of last year  it said it had  4 29 in EPS and  4 08 billion in revenue Allergan stock has underperformed the broad markets with a gain of only 19  in the past 52 weeks  In the past quarter  the stock is up closer to 7 5  A few analysts have weighed in on Allergan 
Wells Fargo rates it as Equal Weight with a  198 price target 
UBS Group has a Neutral rating and a  203 price target 
RBC has a Hold rating with a  178 price target 
Allergan traded at  189 44 a share  in a 52 week range of  114 27 to  194 61  The consensus price target is  190 14 Biogen Inc   NASDAQ  BIIB  will share its most recent report on Tuesday morning too  The analysts expect to see  7 94 in EPS and  3 53 billion in revenue  In the fourth quarter of last year  it posted  6 99 in EPS and  3 53 billion in revenue Overall  Biogen has performed the worst out of this group  with its stock down 16  in the past 52 weeks  In the past quarter  the stock is flat Analysts had this to say about Biogen 
RBC s Hold rating comes with a  285 price target 
Canaccord Genuity has a Buy rating and a  360 price target 
Credit Suisse has a Hold rating with a  300 target price 
Robert Baird s Sell rating comes with a  250 price target 
Morgan Stanley has an Underweight rating and a  270 target 
Cowen has a Buy rating with a  325 price target 
Biogen stock traded at  278 71 a share  The 52 week range is  215 78 to  338 87  and the consensus analyst target is  304 57  


				ALSO READ  Intel s Strong Quarter Is Huge for Data Center Stocks  4 to Buy Now				


By Chris Lange",2020-01-27,247wallst,https://invst.ly/pnh94,2068588
104179,325694,AGN,AbbVie Lays Out Plans to Integrate Allergan,news,"As AbbVie  NYSE ABBV  gets closer to completing its  63 billion acquisition of Allergan  NYSE AGN   the company is laying out its plan for the integration  When the deal closes  which is scheduled to happen this quarter  AbbVie will keep Allergan s aesthetics as a separate unit with its own research and development function 
The unit will remain in Irvine  Calif  and be led by Carrie Strom  who currently serves as the senior vice president of U S  medical aesthetics at Allergan  Strom  who will become president of Allergan Aesthetics as well as being a vice president of AbbVie  will report directly to AbbVie s CEO Richard Gonzalez 
The rest of Allergan  including its eye care and treatments for central nervous system  women s health  and gastrointestinal diseases  will be integrated into AbbVie  In the deal  AbbVie gets antispychotic Vraylar  irritable bowel syndrome treatments Linzess and Viberzi  and oral contraceptive Lo Loestrin  among other drugs  as well as a pipeline of potential new therapies 

The health company plans to split the Botox franchise  People supporting its use as a cosmetic for reducing wrinkles will stay with Allergan Aesthetics  while Botox therapeutics will be integrated into AbbVie  The drug is approved for nine different indications that can benefit from the muscle relaxing neurotoxin  including overactive bladder  migraines  and spasticity  where muscles continually contract 
AbbVie expects the acquisition to immediately improve its bottom line with earning per share  EPS  expected to increase 10  over the first full year following the close of the transaction  The company estimates at its peak  the deal will add more than 20  to EPS ",2020-01-08,The Motley Fool,https://invst.ly/pfkbw,2055319
104180,325695,AGN,AbbVie Allergan tie up conditionally OK d in Europe,news,"The European Commission has signed off on AbbVie s  ABBV  0 3   planned merger with Allergan  AGN  0 3   with the proviso that Allergan sell IL 23 inhibitor brazikumab to a third party 
AbbVie planned to terminate development of brazikumab in favor of risankizumab  a move deemed anticompetitive by the EC ",2020-01-10,Seeking Alpha,https://invst.ly/pggab,2056919
104181,325696,AGN,Should You Buy Allergan Before the AbbVie Acquisition Closes ,news,"Allergan s  NYSE AGN  days as a standalone company are numbered  We don t know exactly when AbbVie s  NYSE ABBV  pending acquisition of Allergan will close  but it should happen sometime in the first quarter of 2020 
This deal certainly lit a fire beneath Allergan stock  with the drugmaker s shares soaring 45  since the transaction was first announced  But is Allergan still a stock to buy with the AbbVie acquisition likely to close so soon 

Understanding the deal
It s first important to understand the terms of AbbVie s acquisition offer  Allergan shareholders stand to receive 0 866 AbbVie shares plus  120 30 in cash for each Allergan share that they own 
When the deal was announced in June 2019  this translated to a total transaction value of around  63 billion  Based on AbbVie s share price at the time  the acquisition valued Allergan at  188 24 per share 
Today  though  AbbVie s shares are trading more than 10  higher than they were seven months ago  And Allergan s share price is now around  192  a little higher than its valuation when AbbVie s plan to buy the drugmaker was disclosed 
Joined at the hip
These transaction terms should be at the forefront of investors  minds when considering whether or not to buy Allergan stock  The reality is that AbbVie and Allergan are already joined at the hip even before the deal is finalized 
If you re hoping to make a quick profit  Allergan s share price will depend largely on whether AbbVie s shares go up  Even if Allergan announces wonderful news over the next few weeks  shareholders will still only receive  120 30 in cash for each Allergan share they own  But any significant good news for Allergan should push AbbVie s share price higher  which in turn will benefit Allergan shareholders when the transaction closes 
Long term investors thinking about buying Allergan stock should focus even more on AbbVie s prospects  This isn t a merger of equals  AbbVie is a much bigger company than Allergan is  AbbVie s shareholders will own 83  of the combined entity 
It s important to remember the main reason why AbbVie is buying Allergan  Sales are declining for AbbVie s top selling drug  Humira  in the face of competition from biosimilars in Europe  Biosimilars will enter the U S  market in 2023    and that s when the pain will really intensify for AbbVie  The Allergan acquisition is being made to reduce AbbVie s dependence on Humira  but the immunology drug will still contribute close to 40  of the company s total revenue even after the Allergan transaction closes 
Buy Allergan if   
Basically  there are only three reasons to buy Allergan right now 

You expect some big catalyst for Allergan or AbbVie in the very near future and plan to sell on any major jump in Allergan s share price 
You think that AbbVie will be able to deliver solid returns over the long run with Allergan s products and pipeline in its lineup 
You re seeking income from dividends 

If the first reason is your primary motivation for buying Allergan  my view is that you re making a mistake  There s no guarantee that either AbbVie or Allergan stocks will pop over the next few weeks before the acquisition closes 
However  I think that the second reason listed to buy Allergan right now makes sense  Although Humira s best days are behind it  AbbVie has other drugs that should drive growth  especially including cancer drugs Imbruvica and Venclexta and new immunology drugs Rinvoq and Skyrizi  Allergan s Botox and antipsychotic drug Vraylar should also boost AbbVie s sales 
If you re an income seeking investor  buying Allergan before the AbbVie acquisition closes seems like a pretty astute move  You ll get a lot of your cash back relatively quickly thanks to the cash portion of AbbVie s acquisition offer  You ll also own shares of one of the more attractive dividend stocks on the market  with AbbVie s dividend currently yielding nearly 5 4  
All this  of course  assumes that AbbVie s acquisition of Allergan will wrap up as expected  Could something derail the deal  It s possible but very unlikely at this point  If you re considering buying Allergan  your fortunes are almost certainly linked to AbbVie  too ",2020-01-26,The Motley Fool,https://invst.ly/pm-ut,2067917
104193,325708,AGN,AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates,news, Reuters     AbbVie Inc   N ABBV  posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast  getting a boost from strong demand for cancer medicine Imbruvica and a lower than expected drop in bestseller Humira s revenue   Shares of the Chicago  Illinois based drugmaker rose nearly one percent to  80 before the bell  In June  AbbVie announced a  63 billion deal for Botox maker Allergan Plc  N AGN   in a bid to diversify its drug pipeline amid growing threats to Humira s longevity  The world s top selling drug  which treats rheumatoid arthritis and psoriasis  has come under pressure from cheaper rivals in Europe and faces patent expiration in the United States   its biggest market  in 2023  Humira sales was about  20 billion last year and the drug has accounted for the bulk of AbbVie s revenue for years   In the quarter ended Sept  30  Humira sales dipped 3 7  to  4 94 billion  hurt by biosimilar competition outside the United States  but beat estimates of  4 89 billion  according to five analysts polled by Refinitiv IBES  Sales of cancer drug Imbruvica rose nearly 30  to  1 26 billion  ahead of estimates of  1 19 billion  AbbVie raised the lower end of its 2019 adjusted earnings per share forecast by 8 cents to  8 90  while maintaining the top end at  8 92   Net earnings fell to  1 88 billion  or  1 26 per share  from  2 75 billion  or  1 81 per share  a year earlier  as research and development costs soared and the company took a charge related to assets acquired as part of an acquisition in 2016   Excluding items  AbbVie earned  2 33 per share  above the average analyst estimate of  2 30  Total revenue rose nearly 3  to  8 48 billion  beating estimates of  8 38 billion  AbbVie said it still expects the deal for Allergan to close early next year and that both companies were cooperating with regulators after receiving a request for more information from the U S  Federal Trade Commission in September ,2019-11-01,Reuters,https://www.investing.com/news/stock-market-news/abbvie-lifts-2019-profit-forecast-as-humira-helps-beat-revenue-estimates-2009896,2009896
104194,325709,AGN,Day Ahead  Top 3 Things to Watch,news,"Investing com   Here s a preview of the top 3 things that could rock markets tomorrow  
1  U S  Services  Trade and Labor Data Due
U S  trade data due Tuesday will offer clues on President Donald Trump s efforts to reduce the deficit between the U S  and its trading partners at a time when trade tensions continue to cool amid reports that phase one of the U S  China trade deal is nearing the end game   
The Commerce Department will release the latest trade balance figures at 8 30 AM ET  13 30 GMT  
On average  economists expect that the U S  trade deficit narrowed to  52 50 billion in September  according to forecasts compiled by Investing com 
With manufacturing activity on the wane   largely due to the U S China trade war   the services sector  which makes about two thirds of U S  economic growth  has picked the slack 
The ISM survey on service sector activity is due at 10 AM ET  15 00 GMT   Economists predict ISM nonmanufacturing data for October to show an uptick to a reading of 53 5 from the prior reading of 52 6 
On the heels of the services data  the Labor Department will release its September Job Openings and Labor Turnover Survey  JOLTs  
On average  economists expect that job openings fell to 7 028 million in September from 7 051 million the prior month  according to forecasts compiled by Investing com 
2  API Crude Inventories in Spotlight 
Oil prices got the week off to a winning start  buoyed by hopes that the U S  and China are closing in on a partial trade deal that some hope could steady global growth and support oil demand   
Late Tuesday  domestic crude supply will come into focus as American Petroleum Institute is set to release its weekly petroleum inventory numbers 
The API data often serves as a snapshot of the Energy Department s petroleum data slated for a day later on Wednesday 
Crude oil futures rose 0 6  to settle at  56 54 a barrel 
3  Peloton Rolls Out Earnings 
Peloton  NASDAQ PTON   seller of connected exercise machines that are paired with on demand fitness classes  is scheduled to report fiscal first quarter earnings on Tuesday before the opening bell 
Ahead of its earnings  Peloton  NASDAQ PTON  has struggled to find its footing  Shares have fallen about 15  since going public at  29 in September as traders have ditched loss making entities 
The company said it sold 577 000 fitness machines and scooped up 511 000 subscribers to its core streaming offering in fiscal 2019  which costs  40 a month 
Its net loss widened to  245 7 million in the fiscal year ended June  from a net loss of  47 9 million a year earlier  largely driven by a surge in spending on sales and marketing 
But with its ability to generate repeat revenue from subscribers  Peloton has won the backing of many on Wall Street  who believe the company will be able to cash in on efforts to create a new market in connected fitneso 
New York based Peloton is expected to report a loss of 36 cents a share on revenue of  199 06 million 
Among other notable earnings  Allergan  NYSE AGN  and Mylan  NASDAQ MYL  both release quarterly earnings before the U S  stock market opens 
Allergan  NYSE AGN  is expected to generate earnings of  4 23 a share on revenue of  3 89 billion  while Mylan  NASDAQ MYL  is forecast to report earnings of  1 13 a share on revenue of  3 01 billion ",2019-11-04,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-2011618,2011618
104197,325712,AGN,J J Seeks Label Expansion For Spravato Nasal Spray In EU,opinion,Johnson   Johnson s   NYSE JNJ   submitted a type II variation application to the European Medicines Agency  EMA   seeking label expansion of Spravato  esketamine  nasal spray in patients with major depressive disorder  MDD  who have current suicidal ideation with intent in Europe A supplemental new drug application seeking a similar label expansion was filed in the United States in October this year  The application was based on data from two phase III studies  ASPIRE I   II  which demonstrated that Spravato combined with comprehensive standard of care led to rapid reduction of depressive symptoms in adult MDD patients who have active suicidal ideation with intent J J s shares have performed in line with the large cap pharma  in the past year  The stock has returned 14 9  in the said timeframe   Spravato was approved by the FDA in March last year for treatment resistant depression  TRD  in adults  With the approval  Spravato  which was thought to work differently than currently approved therapies  was the first new medicine in 30 years to treat depression  a difficult to treat mental disease  J J claimed that while most antidepressants take a couple of weeks or months to show effects  Spravato works in hoursTo avoid misuse and abuse of the drug  Spravato was approved with a boxed warning on its label regarding a Risk Evaluation and Mitigation Strategy  REMS  and the risk of suicidal thoughts and behaviors in pediatric patients and young adults  Spravato was approved in Europe in December last year On the third quarter conference call  J J had said that the drug was off to a strong start and patient demand was strong J J s another new drug approved last year was Balversa  erdafitinib  for metastatic urothelial cancer  J J believes that both Spravato and Balversa have the potential for more than  1 billion of peak revenues The depression market is quite large and has many players including biggies like Allergan   NYSE AGN   with products like Vraylar and Viibryd and Eli Lilly   NYSE LLY   with Cymbalta and Zyprexa J J currently carries a Zacks Rank  2  Buy   You can see  Another top ranked stock in the space is Bristol Myers   NYSE BMY   with a Zacks Rank  2  Bristol Myers  earnings estimates have increased 9  for 2020 over the past 60 days  The stock has risen 35 6  in the past year Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/jj-seeks-label-expansion-for-spravato-nasal-spray-in-eu-200499276,200499276
104199,325714,AGN,Dealmakers eye cross border M A recovery as mega mergers roll on,news,"By Greg Roumeliotis and Pamela Barbaglia
NEW YORK LONDON  Reuters    A rise in large mergers and acquisitions  M A  helped offset a plunge in cross border deals in 2019  and many dealmakers say they expect subsiding geopolitical risk to embolden companies to pursue more tie ups across regions in 2020 
The value of M A globally totaled about  3 9 trillion in 2019  making it the fourth strongest year for dealmaking  according to preliminary figures published by financial data provider Refinitiv  This is only slightly lower than the  3 96 trillion in deals recorded in 2018 
Cross border M A totaled  1 2 trillion  down 25  year on year to its lowest level since 2013  as rising geopolitical uncertainty and regulatory scrutiny of deals made many corporate chiefs and boards wary of expanding beyond their home markets 
 Companies were more comfortable this year doing deals within their own regions given the macroeconomic risks such the trade tariffs and Brexit  so cross border M A was down   said JPMorgan Chase   Co  N JPM  global M A co head Chris Ventresca 
Large deals  on the other hand  were on the rise  as companies were spurred on by their strong stock performance and cheap financing to pursue transformative acquisitions 
The number of M A transactions worth more than  10 billion increased 8  year on year to 43 this year  their highest level since 2015  according to Refinitiv  Some 21 deals  each worth more than  20 billion  accounted for almost a quarter of global volume in 2019 
 Mega deals were the main feature of this year s deal making  especially in the United States  where the bulk of these transactions took place   said  Goldman Sachs Group  Inc  N GS  global M A co head Gilberto Pozzi 
The biggest deals of the year included U S  drug maker Bristol Myers Squibb Co s  N BMY   74 billion acquisition of  Celgene Corp   NASDAQ CELG   U S  defense contactor Raytheon Co s  N RTN  merger with the aerospace business of United Technologies Corp  N UTX  into a  135 billion company  and U S  pharmaceutical company AbbVie Inc s  N ABBV   64 billion purchase of Botox maker Allergan Plc  N AGN  
The United States accounted for close to half of global M A volume in 2019  with  1 8 trillion worth of deals announced  up 6  from a year ago  Europe and Asia tied for a distant second  with a little over  740 billion worth of M A transactions announced in each region 
 Europe has been hit by macroeconomic headwinds in key markets  including Britain  Germany and France  where Brexit uncertainty  slow growth and social unrest have been some of the main hurdles   said Pier Luigi Colizzi   Barclays  Plc s  L BARC  head of M A for Europe and the Middle East 
In Britain  Europe s largest M A market  dealmaking dropped 4  year on year to  220 6 billion  with much of the year dominated by political debate over when and how Britain will leave the European Union 
 Market uncertainty in the UK has played in favor of private equity funds  which have been very active and have carried out a number of take private deals  including Merlin Entertainments  Sophos and Cobham   said Cyrus Kapadia  chief executive officer of Lazard Ltd s  N LAZ  British operations 
In Asia  China s economic slowdown led to M A volume in the country dropping 14  year on year to  380 3 billion  while the political turmoil fueled by Hong Kong s pro democracy turmoils unnerved dealmakers in the wider region 
ROOM FOR M A TO PICK UP
After world stocks added over  25 trillion in value in the past decade  and a bond rally put  13 trillion worth of bond yields below zero  some investors have been asking whether a recession could be around the corner that would put the brakes on the wave of dealmaking 
Yet companies have not been holding back on M A because of concerns about an economic slowdown  deal advisers say 
 The next economic downturn is not expected to be as severe as the 2008 financial crisis  and when it happens many well capitalized companies may seek to capitalize on a drop in corporate valuations to pursue their dream deals   said Perella Weinberg Partners Chief Executive Officer Peter Weinberg 
The U S  economy grew 2 9  in 2018  but forecasts for 2019 are for around 2 5  growth  due to the fading impact of U S  President Donald Trump administration s tax cut package and slowing global growth  At this level  dealmakers say the environment would be conducive for more transactions 
 A lukewarm economy is ideal for acquisitions  because companies need M A to ensure growth  and business sentiment is sufficiently strong for CEOs and boards to be comfortable with pursuing deals   said Sullivan   Cromwell LLP partner Frank Aquila 
Moreover  some of the geopolitical risks that weighed on cross border M A in 2019 are gradually dissipating  The United States and China are close to signing their Phase 1 trade deal  while a strong electoral victory for Britain s Conservative Party earlier this month offered clarity on the country s timetable for Brexit 
 About a month and a half ago  activity levels started to pick up  and it seems people feel a lot better about the M A pipeline   said Alan Klein  co head of Simpson Thacher   Bartlett LLP s M A practice 
Despite the boom in dealmaking over the last few years  global M A volumes are below their long term average when viewed against the value of equity markets or global economic growth  Some deal advisers cite this to argue M A volumes are not close to reaching a ceiling 
 In real terms  we have a good but not great level of M A activity  with the potential for upside   said  Citigroup  Inc  N C  global co head of M A Cary Kochman ",2019-12-31,Reuters,https://www.investing.com/news/stock-market-news/dealmakers-eye-crossborder-ma-recovery-as-mega-mergers-roll-on-2050427,2050427
104200,325715,AGN,5 Big Drug Biotech Stocks Set To Trump Q4 Earnings Estimates ,opinion,The fourth quarter earnings season for pharma stocks has started with Johnson   Johnson  NYSE JNJ  reporting fourth quarter results before market open  Pharma stocks include large and small drug makers as well as biotechs focused on developing novel therapies  These stocks form part of the wider  sector  which comprises pharma biotech as well as medical device companies The  report  published last week  shows that the companies from the Medical sector are set to deliver 3 5  earnings growth on the back of 5 7  growth in sales year over year  New drugs and label expansions of blockbuster drugs are expected to have driven the top line of most of the big shots backed by higher demand  combating generic plus biosimilar competition for older medicines Moreover  drug stocks benefited from a plethora of mergers and acquisitions  M A   which pumped billions of dollars in the pharma drug industry in 2019  The year saw 14 billion dollar deals  the largest being Bristol Myers Squibb s acquisition of Celgene  NASDAQ CELG  in January for  74 billion  A pending takeover in the spotlight is that of AbbVie s by Allergan  NYSE AGN   Last month  Novartis reached an agreement to buy The Medicines Company for  9 7 billion  In October  Alexion Pharmaceuticals offered  930 million to acquire Achillion Pharmaceuticals The  industry has rallied 5 1  in the past six months and currently carries a Zacks Sector Rank in the top 44   113 out of 256 industries   Several companies from this industry appear to be attractive bets ahead of earnings Zeroing in on WinnersHere we have highlighted five big drug biotech companies  which are expected to deliver positive earnings surprise in their upcoming quarterly earnings announcements  is our proprietary methodology for determining the stocks that have the best chance to deliver a positive earnings surprise in their next earnings announcement  Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate According to the Zacks model  the combination of a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  The selection can be done with the help of the  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70   You can uncover the best stocks to buy or sell before they re reported with our  5 Drug Biotech Stocks That Match the CriteriaAbbVie Inc    NYSE ABBV   This North Chicago  IL based maker of medicines to inflammatory and cancer diseases has an Earnings ESP of  2 79  and a Zacks Rank of 3  The Zacks Consensus Estimate for the fourth quarter is pegged at  2 27 per share  The company is scheduled to release results on Feb 7  You can see AbbVie beat estimates in three of the last four quarters while missing the same in one quarter  with the average positive surprise being 1 71  AstraZeneca PLC   NYSE AZN   The UK based drugmaker has an Earnings ESP of  3 31  and a Zacks Rank  3  The Zacks Consensus Estimate for the fourth quarter is pegged at 50 cents per ADS  The company is scheduled to release results on Feb 14 AstraZeneca s earnings performance has been encouraging with the company delivering a positive surprise in all the trailing four quarters with the average beat being 36 96  Merck   Co   Inc    NYSE MRK   This Kenilworth  NJ based pharmaceutical company has an Earnings ESP of  1 05  and a Zacks Rank  3  The Zacks Consensus Estimate for the fourth quarter is pegged at  1 14 per share  The company is scheduled to release results on Feb 5 In the trailing four quarters  Merck delivered a positive earnings surprise in all the quarters with the average being 12 51  Alexion Pharmaceuticals  Inc    NASDAQ ALXN   The New Haven  CT based biotech developing therapies for rare disease has an Earnings ESP of  5 93  and is  2 Ranked  The Zacks Consensus Estimate for the fourth quarter is pegged at  2 57 per share  The company is scheduled to release results on Feb 3 Alexion s earnings performance has been positive  Its earnings beat expectations in the last four quarters with the average positive surprise being 12 5  Amgen Inc    NASDAQ AMGN   This Thousand Oaks  CA based biotech with strong presence in several disease segments has an Earnings ESP of  3 31  and a Zacks Rank of 3  The Zacks Consensus Estimate for the fourth quarter is pegged at  3 49 per share  The company is scheduled to release results on Jan 30 Amgen beat estimates in each of the trailing four quarters  with the average surprise being a positive 5 82  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/5-big-drugbiotech-stocks-set-to-trump-q4-earnings-estimates-200500558,200500558
104205,325720,AGN,Novartis  Merck and Allergan join those raising U S  drug prices for 2020,news,"By Michael Erman NEW YORK  Reuters    Novartis AG  Merck   Co Inc and Allergan  NYSE AGN  Plc were among companies that raised U S  prices on more than 100 prescription medicines on Friday  bringing the tally to 445 drugs that will cost more in 2020  according to data analyzed by healthcare research firm 3 Axis Advisors   That is above the average of 404 drug price increases in the first three days of January over the past five years  Nearly all of the price increases are below 10   with the median price increase around 5   according to 3 Axis  Swiss drugmaker Novartis raised prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya  3 Axis said  Most of those increases were in the range of 5 5  to 7   Novartis said that while it is raising the list prices of about 7 percent of its U S  medicines  after discounts and rebates to commercial and government payers it expects a net price decrease of 2 5  in 2020   U S  drugmaker Merck raised prices on about 15 drugs  including diabetes medicines Januvia and Janumet  mostly around 5   3 Axis said   The list price of its top selling cancer immunotherapy Keytruda  expected to tally more than  13 billion in 2019 sales  was pushed up 1 5   Merck in a statement said the increases are consistent with its commitment to not raise U S  net prices by more than inflation annually  Ireland based Allergan  which is being acquired by rival  AbbVie Inc   NYSE ABBV  for more than  60 billion  said it was raising prices on 25 drugs by 5  and on two more medicines by 2 3   But with higher rebates and discounts  it said  net pricing would be flat to lower in 2020  Reuters previously reported that  Pfizer  Inc  NYSE PFE   Bristol Myers Squibb  NYSE BMY  Co and AbbVie were among drugmakers that had raised prices on more than 330 drugs to start the year  Soaring healthcare costs for U S  consumers  and prescription drug prices in particular  are expected to again be a central issue in the 2020 presidential campaign for both parties  President Donald Trump  a Republican who made bringing them down a core pledge of his 2016 campaign  is running for re election in 2020  Under pressure from politicians and patients  many makers of branded drugs have pledged to keep annual U S  price increases below 10  a year   Prescription drug prices are higher in the United States than most developed countries where governments directly or indirectly control the costs  making it the world s most lucrative market for manufacturers  
Drugmakers often negotiate rebates or discounts on their list prices in exchange for favorable treatment from insurers and other healthcare payers  As a result  insurers and covered patients rarely pay the full list price of a drug ",2020-01-03,Reuters,https://www.investing.com/news/stock-market-news/novartis-merck-and-allergan-join-those-raising-us-drug-prices-for-2020-2052038,2052038
104209,325724,AGN,Allergan To Divest Brazikumab  Zenpep To Close AbbVie Merger,opinion,"Allergan plc   NYSE AGN   along with AbbVie   NYSE ABBV   announced a definitive agreement to divest Allergan s mid stage candidate brazikumab and marketed drug  Zenpep to UK based AstraZeneca   NYSE AZN   and Swiss consumer giant Nestle  respectively  The terms of the deal are yet to be announced Brazikumab  an IL 23 inhibitor  is currently being evaluated in a phase IIb III study as a potential treatment for Crohn s Disease  It is also being developed for treating ulcerative colitis in a mid stage study  Zenpep is approved for treating exocrine pancreatic insufficiency due to cystic fibrosis and other conditions  Moreover  Nestle will also acquire another pancreatic enzyme preparation drug  Viokace  as part of the agreement These divestments are subject to approval from Federal Trade Commission   FTC   and European Commission   EC    closing of pending acquisition of Allergan by AbbVie and fulfillment of other customary closing conditions Allergan s share price has risen 30 2  in the past year against the  s decrease of 5 4  In June 2019  AbbVie announced an agreement to acquire Allergan in a cash and stock deal worth nearly  63 billion  AbbVie offered  120 30 in cash and 0 866 of its share for each share of Allergan  The acquisition is expected to close in early 2020  if all necessary approvals are obtained  The deal is likely to help AbbVie to diversify its portfolio and reduce dependency on Humira The divestment deals were made in relation to satisfy ongoing regulatory approval process being conducted by FTC and EC  which are reviewing the acquisition of Allergan by AbbVie  Please note that the EC conditionally approved the acquisition earlier this month  subject to the approved divestiture of brazikumab and other conditions We remind investors that the company has IL 23 inhibitor  Skyrizi  in its portfolio which was approved in April 2019 as a treatment for moderate to severe plaque psoriasis  The regulatory agencies were concerned about a possible overlap between Skyrizi and brazikumab  AbbVie is currently developing Skyrizi as a potential treatment for psoriatic arthritis  Sales of the drug in 2019 is estimated to be approximately  275 million  The drug also has multi billion dollar potential and will likely partially offset loss of sales from AbbVie s key drug  Humira  following generic entry in the United States Allergan plc Price
    Zacks Rank   Key PickAllergan carries a Zacks Rank  2  Buy   Pfizer   NYSE PFE   is another top ranked stock in the large cap space and sports a Zacks Rank  1  Strong Buy   You can see  Pfizer s earnings per share estimates have moved up from  2 59 to  2 62 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters with the average positive surprise being 8 73  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/allergan-to-divest-brazikumab-zenpep-to-close-abbvie-merger-200502223,200502223
104210,325725,AGN,Allergan  AGN  Earnings Expected To Grow  Should You Buy ,opinion,"Allergan  NYSE AGN  is expected to deliver a year over year increase in earnings on lower revenues when it reports results for the quarter ended December 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This Botox maker is expected to post quarterly earnings of  4 61 per share in its upcoming report  which represents a year over year change of  7 5  
Revenues are expected to be  4 07 billion  down 0 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 8 33  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Allergan 
For Allergan  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 04  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination makes it difficult to conclusively predict that Allergan will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Allergan would post earnings of  4 25 per share when it actually produced earnings of  4 25  delivering no surprise 
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Allergan doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-earnings-expected-to-grow-should-you-buy-200502329,200502329
104211,325726,AGN,Merck s Dificid Gets FDA Approval In Pediatric Indication ,opinion,"Merck   Co   Inc    NYSE MRK   announced that the FDA has granted approval to its new drug application   NDA   and a supplemental NDA  sNDA  for its antibacterial medicine Dificid  fidaxomicin   The NDA sought approval for an oral suspension formulation of Dificid  which is presently available in tablet form  The sNDA aimed at approval for Dificid tablets to treat Clostridium difficile associated diarrhea   CDAD   in children aged six months and above 
The approval for Dificid tablets and oral suspension was based on data from the phase III SUNSHINE study 
Shares of Merck have increased 17 6  in the past year compared with the  s rally of 14 9  

 
The SUNSHINE study evaluated Dificid in patients aged six months to less than 18 years in comparison to antibiotic  vancomycin  Data from the SUNSHINE study showed that while CDAD clinical response was similar for both drugs  sustained clinical response was higher for patients receiving Dificid 
The company stated that there are almost 500 000 infections caused by Clostridioides difficile every year in the United States  This bacterial infection is also estimated to cause approximately 29 000 deaths within 30 days of initial diagnosis  These numbers suggest that the drug has significant potential in the targeted indication 
Merck has many pipeline candidates in advanced stages of development  targeting multiple disease areas such as oncology  cardiovascular diseases  diabetes  infectious diseases  neurosciences  respiratory and immunology diseases  and vaccines  Some of the important pipeline candidates include selumetinib  which is under review in the United States for pediatric neurofibromatosis type 1  MK 6482 in mid stage study for renal cell carcinoma  V114  15 valent pneumococcal conjugate vaccine  and chronic heart failure candidate  vericiguat in late stage studies Merck   Co   Inc  Price
 

    
Zacks Rank   Stocks to Consider
Merck currently carries a Zacks Rank  3  Hold  
Some better ranked large cap pharma stocks are Pfizer   NYSE PFE   Allergan   NYSE AGN   and Eli Lilly   NYSE LLY    While Pfizer sports a Zacks Rank  1  Strong Buy   Allergan and Lilly carry a Zacks Rank  2  Buy   You can see  
Pfizer s earnings per share estimates have moved up from  2 59 to  2 62 for 2020 in the past 60 days  The company delivered a positive earnings surprise in each of the trailing four quarters with the average positive surprise being 8 73  
Allergan s earnings per share estimates have increased from  16 87 to  16 95 for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with the average beat being 2 76   The stock has rallied 30 2  in the past year 
Lilly s earnings per share estimates have increased from  6 56 to  6 77 for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with the average beat being 1 2   The stock has risen 19 5  in the past year 
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/mercks-dificid-gets-fda-approval-in-pediatric-indication-200502344,200502344
104212,325727,AGN,Alkermes   ALKS  NDA For ALKS 3831 Accepted By FDA For Review,opinion,Alkermes Plc  s   NASDAQ ALKS   new drug application  NDA  seeking approval of ALKS 3831  olanzapine samidorphan  for the treatment of schizophrenia and for the treatment of bipolar I disorder has been accepted by the FDA for review  The NDA has been given an action date of Nov 15  2020 Schizophrenia is a chronic  severe and disabling brain disorder  Bipolar disorder is a brain disorder that causes unusual shifts in a person s mood  energy and ability to function  The NDA for ALKS 3831 includes data from the completed ENLIGHTEN clinical development program in patients with schizophrenia and the pharmacokinetic  PK  bridging data comparing ALKS 3831 with Eli Lilly   Co  s   NYSE LLY   Zyprexa  olanzapine  The NDA includes data to support the treatment of manic or mixed episodes associated with bipolar I disorder  with ALKS 3831 as a monotherapy  or adjunct to lithium or valproate  and the maintenance treatment of bipolar I disorder Approval of the additional indication will help Alkermes gain access to a broader patient population Shares of Alkermes have slumped 45 6  in the past year compared with the  s decline of 5 6  We remind investors that in July 2019  after a pre NDA meeting with the FDA  Alkermes planned to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to that of schizophrenia   In November 2019  the company submitted an NDA to the FDA seeking approval of the candidate for the treatment of both diseases  Alkermes is seeking approval of fixed dosage strengths of ALKS 3831 composed of 10 mg of samidorphan co formulated with 5 mg  10 mg  15 mg or 20 mg of Zyprexa Other players in the schizophrenia treatment market include Johnson   Johnson s   NYSE JNJ   Risperdal Consta and Allergan s   NYSE AGN   Vraylar  Vraylar is also approved for the treatment of adults with major depressive episodes related to bipolar I disorder Alkermes currently carries a Zacks Rank  3  Hold   You can see   Alkermes plc Price    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/alkermes-alks-nda-for-alks-3831-accepted-by-fda-for-review-200502717,200502717
104214,325729,AGN,Allergan and Ironwood Pharma settle Linzess patent dispute with Sandoz,news,"Ironwood Pharmaceuticals  IRWD  2   and licensee Allergan  AGN  0 1   have settled their patent infringement litigation with Novartis   NVS  0 1   Sandoz unit related to constipation med Linzess  linaclotide  
Under the terms of the settlement  Sandoz will have a non exclusive license to market a generic version  145 mcg and 290 mcg  in the U S  effective February 5  2030 or earlier depending on certain circumstances ",2020-01-06,Seeking Alpha,https://invst.ly/pe9v-,2053136
104215,325730,AGN,Pharma Stock Roundup  LLY  PFE Q4 Results  JNJ s Coronavirus Vaccine Initiative,opinion,"This week Lilly   NYSE LLY    Pfizer   NYSE PFE   and Novartis   NYSE NVS   reported fourth quarter earnings and sales  J J   NYSE JNJ   said it is working on developing a vaccine for the new coronavirus that has killed many and affected thousands in China  Allergan   NYSE AGN   announced a definitive deal to divest brazikumab and Zenpep to close the merger with AbbVie  NYSE ABBV  Recap of the Week s Most Important Stories Lilly  Pfizer   Novartis Q4 Update   announced strong fourth quarter results  beating estimates for both earnings and sales  Lilly re affirmed its 2020 adjusted earnings guidance while slightly raising its revenue guidance  s fourth quarter 2019 performance was weak as it missed estimates for both earnings and sales  Revenues declined 8  year over year on an operational basis  The company issued its financial guidance for 2020 for the present Pfizer as well as for the  New Pfizer   after the Upjohn divesture    earnings and sales also missed estimates for both earnings and sales  Nevertheless  sales were up year over year  driven by the solid performance of key drugs like Cosentyx and Entresto  and contribution from gene therapy  Zolgensma  The sales guidance for 2020 was encouraging as well  The company expects net sales in 2020 to grow in mid to high single digits  s sales rose 6  in the quarter propelled by strong performance of new drugs  While sales at the Pharmaceuticals division increased 11   the same at the Diagnostics division climbed 3  J J Begins Making Vaccine to Fight Coronavirus  J J said that it is working on developing a vaccine to address the current novel   2019 nCoV  outbreak  The company aims to identify compounds with antiviral activity against 2019 nCoV  The program will leverage J J s same technologies that were used in making its investigational Ebola vaccine  which is currently being administered in the Democratic Republic of Congo and Rwand Meanwhile  the European Commission granted approval to J J s Erleada for expanded use   for the treatment of patients with metastatic hormone sensitive prostate cancer  mHSPC   Erleada is already marketed in the EU for the treatment of men with non metastatic castration resistant prostate cancer  The approval was based on data from the phase III TITAN study  Erleada was approved for a similar indication in the United States in September last year Allergan to Divest Brazikumab   Zenpep for AbbVie Merger  Allergan announced a definitive agreement to divest its mid stage candidate and marketed medicine  Zenpep to AstraZeneca and Nestle  respectively in connection with its pending merger with AbbVie   AbbVie is due to buy Allergan in a cash and stock deal for  63 billion  The deal  if it gets all necessary approvals  is expected to close in early 2020 Brazikumab is in phase IIb III development for Crohn s Disease and in phase II development for ulcerative colitis  while Zenpep is marketed in the United States for exocrine pancreatic insufficiency due to cystic fibrosis and other conditionsAstraZeneca and Allergan had a license agreement for brazikumab  which is now terminated and all rights to this monoclonal antibody targeting IL23  go back to AstraZeneca  Financial terms of the transactions were not disclosedRoche Seeks Approval of Tecentriq Combo in Liver Cancer  Roche submitted a supplemental biologics license application  sBLA  to the FDA seeking approval of its PD L1 inhibitor    in combination with Avastin for the unresectable hepatocellular carcinoma  HCC   the most common form of liver cancer  The sBLA was based on data from the phase III IMbrave150 study  which demonstrated that the Tecentriq plus Avastin combo improved overall survival  OS  by 42  and progression free survival  PFS  by 41  compared with standard of care  Bayer s Nexavar  sorafenib   OS and PFS were the co primary endpoints of the study AstraZeneca s Enhertu Meets Goal in Gastric Cancer Study  AstraZeneca s   NYSE AZN   phase II study evaluating its newly approved cancer medicine  Enhertu  trastuzumab deruxtecan  in gastric cancer met the primary endpoint  Top line data from the study showed that treatment with Enhertu led to statistically significant and clinically meaningful improvement in objective response rate  ORR    primary endpoint and OS   a key secondary endpoint in patients with previously treated HER2 positive metastatic gastric cancer  Enhertu  which AstraZeneca is jointly developing and commercializing with Japan s Daiichi Sankyo  was approved by the FDA for metastatic breast cancer in December AstraZeneca also announced an agreement to sell global commercial rights to some hypertension medicines  Inderal  Tenormin  Tenoretic  Zestril and Zestoretic to Atnahs Pharma to allow it to focus on its portfolio of new medicines  The agreement excludes the rights in the United States and India  which were previously divested  and in Japan  which will be retained by AstraZeneca Meanwhile  AstraZeneca s blood thinner  Brilinta met primary endpoint in phase III THALES study in stroke  The data from the study showed that Brilinta in combination with aspirin led to a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death  in patients who had experienced a minor acute ischemic stroke or high risk transient ischemic attack  FDA Grants Approval to Merck s Dificid for New Formulation and Pediatric Indication  Merck   NYSE MRK   announced that the FDA has granted approval to two regulatory applications seeking expanded approval of its antibacterial medicine   The first application was an NDA looking for approval of an oral suspension formulation of Dificid  which is presently available in tablet form  The second application was a sNDA looking for approval of Dificid for the treatment of pediatric patients aged 6 months or older with Clostridioides  formerly Clostridium  difficile associated diarrhea  Lilly s Two Phase III Studies on Olumiant in Eczema Succeed  Lilly   Incyte s two phase III studies evaluating their JAK inhibitor  Olumiant  in patients with moderate to severe atopic dermatitis  AD   met the primary endpoint of at least 75  improvement of skin inflammation  The primary endpoint of both the studies was defined by the proportion of participants achieving at least 75  or greater change from baseline in their Eczema Area and Severity Index  EASI  at week 16 The study  which was conducted outside the United States  evaluated Olumiant  1 mg  2 mg and 4 mg doses  in combination with topical corticosteroids  TCS  in patients with moderate to severe AD who failed conventional systemic treatments like cyclosporine  In the study  the 4 mg dose of baricitinib plus TCS met the primary endpoint  The BREEZE AD5  conducted in North America  evaluated 1 mg and 2 mg doses of baricitinib as a monotherapy in AD patients  In this study  the 2 mg dose of baricitinib met the primary endpoint as well as some key secondary endpoints Olumiant  which is the presently marketed to treat active rheumatoid arthritis  is under review in Europe as a treatment for patients with moderate to severe atopic dermatitis  Lilly also plans to submit regulatory application in the United States for the atopic dermatitis indication this year  The data from the BREEZE AD5 study will support the U S  filing The FDA granted priority review status to Lilly s new drug application  NDA  for its investigational oral RET inhibitor    The NDA seeks approval of selpercatinib for RET altered lung and thyroid cancers based on data from the LIBRETTO 001 phase I II study  With the FDA granting priority review to the NDA  a decision is expected in the third quarter of this year The FDA also approved Lilly and partner  Boehringer Ingelheim s Trijardy XR  a triple combination tablet  for adults with type II diabetes  Trijardy XR  a once daily therapy provides three type II diabetes medicines  Jardiance  Tradjenta and metformin hydrochloride extended release  in one pill  Trijardy XR will be available in four different dosages The NYSE ARCA Pharmaceutical Index declined 1 8  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return

Here is how the seven major stocks performed in the last five trading sessions Last week  J J recorded the maximum gain  1 2   while Pfizer declined the most  9 0   In the past six months  Bristol Myers has risen the most  41 2   while Pfizer  PFE  lost the maximum  3 1    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for fourth quarter 2019 results of Bristol Myers  AbbVie  Merck and regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-lly-pfe-q4-results-jnjs-coronavirus-vaccine-initiative-200503728,200503728
104229,325744,AGN,J J liable for  572 million in Oklahoma opioid epidemic trial  shares rise,news,"By Heide Brandes and Nate Raymond NORMAN  Okla  BOSTON  Reuters    An Oklahoma judge on Monday ordered Johnson   Johnson  N JNJ  to pay  572 1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers  a sum that was substantially less than investors had expected  driving up J J s shares  The state s attorney general had filed the lawsuit  seeking  17 billion to address the impact of the drug crisis on Oklahoma  It had been considered a bellwether for other litigation nationwide over the opioid epidemic    The expectation was this was going to be a  1 5 billion to  2 billion fine   said Jared Holz  healthcare strategist for Jefferies   Co    572 million is a much lower number than had been feared   J J said it would appeal the decision  Shares of J J were up 2  in extended trading following the decision  after an initial gain of more than 5   Other drugmakers that sell opioid painkillers and are defending against similar lawsuits also rose after hours  including Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  up 2 6   and Endo International Plc  O ENDP   up 1 4  higher  Opioids were involved in almost 400 000 overdose deaths from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  Since 2000  some 6 000 Oklahomans have died from opioid overdoses  according to the state s lawyers  Roughly 2 500 lawsuits have been brought by states  counties and municipalities nationally seeking to hold drugmakers responsible for opioid abuse nationwide  Oklahoma s case was the first to go to trial  Some drugmakers have chosen to settle cases  In holding J J liable after a seven week  non jury trial  Judge Thad Balkman of Cleveland County District Court in Norman  Oklahoma  said the state proved that J J s misleading marketing and promotion of its Duragesic and Nucynta painkillers created a public nuisance   The opioid crisis is an imminent danger and menace to Oklahomans   Balkman said  Oklahoma wanted J J to help it address the epidemic for the next 30 years by funding addiction treatment and prevention programs  Balkman said in his written ruling that the award covered only one year of addressing the crisis because Oklahoma did not demonstrate the time and costs needed beyond that  Lance Lang  a 36 year old recovering user of opioids turned activist in Oklahoma City  said it was  short sighted  for the judge to have only ordered funding for a year   There s going to be people struggling with this for years   he said in an interview  J J said it will ask that the award be put on hold during an appeal process that could stretch into 2021  The company also said Oklahoma failed to show that its products and activities had created a public nuisance   You can t sue your way out of the opioid abuse crisis   Sabrina Strong  a lawyer for J J  said at a news conference after the verdict   Everyone must come together to address this  But J J did not cause the opioid crisis    ACCOUNTABLE FOR DEATHS AND ADDICTIONS  The case was brought by Oklahoma Attorney General Mike Hunter  who alleged that J J s marketing practices helped fuel the opioid epidemic by flooding the market with painkillers   Johnson   Johnson will finally be held accountable for thousands of deaths and addictions caused by their actions   Hunter said  The trial came after Oklahoma had resolved claims against OxyContin maker Purdue Pharma LP in March for  270 million and Teva in May for  85 million  leaving J J as the lone defendant  The verdict came as two Ohio counties prepare for a scheduled October trial before a federal judge in Cleveland  About 2 000 lawsuits out of some 2 500 filed nationwide are consolidated in the case in Cleveland  Endo International Plc  O ENDP  and Allergan Plc  N AGN  last week agreed to pay  15 million to avoid going to trial in October in a case by two Ohio counties  subject to court approval  Some plaintiffs  lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a  246 billion settlement in 1998  Joe Rice  a lead plaintiff s attorney for municipalities in the federal litigation  said if the Oklahoma award were extrapolated to other states  it could mean an annual abatement cost of around  38 billion    It does indicate that if I m in the pharmaceutical business  I ve got to think long and hard about annual payments of my share of that   he said  The judge overseeing the federal litigation in Ohio has been pushing for a global settlement  J J  which is among multiple pharmaceutical companies that are defendants in the federal litigation  said it remains  open to viable options  to resolve the Ohio case  including through settlement  During the Oklahoma trial  lawyers for the state argued that J J carried out a years long marketing campaign that minimized the painkillers  addiction risks and promoted their benefits  The lawyers called J J an opioid  kingpin  and argued that its marketing created a public nuisance as doctors over prescribed the drugs  leading to a surge in overdose deaths  J J countered that its marketing claims had scientific support and its painkillers accounted for a tiny fraction of opioids prescribed in Oklahoma  The company said in a statement that since 2008  its painkillers accounted for less than 1  of the U S  market  including generics  Teva said the ruling supported its rationale for settling the case before trial  and said it was preparing to defend itself in the upcoming trial in Ohio  
Purdue  which is also among the defendants in the Ohio litigation  did not immediately respond to a request for comment ",2019-08-27,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-judge-to-rule-in-17-billion-opioid-lawsuit-against-jj-1963241,1963241
104239,325754,AGN,J J liable for  572 million in Oklahoma opioid epidemic trial  shares rise,news,"By Heide Brandes and Nate Raymond
NORMAN  Okla  BOSTON  Reuters    An Oklahoma judge on Monday ordered Johnson   Johnson  N JNJ  to pay  572 1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers  a sum that was substantially less than investors had expected  driving up J J s shares 
The state s attorney general had filed the lawsuit  seeking  17 billion to address the impact of the drug crisis on Oklahoma  It had been considered a bellwether for other litigation nationwide over the opioid epidemic 
 The expectation was this was going to be a  1 5 billion to  2 billion fine   said Jared Holz  healthcare strategist for Jefferies   Co    572 million is a much lower number than had been feared  
J J said it would appeal the decision 
Shares of J J were up 2  in extended trading following the decision  after an initial gain of more than 5   Other drugmakers that sell opioid painkillers and are defending against similar lawsuits also rose after hours  including Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  up 2 6   and Endo International Plc  O ENDP   up 1 4  higher 
Opioids were involved in almost 400 000 overdose deaths from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  Since 2000  some 6 000 Oklahomans have died from opioid overdoses  according to the state s lawyers 
Roughly 2 500 lawsuits have been brought by states  counties and municipalities nationally seeking to hold drugmakers responsible for opioid abuse nationwide  Oklahoma s case was the first to go to trial  Some drugmakers have chosen to settle cases 
In holding J J liable after a seven week  non jury trial  Judge Thad Balkman of Cleveland County District Court in Norman  Oklahoma  said the state proved that J J s misleading marketing and promotion of its Duragesic and Nucynta painkillers created a public nuisance 
 The opioid crisis is an imminent danger and menace to Oklahomans   Balkman said 
Oklahoma wanted J J to help it address the epidemic for the next 30 years by funding addiction treatment and prevention programs 
Balkman said in his written ruling that the award covered only one year of addressing the crisis because Oklahoma did not demonstrate the time and costs needed beyond that 
Lance Lang  a 36 year old recovering user of opioids turned activist in Oklahoma City  said it was  short sighted  for the judge to have only ordered funding for a year   There s going to be people struggling with this for years   he said in an interview 
J J said it will ask that the award be put on hold during an appeal process that could stretch into 2021  The company also said Oklahoma failed to show that its products and activities had created a public nuisance 
 You can t sue your way out of the opioid abuse crisis   Sabrina Strong  a lawyer for J J  said at a news conference after the verdict   Everyone must come together to address this  But J J did not cause the opioid crisis  
 ACCOUNTABLE FOR DEATHS AND ADDICTIONS 
The case was brought by Oklahoma Attorney General Mike Hunter  who alleged that J J s marketing practices helped fuel the opioid epidemic by flooding the market with painkillers 
 Johnson   Johnson will finally be held accountable for thousands of deaths and addictions caused by their actions   Hunter said 
The trial came after Oklahoma had resolved claims against OxyContin maker Purdue Pharma LP in March for  270 million and Teva in May for  85 million  leaving J J as the lone defendant 
The verdict came as two Ohio counties prepare for a scheduled October trial before a federal judge in Cleveland  About 2 000 lawsuits out of some 2 500 filed nationwide are consolidated in the case in Cleveland 
Endo International Plc  O ENDP  and Allergan Plc  N AGN  last week agreed to pay  15 million to avoid going to trial in October in a case by two Ohio counties  subject to court approval 
Some plaintiffs  lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a  246 billion settlement in 1998 
Joe Rice  a lead plaintiff s attorney for municipalities in the federal litigation  said if the Oklahoma award were extrapolated to other states  it could mean an annual abatement cost of around  38 billion 
 It does indicate that if I m in the pharmaceutical business  I ve got to think long and hard about annual payments of my share of that   he said 
The judge overseeing the federal litigation in Ohio has been pushing for a global settlement 
J J  which is among multiple pharmaceutical companies that are defendants in the federal litigation  said it remains  open to viable options  to resolve the Ohio case  including through settlement 
During the Oklahoma trial  lawyers for the state argued that J J carried out a years long marketing campaign that minimized the painkillers  addiction risks and promoted their benefits 
The lawyers called J J an opioid  kingpin  and argued that its marketing created a public nuisance as doctors over prescribed the drugs  leading to a surge in overdose deaths 
J J countered that its marketing claims had scientific support and its painkillers accounted for a tiny fraction of opioids prescribed in Oklahoma  The company said in a statement that since 2008  its painkillers accounted for less than 1  of the U S  market  including generics 
Teva said the ruling supported its rationale for settling the case before trial  and said it was preparing to defend itself in the upcoming trial in Ohio 
Purdue  which is also among the defendants in the Ohio litigation  did not immediately respond to a request for comment ",2019-08-28,Reuters,https://www.investing.com/news/stock-market-news/jj-liable-for-572-million-in-oklahoma-opioid-epidemic-trial-shares-rise-1965094,1965094
104240,325755,AGN,Consumer groups  unions urge caution on  63 billion AbbVie deal for Allergan,news,"WASHINGTON  Reuters    About a dozen advocacy groups and unions  including Public Citizen and the American Federation of Teachers  wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc s  N ABBV  planned  63 billion purchase of Botox maker Allergan Plc  N AGN   The combination of two of the world s biggest pharmaceutical companies  which was announced in June  would feature a portfolio that includes the world s top selling medicine   AbbVie s rheumatoid arthritis drug Humira   as well as its cancer drugs and Allergan s blockbuster wrinkle treatment  Botox  and big selling dry eye drug Restasis  In the letter seen by Reuters  Consumer Action and others  working with the Service Employees International Union  SEIU  and American Federation of State  County    Municipal Employees  AFSCME   noted the deal would create the fourth largest pharmaceutical company with strong markets for many drugs at a time when rising prices of many medicines have become a hot political issue  For example  a four week supply of Humira has a list price of about  5 174  amounting to more than  60 000 for a year  Humira sales reached  20 billion in 2018   We request that the Commission investigate this proposed merger thoroughly and take all necessary action  includ ing  blocking the merger  to prevent further harm to consumers   the groups said in the letter  The FTC declined comment  Neither of the companies immediately responded to a request for comment  AbbVie has previously said that it would work with the FTC to discuss asset sales  which are sometimes needed to make deals conform with antitrust law  The organizations urged the FTC to go further than simply identifying where there are product overlaps between the two companies  which is a big part of a traditional antitrust review of a merger of drug companies  They argued in particular the merger could lead to a broader use of volume based rebates or other incentives to insurers or pharmacy benefit managers  Drugmakers have said that their need to provide discounts and rebates to payers is one reason they have to keep prices high  The group also criticized Allergan for practices like attempting to transfer patents for Restasis to a Native American tribe to protect it from patent challenges and delay market entry of cheaper generic versions  
 These practices should receive careful attention as part of the Commission s investigation into the effects of this proposed merger and if an adequate remedy can not be found  the Commission should challenge this acquisition   the group said in their letter ",2019-09-12,Reuters,https://www.investing.com/news/stock-market-news/consumer-groups-unions-urge-caution-on-63-billion-abbvie-deal-for-allergan-1977128,1977128
104241,325756,AGN,U S  Senators urge FTC to scrutinize multi billion dollar pharma mergers,news," Reuters    U S  presidential hopeful Amy Klobuchar on Tuesday led a letter by U S  senators that urged the Federal Trade Commission  FTC  to closely scrutinize pharma mergers  raising concerns about the potential harm to customers 
The U S  healthcare industry has seen a string of multi billion dollar deals and consolidation is expected to remain a major theme for the rest of the year 
Bristol Myers Squibb s  N BMY   74 billion buyout of  Celgene Corp   O CELG  and AbbVie Inc s  N ABBV   63 billion bid for troubled smaller rival Allergan Plc  N AGN  were among the largest deals announced this year 
The deals proposed by AbbVie and Bristol Myers raise significant antitrust issues  the senators wrote  calling on the FTC to  take appropriate action  to protect consumers from mergers that may threaten competition  raise drug prices or reduce patient access to essential medications 
They also raised concerns that the deals may reduce innovation in drug development and give the merged companies increased negotiating leverage to secure positions on drug formularies and greater ability to condition buyers  access to their multi billion dollar drugs 
 This industry consolidation is occurring against a backdrop of ever rising prescription drug spending    It is more important than ever that the FTC take appropriate action to protect consumers   Klobuchar wrote in the letter signed by senators Bernie Sanders  Kamala Harris  Elizabeth Warren and Cory Booker among others ",2019-09-17,Reuters,https://www.investing.com/news/stock-market-news/us-senators-urge-ftc-to-scrutinize-multibillion-dollar-pharma-mergers-1980129,1980129
104242,325757,AGN,FTC requests AbbVie  Allergan for more information on  63 billion deal,news," Reuters    The U S  Federal Trade Commission  FTC  has requested for more information from  AbbVie Inc   N ABBV  and botox maker Allergan Plc  N AGN  on their  63 billion deal  the companies said on Friday 
AbbVie and Allergan said they still expect the deal to close in early 2020  and were cooperating with the antitrust regulator 
The scrutiny into the deal  which combines two of the world s biggest pharmaceutical companies  follows a request by a dozen advocacy groups and unions to the FTC to block the purchase 
In a letter seen by Reuters  the groups noted that the deal would create the fourth largest pharmaceutical company at a time when rising drug prices have become a hot political issue 
AbbVie said the FTC s second request for information was expected 
The deal to buy Allergan  announced in June  came as Abbvie faced pressure to diversify its portfolio  and as its blockbuster drug Humira  the world s best selling medicine  faces competition from cheaper versions ",2019-09-27,Reuters,https://www.investing.com/news/stock-market-news/ftc-requests-abbvie-allergan-for-more-information-on-63-billion-deal-1988199,1988199
104243,325758,AGN,Bull Of The Day  InMode  INMD  ,opinion,"InMode Ltd   INMD  is one of the most successful IPOs of 2019 as shares have soared nearly 200   This Zacks Rank  1  Strong Buy  is riding the social media  selfie  wave to double digit revenue growth in 2020 InMode develops and manufactures devices harnessing novel radio frequency  RF  based devices for the plastic surgery  gynecology  dermatology  otolaryngology and ophthalmology categories It s procedures are minimally invasive InMode went IPO in August of 2019  It s a small cap company with a market cap of  1 3 billion A Big Beat in the Third QuarterOn Nov 5  InMode reported its third quarter results and beat the Zacks Consensus by  0 13  or 44   Earnings were  0 42 versus the consensus of  0 29 Earnings were up 62  compared to third quarter 2018 This was its second quarterly report to Wall Street after the IPO Revenue soared 57  year over year to a third quarter record of  40 million  fueled by a 88  increase in international revenue compared to 2018  driven primarily by European and Asian sales In the age of the  selfie  and Instagram  FB   consumers are willing to spend money on looking better  Procedures which are lower cost and have less downtime are becoming increasingly popular Earnings Estimates on the RiseAs a small cap company and recent IPO  there s little analyst coverage of InMode  so far But the Zacks Consensus Estimate for both 2019 and 2020 have been on the move higher since the big earnings beat Over the last 60 days  the 2019 Zacks Consensus Estimate has risen to  1 55 from  1 38 Similarly  the 2020 Zacks Consensus has jumped to  1 76 from  1 55 during that same time That s earnings growth of 13 5  Shares on FireInMode is one of the few recent IPOs that is actually profitable  And given its product position in the Instagram generation  investors have jumped in to grab the shares Shares are up 189  since the August IPO 
They aren t crazy expensive for a small cap growth company  with a forward P E of 27 They compete with the big  selfie  type products like Allergan  NYSE AGN  s  AGN  Botox Shares are down 14  over the past month as the rest of the stock market has rallied  A further pullback could be a buying opportunity For investors looking for ways to play the Instagram and social media craze  InMode is one to add to the short list The Hottest Tech Mega Trend of All Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-12-26,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day-inmode-inmd-200494907,200494907
104244,325759,AGN,3 Dividend Paying Large Cap Pharma Stocks To Consider For 2020,opinion,"The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs  The tech heavy NASDAQ hit 9 000 for the first time Thursday after Amazon   NASDAQ AMZN   stock popped on a solid holiday shopping season 
The strong end to the year has helped lift the S P 500 over 28  in 2019  But investors now wonder what might be in store for equities in the upcoming year 
Let s take a look at a few stocks in the large cap pharma industry  which ranks in the top 9  of our over 250 Zacks industires  that look poised to have a strong 2020 
AbbVie  NYSE ABBV   has been able to outpace the S P 500 since its spinoff from Abbott Labs   NYSE ABT   in early 2013  AbbVie s cash cow is Humira  which accounts for about 60  of its total revenue  The company s dependence on Humira has been a cause for concern with many investors  as its patent expired in Europe this year  This caused the decline in Humira sales 
The firm s US patent is also scheduled to expire in 2023  But AbbVie has started to strategically prepare itself for the emergence of biosimilars in the US market  The company currently boasts a diverse portfolio of products that consists of oncology medicines such as Imbruvica and Venclexta and immunology products like Skyrizi and Rinvoq 
In addition  AbbVie expects its Allergan   NYSE AGN   acquisition to close by the end of the first quarter of 2020  which will further diversify its portfolio  AbbVie has also been an income investor friendly stock as it has averaged over a 24  annual hike to its dividend since its inception 
ABBV stock currently sports a dividend with a hefty 4 76  yield and trades at 10X its forward earnings  which is below the industry average of 15X  Our consensus fiscal 2020 estimates call for earnings to grow over 5 2  to  9 41 per share and for net revenue to increase 8 3  to  36 1 billion 

Johnson   Johnson  NYSE JNJ   is the largest pharmaceutical company in the world in terms of market cap  The pharma titan has been hit recently with an onslaught of legal headwinds from its alleged involvement in the opioid crisis to its alleged harmful talcum powder  However  despite the recent litigation  the firm s diversified operations in the healthcare industry are unrivaled  Johnson   Johnson s pharmaceutical portfolio is well diversified across the oncology and immunology fields 
In the immunology segment  the firm s key growth drivers are Stelara and Tremfya  which climbed 30  and 69  in the third quarter  respectively  Meanwhile  Imbruvica is at the forefront of the company s oncology portfolio and saw an increase of 31  in the third quarter 
In addition to JNJ s impressive pharmaceutical portfolio  the firm also operates in other channels such as medical devices and its consumer segment  which includes the popular skin care treatment Neutrogena  This large cap pharma stock also boasts a dividend with a solid 2 61  yield that has been increased for the past 57 years 
Our fiscal 2020 estimates forecast a top line rally of 4 2  to  85 5 billion and a bottom line jump of 4 8  to  9 08 per share  Johnson   Johnson has an average EPS surprise of 4 27  over the past four quarters and sits at a Zacks Rank  2  Buy  
Merck   Co  NYSE MRK   is a large cap pharma stock that has put together a solid year as its shares have risen over 19  and have outpaced the industry s 12  YTD run  This pharmaceutical giant is currently focused on the oncology realm with its crown jewel  Keytruda  The drug has been approved for a plethora of cancers including lung cancer and melanoma  The company s top line is also driven by its vaccine business  which includes its HPV vaccine Gardasil Gardasil 9 
In the most recent quarter  Keytruda sales soared 62  to roughly  3 1 billion and Gardasil Gardasil 9 sales climbed 26  to  1 32 billion  Keytruda is expected to be Merck s bread and butter for the foreseeable future as  to become the world s bestselling drug by 2025 
Merck also offers a dividend with a healthy 2 67  yield  The stock currently trades at about 16X its forward earnings  which is just below the S P 500 average of 18X  Our fiscal 2020 estimates anticipate an almost 6  top line hike to  49 8 billion and a bottom line jump of over 6  to  5 49 per share  MRK s earnings estimate revisions have trended higher  helping earn the stock a Zacks Rank  2  Buy  
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-12-27,Zacks Investment Research,https://www.investing.com/analysis/3-dividendpaying-large-cap-pharma-stocks-to-consider-for-2020-200495244,200495244
104245,325760,AGN,The Zacks Analyst Blog Highlights  AbbVie  Abbott Labs  Allergan  Johnson   Johnson And Merck,opinion,For Immediate ReleaseChicago  IL   December 30  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  AbbVie   NYSE ABBV    Abbott Labs   NYSE ABT    Allergan   NYSE AGN    Johnson   Johnson   NYSE JNJ   and Merck   Co    NYSE MRK   Here are highlights from Friday s Analyst Blog  3 Dividend Paying Large Cap Pharma Stocks to Consider for 2020The strong end to the year has helped lift the S P 500 over 28  in 2019  But investors now wonder what might be in store for equities in the upcoming year Let s take a look at a few stocks in the large cap pharma industry  which ranks in the top 9  of our over 250 Zacks industries  that look poised to have a strong 2020 AbbViehas been able to outpace the S P 500 since its spinoff from Abbott Labs in early 2013  AbbVie s cash cow is Humira  which accounts for about 60  of its total revenue  The company s dependence on Humira has been a cause for concern with many investors  as its patent expired in Europe this year  This caused the decline in Humira sales The firm s US patent is also scheduled to expire in 2023  But AbbVie has started to strategically prepare itself for the emergence of biosimilars in the US market  The company currently boasts a diverse portfolio of products that consists of oncology medicines such as Imbruvica and Venclexta and immunology products like Skyrizi and Rinvoq In addition  AbbVie expects its Allergan acquisition to close by the end of the first quarter of 2020  which will further diversify its portfolio  AbbVie has also been an income investor friendly stock as it has averaged over a 24  annual hike to its dividend since its inception ABBV stock currently sports a dividend with a hefty 4 76  yield and trades at 10X its forward earnings  which is below the industry average of 15X  Our consensus fiscal 2020 estimates call for earnings to grow over 5 2  to  9 41 per share and for net revenue to increase 8 3  to  36 1 billion Johnson   Johnsonis the largest pharmaceutical company in the world in terms of market cap  The pharma titan has been hit recently with an onslaught of legal headwinds from its alleged involvement in the opioid crisis to its alleged harmful talcum powder  However  despite the recent litigation  the firm s diversified operations in the healthcare industry are unrivaled  Johnson   Johnson s pharmaceutical portfolio is well diversified across the oncology and immunology fields In the immunology segment  the firm s key growth drivers are Stelara and Tremfya  which climbed 30  and 69  in the third quarter  respectively  Meanwhile  Imbruvica is at the forefront of the company s oncology portfolio and saw an increase of 31  in the third quarter In addition to JNJ s impressive pharmaceutical portfolio  the firm also operates in other channels such as medical devices and its consumer segment  which includes the popular skin care treatment Neutrogena  This large cap pharma stock also boasts a dividend with a solid 2 61  yield that has been increased for the past 57 years Our fiscal 2020 estimates forecast a top line rally of 4 2  to  85 5 billion and a bottom line jump of 4 8  to  9 08 per share  Johnson   Johnson has an average EPS surprise of 4 27  over the past four quarters and sits at a Zacks Rank  2  Buy  Merck   Co is a large cap pharma stock that has put together a solid year as its shares have risen over 19  and have outpaced the industry s 12  YTD run  This pharmaceutical giant is currently focused on the oncology realm with its crown jewel  Keytruda  The drug has been approved for a plethora of cancers including lung cancer and melanoma  The company s top line is also driven by its vaccine business  which includes its HPV vaccine Gardasil Gardasil 9 In the most recent quarter  Keytruda sales soared 62  to roughly  3 1 billion and Gardasil Gardasil 9 sales climbed 26  to  1 32 billion  Keytruda is expected to be Merck s bread and butter for the foreseeable future as  to become the world s bestselling drug by 2025 Merck also offers a dividend with a healthy 2 67  yield  The stock currently trades at about 16X its forward earnings  which is just below the S P 500 average of 18X  Our fiscal 2020 estimates anticipate an almost 6  top line hike to  49 8 billion and a bottom line jump of over 6  to  5 49 per share  MRK s earnings estimate revisions have trended higher  helping earn the stock a Zacks Rank  2  Buy  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-29,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-abbvie-abbott-labs-allergan-johnson--johnson-and-merck-200495405,200495405
104246,325761,AGN,Axsome s  AXSM  Migraine Drug Meets Goals In Late Stage Study ,opinion,Axsome Therapeutics  Inc    NASDAQ AXSM   announced that its novel  oral  multi mechanistic investigational candidate  AXS 07  met the two regulatory co primary endpoints in a late stage study The phase III MOMENTUM study was a randomized  double blind  placebo  and active controlled trial  which enrolled only patients with a history of inadequate response to prior acute migraine treatments  assessed using the Migraine Treatment Optimization Questionnaire  mTOQ 4   The study was conducted pursuant to an FDA Special Protocol Assessment  SPA  A total of 1 594 patients were randomized in a 2 2 2 1 ratio to AXS 07  20 mg MoSEIC meloxicam 10 mg rizatriptan   Maxalt  MoSEIC meloxicam  20 mg   or placebo  to treat a single migraine attack of moderate or severe intensity  Additionally  the enrolled patients exhibited a high rate of characteristics that are strongly associated with poor treatment outcomes  including cutaneous allodynia  75 4    severe migraine pain intensity  41 2    obesity  43 7   and morning migraine  36 6   Maxalt  rizatriptan   an active comparator in the trial  is considered to be the fastest acting oral triptan and one of the most effective medications currently available for the acute treatment of migraine Results showed that AXS 07 met the two regulatory  co primary endpoints and significantly improved migraine pain and most trouble symptoms as compared to placebo  The candidate also met the key secondary endpoint  demonstrating statistically significant superiority to the active comparator rizatriptan on sustained freedom from migraine pain  A greater percentage of patients achieved pain freedom and absence of most bothersome symptom with AXS 07 after two hours of dosing as compared to placebo  The candidate was safe and well tolerated in the trial Hence  the positive results on both co primary endpoints along with the demonstration of component contribution support the filing of an NDA for AXS 07 in the acute treatment of migraine  Per its discussions with the FDA  Axsome believes that MOMENTUM will be the only efficacy study required to support an NDA filing for the same  The company plans to file the NDA in the second half of 2020 The successful development and commercialization of the candidate will be a significant boost for this clinical stage biopharmaceutical company  AXS 07 is currently in two phase III studies for the same indication The company s shares have skyrocketed 3581 9  in the past year compared with the  s growth of 7 7   Axsome is developing novel therapies for the management of central nervous system  CNS  disorders  for which there are limited treatment options  Apart from ASX 07  the company s core CNS product portfolio includes three clinical stage candidates   AXS 05  AXS 09 and AXS 12  AXS 05 is currently in a phase III study for treatment resistant depression  TRD   a phase II III study in agitation associated with Alzheimer s disease  AD   AXS 05 is also being developed for smoking cessation treatment and for major depressive disorder  MDD    AXS 12 is being developed for the treatment of narcolepsy The FDA recently approved Allergan s   NYSE AGN   Ubrelvy  ubrogepant  for the acute treatment of migraine with or without aura in adults  Other approved drugs include Eli Lilly s   NYSE LLY   Emgality and Teva Pharma s   NYSE TEVA   Ajovy Axsome currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-30,Zacks Investment Research,https://www.investing.com/analysis/axsomes-axsm-migraine-drug-meets-goals-in-latestage-study-200495640,200495640
104247,325762,AGN,5 Reasons Why Ironwood Stock Should Be In Your Portfolio,opinion,"Cambridge  MA based Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   is focused on the development and commercialization of treatments primarily addressing gastrointestinal   GI   diseases  The company has one marketed product   Linzess   in its portfolio that has been approved for treating irritable bowel syndrome with constipation  IBS C  or chronic idiopathic constipation   CIC   Here we provide five reasons why adding Ironwood s stock to a portfolio can be beneficial in 2020 Strong Quarterly Results  Ironwood has delivered strong year over year growth in earnings and sales in the first nine months of 2019  The company reported adjusted earnings of 25 cents per share during the said period against adjusted loss of 74 cents in the year ago period  Moreover  earnings have surpassed estimates in the past two quarters  Notably  the company generated profits for the first time in the second quarter  following the separation of its Soluble Guanylate Cyclase  sGC  pipeline in April  The company reported positive operating cash flow in the third quarter The company derives majority of its revenues from the sales of Linzess in the United States  The drug generated net sales of  572 million in the United States  up 2 9  year over year in the first nine months of 2019  Ironwood and Allergan equally share Linzess  brand collaboration profits or losses  Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  223 8 million in the third quarter  up approximately 22 5  year over year Moreover  Linzess  prospects look encouraging owing to strong demand trends and the drug s expansion to new patient population and geographies  Ironwood expects annual sales of Linzess to cross  1 billion by the end of 2020 Rising Estimates  Ironwood s earnings estimates for 2020 have increased 30  in the past 60 days  In fact  the company has reported impressive earnings performance and exceeded expectations in three of the trailing four quarters  Ironwood recorded an average positive earnings surprise of 135 01  Favorable Share Price Movement  Strong performance of Linzess has enabled Ironwood to outperform the   Shares of the company have rallied 34 7  in the past year compared with the industry s growth of 14 5  Label Expansion Efforts for Linzess  Ironwood and Allergan are looking to expand Linzess  label to include new indications and populations as well as develop the drug as a non opioid  pain relieving agent for IBS patients  In June  Ironwood and Allergan announced positive top line data from the phase IIIb study on Linzess for treating multiple abdominal symptoms in adult patients with IBS C  The company will file a supplemental new drug application to expand the drug s label to include the indication soon  It is also striving to expand the drug s label to include pediatric patients with IBS C Ironwood is also developing a delayed release formulation of Linzess  MD 7246  in a mid stage study to treat abdominal pain associated with IBS with diarrhea  The company is also developing an interesting candidate called IW 3718  It is currently enrolling patients in two identical phase III studies  evaluating IW 3718 for treating gastroesophageal reflux disease  Results from the studies are expected in the second half of 2020  Positive data will be a boost for the company s share price Global Collaborations and Partnerships  Ironwood co develops and co commercializes Linzess in the United States and Europe with Botox maker Allergan   NYSE AGN    The company has a collaboration agreement with AstraZeneca   NYSE AZN   for development and commercialization of Linzess in China  It also has a deal with Astellas for the development of the drug in Japan These deals enable the company to reduce development costs for the drug and also provide support for better commercialization of Linzess as the partners have strong presence in their respective territories ConclusionStrong demand for Ironwood s Linzess has driven the top line consistently in the past few quarters  The strong performance is expected to continue in 2020  With the separation of its sGC pipeline  operating expenses are likely to decline as well However  the company is over dependent on Linzess for its growth  Any negative news related to Linzess will affect the company and its growth prospects  The company s pipeline candidates are also in mid  to late stage development  It is unlikely that any of these candidates will be commercialized in 2020  Linzess also faces competition from Bausch Health s   NYSE BHC   Trulance as well as Takeda s Amitiza and Motegrity among others  Several biotechs are focused on developing novel therapies targeting IBS  In September  Ardelyx s Ibsrela was approved by the FDA for treating IBS C patients  The rising competition can pose threat to Linzess  dominance in the IBS segment Ironwood Pharmaceuticals  Inc  Price
    Zacks RankIronwood sports a Zacks Rank  1  Strong Buy  and is a good investment option  You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-01,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-why-ironwood-stock-should-be-in-your-portfolio-200495974,200495974
104248,325763,AGN,3 Stocks With Solid Entry Points To Consider For 2020,opinion,Geopolitcal headwinds sent stocks lower on Friday as US officials confirmed that President Trump s airstrike killed Iran s top military commander  The news of the airstrike sent oil prices soaring while the DJIA dropped over 230 points and the S P 500 closed down over 0 7   Despite the backlash felt on equities  the valuation of many stocks still hovers at expensive premiums because of 2019 s historic run  Let s take a look at a few stocks that trade at a more buyer friendly valuation  Best Buy   NYSE BBY   has been able to successfully fend off the onslaught of competition from not only other retailers  but from e commerce giants like Amazon   NASDAQ AMZN    The electronics retailer has done this by offering a variety of services like consultation  installation  and technical support  These initiatives have yielded positive results for the firm as Best Buy has boasted positive comparable sales since fiscal 2014  Best Buy s Total Tech Support system has also seen success as memberships have increased from 200 000 in May 2018 to 2 million  BBY stock currently trades for about 14X its forward earnings  which is below the S P 500 average of about 19X forward earnings  Our Q4 consensus estimates call for earnings to rise 1 5  to  2 76 per share while net revenue grows over 2  to  15 1 billion  Best Buy boasts a Zacks Rank  2  Buy  with a Style Score of A in Value  Sonic Automotive   NYSE SAH   is a stock that has more than doubled in the past 12 months and looks poised to continue its run in 2020  The company s EchoPark initiative continued to yield successful results as it generated  312 2 million in revenue in Q3  which represented an increase of roughly 68  from the year ago quarter  The strong performance its EchoPark business saw in the third quarter prompted management to raise its guidance for EchoPark s fiscal 2019 total sales to  1 2 billion  which would be a 71  surge  SAH stock currently trades for a little over 10X its forward earnings  which is a solid entry point for a stock that carries momentum from 2019  Our Q4 consensus estimates forecast a top line rally of 7 4  and a bottom line hike of 15 8   Sonic Automotive is listed as a Zacks Rank  1  Strong Buy  with a Style Score of A in Value  AbbVie   NYSE ABBV   has actively tried to diversify its product portfolio to better adapt its business to the contemporary pharma market  The company announced in June that it would acquire Allergan   NYSE AGN    in an effort to diversify its revenue streams  The two companies expect the deal to close in early 2020  which could provide a boost for AbbVie  Allergan can add valuable diversification through its medical aesthetics and botox products  These added revenue streams would bode well for AbbVie as it weens itself off of Humira  which makes up more than half of its revenue  The dependency AbbVie has on Humira has worried investors as biosimilars have entered the European market and caused a decline in the drug s sales  These worries have sent the stock to an opportune valuation for investors at about 9 5X its forward earnings  In addition  our Q4 estimates call for a top line climb of 5 48  and a bottom line gain of 19 5   AbbVie currently sports a Zacks Rank  2  Buy  with a Style Score of A in Growth  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-03,Zacks Investment Research,https://www.investing.com/analysis/3-stocks-with-solid-entry-points-to-consider-for-2020-200496392,200496392
104249,325764,AGN,Endo Up On Opioid Abuse Settlement Agreement With Oklahoma,opinion,"Endo International plc   NASDAQ ENDP   announced that it has executed a settlement agreement with the state of Oklahoma related to a litigation that alleged the company s involvement in opioid abuse crisis in the state  The company has agreed to pay  8 75 million to the state in connection with the settlement Shares of Endo were up 3 2  on Jan 10  following the announcement  However  the company s shares have declined 51 1  in the past year against the i s increase of 0 7  However  Endo and its affiliates do not admit any wrongdoing and are not liable for any opioid abuse in the state  The company stated in the press release that it had ceased promotion of all its opioid medications including withdrawal of one of its leading branded opioid medications in 2017 We note that Endo had settled another opioid abuse litigation with two counties   Cuyahoga and Summit   in Ohio last year  The company had paid almost  10 million to resolve all claims against itself related to a federal multidistrict litigation With a significant increase in the number of deaths or instances of misuse of opioid based drugs in the past decade  and high costs related to opioid abuse  it has become a public crisis  Several government organizations are taking steps to contain the widespread misuse of these drugs  Lawsuits have been filed against pharma companies for generating funds through penalties for abatement plans Last year  several companies faced difficult times due to the ongoing litigation related to  in the United States  The litigations allege that the marketing practices of pharma companies including Teva   NYSE TEVA    Allergan   NYSE AGN       NYSE MNK      Endo and privately held Purdue Pharma  since late 1990s  increased prescribing of opioid based drugs as painkillers  Several thousands of cases are pending against these companies across the country In a major move  J J was  to pay  527 million in an opioid abuse case with the state of Oklahoma last year  which was later reduced to  465 million  The company has appealed against the ruling  Such ruling related to similar ongoing litigations can severely impact the companies involved  These litigations will continue to remain an overhang for these companies going forward Endo International plc Price
    Zacks RankEndo currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/endo-up-on-opioid-abuse-settlement-agreement-with-oklahoma-200498297,200498297
104250,325765,AGN,Aclaris  MK2 Inhibitor Shows Encouraging Data In Phase I,opinion,"Aclaris Therapeutics  Inc    NASDAQ ACRS   announced positive data from the phase I ATI 450 PKPD 101 study on it investigational MK2 inhibitor  ATI 450  currently being developed for addressing immuno inflammatory diseases 
The single ascending dose and multiple ascending dose  SAD MAD  clinical study evaluated the safety  tolerability  pharmacokinetics and pharmacodynamics of orally administered ATI 450 in healthy patients 
Preliminary data from the study showed that treatment with ATI 450 led to marked inhibition of key inflammatory cytokines  such as TNF   IL1   IL8  and IL6 and was generally well tolerated across all dose level tested  No serious side effects were reported from the same 
Importantly  preliminary data from the study supports progression to a phase IIa proof of concept studies for immuno inflammatory diseases  Aclaris plans to initiate a phase II study for treating rheumatoid arthritis in the first half of this year 
Shares of Aclaris rallied 17 2  following this announcement  However  the stock has plunged 68 2  in the past year against the  rise of 0 8  

 
We remind investors that in October 2019  Aclaris sold the worldwide rights to its rosacea drug Rhofade Cream and certain licenses to its related intellectual property assets to privately held  specialty pharmaceutical company EPI Health for  55 million  The divestiture is part of Aclaris  ongoing restructuring program to focus on its immuno inflammatory pipeline 
Notably  Aclaris acquired the rights to Rhofade from Allergan   NYSE AGN   in 2018 
The company is currently developing its pipeline candidate  A 101 45  topical solution for the treatment of common warts in two late stage studies  The candidate met the primary and all secondary efficacy endpoints  achieving clinically and statistically significant clearance of common warts in both phase III studies of THWART 1 and THWART 2 
This apart  Aclaris has two JAK inhibitors  namely ATI 501 and ATI 502 in mid stage development for the treating alopecia  The company had in licensed these two candidates from Rigel Pharmaceuticals  Inc    NASDAQ RIGL   in 2015  It has several other pre clinical candidates in its portfolio 
Zacks Rank   Key Pick
Aclaris currently carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is Karyopharm Therapeutics Inc    NASDAQ KPTI    sporting a Zacks Rank  1  Strong Buy   You can see  
Karyopharm s loss per share estimates have narrowed 0 5  for 2020 over the past 60 days  The stock has surged 89 6  in the past year 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/aclaris-mk2-inhibitor-shows-encouraging-data-in-phase-i-200498448,200498448
104285,325800,AGN,Wall Street drops on trade worries  Fed Chair Powell s speech,news,"By Stephen Culp NEW YORK  Reuters    Wall Street lost ground on Tuesday as simmering trade concerns  combined with disappointing economic data  sent buyers to the sidelines  where they remained after Federal Reserve Chair Jerome Powell pushed back on pressure from President Donald Trump to cut rates  All three major U S  stock indexes were in the red  weighed most heavily by technology stocks  after Powell said the Fed was grappling with whether trade uncertainties and other issues support interest rate cuts   Powell  speaking at the Council on Foreign relations  also reiterated the Fed s independence  a day after Trump tweeted that the Fed  doesn t know what it s doing   Earlier  St  Louis Federal Reserve Bank President James Bullard in an interview with Bloomberg said he does not think the Fed needs to cut rates by a half percentage point at its next policy meeting  in late July   You had a one two punch   said Art Hogan  chief market strategist at National Securities in New York   Powell came out and warned against policy bending to short term political interests  but it is also Bullard  who is a dissenter  saying 50 basis points would be too much    Bullard last week said he had dissented at the Fed s June policy meeting because he felt that weak inflation and uncertainties about the economic outlook warranted a rate cut  Despite Tuesday s sell off  June is shaping up to be a good month for U S  equities  The benchmark S P 500 continued to hover within a percent of the all time high reached last Thursday  Still  anxieties stemming from the U S  China trade war found no relief in a White House official s remarks that Trump is  comfortable with any outcome  arising from a planned meeting with Chinese President Xi Jinping at the Group of 20 summit convening in Japan on Friday   The market   is really looking at two issues that push it higher   said Rick Meckler  partner at Cherry Lane Investments in New Vernon  New Jersey   One is the trade agreement and the other is Fed policy  It s really trade policy that s going to be more meaningful    On the economic front  sales of newly constructed homes and consumer confidence numbers both came in well below economist expectations  according to separate reports from the U S  Commerce Department and the Conference Board  Growing signs of economic softness  especially related to the trade disputes between the United States and its major trading partners  contributed to the Federal Reserve s last week signaling that interest rate cuts could begin as early as July  The Dow Jones Industrial Average fell 114 25 points  or 0 43   to 26 613 29  the S P 500 lost 17 36 points  or 0 59   to 2 927 99 and the Nasdaq Composite dropped 80 27 points  or 1   to 7 925 42  Of the 11 major indexes in the S P 500  10 were in negative territory  with technology and communications services seeing the biggest percentage drops   Rate sensitive bank stocks were down 0 2   as U S  Treasuries benchmark yields fell below the closely watched 2  level   AbbVie Inc   NYSE ABBV  said it would buy Allergan  NYSE AGN  Plc for about  63 billion  sending the Botox maker s shares up by 26 9   AbbVie s stock dropped 15 4   Declining issues outnumbered advancing ones on the NYSE by a 1 37 to 1 ratio  on Nasdaq  a 1 29 to 1 ratio favored decliners  
The S P 500 posted 30 new 52 week highs and five new lows  the Nasdaq Composite recorded 22 new highs and 79 new lows ",2019-06-25,Reuters,https://www.investing.com/news/stock-market-news/futures-lower-on-iran-tensions-trade-worries-1906740,1906740
104286,325801,AGN,U S  dominates second quarter global M A as mega deals roll on,news,"By Greg Roumeliotis and Pamela Barbaglia NEW YORK LONDON  Reuters    Mega deals set the pace for mergers and acquisitions  M A  globally in the second quarter of 2019  as large U S  companies defied trade row jitters and seized on strong equity and debt capital markets to agree on transformative combinations  Global M A volume reached  842 billion in the second quarter  down 13  and 27  from the first quarter of 2019 and second quarter of 2018 respectively  according to preliminary data from financial data provider Refinitiv   Geopolitical risks that weighed on dealmakers  confidence  such as the trade dispute between the United States and China and the potential for a military confrontation between the United States and Iran  were partly offset by supportive financing markets that made big acquisitions possible  This quarter s volume would have been significantly lower were it not for U S  mega deals  given that total deal count globally fell to its lowest quarterly level since the 2008 financial crisis  Refinitiv data showed    The vast majority of transforming deals worth more than  10 billion have taken place in the U S  This means Europe is lagging behind  and while U S  companies are doubling in size  their European counterparts risk losing their competitive edge   said JPMorgan Chase   Co  N JPM  global M A co head Hernan Cristerna  Among the top deals this quarter were the  121 billion agreed merger of United Technologies  NYSE UTX  Corp s airspace division with U S  contractor  Raytheon Co   N RTN   U S  drugmaker AbbVie Inc s  N ABBV   63 billion agreement to acquire peer Allergan Plc  N AGN   and Occidental Petroleum Corp s  N OXY   38 billion deal to buy Anadarko Petroleum Corp  N APC   U S  M A totaled  466 billion in the second quarter  down just 3  from a year ago  Dealmaking in Europe  however  plunged 54  to  152 billion  while Asia M A dived 49  to  132 billion  Some attempts at big European mergers  such as a tie up of auto makers  Fiat  Chrysler Automobiles BV  MI FCHA  and  Renault  SA  PA RENA   as well as of  Deutsche Bank  AG  DE DBKGn  and  Commerzbank AG   DE CBKG   failed amid political resistance and concerns over regulatory scrutiny   Every quarter that goes by without progress in combining European companies and helping them adjust to technological and geopolitical disruption means there will be pent up supply and demand for deals down the line to achieve that adjustment   said Perella Weinberg Partners LP founding partner Paulo Pereira   Cross border M A also suffered because of the trade jitters  It has been over 400 days since a cross border deal of more than  20 billion has been announced  said  Citigroup  Inc  N C  global M A co head Cary Kochman   The ease with which corporates approached globalization has waned  In its place are regional models and the realignment of domestic supply chains   said Kochman  Dealmaking by private equity firms soared to  136 billion  almost an all time high  as cheap debt fueled leveraged buyouts  Some dealmakers now say they see confidence in smaller companies to explore M A following the wave of mega deals  which may lead to a bump in the number of transactions   What we have seen so far this year is a steady number of mega deals  and all signs suggest this will continue   said  Morgan Stanley   N MS  Americas head of M A Tom Miles  
 But what is also beginning to happen is that smaller and mid sized companies  that were nervous about pursuing deals early in the year  are now feeling comfortable enough with the economic environment to also explore M A   Miles added ",2019-06-28,Reuters,https://www.investing.com/news/stock-market-news/us-dominates-secondquarter-global-ma-as-mega-deals-roll-on-1910280,1910280
104287,325802,AGN,Gilead to Boost Stake in Galapagos as Part of  5 1 Billion Deal,news," Bloomberg      Gilead Sciences Inc   NASDAQ GILD   agreed to pay  5 1 billion to raise its stake in biotechnology company Galapagos NV to deepen its research into inflammatory diseases and other disorder  sending the Belgian drugmaker s stock to an all time high 
The deal is the largest Gilead has executed since new Chief Executive Officer Dan O Day took the reins in March as he attempts to bolster the San Francisco giant s drug pipeline  Gilead is in danger of becoming a victim of its own success after launching some of the top drugs of all time  its bestselling hepatitis C franchise  Sales from those therapies have since declined due to increased competition 
Under the agreement  Gilead  which will pay  3 95 billion upfront to Mechelen  Belgium based Galapagos and invest  1 1 billion to raise its stake to 22  from 12 3   the companies said in a statement  The investment  at 140 59 euros a share  is 9 7  higher than the Belgian company s closing price on Friday  Galapagos shares surged as much as 17  on Monday  reaching 149 55 euros a share 
 Gilead will significantly expand its pipeline in a smart and financially savvy expanded partnership deal with Galapagos  essentially gaining options on everything in their pipeline without having to acquire the company full out   Jefferies analysts including Michael J  Yee and Andrew Tsai wrote in a note 
As Gilead seeks to fill the growing hole left from its hepatitis drugs  the Galapagos announcement may signal a shift in focus  The smaller biotech has no oncology programs and instead focuses on research into diseases that have to do with inflammation and fibrosis  which is a kind of internal scarring 
Gilead has also had research programs in such diseases  including through its collaboration with Galapagos  though some had speculated it may stake its future on cancer  Gilead is already the biggest shareholder of the Belgium company before the increase in stake  according to data compiled by Bloomberg  Now it gets the option to license all of Galapogos s future  late stage drug candidates 
Gilead CEO
O Day  who joined Gilead from cancer giant Roche AG  said he s not done making good on his promise to expand the pipeline  He noted the deal almost doubles Gilead s research capacity and establishes a strong research base in Europe where the company has historically not been as active 
 In no way is this the only thing that we re looking at or the only thing that we re going to do   O Day said in an interview   You can look at this like it s the beginning  
Gilead and Galapagos held talks about an expanded partnership prior to O Day joining the company  He was briefed on those discussions after taking the top job and within the first couple of weeks  got to know the CEO of Galapagos better  Following those talks  the pair decided to being finalizing the agreement 
Jobs in Europe
This is a  science driven deal   Onno van de Stolpe  founder and chief executive officer of Galapagos  said in an interview  Gilead will be taking on more of the commercial side for Galapagos  helping the smaller company to focus on research   We can now do more of what we re good at  
The money being invested beyond the equity stake will be used largely to double Galapagos s R D staff to 1 000 from 500 over an unspecified time  Van de Stolpe said  Those jobs will be added in Belgium  the Netherlands and France   It s massive funding    we don t have a detailed plan yet on how to spend it   he said 
The pact includes a provision in which Gilead s stake could rise to 29 9   if Galapagos shareholders approve two warrants  The companies were already partners on an experimental drug for rheumatoid arthritis  That drug  filgotinib  hit its main goal in a late stage study in March  triggering the Belgian biotech company s shares to surge by the most in six months 
Galapagos shares have risen 59  since the start of the year  compared with the 5 9  gain in Gilead s stock 
O Day had a reputation as a dealmaker while at Roche  likely one of the reasons he was selected for Gilead s top job at a time when the company needs to look externally to drive growth  He said that in this case  the companies opted for a partnership style deal rather than a full takeover because full mergers can often destroy innovation as research and executive teams disband  Roche s deal philosophy is much the same with the Swiss giant opting to leave many its units independently managed  even if it owns them in full 
Gilead spent about  12 billion to buy Kite Pharma in 2017 for its research into a cutting edge therapies known as CAR T  While the treatments can prove near miraculous for some patients  CAR Ts have yet to become large sales drivers  falling far below the revenues Gilead needs to replace declining sales from its hepatitis C franchise 
Gilead is not the only large company with fading blockbusters  In June  AbbVie  NYSE ABBV  agreed to buy Allergan  NYSE AGN  in a  63 billion megadeal in a bid to replace its bestselling Humira  the bestselling drug in the world   Celgene Corp   NASDAQ CELG   faced similar questions as the patent of its bestselling cancer drug aged before Bristol Myers Squibb  NYSE BMY  agreed to buy it for  74 billion in January ",2019-07-15,Bloomberg,https://www.investing.com/news/stock-market-news/gilead-to-boost-stake-in-galapagos-as-part-of-51-billiondeal-1923312,1923312
104288,325803,AGN,Pfizer to merge generics unit with Mylan  seeks to sharpen cancer focus,news,"By Michael Erman and Ankur Banerjee  Reuters     Pfizer  Inc  N PFE  has agreed to spin off its off patent branded drugs business and combine it with generic drugmaker Mylan NV  O MYL   a move that leaves Pfizer with its more profitable innovative drugs  including cancer treatment Ibrance and pneumonia vaccine Prevnar  The move  which brings blockbuster treatments Viagra and Lipitor under one umbrella with Mylan s EpiPen  is part of a years long effort by Pfizer to split into three parts   innovative medicines  lower margin off patent drugs facing generic competition and consumer healthcare  Pfizer agreed in December to combine its consumer health business with GlaxoSmithKline Plc s   L GSK   The combined company  which will get a new name  is expected to have 2020 revenue of  19 billion to  20 billion  with free cash flow expected to be more than  4 billion  The pharmaceutical industry has been under intensifying pressure from lawmakers  including President Donald Trump  to keep prices down for U S  consumers  which has limited profits and led to recent deals  such as Bristol Myers Squibb Co s  N BMY  plan to buy  Celgene Corp   O CELG  and AbbVie Inc s  N ABBV  acquisition of Allergan Plc  N AGN   The new company  to be based in the United States and incorporated in Delaware  will be led by Michael Goettler  president of Pfizer s Upjohn unit  which sells Pfizer s older drugs that have lost patent protection  Upjohn will issue  12 billion of debt at or before the separation  with proceeds going to Pfizer  Pfizer said it plans to use that cash to pay down its own debt  Mylan said Chief Executive Heather Bresch  who took the helm in 2012 and faced intense political pressure over the high price of EpiPen  will retire after the deal closes  Mylan Chairman Robert Coury will become executive chairman of the new company   We think it is clear Mylan needed to do something to change direction    Wells Fargo   NYSE WFC  analyst David Maris said  adding that the deal is also recognition that Pfizer wanted out of generics  Pfizer s older drugs business has a much higher operating margin than Mylan s  Maris added  Mylan  which had a market value of  9 5 billion prior to Monday s announcement  last year said it would review its business as it grapples with lower prices of generic drugs and declining sales of its EpiPen emergency allergy treatment  In 2015  Mylan fended off a takeover attempt from rival Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA  that would have valued the company at around  40 billion  Based on Monday s share price  the company is worth around  11 billion  EpiPen sales fell sharply after Mylan was heavily criticized for steep price hikes on its device that delivers a life saving shot epinephrine to treat severe allergic reactions  Bresch was called to testify before Congress in 2016  as the controversy put Mylan at the center of the ongoing U S  debate over the high cost of prescription medicines  Mylan s shares have lost about a third of their value in 2019 through Friday s close  The stock was up more than 12 9  at  20 84 on Monday  while Pfizer slipped 2  to  42 23  Graphic  Mylan shares    STREAMLINED PFIZER Pfizer CEO Albert Bourla and his predecessor Ian Read have been saying for more than a year that the company would eschew large  transformative deals because of confidence in the strength of its pipeline   But if the Mylan and GSK deals both close  the company will have shed two large businesses to tighten its focus on newer  patent protected innovative medicines   Pfizer CFO Frank D Amelio said on a conference call that the streamlined company will grow sooner and faster beginning in 2020 than it would have otherwise   Under terms of the agreement  Pfizer shareholders will own 57  of the new company and Mylan shareholders the rest  Each Mylan share will be converted into one share of the new company under the all stock deal  Revenue from the Upjohn unit in the second quarter was  2 81 billion  accounting for a fifth of Pfizer s total sales  Mylan brought in revenue of  2 85 billion in the same quarter  Pfizer  which acquired Upjohn as part of its 2002 purchase of Pharmacia for  60 billion  will separate Upjohn in a tax free spinoff and combine with Mylan  Once the deal closes  the new company will have about  24 5 billion of total debt outstanding  
Separately  Pfizer reported its quarterly results on Monday  a day earlier than planned  The company cut its profit and revenue forecast for the year  largely due to the joint venture with GSK last year ",2019-07-29,Reuters,https://www.investing.com/news/stock-market-news/mylan-to-combine-with-pfizers-offpatent-medicines-unit-1937374,1937374
104289,325804,AGN,Merck profit surges on strong sales of Keytruda  vaccines,news,"By Manas Mishra  Reuters    Merck   Co Inc  N MRK  reported better than expected second quarter results on Tuesday and raised its full year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines  Merck shares rose 1 3  to  83 56 in afternoon trading  Sales of Keytruda surged 58  to  2 63 billion in the quarter  ahead of Wall Street estimates for about  2 5 billion  A run of positive clinical data for Keytruda and setbacks for its biggest rival   Bristol Myers Squibb Co s  N BMY  Opdivo   has led to a dominant position for Merck s drug as an initial treatment for advanced lung cancer  the most lucrative oncology market  Keytruda  Merck s most important growth driver  has racked up U S  approvals to treat numerous cancer types since it was first approved for advanced melanoma in 2014    We right now have built a wall of data that we feel very comfortable with   Chief Commercial Officer Franklin Clyburn said on a conference call with analysts  Some investors have raised concerns about Merck over reliance on Keytruda and have looked for a large deal to lessen that dependence  along the lines of AbbVie s  N ABBV   63 billion deal for Allergan Plc  N AGN   But analysts have forecast continued strong Keytruda growth for several years  Merck Chief Executive Officer Kenneth Frazier reiterated that Merck would focus on bolt on deals  across the spectrum in terms of size  rather than a large  transformative acquisition  Sales of Merck s Gardasil vaccine to prevent cancers associated with the human papillomavirus jumped 45 7  to  886 million  helped by both demand and a U S  price increase   Overall vaccine sales rose 33  to  2 billion  also boosted by the company s measles mumps rubella  MMR  shot amid the worst U S  measles outbreak since 1992   Sales of Merck s MMR and chicken pox vaccines rose 58  to  675 million in the quarter  Chief Financial Officer Robert Davis said he expects that business to grow  a forecast that is not based on the assumption of additional outbreaks  The U S  drugmaker increased its forecast for 2019 adjusted earnings  raising the midpoint by 16 cents  Merck now expects to earn between  4 84 and  4 94 per share  up from its prior view of  4 67 to  4 79  Excluding items  Merck earned  1 30 per share  beating the average analysts  estimate by 14 cents  according to IBES data from Refinitiv   Merck said net income for the quarter rose to  2 67 billion  or  1 03 per share  from  1 71 billion  or 63 cents per share  a year earlier  
Sales rose 12 4  to  11 76 billion  beating Wall Street estimates of  10 96 billion ",2019-07-30,Reuters,https://www.investing.com/news/stock-market-news/merck-profit-surges-on-strong-sales-of-keytruda-vaccines-1938734,1938734
104290,325805,AGN,Roche Spark Deal s Mystery Delay Makes Investors Jittery,news," Bloomberg     Delays from the Federal Trade Commission and concerns about the timing of Roche Holding  SIX ROG  AG s planned  4 8 billion deal to buy small cap drug developer Spark Therapeutics Inc  are stoking concerns across Wall Street as investors question what the agency is hung up on 
Some in the investment community argue that thanks to a more nit picky FTC  a deal that should have been cleared with flying colors continues to be clouded with questions  Many on the Street guess that the holdup is tied to competitive concerns for Roche s blockbuster Hemlibra  a medicine for the clotting disorder hemophilia  and a gene therapy for the disease in development from Spark 
However  the FTC s closed door meetings and the secrecy about its reasoning have left investors in the dark  That s prompted jitters among investors  from those that specialize in risk arbitrage to the sell side analysts that closely follow the space 
 Those of us in the public markets don t have much of a clear view  on why the deal is held up   and that creates a lot of potential execution risk for anyone else looking to make a move and vertically consolidate with a gene therapy or gene editing player to add their own disruptor   SVB Leerink analyst Mani Foroohar said in an interview 
Betsy Lordan  a spokeswoman for the FTC  said the agency can t confirm or comment on potential investigations  Roche has repeatedly declined to comment on the source of the holdup  Chief Executive Officer Severin Schwan wouldn t elaborate either at a meeting last week  but said he s  very confident  that the transaction will close by the end of the year  Swiss financial markets were closed on Thursday  and the company again declined to comment ahead of an FTC meeting in Washington 
Bolt on bottle neck 
A slowdown in smaller deals or the FTC halting the Spark Roche tie up would whipsaw some biopharma high fliers that many on the Street see as logical bolt ons for larger companies looking to replenish their pipelines  A number of the year s top performing biotechnology companies  such as gene therapy focused drugmaker uniQure NV  have seen shares appreciate on drug expectations paired with speculation that they may be the next shoe to drop in the sector s spending spree 
Deals are seen as the lifeblood of biotech and drug development  with smaller companies that lack the infrastructure to bring drugs to market frequently opting to sell to those who can 
Some on Wall Street have questioned how deals for a company like uniQure would be affected by the FTC s more hands on approach  which may have implications for companies looking to double down in a specific disease area 
 For anyone trying to make that deal there s a paralyzing effect   Foroohar said   What would ve been seen as a low execution risk  low regulatory risk  straightforward deal is suddenly something caught up for a year and a half  and you have to look at divesting  the drug which drove the deal in the first place  he said 
Increased scrutiny
Six of the nine deal specialists Bloomberg News surveyed said they are concerned the FTC has shifted its approach  as evidenced by the Roche delays  The same proportion agreed that the stumbles for Roche and Spark may have a chilling effect on innovative deals within the space until more is understood 
The majority of concerned investors said an earlier stage deal like Roche s planned purchase of Spark should not warrant the level of scrutiny it s facing  Some analysts forecast sales of Roche s Hemlibra may near  4 9 billion annually by 2028  more than the current offer for the entirety of Spark 
 When one of the largest companies in the world is buying a minnow  and it s being held back   that s very concerning   Brad Loncar  chief executive officer of Loncar Investments  said in a phone interview   You have to start wondering if this scrutiny will slow down or prohibit these kinds of deals  which would be a huge deal for the sector  
While Roche s planned purchase of Spark has garnered the majority of headlines triggering nervousness for those betting on deals  it isn t a one off  Bristol Myers Squibb  NYSE BMY  Co  has agreed to divest one of  Celgene Corp   NASDAQ CELG   s best selling drugs to placate regulators in hope of closing their planned  74 billion deal 
Bristol Myers s plans to sell off the psoriasis pill  Otezla   was a very big surprise   according to SVB Leerink analyst Geoffrey Porges  He called the FTC actions  very strange   adding that investors in  AbbVie Inc   NYSE ABBV   and Allergan  NYSE AGN  Plc are now focused on the future of AbbVie s psoriasis treatment  Skyrizi 
Biopharma mergers aren t the only deals within health care that have drawn regulatory concern  Illumina Inc  NASDAQ ILMN   s proposed purchase of Pacific Biosciences of California Inc  has been held up by both U S  and U K  agencies  while the deal s spread remained near its widest since the announcement 
The next event on the FTC s calendar is an Aug  1 meeting in Washington  The group voted 5 0 to keep the meeting closed  further adding mystery to who will be in attendance and what the topic will be 
 Adds Roche declining to comment in fifth paragraph  ",2019-08-01,Bloomberg,https://www.investing.com/news/stock-market-news/rochespark-deals-mystery-delay-makes-investors-jittery-1942034,1942034
104291,325806,AGN,Who is next in big pharma s merger spree ,news," Reuters    Consolidation in the U S  healthcare industry  which has already witnessed a string of multi billion dollar deals  is expected to remain a major theme for the rest of 2019 
Bristol Myers Squibb s  74 billion acquisition of Celgene  NASDAQ CELG  set the M A ball rolling in January  and was followed by AbbVie  NYSE ABBV  Inc s  63 billion bid for troubled smaller rival Allergan  NYSE AGN  Plc 
Regulators are pressuring companies to cut drug costs and takeovers have become the preferred method of combating looming patent expiries on some of the top selling medicines they have relied upon in recent years 
Following is a list of big healthcare companies and their recent deals and possible future acquisitions 
BIOGEN INC 
   Since the halt in its development of a promising Alzheimer s therapy wiped  18 billion off Biogen s stock in March  Wall Street has been calling on the company to beef up its drug development pipeline through acquisitions 
   Possible deals would give the company access to drugs for lucrative therapeutic areas such as Duchenne muscular dystrophy and depression 
   Recent deal was the  877 million buyout of gene therapy developer Nightstar Therapeutics  and as of June 30 the company still had cash reserves of almost  2 billion 
ELI LILLY AND CO  
   Lilly spun off its animal health unit earlier this year  and has reiterated its commitment to making bolt on acquisitions to diversify its portfolio  as its long term top sellers Humalog and Cialis face intensifying competition 
   Company has also been focusing on cancer drug development and its  8 billion buyout of Loxo Oncology helped it delve deeper into the lucrative business 
   The company reported  2 29 billion in cash and cash equivalents as of June 30 
PFIZER INC 
   The world s largest drugmaker has repeatedly said it would steer clear of large scale M A  citing confidence in its own drug pipeline  But in April it said it would look at bolt on deals worth  a few  billion dollars to complement its pipeline
   The spin off and merger of its consumer healthcare unit with GlaxoSmithKline Plc  as well as its off patent branded drugs business has simplified the company s business structure 
   Analysts say that may still leave room for smaller deals like its  10 6 billion buy of Array Biopharma  which boosted its arsenal of oncology drugs and set the stage for the company to become a leader in colon cancer treatments 
   Shares of the company are down 20 6  so far this year 
AMGEN INC  
   A recent U S  court ruling win on Amgen  NASDAQ AMGN  patents for rheumatoid arthritis drug Enbrel is seen as having left the company free to pursue business development plans  including M A 
   The drugmaker said previously it would look for both big and small deals to push deeper into areas like cancer and metabolic disorders  where it already has a firm footing 
   Analysts have also suggested buying Celgene Corp s psoriasis drug Otezla  which Bristol Myers Squibb  NYSE BMY  Co is looking to sell in order to allay antitrust concerns 
   Amgen had  5 53 billion in cash and cash equivalents as of June 30  Shares of the company are up nearly 5  this year 
MERCK   CO INC 
   Investors have raised concerns about Merck s increasing dependence on blockbuster cancer drug Keytruda  highlighting the need for the drugmaker to engage in M A 
   The company has said it would focus on bolt on deals rather than a large  transformative acquisition 
   War chest stood at  6 7 billion in cash and cash equivalents  as of June 30 with shares up nearly 11 3  this year 
GILDEAD SCIENCES INC  
   CEO Daniel O Day has raised expectations for consolidation since taking the helm in March  prioritizing pipeline diversification and announcing a  5 1 billion investment in Belgo Dutch biotech Galapagos NV  which pushed deeper into areas such as fibrosis and arthritis 
   California based Gilead  NASDAQ GILD  had cash and cash equivalents of  11 24 billion as of June 30  Shares up about 1  this year 
For an interactive graphic  click here ",2019-08-19,Reuters,https://www.investing.com/news/stock-market-news/who-is-next-in-big-pharmas-merger-spree-1958548,1958548
104292,325807,AGN,Top Research Reports For Novartis  AbbVie   Sanofi,opinion,"Wednesday  December 11  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Novartis  NVS   AbbVie  ABBV  and Sanofi  PA SASY   SNY   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Novartis s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date  8 2  vs  8 1    The Zacks analyst believes that Novartis  performance in the year so far has been stellar on key drugs like Cosentyx and Entresto  its contribution from Zolgensma  and the Xiidra acquisition 
The impending acquisition of The Medicines Company should broaden its portfolio  New launches like Piqray and Beovu should further propel performance in the upcoming quarters  A strong uptake is expected particularly from Beovu as it is the first FDA approved anti VEGF to offer greater fluid resolution compared to Eylea 
However  price erosion in the United States has adversely impacted the generic business  Recently  Novartis has restructured its business and spun off the eye care unit  Alcon  to become a core drug focused company  However  pipeline setbacks and generic competition for key drugs are concerns
 You can  
Shares of AbbVie have gained 22 2  in the past three months against the Zacks Large Cap Pharmaceuticals industry s rise of 9 3   The Zacks analyst believes that AbbVie s Humira is performing well driven by strong demand trends amid new competition 
Imbruvica has multibillion dollar potential  AbbVie has been successful in expanding approvals for its cancer drugs  Imbruvica and Venclexta  It also has an impressive late stage pipeline  It gained approvals for two new drugs with significant potential  Skyrizi  risankizumab  and Rinvoq this year  Both are off to a strong start 
The acquisition of Allergan  NYSE AGN   if successful  should diversify AbbVie s revenue base and accelerate its non Humira business  Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind  Also  the decline in HCV sales is a concern 
 You can  
Sanofi s shares have gained 11 2  over the past six months against the Zacks Large Cap Pharmaceuticals industry s rise of 5   The Zacks analyst believes that Sanofi s focus on streamlining operations and pursuing business development deals is encouraging 
The company s Specialty Care segment is on a strong footing  particularly with regular label expansion of Dupixent  Dupixent is now annualizing at around  2 billion in sales after just around two years in the market and could prove to be key long term driver  The performance of the Vaccines and Consumer Healthcare franchises also improved of late 
Sanofi s R D pipeline is strong and has delivered important results with several positive data read outs and the achievement of regulatory milestones this year  However  headwinds include weak performance of the Diabetes unit  generic competition for many drugs and slower than expected uptake of core products like Praluent 
 You can  
Other noteworthy reports we are featuring today include Southern  SO   Pioneer Natural Resources  PXD  and Aqua America  WTR  
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor 

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Cosentyx  Entresto  Fuel Novartis  NVS   Sandoz Weak


AbbVie s  ABBV  Pipeline Solid  Skyrizi  Rinvoq Start Strong


Sanofi  SNY  Diabetes Sales Weak  Specialty Care Unit Strong


Featured Reports
Southern Company  NYSE SO  Buoyed by Regulated Customer Growth
The Zacks analyst believes that steady increase in Southern Company s regulated business customer base should support its revenue growth 

Pioneer s  PXD  Permian Focus Offsets Rising Production Cost
Per the Zacks analyst  strong focus on the low cost and lucrative Permian Basin is likely to help Pioneer Natural to combat the rise in production expenses 

Organic Growth   Customer Additions Aid Aqua America  WTR 
Per the Zacks analyst Aqua America is gaining from customer growth and steady investments is driving organic growth  that are assisting the company to come out with solid performance 

Guidewire  GWRE  Banks on Expanding Clientele   Partnerships
Per the Zacks analyst  Guidewire is benefiting from high demand for its cloud based products  Further  expanding partnership programs and strategic collaborations are tailwinds 

Mobile Traffic   Premier Agent Business Aid Zillow Group  ZG 
Per the Zacks analyst  Zillow Group s growth can be attributed to its Premier Agent Business  new construction marketplaces and increasing traffic at its mobile apps as well as websites 

Regulatory Approval Delays  High Costs Hurt PG E Corp  PCG 
Per the Zacks Analyst  any delays in acquiring regulatory approvals may impact financial performance 

Higher Sales Volumes Aid Oshkosh  OSK  Amid Input Cost Woes
Per the Zacks analyst  Oshkosh is gaining from higher sales volumes in Defense  Fire   Emergency and Commercial segments  However  rising raw material costs of steel and aluminum remains a concern 

New Upgrades
Loan Growth and Digitization Supports TCF Financial  TCF 
Per the Zacks analyst  organic growth remained a key strength at TCF Financial  as reflected by strong loans and deposit balance  Moreover  investments in technology are likely to aid further growth 

B G Foods  BGS  Likely to Gain on Solid Pricing Initiatives
Per the Zacks analyst  B G Foods  pricing initiatives have been a significant driver  Notably  solid pricing and cost saving efforts are expected to help B G Foods battle input cost inflation in 2019 

Zumiez s  ZUMZ  Sturdy Comps Performance to Propel Top Line
Per the Zacks analyst  Zumiez s sturdy comps performance and omni channel capabilities bode well  Comps rose 5 5  in the third quarter  Management expects fiscal 2019 comps to rise in 4 4 5  range 

New Downgrades
Surface Technologies Segment Woes to Hurt TechnipFMC  FTI 
The Zacks analyst is concerned over the weak market sentiment and unfavorable product mix in TechnipFMC s Surface Technologies unit  which is set to impact the company s near term earnings growth 

TriMas  TRS  Weighed Down by Weak End Markets   Higher Costs
Per the Zacks analyst  the ongoing weakness in the North American industrial and upstream oil and gas end markets will hurt TriMas  top line while higher freight and commodity costs will dent margins 

Hawaiian Holdings  HA  Hurt by Declining Passenger Revenues
Per the Zacks analyst  competition from Southwest Airlines  NYSE LUV  is affecting Hawaiian Holdings  passenger revenues  Notably  passenger revenues slipped 0 8  in the first nine months of 2019 
undefined undefined",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-novartis-abbvie--sanofi-200491963,200491963
104293,325808,AGN,The Zacks Analyst Blog Highlights  Novartis  AbbVie  Sanofi  Pioneer Natural Resources And Aqua America,opinion,For Immediate ReleaseChicago  IL  December 12  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Novartis   NYSE NVS    AbbVie   NYSE ABBV    Sanofi   NASDAQ SNY    Pioneer Natural Resources   NYSE PXD   and Aqua America   NYSE WTR   Here are highlights from Wednesday s Analyst Blog Top Research Reports for Novartis  AbbVie and SanofiThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Novartis  AbbVie and Sanofi  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Novartis s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date  8 2  vs  8 1    The Zacks analyst believes that Novartis  performance in the year so far has been stellar on key drugs like Cosentyx and Entresto  its contribution from Zolgensma  and the Xiidra acquisition The impending acquisition of The Medicines Company should broaden its portfolio  New launches like Piqray and Beovu should further propel performance in the upcoming quarters  A strong uptake is expected particularly from Beovu as it is the first FDA approved anti VEGF to offer greater fluid resolution compared to Eylea However  price erosion in the United States has adversely impacted the generic business  Recently  Novartis has restructured its business and spun off the eye care unit  Alcon  to become a core drug focused company  However  pipeline setbacks and generic competition for key drugs are concerns You can  Shares of AbbVie have gained 22 2  in the past three months against the Zacks Large Cap Pharmaceuticals industry s rise of 9 3   The Zacks analyst believes that AbbVie s Humira is performing well driven by strong demand trends amid new competition Imbruvica has multibillion dollar potential  AbbVie has been successful in expanding approvals for its cancer drugs  Imbruvica and Venclexta  It also has an impressive late stage pipeline  It gained approvals for two new drugs with significant potential  Skyrizi  risankizumab  and Rinvoq this year  Both are off to a strong start The acquisition of Allergan  NYSE AGN   if successful  should diversify AbbVie s revenue base and accelerate its non Humira business  Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind  Also  the decline in HCV sales is a concern  You can  Sanofi s shares have gained 11 2  over the past six months against the Zacks Large Cap Pharmaceuticals industry s rise of 5   The Zacks analyst believes that Sanofi s focus on streamlining operations and pursuing business development deals is encouraging The company s Specialty Care segment is on a strong footing  particularly with regular label expansion of Dupixent  Dupixent is now annualizing at around  2 billion in sales after just around two years in the market and could prove to be key long term driver  The performance of the Vaccines and Consumer Healthcare franchises also improved of late Sanofi s R D pipeline is strong and has delivered important results with several positive data read outs and the achievement of regulatory milestones this year  However  headwinds include weak performance of the Diabetes unit  generic competition for many drugs and slower than expected uptake of core products like Praluent  You can  Other noteworthy reports we are featuring today include Pioneer Natural Resources and Aqua America 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-novartis-abbvie-sanofi-pioneer-natural-resources-and-aqua-america-200492214,200492214
104294,325809,AGN,Why Is Editas  EDIT  Up 28 7  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Editas Medicine  EDIT   Shares have added about 28 7  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Editas due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Editas Beats on Q3 Earnings  Amends Celgene  NASDAQ CELG  DealEditas incurred a loss of 66 cents per share in the third quarter of 2019  narrower than the Zacks Consensus Estimate of 73 cents but wider than the year ago quarter s loss of 32 cents Collaboration and other research and development revenues comprising the company s total revenues came in at  3 8 million  down 73 8  year over year  Meanwhile  sales were almost in line with the Zacks Consensus Estimate of  4million Editas has no approved product in its portfolio at the moment  The company generates collaboration revenues and other research and development revenues  Its collaboration revenues declined in the quarter due to lower revenues recognized under its collaboration with Allergan  NYSE AGN  Quarter in DetailIn the reported quarter  research and development expenses were  22 7 million  up 30 5  from the year ago period s figure due to increased process and platform development costs General and administrative expenses rose 18 1  to  15 7 million due to higher professional services costs 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates flatlined during the past month  The consensus estimate has shifted 104 63  due to these changes 
VGM Scores
Currently  Editas has a poor Growth Score of F  however its Momentum Score is doing a lot better with an A  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Editas has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/why-is-editas-edit-up-287-since-last-earnings-report-200492189,200492189
104295,325810,AGN,3 Top Dividend Aristocrats To Buy For The Long Term,opinion,"Income investors looking for high yields and sustainable dividend growth should inspect the list of Dividend Aristocrats  as it contains many strong dividend stocks  The Dividend Aristocrats are a group of just 57 companies within the S P 500 Index  that have raised their dividends annually for at least 25 years in a row 
The Dividend Aristocrats have outperformed the broader market for the past decade  In the past 10 years through November 29th  the Dividend Aristocrats generated total returns of 13 8  per   compared with 12 7  annual returns for the S P 500 Index 
The Dividend Aristocrats also provide higher levels of investment income  which is particularly important for investors in or nearing retirement  The following 3 Dividend Aristocrats each have long histories of dividend growth  plus current dividend yields of at least 4   And  these 3 stocks are highly likely to continue raising their dividends for many years to come 
Dividend Aristocrat  1  AT T Inc   T 
AT T  NYSE T  is a giant telecommunications company with a market capitalization above  280 billion  AT T is a large telecommunications company with over 100 million customers in the U S   as well as a significant presence in Latin America  The company provides a wide range of telecom services  including wireless  broadband  and television through its cable operations and its DIRECTV satellite business 
AT T generates more than  180 billion in annual revenue  It has increased its dividend for 36 consecutive years  including a recent 2  increase on December 13th  AT T s primary competitive advantage is its scale  The U S  telecom industry is dominated by AT T and rival telecom Verizon  NYSE VZ  
In addition  AT T has highly valuable media properties  the result of its  81 billion acquisition of Time Warner  While AT T s telecom businesses provide the company with strong cash flow and steady growth  its content assets will help drive its future growth  AT T now owns multiple media brands  including TNT  TBS  CNN  and HBO  as well as the Warner Brothers movie studio and sports rights across the NFL  NBA  MLB  and NCAA 
AT T reported solid third quarter financial   Revenue came in 3  lower year over year but higher profit margins resulted in 4  growth in adjusted earnings per share  The company also said it expects 2022 adjusted earnings per share in the range of  4 50 to  4 80  which at the midpoint would represent roughly 10  annual growth  It also expects revenue to climb between 1  and 2  each year  We expect 4  annual EPS growth for AT T over the next five years  AT T is a cash machine  The company expects free cash flow of  30 billion to  32 billion by 2022  This will allow it to steadily pay down debt and continue to reward shareholders with high dividend payouts 
AT T is an undervalued dividend stock  with a price to earnings ratio of just 10 5  In addition to earnings growth and the 5 4  current dividend yield  we view AT T as a blue chip dividend stock 

Dividend Aristocrat  2  AbbVie Inc 
AbbVie  NYSE ABBV  is a pharmaceutical company that was spun off by  Abbott Laboratories   NYSE ABT  in 2013  AbbVie currently has a market capitalization of  133 billion  AbbVie has generated strong growth in recent years  but investors are concerned that growth could slow down moving forward  Its flagship product Humira which by itself represents approximately 60  of AbbVie s total revenue has lost patent exclusivity in Europe  Complicating matters further is that AbbVie will lose patent exclusivity for Humira starting in 2023 

Fortunately  the company has a well stocked pipeline to help replace any declines in Humira sales  For example  in the most recent  AbbVie generated 3 5  revenue growth  New products like Imbruvica led the way with 29  sales growth  Overall  AbbVie reported 9  adjusted earnings per share growth  a very satisfactory result 

Along with its quarterly results  the company raised its full year guidance  AbbVie  now expects 2019 adjusted EPS in a range of  8 90 to  8 92  up from  8 82 to  8 92 previously  The new guidance range represents full year adjusted EPS growth of 12  to 13   at the midpoint  In addition  AbbVie raised its quarterly dividend by 10  

AbbVie has multiple organic growth opportunities to replace Humira declines  In addition  acquisitions are a major catalyst for AbbVie  it recently acquired Allergan  NYSE AGN  for  63 billion  This acquisition will meaningfully boost AbbVie s growth  and further diversify its product portfolio  The combined company will have annual revenues of nearly  50 billion  AbbVie expects the transaction to be 10  accretive to adjusted EPS over the first full year following the close of the transaction  with peak accretion of greater than 20  

Based on expected 2019 earnings per share of   8 91  AbbVie stock trades for a price to earnings ratio of just 10 1  We view AbbVie  NYSE ABBV  as significantly undervalued  considering its growth potential  The stock has a high current dividend yield of 5 2   making it an attractive dividend stock for value and income 
Dividend Aristocrat  3  People s United Financial  PBCT 
People s United Financial  NASDAQ PBCT  is one of the lesser known Dividend Aristocrats  With a market capitalization of just  7 4 billion  it flies under the radar relative to the many large cap stocks on the list of Dividend Aristocrats  But People s United Financial has a strong business model  as a leading regional bank and financial services company 
It provides various services including real estate and mortgage lending  equipment financing  consumer loans  life insurance  brokerage services  wealth management  and traditional banking  The company has a network of 400  branches  with total assets of  52 billion 
People s United Financial reported strong results last quarter  While net interest margin remained flat year over year  due to falling interest rates throughout 2019  operating earnings per share increased 3   The company grew non interest income rose 15  for the quarter 
Continued growth is likely for this Dividend Aristocrat  due to its recent  759 million  of United Financial Bancorp  This acquisition will enhance the presence of the company in central Connecticut and western Massachusetts Earlier in 2019 it also acquired VAR Technology Finance  which focuses on serving the technological sector  and BSB Bancorp  The company should be able to continue growing earnings per share at a mid single digit pace going forward  as it will benefit from stable growth of the U S  economy 
People s United is a rare stock  as it is the only bank stock on the list of Dividend Aristocrats  It has maintained steady dividend growth  even during recessions  which are typically very damaging to banks  For example  from 2007 2010  earnings per share declined 54  as the Great Recession took its toll  With that said  it remained profitable throughout  and continued to increase its dividend through the Great Recession 
We believe the dividend remains secure  with room for continued growth  The company is expected to maintain a dividend payout ratio of 52  for 2019  which indicates a sustainable distribution And  the stock is valued at just 13 times this year s earnings per share  People s United stock is trading for a reasonable valuation  along with a high dividend yield of 4 2  ",2019-12-18,Bob Ciura,https://www.investing.com/analysis/3-top-dividend-aristocrats-to-buy-for-the-long-term-200493307,200493307
104296,325811,AGN,Allergan  AGN  Gets FDA Approval For Migraine Drug Ubrelvy,opinion,Allergan plc   NYSE AGN   announced that the FDA approved a new drug application  NDA  for Ubrelvy  ubrogepant  for the acute treatment of migraine with or without aura in adults  Ubrelvy is the first and only orally administered calcitonin gene related peptide  CGRP  receptor antagonist  gepant  for the treatment of migraine attacks  It has been approved in two dose strengths   50 mg and 100 mg Migraine is a neurological disease with episodic attacks defined by symptoms such as headache  sensitivity to light and sound  and nausea  With just one dose  this drug can quickly eliminate patients  migraine pain and symptoms compared with placebo at two hours The approval was supported by data from two pivotal phase III studies   ACHIEVE I   II   and two additional safety studies evaluating ubrogepant  The candidate demonstrated positive results in both pivotal studies  which evaluated it for the treatment of a single migraine attack Data from the additional safety studies demonstrated that ubrogepant was able to treat migraine patients who have an insufficient response to or are ineligible for treatment with triptan  one of the commonly used medications for migraine  Migraine patients with moderate to severe cardiovascular risk will also be eligible for treatment with ubrogepant The NDA for ubrogepant was accepted for review by the FDA in March  The FDA granted the application a normal review period of 10 months  Shares of the company have surged 43 3  year to date compared with the  s growth of 8 8  Meanwhile  the company has another oral anti CGRP candidate  atogepant  in its pipeline that demonstrated positive results in a phase II study  which evaluated it for the treatment of episodic migraine attack Allergan s largest product  Botox  is also approved for treating migraine  among several other indications  However  the competition in the anti CGRP segment is strong  In 2018  three anti CGRP drugs   Amgen Novartis    NYSE NVS   Aimovig  Eli Lilly s   NYSE LLY   Emgality and Teva Pharma s   NYSE TEVA   Ajovy   received approval from the FDA for treating migraine  However  oral administration may help ubrogepant gain strong adoption compared to the other anti CGRP drugs  which are approved as injections Allergan has more than 46 projects in mid to late stage development  including six key programs on ubrogepant and atogepant for migraine  Abicipar for age related macular degeneration   AMD    label expansion of Vraylar  cariprazine  for bipolar depression  and Bimatoprost SR for glaucoma  The company s biosimilar pipeline also provides significant growth opportunities However  the company is facing loss of exclusivity for many blockbuster products  Rising generic competition and anticipated branded competition for key drugs are likely to negatively impact revenues  Hence  the successful development of the pipeline candidates is necessary for the company to offset such competition Allergan currently carries a Zacks Rank  3  Hold   You can see   Allergan plc Price    The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-23,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy-200494670,200494670
104333,325848,AGN,Stocks   Dow Falls Triple Digits Amid U S  China Trade Standoff,news,"Investing com   Wall Street traded lower on Tuesday  with the Dow falling by over a hundred points for the second straight day  as markets worried that neither the U S  nor China would back down in order to reach an agreement in their current trade dispute 
The Dow Jones fell 190 points  or 1 5   at 26 248 66 points by 9 38 AM ET  13 38 GMT   the S P 500 lost 23 points  or 0 8   to 2 909 90 points  while the tech heavy Nasdaq Composite traded down 65 points  or 0 8   at 8 057 83 points 
 The Chinese public wants an agreement  but meanwhile is well prepared for other potential outcomes  including a temporary breakdown in talks   said an editorial in the Global Times  an English language publication that regularly serves as a mouthpiece for official Chinese foreign policy 
The comments came after U S  Trade Representative Robert Lighthizer confirmed that the U S  will raise tariffs on  200 billion worth of Chinese imports from 10  to 25  as of Friday  a step that sharply escalates the trade dispute between the two countries after months of talks that appeared to be making progress in avoiding such an outcome 
Many analysts commented that both sides may only be posturing ahead of the high level trade talks between Lighthizer  U S  Treasury Secretary Steven Mnuchin and Chinese Vice Premier Liu He scheduled for Wednesday and Thursday 
But the determination of both sides not to  flinch first  has markets concerned that the increased tariffs will come into force 
 It s imperative that trade tensions are resolved in a way satisfying for everyone because clearly tensions between the United States and China are the threat to the global economy   Reuters quoted International Monetary Fund managing director Christine Lagarde as saying in Paris on the sidelines of a meeting with the French government 
Markets want trade  results   Investing com analyst Pinchas Cohen said 
Cohen warned of further volatility ahead  noting that   CBOE contracts speculating on market volatility spiked to levels not seen since late January  closing at the highest levels since late March  
The health sector did little to reassure investor sentiment in early trading  with Allergan  NYSE AGN   Mylan  NASDAQ MYL  and Regeneron  NASDAQ REGN  all trading sharply lower 
Insurer AIG  NYSE AIG  was a notable outlier with shares soaring nearly 8  after it recorded its first underwriting profit since the financial crisis  smashing expectations with its first quarter results 
Outside of equities  the U S  dollar index  which measures the greenback against six rival currencies  gained 0 2  to 97 44 by 9 40 AM ET  13 40 GMT   while the yield on the 10 year Treasury dropped 3 basis points to 2 47  
In commodities  gold futures dipped  1 10  or 0 1   to  1 282 75 a troy ounce  while crude oil traded down 92 cents  or 1 5  at  61 33 a barrel ",2019-05-07,Investing.com,https://www.investing.com/news/stock-market-news/stocks--dow-falls-triple-digits-amid-uschina-trade-standoff-1859033,1859033
104334,325849,AGN,Pfizer makes  10 6 billion cancer bet in cash deal for Array Biopharma,news,"By Michael Erman and Tamara Mathias  Reuters     Pfizer  Inc  NYSE PFE  on Monday said it would buy Array Biopharma Inc for  10 64 billion in cash  a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs  The largest U S  drugmaker agreed to pay a hefty premium of 62  for Array  which sells the combination treatment Braftovi and Mektovi for melanoma  But those drugs appear poised to become part of a promising triple combination for advanced colorectal cancer  Pfizer executives said the company began actively pursuing Array last month after it released positive clinical data showing that Braftovi and Mektovi in combination with Eli Lilly  NYSE LLY  and Co s Erbitux helped reduce the risk of death from colorectal cancer by 48  compared to the standard of care in patients with a gene mutation known as BRAF V600E  The data  is really a landmark publication in one of the most dismal tumors   Pfizer research chief Mikael Dolsten said in a phone interview   There will be ample opportunities to do combinations and build a whole science platform around colorectal cancer   said Dolsten  adding that he believes the Array drugs could eventually tackle colon cancer earlier in the disease process  That is a type of cancer where the class of immunotherapies that include Merck and Co s blockbuster Keytruda have not been as compelling as Array s results  Morningstar analyst Damien Conover said  Braftovi and Mektovi  launched last July for the deadliest form of skin cancer at a price of  22 000 per month  had sales of around  72 million over their first nine months  The company also has revenue from royalty and licensing deals  Pfizer is paying  48 per share for Array  which rose 55  to  45 95 in midday trading  Pfizer s shares fell 0 4 percent to  42 59   Graphic  Array biopharma shares     Oncology has become one of the most profitable areas for drug companies as breakthroughs in treatments have improved survival rates and costs for the drugs have surged  Array is Pfizer s first major purchase under new Chief Executive Albert Bourla  who took on the role in January  It is also its biggest acquisition since a  14 billion purchase of Medivation in 2016 gave it the prostate cancer drug Xtandi  forecast by analysts to top  1 billion in sales next year  Bourla and his predecessor Ian Read have been saying for more than a year that the company would eschew transformative deals because of the strength of its pipeline  But in April  Pfizer said it would consider bolt on deals worth a few billion dollars to complement its pipeline  Read had previously failed to close megadeals to acquire rivals AstraZeneca and later Allergan  NYSE AGN   Pfizer s growth has slowed in recent years and Bourla has been touting the company s  15 in 5  plan to launch 15 experimental treatments  each with at least  1 billion annual sales potential  over a five year period  The company been investing in cancer drugs and gene therapies  Pfizer said it expects to complete the deal in the second half of 2019  The transaction is expected to add to earnings beginning 2022  and will reduce adjusted earnings per share by between 4 and 5 cents this year and in 2020  Pfizer said  Pfizer said it expects to finance the majority of the deal  which has an enterprise value of about  11 4 billion  with debt and the remaining with existing cash  
Pfizer was advised by Guggenheim Securities and  Morgan Stanley   NYSE MS  on the deal  Array s advisor was Centerview Partners ",2019-06-17,Reuters,https://www.investing.com/news/stock-market-news/pfizer-to-buy-array-for-1064-billion-1899252,1899252
104335,325850,AGN,Stocks approach record as Fed soothes Wall Street s fears,news,"By Noel Randewich  Reuters    The S P 500 approached a record high on Wednesday after the Federal Reserve signaled potential interest cuts later this year  reassuring investors worried that the U S  China trade war could stall economic growth   Saying it  will act as appropriate to sustain  economic expansion  the central bank signaled rate cuts of as much as half a percentage point over the remainder of 2019  In its statement following a two day policy meeting  the Fed held rates steady  as expected  but dropped a previous promise to be  patient  in adjusting rates   That elevated the S P 500 and Dow Jones Industrial average to less than 1  from their record high closes set in late April    We think the Fed delivered  It did no harm  It walked right up to a cut without doing it today  It ll likely be coming in July absent some big trade news or other news   said John Augustine  chief investment officer at Huntington Bank in Columbus  Ohio  Buoyed by growing confidence the Fed will cut rates  and by hopes of an end to the U S  China trade war  U S  stocks have climbed in recent weeks  The S P 500 has gained 6  in June   At the end of the day what they  the Fed  want to do is give a nod to the market  Expectations had gotten so dovish that they need to give a nod to that  but at the same time not make any commitment and be forced to cut rates later on if conditions perhaps changed   said Kristina Hooper  Chief Global Market Strategist at Invesco in New York  The financial sector fell 0 2   with bank stocks dipping 0 2   Lower interest rates tend to hurt banks  profits  The Dow Jones Industrial Average rose 0 15  to end at 26 504 27 points  while the S P 500 gained 0 30  to 2 926 44  The Nasdaq Composite added 0 42  to 7 987 32   Contributing more than any other stock to advances on the Nasdaq and S P 500  Adobe  NASDAQ ADBE  Inc surged 5 2  after the Photoshop software provider beat analysts  estimates for quarterly profit and revenue  Facebook  NASDAQ FB  fell 0 5  as its ambitious plan to launch a digital currency faced a backlash from regulators and politicians in the United States and abroad  The healthcare sector rose 1   helped by gains in UnitedHealth Group Inc  NYSE UNH    Pfizer  Inc  NYSE PFE  and Allergan  NYSE AGN  Plc   Allergan jumped 6 2  after the drugmaker said its constipation drug  jointly developed with Ironwood Pharmaceuticals Inc  improved symptoms in patients suffering from irritable bowel syndrome with constipation   Advancing issues outnumbered declining ones on the NYSE by a 1 65 to 1 ratio  on Nasdaq  a 1 40 to 1 ratio favored advancers  The S P 500 posted 48 new 52 week highs and 2 new lows  the Nasdaq Composite recorded 63 new highs and 59 new lows   
Volume on U S  exchanges was 6 5 billion shares  compared to the 6 8 billion average for the full session over the last 20 trading days ",2019-06-19,Reuters,https://www.investing.com/news/stock-market-news/stocks-futures-subdued-ahead-of-fed-statement-1901645,1901645
104336,325851,AGN,AbbVie looks beyond Humira with  63 billion deal for Botox maker Allergan,news,"By Michael Erman and Ankur Banerjee  Reuters    Drugmaker  AbbVie Inc   NYSE ABBV  said on Tuesday it would buy Botox maker Allergan  NYSE AGN  Plc for about  63 billion  grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira  AbbVie has been under pressure to diversify its portfolio as Humira  the world s best selling drug  is already in competition with cheaper versions in Europe and faces expiration of its patents in 2023 in the United States  its most important market  Humira  which brought in revenue of about  20 billion last year  reported the first fall in quarterly sales in years in the January March period  AbbVie CEO Richard Gonzalez said the company was well positioned to buy Allergan because of the massive amount of cash that Humira generates   Humira is buying the assets that replace it over the long term   said Gonzalez  who will lead the combined company and remain chairman and chief executive through 2023   Allergan Chief Executive Officer Brent Saunders  who put together the current version of his company through a series of deals to roll up several pharmaceutical firms in 2014  will join AbbVie s board upon completion of the deal   Saunders built his reputation as a dealmaker  but Allergan has struggled since  Pfizer  Inc  NYSE PFE  walked away from a  160 billion deal in 2016  Allergan s shares have lost around half their value since then  He has been under pressure over the last year to break up or sell the company  with activist investor David Tepper running a campaign to urge Allergan to hire an independent chairman  Investors have also questioned Saunders  growth plans beyond acquisitions and the quality of the company s drug pipeline   On a conference call  Gonzalez said the deal was not a pipeline driven transaction  and AbbVie executives downplayed the role Allergan s experimental drugs would play in the combined company  Shares of AbbVie have also languished  losing more than a third of their value from highs hit in January 2018 over concerns about competition to Humira  The deal  which comes months after Bristol Myers Squibb  NYSE BMY  Co agreed to buy  Celgene Corp   NASDAQ CELG  in a  74 billion transaction  will redomicile Dublin based Allergan to the United States   AbbVie and Allergan senior management had been discussing a possible deal since late April  the companies said   Allergan remains an industry leader in aesthetics  and is likely to be the cornerstone of AbbVie s valuation  SVB Leerink analyst Geoffrey Porges said in a note   This is yet another transaction driven by diversification  scale and low borrowing costs  rather than portfolio or top line synergies   Porges said  Allergan shareholders will receive 0 8660 AbbVie shares and  120 30 in cash for each share held  for a total consideration of  188 24 per Allergan share  a premium of 45  to the stock s Monday close  Including debt  the deal values Allergan at  83 billion  AbbVie shares were down 14  at  67 54  while Allergan s stock was up 27 60  at  165 13 in morning trading  Shares of other specialty pharmaceutical companies also moved higher  Mylan  NASDAQ MYL  NV  Bausch Health Co Inc and Teva Pharmaceutical  NYSE TEVA  Ltd were all up 2  to 4    AbbVie s offer price is a far cry from Pfizer s all stock offer for Allergan that valued the Ireland based drugmaker at  363 63 per share in 2015  AbbVie said it expects annual pretax savings and other cost reductions of at least  2 billion in its third year  after the deal closes in early 2020  The transaction is expected to add 10  to adjusted earnings per share over the first full year following the close  the companies said   
The deal was a better than expected outcome for Allergan as investors and analysts were expecting a split  Cantor Fitzgerald analyst Louise Chen wrote in a note  adding that it is unlikely that anyone else will step in and bid for Allergan at this point ",2019-06-25,Reuters,https://www.investing.com/news/stock-market-news/abbvie-nears-deal-to-buy-allergan-for-more-than-60-billion-wsj-1906663,1906663
104337,325852,AGN,NASH Scorecard Year To Date  The Winners And The Losers,opinion,The promising but challenging indication of nonalcoholic steatohepatitis  NASH  hit headlines following two major developments Firstly  the frontrunner in the NASH space  Intercept Pharmaceuticals  Inc    NASDAQ ICPT    broke positive news at the start of this week  The company recently announced that the FDA accepted its New Drug Application  NDA  for obeticholic acid  OCA  seeking accelerated approval for the treatment of fibrosis due to NASH  The regulatory agency also granted Priority Review to the same  The authority assigned a Prescription Drug User Fee Act  PDUFA  target action date of Mar 26  2020 for the NDA  It indicated to hold an advisory committee meeting for discussing the application  However  the conference date is yet to be finalized and the timeline for the NDA review is subject to change A potential approval of OCA for NASH will significantly boost Intercept s prospects  given the market opportunity for patients with fibrosis due to NASH Concurrently  CymaBay Therapeutics  Inc    NASDAQ CBAY   announced the termination of mid stage study of seladelpar for NASH  The company stopped its phase IIb study of seladelpar in patients with NASH and its recently initiated phase II study of the drug in patients with primary sclerosing cholangitis  PSC   Moreover  it is putting a hold on all studies of seladelpar in patients with primary biliary cholangitis  PBC   The decision to discontinue these studies was based on initial histological findings observed in the phase IIb study of seladelpar for NASH after data showed some patients experiencing liver damage  These planned  blinded  histological assessments of the first tranche of liver biopsies in the study demonstrated atypical histological outcomes including histology characterized as an interface hepatitis presentation  with or without biliary injury In June 2019  Conatus   NASDAQ CNAT   announced that top line results from its ENCORE LF clinical study of emricasan failed to meet its primary endpoint  Consequently  Conatus and partner Novartis mutually agreed to cease the collaboration agreement for the global development and commercialization of emricasan As a result  the spotlight is back on this space  The market for NASH holds promises and is expected to be tapped by most pharma biotech bigwigs in the near future  It is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer More on NASHA chronic liver disease  NASH is caused by excessive fat accumulation in the liver or steatosis  Per statistics  it affected up to 15 million people in the United States causing inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  The ailment is anticipated to be the leading reason for liver transplantation by 2020  Currently  NASH is the primary reason for liver transplants in people under 50 across the United States  Such patients also suffer obesity and type II diabetes  With no treatments presently approved to address this disease  the market scope is substantially huge and many companies are investing a major chunk of their R D budget in the same Pharma Players With an Edge in NASHThe latest news from industry players in the NASH area underscores the complexity of treatments being developed  The winner so far in the race seems to be Intercept Pharmaceuticals  courtesy of the aforementioned news Let us take a look at some other players with promising candidates for the indication France based Genfit s lead candidate elafibranor  which is in late stage studies  also buoys hope in this regard  The phase III study RESOLVE IT is evaluating the efficacy and safety of elafibranor 120 mg versus placebo in patients with NASH and fibrosis  Most recently  the Data Safety Monitoring Board  DSMB  issued a positive recommendation for the continuation of the study evaluating elafibranor for NASH without any modifications  The 42 month DSMB safety review supports Genfit s continuation of the RESOLVE IT study  This DSMB sanction marks the seventh review with no safety signals that would justify modification or shelving of the study including review of safety data from patients enrolled in the study  who have received elafibranor for three years   An NDA is expected to be filed by 2020 end Allergan plc   NYSE AGN   too has an interesting candidate in its pipeline  cenicriviroc  for the treatment of NASH  The 2016 Tobira acquisition added the candidate to its profile  The candidate is being evaluated in a phase III study  AURORA Clinical stage biopharmaceutical company Galmed Pharmaceuticals Ltd    NASDAQ GLMD   is firmly eyeing the development of Aramchol  a liver targeted  oral SCD1 modulator  The company recently began a phase III IV ARMOR  a double blind  placebo controlled  global study  to evaluate the efficacy and safety of Aramchol in patients with NASH and fibrosis  The company targets to complete enrollment by the second quarter of 2021 and report top line results by the fourth quarter of 2022  Galmed currently carries a Zacks Rank  2  Buy  You can see  Madrigal Pharmaceuticals  Inc    NASDAQ MDGL    a clinical stage biopharmaceutical company  is evaluating its lead candidate MGL 3196   resmetirom   a first in class  orally administered  small molecule  liver directed  thyroid hormone receptor  THR    selective agonist  for NASH  Earlier in the year  the company commenced a phase III study on MGL 3196 for NASH Bottom LineGiven the fact that NASH has a profitable market  quite a few companies inked deals to enter this space  Evidently  approval of any of the candidates will attract more players and investments in this space under healthcare Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/nash-scorecard-year-to-date-the-winners-and-the-losers-200488987,200488987
104338,325853,AGN,Market Serves Up More Records For Thanksgiving ,opinion,"This impressive holiday week continued on Thanksgiving eve as each of the major indices enjoyed new all time highs  just as they did yesterday and the day before 
	The NASDAQ jumped 0 66   or about 57 points  to 8705 17  while the S P rose 0 42  to 3153 63  The Dow started the session in negative territory but eventually finished higher by 0 15   or around 42 points  to 28 164 
	This marks the fourth straight day of gains for the indices and the third consecutive session with each of them reaching new highs 
	That s quite a difference from last year  You ve probably blocked it out of your mind  but Thanksgiving week 2018 started with back to back selloffs  The Dow lost nearly 1 000 points on Monday and Tuesday and we were in the midst of a  tech wreck  
	The Wednesday before the holiday last year was mostly positive  but the indices nearly squandered a morning rally  And this all came after a horrible month of October 
	Now here in 2019  the market is about to put together its third straight month in the green   With Thanksgiving so late this year  Friday will be it for November   And its also enjoying record highs 
	And you know what the funniest thing is  We re STILL waiting for some real progress on the trade front  Just as we were last year 
	In fact  optimism over signing a Phase 1 trade deal is probably the biggest reason why we re enjoying such a rollicking start to the holiday season 
	It s been the best of both worlds recently  with the market running higher on positive trade headlines while taking the negative ones in stride without any major selloffs  Fortunately  the recent headlines have been encouraging ones with both sides boasting of progress being made 
	Along with hopes for a trade deal  we also enjoyed some positive economic data on Wednesday  Most importantly was that GDP for the third quarter was revised upward to 2 1   compared to the previous reading of 1 9    
	Investors don t need a holiday to be thankful for the market of late  It should be easy to appreciate just how good things are right now  especially when compared to 2018 
	What they DO need  however  is a strong holiday shopping season and a trade deal 
	But let s just be grateful for how far we ve come and worry about that stuff when we get back to work Today s Portfolio Highlights Options Trader  With the weather getting colder everyday as we move toward winter  you can bet that Comfort Systems  FIX  will be busy  This Zacks Rank  1  Strong Buy  is a national provider of comprehensive HVAC installation  maintenance  repair and replacement services  Kevin sees the stock in a bull pennant chart pattern  which projects an upside breakout  Therefore  he added a few bull call spreads on Wednesday by buying to open 4 March 50 00 Calls AND selling to open 4 March 55 00 Calls  If FIX gets to  55 or higher by the mid March expiration  this move will make 122   Meanwhile  the editor also bought to open 2 March 75 00 Puts in Pegasystems  PEGA   a Zacks Rank  4  Sell  provider of CRM software  The stock is in a bearish head and shoulders pattern  which projects a downside breakout  Read the full write up for a lot more on today s moves Home Run Investor   Tis the season to talk turkey  but this portfolio would rather talk about chicken  So who do you think has the best chicken sandwich  Popeyes or Chick fil A  Brian says NEITHER  He s all about El Pollo Loco  LOCO   which isn t in the discussion very much because of its size  However  the editor really does prefer their chicken and also appreciates the good earnings history that has made it a Zacks Rank  2  Buy   The value is also pretty good  Now if LOCO could get some attention in this current chicken sandwich craze  Brian thinks its all set to take off  He also sold e l f  Beauty  ELF  today  See the complete commentary for more Surprise Trader  The bulk of earnings season may be over  but there are still enough reports coming out to make an addition to the portfolio  On Wednesday  Dave added Yext  YEXT   a Zacks Rank  1  Strong Buy  provider of digital media technology services  It has a positive Earnings ESP of 5 56  for the report coming after the bell on Thursday  December 5  Sales estimates for the quarter suggest growth of 30  year over year  The editor also decided to sell the lethargic Ross Stores  NASDAQ ROST  for an approximately 3 3  return in a little over a week  Read the full write up for more on today s moves Value Investor  The portfolio didn t have any pharma names  until today  Tracey added large cap drug company AbbVie  NYSE ABBV  on Wednesday  which beat the Zacks Consensus Estimate in its most recent report and is expected to consistently grow earnings over the next two years  It also has a dividend yielding 4 8   While drugs like Skyrizi and Rinvoq performed better than expected  the company s pipeline could use some help  That s why ABBV is in the middle of buying Allergan  NYSE AGN   which should close early next year  And don t be surprised if its keeps acquiring moving forward  Despite a big rally off its recent lows  the editor still believes ABBV is attractively priced  Take a look at the complete commentary for more on this new buy 
	Happy Thanksgiving 
	Jim Giaquinto 
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy    Click here to  test drive  Zacks Ultimate for FREE   ",2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/market-serves-up-more-records-for-thanksgiving-200488873,200488873
104339,325854,AGN,Allergan  AGN  Up 4 5  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Allergan  NYSE AGN   Shares have added about 4 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Allergan due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Allergan Meets Q3 Earnings Estimates  Ups  19 Sales ViewAllergan s third quarter adjusted earnings came in at  4 25 per share  in line with the Zacks Consensus Estimate  Earnings were flat year over year as higher revenues were offset by lower operating profits Revenues came in at  4 05 billion  which exceeded the Zacks Consensus Estimate of  3 89 billion  Revenues rose 3 6  from the year ago quarter as higher sales of key products like Botox  cosmetic and therapeutics   Juv derm collection of fillers  Vraylar  Ozurdex  and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues declined 2 1  to  1 67 billion  Strong demand for its facial aesthetics products  Botox and Juv derm and Botox Therapeutic was offset by decline in sales of Restasis and divestiture of Medical Dermatology business in September 2018  Sales of CoolSculpting and Alloderm also declined in the quarter In Facial Aesthetics  Botox  cosmetic  recorded sales of  237 6 million  up 10  year over year  Juv derm collection of fillers rose 6  to  134 8 million Alloderm sales  however  fell 10 2  to  95 0 million while CoolSculpting sales of  53 0 million declined 37 6  year over year  Allergan expects to launch the CoolTone body contouring device in fourth quarter 2019  which can revive sales of this aesthetics franchise In Eye Care  while Ozurdex sales rose 17 8  to  33 7 million  Restasis sales fell 3 8  to  286 8 million  A generic version of Restasis is expected to be launched this year Botox Therapeutic revenues were  431 6 million  up 5 9  year over year U S  General Medicine net revenues were up 9 9  year over year to  1 52 billion in the reported quarter as strong demand growth of Vraylar  Viibryd and Lo Loestrin was offset by lower sales of drugs that lost exclusivity Vraylar sales were  234 6 million in the third quarter  70  higher than the year ago quarter  In May  Vraylar was approved for the new indication of bipolar depression  which may have contributed to higher sales of the drug in the quarter Linzess sales rose 4 8  to  214 7 million  Lo Loestrin sales grew 14 1  to  161 4 million while Bystolic sales rose 0 7  to  152 2 million  Viibryd sales were  105 1 million  up 18 8  from the year ago quarter The International segment recorded net revenues of  835 1 million  up 5  from the year ago period  excluding the impact of foreign exchange as growth in Facial Aesthetics and Botox  therapeutic  was partially offset by regulatory changes for textured breast implants and lower glaucoma and eye drop revenues Profits DeclineAdjusted gross margin declined 100 basis points  bps  in the quarter to 84 2    Adjusted operating income decreased 7 7  to  1 76 billion in the third quarter due to LOEs  divestitures and higher costs Selling  general and administrative expenses increased 14 3  to  1 18 billion in the third quarter  owing to higher marketing spending to support product launches Research and development  R D  expenses rose 14  to  448 9 million due to pipeline progress 2019 OutlookAllergan slightly raised its sales guidance for 2019 to account for the delay in Restasis generic while maintaining the previously issued earnings view Allergan expects sales to be in the range of  15 63  15 83 billion  up from the previous guidance of  15 43  15 63 billion  The company still estimates adjusted earnings to be more than  16 55 per share Adjusted tax rate is expected to be approximately 12  12 5  versus prior expectation of approximately 13  in 2019  Adjusted R D expense guidance was increased from a range of  1 6    1 7 billion to  1 75 billion while the SG A range was increased from  4 4    4 5 billion to  4 5 billion  Adjusted gross margin is expected to be 85   previously 85  85 5   
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended upward during the past month  The consensus estimate has shifted 5 41  due to these changes 
VGM Scores
At this time  Allergan has a nice Growth Score of B  however its Momentum Score is doing a bit better with an A  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Allergan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-up-45-since-last-earnings-report-can-it-continue-200490375,200490375
104340,325855,AGN,Amgen Gets FDA Approval For J J Merck s Remicade Biosimilar,opinion,Amgen   NASDAQ AMGN   announced that the FDA has granted approval to its biosimilar version of Johnson and Johnson   NYSE JNJ   Merck s   NYSE MRK   blockbuster immunology medicine  Remicade  infliximab   The biosimilar will be marketed by the trade name of Avsola  ABP 710  for all approved indications of Remicade  which includes a range of autoimmune disorders  ABP 710 is an anti TNF monoclonal antibody  However  Amgen did not mention when it plans to launch Avsola The approval was based  in part  on data from a late stage study  which evaluated ABP 710 versus branded Remicade  for the treatment of moderate to severe rheumatoid arthritis  RA   Data from the phase III study showed that ABP 710 was non inferior compared to Remicade based on its primary endpoint  which was assessment of 20  improvement in American College of Rheumatology core set measurements  ACR20  at week 22 ABP 710 is also under review in the EU  Pfizer   NYSE PFE   was the first company to have launched a biosimilar version of Remicade  Inflectra in 2016  Merck Samsung Bioepis also market Renflexis  a biosimilar of Remicade Amgen s shares have risen 20 1  this year so far compared with 6 6  increase registered by the  during this period Amgen boasts a strong biosimilars portfolio pipeline  which could be an important long term growth driver for the company  Amgen achieved several important milestones with its biosimilars portfolio in 2018 2019 including its first two launches in EU   Amjevita  biosimilar of AbbVie s Humira  and Kanjinti  biosimilar of Roche s Herceptin  as well as United States    Kanjinti and Mvasi  biosimilar of Roche s Avastin   In the United States  Amjevita is expected to be launched in the United States in 2023  Avsola is Amgen s fourth biosimilar product to be approved in the United States  A biosimilar of Alexion s Soliris  ABP 959  is in late state development Amgen s biosimilars business is already annualizing at approximately  700 million in sales  Amgen expects to launch additional biosimilars in 2020 across multiple geographies Amgen has collaborated with Allergan  NYSE AGN  for the worldwide development and commercialization of Mvasi  Kanjinti and biosimilar Rituxan  in late stage development   Amgen has also tied up with Daiichi Sankyo for the commercialization of nine biosimilars in Japan Amgen currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-fda-approval-for-jjmercks-remicade-biosimilar-200491194,200491194
104341,325856,AGN,Sanofi To Buy Synthorx For  2 5B To Boost Cancer Portfolio,opinion,French drug giant  Sanofi  PA SASY    NASDAQ SNY   announced a definitive agreement to buy small biotech Synthorx  Inc    NASDAQ THOR   for  2 5 billion to boost its immuno oncology   IO   portfolio  Per the terms of the merger agreement  Sanofi has offered to acquire all the outstanding shares of Synthorx for  68 per share in cash  a premium of almost 172  to the latter s Friday closing price of  25 03The deal  approved by the board of directors of both the companies  will add Synthorx s lead pipeline candidate  THOR 707 to Sanofi s oncology portfolio  Synthorx s proprietary IO technology platform  Expanded Genetic Alphabet  NASDAQ GOOGL   should also prove to be synergistic with Sanofi s existing therapeutic platforms  including its Nanobody technology THOR 707 is being evaluated across multiple solid tumor types alone and in combination with immune checkpoint inhibitors  Once acquired  it can be evaluated in combination with Sanofi s present oncology medicines as well as immuno modulatory agents in pipeline  Meanwhile  the acquisition will also boost Sanofi s pipeline with Synthorx s pre clinical candidates for oncology and autoimmune disorders  The transaction is expected to close in the first quarter of 2020 Sanofi s shares have underperformed the industry this year so far  It has risen 6  in the said time frame compared with the increase of 7 2    Sanofi has significantly stepped up its acquisition and alliance activity over the past few years  Among the more recent deals  the 2018 acquisitions of Ablynx and Bioverativ have strengthened Sanofi s position in the rare blood disorders market In fact  there has been a flurry of M A deal announcements this year in the biotech drug industry with two mega merger announcements  Bristol Myers Squibb   NYSE BMY     Celgene  NASDAQ CELG  and AbbVie   NYSE ABBV     Allergan  NYSE AGN  Zacks Rank Sanofi currently carries a Zacks Rank  3  Hold   You can  The Hottest Tech Mega Trend of All                 Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-12-08,Zacks Investment Research,https://www.investing.com/analysis/sanofi-to-buy-synthorx-for-25b-to-boost-cancer-portfolio-200491180,200491180
104378,325893,AGN,Stocks   Dow Posts Triple Digit Loss as ECB Flags Slowing Growth,news,"Investing com   The Dow closed lower Thursday  as sentiment on stocks was soured by slowing global growth concerns after the European Central Bank slashed its growth forecasts and launched fresh stimulus 
The Dow Jones Industrial Average fell 0 78  or 200 points  after falling as many as 321 points  The S P 500 lost 0 81   while the Nasdaq Composite fell 1 13   The S P broke below its 200 day moving average for the first time since Feb  11 
In the clearest signal yet the global economy is stuck in a rut  European Central Bank president Mario Draghi said sizable moderation in euro area growth would continue into the current year 
Draghi s downbeat remarks arrived just after the ECB downgraded its forecast on 2019 euro area growth to 1 1  from a previous forecast of 1 7   The central bank also detailed fresh stimulus measures intended to encourage lending  just three months after announcing an end to its bond buying program 
Concerns about slowing global growth fueled demand for U S  government bonds  pushing prices higher and yields lower  keeping a lid on bank stocks 
Goldman Sachs  NYSE GS    Citigroup   NYSE C  and  Morgan Stanley   NYSE MS  fell 1  as 10 Year Treasury yields ended the day lower 
Falling Treasury yields are seen as a headwind for banks  reducing their net interest margin  the difference between the interest income generated by operations and the amount of interest paid out to their lenders 
Energy stocks struggled to shake off the broad market selloff  U S  oil prices settled higher  but remained under pressure as traders continued to weigh up ongoing output cuts from major oil producers against data from a day earlier showing a surge in domestic crude supplies 
As the curtain closes on the quarterly earnings season  the latest batch of corporate results were mostly negative  adding to losses in the major averages 
Kroger  NYSE KR  stock slumped 10  after the grocery store chain released fourth quarter results that missed expectations from Investing com on both the top and bottom lines 
 American Eagle Outfitters   NYSE AEO  stock ended the day 0 38  lower after clawing back early losses following softer than expected first quarter guidance 
On the economic front  investors digested mixed economic data showing subdued quarterly productivity gains and a decline in jobless claims 
The decline in jobless claims comes a day ahead of the U S  Labor Department s nonfarm payrolls data due Friday 8 30 AM ET  13 30 GMT  
Top S P 500 Gainers and Losers Today 
Electronic Arts  NASDAQ EA    CenturyLink   NYSE CTL  and Allergan  NYSE AGN  were among the top S P 500 gainers for the session 
Kroger  NYSE KR   Mosaic  NYSE MOS  and Wynn Resorts  NASDAQ WYNN  were among the worst S P 500 performers of the session ",2019-03-07,Investing.com,https://www.investing.com/news/stock-market-news/stocks--dow-posts-tripledigit-loss-as-ecb-flags-slowing-growth-1801235,1801235
104379,325894,AGN,Allergan promises independent board chair in next leadership change,news, Reuters    Allergan  NYSE AGN  Plc plans to elect an independent board chairman  starting with the next leadership transition  the Botox maker said on Friday  as the drugmaker responds to calls from hedge fund Appaloosa LP to separate the roles of chairman and chief executive officer  Appaloosa  led by billionaire David Tepper  has been pressing Allergan since last year to separate the roles  but the company has said it would do so only when the person who now holds the positions is replaced  Brent Saunders currently holds the roles  and Allergan has said implementing Appaloosa s recommendations would be  highly disruptive  to the company s operations and impact his ability to continue to execute its current strategy  Allergan also said  in a regulatory filing on Friday that it had formed a committee to oversee mergers  acquisitions  divestitures and other transactions  The company also named Thomas Freyman as the chair of the compensation committee  replacing Catherine Klema  who will not be standing for re election  A spokesman for Tepper did not immediately respond to a request for comment  The company in February had named former CEO of drugmaker Celgene  NASDAQ CELG   Robert Hugin  as a director  saying the appointment reflected its commitment to  active board refreshment  ,2019-03-22,Reuters,https://www.investing.com/news/stock-market-news/allergan-promises-independent-board-chair-in-next-leadership-change-1815938,1815938
104380,325895,AGN,Hedge fund Appaloosa unimpressed by Allergan board promises,news," Reuters    Activist investor Appaloosa LP responded to proposed concessions from the board of Allergan  NYSE AGN  Plc by saying it had done everything  except what needs to be done  and calling on other investors to take further  disruptive  steps to change the company  The hedge fund  led by billionaire David Tepper  has been pressing Allergan since last year to separate the roles of CEO and chairman or potentially sell or merge the company  Allergan on Friday agreed to split its chairman and chief executive roles  but only at its next scheduled leadership change   Unless the board intends to make a CEO transition in the very near term  these measures are no more than a meaningless series of gestures intended to preserve the current system of lax oversight and further entrench management   Appaloosa said in a statement  
 The status quo is unacceptable and disruptive measures are necessary for shareholders to convince this board that it must make the decisions required to fix the company or  if they are unwilling  sell it to a more capable acquirer or merger partner  ",2019-03-25,Reuters,https://www.investing.com/news/stock-market-news/hedge-fund-appaloosa-unimpressed-by-allergan-board-promises-1816906,1816906
104381,325896,AGN,U S  Supreme Court rejects Allergan bid to use tribe to shield drug patents,news,By Lawrence Hurley WASHINGTON  Reuters    The U S  Supreme Court on Monday cast aside pharmaceutical company Allergan  NYSE AGN  Plc s unorthodox bid to shield patents from a federal administrative court s review by transferring them to a Native American tribe  The justices left in place a lower court ruling upholding the authority of a U S  Patent and Trademark Office tribunal to decide the validity of patents covering Allergan s dry eye drug Restasis  refusing to hear the company s appeal  Allergan had argued that the tribe s sovereign status under federal law made the patents immune from administrative review by the agency  Generic drug company Mylan  NASDAQ MYL  NV  seeking to sell its own lower cost version of Restasis  in 2016 asked the agency s Patent Trial and Appeal Board to invalidate the Allergan patents on the grounds that they described obvious ideas  Allergan  which has its headquarters in Dublin  in September 2017 transferred the patents to New York s Saint Regis Mohawk Tribe  which took legal ownership of the patents and then licensed them back to Allergan in exchange for ongoing payments  Allergan said it was protecting itself from the patent court  which it called a flawed and biased forum  The company said it did not object to the validity of its patents being reviewed by federal judges but took issue with the administrative court  U S  lawmakers from both political parties have called Allergan s deal with the tribe a sham  The patent tribunal in February 2018 rejected Allergan s maneuver  saying tribal sovereign immunity does not apply to its patent review proceedings  The U S  Court of Appeals for the Federal Circuit  which specializes in patent law  affirmed that decision five months later  Separate from the current court fight  the Restasis patents already have been invalidated  In October 2017  a federal judge in Texas took that step instead of waiting for the patent board to rule  a decision that was upheld on appeal  Mylan and Teva Pharmaceutical Industries  NYSE TEVA  Ltd have sought approval from U S  regulators to sell generic versions of Restasis ,2019-04-15,Reuters,https://www.investing.com/news/stock-market-news/us-supreme-court-rejects-allergan-bid-to-use-tribe-to-shield-drug-patents-1836319,1836319
104382,325897,AGN,Proxy firms Glass Lewis  ISS back Allergan in fight against Appaloosa,news,"By Manas Mishra  Reuters    Two major shareholder advisory firms urged investors to vote against billionaire investor David Tepper s hedge fund demand that Allergan  NYSE AGN  Plc immediately split the roles of chief executive officer and chairman  in a boost to the Botox maker  The recommendation from Institutional Shareholder Services LP and Glass Lewis   Co against the proposal of Tepper s Appaloosa gives firepower to Allergan Chairman and CEO Brent Saunders ahead of the drugmaker s shareholder meeting on May 1   Their recommendations affirm our position that our plan to adopt separate Chair and CEO positions with the next leadership transition is the best approach for Allergan shareholders   Allergan said in a statement  However  an analyst said the recommendations were contrary to the views of many investors   This news is likely to frustrate a sizeable group of shareholders and we continue to await the result of the vote   RBC Capital Markets analyst Randall Stanicky said   Appaloosa has been pressing Allergan since last year to separate the two roles  and asked for an immediate split after Allergan said an independent member of its board would be chairman  but only at its next leadership change   Both the proxy firms said that an immediate separation of the roles was not necessary   There are no significant concerns regarding the board s current leadership structure sufficient to suggest that an immediate split of the CEO and chairman roles is warranted at this time rather than at the next CEO transition   ISS was quoted as saying in the Allergan statement  Appaloosa said ISS  recommendations were  baffling  as they were inconsistent with the firm s support for a similar proposal last year  and asked shareholders to vote for its proposal  Allergan  under pressure to rescue the company s falling stock prices  launched a review of its strategy last year  But that review is likely to result in the sale of its relatively small infectious disease unit  Appaloosa has voiced its discontent with the results of the review  and has called for a breakup or sale of the company  citing recent clinical failures such as that of its depression treatment rapastinel  
Allergan s shares have fallen about 12 percent in the past 12 months  They trade nearly 60 percent below their record high of  340 33 in 2015 ",2019-04-15,Reuters,https://www.investing.com/news/stock-market-news/proxy-firms-glass-lewis-and-iss-back-allergan-in-fight-against-appaloosa-1836093,1836093
104383,325898,AGN,Allergan to prevail in vote over CEO Saunders  chairman role  sources,news,"By Jessica DiNapoli and Svea Herbst Bayliss  Reuters    Allergan  NYSE AGN  Plc is on course to defeat a shareholder resolution tabled by David Tepper s hedge fund Appaloosa LP that would have forced the drugmaker s CEO Brent Saunders to immediately give up his role as chairman  people familiar with the matter said on Tuesday  A loss would have been bruising for Saunders  a prolific dealmaker who has served as CEO of Allergan since 2014  Allergan has committed to separating the CEO and chairman roles no later than the next leadership change when Saunders  49  steps down  rather than immediately  He has not set any public timetable for his exit  Enough votes have been cast for Allergan to prevail against Appaloosa  the sources said  However  Appaloosa s resolution is expected to attract the votes of a substantial minority of Allergan s shareholders  the sources added  highlighting the displeasure of many investors focused on stricter corporate governance standards  The sources asked not to be identified because the outcome of the shareholder vote is not yet public  Allergan declined to comment  and Appaloosa could not be reached for comment  Saunders has held the roles of CEO and chairman since October 2016  Before then Saunders served as CEO of the company alongside Paul Bisaro  who was executive chairman  He left to become CEO of Impax Laboratories Inc   Two leading shareholder advisory firms  Institutional Shareholder Services LP and Glass Lewis   Co  earlier this month threw their support behind Allergan s management by recommending that investors vote against Appaloosa s proposal  Allergan  under pressure to bolster its sagging stock price  launched a review of its strategy last year  That review is only likely to result in the sale of its relatively small infectious disease unit  Appaloosa has voiced its discontent with the results of the review and has called for a breakup or sale of the company  citing recent clinical failures such as that of Allergan s depression treatment rapastinel  Saunders was instrumental in putting Allergan together through a series of deals with companies including Forest Laboratories Inc and  Actavis  Plc   
But Saunders  biggest deal  Allergan s  160 billion sale to  Pfizer  Inc  NYSE PFE  was killed in 2016 after the U S  President Barack Obama s administration changed the rules on corporate tax inversions  Allergan s shares have lost nearly half their value since then ",2019-04-30,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-prevail-in-vote-over-ceo-saunders-chairman-role-sources-1851763,1851763
104384,325899,AGN,Allergan CEO Saunders wins vote to keep chairman role,news,"NEW YORK  Reuters    Allergan  NYSE AGN  Plc shareholders have voted down a proposal to order the immediate split of the roles of chairman and chief executive  with 61 3 percent of shareholders backing Chairman and CEO Brent Saunders  Billionaire investor David Tepper s hedge fund Appaloosa LP made the proposal  arguing that Allergan currently has a questionable business strategy and excessive pay for executives  Proxy advisory firms backed keeping the current structure  However  Appaloosa s success in attracting the votes of a substantial minority highlights the displeasure of many investors  The voting results represent 85 9 percent of shares eligible to vote  Allergan said in a statement on Wednesday  Allergan  under pressure to rescue the company s falling stock price  launched a review of its strategy last year  But that review is only likely to result in the sale of its relatively small infectious disease unit  Appaloosa has voiced its discontent with the results of the review  and has called for a breakup or sale of the company  citing recent clinical failures such as that of its depression treatment rapastinel  In an effort to fend off Appaloosa  Allergan agreed in March to split the chairman and CEO roles  but only at its next leadership change  Saunders  49  has no plans to step down  a source close to the company told Reuters then  Saunders put together the current version of Allergan through a series of deals to roll up several pharmaceutical companies in 2014  and has run the company since then  He built his reputation as a dealmaker  but he has struggled since  Pfizer  Inc  NYSE PFE  walked away from a  160 billion deal to buy Allergan in 2016  Allergan s shares have lost nearly half their value since then  
Reuters on Tuesday had reported that enough votes had been cast for Allergan to prevail against Appaloosa ",2019-05-01,Reuters,https://www.investing.com/news/stock-market-news/allergan-ceo-saunders-wins-vote-to-keep-chairman-role-1852108,1852108
104385,325900,AGN,Stocks   U S  Futures Head Lower Again on China Trade Jitters,news,"Investing com    U S  futures were set for another bumpy ride at the opening Tuesday  after China warned that it was ready to let trade talks with the U S  collapse   at least temporarily 
 The Chinese public wants an agreement  but meanwhile is well prepared for other potential outcomes  including a temporary breakdown in talks   said an editorial in the Global Times  an English language publication that regularly serves as a mouthpiece for official Chinese foreign policy 
The comments came after U S  Trade Representative Robert Lighthizer confirmed that the U S  will raise tariffs on  200 billion worth of Chinese imports from 10  to 25  as of Friday  a step that sharply escalates the trade dispute between the two countries after months of talks that appeared to be making progress in avoiding such an outcome 
Dow futures were down 125 points or 0 5  by 6 50 AM ET  1050 GMT   while S P 500 futures lost 15 points or 0 5  and the tech heavy Nasdaq 100 futures was down 46 points or 0 6  
The same concerns about trade wars and global growth led U S  crude oil futures to dip as low as  61 64 a barrel  down nearly 1  from late Monday 
 Overall  markets appear to be taking a sanguine view on the Trump China trade deal  tweets  after the initial  helter skelter    said Marc Ostwald  a strategist with ADM ISI in London  He suggested markets are interpreting President Trump s tweets as an attempt to  game  China in the final stages of the negotiation  and part of a routine aimed at squeezing maximum capital out of any deal that is ultimately agreed    even if the details of any deal that may be reached may well be very meagre fare  
Tuesday s earnings schedule is dominated by the health sector  with Allergan  NYSE AGN   Mylan  NASDAQ MYL  and Regeneron  NASDAQ REGN  all set to report before the open 
Earlier in Europe  Anheuser Busch Inbev  NYSE BUD  fell 2 1  after its first quarter sales and profit both fell short of expectations  due largely to currency headwinds  The company said it s looking at a partial sale of its Asian brewing operations through an IPO  in order to pay down a debt burden that investors still see as worryingly high 
Elsewhere in commodities  gold futures were little changed at  1 282 65 a troy ounce  while in the currency market  the U S  dollar index  which measures the greenback against a basket of six major currencies  was also effectively flat at 97 21 ",2019-05-07,Investing.com,https://www.investing.com/news/stock-market-news/stocks--us-futures-head-lower-again-on-china-trade-jitters-1858697,1858697
104386,325901,AGN,Allergan raises profit  sales forecasts on Botox boost,news," Reuters    Allergan  NYSE AGN  Plc reported a better than expected quarterly profit on Tuesday and raised its profit and revenue forecasts for the year  fueled by higher sales of its growth driver Botox  The company s medical aesthetics unit  which includes top seller Botox  brought in sales of  648 2 million for the quarter  a 2 percent rise from a year ago  Excluding items  the company earned  3 79 per share  well above the average analyst estimate of  3 55  according to Refinitiv IBES data  The company s net loss  however  widened to  2 41 billion in the first quarter  hit by a  2 5 billion charge related to the clinical failure of its depression treatment candidate rapastinel  The company had posted a loss of  332 5 million a year earlier  Revenue fell 2 percent to  3 59 billion but beat the average Wall Street estimate of  3 54 billion  The company said it now expects 2019 adjusted profit to be greater than  16 55 per share  compared with its prior expectation of profit greater than or equal to  16 36 per share  
Allergan now expects 2019 sales between  15 13 billion and  15 43 billion  compared with its prior forecast of  15 00 billion to  15 30 billion ",2019-05-07,Reuters,https://www.investing.com/news/stock-market-news/allergan-reports-bigger-firstquarter-loss-on-25-billion-charge-1858735,1858735
104387,325902,AGN,Top Stock Reports For Booking Holdings  Allergan   Honda Motor Co ,opinion,"Tuesday  November 12  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Booking  NASDAQ BKNG  Holdings  BKNG   Allergan  NYSE AGN   AGN  and Honda Motor Co   HMC   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Booking Holdings  shares have underperformed the Zacks Internet Commerce industry year to date  10 1  vs  20 4    The Zacks analyst believes that a secular growth trend in the online travel booking market and growing mobile usage penetration are tailwinds 
Booking Holdings reported third quarter results  wherein both earnings and revenues have grown year over year on the back of improving gross bookings  Moreover  solid growth in the booked room nights and strong momentum across global accommodation space contributed well  Also  strong efforts toward ramping up of merchant business drove the top line growth further 
Moreover  the company s strong position in international markets and growth opportunities in the domestic market are major positives  However  continued softness in agency business of the company remains a headwind  Further  macro headwinds and increasing advertising spend are concerns 
 You can  
Shares of Allergan have gained 34 5  in the past six months against Zacks Generic Drugs industry s rise of 4 7   The Zacks analyst believes that Allergan s key products like Botox and new products such as Viberzi and Vraylar support sales 
Allergan also continues to deliver on its R D pipeline with some major product launches expected over the next couple of years  Biosimilars also represent significant opportunity  The acquisition by AbbVie  NYSE ABBV  could prove to be rewarding for Allergan s shareholders  Allergan s stock has outperformed the industry this year so far  
However  in 2019  sales are being hurt by loss of exclusivity of key drugs  product recalls  pricing pressure and currency headwinds  Its blockbuster eye drug  Restasis  is also expected to face generic competition this year  Meanwhile  new competition for key growth drivers  Botox  Restasis and Linzess  is a concern 
 You can  
Honda Motor s shares have gained 23 1  over the past three months against the Zacks Foreign Automotive industry s rise of 15 3   The Zacks analyst believes that focus on the development of EVs and self driving cars bodes well for the company  given the changing circumstances in the automobile industry 
The firm s frequent collaborations with companies like General Motors  NYSE GM  and Hitachi  among others  are expected to expand business and bolster prospects  Its healthy balance sheet  improving cash flows and investor friendly moves are other positives 
However  in anticipation of a slowdown in India and North America  along with a stronger yen  the company has narrowed sales and profit forecast for fiscal 2020  Further  high capex to develop advanced technologies may also limit its cash flows  Frequent recalls also remain a concern  As such  investors are recommended to wait for a better entry point 
 You can  
Other noteworthy reports we are featuring today include BCE Inc   BCE   Infosys  INFY  and Activision Blizzard  NASDAQ ATVI   ATVI  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look 

Mark VickerySenior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Solid Gross Bookings Momentum Aids Booking Holdings  BKNG 


Allergan  AGN  Rides on Botox Sales  Generic Woes Remain


Honda s  HMC  Focus on Electric Cars to Aid Amid High Capex


Featured Reports
BCE to Benefit from Wireless   Wireline Subscriber Growth
Per the Zacks analyst  BCE is likely to benefit from customer growth and higher contribution from prepaid services  along with increase in business IP broadband connectivity and service solutions 

Infosys  INFY  Rides on Digital Business and Partnerships
Per the Zacks analyst  Infosys is benefiting from digital services growth  which is helping it win customers  Its partnership with the likes of Google  NASDAQ GOOGL  Cloud  Adobe  NASDAQ ADBE    Amazon  NASDAQ AMZN  Web Services is a tailwind 

Growth in Famous Franchises  E Sports Aids Activision  ATVI 
Per the Zacks analyst  Activision s foray into e sports and user base expansion from strength in popular franchises bodes well for its growth prospects 

TD Ameritrade  AMTD  Records High Trading Volumes and Revenue
The Zacks analyst believes TD Ameritrade is poised to growth through improving trading activities as DARTs expected to rise 

Match Group  NASDAQ MTCH  Rides on Solid Tinder Adoption   Buyouts
Per the Zacks analyst  Match Group is benefiting from increasing subscriber base  driven by solid contribution from Tinder 

Core CVI Arm Aids Cooper  COO   Soft Fertility Sales Ail
Cooper has been gaining consistently from solid prospects of its core CVI segment  The Zacks Analyst is apprehensive about softness in the company s Fertility sales 

Omnicare s Global Uptake  New FDA Nods Buoy Insulet  PODD 
The Zacks analyst is bullish about Insulet s steady global rollout of Omnipod systems across all international geographies 

New Upgrades
Solid End Market Prospects to Aid Quanta Services  NYSE PWR 
Per the Zacks analyst  solid end market prospects across its business segments  namely Electric Power and Pipeline and Industrial Infrastructure  to drive growth for Quanta Services 

CyberArk  CYBR  Benefits From Strategic Buyouts   Deal Wins 
Per the Zacks analyst  CyberArk is gaining from its strategic acquisitions like Conjur and Vaultive  Moreover  deal wins from advisory firms and U S  military and intelligence agencies are a tailwind 

Groupon  GRPN  Rides on Strategic Deals   Product Rollouts
Per the Zacks analyst  Groupon s partnership with Grubhub and ParkWhiz along with ongoing brand awareness programs will aid revenues  Further  launching new products on a regular basis is a positive 

New Downgrades
Dr  Reddy s  RDY  Sales Affected by Price Erosion In Generics Market
Per the Zacks analyst  Dr  Reddy s sales will be hurt by the price erosion in the North America generics market  Moreover  the European market is also witnessing high price erosion in some of the key 

Insperity  NSP  Hurt by Increasing Expenses  Competition
Per the Zacks analyst  Insperity s bottom line is under pressure due to increased expenses related to investment in technology and products  Intense competition remains another concern 

Soft International Sales Likely to Hurt Papa John s  PZZA 
Per the Zacks analyst  softer revenues in the international segment likely to hurt Papa John s top line  Higher costs pertaining to technology remains an added concern  
undefined undefined",2019-11-12,Zacks Investment Research,https://www.investing.com/analysis/top-stock-reports-for-booking-holdings-allergan--honda-motor-co-200484739,200484739
104388,325903,AGN,Editas  EDIT  Beats On Q3 Earnings  Amends Celgene Deal,opinion,"Editas Medicine  Inc    NASDAQ EDIT   incurred a loss of 66 cents per share in the third quarter of 2019  narrower than the Zacks Consensus Estimate of 73 cents but wider than the year ago quarter s loss of 32 cents Collaboration and other research and development revenues comprising the company s total revenues came in at  3 8 million  down 73 8  year over year  Meanwhile  sales were almost in line with the Zacks Consensus Estimate of  4million Editas has no approved product in its portfolio at the moment  The company generates collaboration revenues and other research and development revenues  Its collaboration revenues declined in the quarter due to lower revenues recognized under its collaboration with Allergan   NYSE AGN    In the third quarter of 2018  Allergan exercised its option to develop and commercialize Editas  lead pipeline candidate EDIT 101 globally  which resulted in higher revenues in the period In the reported quarter  research and development expenses were  22 7 million  up 30 5  from the year ago period s figure due to increased process and platform development costs  General and administrative expenses also rose 18 1  to  15 7 million due to higher professional services costs Amendment of Collaboration With CelgeneThe company has a collaboration and licensing deal with Juno Therapeutics  now part of Celgene   NASDAQ CELG    to develop autologous and allogeneic engineered alpha beta T cell medicines for treating cancer and  and autoimmune diseases  Along with the earnings release  Editas announced an amended agreement with Celgene to focus on engineered alpha beta T cell medicines  The original collaboration covered the entire field of engineered T cells  With this amendment  Celgene will focus on alpha beta T cells while Editas regained rights to develop non alpha beta T cells in all disease areas  For the amendment  Editas will receive a  70 million payment from Celgene and will also be entitled to future milestones and royalties Following the better than expected earnings results and the favorable amendment to the Celgene deal  Editas  shares rose 10  on Tuesday   This year so far  the stock has declined 1 9  against the  s increase of 1 1    Pipeline UpdateEDIT 101 uses CRISPR gene editing to treat Leber congenital amaurosis type 10  LCA10   a rare genetic illness that causes blindness  Editas is developing EDIT 101 in partnership with Allergan  Both companies plan to initiate patient dosing in the phase I II dose escalation study of Brilliance on EDIT 101 for LCA10 in early 2020  However  this is slightly delayed from the prior expectation of second half 2019  The Brilliance study opened for patient enrolment in July Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10 including Usher Syndrome type 2A  USH2A  and the recurrent ocular Herpes Simplex Virus type 1  HSV 1  fibrosis  It expects to be ready for investigational new drug  IND  enabling activities for a USH2A program by this year end The company is also designing novel medicines for non malignant hematologic diseases  such as sickle cell disease and beta thalassemia  It initiated IND enabling activities for EDIT 301  an experimental CRISPR medicine designed to treat sickle cell disease and beta thalassemia by editing the beta globin locus In the reported quarter  Editas signed a collaboration with AskBio  a leader in AAV gene therapy  to develop in vivo CRISPR medicines for the treatment of neurological diseases Genomic editing using CRISPR technology to repair a defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations seen in decades  There are only a few companies making medicines using this revolutionary technology  Other than Editas  companies  namely CRISPR Therapeutics AG   NASDAQ CRSP   and Intellia Therapeutics are either planning to conduct or already started clinical studies to develop curative CRISPR Cas9 based medicines Editas currently carries a Zacks Rank  4  Sell   Editas Medicine  Inc  Price  Consensus and EPS Surprise
    
 
You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-11-12,Zacks Investment Research,https://www.investing.com/analysis/editas-edit-beats-on-q3-earnings-amends-celgene-deal-200484955,200484955
104389,325904,AGN,4 Big Drugmakers To Bet On After A Great Earnings Season,opinion,"Third quarter earnings performance of the big drugmakers has mostly been better than expected  J J   NYSE JNJ    Bristol Myers Merck  Novartis  Pfizer   NYSE PFE    AstraZeneca  AbbVie   NYSE ABBV   beat estimates for both earnings and sales  Lilly and Sanofi  PA SASY  beat the Zacks Consensus Estimate for earnings but missed the same for sales  Allergan  NYSE AGN  met estimates for earnings while beating the same for sales Overall  new drugs and label expansions of blockbuster drugs drove the top line of most of the big shots backed by higher demand  which countered headwinds from generic biosimilar competition for older medicines  However  greater pricing pressure in the United States increased competition and negative currency impacts hurt the top line  Importantly  the better than expected results coupled with an optimistic outlook for the fourth quarter led most of the companies to raise financial guidance for the year  buoying investor optimism The Zacks industry  comprising some of the biggest drugmakers in the world  has risen 4 7  since Oct 15  after J J reported its earnings results   the first for the big pharma sector  Please note that the sector was down 0 8  from Jan 1 till Oct 14  This clearly indicates how the solid third quarter performance gave an impetus to stocks in this industry Moreover  the industry belongs in the top 30  of the 254 Zacks ranked industries and there are many stocks in the industry  which can boost investors  portfolio The sector faces headwinds like government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and most importantly  major pipeline setbacks Nonetheless  we believe increase in product sales backed by rising demand  pipeline success  frequent FDA approvals  35 new drugs approved so far in 2019   cost cutting  share buybacks  product launches  higher M A and collaboration activity and appropriate utilization of cash will boost the sector In this scenario  investing in stocks with a large market cap is a prudent move  given the fact that they control a large portion of the industry Here we have highlighted four bigshot drugmakers  which may prove to be good buys  These Zacks Rank  2  Buy  stocks have outperformed the industry so far this year and witnessed positive estimate revisions in the past 60 days You can see  A chart showing the share price movement of the four stocks and the Large Cap Pharmaceuticals industry this year so far is given below   4 Stocks to BuyMerck   NYSE MRK  Shares of Merck have risen 10 7  this year so far  Earnings estimates for 2019 and 2020 have risen 5 1  and 1 9   respectively over the past 60 days A significant part of Merck s outperformance this year so far has been driven by its PD 1 inhibitor  Keytruda  and positive regulatory updates related to it  Keytruda is continuously growing and expanding into new indications and markets globally  The drug generated sales of almost  8 billion in the first nine months of 2019  reflecting a massive 63  surge year over year The Keytruda development program is also progressing well with Merck spending billions for research and development of this medicine to secure more approvals in earlier lines of treatment  Undoubtedly  Keytruda has strong growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwide  In addition  Merck s other new products  Lynparza  and Bridion are contributing meaningfully to its top line The company has also been on a strong footing in terms of collaborations and M A activity  Merck s animal health and vaccine products are also performing well and remain core growth drivers Glaxo   NYSE GSK  Glaxo s earnings estimates have increased 6 2  for 2019 and 2 0  for 2020 over the past 60 days  The company s shares have rallied 14 8  this year so far Glaxo s three newest products approved in 2017   Trelegy Ellipta  Shingrix and Juluca   did well in 2018 and so far in 2019  particularly Shingrix  In fact  these new products coupled with the restructuring in the Consumer Health unit strengthened Glaxo s competitive position  It has also made significant progress with its late stage pipeline  The company has had major positive data read outs on multiple new medicines in HIV  oncology  immuno inflammation and respiratory in 2019  Glaxo has also made significant progress in its oncology pipeline recently and now has 16 assets in development  up from 8 as of July 2018  Meanwhile  Glaxo now has a number of molecules with diverse mechanisms of action  offering an opportunity for many innovative cancer combinations The company has its share of challenges in the form of stiff competition  genericization and pricing pressure on key drugs in the Pharma segment  Nonetheless  higher sales of new products  pipeline success and accretive deals are expected to keep the stock afloat through the rest of the year Bristol Myers   NYSE BMY  Bristol Myers  earnings estimates have increased 2 6  for 2019 and 2 7  for 2020 over the past 60 days  The stock has returned 12 6  so far in 2019 Bristol Myers  lead immuno oncology drug  Opdivo  continues to drive growth  Label expansion of the drug into additional indications should boost the top line in the future  Its multiple myeloma drug  Empliciti and leukemia medicine  Sprycel are also performing well on label expansions  Moreover  Bristol Myers has presence in other core therapeutic areas  including immunoscience and cardiovascular  Blood thinner drug  Eliquis  is also expected to drive further growth  Meanwhile  the impending acquisition of Celgene  NASDAQ CELG  will broaden the company s oncology portfolio with the addition of Revlimid Novo Nordisk   NYSE NVO  Shares of Novo Nordisk  CSE NOVOb  have risen 25 7  this year so far  Earnings estimates for 2019 and 2020 have jumped 0 8  and 1 0   respectively  over the past 60 days Novo Nordisk has one of the broadest diabetes portfolios in the industry  A solid performance from Tresiba  Victoza  Ozempic  Xultophy and Saxenda drove the company s sales in the year so far  Label expansion of Victoza continues to boost performance  Its newest diabetes injection  Ozempic  continues to gain market share  The FDA recently approved semaglutide in tablet form under the brand name  Rybelsus  which should bring in more sales  Large Cap Pharmaceuticals Industry 5YR   Return
  
Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-11-15,Zacks Investment Research,https://www.investing.com/analysis/4-big-drugmakers-to-bet-on-after-a-great-earnings-season-200485564,200485564
104424,325939,AGN,Appaloosa renews call to separate chairman  CEO roles at Allergan,news," Reuters    Hedge fund Appaloosa LP has urged Allergan  NYSE AGN  Plc s board to separate the roles of chairman and chief executive officer  it said on Tuesday  a year after making a similar effort  The David Tepper led hedge fund has a 0 59 percent stake in the drugmaker  according to Refinitiv data  Last week  Allergan shelved plans to sell its women s health business  which it had put on the block in May along with its infectious disease unit to focus on its core businesses  Analysts have said that Allergan is ripe for reentry of shareholder activism following a disappointing earnings report last week   In the wake of last Tuesday s earnings call     it should by now be readily apparent to all interested and responsible parties that Allergan requires a fresh approach to its business strategy and an unbiased review of its capabilities  opportunities  and way forward   Appaloosa President Tepper said in a letter to Allergan s board  The company did not immediately respond to Reuters  request for comment  
Allergan s shares have fallen about 20 percent over the past 12 months ",2019-02-05,Reuters,https://www.investing.com/news/stock-market-news/appaloosa-renews-call-to-separate-chairman-ceo-roles-at-allergan-1769650,1769650
104425,325940,AGN,Growing field of activist investors pushes companies to perform better,news,By Svea Herbst Bayliss BOSTON  Reuters    More investors who typically make passive bets flexed their muscles last year and helped push a total of 922 companies to perform better by improving operations and capital allocation  data from research group Activist Insight show  The data show that 922 companies were approached last year compared with 856 companies approached in 2017 by investors who had ideas on how management could run the business better or who asked for board seats  So called occasional activists were the most pushy last year  contacting 266 companies with public demands  the data show  In 2017 they reached out to 240 companies  These investors are typically passive shareholders who try to protect existing investments by demanding improvements at underperforming companies  The numbers also show that only 116 companies were contacted by primary focus activists  the large hedge funds that have made their reputations over the years by pushing for change at companies from Allergan  NYSE AGN  to Yahoo   NASDAQ AABA    More entrants into the activism space does limit the options for the big name activists   said Josh Black  an analyst at Activist Insight  which tracks activist fund managers and their activities  Activist Insight worked with law firm Schulte Roth   Zabel to compile its annual review  To be sure many primary focus activists like Starboard Value  Pershing Square  NYSE SQ  Capital Management and Third Point were busy in 2018 targeting companies ranging from Newell Brands to United Technologies  NYSE UTX  to Campbell Soup   But as a group  primary focus activists targeted only 116 companies in 2018 after having reached out to 121 companies in 2017  This made them the least pushy last year  the data show  And the brand name activists are still commanding attention from corporate chiefs  Elliott Management  one of the biggest firms to pursue activist strategies  was busier than ever in 2018 and launched 24 new campaigns  And Starboard won 29 seats through negotiated settlements in 2018  Referring to these types of firms who started 2019 on a busy note  Schulte Roth partner Eleazer Klein said pure play activists will always be around and working   These people are not going away   And they will raise money even amid poor returns where the average activist hedge fund lost roughly 11 percent last year   Fund raising is certainly more challenging especially when firms are not performing  But I don t think these types of firms will have problems  ,2019-02-05,Reuters,https://www.investing.com/news/stock-market-news/growing-field-of-activist-investors-pushes-companies-to-perform-better-1769745,1769745
104426,325941,AGN,Allergan should explore selling itself  Appaloosa s Tepper,news," Reuters    Billionaire hedge fund manager David Tepper stepped up pressure on Allergan  NYSE AGN  Plc  saying on Tuesday the drugmaker should consider selling itself if management is unable to turn around recent lagging performance  Tepper s hedge fund Appaloosa LP wrote to Allergan s board  just hours after the Botox maker announced it added a former industry executive to its board but would split the roles of chairman and chief executive only when the person who now holds the positions is replaced   While we appreciate the input of Appaloosa as we do all of our shareholders  we strongly disagree that an immediate separation of the CEO and Chair positions is warranted   Allergan s board said in a statement  Appaloosa has since last year pressed Allergan to separate the roles   currently held by Brent Saunders  who joined the company in 2014   and recruit an outsider to oversee its board   If in fact  Allergan s  Board is unable or unwilling to hold management accountable for its shortcomings or find a suitable replacement  it is your fiduciary obligation to explore other options  including a merger or sale of the Company   Tepper said in the letter  Splitting the chairman and CEO roles has become a favorite call for some investors who feel it would help companies be run better  Earlier this month Appaloosa argued that by adding an independent chairman  Saunders might receive the help he needs to improve returns  Allergan  however  said on Tuesday implementing Appaloosa s recommendations would be  highly disruptive  to the company s operations and impact Saunders  ability to continue to execute its current strategy  Appaloosa  which oversees about  12 billion  cut its stake in Allergan by some 42 percent to nearly 1 2 million shares at the end of December  regulatory filings showed last week  Allergan s shares have been lagging those of its industry peers   they have fallen 15 percent over the past year   since it dropped plans to sell some businesses  gave a disappointing revenue outlook for 2019 and as it faces rising competition for several important drugs  
The company earlier on Tuesday named Robert Hugin  a former CEO of U S  drugmaker Celgene  NASDAQ CELG   as a director  saying the appointment reflected its commitment to  active board refreshment  ",2019-02-19,Reuters,https://www.investing.com/news/stock-market-news/appaloosas-tepper-says-allergan-should-consider-selling-itself-1783594,1783594
104427,325942,AGN,Appaloosa steps up pressure on Allergan after failed drug trials,news," Reuters    Hedge fund Appaloosa LP on Thursday repeated its call for an independent chairman at Allergan  NYSE AGN  Plc  after the Botox producer revealed that one of its drugs had failed three clinical studies  Allergan announced on Wednesday that rapastinel  its depression treatment  had failed to meet clinical goals in three late stage trials  spurring concerns among analysts over the drugmaker s pipeline of products   With this latest fiasco  we again call on the Company to install an independent chairman with suitable experience to bring new leadership to the Board and rein in management s predilection for value destruction   Appaloosa said  The hedge fund  led by billionaire David Tepper  has also said Allergan should consider selling or separating itself  and demanded that it split the role of chairman and chief executive officer  Implementing Appaloosa s recommendations would be  highly disruptive  to its operations  Allergan has said   The Board s misplaced fear of  disrupting  Allergan is wearing thin as an excuse for inaction and can only perpetuate further erosion in the shareholders  investment   Appaloosa added on Thursday  Allergan did not immediately respond to a request for comment  
Its shares have been lagging those of its industry peers on account of abandoned plans to sell some businesses  a disappointing 2019 revenue forecast and rising competition for several important drugs ",2019-03-07,Reuters,https://www.investing.com/news/stock-market-news/appaloosa-steps-up-pressure-on-allergan-after-failed-depression-drug-trials-1800942,1800942
104428,325943,AGN,Allergan  AGN  Hits 52 Week High  Can The Run Continue ,opinion,"Have you been paying attention to shares of Allergan plc  NYSE AGN   Shares have been on the move with the stock up 5 3  over the past month  The stock hit a new 52 week high of  179 52 in the previous session  Allergan plc has gained 31 8  since the start of the year compared to the 3 8  move for the Zacks Medical sector and the 0 3  return for the Zacks Medical   Generic Drugs industry 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on August 6  2019  Allergan reported EPS of  4 38 versus consensus estimate of  4 34 while it beat the consensus revenue estimate by 3 89  
For the current fiscal year  Allergan is expected to post earnings of  16 7 per share on  15 56 billion in revenues  This represents a 0 06  change in EPS on a  1 45  change in revenues  For the next fiscal year  the company is expected to earn  16 85 per share on  15 83 billion in revenues  This represents a year over year change of 0 88  and 1 76   respectively 
Valuation Metrics
Allergan may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level 
On this front  we can look at the Zacks Style Scores  as they provide investors with an additional way to sort through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
Allergan has a Value Score of B  The stock s Growth and Momentum Scores are C and B  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 10 7X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 4 8X versus its peer group s average of 4 7X  Additionally  the stock has a PEG ratio of 2 11  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to consider the stock s Zacks Rank  as this supersedes any trend on the style score front  Fortunately  Allergan currently has a Zacks Rank of  2  Buy  thanks to favorable earnings estimate revisions from covering analysts 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if Allergan passes the test  Thus  it seems as though Allergan shares could have a bit more room to run in the near term ",2019-11-03,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-hits-52week-high-can-the-run-continue-200481807,200481807
104429,325944,AGN,The Zacks Analyst Blog Highlights  Pfizer  Merck  Bristol Myers And Glaxo,opinion,For Immediate ReleaseChicago  IL   November 4  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Pfizer   NYSE PFE    Merck   NYSE MRK    Bristol Myers   NYSE BMY   and Glaxo   NYSE GSK   Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  MRK  PFE  GSK and MorePfizer  Merck  Bristol Myers  Glaxo and Bayer  DE BAYGN  released their third quarter results this week  In other important news  AstraZeneca s  AZN  first line lung cancer study on Imfinzi showed positive results  Recap of the Week s Most Important Stories  Earnings Update       and beat estimates for both earnings and sales  Higher sales of some of Pfizer s key brands like Eliquis  Ibrance  Inlyta and Xeljanz were offset by lower sales of Lyrica due to loss of exclusivity in July 2019 in the United States  Merck s blockbuster cancer drug  Keytruda continued its robust performance on strong demand   Both Merck   Pfizer raised their earnings guidance for 2019 while tightening the same for revenues  Strong performance of relatively newer vaccine and respiratory products boosted Glaxo s sales  Glaxo raised its 2019 adjusted earnings growth expectations to around flat at CER from a decline of 3  to 5  expected previously Bristol Myers  sales growth of 6  was led by robust sales of Eliquis and Sprycel while sales growth of its PD 1 inhibitor  Opdivo was weak  The company raised its guidance range for earnings s third quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales  Double digit growth in Sanofi s Specialty Care unit was offset by a weak performance in the Consumer Healthcare and Vaccines units in the quarter s sales increased 5 4  on an organic basis in the quarter  All the three segments  Crop Science  Pharmaceuticals and Consumer Health  witnessed higher sales AstraZeneca s Imfinzi Combo Meets Goal in First Line Lung Cancer Study   AstraZeneca s phase III POSEIDON study evaluating Imfinzi plus platinum based chemotherapy or the triple combination of Imfinzi plus tremelimumab and chemotherapy in first line treatment of patients with metastatic  non small cell lung cancer  NSCLC  met the primary endpoint  Imfinzi plus multiple choices of chemotherapy regimens led to a statistically significant and clinically meaningful improvement in the final progression free survival  PFS  analysis in such patients versus chemotherapy alone  thereby meeting the study s primary endpoint  The triple regimen of Imfinzi plus tremelimumab and chemotherapy also met the key secondary endpoint by demonstrating a statistically significant and clinically meaningful PFS improvement  versus chemotherapy alone  The study continues to assess the co primary endpoint of overall survival with data expected to be presented next year AstraZeneca also announced an agreement to sell rights to Seroquel and Seroquel XR  a treatment for schizophrenia and bipolar disease  in Europe and Russia to Cheplapharm Arzneimittel GmbH J J  NYSE JNJ  Says Tests Find No Asbestos in Baby Powder J J announced that 15 new tests conducted on the same bottle of Johnson s Baby Powder that was previously tested by the FDA  found no asbestos  a known carcinogen  The product is the subject of numerous lawsuits  which claim that J J s talc based products contain asbestos that causes cancer  Earlier this month  J J announced a voluntary recall of one lot of its Johnson s The recall was initiated following a test done by the FDA  which revealed traces of asbestos in samples from one bottle purchased online  J J also said that an additional 48 independent third party lab tests of samples from the same lot that was recalled also confirm that the talc does not contain asbestos Pfizer Gets EU Nod for Bavencio Inlyta Combo in Kidney Cancer  Pfizer and partner Merck KGaA gained approval from the European Commission for Bavencio  avelumab  in combination with Inlyta  axitinib  for the first line treatment of patients with advanced renal cell carcinoma  RCC   the most common form of kidney cancer  The combination of Bavencio and Inlyta received approval in the United States for a similar indication in May  In January  a similar application had been submitted in Japan   Glaxo Begins Phase III Program on New Antibiotic  Glaxo announced initiation of patient dosing in a phase III program on its investigational oral antibiotic  gepotidacin  which Glaxo claims has mechanism of action distinct from any currently approved antibiotic  The program will comprise two studies with one evaluating the use of gepotidacin for uncomplicated urinary tract infection and the other for urogenital gonorrhea  a common sexually transmitted infection Meanwhile  the European Commission gave approval to the intravenous formulation of Benlysta for systemic lupus erythematosus in children aged five years and above  The intravenous formulation is already approved in EU as well as the United States for adults while it was approved in the United States for children in April The NYSE ARCA Pharmaceutical Index rose 3 3  in the last five trading sessions Here is how the seven major stocks performed in the last five trading sessions Last week  all the stocks were in the green supported by strong third quarter results of most companies in the sector  Lilly was the biggest gainer  5 6   In the past six months  AstraZeneca has risen the most  30 3   while J J lost the most  6 5   mainly due to its litigation issues  See the last pharma stock roundup here  What s Next in the Pharma World Watch out for third quarter results of Novo Nordisk  CSE NOVOb  and Allergan  NYSE AGN  and regular pipeline and regulatory updates next week 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-11-03,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-pfizer-merck-bristolmyers-and-glaxo-200481906,200481906
104430,325945,AGN,Allergan  AGN  Q3 Earnings Meet Estimates,opinion,"Allergan  NYSE AGN  came out with quarterly earnings of  4 25 per share  in line with the Zacks Consensus Estimate  This compares to earnings of  4 25 per share a year ago  These figures are adjusted for non recurring items 
A quarter ago  it was expected that this Botox maker would post earnings of  4 34 per share when it actually produced earnings of  4 38  delivering a surprise of 0 92  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Allergan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  4 05 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 4 01   This compares to year ago revenues of  3 91 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Allergan shares have added about 33 8  since the beginning of the year versus the S P 500 s gain of 22 8  
What s Next for Allergan 
While Allergan has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Allergan was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 31 on  3 97 billion in revenues for the coming quarter and  16 70 on  15 55 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the top 24  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-q3-earnings-meet-estimates-200482208,200482208
104431,325946,AGN,Aerie  AERI  Q3 Loss Wider  Sales Beat  Guidance Slashed,opinion,Aerie Pharmaceuticals  Inc    NASDAQ AERI   reported mixed results for the third quarter of 2019  The company lowered its annual revenue guidance  Consequently  shares are down in after market trading Notably  Aerie s stock has plunged 34  in the year so far against the  s growth of 3 7  The company reported a loss of 86 cents per share in third quarter 2019  wider than the Zacks Consensus Estimate of a loss of 84 cents  The loss in the year ago quarter was  1 73 per share The company s first drug Rhopressa  netarsudil ophthalmic solution  is approved for the reduction of elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension  Aerie s second drug  Rocklatan  a once daily  quadruple action  fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  is approved to reduce elevated IOP in patients with open angle glaucoma or ocular hypertension Sales from both drugs came in at  18 5 million in the quarter  beating the Zacks Consensus Estimate of  18 million and increasing from  7 3 million in the year ago quarter  Sequentially  revenues were up 17 1  Quarter in DetailTotal operating expenses  excluding stock based compensation expenses  in the quarter were  49 2 million  down from  58 5 million in the year ago quarter Pipeline UpdateIn September  the European Medicines Agency s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of the marketing authorization application for Rhokiinsa  the name for Rhopressa in Europe  0 02   A final decision from the European Commission is expected in the fourth quarter of 2019  The phase III trial  Mercury 3  designed to support the commercialization of Rocklatan in Europe  continues to progress Aerie s retina program  evaluating AR 13503  Rho kinase and Protein kinase C inhibitor implant  and AR 1105  dexamethasone steroid implant   continues to advance as well   In March  a phase II study was initiated on AR 1105 for macular edema due to retinal vein occlusion and the study is fully enrolled ahead of schedule  A study on AR 13503  Rho kinase and Protein kinase C inhibitor implant  commenced in August for wet age related macular degeneration and diabetic macular edema 2019 GuidanceAerie lowered its annual revenue guidance  The company expects full year 2019 net revenues of  61  66 million  down from the previous guidance of  70  80 million  as volumes have been lower than expected Our TakeThough Aerie reported mixed results for the third quarter  the slashed guidance was disappointing  The volumes have not picked up as the company had projected  Also  competition is stiff from the likes of Allergan s   NYSE AGN   Lumigan and Bausch Health s   NYSE BHC   Vyzulta  among others Zacks Rank Aerie currently carries a Zacks Rank  3  Hold   You can seeWall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-11-06,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-q3-loss-wider-sales-beat-guidance-slashed-200483526,200483526
104432,325947,AGN,Pharma Stock Roundup  AGN  NVO Q3 Earnings  FDA Nod To SNY   NVS  Products,opinion,It was a relatively quieter week for the pharma sector  barring the earnings reports of Novo Nordisk   NYSE NVO   and Allergan   NYSE AGN    The FDA approved Sanofi s   NASDAQ SNY   Fluzone Quadrivalent flu vaccine for adults 65 years and above and Novartis    NYSE NVS   long acting biosimilar version of Amgen s febrile neutropenia medicine  Neulasta Recap of the Week s Most Important Stories  Earnings Update   reported decent third quarter results  meeting estimates for earnings while beating the same for sales  Revenues rose 3 6  from the year ago quarter as higher sales of key products like Botox  cosmetic and therapeutics   Juv derm collection of fillers  Vraylar  Ozurdex  and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others  It slightly raised its sales guidance for 2019 while maintaining the previously issued earnings view  missed estimates for sales while beating the same for earnings in the third quarter  Sales in the Diabetes and Obesity Care segment increased 5  at constant exchange rate  CER  while that in the Biopharmaceuticals segment increased 6   Novo Nordisk raised its sales growth expectations from a range of 4 6  at CER to a range of 5 6  at CER FDA Approves Sanofi s Quadrivalent Flu Vaccine for Older Adults  The FDA granted approval to Sanofi s influenza vaccine  Fluzone High Dose Quadrivalent for use in adults 65 years and above  Fluzone High Dose is presently marketed as a trivalent influenza vaccine  including two influenza A strains and one influenza B strain  The FDA approval of the Fluzone High Dose Quadrivalent vaccine expands protection for an additional influenza B strain  The new quadrivalent vaccine is expected to be available in fall 2020  in time for the 2020 2021 flu season Sanofi  PA SASY  also presented data from a phase III study  EDITION JUNIOR  evaluating Toujeo  insulin glargine 300 Units mL  in children and adolescents with type 1 diabetes  The data showed that the group of patients administered Toujeo achieved comparable reduction in average blood sugar  HbA1c  and similar risk of low blood sugar events compared to insulin glargine 100 Units mL  Meanwhile  the percentage of patients who experienced severe hypoglycemia  and the percentage with hyperglycemia with ketosis were numerically lower with Toujeo Sanofi also said that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use gave a positive opinion  recommending expansion of Toujeo s indication in Europe to allow use in adolescents and children based on EDITION JUNIOR study data Sandoz Gets FDA Nod for Long Acting Neulasta Biosimilar  Novartis  generic subsidiary Sandoz gained FDA approval for Ziextenzo  its long acting biosimilar version of Amgen s febrile neutropenia medicine  Neulasta  filgrastim   Sandoz already markets Ziextenzo in Europe as well as a short acting filgrastim biosimilar  Zarxio  in the United States With the approval of Ziextenzo  Sandoz becomes the only company  which offers long  as well as short acting filgrastim biosimilar treatment options  Sandoz will launch Ziextenzo in the United States this year J J Files for Ebola Vaccine in EU  J J   NYSE JNJ   submitted a marketing application to the EMA seeking approval for its two dose investigational Ebola vaccine regimen  J J has developed the vaccine for the prevention of Ebola Virus caused by Zaire strain Novo Nordisk Buys Rights to NASH Candidate  Novo Nordisk obtained an exclusive worldwide license to a potential NASH candidate  UD 014  from Japan s UBE Industries Ltd for an undisclosed upfront payment  Novo Nordisk will take care of future development commercialization of UD 014  which is now in pre clinical studies The NYSE ARCA Pharmaceutical Index declined 1 4  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   ReturnHere is how the seven major stocks performed in the last five trading sessions Last week  all the stocks were in the red except Bristol Myers   NYSE BMY    which rose 0 4   AstraZeneca lost the maximum value  4 5   In the past six months  AstraZeneca   NYSE AZN   has risen the most  22   while J J lost the most  9 1   mainly due to its litigation issues  See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-agn-nvo-q3-earnings-fda-nod-to-sny--nvs-products-200483911,200483911
104433,325948,AGN,Teva  TEVA  Q3 Earnings Miss  Stock Up On Guidance Increase,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   reported third quarter 2019 earnings of 58 cents per share  which missed the Zacks Consensus Estimate of 60 cents  Earnings per share also declined 14 7  year over year due to lower sales and operating profit and higher taxes Adjusted earnings excluded a  468 provision for legal settlements and loss contingencies mainly related to Teva s opoid litigation  impairment of intangible assets and product rights and amortization and restructuring charges Revenues came in at  4 26 billion  which beat the consensus estimate of  4 24 billion  Sales however declined 6   down 5  in constant currency terms  year over year On a year over year basis  generic erosion in sales of Teva s key multiple sclerosis injection  Copaxone  lower sales of other branded drugs  Bendeka Treanda  and soft performance of markets like Russia and Japan hurt the top line Also  negative currency impact due to the strengthening of the dollar hurt sales by  55 million and operating profits by  19 million in the quarter Segment DiscussionTeva reports under segments based on three regions   North America  United States and Canada   Europe and International Markets North America segment sales were  2 05 billion  down 9  year over year due to lower sales of Copaxone as well as Bendeka Treanda  In the United States  revenues declined 10  year over year to  1 91 billion Copaxone posted sales of  271 million in North America  down 41  year over year due to generic erosion  Copaxone revenues in the United States were  257 million Combined sales of Bendeka and Treanda declined 23  to  124 million Qvar sales surged 68  to  60 million in the quarter  ProAir sales declined 34  year over year to  71 million due to lower volumes and price  Teva launched its own ProAir HFA authorized generic for select customers in January 2019  following launch of generic versions of Glaxo s   NYSE GSK   albuterol inhaler Ventolin HFA  Sales of the authorized generic are included in Teva s Generics revenues Austedo  a new drug approved to treat chorea associated with Huntington s disease and tardive dyskinesia  recorded sales of  105 million in the quarter in North America compared with  96 million in the previous quarter  Teva s newest drug is its anti calcitonin gene related peptide   CGRP   injection  Ajovy  fremanezumab   approved as a preventive treatment for migraine Ajovy recorded sales of  25 million in the quarter compared with  23 million in the previous quarter  Teva said that Ajovy captured about 19  share of total prescription in the United States  However  it saw a decline in new prescription share  which management said was due to preference of patients for auto injectors while Ajovy is available as a subcutaneous injection Generic products revenues were almost flat at  914 million in the quarter as additional sales from the launch of generic products were offset by price erosion in the U S business and unfavorable product mix Teva has launched 39 new generic products this year so far including generic version of Mylan s   NASDAQ MYL   popular EpiPen Jr auto injector  0 15 mg  allergy treatmentOn the call  the company reiterated seeing stabilization of the generic pricing environment in the United States as well as Europe  which coupled with new generic launches  is strengthening these businesses Distribution revenues  generated by Anda  acquired from Allergan   NYSE AGN   in 2016  rose 5  in the quarter to  351 million The Europe segment recorded revenues of  1 16 billion  down 4   flat in constant currency terms  year over year as higher sales of generic products were offset by lower Copaxone revenues Generic products revenues in Europe declined 1  to  836 million due to currency headwinds   Excluding the impact of currency  sales rose 4  due to higher sales of OTC products and new generic launchesCopaxone sales declined 10  on a constant currency basis to  106 million due to price reductions  following the entry of generics Respiratory products sales in Europe segment declined 2  on a constant currency basis to  87 million mainly due to lower sales in the United Kingdom In the International Markets segment  sales rose 1   same in constant currency terms  to  736 million as lower sales in Japan and Russia were offset by higher distribution activities in Israel Generic products revenues declined 5  in constant currency terms to  474 million  Copaxone sales declined 46  to  20 million  Distribution revenues increased 15  in constant currency terms to  176 million in the quarterThe Other segment  API manufacturing business and certain contract manufacturing services  recorded revenues of  314 million  down 2  year over year  in constant currency terms Profits DeclineAdjusted gross margin declined 60 basis points  bps  to 49 3  in the quarter  Adjusted research   development expenses were flat year over year at  242 million as pipeline optimization and project terminations and resultant workforce reductions were offset by increased investment in early stage pipeline projects  Selling and marketing  S M  expenditure declined 13 1  from the year ago level to  551 million due to cost cutting and re structuring activities  General and administrative  G A  expenses declined 4 9  year over year to  270 million  Adjusted operating income declined 5  in the quarter to  1 05 billion due to lower profits in North America segment Lower End of 2019 View RaisedTeva raised the lower end of previously issued guidance for sales and earnings in 2019  The company expects revenues to be in the range of  17 2    17 4 billion compared with  17    17 4 billion expected previously  Earnings are expected in the band of  2 30 2 50 per share versus  2 20 2 50 per share expected previously  The earnings and sales guidance  however  indicates a decline from 2018 levels Adjusted operating income is expected to be between  4 0 billion and  4 2 billion in 2019  previously  3 8 billion and  4 2 billion   Free cash flow was guided in the range of  1 7  2 0 billion  previously  1 6  2 0 billion  New CFOTeva also named Eli Kalif as its new executive vice president and chief financial officer effective Dec 22  Eli Kalif  who previously served at Flex  a technology design and manufacturing company  will replace Michael  Mike  McClellan who resigned in August due to personal reasons Update on Opioid LitigationTeva faces several lawsuits  which claim that it is one of the several companies whose opioid based drugs were responsible for fueling nationwide opioid epidemic  In May  Teva agreed to pay  85 million to the state of Oklahoma s in this regard  Last month  it settled with two counties of Ohio  Cuyahoga and Summit  thereby resolving the counties  opioid claims  which removed Teva from the Track 1 opioid litigation Importantly  Teva has entered into a proposed nationwide settlement with attorneys general of the four states  which requires it to supply  23 billion worth of generic Suboxone and pay  250 million in cash over 10 years  On the third quarter conference call  Teva said that even if it has to pay for these settlements  it will not affect its ability to cut down debt Our TakeTeva s third quarter results were mixed as it missed earnings estimates but beat the same for sales  However  despite the earnings miss  the generic drugmaker raised the bottom end of its 2019 sales and earnings guidance  which led to a 5  increase in share price on Thursday  Teva s shares have declined 45 1  this year so far compared with the  s decrease of 3 2    Teva is facing significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business and a massive debt load However  Teva is progressing well on its restructuring plan to revive growth and is on track to meet its goal to save  3 billion by the end of 2019 from these initiatives with  2 9 billion already achieved since initiation of the restructuring plan in 2018  Its newest drugs  Austedo and Ajovy could emerge as significant contributors to long term sales growth  Importantly  portfolio optimization and new launches have steadied its North American and European generics business  It also has a more stable financial position than before However  resumption of organic growth seems unlikely until 2020  Meanwhile  the opioid litigation and investigations for price fixing are overhangs on the stock Currently  Teva has a Zacks Rank  2  Buy   You can see  
Teva Pharmaceutical Industries Ltd  Price and Consensus    
Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q3-earnings-miss-stock-up-on-guidance-increase-200483867,200483867
104434,325949,AGN,AbbVie Eyes Approval For Imbruvica Rituxan In First Line CLL,opinion,"AbbVie Inc    NYSE ABBV   and J J   NYSE JNJ   announced that they have submitted a supplemental new drug application  sNDA  seeking label expansion of their blood cancer drug  Imbruvica  The sNDA is seeking approval of Imbruvica in combination with Roche   OTC RHHBY   Biogen s   NASDAQ BIIB   monoclonal antibody  Rituxan  Rituximab   as a first line treatment of patients with chronic lymphocytic leukemia   CLL   or small lymphocytic lymphoma   SLL    who are 70 years old or younger The sNDA wasbased on positive data from the phase III E1912 study  which showed that treatment with the Imbruvica combination regimen significantly improved progression free survival and overall survival in the above patients compared to the FCR chemoimmunotherapy regimen The regulatory application is being reviewed by the FDA under its Real Time Oncology Review pilot program  which allows the regulatory body to initiate review clinical data before complete submission of any regulatory application  This is likely to expedite the review process for this sNDA  If approved for the combination use  it will be the 11th FDA approval for Imbruvica across six distinct disease areasA combination regimen of Imbruvica  Rituxan and Teva Pharmaceutical s Treanda  bendamustine  is already approved for previously treated CLL SLL patients  Moreover  Imbruvica is approved in previously untreated CLL SLL patients as monotherapy and in combination with Roche s Gazyva  The FDA granted an  for the Imbruvica Gazyva combo in January 2019 AbbVie s shares have declined 7 6  so far this year against the  s increase of 3 6  Imbruvica is a key drug in AbbVie s oncology franchise along with Venclexta   Oncology has become a key therapeutic area for AbbVie and the company believes that it will be its major driver over the next 10 years  Several studies on Imbruvica are underway to evaluate the drug alone or in combination across different patient segments  including cancer as well as autoimmune diseases  AbbVie is also studying Venclyxto Venclexta to expand its label to address a broader relapsed refractory CLL patient population  extend into earlier lines of therapy and cover other hematologic malignancies like multiple myeloma and acute myeloid leukemia In July  AbbVie  Seattle based  privately held company Mavupharma to develop novel treatments for cancer using the latter s STING signaling pathway and enhance its early stage oncology pipeline Moreover  in a bid to diversify its portfolio AbbVie announced an acquisition offer approximately worth  63 billion for Botox maker  in June  The company remains on track to complete the acquisition in the first quarter of 2020 AbbVie Inc  Price
    Zacks RankAbbVie currently carries a Zacks Rank  3  Hold  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/abbvie-eyes-approval-for-imbruvicarituxan-in-firstline-cll-200484326,200484326
104435,325950,AGN,The Zacks Analyst Blog Highlights  Novo Nordisk  Allergan  Sanofi  Novartis And JJ,opinion,For Immediate ReleaseChicago  IL   November 11  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Novo Nordisk   NYSE NVO    Allergan   NYSE AGN    Sanofi   NASDAQ SNY    Novartis   NYSE NVS   and J J   NYSE JNJ   Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  AGN  NVO  SNY and MoreIt was a relatively quieter week for the pharma sector  barring the earnings reports of Novo Nordisk and Allergan  The FDA approved Sanofi s Fluzone Quadrivalent flu vaccine for adults 65 years and above and Novartis  long acting biosimilar version of Amgen s febrile neutropenia medicine  Neulasta Recap of the Week s Most Important Stories  Earnings Update   reported decent third quarter results  meeting estimates for earnings while beating the same for sales  Revenues rose 3 6  from the year ago quarter as higher sales of key products like Botox  cosmetic and therapeutics   Juv derm collection of fillers  Vraylar  Ozurdex  and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others  It slightly raised its sales guidance for 2019 while maintaining the previously issued earnings view  missed estimates for sales while beating the same for earnings in the third quarter  Sales in the Diabetes and Obesity Care segment increased 5  at constant exchange rate  CER  while that in the Biopharmaceuticals segment increased 6   Novo Nordisk raised its sales growth expectations from a range of 4 6  at CER to a range of 5 6  at CER FDA Approves Sanofi s Quadrivalent Flu Vaccine for Older Adults  The FDA granted approval to Sanofi s influenza vaccine  Fluzone High Dose Quadrivalent for use in adults 65 years and above  Fluzone High Dose is presently marketed as a trivalent influenza vaccine  including two influenza A strains and one influenza B strain  The FDA approval of the Fluzone High Dose Quadrivalent vaccine expands protection for an additional influenza B strain  The new quadrivalent vaccine is expected to be available in fall 2020  in time for the 2020 2021 flu season Sanofi also presented data from a phase III study  EDITION JUNIOR  evaluating Toujeo  insulin glargine 300 Units mL  in children and adolescents with type 1 diabetes  The data showed that the group of patients administered Toujeo achieved comparable reduction in average blood sugar  HbA1c  and similar risk of low blood sugar events compared to insulin glargine 100 Units mL  Meanwhile  the percentage of patients who experienced severe hypoglycemia  and the percentage with hyperglycemia with ketosis were numerically lower with Toujeo Sanofi also said that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use gave a positive opinion  recommending expansion of Toujeo s indication in Europe to allow use in adolescents and children based on EDITION JUNIOR study data Sandoz Gets FDA Nod for Long Acting Neulasta Biosimilar Novartis  generic subsidiary Sandoz gained FDA approval for Ziextenzo  its long acting biosimilar version of Amgen s febrile neutropenia medicine  Neulasta  filgrastim   Sandoz already markets Ziextenzo in Europe as well as a short acting filgrastim biosimilar  Zarxio  in the United States With the approval of Ziextenzo  Sandoz becomes the only company  which offers long  as well as short acting filgrastim biosimilar treatment options  Sandoz will launch Ziextenzo in the United States this year J J Files for Ebola Vaccine in EU J J submitted a marketing application to the EMA seeking approval for its two dose investigational Ebola vaccine regimen  J J has developed the vaccine for the prevention of Ebola Virus caused by Zaire strain Novo Nordisk Buys Rights to NASH Candidate Novo Nordisk obtained an exclusive worldwide license to a potential NASH candidate  UD 014  from Japan s UBE Industries Ltd for an undisclosed upfront payment  Novo Nordisk will take care of future development commercialization of UD 014  which is now in pre clinical studies The NYSE ARCA Pharmaceutical Index declined 1 4  in the last five trading sessions Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-11-10,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-novo-nordisk-allergan-sanofi-novartis-and-jj-200484338,200484338
104472,325987,AGN,Drug companies greet 2019 with U S  price hikes,news,By Michael Erman NEW YORK  Reuters    Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs  including the world s top selling medicine  Humira  although the pace of price hikes was slower than last year  The industry has been under pressure by the U S  President Donald Trump to hold their prices level as his administration works on plans aimed at lowering the costs of medications for consumers in the world s most expensive pharmaceutical market  During a White House meeting with members of his Cabinet  U S  President Donald Trump on Wednesday said he expected to see a tremendous decrease in drug prices  Health and Human Services  HHS  Secretary Alex Azar was at the meeting  The overall number of price increases was down by around a third from last year  when drugmakers raised prices on more than 400 medicines  according to data provided by Rx Savings Solutions  which helps health plans and employers seek lower cost prescription medicines   Allergan  NYSE AGN  Plc was particularly aggressive  It raised list prices on more than 50 drugs  and more than half of those by 9 5 percent  according to the Rx Savings data   AbbVie Inc   NYSE ABBV  increased by 6 2 percent the list price of its blockbuster rheumatoid arthritis treatment Humira  which is on pace to record about  20 billion in sales in 2018  Allergan said in a statement that its average list price increase across its portfolio is around 3 8 percent this year  It said it does not expect to realize any net benefit from the increases this year because of higher rebates and discounts it expects to make to payers  AbbVie did not immediately respond to request for comment  More price increases are expected this month  Reuters reported late last year that nearly 30 drugmakers had notified California agencies they plan to raise list prices of their drugs  Not all of those increases have been announced yet  The United States  which leaves drug pricing to market competition  has higher prices than in other countries where governments directly or indirectly control the costs  making it the world s most lucrative market for manufacturers  HHS has proposed policy changes aimed at lowering drug prices and passing more of the discounts negotiated by health insurers on to patients  Those measures are not expected to provide relief to consumers in the short term  however  and fall short of giving government health agencies direct authority to negotiate or regulate drug prices   It s business as usual  for drugmakers  said Rx Savings Solutions Chief Executive Michael Rea  who said he believes there has to be meaningful changes to the marketplace  rather than new regulations in order for drug prices to drop ,2019-01-02,Reuters,https://www.investing.com/news/stock-market-news/drug-companies-greet-2019-with-us-price-hikes-1735343,1735343
104473,325988,AGN,Bristol Myers to buy Celgene for  74 billion in largest biopharma deal,news,"By Michael Erman and Ankur Banerjee  Reuters    Bristol Myers Squibb Co  N BMY  said on Thursday it would buy  Celgene Corp   O CELG  for about  74 billion  combining two of the world s largest cancer drug businesses in the biggest pharmaceutical deal ever  Both Bristol Myers and Celgene face separate challenges  and some Wall Street analysts questioned whether the combination   which the companies said would create  2 5 billion in cost savings and significantly raise earnings   would solve them  Amid clinical setbacks and other missteps  Bristol Myers shares fell 15 2 percent in 2018 while Celgene plunged nearly 40 percent last year   Bristol s most important cancer immunotherapy and growth driver  Opdivo  has lost much of its luster as Merck   Co s  N MRK  rival drug Keytruda seized dominance in advanced lung cancer  the most lucrative oncology market  Meanwhile  Celgene has endured high profile clinical failures and U S  exclusivity on its flagship multiple myeloma drug  Revlimid  will start being phased out in 2022  On Thursday  Bristol s stock ended another 13 3 percent lower at  45 12   Doing this transaction clearly indicates that risk to Opdivo in lung cancer is obviously a concern   SunTrust Robinson Humphrey analyst John Boris said in an interview  There is also shareholder concern that drugs in development would not have enough sales to offset major products losing exclusivity between 2022 and 2026  But cash flow from Revlimid buys Bristol Myers time to pay down debt and position for another transaction  Boris said  Revlimid is expected to record nearly  10 billion in 2018 sales  Celgene shares were up 20 7 percent at  89 43   Both of them were coming into this year kind of limping   said Brad Loncar  who runs the Loncar Cancer Immunotherapy ETF  The deal makes  the combined entity a lot stronger   he added  Including debt  the deal is worth  95 billion  eclipsing Pfizer s  89 billion purchase of Warner Lambert in 2000  according to Refinitiv   Graphic    Some analysts  including Baird Equity s Brian Skorney  said it raised the possibility of a new era of big drug deals  much like in 2009  when  Pfizer  Inc  N PFE   Merck  and Roche Holding AG  S ROG  all pulled off transformational acquisitions  The news pushed up shares of rivals  Gilead Sciences Inc   O GILD   Allergan Plc  N AGN   Biogen Inc  O BIIB  and Regeneron Pharmaceuticals Inc  O REGN   Bristol expects to achieve the  2 5 billion in cost savings by 2022  with 55 percent coming from cuts in sales  general and administrative expenses  35 percent through reduction in research   development spending and 10 percent from manufacturing  It said the deal will add more than 40 percent to its earnings in the first year after the deal closes  expected in the third quarter of 2019  Under terms of the deal  Celgene shareholders will receive one Bristol Myers Squibb share and  50 in cash for each share held  or  102 43 per share  a premium of 53 7 percent to Celgene s Wednesday close  Celgene shareholders will also receive a so called CVR payment  or contingent value right  of  9 if three treatments in development achieve timely approvals  Those are the high profile multiple sclerosis drug ozanimod  lymphoma treatment liso cel by Dec  31  2020 and a CAR T therapy for multiple myeloma known as bb2121 from a partnership with bluebird bio  O BLUE  by March 31  2021  BLOOD CANCER DOMINANCE  What s important to us is the sustainability of Celgene s leadership position in hematology through their pipeline  even after Revlimid loses patent protection  Bristol Myers Chief Executive Giovanni Caforio said in an interview  His company s strength has primarily been in solid tumor cancers  The New York based drugmaker said it expects six product launches over the next two years   five coming from Celgene s pipeline  It also highlighted promising early clinical assets it would gain with the New Jersey based biotech  Celgene brings experience with potentially revolutionary CAR T therapies from its  9 billion purchase of Juno Therapeutics and the bluebird collaboration  The therapy takes immune cells from a patient  engineers them to better recognize and attack cancer and returns them to the patient  The deal could also provide a graceful exit for Celgene CEO Mark Alles  who has only committed to staying through the transition  His rocky tenure included management shakeups and the loss of more than half its market value since October 2017 as an expensive experimental Crohn s disease drug touted as a future multibillion dollar product failed and the expected approval of ozanimod was delayed  Alles  on a conference call  urged shareholders to support the deal  Jeremy Bryan  portfolio manager at Gradient Investments  which has small positions in both companies  said the Celgene purchase puts Bristol Myers  on the clock  to do more deals   When you have a significant amount of cash coming in in the next three years  it gives you the flexibility     for deals if they are out there or to buy back significant amounts of stock   Bryan said  Talks between Bristol and Celgene opened in September  with Bristol approaching Celgene  according to two sources familiar with the matter   Bristol has obtained fully committed debt financing from  Morgan Stanley  Senior Funding Inc and MUFG Bank Ltd   Morgan Stanley   Co  NYSE MS   LLC is the lead financial adviser to Bristol Myers  and Evercore and Dyal Co LLC are its financial advisers  Kirkland   Ellis LLP is its legal counsel   
J P  Morgan Securities LLC is serving as lead financial adviser and Citi is the financial adviser to Celgene  Wachtell  Lipton  Rosen   Katz is its legal counsel ",2019-01-03,Reuters,https://www.investing.com/news/stock-market-news/bristolmyers-to-buy-celgene-for-74-billion-1736008,1736008
104474,325989,AGN,Hospitals squeezed by high drug costs,news,A study funded by the American Hospital Association  Federation of American Hospitals and the American Society of Health System Pharmacists found that total drug spend per hospital admission rose 18 5  between 2015 and 2017  adding  1 8M in additional costs for an average hospital Outpatient drug spending per admission rose almost 30  while inpatient spending for medicines rose 10   Price hikes as high as 80  or more occurred in anesthetics  parenteral solutions  opioid agonists and chemo More than 90  of hospitals surveyed had to identify alternative therapies to mitigate the impact of price increases and drug shortages  One in four had to downsize staff The price of Roche s stroke med Activase increased 19  to  4 143  Johnson   Johnson s Remicade  AbbVie s Humira and Amgen s Enbrel increased between 15   21  The majority of hospitals reported that competition had little effect on prices  Two of the 10 most expensive drugs in fiscal 2017 had generic or biosimilar alternatives enter the market in 2016  but the two still increased 4 1   albeit more modestly than the 14 4  average hike among the other eight About 750 hospitals have joined a non profit venture called Civica Rx aimed at managing drug costs and supply XLV  IBB  XBI  XPH  IHE  PPH  VHT  OTCQX RHHBY  ABBV  AGN  AZN  BMY  GSK  JNJ  MRK  NVS  BHC  TEVA  AMGN  BIIB  GILD  VRTX  TAK  ESRX  WBA  CVS  UNH  PFE  CELG  LLY Now read ,2019-01-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/hospitals-squeezed-by-high-drug-costs-1748944,1748944
104475,325990,AGN,Exclusive  Private equity firms circling Nestle s skin health business   sources,news,"By Arno Schuetze  Pamela Barbaglia and Martinne Geller FRANKFURT LONDON  Reuters    Private equity firms Cinven and Advent have teamed up to bid in an auction that could value Nestle s  S NESN  skin health business at about 7 billion Swiss francs   7 billion   three sources familiar with the matter said   Private equity companies Blackstone  N BX   KKR  N KKR   Carlyle  CVC  EQT and Partners Group are also expected to bid and might look for partners  according to the sources  who declined to be identified as the process is private  Nestle launched a review of the unit in September  as the maker of Nescafe coffee and Perrier water ditches underperforming businesses and fends off criticism from an activist investor who wants an overhaul  The fragmented consumer health sector is attractive for deals because of aging populations in many industrialized nations  increased interest in health and rising incomes  analysts say  Information memorandums on the skin health business sale  being run by  Credit Suisse   SIX CSGN  and Evercore  are expected to be sent by the end of January and first round bids are likely to be submitted in early March  the sources said  Nestle and all the funds declined to comment  Merz Pharma  a private German company that sells wrinkle fillers and other skin treatments  has reached out to several private equity bidders to find a partner  the sources said  The move by Merz shows the strength of private equity in the auction  given they want the whole Nestle unit  Industry rivals are only expected to bid for parts of the business  Nestle Skin Health  which sells Cetaphil and Proactiv skin care products  Restylane wrinkle fillers and prescription dermatology medicines  had sales of 2 7 billion Swiss francs last year  accounting for about 3 percent of Nestle s total  The sources said industry players which might take part in the auction included  Beiersdorf   DE BEIG   Allergan  N AGN   Henkel  DE HNKG p   Johnson   Johnson  J J   N JNJ   L Oreal  PA OREP    Pfizer   N PFE  and  Unilever   L ULVR   They all declined to comment as well   Sources previously estimated the unit could fetch 6 billion to 8 billion francs  On Monday  one source put the range at 7 5 billion to 8 5 billion francs  based on 2018 operating earnings of 500 million to 550 million francs  Another source said the price tag could reach more than 9 billion francs if the unit was broken up   Nestle  the world s largest packaged food maker  created the Skin Health unit in 2014 when it bought out L Oreal s stake in their Galderma joint venture  Under CEO Paul Bulcke  skin treatments were part of Nestle s push into higher growth health products to counter a slowdown in its traditional food business  But the unit has performed poorly  leading to one off costs and restructuring  
  1   0 9972 Swiss francs ",2019-01-21,Reuters,https://www.investing.com/news/stock-market-news/exclusive-private-equity-firms-circling-nestles-skin-health-business--sources-1752550,1752550
104476,325991,AGN,Evolus Rises Midday as Botox Drama Unfolds   ,news,"Investing com   Evolus was higher in midday trading after it received regulatory approval for a cheaper version of Botox  just days after rival Allergan  NYSE AGN  claimed the company stole trade secrets 
Evolus  NASDAQ EOLS  jumped more than 18  after the U S  Food   Drug Administrations approved the treatment on Friday  which is expected to be 20  to 25  cheaper than Botox 
Allergan and partner Medytox  who make Botox  are hoping to block U S  imports of the Evolus product  They filed a complaint with the U S  International Trade Commission on Wednesday accusing Evolus of developing its wrinkle treatment using stolen manufacturing secrets from a former employee 
Allergan was down 3 3   Elsewhere in the sector  Alexion Pharmaceuticals  NASDAQ ALXN  fell 2 5  and Regeneron Pharmaceuticals  NASDAQ REGN  slipped 1 6   The S P Pharmaceuticals Select Industry ETF inched down 0 18  ",2019-02-04,Investing.com,https://www.investing.com/news/stock-market-news/evolus-rises-midday-as-botox-drama-unfolds-1768566,1768566
104477,325992,AGN,What s In The Cards For AbbVie  ABBV  This Earnings Season ,opinion,AbbVie Inc    NYSE ABBV   is scheduled to report third quarter 2019 results on Nov 1  before market opens The company s earnings beat estimates in three of the past four quarters and missed the same once with the average surprise being 2 89   In the last reported quarter  AbbVie delivered a positive earnings surprise of 2 26  Shares of AbbVie have declined 16 7  so far this year against the  s increase of 0 3  Factors to ConsiderAbbVie expects earnings per share for the quarter to be in the range of  2 28 and  2 30  Revenues are expected to be approximately  8 4 billion  However  currency movement is likely to have a modest unfavorable impactFor the third quarter  the company guided adjusted operating margin to be slightly lower than the second quarter level at 48  Although U S  sales of AbbVie s flagship product  Humira are expected to have increased in the soon to be reported quarter  international sales may have declined significantly due to the impact of biosimilars in Europe  The company expects an increase of 8  in U S  sales and estimates international sales to be approximately  1 billion  The Zacks Consensus Estimate for the drug stands at  4 9 billion The company s key oncology drug  Imbruvica  which is marketed in partnership with J J   NYSE JNJ    is on growth path  given impressive adoption in first line chronic lymphocytic leukemia   CLL    The increased adoption is expected to have aided third quarter results  The company anticipates total sales of  1 2 billion from the drug in the third quarter  Label expansions of another oncology drug  Venclexta  drove sales in the past two quarters  We expect a similar trend to have continued in the third quarter  In May  the drug was approved for the first line treatment of CLL patients  This is likely to have brought additional sales  The Zacks Consensus Estimate for Imbruvica and Venclexta stand at  1 2 billion and  208 million  respectively However  AbbVie s new HCV drug  Mavyret recorded a decline in the first half of 2019  following an impressive performance in 2018  due to lower sales in international markets  We expect the declining trend to have continued in the third quarter  The Zacks Consensus Estimate for the HCV segment stands at  762 million Psoriasis drug  Skyrizi  was off to a strong start following its launch the second quarter  We expect strong uptake to have continued in the third quarter Last month  the Federal Trade Commission requested additional information relating to the pending acquisition of Botox maker Allergan   NYSE AGN   by AbbVie  In August  the FDA approved AbbVie s oral JAK inhibitor  Rinvoq  upadacitinib  for treating rheumatoid arthritis  Investors will likely focus on updates related to Allergan deal and launch plans for Rinvoq on the company s third quarter earnings call Earnings WhispersOur proven model does not conclusively predict an earnings beat for AbbVie in this reporting cycle  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that is not the case here as you will see below Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate  earnings of  2 23 per share  and the Zacks Consensus Estimate  earnings of  2 29 per share  is  2 62    You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AbbVie carries a Zacks Rank  3 AbbVie Inc  Price and Consensus   A Stock That Warrants a LookHere is a biotech stock that you may want to consider  as our model shows that it has the right combination of elements to deliver an earnings beat in its upcoming release Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  1 15  and a Zacks Rank  1  The company is scheduled to release third quarter results on Oct 29  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-200478504,200478504
104478,325993,AGN,Allergan  AGN  Expected To Beat Earnings Estimates  What To Know Ahead Of Q3 Release,opinion,"The market expects Allergan  NYSE AGN  to deliver flat earnings compared to the year ago quarter on lower revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on November 5  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This Botox maker is expected to post quarterly earnings of  4 25 per share in its upcoming report  which represents no change from the year ago quarter 
Revenues are expected to be  3 89 billion  down 0 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 95  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Allergan 
For Allergan  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 51  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Allergan will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Allergan would post earnings of  4 34 per share when it actually produced earnings of  4 38  delivering a surprise of  0 92  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Allergan appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release-200479584,200479584
104479,325994,AGN,Mylan  MYL  To Report Q3 Earnings  What s In The Offing ,opinion,"Mylan N V    NASDAQ MYL   is scheduled to report third quarter 2019 results on Nov 5  before market open The company s performance has been mixed so far  with earnings beating estimates in three of the trailing four quarters by average of 4 20  over the said time frame  In the last reported quarter  the company s earnings beat estimates by 8 42  Mylan N V  Price  Consensus and EPS Surprise
    Why a Likely Earnings Beat Our proven model predicts an earnings beat for Mylan this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP  Mylan has an Earnings ESP of  0 70  as the Zacks Consensus Estimate is pegged at  1 14 and the Most Accurate Estimate at  1 15 Zacks Rank  The company has a Zacks Rank  3 Factors to ConsiderThe company posts results in three segments on a geographic basis   North America  Europe and Rest of the World North America reported 2  year over year growth in the second quarter  driven by new product sales  a trend that most likely continued in the third quarter  New product sales are being primarily driven by the robust performance of Fulphila  biosimilar to Neulasta  and Wixela Inhub  the generic of Advair Diskus  New launches should further boost sales In September  Mylan launched fulvestrant Injection  a generic version of AstraZeneca s   NYSE AZN   Faslodex Injection  which is used in women with certain types of advanced breast cancer  who have experienced menopause  as monotherapy and in advanced or metastatic breast cancer in combination with other products Net sales in Europe might have benefited from new products  including Hulio and the TOBI Podhaler  and higher volumes of existing products in the third quarter  Rest of the World segment s net sales are likely to have benefited in the third quarter primarily owing to products sold in China and new product sales in Australia and emerging markets Key Anticipated UpdatesConcurrent with the second quarterly results  Mylan announced a merger agreement with Upjohn  Pfizer  NYSE PFE  s off patent branded and generic established medicines business  includes Lipitor  Celebrex and Viagra   to create a new global pharmaceutical company   Per the agreement  which is structured as an all stock  Reverse Morris Trust transaction  each Mylan share would be converted into one share of the new company  Mylan had previously undertaken a strategic review of its business due to challenging business conditions in North America and pricing pressure  The decision to merge with Upjohn comes as a result of this review  We expect management to throw more light on the progress made so far in this deal Share Price PerformanceMylan s stock has lost 28 5  in the year so far compared with the  s decline of 2 9  Other Stocks to ConsiderHere are a few other companies worth considering  as per our model these have the right mix of elements to beat on earnings this reporting cycle Allergan   NYSE AGN   has an Earnings ESP of  2 51  and a Zacks Rank of 2  The company is scheduled to release third quarterly results on Nov 5  You can see  Mallinckrodt   NYSE MNK   has an Earnings ESP of  0 36  and a Zacks Rank of 3  The company is scheduled to release third quarterly results on Nov 5 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-to-report-q3-earnings-whats-in-the-offing-200480207,200480207
104480,325995,AGN,AbbVie  ABBV  Set To Report Q3 Results  Can Things Turnaround  ,opinion,"AbbVie   NYSE ABBV   is set to report its third quarter results before the opening bell on Friday  November 1  The large cap pharmaceutical company has seen its shares decline over 15  in 2019 thus far  lagging behind the broader pharma market s gain 
The Humira manufacturer boasts a hefty dividend that it has steadily increased over the past several years and is actively adding new medications to its portfolio  but should it be enough for investors to bet on the company  Let s take a closer look at AbbVie and how the company might report its third quarter results 
Allergan  NYSE AGN  Acquisition 
AbbVie has become almost synonymous with its best selling drug  Humira  as it has generated the majority of its revenues for the past couple of years  Despite the success the company has had with Humira  it has done anything but become complacent 
AbbVie recently acquired Botox manufacturer  Allergen  for about  63 billion  The blockbuster deal strengthened AbbVie s portfolio of drugs and gave it more avenues to find new potentially high revenue treatments  Allergan s pipeline has a number of promising products that can accelerate revenue growth in the company immediately as well as in the long term 
This includes its depression treatment Vraylar as well as a new pipeline of drug candidates intended to treat gastroparesis and nonalcoholic steatohepatitis  NASH   In addition to these revenue boosting pipelines  Allergan s Botox and implant products are also expected to remain solid revenue drivers for AbbVie once the merger comes together 
The sheer size of the deal with all that it brings to the table for AbbVie helps the pharmaceutical company secure a portfolio of drugs that can provide stable revenue streams for years to come  The Allergan acquisition comes just as AbbVie needed to start weening itself off of its financial dependence on Humira 
Outlook 
AbbVie s leading income generator  Humira  is expected to decline in sales over the next several years as the company s patent expired in 2016 and low cost biosimilars were introduced in Europe late last year  The European biosimilars will likely lead to eroding international sales but Humira should continue to dominate the domestic market until biosimilars are introduced in around 2023  Currently  Humira accounts for 60  of AbbVie s sales  but following the merger  Humira accounts for only 40  of the company s revenues 
AbbVie has also been ramping up its development of its own drugs to combat eroding Humira sales such as Skyrizi  Venclexta  and Imbruvica  Skyrizi  a medicine for moderate to severe plaque psoriasis  was approved in both the US and Europe in April  and generated  42 million in revenues during the second quarter  Venclexta and Imbruvica had combined sales of  1 2 billion for a 35 5  year over year jump 
Our Q3 consensus estimates forecast a bottom line hike of 7 01  to  2 29 per share on the back of a 2 14  pop in sales to  8 41 billion  Humira is projected to generate  4 92 billion for a 3 95  drop off from the year ago quarter  Imbruvica is estimated to grow 22 98  to  1 2 billion and Venclexta is projected to more than double from Q3 2018 s figure to  207 5 million  Looking at fiscal 2019  our estimates call for earnings to grow 12 9  to  8 93 per share and for net sales to rally 1 46  to  33 23 billion 
Takeaway 
AbbVie has been making several moves to bolster and diversify its portfolio as it recognizes the decline of its Humira sales will be imminent as biosimilar products hit the markets  The company s investment in the Allergen acquisition while debt heavy  is a move in the right direction as the company prioritizes the long term trajectory of the business  Keeping busy with patent files for newly developed drugs like Skyrizi should also drive the company s top line for years to come 
Apart from its hefty 5 45  dividend yield  ABBV stock is currently trading at a discounted forward multiple relative to the industry average that provides a good entry point for investors who are feeling bullish about the company s newly structured portfolio  AbbVie s earning estimates have been revised higher earning the stock a Zacks Rank  2  Buy  
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-set-to-report-q3-results-can-things-turnaround-200480368,200480368
104481,325996,AGN,Is A Beat In The Cards For Regeneron  REGN  Q3 Earnings ,opinion,Regeneron Pharmaceuticals  Inc    NASDAQ REGN   is scheduled to release third quarter 2019 results on Nov 5  before the opening bell Regeneron has a decent track record  In the last reported quarter  the company beat earnings expectations by 11 07   It surpassed earnings estimates by average of 6 14  in the last four quarters Regeneron Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Let s see how things are shaping up for the to be reported quarter Why a Likely Earnings Beat Our proven model predicts an earnings beat for Regeneron this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Regeneron has an Earnings ESP of  4 41  as the Zacks Consensus Estimate is pegged at  6 35 and the Most Accurate Estimate at  6 63 Zacks Rank  The company has a Zacks Rank  3 Factors Influencing Q3Regeneron s key drug  Eylea  drove performance in the first half of 2019  a trend that most likely continued in the third quarter  Eylea was developed in collaboration with Bayer  DE BAYGN  AG   OTC BAYRY    The drug is approved in the United States  the EU  Japan and other countries for the treatment of neovascular age related macular degeneration  wet AMD   diabetic macular edema  DME  and macular edema following retinal vein occlusion  which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion In May  the FDA approved Eylea injection to treat all stages of diabetic retinopathy  DR   Label expansion into additional indications would provide the drug access to a higher patient population and increase its commercial potential  We expect sales to have benefited from the first full quarter for this expanded indication In August  the FDA has approved the Chemistry  Manufacturing and Controls  CMC  Prior Approval Supplement  PAS  for the Eylea injection prefilled syringe  Consequently  the drug became the only anti VEGF approved to treat four retinal conditions with a single dose strength prefilled syringe Apart from Eylea  investors will be focusing on the uptake of Dupixent and its label expansion Asthma drug Dupixent s sales have been impressive in the first half of 2019 on continuous label expansion and the same is expected to have prevailed in the third quarter  Label expansion of the drug in the last few months has most likely boosted sales  In May  the European Commission approved Dupixent for use in adults and adolescents 12 years and older as an add on maintenance treatment for severe asthma  In June  the FDA approved the drug for use with other medicines to treat chronic rhinosinusitis with nasal polyposis  CRSwNP  in adults whose disease is not controlled  The European Commission approved another label expansion of Dupixent  extending its approval to include adolescents 12 17 years of age with moderate to severe atopic dermatitis  who are candidates for systemic therapy Regeneron also has Kevzara in its portfolio  Kevzara  an anti interleukin  IL  6 receptor monoclonal antibody used for the treatment of adult patients with moderately  to severely active rheumatoid arthritis  was approved by the FDA in May 2017 Investors will also focus on the performance of PCSK9 inhibitor  Praluent  and Libtayo  Sales of Libtayo came in at  40 8 million in the second quarter  In June  the drug got approval in Europe for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma  CSCC   who are not candidates for curative surgery or curative radiation  Consequently  sales have most likely increased in the third quarter as a result of geographical expansion Praluent sales came in at  73 7 million in the second quarter  In April  the FDA approved a label expansion of the drug to reduce the risk of heart attack  stroke and unstable angina requiring hospitalization of adults suffering from established cardiovascular  CV  disease  Hence  this is likely to have driven sales in the third quarter Apart from top line numbers  investors will focus on Regeneron s pipeline updates  The company announced positive pivotal phase III results for evinacumab  an investigational angiopoietin like 3  ANGPTL3  antibody  in patients with homozygous familial hypercholesterolemia  HoFH  Share Price PerformanceRegeneron s stock has lost 18  in the year so far compared with the  s decline of 0 8   Other Stocks to ConsiderHere are some other healthcare stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Allergan plc   NYSE AGN   has an Earnings ESP of  2 51  and a Zacks Rank of 2  The company is scheduled to release third quarter results on Nov 5  You can see  Jazz Pharmaceuticals  Inc    NASDAQ JAZZ   has an Earnings ESP of  1 70  and a Zacks Rank  2  The company is scheduled to release third quarter 2019 results on Nov 5 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-regeneron-regn-q3-earnings-200481368,200481368
104482,325997,AGN,Ironwood  IRWD  Beats On Q3 Earnings   Revenues  Ups  19 View,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   reported third quarter 2019 adjusted earnings of 40 cents per share  surpassing the Zacks Consensus Estimate of 10 cents  In the year ago period  the company had reported a loss of 38 cents The company turned profitable for the first time in the second quarter of 2019  following the separation of its Soluble Guanylate Cyclase  sGC  pipeline for treating serious and orphan diseases into a new public entity  Cyclerion Therapeutics  Inc    NASDAQ CYCN   in April 2019 Total revenues of  131 2 million comprehensively beat the Zacks Consensus Estimate of  96 01 million  Revenues nearly doubled year over year  The significant increase in revenues was due to certain negative  related to Linzess sales in the year ago quarter and one time payments made during the third quarter of 2019 related to amendments of license collaboration agreements for Linzess Ironwood s shares rallied almost 6 5  on Oct 31  following the impressive results  However  shares of Ironwood have decreased 3 1  so far this year against the  s increase of 3 1  Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess  generated net sales of  214 7 million in the United States  up 4 8  year over year  Ironwood and Allergan equally share Linzess  brand collaboration profits or losses Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  84 6 million in the third quarter  up approximately 61 8  year over year  Net commercial profit in the reported quarter was  134 4 million Per data provided by IQVIA  volume of prescribed Linzess capsules in the third quarter increased about 15  year over year The company stated on its earnngs call thatLinzess became the most prescribed drug in its approved indications during the third quarter Sales of linaclotide API to Ironwood s Japanese partner  Astellas Pharma  was  0 6 million compared to the  10 3 million in the year ago period 2019 Guidance RaisedIronwood increased its guidance for total revenues to the range of  410  420 million from the previously announced range of  370  390 million for 2019 on the back of strong growth momentum in Linzess sales  Net interest expenses are anticipated to be approximately  35 million The company also raised its EBITDA guidance for 2019 including the impact of the business separation  The company expects adjusted EBITDA to be more than  130 million  previously  65 million   reflecting strong top line growth  and license and milestone payments recorded during the third quarter  It also expects net sales of Linzess to grow by mid single digit percentage point  previously low  to mid single digit  The company expects to save  25 million over the next five years by shifting its headquarters to downtown Boston from its current location in Cambridge  MA  The relocation was completed in October Pipeline UpdatesLinzess is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation  Ironwood and Allergan are looking to expand Linzess  label into additional symptoms and develop the drug as a non opioid  pain relieving agent for IBS patients In June  Ironwood and Allergan announced positive top line data from the phase IIIb study on Linzess for treating multiple abdominal symptoms in adult patients with IBS C In May  the companies initiated a phase IIb study for evaluating three once daily doses   300  600 and 1 200 mcg   of MD 7246  delayed release formulation of Linzess  to treat abdominal pain associated with IBS with diarrhea  The companies are enrolling patients in the study and top line data is expected by mid 2020 Ironwood is also developing an interesting candidate called IW 3718  It is currently enrolling patients in two identical phase III studies  evaluating IW 3718 for treating gastroesophageal reflux disease  Results from both studies are expected in the second half of 2020 Global Collaborations and PartnershipsIronwood has a license agreement with Japan based  Astellas Pharma  Ironwood supplies linaclotide API to Astellas Pharma for manufacturing and developing Linzess for sale in Japan  Ironwood amended this license agreement with Astellas Pharma for an upfront payment of  10 million and recorded it as revenues in the third quarter  Per the amended terms  Astellas will be manufacturing linaclotide API in Japan and Ironwood will receive royalties on net sales of Linzess in the country In China  Hong Kong and Macau  Ironwood has a collaboration agreement with AstraZeneca   NYSE AZN   for development and commercialization of Linzess  Ironwood also amended the agreement in the third quarter  Per the amended terms  Ironwood has granted AstraZeneca exclusive rights to develop  manufacture  and commercialize Linzess in these territories  AstraZeneca will be responsible for all expenses associated with Linzess and Ironwood will no longer be jointly funding the development and commercialization of Linzess neither will it share profits on the drug s sales in China  The company will receive royalties on net sales of Linzess in China and included territories Per the terms of the amended agreement  Ironwood is eligible to receive payments up to a total of  125 million  which includes  35 million in non contingent payments and  90 million payment contingent to achieving certain annual net sales targets It received  32 4 million of the non contingent payments and recorded as revenues in the third quarter In January  Linzess was granted marketing approval by Chinese regulatory authorities to treat adults with IBS C  AstraZeneca plans to launch the drug in China for IBS C soon The drug is already available and the field force has completed training Our TakeIronwood reported encouraging third quarter results with sales and earnings beating estimates  Linzess  prospects look encouraging owing to strong demand trends and the drug s expansion to new patient population and geographies  Moreover  amendments to collaboration agreement in China will likely lead to decline in operating expense going forward The new Ironwood entity has solid potential and its focus on the gastrointestinal product of the commercial portfolio and pipeline is impressive The company s  139 2 million cash resources as of September end  separation of sGC pipeline and a strong partner in Allergan bode well Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks RankIronwood currently sports a Zacks Rank  1  Strong Buy   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-beats-on-q3-earnings--revenues-ups-19-view-200481365,200481365
104483,325998,AGN,Pharma Stock Roundup  MRK  PFE  GSK  BMY Q3 Earnings  Other Updates,opinion,"Pfizer   NYSE PFE    Merck   NYSE MRK    Bristol Myers   NYSE BMY    Sanofi   NASDAQ SNY    Glaxo   NYSE GSK   and Bayer  DE BAYGN  released their third quarter results this week  In other important news  AstraZeneca s first line lung cancer study on Imfinzi showed positive results and J J s   NYSE JNJ   new tests revealed no asbestos in its baby powder  Recap of the Week s Most Important Stories  Earnings Update       and beat estimates for both earnings and sales  Higher sales of some of Pfizer s key brands like Eliquis  Ibrance  Inlyta and Xeljanz were offset by lower sales of Lyrica due to loss of exclusivity in July 2019 in the United States  Merck s blockbuster cancer drug  Keytruda continued its robust performance on strong demand   Both Merck   Pfizer raised their earnings guidance for 2019 while tightening the same for revenues  Strong performance of relatively newer vaccine and respiratory products boosted Glaxo s sales  Glaxo raised its 2019 adjusted earnings growth expectations to around flat at CER from a decline of 3  to 5  expected previously Bristol Myers  sales growth of 6  was led by robust sales of Eliquis and Sprycel while sales growth of its PD 1 inhibitor  Opdivo was weak  The company raised its guidance range for earnings s third quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales  Double digit growth in Sanofi s Specialty Care unit was offset by a weak performance in the Consumer Healthcare and Vaccines units in the quarter s sales increased 5 4  on an organic basis in the quarter  All the three segments  Crop Science  Pharmaceuticals and Consumer Health  witnessed higher sales AstraZeneca s Imfinzi Combo Meets Goal in First Line Lung Cancer Study   AstraZeneca s phase III POSEIDON study evaluating Imfinzi plus platinum based chemotherapy or the triple combination of Imfinzi plus tremelimumab and chemotherapy in first line treatment of patients with metastatic  non small cell lung cancer  NSCLC  met the primary endpoint  Imfinzi plus multiple choices of chemotherapy regimens led to a statistically significant and clinically meaningful improvement in the final progression free survival  PFS  analysis in such patients versus chemotherapy alone  thereby meeting the study s primary endpoint  The triple regimen of Imfinzi plus tremelimumab and chemotherapy also met the key secondary endpoint by demonstrating a statistically significant and clinically meaningful PFS improvement  versus chemotherapy alone  The study continues to assess the co primary endpoint of overall survival with data expected to be presented next year AstraZeneca also announced an agreement to sell rights to Seroquel and Seroquel XR  a treatment for schizophrenia and bipolar disease  in Europe and Russia to Cheplapharm Arzneimittel GmbH J J Says Tests Find No Asbestos in Baby Powder  J J announced that 15 new tests conducted on the same bottle of Johnson s Baby Powder that was previously tested by the FDA  found no asbestos  a known carcinogen  The product is the subject of numerous lawsuits  which claim that J J s talc based products contain asbestos that causes cancer  Earlier this month  J J announced a voluntary recall of one lot of its Johnson s The recall was initiated following a test done by the FDA  which revealed traces of asbestos in samples from one bottle purchased online  J J also said that an additional 48 independent third party lab tests of samples from the same lot that was recalled also confirm that the talc does not contain asbestos Pfizer Gets EU Nod for Bavencio Inlyta Combo in Kidney Cancer  Pfizer and partner Merck KGaA gained approval from the European Commission for Bavencio  avelumab  in combination with Inlyta  axitinib  for the first line treatment of patients with advanced renal cell carcinoma  RCC   the most common form of kidney cancer  The combination of Bavencio and Inlyta received approval in the United States for a similar indication in May  In January  a similar application had been submitted in Japan   Glaxo Begins Phase III Program on New Antibiotic  Glaxo announced initiation of patient dosing in a phase III program on its investigational oral antibiotic  gepotidacin  which Glaxo claims has mechanism of action distinct from any currently approved antibiotic  The program will comprise two studies with one evaluating the use of gepotidacin for uncomplicated urinary tract infection and the other for urogenital gonorrhea  a common sexually transmitted infection Meanwhile  the European Commission gave approval to the intravenous formulation of Benlysta for systemic lupus erythematosus in children aged five years and above  The intravenous formulation is already approved in EU as well as the United States for adults while it was approved in the United States for children in April AbbVie s Rinvoq Meets Goal in Psoriatic Arthritis Study  AbbVie s   NYSE ABBV   phase III study evaluating Rinvoq  upadacitinib  for active psoriatic arthritis in adult patients who had an inadequate response to other bDMARDs met the primary endpoint  Top line data from the study  SELECT PsA 2  showed that both doses of Rinvoq  15 mg and 30 mg  once daily  met the primary endpoint of ACR20 response or at least a 20  reduction in the number of both tender and swollen joint counts  at week 12 versus placebo  After 12 weeks of treatment  the ACR20 response  primary endpoint  was achieved in 57  of the patients receiving the 15 mg oral once daily dose of upadacitinib and 64  of the patients taking the 30 mg dose versus 24  for patients in the placebo group  In addition  patients treated with Rinvoq  both doses  achieved significantly greater responses for all ranked secondary endpoints compared to placebo  Rinvoq was approved for the treatment of moderate to severe rheumatoid arthritis in August FDA Puts Hold on Novartis  AVXS 101 Intrathecal Studies  The FDA placed a partial clinical hold on studies testing intrathecal administration of its newly approved spinal muscular atrophy  SMA  treatment  Zolgensma  AVXS 101  based on findings of a small pre clinical animal study  Zolgensma is presently available as an intravenous administration after FDA granted approval in May this year for pediatric SMA patients  Novartis said that the clinical hold has no impact on intravenous Zolgensma FDA and EMA Accept Roche s Applications for Satralizumab  Roche s marketing applications for satralizumab developed to treat neuromyelitis optica spectrum disorder were accepted for review by the European Medicines Agency and FDA  The regulatory applications were based on data from two studies  SAkuraStar and SAkuraSky The NYSE ARCA Pharmaceutical Index rose 3 3  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Last week  all the stocks were in the green supported by strong third quarter results of most companies in the sector  Lilly was the biggest gainer  5 6   In the past six months  AstraZeneca has risen the most  30 3   while J J lost the most  6 5   mainly due to its litigation issues  See the last pharma stock roundup here  What s Next in the Pharma World Watch out for third quarter results of Novo Nordisk  CSE NOVOb  and Allergan  NYSE AGN  and regular pipeline and regulatory updates next week 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-pfe-gsk-bmy-q3-earnings-other-updates-200481357,200481357
104484,325999,AGN,Is A Beat In The Cards For Mallinckrodt  MNK  In Q3 Earnings ,opinion,"Mallinckrodt plc   NYSE MNK   is scheduled to report third quarter 2019 results on Nov 5  before market open Mallinckrodt has surpassed expectations in the last four quarters  the average positive earnings surprise being 15 56   Let s see how things are shaping up for this announcement Mallinckrodt public limited company Price  Consensus and EPS Surprise
    Why a Likely Earnings BeatOur proven model predicts an earnings beat for Mallinckrodt this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Mallinckrodt has an Earnings ESP of  0 36  as the Zacks Consensus Estimate is pegged at  1 98 and the Most Accurate Estimate stands at  1 99 Zacks Rank  The company has a Zacks Rank  3 Factors Impacting Q3The company operates in two reportable segments   the Specialty Brands and the Specialty Generics Specialty Brands produces and markets branded pharmaceutical products like Acthar  Inomax and Ofirmev  among others Sales of Acthar  Mallinckrodt s largest product  were down in the second quarter primarily due to continued reimbursement challenges affecting new and returning patients  and constant payer scrutiny on overall specialty pharmaceutical spending  This trend most likely continued in the third quarter as well Inomax  the company s second largest product  put up a strong performance in the second quarter  driven by continued demand and contract renewals  and the same has most likely prevailed in the third quarter  Also  Ofirmev and Therakos might have boosted performance in the third quarter owing to strong demand Apart from the regular top and bottom line numbers  we expect investors to focus on the company s two late phase programs on terlipressin and StrataGraft   In September  the company announced positive top line results from the pivotal phase III study of its investigational StrataGraft regenerative tissue  The study  which met both primary endpoints  evaluated the efficacy and safety of a single application of StrataGraft for the treatment of deep partial thickness thermal burns  Update on Specialty Generics SeparationLast December  the company announced its plan to spin off the Specialty Generics business into a new entity  However  based on market conditions and developments  including increasing uncertainties regarding the opioid litigation  the company shelved this plan  Mallinckrodt continues to evaluate a range of options for the separation of the Specialty Generics business and we expect it to throw more light on this Share Price PerformanceMallinckrodt s stock has plunged 80 3  in the year so far compared with the  s decline of 2 5   Other Stocks to ConsiderHere are some other healthcare stocks you may want to consider  as our model shows that these too have the right combination of elements to post an earnings beat this quarter Allergan plc   NYSE AGN   has an Earnings ESP of  2 51  and a Zacks Rank of 2  The company is scheduled to release third quarter results on Nov 5  You can see  Jazz Pharmaceuticals  Inc    NASDAQ JAZZ   has an Earnings ESP of  1 70  and a Zacks Rank  2  The company is scheduled to release third quarter 2019 results on Nov 5 Regeneron   NASDAQ REGN   has an Earnings ESP of  4 41  and a Zacks Rank  3  The company is scheduled to release third quarter 2019 results on Nov 5 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-mallinckrodt-mnk-in-q3-earnings-200481429,200481429
104485,326000,AGN,WIll Allergan  AGN  Beat Estimates This Earnings Season ,opinion,"We expect Allergan plc   NYSE AGN   to beat expectations when it reports third quarter 2019 results on Nov 5  In the last reported quarter  the company delivered a positive earnings surprise of 0 92  Allergan s share price has risen 31 8  this year so far against the  s decrease of 2 8    Allergan s earnings performance has been strong  with the company beating expectations in each of the past four quarters  The average positive earnings surprise over the last four quarters is 4 26  Allergan plc Price and EPS Surprise
    Factors to ConsiderSales in the third quarter are likely to have been hurt by loss of exclusivity on some brands  divestitures of some brands in 2018 and lower sales of textured breast implants due to a global recall  Like the previous couple of quarters  sales of blockbuster drug Restasis may have declined in the quarter Nonetheless  key products like Botox  both cosmetic and therapeutic   Juv derm collection of fillers  Vraylar  Ozurdex and Lo Loestrin are likely to have supported sales growth in the quarter Importantly  in May  Allergan gained FDA approval for the new indication of bipolar depression for Vraylar  Investors will be keen to know the contribution of this label expansion to sales of the drug in the quarter to be reportedIn August  Allergan entered into a settlement with two Ohio plaintiffs in connection with the federal multidistrict litigation related to abuse of opioid based drugs  Allergan has agreed to pay  5 million to resolve all claims pertaining to the scheduled trial  Investors will throw questions at Allergan management for any updates on the issue Importantly  in June  Allergan announced that it has entered into a definitive transaction to be acquired by AbbVie   NYSE ABBV   in a cash and stock deal worth nearly  63 billion  Last month  Allergan s shareholders gave green signal to the pending merger  Some questions on the progress of the merger deal are expected on the third quarter conference call Earnings WhispersOur proven model predicts an earnings beat for Allergan in the soon to be reported quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Allergan s Earnings ESP is  2 51  as the Zacks Consensus Estimate of  4 25 is lower than the Most Accurate Estimate of  4 36  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Allergan has a Zacks Rank  2 Other Stocks to Consider Here are a few other healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Jazz Pharmaceuticals   NASDAQ JAZZ   has an Earnings ESP of  1 70  and is Zacks  2 Ranked  The company is scheduled to release results on Nov 5  You can see  Portola Pharmaceuticals   NASDAQ PTLA   has an Earnings ESP of  6 33  and a Zacks Rank of 1  The company is scheduled to release results on Nov 5 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/will-allergan-agn-beat-estimates-this-earnings-season-200481428,200481428
104486,326001,AGN,AbbVie  ABBV  Beats On Q3 Earnings   Sales  Tweaks EPS View,opinion,"AbbVie Inc    NYSE ABBV   delivered better than expected third quarter 2019 earnings and revenues  The company also raised the lower end of the guidance for 2019 adjusted earnings  Shares inched up around 1  in pre market trading 
However  shares of AbbVie have lost 13 7  so far this year against the increase of 4 2  

 
AbbVie reported earnings of  2 33 per share in the third quarter  beating the Zacks Consensus Estimate of  2 29 as well as the company s guided range of  2 28  2 30  The bottom line also rose 8 9  year over year 
Moreover  the company s revenues of  8 48 billion surpassed the Zacks Consensus Estimate of  8 41 billion  Also  the top line was marginally higher than the guided figure of approximately  8 4 billion 
Additionally  the top line improved 3  year over year  Excluding the unfavorable impact from foreign exchange rate fluctuations  operational revenues increased 3 5  
Quarter in Detail
Key drug Humira recorded sales decline of 3 2  on an operational basis with revenues from the same coming in at  4 94 billion  However  sales in the United States increased 9 6  to  3 89 billion  Humira sales in the ex U S  markets were but down 31 8  on an operational basis and 33 5  on a reported basis to  1 05 billion  International sales were severely impacted by the launch of several direct biosimilar drugs in Europe by other pharma companies including Amgen   NASDAQ AMGN    Sandoz and Biogen  NASDAQ BIIB  
New immunology drugs Skyrizi and Rinvoq registered sales of  91 million and  14 million  respectively  While Skyrizi  risankizumab  was approved in the United States and Europe for plaque psoriasis in April 2019  Rinvoq  upadacitinib  was approved by the FDA in August 2019 for moderate to severe rheumatoid arthritis  RA  
Per the company  both Skyrizi and Rinvoq are off to an impressive start and are well positioned to boost the company s immunology category as well as lower its heavy dependence on Humira  which is hit by weaker sales due to biosimilar competition 
AbbVie s oncology hematology  including Imbruvica and Venclexta  sales surged 38 5  on an operational basis to  1 5 billion in the quarter  driven by strong growth of both Imbruvica and Venclexta 
Third quarter net revenues from Imbruvica were  1 26 billion  up 29 3  year over year  U S  sales of Imbruvica grossed  1 04 billion  up 28 3  from the year ago figure  International sales of the drug increased 34 5  to  215 million  Notably  AbbVie shares international profit earned from Imbruvica with Johnson   Johnson   NYSE JNJ   
The company s leukemia drug Venclexta generated revenues of  221 million in the reported quarter  skyrocketing more than 100  year over year  AbbVie has partnership with Roche for Venclexta 
Other products that delivered an encouraging performance include Duodopa  It recorded revenue growth of 14 4  on an operational basis and 11 3  reportedly  While Creon  which generates sales only from U S  markets  witnessed an increase of 11 2  in revenues  sales of Synthroid grew 2 3   Synagis and Lupron sales increased 35 4  and 8 2   respectively  on an operational basis during the quarter 
Chronic hepatitis C virus products recorded sales of  698 million  down 18 6  operationally year over year  Sales of Mavyret were  695 million  reflecting a 16 7  decrease operationally due to a decline in the United States as well as the international markets 
Other drugs that recorded sales decline include Androgel  Kaletra and Sevoflurane  which fell 61 1   13 9  and 0 9   respectively on operational basis during the quarter 
Adjusted SG A expenses were almost flat year over year to  1 6 billion while R D expenses were  1 23 billion in the third quarter  Adjusted operating margin was 48 4  of sales 
Update on Allergan Acquisition
On June 24  2019  AbbVie announced a definitive agreement to buy Botox maker Allergan   NYSE AGN   in a cash and stock deal for  63 billion  AbbVie will pay Allergan a price of  120 30 in cash and 0 8660 AbbVie shares per Allergan share The deal  if it gets all the necessary approvals  is expected to close in early 2020 
Last month  the shareholders of Allergan  its pending acquisition by AbbVie 
2019 Guidance
AbbVie raised the lower end of its guidance for adjusted EPS to the range of  8 90  8 92 from the previous guidance of  8 82  8 92 for 2019  The earnings guidance indicates a year over year increase of 12 6  at the mid point  The Zacks Consensus Estimate for current year earnings per share is pegged at  8 93 
AbbVie Inc  Price  Consensus and EPS Surprise
    
Zacks Rank
AbbVie currently carries a Zacks Rank  2  Buy   You can see  
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ",2019-11-01,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-beats-on-q3-earnings--sales-tweaks-eps-view-200481540,200481540
104521,326036,AGN,Allergan Earnings  Revenue beat in Q3,news,"Investing com   Allergan  NYSE AGN  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  4 25 on revenue of  3 91B  Analysts polled by Investing com anticipated EPS of  4 03 on revenue of  3 89B  That compared to EPS of  4 15 on revenue of  4 03B in the same period a year earlier  The company had reported EPS of  4 42 on revenue of  4 1B in the previous quarter 
For the year  Allergan shares are up 6 25   outperforming the S P 500 which is down 1 58  year to date 
Allergan follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 3 on revenue of  12 94B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-30,Investing.com,https://www.investing.com/news/stock-market-news/allergan-earnings-revenue-beat-in-q3-1665305,1665305
104522,326037,AGN,Leerink sees 34  upside in Allergan in premarket analyst action,news,"ACADIA Pharmaceuticals   NASDAQ ACAD  initiated with Market Perform rating at Leerink Partners 
AC Immune SA  NASDAQ ACIU  initiated with Outperform rating at Leerink 
Adamas Pharmaceuticals  NASDAQ ADMS  resumed with Outperform rating and  20  75  upside  price target at Leerink 
Aerie Pharmaceuticals  NASDAQ AERI  initiated with Outperform rating and  64  43  upside  price target at Oppenheimer 
Allergan  NYSE AGN  resumed with Outperform rating and  220  34  upside  price target at Leerink  Shares down a fraction premarket 
Alkermes plc  NASDAQ ALKS  resumed with Market Perform rating at Leerink 
GW Pharmaceuticals  NASDAQ GWPH  initiated with Outperform rating and  185  38  upside  price target at Leerink 
Neurocrine Biosciences  NASDAQ NBIX  initiated with Market Perform rating at Leerink 
Molina Healthcare  NYSE MOH  upgraded to Buy with a  169  27  upside  price target at Jefferies 
Magellan Health  NASDAQ MGLN  downgraded to Market Perform at Leerink 
Perrigo  NASDAQ PRGO  downgraded to Hold with a  72  10  upside  price target at Berenberg  Shares down a fraction premarket 
Sabra HealthCare REIT  NASDAQ SBRA  downgraded to Neutral with a  21  flat  price target at Mizuho Securities  Shares up a fraction premarket 
Now read ",2018-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/leerink-sees-34-upside-in-allergan-in-premarket-analyst-action-1685878,1685878
104523,326038,AGN,Ad Com approaches for Mallinckrodt s abuse deterrent oxycodone,news,"The FDA s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly meet tomorrow  November 14  to review and discuss  Mallinckrodt  s  NYSE MNK  marketing application seeking approval for MNK 812  an abuse deterrent formulation of opioid oxycodone  for the management of severe pain 
FDA briefing doc
Company briefing doc 
Now read ",2018-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/ad-com-approaches-for-mallinckrodts-abusedeterrent-oxycodone-1686016,1686016
104524,326039,AGN,Pfizer loses blockbuster drug patent fight in UK Supreme Court,news,"By Ben Hirschler LONDON  Reuters     Pfizer   NYSE PFE  lost the final round in a long running patent battle in Britain on Wednesday after the country s highest court ruled against it in a case involving its  5 billion a year pain drug Lyrica  The Supreme Court decision is a blow for the U S  drugmaker    which had sought to affirm a secondary medical use patent for the product    and a win for generic drug companies  Actavis   now renamed Allergan  NYSE AGN   and Mylan  NASDAQ MYL   Lyrica  known generically as pregabalin  was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain  which soon became its main market  In a bid to protect this lucrative section of the market  Pfizer secured a secondary patent  valid beyond the life of the original one  The Supreme Court  however  ruled that the secondary patent claims relevant to neuropathic pain were invalid  For Pfizer  the legal fight had become a point of principle  following years of battles in lower courts  since its key secondary pain patent has now expired in Europe  Pfizer said it was disappointed by the ruling and the decision would have a significant impact on incentives for innovation in public health   The period that a medicine is under patent is a critical phase in its lifecycle that fuels innovation    as science evolves and knowledge grows  patients increasingly benefit from ongoing research into new uses for existing medicines   the company said   As situations such as these are expected to become more common  it s important for patients that pharmaceutical companies are able to protect patents  including second medical use patents   The expiry of the basic patent on Lyrica five years ago had allowed generic drugmakers to launch cut price versions of Pfizer s medicine  which carried a  skinny label  limiting their use to epilepsy and general anxiety disorder  Pfizer sued  arguing it was inevitable that the copycat versions would be dispensed for pain as well as other conditions   The U S  group took the case to the Supreme Court after a appeal in the case was rejected in 2016  Since then Pfizer s secondary neuropathic pain patent in Britain has also expired  in July 2017  In the United States  by contrast  Pfizer is only expecting generic competition to Lyrica in 2019   
The Supreme Court is the final court of appeal in Britain for civil cases  Pfizer said it was  too early  for it to determine or comment on any possible next steps ",2018-11-14,Reuters,https://www.investing.com/news/stock-market-news/pfizer-loses-blockbuster-drug-patent-fight-in-uk-supreme-court-1687562,1687562
104525,326040,AGN,Senate Dems introduce bill to block  excessive  increases in drug prices,news,Four democratic senators  Richard Blumenthal  D CT   Kamala Harris  D CA   Amy Klobuchar  D MN  and Jeff Merkley  D OR   have introduced a bill aimed at blocking drug price hikes  Specifically  it will allow the Department of Health and Human Services to prohibit price increases that it considers excessive  although there are no details provided regarding the criteria for such decisions House Speaker Nancy Pelosi has pledged an agenda for next year to combat high drug prices Selected tickers  BIB  GRX  THW  BME  BIS  IXJ  ARKG  GNRX  CHNA  XLV  XBI  BHC  OTCQX RHHBY  ABBV  AGN  AZN  BMY  GSK  JNJ  LLY  MRK  NVO  PFE  NVS  SHPG  TEVA  MYL  AMGN  BIIB  GILD  CELGNow read ,2018-12-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/senate-dems-introduce-bill-to-block-excessive-increases-in-drug-prices-1721150,1721150
104526,326041,AGN,Exclusive  Big Pharma returning to U S  price hikes in January after pause,news,"By Michael Erman and Robin Respaut NEW YORK SAN FRANCISCO  Reuters     Novartis  AG  S NOVN  and  Bayer AG   DE BAYGn  are among nearly 30 drugmakers that have taken steps to raise the U S  prices of their medicines in January  ending a self declared halt to increases made by a pharma industry under pressure from the Trump administration  according to documents seen by Reuters   Other drugmakers set to raise prices at the start of 2019 include Allergan Plc  N AGN   GlaxoSmithKline Plc  L GSK    Amgen Inc   O AMGN   AstraZeneca Plc  L AZN  and Biogen Inc  O BIIB   the documents show    The hikes will pose a new challenge to President Donald Trump s pledge to lower the costs of prescription medications in the world s most expensive pharmaceutical market  The U S  Department of Health and Human Services  HHS  has proposed a slew of policies aimed at lowering prices and passing more of the discounts negotiated by health insurers on to patients  Those measures are not expected to provide relief to consumers in the short term  however  and fall short of giving government health agencies direct authority to negotiate or regulate drug prices  Twenty eight drugmakers filed notifications with California agencies in early November disclosing that they planned to raise prices in 60 days or longer  Under a state law passed last year  companies are required to notify payers in California if they intend to raise the U S  list price on any drug by more than 16 percent over a two year period   The details were provided to Reuters in response to a public records request to California Correctional Health Care Services  which provides healthcare services to the state s corrections department  The department spends more than  3 billion annually on drugs for inmates  more than any other state    Requests and public shaming haven t worked  to lower drug prices  said Michael Rea  chief executive of RX Savings Solutions  which helps health plans and employers seek lower cost prescription medicines   We expect the number of 2019 increases to be even greater than in past years    Pfizer  Inc  NYSE PFE  rolled back planned price increases in July after President Trump said in a tweet that the drugmaker  should be ashamed  and that his administration would respond to the hikes   Pfizer said it would defer hikes until January 2019 to support the administration as it pursued its new pricing policies  Pfizer s move prompted many of its industry peers  including Bayer  Novartis  Allergan  AstraZeneca and Amgen  to follow suit   Drug price increases implemented by the 20 biggest drugmakers did slow down during the second half of 2018  with those companies raising prices on just over half the number of drugs as in 2017  according to data compiled by consultancy RX Savings Solutions   Pfizer has already announced plans to hike prices on 41 of its drugs in mid January  60 DAY NOTICE        The California corrections department documents indicate that the companies plan to increase prices as early as Jan  1  Most do not detail for which drugs or by how much  but specific details were given in the case of Novartis and Bayer  Novartis is planning to raise prices on more than 100 indications of over 30 different drugs in January  the documents show  with increases ranging from 4 5 percent to 9 9 percent  Drugs on the list are expected to account for more than  20 billion of Novartis  revenue this year and include multiple sclerosis drug Gilenya  psoriatic arthritis treatment Cosentyx  and leukemia treatment Tasigna   The list also includes Diovan  the brand name version of blood pressure treatment valsartan  generic versions of which are currently in shortage after a potential carcinogen was detected in active ingredients made in China  prompting widespread recalls  Novartis spokesman Eric Althoff said the company plans to raise U S  list prices on 14 percent of the medicines it sells in the country in 2019  for an average increase of 4 7 percent on those drugs   Our rebates and discounts  however  continue to grow even faster   Althoff said  As a result  the company expects a net price decrease of nearly 5 percent across the whole U S  portfolio  he said  Over the last three years  net price decreases for its U S  business have ranged from 2 percent to 2 6 percent  the company said  Bayer filed notifications with California agencies to increase prices on six of its drugs in January  many of which are birth control products  Most of these price increases are 5 percent   Bayer said that the U S  wholesale price of its products are not representative of what most consumers pay and that  list price increases are expected to be offset by higher rebates and discounts paid to insurance companies and pharmacy benefit managers   Amgen did not respond to requests for comment  AstraZeneca and Biogen declined to comment for this story   GSK would not give details about its specific price increases  which are set to take effect on or around Jan  1 and could change before then  Allergan said that all of its price increases will be aligned with its pledge made in 2016 to limit drug price increases on its products to less than 10 percent annually  The United States  which leaves drug pricing to market competition  has higher drug prices than in other countries where governments directly or indirectly control the costs  making it the world s most lucrative market for manufacturers  Lowering prescription drug prices was a top priority in Republican Trump s 2016 presidential campaign  Rival Democrats are expected to step up congressional scrutiny of drug price hikes next year after gaining control of the U S  House of Representatives in elections in November   Drug companies raising their prices and offsetting them with higher rebates benefits everyone but the consumer   HHS spokeswoman Caitlin Oakley said in a statement  
Trump and HHS Secretary Alex Azar  remain committed to lowering drug prices and reducing out of pocket costs  and will continue to take bold action to restructure this broken market   she said ",2018-12-19,Reuters,https://www.investing.com/news/stock-market-news/exclusive-big-pharma-returning-to-us-price-hikes-in-january-after-pause-1726999,1726999
104527,326042,AGN,Drug makers OK with price inclusion in TV ads if done fairly,news,Four members of Big Pharma   Pfizer   PFE  1 6     Sanofi   PA SASY   SNY  1 6    Eli Lilly  LLY  1 5   and Johnson   Johnson  JNJ  0 9    responding to the federal government s proposed inclusion of prices in TV drug ads generally support the value of increased transparency for patients  but caution that it needs to be done fairly They say that including just the list price will confuse patients since most are only responsible for co payments  Some may not fill prescriptions if they perceive that they will have to pay the full monty  shockingly high in many cases  J J says that if list price disclosures are required for drugs  then hospitals  health insurers and pharmacy benefit managers should play by similar rules Sanofi was the least supportive  regarding CMS s proposal as  oversimplified  since would fail to grasp the  nuance and complexity  of prescription drugs and biologics The trade association  Pharmaceutical Research and Manufacturers of America  PhRMA   has proposed its own voluntary guidelines that will take effect in April  It prefers to link drug price information to ads and wants to partner with advocacy groups on an online patient affordability platform that will allow them to access information on insurance coverage  co payments and other factors in addition to drug prices The 60 day comment period ended last month  CMS will now decide on the specific regulation  Legal challenges are a near certainty if prices are required in advertisements Selected tickers  BIB  GRX  THW  BME  BIS  IXJ  ARKG  GNRX  CHNA  XLV  XBI  VHT  IYH  RYH  IBB  XHE  PJP  OTCQX RHHBY  ABBV  AGN  AZN  BMY  MRK  NVS  BHC  TEVA  AMGN  BIIB  GILD  VRTX  ESRX  WBA  CVS  UNH  CELG  LLY  CINow read ,2019-01-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/drug-makers-ok-with-price-inclusion-in-tv-ads-if-done-fairly-1735248,1735248
104528,326043,AGN,Wet AMD Space In Focus  New Drug Approvals   Key Advancements,opinion,The recent FDA approval of Novartis AG s   NYSE NVS   Beovu  brolucizumab  injection for the treatment of wet age related macular degeneration  AMD  has put the spotlight on this promising space What is Wet AMD Wet AMD is a chronic  degenerative eye disease caused by an excess of a protein called vascular endothelial growth factor  VEGF   The protein triggers growth of abnormal blood vessels underneath the macula  the area of the retina responsible for sharp  central vision  The fluid that seeps through these abnormal blood vessels disrupts the normal retinal structure and ultimately damages the macula  It is the main cause of blindness  which per estimates affects more than 20 million people Approved Treatments for Wet AMDRegeneron Pharmaceuticals    NASDAQ REGN   and Bayer s   OTC BAYRY   blockbuster drug Eylea  aflibercept  is one of the market leading treatments for wet AMD  Eylea is a VEGF inhibitor indicated for the treatment of patients with wet AMD along with other retinal conditions  The drug holds a dominant position in this area Roche s   OTC RHHBY   Lucentis  ranibizumab  is another leading drug to address wet AMD  Novartis has a collaboration with Roche for Lucentis  The latter has another drug by the name Avastin  bevacizumab  for the treatment of wet AMD  off label  Hence  the approval of Beovu will induce stiff competition for both Eylea and Lucentis  Beovu is the first FDA approved anti VEGF to offer greater fluid resolution compared to Eylea  The former also has the ability to maintain eligible wet AMD patients on a three month dosing interval immediately after a three month loading phase with uncompromised efficacy  Frequent injections are a common reason why patients discontinue with the treatment  Therefore  Beovu s potential to treat patients with quarterly injections is a major positive and should enable it to capture a decent market share Promising Candidates in PipelineMeanwhile  given the global market prospects  there are many candidates in development for wet AMD Let us take a look at some of the promising ones Allergan s   NYSE AGN   anti VEGF treatment abicipar pegol is one of the most promising candidates being developed for the treatment of wet AMD  The company has partnered with clinical stage biotechnology company Molecular Partners for the development of abicipar pegol  The FDA has accepted a Biologics License Application  BLA  for abicipar pegol and is expected to deliver its verdict in mid 2020  The European Medicines Agency  EMA  too has validated a Marketing Authorisation Application  MAA  for abicipar pegol and a decision from the European Commission is awaited in the second half of 2020 Meanwhile  Roche is developing a port delivery system implant for ranibizumab  The company is also developing a bispecific antibody faricimab  RG7716  that targets both VEGF and Ang2 for wet AMD  currently in phase III studies  Privately held Graybug Vision  Inc  is a clinical stage pharmaceutical company developing long acting therapies for ocular diseases including wet AMD  The company is developing GB 102  a microparticle depot formulation of the small molecule tyrosine kinase inhibitor sunitinib  The candidate is a pan VEGF receptor inhibitor  currently under evaluation as a twice per year therapy using a simple intravitreal injection for wet AMD The company recently initiated a phase IIb study called ALTISSIMO  It is a 12 month  3 arm  randomized controlled analysis to evaluate two dose levels of GB 102  1 mg and 2 mg  administered every six months compared to Eylea  2 mg   which is administered every two months to patients with wet AMD  Meanwhile  the clinical stage biotechnology company REGENXBIO Inc    NASDAQ RGNX   is developing a gene therapy RGX 314 for the treatment of wet AMD  The entity completed dosing in the phase I IIa study for RGX 314 to treat wet AMD and further intends to initiate a phase IIb program in late 2019 Of all the above mentioned stocks  Novartis currently carries a Zacks Rank  3  Hold   You can see  ConclusionGiven the substantial market opportunity  quite a few pharma biotech companies are scampering in to develop effective treatments for wet AMD that can manage less frequent dosing  Hence  we expect a flurry of activity in this space in the near future 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/wet-amd-space-in-focus-new-drug-approvals--key-advancements-200472319,200472319
104529,326044,AGN,Aclaris Divests Rhofade To EPI Health For  55M  Shares Up,opinion,"Aclaris Therapeutics  Inc    NASDAQ ACRS   announced that it has sold worldwide rights to its rosacea drug  Rhofade Cream  and certain licenses to related intellectual property assets to privately held wholesale distributor of prescription drugs  EPI Health for  55 million  The divestiture is part of Aclaris  ongoing restructuring program to focus on its immuno inflammatory pipeline Shares of Aclaris rallied 19 3  on Oct 11  following the announcement  However  the company s shares have declined 80 8  so far this year compared with the  s decrease of 0 4  Per the terms of the deal  Aclaris is eligible to receive  35 million in upfront payment and up to  20 million in potential sales based milestone payments t  In addition  Aclaris is also eligible to receive tiered royalties on net sales of the products  EPI Health will also pay 25  of any potential upfront  license  milestone  maintenance or fixed payment to Aclaris  paid by a licensee or sublicensee in ex U S  markets  subject to specified exceptions In September  Aclaris completed a strategic review of its business and announced a restructuring plan to reform itself from a dermatology company to development stage biotech focusing on developing treatment options targeting immunology and inflammation indications  Moreover  the company announced workforce reduction by 86 employees to streamline operations and reduce costs The Rhofade divestment deal helped Aclaris to clear its  30 million debt with Oxford Finance  Following the deal  given its restructuring initiatives  the company anticipates its cash resources to be sufficient to fund its operations into the third quarter of 2021 Please note that Rhofade was a major revenue generator for Aclaris so far in 2019  The company acquired rights to Rhofade from Allergan   NYSE AGN   in 2018  Aclaris has another drug in its portfolio  Eskata  which was approved by the FDA in 2017 for treating seborrheic keratosis  a common non malignant skin tumor  The company voluntarily discontinued commercialization of the drug in August 2019 due to lower than expected sales  It is seeking a strategic partner to commercialize the drug The company is currently developing its lead pipeline candidate  A 101 45  topical solution for treatment of common warts in two late stage studies  The candidate achieved clinically and statistically significant clearance of common warts in phase III THWART 2 study  per data announced last month Apart from A 101 45  topical solution  Aclaris has two JAK inhibitors   ATI 501 and ATI 502   in mid stage development targeting atopic dermatitis and alopecia  respectively  The company had in licensed these two candidates from Rigel Pharmaceuticals  Inc    NASDAQ RIGL   in 2015  The company also has an early stage candidate  ATI 450  which is being developed for treating rheumatoid arthritis and psoriasis along with other pre clinical candidates Aclaris Therapeutics  Inc  Price
    Zacks Rank   Key PickAclaris currently carries a Zacks Rank  2  Buy   Dermira  Inc    NASDAQ DERM   is another top ranked stock from the same sector  sporting a Zacks Rank  1  Strong Buy   You can see  Estimates for Dermira s loss have narrowed 2  for 2019 and 1 9  for 2020 in the past 30 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/aclaris-divests-rhofade-to-epi-health-for-55m-shares-up-200473189,200473189
104530,326045,AGN,Johnson   Johnson s  JNJ  Legal Problems Continue To Worry Investors,opinion,"Johnson   Johnson   NYSE JNJ   is set to report their third quarter results as pending lawsuits loom over the company  The pharmaceutical giant s shares have barely moved in 2019 thus far  rising only 1 9   but the stock has outpaced the broader large cap pharmaceutical market s 0 8  decline 
The firm has seen its litigation challenges mount recently  A Philadelphia jury recently ruled that J J should pay a whopping  8 billion to a man who claimed its anti psychosis drug Risperdal caused him to develop gynecomastia  enlarged breasts   The lawsuits the company faces from over 100 000 plaintiffs have spurred uncertainty over the company and the large cap pharmaceutical industry as a whole  
Litigation Looms Over Large Cap Pharma 
As previously mentioned  Johnson   Johnson is facing lawsuits from thousands of plaintiffs over its product safety and marketing tactics  Juries and judges have ordered the health care company to pay billions in recent trials that blame its signature baby powder and other products for health complications 
The large cap pharma company s marketing tactics is accused of fueling the opioid addiction epidemic that still goes on today  Two Ohio counties recently settled with Johnson   Johnson and drug manufacturers like Allergen   NYSE AGN   and Endo International   NASDAQ ENDP   for lawsuits that accused the companies of fueling the opioid crisis  And back in August  an Oklahoma judge ordered the company to pay  572 million to the state for its contribution to the opioid addiction epidemic 
In 2018  a St  Louis jury mandated for J J to pay  4 7 billion to 22 women who alleged that they developed ovarian cancer because of their use of J J s signature baby powder  Johnson   Johnson appealed the decision and insists that their baby powder product is safe and does not cause cancer 
The recent amount of litigation the company is facing has skyrocketed from years ago  J J was facing legal action from over 100 000 plaintiffs in the middle of 2019  up significantly from the roughly 8 500 plaintiffs it faced in October of 2011  Talcum powder lawsuit plaintiffs rose to 15 500 as of June  30th 2019 from 1 400 in early 2016 
Possible Long Term Effects
Investors are split over how this might play out for J J in the upcoming months  Some believe that the pharmaceutical giant should settle some of the larger opioid cases so it can avoid long costly trials that would be largely publicized and be potentially detrimental to J J s reputation in the health care field  Furthermore  some lawyers believe that the longer the litigation is dragged on  the easier it would be for the plaintiffs to win their cases as potential groundbreaking developments in the case may be uncovered 
The  8 billion ruling the company was ordered to pay in Philadelphia can also spell further trouble for the business  it opens up the possibility of J J having to deal with billion dollar payouts for its roughly 13 000 Risperdal lawsuits  J J s legal team is likely to appeal the magnitude of the fine but the loss still represents a major liability 
J J is facing litigation on a large scale for multiple products  and Wells Fargo   NYSE WFC   analysts estimate that the opioid litigation alone could cost the company  5  10 billion to settle 
Takeaway 
J J is in jeopardy of potentially losing a groundbreaking case that can set off a domino effect in the rest of its other cases  Its reputation as a renowned health care company and billions of dollars in reparations are at stake in the upcoming months and as a result  investors are right to be worried about the staggering number of pending lawsuits the corporation is facing 
Our Q3 estimates forecast J J to report a 2 44  drop in earnings to  2 00 per share while sales are expected to fall 1 31  to  20 08 billion  JNJ stock sits at a Zacks Rank  4  Sell  
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnsons-jnj-legal-problems-continue-to-worry-investors-200473322,200473322
104531,326046,AGN,Allergan  AGN  Shareholders Approve Acquisition By AbbVie,opinion,"Allergan plc   NYSE AGN   announced that its shareholders have approved its pending acquisition by AbbVie  Inc    NYSE ABBV    Allergan said that approximately 68 6  of shareholders eligible to vote at Allergan s extraordinary general meeting of shareholders as well as a special court ordered meeting of shareholders voted in favor of the transaction 
Allergan announced the definitive transaction to be acquired by AbbVie in a cash and stock deal in June this year  AbbVie is offering  120 30 in cash and 0 866 of its share  worth  67 94  for each share of Allergan  The total transaction value is nearly  63 billion  The acquisition is expected to close by early 2020  if all necessary approvals are obtained 
Allergan s share price has risen 26 4  this year so far against the  s decrease of 8 8  
 

 
AbbVie s offer represented a premium of 45  to Allergan s closing price on Jun 24  thereby proving to be rewarding for its shareholders  Moreover  with blockbuster eye drug  Restasis expected to face generic competition  fears of new competition to Allergan s key drug  Botox and some recent pipeline setbacks  the merger with AbbVie could prove to be the best way out for Allergan 
Meanwhile  AbbVie s rationale behind the Allergan deal is to add a new blockbuster product to its portfolio  Botox  ahead of generic competition for its blockbuster inflammatory medicine  Humira  Generic versions of Humira are already denting revenues in Europe and are expected to be launched in the United States in 2023  AbbVie is heavily dependent on Humira and is looking to diversify its portfolio 
Approved for therapeutic and aesthetic use  Botox is a key top line driver for Allergan and looks fit to be the next revenue driver for AbbVie after Humira loses exclusivity  Overall  the Allergan acquisition should diversify AbbVie s revenue base to markets categories outside AbbVie s present drug portfolio and accelerate its non Humira business 
However  after the deal was announced  some investors expressed concerns that AbbVie has overpaid for Botox as new competitive pressure looms large 
In February 2019  Evolus  Inc  s   NASDAQ EOLS   Jeuveau injection  indicated to improve the appearance of glabellar or frown lines  was approved by the FDA  which can pose competition to Botox  In the fall of 2019  Revance Therapeutics  Inc    NASDAQ RVNC   will file for approval of DaxibotulinumtoxinA for Injection  DAXI   a rival treatment to Botox for the frown lines indication  It has demonstrated longer duration of efficacy compared to Botox in late stage studies 
Allergan currently has a Zacks Rank  3  Hold   You can see  
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-shareholders-approve-acquisition-by-abbvie-200473711,200473711
104532,326047,AGN,Editas Inks Deal For Gene Editing Neurological Disease Drugs,opinion,Editas Medicine  Inc    NASDAQ EDIT   announced that it has entered into a strategic research collaboration with privately held gene therapy company Asklepios BioPharmaceutical  AskBio  to jointly explore in vivo delivery of genome editing medicines for treating neurological diseases The collaboration will integrate AskBio s AAV technology and clinical stage manufacturing with Editas  genome editing technologies to innovative genome editing medicines for treating neurological diseases with high unmet need Financial terms of the deal were not disclosed Shares of Editas have lost 10 9  so far this year compared with the  decrease of 6 4  Notably  Editas makes medicines to treat serious diseases using its proprietary genome editing platform based on CRISPR technology The company s lead pipeline candidate is EDIT 101 which uses CRISPR gene editing to treat Leber congenital amaurosis type 10  LCA10    a rare genetic illness that causes blindness Editas is developing EDIT 101 in partnership with Allergan   NYSE AGN    Both companies plan to initiate patient dosing in the phase I II dose escalation study called Brilliance on EDIT 101 for addressing LCA10 in the second half of 2019  The study opened for patient enrolment in July The company is also pursuing the development of CRISPR candidates for eye diseases other than LCA10  which include Usher Syndrome type 2A  USH2A  and the recurrent ocular Herpes Simplex Virus type 1  HSV 1  Meanwhile  Editas has some high profile collaborations with big pharma entities for its CRISPR technology  which provide research support and sufficient funds to fulfill its pipeline development plans  Apart from Allergan  it has a collaboration and licensing pact with Juno Therapeutics   now part of Celgene   NASDAQ CELG     to use the latter s gene editing approaches including CRISPR Cas9 for developing the engineered T cell medicines to tackle cancer In April 2019  Editas inked a research and cross licensing deal with privately held BlueRock Therapeutics  LP  to combine the respective genome editing and cell therapy technologies to discover  develop and manufacture novel engineered cell medicines Zacks Rank   Key PickEditas currently carries a Zacks Rank  4  Sell  A better ranked stock in the healthcare sector is Incyte Corporation   NASDAQ INCY    which sports a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates have been revised 1 5  upward for 2019 and 1 5  for 2020 over the past 60 days  The stock has rallied 23 5  year to date Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/editas-inks-deal-for-gene-editing-neurological-disease-drugs-200474174,200474174
104564,326079,AGN,Allergan sues Pfizer over costs of opioid litigation,news,"By Nate Raymond  Reuters    Allergan  NYSE AGN  Plc on Thursday sued  Pfizer  Inc  NYSE PFE  to require its rival to cover any damages it is forced to pay as a result of hundreds of lawsuits claiming Allergan deceptively marketed an opioid it acquired from a company Pfizer bought  In a lawsuit filed in federal court in Cleveland  Ohio  Allergan said the  primary basis  for the claims against it was the alleged improper marketing and sale of Kadian  a form of morphine  in the years before it gained rights to the painkiller in late 2008   But now that more than a thousand lawsuits seek to impose liability for that very marketing and sale  Pfizer has rejected any responsibility to indemnify Allergan   alleged Allergan Finance LLC  the subsidiary that filed the lawsuit  Pfizer in a statement said Allergan s claims related to a drug it never sold and arise from a contract with King Pharmaceuticals Inc  which Pfizer acquired in 2010    We will review Allergan s suit and respond accordingly   Pfizer said  Opioids were involved in more than 42 000 overdose deaths in 2016  according to the U S  Centers for Disease Control and Prevention  Drugmakers including Allergan  Purdue Pharma LP and Endo International Plc are facing a wave of lawsuits by state and local governments accusing them of pushing addictive painkillers through deceptive marketing  At least 1 021 lawsuits are consolidated before U S  District Judge Dan Polster in Cleveland  The first trial is set for March  Plaintiffs  lawyers pursuing the cases have compared them to the litigation by states against the tobacco industry that led to a  246 billion settlement in 1998   In its complaint  Allergan said most of the lawsuits it faces seeking to hold it responsible for playing a role in the opioid crisis primarily relate to improper marketing of Kadian and involve allegations dating back to the mid 1990s  The drug at that time was owned by Alpharma Inc  which King Pharmaceuticals acquired in 2008  the same year King sold the rights to Kadian to  Actavis   In 2016  Actavis acquired Allergan and took on the company s name  Sale of rights to Kadian was a condition of winning U S  antitrust approval for King s acquisition of Alpharma  Allergan argued that Pfizer under the terms of an agreement Actavis signed with King in 2008 was required to indemnify it for any damages arising out of the pre 2009 marketing of Kadian  But Allergan said Pfizer has rejected its claim for indemnification  
The case is In re National Prescription Opiate Litigation  U S  District Court  Northern District of Ohio  No  17 md 2804 ",2018-08-02,Reuters,https://www.investing.com/news/stock-market-news/allergan-sues-pfizer-over-costs-of-opioid-litigation-1557993,1557993
104565,326080,AGN,U S  tax cuts prompt rethink by some  inverted  companies,news,"By David Morgan WASHINGTON  Reuters    A few U S  companies that moved offshore in a wave of inversion deals are considering returning to the United States now that domestic tax rates are lower and tax policing is tougher abroad  attorneys and consultants said  A handful of clients have asked about redomestication  which could involve buying a U S  headquartered company  the tax advisers said  No specific companies or deals were identified   Uncertainties about U S  Republican President Donald Trump s trade policies have also prompted the conversations  the advisers said    Inverted companies have reason to look at whether or not it still makes sense for them to be offshore  particularly those that manufacture product outside the U S  and sell it back into the U S    said Pam Olson  a Washington based tax expert at accounting and consulting group PwC  A surge of homecomings would reverse an on again  off again trend since the 1980s of U S  companies reincorporating overseas to cut tax costs  In an inversion  a U S  company typically buys a smaller foreign firm in a lower tax country and adopts the acquired firm s headquarters  That maneuver means the company does not have to pay U S  taxes on foreign income  even if its management and operations remain in the United States   Trump s public shaming of companies that move plants and jobs overseas has also made some consumer focused firms rethink inversions  advisers said  Executives at inverted companies see less tax  friction  under the new tax regime that would discourage redomiciling  advisers said  and have also mentioned the appeal of corporate friendly  low tax states and improved access to U S  government contracts in the discussions   More than 60 U S  companies have inverted  including medical device maker  Medtronic  Plc  N MDT   There was a wave of deals in 2011 2014  but inversions largely ended in 2015 after a regulatory crackdown by Democratic President Barack Obama   Pfizer  Inc  N PFE  walked away from a  160 billion merger with Ireland based Allergan Plc  N AGN  in 2016 because of new U S  Treasury rules   The Trump administration last month finalized and left in place the Obama era rules  The Republican tax overhaul signed into law in December eliminated a key inversion incentive by slashing the U S  corporate rate to 21 percent from 35 percent and altering how foreign profits are taxed  A push to prevent profit shifting strategies and corporate tax base erosion across the 36 nation Organisation for Economic Co operation and Development is also making foreign tax domiciles marginally less attractive  especially in Europe  Tax advisers said it is still possible to structure lower tax rates in countries such as Ireland and the Netherlands  How the U S  Treasury implements parts of the new tax law will help determine whether companies return to the United States  A new tax on Global Intangible Low Taxed Income  or GILTI  on its face imposes a 10 5 percent tax rate  But because the bill is poorly worded  it can result in rates of 15 percent or more due to unfavorable effects on foreign tax credits  GILTI s implementation could influence tax base decisions among companies redomiciled in Britain  which may consider whether to relocate to the United States or other countries to avoid the effects of Brexit  Redomiciling to the United States is a case by case decision  said Joe Calianno  tax partner at financial advisory firm BDO   
 It really is a modeling exercise to determine whether it s more beneficial being a U S  based company versus a foreign based company   he said ",2018-08-03,Reuters,https://www.investing.com/news/economy-news/us-tax-cuts-prompt-rethink-by-some-inverted-companies-1559919,1559919
104566,326081,AGN,Allergan s Esmya fibroid treatment rejected by FDA,news,Allergan  NYSE AGN   1 6  after hours on news that the Food and Drug Administration rejected the company s Esmya treatment for uterine fibroids  requesting more information and citing safety issues outside the U S  AGN says its New Drug Application for ulipristal acetate included results of a clinical trial program which included two U S  Phase 3 clinical trials and all Phase 3 EU registration studies as well as real world data in more than 700K women with uterine fibroids  across 80 countries  The FDA decision could affect AGN s plan to sell its women s health unit  as CEO Brent Saunders said last month that potential bidders were waiting to see how the FDA would handle Esmya s approval in order to properly value the business  Now read ,2018-08-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergans-esmya-fibroid-treatment-rejected-by-fda-1582617,1582617
104567,326082,AGN,Oklahoma first state to negotiate efficacy based drug prices,news,Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice  CMS signed off on allowing the state to employ the approach two months ago The first contract to be inked was with Alkermes plc  ALKS  1   for schizophrenia med ARISTADA  aripiprazole lauroxil   The agreed upon price decreases every other month as long as the prescription is refilled  compliance with drug regimens is a major problem in this patient population   The longer the patient takes the drug  the better the rebate Contracts for an expensive antibiotic and an epilepsy drug are nearing completion By law  state Medicaid programs  key buyers in the  450B U S  prescription drug market  received a mandatory 23  discount of list which  of course  does nothing to constrain costs since most drug companies hike prices one or two times each year  State Medicaid administrators often negotiate additional rebates for individual medicines Michigan is reportedly pursuing CMS approval to try its hand at Oklahoma s initiative  Colorado says it is in the  early planning stages  for a similar move Selected tickers  XLV  IBB  XBI  XPH  IHE  PPH  VHT  OTCQX RHHBY  ABBV  AGN  AZN  BMY  GSK  JNJ  MRK  NVS  BHC  TEVA  AMGN  BIIB  GILD  VRTX  OTCPK TKPYY  ESRX  WBA  CVS  UNH  PFE  CELG Now read ,2018-08-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/oklahoma-first-state-to-negotiate-efficacybased-drug-prices-1584868,1584868
104568,326083,AGN,Supernus prevails on appeal of Oxtellar XR patents by TWi Pharma,news,The U S  Court of Appeals affirms a district court decision that TWi Pharmaceuticals infringed on three patents protecting Supernus Pharmaceuticals   SUPN  1 7   epilepsy med Oxtellar XR  The ruling means TWi will not be able to market its version until at least 2027 About two years ago  the appellate court found that  Actavis   NYSE AGN   TEVA  3 7   also infringed in Oxtellar XR patents Now read ,2018-09-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/supernus-prevails-on-appeal-of-oxtellar-xr-patents-by-twi-pharma-1601080,1601080
104569,326084,AGN,Allergan says revenue from aesthetics unit may double by 2025,news,"By Michael Erman NEW YORK  Reuters    Allergan Plc  N AGN  said revenue from its medical aesthetics business could double by 2025  even as it faces increasing competition for its blockbuster wrinkle treatment  Botox  The drugmaker announced earlier on Friday the acquisition of Bonti Inc  which makes a shorter acting neurotoxin than Botox  Allergan is also doubling its investment in direct to consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc  O RVNC  and  Evolus Inc   O EOLS  vie to wrest market share with rival treatments to Botox  The company made the announcements at its Medical Aesthetics Day in New York  Chief Commercial Officer Bill Meury said Allergan expects revenue at its medical aesthetics unit to grow to  7 billion to  8 billion  That compares with revenue of  3 8 billion from the business in 2017   Beyond Botox  the unit includes dermal filler Juvederm  the CoolSculpting fat freezing systems  and other treatments  He said the forecast implied an 8 to 10 percent compound annual growth rate  Meury said the Bonti acquisition would allow the company to market a new  starter toxin   Patients could test drive the treatment  which lasts for two to four weeks  to help them decide if they want to use longer term Botox  
Shares of Allergan fell 2 cents to  90 06  while shares of Revance and Evolus each fell around 2 5 percent in Friday morning trading ",2018-09-14,Reuters,https://www.investing.com/news/stock-market-news/allergan-says-aesthetics-unit-revenue-may-double-by-2025-1610883,1610883
104570,326085,AGN,Huge traffic for MGM Springfield,news,MGM Resorts  MGM  officials say that traffic at the MGM Springfield is way ahead of expectations  The new casino is averaging about 50K daily visitors during the weekends and 25K daily visitors during the week since the August 24th opening  Early forecasts for the MGM Springfield were for traffic of around 15K to 20K per day  Shares of MGM are down 18  YTD  Now read ,2018-09-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/huge-traffic-for-mgm-springfield-1611196,1611196
104571,326086,AGN,Pfizer replaces long time CEO Read with veteran Bourla,news,"By Tamara Mathias and Ankur Banerjee  Reuters     Pfizer  Inc  N PFE  said on Monday Chief Executive Ian Read would become executive chairman from the start of next year  handing the reins of the largest U S  drugmaker to veteran insider Albert Bourla after eight years in charge   Under Read  a Scot who joined Pfizer in 1978  the drugmaker won 30 approvals from the U S  health regulator while weathering patent expirations on several of its blockbusters  including cholesterol drug  Lipitor  Read  however  failed in his efforts to pull off two mega deals  with plans to buy British drugmaker AstraZeneca  L AZN  in 2014 and Ireland based Allergan Plc  N AGN  in 2016 both falling through   Bourla  56  was appointed chief operating officer at the start of this year  after leading the drugmaker s Innovative Health business  which recorded revenue of  31 4 billion in 2017   This looks like a well considered transition thus I m not convinced it will herald a major change in strategic thinking  particularly as Ian will still stay on as chairman   Berenberg analyst Alistair Campbell said  The appointment comes at a time when drugmakers are facing intense scrutiny over drug pricing  with regulators and the Trump administration aiming to lower prescription drug costs   In July  Pfizer said it was deferring drug price increases for no more than six months after a conversation between Read and President Trump  Pfizer s shares  which have risen about 160 percent since Read took over as CEO in December 2010  were trading up 0 36 percent at  44 23 before the bell   It s been an honor to serve as Pfizer s CEO for the past eight years   Read said   However  now is the right time for a leadership change  and Albert is the right person to guide Pfizer through the coming era    
Last week  rival Merck   Co Inc  N MRK  said it would amend a policy to allow its head  Kenneth Frazier  to remain CEO beyond 2019 when he was expected to retire ",2018-10-01,Reuters,https://www.investing.com/news/stock-market-news/pfizer-ceo-to-step-down-1629703,1629703
104572,326087,AGN,AstraZeneca halts UK investments over Brexit uncertainties   Reuters,news,Citing a lack of clarity related to Brexit  AstraZeneca  AZN  1 2   non executive Chairman Leif Johansson told French newspaper Le Monde that the company has suspended investments in Britain It has already spent  40M   53M  stockpiling drugs to prevent supply disruptions if there is no formal withdrawal agreement Other drugmakers have warned that a  no deal  Brexit could bring shortages Source  ReutersNow read ,2018-10-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/astrazeneca-halts-uk-investments-over-brexit-uncertainties--reuters-1644584,1644584
104573,326088,AGN,FDA issues new guidance aimed at more efficient drug development,news,The FDA has issued two guidance documents that it says should help make the drug development process more efficient The first addresses the use of minimal residual disease  MRD  as a biomarker in clinical trials for certain blood cancers  The agency believes it clarifies how best to use MRD as a general measure of tumor burden or assess the likelihood of relapse The second is final guidance on the regulatory framework for finding treatments that address underlying molecular changes that cause or contribute to disease  e g   gene therapies   It includes an approach for drug developers for enrolling patients with rare genetic variants in clinical trials and the evidence required to demonstrate efficacy Selected tickers  BIB  GRX  THW  BME  BIS  IXJ  ARKG  CHNA  XLV  XBI  IBB  XBI  XPH  IHE  PPH  VHT  OTCQX RHHBY  ABBV  AGN  AZN  BMY  GSK  JNJ  MRK  NVS  BHC  TEVA  AMGN  BIIB  GILD  VRTX  OTCPK TKPYY  ESRX  WBA  CVS  UNH  PFE  CELGNow read ,2018-10-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-issues-new-guidance-aimed-at-more-efficient-drug-development-1644755,1644755
104574,326089,AGN,FDA Warns About Safety Of Breast Implant  3 Stocks At Risk,opinion,Breast augmentation tops the plastic surgery trends in the United States  rapidly attracting investors  interest  Last year alone  a total of 313 735 breast augmentation procedures were executed in the country On average  an implant costs  5 925  raking in huge profits for manufacturers  In fact   states that the global breast implant market was valued at  2 3 billion in 2018 and is expected to see a CAGR of 10 5  by 2025  drawing potential investors Health PerilsHowever  with a steady rise in breast implant use  the FDA has identified the development of anaplastic large cell lymphoma  non Hodgkin s   a rare type of cancer Last month  the agency asked pharmaceutical bigwig Allergan   NYSE AGN   to voluntarily recall nearly a dozen of its Biocell textured implants since those were linked to non Hodgkin s lymphoma  Notably  the FDA cited an additional 116 cases of breast implant anaplastic large cell lymphoma in women undergoing breast augmentations  Moreover  regulators have become aware of 33 deaths related to the disease  up significantly from nine deaths in February This emerging health hazard is likely to build pressure on several breast implant manufacturers  keeping potential investors at bay Let s take a look at a few companies which offer a broad spectrum of breast implants and therefore might experience a slump owing to rising health concerns Stocks Likely to Bear the BruntGiven the health concern  we have zeroed down on three stocks  each carrying a Zacks Rank  3  Hold   which might be in for trouble  You can see  Also  these stocks have underperformed their respective industries over the past month We have already discussed the recall of Allergan s breast implant devices  It is disappointing to note that the implants were banned in Europe last December  following 481 deaths resulting from the company s Biocell implants  Additionally  nine models of Allergan s textured breast implants may soon face a ban in Australia for similar reasons Resultantly  the company s second quarter revenues have been impacted  Earlier  it also saw a 30  drop in worldwide breast implant revenues Experts opine that Allergan might as well be required to cease import  manufacture and export of the devices Reflective of these  over the past month  the stock has rallied 4 3   underperforming the  s 5 7  rise Next on our list is Johnson   Johnson   NYSE JNJ    The New Jersey based MedTech bigwig acquired aesthetic surgical product manufacturer  Mentor  in 2017  Since then  the company has been raking in billions from its breast augmentation and breast reconstruction products  Notably  the FDA approved flagship MemoryGel   a silicone breast implant   has seen robust demand  However  in the recent past  the implants have been said to be causing muscle pain  nausea and other such discomforting symptoms  leading to the filing of a lawsuit in a California state court Also  in March  Johnson and Johnson received a warning letter from the FDA for not having conducted post approval long term safety studies on their breast implants  The company is also yet to respond to the TGA  Therapeutic Goods Administration  in Australia  following Allergan s product recalls Over the past month  the stock has slipped 0 2  against the  s 0 4  rise California based Sientra  Inc    NASDAQ SIEN   is also under threat  The company offers a wide spectrum of breast implants like Sientra Platinum20  OPUS  AlloX2 for augmentations  Earlier  the company faced potential risks in the wake of the filing of cases against Johnson and Johnson s products  In March  the company received a warning letter from the FDA for not having conducted post approval long term safety studies on their breast implants However  in the last reported quarter  Sinetra saw 25  year over year growth in its breast products Over the past month  the stock has rallied 0 9  compared with the  s 2 3  rise 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-09-18,Zacks Investment Research,https://www.investing.com/analysis/fda-warns-about-safety-of-breast-implant-3-stocks-at-risk-200466135,200466135
104575,326090,AGN,Ironwood Amends Linzess Agreement With AstraZeneca In China,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   amended its collaboration agreement with UK based pharma giant AstraZeneca   NYSE AZN   related to development and commercialization of its gastrointestinal drug  Linzess  linaclotide   in China  Both companies had entered into an agreement in 2012 
Linzess is currently approved as a treatment for irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation in the United States and Japan  The drug was approved for IBS C in China in January this year 
The deal gives AstraZeneca exclusive rights to develop  manufacture and commercialize Linzess in China  AstraZeneca will be responsible for all expenses related to Linzess in China  Ironwood will stop joint funding for development and commercialization of linaclotide in China and will no longer share profit from net sales of Linzess in that country 
Per the terms of the deal  Ironwood will receive up to  15 million from AstraZeneca  which includes  35 million in non contingent payments to be paid in three installments through 2024  The remaining  90 million will be paid as commercial milestone payments upon achievement of certain net sales targets  Ironwood is also eligible to receive tiered royalties  up to 20   on annual net sales of Linzess in China 
So far this year  shares of Ironwood have declined 7 1  against 7  increase for the  

 
Ironwood also amended its agreement with Japanese pharma company  Astellas Pharma  last month  Ironwood will receive  10 million and will be no longer responsible for the supply of linaclotide active pharmaceutical ingredient to Astellas for manufacturing of Linzess as per the amended deal 
Please note that Ironwood markets Linzess in the United States in partnership with Allergan   NYSE AGN    The amendments to the existing collaboration agreements for Linzess in international markets are part of Ironwood s strategy to streamline its business and focus its efforts on the United States 
Ironwood is currently developing Linzess for treating multiple abdominal symptoms in adult patients with IBS C  In June  the company  positive top line data from a phase IIIb study  It is also developing a delayed release version of Linzess  MD 7246  in a phase II study 
Notably  Linzess has performed encouragingly on the back of strong demand and expansion in new patient population and geographical regions  However  the drug may face rising competition going forward with other companies developing treatment for IBS C  Earlier this month  Ardelyx  Inc    NASDAQ ARDX   received  for Ibsrela  tenapanor  as a treatment for IBS C Ironwood Pharmaceuticals  Inc  Price
 

    
Zacks Rank
Ironwood currently carries a Zacks Rank  3  Hold   You can see  
5 Stocks Set to Double
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth 
Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-09-19,Zacks Investment Research,https://www.investing.com/analysis/ironwood-amends-linzess-agreement-with-astrazeneca-in-china-200466319,200466319
104576,326091,AGN,FDA Warns About Safety Of Breast Implant  3 Stocks At Risk  Revised ,opinion,Breast augmentation tops the plastic surgery trends in the United States  rapidly attracting investors  interest  Last year alone  a total of 313 735 breast augmentation procedures were executed in the country On average  an implant costs  5 925  raking in huge profits for manufacturers  In fact   states that the global breast implant market was valued at  2 3 billion in 2018 and is expected to see a CAGR of 10 5  by 2025  drawing potential investors Health PerilsHowever  with a steady rise in breast implant use  the FDA has identified the development of anaplastic large cell lymphoma  non Hodgkin s   a rare type of cancer Last month  the agency asked pharmaceutical bigwig Allergan   NYSE AGN   to voluntarily recall nearly a dozen of its Biocell textured implants since those were linked to non Hodgkin s lymphoma  Notably  the FDA cited an additional 116 cases of breast implant anaplastic large cell lymphoma in women undergoing breast augmentations  Moreover  regulators have become aware of 33 deaths related to the disease  up significantly from nine deaths in February This emerging health hazard is likely to build pressure on several breast implant manufacturers  keeping potential investors at bay Let s take a look at a few companies which offer a broad spectrum of breast implants and therefore might experience a slump owing to rising health concerns Stocks Likely to Bear the BruntGiven the health concern  we have zeroed down on three stocks  each carrying a Zacks Rank  3  Hold   which might be in for trouble  You can see  Also  these stocks have underperformed their respective industries over the past month We have already discussed the recall of Allergan s breast implant devices  It is disappointing to note that the Biocell implants were banned in Europe last December  following 481 cases of lymphoma resulting from the company s Biocell implants  Additionally  nine models of Allergan s textured breast implants may soon face a ban in Australia for similar reasons Resultantly  the company s second quarter revenues have been impacted  Earlier  it also saw a 30  drop in worldwide breast implant revenues Experts opine that Allergan might as well be required to cease import  manufacture and export of the devices Reflective of these  over the past month  the stock has rallied 4 3   underperforming the  s 5 7  rise Next on our list is Johnson   Johnson   NYSE JNJ    The New Jersey based MedTech bigwig acquired aesthetic surgical product manufacturer  Mentor  in 2017  Since then  the company has been raking in billions from its breast augmentation and breast reconstruction products  Notably  the FDA approved flagship MemoryGel   a silicone breast implant   has seen robust demand  However  in the recent past  the implants have been said to be causing muscle pain  nausea and other such discomforting symptoms  leading to the filing of a lawsuit in a California state court Also  in March  Johnson and Johnson received a warning letter from the FDA for not having conducted post approval long term safety studies on their breast implants  The company is also yet to respond to the TGA  Therapeutic Goods Administration  in Australia  following Allergan s product recalls Over the past month  the stock has slipped 0 2  against the  s 0 4  rise California based Sientra  Inc    NASDAQ SIEN   is also under treat  The company offers a wide spectrum of breast implants like Sientra Platinum20  OPUS  AlloX2 for augmentations  Earlier  the company faced potential risks in the wake of the filing of cases against Johnson and Johnson s products  In March  the company received a warning letter from the FDA for not having conducted post approval long term safety studies on their breast implants However  in the last reported quarter  Sientra saw 25  year over year growth in its breast products Over the past month  the stock has rallied 0 9  compared with the  s 2 3  rise  We are reissuing this article to correct a mistake  The original article  issued on September 19  2019  should no longer be relied upon  ,2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/fda-warns-about-safety-of-breast-implant-3-stocks-at-risk-revised-200466945,200466945
104577,326092,AGN,The Zacks Analyst Blog Highlights  Bristol Myers  Lockheed  Alphabet  Allergan And Kinder Morgan,opinion,For Immediate ReleaseChicago  IL  September 24  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Bristol Myers Squibb   NYSE BMY    Lockheed Martin   NYSE LMT    Alphabet   NASDAQ GOOGL    Allergan   NYSE AGN   and Kinder Morgan   NYSE KMI   Here are highlights from Monday s Analyst Blog Top Analyst Reports for Bristol Myers  Lockheed Martin and AlphabetThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Bristol Myers Squibb  Lockheed Martin and Alphabet  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Bristol Myers Squibb s shares have outperformed the Zacks Large Cap Pharmaceuticals industry in the past six months   6 5  vs   3    The Zacks analyst thinks that Bristol Myers  lead immuno oncology drug  Opdivo  continues to drive growth  Label expansion of the drug into additional indications should further boost the top line Empliciti and Sprycel are also performing well on label expansion  Moreover  Bristol Myers has presence in other core therapeutic areas  including immunoscience and cardiovascular  Blood thinner drug  Eliquis  is expected to drive further growth  propelled by increased share in the novel oral anticoagulant market Meanwhile  the impending acquisition of Celgene  NASDAQ CELG  will broaden the company s oncology portfolio with the addition of the blockbuster drug  Revlimid  However  pipeline setbacks are concerns  The failure of the part 2 of the Checkmate 227 study was disappointing  given the potential in the NSCLC market  You can  Shares of Lockheed Martin have gained 7 9  in the past three months  outperforming the Zacks Aerospace Defense industry s rise of 5 1   The Zacks analyst believes that Lockheed Martin enjoys strong demand for its high end military equipment in domestic and international markets Lockheed Martin is also the largest U S  defense contractor with a platform centric focus that guarantees a steady inflow of follow on orders from a leveraged presence in the Army  Air Force  Navy and IT programs  As a result  it witnesses solid order growth  In a year s time  Lockheed Martin has outperformed the industry However  the company s higher debt to equity ratio shows that the stock is highly leveraged when compared with its industry  Lockheed Martin also faces intense global competition for its broad portfolio of products and services  Additionally  suspension of the Turkish contract for the F 35 program may hurt the company s operating results  You can   Alphabet s shares have gained 17 7  year to date  outperforming the Zacks Internet Services industry s rise of 3 8  over the same period  The Zacks analyst believes that Alphabet will continue to be driven by improving search   advertising revenues  hardware and AI The company s strong focus on bolstering its presence in the cloud market on the back of expanding data centers and robust cloud offerings continues to aid growth  Its initiatives toward elimination of bad ads and introducing useful major search updates are tailwinds Google s robust mobile search is also a positive  Its strong focus on innovation of its AI techniques and the home automation space is aiding business growth  However  the company s growing litigation issues  growing competition and increased spending on YouTube might hurt profitability   You can   Other noteworthy reports we are featuring today include Allergan and Kinder Morgan Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-bristolmyers-lockheed-alphabet-allergan-and-kinder-morgan-200467523,200467523
104578,326093,AGN,Allergan  AGN  Stock Moves  0 1   What You Should Know,opinion,"Allergan  NYSE AGN  closed at  166 69 in the latest trading session  marking a  0 1  move from the prior day  This change was narrower than the S P 500 s daily loss of 0 84   Meanwhile  the Dow lost 0 53   and the Nasdaq  a tech heavy index  lost 1 47  
Heading into today  shares of the Botox maker had gained 4 14  over the past month  outpacing the Medical sector s gain of 2 64  and lagging the S P 500 s gain of 5 2  in that time 
Wall Street will be looking for positivity from AGN as it approaches its next earnings report date  The company is expected to report EPS of  4 22  down 0 71  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  3 87 billion  down 1 14  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  16 68 per share and revenue of  15 48 billion  which would represent changes of  0 06  and  1 92   respectively  from the prior year 
Investors should also note any recent changes to analyst estimates for AGN  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 02  lower  AGN is holding a Zacks Rank of  3  Hold  right now 
Looking at its valuation  AGN is holding a Forward P E ratio of 10  This valuation marks a premium compared to its industry s average Forward P E of 7 72 
We can also see that AGN currently has a PEG ratio of 1 98  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  AGN s industry had an average PEG ratio of 0 98 as of yesterday s close 
The Medical   Generic Drugs industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 78  which puts it in the top 31  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-stock-moves-01-what-you-should-know-200467676,200467676
104579,326094,AGN,IntelGenx  IGXT  Resubmits NDA For Migraine Candidate To FDA,opinion,"IntelGenx Corp    OTC IGXT   announced that it has resubmitted its new drug application   NDA   for Rizaport VersaFilm for the treatment of acute migraines to the FDA   
The company received a Complete Response Letter   CRL   from the FDA regarding the NDA in April 2019  The FDA cited the issues related to the Chemistry  Manufacturing and Controls section of the application  The agency requested additional information  but no new bioequivalence study was asked for 
We note that Rizaport is a patent protected  proprietary  oral thin film formulation of rizatriptan benzoate  a 5 HT1 receptor agonist  and the active drug in Merck   Co  s   NYSE MRK   Maxalt  Rizaport offers a potentially advantageous therapeutic alternative for many migraine patients due to its convenient dosing  facile intake due to the lack of need for water  and neutral flavor  Rizaport is developed using VersaFilm  IntelGenx s proprietary oral film technology 
Rizaport 5 mg and 10 mg were approved for marketing in Germany in October 2015 and in Luxembourg in April 2017 under the European Decentralized Procedure 
IntelGenx looks forward to working with partner  Gensco Pharma  to commercialize Rizaport in the United States upon FDA approval 
Shares of the company have gained 10 4  year to date compared with the  s growth of 3 7  

 
We remind investors that  Allergan plc s   NYSE AGN   NDA for oral anti calcitonin gene related peptide   CGRP   candidate  ubrogepant is under review by the FDA for the acute treatment for migraine in adult patients  Allergan s largest product  Botox  is approved for treating migraine and several other diseases  In 2018  three anti CGRP drugs received approval from the FDA for treating migraine   Amgen Novartis  Aimovig  Eli Lilly s   NYSE LLY   Emgality and Teva Pharma s Ajovy 
IntelGenx currently carries a Zacks Rank  4  Sell   You can see  IntelGenx Technologies Corp  Price

    
Breakout Biotech Stocks with Triple Digit Profit Potential 
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-09-27,Zacks Investment Research,https://www.investing.com/analysis/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda-200468857,200468857
104580,326095,AGN,Allergan  AGN  Stock Moves  1 09   What You Should Know,opinion,"Allergan  NYSE AGN  closed the most recent trading day at  166 46  moving  1 09  from the previous trading session  This change was narrower than the S P 500 s daily loss of 1 23   At the same time  the Dow lost 1 28   and the tech heavy Nasdaq lost 1 13  
Coming into today  shares of the Botox maker had gained 5 37  in the past month  In that same time  the Medical sector lost 1 2   while the S P 500 gained 1 95  
Investors will be hoping for strength from AGN as it approaches its next earnings release  The company is expected to report EPS of  4 22  down 0 71  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  3 87 billion  down 1 14  from the year ago period 
AGN s full year Zacks Consensus Estimates are calling for earnings of  16 68 per share and revenue of  15 48 billion  These results would represent year over year changes of  0 06  and  1 92   respectively 
Any recent changes to analyst estimates for AGN should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 02  lower within the past month  AGN is currently sporting a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that AGN has a Forward P E ratio of 10 09 right now  This valuation marks a premium compared to its industry s average Forward P E of 5 93 
Also  we should mention that AGN has a PEG ratio of 1 99  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Medical   Generic Drugs stocks are  on average  holding a PEG ratio of 0 9 based on yesterday s closing prices 
The Medical   Generic Drugs industry is part of the Medical sector  This group has a Zacks Industry Rank of 77  putting it in the top 31  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-stock-moves-109-what-you-should-know-200469688,200469688
104611,326126,AGN,Rise in U S  suicides highlights need for new depression drugs,news,"By Julie Steenhuysen CHICAGO  Reuters    A spike in suicide rates in the United States has cast fresh light on the need for more effective treatments for major depression  with researchers saying it is a tricky development area that has largely been abandoned by big pharmaceutical companies  U S  health authorities said on Thursday that there had been a sharp rise in suicide rates across the country since the beginning of the century and called for a comprehensive approach to addressing depression  The report was issued the same week as the high profile suicides of celebrities Anthony Bourdain and Kate Spade  Reuters was not able to determine if either Bourdain or Spade were getting drug treatment   Kate Spade s husband Andy Spade said in a statement this week that she had suffered from depression for many years and was working closely with her doctors  A representative for Andy Spade said he had no further comment on Saturday  A representative for Bourdain could not immediately be reached for comment  With the availability of numerous cheap generic antidepressants  many of which offer only marginal benefit  developing medicines for depression is a tough sell  Drugmakers have 140 therapies in development targeting mental health issues  including 39 aimed at depression  according to the Pharmaceutical Research and Manufacturers of America trade group  That compares with the industry s work on some 1 100 experimental cancer drugs  which can command some of the highest prices   Psychiatry has become a disfavored area for investment   said Harry Tracy  whose newsletter NeuroPerspective tracks developments in drug treatments for psychiatric problems   Insurers say  why should we pay more for a new treatment     Some say anti depressant drugs take too long to become effective  if they are effective at all  About half of people with depression fail to respond to current therapies  said Dr  Husseini Manji  global head of neuroscience at Johnson   Johnson  N JNJ  s Janssen unit  Developing antidepressants is risky  Patients in clinical trials often show a big placebo response  masking the efficacy of the drug being tested  In addition  once approved  antidepressants require a large sales force to reach psychiatrists as well as primary care providers  Another impediment is the difficulty of conducting early depression research on animals that could form a basis for trials in people   This has been a big challenge to translate over to human clinical trials   said Caroline Ko  project leader of NewCures  a newly formed program at Northwestern University aimed at reducing the risk of investment in treatments for depression  pain  Parkinson s and other diseases  J J is the only large pharmaceutical company making a major investment in a new antidepressant  Tracy said  Smaller players include Sage Therapeutics  O SAGE   which expects a decision from U S  regulators on a treatment for post partum depression by the end of the year  J J s esketamine targets treatment resistant depression  It is similar to ketamine  which is used as an anesthetic and to relieve pain  and often abused as a recreational party drug with the street nickname Special K  The company expects to file for U S  Food and Drug Administration approval of esketamine  a rapid acting nasal spray  this year   Standard antidepressants can take weeks to work  They really are not useful in a crisis situation   said Carla Canuso  who is leading J J s effort testing the drug in people deemed at imminent risk for suicide  which is most commonly associated with depression   Allergan Plc  N AGN  is developing rapastinel  a fast acting intravenous antidepressant the company purchased in 2015   The drug has breakthrough therapy designation from the FDA  with clinical trial results expected in early 2019  Last month  the company acquired another depression drug from its collaborator Aptinyx  Dr  Julie Goldstein Grumet  a behavioral health expert from the Suicide Prevention Resource Center  said 122 people in the United States took their lives by suicide each day last week  Many were never even diagnosed with a mental illness  
 We re missing opportunities to screen people for the risk of suicide   she said ",2018-06-09,Reuters,https://www.investing.com/news/world-news/rise-in-us-suicides-highlights-need-for-new-depression-drugs-1486963,1486963
104612,326127,AGN,Allergan s positive data on migraine prevention med atogepant pressures Alder Bio  down 4 ,news,As is so often the case  good news for one biotech is bad for another  Allergan  AGN  1 1   is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine Alder Biopharmaceuticals  ALDR  3 5   is in the red  albeit on below average volume  as some investors react to the potential threat to lead candidate eptinezumab  a monoclonal antibody CGRP inhibitor in late stage development for migraine prevention  A U S  marketing application is on tap for early 2019 Previously  Alder s eptinezumab shows treatment benefit in late stage migraine study  April 24 Now read ,2018-06-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergans-positive-data-on-migraine-prevention-med-atogepant-pressures-alder-bio-down-4-1488340,1488340
104613,326128,AGN,Allergan appoints former Abbott executive to its board,news," Reuters    Allergan Plc  N AGN  said on Thursday former  Abbott Laboratories   N ABT  executive Thomas Freyman will join its board  a week after two of its shareholders criticized the drugmaker s acquisition strategy and board composition  Allergan  whose director Patrick O Sullivan will retire from the board in July  said its board will continue to have 12 members of which 10 are independent  following the changes  Freyman  who retired from Abbott in 2017  most recently served as executive vice president  finance and administration for the company since June 2015   
Last week  two of Allergan s shareholders  hedge funds Appaloosa Management and Senator Investment Group  asked the drugmaker s board to split the role of chief executive officer and chairman as well as reconsider its acquisition strategy ",2018-06-14,Reuters,https://www.investing.com/news/stock-market-news/allergan-appoints-former-abbott-executive-to-its-board-1492906,1492906
104614,326129,AGN,Healthcare   Top 5 Gainers   Losers as of 11 00 AM  06 25 2018 ,news,Gainers  XBIO  92   VLRX  32   ZFGN  14   INNT  13   SLDB  9  Losers  SPHS  42   MACK  35   ZOM  16   SLNO  11   CHRS  10  Now read ,2018-06-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-06252018-1506169,1506169
104615,326130,AGN,NIH awards grant to support early stage study of MabVax imaging agent  Shares down 11  premarket,news,MabVax Therapeutics Holdings  NASDAQ MBVX  announced that Memorial Sloan Kettering Cancer Center was awarded an R01 research project grant by the National Institutes of Health to extend the Phase 1 clinical study of the Company s immunoPET imaging agent  MVT 2163  for patients with pancreatic cancer and scheduled for surgical resection Previously  MabVax bails on plan to regain compliance with Nasdaq listing requirements  shares down 45   July 2 Update  Shares are down 11  premarket on Nasdaq s determination to delist the Company s securities  Now read ,2018-07-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/nih-awards-grant-to-support-earlystage-study-of-mabvax-imaging-agent-shares-down-11-premarket-1520077,1520077
104616,326131,AGN,Soligenix receives European and Canadian patents for its ricin toxin vaccine formulation  Shares up 5 7  premarket,news,Soligenix  NASDAQ SNGX  received notice of allowance for European and Canadian patent applications further extending protection around ThermoVax including coverage of the Company s ricin toxin vaccine  RiVax  RiVax also has the potential to qualify for a priority review voucher  PRV  upon FDA approval  Recent PRVs have sold for as much  350M   Soligenix continues to advance its RiVax program with funding from the US government   stated Christopher J  Schaber  PhD  President and Chief Executive Officer of Soligenix   Soligenix is a world leader in ricin toxin vaccine development  with a Phase 2 clinical trial planned to begin this year  SNGX  5 7  premarket  Now read ,2018-07-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/soligenix-receives-european-and-canadian-patents-for-its-ricin-toxin-vaccine-formulation-shares-up-57-premarket-1521922,1521922
104617,326132,AGN,Biotechs give up gains after Trump tweet on prices,news,The SPDR S P Biotech  MX XBI  ETF  XBI  0 7   slips 1 5  from its intraday high of  101 17 after President Trump tweeted  again  his displeasure over recent price hikes by drug makers  including  Pfizer  Selected tickers   XLV  0 6   IBB  0 1   IHE  0 5   XPH  1 1   PPH  0 5   VHT  0 5   OTCQX RHHBY  0 1   PFE  0 3   AMGN  1 4   BIIB  2 4   GILD  2 4   VRTX  0 1   AGN  1 1   ABBV  0 5   LLY  0 8   GSK  0 2   AZN  0 4   JNJ  0 2   MRK  NVS  0 4   SHPG  0 1   VRX  2 6   TEVA  0 5  Now read ,2018-07-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-give-up-gains-after-trump-tweet-on-prices-1522505,1522505
104618,326133,AGN,Pricing transparency law in California having effect  drug makers nix planned increases,news,Bloomberg reports that some drug firms have axed plans to increase pricing for certain products or have rolled back hikes in response to a new law in California aimed at pricing transparency  The law  requiring drug makers to give advance notice of significant price increases  is designed to pressure companies to keep prices down  It appears to be working In the past several weeks  Novartis  NYSE NVS   Gilead Sciences  NASDAQ GILD   Roche  OTCQX RHHBY  and Novo Nordisk  NYSE NVO  have notified California health plans rolling back or reducing price hikes on at least 10 drugs Pharma companies are far from accepting the new reality  however  Its lobbying group  Pharmaceutical Research and Manufacturers of America  is challenging the law in court Selected tickers  XLV  IBB  IHE  XPH  PPH  VHT  PFE  AMGN  BIIB  VRTX  AGN  ABBV  LLY  GSK  AZN  JNJ  MRK  SHPG  VRX  TEVANow read ,2018-07-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/pricing-transparency-law-in-california-having-effect-drug-makers-nix-planned-increases-1524412,1524412
104619,326134,AGN,Big Pharma in the red after Pfizer backs away from price hikes,news,Members of Big Pharma are down in early trade after  Pfizer   PFE  0 6   rolled back its planned price increases after direct intervention from President Trump  Investors apparently perceive diminished prospects for large price increases in the future for drug makers Selected tickers   XLV  0 7   IBB  0 6   XBI  0 6   XPH  0 2   IHE  0 2   PPH  0 7   VHT  0 5   OTCQX RHHBY  0 4   ABBV  3   AGN  0 6   AZN  0 7   BMY  0 6   GSK  0 5   JNJ  0 5   LLY  0 2   MRK  0 6   NVO  0 6   NVS  0 8   SHPG  1 1   VRX  2 6   TEVA  2 6   AMGN  0 8   BIIB  GILD  1 3   VRTX  0 9   CELG  1 1  Previously  Pfizer to defer price increases following CEO s talk with Trump  July 10 Now read ,2018-07-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/big-pharma-in-the-red-after-pfizer-backs-away-from-price-hikes-1525545,1525545
104620,326135,AGN,CVS responds to Trump Administration s request for info on now to lower drug prices,news,CVS Health  NYSE CVS  has submitted a letter to HHS Secretary Alex Azar emphasizing its support for the Administration s goal of lowering drug prices  It says its PBM unit Caremark kept drug price growth at 0 2  last year despite drug makers raising prices almost 10   adding that its point of sales rebates help consumers reduce out of pocket costs Related tickers  XLV  IBB  XBI  XPH  IHE  PPH  VHT  OTCQX RHHBY  ABBV  AGN  AZN  BMY  GSK  JNJ  MRK  NVS  BHC  TEVA  AMGN  BIIB  GILD  CELG  VRTX  CI  AET  UNH  ESRX  WBANow read ,2018-07-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/cvs-responds-to-trump-administrations-request-for-info-on-now-to-lower-drug-prices-1531966,1531966
104621,326136,AGN,Pharma Stock Roundup  AGN s Opioid Settlement  Line Extension Nod In EU For MRK  JNJ Drugs ,opinion,"This week  Allergan   NYSE AGN   settled with two counties of Ohio for  5 million related to the upcoming multidistrict litigation for opioid based drug abuse  The European Commission granted approvals to Merck   NYSE MRK   and Roche s   OTC RHHBY   PD L1 inhibitors Keytruda and Tecentriq  respectively  and J J s   NYSE JNJ   immunology drug Stelara for expanded use Recap of the Week s Most Important StoriesAllergan Settles With Two Ohio Plaintiffs  The settlement with two  plaintiffs is in connection with the upcoming October 2019 trial under the federal multidistrict litigation related to abuse of opioid based drugs  Allergan has agreed to pay  5 million to resolve all claims pertaining to the scheduled trial  This includes payment of  1 9 million to Summit County  OH and  3 1 million to Cuyahoga County  OH  Allergan stated that it has not been actively involved in marketing or promoting opioid products since 2013  Opioid based drug abuse came in the limelight recently with more than 2000 lawsuits being filed against pharma companies across multiple states  holding them responsible for the opioid epidemic and deaths due to opioid overdose EU Approval for Expanded Use of Merck  Roche   J J s Blockbuster Drugs  The European Commission granted approval to Merck s main top line driver for expanded usein combination with Pfizer s Inlyta  axitinib  for the first line treatment of advanced renal cell carcinoma  RCC   the most common type of kidney cancer  The approval was based on the results of KEYNOTE 426  Data from this study showed that Keytruda combined with Inlyta reduced the risk of death by nearly half compared to Pfizer s another cancer drug Sutent  Keytruda was approved for the same indication in the United States in April The EC also granted marketing authorisation to Roche s cancer immunotherapy   Tecentriq   in combination with chemotherapy for the first line treatment of extensive stage small cell lung cancer  ES SCLC   With this approval  Tecentriq became the first cancer immunotherapy to win an approval in the EU for the initial treatment of ES SCLC  which is a difficult to treat cancer with limited treatment options  The approval was based on results from the phase III IMpower133 study  Tecentriq was approved for the same indication by the FDA in March Tecentriq was also approved by the EC in combination with Celgene s Abraxane and carboplatin for the first line treatment of patients suffering metastatic non squamous non small cell lung cancer  NSCLC  without EGFR or ALK genomic tumour aberrations The European regulatory agency also approved J J s for a new indication  moderately to severely active ulcerative colitis  The regulatory application was based on data from the phase III UNIFI global clinical development program  A similar application is also under review in the United States  Stelara is approved in the EU for treating severe plaque psoriasis  active psoriatic arthritis and Crohn s disease and is also being evaluated in late stage development for axial spondylitis Bristol Myers  Opdivo Fails to Meet Co Primary Endpoint in Brain Cancer Study  Bristol Myers    NYSE BMY   phase III study evaluating a combination of its PD L1 inhibitor Opdivo plus standard of care to treat MGMT methylated glioblastoma multiforme failed to meet one of its primary endpoints   progression free survival  PFS   The phase III CheckMate  548 study did not show any statistically significant improvement in PFS in patients suffering from this aggressive and rare brain cancer  However  the study will continue as planned on recommendation of the data monitoring committee to evaluate the other primary endpoint that is  overall survival AstraZeneca s Tagrisso Gets China Approval in First Line Setting  AstraZeneca   NYSE AZN   received a marketing approval from Chinese regulatory authorities for or the first line treatment of adult patients with metastatic NSCLC whose tumors have EGFR mutations  The sNDA was based on data from the phase III FLAURA study  Tagrisso was approved for this indication based on PFS data from the same study in the United States and the EU in 2018  In August  AstraZeneca announced OS data from the study which showed that Tagrisso significantly improved OS  OS was the secondary endpoint in the study and AstraZeneca expects to present this data at an upcoming medical meeting Novartis In Licenses Rights to Tysabri Biosimilar  Novartis    NYSE NVS   generic arm gained global commercialization rights to a proposed biosimilar of Biogen s key multiple sclerosis medicine Tysabri  natalizumab  from a European biotech Polpharma Biologics  This is the fifth proposed biosimilar in licensed by Sandoz in the past nine months  The biosimilar is being developed in late stage studies Meanwhile  Novartis  investigational lung cancer therapy capmatinib was granted a Breakthrough Therapy designation by the FDA for the treatment of MET mutated advanced non small cell lung cancer  Novartis plans to file regulatory application for capmatinib in the United States in the fourth quarter Breakthrough Therapy Status to J J s RSV Vaccine  The FDA granted a Breakthrough Therapy designation to J J investigational prophylactic vaccine for the prevention of respiratory syncytial virus  RS   in older adults  who are at high risk from this disease  J J is current developing this RSV vaccine in a phase IIb proof of concept study The NYSE ARCA Pharmaceutical Index inched up 0 9  in the last four trading sessions 
 Large Cap Pharmaceuticals Industry 5YR   Return
  
 
Here is how the seven major stocks performed in the last four trading sessions Last week  while Pfizer  NYSE PFE  rose to maximum  2 8    AstraZeneca hit the lowest level  1 5   In the past six months  AstraZeneca has been the biggest gainer  7 4   while Pfizer shed its value most  12 2    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-09-05,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-agns-opioid-settlement-line-extension-nod-in-eu-for-mrk-jnj-drugs-200462471,200462471
104622,326137,AGN,ETFs Poised To Benefit From Gene Editing Revolution,opinion,A decade ago it would have been hard to believe that someone has created a gene edited human baby or a human animal hybrid embryo or has cured diabetes and by making some changes in the DNA  But  following investments of billions of dollars  stories of technological advancement like these are pouring in from across the globe  is said to have created genetically edited  and is also making  of having found the cure for male infertility using the same technique  Encouragingly   has lifted its ban on human animal hybrids  Meanwhile   is planning to produce more babies by editing the DNA and is also preparing to conduct the   Ever wondered what s the science behind such inconceivable biological accomplishments  It s genome editing  read    is a technique to alter or modify the DNA of a cell or organism  It uses an enzyme to cut the DNA at a particular sequence and then it is repaired by the cell  making a change to the   As a result  the characteristics  are changed Given the growing applications of gene editing  it is a rising market which offers endless opportunities  In fact  going by a  report  the  3 7 billion global genome editing market of 2018 is expected to reach  9 66 billion by 2025  at a CAGR of 14 7  Genomic Editing Advancements and the USThe island of Nantucket    is soon to see an application of CRISPR to combat the Lyme disease    an evolutionary biologist at MIT  is planning to create Lyme resistant mice using the gene editing tool   CRISPR  The researcher will edit the genes of white footed mice  which are the main carriers of the  Notably   Clustered Regularly Interspaced Short Palindromic Repeats  Cas9 is a very efficient and fast technique to edit genomes  It is now in early clinical trials for certain disorders like sickle cell disease  cystic fibrosis and   This comes after six years of CRISPR technique s first application on   Moreover  a new advanced technique addressing the shortcomings of existing gene editing platforms      intercellular linearized Single homology Arm donor mediated intron Targeting Integration    has been developed by scientists at the Salk Institute  read    In fact    NASDAQ EDIT   and partner Allergan   NYSE AGN   announced the start of enrollments in the Phase 1 2 trial  BRILLIANCE  including 18 patients with an inherited form of blindness called Leber congenital amaurosis 10  or LCA10  Editas  CRISPR based medicine     is expected to be a potent remedy for the disease  Philadelphia based Spark Therapeutics   NASDAQ ONCE   has also developed a gene therapy     for patients with inherited retinal disease  Moreover  Chicago based AveXis  injects a completely functional copy of the human SMN gene into target motor neuron cells to cure spinal muscular dystrophy The FDA is actively supporting advancements in the field of medical science by approving therapies based on the genomic editing   In this regard  the has commented   the FDA will continue to support the progress in this field by helping to expedite the development of products for unmet medical needs through the use of review pathways designed to advance innovative  safe and effective treatment options  Genomic ETFs in FocusThe above mentioned trends have been benefiting genomics ETFs  Here we highlight a host of ETFs that investors can keep a tab on ARK Genomic Revolution Multi Sector ETF This is an actively managed ETF focusing on companies likely to benefit from the extension and enhancement of the quality of human and other life by incorporating technological and scientific developments plus improvements and advancements in genomics into their business  The fund holds 39 stocks in its basket and has 0 75  in expense ratio  It has accumulated  417 3 million in its asset base  read    Invesco Dynamic Biotechnology   Genome ETF This fund follows the Dynamic Biotech   Genome Intellidex Index  The index comprises companies that are majorly engaged in the research  development  manufacturing and marketing plus distribution of various biotechnological products  services and processes and companies that gain significantly from scientific and technological advances in biotechnology and genetic engineering and research  The fund holds 32 stocks in its basket  It has managed  226 2 million in its asset base  Expense ratio comes in at 0 59   read    Global X Genomics   Biotechnology ETF This is a new entrant in the space  having accumulated  14 7 million since its inception on Apr 5  2019  It seeks to invest in companies that potentially stand to benefit from further advancements in the field of genomic science  such as companies involved in gene editing  genomic sequencing  genetic medicine therapy  computational genomics and biotechnology  The product follows the Solactive Genomics Index  charging 68 bps in annual fees  It holds 41 stocks in its basket  read    iShares Genomics Immunology and Healthcare ETF This is another new entrant  which was launched in June 2019  Tracking the NYSE FactSet Global Genomics and Immuno Biopharma Index  the fund provides exposure to developed and emerging market companies that could gain from long term growth and innovation in genomics  immunology and bioengineering  Holding a basket of 44 securities  the fund has an AUM of  22 9 million  It charges a fee of 47 basis points  Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-09-06,Zacks Investment Research,https://www.investing.com/analysis/etfs-poised-to-benefit-from-gene-editing-revolution-200462535,200462535
104623,326138,AGN,Mallinckrodt Mulls Bankruptcy Ahead Of Major Opioid Litigation,opinion,"Shares of Mallinckrodt plc   NYSE MNK   declined 38 6  on Sep 5  following a Bloomberg  stating that the company is considering restructuring and may file for bankruptcy to limit its liabilities related to pending opioid litigations Per the report  Mallinckrodt hired restructuring advisers to explore options to avoid the multi district litigation scheduled in October  The company is mulling for bankruptcy if costs become too high to manage  Moreover  its high debt levels make the situation worse as it may become a hurdle in case a settlement is reached or a penalty is levied by the court  The company may also divest its generic business  which includes opioid drugs In fact  Mallinckrodt s shares have declined 89 9  so far this year compared with the  s fall of 7 9  on pricing pressure in the generic segment and rising risk of penalties related to litigations   Mallinckrodt is one of the defendants in more than 2 000 litigations filed by several states  counties and other political subdivisions in the United States related to the abuse of opioid based drugs  Several pharma companies are  for their marketing practices  which downplayed the risk of addiction from these drugs and boosted their use Per the National Institute of Drug Abuse  opioid overdose claimed lives of 47 000 Americans in 2017  Moreover  prescription opioid misuse alone creates a total economic burden of  78 5 billion every year  In the past two decades  400 000 deaths occurred due to opioid based drug abuse  per the estimate of Centers for Disease Control and Prevention Several analysts expect penalties to run into several billions of dollars for the accused pharma companies in opioid litigations  However  penalties of  levied on J J   NYSE JNJ   in the recently concluded opioid litigation with the state of Oklahoma were at the lower end of the market expectation  But we note that the amount is manageable for J J as it has good balance sheet  with significant cash in hand Other companies  especially in the generic segment  with high debt levels as well as low cash resource will likely face unfavorable impact  Shares of Teva Pharma   NYSE TEVA   and Endo International   NASDAQ ENDP   also fell on Sep 5  following the Bloomberg report on Mallinckrodt as these companies also face opioid litigations and may seek similar alternatives Notably  Endo settled for almost  10 million  resolving all claims against itself related to the upcoming federal multidistrict litigation  Allergan  NYSE AGN   another defendant in the case  also settled in similar litigation  Meanwhile  Purdue Pharma is planning to file for bankruptcy  which may include a settlement of  10  12 billion to resolve all pending claims against its opioid based drugs Mallinckrodt public limited company Price
    Zacks RankMallinckrodt currently carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-09-06,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mulls-bankruptcy-ahead-of-major-opioid-litigation-200462282,200462282
104624,326139,AGN,The Zacks Analyst Blog Highlights  Allergan  Merck  Roche  J J And Bristol Myers,opinion,For Immediate ReleaseChicago  IL  September 9  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Allergan   NYSE AGN    Merck   NYSE MRK   and Roche   OTC RHHBY    J J   NYSE JNJ   and Bristol Myers   NYSE BMY   Here are highlights from Friday s Analyst Blog Pharma Stock Roundup  Opioid Settlements   MoreThis week  Allergan settled with two counties of Ohio for  5 million related to the upcoming multidistrict litigation for opioid based drug abuse  The European Commission granted approvals to Merck and Roche s PD L1 inhibitors Keytruda and Tecentriq  respectively  and J J s immunology drug Stelara for expanded use Recap of the Week s Most Important StoriesAllergan Settles With Two Ohio Plaintiffs The settlement with two  plaintiffs is in connection with the upcoming October 2019 trial under the federal multidistrict litigation related to abuse of opioid based drugs  Allergan has agreed to pay  5 million to resolve all claims pertaining to the scheduled trial  This includes payment of  1 9 million to Summit County  OH and  3 1 million to Cuyahoga County  OH  Allergan stated that it has not been actively involved in marketing or promoting opioid products since 2013  Opioid based drug abuse came in the limelight recently with more than 2000 lawsuits being filed against pharma companies across multiple states  holding them responsible for the opioid epidemic and deaths due to opioid overdose EU Approval for Expanded Use of Merck  Roche   J J s Blockbuster Drugs  The European Commission granted approval to Merck s main top line driver for expanded usein combination with Pfizer s Inlyta  axitinib  for the first line treatment of advanced renal cell carcinoma  RCC   the most common type of kidney cancer  The approval was based on the results of KEYNOTE 426  Data from this study showed that Keytruda combined with Inlyta reduced the risk of death by nearly half compared to Pfizer s another cancer drug Sutent  Keytruda was approved for the same indication in the United States in April The EC also granted marketing authorization to Roche s cancer immunotherapy   Tecentriq   in combination with chemotherapy for the first line treatment of extensive stage small cell lung cancer  ES SCLC   With this approval  Tecentriq became the first cancer immunotherapy to win an approval in the EU for the initial treatment of ES SCLC  which is a difficult to treat cancer with limited treatment options  The approval was based on results from the phase III IMpower133 study  Tecentriq was approved for the same indication by the FDA in March Tecentriq was also approved by the EC in combination with Celgene s Abraxane and carboplatin for the first line treatment of patients suffering metastatic non squamous non small cell lung cancer  NSCLC  without EGFR or ALK genomic tumour aberrations The European regulatory agency also approved J J s for a new indication  moderately to severely active ulcerative colitis  The regulatory application was based on data from the phase III UNIFI global clinical development program  A similar application is also under review in the United States  Stelara is approved in the EU for treating severe plaque psoriasis  active psoriatic arthritis and Crohn s disease and is also being evaluated in late stage development for axial spondylitis Bristol Myers  Opdivo Fails to Meet Co Primary Endpoint in Brain Cancer Study  Bristol Myers  phase III study evaluating a combination of its PD L1 inhibitor Opdivo plus standard of care to treat MGMT methylated glioblastoma multiforme failed to meet one of its primary endpoints   progression free survival  PFS   The phase III CheckMate  548 study did not show any statistically significant improvement in PFS in patients suffering from this aggressive and rare brain cancer  However  the study will continue as planned on recommendation of the data monitoring committee to evaluate the other primary endpoint that is  overall survival Meanwhile  Novartis  investigational lung cancer therapy capmatinib was granted a Breakthrough Therapy designation by the FDA for the treatment of MET mutated advanced non small cell lung cancer  Novartis plans to file regulatory application for capmatinib in the United States in the fourth quarter Breakthrough Therapy Status to J J s RSV Vaccine The FDA granted a Breakthrough Therapy designation to J J investigational prophylactic vaccine for the prevention of respiratory syncytial virus  RS   in older adults  who are at high risk from this disease  J J is current developing this RSV vaccine in a phase IIb proof of concept study The NYSE ARCA Pharmaceutical Index inched up 0 9  in the last four trading sessions Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-09-08,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-allergan-merck-roche-jj-and-bristolmyers-200462987,200462987
104625,326140,AGN,Allergan s Filings For Abicipar Pegol Accepted In U S Europe,opinion,"Allergan plc   NYSE AGN   and partner Molecular Partners announced that the filings for their long acting anti VEGF product  abicipar pegol  developed for the treatment of age related neovascular macular degeneration  nAMD   has been accepted for review by regulatory authorities in the United States and Europe While the FDA has accepted a biologics license application  BLA   the European Medicines Agency  EMA  has validated a marketing authorization application  MAA  for abicipar pegol   While the FDA is expected to give its decision in mid 2020  the same from EMA is expected in the second half of 2020 The BLA and MAA filings were based on two phase III studies   SEQUOIA and CEDAR   evaluating abicipar compared with Novartis   NYSE NVS   Roche s   OTC RHHBY   Lucentis  ranibizumab  in treatment na ve patients with nAMD  Data from the studies demonstrated that treatment with six or eight injections of abicipar resulted in similar efficacy for the primary endpoint  proportion of treated patients achieving stable vision at week 52  compared to 13 injections for Lucentis Allergan s share price has risen 22 7  this year so far against the  s decrease of 6 5   Please note that Regeneron Pharmaceuticals    NASDAQ REGN   blockbuster anti VEGF drug Eylea  aflibercept  Injection is another popular drug approved to treat patients with nAMD  However  abicipar  with its quarterly dosing regimens  has the potential to reduce patient burden by lowering the frequency of injections while maintaining vision gains In April  Allergan announced data from another study on abicipar  MAPLE  a 28 week open label study which used a modified manufacturing process to test an optimized 12 week formulation of abicipar in nAMD patients  Following the improved manufacturing process  it was observed that the incidence of intraocular inflammation  IOI  in the study was lower than SEQUOIA and CEDAR studies  In the MAPLE study  the reported incidence of IOI was 8 9   which was less than around 15  observed in the SEQUOIA and CEDAR studies  If abicipar pegol is later approved as a fixed 12  week anti VEGF treatment for nAMD based on MAPLE data  it will reduce the treatment burden for these patients Allergan currently has a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/allergans-filings-for-abicipar-pegol-accepted-in-useurope-200463581,200463581
104626,326141,AGN,Pharma Stock Roundup  Pipeline Regulatory Updates From GSK  PFE   Others,opinion,"This week  the FDA granted approval to Glaxo s   NYSE GSK   asthma drug  Nucala for pediatric use  Meanwhile  Pfizer   NYSE PFE    Allergan   NYSE AGN   and Roche   OTC RHHBY   provided regular pipeline regulatory updates J J   NYSE JNJ    AstraZeneca   NYSE AZN   and Eli Lilly   NYSE LLY   presented data from studies at medical conferences held this week Recap of the Week s Most Important StoriesFDA Nod to Glaxo s Asthma Drug for Children  The FDA granted approval to Glaxo s severe eosinophilic asthma drug Nucala for use in pediatric patients  aged six to 11 years  in the United States  The drug is already marketed in the United States and EU for severe eosinophilic asthma patients aged 12 years or older  In the EU  it received approval for pediatric use  from aged six 17 years  in August last year Lilly s RET Inhibitor Shrinks Tumors in NSCLC Study  At the World Conference on Lung Cancer  WCLC  2019 held in Spain  Lilly presented data from a phase I II registrational study on its oral RET inhibitor   LOXO 292   which was added to its pipeline following the February acquisition of Loxo Oncology  As of the cut off date of Jun 17  2019  the candidate demonstrated a 68  objective response rate  ORR  or shrinkage in tumor size in heavily pretreated patients with RET fusion positive non small cell lung cancer  NSCLC   Meanwhile  the median duration of response was 20 3 months and median progression free survival  PFS  was 18 4 months in the selpercatinib arm as of the same date  Lilly plans to file a regulatory application for selpercatinib later this year FDA and EMA Accept Allergan s Filings for Abicipar Pegol  Allergan and its partner Molecular Partners announced that the filings for its long acting anti VEGF product   has been accepted for review by regulatory authorities in the United States and Europe  Abicipar pegol has been developed for the treatment of age related neovascular macular degeneration  nAMD   While the FDA is expected to give its decision in mid 2020  European Medicines Agency  EMA  is expected to decide on the same in the second half of 2020  The biologics license application  BLA  and marketing authorization application  MAA  filings were based on data from two phase III studies   SEQUOIA and CEDAR Pfizer s Positive Preliminary Data on Pneumococcal Vaccine Candidate  Pfizer announced positive preliminary results from initial three doses of a phase II study on its 20 valent pneumococcal conjugate vaccine  20vPnC  candidate    The study evaluated the candidate for the prevention of invasive disease and otitis media caused by Streptococcus pneumoniae serotypes in healthy infants  Data showed that PF 06482077 has an overall similar safety profile to Pfizer s popular 13 valent pneumococcal conjugate vaccine  Prevnar 13 in this patient population  The vaccine candidate also induced immune responses for all 20 serotypes in infants  PF 06482077 includes all the 13 serotypes contained in Prevnar 13 along with seven additional serotypesMeanwhile  the company also said it has completed enrolment of its three phase III studies evaluating PF 06482077 for the prevention of invasive disease and pneumonia in adults  Pfizer plans to file a BLA for the PF 06482077 by the end of 2020 Roche s Tecentriq Shows OS Benefit in Some Lung Cancer Patients  Roche announced positive data from the phase III   which evaluated its PD L1 inhibitor  Tecentriq as a first line monotherapy treatment in advanced non squamous and squamous NSCLC patients without ALK or EGFR mutations  The data demonstrated that Tecentriq  as a first line monotherapy  helped these patients live longer compared with chemotherapy  Tecentriq monotherapy showed significant overall survival  OS  benefit over chemotherapy in patients with high PD L1 expression  thereby meeting the study s primary endpoint Roche s phase III FeDeriCa study  evaluating its fixed dose subcutaneous combination of Perjeta and Herceptin in patients with HER2 positive breast cancer  met its primary endpoint  The single injection  which has been developed to reduce the time spent receiving treatment as it is administered under the skin quickly  showed non inferiority when compared to intravenous formulations  Roche also presented full pivotal data from a phase III study on satralizumab evaluating it for the treatment of neuromyelitis optica spectrum disorder at the annual conference of The European Committee for Treatment and Research in Multiple Sclerosis  ECTRIMS  held in Stockholm  Sweden  The data showed that satralizumab monotherapy reduced the risk of relapses by 55  compared to placebo in the overall population J J Presents New Data on Ponesimod and Spravato  J J presented new data from a phase III head to head study  OPTIMUM  evaluating versus Sanofi s Aubagio in adults with relapsing multiple sclerosis at ECTRIMS  The data demonstrated superior efficacy of ponesimod versus Aubagio on the primary endpoint and most secondary endpoints  In July  the company had announced that the OPTIMUM study met its primary and most secondary endpoints  Along with the latest release  the company said that treatment with ponesimod led to a statistically significant reduction of annualized relapse rate  ARR   which was the study s primary endpoint  compared to Aubagio J J s two phase III studies evaluating its newly approved anti depressant  Spravato  esketamine  nasal spray in severely ill patient population  met their respective primary efficacy endpoint  The primary endpoint of the studies was a reduction in depressive symptoms at 24 hours after the first dose  as measured by the Montgomery  sberg Depression Rating Scale  MADRS   Data showed that treatment with Spravato plus comprehensive standard of care  SOC  treatment led to rapid reduction of depressive symptoms in adult patients with major depressive disorder who have active suicidal ideation with intent  The data was presented at the European College of Neuropsychopharmacology  ECNP  meeting held in Copenhagen  Denmark Detailed Data from AstraZeneca s CASPIAN Study  At the WCLC  AstraZeneca presented detailed data from the phase III CASPIAN study on Imfinzi in first line extensive stage small cell lung cancer   the most aggressive type of lung cancer  Interim data from the study was presented in June when the company said that that treatment with Imfinzi plus platinum based chemotherapy led to a statistically significant and clinically meaningful improvement in OS versus chemotherapy alone  Along with the latest release  AstraZeneca said that the median OS was 13 0 months in the Imfinzi plus chemotherapy arm versus 10 3 months for standard of care medicines  The PFS rate at 12 months was higher at 17 5  in the Imfinzi plus chemotherapy arm versus 4 7  in the SOC arm  The confirmed ORR was 67 9  in the Imfinzi plus chemotherapy arm versus 57 6  in the SOC arm The NYSE ARCA Pharmaceutical Index declined 0 3  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Last week  while Pfizer rose the most  2 6    AstraZeneca declined the most  4 1   In the past six months  Merck has been the biggest gainer  2 2   while Lilly lost the most  9 5    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pipelineregulatory-updates-from-gsk-pfe--others-200464489,200464489
104627,326142,AGN,Ardelyx Gets FDA Approval For Ibsrela As IBS C Treatment,opinion,"Ardelyx  Inc    NASDAQ ARDX   announced that it has received FDA approval for Ibsrela  tenapanor  as a treatment for irritable bowel syndrome with constipation  IBS C  in adults  This marks the first FDA approval for the company for any of its pipeline candidates Ibsrela  an NHE3 sodium transport inhibitor  received approval in the United States based on encouraging data from two phase III studies  which evaluated twice daily  50 mg dose of the drug in IBS C patients  Data from the studies demonstrated that Ibsrela achieved a statistically significant reduction in constipation and abdominal pain Ardelyx is in discussions to ink a collaboration deal to support the launch of Ibsrela  With no deal  the company s cash resources may prove to be inadequate for successful commercialization of the drug  Please note that the drug is likely to face stiff competition from Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   Allergan s   NYSE AGN    Linzess  which holds a strong position in the IBS C segment  Bausch Health   NYSE BHC   also has an IBS C drug  Trulance  in its portfolio Shares of Ardelyx however declined 10 5  in pre market trading on Sep 13  presumably due to the absence of a collaboration partner  However  the company s shares have surged 250 9  so far this year compared with  s increase of 6 7   The significant year to date increase in shares is driven by encouraging progress of Ibsrela in other indications  Apart from IBS C  Ardelyx is developing tenapanor for treating hyperphosphatemia as monotherapy or in combination with phosphate binders Earlier this month  the company  that the drug met primary and all key secondary endpoints in the pivotal phase III study   AMPLIFY   evaluating its combination regimen for treating hyperphosphatemia  The tenapanor combination regimen achieved a statistically significant reduction in serum phosphorus from baseline after four weeks of treatment  Top line data from the phase III study   PHREEDOM   evaluating tenapanor monotherapy is expected in the fourth quarter of 2019  The company expects to file regulatory applications following the PHREEDOM data  seeking approval for tenapanor monotherapy and combination therapy The company is also developing another pipeline candidate  RDX013  as a treatment for hyperkalemia   a condition of elevated level of potassium in the blood Ardelyx  Inc  Price
    Zacks RankArdelyx currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-12,Zacks Investment Research,https://www.investing.com/analysis/ardelyx-gets-fda-approval-for-ibsrela-as-ibsc-treatment-200464521,200464521
104653,326168,AGN,Premarket analyst action   healthcare,news,Enanta Pharmaceuticals  NASDAQ ENTA  initiated with Outperform rating and  135  38  upside  price target at Oppenheimer  Celyad SA   NASDAQ CYAD  initiated with Outperform rating and  44  52  upside  price target at  Wells Fargo   NYSE WFC   Shares up 3  premarket Novartis  NYSE NVS  upgraded to Neutral at  Credit Suisse   SIX CSGN  Now read ,2018-05-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1463139,1463139
104654,326169,AGN,Pivot signs option agreement with IP Med to acquire licensing rights to Trivair for its ready to infuse cannabis powder,news,Pivot Pharmaceuticals  OTCQB PVOTF  has signed an Option Agreement with IP Med Inc   based in Oceanside  New York  to acquire an exclusive worldwide license for Trivair Nasal and Pulmonary Breath Propelled Drug Delivery Systems for the delivery of Pivot s Ready To Infuse Cannabis   RTIC   cannabinoid products The Option expires in 6 months during which Pivot will determine compatibility with its RTIC powder formulations  Upon completing evaluation Pivot will have the Option to enter into a Definitive Licensing Agreement with IP Med for the TriVair device Financial terms are not disclosed  Now read ,2018-05-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/pivot-signs-option-agreement-with-ip-med-to-acquire-licensing-rights-to-trivair-for-its-readytoinfusecannabis-powder-1469801,1469801
104655,326170,AGN,Pershing Square s Fraidin to join Cadwalader as M A lawyer,news,"By Svea Herbst Bayliss
BOSTON  Reuters    Stephen Fraidin  a prominent mergers lawyer who has been a top executive at billionaire investor William Ackman s hedge fund  is joining law firm Cadwalader  Wickersham   Taft LLP 
The firm plans to soon announce that Fraidin will join its New York office as a partner  Cadwalader s managing partner  Pat Quinn  told Reuters 
Fraidin  78  joined Ackman s Pershing Square  NYSE SQ  Capital Management as vice chairman three years ago after working for five decades as a Wall Street lawyer 
He arrived at the hedge fund soon after Ackman teamed up with pharmaceutical company Valeant as it sought to buy Botox maker Allergan  NYSE AGN  when the investor looked ready to structure more deals that require intense in house legal supervision  Pershing Square s later investment in Valeant failed  contributing to a string of losses and reduced deal making appetite 
Fraidin is leaving the activist hedge fund which generally makes only about a dozen long term investments  for a law firm that has been in business since George Washington was the U S  president  and now frequently works for Ackman s  8 billion hedge fund 
 This is an opportunity to return to helping clients deal with challenging corporate governance and mergers and acquisitions situations  and I think it is a good move for me   Fraidin told Reuters 
At Cadwalader Fraidin he will reunite with Richard Brand  co chairman of the firm s corporate group  who often handles legal matters for Pershing Square  The two men had worked together at Kirkland   Ellis  Before that  Fraidin was a partner at Fried  Frank  Harris  Shriver   Jacobson 
He returns to practicing merger law as dealmaking is off to a strong start this year  But gradually rising interest rates  concerns over U S  trade policy  and worries about unfriendly regulators have raised questions on Wall Street whether the robust pace will continue 
During his career  Fraidin has advised prominent clients including private equity firm 3G Capital Partners which teamed up with Warren Buffett to buy H J  Heinz Co for  28 billion in 2013  In 2014  he represented the  London Stock Exchange  Group  LON LSE  in its  2 7 billion acquisition of U S  index compiler Frank Russell Co 
Fraidin will keep ties to Pershing Square and remain on its advisory board  Ackman  52  who has known Fraidin since his teenage years and calls him a mentor  said  I am looking forward to working with Steve in his new role at Cadwalader  ",2018-06-04,Reuters,https://www.investing.com/news/stock-market-news/pershing-squares-fraidin-to-join-cadwalader-as-ma-lawyer-1478589,1478589
104656,326171,AGN,Wize Pharma signs distribution agreement in China for LO2A,news,Wize Pharma   OTCQB WIZP  signed an exclusive distribution agreement with HPGC Medical Co   Ltd   HPGC  for the distribution in China by HPGC of a formula known as LO2A The agreement includes minimum quantities of LO2A to be purchased by HPGC from Wize  after obtaining the necessary regulatory approvals in China The company expects between  22 5M and  40M in sales in China over a five year term  The ophthalmology market in China is growing at a CAGR of over 11  and is expected to reach  4 5B in 2023  according to Market Scope  Press ReleaseNow read ,2018-06-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/wize-pharma-signs-distribution-agreement-in-china-for-lo2a-1481145,1481145
104657,326172,AGN,Two Allergan shareholders call for split of chairman CEO role,news,"By Manas Mishra  Reuters    Two of Allergan Plc s  N AGN  shareholders  hedge funds Appaloosa Management and Senator Investment Group  asked the drugmaker s board to split the role of chief executive officer and chairman as well as reconsider its acquisition strategy  The company has spent billions of dollars in deals in the past years  ballooning its debt to  26 6 billion  more than half of its current market value    It is time for Allergan s management to concentrate on running a world class pharmaceutical and aesthetics business and forego thoughts of  or the exhilaration from  an ambitious acquisition strategy   the shareholders said in a letter  Billionaire investor David Tepper s Appaloosa and Senator Investment  led by Douglas Silverman  together hold a nearly 2 percent stake in the company   The stock rose as much as 2 5 percent on Tuesday  before paring some of its gains to trade up 1 percent at  151 95 in late afternoon trading  They have fallen about 33 percent in the past 12 months  The Dublin based company decided to sell its women s health and infectious disease businesses last week  an outcome of a strategic review that the company had undertaken under CEO Brent Saunders earlier this year  However  some investors had hoped for more dramatic actions from the review   Like the rest of the investment community  we were underwhelmed by the company s half hearted attempt to restore strategic momentum   Appaloosa s Tepper and Senator Investment s Silverman said  In response  Allergan said the conclusion of its strategic review was to pursue a disciplined capital allocation strategy   The hedge funds said the company should hire a new person for one of the posts from outside the company after splitting the position   They also asked the company to replace two additional directors on the company s board   Allergan said it remained active and aggressive in board refreshment  pointing to three recent director appointments in the past 16 months   The shareholders said they had previously sent similar letters to the drugmaker s board in April and May  
In May  Appaloosa received Federal Trade Commission s anti trust clearance to become an activist investor in Allergan ",2018-06-05,Reuters,https://www.investing.com/news/stock-market-news/hedge-fund-appaloosa-asks-allergan-to-split-chairmanceo-position-1480971,1480971
104658,326173,AGN,Icahn buys small stake in drugmaker Allergan  sources,news," Reuters    Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc  N AGN  at a time when the drugmaker is under pressure from other activist shareholders  people familiar with the matter said on Wednesday  Icahn s intentions are not clear  though he has been a longtime supporter of Allergan Chief Executive Brent Saunders  pushing for him in 2013 to become CEO of Forest Laboratories  which through mergers and acquisitions became Allergan  Icahn  who had invested in Allergan in the past  believes the company s stock is undervalued  the sources said  asking not to be identified because the matter is confidential  Icahn did not respond to a request for comment    We welcome all investments in the company   Allergan spokeswoman Amy Rose said  Bloomberg News first reported on Icahn s new position in Allergan  Earlier this week  investment firms Appaloosa LP and Senator Investment Group LP wrote a letter to Allergan s board of directors urging it not to pursue transformative acquisitions but instead shake up its board  including separating the roles of CEO and chairman  which are both held by Saunders   The letter came shortly after Allergan said it had concluded a strategic review it launched earlier this year   As a result of the review  Allergan is exploring divesting its women s health and infectious disease businesses  opting to focus on areas where it has strong leadership positions   It also said it would pursue a more disciplined capital allocation strategy   Icahn last showed his support for Saunders in 2016  when he unveiled a stake in Allergan after its planned  150 billion sale to  Pfizer  Inc  N PFE  was shot down by changes the U S  government implemented to the rules on corporate tax inversions   In 2016  Allergan sold its generic drug business to Teva Pharmaceuticals Inc for about  40 billion  In April  Allergan said it was considering an offer for rare disease drug maker  Shire  Plc  L SHP   only to reverse course after Allergan shares plummeted on the news  
It has spent much of the money on stock buybacks  debt reduction and a series of small to midsized acquisitions  including medical technology company ZELTIQ Aesthetics Inc and drugmaker Tobira Therapeutics ",2018-06-06,Reuters,https://www.investing.com/news/stock-market-news/icahn-buys-small-stake-in-drugmaker-allergan-sources-1483485,1483485
104659,326174,AGN,Amgen Presents Positive Data From Rituxan Biosimilar Study,opinion,Amgen Inc   NASDAQ AMGN   and partner Allergan s   NYSE AGN   comparative clinical study evaluating ABP 798  their biosimilar candidate  to Roche s   OTC RHHBY   Rituxan showed clinical equivalence of the biosimilar product to the branded version  The study evaluated efficacy and safety of ABP 798 compared to Rituxan in patients with non Hodgkin s lymphoma  NHL  Top line data from the JASMINE study showed that the primary endpoint  an assessment of overall response rate  ORR  by week 28  was within the pre specified margin for ABP 798 compared to Rituxan  This is the second study on ABP 798 that has shown positive top line results In January  Amgen and Allergan announced positive top line results from phase I III study of ABP 798  evaluating pharmacokinetics  efficacy and safety of ABP 798 compared to Rituxan in patients with moderate to severe rheumatoid arthritis  The study met its primary endpoint of pharmacokinetic  PK  similarity  The study also established equivalent efficacy and demonstrated a similar safety profile to Rituxan Shares of Amgen have risen 4 5  this year so far against a 1 2  decrease registered by the during this period   Amgen has a total of 10 biosimilars in its portfolio  It has collaborated with Allergan for the worldwide development and commercialization of four oncology antibody biosimilar medicines including Rituxan  Last month  Amgen and Allergan  AGN  launched Mvasi and Kanjinti  biosimilar versions of Roche s blockbuster medicines  Avastin and Herceptin  respectively in the United States  While Kanjinti is marketed in EU as well  Mvasi is approved in EU but not yet launched Meanwhile  Amgen has been marketing Amgevita  biosimilar of AbbVie s    NYSE ABBV    Humira  in the EU since October last year  Amjevita  trade name of Humira biosimilar in the United States   though approved in the country  is expected to be launched in 2023 per a settlement with AbbVie  A biosimilar version of Johnson and Johnson Merck s Remicade  ABP 710  is also under review in the United States  FDA decision expected in December  and EU while a biosimilar of Alexion s Soliris  ABP 959  is in late state development Amgen expects to launch additional biosimilars in the second half 2020 across multiple geographies  Amgen has also tied up with Daiichi Sankyo for the commercialization of some biosimilars in Japan In 2019 so far  biosimilars have generated revenues of  137 million for Amgen  all from international markets  With Mvasi and Kanjinti launched in the United States  biosimilars revenues should be higher in the second half  Biosimilars could be an important long term growth driver for the company  especially as its mature drugs like Enbrel  Aranesp  Epogen  Neupogen and Neulasta are facing an array of branded and biosimilar competitors Amgen currently carries a Zacks Rank  2  Buy   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/amgen-presents-positive-data-from-rituxan-biosimilar-study-200458076,200458076
104660,326175,AGN,Lilly  LLY  Up 1 9  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Eli Lilly  LLY   Shares have added about 1 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Lilly due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Lilly Q2 Earnings Beat  New Drugs Drive SalesLilly reported second quarter 2019 adjusted earnings per share of  1 50  which beat the Zacks Consensus Estimate of  1 46  Earnings rose 1  year over year as higher operating costs were partially offset by a lower tax rate and reduction in shares outstanding due to share repurchase Revenues in DetailRevenues of  5 64 billion missed the Zacks Consensus Estimate of  5 65 billion  Sales however grew 1  year over year  backed by strong demand for its newer drugs  namely Trulicity  Taltz  Jardiance  Basaglar  Olumiant and Verzenio  which compensated for lower sales of older products like Cialis due to the loss of U S  exclusivity and the impact of Lartruvo s impending product withdrawal Foreign exchange hurt sales growth by 2  in the quarter  Also  lower realized prices had a negative impact of 3  on sales mainly due to increased coverage gap funding requirements in Medicare Part D  which hurt prices of some diabetes medicines like Trulicity and Humalog  Volumes rose 6   Excluding Cialis  loss of exclusivity and the impact of Lartruvo  volume grew nearly 15  New pharma products  products launched since 2014  drove 13  of sales growth and 15 4  of volume growth in the second quarter     and represented nearly 43  total revenues  up from 39  in the previous quarter  The loss of exclusivity hurt volumes by 650 basis points primarily attributed to Cialis U S  revenues were flat at  3 25 billion while ex U S  revenues rose 2  to  2 38 billion Among the established products  Forteo sales declined 17  to  360 8 million  Alimta sales rose 4  to  577 8 million  Humalog sales dropped 12  to  677 6 million  Humulin sales declined 7  to  322 6 million Cialis sales declined 63  to  200 2 million as U S  sales were hurt by entry of generic products  Outside U S  sales were also hurt by generic competition  lower realized prices and currency headwinds  Generic erosion is expected to hurt Cialis sales in the third quarter and thereafter begin to normalize in the fourth quarter Among the new products  Trulicity generated revenues of  1 03 billion  up 32  year over year driven by higher demand in the United States and higher volumes in ex U S  markets  which offset the impact of lower realized prices and changes in segment mix  The prices were lower mainly in the United States due to higher contracted rebates and increased coverage gap funding requirements in Medicare Part D Cyramza revenues were  241 8 million  up 11  year over year driven by higher sales in both the United States and international markets Jardiance sales surged 58  to  231 9 million  driven by increased demand trends within the SGLT2 class of diabetes medicines in the United States and increased volume outside the United States  which offset the negative impact of currencyBasaglar recorded revenues of  290 7 million  up 44  year over year  In the United States  sales rose 48   benefiting from higher demand and the impact of higher realized prices  Outside U S  sales growth of 29  was driven by increased volume  which offset the impact of currency headwinds Taltz brought in sales of  353 8 million  up 61  year over year as U S  sales gained from higher demand  Ex U S  sales were driven by increased volume from launches in new countries  which offset the impact of currency headwinds Olumiant generated sales of  102 4 million in the quarter backed by increased demand in international markets  compared with  82 1 million in the previous quarter  In the United States  Olumiant recorded sales of  10 7 million  higher than  6 4 million in the previous quarter Verzenio generated sales of  133 9 million in the quarter  which was more than  109 4 million in the previous quarter  This was because of increased demand in the United States wherein Verzenio recorded sales of  105 2 million Emgality generated revenues of  34 3 million in the quarter compared with  14 2 million generated in the previous quarter  In the United States  Emgality sales were  33 8 million compared with  12 2 million in the previous quarter  Emgality captured 41  share of market for new prescriptions in the United States  an increase of almost 9 points from the end of first quarter Gross Margin   Operating IncomeAdjusted gross margin of 81  in the quarter expanded 120 basis points driven by favorable effect of foreign exchange rates on international inventories sold and greater manufacturing efficiencies  which offset the impact of unfavorable product mix  due to lower volumes from post patent products  and negative impact of price on revenues Operating income decreased 7  year over year to  1 58 billion  Operating margin was 27 9  in the quarter  down 250 basis points year over year due to lower gross margins and higher operating costs Total operating expenses  including research and development and marketing  selling and administrative expenses  rose 8  in the quarter as the company invested in recently launched products and late stage assets  Marketing  selling and administrative expenses rose 7   R D expense rose 10  in the quarter due to higher development expenses for late stage assets Adjusted effective tax rate was 10   lower than 16 7  in the year ago quarter  driven primarily by the impact of U S  tax reform 2019 Earnings Guidance RaisedLilly raised its expectations for full year earnings while keeping its revenue guidance intact   The earnings forecast was increased from a range of  5 60 to  5 70 per share to  5 67 to  5 77 driven by a lower tax rate  The range indicates growth of 4  to 6  from the year ago levels  The guidance excludes discontinued operations results for Elanco  following disposition of Lilly s remaining ownership in the company The revenue guidance was maintained in the range of  22 0 billion    22 5 billion  which indicates 5  growth  at mid point  over 2018 level on a constant currency basis Gross margin is still expected to be approximately 80   Adjusted tax rate is expected to be in the range of 13 versus 14 expected previously  Adjusted operating margin is expected to be 28  in 2019 Marketing  selling and administrative expense are expected to be in the range of  5 9 billion to  6 1 billion versus  5 7 billion to  6 0 billion expected previously  Research and development expense is still expected to be in the range of  5 5 billion to  5 7 billion In the second half  revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity  Taltz  Basaglar  Jardiance  Verzenio  Cyramza  Olumiant and Emgality  However  generic competition for several drugs including Cialis  rising pricing pressure in the United States due to rebates and legislated increases in Medicare Part D cost sharing  price cuts in some international markets  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line Initial 2020 GoalsIn 2020  Allergan  NYSE AGN  expects to grow sales at 6  to be able to meet the 2015 2020 target of minimum compounded annual growth rate of 7   It sounded confident that its new products will help it achieve growth as the headwind from Cialis LOE and Lartruvo will abate in 2020 It expects to achieve adjusted operating margin of 31  in 2020 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
At this time  Lilly has a subpar Growth Score of D  though it is lagging a bit on the Momentum Score front with an F  However  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise Lilly has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/lilly-lly-up-19-since-last-earnings-report-can-it-continue-200459836,200459836
104661,326176,AGN,Will Opioid Litigation Take Its Toll On Pharma Companies ,opinion,The recent verdict by an Ohio district court against J J   NYSE JNJ    related to its involvement in the abuse of its opioid based drugs  has brought the rising litigation related liabilities of several other large pharma companies into focus  There are thousands of pending lawsuits in several states  which may run into billions of dollars in penalties or settlements and significantly impact the companies  margins going forward The U S  Opioid EpidemicOpioid drugs  which are used as painkillers  have high abuse potential  Use of drugs like morphine  codeine  oxycodone and fentanyl are opioid based and highly controlled by the FDA However  the marketing practices of pharma companies including Teva   NYSE TEVA    Allergan   NYSE AGN    Mallinckrodt   NYSE MNK    Endo International   NASDAQ ENDP   and privately held Purdue Pharma  since late 1990s  increased prescribing of opioid based drugs as painkillers  These pharma giants assured that patients will not get addicted to opioid pain relievers  It is rumored that Purdue Pharma was the biggest beneficiary of this crisis as it aggressively marketed its opioid analgesic  OxyContin  and made huge profits from the sale of the drug  used either as a medicine or for addiction Per the National Institute of Drug Abuse  opioid overdose claimed lives of 47 000 Americans in 2017  About 1 7 million people in the United States  taking prescription opioid pain relievers  suffered from substance use disorders in the same year  Per Centers for Disease Control and Prevention s estimate  prescription opioid misuse alone creates a total economic burden of  78 5 billion every year  In the past two decades  400 000 deaths occurred related to opioid based drug abuse With a significant increase in the number of deaths or instances of misuse of these drugs  and high costs related to opioid abuse  it has become a public crisis  Several government organizations are taking steps to contain the widespread misuse of these drugs  Lawsuits have been filed against pharma companies for generating funds through penalties for abatement plans  J J is the first company this year to have received an unfavorable ruling  It has to pay a penalty of  527 million in the opioid abuse case brought by the state of Oklahoma  Two other defendants in the same case  Teva and Purdue Pharma  settled earlier by paying significant amounts  Meanwhile  Endo International and Allergan reached settlements in opioid abuse case with the state of Ohio Impact of Pending LawsuitsJ J has decided to appeal against the ruling in the litigation with the state of Oklahoma  The company stated that though it acknowledges the opioid crisis as a real problem  its drugs or marketing campaigns are not responsible for the widespread abuse  Other companies that have settled outside the court also denied any wrongdoings  J J is set to face a federal multidistrict litigation in October  which includes several defendants and multifarious claims There are more than 2 000 cases against J J and similar penalties in all these cases will aggregate to billions of dollars  Although J J has significant cash resources to meet these liabilities  it will likely hamper its future earnings  Moreover  appealing against such decisions will also increase litigation costs  Following the Oklahoma ruling  Moody s has revised its outlook on J J to negative Meanwhile  Purdue Pharma and its owners  the Sackler family  are reportedly in discussions to settle all pending litigation related to the company s opioid based drugs for payment in the range of  10 billion to  12 billion  However  no agreement has been reached yet  The company would file for bankruptcy if a deal materializes to meet the settlement payment The path forward for Teva  Allergan  Mallinckrodt and Endo International will also not be rosy  following J J s penalty and Purdue Pharma s rumored settlement discussions  Most of these companies are already reeling under pressure due to pricing pressure in the generic market as well as rising competition in the branded segment  Based on the current scenario  cash resources of these companies are likely to be insufficient to meet settlement costs or penalties  They may follow the path of Purdue Pharma and declare bankruptcy  A decision related to the multidistrict litigation  due in October  will provide a better picture Please note that although AbbVie  NYSE ABBV  is not named in any opioid abuse litigation  the company s pending acquisition of Allergan may have an impact on the company  Negative rulings will prove to be unfavorable for the merged entity Will Cannabis Become the Next Opioid The current state of opioid crisis has raised some questions related to recent legalization of cannabis marijuana in certain states  which is a highly regulated substance  Cannabis based drugs also have a high potential of abuse  These drugs may lead to a more severe crisis than opioid in the next couple of decades  However  cannabis is not yet legalized at the federal level in the United States and none of the U S  based pharmaceutical companies can market cannabis based drugs  at present  However  a few companies with cannabis based drugs are registered outside the country and they do market their drugs in the United States  These drugs should be made available in the U S  market only after thorough research to avoid another financial burden J J  Endo  Teva  Allergan and Mallinckrodt carry a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/will-opioid-litigation-take-its-toll-on-pharma-companies-200460236,200460236
104662,326177,AGN,Allergan Settles Ahead Of Multi District Opioid Litigation,opinion,"Allergan   NYSE AGN   announced that it has settled with two counties of Ohio for almost  5 million  resolving all claims against itself related to the federal multidistrict litigation for opioid drug abuse scheduled in October Per the settlement terms  Allergan will pay  1 9 million to Summit County and  3 1 million to Cuyahoga County  which will remove the company from the defendant list in the first ever multidistrict litigation related to opioid drug abuse  The company stated that these settlements have been done keeping in view the timeline for the trial outcomes and costs related to it  The settlement should remove an overhang on the company Please note that the two Ohio counties  Summit and Cuyahoga  are the bellwethers in the multidistrict litigation  and will represent nearly 2 000 political subdivisions   cities    counties  townships  and others  Thus  the settlement will relieve Allergan from a major chunk of opioid abuse claims  The company is seeking indemnification with other related parties  Moreover  Allergan stated that it does not have any pending generic claim as the company had sold its related assets to Teva   NYSE TEVA   in 2016  It has not been actively involved in marketing or promotion of opioid products since 2013 Last month  Endo International   NASDAQ ENDP   announced a settlement in a similar litigation for  10 million  There are several other pharma companies still on the defendant list in the multidistrict litigation  We expect similar settlements to be offered by some of them Allergan s shares have increased 19 5  so far this year against the  s decline of 9 1  Opioid based drug abuse has come to the limelight as 400 000 patients are estimated to have died in the past couple of decades due to overdose  Per the United States Department of Health and Human Services  pharmaceutical companies encouraged use of opioid pain relievers by assuring that patients will not get addicted to the drugs  More than 2000 lawsuits have been filed against pharma companies in multiple states  holding them responsible for the opioid epidemic and deaths due to opioid overdose The multidistrict litigation  scheduled to start next month  will provide a clearer picture of the impact on pharma companies as it represents nearly 2 000 different lawsuits clubbed under a single trial  The trial is expected to span over seven weeks However  the market is already predicting a gloomy outlook for pharma companies due to the risk of increasing litigation costs  In August  an Ohio district court provided its ruling in the opioid litigation brought by the state of Oklahoma  directing the only defendant  J J   NYSE JNJ    to pay  572 million  Teva and Endo had settled their litigation with the state of Oklahoma prior to the start of the trial Meanwhile  Purdue Pharma and its owners  the Sackler family  are reportedly in discussions to settle all pending litigations related to its opioid based drugs for payment in the range of  10 billion to  12 billion  However  no agreement has been reached yet  The company will file for bankruptcy if any deal materializes to meet the settlement payment Allergan plc Price
    Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-09-01,Zacks Investment Research,https://www.investing.com/analysis/allergan-settles-ahead-of-multidistrict-opioid-litigation-200460832,200460832
104663,326178,AGN,Allergan  AGN  Outpaces Stock Market Gains  What You Should Know,opinion,"In the latest trading session  Allergan  NYSE AGN  closed at  161 69  marking a  1 18  move from the previous day  The stock outpaced the S P 500 s daily gain of 1 08   Meanwhile  the Dow gained 0 91   and the Nasdaq  a tech heavy index  added 1 31  
Prior to today s trading  shares of the Botox maker had gained 0 19  over the past month  This has outpaced the Medical sector s loss of 1 27  and the S P 500 s loss of 0 68  in that time 
AGN will be looking to display strength as it nears its next earnings release  The company is expected to report EPS of  4 21  down 0 94  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  3 85 billion  down 1 51  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  16 69 per share and revenue of  15 45 billion  These totals would mark changes of 0  and  2 14   respectively  from last year 
Any recent changes to analyst estimates for AGN should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 49  lower within the past month  AGN is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  AGN currently has a Forward P E ratio of 9 58  This represents a premium compared to its industry s average Forward P E of 7 33 
We can also see that AGN currently has a PEG ratio of 1 65  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Medical   Generic Drugs stocks are  on average  holding a PEG ratio of 0 8 based on yesterday s closing prices 
The Medical   Generic Drugs industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 63  which puts it in the top 25  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-outpaces-stock-market-gains-what-you-should-know-200461624,200461624
104664,326179,AGN,Allergan  AGN  Up 1 8  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Allergan  NYSE AGN   Shares have added about 1 8  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Allergan due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Allergan s Q2 Earnings   Sales Top  2019 Sales View UpAllergan beat estimates for both earnings and sales in the second quarter and raised its sales guidance for the year Allergan second quarter adjusted earnings came in at  4 38 per share  which beat the Zacks Consensus Estimate of  4 34 and came within the guidance of  4 20 and  4 40  Earnings however declined 0 9  year over year due to lower operating profits Revenues came in at  4 09 billion  which exceeded the Zacks Consensus Estimate of  3 94 billion as well as the guidance of  3 88 billion to  4 03 billion  Revenues fell 0 8  from the year ago period primarily due to currency headwinds  Excluding the impact of currency  total revenues rose 1 2  as higher sales of key products like Botox  cosmetic and therapeutics   Juv derm collection of fillers  Vraylar  Ozurdex  and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others in 2018 Moreover  sales of Restasis also declined in the quarter  ahead of anticipated generic competition  Also  decline in textured breast implants due to a global recall hurt sales Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues declined 2 3  to  1 79 billion  Strong sales growth of its facial aesthetics products  Botox and Juv derm and Botox Therapeutic was offset by decline in sales of Restasis and divestiture of Medical Dermatology business in September 2018  Sales of CoolSculpting and breast implants also declined in the quarter In Facial Aesthetics  Botox  cosmetic  raked in sales of  252 4 million  up 6 7  year over year  Juv derm collection of fillers rose 12  to  156 6 million Alloderm sales  however  fell 5 5  to  101 2 million while CoolSculpting sales of  78 9 million declined 27 1  year over year In Eye Care  while Ozurdex sales rose 8 3  to  29 9 million  Restasis sales fell 2 3  to  310 9 million Botox Therapeutic revenues were  447 0 million  up 5 9  year over year U S  General Medicine net revenues were up 10 3  year over year to  1 46 billion in the reported quarter as strong growth of Vraylar  Viibryd  Linzess and Lo Loestrin was offset by lower sales of drugs that lost exclusivity Linzess sales rose 2 2  to  196 0 million  Lo Loestrin sales grew 13 8  to  145 5 million while Bystolic sales rose 1 6  to  150 5 million  Vraylar sales were  196 1 million in the second quarter  71 7  higher than the year ago quarter  while Viibryd sales were  107 8 million  up 24 3  from the year ago quarter  In May  Vraylar was approved for the new indication of bipolar depression  which may have contributed to higher sales of the drug in the quarter The International segment recorded net revenues of  847 7 million  down 4 3  from the year ago period  excluding the impact of foreign exchange as growth in Facial Aesthetics and Ozurdex implant was partially offset by regulatory changes for textured breast implants and lower glaucoma and eye drop revenues Profits RiseAdjusted gross margin declined 70 basis points  bps  in the quarter to 84 7    Adjusted operating income decreased 6 3  to  1 85 billion in the second quarter due to lower revenues and higher costs Selling  general and administrative expenses increased 2 5  to  1 16 billion in the second quarter  owing to higher marketing spending in Medical Aesthetics and for product launches Research and development  R D  expenses rose 14 9  to  447 0 million due to pipeline progress 2019 OutlookAllergan slightly raised its sales guidance for 2019  mainly benefiting from delayed generic entry of Restasis while maintaining the previously issued earnings view Allergan expects sales to be in the range of  15 43  15 63 billion  up from the previous guidance of  15 13  15 43 billion   The company still estimates its adjusted earnings to be more than  16 55 per share  Adjusted tax rate is expected to be approximately 13  in 2019 versus 13  13 5  expected previously   Adjusted R D expense guidance was maintained in the range of approximately  1 6    1 7 billion while the SG A range was increased from approximately  4 1    4 3 billion to approximately  4 4    4 5 billion  Adjusted gross margin is expected to be approximately 85  85 5   maintained  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in estimates revision 
VGM Scores
At this time  Allergan has an average Growth Score of C  however its Momentum Score is doing a bit better with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Allergan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-up-18-since-last-earnings-report-can-it-continue-200461874,200461874
104665,326180,AGN,Endo Gains FDA Nod For Orfadin Generic To Treat Rare Disease,opinion,Endo International plc   NASDAQ ENDP   announced that Novitium Pharma  LLC  a partner of its subsidiary Endo Ventures Limited  secured an approval from the FDA for a room temperature stable  AB rated  generic equivalent of Swedish Orphan Biovitrum s Orfadin  nitisinone capsules  These capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1  HT 1  in combination with dietary restriction of tyrosine and phenylalanine  Global sales for Orfadin were approximately  85M over the last four quarters Par Pharmaceutical  Inc   Endo s operating company  expects to distribute the product through specialty pharmacies beginning this month  HT 1 affects at least 1 in 100 000 patients worldwide with approximately 150 patients alone in the United States Earlier in the week  Par Pharmaceutical began shipping an authorized generic version of Merck s   NYSE MRK   Noxafil delayed release tablets  100 mg   The shipping was started after Endo Ventures Limited entered into an exclusive U S  supply and distribution agreement with a unit of Merck   Co   Inc   of Kenilworth  NJ  thereby allowing Par to launch and distribute an authorized generic version of the product  These new launches will boost Endo s dwindling business  Meanwhile  generics base business plummeted significantly due to the loss of marketing exclusivity of a few products  Moreover  the business line is facing competitive pressures  Product discontinuances and pricing pressure from an increased competition impacted the same Notably  Endo has been in news of late due to the ongoing opioid litigation cases  Last month  the company reached a settlement in principle with the County of Cuyahoga  Ohio  the County of Summit  Ohio and specific persons in connection with the pending lawsuits at various U S  District cases  The settlement will resolve the Track 1 Cases regarding claims related to the manufacturing  marketing  distribution  supply  sale  prescribing  use and or abuse of branded and generic opioid medications  The cases are scheduled to go under trial in October 2019 Per the settlement terms  Endo will pay a total sum of  10 million and provide up to  1 million of Vasostrict and Adrenalin products free of charge  While the company still has many pending litigations related to opioid drugs  investors seem upbeat about the settlement terms of these cases   The settlement relieves Endo of a major hangover  giving its investors some respite  Notably  shares of the company have slumped 66 6  in the year so far against the  s 6 1  growth  Last week  Johnson   Johnson   NYSE JNJ   received an unfavorable ruling in the court case filed by the state authorities of Oklahoma pertaining to the abuse of its opioid based drugs  namely Duragesic  Nucynta and Nucynta ER  The Cleveland County District Court has ordered the company to pay  572 million to the state   Allergan   NYSE AGN   too has settled with two counties of Ohio for almost  5 million  thereby resolving all claims against itself in relation to the federal multidistrict litigation for opioid drug abuse scheduled in October Endo currently carries a Zacks Rank  3  Hold   You can see  It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/endo-gains-fda-nod-for-orfadin-generic-to-treat-rare-disease-200461927,200461927
104697,326212,AGN,Allergan CEO opposes fundamental shift in strategy  shares dip,news,"By Michael Erman and Manas Mishra  Reuters    Allergan Plc s  N AGN  chief executive on Monday said he was opposed to fundamental changes to the drug company s business strategy  even as its board considers drastic moves like splitting the company  selling off assets or doing deals to turn around a steep drop in its share price  Botox maker Allergan s shares fell 2 2 percent to  158 42 in early trading on Monday  They have lost more than a third of their value over the last year  The company announced a strategic review of its business earlier this year  Allergan has hired multiple advisers  CEO Brent Saunders said on a conference call following the company s quarterly earnings  It is considering five options  deploying capital to buy back shares  doing divestitures  splitting the company  making acquisitions  or continuing to operate Allergan as is  Investors hoping for a major shift in strategy may be disappointed   Running the company in large part as it exists today is not only an option  but also the baseline against which all options need to be considered   Saunders said on the call  noting that his preliminary view was that a fundamental shift was unnecessary   We re not going to execute an activity that doesn t recognize the full inherent value of our assets at Allergan   Allergan did not bid for  Shire  Plc  L SHP  earlier this month  after confirming reports that it considered an offer for the rare disease treatment specialist  Saunders said in an interview that large transformational deals are a  very low priority and a very unlikely outcome  of the review  BETTER THAN EXPECTED EARNINGS Allergan reported a better than expected first quarter profit and raised its full year earnings forecast  driven by higher sales of its medical aesthetics products including blockbuster wrinkle treatment Botox  Sales of Botox  its biggest drug by revenue  jumped 14 5 percent to  817 3 million in the quarter  The company s aesthetics unit posted a near 30 percent jump in sales  U S  Sales of Allergan s eye drug  Restasis  which is expected to face competition from cheaper drugs  fell 17 2 percent   The company now expects 2018 adjusted earnings of  15 65 to  16 25 per share  slightly above its previous forecast of  15 25 to  16 per share  Its net loss was  332 5 million  or 99 cents per share  compared with  2 63 billion  or  7 86 per share  a year earlier  Excluding one time items  Allergan reported a profit of  3 74 per share  topping analysts  average expectation of  3 36  according to Thomson Reuters I B E S  
Total revenue rose 2 8 percent to  3 67 billion  topping analysts  average estimate of  3 59 billion ",2018-04-30,Reuters,https://www.investing.com/news/stock-market-news/allergan-tops-estimates-as-botox-aesthetics-products-drive-gains-1421138,1421138
104698,326213,AGN,Pfizer first quarter results miss estimates as key drug sales fall short,news,"By Bill Berkrot NEW YORK  Reuters     Pfizer  Inc  N PFE  on Tuesday reported lower than expected first quarter revenue as demand for some key drugs and international sales fell short of estimates  sparking a 5 1 percent drop in shares of the largest U S  drugmaker  The company  which is exploring a sale of its consumer healthcare business but has seen potential suitors drop out  said it has not received an acceptable offer at this time   If we can t get value  we ll retain it and invest in it   Chief Executive Officer Ian Read told analysts  A final decision is still expected this year  Read  whose previous attempts at huge acquisitions of AstraZeneca  L AZN  and Allergan  N AGN  were thwarted  said the company does not need a megamerger to drive future growth   I don t see that we need a transformative deal or see one at an appropriate value   Read said  adding that drugs in development and newer medicines will be able to drive future growth  He said the company has 15 potential blockbuster medicines in the pipeline that could be launched by 2022  Pfizer also sees opportunities to significantly expand sales of prostate cancer drug Xtandi for treating less advanced patients  and arthritis drug Xeljanz for ulcerative colitis  U S  regulatory decisions on the expanded uses are expected later this year   Pfizer posted adjusted earnings of 77 cents per share that topped analysts  average expectations by 4 cents  according to Thomson Reuters I B E S  on lower taxes and cost of goods sold  It did not raise its full year earnings or revenue forecasts  Despite strong growth  sales of oral rheumatoid arthritis drug Xeljanz and blockbuster breast cancer treatment Ibrance missed expectations largely due to inventory stocking issues but are likely to rebound  analysts said  Injected arthritis drug Enbrel was hit by competition from cheaper biosimilars outside the United States  Vaccines and other older drugs  such as Lyrica  Premarin and Celebrex all fell short of analysts  estimates  Ibrance sales rose 37 4 percent to  933 million  while analysts looked for  956 6 million  Xeljanz sales totaled  326 million  missing the Wall Street outlook by about  72 million  Total revenue rose 1 percent to  12 91 billion  while analysts expected  13 13 billion  SunTrust Robinson Humphrey analyst John Boris said he expected stronger international sales  given favorable foreign exchange rates   If you remove the FX tailwind it would have been a much more substantial miss   he said  adding that it was disappointing Pfizer did not raise its 2018 forecasts after rivals  such as Merck   Co  N MRK  and AbbVie  N ABBV   raised their outlooks after reporting first quarter results  Pfizer still expects adjusted full year earnings of  2 90 to  3 00 per share on revenue of  53 5 billion to  55 5 billion  Net profit rose to  3 56 billion  or 59 cents per share  for the quarter  from  3 12 billion  or 51 cents  a year earlier  
Pfizer shares fell  1 87 to  34 74 ",2018-05-01,Reuters,https://www.investing.com/news/stock-market-news/pfizer-tops-profit-estimates-driven-by-prevnar-sales-1423439,1423439
104699,326214,AGN,Trump plan on drug prices to be announced this afternoon,news,President Trump is set to announce his plan to corral drug prices in a speech set to begin at 2 00 pm ET today  According to administration officials the plan will not include a call to Congress to allow Medicare to negotiate drug prices  a move currently prohibited under federal law The plan aims to increase competition by making it easier for generics and biosimilars to reach the market and eliminating certain government rules that prevent seniors from getting lower priced medications  It will also create incentives for lower prices and lower co pays for patients Selected tickers  XLV  VHT  XBI  IYH  RYH  IBB  PJP  XPH  IHE  PPH  BBH  AMGN  BIIB  GILD  CELG  VRTX  OTCQX RHHBY  ABBV  AGN  BMY  GSK  JNJ  LLY  MRK  NVO  NVS  PFE  SHPG  VRX  TEVA  PRGO  MYLNow read ,2018-05-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/trump-plan-on-drug-prices-to-be-announced-this-afternoon-1443334,1443334
104700,326215,AGN,Trump speech on drug prices light on specifics,news,Key points from President Trump s speech detailing his plan to lower U S  drug prices called American Patients First Bans pharmacist gag rule against advising patients on pricing FDA will accelerate approval process for generics and biosimilars Will  fix  price disparity between U S  and foreign markets  specifics not provided  HHS Secretary Alex Azar  plan will leverage private sector dynamics  Will investigate having the FDA mandate the disclosure of pricing in TV drug ads More details to follow in a press briefing Selected tickers  XLV  VHT  XBI  IYH  RYH  IBB  PJP  XPH  IHE  PPH  BBH  AMGN  BIIB  GILD  CELG  VRTX OTCQX RHHBY  ABBV  AGN  BMY  GSK  JNJ  LLY  MRK  NVO  NVS  PFE  SHPG  VRX  TEVA  PRGO  MYLNow read ,2018-05-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/trump-speech-on-drug-prices-light-on-specifics-1443725,1443725
104701,326216,AGN,Evolus investors frown as FDA declines to approve Botox rival,news,"By Manas Mishra  Reuters    U S  health regulators on Wednesday declined to approve Evolus Inc s  O EOLS  rival product to Allergan Plc s  N AGN  Botox  citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines  sending its shares down as much as 35 percent  The deficiencies cited by the U S  Food and Drug Administration were  manageable   according to Chief Executive Officer David Moatazedi  who joined the company earlier this month after serving as U S  head of Allergan s medical aesthetics business   They are all questions we have considered and contemplated prior to the response from the FDA   Moatazedi said on a call with analysts  but refused to specify the exact questions asked by the FDA   The company said it was committed to getting its DWP 450  which is being developed to treat glabellar lines or frown lines in adult patients  to the market by spring 2019   Evolus expects to respond to the FDA with a complete submission within 90 days  The deficiencies cited by the FDA were isolated to items related to chemistry  manufacturing  and controls processes  and none related to clinical or non clinical matters  the company said  The deficiencies were communicated in a so called complete response letter related to Evolus  marketing application for DWP 450  a Botox like treatment   Allergan s Botox is the market leader for treatment of wrinkles and frown lines  but the threat of looming competition for the blockbuster treatment has put some pressure on the drugmaker   Revance Therapeutics  O RVNC  in February teamed up with Mylan NV  O MYL  to develop a biosimilar to Botox  A likely delay for Evolus  treatment sent Allergan s shares up 2 1 percent in morning trading   The FDA s decision on DWP 450 was widely anticipated by analysts  after the agency had issued a  form 483   which outlined violations at the company s facility following inspections in 2017   Also on Wednesday  the company said that its partner Daewoong Pharmaceutical Co received a favorable inspection report of its manufacturing facility  which makes DWP 450   
Shares of Evolus  which went public about three months ago  were down 31 percent at  10 18 in morning trading ",2018-05-16,Reuters,https://www.investing.com/news/stock-market-news/evolus-investors-frown-as-fda-declines-to-approve-botox-rival-1450164,1450164
104702,326217,AGN,Walgreen  Kroger  Albertsons  HEB sue Allergan over dry eye drug,news,"By Jonathan Stempel NEW YORK  Reuters    Allergan Inc  NYSE AGN  was sued on Wednesday by four large U S  retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis  its medication to treat dry eye disease   Walgreen Co   NASDAQ WBA   Kroger  NYSE KR  Co  Albertsons Cos and HEB Grocery Co accused Allergan of illegally preserving its monopoly by obtaining illegal patents  suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe  New York s Saint Regis Mohawk Tribe  to escape scrutiny by U S  courts  The retailers said generic Restasis would have been on the U S  market by May 2014 but for Allergan s activities  and that the Dublin  Ireland based company should pay triple and other damages for its anticompetitive conduct  Allergan did not immediately respond to requests for comment  The company holds patents covering various elements of Restasis that expire in 2024  On Feb  26  the U S  Patent Trial and Appeal Board refused to dismiss litigation by generic drugmaker Mylan  NASDAQ MYL  NV challenging the validity of Allergan s patents  Sales of Restasis totaled  1 47 billion in 2017  accounting for about 9 percent of Allergan s  15 94 billion of overall net revenue  according to a regulatory filing  Wednesday s lawsuit was filed in the federal court in Brooklyn  New York  which oversees nationwide litigation by various pension plans  healthcare companies  Stop   Shop parent Ahold USA and others over Restasis  
The cases are Walgreen Co et al v Allergan Inc  U S  District Court  Eastern District of New York  No  18 02907  and In re  Restasis  Cyclosporine Ophthalmic Emulsion  Antitrust Litigation in the same court  No  18 md 02819 ",2018-05-16,Reuters,https://www.investing.com/news/stock-market-news/walgreen-kroger-albertsons-heb-sue-allergan-over-dryeye-drug-1450925,1450925
104703,326218,AGN,Appaloosa gets permission for activist stance with Allergan stake,news,"NEW YORK  Reuters    David Tepper s Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan  NYSE AGN  Plc  Tepper received the Hart Scott Rodino anti trust clearances on Wednesday  according to the FTC s website   Wells Fargo   NYSE WFC  analyst David Maris said in a research note that Allergan  indicated this clearance provides flexibility to the filer as to whether they want take an activist approach to the investment or not   Tepper s Appaloosa LP increased its stake in Allergan to 3 7 million shares from around 3 5 million shares over the last quarter  the firm said in a filing with the Securities and Exchange Commission on Tuesday   Allergan welcomes all investments in our company   spokeswoman Amy Rose said  when asked about the clearances  Appaloosa was not immediately available for comment  The company s shares roe  5 70  or 3 7 percent  to  160 23 on Thursday   Botox maker Allergan launched a strategic review of its business earlier this year  CEO Brent Saunders said in March the declining stock price required the company to look at all options  with a sense of urgency   
Still  Saunders indicated on the company s earnings conference call last month that he did not feel a fundamental change to the company s strategy was necessary ",2018-05-17,Reuters,https://www.investing.com/news/stock-market-news/appaloosa-gets-permission-for-activist-stance-with-allergan-stake-1452818,1452818
104704,326219,AGN,Investors bullish on biotechs after Trump drug pricing speech,news,As any student of the healthcare equity market knows by now  money flow into biotech and healthcare funds jumped after President Trump revealed his  rather benign  plan to curb U S  drug prices  STAT News  Adam Feuerstein reports that  819M flowed into the funds this week  the largest infusion since July of last year  Investors were apparently relieved that his plan did not include allowing Medicare to negotiate drug prices  although HHS Alex Azar disclosed that this may still be on the table Selected tickers  XLV  IBB  XBI  IHE  IYH  RYH  PJP  XPH  PPH  BBH  AMGN  BIIB  GILD  CELG  VRTX  OTCQX RHHBY  ABBV  AGN  BMY  GSK  JNJ  LLY  MRK  NVO  NVS  PFE  SHPG  VRX  TEVA  MYL  PRGOPreviously  Expanding Medicare drug price negotiation   May 15 Previously  Trump speech on drug prices light on specifics  May 11 Now read ,2018-05-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/investors-bullish-on-biotechs-after-trump-drug-pricing-speech-1453485,1453485
104705,326220,AGN,Pharma Stock Roundup  AGN  NVO Earnings  EU Nod To SNY   ABBV Drugs For New Patients,opinion,"This week Allergan   NYSE AGN   and Denmark s Novo Nordisk   NYSE NVO   announced second quarter results  The European Commission granted approval to AbbVie s   NYSE ABBV   chronic hepatitis C drug Maviret and Sanofi s   NASDAQ SNY   eczema medicine Dupixent for expanded patients groups  Pfizer   NYSE PFE    Roche   OTC RHHBY   AstraZeneca and Lilly   NYSE LLY   provided pipeline regulatory updates Recap of the Week s Most Important StoriesAllergan   Novo Nordisk Report Q2 Results  Allergan  for both earnings and sales in the second quarter and raised its sales guidance for the year Earnings declined 0 9  year over year due to lower operating profits while sales rose 1 2   excluding the impact of currency  Botox  Juv derm fillers  Vraylar and Ozurdex drove sales growth  making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants Novo Nordisk missed estimates for both earnings and sales in the second quarter  Sales in both the Diabetes and Obesity Care segment and Biopharmaceuticals segment increased 6  at constant exchange rate  CER   Novo Nordisk raised its sales growth expectations from a range of 2 5  at CER to a range of 4 6  at CER EU Approval for AbbVie s Maviret and Sanofi s Dupixent for New Patient Groups  The European Commission granted approval to AbbVie s Maviret as a once daily  8 week regimen for treatment na ve  chronic hepatitis C  HCV  patients with genotype  GT  1  2  4  5 and with compensated cirrhosis  The approval was based on data from a study  which showed 97 9  cure rate across this group of patients with no reported virologic failures  However  analysis of data from the same study evaluating Maviret as an 8 week  once daily treatment option for GT3 chronic HCV patient population  with cirrhosis  is ongoing  At present  Maviret is approved as a once daily  8 week regimen for treatment na ve HCV patients without cirrhosis The regulatory agency also approved Sanofi s new drug  Dupixent for atopic dermatitis  AD   also called eczema  in the adolescent  aged 12 17 years  patient population  Dupixent was approved for this patient population by the FDA in March Meanwhile  the European Commission also granted approval to include positive cardiovascular outcomes and renal data from the DECLARE outcomes study on the label of AstraZeneca s type II diabetes medicine  Forxiga  The DECLARE TIMI 58 study evaluated the cardiovascular  CV  and renal effects of Forxiga  dapagliflozin  in adults with type II diabetes compared to placebo  A similar application is under review in the United States Bayer  DE BAYGN  to Buy Remaining Stake in BlueRock Therapeutics  Bayer announced a deal to buy its remaining stake in Cambridge  MA based private biotech BlueRock Therapeutics to strengthen its position in cell therapy  BlueRock makes engineered cell therapies focused on neurology  cardiology and immunology  using a proprietary induced pluripotent stem cell  iPSC  platform  Its lead program is a pre clinical candidate in Parkinson s disease  which is expected to enter clinical studies by the end of this year  Bayer presently holds 40 8  stake in BlueRock and has agreed to pay  240 million upfront and potential milestone payments of  360 million to buy the rest of BlueRock s stake  This will bring the total value of 100  stake in BlueRock to  1 billion  BlueRock was established in 2016 as a joint venture between Bayer and Versant Ventures  The deal is expected to close in the third quarter of 2019 Sanofi s Dupixent Succeeds in Eczema Study in Children  Sanofi  PA SASY  and partner Regeneron s phase III study evaluating Dupixent in pediatric AD population met the primary and secondary endpoints   Top line data from the study showed that Dupixent plus standard of care topical corticosteroids  TCS  significantly improved measures of overall disease severity  skin clearing  itching and health related quality of life in children  aged 6 to 11 years   with severe AD compared to TCS alone  The companies expect to submit an application in the United States to get approval for use in children in the fourth quarter Dupixent is also marketed to treat moderate to severe asthma and was approved by the FDA for the third indication  chronic rhinosinusitis with nasal polyposis in adults in June AbbVie Files NDA for Elagolix in Uterine Fibroids  AbbVie and partner Neurocrine Biosciences announced the filing of a new drug application  NDA  looking for approval of elagolix for reducing heavy menstrual bleeding  HMD  in premenopausal women with uterine fibroids  The NDA was based on data from two pivotal phase III studies  ELARIS UF I and ELARIS UF II   which showed a statistically significant reduction in HMB with elagolix  in combination with add back therapy  compared to placebo  Elagolix is already marketed as Orilissa for management of pain associated with endometriosis  a common gynecologic disorder  for which approval was received in July last year Pfizer s Sickle Cell Disease Candidate Fails  Pfizer s phase III study evaluating its investigational candidate  rivipansel in patients with sickle cell disease experiencing acute pain crises or VOC did not meet its primary or key secondary efficacy endpoints  The primary endpoint of the study was the time to readiness for discharge  Rivipansel was initially being developed under a worldwide licensing agreement with GlycoMimetics  After completion of the phase II study  Pfizer took charge of the development of rivipansel AstraZeneca s Lynparza Phase III Study Meets Endpoint  AstraZeneca announced positive results from a phase III study evaluating its successful PARP inhibitor  Lynparza in men with metastatic castration resistant prostate cancer  mCRPC  selected for BRCA1 2 or ATM gene mutations  a subpopulation of HRR gene mutations  The study met the primary endpoint of significantly increasing the time patients live without radiographic disease progression versus standard of care treatmentRoche s Tecentriq Combo Improves PFS in Bladder Cancer Study  Roche announced interim data from a phase III study evaluating its PD L1 inhibitor  Tecentriq plus platinum based chemotherapy for the treatment of patients with previously untreated advanced bladder cancer  The IMvigor130 study reduced the risk of disease worsening or death in such patients compared with chemotherapy alone  thereby meeting the study s co primary endpoint  progression free survival  PFS   While encouraging overall survival results were observed as well  these data were not mature  Roche will submit the PFS data to the FDA and European Medicines Agency for approval Lilly s Emgality Succeeds in Phase III Study in Difficult to Treat Migraine Patients  Lilly s new migraine drug  Emgality  met the primary and all key secondary objectives in a phase III study  evaluating it in patients with chronic and episodic migraine who failed previous migraine preventive treatments  Treatment with Emgality led to reduction in monthly migraine headache days in such patients by 4 1 days  compared with 1 day for placebo  thereby meeting the study s primary endpoint of superiority over placebo in reducing the number of monthly migraine headache days The NYSE ARCA Pharmaceutical Index rose 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions 
 Bristol Myers recorded the highest increase  4 6   while Pfizer declined the most  3 6  In the past six months  AstraZeneca has been the biggest gainer  20 4   while Pfizer declined the most  11 5    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-agn-nvo-earnings-eu-nod-to-sny--abbv-drugs-for-new-patients-200453719,200453719
104706,326221,AGN,Currency  Conundrum And Fixed Income Follies Spark Market Volatility,opinion,"The world is getting more connected through technology and travel  Cuisines are evolving  Some people are scared of globalization  but I think people will always take pride in cultural heritage  John Mackey
A few years ago  there was a movie called Benjamin Button about a person living backwards from death to birth  It starred the handsome Brad Pitt  he of Angelina Jolie fame  In the story  there is a segment where the main character suffers an unfortunate accident  The story goes on to account for every single action the character made and how it delayed his time horizon  which affected the characters timeline  which ultimately produced the problematic incident  I bring this up because one can make a case that in many situations  lots of independent events are linked to produce an outcome  Essentially  to see the world is to understand how small events in one area can affect larger countries even though they do not appear related  Let s turn to the current market environment with this thought in mind 
As I am sure you are quite aware  global equity markets have been experiencing heightened volatility over the last few weeks  There are quite a few important issues that are related here  First  China s economy has a large export component  nearly 50  of all GDP  China has made the domestic economy a focus  to reduce it s dependence on exports over the last decade  Second  we all know about Mr  Trump s announcement of another 10  tariff on all Chinese exported goods to the United States  Last Monday  China announced  it would alter it s currency band of Yuan  Renmimbi  that is pegged to the dollar  It was lowered to above the all important 7 1 ratio  If you are not familiar with currency markets  when I say lowered  what I mean is that one U S  dollar would exchange for more Chinese Yuan  in this case  more than 7 yuan to one U S  dollar  Currency markets also reacted to central banks across the globe further lowering their interest rates  which included India  Currency markets affect interest rates  which affect the bond market  In Japan  the Yen is considered a safe haven during heightened economic stress  so buyers bought the Yen  strengthening it against the dollar  it means one U S  dollar exchanges for fewer Yen   Japan is an important country to look at when you consider the effect of weak monetary policy  For more than three decades  the Japanese government has tried to help their domestic economy by keeping interest rates quite low  currently yielding a   144  on the Japanese 10 year JGB  As a result  their banking sector is under serious economic pressure as many smaller banks cannot make enough interest income from loans to be profitable or compete with the larger banks  The larger Japanese banks have turned to global markets to find areas to make more interest income  especially in the United States  Here is a very nice  from the WSJ which details this issue  With the heightened volatility in the currency markets  scared investors rush into the bond market to buy Treasuries and other government bonds  Bond yields fell  so much so that they broke the 1 7  level this week before recently rebounding  Relatedly  stock markets were pummeled on Monday after all of these moves  with the Dow falling nearly a thousand points in one day  You notice we did not bring up what is taking place in Britain either  With a new Prime Minister  the always politically correct Boris Johnson  the deadline for a complete and hard Brexit is fast approaching  which is the end of October  Investors see this as quite problematic  and the pound has been pounded nearly every day  as have British equities  Logically  the political events in British and Europe naturally affect all markets as well  So you can see  like Benjamin Button s situation  global markets are very much related  It is important to keep that in mind  especially when looking for investment opportunities 
In the earnings season  global bank HSBC reported soft numbers  as did gaming powerhouse Take Two Interactive  Disney was the headliner on Tuesday  in a disappointing way as integration with the Fox purchase plagued the bottom line  Health care giants Becton Dickinson  NYSE BDX  and Allergan  NYSE AGN  showed strong profits  while giant Wynn Resorts  NASDAQ WYNN  put up a nice results   CenturyLink   NYSE CTL  pleased the street for the first time in probably a decade  while real estate giant Zillow showed the affects of trying to enter into the buying and selling arena  In the energy markets  investors were roiled by the China devaluation situation  and oil prices suffered accordingly  For those of you who are self directed investors  it is pretty clear where value is becoming more evident 
Finally  many long time readers are aware of the repeated difficulties I ve had while traveling  We will make our last sojourn of the summer and hopefully it will go better than some of the prior trips  I hope yours do as well  Thanks for reading the blog this week Thanks for reading the blog this week ",2019-08-11,Yale Bock,https://www.investing.com/analysis/currency--conundrum-and-fixed-income-follies-spark-market-volatility-200453939,200453939
104707,326222,AGN,Implied Volatility Surging For Allergan  AGN  Stock Options,opinion,Investors in Allergan plc   NYSE AGN   need to pay close attention to the stock based on moves in the options market lately  That is because the Aug 16  2019  110 00 Call had some of the highest implied volatility of all equity options today What is Implied Volatility Implied volatility shows how much movement the market is expecting in the future  Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other  It could also mean there is an event coming up soon that may cause a big rally or a huge sell off  However  implied volatility is only one piece of the puzzle when putting together an options trading strategy What do the Analysts Think Clearly  options traders are pricing in a big move for Allergan shares  but what is the fundamental picture for the company  Currently  Allergan is a Zacks Rank  3  Hold  in the Medical   Generic Drugs industry that ranks in the Top 26  of our Zacks Industry Rank  Over the last 30 days  three analysts have increased their earnings estimates for the current quarter  while two have dropped their estimates  The net effect has taken our Zacks Consensus Estimate for the current quarter from  4 16 per share to  4 21 in that period Given the way analysts feel about Allergan right now  this huge implied volatility could mean there s a trade developing  Oftentimes  options traders look for options with high levels of implied volatility to sell premium  This is a strategy many seasoned traders use because it captures decay  At expiration  the hope for these traders is that the underlying stock does not move as much as originally expected Looking to Trade Options Check out the simple yet high powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple digit winners  In addition to impressive profit potential  these trades can actually reduce your risk ,2019-08-12,Zacks Investment Research,https://www.investing.com/analysis/implied-volatility-surging-for-allergan-agn-stock-options-200454758,200454758
104708,326223,AGN,Here s Why Allergan Is Outperforming Its Industry Of Late,opinion,Shares of Allergan plc   NYSE AGN   have risen 19 1  this year so far against the  s decline of 10 9    AbbVie   NYSE ABBV   offered to buy Allergan in a cash and stock deal worth nearly  63 billion in June  which has been driving Allergan s shares since then  AbbVie offered  120 30 in cash and 0 866 of its share  worth  67 94  for each share of Allergan  representing a premium of 45  to Allergan s closing price on Jun 24  The deal should  thus  prove to be rewarding for its shareholders  Amid expectations of generic competition for its blockbuster eye drug  Restasis  fears of new competition for key drug Botox and some recent pipeline setbacks  the merger with AbbVie could prove to be the best way out for Allergan Allergan also continues to deliver on its R D pipeline with some major product launches expected over the next couple of years  Key programs include Ubrogepant  an oral CGRP antagonist for migraine  Abicipar for age related macular degeneration  Atogepant  an oral CGRP antagonist  for migraine prevention and Bimatoprost SR for glaucoma  A regulatory application in the United States for Ubrogepant was filed in March 2019  FDA decision expected in December 2019  while that for Bimatoprost SR was filed in July 2019  FDA decision in first half of 2020   A regulatory application for Abicipar is expected to be filed in 2019  This late stage pipeline has the potential to lead to major product launches over the next couple of years The company is also working on expanding the labels of marketed products like Botox and Linzess among others  Importantly  in May  its schizophrenia drug  Vraylar  cariprazine  was approved by the FDA for a new indication   bipolar depression   which expands the drug s eligible patient population  thereby providing an incremental sales opportunity  Botox was approved by the FDA for upper limb spasticity in pediatric patients in June  In the same month  Allergan received FDA clearance for its CoolTone device for muscle toning  strengthening and firming of the abdomen  buttocks and thighs Meanwhile  biosimilars represent significant opportunity for Allergan  It has a collaboration agreement with Amgen   NASDAQ AMGN   for the worldwide development and commercialization of four oncology antibody biosimilars  Amgen Allergan s biosimilar version of Roche s   OTC RHHBY   Avastin  Mvasi  was launched the United States last month and was approved in the EU last year  However  it has not been launched yet  Meanwhile  Kanjinti  the biosimilar version of Roche s Herceptin was launched in the United States and EU in July 2019 and May 2018  respectively  A biosimilar of Roche s Rituxan  ABP 798  is in phase III development However  Allergan has its share of challenges  Its sales are being hurt by loss of exclusivity of key drugs  recalls of textured breast implants  pricing pressure and currency headwinds  Restasis is also expected to face generic competition this year   Please note  however  that a delayed generic entry of Restasis has allowed Allergan to raise its sales guidance twice this year  However  new competition for key growth drivers  Botox  Restasis and Linzess  is a concern In February  Evolus  Jeuveau injection indicated to improve the appearance of glabellar or frown lines was approved by the FDA  which can pose competition for Botox  In the fall of 2019  Revance Therapeutics will file for approval of DaxibotulinumtoxinA for Injection  DAXI   a rival treatment to Botox for the frown lines indication  It has demonstrated longer duration of efficacy compared to Botox in late stage studies  Allergan has also faced its share of setbacks  the most recent being the failure of its three acute pivotal studies on depression candidate  rapastinel  which failed to meet the primary endpoints Despite all the negatives  strong performance of its key products like Botox  Viberzi and Vraylar  product launches and potentially successful closing of the merger with AbbVie should keep the stock afloat through the rest of the year Allergan has a Zacks Rank  3  Hold   You can see  Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-08-19,Zacks Investment Research,https://www.investing.com/analysis/heres-why-allergan-is-outperforming-its-industry-of-late-200456769,200456769
104709,326224,AGN,Top Analyst Reports For Estee Lauder  Becton  Dickinson   Applied Materials,opinion,"Tuesday  August 20  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features updated research reports on 16 major stocks  including Estee Lauder  EL   Becton  Dickinson  BDX  and Applied Materials  NASDAQ AMAT   These research reports have been hand picked from roughly 70 reports published by our analyst team today 
You can see 
Estee Lauder s shares are up  43 5  in the past year  outperforming the Zacks Cosmetics industry  which is up  25 9  over the same period  The Zacks analyst thinks that this is largely attributable to the company s robust sales and earnings history  backed by growth across most brands as well as sales channels  
The trend continued in the fourth quarter of fiscal 2019  wherein the top and the bottom line surpassed estimates and rose year on year  Performance in the quarter and fiscal 2019 was supported by growth in emerging markets  strong travel retail and online sales  Additionally  management provided an optimistic view for fiscal 2020 and for the first quarter  
However  the company is mindful regarding certain headwinds such as soft retail trends in the United States and the U K   costs related to Brexit  impact of tariffs in China as well as moderation of sales in China and travel retail network  Moreover  adverse currency rates are a concern 
 You can   
Shares of Becton  Dickinson have outperformed the Zacks Dental Supplies industry in the past year  losing  0 6  vs   5 3   Becton  Dickinson  also known as BD  exited the fiscal third quarter on a strong note  The Zacks analyst likes the solid show by the core BD Medical and Interventional units  
Domestic revenues increased year over year in the quarter under review  driven by segmental strength  Growth was observed in China and EMEA  Expansion in gross and operating margins is another encouraging factor  BD kept its fiscal 2019 guidance intact  However  sluggishness in the core Life Sciences unit raises concern  International sales also declined in the quarter  
Contraction in operating margins is a concern  Management expects unfavorable foreign currency to partially mar BD s bottom line in fiscal 2019  Stiff competition in the MedTech space adds to the company s woes 
 You can   
Applied Materials  shares have outperformed the Zacks Semiconductor Equipment   Wafer Fabrication industry in the past three months   14  vs   11 8    Applied Materials reported fiscal third quarter results wherein both earnings and revenues topped the estimates 
The company witnessed solid customer spending in foundry and logic  thanks to IoT  communications  automotive  power and sensor applications  The company also experienced solid momentum across United States and Taiwan during the reported quarter  The Zacks analyst remains optimistic about the price elasticity of NAND  which is expected to bolster NAND customer spending in the near term  
The company s expanding etch footprint bodes well for its semiconductor portfolio  However  market uncertainties remain a headwind  Softness in semiconductor and display markets on account of slowdown in memory and display customers  spending is major concern 
 You can   
Other noteworthy reports we are featuring today include Regeneron  REGN   Aspen  AZPN  and HollyFrontier  HFC  
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana 
Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge 

Note  Our Director of Research Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Growth in Emerging Markets to Keep Fueling Estee Lauder  EL 


BD Medical Arm Aids Becton  Dickinson  BDX  Amid Forex Woes


Applied Materials  AMAT  Rides on Foundry   Logic Spending


Featured Reports
Eylea  Dupixent Fuel Regeneron  REGN  Amid Stiff Competition
Per the Zacks analyst  the label expansion of lead drug Eylea and strong performance of asthma drug Dupixent boost Regeneron  However  competition and pipeline setbacks might dent performance 

Robust Product Portfolio   Higher bookings Aid Aspen  AZPN 
Per the Zacks analyst  robust adoption driven by high demand for asset optimization and management solutions  sticky customer base and a strong pipeline for new business bookings are positives 

Generation Projects Aids OGE Energy  OGE   Regulations Hurt
Per the Zacks analyst  OGE Energy s generation projects will likely boost its performance  

Refining Margins Buoy HollyFrontier  HFC  Amid Base Oil Woes
The Zacks analyst believes stronger refining margins should bolster HollyFrontier s earnings  

bluebird  BLUE  Focuses on Developing Pipeline Amid Competition
Per the Zacks analyst  bluebird s efforts to develop its pipeline is impressive 

Partner Base Expansion Aids Grubhub  GRUB  Amid Competition
Per the Zacks analyst  partnerships with the likes of Taco Bell  Dunkin Bands and Shake Shack  NYSE SHAK  boost Grubhub s prospects amid rising competition from UberEats and DoorDash 

Allergan  NYSE AGN  Buyout by AbbVie  NYSE ABBV  Rewarding for Shareholders
With Restasis expected to face generic competition  fears of new competition to Botox and recent pipeline setbacks  the merger with AbbVie may be rewarding for its shareholders  per the Zacks analyst 

New Upgrades
Transformation Plan to Aid NRG Energy  NYSE NRG  Via Cost savings
Per the Zacks analyst  NRG Energy s balance sheet is likely to get a boost from its Transformation Plan  Under this plan  the company is on track to realize  590 million of cost savings in 2019 

Fossil s  FOSL  Margins to Gain on New World Fossil plan
Per the Zacks analyst  the New World Fossil plan helped lower costs and aid gross margin in second quarter 2019  Fossil expects to achieve run rate savings of  200 million from this plan in 2019 

Dr  Reddy s  RDY  Strong Position in Generics Market Impressive
Per the Zacks analyst  Dr  Reddy s enjoys a strong position in the generics market  Efforts on strengthening its presence in the biosimilars market have been commendable too 

New Downgrades
Weakness in Kate Spade  High SG A Worry for Tapestry  TPR 
Per the Zacks analyst  softness in Kate Spade is likely to persist in the near term and may hurt Tapestry s sales  Also  expectation of higher SG A in the first quarter may hurt margins to an extent 

End Market Uncertainties to Hurt Applied Industrial  AIT 
Per a Zacks analyst  Applied Industrial is cautious about uncertainties related to the broader industrial cycle  It predicts organic sales to decline 1 5  in fiscal 2020 

Decline in GeneSight Revenue Deters Myriad Genetics  MYGN 
The Zacks analyst is concerned about revenue decline within GeneSight  Vectra as well as Prolaris  Foreign exchange headwinds and escalating expenses continue to plague Myriad Genetics 
undefined undefined",2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/top-analyst-reports-for-estee-lauder-becton-dickinson--applied-materials-200456894,200456894
104710,326225,AGN,J J s  JNJ  Opioid Lawsuit Verdict In Oklahoma Due Next Week,opinion,"Johnson   Johnson   NYSE JNJ   is awaiting the verdict of an Oklahoma court  which is slated to provide a ruling on Aug 26 in a lawsuit filed by the state against the company  The state claims that J J is primarily responsible for the opioid epidemic in the state through aggressive marketing of its opioid based drugs  The state has demanded  17 billion to be paid by J J over 30 years to support the state s initiatives for opioid addiction treatment and prevention programs We note that J J has been indicted in more than 2 000 litigation filed by various state and local governments in the United States related to the marketing of its opioid drugs including Duragesic  Nucynta and Nucynta ER  Such litigation have also been filed against other pharma companies in several states Per a Reuters article  lawyers for the Oklahoma state stated that J J  through its marketing campaigns  had made opioid analgesics the first line treatment option for any pain since mid 90s  They also stated that it has created an opioid crisis leading to 6 000 deaths in the state so far  Moreover  data from the U S  Centers for Disease Control and Prevention shows that opioid overdose resulted in 400 000 deaths countrywide from 1999 to 2017 J J has accepted opioid abuse as a real problem but denies its role in the widespread use of opioid based drugs in the Oklahoma state  The company stated that its opioid analgesics were a tiny fraction of total sales from this class of drugs in Oklahoma Investors will be eagerly awaiting the ruling scheduled next week as the Oklahama litigation is a key overhang on the stock  A win for the state will likely increase pressure on the pharma companies involved in opioid litigation cases in several states  Settlements may run into billions of dollars  A potential loss for J J would increase litigation costs significantly Please note that two other companies      NYSE TEVA   and privately held Purdue Pharma   were also accused by the state of Oklahoma for their involvement in opioid abuse  However  both the companies settled with the state of Oklahoma outside court earlier this year  While Purdue Pharma had to pay  270 million  Teva paid  85 million  However  both the companies have denied any wrongdoing in the opioid abuse case Meanwhile  another opioid maker Endo International   NASDAQ ENDP   reached s with the state of Ohio and certain other U S  Districts  earlier this month  in lawsuits related to abuse of branded and generic opioid medications  Allergan   NYSE AGN   too has reportedly settled cases related to its branded opioid drugs Other than the opioid litigation  litigation related to talc based products are also a major overhang on J J  A Missouri court ruled against the company last year in one of the pending cases related to its talc powder  However  J J intends to appeal the case  Meanwhile  the ruling on Monday will provide insight into the company s position in opioid cases and its litigation liabilities  Any negative update on the pending litigation will pull down the company s stock Shares of J J have increased 1 7  so far this year against the  s decline of 2 1  Zacks RankJ J currently carries a Zacks Rank  3  Hold   You can see  Johnson   Johnson Price
    Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/jjs-jnj-opioid-lawsuit-verdict-in-oklahoma-due-next-week-200458091,200458091
104738,326253,AGN,Novartis Q1 results weigh on pharma stocks,news,Big Biopharma and generic drug makers are in the red  pressured by Novartis   NVS  3 1   Q1 results that included 6  of price erosion in its Sandoz unit and less than expected sales of Cosentyx Shire plc  SHPG  0 3   is now treading water after Allergan announced that it would not submit a bid leaving only Takeda  who may not have the resolve to pay what Shire demands Selected tickers   OTCQX RHHBY  0 6   ABBV  2   AGN  3 8   BMY  1 1   GSK  1 7   JNJ  0 6   LLY  1 1   MRK  0 7   NVO  2 3   PFE  0 4   VRX  2 5   TEVA  2 7   MNK  0 9   PRGO  1   MYL  0 9   ENDP  3 5  Now read ,2018-04-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/novartis-q1-results-weigh-on-pharma-stocks-1404085,1404085
104739,326254,AGN,Shire rejects  63 billion Takeda bid as Allergan drops pursuit,news,By Greg Roumeliotis  Ben Martin and Ben Hirschler NEW YORK LONDON  Reuters    Rare disease drug maker  Shire  Plc  L SHP  said on Thursday it had rejected a  63 billion cash and stock acquisition offer by Japan s Takeda Pharmaceutical Co Ltd  T 4502   while Allergan Plc  N AGN  reversed course on pursuing a rival bid   The high stakes drama underscores the surge in dealmaking this year in the pharmaceutical sector  as large players look for promising assets to improve their pipelines  An acquisition of Shire by Takeda would be by far the biggest acquisition of a drug company year to date  Botox maker Allergan confirmed on Thursday it was considering an offer for Shire after Reuters reported on its interest  sending its shares down 7 percent  Later on Thursday  Allergan Chief Executive Brent Saunders decided to drop his pursuit of London listed Shire after receiving pushback from some of his shareholders  who were concerned about the company overstretching its resources  according to people familiar with the matter  who asked not be identified discussing confidential talks  Allergan then issued a second announcement stating it did not intend to make an offer for Shire  Dublin based Allergan  which has a market capitalization of  52 billion  had  30 billion in debt as of the end of December  the legacy of a string of acquisitions  This has weighed on Allergan s ability to carry out big acquisitions   Allergan s exploration of a bid for Shire was part of its wider strategic review  Allergan said in a statement  This review is currently unlikely to lead either to a major acquisition or a breakup of the company  one of the sources said  Reuters also first reported on Thursday that Takeda had made a cash and stock offer of 46 50 pounds   66 20  a share for Shire  This prompted both companies to confirm the move and announce that Shire had rejected it  although their negotiations are continuing  Buying Shire would be the largest ever overseas acquisition by a Japanese company and propel Takeda  led by Frenchman Christophe Weber  into the top ranks of global drugmakers  It would be Weber s boldest move by far  significantly boosting Takeda s position in rare diseases  including a blockbuster hemophilia franchise  gastrointestinal disorders and neuroscience  where Shire is a leader in drugs to treat hyperactivity  But it would be a big financial stretch since Shire  with a market value of more than 34 billion pounds   48 3 billion   is worth a lot more than Japan s biggest drugmaker  which has a market capitalization of 4 1 trillion yen   31 billion   An acquisition of Shire would have given Allergan heft in the rare diseases space at a time when Saunders is seeking to cement its status as a purveyor of innovative drugs  Saunders  plans to sell Allergan to  Pfizer   NYSE PFE  for  160 billion were scuppered two years ago after the U S  Treasury changed the rules on corporate tax inversions   Saunders  was a huge deal guy and everyone was kind of waiting for the next big deal   said Kevin Kedra  an analyst with Gabelli   Co  which holds shares of both Allergan and Shire  If there was to be a big share component to a deal it would have to come before a vote of shareholders  he noted   Shareholders seem to be voting this morning   Kedra said  Takeda said it would remain disciplined in its approach and intended to maintain its dividend policy and investment grade credit rating  adding that   Discussions between the parties regarding a potential offer are ongoing    MORE CASH WANTED Shire confirmed it had received three conditional proposals from Takeda  but said they significantly undervalued the company s growth prospects and drugs in development  Takeda s latest 46 50 pounds offer was made on April 12 and comprised 17 75 pounds in cash  which would be paid in U S  dollars  and 28 75 pounds worth of new Takeda shares  Shire said that valued it at approximately 44 billion pounds   62 6 billion   based on total issued and to be issued share capital  The two earlier cash and share offers were worth 44 and 45 50 pounds per share  respectively  Under UK takeover rules  Takeda has until April 25 to make a firm offer or walk away  after it said last month it was considering a bid  Based on Takeda s market capitalization  Shire shareholders would end up owning approximately 51 percent of the enlarged group  Shire noted  Bernstein analyst Wimal Kapadia said Shire was likely to be pushing for a larger cash component in current talks but Takeda was already stretched  suggesting the chances of a deal being consummated were still  reasonably risky   Shire has been under pressure in the past 12 months  with its shares down by a third before Takeda s interest was made public  due to greater competition from generic drugs and debts from its  32 billion acquisition of Baxalta in 2016  Shire said in January it would run its attention deficit hyperactivity disorder  ADHD  business  which consists mainly of its blockbuster drug Vyvanse  separately and possibly seek a separate listing  Earlier this week it struck a deal to sell its cancer drugs for  2 4 billion to unlisted French group Servier ,2018-04-19,Reuters,https://www.investing.com/news/stock-market-news/takeda-in-talks-with-shire-after-61-billion-bid-rejected-1403323,1403323
104740,326255,AGN,Japan s Takeda shares drop as investors fret over Shire pursuit,news,By Sam Nussey TOKYO  Reuters    Takeda Pharmaceutical Co Ltd shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make to seal its record breaking purchase of London listed Shire PLC  Shire late on Thursday said it had rejected Takeda s  63 billion cash and stock conditional offer  saying the offer   and two previous offers   significantly undervalued its growth prospects and drugs in development  The rare disease drugmaker said talks continued over  whether a further  more attractive  proposal may be forthcoming   Several analysts said Takeda  Japan s biggest drugmaker by sales  will need to substantially raise the cash component of its offer make it attractive to Shire shareholders  Takeda s shares closed down 4 67 percent in afternoon trade  The stock is down more than 12 percent since news of its initial bid emerged  A successful bid would be the most radical step yet by Chief Executive Christophe Weber  propelling Takeda into the top ranks of global drugmakers with what would be Japan s largest ever outbound deal  Other cross border deals chased down by the Frenchman include the  5 20 billion acquisition of U S  cancer drug maker Ariad Pharmaceuticals Inc last year  as well as the purchase of Belgian biotech group TiGenix NV announced in January  For Shire  Takeda s most recent rejected offer of 46 50 pounds per share   made on April 12   comprised 17 75 pounds in cash  paid in U S  dollars  and 28 75 pounds worth of new Takeda shares  The cash portion  at 38 percent  compared with the 36 percent originally offered  Takeda has room to raise its cash offer but  we do not see a lot of margin   Daiwa Securities analyst Kazuaki Hashiguchi wrote in a client note   The deal would also be a financial stretch since Shire  with a market value of over 36 6 billion pounds   51 5 billion   is worth more than Takeda  which has a market capitalization of 3 9 trillion yen   36 24 billion    Regarding new Takeda shares  analysts said any issuance could lead to a further drop in demand for Takeda stock  They also said there were concerns over whether Takeda may end up overpaying   an accusation frequently leveled at Japanese firms investing overseas  CLSA analyst Stephen Barker  however  wrote in a client note earlier in the week that a successful bid would likely see Takeda s share price rise as the deal would greatly increase the Japanese drugmaker s earnings per share   Under British takeover rules  Takeda has until April 25 to make a firm offer or walk away  British Botox maker Allergan  NYSE AGN  PLC also said it was considering an offer for Shire before deciding otherwise ,2018-04-20,Reuters,https://www.investing.com/news/stock-market-news/takeda-shares-down-3-percent-after-shire-rejects-63-billion-offer-1404821,1404821
104741,326256,AGN,Premarket analyst action   healthcare,news,Aeglea BioTherapeutics  NASDAQ AGLE  initiated with Outperform rating and  37  368  upside  price target at Evercore ISI  Shares up 5  premarket Alder Biopharmaceuticals  NASDAQ ALDR  initiated with Neutral rating and  17  25  upside  price target at Goldman Sachs  NYSE GS  Homology Medicines  NASDAQ FIXX  initiated with Buy rating and  35  76  upside  price target at BTIG Research Allscripts Healthcare Solutions  NASDAQ MDRX  resumed with Overweight rating and  16  31  upside  price target at JPMorgan  NYSE JPM   Shares up 6  premarket Athenahealth  NASDAQ ATHN  resumed with Neutral rating and  159  11  upside  price target at JPMorgan Allergan  NYSE AGN  resumed with Buy rating and  200  25  upside  price target at  Citigroup   NYSE C   Shares up 1  premarket HealthEquity  NASDAQ HQY  assumed with Overweight rating and  69  5  upside  at JPMorgan BIO key International  OTCQB BKYI  resumed with Buy rating and  5 50  163  upside  price target at Maxim Group  Cardinal Health   NYSE CAH  upgraded to Outperform at Leerink Prothena  NASDAQ PRTA  downgraded to Neutral at Oppenheimer and BTIG Research after NEOD001 flop in Alzheimer s  Henry Schein   NASDAQ HSIC  downgraded to Neutral at Goldman Sachs  Shares down 1  premarket ResMed  NYSE RMD  downgraded to Neutral with a  104  6  upside  price target at UBS  Shares down 1  premarket Cotiviti Holdings  NYSE COTV  downgraded to Neutral with a  37  7  upside  price target at JPMorgan Quality Systems  NASDAQ QSII  assumed at JPMorgan with Underweight rating and  15  6  upside  price target at JPMorgan Now read ,2018-04-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1410733,1410733
104742,326257,AGN,Shire receives new bid from Takeda as takeover deadline looms,news,By Ben Martin LONDON  Reuters    Japan s Takeda Pharmaceutical  T 4502  has sweetened its  62 billion bid for  Shire   L SHP  as it races to agree terms with the drugmaker before a deadline to strike a deal expires on Wednesday  Dublin based Shire  a member of Britain s benchmark FTSE 100 stock index  said it had received a fifth takeover proposal from Takeda on Tuesday but gave no details of the revised bid  It said its board was considering its position  Takeda  which confirmed the new proposal without providing details  said there was no certainty a firm offer will be made   It comes after Takeda s fourth bid for Shire on Friday  which was pitched at 47 pounds per share and made up of 26 pounds in Takeda stock and 21 pounds in cash  That valued Shire  which is led by Chief Executive Flemming Ornskov  at 44 3 billion pounds   61 8 billion   Under British rules  Takeda has until 5 p m   1600 GMT  on Wednesday to make a firm offer or walk away from Shire   However  that deadline can be moved back at the request of the FTSE 100 drugmaker and Takeda had said on Friday that it hoped negotiations with Shire would lead to an extension of the cut off date  Shares in the London listed company were up 3 4 percent at 39 30 pounds in afternoon trade  The latest bid came just before Shire held its annual shareholder meeting in Dublin on Tuesday   As of now we can only say that discussions between the advisers of Shire and Takeda are ongoing   Susan Kilsby  the drugmaker s chairwoman  told investors at the meeting  which lasted less than 15 minutes  Shire focuses on treatments for rare diseases and attention deficit hyperactivity disorder and a takeover would catapult Takeda into the top ranks of global drugmakers   BIGGEST OVERSEAS ACQUISITION It would also mark the biggest overseas acquisition by a Japanese firm and an audacious move by Takeda s French chief executive  Christophe Weber  Allergan  N AGN   the U S  maker of Botox  had been considering a rival bid for Shire but ruled itself out of making an offer on April 19  Shire also announced last week it was selling its oncology business to unlisted French drugmaker Servier for  2 4 billion   Takeda s shares closed down 1 5 percent on Tuesday  giving it a market value of 3 86 trillion yen   35 5 billion   according to Thomson Reuters data  That is much smaller than the value of the fourth bid for Shire that Takeda disclosed last week  Takeda investors have been skeptical about the merits of a Shire deal  given the size of the potential purchase and the likely need for a large share issue  which could be highly dilutive  Weber was promoted to chief executive in 2015  becoming the drugmaker s first non Japanese boss  The Japanese firm said last month that buying Shire would bolster its position in the United States  in gastrointestinal diseases and neuroscience  Its bid comes amid a surge in dealmaking in the pharmaceuticals industry as the biggest players hunt for promising assets to bolster their pipelines  Shire traces its roots back to 1986  when it began as a seller of calcium supplements to treat osteoporosis  operating from an office above a shop in Hampshire  Since then it has grown rapidly through acquisitions into a giant that generated annual revenues of about  15 2 billion last year    1   0 7170 pounds ,2018-04-24,Reuters,https://www.investing.com/news/stock-market-news/shire-receives-new-bid-from-takeda-as-takeover-deadline-looms-1410695,1410695
104743,326258,AGN,Shire says willing to recommend Takeda s  64 billion offer to shareholders,news,"By Ben Martin and Carl O Donnell LONDON NEW YORK  Reuters    London listed drugmaker  Shire  Plc  LON SHP  said it was willing to recommend a deal with Takeda Pharmaceutical Co to its shareholders  after the Japanese company sweetened its acquisition offer to 46 billion pounds   64 billion   The development  first reported by Reuters  represents a major breakthrough for the companies in their negotiations  following a pursuit that started on March 28 when Takeda said it was considering a bid for Shire  Since then  Takeda has made five offers  the latest on Tuesday  Shire said in a statement it had agreed to extend a Wednesday regulatory deadline for the deal talks to conclude to May 8 in order to allow Takeda to carry out more due diligence and firm up its bid  Shire added that the deadline could be extended further  if needed  Takeda s shares slid almost 6 percent in early Tokyo trade on Wednesday as investors fretted over its ability to finance the cash and stock deal   Any deal between the two companies is still subject to the resolution of several issues  including completion of due diligence by Shire on Takeda  Shire said  Takeda added in its own statement that it intended to maintain its dividend policy and investment grade credit rating following the deal  Shire focuses on treatments for rare diseases and attention deficit hyperactivity disorder  A deal would be the largest ever overseas acquisition by a Japanese company and propel Takeda  led by Frenchman Christophe Weber  into the top ranks of global drugmakers  It would significantly boost Takeda s position in gastrointestinal disorders  neuroscience  and rare diseases  including a blockbuster hemophilia franchise  But the transaction would be a huge financial stretch  since Shire is worth considerably more than the Japanese group  Ambitious cost cutting will be required to make the deal pay  Dealmaking has surged in the drug industry this year as large players look for promising assets to improve their pipelines  A Takeda Shire transaction would be by far the biggest  Shire has long been seen as a likely takeover target and was nearly bought by U S  drugmaker  AbbVie Inc   NYSE ABBV  in 2014  until U S  tax rule changes caused the deal to fall apart  Shire also has a track record of acquisitions  but its biggest ever deal   the  32 billion purchase of Baxalta in 2016   was widely criticized by shareholders   Dublin based Shire  a member of Britain s benchmark FTSE 100 stock index  said Takeda s fifth offer was worth 49 01 pounds per share  comprised of the equivalent of 27 26 pounds per share in new Takeda shares and 21 75 pounds per share in cash  Under these terms  Shire shareholders would own half of the combined company  ALLERGAN BOWED OUT Allergan  NYSE AGN  Plc  the U S  maker of Botox  had been considering a rival bid for Shire but ruled itself out of making an offer last week   Shire also announced last week it was selling its oncology business to unlisted French drugmaker Servier for  2 4 billion  Takeda has lost more than 17 percent since the news broke that it was considering a bid for Shire  reducing its market value to 3 6 trillion yen   33 billion    Takeda investors have been skeptical about the merits of a Shire deal  given the size of the potential purchase and the likely need for a large share issue  which could be highly dilutive  Weber was promoted to CEO in 2015  becoming the drugmaker s first non Japanese boss  
Shire traces its roots back to 1986  when it began as a seller of calcium supplements to treat osteoporosis  operating from an office above a shop in Hampshire  Since then it has grown rapidly through acquisitions to generate revenues of about  15 2 billion last year ",2018-04-24,Reuters,https://www.investing.com/news/stock-market-news/exclusive-shire-takeda-reach-breakthrough-in-deal-talks--sources-1411930,1411930
104744,326259,AGN,Teva to reduce size of board after June shareholders meeting,news,"JERUSALEM  Reuters    Three directors are stepping down from the board at Teva Pharmaceutical Industries  TA TEVA   N TEVA  and only one new director is being nominated to replace them  the company said on Thursday  Israel based Teva  the world s largest generic drugmaker  is in the midst of an overhaul to deal with the  35 billion of debt it amassed after buying Allergan s  Actavis   NYSE AGN  generic drug business for  40 5 billion in 2016  Analysts and investors have criticized the company s management and board of directors for overpaying for this deal  Teva has since replaced most of its management and announced major job cuts  It has also reduced both the average tenure and age of its directors  In the latest changes  Ronit Satchi Fainaro  a Tel Aviv University professor who heads the Cancer Research and Nanomedicine Laboratory  will be the only new nominee at a June 5 shareholders meeting  the company said in a statement  Current directors Galia Maor  Gabrielle Sulzberger and Dan Suesskind will not submit their candidacy for reelection  This will leave the board with 11 members  down from the current 13  Suesskind  a former chief financial officer of Teva  was brought in last year as the company grappled with a financial crisis  Maor  a former CEO of Bank Leumi  has served since 2012  Sulzberger  who has served since 2015  is a general partner of the Rustic Canyon Fontis Partners investment fund   We continue to evaluate the size and composition of our board of directors to ensure it maintains dynamic  exceptionally qualified members and that the mix of talent and experience on the board reflects all the challenges that the company faces   the company said in an emailed statement to Reuters  At the June meeting shareholders will also vote on a proposal to give them more say in determining compensation for Teva executives  
Teva has repaid over  2 billion of its debt this year  mostly from the proceeds of the sale of its women s health business  In March  it completed a  4 5 billion bond offering  which was used to repay existing loans ",2018-04-26,Reuters,https://www.investing.com/news/stock-market-news/teva-to-reduce-size-of-board-after-june-shareholders-meeting-1415210,1415210
104745,326260,AGN,Flexion up 2  on new Zilretta data in OAK,news,Flexion Therapeutics  FLXN  2 3   is up  albeit on light volume  on the heels of its announcement of additional data from the open label Phase 3b study evaluating ZILRETTA  triamcinolone acetonide  in patients with osteoarthritis of the knee  OAK   The results will be presented tomorrow  April 27  at the Osteoarthritis Research Society International Congress in Liverpool  England Adding to its January report that 95  of treated patients experienced clinical benefit by week 12  the magnitude and duration of pain relief  measured by a scale called WOMAC A  were inline with the results observed in the pivotal Phase 3 study  By the fourth week  patients experienced a 64  improvement in both pain relief and function and a 66  improvement in joint stiffness  The treatment benefit was maintained in a  substantial portion  of patients through week 12 92  of the treatment group received a second injection between weeks 12 and 24 and will be followed for a total of 52 weeks after the first injection  Complete results should be available in Q3 The FDA approved ZILRETTA in October 2017 Previously  Flexion s Zilretta shows treatment benefit in late stage OAK study evaluating second injection  Jan  8 Now read ,2018-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/flexion-up-2-on-new-zilretta-data-in-oak-1416515,1416515
104746,326261,AGN,Allergan  AGN  Gains As Market Dips  What You Should Know,opinion,"In the latest trading session  Allergan  NYSE AGN  closed at  161 02  marking a  0 07  move from the previous day  This move outpaced the S P 500 s daily loss of 0 73   Elsewhere  the Dow lost 0 37   while the tech heavy Nasdaq lost 1 32  
Heading into today  shares of the Botox maker had lost 5 13  over the past month  lagging the Medical sector s loss of 1 96  and the S P 500 s loss of 0 27  in that time 
Wall Street will be looking for positivity from AGN as it approaches its next earnings report date  The company is expected to report EPS of  4 34  down 1 81  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  3 94 billion  down 4 54  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  16 77 per share and revenue of  15 31 billion  These totals would mark changes of  0 48  and  3 01   respectively  from last year 
Investors should also note any recent changes to analyst estimates for AGN  These revisions help to show the ever changing nature of near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 0 55  higher  AGN is holding a Zacks Rank of  3  Hold  right now 
Valuation is also important  so investors should note that AGN has a Forward P E ratio of 9 6 right now  For comparison  its industry has an average Forward P E of 7 65  which means AGN is trading at a premium to the group 
Meanwhile  AGN s PEG ratio is currently 1 51  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Medical   Generic Drugs industry currently had an average PEG ratio of 0 88 as of yesterday s close 
The Medical   Generic Drugs industry is part of the Medical sector  This group has a Zacks Industry Rank of 65  putting it in the top 26  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-08-02,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-gains-as-market-dips-what-you-should-know-200450334,200450334
104747,326262,AGN,Will Cost Control Help Teva  TEVA  Beat On Q2 Earnings ,opinion,"We expect Teva Pharmaceutical Industries Limited   NYSE TEVA   to beat estimates when it reports second quarter 2019 results on Aug 7  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 3 45  Teva s earnings surpassed expectations in three the last four reported quarters  with the average positive surprise being 9 54  Teva Pharmaceutical Industries Ltd  Price and Consensus
    
 
This generic drugmaker s shares have declined 49  this year so far compared with the  s decline of 4 7  
 
 Let s see how things are shaping up for this announcement Factors to ConsiderTeva reports under three segments based on three regions   North America  United States and Canada   Europe and International Markets In the second quarter  pricing erosion in the U S  generics market  continued sales erosion of Copaxone due to introduction of generics and lower sales of other branded drugs Bendeka  Treanda  ProAir and Qvar will continue to hurt North America segment sales  Particularly  ProAir sales are likely to be hurt by the launch of a generic version of the drug  In Europe as well as International Markets segments  loss of revenues from divestitures and discontinued business activities is likely to hurt sales  The decline in sales of generic medicines and Copaxone is expected to continue  which can offset the positive impact of generic launches Additional competition for Teva s largest product  Concerta authorized generic  will also hurt generics sales in the quarter  However  on the first quarter conference call  the company had noted signs of stabilization in the US generics and European generics business helped by launches and strong key products  Revenues lost due to price erosion in the U S generics business and portfolio optimization were partially offset by additional sales from the launch of generic products  We can expect a similar trend in the to be reported quarter Generic launches in the second quarter include that of Gilead s   NASDAQ GILD   Letairis  Roche s Tarceva and Allergan s   NYSE AGN   Delzicol in May  In March April  Teva launched generic versions of VESIcare  solifenacin succinate  tablets and AndroGel  testosterone gel  and Exjade tablets and an authorized generic version of Flector patch  a nonsteroidal anti inflammatory medicine to treat acute pain Its new drugs  Austedo and Ajovy should contribute to the top line  Importantly  Ajovy was approved in the EU in April  which should add to sales in the second quarter  Investors will also be interested to know how management plans to capture market share for Ajovy against Amgen  NASDAQ AMGN  and Lilly s CGRP s  which were also launched last year Research and development costs could be lower due to pipeline optimization  concluded phase III studies and resultant workforce reductions  Also  cost cutting and re structuring activities should result in lower selling and marketing expenditure In April  Teva announced the discontinuation of a late stage study evaluating Ajovy for episodic cluster headache  Investors are expected to question management on the issue on the second quarter conference call  In June 2018  Teva had stopped a study on the same candidate for chronic cluster headache Earnings WhispersOur proven model shows that Teva is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Its Earnings ESP is  1 07   The Zacks Consensus Estimate stands 58 cents per share  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Teva has a Zacks Rank  3  The combination of Teva s Zacks Rank  3 and positive ESP makes us reasonably confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Another Stock to ConsiderHere is another large biotech stock that has the right combination of elements to beat on earnings this time around Regeneron Pharmaceuticals   NASDAQ REGN   has an Earnings ESP of  3 64  and a Zacks Rank  3  The company is scheduled to release results on Aug 6 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/will-cost-control-help-teva-teva-beat-on-q2-earnings-200450769,200450769
104748,326263,AGN,Is A Beat In Store For Melinta  MLNT  This Earnings Season ,opinion,"We expect Melinta Therapeutics  Inc    NASDAQ MLNT   to beat expectations when it reports second quarter 2019 results on Aug 7  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 14 29  Shares of Melinta have declined 3 2  so far this year against the  s increase of 7 1   Melinta s earnings history is not quite encouraging with the company outpacing estimates in two of the last four quarters and missing the same twice  delivering average negative surprise of 14 28  Let s see how things are shaping up for the upcoming announcement Factors to ConsiderLast month  Melinta provided preliminary results for the quarter  Sales of the company s marketed drugs are estimated to be approximately  13 8 million  The estimated numbers indicate sequential growth of 17  and year over year growth of approximately 51  Please note that the company s marketed portfolio includes Baxdela  which was launched in February 2018 in the United States for treating acute bacterial skin and skin structure infection  In January 2018  Melinta acquired Infectious Disease Business   IDB   from The Medicines Company   NASDAQ MDCO   which added three drugs to its portfolio   Vabomere  Orbactiv and Minocin   approved for infectious diseases  Vabomere and Orbactiv is approved in the United States and Europe while Baxdela in under review in Europe  The company is seeking a label expansion of Baxdela in the United States to include community acquired bacterial pneumonia   CABP    In June  the FDA granted priority review to the supplemental New Drug Application seeking approval of Baxdela in CABP with a decision expected in October In the past couple of quarters  revenues were driven by Vabomere and Minocin and we expect the trend to continue in the soon to be reported quarter  However  softer sales trend of Baxdela and Orbactiv may partially offset the growth The company had initiated several initiatives in the fourth quarter of 2018 to reduce expenses  which led to reduction in selling  general and administrative expenses in the first quarter  Moreover  completion of phase III study on Baxdela for label expansion in CABP and winding down of early research and discovery programs resulted in lower research and development expenses year over year in the first quarter  We expect the declining trend in operating expense to continue in the second quarter  Moreover  the acquisition of IDB had driven operating expense higher in the second quarter of 2018  With no acquisition related costs  operating expense will be lower in the to be reported quarter  However  plans to support label expansion of Baxdela may partially offset the decline Investor focus will be on the commercial plan for launch of Baxdela in an expanded label upon potential approval and progress of Vabomere in Europe Why a Likely Positive Surprise Our proven model indicates that Melinta is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate  loss of  2 56  and the Zacks Consensus Estimate  loss of  2 57   stands at  0 26   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Melinta has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Melinta Therapeutics  Inc  Price and Consensus
    Other Stocks That Warrant a LookHere are some pharma biotech stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases Regeneron Pharmaceuticals   NASDAQ REGN   has an Earnings ESP of  3 64  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Aug 6  You can see  Allergan   NYSE AGN   has an Earnings ESP of  3 87  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Aug 6 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-melinta-mlnt-this-earnings-season-200450845,200450845
104749,326264,AGN,Company News For Aug 6  2019,opinion,Allergan plc s   NYSE AGN   shares dipped 0 2  after the company reported second quarter 2019 earnings per share of  4 38  lower than  4 42 a share in the year ago quarterEnergizer Holdings  Inc  s   NYSE ENR   shares lost 3 7  after the company reported third quarter fiscal 2019 earnings per share of  0 37  lower than the Zacks Consensus Estimate of  0 47Shares of Edgewell Personal Care Company   NYSE EPC   lost 4 7  after the company reported third quarter fiscal 2019 revenues of  609 million  lower than the Zacks Consensus Estimate of  614 millionShares of Mallinckrodt plc   NYSE MNK   fell 2 1  afterthe company reported second quarter 2019 revenues of  823 million  lower than the Zacks Consensus Estimate of  824 million,2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-aug-6-2019-200451579,200451579
104750,326265,AGN,Allergan  AGN  Q2 Earnings   Sales Top   19 Sales View Up,opinion,"Allergan plc s   NYSE AGN   second quarter adjusted earnings came in at  4 38 per share  which beat the Zacks Consensus Estimate of  4 34 and came within the guided range of  4 20 and  4 40  Earnings however declined 0 9  year over year due to lower operating profits Revenues came in at  4 09 billion  which exceeded the Zacks Consensus Estimate of  3 94 billion as well as the guidance of  3 88 billion to  4 03 billion  Revenues fell 0 8  from the year ago period primarily due to currency headwinds  Excluding the impact of currency  total revenues rose 1 2  as higher sales of key products like Botox  cosmetic and therapeutics   Juv derm collection of fillers  Vraylar  Ozurdex  and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others in 2018 Moreover  sales of Allergan s blockbuster eye drug  Restasis also declined in the quarter ahead of anticipated generic competition  Also  decline in textured breast implants due to a global recall hurt sales Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized net revenues declined 2 3  to  1 79 billion  Strong sales growth of its facial aesthetics products  Botox and Juv derm and Botox Therapeutic was offset by decline in sales of Restasis and divestiture of Medical Dermatology business in September 2018  Sales of CoolSculpting and breast implants also declined in the quarter In Facial Aesthetics  Botox  cosmetic  raked in sales of  252 4 million  up 6 7  year over year  Juv derm collection of fillers rose 12  to  156 6 millionAlloderm sales  however  fell 5 5  to  101 2 million while CoolSculpting sales of  78 9 million declined 27 1  year over year In Eye Care  while Ozurdex sales rose 8 3  to  29 9 million  Restasis sales fell 2 3  to  310 9 million Botox Therapeutic revenues were  447 0 million  up 5 9  year over year There have been concerns regarding possible new competitors to blockbuster product Botox  The entry of CGRP antibodies may have a negative impact on sales of Botox Therapeutics  mainly for the chronic migraine indication  Amgen   NASDAQ AMGN    Eli Lilly   NYSE LLY   and Teva Pharma s CGRP migraine treatments  Aimovig  Emgality and Ajovy  respectively were all launched in 2018 Meanwhile  in February  Evolus  Jeuveau injection indicated to improve the appearance of glabellar or frown lines was approved by the FDA  which can pose competition to Botox  In the fall of 2019  Revance Therapeutics will file for approval of DaxibotulinumtoxinA for Injection  DAXI   a rival treatment to Botox for the frown lines indication  It has demonstrated longer duration of efficacy compared to Botox in late stage studies U S  General Medicine net revenues were up 10 3  year over year to  1 46 billion in the reported quarter as strong growth of Vraylar  Viibryd  Linzess and Lo Loestrin was offset by lower sales of drugs that lost exclusivity Linzess sales rose 2 2  to  196 0 million  Lo Loestrin sales grew 13 8  to  145 5 million while Bystolic sales rose 1 6  to  150 5 million  Vraylar sales were  196 1 million in the second quarter  71 7  higher than the year ago quarter  while Viibryd sales were  107 8 million  up 24 3  from the year ago quarter  In May  Vraylar was approved for the new indication of bipolar depression  which may have contributed to higher sales of the drug in the quarter The International segment recorded net revenues of  847 7 million  down 4 3  from the year ago period  excluding the impact of foreign exchange as growth in Facial Aesthetics and Ozurdex implant was partially offset by regulatory changes for textured breast implants and lower glaucoma and eye drop revenues Profits DeclineAdjusted operating income decreased 6 3  to  1 85 billion in the second quarter due to lower revenues and higher costs Selling  general and administrative expenses increased 2 5  to  1 16 billion in the second quarter  owing to higher marketing spending in Medical Aesthetics and for product launches Research and development  R D  expenses rose 14 9  to  447 0 million due to pipeline progress 2019 GuidanceAllergan slightly raised its sales guidance for 2019 while maintaining the previously issued earnings view Allergan expects sales to be in the range of  15 43  15 63 billion  up from the previous guidance of  15 13  15 43 billion  The company still estimates its adjusted earnings to be more than  16 55 per share Adjusted tax rate is expected to be approximately 13  in 2019 versus 13 13 5  expected previously  Adjusted R D expense guidance was maintained in the range of approximately  1 6    1 7 billion while the SG A range was increased from approximately  4 1    4 3 billion to approximately  4 4    4 5 billion  Adjusted gross margin is expected to be approximately 85  85 5   maintained  Our TakeAllergan beat estimates for both earnings and sales in the second quarter and raised its sales guidance for the year  As expected  Allergan delivered a sequentially stronger top line performance in the second quarter  Shares were up less than 1  in pre market trading on Tuesday  So far this year  Allergan s share price has risen 20 2  against the  s decrease of 5 9    Allergan s key products like Botox and new products such as Viberzi and Vraylar are supporting sales  Allergan also continues to deliver on its R D pipeline with some major product launches expected over the next couple of years  Biosimilars also represent significant opportunity  Allergan is also consistently paying down debt and cutting costs  However  in 2019  sales are expected to be hurt by loss of exclusivity of key drugs including Restasis Meanwhile  Allergan refrained from holding a conference call due to its proposed acquisition by AbbVie   NYSE ABBV   for a total transaction value of nearly  63 billion  The companies had announced the buyout deal in June  The deal is expected to close in early 2020  The acquisition by AbbVie could prove to be rewarding for Allergan s shareholders  Moreover  with Restasis expected to face generic competition  fears of new competition to Botox and recent pipeline setbacks  the merger with AbbVie could prove to be the best way out for Allergan Allergan currently carries a Zacks Rank  3  Hold   You can see  
 Allergan plc Price  Consensus and EPS Surprise
    
 
The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-q2-earnings--sales-top-19-sales-view-up-200451574,200451574
104751,326266,AGN,Top Research Reports  Chevron  AbbVie  Phillips 66   More,opinion,"Tuesday  August 6  2019
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features updated research reports on 16 major stocks  including Chevron  CVX   AbbVie  ABBV  and Phillips 66  NYSE PSX   These research reports have been hand picked from roughly 70 reports published by our analyst team today 
You can see 
Chevron s shares have outperformed the Zacks Integrated Oil industry year to date   9 1  vs   2 7    Chevron s second quarter earnings increased 26  year over year and exceeded the consensus estimate  Free cash flow rose and production hit a record level  The Zacks analyst thinks Chevron s existing project pipeline is among the best in the industry  targeting volume growth of around 4 7  in 2019 thanks to planned expansion in the Permian Basin  Chevron pumped 55  more out of the West Texas shale play in the quarter compared with the year ago period  with output set to soar in coming years  Moreover  growing free cash flow should enable Chevron to distribute steady and attractive dividends in the future  However  drop in refining earnings once again cut into gains from rising E P income  Its massive capex might also play spoilsport  Hence  investors are advised to wait for a better entry point 
 You can   
Shares of AbbVie have lost  29 2  year to date  versus the Zacks Large Cap Pharmaceuticals industry s decline of  2 9   AbbVie beat estimates for earnings and sales in the second quarter and raised its earnings guidance for the second time this year  The Zacks analyst thinks AbbVie s key drug  Humira  is performing well based on strong demand trends despite new competition  Additionally  Imbruvica has multibillion dollar potential  AbbVie has been successful in expanding approvals for its cancer drugs  Imbruvica and Venclexta  Moreover  it has an impressive late stage pipeline  comprising several products with multibillion dollar potential which are expected to be launched in the near term  The acquisition of Allergan  NYSE AGN   if successful  should diversify AbbVie s revenue base and accelerate its non Humira business  Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind 
 You can   
Phillips 66 s shares have outperformed the Zacks Oil Refining and Marketing industry over the past year  losing  22  vs   36   The Zacks analyst thinks Phillips 66 is strongly positioned to gain from the rising demand for midstream assets in the United States  where takeaway capacity constraint is a significant problem  Moreover  the company is well placed for the upcoming change in regulations  namely IMO 2020  with its updated refining assets  It is also committed to returning cash back to stockholders through dividend payments and share repurchases  Recently  the company reported strong second quarter 2019 earnings  courtesy of contributions from pipeline transportation businesses  However  a lower crude utilization rate has hurt refining operations  Moreover  uncertainties in the global market are likely to hamper demand for petrochemicals  which will affect the firm s Chemical business  Rising operating costs are also a threat to the company 
 You can   
Other noteworthy reports we featured today include ConocoPhillips  NYSE COP   Qualcomm  QCOM  and Marriott  MAR  
The Hottest Tech Mega Trend of All                 
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early 
  
Note  Our Director of Research Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Chevron  CVX  to Gain from Strong Permian Operation


AbbVie  ABBV  Eyes Diversification With Allergan Buyout


Phillips 66  PSX  Banks on Midstream Unit  Refining Hurts


Featured Reports
Qualcomm  QCOM  Plagued by Softness in Demand from China
Per the Zacks analyst  Qualcomm is anticipated to face continued softness in demand from China with Huawei gaining prominence in the local market  

ConocoPhillips  COP  Hurt by Rising Production Expenses
Increasing production costs and operating expenses in 2019 will affect ConocoPhillips  bottom line  according to the Zacks analyst 

Marriott  MAR  Banks on Expansion Plans to Drive Growth
The Zacks analyst believes that Marriott s efforts to capitalize on the demand for hotels in international markets will continue to drive growth  

Premium Shale Properties Aid Anadarko s  APC  Production
Per the Zacks analyst  Anadarko s premium shale properties in Delaware  Denver Julesburg basins and the Deepwater Gulf of Mexico are key production drivers 

Loan Growth Aids SunTrust  STI   Mortgage Business a Concern
Per the Zacks analyst  loan growth will aid SunTrust s revenues and its branch consolidation efforts will keep costs low  

Investments Aids Eversource  ES  Amid Northern Pass Loss
Per the Zacks analyst  Eversource s planned investments in 2019 2023 to strengthen operations will help it to overcome loss due to discontinuation of Northern Pass project 

Capital Growth Projects to Benefit ONEOK s  NYSE OKE  Production
Per the Zacks analyst  higher natural gas and natural gas liquids volumes   capital growth projects in the Permian Basin area will boost ONEOK s future performance 

New Upgrades
Fiserv  NASDAQ FISV  Benefits From Strategic Buyouts  Partnerships
The Zacks analyst is impressed with Fiserv s strategy to widen its client base and enhance its product portfolio with the help of buyouts and partnerships 

CDW Benefits From Robust Growth in Customer End Markets
Per the Zacks analyst  CDW s broad based product and solutions portfolio is boosting growth across its customer markets  which include corporates  small business  government  education and healthcare 

Cardio and Vascular Unit Boosts Integer Holdings  ITGR 
Per the Zacks analyst  Integer Holdings continues to gain from its Cardio and Vascular product line on the back of solid peripheral vascular and structural heart growth 

New Downgrades
Lower Rates  Rising Expenses to Hamper BB T s  NYSE BBT  Growth
Per the Zacks analyst  the Federal Reserve s accommodative monetary policy  lower interest rates and steadily increasing operating expenses will hamper BB T s profitability in the quarters ahead 

Lower Containerboard Prices to Hurt WestRock  WRK  
The Zacks analyst is worried that lower containerboard prices  higher maintenance downtime as well as shrinking demand for processed and frozen food will dent WestRock s results 

Weak Demand  Higher Input Costs Ail Huntsman  HUN 
Per the Zacks analyst  weak demand in China and Europe will continue to hurt Huntsman s sales volumes  Higher raw material costs will also put pressure on its margins 
undefined undefined",2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-chevron-abbvie-phillips-66--more-200451670,200451670
104752,326267,AGN,Biotech ETFs In Focus On Impressive Q2 Earnings Results,opinion,Startling investors around the globe  President Trump announced  on the remaining  300 billion on almost all exports from China to the United States  This move has  trumped  hopes of many investors waiting for a truce between the two largest economies  Amid this political conundrum  the industry has kept its promise of solid returns so far with rally in some major biotechnology indexes reflecting the same  In this context  the has returned 8 5  year to date Increasing M A deals  growing AI dominance and favorable regulatory tidings continue to boost the biotech market  read    Let s take a look at some big biotechnological earnings releases and see if these will impact ETFs exposed to the space Earnings in FocusOn Jul 30  Amgen   NASDAQ AMGN   reported second quarter 2019 earnings of  3 97 per share  which surpassed the Zacks Consensus Estimate of  3 58  Earnings rose 4  year over year helped by a lower share count  Total revenues of  5 87 billion in the quarter also outpaced the Zacks Consensus Estimate of  5 68 billion  However  total revenues declined 3  year over year  The company raised the low end of its 2019 sales and earnings guidance for the second time this year buoyed by a strong second quarter performance  The company expects revenues in the range of  22 4  22 9 billion versus  22 0  22 9 billion expected earlier  Adjusted earnings per share are anticipated in the band of  13 75  14 30 versus  13 25  14 30 projected previously  Shares rose about 6 1  since the earnings release  as of Aug 2  2019  On Jul 30  Gilead Sciences   NASDAQ GILD   reported better than expected results for the second quarter of 2019 on strong Biktarvy sales  It also raised its sales guidance for 2019  The company reported earnings of  1 82 per share in the second quarter  falling from  1 91 a year ago but surpassing the Zacks Consensus Estimate of  1 74  Total revenues of  5 68 billion outpaced the Zacks Consensus Estimate of  5 56 billion but were almost flat year over year  see  here  Based on favorable a demand trend in the first half of 2019  Gilead raised its guidance for net product sales  The company now expects sales of  21 6  22 1 billion compared with the previous guidance of  21 3  21 8 billion  However  the stock has slipped 3 2  since reporting earnings  as of Aug 2  On Jul 23  Biogen   NASDAQ BIIB   reported second quarter 2019 earnings per share of  9 15 which surpassed the Zacks Consensus Estimate of  7 58  Earnings increased 58  year over year on higher revenues and lower R D costs  Also  a lower share count due to share buybacks in the quarter benefited earnings  Sales came in  3 62 billion  up 8  from the year ago quarter  Sales also surpassed the Zacks Consensus Estimate of  3 48 billion  Sales growth was primarily led by impressive performance by the key multiple sclerosis drug  Tecfidera  globally and spinal muscular atrophy drug  Spinraza  in the United States  The stock has gained 4 2  since the earnings report  as of Aug 2  On Jul 24  Alexion Pharmaceuticals   NASDAQ ALXN   posted second quarter 2019 adjusted earnings per share of  2 64  which rose 27 5  from the year ago quarter s  2 07  Earnings also outpaced the Zacks Consensus Estimate of  2 36  Solid product revenues drove the bottom line in the quarter  Revenues were up 15 2  year over year to  1 20 billion and surpassed the Zacks Consensus Estimate of  1 17 billion  Revenues were led by higher sales of Soliris  Strensiq and Kanuma  However  foreign currency dented revenue growth by 1  The company raised its revenue and earnings guidance for 2019  The company expects earnings per share of  9 65  9 85  up from the previous guidance of  9 25  9 45  Alexion projects revenues of  4 75  4 80 billion  up from the prior outlook of  4 68  4 75 billion  However  the stock has lost 8 2  since the earnings release  as of Aug 2  2019  Biotech ETFs in FocusIn the current scenario  we believe it is prudent to discuss a few ETFs which have a relatively wide exposure to the companies discussed iSharesNasdaq Biotechnology ETF This fund seeks to provide exposure to U S  biotechnology stocks and tracks the NASDAQ Biotechnology Index  It comprises 219 holdings with the above mentioned companies taking about 24 2  of the fund  It has AUM of  7 04 billion and charges a fee of 47 basis points a year  The fund carries a Zacks ETF Rank  2  Buy  with a High risk outlook  read    VanEck Vectors Biotech ETF   LON BBH  The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  It holds about 25 securities in its basket  with the concerned companies having 26 5  weight in the fund  Its AUM is  358 9 million and expense ratio is 0 35   The fund carries a Zacks ETF Rank  2 with a High risk outlook  read    SPDR S P Biotech  NYSE XBI  ETF The fund seeks daily investment results  before fees and expenses  which match the S P Biotechnology Select Industry Index  It holds about 118 securities in its basket and puts about 5 7  weight in the in focus companies  Its AUM is  4 04 billion and expense ratio is 0 35   The fund carries a Zacks ETF Rank  2 with a High risk outlook  read    First Trust Amex Biotechnology Index The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  It holds about 31 securities in its basket with the concerned companies having 13 6  weight in the fund  Its AUM is around  2 81 billion and expense ratio is 0 57   The fund carries a Zacks ETF Rank  3  Hold  with a High risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-in-focus-on-impressive-q2-earnings-results-200451743,200451743
104753,326268,AGN,Allergan  AGN  Surpasses Q2 Earnings And Revenue Estimates,opinion,"Allergan  NYSE AGN  came out with quarterly earnings of  4 38 per share  beating the Zacks Consensus Estimate of  4 34 per share  This compares to earnings of  4 42 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 0 92   A quarter ago  it was expected that this Botox maker would post earnings of  3 55 per share when it actually produced earnings of  3 79  delivering a surprise of 6 76  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Allergan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  4 09 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 3 89   This compares to year ago revenues of  4 12 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Allergan shares have added about 20 2  since the beginning of the year versus the S P 500 s gain of 13 5  
What s Next for Allergan 
While Allergan has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Allergan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 22 on  3 81 billion in revenues for the coming quarter and  16 77 on  15 33 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the top 22  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-surpasses-q2-earnings-and-revenue-estimates-200451428,200451428
104754,326269,AGN,Editas  EDIT  Misses On Q2 Earnings   Sales  Gets New CEO,opinion,"Editas Medicine  Inc    NASDAQ EDIT    incurred a loss of 69 cents per share in the second quarter of 2019  wider than the Zacks Consensus Estimate of 59 cents but narrower than the year ago quarter s loss of 82 cents Collaboration and other research and development revenues  comprising the company s total revenues  came in at  2 3 million  down 68 9  year over year  Moreover  the top line missed the Zacks Consensus Estimate of  6 million Editas has no approved product in its portfolio at the moment  The company generates collaboration revenues and other research and development revenues  Its collaboration revenues declined in the quarter due to lower revenues recognized under Editas  collaboration with Celgene   NASDAQ CELG    Meanwhile  an out license arrangement was entered into during the second quarter of 2018  which had generated some collaboration revenues in the year ago quarter The company has a collaboration and licensing pact with Juno Therapeutics   now part of Celgene   to use the latter s gene editing approaches including CRISPR Cas9 for developing engineered T cell medicines to tackle cancer This year so far  Editas  stock has risen 8 3  against the  s decrease of 4 4    Quarter in DetailIn the reported quarter  research and development expenses were  23 6 million  down 27 8  from the year ago period s figure  mainly owing to lower spending associated with the sublicensing and success payment  General and administrative expenses were almost flat at  14 4 million Along with the earnings  Editas announced the appointment of Cynthia Collins as president and chief executive officer  CEO   Collins has been acting as the interim CEO since January when Katrine Bosley announced her decision to step down from the position Pipeline UpdateThe company s lead pipeline candidate is EDIT 101 that uses CRISPR gene editing to treat Leber congenital amaurosis type 10  LCA10    a rare genetic illness that causes blindness Editas is developing EDIT 101 in partnership with Allergan   NYSE AGN    Both companies plan to initiate patient dosing in the phase I II dose escalation study called Brilliance on EDIT 101 in LCA10 in the second half of 2019  The Brilliance study opened for patient enrolment in July Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10  including Usher Syndrome type 2A  USH2A  and recurrent ocular Herpes Simplex Virus type 1  HSV 1  fibrosis  It expects to be ready for investigational new drug  IND  enabling activities for a USH2A program by the end of the year It is also designing novel medicines for non malignant hematologic diseases such as sickle cell disease and beta thalassemia  Editas has initiated IND enabling activities for EDIT 301  an experimental CRISPR medicine designed to treat sickle cell disease and beta thalassemia by editing the beta globin locus Genomic editing using CRISPR technology to repair a defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations seen in decades  There are only a handful of companies making medicines using this revolutionary technology  Other than Editas  companies such as CRISPR Therapeutics AG   NASDAQ CRSP   and Intellia Therapeutics are either planning to conduct or have already started clinical studies to develop curative CRISPR Cas9 based medicines  The company has two CRISPR platforms  one using the Cas9 protein and the other  the Cpf1 protein Editas currently carries a Zacks Rank  3  Hold   You can see   Editas Medicine  Inc  Price  Consensus and EPS Surprise
    
 
This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/editas-edit-misses-on-q2-earnings--sales-gets-new-ceo-200452170,200452170
104755,326270,AGN,Pharma Q2 Earnings Growth Highest  Time To Buy ETFs ,opinion,Total earnings of the  of the entire healthcare market capitalization that has reported so far are up 9  on revenue growth of 8   The earnings growth rates seem to be the highest of all the sectors till now  Earnings and revenue beat ratios of 97 1  and 74 3   respectively also appear strong Most industry bigwigs delivered encouraging results  either beating on earnings or revenues or both and also raised revenue or earnings outlook or both  Let s delve into a few of them Earnings in FocusJohnson and JohnsonThe world s biggest health care products maker continued its long streak of earnings beat and also outpaced revenue estimates  Earnings per share came in at  2 58  16 cents ahead of the Zacks Consensus Estimate and 22 9  higher than the year ago quarter  Revenues fell 1 3  year over year to  20 56 billion but edged past the Zacks Consensus Estimate of  20 32 billion  Johnson   Johnson  NYSE JNJ  raised its sales forecast to  80 8  81 6 billion from  80 4  81 2 billion on robust demand for its cancer drugs  It reaffirmed its earnings per share guidance of  8 53  8 63  However  the company warned competition from generics and biosimilars that could impact its third quarter results  read    Pfizer  NYSE PFE Earnings per share of 80 cents were 3 cents above the Zacks Consensus Estimate while revenues of  13 26 billion lagged the consensus mark of  13 32 billion  On a year over year basis  earnings per share and revenues rose 4  and 2   respectively  For 2019  the U S  drug giant slashed sales guidance to  50 5  52 5 billion from  52  54 billion and earnings per share to  2 76  2 86 from  2 83  2 93 MerckEarnings per share of  1 30 surpassed the Zacks Consensus Estimate of  1 16 and also improved 23  from the year ago quarter  Moreover  revenues grew 12  year over year to  11 76 billion  edging past the consensus mark of  10 91 billion  Merck increased its revenue projection from  43 9  45 1 billion to  45 2  46 2 billion for this year and earnings per share view from  4 67  4 79 to  4 84  4 94 Bristol MyersBristol Myers s earnings per share of  1 18 beat the Zacks Consensus Estimate by 12 cents and also rose from the year ago figure of  1 01  Revenues grew 10  year over year to  6 27 billion and also trumped the Zacks Consensus Estimate of  6 04 billion  The company lifted its earnings per share guidance to  4 20  4 30 from  4 10  4 20  read    Eli Lilly  NYSE LLY Eli Lilly also delivered better than expected earnings but lagged on revenues  Earnings of  1 50 per share were 4 cents ahead of the Zacks Consensus Estimate and came in 1  higher than the year earlier quarter  Revenues grew 1  to  5 64 billion but slightly fell short of the estimated  5 65 billion  While Eli Lilly maintained its 2019 revenue guidance of  22  22 5 billion  it raised its earnings prediction to  5 67  5 77 from  5 60  5 70 ETF AngleDespite such robust results  pharma ETFs have been trending downward in a month  Below  we have highlighted those in detail iShares U S  Pharmaceuticals ETF This ETF provides exposure to 43 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top 10 holdings in the basket  accounting for 54 8  of the total assets  suggesting heavy concentration  The product has  331 1 million in AUM and charges 42 bps in fees and expense  Volume is light as it exchanges about 11 000 shares a day  The fund has lost 6 5  in a month and has a Zacks ETF Rank  3  Hold  with a High risk outlook  read    First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  The in focus firms account for a combined 34 6  of the assets  FTXH has a lower level of  7 million in AUM and 3 000 shares in average daily volume  It charges 60 bps in annual fees and is down 6 8  in the same time frame  The product has a Zacks ETF Rank  3 SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  196 1 million  it trades in good volume of around 56 000 shares a day and charges 35 bps in fees a year  In total  the product holds 41 securities with the in focus five firms making up for at least 4  share each  The product is down 7 9  in the same period and has a Zacks ETF Rank  3 with a High risk outlook VanEck Vectors Pharmaceutical ETF   ASX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  The in focus five firms account for a combined 23 6  share  The product has amassed  163 2 million in its asset base and trades in moderate volume of about 46 000 shares a day  Expense ratio comes in at 0 36   The fund has shed 4 8  of value in a month and has a Zacks ETF Rank  3 with a Medium risk outlook Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  378 5 million and sees a lower volume of around 36 000 shares a day  The fund charges 57 bps in fees and expenses  Holding 30 stocks  the fund invests nearly 5  share each in the five firms  The ETF has declined 6 3   in a month and has Zacks ETF Rank  3 with a High risk outlook  see    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/pharma-q2-earnings-growth-highest-time-to-buy-etfs-200452375,200452375
104785,326300,AGN,Mylan on go with planned challenge to Allergan s Restasis patents,news,In a setback for Allergan s  AGN  Restasis patent protecting scheme with the St  Regis Mohawk Tribe  the USPTO s Patent Trial and Appeal Board  PTAB  has denied a motion by St  Regis to terminate Mylan s  MYL  1 1   challenge to six related patents  An oral hearing is set for April 3 followed by a written decision by June 6 The PTAB denied the motion on multiple grounds  citing the Tribe s failure to establish the doctrine of tribal sovereign immunity related to an inter partes review and the fact that the proceedings would continue anyway since Allergan still owns the patents Mylan CEO Heather Bresch says   Mylan has always been vocal in its efforts to challenge and break down barriers to access  The PTAB s ruling reinforces our belief that Allergan s maneuvers to engage the St  Regis Mohawk Tribe for patent protection were a sham  We will continue to be steadfast in our efforts on both the legal and regulatory fronts to bring a generic version of Restasis to patients as quickly as possible  Previously  Heavy hitter lobbying groups line up against Allergan s controversial Restasis patent ploy  Oct  11  2017 Now read ,2018-02-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-on-go-with-planned-challenge-to-allergans-restasis-patents-1311924,1311924
104786,326301,AGN,Positive late stage results for Biohaven s rimegepant fails to lift shares  down 29  premarket,news,Biohaven Pharmaceutical Holding Company  NYSE BHVN  slumps 29  premarket despite reporting successful results from two Phase 3 clinical trials assessing rimegepant for the acute treatment of migraine Both studies  BHV3000 301 and BHV3000 302  met the co primary endpoints  pain freedom and freedom from the most bothersome symptom  MBS   at two hours post dose compared to placebo The proportions of patients achieving pain freedom in Study 301 and 302 were 19 2  and 19 6   respectively  versus 14 2  and 12 0   respectively  for placebo  p 0 03 and p 0 001  respectively  The proportions achieving freedom from the MBS were 36 6  and 37 6   respectively  compared to 27 7  and 25 2   respectively  for placebo  p 0 002 and p 0 0001  respectively  Investors appear disappointed that the results were not more pronounced considering the crowded field  John Carroll reports that Allergan  NYSE AGN  s ubrogepant  for example  showed pain freedom of 19 2  and 21 2  for two different doses and 38 6  and 37 7  on MBS compared to 27 8  for placebo  Novartis  NYSE NVS   Amgen  NASDAQ AMGN   Teva  NYSE TEVA   Eli Lilly  NYSE LLY  and Alder  NASDAQ ALDR  are all aiming for a slice of the market Now read ,2018-03-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/positive-latestage-results-for-biohavens-rimegepant-fails-to-lift-shares-down-29-premarket-1361426,1361426
104787,326302,AGN,Premarket analyst action   healthcare,news,Allergan  NYSE AGN  initiated with Outperform rating and  227  43  upside  price target at Leerink Viking Therapeutics  NASDAQ VKTX  initiated with Buy rating and  11  139  upside  price target at H C  Wainwright  ImmunoGen   NASDAQ IMGN  initiated with Outperform rating and  15  24  upside  price target at Leerink Sabra Healthcare REIT  NASDAQ SBRA  upgraded to Neutral with a 19 50  17  upside  price target at BofA Merrill Lynch  Alnylam Pharmaceuticals   NASDAQ ALNY  price target raised to Street high of  207  50  upside  at JMP Securities Hologic  NASDAQ HOLX  removed from Conviction List at Goldman Sachs  NYSE GS  PLx Pharma  NASDAQ PLXP  downgraded to Neutral with a  6  17  upside  price target at Janney Now read ,2018-03-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1361553,1361553
104788,326303,AGN,FDA working on policies to boost biosimilars,news,Reuters reports that the FDA is working on  about a dozen  policies aimed at making it easier for biosimilars to gain a foothold in the U S  market Unlike Europe where biosimilars have made inroads  U S  drugmakers have been successful in blocking the entry of the lower priced competition Commissioner Scott Gottlieb  M D  has criticized the industry for its  Kabuki drug pricing constructs   One action the agency intends to pursue is making it more difficult for biologic developers to tweak existing patents in order to extend coverage He is also concerned with the competition stifling consolidation in the drug supply chain Selected tickers   XLV  0 8   IHE  XBI  0 6   AMGN  0 1   BIIB  2 4   JNJ  0 8   OTCQX RHHBY  1 4   ABBV  4 1   AGN  3 9   AZN  2 2   BMY  0 7   GSK  3 3   LLY  2 1   MRK  2   NVS  2 8   NVO  1 8   PFE  1 4   VRX  1 7   TEVA  1 2   MYL  1 8   CHRS  3  Now read ,2018-03-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-working-on-policies-to-boost-biosimilars-1367918,1367918
104789,326304,AGN,Diminished prospects for fibroid med Esmya may be motivation for possible sale of Allergan s women s health business   Mizuho,news,In a note  Mizuho Securities says Allergan  NYSE AGN  may be advancing the sale of its women s health unit due to lower expectations for uterine fibroid med Esmya  ulipristal acetate  The product was withdrawn from the European market on the heels of toxicity concerns and the FDA recently extended its review period for the company s U S  application until August Without Esmya  Mizuho says the business no longer meets the company s market leadership criteria so divestment makes sense Previously  FDA extends action date for Allergan s uterine fibroid med ulipristal acetate to August  shares down 3   March 1 Now read ,2018-04-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/diminished-prospects-for-fibroid-med-esmya-may-be-motivation-for-possible-sale-of-allergans-womens-health-business--mizuho-1375246,1375246
104790,326305,AGN,MabVax receives listing deficiency notice from Nasdaq,news,MabVax Therapeutics Holdings  OTCQB MBVX  reports that it has received a notice from Nasdaq that its  1 1M in stockholders   SE  equity is below the listing minimum of  2 5M The company says SE dropped due to the capital required for clinical trials  adding that it raised  2 7M in February and seeks one or more strategic transactions this quarter Per Nasdaq rules  MabVax has 45 calendar days to submit a plan to address the issue and may receive an additional 180 days for implementation Now read ,2018-04-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/mabvax-receives-listing-deficiency-notice-from-nasdaq-1395118,1395118
104791,326306,AGN,Exclusive  Allergan in talks to acquire Shire  competing against Takeda   sources,news," Reuters    Botox maker Allergan  NYSE AGN  Plc is in talks to acquire  Shire  Plc  LON SHP   competing against Japan s Takeda Pharmaceutical Co Ltd for the London listed drugmaker  two sources familiar with the matter said on Thursday  It is not clear whether Allergan has submitted an offer  and there is no certainty of a bid  the sources said  Shire on Thursday said it had rejected an offer worth around  61 billion from Takeda  
The sources asked not to be identified because the matter is confidential  Allergan declined to comment  while Shire and Allergan did not immediately respond to requests for comment ",2018-04-19,Reuters,https://www.investing.com/news/stock-market-news/exclusive-allergan-in-talks-to-acquire-shire-competing-against-takeda--sources-1403552,1403552
104792,326307,AGN,U S  opioid prescriptions down 12  last year  largest drop in 25 years,news,According to IQVIA  IQV  0 8    U S  opioid prescriptions declined 12  in 2017  the largest annual drop in 25 years as doctors respond to the opioid crisis Specific contributing factors continue to be shifts in clinical practice guidelines  more controls from payers  increased medical education and legislative regulatory restrictions  not to mention intense media pressure  Selected tickers  INSY  JNJ  TEVA  ENDP  MNK PFE  AGN  PRGO  ABBV  AMPH TTNP  BDSI DRRX  PTIE  ACUR  PTX  ACRX  IPCI  KMPH  OTCQB ELTP  TRVN  OPNT  ANIP  XLV  VHT  XBINow read ,2018-04-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/us-opioid-prescriptions-down-12-last-year-largest-drop-in-25-years-1403758,1403758
104793,326308,AGN,Is A Beat In The Cards For Bristol Myers  BMY  Q2 Earnings ,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report second quarter 2019 results on Jul 25  before the market opens 
The company s shares have lost 16 1  in the year so far compared with the  s decline of 0 1  

 
Bristol Myers delivered average positive earnings surprise of 11 85  in the trailing four quarters  In the last reported quarter  the company delivered a positive surprise of 0 92  Bristol Myers Squibb Company Price  Consensus and EPS Surprise
 

   
 
Let s see how things are shaping up for this quarter 
Why a Likely Beat 
Our proven model shows that Bristol Myers is likely to beat on earnings this quarter  This is because it has two key ingredients   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for the same 
Earnings ESP  Earnings ESP for Bristol Myers is  0 28    You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Bristol Myers currently carries a Zacks Rank  3  which when combined with a positive ESP makes us confident of an earnings beat 
Note  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Factors Driving Growth
Bristol Myers  key immuno oncology drug  Opdivo  is expected to be the primary revenue driver in the to be reported quarter  extending its previous performance  The drug  which is approved for multiple indications  generated sales of  1 8 billion in the first quarter  increasing 19  year over year 
Blood thinner drug  Eliquis  witnessed strong growth   28   and became the top revenue generator for the company in the first quarter  We expect the momentum to continue in the second quarter 
Oncology drug  Sprycel  is also maintaining momentum  In January  the FDA approved a label expansion of Sprycel  in combination with chemotherapy  to include pediatric patients aged a year or above with newly diagnosed Philadelphia chromosome positive  Ph   acute lymphoblastic leukemia  ALL   The European Commission also approved the drug for the same indication in February  We expect the recent label expansion to boost sales of the drug in the second quarter 
Orencia and Yervoy should also continue their stellar performance in the second quarter  
However  the Hepatitis C and HIV businesses continue to face competitive pressure  Sales for the franchises are expected to decline 
Concurrent with the first quarter results  Bristol Myers reiterated its adjusted earnings and revenue expectations for 2019  The company projects earnings of  4 10  4 20 per share  The Zacks Consensus Estimate for earnings is pegged at  4 16  It expects worldwide revenues to increase mid single digits 
The Zacks Consensus Estimate for second quarter sales and earnings is pegged at  6 03 billion and  1 06  respectively 
Apart from the top  and bottom line numbers  investors will also focus on pipeline updates on label expansion of drugs  The phase III CheckMate 498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6 methylguanine DNA methyltransferase  MGMT  unmethylated glioblastoma multiforme  GBM  did not meet its primary endpoint of overall survival  OS  at final analysis 
Moreover  CheckMate 459  a randomized phase III study evaluating Opdivo compared to Nexavar as a first line treatment in patients with unresectable hepatocellular carcinoma  HCC   also did not achieve statistical significance for its primary endpoint of overall survival  OS  
Key Anticipated Updates
Investors will also focus on further updates on the company s impending acquisition of Celgene Corp    NASDAQ CELG    The acquisition earlier was being opposed by a few large shareholders  Wellington and Starboard  of Bristol Myers  expressing multiple concerns regarding its growth following the acquisition  The acquisition was finally given a green signal a couple of months back 
Meanwhile  Bristol Myers needs to sell one of Celgene s blockbuster drugs  Otezla  to complete the impending merger on a timely basis in light of concerns expressed by the U S  Federal Trade Commission  FTC   We remind investors that the company has a tyrosine kinase 2  TYK2  inhibitor  BMS 986165  in its pipeline  which is being evaluated in several autoimmune diseases  including psoriasis 
The regulatory agency was concerned about a possible overlap between Otezla and BMS 986165 in the pipeline  Hence  Bristol Myers decided to sell Otezla 
Moreover  the company now expects to complete the merger by the end of 2019 or beginning of 2020  The divestiture of the drug also puts a question mark on the targeted synergies and anticipated sales of the combined company  per Bristol Myers 
Other Stocks to Consider
Here are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Merck   NYSE MRK   has an Earnings ESP of  0 80  and a Zacks Rank  2  The company is scheduled to release results on Jul 30  You can see   
Allergan  plc   NYSE AGN   has an Earnings ESP of  3 52  and a Zacks Rank  3 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-19,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-bristolmyers-bmy-q2-earnings-200442175,200442175
104794,326309,AGN,Can Allergan  AGN  Keep The Earnings Streak Alive In Q2 ,opinion,We expect Allergan plc   NYSE AGN   to beat expectations when it reports second quarter 2019 results  In the last reported quarter  the company delivered a positive earnings surprise of 6 76  Allergan s share price has risen 22 1  in the past year against the  s decline of 4 3 Allergan s earnings performance has been strong  with the company beating expectations in each of the past four quarters  The average positive earnings surprise over the last four quarters is 5 79  Allergan plc Price and EPS Surprise   Let s see how things are shaping up for this announcement Factors to ConsiderSales in the second quarter are expected to be hurt by generic competition due to loss of exclusivity on some brands  impact of divestitures  regulatory changes for textured breast implants in certain international markets as well as industry wide pricing pressure and currency headwinds For the second quarter  the company expects revenues to be in the range of  3 88 billion to  4 03 billion and earnings per share between  4 20 and  4 40 While generic versions of Alzheimer s treatment  Namenda XR and Estrace cream are already launched that of Restasis  Allergan s second best selling drug  is expected to be launched in 2019  On the first quarter conference call  Allergan had said that generic version of Restasis should be launched by May  However  no such generics have been launched yet  The delayed generic entry of Restasis may prove to a tailwind for the top line in the second quarter Nonetheless  despite the absence of generic competition  sales of Restasis declined in the first quarter due to lower selling price   We do not expect any improvement in the second quarter  Meanwhile  generic versions of Canasa and Rapaflo were launched in December 2018 while that of Delzicol was launched in May 2019  which can hurt sales of the branded drugs Key products like Botox  both cosmetic and therapeutic   Juv derm collection of fillers  Vraylar  Linzess and Lo Loestrin are likely to support sales growth in the to be reported quarter  The Zacks Consensus Estimate for Botox is  1 0 billion Importantly  in May  Allergan gained FDA approval for the new indication of bipolar depression for Vraylar  Investors will be keen to know the contribution of this label expansion to sales of the drug in the second quarter Last month  Allergan announced that it has entered into a definitive transaction to be acquired by AbbVie  Inc    NYSE ABBV   in a cash and stock deal with transaction value of nearly  63 billion  Questions on the proposed merger with AbbVie are expected on the second quarter conference call Earnings WhispersOur proven model shows that Allergan is likely to beat estimates in the soon to be reported quarter because it has the right combination of two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate   4 46 per share  and the Zacks Consensus Estimate   4 30 per share   is  3 52   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Allergan has a Zacks Rank  3  The combination of Allergan s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderHere are some other large drug biotech stocks that also have the right combination of elements to beat on earnings this time around AbbVie has an Earnings ESP of  0 12  and a Zacks Rank  2  The company is slated to release results on Jul 26  You can see  Bristol Myers Squibb Company   NYSE BMY   has an Earnings ESP of  0 28  and a Zacks Rank  3  The company is scheduled to release results on Jul 25 GlaxoSmithKline plc    NYSE GSK   has an Earnings ESP of  1 31  and a Zacks Rank  3  The company is scheduled to release results on Jul 24 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/can-allergan-agn-keep-the-earnings-streak-alive-in-q2-200442674,200442674
104795,326310,AGN,AbbVie  ABBV  Set To Report Q2 Earnings  What To Expect,opinion,"AbbVie   NYSE ABBV   is set to release its Q2 earnings before market open on Friday  AbbVie stock has performed very poorly YTD  falling 26  
 

 
Overview
AbbVie Inc  is an American biopharmaceutical company based in Illinois  AbbVie was established as a spin off of Abbott Laboratories  NYSE ABT  in 2013  AbbVie is the marketer and producer of Humira  the best selling drug in the world  Humira is used to treat rheumatoid arthritis  Crohn s disease  ulcerative colitis  and other issues related to these diseases 
AbbVie has also made a couple of acquisitions over the past couple of months  In June  AbbVie acquired Botox producer Allergan  NYSE AGN  plc for  63 billion  In July  AbbVie announced it would acquire Mavupharma  which would help bolster the company s cancer drug pipeline 
Since the Allergan acquisition announcement  ABBV stock has fallen 13   Currently  AbbVie shares are trading at 7 39 times earnings  which may make the stock seem undervalued compared to its industry s average P E of 14 37  However  ABBV s lower P E is most likely due to its falling stock price in recent months and may not be a good representation of the stock s value 
Additionally  AbbVie is a solid dividend stock  Since November 2017  AbbVie has increased its dividend three times  the most recent being an 11  increase that came in February 2019  The annual dividend is currently at  4 28  which amounts to a dividend yield of about 6 2  
Q2 Outlook   Earnings Trends
Revenues for Q2 are expected to fall 2  year over year from  8 28 billion to  8 10 billion  according to our Zacks Consensus Estimates  After years of year over year revenue growth  predictions suggest this will be the second quarter in a row of shrinking revenues 
 

 
In Q1  revenues fell 1 3  from Q1 2018  The primary source of the revenue decline was a decrease in international sales  International sales of Humira declined by nearly half a billion dollars  or over 25   Humira accounts for over 50  of AbbVie s revenue  so investors are clearly worried about the firm s overreliance on the drug 
Our  predict international Humira sales will slip by a similar amount again for Q2  While U S  sales are expected to increase slightly  from  3 521 billion in Q2 2018 to  3 785 billion  But this growth is simply not enough to make up for the expected international revenue decrease from  1 664 billion to  1 028 billion  The decrease in international Humira sales is a result of competition in Europe 
Meanwhile  AbbVie s earnings are expected to grow by 10 5   The quarterly growth will help contribute to an expected fiscal 2019 growth of 11 5   which would give fiscal EPS of  8 82 compared to  7 91 in 2018 
Bottom Line
Humira s patent in the U S  expired in 2016  but domestic competitors are not expected to hit the market until 2023 due to AbbVie s strong and persistent litigation leading up to the patent expiration  Until then  AbbVie needs to continue to grow its portfolio and the addition of Botox was a big one as it can help make up for some of the revenue that will be lost to Humira competitors  The firm s international competitors have already taken a large toll on AbbVie s revenue  And the arrival of domestic competitors will most likely have an even more significant impact on the company 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-set-to-report-q2-earnings-what-to-expect-200443356,200443356
104796,326311,AGN,Large Cap Pharmaceuticals Industry Near Term Outlook Bright,opinion,"The Zacks  industry comprises some of the largest global companies that developmulti million dollar drugs for a broad range of therapeutic areas such as neuroscience  cardiovascular and metabolism  rare diseases immunology and oncology  Some of these companies also make vaccines  animal health  medical devices and consumer related healthcare products  All these players invest millions of dollars in their product pipelines and line extensions of their already marketed drugs  Here are the industry s three major themes Demand driven growth in sales of new products  successful innovation and product line extensions in important therapeutic areas  strong clinical study results  and frequent FDA approvals  continued strong performance of key products  growing demand for drugs  especially for rare to treat diseases  an aging population and increased health care spending are some of the factors boosting this industry s growth  A faster drug approval process and the proposed removal of outdated regulations  which are escalating costs and slowing down innovation  are the other positives  Mergers and acquisitions activity has increased significantly  especially after the tax overhaul in 2017  which reduced tax rate  The cash rich big players are on the lookout for companies with innovative pipelines technology  Meanwhile  in licensing deals continue to be popular with several big companies collaborating with smaller and mid sized players that have promising mid to late stage pipeline candidates or interesting technology  These deals make sense for both larger and smaller companies  While the big shots are able to improve their pipelines with prospective candidates  the smaller entities gain access to a non dilutive source of funds that allows consistent investment in the pipelines  Headwinds for the industry include government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and most importantly major pipeline setbacks Overall  we believe that pipeline success  cost cutting measures  share buybacks  product launches  ramped up M A and collaboration activities and appropriate utilization of cash should keep the sector afloat  going forward Zacks Industry Rank Indicates Solid ProspectsThe group s is basically the average of the Zacks Rank of all the member stocks The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank  48  which places it in the top 19  of more than 250 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 Before we present a few large drug stocks that are well positioned to outperform the market based on a strong earnings outlook  let s take a look at the industry s stock market performance and its current valuation 
Industry Underperforms Sector   S P 500The Zacks Large Cap Pharmaceuticals industryis a 14 stock group within the broader  sector  It has underperformed the S P 500 and the Zacks Medical Sector on a year to date basis While the stocks in this industry have collectively declined 1 3  year to date  the Zacks S P 500 composite and the Zacks Medical Sector have increased 2 7  and 17 4   respectively Year to Date Price Performance  
 
 Industry s Current ValuationOn the basis of the forward 12 month price to earnings  P E   a commonly used multiple for valuing large pharma companies  the industry is currently trading at 14 35X compared with the S P 500 s 17 21X and the Zacks Medical sector s 20 00X Over the last five years  the industry has traded as high as 18 10X  as low as 13 94X and at a median of 15 76X as the chart below shows 
 Forward 12 Month Price to Earnings  P E  Ratio 
 
 Bottom LineIn order to succeed in a changing global market and evolv ing healthcare landscape  pharma ceutical companies need to adopt innovative business models  invest in new technologies  raise investments in personalized medicines and seek external partners and collabora tors for complementary strengths The sector may face some volatility due to the drug pricing issue  pricing re imbursement pressure  stiff competition  sluggish legacy product sales  loss of patent exclusivity of some key drugs and pipeline related setbacks  However  pipeline success in innovative and important therapeutic areas  cost control  share repurchases  product introductions  heightened M A activity and appropriate utilization of cash should put the sector on a firm footing as the year progresses In the Large Cap Pharmaceuticals universe  five companies have a Zacks Rank  2  Buy   Most of these have witnessed positive earnings estimate revisions in the past 30 days You can see  Roche Holding  SIX ROG  AG  RHHBY   Shares of this Swiss drugmaker have gained 9 2  this year so far  The Zacks Consensus Estimate for current year EPS has been revised 2 9  upward over the past 30 days  Roche carries a Zacks Rank  2 Price and Consensus  RHHBYMerck   Co   Inc   MRK   The Zacks Consensus Estimate for this Kenilworth  NJ  based drugmaker s current year EPS has remained stable over the past 30 days  Merck has a Zacks Rank of 2  The stock has risen 7 4  so far this year Price and Consensus  MRKSanofi  PA SASY   SNY   The stock of this French drugmaker has moved 1 8  downward year to date  However  the Zacks Consensus Estimate for this Zacks  2 Ranked company s current fiscal EPS has been raised 0 3  over the past 30 days Price and Consensus  SNYBayer  DE BAYGN  Aktiengesellschaft  BAYRY   This Leverkusen  Germany based drug giant has seen a 2 1  decline in share price so far this year  However  the Zacks Consensus Estimate for this  2 Ranked stock s current year EPS has increased 5 8  over the past 30 days Price and Consensus  BAYRYAbbVie  Inc   ABBV   This North Chicago  IL based drugmaker  which recently offered to buy Allergan  NYSE AGN  plc  has seen a 26 5  decline in share price so far this year  However  the Zacks Consensus Estimate for this  2 Ranked stock s current year EPS has increased 0 1  over the past 30 days Price and Consensus  ABBV
  
The Hottest Tech Mega Trend of All 
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/largecap-pharmaceuticals-industry-nearterm-outlook-bright-200444198,200444198
104797,326312,AGN,Proteostasis  PTI  To Post Q2 Earnings  What s In Store ,opinion,Investors will focus on Proteostasis Therapeutics  Inc  s   NASDAQ PTI   studies on triple combination regimes for cystic fibrosis  when it reports second quarter 2019 results The company s performance over the previous four quarters has been mixed  beating earnings estimates in two  The average positive surprise over the trailing four quarters is 10 76   In the last reported quarter  Proteostasis delivered a positive surprise of 34 88  Shares of the company have plunged 74 6  so far this year while the showed no movement Let s see  how things are shaping up for this announcement Factors to ConsiderProteostasis has been developing its proprietary triple combination candidates   PTI 801  a cystic fibrosis transmembrane conductance regulator  CFTR  corrector  PTI 808  a CFTR potentiator  and PTI 428  a CFTR amplifier In March  Proteostasis announced disappointing data from a dose selecting phase I program on its triple combination candidates in patients with cystic fibrosis  CF   Data showed that a statistically significant improvement in percent predicted FEV1  ppFEV1   measurement of lung function  at day 14 was achieved in the study cohort with a higher dose of the company s CFTR corrector  However  the uptrend was much lower than what was attained by the triple combinations of Vertex Pharmaceuticals   NASDAQ VRTX   in late stage clinical analyses of the treatment of CF In July 2019  the company announced that the first patient has been dosed in the 28 day phase II study evaluating its CFTR modulator combinations in F508del homozygous and heterozygous CF subjects  The ongoing phase II study will explore efficacy over a longer duration and in additional genotypes  including subjects heterozygous for the F508del mutation with Proteostasis  doublet and triplet combinations  We expect the company to provide updates on the same during the second quarter earnings call In June  the European Commission  EC  granted Orphan Drug designation  ODD  to PTI 428 for the treatment of cystic fibrosis  We expect management to provide an update on the same during the upcoming earnings call Earnings WhispersThe proven Zacks model does not conclusively show that Proteostasis is likely to beat estimates this earnings season  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  Proteostasis has an Earnings ESP of 0 00   This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 35 cents each  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Proteostasis currently carries a Zacks Rank  3  which increases the predictive power of ESP  You can see  We caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions  Proteostasis Therapeutics  Inc  Price and Consensus     Stocks That Warrant a LookHere are a few healthcare stocks worth considering  as our model shows that these have the right mix of elements to beat on earnings this time around Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  3 64  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Aug 6 Allergan plc    NYSE AGN   has an Earnings ESP of  2 74  and a Zacks Rank  3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/proteostasis-pti-to-post-q2-earnings-whats-in-store-200448989,200448989
104826,326341,AGN,Allergan to pay Israel s Teva Pharm  700 million to settle dispute,news,"TEL AVIV  Reuters    Allergan  N AGN  will make a one time payment of  700 million to Teva Pharmaceutical Industries  TA TEVA  to settle a dispute over working capital  Israel based Teva said on Thursday  Teva will use the payment  which is expected during the first quarter of 2018  to repay part of its debt  Teva  N TEVA  and Allergan agreed to jointly dismiss the working capital dispute arbitration  
As of Jan  12  2018  Allergan owned 68 7 million shares in Teva  which it received as partial payment for Teva s  40 5 billion acquisition of  Actavis  Generics from Allergan in 2016 ",2018-02-01,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-pay-israels-teva-pharm-700-million-to-settle-dispute-1182053,1182053
104827,326342,AGN,BTIG turns bearish on Teva  cuts to Sell  shares down 2  premarket,news,Teva Pharmaceutical Industries  NYSE TEVA  slips 2  premarket on increased volume on the heels of a downgrade to SELL with a  17  20  downside risk  at BTIG Research  Analyst Timothy Chiang cites continued pressure on its U S  generics business and expected sales declines for top seller Copaxone For good measure  he also says the company will face higher borrowing costs considering the rising interest rate environment and recent credit downgrade  He sees its debt EBITDA ratio rising to  5 9x despite the  700M payment from Allergan  NYSE AGN  Source  BloombergNow read ,2018-02-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/btig-turns-bearish-on-teva-cuts-to-sell-shares-down-2-premarket-1188111,1188111
104828,326343,AGN,Allergan completes restructuring  pushes hard in China,news,By Matthias Blamont PARIS  Reuters    Botox maker Allergan  N AGN  has embarked on a big push in China where it plans to hire 200 additional staff this year and will also be on the lookout for potential acquisitions in the country  a senior executive told Reuters on Friday  The drugmaker is about to complete a restructuring in which more than 1 000 staff will leave the company  more than 5 percent of its current workforce  as it faces a drop in revenues coming from new competition for its second most important drug  dry eye treatment Restasis  Speaking on the sidelines of aesthetic and cosmetic dermatology congress IMCAS in Paris  Allergan s Executive Vice President in charge of international operations Marc Princen said Allergan was eyeing annual sales of around  500 million in China by 2022  The company recorded sales of around  180 million there last year  he said   At this point in time  80 percent of our sales are in the U S and 20 percent abroad  Over the next five years  we will bring the 20 percent to 30 percent   Princen said in an interview   The focus will be on high potential must win markets  for example China  We have added 300 staff there in 2017 and we grew revenues by 60 percent  We will add another 200 this year   he said  Princen said his team had identified 12 key markets outside the United States  Among them China  Brazil  Russia as well as European countries such as France  Italy  Germany and Spain   I am a strong believer in mainland Europe for instance  We can have double digit growth there by doing the right things  At the moment  in Europe  we have growth of around between 7 8 percent  it will grow     he said  The executive said the company  which has recently bought Zeltiq Aesthetics for  2 48 billion  had many options to grow out of its own resources but that other acquisitions would also be considered   What we are not going to do   mega deals  We will not go into that  But we will buy early stage products that we will develop and market further  the closer they are to launch  the better   he said without giving further details   I will not go country by country on M A  I would say though mainland Europe is important as well as Asia   Princen said 90 percent of the job cuts announced in November were completed   If we look at the proportion  its 800 departures in the U S and 200 outside the U S   he said  The company is due to publish its annual results on Feb 6 ,2018-02-02,Reuters,https://www.investing.com/news/stock-market-news/allergan-completes-restructuring-pushes-hard-in-china-1189981,1189981
104829,326344,AGN,Will Patent Woes Boost Pharma Stock Megamergers Further ,opinion,Generic competition can lower revenues of pharma stocks since blockbuster drugs are facing patent expirations  Moreover  President Trump s issuance of an executive order to slash drug prices did not go down well with pharmaceutical stocks  Both these events could create appetites for further mergers and acquisitions among major pharma socks to combat the pricing pressure prevailing in the industry Notably  the fundamentals of most of the drug giants are highly favorable to carry on further acquisitions  since their balance sheets are investment graded and generating handsome cash flows  Thus  the majority of  pharma firms are in a favorable position to raise debt capital from the market  which could be favored by low interest rates  to further boost merger transactions  Major Pharma Deals in Recent TimesWe have seen a spree of mergers among key pharmaceutical players  in hopes of better sustaining themselves in challenging business scenarios  The remarkable one is the planned acquisition of Allergan plc   NYSE AGN   by AbbVie Inc    NYSE ABBV   that was announced in June 2019  This transaction was valued at  63 billion  Both Allergan and AbbVie carry a Zacks Rank  3  Hold   You can see  Another notable deal is Bristol Myers Squibb Company s   NYSE BMY    74 billion acquisition agreement  which was announced in January 2019  with rival Celgene Corporation   NASDAQ CELG    Last year s acquisition of Shire plc by leading Japanese drug manufacturer Takeda Pharmaceutical Co  for  58 billion is also noteworthy Patent expirations of top selling drugs and pricing pressure are among the major challenges haunting pharma stocks  Although AbbVie s Humira   which is prescribed for treating rheumatoid arthritis   is safe from biosimilar competition in the United States till 2023  the top selling anti inflammatory drug is losing sales in European market  Moreover  Restasis  prescribed for chronic dry eye problem  is losing exclusivity  Importantly  Restasis is the leading selling product of drug maker Allergan   Factors Driving Merger Spree to Continue in 2HPatent expiry is probably increasing the appetite of pharma stocks for more megamergers in the second half of this year at bargain prices  This is because  via mergers and acquisitions  the companies will be able to boost product lines  thereby maximizing annual revenues  In other words  with blockbuster drugs losing exclusivity  key drug makers are poised to face deep trouble  thereby creating rooms for megamergers  This is because sales of many of the firms are significantly dependent on a single drug Another notable factor that could drive the merger spree is the prolonged period of no new blockbuster drug  which is limiting the growth potential of pharma stocks  according to The Wall Street Journal  The source added that many serious medical threats have already been encountered in the pharma space  thereby creating limited rooms for fresh shareholder wealth generations  Notably  the pharma sector is focusing on a few target areas that include certain liver diseases and Alzheimer s disease  However  these targets are unlikely to generate revenues following failures in a series of clinical trials  Potential Acquisition TargetsMizuho Securities has pinpointed three pharma stocks  namely Amgen Inc    NASDAQ AMGN    Biogen Inc    NASDAQ BIIB   and Gilead Sciences Inc    NASDAQ GILD    which could be potential acquisition targets at bargain prices  The Japanese investment bank added that the stocks are not expected to witness massive revenue growth in the coming five years  which further encourages the firms to enter into merger deals Amgen  Biogen and Gilead Sciences are trading at 12 65X  7 76X and 9 70X  respectively  significantly lower than the forward 12 month price to earnings of 55 74X for the Zacks  industry  The valuation picture confirms that the stocks are significantly undervalued to invite potential acquirers Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-10,Zacks Investment Research,https://www.investing.com/analysis/will-patent-woes-boost-pharma-stock-megamergers-further-200438545,200438545
104830,326345,AGN,Allergan s migraine candidate ubrogepant successful in late stage study  shares ahead 2  premarket,news,Allergan  NYSE AGN  is up 2  premarket on light volume in response to its announcement of positive results from a Phase 3 clinical trial  ACHIEVE I  evaluating ubrogepant in adult patients experiencing a single migraine attack  Both co primary endpoints were met 19 2   n 81 423  of those receiving 50 mg and 21 2   n 95 448  of those receiving 100 mg achieved pain freedom at two hours versus 11 8   n 54 456  for placebo  p 0 0023 and p 0 0003  respectively  38 6   n 163 423  of the 50 mg cohort and 37 7   n 169 448  of the 100 mg cohort achieved absence of the most bothersome migraine associated symptom at hour two compared to 27 8   n 127 456  for placebo   p 0 0023 and p 0 0023  respectively  On the safety front  ubrogepant was well tolerated with a profile similar to placebo  The most common adverse events were nausea  drowsiness and dry mouth  all less than 5    There were six cases of elevated liver enzymes greater than three times the upper limit of normal across both treatment arms and placebo  All were determined to be related to other medications or illness Additional data will be submitted for presentation at future medical conferences Results from a second Phase 3  ACHIEVE II  should be available next quarter The company expects to file its U S  marketing application in 2019 Ubrogepant is an orally available calcitonin gene related peptide  CGRP  receptor antagonist  CGRP and its receptors are expressed in regions on the nervous system associated with migraine pathophysiology MIgraine rival Teva Pharmaceutical Industries  NYSE TEVA  is down 2  premarket Now read ,2018-02-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergans-migraine-candidate-ubrogepant-successful-in-latestage-study-shares-ahead-2-premarket-1202471,1202471
104831,326346,AGN,Allergan  AGN  Dips More Than Broader Markets  What You Should Know,opinion,"In the latest trading session  Allergan  NYSE AGN  closed at  164 26  marking a  1 1  move from the previous day  This move lagged the S P 500 s daily loss of 0 34   Meanwhile  the Dow lost 0 09   and the Nasdaq  a tech heavy index  lost 0 43  
Prior to today s trading  shares of the Botox maker had gained 43 51  over the past month  This has outpaced the Medical sector s gain of 0 2  and the S P 500 s gain of 4 46  in that time 
Investors will be hoping for strength from AGN as it approaches its next earnings release  On that day  AGN is projected to report earnings of  4 28 per share  which would represent a year over year decline of 3 17   Our most recent consensus estimate is calling for quarterly revenue of  3 90 billion  down 5 39  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  16 68 per share and revenue of  15 21 billion  These totals would mark changes of  0 06  and  3 63   respectively  from last year 
Any recent changes to analyst estimates for AGN should also be noted by investors  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 04  higher  AGN is holding a Zacks Rank of  3  Hold  right now 
Digging into valuation  AGN currently has a Forward P E ratio of 9 96  This represents a premium compared to its industry s average Forward P E of 6 68 
Meanwhile  AGN s PEG ratio is currently 1 56  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Medical   Generic Drugs was holding an average PEG ratio of 0 98 at yesterday s closing price 
The Medical   Generic Drugs industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 102  which puts it in the top 40  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-dips-more-than-broader-markets-what-you-should-know-200440456,200440456
104832,326347,AGN,Healthcare ETFs In Focus On JNJ s Q2 Earnings Beat,opinion,Johnson   Johnson   NYSE JNJ   set the ball rolling for pharma earnings when it reported second quarter results on Jul 16  before the opening bell  The world s biggest health care products maker continued its long streak of earnings beat and also outpaced revenue estimates  It also raised its guidance for full year sales growth Earnings per share came in at  2 58  16 cents ahead of the Zacks Consensus Estimate and 22 9  higher than the year ago quarter  Revenues fell 1 3  year over year to  20 56 billion but edged past the Zacks Consensus Estimate of  20 32 billion  read    For 2019  Johnson   Johnson raised its sales forecast to  80 8  81 6 billion from  80 4  81 2 billion on robust demand for its cancer drugs  It reaffirmed its earnings per share guidance of  8 53  8 63  However  the company warned competition from generics and biosimilars that could impact its third quarter results  This sent shares of JNJ down 1 6  despite the strong results Currently  the stock has a Zacks Rank  2  Buy  and a VGM Score of A  Additionally  Johnson   Johnson belongs to a top ranked Zacks industry Rank     suggesting smooth trading in the days ahead ETFs in FocusGiven this  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below we have highlighted them  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 43 companies that manufacture prescription or over the counter drugs or vaccines by tracking the Dow Jones U S  Select Pharmaceuticals Index  Of these  Johnson and Johnson takes the second spot  accounting for 21 2  share  The product has  295 million in AUM and charges 43 bps in fees and expenses  Volume is lower as it exchanges about 11 000 shares a day  The fund has a Zacks ETF Rank  3  Hold  with a High risk outlook  read    iShares Evolved U S  Innovative Healthcare ETF This actively managed ETF employs data science techniques to identify companies with exposure to the innovative health care sector  Holding 214 stocks in its basket  JNJ is the top firm with 11 2  allocation  The product has accumulated  5 million in its asset base and trades in a meager volume of 3 000 shares per day on average  It charges 18 bps in annual fees Health Care Select Sector SPDR Fund The most popular health care ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  17 8 billion in its asset base and trades in heavy volume of around 11 2 million shares  Expense ratio comes in at 0 13   In total  the fund holds 62 securities in its basket  with JNJ taking the top spot at 10 3  of the assets  Pharma accounts for 31 6  share from a sector look  while health care equipment and supplies  health care providers and services  and biotech have double digit exposure each  It has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  read    iShares U S  Healthcare ETF This fund offers exposure to 130 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s returns with 9 5  of the total assets  In terms of industrial exposure  pharma takes the top spot at 30 2   followed by health care equipment  23 7   and biotech  17 3    The product has amassed nearly  2 2 billion in its asset base and charges 43 bps in annual fees  It trades in a good volume of around 104 000 shares a day and has a Zacks ETF Rank  2 with a Medium risk outlook Vanguard Health Care ETF   ASX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 391 stocks in its basket  Of these  Johnson   Johnson occupies the top position with 9  allocation  Pharma takes the largest share at 29 1   while health care equipment and biotech round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  9 2 billion and average daily volume of about 252 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank  2 with a Medium risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etfs-in-focus-on-jnjs-q2-earnings-beat-200440862,200440862
104833,326348,AGN,Allergan s profit beats  migraine treatment succeeds key study,news," Reuters    Allergan  NYSE AGN  Plc on Tuesday reported a better than expected profit on strong demand  and the company said its migraine treatment met the main goals in a late stage study  Allergan s shares were up 1 2 percent at  167 00 before the bell  The drugmaker said patients on its treatment were relieved of pain after two hours  and did not experience migraine symptoms compared to a placebo  meeting the main goals of the first of two late stage studies  The company s net profit attributable to shareholders was  3 05 billion  or  8 88 per share  in the fourth quarter ended Dec  31  compared with a loss of  70 2 million  or  0 20 per share  a year earlier  Allergan recorded a gain of about  2 8 billion related to recent changes to the U S  tax law  helping the company report a profit after six straight quarters of loss  Excluding items  the company earned  4 86 per share  beating the average analyst estimate of  4 74  according to Thomson Reuters I B E S  Allergan s net revenue rose to  4 33 billion from  3 86 billion  and beat analysts  estimates of  4 28 billion  
Sales of Allergan s Botox increased to  864 3 million from  739 3 million ",2018-02-06,Reuters,https://www.investing.com/news/stock-market-news/allergan-posts-quarterly-profit-migraine-treatment-succeeds-key-study-1202111,1202111
104834,326349,AGN,Allergan s late stage success with migraine candidate pressures Teva  down 2  premarket,news,Teva Pharmaceutical Industries  NYSE TEVA  is under modest pressure premarket  down 2  on light volume  on the heels of Allergan  NYSE AGN  s announcement of positive results from a Phase 3 clinical trial evaluating orally administered migraine med ubrogepant  a calcitonin gene related peptide  CGRP  antagonist Teva s migraine candidate  fremanezumab  is also a CGRP antagonist  It is administered once month or once quarter via injection  Its marketing applications in the U S  and Europe are currently under review Previously  Allergan s migraine candidate ubrogepant successful in late stage study  shares ahead 2  premarket  Feb  6 Now read ,2018-02-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergans-latestage-success-with-migraine-candidate-pressures-teva-down-2-premarket-1202455,1202455
104835,326350,AGN,Biodelivery Sciences settles Belbuca patent dispute with Teva  shares up 4  premarket,news,Biodelivery Sciences  NASDAQ BDSI  has settled its litigation with Teva Pharmaceutical Industries  NYSE TEVA  over the latter s proposed generic version of BELBUCA  buprenorphine  buccal film  CIII  Under the terms of the settlement  Teva will be allowed to market its generic product in the U S  starting on January 23  2027 or earlier under certain circumstances  Other terms are not disclosed BDSI is up 4  premarket on light volume Now read ,2018-02-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/biodelivery-sciences-settles-belbuca-patent-dispute-with-teva-shares-up-4-premarket-1203021,1203021
104836,326351,AGN,Allergan  AGN  Expected To Beat Earnings Estimates  What To Know Ahead Of Q2 Release,opinion,"Wall Street expects a year over year decline in earnings on lower revenues when Allergan  NYSE AGN  reports results for the quarter ended June 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This Botox maker is expected to post quarterly earnings of  4 30 per share in its upcoming report  which represents a year over year change of  2 7  
Revenues are expected to be  3 91 billion  down 5 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 65  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Allergan 
For Allergan  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  3 52  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Allergan will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Allergan would post earnings of  3 55 per share when it actually produced earnings of  3 79  delivering a surprise of  6 76  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Allergan appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q2-release-200441348,200441348
104837,326352,AGN,Pharma Stock Roundup  JNJ   NVS  Q2 Earnings  Pipeline Regulatory Updates In Focus,opinion,"This week marked the start of the second quarter earnings season for the pharma space with J J   NYSE JNJ   and Novartis   NYSE NVS   releasing their results  Meanwhile  the FDA granted approval to Merck s   NYSE MRK   new antibiotic  Recarbrio  issued a complete response letter  CRL  to AstraZeneca s   NYSE AZN   Farxiga for type I diabetes and gave priority review to Novartis   sickle cell pain crisis candidate  crizanlizumab Recap of the Week s Most Important StoriesInside J J   Novartis  Q2 Earnings  J J  for both earnings and sales in the second quarter of 2019 and raised full year operational sales growth guidance for the second time this year  Its Pharma segment continued to perform well despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga  The decent sales performance was led by the company s oncology drugs Imbruvica and Darzalex as well as psoriasis treatment  Stelara  Meanwhile  the Consumer segment also showed some improvement in the second quarter Novartis  earnings and sales also beat estimates and the company raised its guidance for the year  Its Pharmaceuticals business unit grew 10  driven by performance of key drugs like Entresto and Lutathera while the Sandoz division rose 1  as strong uptake of biosimilars was offset by price erosion in the United States FDA Approves Merck s New Antibiotic Recarbrio  The FDA granted approval to Merck s new combination antibacterial injection  MK 7655A  which is a fixed combination of relebactam with imipenem cilastatin  The medicine  to be marketed as   is approved for the treatment of adults with complicated urinary tract infections and complicated intra abdominal bacterial infections caused by certain susceptible gram negative bacteria in patients who have limited or no alternative therapeutic optionsAstraZeneca s Farxiga Gets CRL for Type I Diabetes  The FDA issued a CRL to AstraZeneca s supplemental new drug application  sNDA  looking for approval of its type II diabetes drug  for type I diabetes  T1D   The sNDA was based on data from the phase III DEPICT study for Farxiga in T1D  Forxiga  trade name of Farxiga in Europe  was approved for T1D in the EU in March Meanwhile  the FDA granted an orphan drug designation to AstraZeneca s PD L1 inhibitor  Imfinzi  durvalumab   for the treatment of patients with extensive stage small cell lung cancer  the most aggressive type of lung cancer FDA Grants Priority Review to Novartis  Sickle Cell Pain Crisis Candidate  The FDA granted priority review designation to Novartis  biologics license application  BLA  for its pipeline candidate  SEG101   Novartis is looking for approval of crizanlizumab to prevent pain crisis  also called vaso occlusive crises  or VOCs  in patients with sickle cell disease  With the FDA granting a priority review designation to the BLA  a decision is expected in the next six months FDA Accepts Allergan s NDA for Bimatoprost SR  The FDA accepted Allergan s   NYSE AGN   NDA looking for approval of Bimatoprost Sustained Release  Bimatoprost SR  for treatment of open angle glaucoma or ocular hypertension    an investigational implant  has been developed as the first sustained release drop free treatment option for lowering intraocular pressure in patients with open angle glaucoma or ocular hypertension  The FDA is expected to give its decision in the first half of 2020 J J Files for Approval of Subcutaneous Darzalex  J J filed an application with the FDA looking for approval of a of its multiple myeloma drug  Darzalex  The BLA was based on data from the phase III COLUMBA study  Data from the study presented in June showed non inferiority of the subcutaneous formulation  both as a monotherapy and as a combination medicine  compared to the currently approved formulation of intravenous administration Glaxo s Zejula Meets Main Goal in Late Stage Study  Glaxo s   NYSE GSK   phase III  study  evaluating Zejula  niraparib  for patients with ovarian cancer in first line maintenance setting  met the primary endpoint  Data from the study showed that treatment with its PARP inhibitor  Zejula led to a statistically significant improvement in progression free survival in women regardless of their biomarker status  thereby meeting the study s primary endpoint  Zejula was added to Glaxo s portfolio following the acquisition of Tesaro earlier this year AbbVie Buys Mavupharma to Boost Cancer Pipeline  AbbVie   NYSE ABBV   announced the acquisition of Seattle based private drug discovery company  for an undisclosed amount  The acquisition is expected to enhance AbbVie s early stage oncology pipeline  Mavupharma is focused on novel approaches to target the STING pathway for the treatment of cancer that could result in the development of transformative medicines to treat cancer Bristol Myers Bayer Collaborate  Bristol Myers announced an agreement with Bayer  DE BAYGN  and Ono Pharmaceutical to evaluate a combination of Bayer s kinase inhibitor Stivarga  regorafenib  and Bristol Myers s PD L1 inhibitor Opdivo  nivolumab  in patients with micro satellite stable metastatic colorectal cancer  The terms of the collaboration were not discussed The NYSE ARCA Pharmaceutical Index declined 0 6  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Merck recorded the highest rally  2 1   while J J declined the most  5 8  In the past six months  AstraZeneca has been the biggest gainer  11 4   while Bristol Myers declined the most  12 1    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for second quarter earnings of Bristol Myers  AbbVie  Glaxo  AstraZeneca and others and regular pipeline and regulatory updates next week Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-18,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-jnj--nvs-q2-earnings-pipelineregulatory-updates-in-focus-200442006,200442006
104864,326379,AGN,Allergan sees revenues as high as  15 3B this year,news,At JPM18  Allergan  NYSE AGN  provides its outlook for this year Revenues   15 0B   15 3B  EPS    0 84   non GAAP EPS  at least  15 25 Additional guidance will be provided during its Q4 earnings call on Tuesday  February 6 Now read ,2018-01-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-sees-revenues-as-high-as-153b-this-year-1078096,1078096
104865,326380,AGN,U S  pharma executives expect deals to pick up after tax overhaul,news,"By Caroline Humer and Carl O Donnell SAN FRANCISCO  Reuters    The Trump administration s tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017  according to senior executives from some of the largest pharmaceutical manufacturers  The  1 5 trillion bill  which U S  President Donald Trump signed into law in December  lowers the income tax rate for U S  companies to 21 percent from 35 percent  encourages them to repatriate cash  and modifies numerous deductions  Brent Saunders  chief executive officer of Allergan Inc  NYSE AGN   expects tax reform to finally clear the decks for big industry consolidation  Such moves will likely materialize over months as companies study the new bill and devise appropriate strategies   In the first half of the year  he expects to see more oncology deals like the one  Celgene Corp   NASDAQ CELG  announced on Sunday  a smaller acquisition of cancer drug developer Impact Biomedicines   Bigger  transformative deals   like the ones where large cap pharmaceutical companies consolidate with rivals and biotechnology players   will likely take longer  bankers said    I think the industry ultimately consolidates   Saunders said in an interview at the J P  Morgan Healthcare Conference in San Francisco   I have a sense  though  in terms of a bigger wave of  mergers   it will either happen in the back half of 2018 or in 2019   The U S  pharmaceutical industry has been consolidating for years even without tax reform  Large companies like Merck  NYSE MRK    Co Inc  Bristol Myers Squibb Co and Johnson   Johnson  NYSE JNJ  regularly buy or do licensing deals with small companies to help maintain a continuous pipeline of new medicines   But large scale deals   like Merck s  41 1 billion acquisition of Schering Plough in 2009  or  Pfizer   NYSE PFE  Inc s  68 billion purchase of Wyeth   have dried up   In early 2016  the Obama administration introduced rules that would punish companies for so called inversion deals  in which a U S  based acquirer bought a smaller firm overseas and moved the combined corporate headquarters abroad to benefit from lower tax rates  The move scuttled Pfizer Inc s proposed  160 billion purchase of Dublin based Allergan  Saunders said Allergan would only begin to look at smaller deals in the second half of the year as the company  known for its Botox anti wrinkle treatment  as it is currently focused on cost cutting  BRINGING BACK THE CASH Saunders  comments echo those of healthcare industry bankers  who say that uncertainty around the tax bill  drug pricing and Republican efforts to repeal Obamacare had cooled merger activity in 2017   Now that the tax law is in place  these bankers say  it should provide a catalyst to drugmaker deals by allowing them to repatriate billions of dollars in foreign profits held abroad  and by making it easier to agree on a value for their acquisition targets since they have a better idea of the company s tax rate   Several drugmakers have already announced plans to bring overseas cash into the United States  including  Amgen Inc   NASDAQ AMGN  and Bristol Myers  incurring some short term charges  Horizon Pharma CEO Tim Walbert said that when larger companies benefit from that repatriation of cash  they are likely to lift the whole market   To the extent that you see acceleration of large cap deals     that will bring more confidence in the sector and allow for more strategic opportunities for everyone   Walbert said  Horizon does not have substantial money parked overseas  and expects to continue its current strategy of small  and medium sized acquisitions for drugs treating rare diseases  its primary focus      DEALS TRENDED LOWER Drug industry deals have been trending lower for the past two years  Thomson Reuters data shows that in 2017  there were  52 billion worth of pharma and biotech deals  less than 25 percent of 2015 s  212 billion in deals and down from 2016 s  54 billion   Johnson   Johnson Chief Financial Officer Dominic Caruso said during a conference session that one reason deals were not getting done was that companies needed to borrow money in the United States  and because it was difficult to structure a deal with low enough taxes  And Eli Lilly   Co CEO Dave Ricks said that among the uses for cash it repatriates   it has  10 billion overseas   would be more business development including the small  early stage mergers and acquisitions that are typical of the Indianapolis based drugmaker  Merck said that tax reform could spur large deals among companies that are focused on general cost savings  However  that is not Merck s deal focus  CFO Robert Davis said the company will continue to seek smaller acquisitions to enhance its portfolio of medicines   That being said  getting access now to foreign cash  in a way where you don t have to worry about the location of the cash will improve our flexibility    he said  
 We re not planning a large one time repatriation  We will repatriate in a normal course as we see what the needs are for the business  ",2018-01-09,Reuters,https://www.investing.com/news/stock-market-news/us-pharma-executives-expect-deals-to-pick-up-after-tax-overhaul-1082804,1082804
104866,326381,AGN,Allergan reduces stake in Teva by 1 55M shares,news,Allergan  AGN  0 9   sold 1 55M shares of Teva Pharmaceutical Industries  TEVA  3 2   at an average price of  20 03 per share on January 10  reducing its stake to 6 8    68 7M shares  Allergan previously announced that it intended to decrease its position over time  It acquired an original 10  stake in Teva as part of the  Actavis  transaction in 2015 Now read ,2018-01-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-reduces-stake-in-teva-by-155m-shares-1097496,1097496
104867,326382,AGN,FDA launches new program to boost transparency of clinical data used to support approvals,news,Aimed at improving the transparency of its drug approvals  the FDA launches a pilot program under which it will post certain information contained in clinical study reports  CSRs  on its website  The agency hopes the additional data will make it easier for stakeholders to access and understand the information that it used in approving a new drug CSRs are company generated summaries of clinical trial results The pilot will launch this month and will include up to nine new drug applications across a range of diseases submitted by participating companies  sponsors   Once completed  the FDA will seek public feedback through a notice in the Federal Register and docket for public comments Selected tickers  PJP IHE XPH PPH IBB XBI BIB ABBV JNJ AGN AZN BMY LLY GSK MRK PFE NVS OTCQX RHHBY NVO SHPG VRX GILD CELG BIIB AMGNNow read ,2018-01-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-launches-new-program-to-boost-transparency-of-clinical-data-used-to-support-approvals-1110074,1110074
104868,326383,AGN,Exclusive  Ackman cuts staff  shuns limelight as he seeks to turn around fund,news,"By Svea Herbst Bayliss BOSTON  Reuters    William Ackman is cutting almost a fifth of staff and looking to lower his public profile as he seeks to turn around Pershing Square  NYSE SQ  Capital Management after three straight years of losses  people familiar with the move told Reuters on Monday  The billionaire hedge fund manager  who recently suffered big losses on Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  and  Herbalife  Ltd  N HLF  and lost a proxy fight with Automatic Data Processing Inc  O ADP   will spend more time investing and stop being the firm s No  1 marketer  the people said  The first step in turning around Pershing Square is laying off 10 people  shrinking the firm to 46 employees from 56  to oversee the roughly  9 billion in assets the firm manages for clients  the people said   That is about half the assets he had at Pershing Square s peak in 2015  Most of the reduction will involve back office employees  although one investment team member is also leaving  Ackman also plans to go silent  at least for awhile  the people said  a major change in style for one of Wall Street s most voluble investors  The 51 year old hedge fund manager  who made his name with winning bets on Allergan Plc  N AGN    Canadian Pacific Railway  Ltd  TO CP  and others  became one of the world s most visible activist investors through lengthy public appearances  He hosted hours long conferences in Manhattan to answer every question about his short bet against Herbalife and his plan for drugmaker Valeant to buy rival Allergan  Ackman plans to curtail all of his own marketing and public relations meetings associated with running a big hedge fund  said the people familiar with the matter  who were not authorized to discuss the changes publicly  Instead  Ben Hakim  a partner who joined Pershing Square in 2012  will do the traveling and bulk of talking to clients  Ackman will stay in the office  concentrating on financial analysis  Pershing Square spokesman Francis McGill declined to comment  DINNER DATE  Ackman plans to announce the personnel changes and new direction on Thursday at the firm s annual client dinner at the New York Public Library  That dinner  and another similar event in London  will become the once a year chance for pension funds  endowments and wealthy investors to see and hear Ackman discuss performance and lay out his strategy  the people said  This time  Ackman will detail how his private funds lost between 1 6 percent and 3 2 percent in 2017  For months  Ackman has been promising a comeback  In the first few weeks of this year  Pershing Square s funds are up about 2 percent while the stock market has been setting new records  with the S P 500 Index gaining more than 5 percent year to date  As Ackman s fame and investing prowess grew over the years with successful bets on Canadian Pacific  General Growth Properties and Air Products and Chemicals Inc  N APD   Pershing Square s assets also grew  But investors traditionally pull 10 percent to 15 percent of capital from a hedge fund every year  making it more difficult for larger firms to keep replacing assets  New clients often demand an audience with the boss  but Ackman has told people he is putting an end to that practice  He still plans to communicate with investors through letters and quarterly calls  and occasionally make public statements about investments  Hakim and Pershing s investor relations team will be available to handle day to day queries that Ackman previously spent a significant amount of time on  In making the changes  Ackman wants the firm to operate more as it did in 2012  when he won a big proxy contest at Canadian Pacific  people familiar with the matter said  Pershing Square then employed 46 people and managed  11 billion  The firm s staff peaked at 70 people in 2016  One member of the investment team is among the job cuts  people familiar with the matter said   David Klafter  a senior lawyer at the firm  will join the investment team to handle legal matters associated with the firm s bets  which usually total only about a dozen  Pershing Square s investment team has historically had between eight and 10 members and will stay at its current size of 10 people  the people said   
Ackman also laid off his driver  saying he can walk or take the subway to his Midtown Manhattan office  the people familiar with the matter said  The staff were told the news of the layoffs late last week ",2018-01-22,Reuters,https://www.investing.com/news/stock-market-news/exclusive-ackman-cuts-staff-shuns-limelight-as-he-seeks-to-turn-around-fund-1136385,1136385
104869,326384,AGN,FDA OKs two new Perrigo generics,news,The FDA approves Perrigo s  NASDAQ PRGO  generic version of Allergan s  NYSE AGN  ESTRACE Cream  estradiol vaginal cream  for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause  According to IQVIA  the U S  market is   457M The FDA also approves its generic version Galderma Labs  Epiduo  adapalene and benzoyl peroxide  Gel for the topical treatment of acne vulgaris  According to IQVIA  the U S  market is   164M Shares are up a fraction premarket on light volume Now read ,2018-01-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-two-new-perrigo-generics-1144502,1144502
104870,326385,AGN,Profit taking weighs on biotechs and biopharmas,news,Investors appear to be bagging profits after the healthy runup since mid December  The Nasdaq composite is down 1  while the SPDR S P Biotech  MX XBI  ETF  XBI  2 2   is down even more Selected tickers   IBB  1 2   BIB  2 6   BBH  0 5   ARKG  1 5   BBC  2   PJP  1   IHE  0 9   XPH  1 1   PPH  0 4   BIIB  0 7   AMGN  0 4   CELG  1 4    GILD  0 1    VRTX  0 6   SHPG  1 8   REGN  0 2   SGEN  2 4   JNJ  0 1   ABBV  AGN  0 9   AZN  0 7   BMY  0 1   LLY  0 1   GSK  0 4   MRK  1 1   PFE  0 1   VRX  11 1  Now read ,2018-01-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/profittaking-weighs-on-biotechs-and-biopharmas-1146511,1146511
104871,326386,AGN,Big biopharma in the green after AbbVie s Q4 beat,news,AbbVie  ABBV  10 6   is leading its large cap brethren after posting steller Q4 results and bullish 2018 guidance Related tickers   JNJ  0 2   OTCQX RHHBY  0 2   AGN  0 6   AZN  1 3   BMY  1   LLY  1 1   GSK  1 4   MRK  0 7   PFE  4 4   NVS  0 4   NVO  0 8   SHPG  2 3   VRX  1 8  Previously  AbbVie Q4 revenues up 14   non GAAP EPS up 23   updates guidance  Jan  26 Now read ,2018-01-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/big-biopharma-in-the-green-after-abbvies-q4-beat-1157814,1157814
104872,326387,AGN,Pharma Stock Roundup  ABBV To Buy AGN  BMY To Sell CELG s Otezla To Close Merger,opinion,"This week AbbVie   NYSE ABBV   announced a definitive deal to buy Allergan plc   NYSE AGN   in the hope of finding a replacement for Humira  which is nearing patent expiration  Bristol Myers   NYSE BMY   said it will sell Celgene s blockbuster psoriasis drug  Otezla  to complete the impending merger  In other news  Pfizer s   NYSE PFE   orally available PARP inhibitor  Talzenna gained approval in EU  Meanwhile  the FDA granted approval to Allergan s blockbuster product Botox for another therapeutic indication and J J s   NYSE JNJ   blockbuster multiple myeloma drug  Darzalex in newly diagnosed patients who are transplant ineligible Recap of the Week s Most Important StoriesAbbVie to Buy Allergan for  63B  In a surprising move  AbbVie announced a  to buy Botox maker Allergan in a cash and stock deal for  63 billion  AbbVie will pay Allergan a price of  120 30 in cash and 0 8660 ABBV shares  worth  67 94  per AGN share  bringing the total valuation to  188 24  a 45  premium from Allergan s closing price on Monday  AbbVie s rationale behind the deal is to add a new blockbuster product to its portfolio  Allergan s Botox  as its own blockbuster drug  Humira faces patent expiration  Humira generics are already denting revenues in Europe are expected to be launched in the United States in 2023  AbbVie is heavily dependent on Humira and is looking to diversify its portfolio  Approved for therapeutic and aesthetic use  Botox is a key top line driver for Allergan and looks fit to be the next revenue driver for AbbVie after Humira loses exclusivity  The acquisition is expected to close by early 2020 With imminent generic competition for Allergan s Restasis  fears of new competition to Botox and some recent pipeline setbacks  the merger with AbbVie could prove to be the best way out Investors have their doubts as far as necessary approvals are concerned although the lack of overlapping products abates anticompetitive concerns  Some investors expressed concerns that AbbVie has overpaid for Botox as new competitive pressure looms large Bristol Myers to Divest Celgene s Otezla to Gain FTC Approval for Merger  Bristol Myers said that it will to gain approval from U S  Federal Trade Commission  FTC  for its pending merger with Celgene  NASDAQ CELG  on a timely basis  Bristol Myers had announced the buyout of Celgene in January  in a cash and stock deal  for a whopping sum of  74 billion  The divestiture is subject to further review by the FTC and requires Bristol Myers to enter a consent decree with the commission  The deal is now expected to be closed by the end of 2019 or the beginning of 2020  delayed from the earlier timeline of the third quarter of 2019 The deal faced strong criticism from Bristol Myers  activist investors who found it to be overpriced and also questioned the company s growth prospects following the merger  However  eventually  the shareholders gave green signal to the merger in April Separately  Bristol Myers  phase III study  CheckMate  459  evaluating Opdivo  nivolumab  as a first line treatment for patients with unresectable hepatocellular carcinoma did not achieve statistical significance for its primary endpoint of overall survival  OS  Pfizer s Talzenna Gets Approval in EU  The European Commission granted approval to for the treatment of patients with inherited  germline  BRCA mutated locally advanced or metastatic breast cancer  It was approved in the United States in October last year FDA Nod to Allergan s and J J s sBLA  Allergan s  AGN  Botox gets FDA approval for the 10th therapeutic indication  in the age group of 2 to 17 years  Botox is approved for the indication in adults  Another sBLA looking for approval of Botox for pediatric lower limb spasticity indication is also under FDA s review with a decision expected in the fourth quarter The FDA also approved J J s sBLA seeking approval for Darzalex in combination with Revlimid  lenalidomide  and dexamethasone in newly diagnosed  transplant ineligible multiple myeloma patient population  The filing was based on data from a phase III MAIA study  This marked Darzalex s sixth FDA approved indication in multiple myeloma and the second for newly diagnosed patientsFDA Lifts Partial Hold on AbbVie s Venclexta Multiple Myeloma Study  The FDA lifted partial clinical hold placed on   The study evaluated AbbVie s leukemia drug  Venclexta  venetoclax  for relapsed refractory multiple myeloma positive for the translocation abnormality  the most common genetic abnormalities in patients with multiple myeloma  The hold was lifted and the study was allowed to resume upon agreement on revisions of the study protocol The clinical hold on CANOVA and on al lmultiple myeloma studies on Venclexta was placed in March this year  The decision was taken after  in the ongoing phase III BELLINI study  a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the study  All multiple myeloma studies on Venclexta  other than CANOVA  remain on partial clinical hold FDA s Priority Review for Glaxo s Zejula sNDA  Glaxo s   NYSE GSK   supplemental new drug application  sNDA  looking for label expansion of its once daily PARP inhibitor  Zejula was granted priority review by the FDA  The sNDA is looking for approval of Zejula for ovarian cancer patients who have been treated with three or more previous chemotherapy regimens  The FDA is expected to announce its decision on Oct 24  2019 Meanwhile  the FDA also accepted for review Sanofi s BLA for  a meningococcal vaccine candidate  currently being developed for the prevention of meningococcal meningitis  The FDA s decision on this product is expected on Apr 25  2020 Lilly s Trulicity Higher Dose Study Succeeds  Lilly s   NYSE LLY   phase III study evaluating higher doses of its GLP 1 receptor agonist  Trulicity met the primary and secondary efficacy endpoints  Data from AWARD 11 phase III study showed that the  3 0 mg and 4 5 mg  led to superior reduction in A1C  a measure of blood glucose  compared to Trulicity doses already available AstraZeneca s Imfinzi Improves OS in SCLC Study  AstraZeneca announced that a phase III study CASPIAN study on Imfinzi in first line extensive stage small cell lung cancer  SCLC    the most aggressive type of lung cancer   met the primary endpoint  Data from an interim analysis conducted by an Independent Data Monitoring Committee showed that treatment with Imfinzi plus platinum based chemotherapy led to a statistically significant and clinically meaningful improvement in OS versus chemotherapy aloneThe NYSE ARCA Pharmaceutical Index declined 1 3  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
Here is how the seven major stocks performed in the last five trading sessions Last week  all the stocks declined with Bristol Myers recording the highest decline  7 7   and Pfizer decreasing the least  0 4  In the past six months  Merck has been the biggest gainer  9 7   while Bristol Myers  BMY  has declined the most  13 3    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-27,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-abbv-to-buy-agn-bmy-to-sell-celgs-otezla-to-close-merger-200435639,200435639
104873,326388,AGN,Enrollment halfway there in Bellerophon s late stage study of INOpulse in pulmonary arterial hypertension  interim data expected mid year,news,Bellerophon Therapeutics  BLPH  0 8   reports that enrollment in its Phase 3 INOvation 1 study evaluating INOpulse in patients with pulmonary arterial hypertension is now over 100  more than halfway to the target Interim data should be available mid year with topline results from the full study to follow by year end INOpulse is a drug device combination system that delivers pulsed doses of nitric oxide  It is portable  suitable for at home use and automatically adjusts to the patient s breathing patterns to deliver consistent dosing Previously  Bellerophon s INOpulse shows treatment benefit in mid stage study  shares ahead 15  premarket  Sept  5  2017 Now read ,2018-01-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/enrollment-halfway-there-in-bellerophons-latestage-study-of-inopulse-in-pulmonary-arterial-hypertension-interim-data-expected-midyear-1165778,1165778
104874,326389,AGN,Email API Platforms Gather Steam  VG  TWLO And AMZN In View,opinion,"The cloud communications market is rapidly evolving and becoming increasingly competitive with players striving hard to gain an edge Per   worldwide voice and text messaging communications platform as a service  CPaaS  market is likely to reach a value of  10 9 billion by 2022 from  2 billion in 2017 As a result  cloud communication providers like Vonage   NYSE VG   and Twilio   NYSE TWLO   among others are undertaking key partnerships and also resorting to acquisitions to bring a bouquet of various marketing channels to attract customers Notably  despite the growing popularity of video  voice and chat communications  demand for transactional email services is also shooting up  Significantly  email still remains an imperative conduit for businesses to communicate with customers as it aids in more prudently addressing the respective client s engagement strategy Given these  demand for email application program interfaces  API  providers like SendinBlue  SendGrid  Amazon s   NASDAQ AMZN   Simple Email Service  SES  and Mailgun is shoring up Vonage Partners SendinblueRecently  Vonage in its bid to bolster the number of communication channels it offers  partnered Sendinblue to add email capabilities to its API platform  Nexmo Reportedly  the collaboration with Sendinblue email platform will enable Nexmo to provide businesses with the force to apply programmable capabilities to springboard the email marketing campaigns  Further  it will allow direct exchanges with customers for emergency data or time sensitive offers  Moreover  Nexmo will deliver as the sole SMS provider for Sendinblue In the last reported quarter  Vonage s API platform delivered adjusted revenue growth of 42   driven by higher value APIs like voice and video  The import of Sendinblue s expertise to its portfolio is likely to lend a further stimulus Twilio s Acquisition of Sendgrid   A Key CatalystIn February 2019  Twilio completed the buyout of SendGrid  the leading email API platform  With this transaction  Twilio s onmichannel communications capabilities are likely to be strengthened by enhancing its Programmable Communications Cloud software  which allows developers to embed voice  messaging  video and authentication skills Through the integration of SendGrid s services  Twilio expects to add more than half a trillion customer interactions annually to its communications platform Notably  Twilio ended the last reported quarter boasting 154 797 active customer accounts with SendGrid contributing more than 84 000 to the count  Moreover  SendGrid boosted gross margins by 300 basis points sequentially Thomas Bravo Purchases MailgunIn April  private equity firm Thoma Bravo purchased a majority stake in Mailgun Technologies  which provides API services for developing email functionality to more than 150 000 customers 
Amazon SES   Smart WarhorseIn 2011  Amazon launched a cloud based email sending service   Amazon SES   designed to help digital marketers and application developers send marketing  notification and transactional emails Amazon SES is a cost effective service for businesses of all scales that use email to connect with customers  The company boasts clientele like Vodafone  LON VOD   SIEMENS  HBO and Allergan   NYSE AGN   among others  per its website Amazon s financial forte coupled with its technical knowhow helps it respond more promptly and adeptly to variable opportunities  technologies  standards or customer needs  which is an alarm bell for players like Vonage and Twilio Year to Date Price PerformanceTwilio  Amazon and Vonage carry a Zacks Rank  3  Hold   You can see The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/email-api-platforms-gather-steam-vg-twlo-and-amzn-in-view-200436046,200436046
104875,326390,AGN,Can Allergan  AGN  Keep The Earnings Surprise Streak Alive ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Allergan  NYSE AGN   which belongs to the Zacks Medical   Generic Drugs industry  could be a great candidate to consider 
This Botox maker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 5 07  
For the most recent quarter  Allergan was expected to post earnings of  3 55 per share  but it reported  3 79 per share instead  representing a surprise of 6 76   For the previous quarter  the consensus estimate was  4 15 per share  while it actually produced  4 29 per share  a surprise of 3 37  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Allergan lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Allergan currently has an Earnings ESP of  2   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner 
With the Earnings ESP metric  it s important to note that a negative value reduces its predictive power  however  a negative Earnings ESP does not indicate an earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-02,Zacks Investment Research,https://www.investing.com/analysis/can-allergan-agn-keep-the-earnings-surprise-streak-alive-200436836,200436836
104876,326391,AGN,Allergan  AGN  Gains But Lags Market  What You Should Know,opinion,"Allergan  NYSE AGN  closed the most recent trading day at  169 61  moving  0 04  from the previous trading session  This change lagged the S P 500 s 0 77  gain on the day  At the same time  the Dow added 0 67   and the tech heavy Nasdaq gained 0 75  
Heading into today  shares of the Botox maker had gained 31 83  over the past month  outpacing the Medical sector s gain of 7 75  and the S P 500 s gain of 8 19  in that time 
Wall Street will be looking for positivity from AGN as it approaches its next earnings report date  The company is expected to report EPS of  4 27  down 3 39  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  3 90 billion  down 5 39  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  16 68 per share and revenue of  15 21 billion  These totals would mark changes of  0 06  and  3 63   respectively  from last year 
It is also important to note the recent changes to analyst estimates for AGN  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0  higher  AGN is currently sporting a Zacks Rank of  3  Hold  
Investors should also note AGN s current valuation metrics  including its Forward P E ratio of 10 17  This represents a premium compared to its industry s average Forward P E of 6 61 
Investors should also note that AGN has a PEG ratio of 1 57 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Medical   Generic Drugs was holding an average PEG ratio of 1 at yesterday s closing price 
The Medical   Generic Drugs industry is part of the Medical sector  This group has a Zacks Industry Rank of 103  putting it in the top 41  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow AGN in the coming trading sessions  be sure to utilize Zacks com ",2019-07-03,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-gains-but-lags-market-what-you-should-know-200436927,200436927
104877,326392,AGN,Editas  EDIT  Focuses On Developing Eye Candidate EDIT 101,opinion,On Jul 3  we initiated a research report on Editas Medicine  Inc    NASDAQ EDIT   The company s lead pipeline candidate  EDIT 101  which uses CRISPR gene editing  is being developed for treating Leber congenital amaurosis type 10  LCA10   a rare genetic illness that causes blindness Editas is developing EDIT 101 in partnership with Allergan   NYSE AGN    The company has a strategic alliance and option agreement with Allergan under which  the latter reserves rights to in license up to five of Editas  genome editing ocular programs  Last July  Allergan exercised its option to develop and commercialize EDIT 101 globally while Editas exercised its right to a profit sharing understanding with Allergan under which  the company will co develop and equally divide the profits and losses from EDIT 101 in the United States Both companies plan to begin patient dosing in the phase I II dose escalation study on EDIT 101 during the second half of 2019 The company is also pursuing the development of CRISPR candidates for eye diseases other than LCA10  which include Usher Syndrome type 2A  USH2A  and the recurrent ocular Herpes Simplex Virus type 1  HSV 1  Last month  Editas commenced investigational new drug  IND  enabling activities for EDIT 301  an experimental CRISPR medicine  designed to treat sickle cell disease and beta thalassemia by editing the beta globin locus By the end of 2022  Editas targets to have three medicines in early stage clinical development and at least two in or ready for late stage studies Shares of Editas have gained 8  so far this year  underperforming the  rise of 8 3  We would like to remind investors that genomic editing using CRISPR technology to repair a defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations seen in decades  There are only a handful of companies making medicines using this revolutionary technology and Editas is one  The company has two CRISPR platforms  one using the Cas9 protein and the other  the Cpf1 protein Presently  Editas has no approved product in its portfolio  The company has a couple of high profile collaborations with big pharma entities for its CRISPR technology  which provide research support and sufficient funds to fulfill its pipeline development plans  Apart from Allergan  it has a collaboration and licensing pact with Juno Therapeutics   now part of Celgene   NASDAQ CELG     to use the latter s gene editing approaches including CRISPR Cas9 for developing the engineered T cell medicines to tackle cancer In April this year  Editas inked a research and cross licensing deal with BlueRock Therapeutics  LP  to combine the respective genome editing and cell therapy technologies to discover  develop and manufacture novel engineered cell medicines Due to dearth of a marketed product  Editas is heavily dependent on its partners for collaboration revenues  Apart from EDIT 101  all of Editas  pipeline candidates are still in the preclinical or research stage of development and will take several years prior to commercialization  Moreover  stiff competition persists as a major concern as other companies  such as CRISPR Therapeutics and Intellia Therapeutics   NASDAQ NTLA   are either planning to conduct or have already started clinical probes to develop curative CRISPR Cas9 based medicines  As a result  any regulatory setback in the company s pipeline development might dent the stock Editas Medicine  Inc  Price and Consensus   Zacks RankEditas currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-05,Zacks Investment Research,https://www.investing.com/analysis/editas-edit-focuses-on-developing-eye-candidate-edit101-200437249,200437249
104878,326393,AGN,AbbVie  ABBV  Shares Down So Far This Year  Here s Why,opinion,AbbVie  Inc    NYSE ABBV   stock has declined 20 8  this year so far against an increase of 2 9  recorded by the  A couple of pipeline setbacks as well as erosion of sales of its blockbuster drug Humira in EU due to biosimilar launches hurt the stock this year despite several regulatory approvals and pipeline successes  Importantly  its proposed acquisition of Botox maker Allergan   NYSE AGN   last month did not go down well with investors as AbbVie s stock declined thereafter AbbVie s rationale behind the deal was to add a new blockbuster product to its portfolio  Allergan s Botox  as its own blockbuster drug  Humira faces patent expiration  Humira generics are already denting revenues in Europe  Moreover  biosimilars are expected to be launched in the United States in 2023  AbbVie is heavily dependent on Humira and is looking to diversify its portfolio  Approved for therapeutic and aesthetic use  Botox is a key top line driver for Allergan and AbbVie feels it could be the next revenue driver for AbbVie after Humira loses exclusivity  The acquisition is expected to close by early 2020  if all necessary approvals are obtained However  investors have their doubts as far as necessary approvals are concerned although the lack of overlapping products abates anticompetitive concerns  Some investors expressed concerns that AbbVie has overpaid for Botox as new competitive pressure loomslarge In February 2019  Evolus  Inc  s   NASDAQ EOLS   Jeuveau injection  indicated to improve the appearance of glabellar or frown lines  was approved by the FDA  which can pose competition to Botox  Revance Therapeutics  Inc    NASDAQ RVNC   is also developing RT002  a rival treatment to Botox for the frown lines indication  which has demonstrated longer duration of efficacy compared to Botox in late stage studies Meanwhile  AbbVie faced a couple of major pipeline setbacks this year late last year  which hurt stock price In early December  AbbVie   evaluating its cancer candidate rovalpituzumab tesirine or Rova T in second line small cell lung cancer  SCLC   In March 2018  Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC  Rova T was added to AbbVie s portfolio following the  5 8 billion acquisition of Stemcentrx in June 2016  The failure of TRINITY and the clinical hold on TAHOE raised skepticism about Rova T s potential and has brought into question the viability of the Stemcentrx deal  In March 2019  the FDA placed a partial clinical hold on all studies evaluating Venclexta for the treatment of multiple myeloma  The decision was taken after  in the ongoing phase III BELLINI study  a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the study  Though  in June  the partial clinical hold placed on CANOVA phase III study was lifted  all other multiple myeloma studies on Venclexta remain on partial clinical hold  In May  a phase III study evaluating AbbVie s pipeline candidate  depatuxizumab mafodotin  Depatux M  failed to show any survival benefit in patients with newly diagnosed glioblastoma  an aggressive form of brain cancer  Enrollment has been stopped in all ongoing Depatux M studies Though Humira has been performing well based on strong demand trends  direct biosimilar competition in Europe is eroding international revenues from the drug significantly  Several companies have made biosimilar versions of Humira  In the United States  per settlements with seven manufacturers  Humira biosimilars are expected to be launched in 2023  With Humira accounting for around 61  of AbbVie s sales  the entry of biosimilars would have a huge impact on the company s financials Nonetheless  AbbVie has been successful in expanding approvals for its cancer drugs  Imbruvica and Venclexta  AbbVie has an impressive late stage pipeline comprising several products with multibillion dollar potential expected to be launched in the near term  Key recent FDA approvals include that of Orilissa  elagolix  for management of pain associated with endometriosis  a common gynecologic disorder  in July 2018 and Skyrizi  risankizumab  for plaque psoriasis in April 2019  AbbVie estimates that both the drugs have multi billion dollar sales potential Another important pipeline candidate is upadacitinib  which is under review in the United States  PDUFA date  third quarter of 2019  and EU for rheumatoid arthritis and in late stage studies for Crohn s disease  psoriatic arthritis  ulcerative colitis  atopic dermatitis and giant cell arteritis  Risankizumab and upadacitinib have demonstrated differentiated clinical profiles versus Humira and are on track for launch in 2019 AbbVie currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-07-07,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-shares-down-so-far-this-year-heres-why-200437660,200437660
104906,326421,AGN,Succession doubts cloud Apotex future after billionaire owner s death,news,"By Matt Scuffham TORONTO  Reuters    Canadian pharmaceuticals billionaire Barry Sherman failed to implement a succession plan at his Apotex business before his death last week  two business associates told Reuters  potentially leaving it vulnerable to takeover approaches   The bodies of Sherman  75  and his wife Honey  70  were found in their Toronto mansion last week and their deaths are under investigation by Toronto s homicide squad  A memorial service was held on Thursday   Sherman had always resisted approaches from trade buyers and never wanted to take the generic drugmaker public  the associates said  preferring to keep control and not involve outside shareholders   Despite stepping down as chief executive in 2012  the self confessed workaholic continued to work seven day weeks and twelve hour days  None of Sherman s four children were interested in running the business and only one had worked at the company  the associates said   Sherman s son Jonathan  who has a degree in industrial engineering from Columbia University  took at job at the firm after graduating but quit after less than a year   Sherman founded Apotex in 1974 and grew it through a strategy of launching hundreds of lawsuits against competitors to overturn patent protection for their drugs  Apotex would then manufacture cheaper identical products that did not carry a brand name   The company now employs more than 10 000 worldwide with annual sales exceeding C 2 billion   1 6 billion    The associates said no formal sales process is underway  Any approach would come as the world s biggest generic drug companies are grappling with declining drug prices and intensifying competition   Any potential buyer would also require an appetite for litigation  the associates said  since Apotex is regularly involved in legal actions over patents   And Teva Pharmaceuticals Industries  TA TEVA   N TEVA   the world s biggest maker of generic drugs  is currently in a legal dispute with Apotex over allegations a former Teva executive shared trade secrets with Apotex CEO Jeremy Desai   Teva is also weighed by  35 billion in debt it took on to acquire Allergan s  N AGN   Actavis  generic drug business for  40 5 billion last year  Last week it said it would axe 14 000 jobs  
A Teva spokeswoman in Israel had no immediate comment when asked about any takeover plans or the status of its legal case against Apotex ",2017-12-21,Reuters,https://www.investing.com/news/stock-market-news/succession-doubts-cloud-apotex-future-after-billionaire-owners-death-1021444,1021444
104907,326422,AGN,Pershing Square  Valeant arrive at settlement split for Allergan lawsuit,news," Reuters    Activist investor William Ackman s Pershing Square  AS PHS  and Valeant Pharmaceuticals  TO VRX  on Friday decided to pay  290 million to settle a lawsuit that accused them of insider trading before bidding for Allergan Plc  N AGN  in 2014  Pershing Square said it decided to raise its share of the settlement to 66 8 percent  or  193 75 million  in a bid to quickly wind up the litigation  which it claimed had  no merit     We decided  however  that it was in the best interest of our investors to settle the case now instead of continuing to spend substantial time and resources pursuing the litigation   said Pershing Square CEO Bill Ackman   The hedge fund said Valeant will now pay around 33 percent  or  96 25 million  of the settlement costs  Valeant had previously agreed to pay 60 percent of the costs   We believe this agreement to resolve the legacy litigation is in the best interests of the Company  because it enables us to focus our attention and resources on the transformation of Valeant   said Valeant s Chief Executive Joseph Papa  Papa  who took over the reins of Valeant in April 2016  has been trying to reshape the company and regain investor confidence  after a flurry of investigations into the Canadian drugmaker s accounting and pricing practices hit its shares  The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited  51 billion bid for Allergan    Actavis  Plc eventually bought Allergan in 2015  taking its name  
Both Pershing Square and Valeant did not immediately respond to emails seeking comments ",2017-12-29,Reuters,https://www.investing.com/news/stock-market-news/pershing-square-valeant-arrive-at-settlement-split-for-allergan-lawsuit-1042652,1042652
104908,326423,AGN,U S  drug approvals highest in 21 years,news,Reuters reports that the FDA greenlighted 46 new medicines in 2017  the highest tally in 21 years and more than double the total in 2016 2017 s total was actually 49 if cell therapies from Novartis  KYMRIAH  and Gilead Sciences  YESCARTA  and Spark Therapeutics  gene therapy LUXTURNA are included  all were approved under a different category  The primary reason for the high number of approvals was the FDA s accelerated review process for selected drugs  The number getting the greenlight this year may moderate a bit since several approvals expected this quarter were granted in Q4 2017 Many eyes are on Europe since the European Medicines Agency  EMA  will be moving to Amsterdam from London this year which may disrupt delay approvals there  In 2017  the EMA backed 92 new drugs  including generics  up 12  from 2016 s total of 81 MRK PFE BMY GILD NVS ONCE LLY AZN OTCQX RHHBY GSK TEVA VRX SHPG ABBV AGN JNJ CELG AGN BIIB XBI IBB PJP IHE XPH PPHNow read ,2018-01-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/us-drug-approvals-highest-in-21-years-1053574,1053574
104909,326424,AGN,Drugmakers raise 2018 U S  prices  stick to self imposed limits,news,"By Michael Erman NEW YORK  Reuters    Drugmakers opened the new year by raising U S  prices on dozens of medicines  but early data showed the increases generally remained within a 10 percent self imposed limit in response to a backlash from consumers and politicians  Soaring U S  prices for both branded and generic drugs have sparked public outrage and government investigations over the past few years    Drug price increases are somewhat more constrained in 2017 and 2018 than they have been previously   Cowen and Co analyst Eric Schmidt said  Allergan Inc  N AGN  raised prices on 18 different drugs  including dry eye treatment Restasis and irritable bowel syndrome drug Linzess  by 9 5 percent  according to a research note released by Jefferies on Tuesday   Jefferies cited data collected by Medi Span Price Rx and refers to list price increases  before potentially significant discounts and rebates that drugmakers provide to win preferred coverage by insurers  Medi Span did not respond to requests to confirm the data  Allergan s chief executive  Brent Saunders  in late 2016 pledged to keep price increases below 10 percent as part of what he called the company s  Social Contract with Patients   Allergan spokesman Mark Marmur said the increases will be the only ones taken on those brands in 2018  adding that discounts to various payers should bring the actual increases to consumers down to the low single digits  Other drugmakers raising prices include  Amgen Inc   O AMGN   Teva Pharmaceutical Industries Inc  TA TEVA   N TEVA  and  Horizon Pharma   O HZNP   according to Jefferies and Cowen  Amgen raised the price on its blockbuster rheumatoid arthritis and psoriasis drug Enbrel by 9 7 percent and Teva increased prices on its ProAir HFA and ProAir RespiClick asthma inhalers by 6 and 3 percent  respectively  Drug price increases are coming under more scrutiny from states  California Governor Jerry Brown in October signed legislation requiring drug manufacturers to give 60 day notice if prices are raised more than 16 percent over a two year period  
Shares of Allergan rose 4 1 percent on Tuesday  while Teva and Horizon Pharma shares were up 0 8 percent and 2 9 percent  respectively ",2018-01-02,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-raise-2018-us-prices-stick-to-selfimposed-limits-1054623,1054623
104910,326425,AGN,Pershing Square  Valeant to appear in court on insider trading suit settlement,news," Reuters    A U S  court on Tuesday asked Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  and activist investor Bill Ackman s Pershing Square  AS PSH  to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit  The hearing  set for Jan  16  comes after Pershing Square and Valeant last week decided to pay  290 million to settle the lawsuit that accused them of insider trading before bidding for Allergan Plc  N AGN  in 2014  The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited  51 billion bid for Allergan   The court has  substantial questions regarding whether the settlement amount is reasonable and fair   according to documents filed in the U S  District Court  Central District of California   Today s order is a mandated step in the settlement process   a Valeant spokeswoman said in an email to Reuters   We believe the settlement is fair  reasonable and adequate  and we look forward to explaining our position to the Court   
Pershing Square could not be reached for comment outside regular business hours ",2018-01-03,Reuters,https://www.investing.com/news/stock-market-news/pershing-square-valeant-asked-to-appear-for-hearing-on-insider-trading-suit-1055131,1055131
104911,326426,AGN,Allergan to cut over 1 000 jobs as it works to return to growth,news,"NEW YORK  Reuters    Allergan Plc  N AGN  on Wednesday said it plans to cut over 1 000 jobs and eliminate an additional 400 currently open positions  as it works to cut costs in the face of new competition for its second most important drug  dry eye treatment Restasis   The company said the jobs and positions it plans to eliminate mostly focus on products and categories where the company has or expects to soon lose exclusivity  The drugmaker said it expects to take a  125 million charge from the job cuts  primarily due to severance  most of which will be recorded in the fourth quarter of 2017   Allergan said cost savings from this restructuring program 
should be around  300 million to  400 million per year ",2018-01-03,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-cut-over-1000-jobs-as-it-works-to-return-to-growth-1057933,1057933
104912,326427,AGN,Atara prices stock offering at  18 25,news,Atara Biotherapeutics  NASDAQ ATRA  prices its public offering of 7M shares of common stock at  18 25 per share  Underwriters over allotment is an additional 1 05M shares  Closing date is January 8 Yesterday s close was  19 25 Now read ,2018-01-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/atara-prices-stock-offering-at-1825-1061285,1061285
104913,326428,AGN,New finance chief at Aduro  operating chief to step down,news,Aduro Biotech  ADRO  promotes VP of Finance Jennifer Lew to CFO  She joined the company in October 2013 Chief Operating Officer Gregory Schafer will depart in early March and will continue as a consultant to help with the transition Now read ,2018-01-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/new-finance-chief-at-aduro-operating-chief-to-step-down-1068019,1068019
104914,326429,AGN,Start of JPM18 fails to buoy healthcare stocks,news,The start of JPMorgan  NYSE JPM  s healthcare conference has started with a whimper with no significant news to boost biopharma or biotech stocks  Most issues are under pressure in early trading Selected tickers   GILD  0 5   CELG  2 3   VRTX  0 2   AMGN  0 7   BIIB  3 9   JNJ  0 3   ABBV  1 8   AGN  1 9   AZN  1 1   BMY  0 2   LLY  1   GSK  0 9   MRK  0 7   PFE  1 3   NVS  0 4   NVO  0 4   SHPG  4 7   VRX  4 2  ETFs   BIB  3 8   GRX  0 5   THW  0 1   BME  0 2   CNCR  2   IXJ  0 8   ARKG  3 3   GNRX  PJP  1 8   IHE  1 4   XPH  1 5   PPH  1 1   IBB  1 7   XBI  2 1   JPM18Now read ,2018-01-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/start-of-jpm18-fails-to-buoy-healthcare-stocks-1076635,1076635
104915,326430,AGN,AbbVie  ABBV  Stock Falls After  63 Billion Allergan Acquisition Announcement  ,opinion,"AbbVie   NYSE ABBV   stock fell over 15  through Tuesday morning trading  The significant drop came after the company announced that it will acquire Allergan PLC   NYSE AGN   in a deal worth approximately  63 billion  The drop brought AbbVie stock to a new 52 week low of  66 56 per share  Meanwhile  Allergan stock jumped about 27  after the news 

AbbVie and Allergan agreed on compensation of  120 30 in cash and 0 8660 ABBV shares per AGN share  This valued AGN stock at  188 24  a 45  premium from its closing price on Monday  AbbVie is the producer of the world s best selling drug Humira and Allergen is the producer of Botox 
Allergan shareholders still need to vote to approve the deal  but it looks to be a great one for Allergan as many analysts believed the company was headed toward a split to increase shareholder value  AbbVie  in its press release  stated that it expects  the Acquisition will provide annual pre tax synergies and other cost reductions of at least  2 billion in year three   Combined R D resources as well as a reduction in supply chain and manufacturing redundancies are said to be the main sources of these synergies 
Along with synergies  AbbVie expects the acquisition to provide significant cash flow generation  AbbVie and Allergan generated a combined operating cash flow of  19 billion in 2018  AbbVie is looking to use the new cash flow to reduce its debt and continue its dividend growth  which are reasons for investors to be happy 
AbbVie is heavily reliant on revenue from Humira  which brought in  20 billion in revenue last year  But AbbVie has been looking to diversify its portfolio as cheaper alternatives are already becoming available in Europe  Plus  AbbVie s patent on the drug will expire in 2023 in the U S  Adding Botox  the most popular cosmetic procedure in the U S   to its portfolio is a good way for AbbVie to diversify 
Allergan also has products in other major sectors  These sectors include neuroscience  eye care  women s health  cystic fibrosis  and cardiovascular and infectious diseases  Allergan s stock has struggled since an attempted merger with Pfizer  NYSE PFE   failed in 2016 in which Pfizer valued AGN at  363 63 per share  nearly double the amount AbbVie is set to pay 
Before Tuesday s announcement  AGN stock had fallen around 32  over the past 12 months  while ABBV was down over 15   The acquisition could provide a boost for AbbVie s stock down the road as it is projected to increase the company s cash flow as well as diversify its product portfolio 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-stock-falls-after-63-billion-allergan-acquisition-announcement-200434613,200434613
104916,326431,AGN,AbbVie   Allergan  Where Are The Synergies ,opinion,"AbbVie   NYSE ABBV   is on the hunt for their next big revenue driver as their patent for the world s top selling drug  Humira  is nearing its end  AbbVie just made a  63 billion deal to acquire Dublin based Allergan   NYSE AGN   in an attempt to keep their drive alive This deal would represent a roughly 45  premium over Allergan s closing price yesterday  ABBV investors aren t thrilled with this excessive premium at the end of an economic cycle with the stock falling over 15  so far today  AGN investors  on the other hand  couldn t be more thrilled with their stock surging north of 26  this morning and still 13  below the  188 per share offer price AbbVie   AllerganHumira makes up over 60  of AbbVie s top line and this patent is said to be expiring mid 2023  The Allergan acquisition would significantly boost their portfolio s diversification and reduce the reliance on Humira Allergan s top line has been driven by eye care products  which has been losing momentum  as well as its medical aesthetics segment  which is the firm s saving grace  Medical aesthetics  aka cosmetic appearance products  drives 40  of their revenue and continues to illustrate double digit expansion  Their neuroscience and urology segment has also been driving a lot of growth for Allergan These two pharmaceutical companies don t have an enormous amount of synergies considering that their portfolios and pipelines don t overlap  The synergies will arise from distribution leverage  larger R D departments to push expansive pipelines  and portfolio diversification Although this premium appears high on paper  the actual valuation of AGN is much more reasonable  AGN is trading around its lowest forward P E since the company started below 8x  miles below the pharma industries 20x multiple  The transaction would value Allergan at 11 3x EV EBITDA  still roughly an 8  discount to the broader pharmaceutical industry Allergan has been looking for a change whether it be a new investment opportunity  potential acquisitions  a company split up or a sale for some time now as their top line appears to be stalled  This acquisition comes at an opportune time 
This deal is following the Bristol Myers Squibb s   NYSE BMY    74 billion agreement to buy their rival Celgene   NASDAQ CELG    the largest pharmaceutical acquisition since 1999  This merger is now facing some antitrust concerns that are expected to delay the deals closure  These two mergers would create two of the world s largest pharmaceutical companies PerformanceBoth AGN and ABBV have been underperforming the broader market over the last 52 weeks  These companies both need a change as their revenue slows to decline Take AwayThis acquisition could make or break these firms  As I said above  both these firms need to revitalize their top line and this merger could be the rejuvenating measure that they needed  Whether the 45  premium that AbbVie is paying for Allergan is worth the diversification remains to be seen  The acquisition will be finalized in 2020  Look to see how these firms synergize over the next 24 months  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/abbvie--allergan-where-are-the-synergies-200434622,200434622
104917,326432,AGN,Axsome Initiates Phase III Study On Depression Candidate,opinion,"Axsome Therapeutics  Inc    NASDAQ AXSM   enrolled the first patient in its GEMINI  Glutamatergic and Monoaminergic Modulation in Depression  study  a phase III  randomized  double blind  placebo controlled trial of AXS 05 in the treatment of major depressive disorder  MDD   AXS 05 is a novel  oral  investigational NMDA receptor antagonist with multimodal activity 
Shares of the company have soared 732 3  in the past year compared with the  s growth of 4 6  

 
AXS 05 is a novel  oral  investigational non competitive N methyl D aspartate  NMDA  receptor antagonist with multimodal activity under development for the treatment of central nervous system  CNS  disorder   The company is conducting a phase III STRIDE 1 study of AXS 05 in treatment resistant depression  TRD   and a phase II III ADVANCE 1  study in agitation associated with Alzheimer s disease  AD   The company completed a phase II ASCEND study in MDD  and a phase II study  in smoking cessation 
If successfully developed  AXS 05 will be the first orally administered NMDA receptor antagonist approved for the treatment of MDD  According to the company  the results of either the GEMINI study in MDD or the ongoing STRIDE 1 study  if positive  would  in combination with its previously completed ASCEND study  be sufficient to support the filing of an NDA for AXS 05 for the treatment of MDD  
The company expects top line results from both the STRIDE 1 and GEMINI studies in the second half of 2019 
In March 2019  Axsome received Breakthrough Therapy designation from the FDA for AXS 05 for the treatment of MDD  The candidate has also been granted Fast Track designation by the FDA for the treatment of TRD and agitation associated with Alzheimer s disease 
MDD affects about 7 1  of adults in the United States and is a chronic  mental  disorder that can result in suicide  
The depression market is quite large and has many players  including biggies like Allergan   NYSE AGN   with product Viibryd  and Eli Lilly   NYSE LLY   with Cymbalta and Zyprexa 
In March 2019  the FDA approved Johnson   Johnson s   NYSE JNJ   nasal spray  Spravato  esketamine   for treatment resistant depression  TRD  in adults  but with a boxed warning  The nasal spray has been approved for use in conjunction with an oral antidepressant in patients with MDD  who have not benefited from multiple standard treatments Axsome Therapeutics  Inc  Price

    
Zacks Rank 
Axsome currently has a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/axsome-initiates-phase-iii-study-on-depression-candidate-200434621,200434621
104918,326433,AGN,The Zacks Analyst Blog Highlights  AbbVie  Allergan  Bristol Myers And Celgene,opinion,For Immediate ReleaseChicago  IL  June 26  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  AbbVie   NYSE ABBV    Allergan   NYSE AGN    Bristol Myers Squibb   NYSE BMY   and Celgene   NASDAQ CELG   Here are highlights from Tuesday s Analyst Blog AbbVie   Allergan   Where Are the Synergies AbbVie is on the hunt for their next big revenue driver as their patent for the world s top selling drug  Humira  is nearing its end  AbbVie just made a  63 billion deal to acquire Dublin based Allergan in an attempt to keep their drive alive This deal would represent a roughly 45  premium over Allergan s closing price yesterday  ABBV investors aren t thrilled with this excessive premium at the end of an economic cycle with the stock falling over 15  so far today  AGN investors  on the other hand  couldn t be more thrilled with their stock surging north of 26  this morning and still 13  below the  188 per share offer price AbbVie   AllerganHumira makes up over 60  of AbbVie s top line and this patent is said to be expiring mid 2023  The Allergan acquisition would significantly boost their portfolio s diversification and reduce the reliance on Humira Allergan s top line has been driven by eye care products  which has been losing momentum  as well as its medical aesthetics segment  which is the firm s saving grace  Medical aesthetics  aka cosmetic appearance products  drives 40  of their revenue and continues to illustrate double digit expansion  Their neuroscience and urology segment has also been driving a lot of growth for Allergan These two pharmaceutical companies don t have an enormous amount synergies considering that their portfolios and pipelines don t overlap  The synergies will arise from distribution leverage  larger R D departments to push expansive pipelines  and portfolio diversification Although this premium appears high on paper  the actual valuation of AGN is much more reasonable  AGN is trading around its lowest forward P E since the company started below 8x  miles below the pharma industries 20x multiple  The transaction would value Allergan at 11 3x EV EBITDA  still roughly an 8  discount to the broader pharmaceutical industry Allergan has been looking for a change whether it be a new investment opportunity  potential acquisitions  a company split up or a sale for some time now as their top line appears to be stalled  This acquisition comes at an opportune time This deal is following the Bristol Myers Squibb s  74 billion agreement to buy their rival Celgene  the largest pharmaceutical acquisition since 1999  This merger is now facing some antitrust concerns that are expected to delay the deals closure  These two mergers would create two of the world s largest pharmaceutical companies PerformanceBoth AGN and ABBV have been underperforming the broader market over the last 52 weeks  These companies both need a change as their revenue slows to decline Take AwayThis acquisition could make or break these firms  As I said above  both these firms need to revitalize their top line and this merger could be the rejuvenating measure that they needed  Whether the 45  premium that AbbVie is paying for Allergan is worth the diversification remains to be seen  The acquisition will be finalized in 2020  Look to see how these firms synergize over the next 24 months Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-abbvie-allergan-bristolmyers-and-celgene-200434921,200434921
104919,326434,AGN,Company News For Jun 26  2019,opinion,AbbVie Inc  s   NYSE ABBV   shares plummeted 16 3  after the company announced that it had entered into an agreement to buy Allergan plc   NYSE AGN   in a  63 billion dealLennar Corporation s   NYSE LEN   shares lost 6 2  after the company reported second quarter fiscal 2019 earnings per share of  1 30  lower than the year ago quarter of  1 58 a shareShares of Xencor  Inc    NASDAQ XNCR   gained 13 9  after the company announced that it would replace HFF  Inc    NYSE HF   in the S P SmallCap 600Shares of USANA Health Sciences  Inc    NYSE USNA   gained 7 6  after the company announced that it would replace Fidelity Southern   NASDAQ LION   in the S P SmallCap 600 on Jul 1  2019,2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jun-26-2019-200434951,200434951
104920,326435,AGN,AbbVie To Buy Allergan  Prescribed ETFs ,opinion,"The healthcare space is on an acquisition spree  The latest in the list is the biopharmaceutical company AbbVie Inc    NYSE ABBV    which has agreed to buy Botox maker Allergan   NYSE AGN   for  63 billion in a cash and stock deal  This represents the second largest  deal in the pharmaceutical space this year  after Bristol Myers Squibb s   NYSE BMY    74 billion proposed acquisition of Celgene   NASDAQ CELG    read    Abbvie Allergan Deal in FocusUnder the terms of the deal  Allergan shareholders will receive 0 8660 AbbVie shares and  120 30 in cash for each share held  for a total consideration of  188 24 per Allergan share  This represents a 45  premium to Allergan s closing price of Jun 24  The deal will own approximately 83  of AbbVie on a fully diluted basis and Allergan shareholders will own approximately 17  of AbbVie on a fully diluted basis The deal  which is expected to close in early 2020  will add fast growing therapeutic businesses such as medical aesthetics and eye care to the AbbVie portfolio  The combined company will consist of several attractive franchises with leadership positions across immunology  hematologic oncology  medical aesthetics  neuroscience  women s health  eye care and virology  see      
The transaction is expected to be 10  accretive to adjusted earnings per share in the first full year following the close of the transaction  with peak accretion of greater than 20   It will also provide annual pre tax synergies and other cost reductions of at least  2 billion in year three  AbbVie is expected to generate significant annual operating cash flow  which will support a debt reduction target of  15 billion to  18 billion before the end of 2021 Market ImpactFollowing the megamerger announcement  shares of Allergan surged the most in 26 years  It jumped about 25 4  to close the day  crushing its average volume  as nearly 33 million shares moved hands compared with 2 6 million on average  Meanwhile  shares of ABBV dropped 16 2  The news has put the spotlight on a number of healthcare ETFs  especially biotech and pharma  which could be the best ways for investors to tap the opportunity arising from the ABBV AGN deal  Investors should keep a close eye on the movement of these ETFs over the coming weeks SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  It holds 41 securities in its basket and Allergan occupies the top position with 4 9  share  With AUM of  204 1 million  the product trades in good volume of around 61 000 shares a day and charges 35 bps in fees a year  It has gained 2 4  following the deal and has a Zacks ETF Rank  3  Hold  with a High risk outlook VanEck Vectors Biotech ETF   LON BBH  This fund offers exposure to 25 large biotechnology corporations by tracking the MVIS US Listed Biotech 25 Index  Here  Allergan is the eight firm accounting for 4 8  share  BBH has amassed  370 6 million in its asset base and charges 35 basis points in fees per year  It gained 0 8  on the day and has a Zacks ETF Rank  2  Buy  with a High risk outlook  read    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 43 U S  companies that manufacture prescription or over the counter drugs or vaccines by tracking the Dow Jones U S  Select Pharmaceuticals Index  Allergan takes the third spot at 4 7  share  The product has  340 4 million in AUM and charges 43 bps in fees and expense  Volume is light as it exchanges about 11 000 shares a day  The fund gained 1 9  on the day and has a Zacks ETF Rank  3 with a High risk outlook VanEck Vectors Pharmaceutical ETF   ASX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  Abbvie takes the eighteenth position with 4 13  share  The product has amassed  176 8 million in its asset base and trades in moderate volume of about 43 000 shares a day  Expense ratio comes in at 0 36   The fund added 0 05  on the day and has a Zacks ETF Rank  3 with a High risk outlook  read    Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  Holding 30 stocks in its basket  AbbVie occupies the seventh position at 4 94  allocation  while Allergan takes the twelfth spot with 2 82  share  The product has AUM of about  387 million and sees a lower volume of around 35 000 shares a day  It charges 57 bps in fees and expenses and added 0 05  on the deal news  The fund has a Zacks ETF Rank  3 with a High risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/abbvie-to-buy-allergan-prescribed-etfs-200434941,200434941
104921,326436,AGN,AbbVie  Growth  Dividend Growth And Compelling Valuation,opinion,"Introduction
I have held AbbVie  NYSE ABBV  since it was originally spun off from Abbott Labs  NYSE ABT   Moreover  I have been aggressively adding to my position for clients needing current income and dividend growth  All in all  it has been an excellent performer in spite of the fact that it is being ridiculously undervalued by Mr  Market  No matter what widely accepted valuation measurement I look at  AbbVie appears insanely cheap 
As of yesterday s close  June 24  2019  AbbVie was trading at a blended P E ratio based on adjusted operating earnings of 9 4 offering a dividend yield of 5 5   This represents a significant discount to its historical normal P E ratio of 14 5 and its intrinsic value P E ratio of 15 
Furthermore  as of yesterday s close  AbbVie was also trading at a price to EBITDA of 7 8 which is a significant discount to its normal price to EBITDA of 10 9  Additionally  and I consider this important since AbbVie is a dividend growth stock  AbbVie s normal price to operating cash flow was 9 3 compared to its normal price to operating cash flow of 13 4 and its fair value price to operating cash flow of 15 
AbbVie was also trading at its lowest price to sales ratio of 3 66 since it was spun off and was available to investors at attractive double digit earnings yields and cash flow yields  But most importantly  all these incredible valuations were supported by strong above average historical growth and expectations for continued future growth in each of the above metrics 
On June 20  2019 AbbVie also maintained its  1 07 per share quarterly dividend which is in line to be a significant increase over last year s  3 95 dividend per share  Which by the way  is also well covered by both operating cash flow and free cash flow  Furthermore  according to Argus research in May of this year  AbbVie updated its adjusted earnings 2019 guidance to  8 73 to  8 83 which was up from its prior guidance of  8 65 to  8 75   Note  I will be elaborating on all these metrics and more later in the FAST Graphs analyze out loud video  
Why Are AbbVie s Valuations So Low 
Anyone who has been following AbbVie realizes that the company generates more than half its revenues from its flagship drug Humira which lost its patent protection outside of the US and faces competition from several recently launched biosimilars  However  Humira does not face greater competition from biosimilars in the US until 2023  Nevertheless  according to Argus research  Humira sales fell 23  to  1 23 billion outside the United States  This was in line with company guidance and they also project a 30  decline in Humira sales outside the US in all of 2019 
Humira sales growth in the United States increased 7 1  to  3 2 billion  However  although this is still strong growth  US sales growth has slowed from double digit rates in previous quarters  AbbVie has been fighting back with the recent approval of Skyrizi in both the US and Japan for treatment of moderate to severe psoriasis which clinical trials showed it to be superior to Humira  Skyrizi is also on track for approval in Europe  However  this is only one of many candidates in AbbVie s pipeline  The following description of AbbVie Inc  NYSE ABBV   courtesy of the Wall Street Journal illustrates the diversity of their pipeline 
 AbbVie  Inc  is a research based biopharmaceutical company  which engages in the development and sale of pharmaceutical products  It focuses on treating conditions such as chronic autoimmune diseases in rheumatology  gastroenterology and dermatology  oncology  including blood cancers  virology  including hepatitis C virus  HCV  and human immunodeficiency virus  HIV   neurological disorders  such as as well as Parkinson s disease  metabolic diseases  comprising thyroid disease and complications associated with cystic fibrosis  pain associated with endometriosis  and other serious health conditions  The company was founded on January 1  2013 and is headquartered in North Chicago  IL  
Nevertheless  AbbVie s valuation has been clearly impacted by people s fear of the potential loss of sales for Humira in the not so distant future  However  I think it s important to recognize that this future is still unknown  while AbbVie s current operating results remain excellent  and there is potential in AbbVie s pipeline to not only replace Humira sales but continue growing sales far into the future  Consequently  I am choosing to follow Warren Buffett s suggestion to be  greedy when others are fearful  
Although there is always risk in evaluating the pipeline of any pharmaceutical company  AbbVie clearly has a strong pipeline with numerous candidates in phase 3 and several recent approvals  For those who would like to take a deeper look at AbbVie s pipeline here s a link on their website 
 But That Was Yesterday And Yesterday s Gone 
As the English duo Chad and Jeremy so aptly put it in their 1963 hit   but that was yesterday and yesterday s gone   The preceding was the beginning of my article on AbbVie where I was planning on building the case that AbbVie s fundamentals were significantly stronger than their stock price  Nevertheless  today s announcement that AbbVie was acquiring Allergan  NYSE AGN  solidified and even enhanced my view on this blue chip dividend growth stock 
Suffice it to say that I agree with and even support management s decision to acquire Allergan  I agree with AbbVie s management that this transaction represented a  unique opportunity to acquire attractive and durable growth assets at a highly compelling value   Furthermore  I agree with the additional three highlights that AbbVie s management believes the Allergan transaction offers as depicted on the following slide 

The rest of the slideshow which highlights AbbVie s positions on why they think this is an excellent transaction is worth looking at closely and can be found here 
AbbVie s CEO Richard Gonzales provided his views on why he believes the purchase of Allergan makes good sense for AbbVie and its shareholders  The following excerpts from the video played on CNBC found here highlights his views 


Allergan Cheap Before the AbbVie Acquisition  Still Cheap Afterwards
AbbVie s  63 billion purchase of Allergan is essentially equal to the company s current total enterprise value  TEV  of  65 3 billion  On a per share basis the transaction works out to approximately  188 a share which is approximately a 45  premium to Allergan s closing price on July 24  2019  For Allergan shareholders the deal consists of  120 30 of cash and  8660 shares of the combined company 
To put this transaction into perspective I offer the following earnings and price correlated graph on Allergan where I put a magenta dot on the graph approximately indicating the price that AbbVie is acquiring Allergan at  The important takeaway is that AbbVie is purchasing Allergan shares at a discount to the company s intrinsic valuation and historical normal valuations 
Furthermore  I think the reader should note that Allergan was significantly overvalued in 2015 before earnings weakened  However  the reader should also note that the price reaction in 2018 and thus far in 2019 are clearly significant overreactions to a flattening of the company s operating earnings  Stated differently  Allergan remained a very profitable business where earnings growth merely slowed while stock price collapsed  Again  I believe that was a significant overreaction by the market that appears quite clear when viewing the graphic 

AbbVie Was Already Cheap But Just Got Cheaper
As I indicated in my intro  as of yesterday s close  June 24  2019  AbbVie was already extremely undervalued based on past  present and expected future operating performance  Furthermore  this was supported by virtually every widely used valuation metric  The following adjusted operating earnings and price correlated graph clearly tells that story  As the reader should note  earnings are expected to grow approximately 11  in 2019 which is the midpoint of company guidance as well as the consensus of leading analysts following the company  Furthermore  the reader should also note that earnings beyond 2019 were also expected to increase by 8  and 9  respectively for fiscal years 2020 and 2021 

Most importantly  the earnings expectations on the above graphic represent AbbVie s management and consensus leading analyst expectations for the company prior to the announced acquisition  As the following slide depicts  AbbVie s management expects those numbers to be exceeded as a result of the Allergan purchase  Consequently  AbbVie has become even more valuable today than it was yesterday considering the significant price drop coupled with the higher expected future growth 
 
MorningStar stock analyst note 9 50 AM June 25  2019
MorningStar published a stock analyst note this morning on the AbbVie transaction titled  AbbVie s Acquisition of Allergan Looks Opportunistic and Offers Diversification From Humira  In the analyst note MorningStar suggested that Allergan s portfolio of branded drugs should strengthen AbbVie s moat and that Allergan s pipeline and Botox entrenchment did not seem to be fully factored in Allergan s price  Consequently  they suggested that many of the fears over Humira biosimilar competition would be partially alleviated  Therefore  they continue to believe that AbbVie is undervalued  MorningStar also believes that the  2 billion in annual savings projected by AbbVie s management seems reasonable 
Barron s
At 2 05 PM June 25  2019 Barron s magazine reported that AbbVie shareholders will get no vote on the purchase of Allergan  They did suggest that even though shareholders of Allergan will vote on the sale they believe it s unlikely that it will face opposition considering the stock has increased over 26  thus far today  
FAST Graph Analyze Out Loud Video  AbbVie by the Numbers  Allergan included 
Summary and Conclusions
Although it is very difficult for many investors to accept the idea that the market often mis appraises the market value of publicly traded stocks  my personal experience tells me that it often does  Consequently  I have learned over the many years I ve been doing this to trust fundamentals more than I do short term price volatility  Moreover  my personal experience also tells me that short term market price behavior has a very insidious nature  Unfortunately  investors tend to trust and or believe more in significant levels of overvaluation  than they do significant levels of undervaluation 
To clarify further  investors will ignore the enormous danger of overvaluation and flee like rats from a burning building from the incredible opportunity of significant undervaluation  In other words  investors want to buy when they should sell and sell when they should buy  Therefore  it has never been a surprise to me that so few people make long term money investing in stocks  Stocks rarely recover from massive overvaluation  and almost always recover from significant undervaluation  Nevertheless  when emotions rule reason goes out the window 
Today s reaction to AbbVie s announcement that they were purchasing Allergan represents a quintessential case in point  Prior to the announcement  investors were fearful that AbbVie was going to suffer from the potential competition facing their flagship drug Humira  However  when management announced this transaction that in addition to other benefits should partially mitigate the potential reduction of future Humira sales  the market reacts negatively instead of the more logical positively  Oh  the peculiar illogic of Wall Street 
Personally  I have believed and continue to believe that AbbVie has a bright and profitable long term future ahead of it  After today s announcement  my belief is both solidified and enhanced  Furthermore  my beliefs are primarily based on the actual results that AbbVie is producing  and to a lesser extent on the company s future potential  Common sense suggests that all pharmaceutical companies face pipeline risks and AbbVie is no different  On the other hand  recent successes coupled with several drugs already in phase 3 and notwithstanding the Allergan pipeline suggests my confidence is not without justification 
Nevertheless  there are risks that the Allergan transaction will not go through  If that does happen  I still believe that AbbVie possesses the potential future growth that I showcased in the beginning of this article  Consequently  I believe that the Allergan opportunity represents potential icing on that cake  All stock investments possess risks  and AbbVie is certainly no exception  On the other hand  it is very rare to find a stock that possesses all the attributes and the incredible long term return opportunity that AbbVie currently does  The combination of an extremely high and fast growing current dividend yield coupled with incredible capital appreciation potential make this a risk worth taking  At least in my humble opinion  But with that said  I have elected to let the market digest this news before I add to my positions  which I eventually intend to do  Caveat emptor 
Disclosure  Long ABBV
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2019-06-26,Chuck Carnevale,https://www.investing.com/analysis/abbv-abbvie-has-it-all-growth-dividend-growth-and-compelling-valuation-200434704,200434704
104930,326445,AGN,Premarket analyst action   healthcare,news,Madrigal Pharmaceuticals  NASDAQ MDGL  initiated with Buy rating and  54  17  upside  price target by H C  Wainwright Xencor  NASDAQ XNCR  initiated with Overweight rating and  33  65  upside  price target by Canton Fitzgerald Adamas Pharmaceuticals  NASDAQ ADMS  initiated with Outperform rating and  70  107  upside  price target by Northland Capital Arcturus Therapeutics  NASDAQ ARCT  initiated with Buy rating and  22  153  upside  price target by Ladenburg Thalmann Allergan  NYSE AGN  upgraded to Overweight with a  200  16  upside  price target by  Morgan Stanley   NYSE MS  Zoetis  NYSE ZTS  upgraded to Overweight with an  80  12  upside  price target by Morgan Stanley  Pacira Pharmaceuticals   NASDAQ PCRX  downgraded to Neutral with a  44  6  downside risk  price target by Mizuho Securities Source  BloombergNow read ,2017-11-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-927428,927428
104931,326446,AGN,Tech firms tell patent court to ignore Allergan deal with tribe,news,"By Jan Wolfe  Reuters    Over 30 technology companies including Alphabet Inc  O GOOGL   Amazon com Inc  O AMZN  and  Facebook Inc    O FB  on Friday urged a U S  patent court to disregard drugmaker Allergan Plc s  N AGN  contention that its transfer of some of its patents to a Native American tribe shields them from the court s review  Two trade groups comprised of tech industry leaders argued in a joint brief submitted to the U S  Patent Trial and Appeal Board that the board has the right to review the validity of patents covering the dry eye medicine Restasis that Allergan transferred to the Saint Regis Mohawk Tribe in a deal announced in September   This panel s statutory authority to review whether the Restasis patents were properly granted as a matter of federal law does not and should not depend on the identity of the patents  owner   said the trade group  Allergan is arguing the tribe s sovereign status means the patent review board  an administrative court  has no jurisdiction over the transferred patents  The tribe agreed to exclusively license the Restasis patents back to Allergan in exchange for ongoing payments  Many technology companies have praised the patent court  saying it is a low cost and efficient way to cancel dubious patents used to bring abusive lawsuits  They fear that  if upheld  Allergan s strategy could be widely adopted and used against them  The case before the patent board stems from a challenge to the Restasis patents brought by generic drug companies led by Mylan NV  O MYL   Generic makers had been blocked from selling their own versions of the blockbuster medicine until the patents expired in 2024  But a federal judge in Texas already invalidated the Restasis patents in a separate proceeding  rendering Allergan s tribal deal effectively meaningless  The company had said it did not object to federal court review of its patents but felt the administrative process was unfair   Despite that ruling  the Patent Trial and Appeal Board is hearing arguments on whether it must accept Allergan s tribal immunity argument  A group of prominent law professors  including Laurence Tribe of Harvard Law School and Erwin Chemerinsky of the University of California at Berkeley  submitted a brief on Friday siding with the tribe and Allergan  
 Far from being a scheme to shield patents from review  the agreement from the Tribe s perspective is part of its economic development plan   the academics said   The Allergan Mohawk contract reflects exactly the sort of economic entrepreneurship that Congress has been urging upon tribes  ",2017-12-01,Reuters,https://www.investing.com/news/stock-market-news/tech-firms-tell-patent-court-to-ignore-allergan-deal-with-tribe-943571,943571
104932,326447,AGN,Allergan under modest pressure on potential encroachment of Revance on Botox franchise  shares down 2  premarket,news,Allergan  NYSE AGN  slips 2  premarket on modest volume in apparent response to positive late stage data on Revance Therapeutics   NASDAQ RVNC  DaxibotulinimtoxinA for the treatment of frown lines  Revance s neuromodulator has a six month duration of action  longer than BOTOX Cosmetic s three to four months Previously  Revance s RT002 successful in late stage studies  shares ahead 25  premarket  Dec  5 Now read ,2017-12-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-under-modest-pressure-on-potential-encroachment-of-revance-on-botox-franchise-shares-down-2-premarket-954255,954255
104933,326448,AGN,Affimer   Potential Best In Class Antibody Mimetic,opinion,"Avacta is developing its Affimer technology for use in therapeutic and diagnostic reagent applications  The potential of the Affimer technology lies in its formatting capabilities  particularly in the creation of bispecific and TMAC Affimer drug conjugates  Its lead therapeutic asset  AVA004  is a programmed death ligand 1  PD L1  targeting Affimer for which the company expects to submit an investigational new drug  IND  application in Q420  AVA004 will serve as the first clinical validation of the Affimer technology and will form the base of the clinical development of a PD L1 LAG 3 bispecific  AVA021  and the first TMAC Affimer drug conjugate  AVA004 100   We value Avacta at  51m or 44p share 

Formatting capabilities point to future potential
Avacta is progressing its therapeutic Affimers towards the clinic with its PD L1  AVA004  and PD L1 lymphocyte activation gene 3  LAG 3   AVA021  product candidates expected to start oncology clinical trials in 2021 and 2022 respectively  Post the clinical validation of AVA004  we expect Avacta will focus on the development of the AVA021 bispecific  a component of which is AVA004  and its TMAC Affimer drug conjugate  AfDC   in collaboration with Tufts University  that targets PD L1 and uses an I DASH toxin together with a novel fibroblast activation protein  FAP   cleavable linker  AVA004 100  
TMAC drug conjugate into the clinic in 2020
Avacta has accelerated its tumour microenvironment activated drug conjugates  TMAC  programme and will now test the novel FAP  cleavable linker in a Phase I trial in 2020  The FAP  cleavable linker will be conjugated to a well known chemotherapeutic agent  doxorubicin  rendering it inactive until the linker is cleaved in the tumour microenvironment  The FAP  cleavable linker forms a key component of AVA004 100  for which Avacta expects to submit an IND application in late 2021 
Partnerships continue to validate technology
Avacta s partnerships continue to show the potential of Affimers for multiple applications  most recently it announced a deal with LG Chem worth over  300m    royalties  to develop a range of therapeutic Affimers  In February 2019  Moderna exercised its option on an Affimer developed in its partnership with Avacta 
Valuation   51m or 44p share
We value Avacta at  51m or 44p share based on a sum of the parts valuation built on an rNPV for AVA021  the LG Chem partnership and the peer valuation of the reagents diagnostic and animal health divisions  in addition to adding in net cash  AVA021  PD L1 LAG 3  contributes approximately 50  to our valuation 


Business description
Avacta is focused on the development of its Affimer technology for use in therapeutic and diagnostic reagent applications  Assets include AVA004  PD L1   AVA021  PD L1 LAG 3  and AVA004 100  PD L1 I DASH  
Investment summary
Company description  Antibody mimetics
Avacta is a UK biopharmaceutical company specialising in the development of its proprietary Affimer platform  Its lead assets are its PD L1 Affimer  AVA004   its PD L1 LAG 3 bispecific Affimer  AVA021  and its PD L1 TMAC drug conjugate  AVA004 100  for use in cancers  both in preclinical development  In addition to Avacta s therapeutic platform  it has a diagnostic reagents division and an animal health division  Avacta has multiple partnerships  notably with LG Chem  Moderna and Tufts University  Avacta raised net  10 9m in August 2018  c 46 000 shares at 25p share  and had net cash as of 31 January of  11 8m  In 2018  Avacta s average employee count grew to 114 compared with 103 in 2017 
Valuation   51m or 44p share
We value Avacta at  51m or 44p share  This is based on a sum of the parts model including a risk adjusted NPV of AVA021  PD L1 LAG 3 bispecific   rNPV   23 9m  and LG Chem research partnership  rNPV   7 7m  and a peer valuation of both its reagents and animal health divisions  c  7 2m   in addition to adding in net cash   11 8m   The main driver of our valuation is AVA021  which contributes approximately 50  of the total valuation  We assume AVA021 is out licensed before the Phase I start in 2022 and model c  300m of milestones split across an upfront payment  clinical and commercial milestones  Due to the early nature of its development  we model its market potential in a basket of relapsed refractory cancers that are PD L1 LAG 3 positive and for which patients have already received PD L1 treatment  This is benchmarked against the total PD L1 global market  resulting in approximate market penetration of 5   generating peak sales of c  800m  The next most advanced asset  the AVA004 100  PD L1 I DASH  product candidate  first product from the TMAC platform   is of significant scientific interest  however  due to the very early nature of development and the complexities involved in the asset  we await for its advancement into the clinic before considering its inclusion into our valuation  Potential significant upside exists if Avacta is successfully able to develop the TMAC platform  For the LG Chem partnership  we model the  180m milestone payments for the deal with payments spread to 2030 on assumed classical drug development timelines  eg Phase I start  
Sensitivities  Clinical validation needed
Avacta is subject to the risks typically associated with biotech company drug development  including the possibility of unfavourable outcomes in clinical trials  trial shortfalls or failures  cash flow limitations  success of competitors and negative commercial decisions by partners or potential partners  Cancer immunotherapy has become a highly competitive landscape and Avacta s technology platforms are still in relatively early stages of development  The key short term sensitivities for Avacta relate to crystallising value from the early stage pipeline  particularly the PD L1 LAG 3 bispecific  AVA021   Additionally  the entry of the first Affimer into the clinic  PD L1 Affimer  will be critical inflection point for the company as the technology is tested in humans for the first time  If Affimers are found to be immunogenic or generate severe side effects  it would affect any potential applications  We note AVA021 represents 50  of our valuation and any failure of the asset or changes to timings would materially affect our valuation 
Financials  Cost base expected to rise as the clinic approaches
The net loss for H119 was  5 2m  vs  3 95 in H118  driven by the decrease in revenues and increase in R D investment  Net cash at 31 January 2019 was  11 79m and we forecast a current cash reach into 2020  We forecast illustrative debt of  10m in 2020 to fund operations into 2021 
Affimers  First human data will be a key inflection point
Avacta is built around its proprietary Affimer platform of engineered proteins  acquired IP in 2012  current patents   which are engineered to possess binding capabilities similar to antibodies  antibody mimetics   Since the FDA approved the first antibody in 1985  muromonab   antibodies have become the dominant therapeutic options for countless diseases with total sales of antibodies recently reaching  120bn globally in 2018  source  EvaluatePharma   Although antibodies are  and will continue to be  the dominant therapeutic option in many diseases  there are numerous disadvantages including their relatively bulky size  complexity in creation and manufacturing  difficulties in formatting  making drug conjugates  bispecifics etc  and a high cost of production 
Avacta has developed Affimers to address many of these problems and offer an array of potential advantages including high expression levels  in eukaryotic and prokaryotic cells   customisable kinetics  Koff  Kon etc   stability  AVA04 demonstrated stability up to seven months in phosphate buffered saline at 4 C  and solubility  400mg ml dimeric Affimers  200mg Affimer Fc   One of the key capabilities of Affimers is their formatting flexibility which allows the relatively simple construction of complex molecules such as TMAC drug conjugates  AVA004 100  and bispecifics  AVA021   This could be an important differentiator for the platform  While technically promising  the platform remains in its infancy  not yet tested in humans  and significant risk remains in their ability to perform in a therapeutic clinical context  Questions including whether Affimers will generate an unwanted immune reaction and subsequently be neutralised in the body  preclinical data to date have determined a non immunogenic nature   whether they are therapeutically safe and if there inherently short half life will limit efficacy are all still to be answered  formatting with other component as a bispecific or AfDC will increase half life   Key to Avacta s future prospects will be it rapidly achieving Affimer data in human patients  IND forecast to be submitted for AVA004 in Q420  
All therapeutic Affimers are based on stefin A  Exhibit 1   a human protease inhibitor  They are typically 12 14kDa in size  approximately 10 fold smaller than antibodies   which brings the advantage of typically better tissue penetration and increased packing density  for diagnostics reagent applications   However  their small size means Affimers have a relatively short half life  hours   This can sometimes be advantageous in limiting systemic toxicity  the Affimer acts at site of interest and is cleared from the body before it has a chance to act elsewhere   there are often multiple scenarios where a longer half life is need  Avacta has developed half life extending technologies in the form of serum albumin binding  Affimer XT platform  to address this  Preclinical data to date have demonstrated minimal disruption of Affimer binding to its target when using the XT format  Additionally  the ease of formatting of Affimers means novel drug conjugates and multi specific Affimers can be created  which offer unique ways to increase the half life 
Affimers are selected by phage display   1010 library size  and produced in E  Coli protein expression systems  The time between the initial screen of the Affimer to animal models is typically six months  putting it on par with therapeutic antibody development  Lot to lot variability is a common problem for antibodies  mainly for polyclonal and less so for monoclonal and synthetic   however  as Affimers are manufactured by a non eukaryotic process there is more lot to lot consistency  Due to Affimers  simple  stable  known structure  they can be easily functionalised  which aids in the ability to produce drug conjugates of bispecific molecules without the loss of binding or stability 
While the aforementioned capabilities are key for Affimers to differentiate themselves from antibodies  one key strength is the unencumbered patent protection Avacta holds on the technology  This is a result of Affimers not being based on antibodies and gives Avacta freedom to operate in areas where antibody patents exist and  for example  allows it to go after many well known targets  eg PD L1  without infringing on other antibody patents and is a significant attraction for potential partners 
Therapeutic pipeline
Avacta has multiple Affimer assets in early stage development  Exhibit 2  across three key technology areas  checkpoint antagonists  AVA004 and AVA017   costimulatory agonists  AVA026 and AVA023  and drug conjugates  AVA004 100   Although AVA004  AVA017 and AVA023 are similar to other assets in development in the sector  its Affimer TMAC drug conjugates  of which AVA004 100 is the most advanced  could prove be a key driver of value in the long term  The Affimer TMAC drug conjugates are based around a FAP  cleavable linker that connects a deadly toxin with a tumour targeting Affimer  The FAP  cleavable linker is cleaved in the tumour microenvironment  demonstrated to date by data in animal and in vitro models  and it could enable the localised release of tumour killing toxins in humans  Combined with the multiple formatting options of Affimers  a range of possible combinations and product candidates could emerge  The proprietary  FAP   cleavable linker to be used in AVA004 100 will be tested separately next year  while an IND application testing the full Affimer drug conjugate is expected to be submitted for AVA004 100 in late 2021 
Its most advanced asset in the pipeline is AVA004  a PD L1 targeting Affimer for which Avacta expects to submit an IND application by the end of 2020  Most recently it was announced that a clinical development candidate has been selected for AVA004 and that the Phase I study is expected to test AVA004 in 20 to 30 patients with PD L1 positive solid tumours  The trial will test both intravenous and subcutaneous routes of administration  This clinical trial will provide the first proof of concept for Affimers in humans and would de risk the entire platform if successful  While the data produced by AVA004 will be informative  we do not expect Avacta to progress the asset past Phase I trials and will instead utilise it to inform the design of its bispecific PD L1 LAG3 AVA021 and drug conjugate AVA004 100 trials  We believe this decision will be driven by the significantly increased potential value of developing  if successful  a unique therapy instead of a similar version of an already available commercial product  eg another PD L1 monotherapy in the case of AVA004   We believe long term value for Avacta is developing the AVA021 bispecific  component of which is AVA004   which is expected to enter the clinic in 2022 and its TMAC AfDC  in collaboration with Tufts University  that targets PD L1 and uses an I DASH toxin  AVA004 100  coupled together with a FAP  cleavable linker  IND filling expected in H221  

Checkpoint antagonists  PD L1 and LAG 3
Avacta s lead assets are based on targeting PD L1 and LAG 3  The most advanced is AVA004  in development as a PD L1 inhibitor  Avacta expects to submit an IND by end 2020 with data potentially in 2021  This will be a major inflection point for Avacta as it will represent the first human dataset for an Affimer  As usual  the initial Phase I trial will focus on safety but evidence of efficacy could prove an important early indicator of how the Affimer technology compares to antibodies  particularly PD L1 inhibitors  Preclinical mouse model data have demonstrated that AVA004 produced comparable changes in tumour volume to that of atezolizumab  Tecentriq   Exhibit 3  and avelumab  Bavencio  and durvalumab  imfinzi   We forecast that AVA04 will not be developed past Phase I  as it will have enabled the proof of concept of Affimer technology in humans  and Avacta will focus on AVA021  LAG 3 PD L1 bispecific  and AVA004 100  PD L1 I DASH AfDC  
AVA017 is designed to be an Affimer LAG 3 inhibitor  It is in lead optimisation and Avacta expects to select a lead candidate in H219  Avacta has no plans to develop AVA017 as a monotherapy into the clinic and will utilise it as part of AVA021  which will combine AVA017 and AVA004 into an LAG 3 PD L1 bispecific  Avacta predicts the first patient is likely to be treated with AVA021 in 2022 

Since the commercial launch of Keytruda  Merck  and Opdivo  Bristol Myers Squib  in melanoma in 2014  PD L1 immune checkpoint inhibitors  ICIs  have become the standard of care in many cancers  FY18 sales of Opdivo and Keytruda were  7 6bn and  7 2bn respectively   PD L1 is a transmembrane protein that plays a key role in immune regulation  The binding of receptor PD 1 to its ligand PD L1 activates suppressive signals that limit immune activation  an effect that cancerous cells exploit to limit the response against them  PD L1 inhibitors have been developed to try and prevent this immune suppression and have proven successful across a range of cancers  PD L1 ICIs  alone or in combination  have quickly become the standard of care for many patients  however  the best responses generally remain confined to high PD L1 expressing patients  For example  Keytruda s approved label  Keynote 042  in stage three non small cell lung cancer  NSCLC  demonstrated it had a 39  overall response rate  ORR  as a monotherapy in first line patients whose tumour proportion score  TPS  for PD L1 expression was above 50   however  in a broader patient population  TPS score of 1  and above   the ORR fell to 27   Across indications  companies are now looking to test ICIs in combination with other treatments to broaden their therapeutic window  Avacta is aiming to address this with assets including its AVA021 bispecific and its first TMAC Affimer drug conjugate AVA004 100 
LAG 3 demonstrating potential in the clinic
Like PD L1  LAG 3  also known as CD233  is a transmembrane protein immune checkpoint receptor found on T cells  LAG 3 is typically upregulated to control T cell activation and prevent over activation of T cells  and subsequent autoimmunity   In cancer models it has been demonstrated that persistent expression of antigens to T cells enables continuous LAG3 expression and subsequently T cell exhaustion  limited killing  proliferation and cytokine production   It is thought that inhibition of LAG 3 could prevent T cell exhaustion and lead to tumour killing activity  The target has received significant interest and there are currently 45 LAG 3 trials ongoing  according to clinicaltrials gov  either alone or in combination with other therapies  One of the most advanced is relatlimab  Bristol Myers Squib  and is in 19 active studies across multiple cancer types  the most advanced of which is a Phase III study testing relatlimab in combination with nivolumab  Opdivo  in first line advanced melanoma 
Data were presented at ESMO 2017 on the combination of relatlimab and nivolumab in melanoma patients who have previously progressed on anti PD L1 therapy  Overall  n 68  ORR  one complete response  six partial responses  and disease control rate  DCR  were 11 5  and 49  respectively  In patients with LAG 3 expression  1   the ORR was 18   n 33  compared with 5  in patients with LAG 3 expression  1   n 22   The combination demonstrated a similar AE profile to that of nivolumab alone 
Multiple other LAG 3 antibodies are in development  GSK GSK2831781  MacroGenics  MGD013  Merck  MK 4280   notably FS118 from F star  a bispecific  targets LAG 3 and PD L1  that is in a Phase I trial across a range of advanced metastatic cancers  expected enrolment of 51 patients   F star originally partnered FS118 with Merck in 2017  however  it has recently had the rights returned and will now develop and commercialise it 
Whether a LAG 3 PD L1 bispecific will be more potent than separate mAbs in combination has yet to be clinically determined  however  early pre clinical data hint at the potential  Data on AVA021  LAG 3 PD L1 bispecific  remain early but recently presented data  at the Avacta R D day  February 2019  demonstrated that in ELISA binding assays  AVA021 bound PD L1 and LAG 3 as well as single target Affimers  Exhibit 4   demonstrating the conjugation of the two Affimers did not affect binding  More advanced pre clinical data demonstrating the potential of a LAG 3 PD L1 bispecific come from F star  which demonstrated in a colon carcinoma mouse model that FS118 more potently inhibited tumour growth than a combination of an LAG 3 mAb and PD L1 mAb  Recently F star presented data at ASCO 2019 from its enrolling Phase I trial that demonstrated no dose limiting toxicities were observed to date in the first 29 patients recruited 

Partners  Affimers attractive across applications
Avacta s range of partnerships continues to demonstrate the potential of Affimers for multiple applications  Exhibit 5   These include classical discovery partnerships with LG Chem and Moderna  deals focused on specific applications such as the development of AfDCs with Tufts University and partnerships focused on testing the potential of Affimers in cell and gene therapies with Oncosec and Memorial Sloan Kettering 

Tufts Bach Biosciences  Novel conjugate potential
The collaboration with Tufts Bach Biosciences aims to develop novel AfDC using Tufts novel linker chemistry that is designed to release attached drugs in the tumour microenvironment  This TMAC platform coupled with the Affimer technology could generate a unique pipeline of assets  The first proof of concept AfDC will involve the use of a PD L1 Affimer  AVA004 100  PD L1 I DASH   an FAP  cleavable linker and an I DASH small molecule inhibitor  Exhibit 6   Avacta recently accelerated its TMAC programme and will now test the novel FAP  cleavable linker in a Phase I trial in 2020  The FAP  cleavable linker will be conjugated to a well known chemotherapeutic agent  doxorubicin   rendering it inactive until the linker is cleaved in the tumour microenvironment  The FAP  cleavable linker is key to Avacta s drug conjugate ambitions and these clinical data will be an important inflection point for the technology  The first Affimer drug conjugate to use the FAP  cleavable linker is AVA004 100  for which Avacta expects to submit an IND application in late 2021 

The third component of AVA004 100 is the I DASH inhibitor  The inhibition of DASH enzymes has been demonstrated both in preclinical and clinical populations to promote tumour regression  Positive Phase II study in NSCLC   However  one of the key problems with DASH inhibitors to date has been the dose limiting toxicities commonly associated with chemotherapies  Phase III trial testing talabostat receives a clinical hold and is later terminated   Avacta and Tufts believe AfDC can address the toxic problems seen with DASH inhibitors as administration of I DASH is theorised to be limited to the tumour microenvironment  Additionally  the inherently short half life of Affimers could be beneficial in reducing toxicity  however  it could limit efficacy  As AVA004 100 remains in the early stages of development  clinical data will be needed to confirm or disprove these hypotheses 
Reagents and diagnostics  Stable base
Avacta s reagent and diagnostic division  a separate team based in Wetherby  therapeutics team based in Cambridge  continues to be a key component of the business and Avacta continues to develop in house technologies with the aim of providing a stable revenue base for the company  The ability of Affimers to retain their chemical and thermal stability in a wide array of environments means the technology is suited to a variety of applications  combine this with the ability to easily functionalise Affimers with an array of compounds  enzymes  dyes etc  and Affimers quickly present themselves as ideal research tools 
Avacta has ongoing paid technology evaluations with numerous undisclosed partnerships  including global in vitro diagnostic  pharma  biotech and bioprocessing companies  Avacta is pursuing three commercialisation strategies 
Paid for evaluations of Affimer technology with the aim to generate licence deals where the technology is incorporated into partner products  multiple evaluations ongoing  
Custom Affimer services to support partner in house R D  eg anti idiotypics  
Development of diagnostic assays to be partnered out  Aim to generate two diagnostic assets with supporting data packages during 2019  with the aim of out licensing them once the work is complete 
Paid for evaluations and the development of diagnostic assays remain important for the long term growth of the division  In the short term  custom reagents  particularly anti idiotypics  remain important income generators and continue to demonstrate revenue growth  Anti idiotypics are antibodies or  in Avacta s case  Affimers that bind to the idiotope  variable part of an antibody that includes the unique antigen binding site  of another antibody  These are needed in setting up pharmacokinetic assays that measure total or free drug levels in pre clinical clinical samples  an important step in the drug creation process 
Anti idiotypics are a significant growth area for Avacta  It recently launched a marketing campaign and set up multiple new contracts   40k revenue per anti idiotypics   As the majority of antibodies in development will typically need an anti idiotypic  Avacta believes there is significant market potential and estimates an ongoing revenue stream of several million pounds at peak  We note that while Affimers potentially offer advantages in the creation of anti idiotypics  market leaders such as Bio Rad will be difficult to displace 
In October 2018  Avacta agreed an Affimer reagent licensing deal with NEB to commercialise a product incorporating Affimer technology  The product is for use in both life science research and diagnostic assays and is in final stages of testing  Under the terms of the agreement  Avacta will receive royalties on sales  may occur as soon as this year   NEB and Avacta will continue their collaboration with the aim to generate further products 
Animal health  Pre Affimer legacy business
Avacta Animal Health remains a legacy of the original Avacta business before the acquisition of the Affimer IP in 2012  Employing approximately 20 people  Avacta Animal Health is focused on four main categories  allergy diagnostic tests  immunotherapy vaccine sales  export sales and contract research organisation services  Trading in H119 was broadly in line   0 69m vs  0 77m in H118  with H118 and Avacta expect a pick up in H219 numbers as the seasonal effects of the allergy business boost sales  The division continues to market its capabilities with the pet allergy awareness campaign in its fifth year  In the long term we expect Avacta to spin off or sell the animal health division as it continues to focus on its therapeutic ambitions 
Antibody mimetics continue to generate interest
As the limits of antibody technology become ever clearer  more investment is being made into the sector to develop antibody mimetic technology  Here we highlight a few key competitors 
Molecular Partners  MOLN  is a Switzerland listed biotechnology company  market cap  CHF340m  focused on developing its DARPin platform  The platform is based on a large library  1012  of small proteins with single domains  15kDa  that are used as building blocks for its therapeutic molecules  currently up to six DARPin proteins can be linked together   Multiple assets are in clinical trials with lead assets MP0250  inhibit VEGF and HGF  in multiple myeloma and Abicipar  inhibit VEGF  in wet age related macular degeneration  Abicipar is in development with its partner Allergan  NYSE AGN   which expects to file a BLA in H119  Recently a clinical trial testing MP0250 in combination with Tagrisso in EGFR mutated NSCLC was placed on clinical hold due to adverse events 
Pieris Pharmaceuticals  PIRS  is a Nasdaq listed biotechnology company  market cap   184m  focused on developing its Anticalin technology  The technology is built on engineered lipocalins  a family of proteins that transport small hydrophobic molecules  18 40KDa   which  in a similar vein to Affimers  have a ridged backbone and a  four loop  variable region  Its most advanced assets are in Phase I clinical trials  including a PRS 343  a 4 1BB HER2 bispecific being tested in a range of HER2 positive solid cancers and PRS 060 a IL4Ra inhibitor for use in asthma  partnered with AstraZeneca  
Bicycle Therapeutics  BCYC  is a recently Nasdaq listed biotechnology company  23 May  market cap   278m  focused on developing its bicycle technology  Bicycles are short synthetic peptides constrained to form two loops to stabilise their structure and form regions for binding  The company has one asset in the clinic  BT1718  which targets membrane Type 1 Matrix Metalloproteinase  MT1 MMP  and is believed to be indicated in cancer metastasis  A Phase I trial  carried out by Cancer Research UK  in an array of solid tumours is ongoing 
As evidenced by MOLN  PIRS and BCYC  there is significant investor interest in antibody mimetic platforms  particularly those with clinical assets 
Valuation   51m or 44p share
We value Avacta at  51m or 44p share  Our sum of the parts valuation allows the assessment of a diverse set of technologies that have different applications albeit all based on the same Affimer technology  This is outlined below 
The Affimer therapeutic platform based on rNPV of its PD L1 LAG 3 bispecific and LG Chem research partnership examined against comparative transactions and recent IPOs 
The Affimer reagents  research and diagnostics  business  based on a sales multiple 
The Affimer animal health business based on a sales multiple 

Affimer therapeutic platform
We base our rNPV of the Affimer therapeutic platform on AVA021  PD L1 LAG 3  and the LG Chem research partnership  We do not value the rest of the early stage pipeline or any other partnership 

For AVA021  we model its market potential in a basket of relapsed refractory cancers  which are PD L1 LAG 3 positive and for which patients have already received PD L1 treatment  The early nature of its development means the exact cancer population that AVA021 will be tested in has not yet been defined  Based on comparative trial with F star s PD L1 LAG 3 bispecific FS118  which is being tested in a Phase I trial in an array of advanced metastatic cancers following progression on PD L1 treatment  We believe a similar trial design is reasonable for Avacta  In the long term  the competitive positioning of AVA021  if clinically successful   particularly the cancer in which it is used  will be key to any success  We assume AVA021 is out licensed pre Phase I start  but after initial Phase I data from the PD L1 Affimer AV004  in 2022 and model in c  300m of milestones split across an upfront payment  clinical and commercial milestones  We have additionally assumed a tiered royalty rate of between 5  to 10  and a launch probability of 2 5   Our model is benchmarked against the total PD L1 global market resulting in approximate market penetration of 5   generating peak sales of c  800m in the US and EU  We will update our AVA021 model accordingly as the clinical programme progresses  We forecast a launch in both the EU and US in 2030 at a starting price of c  100 000 in the US and at a 30  discount in the EU 
For the LG Chem partnership we model the  180m milestone payments for the deal with payments spread to 2030 on assumed classical drug development timelines  eg Phase I start   however  as we have no information on the therapeutic indication or target  significant sensitivity relates to these timelines  and milestones could be spread over longer or shorter periods or could not be received at all  We also do not model royalties due to a lack of information on potential patient populations  We forecast that the first Affimer will enter a Phase I clinical trial in 2022 and will update our model once more information is available 
While the other assets in the pipeline are important for Avacta s long term ambitions  we have limited visibility over their development  While AVA004  PD L1  is more advanced then AVA021 we note that there are no plans to develop it past Phase I trials as Avacta plans to focus its late stage development on AVA021 once AVA004 has provided proof of concept of Affimers in humans  Additionally  due to the crowded PD L1 market we believe AVA004 has little commercial potential on its own although its unique IP position  as an Affimer  could be attractive to partners 
The next most advanced asset  the AVA004 100  PD L1 I DASH  product candidate  is of significant scientific interest  however  due to the very early nature of development and the complexities involved in the asset  we await for its advancement into the clinic before considering its inclusion into our valuation  We additionally note that Avacta has multiple partnerships outside of the LG Chem deal  however  due to limited financial visibility on these partnerships we do not include them in our valuation 
Reagents diagnostics and animal health
We value the reagents and diagnostics divisions on a sales multiple of a relevant comparable  In 2012 German monoclonal antibody company Morphosys divested its research antibody business Antibodies by Design  AbD Serotec  to research tools company Bio Rad to focus on its human therapeutic antibody business  AbD  which had FY12 sales of  18 3m  was divested for  53m  which included cash in the business of  5m  This implies an enterprise value  EV  of  48m and a sales multiple of 2 62x 
We have estimated the FY18 sales of Avacta Animal Health and Avacta Reagents to have been  1 57m and  1 19m  not including assumed milestone payments  respectively  Combining the sales of the Avacta services businesses and the implied AbD sales multiple  we derive a component valuation for the Avacta services businesses of  7 24m  While the AbD services business was much more mature than Avacta s services businesses with c 6x the sales of Avacta s reagents and animal health businesses  we have not included any growth in Avacta s services businesses  despite Avacta s FY19 sales targets for the services business growing by 25  to  1 5m 
Benchmarks  Upside potential on entering the clinic
Due to the early nature of Avacta s therapeutic assets and the range of variables in a potential valuation  we have benchmarked our sum of the parts valuation for Avacta to recent relevant deals and IPOs 
On the deal front  the transaction signed between F star  a private Cambridge  UK based preclinical stage developer of bispecific antibody fragments and Merck for an anti LAG 3 PD L1 bispecific  FS118  provides a useful comparison  The deal was signed in June 2017 on the basis of preclinical data and included payments of  115m in the first two years for a total transaction value of  1bn  While we note that the ownership of F stars PD L1 LAG3 bispecific FS118 has been recently transferred back to F star  we believe the comparison still valid  Utilising a risk adjusted VC  venture capital  based methodology  a 15 year timespan of milestone payments  a 12 5  discount rate and a 50  risk adjustment for whether a similar deal would be signed we obtain a  201m valuation including Avacta s cash and services business 
Alternatively  substituting the exit valuation of the F star transaction with the average IPO valuations  less cash  or enterprise valuations  of two recent relevant NASDAQ IPOs  Harpoon Therapeutics and Bicycle Therapeutics  both in Phase I for their lead assets  results in a VC valuation of Avacta plus its cash and the services businesses of  82m 
Based on these benchmarks we believe Avacta s sum of the parts valuation of  54m or 47p share is valid considering the pre clinical status of its lead asset 
Financials  Funded into 2020
H119 revenue was  0 97m  a 44  decrease from H118   1 47m  driven by a significant reduction in life sciences revenue to  0 29m  vs  0 69m in 1H18   This was a result of the planned reduction in Moderna R D income as development at Avacta completed and assets were transitioned to Moderna  In H219  Avacta expects revenue to pick up as the LG Chem partnership comes online and we forecast FY19 revenues of  3 2m  vs FY18   2 8m  driven by income from LG Chem and Moderna in addition to the reagents diagnostics and animal health divisions  We note a substantial increase in FY20 revenue compared with previous years due to the assumption of additional milestone payments from LG Chem 
Admin expenses remained one of the biggest contributors to the cost base and increased slightly to  4 12m  vs H118   4 0m   COGS fell in the period from  0 46m in H118 to  0 31m in H119 and R D costs increased substantially to  2 41m  vs H118   1 47m  as a result of increased investment in the Affimer therapeutics programmes  We forecast FY19 administrative costs of  8 6m  vs FY18   8 5m   COGS of  0 83m  vs FY18   0 9m  and R D of  6 1m  vs FY18   3 8m   The substantial y o y increase in R D costs is a result of the expected ramp in AVA004 related expenses as the asset moves towards the clinic 
Net loss for H119 was  5 2m  vs  3 95 in H118  driven by the aforementioned decrease in revenues and increase in R D costs  We forecast FY19 net loss of  10 5m 
Net cash as of 31 January 2019 was  11 79m  mainly as result of the net  10 9m capital raise in August 2018  We forecast a cash reach into 2020  however  we forecast a cash raise  by illustrative debt  in 2020 of  10m to fund operations into 2021  This is for illustrative purposes only and the funding gap could be provided by additional partnerships  an equity raise or debt  Further funding needs beyond 2021 will predominately depend on the income received from new and existing business and the ramp of R D costs in relation to the clinical programmes ",2019-06-14,Edison,https://www.investing.com/analysis/affimer--potential-bestinclass-antibody-mimetic-200431518,200431518
104934,326449,AGN,Amgen Allergan Get FDA Nod For Herceptin Biosimilar Kanjinti,opinion,"Amgen  Inc    NASDAQ AMGN   and its biosimilar collaboration partner  Allergan   NYSE AGN   announced that the FDA has approved Kanjinti  trastuzumab anns   their biosimilar of Roche s   OTC RHHBY   breast cancer drug  Herceptin  trastuzumab  Kanjinti received approval for all approved indications of the reference product  Herceptin   HER2 overexpressing adjuvant and metastatic breast cancer  and HER2 overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma  Please note that the biologics license application   BLA   had received complete response letter from the FDA in May 2018  We remind investors that the biosimilar drug is already available in EU since last year Since December last year  the FDA has approved four biosimilar version of Herceptin including Kanjinti  Rest of the biosimilar drugs are Pfizer s   NYSE PFE     Merck Samsung Bioepis   and Celltrion Teva Pharmaceutical s  Herzuma Amgen s shares have declined 9 3  this year so far against an increase of 1 9  for the   Amgen is focusing on developing biosimilar versions of popular drugs  which offers significant growth opportunity Kanjinti is the third biosimilar from Amgen s portfolio to receive approval in the United States  The company now has three approved biosimilar drugs in the United States and Europe   Amjevita  Mvasi  Kanjinti  Currently  Amgen has 10 biosimilar products in its portfolio  A biosimilar version of Johnson and Johnson Merck s Remicade  ABP 710  is under review in the United States and EU Amgen has a collaboration agreement with Allergan for the worldwide development and commercialization of four oncology antibody biosimilars  Kanjinti is the second drug to receive FDA approval under this agreement  Mvasi  biosimilar version of another Roche s cancer drug  Avastin  has also been approved by the FDA but not yet launched  A biosimilar version of Roche s Rituxan is in late stage development for non Hodgkin s lymphoma and rheumatoid arthritis Meanwhile  several Amgen s key drugs are facing rising competition from biosimilars  Sales of products like Neupogen and Neulasta have already been adversely impacted  Several generic versions of Neupogen have been launched  Mylan  NASDAQ MYL  and Coherus launched biosimilars of Neulasta in the United States in mid 2018 early 2019  More biosimilars of Neulasta are expected to be launched in 2019  Other drugs set to face generic competition include Enbrel  Aranesp and Epogen Amgen Inc  Price
    Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-14,Zacks Investment Research,https://www.investing.com/analysis/amgenallergan-get-fda-nod-for-herceptin-biosimilar-kanjinti-200431784,200431784
104935,326450,AGN,Premarket analyst action   healthcare,news,Cancer Genetics  NASDAQ CGIX  initiated with Buy rating and  6  179  upside  price target by Maxim Group AMAG Pharmaceuticals  NASDAQ AMAG  initiated with Neutral rating and  16  15  upside  price target by B Riley FBR Celldex  NASDAQ CLDX  resumed with Strong Buy rating and  10  250  upside  price target by WBB Securities DaVita  NYSE DVA  upgraded to Strong Buy with an  84  21  upside  price target by Raymond James Allergan  NYSE AGN  downgraded to Hold by Argus Research Now read ,2017-12-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-965213,965213
104936,326451,AGN,Teva Pharm to lay off a quarter of workforce  suspends dividend,news,"By Tova Cohen and Ari Rabinovitch TEL AVIV  Reuters    Teva Pharmaceutical Industries  TA TEVA   N TEVA  is to cut its workforce by more than a quarter  give up many of its manufacturing plants and suspend its dividend on ordinary shares in a much anticipated overhaul to help pay off its debts  The Israel based company  the world s largest generic drugmaker  said on Thursday the move will result in a reduction of 14 000 jobs globally  with the majority to come in 2018  The two year restructuring plan is intended to reduce Teva s cost base by  3 billion by the end of 2019  out of an estimated cost base for 2017 of  16 1 billion  Shares in Teva were up 14 6 percent at  18 in New York  but are down 53 percent since January  Investors will like this plan as most are focused on the near term cost cuts and not the business outlook   Wells Fargo   NYSE WFC  analyst David Maris said   However  in our view  the new CEO s  3 billion cost savings goal is larger than we had anticipated  and while this is more needed for survival versus optimization  it may also have significant negative effects to Teva s competitiveness   said Maris  who rates the shares  market perform    Saddled with nearly  35 billion in debt since acquiring Allergan s  N AGN   Actavis  generic drug business for  40 5 billion  Teva made a series of changes after Kare Schultz joined as its new chief executive on Nov  1  In a letter to Israeli Prime Minister Benjamin Netanyahu  Schultz said action was needed to ensure Teva s future   It is clear that without taking drastic steps in the coming weeks and months  the company will be increasingly vulnerable to potential takeover by global financial institutions or activists with their own agendas and the risk is real   he said  Teva expects a restructuring charge from the plan in 2018 of at least  700 million  mostly to come in the second and third quarters and mainly related to severance costs  Additional charges may follow decisions on closures or divestment of plants  R D facilities and office locations   A longer term strategy will come later in the year  however  in the near term we must remain focused on cash flow generation  short term revenue and serving our debt   Schultz said in a letter to employees  SERVICING DEBT  Investors and analysts have questioned how Teva will be able to service its debt in coming years   In a conference call with analysts  Schultz said Teva would use cash flow to pay down debt  initially focusing on bank debt   We have no plans for raising new equity  short term or long term   he told Reuters in an interview  The company also expects help next year from two new branded products   its migraine drug fremanezumab and Austedo  which treats abnormal  involuntary movements associated with Huntington s disease  In the U S  generics market  which has suffered from price declines in the past year  Schultz expects further price erosion overall in 2018  This has led to some products becoming unprofitable  Teva is now determining which products it can adjust the price for and which products it  needs to get out of   Despite the consolidation  Schultz said he is confident Teva can remain competitive because of its broad portfolio of generic drugs  Some 1 700 jobs will be cut and a manufacturing site will be closed in Israel  where the main labor federation threatened to hold a half day general strike on Sunday  the start of the Israeli work week  in protest at the layoffs  Schultz said Teva will maintain its headquarters in Israel  The government went into damage control mode ahead of Teva s announcement  including a telephone call from Netanyahu to Schultz  asking that he keep layoffs in Israel to a minimum  Economy Minister Eli Cohen said Teva s employees should not pay for the company s failed investments abroad   Teva has succeeded thanks to grants and tax benefits it received from the state and thanks to developments by Israeli scientists   he said  adding   We will fight for every employee   The company said dividends on convertible preferred shares would be evaluated on a quarterly basis  
Teva will provide its 2018 outlook in February ",2017-12-14,Reuters,https://www.investing.com/news/stock-market-news/teva-pharm-to-lay-off-a-quarter-of-workforce-suspends-dividend-991160,991160
104937,326452,AGN,Biotech Stock Roundup  Amgen Gets FDA Nod For Kanjinti  Regeneron Presents Data ,opinion,"It was a busy week for the biotech sector  The FDA approved Amgen s   NASDAQ AMGN   biosimilar for a leading breast cancer drug  Herceptin  Meanwhile  Alexion s   NASDAQ ALXN   Ultomiris was approved in Japan  Regeneron REGN  presented positive data on an investigational bispecific monoclonal antibody for lymphoma Recap of the Week s Top Stories Amgen Gets Approval for Biosimilar Kanjinti  Amgen and its biosimilar collaboration partner  Allergan   NYSE AGN    that the FDA has approved Kanjinti  trastuzumab anns   their biosimilar of Roche s blockbuster breast cancer drug  Herceptin   The biosimilar was approved for all approved indications of the reference drug  Herceptin   HER2 overexpressing adjuvant and metastatic breast cancer  and HER2 overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma Amgen has a collaboration agreement with Allergan for the worldwide development and commercialization of four oncology antibody biosimilars  Kanjinti is the second drug to receive FDA approval under this agreement In addition  Amgen announced five year overall survival  OS  analysis from the single arm  phase II BLAST study on leukemia drug  BLINCYTO  The study evaluated Blincyto in patients with minimal residual disease  MRD  positive acute lymphoblastic leukemia  ALL   Results from the study showed a median OS of 36 5 months for Blincyto treated patients with a median follow up of 59 8 months   More than half of the patients who achieved a complete MRD response following the first cycle of Blincyto treatment were alive at five years 
Amgen currently carries a Zacks Rank  3  Hold   You can see Regeneron Presents Positive Data on Lymphoma Candidate  Regeneron  positive early stage data for pipeline candidate  REGN1979  The data will be presented at the 24th Congress of the European Hematology Association  EHA   REGN1979  an investigational bispecific monoclonal antibody  is being evaluated in patients with relapsed or refractory  R R  B cell non Hodgkin lymphoma  B NHL   The data also includes patients with R R diffuse large B cell lymphoma  DLBCL   who had progressed after CAR T therapy  The primary objective was to assess the safety  tolerability and dose limiting toxicities of the candidate  High response rates observed with REGN1979 in both relapsed or refractory diffuse large B cell lymphoma and follicular lymphoma were encouraging  Moreover  two patients  who failed CAR T therapy and received REGN1979 80 mg  achieved complete response The R R follicular lymphoma  FL  grades 1 to 3a treatment arm showed an overall response rate of 93   13 of 14 patients  in patients  who received doses of 5 mg or more  with a complete response rate of 71   10 of 14 patients   In DLBCL patients treated with REGN1979 80 mg to 160 mg  an overall response rate of 57  was observed  In R R DLBCL patients  whose disease progressed after CD 19 directed CAR T therapy  two out of four achieved a complete response  The company will initiate a phase II program later in the month for a potential registration  and proactively evaluate active REGN1979 doses in indolent and aggressive non Hodgkin lymphoma Alexion s Ultomiris Gets Approval in Japan   Alexion announced that Japan s Ministry of Health  Labour and Welfare  MHLW  has approved Ultomiris  ravulizumab   the first and only long acting C5 complement inhibitor administered every eight weeks  for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  PNH   The drug is already approved in the United States   The approval was based on comprehensive results from two phase III studies  which included 441 patients who had either never been treated with a complement inhibitor before  or who had been stable on Alexion s lead drug Soliris  Results showed that the efficacy of Ultomiris administered every eight weeks was non inferior to the efficacy of SOLIRIS administered every two weeks on all 11 endpoints Earlier  Alexion announced positive  long term data from the extension of the phase III study on Ultomiris and Soliris in complement inhibitor na ve  adult patients with PNH  The data demonstrated that Ultomiris administered every eight weeks provided consistent efficacy and safety through 52  weeks  with no cases of breakthrough hemolysis associated with incomplete C5 complement inhibition  The data was presented at the Annual Congress of the European Hematology Association  Ultomirus was studied in the largest ever phase III program in PNH Savara Crashes on Late Stage Study Failure  Savara   NASDAQ SVRA    after it announced that its lead pipeline candidate  Molgradex  failed to meet the primary endpoint in the pivotal phase III study   IMPALA   evaluating it in autoimmune alveolar pulmonary proteinosis  aPAP   a rare lung disorder  The IMPALA study evaluated Molgradex  an inhaled formulation of recombinant human granulocyte macrophage colony stimulating factor  GM CSF   in patients with aPAP compared to placebo for improvement in alveolar arterial oxygen gradient  A aDO2  as its primary endpoint  The study evaluated two dose administrations   once daily continuous administration of and once daily in seven day intermittent cycles   of 300  g Molgradex over 24 weeks  Data from the study demonstrated average improvement of 12 1 mmHg in patients who were administered Molgradex once daily continuously compared with an improvement of 8 8 mmHg for placebo  However  the treatment difference of 4 6 mmHg failed to meet the primary endpoint Molgradex also failed to achieve improvement of statistical significance in two key secondary endpoints   the six minute walk distance  6MWD  and requirement for whole lung lavage   WLL   Abeona Gets FDA Fast Track Designation for Gene Therapy  Abeona Therapeutics   NASDAQ ABEO   announced that the FDA has granted Fast Track designation to its gene therapy ABO 202 program  ABO 202 is administered as a one time adeno associated virus 9  AAV9  gene therapy that delivers a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs  It is being evaluated for CLN1 disease  which is also known as Infantile Neuronal Ceroid Lipofuscinosis or infantile Batten disease  The company is planning to initiate a phase I II study evaluating ABO 202 in patients with CLN1 disease and will provide guidance on the timing of the study later in the year PerformanceMedical   Biomedical and Genetics Industry 5YR   ReturnThe NASDAQ Biotechnology index gained 4 67  in the last five trading sessions  Among the major biotech giants  Alexion gained 4 46  in the period  Over the past six months  shares of Celgene  NASDAQ CELG  have surged 45 81  whereas Biogen  NASDAQ BIIB  stock has lost 20 95    See the last biotech stock roundup here    What s Next in Biotech Stay tuned for more pipeline and regulatory updates This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data-200432879,200432879
104938,326453,AGN,Ironwood s Linzess Lowers Abdominal Symptoms In IBS C Patients,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   along with partner Allergan   NYSE AGN   announced positive top line data from the phase IIIb study on Linzess  linaclotide  for treating multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation  IBS C  
The study met both primary and secondary endpoints with statistical significance and showed that Linzess improved the overall abdominal symptoms of bloating  pain and discomfort in adult patients with IBS C as compared to placebo 
Shares of Ironwood were up almost 8 1  following this news on Tuesday  In fact  the stock has rallied 11  so far this year  outperforming the  rise of 6 6  

 
Linzess is marketed to treat IBS C as well as chronic idiopathic constipation  CIC  in the United States and across 30 other countries  It is commercialized in collaboration with Allergan in the United States  Ironwood and Allergan co develop and co commercialize Linzess and equally share the U S  collaboration profits or losses as well as development costs of the drug 
Linzess is marketed by Allergan for IBS C in Europe and Canada under the brand name  Constella 
However  in the United States  majority of adult IBS C patients complain of symptoms  such as abdominal bloating  pain and discomfort at least once a week  If approved  this new indication would expand the eligible patient population for the drug and drive its sales higher 
This double blind placebo controlled phase IIIb study evaluated the safety and efficacy of Linzess 290 mcg in adult IBS C patients  who took the drug once daily for 12 weeks  followed by a four week withdrawal period  The primary efficacy endpoint measured the change in patients  abdominal score based on daily assessments of their abdominal bloating  discomfort and pain  Additional endpoints included change in the spontaneous bowel movement frequency  complete spontaneous bowel movement frequency  stool consistency and straining 
Ironwood plans to present additional results from this analysis at an upcoming scientific conference and via peer reviewed publications 
Notably  Linzess has performed encouragingly on the back of strong demand and expansion in new patient population and geographical regions  Sales of Linzess were impressive in 2018 and the drug also started 2019 on a strong note  It generated net sales of  161 3 million in the United States during the first quarter of 2019  Label expansion and approval in new countries for this medicine are driving its sales higher  The product is set to achieve a blockbuster status by 2020 end 
Earlier this month  Ironwood and Allergan initiated its dosing in the phase II study on MD 7246  a delayed release version of Linzess  The study is evaluating the candidate on patients suffering abdominal pain associated with irritable bowel syndrome alongside diarrhea  IBS D   Top line data from the study are expected in the second half of 2020 
Earlier this January  Linzess received an approval in China for IBS C  The company along with its partner AstraZeneca   NYSE AZN   will launch the same in the country in the second half of 2019  This  in turn  is likely to boost Ironwood s top line 
Zacks Rank   Key Pick
Ironwood currently carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is Evotec AG   OTC EVTCY    which sports a Zacks Rank  1  Strong Buy   You can see  
Evotec s earnings estimates have been revised 14 4  upward for 2019 and 41 2  for 2020 over the past 60 days  The stock has surged 32 7  year to date 
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/ironwoods-linzess-lowers-abdominal-symptoms-in-ibsc-patients-200433065,200433065
104939,326454,AGN,Strike over Teva Pharm job cuts briefly shuts down Israel,news,By Steven Scheer JERUSALEM  Reuters    Israel s main public sector labor union staged a half day strike on Sunday  closing the airport  stock exchange  banks and all government ministries to protest at mass layoffs planned by Teva Pharmaceutical Industries  TA TEVA   Debt ridden Teva  N TEVA   one of Israel s largest companies and the world s largest generics drugmaker  said last week it would cut its global workforce by more than a quarter  or 14 000 jobs  Some 1 700 jobs will be cut and a manufacturing site will be closed in Israel  This has angered unions and politicians  who believe Teva s employees should not pay for the company s failed investments abroad  Sunday is the beginning of the Israeli work week  Hundreds of thousands of workers went on strike until 12 noon  1000 GMT  and many held solidarity rallies outside Teva facilities  Protesters also blocked major roads across the country  including the entrance of Jerusalem  and burned tires outside many Teva offices  Demonstrators sat in the middle of streets and crosswalks  halting traffic in a number of cities  The Histadrut labor federation said hundreds of Teva workers in its Jerusalem plant were squatting inside and would continue a strike again on Monday  while there will also be strikes at other Teva facilities   The Tel Aviv Stock Exchange shortened its trading day  opening at 1 pm and closed as usual at about 4 30 pm  Teva s shares fell 0 8 percent  Departing flights at Tel Aviv s Ben Gurion Airport between 8 a m  and at least 12 p m  were either canceled or delayed  Similarly  no flights were allowed to land until after 12 p m  PUBLIC TRANSIT KEPT RUNNING FOR SOLDIERS Trains and buses were initially supposed to strike as well  but the Histadrut allowed public transit to operate so that soldiers could get back to their bases as usual   We are fighting on behalf of Teva s workers to save Israel s industry     and to convey the message that layoffs are the last and not the first step in the public and private sectors   Histadrut chief Avi Nissenkorn said  He called the current crisis the fault of Teva s management and board  adding   It is the state s responsibility to prevent thousands of Israeli families from paying the price for this   Prime Minister Benjamin Netanyahu said he planned to meet with Kare Schultz  Teva s chief executive  this week to try and minimize the blow to workers   We need to do everything possible to prevent the closure of plants in Jerusalem   Netanyahu said at the outset of a cabinet meeting  adding Teva should remain based in Israel   It employs thousands of workers   he said   It started as an Israeli company and we want it to remain as an Israeli company  We will use various means at our disposal to try and achieve these goals   He did not elaborate  Schultz said Teva would maintain its headquarters in Israel  Saddled with nearly  35 billion in debt since acquiring Allergan s  N AGN   Actavis  generic drug business for  40 5 billion  Teva made a series of changes after Schultz joined as its new chief executive on Nov  1  Its two year restructuring plan is intended to reduce Teva s cost base by  3 billion by the end of 2019  out of an estimated cost base for 2017 of  16 1 billion  Nissenkorn said he would meet with Israel s finance and economy ministers  along with the Teva workers union  on Monday ,2017-12-17,Reuters,https://www.investing.com/news/stock-market-news/strike-briefly-shuts-down-israel-over-teva-pharm-job-cuts-1001058,1001058
104940,326455,AGN,Workers at Israel s Teva Pharm block roads  continue protest over job cuts,news,By Steven Scheer JERUSALEM  Reuters    Workers at Israel s Teva Pharmaceutical Industries  TA TEVA  protested pending job cuts for a second straight day on Monday  blocking roads and shutting down a number of the drugmaker s plants nationwide  Hundreds of Teva  N TEVA  employees  many wearing white lab coats  blocked the road and entrance to the finance ministry in Jerusalem  where union leaders were set to meet with finance and economy ministry officials and Teva representatives  Debt ridden Teva  the world s largest generics drugmaker  said last week it would cut its global workforce by more than a quarter  or 14 000 jobs  including 1 700 in Israel where it will also close a manufacturing site  The plans have angered unions and politicians  who believe employees should not pay for the company s failed investments abroad  Prime Minister Benjamin Netanyahu said on Sunday that he planned to meet with Teva CEO Kare Schultz this week to try and minimize the impact on staff  after thousands of workers belonging to public sector unions staged a half day strike on Sunday to show solidarity with Teva workers  The strike forced closure of Ben Gurion airport  banks  the Tel Aviv Stock Exchange and all government ministries   Teva is one of the biggest employers in Israel  Avi Nissenkorn  head of the Histadrut  the umbrella organization for all public sector unions  said  job cuts were a last resort  and called on the government to minimize harm to workers and ensure Teva s plants remain in Israel  Workers at Teva Medical blocked an entrance to the port city of Ashdod and the company s headquarters  and two other plants were shutdown  At its Jerusalem plant  hundreds of workers have been holed up since Sunday and the facility was likely to remain closed on Monday  At a plant in Kfar Saba  250 staff planned to stop work between 1200 p m and 4 p m  1000 1400 GMT  while protests will take place throughout the day at other Teva facilities  according to Histadrut  The layoffs stem from Teva taking on  35 billion in debt to acquire Allergan s  N AGN   Actavis  generic drug business for  40 5 billion last year  a move that coincided with rapidly declining generic drug prices in the United States and the start of competition to its blockbuster multiple sclerosis drug Copaxone  Under a two year restructuring plan  Teva plans to reduce its cost base by  3 billion by the end of 2019  from an estimated  16 1 billion for 2017 ,2017-12-18,Reuters,https://www.investing.com/news/stock-market-news/workers-at-israels-teva-pharm-block-roads-continue-protest-over-job-cuts-1002344,1002344
104941,326456,AGN,Ionis earns  45M fee from Roche for rights to Huntington s candidate,news,U S  regulators have signed off on Ionis Pharmaceuticals   NASDAQ IONS  license agreement with Roche  OTCQX RHHBY  for the rights to IONIS HTTrx  an antisense drug for the potential treatment of Huntington s disease  HD   an Orphan Drug designation in the U S  and Europe Ionis will transfer the ongoing open label extension study to Roche who will assume responsibility for all clinical development  regulatory and commercialization activities and costs  The action triggers a  45M license fee payment to Ionis from Roche The companies are collaborating in HD under a 2013 agreement Now read ,2017-12-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/ionis-earns-45m-fee-from-roche-for-rights-to-huntingtons-candidate-1002962,1002962
104942,326457,AGN,U S  administrative court deals major blow to patent transfer deals,news,By Jan Wolfe  Reuters    A U S  administrative court on Tuesday asserted its right to review the validity of patents owned by the University of Minnesota  rejecting the public university s argument that its  sovereign  status grants it immunity  The ruling by the U S  Patent Trial and Appeal Board is a setback to efforts by pharmaceutical and technology companies to shield patents from the court by transferring them to entities like state universities and Native American tribes   As government entities  they can assert sovereign immunity  a legal doctrine that holds they cannot be subject to litigation without their consent  In a January ruling in a different case  PTAB said it recognized the defense of sovereign immunity  But the board said on Tuesday the University of Minnesota had waived its immunity by filing lawsuits in federal court in 2014 accusing telecom equipment maker Ericsson  ST ERICb  and several other companies of infringing the same patents  Ericsson challenged the validity of the University of Minnesota s patents before PTAB  and the case was put on hold pending a decision by the board  Neither Ericsson nor the University of Minnesota immediately responded to requests for comment  Many of the patents the board reviews are also being litigated in federal court  so the ruling cuts back sovereign immunity as a viable defense before the tribunal  said Matthew Rizzolo  a patent lawyer at Ropes   Gray not involved in the case  The ruling casts doubt on a strategy adopted by the drug company Allergan Plc  N AGN   which in September transferred patents in its bestselling dry eye treatment Restasis to the upstate New York Saint Regis Mohawk Tribe  which licensed them back in exchange for ongoing payments   Allergan proceeded to argue PTAB had no jurisdiction over the Restasis patents  which had been challenged there by generic manufacturers   Lawmakers criticized the deal as a sham designed to allow Allergan to maintain a drug monopoly  U S  Senator Claire McCaskill  a Missouri Democrat  has introduced legislation aimed at preventing tribes from asserting sovereign immunity in cases before the patent board  At the time it announced its patent transfer  Allergan noted it remained willing to have its patents subject to review in federal court  A federal judge subsequently found its Restasis patents invalid  rendering its deal with the Mohawk tribe largely moot  Other patent owners have adopted similar deals with tribes ,2017-12-19,Reuters,https://www.investing.com/news/stock-market-news/us-administrative-court-deals-major-blow-to-patent-transfer-deals-1011842,1011842
104943,326458,AGN,Allergan Up As Analyst Statement Sparks Business Split Rumors,opinion,"Shares of Allergan plc   NYSE AGN   were up more than 6  on Jun 19 after an analyst at Evercore ISI stated that a break up of the company s business may be in the cards  The analyst also stated that the company is likely to provide an update on the split in the next couple of months  The analysis was based on a conference call with the company s vice president of investor relations on Tuesday Some analysts believe that splitting of Allergan s business  if it materializes  would be a positive and has in fact been debated on for long  Moreover  activist investors have long been pushing for a  of chief executive officer and chairman positions  both currently held by Brent Saunders Shares of the company have decreased 4 1  so far this year compared with the  s decline of 17 1   The stock has declined 25 7  in the past year and has underperformed its peers in the said period The decline in share price can be attributed to multiple challenges that the company is facing for some time now Sales of Allergan s major drugs have declined due to loss of exclusivity  The first generic versions of Alzheimer s treatment  Namenda XR and Estrace cream were launched in the first quarter of 2018  Other products including Bystolic  Delzicol  Gelnique  Saphris and Viibryd are all slated to lose exclusivity over the next few years  Loss of exclusivities hurt sales by  1 2 billion in 2018 and is expected to have an adverse impact of another  1 4 billion in 2019 Competition for Allergan s drugs from other branded drugs is also on the rise  Restasis faces competition from Takeda Pharmaceutical s Xiidra  The drug is set to face generic competition later this year which is likely to impact the sales further  Its most popular drug and the largest revenue generator  Botox is facing tough competition from CGRP antibodies for migraine launched in 2018  These include Amgen Novartis  Eli Lilly   NYSE LLY   and Teva Pharma s CGRP migraine treatments Aimovig  Emgality and Ajovy  respectively  Botox also faces competition in the anti wrinkle segment from Evolus    NASDAQ EOLS   Jeuveau injection approved in February  Linzess faces competition from Bausch Health s   NYSE BHC   Trulance The split could lead to better focus on the company s key therapeutic areas  CNS  eye care and GI  thus enhancing the company s pipeline and portfolio of new drugs  which can offset the loss of sales due to branded and generic competition  The company can also expand its therapeutic areas to include markets with encouraging opportunities Moreover  separation of Allergan into two or more separate entities also increases the viability of a possible acquisition for each entity  However  the company s plan and timeline for a split is not known  Any synergies or dis synergies will be based on the division of products made by the company Allergan plc Price
    Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/allergan-up-as-analyst-statement-sparks-business-split-rumors-200433364,200433364
104944,326459,AGN,Company News For Jun 20  2019,opinion,Shares of Viacom Inc    NASDAQ VIAB   gained 2 1  following news that media giant CBS Corp    NYSE CBS   plans to bid for the companyUnited States Steel Corp  s   NYSE X   shares climbed 4 1  after it decided to close two blast furnaces due to lack of steel demand on the back of current trade conflictAdobe Inc    NASDAQ ADBE   shares surged 5 2  after the company posted second quarter fiscal 2019 adjusted earnings per share of  1 83  beating the Zacks Consensus Estimate of  1 78Shares of Allergan plc   NYSE AGN   soared 6 2  after the company declared positive phase 3b results for its constipation drug jointly developed with Ironwood Pharmaceuticals Inc    NASDAQ IRWD ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jun-20-2019-200433292,200433292
104945,326460,AGN,The Zacks Analyst Blog Highlights  Amgen  Alexion  Regeneron  Allergan And Savara,opinion,"For Immediate Release
Chicago  IL   June 20  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Amgen   NASDAQ AMGN    Alexion   NASDAQ ALXN    Regeneron   NASDAQ REGN    Allergan   NYSE AGN   and Savara   NASDAQ SVRA   
Here are highlights from Wednesday s Analyst Blog  
Biotech Stock Roundup  AMGN  ALXN  REGN and More
It was a busy week for the biotech sector  The FDA approved Amgen s biosimilar for a leading breast cancer drug  Herceptin  Meanwhile  Alexion s Ultomiris was approved in Japan  Regeneron presented positive data on an investigational bispecific monoclonal antibody for lymphoma 
Recap of the Week s Top Stories 
Amgen Gets Approval for Biosimilar Kanjinti  Amgen and its biosimilar collaboration partner  Allergan announced that the FDA has approved Kanjinti  trastuzumab anns   their biosimilar of Roche s blockbuster breast cancer drug  Herceptin   The biosimilar was approved for all approved indications of the reference drug  Herceptin   HER2 overexpressing adjuvant and metastatic breast cancer  and HER2 overexpressing metastatic gastric cancer or gastroesophageal junction adenocarcinoma 
Amgen has a collaboration agreement with Allergan for the worldwide development and commercialization of four oncology antibody biosimilars  Kanjinti is the second drug to receive FDA approval under this agreement 
In addition  Amgen announced five year overall survival  OS  analysis from the single arm  phase II BLAST study on leukemia drug  BLINCYTO  The study evaluated Blincyto in patients with minimal residual disease  MRD  positive acute lymphoblastic leukemia  ALL   Results from the study showed a median OS of 36 5 months for Blincyto treated patients with a median follow up of 59 8 months   More than half of the patients who achieved a complete MRD response following the first cycle of Blincyto treatment were alive at five years 
Amgen currently carries a Zacks Rank  3  Hold   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here  
Regeneron Presents Positive Data on Lymphoma Candidate  Regeneron announced positive early stage data for pipeline candidate  REGN1979  The data will be presented at the 24th Congress of the European Hematology Association  EHA   REGN1979  an investigational bispecific monoclonal antibody  is being evaluated in patients with relapsed or refractory  R R  B cell non Hodgkin lymphoma  B NHL   The data also includes patients with R R diffuse large B cell lymphoma  DLBCL   who had progressed after CAR T therapy  The primary objective was to assess the safety  tolerability and dose limiting toxicities of the candidate  High response rates observed with REGN1979 in both relapsed or refractory diffuse large B cell lymphoma and follicular lymphoma were encouraging  Moreover  two patients  who failed CAR T therapy and received REGN1979 80 mg  achieved complete response 
The R R follicular lymphoma  FL  grades 1 to 3a treatment arm showed an overall response rate of 93   13 of 14 patients  in patients  who received doses of 5 mg or more  with a complete response rate of 71   10 of 14 patients   In DLBCL patients treated with REGN1979 80 mg to 160 mg  an overall response rate of 57  was observed  In R R DLBCL patients  whose disease progressed after CD 19 directed CAR T therapy  two out of four achieved a complete response  The company will initiate a phase II program later in the month for a potential registration  and proactively evaluate active REGN1979 doses in indolent and aggressive non Hodgkin lymphoma 
Alexion s Ultomiris Gets Approval in Japan   Alexion announced that Japan s Ministry of Health  Labour and Welfare  MHLW  has approved Ultomiris  ravulizumab   the first and only long acting C5 complement inhibitor administered every eight weeks  for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  PNH   The drug is already approved in the United States   The approval was based on comprehensive results from two phase III studies  which included 441 patients who had either never been treated with a complement inhibitor before  or who had been stable on Alexion s lead drug Soliris  Results showed that the efficacy of Ultomiris administered every eight weeks was non inferior to the efficacy of SOLIRIS administered every two weeks on all 11 endpoints 
Earlier  Alexion announced positive  long term data from the extension of the phase III study on Ultomiris and Soliris in complement inhibitor na ve  adult patients with PNH  The data demonstrated that Ultomiris administered every eight weeks provided consistent efficacy and safety through 52  weeks  with no cases of breakthrough hemolysis associated with incomplete C5 complement inhibition  The data was presented at the Annual Congress of the European Hematology Association  Ultomirus was studied in the largest ever phase III program in PNH 
Savara Crashes on Late Stage Study Failure  Savara crashed after it announced that its lead pipeline candidate  Molgradex  failed to meet the primary endpoint in the pivotal phase III study   IMPALA   evaluating it in autoimmune alveolar pulmonary proteinosis  aPAP   a rare lung disorder  The IMPALA study evaluated Molgradex  an inhaled formulation of recombinant human granulocyte macrophage colony stimulating factor  GM CSF   in patients with aPAP compared to placebo for improvement in alveolar arterial oxygen gradient  A aDO2  as its primary endpoint  The study evaluated two dose administrations   once daily continuous administration of and once daily in seven day intermittent cycles   of 300  g Molgradex over 24 weeks  Data from the study demonstrated average improvement of 12 1 mmHg in patients who were administered Molgradex once daily continuously compared with an improvement of 8 8 mmHg for placebo  However  the treatment difference of 4 6 mmHg failed to meet the primary endpoint 
Molgradex also failed to achieve improvement of statistical significance in two key secondary endpoints   the six minute walk distance  6MWD  and requirement for whole lung lavage   WLL   
Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-amgen-alexion-regeneron-allergan-and-savara-200433281,200433281
104946,326461,AGN,Allergan  AGN  In Focus  Stock Moves 6 2  Higher,opinion,Allergan plc   NYSE AGN   was a big mover last session  as the company saw its shares rise more than 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  which remained volatile and traded within the range of  115 73   139 51 in the past one month time frame  witnessed a sharp increase yesterday The company s Zacks Consensus Estimate for the current quarter has moved higher over the past few weeks  suggesting that more solid trading could be ahead for Tailored Brands  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road Allergan currently has a Zacks Rank  3  Hold  while its  is positive Allergan plc Price   Investors interested in the Medical   Genetics Drugs industry may consider Adamas Pharmaceuticals  Inc    NASDAQ ADMS    which has a Zacks Rank  2  Buy   You can see Is AGN going up  Or down  Predict to see what others think Up or DownWill you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-in-focus-stock-moves-62-higher-200433276,200433276
104956,326471,AGN,Blueprint up 4  on planned data presentation from early stage study of BLU 285 in systemic mastocytosis,news,Blueprint Medicines  BPMC  3 9   perks up on lower than normal volume in response to its announcement of a data presentation at ASH in December Updated results from a Phase 1 clinical trial assessing BLU 285 in patients with advanced systemic mastocytosis will be presented during the Plenary Scientific Session on December 10  one of only six abstracts chosen Previously  Blueprint s BLU 285 shows encouraging action in early stage GIST study  Dec  1  2016 Now read ,2017-11-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/blueprint-up-4-on-planned-data-presentation-from-earlystage-study-of-blu285-in-systemic-mastocytosis-761868,761868
104957,326472,AGN,CMS issues final list of therapies facing expiration of pass through status for 2018,news,The Centers for Medicare   Medicaid Services  CMS  has issued its final update on the therapies facing expiration of pass through status in 2018 Normal Medicare reimbursement is based on past claims  not possible for new products  Pass through status  which allows payment for new products on a temporary basis  typically runs for two to three years to establish claims history  The pass through price is first determined by the wholesale acquisition cost  WAC  plus 6   then transitions to average selling price plus 6  Affected products include Omeros  NASDAQ OMER   Omidria  phenylephrine and ketorolac injection Eli Lilly  NYSE LLY   Amyvid  florbetapir Astellas  OTCPK ALPMY  Merck  NYSE MRK   Zerbaxa  ceftolozane tazobactam Allergan  NYSE AGN   Dalvance  dalbavancin The Medicines Company  NASDAQ MDCO   Orbactiv  oritavancin Novartis  NYSE NVS   Signifor  pasireotide J J  NYSE JNJ   Sylvant  siltuximab  Alimera Sciences   NASDAQ ALIM   Iluvien  fluocinolone acetonide intravitreal implant Amgen  NASDAQ AMGN   Blincyto  blinatumomab Bristol Myers Squibb  NYSE BMY   Opdivo  nivolumab Merck  Keytruda  pembrolizumab Source  BloombergNow read ,2017-11-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/cms-issues-final-list-of-therapies-facing-expiration-of-passthrough-status-for-2018-763052,763052
104958,326473,AGN,U S  senators press Allergan for details on patent deal with tribe,news,By Jan Wolfe  Reuters    A group of U S  senators on Tuesday asked drugmaker Allergan  NYSE AGN  Plc to produce documents relating to its agreement to transfer patents to a Native American tribe to shield them from review by an administrative court   Democratic Senators Sherrod Brown  Maggie Hassan  Amy Klobuchar  Al Franken and Patty Murray made the request for documents in a letter to Allergan Chief Executive Brent Saunders  The letter was critical of Allergan s deal with New York s Saint Regis Mohawk Tribe  saying  it is difficult to conceive of Allergan s transaction as anything other than a sham to subvert the existing intellectual property system   Allergan contends the tribe s status as a sovereign entity places the patents outside the jurisdiction of the U S  Patent Trial and Appeal Board  or PTAB  Allergan on Sept  8 transferred patents on its dry eye medication Restasis to the tribe  which agreed to license them exclusively back to the company in exchange for ongoing payments  A federal court invalidated Allergan s Restasis patents on Oct  16  rendering the tribal deal mostly meaningless  Allergan has appealed that ruling  In Tuesday s letter  the senators said they were concerned that tribes could reach similar deals with other manufacturers of brand name prescription drugs  They asked Allergan to disclose the terms of its agreement with the tribe and explain whether it has plans for similar patent transactions  The lawmakers also demanded to see  any legal briefs or memos prepared by Allergan regarding sovereign immunity   particularly memos on the question of whether Allergan s agreement could immunize patents from review by federal courts  The lawmakers gave Allergan a December 1 deadline to produce the requested documents   A bipartisan group of representatives from the House Oversight and Government Committee made a similar request for documents from Allergan in October   Allergan spokesman Mark Marmur said the company welcomes the opportunity to continue to brief lawmakers about the deal  Marmur also defended Allergan s bid to avoid PTAB review  saying  experts across the legal  biopharmaceutical and business communities  have raised concerns about the fairness of the administrative process   Allergan has said it does not object to its patents being reviewed in federal court  which it called a fair and time tested process ,2017-11-07,Reuters,https://www.investing.com/news/stock-market-news/us-senators-press-allergan-for-details-on-patent-deal-with-tribe-839738,839738
104959,326474,AGN,Allergan  AGN  Q1 Earnings And Revenues Top Estimates,opinion,"Allergan  NYSE AGN  came out with quarterly earnings of  3 79 per share  beating the Zacks Consensus Estimate of  3 55 per share  This compares to earnings of  3 74 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 6 76   A quarter ago  it was expected that this Botox maker would post earnings of  4 15 per share when it actually produced earnings of  4 29  delivering a surprise of 3 37  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Allergan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  3 60 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 2 04   This compares to year ago revenues of  3 67 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Allergan shares have added about 10 6  since the beginning of the year versus the S P 500 s gain of 17  
What s Next for Allergan 
While Allergan has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Allergan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 17 on  3 85 billion in revenues for the coming quarter and  16 39 on  15 15 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the bottom 33  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-q1-earnings-and-revenues-top-estimates-200417906,200417906
104960,326475,AGN,Allergan to sell a quarter of its Teva stake in first quarter of 2018,news,"By Michael Erman NEW YORK  Reuters    Allergan Plc  N AGN  said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel s Teva Pharmaceutical Industries  TA TEVA   N TEVA  during the first quarter of 2018  as it starts to unwind its position in the struggling generic drugmaker  Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a  JP Morgan Chase  and Co  N JPM  unit   acting as a dealer for the shares   sometime next quarter  The JP Morgan unit will pay a price based on the average trading price over a yet to be determined period before the sale  Allergan sold its generics business to Teva in August 2016 for  33 billion in cash and 100 million shares of the Israeli generic drugmaker  worth around  5 3 billion at the time  Under the terms of the deal  Allergan had to hold the shares for at least one year  That has turned out to be a costly agreement for the drugmaker  as Teva s shares have lost more than three fourths of their value since the deal  Allergan s shares have lost around a third of their value over that period  Allergan said on Nov  1 that it planned to begin selling its Teva stake  and this was the first announced sale of the stock  Two of Israel s leading financial news outlets reported later that week that billionaire businessman Len Blavatnik was looking to buy a significant stake in debt ridden Teva  possibly through a deal with Allergan   It was not clear who the ultimate buyer of Allergan s shares will be in the JP Morgan transaction  In the same filing  Allergan said it had taken a margin loan from JP Morgan on its whole 100 million share stake in Teva  
It did not say how much it was borrowing against the shares  but said it planned to use proceeds from the loan to finance the buyback of 2019 bonds ",2017-11-13,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-sell-a-quarter-of-its-teva-stake-in-q1-2018-852441,852441
104961,326476,AGN,Teva Pharmaceutical set for major layoffs in Israel  U S   report,news,"TEL AVIV  Reuters    Teva Pharmaceutical Industries  NYSE TEVA  is expected to cut 20 25 percent of its workforce in Israel  where it employs 6 860 people  and a few thousand more jobs are to go in the United States  financial news website Calcalist said on Thursday  The world s largest generic drugmaker will send termination letters to  tens of percents  of its 10 000 employees in the United States in coming weeks  Calcalist said  citing people familiar with the matter  Teva s new Chief Executive Kare Schultz is working out the details with regional management in Israel and the United States  Calcalist said  adding that those set to be ousted include its chief scientific officer and president of research and development  Michael Hayden  A spokesman for Teva declined to comment on the report  In response to the report  the Histadrut labor federation said it would not accept any unilateral moves by Teva s management   Any efficiency measures  if and when they arise  will be done through negotiations and with the agreement of the Histadrut and the labor unions   Histadrut spokesman Yaniv Levi said   Lay offs are the last resort   Teva s share price was 2 9 percent lower in Tel Aviv at 1343 GMT  Teva is widely expected to implement a cost cutting program following the publication of third quarter results earlier this month  The company said it would miss 2017 profit forecasts due to falling prices of generics in the U S  market and weakening sales of its multiple sclerosis drug Copaxone  Saddled with nearly  35 billion in debt due to its  40 5 billion acquisition of Allergan s generic drug business  Actavis   NYSE AGN  last year  investors have been pushing Teva for clarity on its future   It will be an absolute priority for me that we stabilize the company s operating profit and cash flow in order to improve our financial profile   Schultz said on a post earnings call with analysts  Interim Chief Financial Officer Mike McClellan has said the company was  working on a 2018 plan and evaluating all options   Teva has been selling off assets to help meet its debt payments  
Fitch Ratings this month downgraded Teva s debt to junk ",2017-11-23,Reuters,https://www.investing.com/news/stock-market-news/teva-pharmaceutical-set-for-major-layoffs-in-israel-us-report-904997,904997
104962,326477,AGN,Orexo  A Robust Q1 Despite A Seasonally Weak Market,opinion,"Orexo AB  ST ORX  s Q119 results reinforced its continuing profitability with total revenues rising 25  y o y to SEK174 3m  Zubsolv led the revenue charge comprising 93  of total revenues and growing 23  y o y despite the seasonally weak first quarter of the opioid use dependency market  The effect on US Zubsolv  which increased in price by 4  from January 2019  from four Suboxone film generic entrants is so far minor 

No real surprises in Q119
Growth of 23 3  in US Q119 Zubsolv revenues to SEK161 7m  SEK131 1m in Q118  continues to dominate Orexo s investment case with a growing product despite an increasingly genericised market  Cost control continues to be a focus  with Orexo s gross margin rising to 85  from 65  in Q118  This helped Q119 profit after tax rise to SEK14 1m compared to SEK25 9m in Q118  when traditionally Q1 is a loss making quarter  This Q1 result was despite R D investment in the pipeline and SEK49m in IP litigation costs  Orexo s cash balance increased to SEK647 4m  SEK437 5m at the end of Q118   With litigation costs now expected to have a minor role for the rest of this year  the use of Orexo s growing cash balance in M A and in licensing transactions will play an important role in diversifying the company s future  The impact of the four generic Suboxone entrants on Zubsolv has been thankfully minor  but the changing market share dynamics will need to be closely watched  Ex US Zubsolv partnerships in 2019 should be expected 
Litigation costs to decline in an appeal process
The earlier decision taken by the US District Court regarding patent  996 is unchanged  The court s recent decision held that Actavis  NYSE AGN  does not infringe patent  996 for its generic versions of Subutex and Suboxone  and we did not include any award for damages in our model  We have increased our FY19 total operational cost estimate mainly driven by a one off SG A expense to SEK538m  which remains close to Orexo s c SEK500m guidance  Irrespective of declining IP legal costs for the remainder of FY19  Orexo s  330 and  996 patents remain in force  ensuring US Zubsolv exclusivity until 2032 
Valuation  A number of moving parts
Our valuation takes into account a number of changes in the quarter and moves from SEK3 42bn or SEK97 7 per share to SEK3 52bn or SEK98 62 per share  Foreign exchange rates carried forward largely cancelled out the increased FY19e administrative expenses  while the reduction in FY19e CoGS from SEK115m to SEK112m and our introduction of a flat total market between Q4 and Q1 for future years resulted in the c 1  increase in our valuation 


Business description
Orexo is a Swedish speciality pharma company  with expertise in drug delivery reformulation technologies  in particular  sublingual formulations  and a US commercial infrastructure for its opioid dependence therapy  Zubsolv  marketed by Orexo in the US and being out licensed to partners ex US   It also has three other clinical assets including OX124  which has reported positive Phase I results ",2019-05-08,Edison,https://www.investing.com/analysis/orexo-a-robust-q1-despite-a-seasonally-weak-market-200418617,200418617
104963,326478,AGN,Conatus Down More Than 60  In The Past 90 Days  Here s Why,opinion,Shares of Conatus Pharmaceuticals Inc    NASDAQ CNAT   have declined sharply in the past three months  In fact  the stock has plunged 60 6   wider than the  dip of 2 8  In March 2019  Conatus announced that the ENCORE NF study  which evaluated its lead pipeline candidate   emricasan   for treating patients with biopsy confirmed nonalcoholic steatohepatitis  NASH  and liver fibrosis  could not achieve the primary goal as it lacked the desired effect on these earlier stage NASH fibrosis patients Earlier last December  Conatus announced top line results from the ENCORE PH study  In the same  emricasan demonstrated clinically meaningful treatment effects on compensated NASH cirrhosis patients  who face the peril of passing to the decompensation state  However  the study failed to meet its primary endpoint  Following a post hoc analysis  emricasan showed a clinically meaningful treatment impact compared with placebo  Additional results are now expected in mid 2019 Failure of both of these studies hurt investor sentiments and shares of the company then significantly plunged  The stock has been persistently down ever since  However  two phase IIb studies are underway on emricasan   a caspase inhibitor   under the ENCORE programs for treating fibrosis or cirrhosis induced by NASH  Those are  ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010  Notably  the company has an exclusive option  collaboration and license agreement with Novartis   NYSE NVS   for the worldwide development and commercialization of emricasan Notably  during the first quarter of 2019  Conatus completed enrolling patients in the ENCORE LF study  the primary endpoint being event free survival  Top line data from this investigation is anticipated in mid 2019 Positive outcomes from the ongoing studies on emricasan will pave the way for a phase III efficacy and safety assessment on the candidate for the given disease Conatus is solely dependent on emricasan for growth as it has got no approved product in its portfolio at the moment  The company s revenues are recognized from its collaboration with Novartis for the worldwide development and commercialization of emricasan Currently  several studies on emricasan are ongoing with data readouts  scheduled in the near term  An unfavorable result in any of the ongoing studies may force the company to defer or discontinue the planned future studies and negatively impact its stock Moreover  several companies like Allergan   NYSE AGN    Intercept Pharmaceuticals  Galectin Therapeutics and Enanta Pharmaceuticals are working on developing therapies for NASH  Additionally  interest in this market has gone up of late  considering that several companies are inking deals and others aiming for an entry into the same space  all because of its high revenue potential Another preclinical candidate in the Conatus  portfolio is CTS 2090  The company plans to submit an investigational new drug  IND  application by the first half of 2020 to begin clinical studies on the candidate for treating autoinflammatory diseases Conatus Pharmaceuticals Inc  Price   Zacks RankConatus currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-05-27,Zacks Investment Research,https://www.investing.com/analysis/conatus-down-more-than-60-in-the-past-90-days-heres-why-200425730,200425730
104964,326479,AGN,Allergan s  AGN  Vraylar Gets FDA Nod For Bipolar Depression,opinion,Allergan plc   NYSE AGN   along with Hungary s Gedeon Richter Plc announced that the FDA has approved a supplemental new drug application  sNDA  of its schizophrenia drug  Vraylar  cariprazine   The company seeks the regulatory body s nod for an expanded patient population  The drug is now approved for the treatment of adults with major depressive episodes related to bipolar I disorder Vraylar is already green lighted in the United States and the EU for acute therapy of manic or mixed episodes associated with bipolar I disorder as well as for schizophrenia The nod for bipolar depression was based on data from the three pivotal studies on Vraylar namely RGH MD 53  RGH MD 54 and RGH MD 56  Data from all three analyses showed that Vraylar demonstrated a statistical significance as compared to placebo in reducing depressive symptoms associated with bipolar I depression Following this win  Vraylar became the first and the only partial agonist approved for both the manic and depressive symptoms of bipolar I disorder  Vraylar is also being investigated in a phase III program for treating major depressive disorder Shares of Allergan have inched up 1 4  so far this year versus the decrease of 7 6  Vraylar has performed extremely well since its approval in September 2015 and has delivered sales above expectation in 2016  2017 and 2018  In the first quarter of 2019  Vraylar generated sales of  143 7 million  having soared 70 3  on a year over year basis  The drug has become a key driver of Allergan s top line Bipolar depression is a difficult to treat disease with approximately 11 million patients suffering the same in the United States  This approval of the expanded indication will help Allergan gain access to a broader section of subjects and boost sales for this promising drug in the future quarters Notably  the bipolar depression market is highly competitive as multiple companies are trying to introduce treatments for the disease  Other players in the bipolar disorder and schizophrenia treatment market include AstraZeneca plc s   NYSE AZN   Seroquel XR  Johnson   Johnson s   NYSE JNJ   Risperdal Consta and Alkermes plc s   NASDAQ ALKS   Aristada Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-28,Zacks Investment Research,https://www.investing.com/analysis/allergans-agn-vraylar-gets-fda-nod-for-bipolar-depression-200426116,200426116
104965,326480,AGN,Why Is Ironwood  IRWD  Up 6 9  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Ironwood Pharmaceuticals  IRWD   Shares have added about 6 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Ironwood due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Ironwood Q1 Earnings   Revenues MissIronwood  incurred first quarter 2019 adjusted loss of 26 cents per share  wider than the Zacks Consensus Estimate of a loss of 16 cents as well as the year ago loss of 25 cents Total revenues in the first quarter were  68 7 million  almost flat year over year as higher Linzess collaboration revenues were partially offset by lower  active pharmaceutical ingredient  API sales to Japan based Astellas  The top line also missed the Zacks Consensus Estimate of  83 14 million On Apr 1  2019  Ironwood completed its previously announced separation into two public entities  From second quarter onward  Ironwood will report assets and business operations related to sGC pipeline as discontinued operations The Quarter in DetailAs reported by partner Allergan  NYSE AGN   Ironwood s key marketed product   Linzess   generated net sales of  161 3 million in the United States  up 1 3  year over year Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  64 3 million in the first quarter  up approximately 5 7  year over year  Total commercial profit in the reported quarter was  94 4 million Sales of linaclotide API added  2 6 million to revenues including sales to the company s Japanese partner Astellas Pharma  The company also earned  1 8 million from linaclotide royalties  co promotion and other revenues Per data provided by IQVIA  volume of prescribed Linzess capsules in the first quarter increased about 14  year over year  However  lower realization of net prices unfavorably impacted sales of the drug During the reported quarter  selling and administrative  SG A  expenses increased 8 8  to  64 7 million mainly due to separation costs  partially offset by lower sales and marketing programs and employee related expenses Research and development  R D  expenses were  54 million  up 47 9  from the year earlier period  primarily due to increase in costs related to early stage pipeline candidates 2019 GuidanceIronwood maintained its guidance for total revenues in the range of  370  390 million for 2019  Net interest expenses are anticipated to be approximately  35 million  The company provided its earnings outlook for 2019 including the impact of the business separation  The company expects adjusted EBITDA to be more than  65 million  It also expects net sales of Linzess to grow by low to mid single digit percentage point The company expects to turn profitable in 2019 for the first time since its inception 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted 31 78  due to these changes 
VGM Scores
Currently  Ironwood has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  Following the exact same course  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision looks promising  Notably  Ironwood has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/why-is-ironwood-irwd-up-69-since-last-earnings-report-200427383,200427383
104966,326481,AGN,Ironwood Initiates Dosing In Mid Stage Study For MD 7246,opinion,Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   and partner Allergan   NYSE AGN   announced that they have initiated dosing of patients in the phase II study on MD 7246  its delayed release version of Linzess  linaclotide   The study is evaluating the candidate in patients with abdominal pain associated with irritable bowel syndrome with diarrhea  IBS D  The phase II study is expected to enroll 400 patients and evaluate three once daily doses   300  600 and 1 200 mcg  of MD 7246  Data from the study is expected in the second half of 2020 The company is also developing the candidate in patients with IBS with constipation  Data from a previously completed phase IIb study in patients with IBS C demonstrated that MD 7246 achieved numerical improvement in abdominal pain compared to placebo Ironwood has a strong portfolio of abdominal pain drugs  Its key product is abdominal pain drug  Linzess  Sales of Linzess were encouraging in 2018 and it also started 2019 on a strong note  Linzess generated net sales of  161 3 million in the United States in the first quarter of 2019  Label expansion and approval in new countries for Linzess are driving sales of the drug higher  The drug is set to achieve blockbuster status by the end of 2020 The company along with its partner AstraZeneca   NYSE AZN   will launch the drug in China in the second half of 2019 Linzess is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation   CIC    Ironwood and Allergan are looking to expand Linzess  label into additional symptoms and develop the drug as a non opioid  pain relieving agent for IBS patients  A late stage study is evaluating a 290 mcg dose of Linzess for multiple abdominal symptoms in addition to pain including bloating and discomfort in adult patients with IBS C Ironwood separated its Soluble Guanylate Cyclase  sGC  business into a new entity named Cyclerion Therapeutics   NASDAQ CYCN   in April  This restructuring initiative is helping the company to focus on its gastro intestinal pipeline  Moreover  the company expects to turn cash flow positive in 2019 following this move However  with a single marketed product  any setback related to manufacturing or commercialization of Linzess will impact the company s top line  The competition in target markets for Linzess is also increasing  Other available products include Takeda Pharma s Amitiza and Motegrity  and Synergy s  now part of Bausch Health Companies  Trulance Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-06-04,Zacks Investment Research,https://www.investing.com/analysis/ironwood-initiates-dosing-in-midstage-study-for-md7246-200428617,200428617
104967,326482,AGN,Allergan  AGN  Down 9 7  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Allergan  NYSE AGN   Shares have lost about 9 7  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Allergan due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Allergan Beats on Q1 Earnings   Sales  Raises 2019 ViewAllergan s first quarter adjusted earnings came in at  3 79 per share  which beat the Zacks Consensus Estimate of  3 55 and came ahead of the guidance of  3 40 and  3 60  Earnings rose 1 3  year over year helped by a lower share count Revenues came in at  3 60 billion  which exceeded the Zacks Consensus Estimate of  3 53 billion as well as the guidance of  3 4 billion to  3 55 billion  Revenues fell 2  from the year ago period primarily due to loss of exclusivity on some brands and divestitures of some others in 2018  On a constant currency basis  sales were flat Moreover  sales of Restasis also declined in the quarter ahead of anticipated generic competition  Also  declines in textured breast implants in certain international markets hurt sales  However  key products like Botox  cosmetic and therapeutics   Juv derm collection of fillers  Vraylar  and Lo Loestrin pulled up the top line in the quarter Allergan said that its core business  Medical Aesthetics  CNS  Eye Care and GI   comprising about 90  of total revenues  grew 4 4  at constant currency in the quarter Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues declined 2 3  to  1 54 billion  Strong sales growth of its facial aesthetics products  Botox and Juv derm and Botox Therapeutic was offset by decline in sales of Restasis and divestiture of Medical Dermatology business in September 2018 In Facial Aesthetics  Botox  cosmetic  raked in sales of  229 5 million  up 16 7  year over year helped by strong advertising promotional efforts  Juv derm collection of fillers rose 5 6  to  129 7 million on strong demand trends in both domestic and international markets  Alloderm sales  however  fell 4 5  to  95 0 million while CoolSculpting sales of  62 9 million declined 27 8  year over year due to lower consumer demand and a reduction in system sales in the United States  Management expects the launch of Cooltone in second half of 2019 to reinvigorate the Coolsculpting business In light of rising competitive pressure  Allergan increased its investments in consumer and digital marketing programs  including new consumer campaigns for both Botox and Juv derm In Eye Care  while Ozurdex sales rose 18 8  to  30 3 million  Restasis sales fell 9 4  to  231 7 million  Restasis sales decreased due to lower selling price Botox Therapeutic revenues were  397 6 million  up 5 8  year over year On the call the company said that its share of new chronic migraine patients is 47   stable from last quarter  It said that 2  of CGRP patients were switched from Botox  Botox Therapeutic is expected to grow in the mid to high single digits range in 2019 U S  General Medicine net revenues were up 2 1  year over year to  1 25 billion in the reported quarter as strong growth of Vraylar  Linzess and Lo Loestrin was offset by lower sales of drugs that lost exclusivity including the generic entry of Canasa Linzess sales rose 1 3  to  161 3 million as demand growth was partially offset by lower average selling price and unfavorable trade buying patterns  Lo Loestrin sales grew 9 8  to  125 8 million while Bystolic sales fell 3 4  to  128 3 million  Vraylar sales were  143 7 million in the first quarter  70 3  higher than the year ago quarter  while Viibryd sales were  85 million  up 18 5  from the year ago quarter Allergan is optimistic that following an approval for the new indication of bipolar depression  which is currently under FDA review  sales of Vraylar can be higher in 2019 The International segment recorded net revenues of  801 5 million  up 1 3  from the year ago period  excluding the impact of foreign exchange as growth in Facial Aesthetics and Botox  therapeutic  was partially offset by regulatory changes for textured breast implants and lower glaucoma and eye drop revenues  Excluding the impact of currency and regulatory changes in the textured Implant market  sales in the segment rose 5 2  Profits RiseAdjusted gross margin rose 50 basis points  bps  in the quarter to 86 7   primarily driven by favorable product mix Adjusted operating income decreased 7 6  to  1 63 billion in the first quarter due to the impact of divestitures  loss of exclusivity of some products and a decline in Restasis Selling  general and administrative  SG A  expenses increased 4 5  to  1 10 billion in the first quarter owing to higher marketing spending in Medical Aesthetics Research and development  R D  expenses rose 11 8  to  397 9 million due to pipeline progress The company said that from the  2 billion share buyback program authorized in 2018   800 million were repurchased in the first quarter  thereby exhausting the 2018 plan  Allergan now will buy back shares under its  2 billion share buyback program authorized in 2019 2019 OutlookAllergan slightly raised its earnings and sales guidance for 2019 benefiting from delayed generic entry of Restasis  Generic versions for Restasis are expected to be launched in mid May versus prior expectations of end of March  Allergan said that each additional month of Restasis exclusivity should add an incremental  60 million to  70 million in revenues Allergan expects sales to be in the range of  15 13  15 43 billion  up from the previous guidance of  15 0  15 3 billion  Allergan expects sequentially stronger top line performance for the remainder of the year The company estimates its adjusted earnings to be more than  16 55 per share versus the prior guidance of greater than or equal to  16 36 Other than generic competition to Restasis  sales in 2019 are expected to be hurt by regulatory changes for textured breast implants in certain international markets as well as industry wide pricing pressure and currency headwinds Adjusted tax rate is expected to be approximately 13 13 5  in 2019  Adjusted R D expenses are expected to be approximately  1 6    1 7 billion and SG A spend is expected to be approximately  4 1    4 3 billion  Adjusted gross margin is expected to be approximately 85  85 5  Second Quarter 2019 OutlookFor the second quarter  the company expects revenues to be in the range of  3 88 billion to  4 03 billion and earnings per share between  4 20 and  4 40 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
At this time  Allergan has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Allergan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-down-97-since-last-earnings-report-can-it-rebound-200429144,200429144
104968,326483,AGN,TherapeuticsMD Enters Agreement To Market Drugs Outside US,opinion,"TherapeuticsMD  Inc    NASDAQ TXMD   announced that it has entered into an exclusive license and supply agreement with leading  global specialty pharmaceutical company dedicated to women s health  Theramex  The agreement grants exclusive commercialization rights for hormone therapy drugs  Bijuva and Imvexxy  to Theramex in markets outside the United States  excluding Canada and Israel Bijuva  a bio identical hormone therapy combination of estradiol and progesterone  is approved for treating moderate to severe vasomotor symptoms   VMS   in post menopausal women  Imvexxy  a vaginal estradiol softgel  is approved for treating moderate to severe dyspareunia  a symptom of vulvar and vaginal atrophy   VVA    due to menopause  Both drugs were approved in 2018  While Imvexxy was launched in the U S  market in July 2018  Bijuva was launched in April 2019 Per the terms of the agreement  TherapeuticsMD is eligible to receive 14 million euro   15 8 million  in upfront fees in cash  an aggregate of 2 million euro   2 3 million  upon approval of the drugs in certain specified markets and up to 27 5 million   31 1 million  in sales milestone payments based on net sales in licensed territories  The agreement will also help TherapeuticsMD to leverage Theramex s extensive women s health capabilities and infrastructure for rapid commercialization of Bijuva and Imvexxy in ex U S  markets Operating expenses for TherapeuticsMD are on the rise mainly driven by expenses to support the launch of its drugs  The upfront and milestone fee will boost the company s fund  which will help it to remain on track with its commercialization plans We remind investors that Imvexxy has generated sales of almost  3 1 million since its launch  Sales more than doubled sequentially in the first quarter of 2019  However  Bijuva is expected to face stiff competition from Pfizer s   NYSE PFE   Prempro  AMAG Pharmaceuticals    NASDAQ AMAG   Intrarosa and Allergan s   NYSE AGN   Estrace  There are several companies marketing generic version of Estrace  which will also compete with Bijuva Apart from Bijuva and Imvexxy  TherapeuticsMD also received approval for another hormone therapy drug  Annovera  as the first and only patient controlled  procedure free  reversible prescription contraceptive in the United States  The drug is expected to be commercially launched by the first quarter of 2020 TherapeuticsMD s shares have declined 17 4  so far this year against the  s increase of 5 5  Zacks RankTherapeuticsMD currently carries a Zacks Rank  3  Hold   You can see  TherapeuticsMD  Inc  Price
    Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-06-09,Zacks Investment Research,https://www.investing.com/analysis/therapeuticsmd-enters-agreement-to-market-drugs-outside-us-200430202,200430202
104989,326504,AGN,Harris bags electronic jammer contract,news,Harris  HRS  0 4   has received a  133M contract to supply electronic jammers to protect U S  Navy and Australian F A 18 Hornet and Super Hornet aircraft Deliveries are expected to be complete by May 2020 Now read ,2017-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/harris-bags-electronic-jammer-contract-542235,542235
104990,326505,AGN,Allergan Restasis patent stoked selloff overdone   JPMorgan,news,JPMorgan  NYSE JPM  s Chris Schott says today s selloff in Allergan  AGN  3 5   after a Texas district court invalidated its RESTASIS patents is overdone considering the company s  very attractive fundamental story   upcoming catalysts and numerous pipeline readouts next year  OVERWEIGHT  300   Wells Fargo   NYSE WFC  s David Maris agrees saying a generic alternative won t be launched in the U S  before the company s appeal runs its course  2019 at the earliest  OUTPERFORM  276  Cowen s Ken Cacciatore adds that RESTASIS is now completely removed from the company s valuation  OUTPERFORM  400   Deutsche Bank   DE DBKGn  has cut its price target to  251 from  262 after accounting for 90  sales erosion in 2019 and 5  per year thereafter Source  BloombergPreviously  U S  court invalidates Allergan s Restasis patents  shares down 5   Oct  16 Now read ,2017-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-restasis-patentstoked-selloff-overdone--jpmorgan-542298,542298
104991,326506,AGN,Imprimis Pharma to offer compounded alternatives to Allergan s Restasis  shares up 63 ,news,Imprimis Pharmaceuticals  IMMY  63   announces that it is making compounded cyclosporine based formulations that will potentially be lower cost alternatives to Allergan s  AGN  1 5   dry eye med RESTASIS  Cyclosporine Ophthalmic Emulsion   Its offerings will be packaged in a multi use preservative free bottle and include  Klarity Drops   a patented formulation developed by ophthalmologist Richard Lindstrom  M D A few days ago  a Texas court invalidated Allergan s patents covering RESTASIS Imprimis intends to make public a presentation on subsidiary Surface Pharmaceuticals  focused exclusively on ocular surface disease  including dry eye disease and blepharitis  inflamed eyelids   Surface has three core drug formulations and plans to seek FDA approval for as many as five indications Previously  U S  court invalidates Allergan s Restasis patents  shares down 5   Oct  16 Now read ,2017-10-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/imprimis-pharma-to-offer-compounded-alternatives-to-allergans-restasis-shares-up-63-544214,544214
104992,326507,AGN,Big pharma biotech players under pressure  Valeant only bright spot,news,The big players in pharmaceuticals and biotech are not faring too well today  Valeant Pharmaceuticals  VRX  1 7   being the exception Biogen  Lilly and Novartis reported quarterly earnings this morning  All three beat consensus but Biogen posted less than expected Spinraza sales in the U S   Lilly is mulling strategic alternatives for its Elanco Animal Health unit and Novartis is delaying spinning off Alcon Selected tickers   IHE  0 3   XPH  0 4   PPH  0 6   JNJ  1 5   ABBV  3 1   AGN  1 5   AZN  0 9   BMY  0 1   LLY  2 8   GSK  0 8   MRK  1   PFE  0 1   NVS  3 1   AMGN  0 1   BIIB  3 6   CELG  1 1   GILD  0 1   XBI  0 1   IBB  0 3  Now read ,2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/big-pharmabiotech-players-under-pressure-valeant-only-bright-spot-546805,546805
104993,326508,AGN,Allergan declares  0 70 dividend,news,Allergan  NYSE AGN  declares  0 70 share quarterly dividend  in line with previous Forward yield 1 59 Payable Dec  15  for shareholders of record Nov  17  ex div Nov  16 Now read ,2017-10-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-declares-070-dividend-549277,549277
104994,326509,AGN,Allergan s Ozurdex OK d in China,news,"The Chinese Food and Drug Administration  CFDA  approves Allergan s  AGN  1 3   Ozurdex  dexamethasone intravitreal implant 0 7 mg  for the treatment of adults with macular edema following either branch retinal vein occlusion or central retinal vein occlusion 
The approval is the first for an intravitreal injection for retinal vein occlusion there  a condition affecting  7 4M Chinese 
Ozurdex is a sustained release biodegradable steroid implant whose long efficacy eliminates the need for monthly injections 
Now read ",2017-10-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergans-ozurdex-okd-in-china-760232,760232
104995,326510,AGN,Pfizer Consumer Unit s Sales Fall Ahead of Divestiture Call,news," Bloomberg     Sales fell for a third straight quarter at the consumer products business that  Pfizer  Inc   NYSE PFE  may offload  a slump that could pressure the price that the drug giant could get for the division  
The drugmaker plans to decide next year what to do with the consumer business  which sells brands including Advil  ChapStick  Centrum  The decision could impact a bigger  later deal that investors have been speculating about since Pfizer s failed attempts to buy Allergan  NYSE AGN  Plc and AstraZeneca PLC  LON AZN  
While third quarter adjusted earnings of 67 cents beat the 65 cents average of analysts  estimates  Pfizer s quarterly results have been overshadowed by speculation about its larger strategic plans 
 We see nothing remarkable about the quarter either way and believe the market will be most focused on management M A commentary   said Jeffrey Holford  an analyst with Jefferies  He has a hold rating on the shares 
At the consumer unit  third quarter sales dropped to  829 million from  846 million in the previous three months 
Drugs Performance
Its pharmaceutical business    which makes up more than 90 percent of the company s sales    is doing better  Sales from its innovative health segment  which includes the company s newest drugs  rose 11 percent from a year prior  The New York based drugmaker raised its 2017 adjusted earnings forecast to  2 58 to  2 62 a share 
Holford mentioned Bristol Myers Squibb Co  as the target on investors  minds  Bristol Myers has been at the center of takeover speculation as it awaits data from a highly anticipated lung cancer trial  and analysts have mentioned Pfizer as a potential suitor  Pfizer Chief Executive Officer Ian Read has said the drugmaker needs clarity about U S  tax reform in order to figure out which potential targets are worth buying 
Pfizer shares were up 0 3 percent to  35 25 at 8 11 a m  in New York 
The company s biggest challenge may be its own size  and finding ways to replace past blockbusters that are losing patent protection  like the erectile dysfunction drug Viagra  Pfizer has made a number of large deals  such as the  14 billion purchase of Medivation in 2016  to add new assets  though none as large as the failed attempts for AstraZeneca or Allergan 
There are several potential buyers who could value the consumer unit at around  13 billion to  17 billion  according to Rosie Edwards  an analyst with Berenberg  Companies like  Reckitt Benckiser  Group Plc  LON RB   Nestle SA  SIX NESN   GlaxoSmithKline Plc  Johnson   Johnson  NYSE JNJ  and Sanofi  PA SASY  have been mentioned by analysts as possible suitors 
Pfizer plans to start the auction for the sale of its consumer business in November  Reuters reported last week  GlaxoSmithKline CEO Emma Walmsley told reporters last week that she plans to take a look at the consumer business  Reckitt Benckiser has also expressed interest  according to Reuters 
 Adds analyst comment in fourth paragraph  ",2017-10-31,Bloomberg,https://www.investing.com/news/stock-market-news/pfizer-consumer-units-sales-fall-ahead-of-divestiture-call-761167,761167
104996,326511,AGN,Pfizer  PFE  To Report Q1 Earnings  Will It Beat Estimates ,opinion,"We expect Pfizer  Inc    NYSE PFE   to beat estimates when it reports first quarter 2019 results on Apr 30  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 1 59  
The pharma giant has a strong record of earnings surprises  The company s earnings surpassed expectations in each of the last four quarters  leading to an average positive surprise of 4 07  Pfizer Inc  Price and EPS Surprise
 

   Pfizer s shares have declined 9 7  this year so far compared with a decline of 3 7  for the  

 
Factors at Play
Higher sales of Pfizer s key brands  Ibrance  Chantix and Xeljanz and alliance revenues from Xtandi and Eliquis in the Innovative Health  IH  segmentshould make up for lower sales in the Essential Health  EH  segment in the first quarter of 2019 
However  in the last two reported quarters  rising competition in the CDK inhibitor category and increased rebates hurt U S  sales of Ibrance  We expect the competitive pressure to continue to hurt sales in the first quarter  For Xeljanz  contributions from the drug s recent expansion into psoriatic arthritis and ulcerative colitis in the United States should support higher sales through 2019 
Xtandi was approved for non metastatic prostate cancer patient population in the United States and EU in 2018  which may add to alliance revenues from the drug in the first quarter 
The Zacks Consensus Estimate for sales of Ibrance  worldwide   Xeljanz and Chantix is  1 1 billion   510 million and  263 million  respectively 
Blockbuster drug Enbrel sales are expected to decline in the quarter due to biosimilar competition in key European markets  Prevnar 13 vaccine revenues declined in the United States in the fourth quarter  It remains to be seen if sales improve in the first quarter  The Zacks Consensus Estimate for sales of Enbrel and Prevnar is  379 million and  1 36 billion  respectively 
In oncology  Pfizer gained FDA approval for four innovative medicines   Daurismo  Lorbrena  Vizimpro and Talzenna   in the last four months of 2018  These drugs may boost its oncology sales in the first quarter  The Zacks Consensus Estimate for total oncology sales is  1 86 billion 
EH revenues were hurt by the loss of exclusivity and associated generic competition for products  primarily Pristiq and Viagra in the United States and Lyrica in Europe and lower revenues from sterile injectables portfolio due to continued legacy Hospira product shortages in the United States  Also  lower sales of legacy Established Products in developed markets driven by industry wide pricing challenges hurt EH segment sales 
We do not expect any improvement in this segment s sales in the first quarter  However  in the EH business  biosimilars and emerging markets should continue to do well 
In 2018  Pfizer made significant progress with its biosimilar portfolio  In the United States  a biosimilar of Amgen s   NASDAQ AMGN   Neupogen was launched in late September 2018 while a biosimilar version of Epogen was approved in May and launched in November 2018  These should add to the company s biosimilar sales in the to be reported quarter 
Importantly  beginning the first quarter of 2019  Pfizer will report under three new business units   Pfizer Biopharmaceuticals Group  previous IH unit except Consumer Healthcare   Upjohn  previous EH unit  and Consumer Healthcare 
We remind investors that Pfizer s Consumer Healthcare unit will merge with Glaxo s unit to form a new joint venture  JV   Pfizer will own a stake of 32  in the JV  Pfizer had been exploring strategic options for its Consumer Healthcare unit since October 2017  The transaction is expected to close in the second half of 2019 
What Our Model Indicates
Our proven model shows that Pfizer is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise 
Earnings ESP  Earnings ESP is  0 65   The Zacks Consensus Estimate is pegged at 77 cents per share  You can uncover the best stocks to buy or sell before they re reported with our 
Zacks Rank  Pfizer has a Zacks Rank  3  The combination of Pfizer s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release 
Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Other Stocks to Consider
Here are some other large drug stocks that have the right combination of elements to beat on earnings this time around 
Allergan plc    NYSE AGN   has an Earnings ESP of  1 05  and a Zacks Rank  3  The company is slated to release results on May 7  You can see  
AbbVie  Inc    NYSE ABBV   has an Earnings ESP of  0 76  and a Zacks Rank  3  The company is slated to release results on Apr 25 
Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates-200410553,200410553
104997,326512,AGN,Teva  TEVA  To Report Q1 Earnings  What s In The Cards ,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   will report first quarter 2019 results on May 2 before market open  In the last reported quarter  the company delivered a negative earnings surprise of 5 36  Teva s earnings surpassed expectations in three the last four quarters  with the average positive surprise being 18 24  This generic drugmaker s shares have declined 0 4  this year so far against the  s increase of 6 6    Let s see how things are shaping up for this announcement Factors to ConsiderTeva reports under three segments   North America  United States and Canada   Europe and International Markets Pricing erosion in U S  generics market  rapid erosion in sales of key multiple sclerosis drug  Copaxone and divestiture of some non core assets are expected to hurt North America segment sales in the first quarter Importantly  sales of all other branded products Bendeka  Treanda  ProAir and Qvar declined in the past three quarters  The chances of sales trends improving in the first quarter are minimal  Moreover  introduction of generic versions of ProAir following patent expiration in 2018 may hurt sales of the branded drug in the first quarter Importantly  on the call  investors will be keen to know the sales numbers of Teva s newly launched anti calcitonin gene related peptide   CGRP   drug  Ajovy  fremanezumab  injection  as a preventive treatment for migraine  Ajovy has been performing strongly since launch  enjoying growing demand due to its flexible dosing options   quarterly and monthly  An update is expected on the first quarter conference call  Investors will also be interested to know how management plans to capture market share for Ajovy against Amgen  NASDAQ AMGN  and Lilly s CGRPs  which were also launched last year Meanwhile  additional competition for Teva s largest product  Concerta authorized generic  should also hurt generics sales in the quarter  Importantly  on the fourth quarter call  the company had said that there were signs of stabilization in U S  generic drug pricing  The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third and the fourth quarters of 2018 from second quarter levels due to optimization of its generics product portfolio as well as product launches  The positive trend is expected to continue as several new generic products were launched in the first quarter An important recent generic launch was that of Mylan s   NASDAQ MYL   EpiPen  epinephrine  auto injector for severe allergy treatment  Regarding its generic launch  Teva had said it expects to see normal supply levels by the end of first quarter early second quarter  An update is expected on the call In Europe as well as International Markets  loss of revenues from divestitures discontinued business activities is likely to hurt sales  The decline in sales of generic medicines and Copaxone is expected to continue  which can offset the positive impact of generic launches Cost savings from Teva s aggressive restructuring initiatives are likely to provide some support to the bottom line  However  marketing costs are expected to be higher in the first quarter due to investments to support Ajovy s launch Earnings WhispersOur proven model does not conclusively show that Teva will beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP  2 95  as the Zacks Consensus Estimate stands at 58 cents per share and the Most Accurate Estimate is pegged at 59 cents per share  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Teva has a Zacks Rank  5  Strong Sell    We caution against Zacks Rank  4  Sell  or 5 going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some large drug stocks that have the right combination of elements to beat on earnings this time around Allergan plc    NYSE AGN   has an Earnings ESP of  0 73  and a Zacks Rank  3  The company is slated to release results on May 7  You can see  GlaxoSmithKline   NYSE GSK   has an Earnings ESP of  1 27  and a Zacks Rank  3  The company is slated to release results on May 1 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-28,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-to-report-q1-earnings-whats-in-the-cards-200412285,200412285
104998,326513,AGN,Allergan  AGN  Expected To Beat Earnings Estimates  What To Know Ahead Of Q1 Release,opinion,"Wall Street expects a year over year decline in earnings on lower revenues when Allergan  NYSE AGN  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on May 7  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This Botox maker is expected to post quarterly earnings of  3 55 per share in its upcoming report  which represents a year over year change of  5 1  
Revenues are expected to be  3 53 billion  down 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 22  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Allergan 
For Allergan  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 73  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Allergan will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Allergan would post earnings of  4 15 per share when it actually produced earnings of  4 29  delivering a surprise of  3 37  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Allergan appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release-200413057,200413057
104999,326514,AGN,Why The Earnings Surprise Streak Could Continue For Allergan  AGN ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Allergan  NYSE AGN   which belongs to the Zacks Medical   Generic Drugs industry 
This Botox maker has an established record of topping earnings estimates  especially when looking at the previous two reports  The company boasts an average surprise for the past two quarters of 4 68  
For the most recent quarter  Allergan was expected to post earnings of  4 15 per share  but it reported  4 29 per share instead  representing a surprise of 3 37   For the previous quarter  the consensus estimate was  4 01 per share  while it actually produced  4 25 per share  a surprise of 5 99  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Allergan  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Allergan currently has an Earnings ESP of  0 74   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on May 7  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-allergan-agn-200416579,200416579
105000,326515,AGN,Pharma Stock Roundup  MRK  LLY  PFE Report Q1 Earnings  SNY  ABBV  Drugs Get EU Nod,opinion,"This week was a relatively busy one for the pharma sector  marked by earnings of bigwigs like Merck   NYSE MRK    Pfizer   NYSE PFE   and Lilly   NYSE LLY    Meanwhile  the European Commission granted approval to AbbVie s   NYSE ABBV   new plaque psoriasis drug Skyrizi  risankizumab  and Sanofi   NASDAQ SNY   Lexicon Pharmaceuticals  dual SGLT1 and SGLT2 inhibitor  Zynquista  sotagliflozin   The Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency  EMA  recommended marketing approval for several drugs Recap of the Week s Most Important Stories
Q1 Earnings Update  Pfizer  Glaxo and Merck beat estimates for first quarter earnings and sales   of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full year sales  for both earnings and sales for the year while Glaxo   NYSE GSK    its previous earnings guidance for 2019 Lilly beat estimates for earnings in Q1  Though the company raised its earnings guidance for 2019  it forecast EU Approval to Sanofi   AbbVie Drugs  The European Commission granted approval to AbbVie s Skyrizi  risankizumab  for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy  Skyrizi was approved in the United States in late April and is expected to be launched this month  It was approved in Japan in March Lexicon Pharmaceuticals and partner Sanofi announced that the European Commission granted approval to their dual SGLT1 and SGLT2 inhibitor  Zynquista  sotagliflozin   in combination with insulin  for the treatment of type I diabetes in adult patients  In March  the FDA had issued a complete response letter   CRL   to the new drug application   NDA   seeking approval for Zynquista CHMP Gives Positive Opinion to Several Drugs  AstraZeneca Merck s PARP inhibitor Lynparza gained a positive CHMP opinion  recommending expanded approval for first line maintenance treatment of BRCA mutated advanced ovarian cancer  It is already approved in the United States for the indication  The CHMP also gave nod to Novo Nordisk s Esperoct  turoctocog alfa pegol  N8 GP  for the treatment of haemophilia A  The drug was approved by the FDA in February this year  Glaxo also gained positive CHMP opinion for its once daily  single tablet two drug regimen  2DR   Dovato for the treatment of newly diagnosed adults with HIV 1 infection  Dovato is a fixed dose combination of Tivicay  dolutegravir   50 mg  in combination with lamivudine  300 mg  and was approved by the FDA last month   Pfizer s new PARP inhibitor  Talzenna also gained a positive opinion from the CHMP for inherited  germline  BRCA mutated advanced breast cancer The final decision by the European Union on these products is expected in the coming months J J Files sNDA to Expand Label of Erleada  J J   NYSE JNJ   filed a supplemental new drug application  sNDA  with the FDA seeking approval of its new prostate cancer drug Erleada in an expanded patient population  The sNDA is looking to get Erleada approved to treat patients with metastatic castration sensitive prostate cancer  mCSPC  while the drug is already marketed in the United States for the treatment of men with non metastatic castration resistant prostate cancer  nmCRPC   The sNDA filing is supported by data from the phase III TITAN study Glaxo J J File NDA for Long Acting Two Drug HIV Regimen  Glaxo s HIV subsidiary  ViiV Healthcare and partner J J filed a NDA looking for approval of long acting  two drug regimen of ViiV Healthcare s cabotegravir and Janssen s Edurant  rilpivirine   The companies are seeking approval for the two drug monthly regimen for the treatment of HIV 1 infected adults who had maintained viral suppression and who are not resistant to cabotegravir or rilpivirine  The approval was based on data from the phase III ATLAS study  which showed that the two drug regimen  injected once a month  had similar efficacy to a standard of care  daily  oral three drug regimen at week 48 Glaxo and its partner Innoviva s phase III study  CAPTAIN  evaluating their triple combination once daily single inhaler Trelegy Ellipta versus Relvar Breo Ellipta for a new indication  uncontrolled asthma   met the primary endpoint  Data from the study showed that treatment with Trelegy Ellipta led to statistically significant improvement in lung function in such patients  thereby meeting the study s primary endpoint  At present  Trelegy Ellipta is approved to treat chronic obstructive pulmonary disease Bayer  DE BAYGN  Gets FDA s Priority Review for Prostate Cancer Candidate  Bayer s new drug application looking for approval of its prostate cancer candidate  darolutamide was accepted and granted priority review by the FDA  In February 2019  Bayer completed the rolling submission of the NDA for darolutamide to the FDA  The submission is based on data from the phase III ARAMIS study in men with non metastatic castration resistant prostate cancer  nmCRPC   Regulatory applications are also under review in Europe and Japan Here is how the seven major stocks performed in the last five trading sessions   It was a mixed performance last week with Pfizer gaining the most  3 6   and AstraZeneca declining the most  1 5  In the past six months too  Merck has been the biggest gainer  8 8   while Bristol Myers declined the most  9 9     See the last pharma stock roundup here  Pharma Stock Roundup   What s Next in the Pharma World Watch out for the earnings of Allergan  NYSE AGN  and regular pipeline and regulatory updates next week Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv--drugs-get-eu-nod-200416444,200416444
105001,326516,AGN,Teva  TEVA  Q1 Earnings Beat  Copaxone Drags Sales Down,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   reported first quarter 2019 earnings of 60 cents per share  which beat the Zacks Consensus Estimate of 58 cents  Earnings per share declined 36  year over year due to lower sales and operating income Revenues came in at  4 3 billion  which missed the consensus estimate of  4 41 billion  Sales declined 15   down 12  in constant currency terms  year over year Sales were hurt by rapid erosion in sales of Teva s key multiple sclerosis injection  Copaxone  lower sales of the branded respiratory and oncology drugs and pricing pressure in the U S  generics market  Also  negative currency impact due to the strengthening of the dollar hurt sales by  177 million and operating profits by  58 million in the quarter Segment DiscussionAs announced in November 2017  Teva no longer reports two separate global groups for its two businesses   generics and specialty medicines  Instead  it reports under new segments based on three regions   North America  United States and Canada   Europe and International Markets North America segment sales were  2 05 billion  down 19  year over year due to pricing erosion in U S  generics market  lower sales of Copaxone as well as other branded drugs  Bendeka Treanda and QVAR  In the United States  revenues declined 20 year over year to  1 91 billion Copaxone posted sales of  208 million in North America  down 56  year over year due to generic competition in the United States  Copaxone recorded sales of  194 million in the United States  In 2019  Teva expects  800 million in U S  revenues for Copaxone versus the previous estimate of approximately  1 billion Sales of other branded products Bendeka  Treanda and Qvar declined in the quarter  ProAir sales declined 55  year over year to  59 million due to the launch of generic version of the drug  Teva launched its own ProAir HFA authorized generic to select customers in January 2019 and these sales were included in the Generics revenues Austedo  a new drug approved to treat chorea associated with Huntington s disease and tardive dyskinesia  recorded sales of  72 million in the quarter in North America compared with  68 million in the previous quarter  Teva expects Austedo to record  350 million in revenues in 2019 In September  Teva gained approval and launched a new branded drug  its anti calcitonin gene related peptide   CGRP   injection  Ajovy  fremanezumab   as a preventive treatment for migraine  Ajovy recorded sales of  20 million in the quarter  Teva said it expects  150 million in Ajovy U S  sales in 2019  Ajovy was approved in Europe in April this year Ajovy will face fierce competition from similar drugs  Amgen   NASDAQ AMGN   and Lilly s   NYSE LLY   CGRPs  Aimovig and Emgality  respectively  which were also launched last year Generic products revenues declined 11  to  966 million in the quarter due to price erosion in the U S business  This decline was partially offset by additional sales from the launch of generic products On the call  the company said it is seeing stabilization of US generics and European generics business helped by ongoing launches and strong key productsDistribution revenues  which are generated by Anda  acquired from Allergan   NYSE AGN   in 2016  rose 14  in the quarter to  379 million The Europe segment recorded revenues of  1 26 billion  down 12   down 5  in constant currency terms  year over year due to divestiture of the women s health business and lower Copaxone revenues  which offset the positive impact of generic launches Generic products revenues in Europe declined 9   flat on a constant currency basis  to  919 million due to lost revenues as a result of the termination of partnership with P G   PGT Healthcare  in July last year  partially offset by generic product launches Copaxone sales declined 20  on a constant currency basis to  114 million due to price reductions  following the entry of generics Respiratory products sales in Europe segment declined 13  on a constant currency basis to  91 million mainly due to lower sales in the United Kingdom In the International Markets segment  sales declined 11   down 3  in constant currency terms  to  668 million due to lower sales in Japan  which were partially offset by higher sales in Russia Generic products revenues declined 10  in constant currency terms to  441 million  Copaxone sales declined 18  to  13 million  Distribution revenues increased 1  in constant currency terms to  151 million in the quarterThe Other segment  API manufacturing business and certain contract manufacturing services  recorded revenues of  317 million  down 5  year over year  in constant currency terms Profits DeclineAdjusted gross margin declined 160 basis points  bps  to 50 1  in the quarter due lower profits in the North America segment Adjusted research   development expenses declined 11 8  from the year ago period to  255 million due to pipeline optimization  concluded phase III studies and resultant workforce reductions  Selling and marketing  S M  expenditure declined 11 7  from the year ago level to  602 million due to cost cutting and re structuring activities  General and administrative  G A  expenses declined 13  year over year to  280 million  Adjusted operating income declined 29  in the quarter to  1 02 billion due to lower profits in North America segment attributable to the decline in Copaxone and other specialty brands 2019 Outlook MaintainedTeva re affirmed its previously issued guidance for sales and earnings in 2019  The company expects revenues to be in the range of  17    17 4 billion  Earnings are expected in the band of  2 20 2 50 per share Our TakeTeva s first quarter results were mixed as it beat expectations for earnings but missed the same for sales  leading the stock to decline 2 1  on Thursday  Teva s shares have fallen 3 4  this year so far against the  s increase of 5 8    Teva is facing significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business and a massive debt load  Teva expects 2019 to be a tough year followed by return to growth in 2020 based on launches However  Teva has a new organizational structure in place  is closing plants  cutting down its generics portfolio  divesting non core assets  eliminating low value R D project  and is reducing global workforce to revive growth  Teva is on track to meet its goal to save  3 billion by the end of 2019 from these initiatives with  2 5 billion already achieved since initiation of the restructuring plan in 2018  Its newest drugs  Austedo and Ajovy could emerge as significant contributors to long term sales growth However  despite impressive progress on restructuring activities  signs of stabilization in U S  generic business and a more stable financial position than before  we believe the company has a long way to go before it gains stability  Resumption of organic growth seems unlikely until 2020 Teva Pharmaceutical Industries Ltd  Price  Consensus and EPS Surprise
    Currently  Teva has a Zacks Rank  5  Strong Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q1-earnings-beat-copaxone-drags-sales-down-200416431,200416431
105002,326517,AGN,Ironwood  IRWD  Q1 Earnings   Revenues Miss  Shares Fall,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   incurred first quarter 2019 adjusted loss of 26 cents per share  wider than the Zacks Consensus Estimate of a loss of 16 cents as well as the year ago loss of 25 cents Total revenues in the first quarter were  68 7 million  almost flat year over year as higher Linzess collaboration revenues were partially offset by lower  active pharmaceutical ingredient  API sales to Japan based Astellas  The top line also missed the Zacks Consensus Estimate of  83 14 million On Apr 1  2019  Ironwood completed its previously announced separation into two public entities Following the separation in April  Ironwood is focusing on commercial drugs and gastrointestinal   GI   pipeline development  The new entity  Cyclerion  will focus on developing the Soluble Guanylate Cyclase  sGC  pipeline for treating serious and orphan diseases From second quarter onward  Ironwood will report assets and business operations related to sGC pipeline as discontinued operations Shares of Ironwood crashed 12 8  following the dismal earnings performance  In fact  the stock has declined 0 8  so far this year agianst the  s rise of 9  Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess  generated net sales of  161 3 million in the United States  up 1 3  year over year  Ironwood and Allergan equally share brand collaboration profits or losses for Linzess Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  64 3 million in the first quarter  up approximately 5 7  year over year  Total commercial profit in the reported quarter was  94 4 million Sales of linaclotide API added  2 6 million to revenues including sales to the company s Japanese partner Astellas Pharma  The company also earned  1 8 million from linaclotide royalties  co promotion and other revenues Per data provided by IQVIA  volume of prescribed Linzess capsules in the first quarter increased about 14  year over year  However  lower realization of net prices unfavorably impacted sales of the drug In January  Ironwood and Allergan settled a pending patent litigation with Mylan Pharmaceuticals   NASDAQ MYL    the third settlement related to Linzess  Per the settlement terms  Mylan will be granted license to launch generic version of Linzess in February 2030 for 145 mcg and 290 mcg doses  and in August 2030 for 72 mcg dose During the reported quarter  selling and administrative  SG A  expenses increased 8 8  to  64 7 million mainly due to separation costs  partially offset by decrease in sales and marketing programs and employee related expenses Research and development  R D  expenses were  54 million  up 47 9  from the year earlier period  primarily due to increase in costs related to early stage pipeline candidates 2019 GuidanceIronwood maintained its guidance for total revenues in the range of  370  390 million for 2019  Net interest expenses are anticipated to be approximately  35 million  The company provided its earnings outlook for 2019 including the impact of the business separation  The company expects adjusted EBITDA to be more than  65 million  It also expects net sales of Linzess to grow by low to mid single digit percentage point The company expects to turn profitable in 2019 for the first time since its inception Pipeline UpdatesLinzess is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation   CIC    Ironwood and Allergan are looking to expand Linzess  label into additional symptoms and develop the drug as a non opioid  pain relieving agent for IBS patients During the quarter  Ironwood and Allergan completed dosing in the phase IIIb program evaluating a 290 mcg dose of Linzess for multiple abdominal symptoms in addition to pain including bloating and discomfort in adult patients with irritable bowel syndrome along with constipation  IBS C   Top line data from the study is expected by mid 2019 Linzess is marketed by Allergan for IBS C in Europe and Canada under the brand name Constella The companies anticipate to initiate a phase IIb study in May for evaluating MD 7246  delayed release formulation of Linzess  to treat abdominal pain associated with IBS with diarrhea The company is also developing an interesting candidate called IW 3718  It is currently enrolling patients in two identical phase III studies  evaluating IW 3718 for treating gastroesophageal reflux disease   GERD    Results from both studies are expected in the second half of 2020 Global Collaborations and PartnershipsIronwood has a license agreement with Japan based  Astellas Pharma  Ironwood supplies linaclotide API to Astellas Pharma for manufacturing and developing Linzess for sale in Japan  In China  Hong Kong and Macau  Ironwood has a marketing agreement with AstraZeneca   NYSE AZN   for Linzess In January  Linzess was granted marketing approval by Chinese regulatory authorities to treat adults with IBS C  Ironwood and AstraZeneca plan to launch the drug in China in the second half of 2019 Our TakeIronwood reported dismal first quarter results with sales and earnings missing estimates  However  Linzess  prospects look encouraging owing to strong demand trends and the drug s expansion to new patient population and geographies The new Ironwood entity has high potential as it is expected to be a profitable venture after the split and its focus on the gastrointestinal product of commercial portfolio and pipeline appears impressive Moreover  the company s  119 million cash resources as of March end  separation of sGC pipeline and a strong partner in Allergan bode well Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks RankIronwood currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-q1-earnings--revenues-miss-shares-fall-200416678,200416678
105004,326519,AGN,Should You Buy Allergan  AGN  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Allergan plc   NYSE AGN   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Allergan is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for AGN in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 57 per share for AGN  compared to a broader Zacks Consensus Estimate of  3 55 per share  This suggests that analysts have very recently bumped up their estimates for AGN  giving the stock a Zacks Earnings ESP of  0 74  heading into earnings season Allergan plc Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that AGN has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Allergan  and that a beat might be in the cards for the upcoming report Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-05,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-allergan-agn-ahead-of-earnings-200417446,200417446
105024,326539,AGN,Trump to keep Obama rule curbing corporate tax inversion deals,news," This October 4 story fixes comment by Organization for International Investment as referring to historically foreign based companies in paragraph 13   WASHINGTON  Reuters    The Trump administration will keep for now an Obama era rule that helped halt a wave of U S  corporations moving abroad via tax driven corporate inversion deals  it said on Wednesday  but added that it expected tax reform to obviate the rule  President Donald Trump ordered a review almost six months ago of tax rules from the final months of the Obama administration  including ones to discourage companies from redomiciling abroad for tax reasons   Treasury plans to retain the distribution requirements under Section 385 pending enactment of tax reform   the department said in a statement  adding  these regulations are necessary to safeguard against earnings stripping   It also said it planned to revoke and streamline some related documentation rules  A 2011 2015 wave of inversion deals prompted Treasury to take a series of actions that culminated in an April 2016 rule release and the collapse of a  160 billion deal between U S  drugmaker  Pfizer  Inc  N PFE  and Ireland s Allergan Plc  N AGN   which would have been the largest inversion ever  Tax inversions occur when a U S  company is acquired by a smaller foreign business from a low tax country and adopts its domicile to reduce the combined firm s overall U S  tax burden  The Section 385 rule was part of Obama s anti inversion effort and was finalized a year ago  It was meant to combat a corporate tax reduction technique known as earnings stripping  Earnings stripping occurs when the U S  subsidiary of a newly inverted company loads up on debt and avoids taxes on its domestic profits by sending them overseas to the foreign parent in the form of tax deductible interest payments  The Obama rule reclassified some forms of debt as equity  changing tax exempt interest payments into taxable dividends and making earnings stripping strategies more difficult to pursue  The Organization for International Investment  OFII   a Washington lobbying group for foreign based companies with U S  operations  praised the documentation portion of Treasury s latest move and criticized the retention of the rest of the Section 385 rule   Unfortunately  in perpetuating an unsubstantiated premise of the Obama administration  Treasury has decided to keep part of these discriminatory regulations   the group said  Companies with historic foreign headquarters that have expanded into the United States  OFII said in a statement   are not overleveraged  their debt levels have remained largely flat and their interest expense has declined while their investments into America s economy have grown   
The Treasury Department said it expected a Republican proposal to overhaul the tax code would eliminate the need for anti inversion rules  The proposal would sharply cut the corporate tax rate and end taxation of multinationals  foreign profits ",2017-10-05,Reuters,https://www.investing.com/news/economy-news/trump-to-keep-obama-rule-curbing-corporate-tax-inversion-deals-536934,536934
105025,326540,AGN,Senator McCaskill drafts bill in response to Allergan patent maneuver,news,"By Michael Erman NEW YORK  Reuters    Democratic U S  Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U S  Patent and Trademark Office review of a patent   Drugmaker Allergan  NYSE AGN  Plc made a deal to transfer some of its patents to a Native American tribe two weeks ago in order to shield them from review   McCaskill s response follows a bipartisan U S  House of Representatives committee decision to investigate the deal earlier this week and previous calls by Democratic Senators for a probe   Any thinking person would look at what this company did and say   That should be illegal   Well  I agree   McCaskill said in a statement   Congress never imagined tribes would allow themselves to be used by pharmaceutical companies to avoid challenges to patents  and this bill will shut the practice down before others follow suit   Allergan was not immediately available for comment  Allergan said last month that it was transferring patents on its blockbuster dry eye medication Restasis to New York s Saint Regis Mohawk Tribe  which agreed to exclusively license them back to the company in exchange for ongoing payments  The Tribe issued a statement expressing outrage at McCaskill s move and accused the senator of engaging in double standards  It said the proposed legislation  specifically targets Indian tribes  yet exempts state universities and other sovereign governments engaged in the very same IPR  inter partes review  process   Allergan has argued that the legal maneuver is aimed at removing administrative patent challenges through inter partes review by the U S  Patent Trial and Appeal Board  and not challenges in federal court  The drugmaker said it believes that the patents should not be subject to the IPR process   which Allergan has called flawed and broken   because of the tribe s sovereign immunity  
The company still faces a challenge to the patents in federal court ",2017-10-05,Reuters,https://www.investing.com/news/politics-news/senator-mccaskill-drafts-bill-in-response-to-allergan-patent-maneuver-537538,537538
105026,326541,AGN,Kitov ups stake in oncology focused TyrNovo to 92   shares ahead 9  premarket,news,Thinly traded nano cap  Kitov Pharmaceuticals Holdings   NASDAQ KTOV  is up 9  premarket on increased volume on the heels of its announcement that it has acquired an additional 27  stake in privately held TyrNovo  a developer of small molecule oncology drugs  Its stake is now  92  In this latest transaction with a group of minority shareholders  Kitov issued 13 169 689 new ordinary shares  equivalent to 658 484 American Depositary Shares  at  2 50 per ADS based on a mutually agreed  7M valuation of TyrNovo Kitov says TyrNovo s lead candidate NT219 has shown encouraging preclinical efficacy in treatment resistant tumors when combined with Merck  NYSE MRK  s Keytruda  pembrolizumab  Now read ,2017-10-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/kitov-ups-stake-in-oncologyfocused-tyrnovo-to-92-shares-ahead-9-premarket-537971,537971
105027,326542,AGN,China to accept out of country trial data to speed up drug approvals,news,"In a potential boon for drugmakers  China has outlined plans to accept data from overseas clinical trials in order to speed up drug approvals  Over the past five years  the China Food and Drug Administration has OK d just over 100 new medicines  about 1 3 the number in developed markets 
The Cabinet stated that it will also look at ways to improve the protection of medical intellectual property and boost the number of and quality of clinical trial testing centers there 
Source  Reuters
IBB XBI FBT PJP IHE XPH MRK PFE BMY LLY NVS AZN GILD CELG BIIB AMGN ABBV GSK AGN JNJ",2017-10-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/china-to-accept-outofcountry-trial-data-to-speed-up-drug-approvals-538724,538724
105028,326543,AGN,California governor signs drug pricing transparency law,news," Reuters    California Governor Jerry Brown on Monday signed state legislation requiring drug companies to report certain price hikes for prescription medicines in a move that could set a model for other states to follow  The law  which aims to provide more transparency around pharmaceutical and biotech company pricing methods for their medicines  requires drug manufacturers to give a 60 day notice if prices are raised more than 16 percent over a two year period  The law also requires health plans and insurers to file annual reports outlining how drug costs affect healthcare premiums in California   Californians have a right to know why their medication costs are out of control  especially when pharmaceutical profits are soaring   Brown  a Democrat  said in a statement on his website announcing the new legislation  The bill has been opposed by drugmakers  who argue that wholesale price increases do not reflect the actual prices paid for medicines after discounts and rebates  Biotechnology Innovation Organization  BIO   the leading biotech industry trade group  issued a statement condemning the bill and arguing that it would not serve its intended purpose   This law will neither provide meaningful information to patients nor lower prescription drug costs   the group said  adding that the law  seriously jeopardizes the future of California s leadership in this innovative industry   California is home to hundreds of biotechnology companies  Pharmaceutical companies have so far dodged stricter federal oversight despite growing public and political outrage over pricing practices for both branded and some generic medicines  But states  struggling to cover rising healthcare costs  have been addressing the issue rather than wait for federal help  At least 176 bills on pharmaceutical pricing and payment have been introduced this year in 36 states  according to the National Conference of State Legislatures  A new Maryland law takes aims at egregious price hikes on generic versions of older off patent drugs that are supposed to be far cheaper than the original branded medicines after some companies took massive increases on generic drugs not facing competition from other distributors  Amid the furor some drugmakers  including Allergan  NYSE AGN  Plc and AbbVie Inc  NYSE ABBV   have voluntarily pledged one annual price increase of under 10 percent on branded prescription medicines  It had been common industry practice to raise prices twice a year  often by double digit percentages  
However  even annual price hikes of 9 percent over a two year period would put a company in the crosshairs of the new California legislation ",2017-10-09,Reuters,https://www.investing.com/news/politics-news/california-governor-signs-drug-pricing-transparency-law-538935,538935
105029,326544,AGN,California enacts law aimed at corralling high drug prices,news,Yesterday  California Governor Jerry Brown signed a bill into law that requires drug makers to explain and justify price increases  Specifically  drug firms must provide 60 day notice to insurers and government health plans before increasing the list price of any medicine that costs more than  40 by at least 16  in a two year period Health plans must provide detailed information about prescription drug costs and the portion of premiums related to this expense The law  vociferously opposed by the pharmaceutical industry  will go into effect January 1  2018 PFE MRK AGN ABBV BMY LLY BMY NVS AZN GSK OTCQX RHHBY GILD BIIB AMGN CELG PJP IHE XPH PPH GNRXNow read ,2017-10-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/california-enacts-law-aimed-at-corralling-high-drug-prices-539250,539250
105030,326545,AGN,Pfizer weighs  15 billion sale of consumer healthcare business,news,"By Manas Mishra and Ben Hirschler  Reuters    Pfizer  NYSE PFE  said on Tuesday it was considering the sale or spin off of its consumer healthcare business  shaking up the industry and potentially putting a headache pill to lip balm operation worth some  15 billion up for grabs  The move comes as Germany s Merck  NYSE MRK  KGaA is also looking to divest its non prescription products  including brands such as Seven Seas vitamins  which could be worth around  4 5 billion  As aging populations and health conscious consumers drive demand for self medication  the fragmented consumer health sector has proved a fertile ground for deal making in recent years  Although consumer remedies sold over the counter have lower margins than prescription drugs  they are typically very long lasting brands with loyal customers  Pfizer s consumer healthcare business  whose brands include painkiller Advil and lip balm Chapstick  had revenue of about  3 4 billion in 2016  Industry experts said it could fetch some four times sales  implying a potential value of just under  14 billion  although two healthcare sector bankers said Pfizer was aiming for at least  15 billion  People familiar with the matter said Swiss food giant Nestle could be among those interested  along with existing manufacturers of over the counter  OTC  treatments and private equity firms  Pfizer  whose shares were little changed on Tuesday  said it would decide on the future of its consumer unit during 2018  Reuters first reported last November that a divestment of the business was under consideration   Established consumer health companies that may be interested in the Pfizer assets include Reckitt Benckiser  Procter   Gamble  GlaxoSmithKline  Johnson   Johnson  NYSE JNJ  and Abbott  They could be joined by Nestle  which is exploring the boundaries between food and healthcare  Nestle s new CEO Mark Schneider told investors last month it would keep identifying new opportunities and that 10 percent of group sales could be ripe for portfolio adjustment   A second person familiar with the matter said Pfizer expected a  broadening  of buyer interest to include Nestle  Bayer  DE BAYGN  and Sanofi  PA SASY  may be less likely to bid  despite their consumer health presence  given they are busy absorbing Monsanto  NYSE MON  and Boehringer Ingelheim s consumer business respectively  In explaining the thinking behind the review  Pfizer Chief Executive Ian Read said consumer healthcare was connected but not integral to its core prescription drug business   Although there is a strong connection between consumer healthcare and elements of our core biopharmaceutical businesses  it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company   he said  Options to be considered include a full or partial separation through a spin off  sale or other transaction  Pfizer may also ultimately decide to keep the business  The Pfizer business includes two of the 10 top selling consumer healthcare brands globally in Advil and the multivitamin line Centrum  It also has 10 brands that each exceeded  100 million in 2016 sales   IRRELEVANT  TO POTENTIAL BRISTOL BID  A Pfizer exit from the consumer health business would be one of its biggest corporate moves since abandoning a  160 billion deal to buy Allergan  NYSE AGN  last year  It also tried and failed to buy AstraZeneca in 2014  Since then there has been persistent speculation that Pfizer is scouting for another major deal  with a bid for cancer specialist Bristol Myers Squibb widely tipped as an option  However  the first source said the consumer healthcare review and the amount of cash it would raise was  irrelevant  to a possible takeover of Bristol Myers  which has a market value of  105 billion  Pfizer has hired Centerview Partners  Guggenheim Securities and Morgan Stanley  NYSE MS  as financial advisers for the review   
Germany s Merck KGaA had hired JP Morgan to sell its consumer health business ",2017-10-10,Reuters,https://www.investing.com/news/stock-market-news/pfizer-mulling-sale-of-consumer-healthcare-business-539219,539219
105031,326546,AGN,Heavy hitter lobbying groups line up against Allergan s controversial Restasis patent ploy,news,An alliance of large lobbying organizations  including the American Hospital Association and America s Health Insurance Plans  has sent a letter to Congress opposing Allergan s  AGN  0 3   recent legal maneuver with the St  Regis Mohawk tribe aimed at maintaining patent protection for dry eye med RESTASIS  Cyclosporine Ophthalmic Emulsion   a  1 5B franchise Critics regard the move as egregiously prioritizing profits over patients adding that CEO Brent Saunders is behaving like pharma bad boy Martin Shkreli Soon after the deal was done  St  Regis went to court to stop an inter partes review  IPR  of the patent Mr  Saunders appears unmoved over the furor  saying   IPR s flaws have been exploited by generic manufacturers and a new breed  of  reverse trolls   There have been many cases of hedge funds that  demanded cash from branded biopharma companies as a payoff for not  filing IPR challenges  Allergan has been the target of  one of these extortion like attacks  Hedge funds have also taken short  positions in companies and then filed IPR challenges to drive down their  stock value  Previously  Allergan uses legal maneuver with sovereign tribal government to protect Restasis patents  Sept  8 Now read ,2017-10-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/heavy-hitter-lobbying-groups-line-up-against-allergans-controversial-restasis-patent-ploy-540217,540217
105032,326547,AGN,President Trump at it again with comments on  out of control  drug prices,news,Drug and biotech stocks are  again  the target of disparaging comments from President Trump who says the companies are  getting away with murder  with their  out of control  drug prices  He says U S  consumers should be paying what patients in other countries are paying  also meaning that other countries should pay more Selected tickers   IBB  0 1   XBI  0 2   PJP  IHE  0 1   AMGN  0 7   BIIB  1 2   GILD  1 4   CELG  BMY  2 3   MRK  0 1   PFE  0 7   LLY  0 7   NVS  0 3   OTCQX RHHBY  0 4   GSK  0 7   AZN  0 1   ABBV  0 8   AGN  0 4   JNJ  0 3  Now read ,2017-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/president-trump-at-it-again-with-comments-on-out-of-control-drug-prices-542149,542149
105033,326548,AGN,U S  court invalidates Allergan s Restasis patents  shares down 5 ,news,A Texas district court has ruled that patents covering Allergan s  AGN  5 1   dry eye med RESTASIS  Cyclosporine Ophthalmic Emulsion  are invalid due to obviousness  The ruling was made in a patent infringement case involving potential generic competitors Mylan N V   MYL  0 4   and Teva Pharmaceutical Industries  TEVA  2 2   The patents at issue at the same ones that Allergan recently transferred to a Native American tribe  but it said that it wiould not invoke the tribe s sovereign immunity in federal court Previously  Allergan uses legal maneuver with sovereign tribal government to protect Restasis patents  Sept  8 Now read ,2017-10-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/us-court-invalidates-allergans-restasis-patents-shares-down-5-542236,542236
105034,326549,AGN,Will Allergan  AGN  Beat Estimates Again In Its Next Earnings Report ,opinion,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report  you should consider Allergan  NYSE AGN   This company  which is in the Zacks Medical   Generic Drugs industry  shows potential for another earnings beat 
When looking at the last two reports  this Botox maker has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 4 68   on average  in the last two quarters 
For the most recent quarter  Allergan was expected to post earnings of  4 15 per share  but it reported  4 29 per share instead  representing a surprise of 3 37   For the previous quarter  the consensus estimate was  4 01 per share  while it actually produced  4 25 per share  a surprise of 5 99  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Allergan  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Allergan has an Earnings ESP of  0 41  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/will-allergan-agn-beat-estimates-again-in-its-next-earnings-report-200403185,200403185
105035,326550,AGN,Genfit IPO Starts Well  Long Term Uncertain,opinion,"Biotech firm Genfit  NASDAQ GNFT  ran the NASDAQ bell on Wednesday  and the company had a solid debut as it went public  The NASDAQ reported that Genfit closed Tuesday s trading to  22 17  a raise of over 9  from its initial price of  20 32  At that  20 32 price  Genfit raised  135 million and would achieve a market not reaching but approximating  1 billion 
But despite this moderately successful debut  the fundamental question which Genfit or any biotech IPO faces is whether it has the funds to keep operational  and there are concerning figures on that front  If investors are interested in Genfit  they will likely be better off waiting for either further trials to progress or the lock up period to end 
Fighting Liver Disease
Genfit is a French company founded in 1999 that boasts in its SEC report of developing  innovative drug candidates  in combatting liver disease  Genfit s current most advanced product is called elafibranor  Genfit is primarily testing to see if elfibranor can combat nonalcoholic steatohepatitis  NASH   with other applications being earlier in the pipeline 
NASH is a liver disease which affects millions of people  can lead to life threatening conditions over time   and for which there are currently no approved therapies   NASH is a growing concern in the developed world  as it is caused by excessive fat build up in the liver and is conflated with obesity and diabetes 
The NASH market is thus expected to explode over the next several years  Genfit states that the global market for the treatment of NASH is projected to reach  20 billion by 2025  and Pharmaceutical Technology reports similar figures with an expected CAGR of 63  
Given the potential rewards  other companies such as Allergan  NYSE AGN  and Intercept Pharmaceuticals  NASDAQ ICPT  are also developing potential treatments  Intercept last month  announced positive results  from its pivotal Phase 3 testing and intends to file for approval in the United States and Europe in the second half of 2019  By contrast  Genfit is still in Phase 3 testing for elafibranor  and will announce results by the end of the year 
But while Genfit is a step behind  this is not a major concern  NASH is a complicated disease  and it is highly unlikely that any single drug will be able to treat it by itself  Given how large the market is expected to grow  there is room for multiple NASH treatments to develop over the next several years 
Genfit will still be in a position to succeed if the test succeeds  but that is a gigantic  if   Genfit has other projects in development to treat fibrosis and auto immune diseases  but these will take years to further develop and test  Furthermore  investors should be concerned about the fact that Genfit does not have a partner or larger corporation willing to subsidize and support its research efforts 
Genfit s Problematic Finances
Like most biotech IPOs  Genfit has little revenue to its name and is losing money  Genfit earned  7 494 million in 2018  but practically all of that comes from a French tax credit designed to encourage scientific research  Even with that subsidy  Genfit reported a net loss of  79 5 million in 2018   2 55 per share  and  55 7 million in 2017   1 79 per share  
Revenue and net losses are not particularly important figures for a late stage biotech company  but Genfit s other numbers are also concerning  As of December 31  2018  Genfit reported having  207 2 million in cash against  208 4 million in total liabilities  Much of Genfit s liabilities will come due during the next 3 to 5 years  with a convertible loan of  180 million due in less than 4 years  Genfit has also reported a negative cash flow loss of about  60 million in both 2017 and 2018 
These factors mean that Genfit will stay operational for at least the next 12 months  at which point we will know whether its Phase 3 elafibranor trial is a success  But Genfit s long term financial picture is much shakier  Maybe it will not matter that much if Genfit can market a drug with such major potential  but the risk is higher 
Until The End Of The Year
The big question surrounding Genfit will not be answered until the end of the year  when we will learn the results of its current Phase 3 test  If the test succeeds  Genfit will be closer to selling a product which would be immensely valuable and profitable given the growing NASH market  But if it fails  Genfit s backup plans are nowhere near enough to justify its current value 
Consequently  there is little reason to jump onto this IPO now  especially given Genfit s shaky financial numbers and its massive long term liabilities  Investors will be better off waiting until the end of the year for further information  especially since the stock will likely fall in value once the lock up period expires  Genfit s stock will likely utterly collapse or explode in December  with not much room in between ",2019-04-02,Alex Newman,https://www.investing.com/analysis/genfit-ipo-starts-well-but-longterm-success-uncertain-200403234,200403234
105036,326551,AGN,Allergan s AMD Drug Lowers Inflammation In Phase III Study,opinion,Allergan plc   NYSE AGN   and partner Molecular Partners announced top line safety data from the phase III MAPLE study on its long acting anti VEGF product  abicipar pegol in age related neovascular macular degeneration  nAMD MAPLE  a 28 week open label study  used a modified manufacturing process to test an optimized 12 week formulation of abicipar in nAMD patients Following the improved manufacturing process  it was observed that the incidence of intraocular inflammation  IOI  in the study was lower than previous phase III studies  In the MAPLE study  the reported incidence of IOI was 8 9   which was less than around 15  observed in the previous studies  SEQUOIA and CEDAR  Meanwhile  the incidence of severe IOI events was also less  Importantly  there were no cases of inflammation complications like endophthalmitis or retinal vasculitis in the study Last July  Allergan and Molecular Partners announced data from two phase III studies   SEQUOIA and CEDAR   evaluating abicipar compared with Novartis   NYSE NVS   Roche s   OTC RHHBY   Lucentis  ranibizumab  in treatment na ve patients with nAMD  Data from the studies demonstrated that treatment with both the 8 week and 12 week regimens of abicipar resulted in a higher percentage of patients achieving stable vision at week 52  primary endpoint   thereby demonstrating non inferiority to Lucentis The companies plan to file a biologics license application  BLA  for abicipar in the first half of 2019 If approved as a fixed 12  week anti VEGF treatment for nAMD  it will reduce the treatment burden for these patients  Detailed safety data from the MAPLE study are expected to be presented later this year  Allergan also said it plans to move forward with a phase III study on abicipar for diabetic macular edema  DME  in the second half of the yearPlease note that Regeneron Pharmaceuticals   NASDAQ REGN    is also seeking approval for a 12 week dosing interval of its blockbuster anti VEGF drug Eylea  aflibercept  Injection in patients with wet age related macular degeneration  wet AMD  Allergan s stock was down slightly on Tuesday after the news was announced as MAPLE study s inflammation rates were still too high compared to those observed in studies on Lucentis and Eylea  Allergan s share price has risen 9 4  this year so far compared with the  s increase of 10 5    Allergan currently has a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/allergans-amd-drug-lowers-inflammation-in-phase-iii-study-200403641,200403641
105037,326552,AGN,Editas  EDIT  Inks Cross Licensing Agreement With BlueRock ,opinion,"Editas Medicine  Inc    NASDAQ EDIT   inked a research and cross licensing agreement with BlueRock Therapeutics  LP  to combine their respective genome editing and cell therapy technologies to discover  develop and manufacture novel engineered cell medicines 
Shares of Editas have increased 17 6  in the past year compared with the  s growth of 14  

 
The collaboration will focus on the creation of novel  allogeneic pluripotent stem cell  PSC  lines by combining Editas  CRISPR genome editing technology and BlueRock s induced pluripotent stem cell  iPSC  platform  Per the agreement  BlueRock will gain non exclusive rights to Editas  CRISPR technology and intellectual property  while Editas will gain non exclusive rights to the latter s iPSC and cell differentiation technology and intellectual property 
According to Editas  combining CRISPR based genome editing with cell therapy can deliver game changing allogeneic medicines  The collaboration with BlueRock provides potential to speed up the development of therapies for people suffering from various diseases 
Per the agreement  both Editas and BlueRock will make development  regulatory and commercial milestone payments to their partners for any licensed engineered cell medicine developed in their respective field  Both the companies will also pay royalties to each other on global net product sales 
Editas makes transformative genomic medicines to treat serious diseases  using its proprietary genome editing platform based on CRISPR technology  The company has a strategic alliance and an option agreement with Allergan Inc    NYSE AGN    under which the latter reserves rights to license up to five of Editas  genome editing ocular programs  
The company also has a collaboration and licensing deal with Juno Therapeutics  which is now part of Celgene   NASDAQ CELG    to use gene editing approaches  including CRISPR Cas9  for developing engineered T cell medicines to treat cancer Editas Medicine  Inc  Price

    
Zacks Rank   Stock to Consider
Editas currently carries a Zacks Rank  3  Hold   
A better ranked stock worth considering is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy   You can see  
Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters at an average of 1 61  
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-04,Zacks Investment Research,https://www.investing.com/analysis/editas-edit-inks-cross-licensing-agreement-with-bluerock-200404079,200404079
105038,326553,AGN,Pharma Stock Roundup  NVS Inks Immunology Deal  PFE  TEVA Get Drug Approvals In EU,opinion,"This week Pfizer   NYSE PFE   and Teva   NYSE TEVA   gained marketing approval from the European Commission for their new medicines  While Pfizer gained approval for its new lung cancer medicine  Vizimpro  Teva s CGRP injection  Ajovy was approved in EU  Meanwhile  Novartis   NYSE NVS   announced plans to acquire IFM Tre  a subsidiary of privately held IFM Therapeutics  The acquisition will give Novartis full rights to IFM s two NLRP3 inhibitors  Meanwhile  Novartis  blockbuster psoriasis drug  Cosentyx was approved in China while Merck s   NYSE MRK   Keytruda was approved in the country for first line lung cancer as a combination therapy Recap of the Week s Most Important HeadlinesTeva   Pfizer s Medicines Get Approval in EU  Teva s CGRP injection  Ajovy was granted for the prophylaxis of migraine in adult patients who experience at least four migraine days per month  Ajovy  fremanezumab   for prevention of chronic episodic migraine  was approved in the United States in September last year and has been enjoying strong demand since launch Pfizer also for its new lung cancer medicine  Vizimpro  dacomitinib  that was approved in the United States last September  Vizimpro  dacomitinib   a tyrosine kinase inhibitor  is now approved in EU for the first line treatment of metastatic non small cell lung cancer  NSCLC  in patients with EGFR activating mutations Novartis  New Immunology Acquisition  Novartis announced plans to   a subsidiary of Boston based IFM Therapeutics  for an upfront payment of  310 million upfront  In addition  IFM will also be eligible to earn up to  1 265 billion in milestone payments  The deal will give Novartis full rights to IFM s two NLRP3 inhibitors   one clinical and two preclinical  These medicines target the NLRP3 inflammasome  a key component of the innate immune system  thereby providing a novel approach to preventing chronic inflammation that results in serious disease  The deal complements Novartis  existing pipeline of anti inflammatory medicines  The transaction is expected to close in the second quarter of 2019 Meanwhile  Novartis  blockbuster psoriasis drug    Cosentyx  a first in class interleukin 17A  IL 17A  inhibitor  is the first biologic approved in China for moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Novartis  generic arm  Sandoz announced to the FDA looking for approval of its biosimilar version of Amgen s neutropenia drug  Neulasta   Novartis had earlier in June 2016 received a complete response letter from the FDA for the same  Neutropenia is one of the most serious side effects of chemotherapy Novartis also notified of a dispute with Amgen  NASDAQ AMGN  relating to their collaboration agreement for the newly launched migraine medicine  Aimovig  Novartis said that Amgen issued a notice of termination of the agreement on Apr 2  Novartis strongly disputes the notice and has sued Amgen accusing the biotech of making an unjustifiable attempt to end the collaboration with Novartis Merck s Keytruda Gets Approval in China for First Line Lung Cancer  Merck announced that the  has granted conditional approval to Keytruda in combination with Lilly s Alimta  pemetrexed  and platinum chemotherapy for the first line treatment of metastatic non squamous non small cell lung cancer  NSCLC  with no EGFR or ALK genomic tumor aberrations  The approval was based on significant survival benefit demonstrated in a key late stage lung cancer study  KEYNOTE 189  Notably  data from the KEYNOTE 189 study is already included in Keytruda s U S  and EU label FDA Grants AstraZeneca Merck s Selumetinib Breakthrough Therapy Status  AstraZeneca   NYSE AZN   and Merck s MEK 1 2 inhibitor   by the FDA for the treatment of neurofibromatosis type 1  NF1  related plexiform neurofibromas  an incurable genetic condition that affects newborns  Selumetinib is being evaluated in a phase II SPRINT study in pediatric patients with inoperable NF1 related PN  which formed the basis of the designation Allergan  Abicipar Shows Better Inflammation in AMD Study  Allergan s   NYSE AGN   phase III MAPLE study evaluating a 12 week dose of its long acting anti VEGF candidate  abicipar pegol  demonstrated in patients with age related neovascular macular degeneration  nAMD   MAPLE used a modified manufacturing process to test an optimized 12 week formulation of abicipar in nAMD patients  Following the improved manufacturing process  it was observed that the incidence of intraocular inflammation  IOI  in the study was lower than previous phase III studies  In the MAPLE study  the reported incidence of IOI was 8 9   which was less than around 15  observed in the previous studies  SEQUOIA and CEDAR  The companies plan to file a biologics license application  BLA  for abicipar in the first half of 2019 Pfizer Sangmo Announce Promising Data on Gene Therapy Candidate  Pfizer and its partner  Sangamo Therapeutics announced from a phase I II study evaluating their gene therapy candidate  SB 525  for treating hemophilia A  Data from the study showed that patients treated with the highest dosage of SB 525  3e13 vg kg  achieved normal factor VIII levels  Dose dependent increase in factor VIII levels was observed in eight patients treated with SB 525 gene therapy across the four dosage cohorts  Excess levels of factor VIII increase blood clotting  which is a major symptom of haemophilia  Based on the data from the study  the Safety Monitoring Committee  SMC  recommended expansion of the 3e13 vg kg cohort Meanwhile  Pfizer s breast cancer drug Ibrance in combination with an aromatase inhibitor or fulvestrant gained FDA s approval for the treatment of men with HR   HER2  metastatic breast cancer The NYSE ARCA Pharmaceutical Index declined 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions   All the stocks were in the red in the last five trading sessions  except Pfizer  which rose 1 1   AstraZeneca declined the most  5 7   In the past six months  Merck has been the biggest gainer  14 5   while Bristol Myers   NYSE BMY   declined the most  25 8    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-04,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu-200404293,200404293
105039,326554,AGN,Will Ironwood Suffer From Dependence On Linzess  Progress ,opinion,"On Apr 4  we issued an updated research report on Ironwood Pharmaceuticals  Inc    NASDAQ IRWD    This biopharmaceutical company  based in Cambridge  MA  is focused on the development and commercialization of treatments primarily addressing gastrointestinal   GI   diseases  The company s sole marketed drug  Linzess  is indicated for the treatment of irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation   CIC   We remind investors that Ironwood co develops and co commercializes Linzess and equally shares Linzess U S  collaboration profits losses as well as development costs with Allergan   NYSE AGN   In April 2018  the company has separated its Soluble Guanylate Cyclase  sGC  business into a new entity named Cyclerion Therapeutics Shares of the company have rallied 22 2  so far this year compared with the  s rise of 19 3  Linzess Remains Impressive Sales of Linzess were encouraging in 2018 as well  Total revenues for 2018 increased 16 2  year over year to  346 6 million primarily on the back of strong sales of Linzess  The drug s sales rose more than 9  in 2018  Prescriptions filled in 2018 were also up almost 7  year over year In January 2019  Linzess received approval in China for IBS C  The company along with its partner  AstraZeneca   NYSE AZN    will launch the drug in China in the second half of 2019  This is likely to boost Ironwood s top line The company also earns by selling linaclotide  Linzess  active pharmaceutical ingredient  API  to Japan based Astellas Pharma  Ironwood Pharma generated almost  70 4 million from this transaction in 2018 compared with  29 7 million in the year ago period  Astellas Pharma started commercializing Linzess in Japan for IBS C in early 2017 Pipeline ProgressIronwood and Allergan are conducting a phase III study to evaluate Linzess in additional abdominal symptoms including bloating and discomfort in adult patients with IBS C  A label expansion in pediatric patients is also being planned A phase IIb study is evaluating MD 7246  a delayed release formulation of Linzess  as a treatment for all subtypes of IBS  including IBS C  IBS with diarrhea and IBS mixed  The company is also developing another GI candidate  IW 3718  in phase III studies for treating persistent refractory gastroesophageal reflux disease   GERD   Cyclerion Spin offOn Apr 1  Ironwood completed the previously announced separation of its sGC business and transferred the sGC pipeline for the treatment of serious and orphan diseases to newly formed Cyclerion  This will help Ironwood to focus on its GI pipeline Ironwood started reducing its workforce following the separation  which is likely to boost margins going forward  The company also reduced employees in 2018 related to separation of business as well as termination of lesinurad license with AstraZeneca  Although the separation of business will increase selling  general and administrative expense  research and development expenses are likely to decrease due to transfer of sGC pipeline in 2019 Our TakeThe spin off of sGC pipeline and focus on developing GI pipeline is a positive for Ironwood  It will help the company invest more resources for the development of its GI candidate  Label expansion of Linzess will further boost the prospects of the drug However  we note that Ironwood is primarily dependent on Linzess for revenues  Any setback related to manufacturing or commercialization of the drug will impact the company s top line  The competition in target markets for Linzess is also increasing  Other available products include Takeda Pharma s   NYSE TAK   Amitiza  Takeda s Motegrity and Synergy s  now a part of   Bausch Health Companies  Trulance  Linzess also faces competition from laxatives and over the counter fiber supplements  Pricing pressure also hurts revenues from Linzess  Moreover  Ironwood s GI pipeline is years away from commercialization Ironwood Pharmaceuticals  Inc  Price
    Zacks RankIronwood currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-04,Zacks Investment Research,https://www.investing.com/analysis/will-ironwood-suffer-from-dependence-on-linzess-progress-200404281,200404281
105040,326555,AGN,Alkermes Reports Positive Data From Schizophrenia Study ,opinion,Alkermes plc   NASDAQ ALKS   announced positive top line results from ALPINE  Aripiprazole Lauroxil and Paliperidone palmitate  INitiation Effectiveness   a six month phase IIIb study evaluating the efficacy  safety and tolerability of its long acting injectable Aristada  aripiprazole lauroxil  and Johnson   Johnson s   NYSE JNJ   monthly injectable Invega Sustenna  paliperidone palmitate  in 200 patients experiencing acute exacerbations of schizophrenia  In the study  both Aristada  given every two months  and Invega Sustenna  given every month  demonstrated statistically significant improvements from baseline in schizophrenia symptoms  The study also showed that the efficacy was similar for both medicines throughout the six month study   The study met its pre specified primary endpoint  with both medications demonstrating statistically significant reductions in Positive and Negative Syndrome Scale  PANSS  total scores at Week 4  Scores were down 17 4 points for the Aristada group and 20 1 points for the Invega Sustenna group  Improvements in PANSS total scores were not statistically different between the groups in any assessment during the course of the study The research proves that these two long acting medicines  each with their own distinct safety and tolerability profile  may be clinically useful to bridge the critical transition between inpatient and outpatient settings of care  The results showed that that long acting atypical antipsychotics can help in rapidly and effectively stabilizing patients in the hospital and supporting their continuity of care after discharge We remind investors that the two month Aristada extended release injectable suspension is marketed for the treatment of schizophrenia  Also  Aristada Initio extended release product is marketed for the treatment of schizophrenia in adults  Shares of Alkermes have rallied 24 5  in the past year compared with the  s growth of 9 9  The company is also developingALKS 3831  which is currently in phase III for the treatment of schizophrenia Other players in the schizophrenia treatment market include AstraZeneca plc s   NYSE AZN   Seroquel XR  Johnson   Johnson s  Risperdal Consta and Allergan s   NYSE AGN   Vrylar Alkermes plc Price   Zacks RankAlkermes currently carries a Zacks Rank  2  Buy   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/alkermes-reports-positive-data-from-schizophrenia-study-200405646,200405646
105041,326556,AGN,Allergan Falls As Supreme Court Dismisses Restasis Litigation,opinion,"Allergan plc s   NYSE AGN   shares declined almost 1  presumably due to the U S  Supreme Court s unfavorable ruling in a litigation related to patents covering its blockbuster eye drug  Restasis  per an  posted on Reuters In October last year  a Texas federal district court invalidated four of the six patents covering Restasis  potentially opening doors for early generic competition  though the patents for the drug are scheduled to expire in August 2024  A generic version of the drug is expected to be launched soon Allergan thus resorted to different ways of protecting Restasis from generic competition In September 2017  the company had transferred legal ownership of six patents related to Restasis to the Saint Regis Mohawk Tribe  It gained exclusive license from the tribe to shield Restasis from generic competition using sovereign status enjoyed by Native American tribes  The transfer of patents to the tribe was expected to keep them out of a federal administrative court s purview Lawmakers questioned the unconventional move adopted by the company to protect Restasis from generic competition  The deal with the tribe has raised concerns that it will curb generic competition in the pharmaceutical industry and discourage generic drugmakers from making cheaper versions of expensive drugs In 2016  Mylan   NASDAQ MYL    in a bid to launch generic version of Restasis  had appealed to the Patent Trial and Appeal Board to invalidate patents covering the drug  Moreover  Teva Pharmaceutical   NYSE TEVA   is also seeking approval for its own Restasis generic The Supreme Court refused to hear Allergan s appeal and upheld the ruling of a lower court  This may lead to generic competition for Restasis sooner than expected Shares of the company are up 7 4  so far this year compared with the  s increase of 6  Sales of Restasis were  1 2 billion in 2018  Sales declined in the past two years mainly due to lower selling price and demand  The launch of the generic version will hurt sales further Allergan is facing declining sales of major drugs due to loss of exclusivity  The first generic versions of Alzheimer s treatment  Namenda XR and Estrace cream were launched in the first quarter of 2018  Other products including Bystolic  Delzicol  Gelnique  Saphris and Viibryd are all slated to lose exclusivity over the next few years  Loss of exclusivities hurt sales by  1 2 billion in 2018 and is expected to have an adverse impact of another  1 4 billion in 2019 Competition for Allergan s drugs from other branded drugs is also on the rise  Restasis faces competition from Teva Pharmaceutical s Xiidra  Allergan s popular drug and the largest revenue generator Botox is facing rising competition with the entry of CGRP antibodies for migraine in 2018  These include Amgen Novartis   NYSE NVS    Eli Lilly  NYSE LLY  and Teva Pharma s CGRP migraine treatments Aimovig  Emgality and Ajovy  respectively  Linzess faces competition from Synergy Pharma s Trulance In a separate press release  Allergan announced that two leading independent proxy advisory firms  Institutional Shareholder Services and Glass Lewis  have advised shareholders to vote for all proposals brought forward by Allergan  Both firms have also recommended against the splitting of chief executive officer and chairman roles  both currently held by Brent Saunders  We  investors that activist investor Tepper from Appaloosa has been insisting on the separation of CEO and chairman roles since early 2018 Allergan plc Price
    Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/allergan-falls-as-supreme-court-dismisses-restasis-litigation-200407364,200407364
105060,326575,AGN,Hurricanes to trim 1 5  off Quest s Q3 sales projection and  0 10 off EPS  shares down 1  after hours,news,Citing the impact of recent hurricanes  Quest Diagnostics  NYSE DGX  lowers its Q3 guidance  Revenues will be 1 5  lower than expected and EPS will be trimmed  0 10  The negative impact is largely attributed to operations in Florida and Texas  which the company says are back to normal Management will provide more detailed data when it releases Q3 results on October 19 Shares are down 1  after hours on light volume Now read ,2017-09-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/hurricanes-to-trim-15-off-quests-q3-sales-projection-and-010-off-eps-shares-down-1-after-hours-533790,533790
105061,326576,AGN,Senators want probe of Allergan transfer deal with tribe  letter,news,"By Jan Wolfe  Reuters    Four U S  senators have asked the Senate Judiciary Committee to launch an investigation into a deal drugmaker Allergan Plc  N AGN  struck with a Native American tribe to protect some of its patents from generic challenge  according to a letter seen by Reuters  Democrats Maggie Hassan  Sherrod Brown  Bob Casey and Richard Blumenthal in the letter to Judiciary Committee Chairman Chuck Grassley and Ranking Member Dianne Feinstein on Wednesday called Allergan s deal  a blatantly anti competitive attempt to shield its patents from review and keep drug prices high   Allergan said on Sept  8 that it was transferring patents on its dry eye medication Restasis to upstate New York s Saint Regis Mohawk Tribe  which agreed to exclusively license them back to the company in exchange for ongoing payments  Allergan said in an emailed response to a Reuters request for comment that it met last week with the staffs of Senators Brown and Hassan to provide detailed briefings on the agreement   We would welcome the opportunity to provide additional briefings for these Senators  as well as the opportunity to brief Senators Casey and Blumenthal  and answer any questions they may have   Allergan said in the email   The tribe and company have said that the tribe s sovereign status shields the patents from review by the U S  Patent Trial and Appeal Board  an administrative court empowered to invalidate patents  On Friday  the tribe asserted this immunity in an ongoing administrative proceeding brought by generic drugmakers led by Mylan NV  O MYL   which are seeking to invalidate Allergan s patents to introduce cheaper versions of Restasis to the market   Mylan has called Allergan s deal with the tribe a  sham transaction  and said the tribe should not be allowed to invoke immunity to prevent administrative review  Some patent lawyers have noted that the patent board has recognized the immunity of state entities like public universities  and tribal immunity is considered to be an even stronger shield  
Generic drug companies often seek to challenge brand name drug patents through administrative proceedings  which are cheaper and faster than federal court litigation  Allergan has said it would not invoke the tribe s immunity in federal court ",2017-09-27,Reuters,https://www.investing.com/news/stock-market-news/exclusive-us-senators-want-probe-of-allergan-transfer-deal-with-tribe--letter-533744,533744
105062,326577,AGN,Washington state sues OxyContin maker Purdue Pharma,news,"By Nate Raymond  Reuters    Washington state on Thursday sued OxyContin maker Purdue Pharma LP  becoming the latest state or local government to file a lawsuit seeking to hold pharmaceutical companies accountable for a national opioid addiction epidemic  The city of Seattle also filed a separate lawsuit against Purdue as well as units of Teva Pharmaceutical Industries  NYSE TEVA  Ltd  Johnson   Johnson  NYSE JNJ   Endo International Plc and Allergan  NYSE AGN  plc   The lawsuit by Washington Attorney General Bob Ferguson accused Purdue of deceptive marketing of OxyContin and convincing doctors and the public that its drugs had a low risk of addiction and were effective for treating chronic pain  He said he would be seeking to force Purdue to pay a  significant  sum for engaging in marketing practices that downplayed the addictiveness of its drugs  allowing it to earn billions of dollars while fuelling the opioid crisis   I don t know how executives at Purdue sleep at night   Ferguson told reporters  Stamford  Connecticut based Purdue said in a statement it was  deeply troubled  by the opioid crisis and that its U S  Food and Drug Administration approved products account for just 2 percent of all opioid prescriptions   We vigorously deny these allegations and look forward to the opportunity to present our defense   Purdue said  According to the U S  Centers for Disease Control and Prevention  opioids were involved in over 33 000 deaths in 2015  the latest year for which data is available  The death rate has continued rising  according to estimates   The lawsuits followed a wave of cases against opioid manufacturers and distributors by Louisiana  West Virginia  New Mexico  Oklahoma  Mississippi  Ohio  Missouri  New Hampshire and South Carolina  as well as several cities and counties  Purdue and three executives pleaded guilty in 2007 to federal charges related to the misbranding of OxyContin  which is used to relieve pain  and agreed to pay a total of  634 5 million to resolve a U S  Justice Department probe  That year  the privately held company also reached a  19 5 million settlement with 26 states and the District of Columbia  It had agreed in 2015 to pay  24 million to resolve a lawsuit by Kentucky  In filing his lawsuit in King County Superior Court in Seattle on Thursday  Ferguson said he was breaking off from an ongoing multi state probe by various attorneys general into companies that manufacture and distribute opioids  
While Ferguson said looked forward to seeing its results   we felt we had a case ready to go  ",2017-09-28,Reuters,https://www.investing.com/news/stock-market-news/washington-state-sues-opioid-manufacturer-purdue-pharma-534319,534319
105063,326578,AGN,AveXis on go to start pivotal study of IV AVXS 101 in SMA,news,The FDA has signed off on a pivotal clinical trial  STRIVE  evaluating AveXis   NASDAQ AVXS  lead gene therapy candidate AVXS 101 in patients with spinal muscular atrophy  SMA  Type 1 using the intravenous  IV  formulation produced by the company s GMP commercial manufacturing process  The trial will be initiated immediately GMP caliber product will be used for all subsequent studies and commercial supply  if approved STRIVE s co primary endpoints are the ability to independently sit for at least 30 seconds at 18 months of age and event free survival at 14 months of age The company says its discussions with the FDA on the details for intrathecal  within the spine  administration of AVXS 101 in an SMA Type 2 study are continuing   It will update investors in Q4 Shares are up 2  premarket but only on 102 shares Now read ,2017-09-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/avexis-on-go-to-start-pivotal-study-of-iv-avxs101-in-sma-534655,534655
105064,326579,AGN,U S  court strikes down Obama era rule on tax inversions,news,"WASHINGTON  Reuters    A federal court in Texas on Friday ruled that the Obama administration acted unlawfully last year when its Treasury Department cracked down on U S  companies that try to reduce their U S  taxes by rebasing abroad  in a process known as inversion 
The U S  Chamber of Commerce and the Texas Association of Business had filed a lawsuit in Texas federal court that said a regulation from the Treasury Department in April 2016 exceeded what the law allows the department to do 
    They argued the Internal Revenue Service rule used was  arbitrary and capricious  because it was instated without notice and opportunity for comment in violation of standards required for rulemaking 
     The U S  District Court for Western Texas in Austin agreed  saying the IRS rule was a substantive or legislative regulation that required a notice and comment period before it was instated 
The U S  Treasury  the U S  Chamber of Commerce and Texas Association of Business could not be immediately reached for comment 
    The lawsuit was the first to challenge a rule on inversion  The deals are legal  but have drawn criticism from some politicians who say U S  companies that do them are avoiding their tax obligations  A wave of inversions largely ended after Treasury moved against the deals 
    The IRS rule had been aimed at transactions involving non U S  companies  such as Ireland based drugmaker Allergan Plc  NYSE AGN N  that have grown through a series of acquisitions 
    It had helped scuttle what had been a planned  160 billion combination of Allergan and U S  drugmaker  Pfizer  Inc  NYSE PFE N  in what would have been the largest inversion ever 
    Dozens of U S  companies have done inversions since 1983  when the first such deal was completed  Treasury has periodically moved to curb the flow of deals because inversions erode the U S  corporate income tax base 
    Treasury unveiled a package of rules in 2016 meant to further discourage the deals  which typically involve a U S  multinational buying a smaller company in a foreign country with lower corporate taxes and then rebasing there  if only on paper 
    Inverting U S  companies usually leave their core U S  operations at home  transferring only their legal tax domicile to the home country of the acquired company  Recent popular destinations for the deals are Ireland  Britain and Canada ",2017-09-29,Reuters,https://www.investing.com/news/economy-news/us-court-strikes-down-obamaera-rule-on-tax-inversions-534874,534874
105065,326580,AGN,Allergan files U S  marketing application for expanded use of Avycaz  shares up 2 ,news,Allergan plc  AGN  2 1   files a supplemental New Drug Application  sNDA  with the FDA seeking approval to use AVYCAZ  ceftazidime and avibactam  to treat adults with hospital acquired bacterial pneumonia ventilator associated bacterial pneumonia  a Priority Review and QIDP indication The agency s action should be in Q1 2018 AVYCAZ is currently approved to treat complicated intra abdominal infections and complicated urinary tract infections Now read ,2017-10-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-files-us-marketing-application-for-expanded-use-of-avycaz-shares-up-2-535450,535450
105066,326581,AGN,Asterias Bio s stem cell therapy shows encouraging long term effect in Phase 1 2 study in spinal cord injury patients  shares up 3 ,news,Asterias Biotherapeutics  AST  2 7   announces positive results from the Phase 1 2 SCiStar study assessing AST OPC1 in patients with subacute motor complete spinal cord injury Results at month 12 showed 67  of those with AIS A categorized injury receiving 10M AST OPC1 cells  Cohort 2  recovered at least two motor levels on at least one side  more than double the rate seen historically with standard of care treatment  The company says it was expecting only 45   50  of patients to achieve this level of recovery Enrollment is complete in Cohort 3  20M cells   AIS A   triggering the final  1 5M payment from the  14 3M grant from the California Institute for Regenerative Medicine  Six month data should be available in Q1 2018 Enrollment is also complete in Cohort 4  10M cells   AIS B   the first group with some sensory function below the injury site  Six month data should be available in Q1 2018 as well Enrollment in Cohort 5  20M cells   AIS B   the final cohort  should be completed this year Now read ,2017-10-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/asterias-bios-stem-cell-therapy-shows-encouraging-longterm-effect-in-phase-12-study-in-spinal-cord-injury-patients-shares-up-3-535574,535574
105067,326582,AGN,Texas court strikes down Treasury Department s inversion law,news,In days old  but significant news  a district court in Texas ruled that the Obama administration overstepped its authority when it cracked down on business inversions in 2016  The ruling  in a case brought by the U S  Chamber of Commerce and the Texas Association of Business  said the IRS rule against the tax reducing maneuver was  arbitrary and capricious  because it was instituted without notice and opportunity for comment  violations of law making standards After the Treasury Department action  the number of proposed inversions dried up  including  Pfizer  s  PFE  0 9   proposed  160B combination with Allergan plc  AGN  2 8   The U S  Treasury and the plaintiffs have yet to comment publicly on the ruling Source  ReutersPJP IHE XPH IBB XBI SHPG ABBVNow read ,2017-10-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/texas-court-strikes-down-treasury-departments-inversion-law-535618,535618
105068,326583,AGN,FDA OKs expanded use of Allergan s BOTOX Cosmetic,news,The FDA approves the use of Allergan s  NYSE AGN  BOTOX Cosmetic  OnabotulinumtoxinA  for the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults The new indication is the third for the product  It was previously approved to provide temporary improvement in the appearance of crow s feet lines around the eyes and glabellar  frown  lines Now read ,2017-10-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-expanded-use-of-allergans-botox-cosmetic-536041,536041
105069,326584,AGN,Allergan CEO says patent review flawed in response to senators,news,"By Michael Erman NEW YORK  Reuters    Allergan Plc  N AGN  Chief Executive Brent Saunders on Tuesday defended his company s decision to transfer drug patents to a Native American tribe as a proper way to shield them from a flawed patent review process  in a response to congressional criticism   Saunders sent a letter to Republican Senator Charles Grassley and Democratic Senator Dianne Feinstein  the chairman and ranking member of the Senate Judiciary Committee  after four Democratic U S  senators asked them to launch a committee investigation into the deal  Allergan said last month that it was transferring patents on its dry eye medication Restasis to New York s Saint Regis Mohawk Tribe  which agreed to exclusively license them back to the company in exchange for ongoing payments   The legal maneuver is aimed at removing administrative patent challenges through inter partes review  IPR  by the U S  Patent Trial and Appeal Board  Generic drug companies often seek to challenge brand name drug patents through these proceedings  which are cheaper and faster than federal court litigation  Saunders said the drugmaker was not trying to shield the patents from review through the deal because it still plans to defend the patents in federal court   He argued  however  that the patents should not be subject to the  flawed and broken  IPR process  because of the tribe s sovereign immunity   Last week  Democratic Senators Maggie Hassan  Sherrod Brown  Bob Casey and Richard Blumenthal called Allergan s transaction with upstate New York s Saint Regis Mohawk Tribe  a blatantly anti competitive attempt to shield its patents from review and keep drug prices high   Allergan competitor Mylan NV  N MYL   which is challenging the patents through the IPR process  has called Allergan s deal with the tribe a  sham transaction  and said the tribe should not be allowed to invoke immunity   
Some patent lawyers have noted that the patent board has recognized the immunity of state entities like public universities  and tribal immunity is considered to be an even stronger shield ",2017-10-03,Reuters,https://www.investing.com/news/stock-market-news/allergan-ceo-says-patent-review-flawed-in-response-to-senators-536236,536236
105070,326585,AGN,Allergan s Anti Infective Gets FDA Nod For Pediatric Patients,opinion,"Allergan plc   NYSE AGN   announced that the FDA has approved a label expansion of its anti infective drug  Avycaz  ceftazidime and avibactam  in pediatric patients  The drug is now approved as monotherapy for complicated urinary tract infections  cUTI   and in combination with metronidazole for complicated intra abdominal infections  cIAI  This is the first drug to receive approval for pediatric patients with cUTI or cIAI in more than a decade  The label expansion is likely to boost sales of the drug in future quarters We remind investors that the company s supplemental new drug application  sNDA  for Avycaz was accepted by the FDA in November 2018 The drug is already approved in adult patients with similar indications  In February 2018  the FDA had approved Avycaz for the treatment of patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP  due to gram negative bacteria So far this year  Allergan s shares have outperformed the   The stock has rallied 12 8  in the period  it compared with the 11 6  gain for the industry  The approval of Avycaz in pediatric patient population  three months and older  was based on data from two active control clinical studies  findings from which were similar to the previous determination of safety for Avycaz  pertaining to the cUTI and cIAI indications in adult patients Avycaz recorded sales of  94 6 million in 2018  soaring 54 6  year over year Significantly  Avycaz is jointly marketed by Allergan and Pfizer   NYSE PFE    While Allergan has commercialization rights to Avycaz in North America  the rest of the world rights are owned by Pfizer under the brand name  Zavicefta Apart from Avycaz  Allergan s anti infectives portfolio comprises antibiotics  namely Teflaro and Dalvance Zacks Rank   Stocks to ConsiderAllergan currently carries a Zacks Rank  3  Hold   Better ranked stocks in the pharma sector include Celgene Corporation   NASDAQ CELG   and Mallinckrodt plc   NYSE MNK    both sporting a Zacks Rank  1  Strong Buy   You can see  Celgene s earnings estimates have been revised 3 8  upward for 2019 over the past 60 days  The stock has rallied 37 3  so far this year Mallinckrodt s earnings estimates have been revised 10 8  upward for 2019 over the past 60 days  The stock has rallied 43 7  so far this year Allergan plc Price
    Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/allergans-antiinfective-gets-fda-nod-for-pediatric-patients-200399199,200399199
105071,326586,AGN,Undervalued Growth And Dividend Growth In Health Technology  Part 11 ,opinion,"Introduction
Although many Health Technology Sector companies have significantly outperformed the market on a long term basis  they have significantly underperformed the market since the beginning of 2015  With only a few minor exceptions  this is true for most companies  especially the pharmaceutical companies  operating in this sector 
On the other hand  there are several examples where operating performance has been exemplary even though stock price performance has been dismal  In my long history analyzing stocks  I have concluded that the combination of strong operating performance coupled with low valuations usually represents great opportunity  The old adage  buy when there s blood in the street  or Warren Buffett s recent recommendation  be greedy when others are fearful and fearful when others are greedy  both apply  This particular scenario applies most aptly to the biotechnology subsector within this broader sector 
Finally  the Health Technology Sector once again provides real life examples and evidence that it is clearly a market of stocks and not a stock market  Consequently  from my point of view  the evidence continues to support the notion that it is more important to pay attention to your individual holdings than it does to the general market at large  As I am now more than halfway through the 20 sectors reported on by FactSet this message becomes crystal clear 
A Sector By Sector Review
In part 1 found here I covered the Consumer Services Sector  In part 2 found here I covered the Communication Sector  In part 3 found here I covered the Consumer Durables Sector and its many diverse subsectors  In part 4 found here I covered Consumer Nondurables  In part 5 found here I covered companies in the Consumer Services Sector  In part 6 found here I covered the Distribution Services Sector  In part 7 found here I covered the Electronic Technology Sector  In part 8 found here I covered the Energy Minerals Sector  In part 9 found here I covered the Finance Sector  In part 10 found here I covered the Health Services Sector 
In this part 11 I will be covering the Health Technology Sector 
In each article in this series  I will be providing a listing of screened research candidates from each of the following industry sectors  the sector I m covering in this article is marked in green 

Sector 11  Health Technology
Pharmaceuticals  Major
Pharmaceuticals  Other
Pharmaceuticals  Generic
Biotechnology
Medical Specialties
A Simple Valuation and Quality Screening Process
With this series of articles  I will be presenting a screening of companies that have become attractively valued primarily as a result of the bearish market activities experienced in 2018 from each of the above sectors  I will be applying a rather simple valuation and quality oriented screen across each of the sectors  First  I have screened for investment grade S P credit ratings of BBB  or above  Next  I have screened for low valuations based on P E ratios between 2 and 17  Finally  I have screened for long term debt to capital no greater than 70  
By keeping my screen simple  and at the same time rather broad  I will be able to identify attractively valued research candidates that I might have overlooked through a more rigorous screening process  In other words  I m looking for fresh ideas that I might have previously been overlooking  Furthermore  I want to be clear that I do not consider every candidate that I have discovered as suitable for every investor  However  I do consider them all to be attractively valued  Additionally  I also believe that every investor will be able to find companies to research that meet their own goals  objectives and risk tolerances as this series unfolds
Portfolio Review  Health Technology Sector  10 Research Candidates

FAST Graphs Screenshots of the 10 Research Candidates
The following screenshots provide a quick look at each of the 10 candidates screened out of over 19 000 possibilities  However  there are only 1256 companies categorized as Health Technology  and these 10 were the only ones I was comfortable presenting in this article  The company descriptions are provided courtesy of the Wall Street Journal  In the FAST Graphs analyze out loud video that follows the screenshots  I will provide additional details and thoughts on the possible attractiveness as well as the potential negatives of each of these research candidates 
AbbVie  ABBV 
AbbVie  NYSE ABBV  is a research based biopharmaceutical company  which engages in the development and sale of pharmaceutical products  It focuses on treating conditions such as chronic autoimmune diseases in rheumatology  gastroenterology and dermatology  oncology  including blood cancers  virology  including hepatitis C virus  HCV  and human immunodeficiency virus  HIV   neurological disorders  such as as well as Parkinson s disease  metabolic diseases  comprising thyroid disease and complications associated with cystic fibrosis  pain associated with endometriosis  and other serious health conditions 
The company was founded on January 1  2013 and is headquartered in North Chicago  IL 

Allergan  AGN 
Allergan  NYSE AGN  engages in the research  development  and manufacture of pharmaceutical products  It operates through the following business segments  US Specialized Therapeutics  US General Medicine  and International 
The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States  The US General Medicine segment involves Central Nervous System  Gastrointestinal  Women s Health  Anti Infectives  and Diversified brands  The International segment comprises of products sold outside the United States 
The company was founded on in 1984 and is headquartered in Dublin  Ireland 

Amgen Inc  AMGN 
Amgen Inc  NASDAQ AMGN  is a biotechnology company  which engages in the discovery  development  manufacture and marketing of human therapeutics  Its products include the following brands  Aranesp  BLINCYTO  Corlanor  ENBREL  EPOGEN  IMLYGIC  KYPROLIS  Neulasta  NEUPOGEN  Nplate  Parsabiv  Prolia  Repatha  Sensipar  Vectibix  and XGEVA 
The company was founded by William K  Bowes  Jr   Franklin Pitcher Johnson  Jr   George B  Rathmann and Joseph Rubinfeld on April 8  1980 and is headquartered in Thousand Oaks  CA 

Biogen Inc  BIIB 
Biogen Inc  NASDAQ BIIB  is a biopharmaceutical company  which engages in discovering  developing  and delivering therapies for neurological and neurodegenerative diseases  It offers TECFIDERA  AVONEX  PLEGRIDY  TYSABRI  ZINBRYTA  and FAMPYRA for the treatment of multiple sclerosis  SPINRAZA for the treatment of spinal muscular atrophy  and FUMADERM for the treatment of severe plaque psoriasis 
The company was founded by Charles Weissmann  Heinz Schaller  Kenneth Murray  Walter Gilbert  and Phillip Allen Sharp in 1978 and is headquartered in Cambridge  MA 

Bristol Myers Squibb Co  BMY 
Bristol Myers Squibb  NYSE BMY  Co  engages in the discovery  development  licensing  manufacture  marketing  distribution  and sale of biopharmaceutical products  It includes chemically synthesized drugs or small molecules and products produced from biological processes called biologics 
The company was founded in August 1933 and is headquartered in New York  NY 

Celgene Corp  CELG 
Celgene Corp  NASDAQ CELG  is an integrated global biopharmaceutical company  which engages in the discovery  development and commercialization of therapies for the treatment of cancer and inflammatory diseases  Its primary commercial stage products include REVLIMID  POMALYST  IMNOVID  OTEZLA  ABRAXANE  and VIDAZA 
The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit  NJ 

Gilead Sciences Inc  GILD 
Gilead Sciences Inc  NASDAQ GILD  is a biopharmaceutical company  which engages in the research  development  and commercialization of medicines in areas of unmet medical need  Its primary areas of focus include human immunodeficiency virus  acquired immunodeficiency syndrome  liver diseases  hematology  oncology  and inflammation and respiratory diseases  It offers antiviral products under Harvoni  Genvoya  Epclusa  Truvada  Atripla  Descovy  Stribild  Viread  Odefsey  Complera Eviplera  Sovaldi  and Vosevi brands 
The company was founded by Michael L  Riordan on June 22  1987 and is headquartered in Foster City  CA 

Mylan  MYL 
Mylan  NASDAQ MYL  NV is a pharmaceutical healthcare company  The firm engages in the development  license  manufacture  market and distribution of generic  branded generic and specialty pharmaceutical products  It operates through the following geographical segments  North America  Europe and Rest of World 
The North America segment develops  manufactures  sells  and distributes pharmaceutical products in tablet  capsule  injectable  transdermal patch  gel  nebulized and cream  or ointment form  The Europe segment operates through subsidiaries in Italy  Germany  the United Kingdom  and Spain  The Rest of World segment comprises of operations in Japan  Australia  China  Brazil  Russia  India  South Africa  Middle East and South East Asia 
The company was founded in 1961 and is headquartered in Hatfield  the United Kingdom 

Pfizer Inc  PFE 
Pfizer Inc   NYSE PFE  engages in the discovery  development  and manufacture of healthcare products specializes in medicines  vaccine  and consumer healthcare  It operates through the Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  segments 
The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine  oncology  inflammation and immunology  rate disease  and consumer healthcare  The EH segment is involved in the development and supply of branded generics  generic sterile injectable products  biosimilars  and select branded products including anti infectives 
The company was founded by Charles Pfizer Sr  and Charles Erhart in 1849 and is headquartered in New York  NY 

Perrigo Co  PRGO 
Perrigo Co  NYSE PRGO  is a healthcare company  which engages in the production of over the counter consumer goods and specialty pharmaceutical products  It operates through the following segments  Consumer Healthcare Americas  Consumer Healthcare International  and Prescription Pharmaceuticals 
The Consumer Healthcare Americas segment comprises the U S   Mexico and Canada consumer healthcare business  The Consumer Healthcare International segment includes branded consumer healthcare business primarily in Europe and consumer focused businesses in the U K   Australia  and Israel 
The Prescription Pharmaceuticals refers to the U S  prescription pharmaceuticals business  The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin  Ireland 
 
F A S T  Graphs Analyze Out Loud Video 


Summary and Conclusions
The Health Technology Sector   perhaps more than most others   provides something for everyone  If your investment objective is growth and total return  the sector offers attractive research candidates  If your investment objective is safe  above average and growing dividend yield  there are attractive opportunities for you as well  In short  this sector holds interesting pure growth opportunities and above average yielding dividend growth opportunities as well 
The real challenge is to evaluate whether  or not  politics represent a true threat or whether demographics provide undeniable long term opportunity  These contra indicators   politics versus demographics   make this sector interesting indeed 
Disclosure   Long ABBV  AMGN  CELG  PFE at the time of writing 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2019-03-20,Chuck Carnevale,https://www.investing.com/analysis/undervalued-growth-and-dividend-growth-in-health-technology-part-11-200399303,200399303
105072,326587,AGN,NASH  Allergies And Beauty Stocks  Invest Or Not ,opinion," 0 15    What Are The NASH stocks  3 20    Investing In Impactful Biotech 6 30    Top Biotech Sectors To Pay Attention Too 11 20    Millennial Help Boost The Beauty Stock s 16 15    Episode Roundup  EW  EXAS  AIMT  SIEN  AGN  EOLS  
Welcome to Episode  170 of the Zacks Market Edge Podcast 
Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life 
In this episode  Tracey is going solo to discuss the latest biopharmaceutical updates 
Some of them have trendy names like NASH  but others are often not discussed like treatments for peanut allergies and beauty products like breast implants and Botox 
Who is close to getting a new product approved 
And what about investing in those in the largest categories  like heart disease 
These are exciting areas for investors  but there s still risk 
Should You Invest in the Hot Biopharmaceutical Stocks 
1        Edwards Lifesciences   NYSE EW   just broke out to another new high  This giant in the heart disease category isn t cheap  with a forward P E of 36  but it s expected to see double digit earnings growth in both 2019 and 2020 
2        Exact Sciences   NASDAQ EXAS   isn t expected to see positive earnings in 2019 or 2020 even though sales are soaring for this colon cancer testing company  Sales are expected to be up another 60 2  in 2019 and 47 5  in 2020 though 
3        Aimmune Therapeutics   NASDAQ AIMT   develops treatments for life threatening food allergies  including peanut and egg allergies  The BLA for AR101 has been submitted to the FDA for treatment of the peanut allergy in children and adolescents ages 4 17  It was the first company to pass a Phase 3 study for peanuts  It also has a Phase 2 for egg allergies that is ongoing 
4        Allergan   NYSE AGN   is the king of Botox  Last year  that product generated over  3 5 billion in revenue  And customers are getting younger and younger thanks to the pressure to appear a certain way in selfies on Instagram and Snap  But Botox  and Allergan s filler product  Juvederm  face competition  Shares are trading at just 9 2x as analysts are wondering where future growth is going to come from 
5        Evolus   NASDAQ EOLS   is the Allergan threat  On Feb 1  it got FDA approval for Jeuveau for frown lines  While earnings are expected to be a loss of  3 25 in 2019  they improve to a loss of just  1 38 by 2020  Watch for the possibility of European approval  which would greatly increase its market possibilities 
Questions investors should ask is  how much cash does the company have to ride out the approval process on a new drug or treatment 
And how expensive is the sales and marketing going to be if they do get a product to market 
What else should investors know about investing in the latest medical breakthroughs 
Tune into this week s podcast to find out 
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-20,Zacks Investment Research,https://www.investing.com/analysis/nash-allergies-and-beauty-stocks-invest-or-not-200399585,200399585
105073,326588,AGN,Zacks Market Edge Highlights  Edwards Lifesciences  Exact Sciences  Aimmune Therapeutics  Allergan And Evolus,opinion,"For Immediate Release
Chicago  IL   March 21  2019   Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec  Every week  Tracey will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life  To listen to the podcast  click here 

Please use the Soundcloud link from this URL for the PR  Thanks  
NASH  Allergies and Beauty Stocks  Invest or Not 
Welcome to Episode  170 of the Zacks Market Edge Podcast 
Every week  host and Zacks stock strategist  Tracey Ryniec  will be joined by guests to discuss the hottest investing topics in stocks  bonds and ETFs and how it impacts your life 
In this episode  Tracey is going solo to discuss the latest biopharmaceutical updates 
Some of them have trendy names like NASH  but others are often not discussed like treatments for peanut allergies and beauty products like breast implants and Botox 
Who is close to getting a new product approved 
And what about investing in those in the largest categories  like heart disease 
These are exciting areas for investors  but there s still risk 
Should You Invest in the Hot Biopharmaceutical Stocks 
1        Edwards Lifesciences   NYSE EW   just broke out to another new high  This giant in the heart disease category isn t cheap  with a forward P E of 36  but it s expected to see double digit earnings growth in both 2019 and 2020 
2        Exact Sciences   NASDAQ EXAS   isn t expected to see positive earnings in 2019 or 2020 even though sales are soaring for this colon cancer testing company  Sales are expected to be up another 60 2  in 2019 and 47 5  in 2020 though 
3        Aimmune Therapeutics   NASDAQ AIMT   develops treatments for life threatening food allergies  including peanut and egg allergies  The BLA for AR101 has been submitted to the FDA for treatment of the peanut allergy in children and adolescents ages 4 17  It was the first company to pass a Phase 3 study for peanuts  It also has a Phase 2 for egg allergies that is ongoing 
4        Allergan   NYSE AGN   is the king of Botox  Last year  that product generated over  3 5 billion in revenue  And customers are getting younger and younger thanks to the pressure to appear a certain way in selfies on Instagram and Snap  But Botox  and Allergan s filler product  Juvederm  face competition  Shares are trading at just 9 2x as analysts are wondering where future growth is going to come from 
5        Evolus   NASDAQ EOLS   is the Allergan threat  On Feb 1  it got FDA approval for Jeuveau for frown lines  While earnings are expected to be a loss of  3 25 in 2019  they improve to a loss of just  1 38 by 2020  Watch for the possibility of European approval  which would greatly increase its market possibilities 
Questions investors should ask is  how much cash does the company have to ride out the approval process on a new drug or treatment 
And how expensive is the sales and marketing going to be if they do get a product to market 
What else should investors know about investing in the latest medical breakthroughs 
Tune into this week s podcast to find out 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better 

Follow us on Twitter   
Join us on Facebook  NASDAQ FB    
Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 
Media Contact
Zacks Investment Research
800 767 3771 ext  9339


Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2019-03-21,Zacks Investment Research,https://www.investing.com/analysis/zacks-market-edge-highlights-edwards-lifesciences-exact-sciences-aimmune-therapeutics-allergan-and-evolus-200399738,200399738
105074,326589,AGN,Aerie  AERI  Improves 22  YTD  Is Momentum Likely To Sustain ,opinion,"Shares of Aerie Pharmaceuticals  Inc    NASDAQ AERI   have rallied 22 4  in the year so far  outperforming 15 3  growth registered by the  

The FDA recently approved Aerie s second drug  Rocklatan  a once daily  quadruple action fixed dose combination of Rhopressa and Xalatan  latanoprost   to reduce elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension  The company s new drug application  NDA  for Rocklatan 0 02  0 005  was submitted to the FDA in May 2018  The company plans to launch the drug in the United States in the second quarter of 2019  The approval further boosted Aerie s portfolio 
Rhopressa  Aerie s first drug  is already approved for lowering elevated IOP in patients with open angle glaucoma or ocular hypertension  The drug was approved in 2017 and the initial uptake has been encouraging  As of February 2019  Rhopressa s market access increased to approximately 90  of commercial lives  including 55  in preferred brand Tier 2 and 35  in Tier 3 
Aerie expects Medicare Part D Tier 2 equivalent coverage to increase to more than 70  within the next few weeks  In October 2018  the European Medicines Agency  EMA  accepted for review the Marketing Authorisation Application  MAA  for Rhokiinsa   An opinion on approval is expected by the second half of 2019 
Glaucoma is one of the largest segments in the global ophthalmic market  and hence we expect Aerie to maintain momentum in the coming months 
The company is making efforts to further develop its portfolio  Earlier in the month  Aerie initiated patient dosing in its phase II study  designed in accordance with the requirements of Japan s PMDA  Pharmaceuticals and Medical Devices Agency  to support potential regulatory submission of netarsudil ophthalmic solution  known as Rhropressa  in Japan 
The company also initiated patient dosing in a phase II clinical trial on AR 1105  its experimental dexamethasone intravitreal implant  in patients with macular edema caused by retinal vein occlusion  RVO  
As the glaucoma market holds potential  Aerie faces stiff competition from established branded and generic pharmaceutical companies  including Novartis   NYSE NVS   for Simbrinza and Travtan  Allergan   NYSE AGN   for Lumigan  and other smaller biotechnology and pharmaceutical companies  Bausch Health Companies    NYSE BHC   Vyzulta is also approved for the treatment of patients suffering from open angle glaucoma or ocular hypertension 
Zacks Rank
Aerie currently carries a Zacks Rank  3  Hold   You can see  
Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-improves-22-ytd-is-momentum-likely-to-sustain-200402053,200402053
105075,326590,AGN,Axsome s Depression Drug Gets Breakthrough Therapy Status,opinion,"Axsome Therapeutics  Inc    NASDAQ AXSM   announced that the FDA has granted Breakthrough Therapy designation to AXS 05 for the treatment of major depressive disorder  MDD   The candidate is a novel  oral  investigational NMDA receptor antagonist with multimodal activity 
The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life threatening conditions 
Shares of the company have soared 521 7  in the past year against the  s decline of 13 7  

 
The designation was supported by positive results from the phase II ASCEND study  in which 80 patients with confirmed moderate to severe MDD were treated with AXS 05 or GlaxoSmithKline s   NYSE GSK   active comparator  Wellbutrin  bupropion   The study showed that treatment with AXS 05 resulted in substantial  rapid and statistically significant reduction in depressive symptoms as compared to bupropion  
MDD affects about 6 7  of adults in the United States and is a chronic  biologically based disorder that can result in suicide  
The depression market is quite large and has many players  including biggies like Allergan   NYSE AGN   with products like Vraylar and Viibryd  and Eli Lilly  NYSE LLY  with Cymbalta and Zyprexa 
In March 2019  the FDA approved Johnson   Johnson s   NYSE JNJ   nasal spray  Spravato  esketamine  for treatment resistant depression  TRD  in adults  but with a boxed warning  The nasal spray has been approved for use in conjunction with an oral antidepressant in patients with MDD who have not benefited from multiple standard treatments Axsome Therapeutics  Inc  Price

    
Zacks Rank
Axsome currently carries a Zacks Rank  4  Sell  You can see  
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/axsomes-depression-drug-gets-breakthrough-therapy-status-200402061,200402061
105076,326591,AGN,NASH Scorecard So Far This Year  A Look At The Hits   Misses,opinion,The recent failure of Conatus Pharmaceuticals    NASDAQ CNAT   phase IIb ENCORE NF study in patients with biopsy confirmed nonalcoholic steatohepatitis  NASH  and liver fibrosis once again puts the spotlight on this promising but challenging space Earlier  biotech bigwig Gilead Sciences  Inc    NASDAQ GILD   had suffered a setback with the failure of a late stage study on pipeline candidate  selonsertib  in patients with compensated cirrhosis  F4  due to NASH  STELLAR 4  a phase III  randomized  double blind  placebo controlled study  n 877   evaluated the safety and efficacy of selonsertib  which is an investigational  once daily  oral inhibitor of apoptosis signal regulating kinase 1  ASK1   in patients with compensated cirrhosis due to NASH  However  the study did not meet the pre specified 48 week primary endpoint of a   1 stage histologic improvement in fibrosis without worsening of NASH  The failure of the STELLAR 4 study is disappointing  given the significant market potential of NASH and increasing competition Notwithstanding the failures  the market for NASH holds potential and is expected to be targeted by most large pharma biotech companies in 2019  It is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer More on NASHA chronic liver disease  NASH is caused by excessive fat accumulation in the liver or steatosis  Per records  it has affected up to 15 million people in the United States and could cause inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  The ailment is anticipated to be the leading reason behind liver transplantation by 2020  Currently  NASH is the primary reason for liver transplants in people under 50 in the United States  Such patients also suffer from obesity and type II diabetes  With no treatments currently approved to address this disease  the market opportunity is substantially huge and many companies are investing a major chunk of their R D budget on the same Pharma Players That Have a Lead in NASHThe recent failures underscore the complexity of the treatments being developed  The winner so far in the NASH race seems to be Intercept Pharmaceuticals  Inc   NASDAQ ICPT    The company recently announced positive top line results from its pivotal phase III REGENERATE study of obeticholic acid  OCA  on patients with liver fibrosis due to NASH   The company stated that the primary endpoint of the study   fibrosis improvement without worsening of NASH at 18 months   was achieved with the 25 mg daily dose of OCA Also  a numerically greater proportion of patients in both OCA treatment arms  taking doses of 10 mg and 25 mg  met the primary endpoint of NASH resolution with no deterioration of liver fibrosis compared to placebo  The study was required to attain one of the two primary goals  per FDA  which it did  Intercept plans to file for an approval for OCA as a NASH treatment both in the United States and in Europe during the second half of 2019 France based  Genfit s lead candidate elafibranor  which is in late stage studies  also holds promise  A phase III study  RESOLVE IT is evaluating the efficacy and safety of elafibranor 120 mg versus placebo in patients with NASH and fibrosis  In December 2018  the Data Safety Monitoring Board  DSMB  recommended the continuation of RESOLVE IT without any modifications  based on the pre planned review of safety data  including adverse events and laboratory data  The company expects to report top line data by the end of 2019  Earlier in the month  the company announced protocol clearance by the FDA for a phase II study evaluating elafibranor in children and adolescents with non alcoholic steatohepatitisAllergan plc   NYSE AGN   too has an interesting candidate in its pipeline  cenicriviroc  for the treatment of NASH  The 2016 Tobira Acquisition added the candidate to its pipeline  The candidate is being evaluated in a phase III study  AURORA  Results from the study are not expected before 2020 Viking Therapeutics   NASDAQ VKTX   is another company  which has a promising NASH candidate  VK2809  in its pipeline Other EntrantsGiven the fact that it is a lucrative market  quite a few companies have inked deals to enter this space  Novartis AG   NYSE NVS   entered into a clinical development agreement with Pfizer  NYSE PFE   The agreement includes a clinical trial to evaluate the combination of tropifexor  LJN452  and one or more Pfizer compounds for the treatment of NASH  Pharma giant Merck   NYSE MRK   exercised its option to license NGM313  an investigational monoclonal antibody agonist of the   Klotho FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type 2 diabetes Bottom LineGiven the huge market potential  we expect a lot of activity in this space going forward  Approval of any of the candidates will attract more players and investment to this corner of the healthcare space Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/nash-scorecard-so-far-this-year-a-look-at-the-hits--misses-200402192,200402192
105077,326592,AGN,Spero Gets Fast Track Designation For SPR994  Shares Improve,opinion,"Shares of Spero Therapeutics  Inc    NASDAQ SPRO   increased about 6  after the company announced that the FDA granted Fast Track designation to SPR994  the company s lead product candidate designed to be the first oral carbapenem antibiotic  for the treatment of complicated urinary tract infections  cUTI  and acute pyelonephritis  
Shares of the company have decreased 9 8  in the past year compared with the  s decline of 4 7  

The FDA grants Fast Track designation to help the development and a faster review of drugs  which treat serious and unmet medical conditions  With this designation  the drug is expected to be granted priority review once the company files a new drug application   NDA   
The company has planned a phase III study  whereinoral SPR994 will be compared with an existing standard of care intravenous  IV  antibiotic  ertapenem in about 1 200 patients randomized 1 1 in each arm   The primary endpoint of the study will be the combined clinical and microbiological response at the test of cure  with a 10  non inferiority margin versus IV ertapenem  The study will incorporate a lead in cohort of 70 patients  with an intensive pharmacokinetics assessment to confirm the dose and exposure in the cUTI patient population  Spero expects to receive pharmacokinetic data from the lead in cohort in the second half of 2019 
Recently  the FDA granted approval for the label expansion of Allergan plc s   NYSE AGN   anti infective drug  Avycaz  ceftazidime and avibactam  in pediatric patients as monotherapy for cUTI  and in combination with metronidazole for complicated intra abdominal infections  cIAI   This is the first drug to receive approval for pediatric patients with cUTI or cIAI in more than a decade  Avycaz is jointly marketed by Allergan and Pfizer   NYSE PFE   
Zacks Rank   Stock to Consider
Spero is currently a Zacks Rank  3  Hold  stock 
A better ranked stock worth considering is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy   You can see  
Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 1 61  
Zacks  Top 10 Stocks for 2019 
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/spero-gets-fast-track-designation-for-spr994-shares-improve-200402849,200402849
105078,326593,AGN,Novartis  NVS  To Acquire Subsidiary Of IFM Therapeutics ,opinion,"Novartis AG   NYSE NVS   announced that it will acquire IFM Tre  a subsidiary of IFM Therapeutics LLC 
The acquisition will add a broad portfolio of immunomodulatory medicines  focused on developing anti inflammatory medicines targeting the NLRP3  nucleotide binding domain  leucine rich repeat containing receptor pyrin domain containing 3  inflammasome  The acquisition will give Novartis full rights to IFM Tre s portfolio of NLRP3 inhibitors 
The three inhibitors include IFM 2427  a clinical stage systemic antagonist for an array of chronic inflammatory disorders  including gout  atherosclerosis and nonalcoholic steatohepatitis  NASH   a preclinical stage gut directed molecule for the treatment of inflammatory bowel disease  and a preclinical stage central nervous system  CNS  penetrant molecule  The acquisition is expected to be complementary to Novartis  pipeline of anti inflammatory medicines 
The transaction will close in the second quarter  Per the agreement  Novartis will acquire all of the outstanding capital stock of IFM Tre  In addition  IFM Tre will receive an upfront payment and will be eligible for downstream milestone payments 
Last year was a transformative year for Novartis  as it restructured its business to focus on becoming a core drug focused company  powered by data and digital technologies 
The company earlier entered into a clinical development agreement with Pfizer   NYSE PFE    The agreement includes a clinical trial to evaluate the combination of tropifexor  LJN452  and one or more Pfizer compounds for the treatment of NASH 
NASH is a key target area for most pharma biotech companies  given the market potential  Key players with promising candidates in the space include Intercept Pharmaceuticals  Inc    NASDAQ ICPT    which recently announced positive top line results from its pivotal phase III REGENERATE study on obeticholic acid  OCA  in patients with liver fibrosis due to NASH   Allergan plc   NYSE AGN   too has an interesting candidate  cenicriviroc in its pipeline for the treatment of NASH 
Shares of the company have gained 13 5  in the past six months compared with the  s 3 6  growth 

 
Meanwhile  Novartis is looking to solidify its presence in the gene therapy space  It acquired U S  based clinical stage gene therapy company  AveXis  Inc  The company also acquired Endocyte to expand expertise in radiopharmaceuticals  We expect more acquisitions in the coming months  as the company looks to further restructure its business 
Zacks Rank
Novartis currently carries a Zacks Rank  4  Sell  
You can see  
Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-to-acquire-subsidiary-of-ifm-therapeutics-200402868,200402868
105091,326606,AGN,MEI Pharma reports FY results,news,MEI Pharma  NASDAQ MEIP   FY EPS of  0 07Revenue of  23 2MPress ReleaseNow read ,2017-09-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/mei-pharma-reports-fy-results-525563,525563
105092,326607,AGN,Allergan uses legal maneuver with sovereign tribal government to protect Restasis patents,news,In what is probably a first in corporate drug patent law  Allergan  AGN  0 5   has struck a deal with the Saint Regis Mohawk Tribe under which it has transferred ownership of all Orange Book listed patents covering dry eye med RESTASIS  Cyclosporine Ophthalmic Emulsion  0 05  to the tribe Claiming sovereign immunity from patent challenges  Saint Regis will file a motion to dismiss the ongoing inter partes review  IPR  proceedings  although it will not affect the litigation in Texas related to a patent challenge there from a would be generic competitor Allergan s Chief Legal Officer Bob Bailey says Saint Regis was the one who approached the company with the strategy  He agreed to proceed based on two previous cases involving universities that successfully used the maneuver to dismiss IPR proceedings Under the terms of agreement  Saint Regis will receive  13 75 upfront and up to  15M per year in royalties Now read ,2017-09-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-uses-legal-maneuver-with-sovereign-tribal-government-to-protect-restasis-patents-526967,526967
105093,326608,AGN,U S  tribal patent deal could have big impact on generic drug market,news,"By Jan Wolfe  Reuters    A groundbreaking deal between Allergan  NYSE AGN  Plc and a Native American tribe to shield the company s patents in administrative proceedings could also be used be to protect them from challenges in federal court  legal experts said  potentially dealing a blow to generic competition  Allergan said on Friday it had transferred patents on its blockbuster dry eye medicine Restasis to the St  Regis Mohawk Tribe  which will exclusively license the patents back to the company in exchange for ongoing payments  The deal takes advantage of the fact that the tribe is treated as a sovereign nation immune to civil lawsuits  In announcing the deal  Allergan said it believed the Restasis patents would no longer be subject to review by the U S  Patent Trial and Appeal Board  an administrative court empowered to cancel patents through a process called inter partes review  The company said it would not claim immunity in an ongoing lawsuit in federal court by generic manufacturers seeking to revoke the same patents   This was directed at and only affects the flawed IPR process   Allergan Chief Executive Brenton Saunders said in an interview   But judges across the country have found tribal immunity applies to litigation in federal court  That means other brand name drug companies could be motivated to follow Allergan s lead and transfer their patents to tribes  severely limiting generic manufacturers  ability to challenge those patents  Drugs made by brand name manufacturers like Allergan   Pfizer  Inc  NYSE PFE  and Merck  NYSE MRK    Co are usually protected by patents for up to 20 years after they are introduced  But generic companies can bring their versions to market earlier if they can successfully sue to have those patents invalidated   The price of a drug drops dramatically once generic versions enter the market  Restasis sales were  1 4 billion last year  The Patent Trial and Appeal Board  which Congress created in 2011 to make it easier and cheaper to challenge patents  has been embraced by generic drug companies  Earlier this year  the board invalidated some of the patents held by Abbvie Inc on its  16 billion immunosuppressant Humira  raising the possibility of low cost competition for the country s best selling drug  Challenging patents in federal court is slower and more expensive  though generic companies certainly do it  Teva Pharmaceuticals Inc and other generic drug companies are suing Allergan in federal court seeking a ruling that the latter s Restasis patents should not have been granted in the first place because they cover obvious concepts   Michael Carrier  a professor at Rutgers Law School  said drug companies may fear a public outcry if they use tribal immunity to remove their patents from scrutiny by both the board and federal court  A spike in drug prices  for example  could lead Congress to pass a law limiting the scope of that immunity in such cases  Saunders said the industry is unlikely to try to shield its patents from federal court litigation   I d be very cautious about creating this parade of horribles   he said  But Rachel Sachs  a patent law professor at Washington University in St  Louis  said it was likely only a matter of time  
 Once the industry begins engaging in a practice  even at a low level     there are actors who will take it to its logical extreme   she said ",2017-09-11,Reuters,https://www.investing.com/news/stock-market-news/us-tribal-patent-deal-could-have-big-impact-on-generic-drug-market-527642,527642
105094,326609,AGN,Matinas Bio to seek commercialization partner for dyslipidemia med MAT9001  shares up 1 ,news,Matinas BioPharma  MTNB  0 7   has retained life sciences advisor JSB Partners  to identify a development and commercialization partner for MAT9001  a prescription only formulation of omega 3 fatty acids for the potential treatment of people with extremely high levels of triglycerides in their blood   500 mg dL  The company says MAT9001 is more effective than  Amarin  s  AMRN  2 5   Vascepa  icosapent ethyl  based on comparative studies  adding that it wants to formalize its efforts ahead of the data readout from Amarin s REDUCE IT study  expected in 2018 Previously  Amarin s REDUCE IT study to continue as planned  shares ahead 4  premarket  Aug  14 Now read ,2017-09-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/matinas-bio-to-seek-commercialization-partner-for-dyslipidemia-med-mat9001-shares-up-1-527981,527981
105095,326610,AGN,Native American tribe moves to dismiss Allergan patent case,news,"By Jan Wolfe  Reuters    A Native American tribe holding patents for drugmaker Allergan Plc  N AGN  on Friday moved to dismiss a case brought by generic drug company Mylan NV  O MYL  challenging the patents  In a filing to the U S  Patent Trial and Appeal Board  the Saint Regis Mohawk Tribe asked that Mylan s case seeking to invalidate Allergan s patents on dry eye medicine Restasis be thrown out on the grounds that the board has no jurisdiction over the tribe  The move was expected after Allergan announced on Sept  8 that it had transferred Restasis patents to the tribe in order to protect them from administrative challenges  Mylan in late 2016 asked the patent board to invalidate Allergan s Restasis patents so it could launch its own generic version of the medicine  which generated  1 5 billion in revenue for Allergan last year  A lawyer for Mylan said at a Sept  11 court hearing that the company would vigorously oppose Allergan s efforts  calling the deal with the tribe a  sham transaction   In its court filing on Friday  the tribe said it is sovereign government that cannot face litigation in an administrative court unless it expressly waives its immunity or the U S  Congress abrogates immunity   Neither of these exceptions apply here   the tribe said  The tribe will receive a one time payment of  13 75 million and annual royalties of around  15 million under the arrangement  Allergan said  Allergan has come under fire over the deal  with U S  Senator Sherrod Brown criticizing the drug company for exploiting a loophole to keep its prices high  
The company has said the transfer is only intended to shield the patents from review at the patent board  which it has called a flawed forum for patent disputes  Allergan has said it will not invoke tribal immunity in federal courts ",2017-09-22,Reuters,https://www.investing.com/news/stock-market-news/native-american-tribe-moves-to-dismiss-allergan-patent-case-532005,532005
105096,326611,AGN,FDA rejects Allergan s application for expanded use of antipsychotic med Vraylar,news,Allergan  NYSE AGN  has received a Refusal to File letter from the FDA regarding its marketing application for an expanded use of antipsychotic medication VRAYLAR  cariprazine   specifically for the treatment of negative symptoms associated with schizophrenia in adults A Refusal to File letter means that the application was not considered complete enough to permit a review The company says it will seek immediate guidance from the agency to clarify the issues preventing acceptance for review VRYLAR is currently approved in the U S  to treat schizophrenia and manic or mixed episodes associated with bipolar I disorder Now read ,2017-09-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-rejects-allergans-application-for-expanded-use-of-antipsychotic-med-vraylar-532058,532058
105097,326612,AGN,Allergan boosts shares with  2 billion buyback,news," Reuters    U S  drugmaker Allergan Plc  N AGN  on Monday authorized a  2 billion buyback of its common stock  sending its shares up after a week of disappointing news on its drug development pipeline  Allergan shares have fallen by around a fifth in value since late July but were up nearly 4 percent in morning trading on Monday  The company also said its Chief Financial Officer Tessa Hilado  53  would retire  The planned stock buyback follows Allergan s completion of a separate  15 billion repurchase  and after the company reported mixed trial data for its experimental treatment of NASH liver fibrosis  Allergan on Friday also received a  refusal to file  letter from the U S  Food and Drug Administration for an expanded approval for its Vraylar drug to treat symptoms associated with schizophrenia in adults  Allergan said it had begun to search for a new finance chief  but declined to provide further comment on Hilado s departure  Analysts at Bernstein  based on discussions with Allergan s investor relations team  said Hilado s departure was her personal decision and should not be viewed as suggesting  issues this year or 2018   Hilado did not have broad support among Allergan investors and her exit would not be a  particularly strong negative   they added  Hilado joined Allergan in 2014 and will continue in her current role until a successor is named  Allergan  which said it was committed to boosting its dividend payout annually  also backed its 2017 financial guidance and its commitment to pay down  3 75 billion of debt in 2018  The drugmaker had  30 24 billion in current and long term debt and capital leases as of June 30  
 While the CFO s departure may create greater uncertainty  we take the company s reaffirmation of 2017 guidance and third quarter revenue projections as offsetting positives    Wells Fargo   NYSE WFC  analyst David Maris said ",2017-09-25,Reuters,https://www.investing.com/news/stock-market-news/allergan-boosts-shares-with-2-billion-buyback-532420,532420
105098,326613,AGN,Allergan Responds To Investor s Call For CEO Chair Role Split,opinion,"Allergan plc   NYSE AGN   issued a statement in response to a letter from one of its public shareholders  Appaloosa  disagreeing with the latter s request of a separation of Chief Executive Officer   CEO   and Chairman roles  both currently held by Brent Saunders Allergan has indicated in its statement that a separation of roles may happen upon departure of Saunders anytime in future  The company also stated that it has transformed itself over the years from a generic drugmaker to a global biopharmaceutical leader with strong positions in its four key therapeutic areas  The company added that it has also appointed Bob Hugin  former CEO and chairman of Celgene  NASDAQ CELG   for strengthening the role of independent director  Last year  it planned to divest Women s Health and Infectious Disease units to focus on key areas  However  on its fourth quarter earnings call the company announced it may only sell the Infectious Disease unit while retaining the other We remind investors that activist investor Tepper from Appaloosa has been insisting on the separation of CEO and chairman roles since early 2018  He is of the view that Allergan needs fresh ideas to support growth and that is not possible with one person holding two key positions   The letter from Appaloosa alleged that Allergan s balance sheet write downs have amounted to billions of dollars over the past four years  along with the acquisition of underperforming products and excessive compensation to management  These factors have resulted in stock price decline  which Appaloosa believes will continue if the requested management changes are not made In the past year  Allergan s share price has declined 13 4  compared with the  s decline of 15 8  We note that Allergan has a significant and expanding branded pharmaceutical business  which includes products like Botox  Restasis  Viibryd  Linzess  Ozurdex among others along with new products with solid potential to support its long term growth  In 2016  the company sold its generic business to Teva Pharma   NYSE TEVA   to focus on its branded segment  The company has also been repaying its debt significantly over the past three years  reducing a major burden on its margins  It also undertook job cuts and other cost savings measures  which led to annual savings of  400 million in 2018 On the flip side  Allergan is facing or set to face generic competition for several of its drugs including its second best selling drug  Restasis  The company is set to lose  1 4 billion in sales due to loss of exclusivity in 2019  Moreover  the approval to Evolus  Inc  s   NASDAQ EOLS   Jeuveau injection for glabellar or frown lines earlier this month is disappointing as it will compete with Allergan s lead product  Botox  which is approved for the same indication as well as other aesthetic and therapeutic indications In the therapeutic area  the drug is set to face competition in the migraine space with recent approval to three anti CGRPs   Amgen s Aimovig  Teva s Ajovy and Eli Lilly s   NYSE LLY   Emgality  However  the company expects the migraine market to expand significantly to support co existence of Botox and anti CGRPs  But it also expects growth rate for Botox to moderate due to competition Meanwhile  the company s outlook for 2019 is not quite encouraging  The 2019 sales outlook  provided at the fourth quarter conference call held last month  missed market expectations and suggests a decline from 2018  Allergan s initiatives in 2019 are going to be crucial for the company s growth as it will face competition for some of its top drugs  It remains to be seen how the company tackles the challenges and offsets any sales decline Allergan plc Price
    Zacks RankAllergan currently carries a Zacks Rank  3  Hold  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/allergan-responds-to-investors-call-for-ceochair-role-split-200390138,200390138
105099,326614,AGN,Editas  EDIT  To Report Q4 Earnings  What s In The Cards ,opinion,Editas Medicine  Inc    NASDAQ EDIT   is scheduled to report fourth quarter and full year 2018 results on February 28 The company s earnings history has been mixed so far  wherein it has surpassed the consensus estimates in two quarters while missing the same in two  recording average beat of 10 9   In the last reported quarter  Editas delivered a positive earnings surprise of 55 56  Let s see  how things are shaping up for the to be reported quarter Factors to ConsiderEditas makes medicines to treat serious diseases using its proprietary genome editing platform based on CRISPR technology  Its lead pipeline candidate is EDIT 101 that uses CRISPR gene editing to treat Leber congenital amaurosis type 10  LCA10    a rare genetic illness that causes blindness  In November  the company announced FDA acceptance of its investigational new drug   IND   application to begin clinical studies for EDIT 101  It got a milestone payment from partner Allergan   NYSE AGN   for IND acceptance which should be recognized as revenues in the fourth quarter Editas has a strategic alliance and an option agreement with Allergan under which the latter reserves its rights to license up to five of Editas  genome editing ocular programs  In July 2018  Allergan exercised its option to develop and commercialize EDIT 101 globally while Editas exercised its right to a profit sharing arrangement with Allergan under which it will co develop and share equally in the profits and losses from EDIT 101 in the United States  Further  the company has the right to choose to co develop and co market another eye disease program in the United States Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10 including Usher Syndrome type 2A  USH2A  and the recurrent ocular Herpes Simplex Virus type 1  HSV 1   Data from pre clinical studies on these diseases has been positive  Editas also has CRISPR drugs in the pipeline to treat cancer  muscular dystrophy  alpha   1 antitrypsin deficiency and cystic fibrosis Moreover  the company has a collaboration and licensing deal with Juno Therapeutics  now part of Celgene   NASDAQ CELG    to use gene editing approaches including CRISPR Cas9 for developing engineered T cell medicines to treat cancer We expect management to provide more updates and detailed information on its pre clinical studies during the upcoming conference call In January this year  Editas announced the resignation of Katrine Bosley from her role as president and CEO  effective Mar 1  2019   Cynthia Collins has been appointed as interim CEO and should address the fourth quarter call  Meanwhile  Editas has initiated a search for a permanent CEO  We expect an update on the progress in this regard at the conference call Earnings WhispersOur proven model does not conclusively show that Editas will beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is 0 00  as both the Zacks Consensus Estimate as well as the Most Accurate Estimate is pegged at a loss of 42 cents  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Editas  Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere is a biotech worth considering with the right combination of elements to beat on earnings BioDelivery Sciences International  Inc    NASDAQ BDSI   has an Earnings ESP of  38 46  and a Zacks Rank  2  The company is scheduled to report results on Mar 14  You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/editas-edit-to-report-q4-earnings-whats-in-the-cards-200392953,200392953
105100,326615,AGN,Okta  OKTA  To Report Q4 Earnings  How Are Things Shaping Up ,opinion,Okta  Inc    NASDAQ OKTA   is set to report fourth quarter fiscal 2019 results on Mar 7 Notably  the company s earnings beat the Zacks Consensus Estimate in the trailing four quarters  with the average positive surprise being 41 4   In the last reported quarter  the company s adjusted loss of 4 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 11 cents Moreover  Okta s top line beat the consensus mark in all the trailing four quarters  In third quarter fiscal 2019  revenues came in at  105 6 million  beating the Zacks Consensus Estimate of  97 million and increasing 58  from the year ago quarter For the fiscal fourth quarter  the Zacks Consensus Estimate for revenues and loss per share is pegged at  107 9 million and 8 cents  respectively  While revenues are expected to grow 38 8   loss is likely to narrow down from 10 cents in the year ago quarter Let s see how things are shaping up prior to this announcement Okta  Inc  Price and EPS Surprise   Key Factors to ConsiderOkta helps companies administer their workforce and customer identities through its cloud platform  which has more than 5 500 pre built applications  The increasing adoption for its product is evident from the expanding customer base Additionally  Okta Identity Cloud s capability to consolidate all customers  applications without sacrificing security or stability is a key catalyst  This along with the company s ability to secure digital assets across a variety of users and technologies helped it to win 450 customers in third quarter fiscal 2019 Notably  companies like Deloitte and VMware   NYSE VMW   along with the U S  Department of State chose Okta s identity solutions in the last reported quarter  Additionally  total customer base increased 42  year over year to 5 600 mainly across enterprise customer base Moreover  momentum in cloud  digital transformation and increasing concern over cybersecurity threats helped Okta retain long time customers like Adobe   NASDAQ ADBE    Experian and Allergan   NYSE AGN   and attract new customers like Major League Baseball in third quarter fiscal 2019 Further  due to increase in upsell activities  customers with more than  100 000 annual recurring revenues increased 55  year over year to 937  Okta added 100 net new customers with over  100 000 annual recurring revenues in the last reported quarter However  increase in expenses to support business growth is negatively impacting profitability  In the last reported quarter  non GAAP research and development expenses increased 52  year over year to  21 3 million due to significant investments in Okta identity platform and integration network  Additionally  headcount increased 29  year over year to 1473 to support business growth We believe that rise in expenses may continue to hurt profitability in the soon to be reported quarter Okta currently carries a Zacks Rank  3  Hold   You can see Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-03,Zacks Investment Research,https://www.investing.com/analysis/okta-okta-to-report-q4-earnings-how-are-things-shaping-up-200394430,200394430
105101,326616,AGN,J J s  JNJ  Nasal Spray Spravato Gets FDA Nod For Depression,opinion,Johnson   Johnson   NYSE JNJ   announced that the FDA has approved its nasal spray Spravato  esketamine  for treatment resistant depression  TRD  in adults but with a boxed warning With the approval  Spravato  which is thought to work differently than currently approved therapies  will be the first new medicine in 30 years to treat depression  a difficult to treat mental disease  It has been seen that while most antidepressants take a couple of weeks or months to show effects  Spravato works in hoursThe nasal spray has been approved for use in conjunction with an oral antidepressant in patients with major depressive disorder  MDD  who have not benefited from multiple standard treatments  Approximately one third of U S  adults with MDD are considered to have TRD as they have not found relief with at least two different antidepressants and could benefit from Spravato Moreover  Spravato has a close chemical relation to ketamine  which is often abused for recreational purposes and is popularly known as Special K  To avoid misuse and abuse of the drug  Spravato has been approved with a boxed warning on its label regarding a Risk Evaluation and Mitigation Strategy  REMS  and the risk of suicidal thoughts and behavior in pediatric patients and young adults  Moreover  the drug will be available through a restricted distribution system and can be given only at a doctor s office and not at home J J s stock has risen 7 5  this year so far compared with an increase of 3 3  recorded by the   Last month an FDA advisory committee had recommended approval of Spravato  The Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted 14 2 in favor of approval of Spravato stating that the data supports the favorable benefit risk profile of the nasal spray J J filed a new drug application for Spravato in September last year while a regulatory application is also under review in the EU  The NDA was based on five pivotal phase III studies of esketamine nasal spray   three short term studies  one withdrawal maintenance of effect study  and one long term safety study   in patients with treatment resistant depression Data from a short term and a long term study showed that Spravato in combination with newly initiated oral antidepressant   NIOD   led to statistically significant  rapid and clinically meaningful improvement in depressive symptoms in patients with TRD  Importantly On the fourth quarter conference call held last month  J J management sounded confident about esketamine approval in 2019  Another investigational medicine  erdafitinib for metastatic urothelial cancer is also expected to be approved this year  J J believes that both these medicines have the potential to garner more than  1 billion of peak revenues The depression market is quite large and has many players including biggies like Allergan   NYSE AGN   with products like Vraylar and Viibryd and Eli Lilly   NYSE LLY   with Cymbalta and Zyprexa J J currently has a Zacks Rank  3  Hold   You can see   A better ranked large cap pharma stock is AstraZeneca  plc   NYSE AZN    carrying a Zacks Rank  2  Buy  AstraZeneca s earnings estimates have risen 5 3  for 2019 and 4 6  for 2020 over the past 30 days  The stock has risen 11 4  this year so far Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression-200395195,200395195
105102,326617,AGN,Allergan s Depression Candidate Fails In Studies  Stock Down,opinion,Allergan plc   NYSE AGN   announced that three acute pivotal studies on depression candidate  rapastinel  failed to meet their primary endpoint  The studies were evaluating rapastinel  its NMDA receptor modulator  as an adjunctive treatment of major depressive disorder  MDD  compared to placebo  both in combination with antidepressant therapy  ADT  In the studies  the rapastinel treatment arms did not differentiate from placebo on the primary and key secondary endpoints  Rapastinel is also being evaluated as a monotherapy treatment for MDD in phase III and for treating MDD patients at imminent risk of suicide in phase II  After evaluating the impact of the data from the failed studies  Allergan said it will make a decision on these monotherapy studies this year Allergan s stock was down 1 9  in response to the news  Allergan s share price has risen 2 9  this year so far compared with the  s increase of 8 3    Please note that Rapastinel was granted breakthrough therapy status for MDD by the FDA in 2016 and was considered by Allergan to be a potentially game changing treatment However  making drugs to treat mental disorders is extremely challenging and there have been several failures in the past Last month  the FDA gave a complete response letter to Alkermes plc s   NASDAQ ALKS   new drug application looking for approval for ALKS 5461  a once daily oral medication for adjunctive treatment of MDD However  the depression market has had its share of successes as well   Earlier this week  J J   NYSE JNJ   gained FDA approval for its new nasal spray  Spravato  esketamine  for treatment resistant depression  TRD   The nasal spray has been approved for use in conjunction with an oral antidepressant in patients with MDD who have not benefited from multiple standard treatments  Approximately  one third of U S  adults with MDD are considered to have TRD as they have not found relief with at least two different antidepressants and could benefit from Spravato The depression market is quite large and has many players  Allergan itself has a couple of products in its portfolio  Vraylar and  Viibryd  Eli Lilly   NYSE LLY   markets depression drugs like Cymbalta  Prozac and Zyprexa Allergan currently has a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future  See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-06,Zacks Investment Research,https://www.investing.com/analysis/allergans-depression-candidate-fails-in-studies-stock-down-200395557,200395557
105103,326618,AGN,Is Allergan  AGN  A Worthy Pick ForValue Investors Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Allergan plc   NYSE AGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Allergan has a trailing twelve months PE ratio of 8 7  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 4  If we focus on the long term PE trend  Allergan s current PE level puts it much below its midpoint of 17 2 over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE also compares pretty favorably with the Medical Market s trailing twelve months PE ratio  which stands at 20 4  At the very least  this indicates that the stock is much undervalued right now  compared to its peers We should also point out that Allergan has a forward PE ratio  price relative to this year s earnings  of 8 9  which is tad higher than the current level  So it is fair to expect an increase in the company s share price in the near term P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Allergan has a P S ratio of about 3 1  This is slightly lower than the S P 500 average  which comes in at 3 2x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  AGN is lower than the mid point of 5 5 of the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Allergan currently has a Value Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Allergan a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the P CF ratio for Allergan is 3 9  a level that is slightly lower than the industry average of 4 6x  Clearly  AGN is a solid choice on the value front from multiple angles What About the Stock Overall Though Allergan might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has Growth and Momentum Scores of B  This gives AGN a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen two upward revisions in the past sixty days compared to six downward revisions  while the full year estimate has seen ten upward and six downward revisions in the same time period This has had a mixed impact on the consensus estimate as the current quarter consensus estimate has declined by 5 1  in the past two months  while the full year estimate has inched up by 0 4   You can see the consensus estimate trend and recent price action for the stock in the chart below Allergan plc Price and Consensus   This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineAllergan is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  among Bottom 41  of more than 250 industries  and a Zacks Rank  3 it is hard to get too excited about this company overall In fact  over the past two years  the broader industry has clearly underperformed the market at large  as you can see below So  value investors might want to wait for estimates and industry rank to turn around in this name first  but once that happens  this stock could be a compelling pick Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-10,Zacks Investment Research,https://www.investing.com/analysis/is-allergan-agn-a-worthy-pick-forvalue-investors-now-200396398,200396398
105104,326619,AGN,Allergan Announces FDA Acceptance Of Migraine Candidate NDA,opinion,"Allergan plc   NYSE AGN   announced that the FDA has accepted its new drug application   NDA   for oral anti calcitonin gene related peptide   CGRP   candidate  ubrogepant  The NDA is seeking approval of the candidate as an acute treatment for migraine in adult patients  A decision from the FDA is expected in the next 10 months or the fourth quarter of 2019 Ubrogepant will be the first orally administered anti CGRP drug available for treating migraine  if approved  in the United States Allergan s shares have increased 9 7  this year so far compared with the i s rise of 7 2  The NDA was supported by data from two pivotal phase III studies   ACHIEVE I   II   and two additional safety studies evaluating ubrogepant  The candidate demonstrated positive results in two pivotal studies  evaluating it for the treatment of single migraine attack Data from the studies also demonstrated that ubrogepant was able to treat migraine patients who have insufficient response or are ineligible for treatment with a triptan  one of the commonly used medications for migraine  Migraine patients with moderate to severe cardiovascular risk will also be eligible for treatment with ubrogepant Meanwhile  the company has another oral anti CGRP candidate  atogepant  in its pipeline that demonstrated positive results in a phase II study  evaluating it for the treatment of episodic migraine attack Allergan s largest product  Botox  is approved for treating migraine among several other indications  However  the competition in the anti CGRP segment is strong  In 2018  three anti CGRP drugs received approval from the FDA for treating migraine   Amgen Novartis    NYSE NVS   Aimovig  Eli Lilly s   NYSE LLY   Emgality and Teva Pharma s   NYSE TEVA   Ajovy  However  oral administration may help ubrogepant to gain strong adoption compared to the other anti CGRP drugs  which are approved as injections Allergan has more than 65 projects in mid to late stage development including six key programs including ubrogepant and atogepant for migraine  Abicipar for age related macular degeneration   AMD    label expansion of Vraylar  cariprazine  for bipolar depression  and Bimatoprost SR for glaucoma  The company s biosimilar pipeline also provides significant growth opportunity However  the company is facing loss of exclusivity for many blockbuster products  Rising generic competition and anticipated branded competition for key drugs are likely to have an unfavorable impact on revenues  Hence  successful development of pipeline candidates is necessary for the company to offset branded generic competition Allergan plc Price
    Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/allergan-announces-fda-acceptance-of-migraine-candidate-nda-200396910,200396910
105108,326623,AGN,Why Is Ironwood  IRWD  Down 0 4  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Ironwood Pharmaceuticals  IRWD   Shares have lost about 0 4  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Ironwood due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Ironwood Q4 Earnings   Revenues BeatIronwood reported fourth quarter 2018 adjusted loss of 2 cents per share  narrower than the Zacks Consensus Estimate of a loss of 17 cents as well as the year ago loss of 14 cents Total revenues in the fourth quarter were  130 7 million  reflecting a surge of 38 7  from the year ago period  mainly owing to Linzess   linaclotide  sales growth  and higher  active pharmaceutical ingredient  API sales to Astellas in Japan  The top line also beat the Zacks Consensus Estimate of  86 72 million The Quarter in DetailAs reported by partner Allergan  NYSE AGN   Ironwood s key marketed product   Linzess  generated net sales of  205 2 million in the United States  up 5 3  year over year Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  81 6 million in the fourth quarter  up approximately 6 5  year over year  Total commercial profit in the reported quarter was  146 million Sales of linaclotide API segment added  45 9 million to revenues including sales to the company s Japanese partner Astellas Pharma  The company also earned  3 2 million from linaclotide royalties  co promotion and other revenues Per data provided by IQVIA  formerly Quintiles and IMS Health   Linzess prescriptions filled during the quarter were more than 868 000  up approximately 7  from the year ago period while volume of prescribed Linzess capsules increased about 12  During the reported quarter  selling and administrative  SG A  expenses inched up 0 5  to  58 2 million  Research and development  R D  expenses were  44 3 million  up 10 5  from the year earlier period Restructuring UpdatesThe company is on track to complete its separation into two publicly trading entities in first half 2019  For the new Ironwood  the company s board has picked Mark Mellon as its CEO  Meanwhile  Peter Hecht  the current CEO of Ironwood Pharma is set to lead the new company   Cyclerion 2019 GuidanceIronwood expects total revenues in the range of  370  390 million during 2019  Net interest expenses are anticipated to be approximately  35 million The company will provide its earnings outlook for 2019 at a future investor update event following the conclusion of the business separation 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  The consensus estimate has shifted  300  due to these changes 
VGM Scores
At this time  Ironwood has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with an F  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Ironwood has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/why-is-ironwood-irwd-down-04-since-last-earnings-report-200398052,200398052
105109,326624,AGN,Pharma Stock Roundup  Regulatory Updates From MRK  PFE  J J  AGN   Others,opinion,"This week the FDA and European Commission were quite active  Pfizer   NYSE PFE   announced FDA approval for its biosimilar version of Roche s   OTC RHHBY   breast cancer medicine  Herceptin while Merck   NYSE MRK   and Roche gained approval in EU to expand labels of their marketed drugs  Keytruda and Hemlibra  respectively   Meanwhile  the FDA granted a 10 month review period to Allergan s   NYSE AGN   regulatory application for key pipeline candidate ubrogepant while J J   NYSE JNJ   filed an application with the same authority looking for approval of its multiple myeloma drug   Darzalex in an expanded patient population Recap of the Week s Most Important HeadlinesPfizer s Biosimilar Herceptin Gets FDA Approval  The   a biosimilar version Roche s breast cancer drug  Herceptin  Trazimera is already approved in the EU  Pfizer s biosimilar versions of Roche s other cancer drugs Rituxan and Avastin  Zirabev  are also under review in the United States with FDA decisions on all expected in 2019 Pfizer and partner Merck KGaA announced that its regulatory filing in the EU looking for approval of Bavencio  avelumab   in combination with Inlyta  axitinib  for advanced renal cell carcinoma   RCC    was validated for review by the European Medicines Agency  A similar application is under priority review in the United States with the FDA s decision expected in June  The regulatory filings in the EU and the United States were based on interim data from the phase III JAVELIN Renal 101 study  which evaluated the Bavencio Inlyta combination against Pfizer s older kidney cancer drug  Sutent EU Nod to Merck s Keytruda Combo in Difficult Lung Cancer  Merck announced that the European Commission granted marketing approval to Keytruda  in combination with chemotherapy  as a first line treatment for metastatic squamous non small cell lung cancer NSCLC   a difficult to treat lung cancer patient population  The filing was based on data from the phase III KEYNOTE 407 study  In the United States  a similar label expansion was approved in early October last year Roche s Hemlibra Gets EU Approval in an Expanded Patient Population  The European Commission granted approval to Roche s regulatory application seeking approval of its drug  Hemlibra for the treatment of hemophilia A patients  adults and children  Hemlibra is presently marketed in the EU for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors  Hemlibra is now the only haemophilia A treatment approved for patients with and without factor VIII inhibitors that can be administered subcutaneously  at multiple dosing options  once weekly  every two weeks  or every four weeks   Hemlibra was approved for a similar indication in the United States in October last year FDA Accepts Allergan s NDA for Ubrogepant  Allergan s new drug application looking for approval of ubrogepant  its oral anti CGRP acute migraine treatment  was   The FDA granted the application a normal review period of 10 months and will give its decision in the fourth quarter of 2019  If approved  ubrogepant would be the first oral CGRP antibody to get approval for migraine and may be used in conjunction with other available migraine treatment J J Files sBLA for Darzalex  J J filed a supplemental biologics license application  sBLA  seeking approval for its immunotherapy  Darzalex in combination with Celgene s Revlimid  lenalidomide  and dexamethasone in  patient population  The filing was based on data from a phase III MAIA study Lilly s Cyramza Meets Primary Endpoint in First Line Lung Cancer Study  Lilly s   NYSE LLY    phase  evaluating Cyramza in first line EGFR mutation positive  NSCLC met the primary endpoint of progression free survival  PFS   The data from the study showed that treatment with Cyramza  in combination with erlotinib significantly delayed disease progression in previously untreated patients with metastatic NSCLC whose tumors have activating EGFR mutations  Detailed efficacy and safety results from the study will be presented at a future medical meeting  Lilly intends to initiate global regulatory submissions in mid 2019  Cyramza is presently approved for second line treatment of advanced metastatic gastric cancer  metastatic NSCLC and metastatic colorectal cancer The NYSE ARCA Pharmaceutical Index rose  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 
Here is how the seven major stocks performed in the last five trading sessions It was a mixed performance in the last five trading sessions  While AstraZeneca recorded the highest gain of 1 5   Bristol Myers   NYSE BMY   declined the most  3 1   In the past six months  Lilly has been the biggest gainer  16 4   while Bristol Myers declined the most  18 6    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn--others-200398173,200398173
105112,326627,AGN,The Zacks Analyst Blog Highlights  Pfizer  Roche  Merck  Allergan And JJ,opinion,For Immediate ReleaseChicago  IL  March 18  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Pfizer   NYSE PFE    Roche   OTC RHHBY    Merck   NYSE MRK    Allergan   NYSE AGN   and J J   NYSE JNJ    Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  PFE  RHHBY  MRK   MoreThis week the FDA and European Commission were quite active  Pfizer announced FDA approval for its biosimilar version of Roche s breast cancer medicine  Herceptin while Merck and Roche gained approval in EU to expand labels of their marketed drugs  Keytruda and Hemlibra  respectively   Meanwhile  the FDA granted a 10 month review period to Allergan s regulatory application for key pipeline candidate ubrogepant while J J filed an application with the same authority looking for approval of its multiple myeloma drug   Darzalex in an expanded patient population Recap of the Week s Most Important HeadlinesPfizer s Biosimilar Herceptin Gets FDA Approval  The   a biosimilar version Roche s breast cancer drug  Herceptin  Trazimera is already approved in the EU  Pfizer s biosimilar versions of Roche s other cancer drugs Rituxan and Avastin  Zirabev  are also under review in the United States with FDA decisions on all expected in 2019 Pfizer and partner Merck KGaA announced that its regulatory filing in the EU looking for approval of Bavencio  avelumab   in combination with Inlyta  axitinib  for advanced renal cell carcinoma   RCC    was validated for review by the European Medicines Agency  A similar application is under priority review in the United States with the FDA s decision expected in June  The regulatory filings in the EU and the United States were based on interim data from the phase III JAVELIN Renal 101 study  which evaluated the Bavencio Inlyta combination against Pfizer s older kidney cancer drug  Sutent EU Nod to Merck s Keytruda Combo in Difficult Lung Cancer  Merck announced that the European Commission granted marketing approval to Keytruda  in combination with chemotherapy  as a first line treatment for metastatic squamous non small cell lung cancer NSCLC   a difficult to treat lung cancer patient population  The filing was based on data from the phase III KEYNOTE 407 study  In the United States  a similar label expansion was approved in early October last year Roche s Hemlibra Gets EU Approval in an Expanded Patient Population  The European Commission granted approval to Roche s regulatory application seeking approval of its drug  Hemlibra for the treatment of hemophilia A patients  adults and children  Hemlibra is presently marketed in the EU for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors  Hemlibra is now the only haemophilia A treatment approved for patients with and without factor VIII inhibitors that can be administered subcutaneously  at multiple dosing options  once weekly  every two weeks  or every four weeks   Hemlibra was approved for a similar indication in the United States in October last year FDA Accepts Allergan s NDA for Ubrogepant  Allergan s new drug application looking for approval of ubrogepant  its oral anti CGRP acute migraine treatment  was   The FDA granted the application a normal review period of 10 months and will give its decision in the fourth quarter of 2019  If approved  ubrogepant would be the first oral CGRP antibody to get approval for migraine and may be used in conjunction with other available migraine treatment J J Files sBLA for Darzalex  J J filed a supplemental biologics license application  sBLA  seeking approval for its immunotherapy  Darzalex in combination with Celgene s Revlimid  lenalidomide  and dexamethasone in  patient population  The filing was based on data from a phase III MAIA study Media ContactZacks Investment Research800 767 3771 ext  9339   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-03-17,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-pfizer-roche-merck-allergan-and-jj-200398664,200398664
105123,326638,AGN,Big name U S  hedge funds shed healthcare stocks during the rally in second quarter,news,"By David Randall and Trevor Hunnicutt NEW YORK  Reuters    Several big name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U S  stock market higher  rallying amid a Republican effort to repeal and replace President Obama s signature healthcare law  Jana Partners sold all of its shares in nine healthcare companies  ranging from small cap biotech company Acadia Pharmaceuticals Inc  O ACAD  to health information company  WebMD Health Corp   O WBMD  to insurer  Aetna Inc   N AET   according to quarterly filings released Monday  Billionaire Daniel Loeb s Third Point sold 175 000 shares  or about 18 percent of its stake  in health insurance company  Humana Inc   N HUM  and 5 million shares of hospital products maker Baxter International Inc  N BAX   or approximately 10 percent of its prior position  Shares of both companies are up more than 20 percent year to date   Farallon Capital Management LLC  founded by Tom Steyer  dissolved its stakes in pharmaceuticals companies Eli Lilly and Co  N LLY  and Bristol Myers Squibb Co  N BMY   according to filings  The hedge fund also trimmed stakes in AstraZeneca Plc  L AZN  and Allergan Plc  N AGN   Healthcare stocks in the S P 500 rose 6 7 percent in the second quarter  more than double the 2 6 percent gain in the broad S P 500 index  after trailing the broad market following Donald Trump s surprise victory in the Nov  8 presidential election   Senate Republicans delayed a vote on a healthcare overhaul bill on June 27 after it became clear that they did not have enough votes for it to pass  One month later  a scaled down plan to replace Obama s Affordable Care Act failed in the Senate   Healthcare stocks have underperformed since the current quarter began on July 1  dipping 0 5 percent compared with a 1 9 percent gain by the broad S P 500  suggesting that the move by hedge fund managers could signal the end of the rally    If sentiment from certain institutional investors weakens for healthcare it could negatively impact stocks  despite the sector s strong fundamentals  said Todd Rosenbluth  director of mutual fund research at CFRA Research   Quarterly disclosures of hedge fund managers  stock holdings  in what are known as 13F filings with the U S  Securities and Exchange Commission  are one of the few public ways of tracking what the managers are selling and buying  But relying on the filings to develop an investment strategy comes with some risk because the disclosures come 45 days after the end of each quarter and may not reflect current positions  Overall  hedge funds gained 1 percent in the second quarter  according to Chicago based fund tracker Hedge Fund Research  less than half of the 2 5 percent gain in the first quarter   There were few signs that hedge fund managers were attempting to call a bottom in energy stocks as the falling price of oil helped send the sector down 7 percent in the quarter  Third Point sold all of its stake in  Rice Energy  Inc  N RICE    Halcon  Resources Corp  N HK    Enerplus Corp   TO ERF   and Pioneer Natural Resources Co   
Jana Partners sold all of its stake in  Resolute Energy Corp   N REN   while Omega Advisors sold its entire stake in seven energy companies  including  Cheniere Energy  Inc  A LNG   Eclipse Resources Corp  N ECR   and  Williams Partners LP   N WPZ  ",2017-08-14,Reuters,https://www.investing.com/news/stock-market-news/bigname-us-hedge-funds-shed-healthcare-stocks-during-the-rally-in-second-quarter-518324,518324
105124,326639,AGN,Indian drug makers in the mix for Teva s European assets  Teva up 5 ,news,LiveMint reports that Indian drug firms Aurobindo Pharma Ltd  and Intas Pharmaceuticals Ltd  are negotiating with banks to finalize funding for a portion of Teva Pharmaceutical Industries   TEVA  4 5   European assets  including its oncology  pain management and women s health businesses  The assets could fetch as much as  1B If the deal goes through  it would be the largest overseas acquisition by an Indian pharmaceutical company  The top spot is currently held by Lupin Ltd  who bought Gavis Pharmaceuticals LLC and Novel Laboratories for  880M in 2015 Last year  Aurobindo was outbid by Intas for Teva s  Actavis   NYSE AGN  UK Ltd  and Actavis Ireland Ltd  units Now read ,2017-08-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/indian-drug-makers-in-the-mix-for-tevas-european-assets-teva-up-5-518910,518910
105125,326640,AGN,Biotechs in the mix on market s rally,news,"Biotech and biopharma firms are not being left behind in today s up move  The iShares Nasdaq Biotechnology ETF  IBB  1 9   is ahead of the broad market  albeit on lower than hoped for volume 
Selected tickers   BIIB  1 1   AMGN  1 3   CELG  2 4   GILD  1   ALXN  3 4   PFE  1 3   NVS  0 7   BMY  1 8   MRK  0 6   AGN  0 5   AZN  0 4   GSK  1 1   LLY  1 2  
Now read ",2017-08-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-in-the-mix-on-markets-rally-521229,521229
105126,326641,AGN,Paratek Pharmaceuticals mulling sale  shares ahead 28  premarket,news,Paratek Pharmaceuticals  NASDAQ PRTK  is up 28  premarket on increased volume on rumored takeover interest  In May  Allergan  NYSE AGN   the U S  licensor of Paratek s sarecycline  was reportedly the interested party The company s lead candidate is antibiotic omadacycline  successful in three late stage studies Previously  Paratek s omadacycline successful in late stage study in ABSSSI  shares ahead 7  after hours  July 17 Previously  FT  Paratek Pharma in play  Shares jump nearly 7   May 4 Now read ,2017-08-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/paratek-pharmaceuticals-mulling-sale-shares-ahead-28-premarket-521478,521478
105127,326642,AGN,Immune Pharma pops  up 118 ,news,Short sellers of Immune Pharmaceuticals  IMNP  117 5   are running for cover  Shares had lost almost 65  of their value since late June before today s high volume action The company is advancing a spinoff of Cytovia which will focus on developing cancer drug CEPLENE  histamine dihydrochloride  On August 14  it announced the hiring of a new COO and Chief Medical Officer to lead the development effort for bertilimumab  a monoclonal antibody for the potential treatment of bullous pemphigoid and ulcerative colitis Previously  New operating chief at Immune Pharma  slide continues  shares down 10   Aug  14 Previously  Immune Pharma s strategic plan and planned Cytovia spinout fail to stem the wave of selling  shares down 21   Aug  4 Now read ,2017-08-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/immune-pharma-pops-up-118-521687,521687
105128,326643,AGN,FDA to clarify comprehensive policy for stem cell therapies  goes after  bad actors ,news,In a statement  FDA Commissioner Scott Gottlieb  M D   says the agency will be advancing a comprehensive policy framework in the coming months aimed at clarifying the  rules of the road  for developers of stem cell and regenerative medicine therapies so the regulatory process will be more efficient and less costly He adds that the regulator will be increasing oversight and enforcement in order to rein in the  bad actors  that are endangering patients with unproven treatments For example  it issued warning letter to a Florida site called US Stem Cell Clinic and its Chief Scientific Officer for marketing unapproved stem cell products and for  significant deviations  from good manufacturing practices  A recent on site inspection found that the clinic was processing body fat into stem cells derived from the body fat and administering the product  intravenously and directly into the spinal cord  to patients with Parkinson s disease  amyotrophic lateral sclerosis  heart disease and other conditions  None of the products have been reviewed or approved by the FDA  The clinic has 15 days to respond with its plan to address the issues Selected tickers   NASDAQ BLRX   NASDAQ BCLI   NASDAQ APOP   OTCQB RCAR   NYSEMKT CUR   NASDAQ VTGN   NASDAQ BSTG   NYSEMKT ONVO   NASDAQ ATHX   NYSE MNK   NYSEMKT AST   NASDAQ HSGX   NASDAQ CYTX   NYSE AGN   OTCPK BAYRY   NASDAQ CLBS Now read ,2017-08-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-to-clarify-comprehensive-policy-for-stem-cell-therapies-goes-after-bad-actors-523016,523016
105129,326644,AGN,London listed drugs firm Indivior suffers setback in U S  patents ruling,news, Reuters    Indivior  L INDV  said on Friday it would appeal against a U S  court ruling that generic drug maker Dr Reddy s  NS REDY  had not infringed its patents  potentially opening the way to a rival to the firm s Suboxone Film opiod addiction treatment  London listed Indivior has said it would not be able to rely on patents to prevent Dr  Reddy s from making and marketing a generic alternative to Suboxone Film in the United States  unless the court s ruling was reversed on appeal  The firm said the average market share of Suboxone Film in the United States was 61 percent in 2016  and accounted for 80 percent of Indivior s total revenues last year  Shares in Indivior  which was spun off from  Reckitt Benckiser   L RB  in 2014  were down 38 percent at 259 5 pence  3 35  after the open  after the ruling by the U S  Delaware District Court  Indivior said in a statement it could not quantify the precise financial impact of generic alternatives to Suboxone Film on revenues but said it  could potentially result in a rapid and material loss of market share for Suboxone Film in the U S   Indivior said if pharmacies could substitute Suboxone Film with a generic rival without direct consultation with the patient it could lead to the British firm s treatment losing up to 80 percent of its market share  within a matter of months   Indivior said that as of Aug  29 the U S  Food and Drug Administration had not announced it had granted tentative or final marketing authorization to any generic Suboxone Film alternative   If the FDA grants approval to Dr  Reddy s  the British firm said its rival would be able to market a generic alternative to Suboxone Film in the United States  Indivior said in June that it had won a U S  patent battle against  Actavis   N AGN  and Par Pharmaceutical  over Suboxone Film    1   0 7746 pounds ,2017-09-01,Reuters,https://www.investing.com/news/stock-market-news/londonlisted-drugs-firm-indivior-suffers-setback-in-us-patents-ruling-524639,524639
105135,326650,AGN,Allergan Hikes Quarterly Dividend By 2 8  Ahead Of Q4 Results,opinion,Allergan plc   NYSE AGN   announced that its board has approved a 2 8  hike in quarterly cash dividend on common stock to 74 cents per share from the earlier payout of 72 cents  The revised amount will be paid on Mar 15 to shareholders of record as of Feb 15  2019 The annual general meeting of shareholders will be held on May 1  2019 in Dublin  Ireland  Allergan s board has set a record date of Mar 5 for deciding on the shareholders  who are eligible to vote at the meeting The increased dividend for 2019 indicates a strong long term business strategy and the capital allocation priority of Allergan  The company remains committed to also raise its dividend in the future quarters We like to remind investors that in November 2016  Allergan announced the initiation of a dividend  This was after the erstwhile Actavis bought Botox maker Allergan Inc   in 2015 and changed its name to Allergan  The company later sold its generics business in August 2016 and the Anda distribution business to Teva Pharmaceutical Industries Limited   NYSE TEVA   in October 2016  It paid out the first dividend of 70 cents in February 2017 Notably  Allergan is scheduled to report fourth quarter and full year 2018 results on Jan 29  We believe that Allergan s key products  namely Botox  Juv derm collection of fillers  Vraylar  Alloderm  Linzess and Lo Loestrin are likely to push up sales in the quarter to be reported However  revenues in the fourth quarter are expected to be hurt by the recall of Ozurdex from the international markets in October  currency translation and lost revenues due to the sale of medical dermatology assets in September 2018 Meanwhile  lower sales of Namenda XR and Estrace cream due to generic competition are expected to persistently drain Allergan s revenues in the fourth quarter While a generic version of Alzheimer s treatment   Namenda XR   was launched by India based company Lupin in February 2018  the same of Estrace cream was unveiled by Mylan   NASDAQ MYL   last January However  no generic version of Restasis  Allergan s second best selling drug  has been introduced yet  The delay in launch of Restasis generics may add to the top line in the fourth quarter Shares of Allergan have lost 14 2  in the past year  narrower than the  decline of 20 4  Zacks Rank   Stock to ConsiderAllergan currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is Eli Lilly and Company   NYSE LLY    which has a Zacks Rank  2  Buy   You can see  Eli Lilly s earnings estimates have moved 1 4  north for 2019 over the past 60 days  The stock has surged 31 2  in a year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/allergan-hikes-quarterly-dividend-by-28-ahead-of-q4-results-200380178,200380178
105136,326651,AGN,Allergan  AGN  Beats Q4 Earnings And Revenue Estimates,opinion,"Allergan  NYSE AGN  came out with quarterly earnings of  4 29 per share  beating the Zacks Consensus Estimate of  4 15 per share  This compares to earnings of  4 86 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 37   A quarter ago  it was expected that this Botox maker would post earnings of  4 01 per share when it actually produced earnings of  4 25  delivering a surprise of 5 99  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Allergan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  4 08 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 1 99   This compares to year ago revenues of  4 33 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Allergan shares have added about 18 7  since the beginning of the year versus the S P 500 s gain of 5 5  
What s Next for Allergan 
While Allergan has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Allergan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 66 on  3 61 billion in revenues for the coming quarter and  16 32 on  15 40 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the bottom 42  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-beats-q4-earnings-and-revenue-estimates-200380405,200380405
105137,326652,AGN,Allergan  AGN  Q4 Earnings Beat Estimates  2019 View Tepid,opinion,"Allergan plc s   NYSE AGN   fourth quarter 2018 earnings came in at  4 29 per share  which beat the Zacks Consensus Estimate of  4 15  However  earnings fell 11 7  year over year mainly due to lower revenues Revenues came in at  4 08 billion  which exceeded the Zacks Consensus Estimate of  3 98 billion  Revenues fell 5 7  from the year ago period primarily due to loss of exclusivity of some brands  However  core business grew 8 3  during the quarter Key products like Botox  Juv derm collection of fillers  Vraylar and Lo Loestrin partially offset the decline in sales of Restasis  Estrace and Namenda XR  Fourth quarter revenues also benefited from higher revenues from Linzess and Lumigan Full Year ResultsEarnings per share for the full year were  16 69  above the Zacks Consensus Estimate of  16 55 as well as the guided range of  16 20 to  16 60 per share  Earnings increased 2 1  year over year Full year revenues were  15 79 billion  down 1  year over year  Revenues however beat the Zacks Consensus Estimate of  15 7 billion and exceeded the guided range of  15 575  15 725 billion Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues decreased 3 9  to  1 81 billion  Decline in sales of Restasis and loss of sales due to divestiture of Medical Dermatology business were partially offset by strong sales growth of its facial aesthetics products  Botox and Juv derm In Facial Aesthetics  Botox  cosmetic  raked in sales of  258 1 million  up 13  year over year  Juv derm collection of fillers rose 13 5  to  158 4 million Alloderm sales  however  fell 3 1  to  94 9 million while CoolSculpting sales  down 13 9   added  81 3 million to sales In Eye Care  while Ozurdex sales rose 11  to  29 3 million  Restasis and Alphagan sales fell 18 8  and 4  to  325 million and  97 7 million  respectively  Restasis sales decreased due to lower selling price and demand  Botox Therapeutic revenues were  433 3 million  up 12 8  year over year U S  General Medicine net revenues were down 8 4  year over year to  1 4 billion in the reported quarter hurt by lower sales of Namenda XR and Estrace  which were partially offset by strong growth of Vraylar  Linzess and Lo Loestrin Linzess  which was co commercialized with Ironwood Pharmaceuticals   NASDAQ IRWD    sales rose 5 3  to  205 2 million  Lo Loestrin sales grew 13 7  to  143 8 million while Bystolic sales fell 3 7  to  151 78 million  Vraylar sales were  150 5 million in the fourth quarter  71 6  higher than the year ago quarter  while Viibryd sales were  95 5 million  up 7 3  from the year ago quarter Namenda XR sales slumped from  97 8 million to  10 7 million in the reported quarter due to generic competition following loss of exclusivity in February The International segment recorded net revenues of  870 2 million  up 1  from the year ago period  excluding the impact of foreign exchange  driven by growth in Facial Aesthetics and Botox  therapeutic   partially offset by the unfavorable impact of Ozurdex recall Profits RiseAdjusted operating income decreased 11 8  to  1 92 billion in the fourth quarter due to impact of divestitures  lower sales due to loss of exclusivity and a decline in Restasis Selling  general and administrative  SG A  expenses increased 0 9  to  1 14 billion in the fourth quarter owing to higher marketing spending in Medical Aesthetics  partially offset by the impact of previous restructurings Research and development  R D  expenses rose 7 5  to  436 1 million due to pipeline progress 2019 OutlookAllergan provided its earnings and sales guidance for 2019  Allergan expects sales to be in the range of  15 0  15 3 billion  The guidance range is lower than the current Zacks Consensus Estimate of  15 4 billion  The company estimates its adjusted earnings to be equal or more than  16 36 per share Adjusted tax rate is expected to be approximately 13 13 5  in 2019  Adjusted R D expenses are expected to be approximately  1 6    1 7 billion and SG A spend is expected to be approximately  4 1    4 3 billion  Adjusted gross margin is now expected to be approximately 85  85 5  In the first quarter of 2019  the company expects revenues to be in the range of  3 4 billion to  3 55 billion and earnings per share between  3 40 and  3 60  The Zacks Consensus Estimate for revenues and earnings per share is pegged at  3 61 billion and  3 66  respectively Our TakeAlthough Allergan beat estimates for both earnings and sales  the metrics declined from the year ago period  The top and the bottom lines were hurt by loss of sales of several drugs including Restasis due to loss of exclusivity  Namenda XR and Estrace also lost significant sales  However  Botox continues to drive the top line along with Juv derm and Linzess among others Meanwhile  the company s sales outlook was far from encouraging  Moreover  the company expects lower sales to severely impact margins in the first quarter  However  it can be presumed that declining sales trend will stabilize in the later part of 2019 due to low base year effect Shares fell 3 7  in pre market trading presumably on lower sales expectation for 2019  Allergan s share price has fallen 13 7  in the past six months compared with the  s decline of 16 5  Zacks Rank   Stocks to ConsiderAllergan currently carries a Zacks Rank  3  Hold   You can see  A couple of better ranked drug biotech stocks include Bristol Myers Squibb Company   NYSE BMY   and Novartis AG   NYSE NVS    Both the stocks carry a Zacks Rank  2  Buy  Bristol Myers  earnings estimates for 2019 have risen from  4 06 to  4 16 over the past 60 days Novartis  shares were up 2 2  in the past six months while earnings estimates have risen from  5 17 to  5 22 for 2019 over the past 60 days Allergan plc Price  Consensus and EPS Surprise
    Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-q4-earnings-beat-estimates-2019-view-tepid-200380739,200380739
105139,326654,AGN,Allergan Stock Falls As FDA OK s Botox Rival For Frown Lines ,opinion,Shares of Allergan plc   NYSE AGN   were down almost 4  on Monday after Evolus  Inc    NASDAQ EOLS   announced FDA approval for its lead product  Jeuveau injection on Feb 1  The injection is indicated for the improvement of the appearance of glabellar or frown lines  Jeuveau will pose competition to Allergan s largest product Botox  which is also marketed for the same indication  Evolus plans to launch Jeuveau this spring  reportedly at a discount of 20  to 25  to Botox Glabellar lines are frown lines found between the eyebrows and the central forehead Meanwhile  Revance Therapeutics  Inc    NASDAQ RVNC   is developing RT002  a rival treatment to Botox for the frown lines indication  Data presented in 2017 had demonstrated that RT002 led to substantial reduction in severity of glabellar lines in phase III studies with a longer duration of efficacy compared to currently marketed neuromodulators including Botox Approved for therapeutic and aesthetic use  Botox is a key top line driver for Allergan  Its cosmetic indications include three facial aesthetic treatments   forehead lines  crow s feet wrinkles at the outer corner of eyes and glabellar lines Botox s approved therapeutic indications include overactive bladder  cervical dystonia and strabismus among others Notably  Botox is one of the key revenue catalysts for Allergan  The drug generated sales of  3 58 billion in 2018  rising almost 13  year over year However  there have been concerns regarding possible new competitors to Botox  mainly for its therapeutic uses  which can pull down the blockbuster drug s sales in the future quarters The entry of calcitonin gene related peptide  CGRP  antibodies in 2018 may have a negative impact on sales of Botox for the chronic migraine indication  Amgen Novartis  Eli Lilly   NYSE LLY   and Teva Pharma s CGRP migraine treatments  Aimovig  Emgality and Ajovy  respectively were all launched in 2018 However  on the fourth quarter conference call  Allergan management said that there was no visible negative impact on Botox demand following the launches of Aimovig  Emgality and Ajovy  Allergan is optimistic that the introduction of the CGRPs should expand the migraine market and Botox and the CGRPs can coexist in the larger market  Management said that the branded migraine prevention market had nearly doubled since the launch of Aimovig and Botox commanded 50  share of new patients Allergan s share price has declined 17 7  in the past year compared with the  s decline of 15 6    Allergan currently has a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-stock-falls-as-fda-oks-botox-rival-for-frown-lines-200383608,200383608
105140,326655,AGN,J J s  JNJ  Depression Treatment Gets FDA Committee s Nod ,opinion,Johnson   Johnson   NYSE JNJ   announced that a FDA advisory committee has recommended approval of its investigational nasal spray Spravato  esketamine   which has been developed for treatment resistant depression in adults The Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted 14 2 in favor of approval of Spravato stating that the data supports the favorable benefit risk profile of the nasal spray  If approved  Spravato  which is thought to work differently than currently approved therapies  will be the first new medicine in 30 years to treat this difficult to treat mental disease  The FDA s decision is scheduled on Mar 4  Although the FDA takes the recommendation of the committees in consideration  it is not bound by it J J s stock has risen 3 3  in the past year compared with an increase of 6 2  recorded by the   J J filed a new drug application for Spravato in September last year while a regulatory application is also under review in the EU  The NDA was based on five pivotal phase III studies of esketamine nasal spray   three short term studies  one withdrawal maintenance of effect study  and one long term safety study   in patients with treatment resistant depression Data from a short term and a long term study showed that esketamine nasal spray in combination with newly initiated oral antidepressant   NIOD   led to statistically significant   rapid and clinically meaningful reduction of depressive symptoms in patients with treatment resistant depression On the fourth quarter conference call held last month  J J management sounded confident that esketamine will get approval in 2019  Another investigational medicine  erdafitinib for metastatic urothelial cancer is also expected to be approved this year  J J believes that both these medicines have the potential for more than  1 billion of peak revenues We remind investors that Spravato is also being developed in phase III studies for major depressive disorder with imminent risk for suicide The depression market is quite large and has many players including biggies like Allergan   NYSE AGN   with products like Vraylar and Viibryd and Eli Lilly   NYSE LLY   with Cymbalta and Zyprexa In a separate press release  J J announced that the FDA has granted approval to a split dosing regimen of its multiple myeloma drug  Darzalex  With the approval  the label of Darzalex has been updated in the United States to allow dosing by splitting the first infusion of Darzalex over two consecutive days  Approval for this split dosing option is likely to improve the administration profile of the medicine  The split dosing regimen of Darzalex was approved in Europe and Canada in December last year J J currently has a Zacks Rank  3  Hold   You can see   A better ranked large cap pharma stock is Bristol Myers   NYSE BMY    carrying a Zacks Rank  2  Buy  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/jjs-jnj-depression-treatment-gets-fda-committees-nod-200387552,200387552
105145,326660,AGN,Biotechs ripping  IBB up almost 8  in three days,news,Money flow into biotech has turned decidedly positive  The iShares Nasdaq Biotechnology ETF  IBB  3   has rallied almost 8  since Friday Key drivers appear to be reduced anxiety over drug prices with the GOP s rebooted healthcare plan  looming M A deals and expectations of bullish Q1 results from Big Biopharma Selected tickers  BIB XBI PFE MRK BMY NVS LLY JNJ AGN AMGN BIIB VRTX GILD CELG NVSNow read ,2017-06-21,Seeking Alpha,"https://www.investing.com/news/stock-market-news/biotechs-ripping,-ibb-up-almost-8-in-three-days-497792",497792
105147,326662,AGN,Teva  TEVA  Q4 Earnings Miss  19 View Weak  Shares Down,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   reported fourth quarter 2018 earnings of 53 cents per share  which missed the Zacks Consensus Estimate of 56 cents per share  Earnings per share declined 43  year over year Revenues came in at  4 56 billion  marginally beating the consensus estimate of  4 55 billion  Sales declined 16   down 14  in constant currency terms  year over year Sales were hurt by rapid erosion in sales of Teva s key multiple sclerosis injection  Copaxone  pricing pressure in the U S  generics market  divestiture of some non core assets  and discontinued business activities Also  negative currency impact due to the strengthening of the dollar hurt sales and earnings in the quarter Segment DiscussionAs announced in November 2017  Teva no longer reports two separate global groups for its two businesses   generics and specialty medicines  Instead  it reports under new segments based on three regions   North America  United States and Canada   Europe and International Markets North America segment sales were  2 23 billion  down 17  year over year due to pricing erosion in U S  generics market  lower sales of Copaxone  ProAir and QVAR  and loss of sales from the discontinued Women s Health business  In the United States  revenues also declined 17  to  2 1 billion Copaxone posted sales of  356 million in North America  down 44  year over year due to generic competition in the United States  Copaxone recorded sales of  341 million in the United States Sales of other branded products Bendeka  Treanda  ProAir and Qvar declined in the quarter  The company expects significant decline in ProAir sales in 2019 due to the launch of generic version of the drug A new product in Teva s branded portfolio  Austedo  recorded sales of  68 million in the quarter in North America compared with  62 million in the previous quarter  Teva expects Austedo to record  350 million in revenues in 2019 In September  Teva launched a new branded drug  its anti calcitonin gene related peptide   CGRP   injection  Ajovy  fremanezumab   as a preventive treatment for migraine  Teva said it expects to generate  150 million in U S  sales in 2019  An approval in Europe is expected in the first half of 2019 Ajovy will face competition from similar drugs  Amgen   NASDAQ AMGN   and Lilly s   NYSE LLY   CGRPs  Aimovig and Emgality  which were also approved last year Generic products revenues declined 10  to  1 1 billion in the quarter due to price erosion in the U S business and increased competition for Concerta authorized generic  This decline was partially offset by additional sales from the launch of generic products However  on the call  the company said it is seeing signs of stabilization in U S  generic drug pricing  The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third and the fourth quarters of 2018 Distribution revenues  which are generated by Anda  acquired from Allergan   NYSE AGN   in 2016  rose 26  in the quarter to  363 million The Europe segment recorded revenues of  1 2 billion  down 17   down 14  in constant currency terms  year over year due to loss of revenues from the closure of a distribution business in Hungary  divestiture of the women s health business and lower Copaxone revenues  which offset the positive impact of generic launches Generic products  including OTC products  revenues in Europe declined 9   6  on a constant currency basis  to  844 million due to lost revenues as a result of the termination of partnership with P G   PGT Healthcare  in July and price reductionsCopaxone sales declined 21  on a constant currency basis to  118 million due to price reductions  following the entry of generics Respiratory products sales in Europe segment rose 18   up 15  on a constant currency basis  to  90 million mainly due to lower sales in the United Kingdom In the International Markets segment  sales declined 19  year over year to  740 million  However  in constant currency terms  sales declined 13  in this segment due to lower sales in Japan and Russia  the effect of the deconsolidation of subsidiaries in Venezuela and loss of revenues from the sale of the women s health business Generic products  including OTC  revenues declined 18  in constant currency terms to  499 million  Copaxone sales declined 6  to  20 million  Distribution revenues increased 6  in constant currency terms to  146 million in the quarterThe Other segment  API manufacturing business and certain contract manufacturing services  recorded revenues of  377 million  up 9  year over year  in constant currency terms on the back of improved API sales to third parties Profits DeclineAdjusted gross margin increased 20 basis points  bps  to 51 1  in the quarter on the back of improved margins in Europe Adjusted research   development expenses declined 2  from the year ago period to  289 million due to pipeline optimization  concluded phase III studies and resultant workforce reductions  Selling and marketing  S M  expenditure was up 2 5  from the year ago level to  768 million due to higher promotional cost related to the launch of Ajovy  partially offset by cost cutting and re structuring activities  General and administrative  G A  expenses declined 1 5  year over year to  330 million  Adjusted operating margin declined 490 bps to 20 8  in the quarter Full Year ResultsTeva reported total revenues of  18 9 billion for 2018  down 16  from year ago period  Adjusted earnings per share declined 27 2  to  2 92 for the full year 2019 Outlook WeakTeva provided its full year sales and earnings guidance for 2019  Revenues are expected in the range of  17    17 4 billion while earnings per share are expected between  2 20 and  2 50 per share  The guided ranges are lower than the current Zacks Consensus Estimate   The disappointing guidance probably pulled down the company s shares Guidance for free cash flow was  1 6 2 billion  The mid point of the guided range is almost half of  3 7 billion in free cash flow in 2018 The company expects global sales of Copaxone to be approximately  1 5 billion in 2019  a decline of 37 5  from 2018 Our TakeTeva s fourth quarter results were mixed as it beat expectations for sales but missed the same for earnings  The company s guidance for 2019 was lower than market expectations  which pulled the stock down nearly 7 8  on Feb 13 The world s largest generic drugmaker s comments about stabilization of its U S  generics business are encouraging  The company expects sales from the North American generics segment to stabilize around  1 billion per quarter  Meanwhile  the company hinted that it will not be looking for mergers and acquisitions in near future and focus on optimizing its current business Teva s shares have fallen 21 6  in the past six months compared with the  s decrease of 19 7  Teva is facing significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business and a massive debt load stemming from its 2016 acquisition of Allergan s generics business  The company expects business to be weaker and sales of its branded drugs  Copaxone and ProAir to be lower However  Teva has a new organizational structure in place  is closing plants  cutting down its generics portfolio  divesting non core assets  eliminating low value R D projects  and is reducing global workforce to revive growth  Teva is on track to meet its goal to save  3 billion by the end of 2019 from these initiatives with  2 2 billion already achieved in 2018 Its financial position seems more encouraging than before as it is regularly paying down debt  Its newest drugs  Austedo and Ajovy could emerge as significant contributors to long term sales growth Currently  Teva has a Zacks Rank  3  Hold   You can see  Teva Pharmaceutical Industries Ltd  Price  Consensus and EPS Surprise
    Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2019-02-13,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q4-earnings-miss19-view-weak-shares-down-200388322,200388322
105150,326665,AGN,Ironwood  IRWD  Q4 Earnings   Revenues Beat  Shares Rise,opinion,Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   incurred fourth quarter 2018 adjusted loss of 2 cents per share  narrower than the Zacks Consensus Estimate of a loss of 17 cents as well as the loss of 14 cents in the year ago period Total revenues in the fourth quarter were  130 7 million  reflecting a surge of 38 7  from the year ago period  mainly owing to Linzess   linaclotide  sales growth  margin expansion and higher  active pharmaceutical ingredient  API sales to Astellas in Japan  The top line also beat the Zacks Consensus Estimate of  86 72 million Shares of Ironwood were up almost 11 7  following the news on Wednesday  In fact  the stock has inched up 1 8  in the past year versus the  decline of 17 8  Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess  generated net sales of  205 2 million in the United States  up 5 3  year over year  Ironwood and Allergan equally share brand collaboration profits or losses for Linzess Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  81 6 million in the fourth quarter  up approximately 6 5  year over year  Total commercial profit in the reported quarter was  146 million Sales of linaclotide API segment added  45 9 million to revenues including sales to the company s Japanese partner Astellas Pharma  The company also earned  3 2 million from linaclotide royalties  co promotion and other revenues Per data provided by IQVIA  formerly Quintiles and IMS Health   Linzess prescriptions filled during the quarter were more than 868 000  up approximately 7  from the year ago period while volume of prescribed Linzess capsules increased about 12  During the reported quarter  selling and administrative  SG A  expenses inched up 0 5  to  58 2 million  Research and development  R D  expenses were  44 3 million  up 10 5  from the year earlier period Restructuring UpdatesThe company is on track to complete its separation into two publicly trading entities in first half 2019  Last May  the company announced its intention to split itself into two bodies for enhancing operational excellence and strategic flexibility  One part  which will continue with the current name  will focus on the commercial drugs and gastrointestinal  GI  pipeline development  While the other called Cyclerion will focus on developing the Soluble Guanylate Cyclase pipeline for treating serious and orphan diseases  The division of the entities is also being anticipated to be tax free Last month  Ironwood s board announced the appointment of chief executive officers  CEO  for the two new companies that will emerge from the planned separation of the erstwhile Ironwood Pharma  For the new Ironwood  the company s board has picked Mark Mellon as its CEO  Meanwhile  Peter Hecht  the current CEO of Ironwood Pharma is set to lead the new company   Cyclerion 2019 GuidanceIronwood expects total revenues in the range of  370  390 million during 2019  Net interest expenses are anticipated to be approximately  35 million  Separation expenses included within SG A expenses are projected in the band of  30  40 million while restructuring expenses are predicted within  3  4 million The company will provide its earnings outlook for 2019 at a future investor update event following the conclusion of the business separation Pipeline UpdatesLinzess is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation  CIC   Ironwood and Allergan are looking to expand Linzess  label into additional symptoms and develop the drug as a non opioid  pain relieving agent for IBS patients Last July  Ironwood and Allergan initiated a phase IIIb program to evaluate a 290 mcg dose of Linzess for multiple abdominal symptoms in addition to pain including bloating and discomfort in adult patients with irritable bowel syndrome along with constipation  IBS C   Top line data from the study is expected by mid 2019 The companies anticipate to initiate a phase II analysis during the second quarter of 2019 for evaluating MD 7246  delayed release formulation of Linzess  to treat all subtypes of IBS including IBS mixed and IBS with diarrhea Linzess is marketed by Allergan for IBS C in Europe and Canada under the brand name Constella Last month  Ironwood and Allergan announced that both have settled all pending patent litigations with Mylan Pharmaceuticals   NASDAQ MYL   related to Linzess  Mylan has filed an abbreviated new drug application  ANDA  seeking an approval to market a generic version of Linzess  However  Mylan is yet to receive an FDA nod for any generic version of Linzess Last August  a label expansion of Linzess in the chronic constipation was approved in Japan  In China  Hong Kong and Macau  Ironwood has a marketing agreement with AstraZeneca   NYSE AZN   for Linzess  Last month  Linzess was granted a marketing approval by Chinese regulatory authorities to treat adults with IBS C  Ironwood plans to launch the drug in China along with AstraZeneca in the second half of 2019 The company is also developing an interesting candidate called IW 3718  It is currently enrolling patients in two identical phase III studies  evaluating IW 3718 for treating gastroesophageal reflux disease  GERD   Results from both studies are expected in the second half of 2020 Praliciguat and olinciguat will be developed by the new entity  Cyclerion  A phase II study is examining olinciguat for the potential treatment of sickle cell disease  SCD   Ironwood is currently enrolling patients in the STRONG SCD Phase II study with outcomes awaited in the second half of 2019 Two phase II investigations to assess praliciguat for diabetic nephropathy and heart failure with preserved ejection fraction  HFpEF  are currently enrolling patients  Top line findings from both studies are expected in the second half of 2019  Last September  the FDA granted a Fast Track designation to Praliciguat as a treatment option for HFpEF However  the company has notified its plan to out license praliciguat to a global partner before progressing to phase III stage Late last month  Ironwood initiated a phase I probe on its orally administered  central nervous system  CNS  penetrant soluble guanylate cyclase  sGC  stimulator  IW 6463  The candidate is currently being evaluated for the treatment of serious and orphan CNS disorders in healthy volunteers  Data from this study is anticipated during the second half of 2019 IW 6463 is the first CNS penetrant sGC simulator to enter clinical studies and is one of the five differentiated sGC stimulator programs  The same will also be developed by Cyclerion Our TakeLinzess  prospects look encouraging owing to strong demand trends and the drug s expansion to new patient population and geographies Meanwhile  the new Ironwood entity has high potential as it is expected to turn out to be a profitable venture after the split and its focus on gastrointestinal portfolio of commercial product and pipeline appears impressive Moreover  the company s  173 2 million cash resources as of last December end and a strong partner in Allergan bode well Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Zacks RankIronwood currently carries a Zacks Rank  3  Hold  You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2019-02-13,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-q4-earnings--revenues-beat-shares-rise-200388284,200388284
105153,326668,AGN,Biotechs blaze as Trump draft order on drug prices would ease regulations,news,Biotech stocks  NASDAQ IBB  were bullish again today  surging another 4 1  and extending this week s sector gain to 8  as sentiment emerges that the Trump Administration s attempt to rein in drug prices might not be as harmful as originally feared  The sentiment got a boost from a NY Times report which cited a draft of an executive order on drug pricing that appears to focus on easing regulatory hurdles for the industry and  largely leaves the drug industry unscathed   The draft  is a far cry from what  Trump  said on the campaign trail  I don t see anything there that addresses the drug companies getting away with murder  and it appears that is because pharma has captured the process   Patients for Affordable Drugs founder David Mitchell told the Times  Among potentially relevant tickers  PFE  MRK  BMY  NVS  LLY  JNJ  AGN  AMGN  BIIB  VRTX  GILD  ABBV  MYL  MNK  TEVA  PRGO  CELG  VRX ETFs  IBB  XBI  PJP  LABU  BBH  FBT  HQL  XPH  PBE  LABD  IHE  BBC  BBP  PPH  UBIO  ZBIONow read ,2017-06-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/biotechs-blaze-as-trump-draft-order-on-drug-prices-would-ease-regulations-498012,498012
105154,326669,AGN,FDA OKs subcutaneous formulation of Roche s Rituxan for certain blood cancers,news,The FDA approves Roche s  OTCQX RHHBY  RITUXAN HYCELA  rituximab and hyaluronidase human  for subcutaneous injection for the treatment of three blood cancers   all previously untreated  follicular lymphoma  diffuse large B cell lymphoma and chronic lymphocytic leukemia The product includes the same monoclonal antibody as the intravenous formulation and combines it with an enzyme that helps deliver it under the skin U S  commercial launch will commence in a week or two Now read ,2017-06-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-subcutaneous-formulation-of-roche's-rituxan-for-certain-blood-cancers-498416,498416
105155,326670,AGN,Lannett receives approval for additional dosage strengths of Hydrocodone Bitartrate and Acetaminophen tablets USP,news,Lannett Company  NYSEMKT LCI  announces that it received approval from the FDA of its Abbreviated New Drug Application for Hydrocodone Bitartrate and Acetaminophen Tablets USP  5 mg 325 mg  7 5 mg 325 mg and 10 mg 325 mg  the therapeutic equivalent to Norco Tablets of Allergan  NYSE AGN  Pharmaceuticals The product is also marketed under the brand name Lortab  According to IMS  total U S  sales for year ended April were   744M  Now read ,2017-06-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/lannett-receives-approval-for-additional-dosage-strengths-of-hydrocodone-bitartrate-and-acetaminophen-tablets-usp-499205,499205
105156,326671,AGN,Oklahoma alleges J J  Allergan  Teva misrepresented addictive risks of opioids,news,Oklahoma becomes the fourth state to file a lawsuit against opioid painkiller makers  alleging they caused widespread addiction by misrepresenting the benefits and addictive risks of their drugs  The lawsuit by the Oklahoma Attorney General s office targets parent companies and subsidiaries of Johnson   Johnson  JNJ  0 1    Allergan  AGN  0 2    Teva Pharmaceutical  TEVA  0 9   and Purdue Pharma  Oklahoma follows Mississippi  Ohio and Missouri in suing the drug manufacturers over their opioid marketing and sales practices  Now read ,2017-06-30,Seeking Alpha,"https://www.investing.com/news/stock-market-news/oklahoma-alleges-j-j,-allergan,-teva-misrepresented-addictive-risks-of-opioids-501148",501148
105157,326672,AGN,FDA rejects Amgen s marketing application for osteoporosis candidate romosozumab  resubmission to include ARCH and BRIDGE data,news,Amgen  NASDAQ AMGN  receives a Complete Response Letter  CRL  from the FDA regarding its Biologics License Application  BLA  seeking approval of EVENITY  romosozumab  for the treatment of postmenopausal women with osteoporosis The submission was based data from the Phase 3 FRAME study  The agency wants data from the Phase 3 active comparator ARCH study to be integrated into the application  in addition to results from the Phase 3 BRIDGE study assessing EVENITY in men with osteoporosis The FDA s action date was July 19 Amgen is developing EVENITY with UCB  OTCPK UCBJF  OTCPK UCBJY  Previously  Unexpected cardiovascular risk with Amgen and UCB s romosozumab and longer timeline for potential U S  approval bodes well for Radius Health s Tymlos  shares ahead 18  premarket  May 22 Now read ,2017-07-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-rejects-amgen's-marketing-application-for-osteoporosis-candidate-romosozumab;-resubmission-to-include-arch-and-bridge-data-506247,506247
105162,326677,AGN,Allergan appoints Joseph H  Boccuzi to Board of Directors,news,Allergan  NYSE AGN  announces that Joseph H  Boccuzi has been appointed to its Board of Directors  effective immediately Prior to joining Alllergan  Mr  Boccuzi retired as a Partner in the Global Life Sciences  Board and CEO Practices at Spencer Stuart  Now read ,2017-07-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-appoints-joseph-h.-boccuzi-to-board-of-directors-507258,507258
105165,326680,AGN,Allergan declares  0 70 dividend,news,Allergan  NYSE AGN  declares  0 70 share quarterly dividend  in line with previous Forward yield 1 11 Payable Sept  15  for shareholders of record Aug  18  ex div Aug  16 Now read ,2017-08-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-declares-070-dividend-513418,513418
105167,326682,AGN,Bull Of The Day  Editas Medicine  EDIT ,opinion,Zacks Ultimate veterans know that I have owned Editas Medicine  EDIT  for Healthcare Innovators since September of 2017 from  20  We watched shares more than double to  45 by March of 2018 on a sizable degree of hype and FOMO  fear of missing out  over the potential of CRISPR  For more background there  see my most recent ZU report on CRISPR from October  The Greatest Discovery in the Century of Biology   access link below    But then reality set in with a new story every other month on the dangers of CRISPR technology  And while I was encouraged to hold the stock around  30  and not take a 50  long term gain  the correction finally took its toll  But if you look at this six month chart  you can see most of the recent price destruction was all about the 11  collapse in the S P 500 from Dec 14 to 24     And right before this  EDIT s fortunes had just improved after hitting some R D milestones that triggered cash payments from Allergan  NYSE AGN   AGN  for their partnership in diseases of the eye  More importantly  on November 30  the FDA accepted the company s Investigational New Drug  IND  application for EDIT 101  an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10  LCA10   LCA10 is a rare inherited eye disease that appears at birth or in the first few months of life  Congenital means a condition present from birth and amaurosis refers to a loss of vision not associated with a lesion  The expression of LCA can vary  because it is associated with multiple genes  EDIT 101 is now set to be the first in vivo CRISPR medicine administered to people anywhere in the world  And this is why EDIT was one of the few green stocks during the Oct Nov portion of the correction  especially headed into early December and the ASH conference where they were expected to present data in other experimental areas  Editas ASH Presentations At the annual American Society of Hematology  ASH  conference in December  Editas presented preclinical data to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle cell disease  SCD  and betathalassemia  Hematopoietic stem cells are the stem cells that give rise to other blood cells  This process  called haematopoiesis  occurs in the red bone marrow at the core of most bones  Data presented at ASH 2018 demonstrated in vivo an increased production of fetal hemoglobin  which can be beneficial to patients with sickle cell disease or beta thalassemia   The biggest Wall Street bull on EDIT is SunTrust  After ASH  their analyst Peter Lawson said the bank s biotech team was encouraged by Editas  systemic analysis for their hematological approach and important data flow in 2019  They reiterated a BUY rating and  45 PT on EDIT   But that s their  base case  built upon only a 40  probability of success in 4 major pipeline targets  Their Bull and Bear cases have probability weighted projections of  72 and  11  with  15 of value assigned to the technology platform  This is not hard science  Assigning Bayesian probabilities to clinical trial research outcomes is just as subjective as many stock market valuation pursuits  But in Biotech  as the R D targets moves closer into view  so do the guesstimates of future success  The EDIT Pipeline Editas will be presenting this week at the JPMorgan  NYSE JPM  Healthcare Conference on Wednesday January 9  Here s an excellent  mind body map  slide from their most recent investor deck     EDIT owns most of their experimental pipeline  including the commercial rights to EDIT 101  And they have a partnership with Celgene s  CELG  JUNO unit in gene editing for T cells  Best of all  EDIT came out on top in the CRISPR patent wars  which was why I bought it again for my TAZR portfolio  EDIT is now full of valuable technology and IP assets patents that could make it very attractive to big BioPharma at only a  1 billion market cap  3 Medical Stocks to Buy Now The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline  So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-01-08,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day-editas-medicine-edit-200373566,200373566
105168,326683,AGN,Amgen Allergan s Rituxan Biosimilar Meets Goal In Phase III,opinion,Amgen Inc    NASDAQ AMGN   and partner Allergan plc   NYSE AGN   announced positive top line results from a phase I III study on the duo s biosimilar candidate  ABP 798  Both companies are developing ABP 798 as a biosimilar version of Roche s   OTC RHHBY   drug  Rituxan  rituximab  The phase I III study evaluated the pharmacokinetics  PK   efficacy and safety of ABP 798 as compared to Rituxan for the treatment of patients with moderate to severe rheumatoid arthritis  RA   The study met the primary endpoint of PK similarity and also demonstrated an equivalent efficacy and a similar safety profile of the branded drug  The primary objective of the program was to compare the PK similarity of ABP 798 with Rituxan This study is one of the two analyses that will support global regulatory submissions of ABP 798  The second one is being conducted on patients with non Hodgkin s lymphoma Notably  Rituxan is approved for treating adult patients with moderate to severe RA  non Hodgkin s lymphoma  chronic lymphocytic leukemia  pemphigus vulgaris  granulomatosis with polyangiitis and microscopic polyangiitis Amgen has collaborated with Allergan for the worldwide development and commercialization of four oncology antibody biosimilar medicines  Among them  a biosimilar version of Roche s Avastin   Mvasi   is already approved in the United States and the EU while a biosimilar version of Herceptin   Kanjinti   is under review in the United States and launched in the EU  Amgen is also developing biosimilar version of Johnson and Johnson Merck s   NYSE MRK   Remicade   ABP 710   which is currently under review in the United States Currently  Amgen has 10 biosimilar products in its portfolio  Several of Amgen s own drugs are facing biosimilar competition  Biosimilars are already adversely impacting key products like Neupogen and Neulasta Shares of Amgen have increased 2 5  in the past year versus the  decline of 25  In a separate press release  Amgen stated that China s National Medical Products Administration  NMPA  has given an approval to include the cardiovascular indication on the label of its PCSK9 inhibitor  Repatha  evolocumab   Repatha has been approved in China for adult patients with established atherosclerotic cardiovascular disease to reduce the risk of myocardial infarction  stroke and coronary revascularization Last July  Repatha was approved in China for addressing adults and adolescents  aged 12 years and above  afflicted with homozygous familial hypercholesterolemia  HoFH  The approval of this new indication in China will help high risk patients  who are unable to control their low density lipoprotein cholesterol  LDL C  levels with statin therapy alone  with a new treatment option to prevent heart attacks and strokes We would like to remind investors that Repatha was approved by the FDA in 2015 for the same indication Zacks RankAmgen currently carries Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/amgenallergans-rituxan-biosimilar-meets-goal-in-phase-iii-200379576,200379576
105169,326684,AGN,Pharma Stock Roundup  JNJ   BMY s Q4 Earnings  Study Failures At LLY   ABBV,opinion,"J J   NYSE JNJ   and Bristol Myers   NYSE BMY   set the earnings season in motion for the pharma space  Meanwhile  Lilly   NYSE LLY   and AbbVie   NYSE ABBV   faced pipeline setbacks with failure of their late stage studies  Lilly s confirmatory study to convert soft tissue sarcoma drug Lartruvo s conditional approval to full approval and AbbVie s Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints Recap of the Week s Most Important HeadlinesInside J J   Bristol Myers  Q4 Earnings  J J beat estimates for both earnings and sales in the fourth quarter of 2018  Sales increased 1  from the year ago quarter to  20 4 billion while earnings per share rose 13 2  to  1 95 per share  Pharmaceutical segment sales rose 5 3  year over year  However  J J s  was below expectation Bristol Myers for earnings while missing the same for sales  Revenues were up 10  year over year to  6 billion while earnings rose 38  to  94 per share  However  the company announced the voluntary withdrawal of a label expansion application for Opdivo   low dose Yervoy combination in first line ling cancer  which pushed its share price down  Opdivo sales were up 33  in the fourth quarter  Bristol Myers confirmed its 2019 earnings guidance range of  4 10 to  4 20 Lilly s Confirmatory Study on Lartruvo Fails  Lilly s drug Lartruvo  which had won conditional approval two years back  with advanced soft tissue sarcoma in a late stage confirmatory study  ANNOUNCE The ANNOUNCE study evaluated Lartruvo in combination with doxorubicin  a standard of care chemotherapy compared with doxorubicin alone  The study did not meet the primary endpoints of overall survival  OS  in the full study population or in the leiomyosarcoma  LMS  sub population  It was noticed that there was no difference in survival between the study arms for either population  The study thus did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as shown earlier in a phase II study  The clinical benefit achieved earlier had led to an accelerated approval of Lartruvo doxorubicin by the FDA and conditional marketing authorization by the European Medicines Agency in 2016 Continued approval was contingent on verification of clinical benefit in a confirmatory study  With ANNOUNCE failing to confirm clinical benefit  Lilly said it will stop promoting Lartruvo while remaining in discussion with global regulators to determine the next steps for the drug AbbVie s Imbruvica Fails in Pancreatic Cancer Study  AbbVie s late stage study evaluating its cancer drug  Imbruvica in combination with chemotherapy for metastatic pancreatic cancer  of statistically significant progression free or overall survival benefit The RESOLVE study evaluated Imbruvica plus chemotherapy agents nab paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents for the treatment of first line metastatic pancreatic cancer  one of the most aggressive and deadliest forms of cancer  Imbruvica  currently approved for nine cancer indications  has multi billion dollar potential and AbbVie is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases FDA Accepts Merck s sNDAs for HIV Medicines  Merck s   NYSE MRK   supplemental new drug applications  sNDAs  looking for label expansion of its two new HIV drugs   Pifeltro and Delstrigo   was accepted by the FDA  Pifeltro and Delstrigo were approved by the FDA in August for the treatment of adults with no prior antiretroviral treatment experience  The sNDAs are looking to get the HIV drugs approved for use in treatment experienced adults living with HIV 1 whose virus is suppressed to switch to Pifeltro  in combination with other antiretrovirals  or Delstrigo  The FDA is expected to give its decision on Sep 20  The sNDAs were based on data from the phase III DRIVE SHIFT study  Data from the study  presented in the past  has shown non inferior efficacy for those who switched to Delstrigo compared to those who continued on their baseline regimen Sanofi s Influenza Vaccine Gets FDA Nod for Kids  Sanofi   NASDAQ SNY   announced FDA approval of 0 5 mL dose of its influenza vaccine  Fluzone Quadrivalent for use in children 6 months through 35 months of age  The 0 5 mL dose is already approved for use in patients 3 years and above  The FDA approval was based on clinical data from a phase IV safety and immunogenicity study conducted in nearly 2 000 children  Fluzone Quadrivalent s lower 0 25 mL dose is already approved for use in this age group The NYSE ARCA Pharmaceutical Index declined 1 9  in the last four trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last four trading sessions 
 All the seven stocks recorded a decline of more than 1  in the last four trading sessions with Pfizer   NYSE PFE   declining the most  3 6   In the past six months  Lilly has been the biggest gainer  20 8   while Bristol Myers declined the most  15 4    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for fourth quarter and full year 2018 earnings results  by Merck  Pfizer  Allergan  NYSE AGN  and others and pipeline and regulatory updates next week The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-jnj--bmys-q4-earnings-study-failures-at-lly--abbv-200379549,200379549
105170,326685,AGN,Drug Biotech Stock Earnings On Jan 29  PFE  AMGN  BIIB   AGN,opinion,"The earnings season for the quarter ending December has been unimpressive from the start except for a few companies  As expected  the momentum has decelerated compared to the first three quarter of 2018  Although more than 75  of the S P 500 companies are yet to report  the weakening earnings trend is expected to continue Per the report  Energy  Transportation  Construction  Finance  and the Retail sectors are expected to drive earnings growth in Q4  The  sector s companies  comprising pharma biotech as well as medical device companies  which have reported so far and constituting almost a third of the sector s market capitalization recorded 18 5  earnings growth and 8 5  sales growth year over year  Overall  fourth quarter earnings and sales growth of this sector is expected to be 8 1  and 6 1   respectively Although pharma bigwig Johnson   Johnson   NYSE JNJ   reported better than expected results  it provided a softer outlook for 2019  which had an unfavorable effect on the sector  Among the other two big pharma companies  which reported earnings last week  Bristol Myers   NYSE BMY   beat earnings while AbbVie   NYSE ABBV   missed the same  Both the companies missed the revenue expectations Several of the companies from the pharma drug biotech sectors have been facing rising generic biosimilar competition for their key drugs and issues related to high drug prices  However  consistent innovation has brought several new drugs  which helped offset declining sales of many legacy drugs so far Let s take a look at four pharma biotech companies that are set to report fourth quarter 2018 results on Jan 29 Pfizer Inc    NYSE PFE  Pfizer  which is scheduled to release earnings before the opening bell  delivered positive earnings surprise of 2 63  last quarter  The company s earnings beat expectations in all the last four quarters with the average positive surprise being 6 35  For this quarter  Pfizer s  of is 0 00  as the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at 63 cents  The company currently holds a Zacks Rank  3  Hold   You can uncover the best stocks to buy or sell before they re reported with our  The company s top line has been driven by strong growth in the sales of new drugs including Eliquis and Prevnar  which have successfully offset the loss due to declining sales of legacy drugs  These drugs along with Xeljanz are likely to contribute to the top line in the fourth quarter  Pfizer also has a strong biosimilar portfolio  which is set to contribute to sales growth  The company is also poised to get a boost from its expansion into emerging markets Ibrance U S  sales declined in the third quarter due to increased rebates and rising competition  The sales trend for the drug in the fourth quarter remains unclear  Meanwhile  during the quarter Pfizer announced the merger of its consumer healthcare unit with Glaxo s unit  creating the world s largest consumer healthcare business   Read more   Pfizer Inc  Price and EPS Surprise
    Amgen Inc    NASDAQ AMGN  Amgen is scheduled to announce results after the closing bell  The company beat estimates in three of the past four quarters while missing the same once  Amgen delivered a positive earnings surprise of 7 89  last quarter  The company delivered four quarter average positive earnings surprise of 4 80   The Zacks Consensus Estimate for earnings per share is pegged at  3 26 The company has an Earnings ESP of  0 23  and a Zacks Rank  3  You can see  Amgen s revenues are likely to be driven by the encouraging performance of its newer drugs like Prolia  Kyprolis  Xgeva and Blincyto  Patient population for the leukemia drug  Blincyto  was expanded in the third quarter with its approval in Japan and U S  label expansion into pediatric patients  These factors are likely to boost sales of the drug in the soon to be reported quarter  Cholesterol drug  Repatha  is expected to see lower revenues on the back of a 60  price cut and payer restrictions  However  investors will remain focused on the performance of the newly approved migraine drug  Aimovig   Read more   Amgen Inc  Price and EPS Surprise
    Biogen Inc    NASDAQ BIIB  The company is expected to report before market open  Biogen beat estimates in three of the past four quarters while missing the same once  with a positive earnings surprise of 8 82  in the last reported quarter  The company delivered average positive earnings surprise of 4 66  The company has an Earnings ESP of  0 45  and a Zacks Rank  3  The Zacks Consensus Estimate for earnings per share is pegged at  6 72 Biogen s sales are mainly driven by its strong portfolio of multiple sclerosis   MS   drugs  Tecfidera sales improved in the third quarter especially driven by European and Japanese markets which is likely to continue in the fourth quarter  The new drug  Spinraza  approved for spinal muscular atrophy performed well on the back of strong uptake  The trend is expected to continue in the soon to be reported quarter  The company on its third quarter earnings call had stated that year over year comparison in revenues will be difficult in the soon to be reported quarter due to favorable timing of contract manufacturing in the fourth quarter of 2017   Read more   Biogen Inc  Price and EPS Surprise
    Allergan plc   NYSE AGN  The company is expected to report before market open  Allergan delivered an earnings surprise of 5 99  last quarter  Allergan s performance has been encouraging with the company reporting positive surprise in all the last four quarters  The average earnings beat over the last four quarters is 6 66  The company has an Earnings ESP of  2 8  and a Zacks Rank  3 The Zacks Consensus Estimate is pegged at  4 15 The company s key products like Botox  Juv derm collection of fillers  Vraylar  Alloderm  Linzess and Lo Loestrin are likely to support sales growth in the quarter  Demand for Botox has been strong despite facing rising competition with the recent launch of Amgen s CGRP antibody  Aimovig  However  sales of several drugs like Namenda XR and Estrace cream are likely to be hurt by generic competition  Delay in the launch of a generic version of Restasis was a relief for the company in the fourth quarter   Read more  Allergan plc Price and EPS Surprise
    Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/drugbiotech-stock-earnings-on-jan-29-pfe-amgn-biib--agn-200380112,200380112
105180,326695,AGN,High profile Snap stakeholders revealed in filings,news,"NEW YORK BOSTON  Reuters    Some of the biggest U S  mutual and hedge funds  including Daniel Loeb s Third Point and Daniel Och s Och Ziff Capital Management  N OZM   owned stakes in  Snap Inc   N SNAP   parent of the wildly popular Snapchat messaging app  at the end of March  regulatory filings on Friday showed  The filings provide the first definitive snapshot on who bought Snap shares when it went public in early March  in the biggest initial public offering for a U S  tech company since Facebook Inc s  O FB  2012 debut  While the shares quickly rose after the IPO  they plunged this week after Snap reported a  2 2 billion first quarter loss  User growth and revenue fell short of some Wall Street estimates as it competed with similar apps  On Wednesday the shares tumbled 23 percent in after hours trading  wiping some  6 billion from Snap s market value  The quarterly disclosures of asset manager stock holdings  in what are known as 13F filings with the U S  Securities and Exchange Commission  offer clues on what big investors are selling and buying  but give no indication of their current stakes  Fidelity was the biggest owner of Snap with 33 4 million shares as of March 31  the filings show  Mutual fund powerhouse Vanguard owned 6 7 million  Loeb s Third Point owned 2 25 million shares and OZ Management held roughly 1 million shares  BlackRock Inc  N BLK   the world s largest asset manager with  5 4 trillion in assets  bought 9 4 million Snap shares during the first quarter  the asset manager s filing showed   BlackRock  which has been vocal on several corporate governance issues including owners  right to weigh in on a company s policies  has not publicly commented on Snap shares  lack of voting rights  A spokesman said the company does not comment on individual stocks   The filings do not show which BlackRock funds held the Snap shares  None of the company s mutual funds or exchange traded funds have disclosed a position in the company yet  David Tepper s Appaloosa Management  which has  17 billion in assets under management  owned 100 000 Snap shares at the end of March  A few days after Snap went public  Tepper  whose views on the market are closely watched  said he had trimmed his position as the stock price ran up and conceded that he might buy more at lower prices  Appaloosa s filing also showed the firm cut its stake in Allergan Plc  N AGN  by 31 1 percent to 2 9 million shares  Appaloosa also went back into General Motors Co  N GM  in the first quarter with 5 2 million shares  as David Einhorn s Greenlight Capital calls for the automaker to dramatically change its capital structure by splitting its stock into two classes as part of a new capital allocation plan  In early 2015  Tepper joined a group that was publicly agitating for a board seat to get GM to repurchase some of its shares  
A spokesman for Tepper declined to comment on Appaloosa s filing ",2017-05-12,Reuters,https://www.investing.com/news/stock-market-news/high-profile-snap-stakeholders-revealed-in-filings-483901,483901
105181,326696,AGN,Icahn takes new 19 8 million share stake in Conduent in first quarter,news,"NEW YORK  Reuters    Billionaire investor Carl Icahn acquired a new 19 8 million share stake in business services provider  Conduent Inc   N CNDT  in the first quarter and sold out of pharmaceutical firm Allergan Plc  N AGN  and speech technology group  Nuance Communications  Inc  O NUAN   according to regulatory filings on Monday  Icahn raised his stake in truck manufacturer  Navistar International Corp   N NAV   according to the regulatory filing  The changes also reflected the takeover of Federal Mogul Holdings by his publicly traded company  Icahn Enterprises  LP  O IEP   Icahn increased his stake in  Herbalife  Ltd  N HLF   which he has been acquiring against the backdrop of a public feud with hedge fund manager William Ackman  Pershing Square  NYSE SQ  Capital Management  run by billionaire Ackman  has had a short position in the nutrition supplements distributor for several years  David Einhorn s Greenlight Capital Inc acquired a 6 million share stake in Conduent during the first quarter  The quarterly disclosures of manager stock holdings  in what are known as 13F filings with the U S  Securities and Exchange Commission  are always intriguing for investors trying to divine a pattern in what savvy traders are selling and buying  But relying on the filings to develop an investment strategy comes with some peril because the disclosures are backward looking and come out 45 days after the end of each quarter  Still  the filings offer a glimpse into what hedge fund managers saw as opportunities to make money on the long side  The filings do not disclose short positions  bets that a stock will fall in price  and there is little disclosure regarding bonds and other securities that do not trade on exchanges  
Upon request  the SEC also permits managers to omit sensitive stock positions from 13F filings  As a result  the public filings do not always present a complete picture of a manager s stock holdings ",2017-05-15,Reuters,https://www.investing.com/news/stock-market-news/icahn-takes-new-19.8-million-share-stake-in-conduent-in-first-quarter-484607,484607
105182,326697,AGN,Several top fund managers trim Allergan stakes in first quarter,news,"By Trevor Hunnicutt NEW YORK  Reuters    Six closely watched investors sliced their stakes in Allergan Plc  N AGN  during the first quarter  recent regulatory disclosures show  cutting what had been one of the years  best performing health stocks that has stumbled in recent days  Billionaire investor Carl Icahn sold out of the pharmaceutical giant entirely  while Farallon Capital Management LLC  David Tepper s Appaloosa LP and Seth Klarman s Baupost Group LLC were among those trimming their stakes by as much as 32 percent  according to regulatory filings  Paulson   Co Inc and Leon Cooperman s Omega Advisors Inc also pulled back on the stock during the quarter  their filings showed  The Botox maker recorded a strong rally in early February after seeing strong sales  but it posted a first quarter loss last week as it took a nearly  2 billion write down on the value of its stake in Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA   William Blair   Co LLC analysts Tim Lugo and Raju Prasad said in a note last week that the company s eye care business also faced some potential challenges this year  President Donald Trump and his Republican party are pushing for a tax reform that could include a border adjustment measure to satisfy Trump s interest in promoting U S  manufacturing by taxing imports and exempting export revenues from taxation  Allergan Chief Executive Brent Saunders has said he does not anticipate U S  tax reforms this year but that an import tax could hurt the Dublin based drugmaker  Omega and Paulson offered no comment  while the other four investors did not respond to inquiries from Reuters  Allergan declined to comment  Shares in Allergan were up 13 77 percent in the first quarter   The quarterly disclosures of manager stock holdings with the U S  Securities and Exchange Commission  in what are known as 13F filings  are always intriguing for investors trying to divine a pattern in what savvy traders are selling and buying  But relying on the filings to develop an investment strategy comes with some peril in part because the disclosures are backward looking and come out 45 days after the end of each quarter  
Still  the filings offer a glimpse into what stocks fund managers saw as opportunities for profit ",2017-05-15,Reuters,https://www.investing.com/news/stock-market-news/several-top-fund-managers-trim-allergan-stakes-in-first-quarter-484619,484619
105186,326701,AGN,Citi downgrades Pfizer sell  cuts price target to  31  shares off 2  premarket,news,Pfizer   NYSE PFE  is under early pressure  down 2  premarket on average volume  on the heels of a downgrade to Sell by  Citigroup   NYSE C   Price target lowered to  31  6  downside risk  from  38 Analyst Andrew Baum says the company needs a deal to hit consensus EPS numbers  Company already cut non GAAP EPS estimates by 5   10   2018   2022   He also cites rising risk from high price oncology drugs like Xtandi  Xalkori and Ibrance Major transactions could involve Bristol Myers Squibb  NYSE BMY  and Allergan  NYSE AGN  Source  StreetInsiderNow read ,2017-05-16,Seeking Alpha,"https://www.investing.com/news/stock-market-news/citi-downgrades-pfizer-sell,-cuts-price-target-to-$31;-shares-off-2-premarket-484840",484840
105189,326704,AGN,Study shows AstraZeneca s T2D med Bydureon does not increase CV risk,news,Results from the Phase 3b 4 clinical trial  EXSCEL  showed AstraZeneca s  NYSE AZN  Bydureon  exenatide extended release for injection  to be non inferior  no worse than  to placebo when added to standard care for type 2 diabetes  T2D  on the risk of MACE  a composite endpoint of CV death  non fatal heart attack or non fatal stroke  at a wide range of CV risk The study satisfies an FDA requirement that T2D medications are not associated with an increase in CV risk Fewer CV events were observed in the Bydureon treatment arm but the study fell short of showing superiority in reducing MACE versus placebo The FDA approved Bydureon on January 27  2012 Now read ,2017-05-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/study-shows-astrazeneca's-t2d-med-bydureon-does-not-increase-cv-risk-487479,487479
105192,326707,AGN,Mylan defends chairman to ISS ahead of June 22 investor vote,news," Reuters    Mylan NV  O MYL  defended Chairman Robert Coury s role to ISS this week as the influential proxy firm prepares to advise shareholders on how they should vote on the re election of Coury and other directors  according to a letter the drugmaker released on Wednesday  New York City and State pension funds and the California Teachers  Retirement System are urging shareholders to vote on June 22 against Coury and five other directors  The funds cite the board s poor oversight of Coury s high pay package  investigations into how much it charged the government and consumers for its EpiPen emergency allergy treatment business and a takeover offer   The investors  who hold 4 3 million shares  said Mylan walked away from a deal with rival Teva International Industries Ltd  TA TEVA   N TEVA  in 2015  causing shares to lose value  ISS is preparing to issue a report on the vote  and Mylan s letter was aimed in part at convincing the firm that it should let it see a copy before publication   ISS spokesman Subodh Mishra said the advisory firm would not do so  which it said is typical in controversial situations    We believe that the pending  vote no  campaign led by certain Mylan shareholders creates a contentious controversial situation and so ISS is not providing MYLAN with a pre publication review   Mishra said   Mylan met with ISS on Monday and discussed the role of Coury in growing the company  according to the letter  and defended his compensation  which was more than  97 million in 2016   Mylan also defended its dealings with Teva  saying it  never  received an offer from the Israeli drugmaker   Teva said in an open letter in April 2015 it would pay  82 per share in cash and stock  and Coury responded in a letter to Teva that the offer was too low and that the starting point for discussions was  100 per share  Teva walked away in July 2015 after reaching a  40 billion deal for Allergan Plc s  N AGN  generic unit  Mylan shares rose 0 5 percent to  38 74 on Wednesday  Mylan has been the subject of federal and state investigations and agreed last fall to pay  465 million to settle U S  Justice Department allegations it overcharged the government for EpiPens  although the agreement has not been finalized  
Last week  a government agency put out a report saying that Mylan may have overcharged the government by  1 27 billion ",2017-06-07,Reuters,https://www.investing.com/news/stock-market-news/mylan-defends-chairman-to-iss-ahead-of-june-22-investor-vote-492848,492848
105193,326708,AGN,Britain s NHS advisor backs Roche s breast cancer med Kadcyla,news,England s National Institute of Health and Care Excellence  NICE   the advisor to the National Health Service  NHS  on service quality and costs  reverses its position and now recommends that Roche s  OTCQX RHHBY  Kadcyla  trastuzumab emtansine  be routinely available to women with previously treated advanced HER2 positive breast cancer  NICE gave it a thumbs down in draft guidance issued in December 2016 About 1 000 women each year in the UK will be candidates for treatment Now read ,2017-06-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/britain's-nhs-advisor-backs-roche's-breast-cancer-med-kadcyla-496004,496004
105199,326714,AGN,FDA Accepts Allergan s  AGN  SNDA For Anti Infective Avycaz ,opinion,"Allergan   NYSE AGN   announced that the FDA has accepted its supplemental new drug application  sNDA  for approval of its antibacterial medicine  Avycaz for the pediatric patient population The sNDA is seeking an approval for Avycaz for the treatment of complicated urinary tract infections  cUTI  and complicated intra abdominal infections  cIAI   in combination with metronidazole  in pediatric patients  aged three months and above  Avycaz is already approved to treat these infections in adult patients  The medicine is a combination of avibactam and ceftazidime 
So far this year  Allergan s shares have outperformed the   Although the stock has declined 6 2  in the period  the loss is narrower than the 8 6  decrease of the industry 
 
 The sNDA filing was based on data from two active control clinical studies  findings from which were similar to the previous determination of safety for Avycaz pertaining to the cUTI and cIAI indications In February  the FDA approved Avycaz for the treatment of patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP  due to gram negative bacteria  The approval marked the third therapeutic indication for the drug in the United States Avycaz recorded sales of  70 million in the first nine months of 2018  soaring 63 9  year over year Significantly  Avycaz is jointly marketed by Allergan and Pfizer   NYSE PFE    While Allergan has commercialization rights to Avycaz in North America  the rest of the world rights are owned by Pfizer under the brand name  Zavicefta Apart from Avycaz  Allergan s anti infectives portfolio comprises antibiotics  namely Teflaro and Dalvance Allergan currently carries a Zacks Rank  3  Hold   You can see  Some better ranked pharma stocks are GlaxoSmithKline plc   NYSE GSK   and Merck   NYSE MRK    both carrying a Zacks Rank  2  Buy  Merck s earnings estimates have risen 1 4  for 2018 and 1 3  for 2019 over the past 30 days  The stock has surged 32 9  so far this year Glaxo s earnings estimates have inched up 0 3  for 2018 and were flat for 2019 over the past 30 days  The stock has rallied 14 6  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/fda-accepts-allergans-agn-snda-for-antiinfective-avycaz-200361441,200361441
105200,326715,AGN,Why Is Ironwood  IRWD  Up 6 7  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Ironwood Pharmaceuticals  IRWD   Shares have added about 6 7  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Ironwood due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Ironwood Q3 Earnings   Revenues MissIronwood reported third quarter 2018 adjusted loss of 38 cents per share  wider than the Zacks Consensus Estimate of a loss of 14 cents  The figure was also wider than the year ago period s loss of 18 cents Total revenues in the quarter decreased 24 3  from the year ago period to  65 7 million mainly due to Linzess net sales adjustments and also missed the Zacks Consensus Estimate of  92 28 million The Quarter in DetailAs reported by partner Allergan  NYSE AGN   Linzess generated U S  net sales of  204 8 million  up 7 3  year over year Ironwood and Allergan equally share brand collaboration profits or losses  Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  52 3 million in the third quarter  down approximately 29  year over year The significant decline in sales was due to a  59 3 million negative adjustment related to Linzess sales over the last three fiscal years  2015  2016    2017   which was shared equally by Allergan and Ironwood  The negative adjustment  as calculated by Allergan  is the cumulative difference between previous gross to net estimates and actual subsequent payments made by Allergan  The difference can primarily be attributed to previous estimation of governmental and contractual rebates  Going forward  such adjustments will be done more frequently to avoid adjustment of a significant magnitude Sales of linaclotide active pharmaceutical ingredient added  10 9 million to revenues  including  9 5 million of sales to the company s Japanese partner  Astellas Pharma  The company also earned  1 9 million from linaclotide royalties  co promotion and other revenues According to data provided by IMS Health  Linzess prescriptions filled during the reported quarter were more than 830 000  up approximately 6  from the year ago period while volume of prescribed Linzess capsules increased about 12  Zurampic and Duzallo  approved for uncontrolled gout  generated sales of  1 2 millionDuring the reported quarter  selling and administrative  SG A  expenses decreased 10 6  to  55 2 million  Research and development  R D  expenses were  46 8 million  up 26 2  from the year ago period Restructuring UpdatesIn August  Ironwood sent a notice of termination to AstraZeneca for a license agreement related to lesinurad franchise which includes Zurampic and Duzallo  With this termination  Ironwood will lose its rights to develop lesinurad based products in the United States  The company expects to save approximately  75 million to  100 million in operating expenses for the full year 2019 2018 Guidance ReiteratedIronwood maintained guidance for 2018 operating expenses  Selling  general and administrative expense is expected to be in the range of  230 million to  250 million while R D expense is anticipated in the range of  160 million to  180 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  136 52  due to these changes 
VGM Scores
Currently  Ironwood has a poor Growth Score of F  however its Momentum Score is doing a lot better with a C  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Ironwood has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-ironwood-irwd-up-67-since-last-earnings-report-200365691,200365691
105201,326716,AGN,Bausch  BHC  Bids For Assets Of Synergy Pharmaceuticals ,opinion,Bausch Health Companies Inc    NYSE BHC   announced that it has entered into a definitive agreement to acquire certain assets of biopharmaceutical Synergy Pharmaceuticals Inc    NASDAQ SGYP   for approximately  200 million Earlier  Synergy Pharma had filed a voluntary petition for reorganization under Chapter 11 of the U S  Code with the U S  Bankruptcy Court for the Southern  NYSE SO  District of New York  Financial Terms of the AcquisitionPursuant to Section 363 of the Bankruptcy Code  Synergy will conduct a court supervised auction and sale process where Bausch will serve as the  stalking horse bidder  Per the terms  Bausch  through its affiliate  has agreed to acquire most of Synergy s assets   intellectual property  customer and vendor contracts  accounts receivable and goodwill  among others  Bausch has also agreed to employ most of the current employees of Synergy Pharma However  Bausch s bid is subject to higher or better offers  as other interested parties will have an opportunity to submit competing bids  Assuming the bid is successful  the transaction is expected to close in the first quarter of 2019 Strategic Value of the BuyoutBausch expects the buyout to be a strategic fit to its gastrointestinal business   Synergy Pharma is focused on the development and commercialization of novel gastrointestinal  GI  therapies  The company s lead drug  Trulance is a once daily tablet approved for adults with chronic idiopathic constipation  CIC  and irritable bowel syndrome with constipation  IBS C  Bausch expects Trulance to complement its leading GI drug  Xifaxan  which is indicated for the treatment of irritable bowel syndrome with diarrhea  IBS D  in adults and reduction in risk of overt hepatic encephalopathy  HE  recurrence in adults Moreover  the acquisition will add a promising candidate to Bausch s pipeline  dolcanatide  which is being evaluated for various GI indications Our TakeWe do not view the acquisition as an outright positive one  While the prospects of Trulance look good  the drug faces stiff competition from the likes of Allergan s   NYSE AGN   Linzess  among others  and hence might not reap the results expected by Bausch Sales of the drug have not been impressive  Moreover  Bausch still owes a lot of debt  The company was once an acquisition giant but some of them turned out to be unfavorable  Bausch s stock has gained 16 1  in the year so far  against the  s 13 8  decline  After a tumultuous period  Bausch started a rebuilding process  The company recently changed its name  Even though it is still early to comment on the rebuilding process  the company s efforts to sell non core assets and pay down huge levels of debt are noteworthy  However  the dermatology market continues to be challenging Zacks Rank   Key PickBausch currently carries a Zacks Rank  1  Strong Buy   Another well positioned stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a same rank as Bausch  You can see  Gilead s earnings per share estimates increased from  6 64 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/bausch-bhc-bids-for-assets-of-synergy-pharmaceuticals-200367728,200367728
105202,326717,AGN,Allergan Drops  Stops Textured Breast Implant Sales In Europe,opinion,Allergan plc   NYSE AGN   announced that it has suspended the sale of its textured breast implants and tissue expanders and will further discontinue the supply of any remaining products in Europe  reportedly due to a cancer risk  The decision was taken following a compulsory recall request from French regulatory authority Agence Nationale de S curit  du M dicament  ANSM  after the product s CE Mark certification expired Shares of Allergan were down almost 7  following this news on Wednesday  Moreover  the stock has lost 16 5  year to date  narrower than the  decline of 19 5  Although the French authority has not identified any major risk associated with women s health regarding these textured breast implants  Allergan is still focused on this serious issue and is fully cooperating with the regulatory body to resolve the same Fortunately for Allergan  the issue will not affect its smooth implants sales  The company has renewed the CE Mark certification for its smooth implants with GMED and will continue to market the same in Europe We would like to remind investors that Allergan s breast implants generated sales of  314 4 million during the first nine months of 2018  an 8 3  increase year over year  The breast implants fall under the Medical Aesthetics products segment  which also includes Allergan s renowned products such as  Botox and Alloderm Approved for therapeutic and aesthetic use  Botox is a key top line driver for Allergan  Its cosmetic indication includes three facial aesthetic treatments  namely forehead lines  crow s feet wrinkles at the outer corner of eyes and the glabellar lines Botox s therapeutic diseases include overactive bladder  cervical dystonia and strabismus among others Botox grossed sales of  2 6 billion in the first nine months of 2018  reflecting a rise of 13  year over year  However  there have been concerns pertaining to the chronic migraine indication  regarding new competitors of Botox with the entry of calcitonin gene related peptide  CGRP  antibodies Notably  Novartis Amgen s   NASDAQ AMGN   CGRP antibody  Aimovig  Teva s   NYSE TEVA   Ajovy  fremanezumab  and Lilly s   NYSE LLY   Emgality  galcanezumab  were all approved by mid 2018 and was launched subsequently However  Allergan  on its third quarter investor conference call stated that introduction of the CGRPs should expand the migraine market and Botox plus the other CGRPs can coexist in the larger market Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/allergan-drops-stops-textured-breast-implant-sales-in-europe-200370081,200370081
105203,326718,AGN,Pharma Stock Roundup  GSK  PFE Ink Consumer Health JV  JNJ Hit By Talc Allegations,opinion,"The pharma sector witnessed heightened activity this week  Glaxo   NYSE GSK   and Pfizer   NYSE PFE   agreed to merge their consumer healthcare units into a new joint venture   JV    A Reuters article about J J s   NYSE JNJ   talc baby powders hit its stock hard  While Merck   NYSE MRK   and AstraZeneca   NYSE AZN   gained line extension approvals for their key cancer drugs  Lilly   NYSE LLY    Merck and Bristol Myers   NYSE BMY   announced collaboration partnership deals  Lilly also issued an upbeat guidance for the upcoming year Recap of the Week s Most Important StoriesGlaxo   Pfizer to Merge Consumer Health Units  Glaxo and Pfizer agreed to into a new joint venture  JV  with almost  13 billion in annual sales  While Glaxo will command a controlling stake of 68  in the JV  Pfizer will own 32   Glaxo  within three years of transaction closing  plans to spin off the JV as an independent company via a demerger of its equity interest  This means eventually Glaxo will split into two UK based global companies with one dealing in prescription drugs and vaccines  and the other focused on over the counter  OTC  drugs  The merger will create the world s largest consumer healthcare business with a market share of 7 3   creating substantial shareholder value  While the Consumer Healthcare unit separation will allow Glaxo to focus on its pharmaceuticals business  it will resolve a long pending issue for Pfizer  Pfizer had been exploring strategic options for its Consumer Healthcare unit since October 2017 but was facing trouble finding a buyer for the same J J Stock Hit Hard by Asbestos Allegations  A Reuters report stated that that its baby powders contained asbestos  which hit its stock hard  J J has more than 11 000 cases pending related to its baby powders containing talc in the United States   Most of these lawsuits allege that its talc based products  including its baby powders contain asbestos  which causes its users to develop ovarian cancer  J J issued a statement where it called the reports by Reuters  one sided  false  and inflammatory   J J said that independent tests by regulators  academic institutions and leading labs have proven that its talc based products never contained asbestos This week J J also lost its motion in a Missouri trial court to overturn the verdict given by a St Louis jury in July to pay approximately  4 7 billion to 22 women in a talc lawsuitJ J s board of directors authorized a share buyback plan worth  5 billion and maintained its previously issued guidance for 2018 Lilly Gives Upbeat 2019 Financial Guidance   At an investor meeting  Lilly provided its   indicating another strong year for the company  Lilly expects revenues to be between  25 3 billion and  25 8 billion in 2019  representing mid single digit growth  driven by higher demand for its newer medicines including the newly launched migraine drug  Emgality  Earnings per share are expected to be in the range of  5 90 to  6 00 Lilly s revenue and earnings guidance range for 2019 was above market expectations as well as the Zacks Consensus Estimate  Lilly raised its long term revenue growth expectations as well as its quarterly dividend by 15  Lilly s  in a head to head phase IIb IV study  SPIRIT H2H  on patients with active psoriatic arthritis  PsA   In the study  Taltz demonstrated superiority in improving signs and symptoms of PsA while also providing skin clearance  Taltz was launched for the psoriatic arthritis indication in the United States last December and across some EU countries in 2018 Lilly also announced a deal to acquire   a TRPA1 antagonist  from a private biotech  Hydra Biosciences  The TRPA1 antagonist is being studied for the potential treatment of chronic pain syndromes  Financial terms of this agreement were not disclosed Lilly also announced an to gain access to the latter s novel molecules that are designed to inhibit the cGAS STING pathway  The companies will jointly develop these molecules into new immunotherapies for autoimmune and other inflammatory diseases  Lilly will make an upfront payment of  12 million to Aduro Merck to Buy France s Antelliq  Keytruda in Focus  Merck announced plans to from BC Partners  Merck will pay 2 1 billion euros  around  2 4 billion  in cash to acquire all outstanding shares of Antelliq and will assume the latter s debt of 1 15 billion euros  Europe s Antelliq will complement Merck s Animal Health portfolio of vaccines and pharmaceuticals with its market leading digital products and services  which can better manage health and well being of livestock and companion animals Merck gained two label expansion approvals for its blockbuster PD 1 inhibitor Keytruda this week  The FDA approved Keytruda for adult and pediatric patients with recurrent locally advanced or   a rare form of skin cancer The second approval was in EU for the treatment of   The drug is already approved in the EU as a monotherapy for the treatment of adult patients with advanced melanoma  The approval in the adjuvant setting will help Merck to gain access to a broader melanoma patient population Meanwhile  the FDA delayed its decision on a Keytruda supplemental new drug application  sNDA  by three months  The sNDA was looking to expand the label of Keytruda for patients with locally advanced or metastatic nonsquamous or squamous NSCLC whose tumors express PD L1 protein levels of 1 percent or greater  TPS of  1 percent   The FDA decision previously expected on Jan 11  2019 will now come by Apr 11  2019  The sNDA was based on overall survival data from the pivotal phase III KEYNOTE 042 study Allegan Stops Sales of Textured Breast Implants in Europe  Allergan  NYSE AGN  announced that it is  of textured breast implants in the European market reportedly due to a cancer risk  The action was taken following CE Mark expiration and compulsory recall request by a French regulatory authority  The French regulator said in a statement that it had not identified any immediate risk for women using these implants AstraZeneca s Lynparza Gets FDA Nod in 1st Line Maintenance Setting  AstraZeneca   Merck s advanced ovarian cancer drugin the first line maintenance setting  With the approval  Lynparza becomes the first PARP inhibitor approved as a first line maintenance therapy for BRCA mutated advanced ovarian cancer  With approvalfor expanded use in the first line setting  sales of Lynparza can improve in the future quarters This approval was based on positive data from the phase III SOLO 1 study Meanwhile  Lynparza met the primary endpoint of objective response rate  ORR  in a phase III study  SOLO 3   which evaluated the drug for the treatment of relapsed BRCA mutated advanced ovarian cancer who had two or more prior lines of chemotherapy  Data from the study demonstrated that treatment with Lynparza led to a statistically significant and clinically meaningful improvement in ORR as well as the key secondary endpoint of progression free survival  PFS  compared to chemotherapy in such patients AstraZeneca s two other late stage studies   OLYMPUS and ROCKIES   evaluating pipeline candidate  roxadustat in chronic kidney disease patients with anaemia  met their primary endpoints  Roxadustat was approved in China   its first regulatory approval   for the treatment of anemia in chronic kidney disease patients on dialysis AbbVie  NYSE ABBV  Files for Upadacitinib in U S  and EU   AbbVie submitted regulatory applications forits investigational JAK1 inhibitor  upadacitiniblooking for approval of the candidate for thetreatment of adults with moderate to severe rheumatoid arthritis  RA   The regulatory filings are based on the SELECT phase III program  which evaluated more than 4 000 patients with RA  Meanwhile  upadacitinib is alsobeing evaluated in late stage studies for Crohn s disease  psoriatic arthritis  ulcerative colitis and atopic dermatitis Approval and successful commercialization of upadacitinib is critical for long term growth at AbbVie  especially as biosimilar competition looms on its blockbuster RA drug  Humira Novartis Offers to Buy French CAR T Therapy Manufacturer  Novartis announced an offer to acquire CellforCure  a French contract development and manufacturing organizations  CDMO  producing cell and gene therapies in Europe  Financial details of the offer were not disclosed Novartis already has an agreement with CellforCure for contract manufacturing of Novartis leading CAR T cell therapy  Kymriah  If the acquisition gets through  it will expand Novartis  cell and gene manufacturing capacity Pfizer Provides Updates on Some Vaccine   Cancer Products   Pfizer announced that it is discontinuing a mid stage study on its staphylococcus aureus vaccine on recommendation of the Independent Data Monitoring Committee  following a planned interim analysis  The committee said that there was low statistical probability for the study to meet the pre defined primary efficacy objective Pfizer and partner Astellas announced positive top line data from a late stage ARCHES study  which evaluated Xtandi in men with metastatic hormone sensitive prostate cancer  mHSPC   The results demonstrate a statistically significant improvement in a key marker of disease progression   radiographic progression free survival in such patients  Xtandi is already approved to treat both metastatic and non metastatic castration resistant prostate cancer  CRPC    If data from ARCHES is approved to be included in the label of Xtandi  it can treat a broader prostate cancer patient population Pfizer gained from the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  for its biosimilar version of Roche s cancer drug Avastin  Pfizer will market the biosimilar by the trade name of Zirabev Pfizer also announced the initiation of a phase III study for its 20 Valent pneumococcal conjugate vaccine candidate  PF 06482077  for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older Bristol Myers to Sell Consumer Health Unit for  1 6B  Bristol Myers received an offer from Japan s OTC drugmaker Taisho Pharmaceutical Holdings for  1 6 billion  The UPSA business no longer fits in Bristol Myers  core focus area of drugs  and hence the company has decided to divest the same  The company has been looking for potential sale options for the business since June 2018 Bristol Myers gained CHMP nod for use of its drug  with newly diagnosed Philadelphia chromosome positive acute lymphob  lastic leukemia  The positive recommendation is for both the tablet form of Sprycel as well as the powder for oral suspension formulation  which were approved for adult patients in July this year Bristol Myers announced a multi year research collaboration with Japan s Eisai and U S  based precision medicine research   development subsidiary H3 Biomedicine to develop novel immune therapies leveraging H3 s RNA Splicing platform The NYSE ARCA Pharmaceutical Index declined 6 7  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
  

 Here is how the seven major stocks performed in the last five trading sessions 
  All the stocks were in the red in the last five trading sessions  While J J declined the most  13 2    Glaxo recorded minimum decline  0 1   In the past six months  Lilly has been the biggest gainer  27 2   while Bristol Myers declined the most  9 1    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-gsk-pfe-ink-consumer-health-jv-jnj-hit-by-talc-allegations-200370280,200370280
105204,326719,AGN,Why Allergan  AGN  Could Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Allergan  NYSE AGN   which belongs to the Zacks Medical   Generic Drugs industry 
This Botox maker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 6 50  
For the most recent quarter  Allergan was expected to post earnings of  4 01 per share  but it reported  4 25 per share instead  representing a surprise of 5 99   For the previous quarter  the consensus estimate was  4 13 per share  while it actually produced  4 42 per share  a surprise of 7 02  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Allergan lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Allergan has an Earnings ESP of  1 28  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  4  Sell   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on January 29  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/why-allergan-agn-could-beat-earnings-estimates-again-200372966,200372966
105205,326720,AGN,Ironwood To Get New CEO  Current CEO To Head Latest Spinoff,opinion,"Ironwood Pharmaceuticals  Inc  s   NASDAQ IRWD   board announced the appointment of chief executive officers   CEO   for the two new companies that will emerge following the planned separation of the erstwhile Ironwood Pharma In a bid to achieve increased operational performance and strategic flexibility  Ironwood Pharma remains on track to spinoff into two separate entities  The entity focused on Linzess and gastrointestinal   GI   pipeline development will retain the current name of the company  Meanwhile  the other entity will focus on the development of the soluble guanylate cyclase  sGC  pipeline for the treatment of serious and orphan diseases and will be named Cyclerion  The transaction is expected to close in the first half of 2019  The separation of the entities is also being anticipated to be tax free For the new Ironwood  the company s board has appointed Mark Mellon as the CEO  Mellon has extensive experience in building and shaping businesses as well as a deep knowledge of GI gained during his 24 years of service at pharma giant  AstraZeneca   NYSE AZN    in several leading positions  Meanwhile  Peter Hecht  the current CEO of Ironwood Pharma is set to lead the new company   Cyclerion Following the news  shares of Ironwood increased 11 3  on Jan 4  However  the stock has lost 45 6  in the past six months compared with the  s 15  decline The new Ironwood Pharma will have one marketed product in its portfolio  Linzess  linaclotide   The drug is approved for irritable bowel syndrome   IBS   with constipation and chronic idiopathic constipation  It is commercialized in collaboration with Allergan   NYSE AGN   and has witnessed solid sales in the first nine months of 2019  generating over half a billion dollars in revenues  The company is also developing Linzess for label expansion in several IBS indications  Additionally  it is developing MD 7246  a delayed release version of linaclotide  for all subtypes of IBS The company will also have another GI candidate  IW 3718  in its pipeline  Currently  it is being developed for treating persistent gastroesophageal reflux disease in a phase III study and targets a patient population of approximately 10 million  Under the able leadership of Mellon  who has successfully launched and helped grow several GI drugs at AstraZeneca  Ironwood Pharma is expected to sail smoothly with its approved and pipeline drugs Furthermore  Ironwood Pharma appointed Michael Shetzline as chief medical officer  senior vice president and head of drug development for the GI focused entity to strengthen its management team for GI pipeline  Shetzline has a proven track record across many areas of GI science and served as vice president and head of gastroenterology clinical sciences at Takeda Pharmaceuticals   NYSE TAK    He will join Ironwood on Jan 28  2019 Moreover  Cyclerion holds potential with two prospective sGC pipeline candidates   praliciguat and olinciguat  Both the candidates are in mid stage of development  While praliciguat enjoys Fast Track designation for diabetic nephropathy and heart failure with preserved ejection fraction  HFpEF   olinciguat was granted Orphan drug status for sickle cell disease in 2018 We expect the spinoff to be favorable for Ironwood Pharma as it will help the company to focus on its already successful GI portfolio  Cyclerion  if successful  will allow the company to look for a potential bidder for the sale of the business without affecting the GI business Ironwood Pharmaceuticals  Inc  Price
    Zacks RankIronwood currently carries a Zacks Rank  3  Hold   You can see  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff-200373284,200373284
105224,326739,AGN,FT  Paratek Pharma in play  Shares jump nearly 7 ,news,Usually knowledgeable sources are convinced Paratek  PRTK  6 6   partner Allergan  NYSE AGN  has already put terms of an offer together  writes Paul Murphy at FT Alphaville The two are already working together on an acne treatment  and with a current market cap in the area of  560M  Paratek would be easily swallowed by the  82B Allergan Now read  Synergy Pharmaceuticals  Where To Next ,2017-05-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/ft:-paratek-pharma-in-play -shares-jump-nearly-7-480278,480278
105225,326740,AGN,Allergan Q1 earnings beat estimates ,news,Investing com    NYSE Allergan  first quarter earnings beat estimates The pharmaceutical reported diluted Q1 EPS of  3 35 v s estimate of  3 29 and  2 99 a year earlier Revenues of the maker of Botox rose 5  from a year earlier to  3 6 bn vs  estimate of  3 53 bn Its guidance for full year 2017 is diluted EPS within a range of  15 85  16 35,2017-05-09,Investing.com,https://www.investing.com/news/stock-market-news/allergan-q1-earnings-beat-estimates-481639,481639
105226,326741,AGN,Allergan Q1 revenues up 5   earnings down 1 516   cash flow down 42   non GAAP earning guidance raised,news,Allergan  NYSE AGN  Q1 results   M   Total Revenues  3 572 9   5 1    U S  Specialized Therapeutics  1 482 0   14 1    U S  General Medicine  1 345 8   7 4    International  737 3   9 5   U S  Specialized Therapeutics  Eye Care  553 1   3 8    Total Medical Aesthetics  490 1   31 1    Neuroscience   Urology  334 7   9 1   U S  General Medicine  Gastrointestinal  387 5   4 0    Central Nervous System  309 1   3 9    Diversified Brands  299 0   27 3    Women s Health  244 7   7 2   Net Income   2 634 8    999    Non GAAP Net Income  1 195 8   4 3    EPS   7 86    999    Non GAAP EPS  3 35   12 0    CF Ops  723 3   42 3   2017 Guidance  Revenues   15 8B   16 0B from  15 5B   15 8B  EPS    10 20   9 70  from   1 80   1 30   Non GAAP EPS   15 85   16 35 from  15 80   16 30 Shares are up a fraction premarket on light volume Now read ,2017-05-09,Seeking Alpha,"https://www.investing.com/news/stock-market-news/allergan-q1-revenues-up-5;-earnings-down-1,516;-cash-flow-down-42;-non-gaap-earning-guidance-raised-481672",481672
105227,326742,AGN,Sanofi pegs U S  drug price rises to below healthcare inflation,news,"By Ben Hirschler  Reuters    French drugmaker Sanofi  PA SASY  has pledged to peg U S  drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5 4 percent  unless there are exceptional circumstances  The price promise goes one step beyond action taken by a number of other large pharmaceutical companies that have undertaken to keep price increases in 2017 below 10 percent  Drugmakers are under fire worldwide over prices  which have been fueled in recent years by a wave of new treatments for cancer and other serious conditions  some costing tens or hundreds of thousands of dollars per patient  The row is particularly fierce in the United States  where prices are higher than in Europe  A complex U S  supply chain has led to a blame game between drugmakers  health insurers and intermediaries known as pharmacy benefit managers   This complexity is undermining the reputation of an entire industry whose purpose is to make a positive change in patients  lives   Sanofi Chief Executive Olivier Brandicourt said in a statement on the group s website announcing the pricing policy  Sanofi will take as its pricing benchmark the national health expenditures  NHE  growth projection  which is calculated by the Department of Health and Human Services and covers spending by all U S  payers  including individuals   By limiting our price increases to the NHE growth projection  we ensure that Sanofi is not contributing to further medical inflation   Brandicourt said  This would cap price increases for any product to 5 4 percent in 2017  but Sanofi said there might be times when there was a  sound reason  for a higher increase  in which case it promised to demonstrate publicly the rationale for such a rise  Sanofi also said it would disclose the gross and net prices for its medicines in future  adding that in 2016 its average aggregate list prices increased by 4 0 percent but net prices fell by 2 1 percent   The company is being hit hard by competition in its core diabetes treatment business  which is driving down prices  
Responding to criticism about high drug prices  other firms such as AbbVie  N ABBV   Allergan  N AGN  and Danish diabetes specialist  Novo Nordisk   CO NOVOb  have promised to keep all drug price increases in 2017 under 10 percent ",2017-05-09,Reuters,https://www.investing.com/news/stock-market-news/sanofi-pegs-u.s.-drug-price-rises-to-below-healthcare-inflation-481722,481722
105228,326743,AGN,Allergan posts loss as it writes down Teva holdings,news,"By Michael Erman and Natalie Grover  Reuters    Botox maker Allergan Plc  N AGN  posted a first quarter loss on Tuesday as it took a nearly  2 billion write down on the value of its stake in Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA   which has lost more than 40 percent of its value since last year  Allergan sold its generics business  Actavis  to Teva in August 2016 for  33 billion in cash and 100 million shares of the Israeli generic drugmaker  worth around  5 3 billion at the time  Under the terms of the deal  Allergan agreed to hold on to the shares for at least one year  Teva has struggled since then  and the company s chief executive stepped down in February after sharp criticism for a string of costly acquisitions and delayed drug launches  Allergan said its net loss was  2 63 billion  or  7 86 per share  compared with a profit of  186 1 million  or 47 cents per share  a year earlier  Most of the loss was from the write down of the Teva stake  as well as research and development related costs  Allergan said it concluded that Teva s decline was not temporary and took the impairment  Allergan Chief Executive Officer Brent Saunders told an Israeli newspaper earlier this year that the company plans to sell the stake in cooperation with Teva after the lockup period ends  OPERATING EARNINGS BEAT ESTIMATES Excluding the write down and other costs  Allergan s earnings exceeded analyst expectations  It earned  3 35 per share in the quarter  beating the average analyst estimate by 5 cents  according to Thomson Reuters I B E S  Higher demand for its facial aesthetics  eye care and newer products  more than offset declining sales of older drugs  The company is armed with its top selling Botox drug  known for smoothing wrinkles  but it also had a busy deal making 2016  announcing at least a dozen deals  This past February  Allergan agreed to buy Zeltiq to gain access to a device which uses cooling to kill fat cells  adding to its line up of aesthetic products that are not dependent on reimbursement for sales  The company raised its forecast for 2017 slightly to reflect the Zeltiq deal  
Shares of the Dublin based company  which also posted first quarter revenue that edged past estimates  fell  1 51  or 0 6 percent  to  240 48 on the New York Stock Exchange on Tuesday afternoon ",2017-05-09,Reuters,https://www.investing.com/news/stock-market-news/allergan's-quarterly-revenue-rises-5.1-percent-481604,481604
105229,326744,AGN,Innovus Pharmaceuticals reports Q1 results,news,Innovus Pharmaceuticals  OTCQB INNV   Q1 EPS of   0 02Revenue of  2 18M   847 8  Y Y Press ReleaseNow read ,2017-05-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/innovus-pharmaceuticals-reports-q1-results-483862,483862
105230,326745,AGN,Options Traders Target Bigger Healthcare Gains,opinion,"AGN Is Trading Higher With Its Sector Peers
Healthcare stocks are trading higher today  extending an impressive run up the charts in recent months  At last check  the Health Care Select Sector SPDR ETF  NYSE XLV  is up 0 4  at  91 46    a chip shot away from its Jan  29 record high of  91 79  Options traders are responding in kind  with calls crossing the tape at four times what s typically seen at this point in the day 
By the numbers  14 400 XLV calls have been exchanged so far  with almost 71  of this volume centered at the September 93 strike  It looks like one trader in particular bought to open 9 159 contracts at 58 cents apiece  creating an initial cash outlay of  531 222  number of contracts   premium paid   100 shares per contract  
This is also the most the call buyer stands to lose if XLV settles below  93 at the close on Friday  Sept  21  when the front month options expire  Profit  meanwhile  will accumulate on a move north of breakeven at  93 58  strike plus premium paid     roughly 2 4  above the fund s current perch 
Additional upside would just mirror the exchange traded fund s longer term trajectory  with XLV up 16  since dipping below the round  80 in early April  Plus  in early July  the shares took out recent resistance in the  86 region  and are now trading above support at their rising 10 day moving average 

One XLV component getting in on today s healthcare rally is Allergan  NYSE AGN   with the shares up 2 8  to trade at  190 83  The stock has added almost 33  since its mid May lows near  143  but is running out of steam in the  190 neighborhood  which contained AGN s late January surge 
Nevertheless  Allergan call options are crossing at three times the expected intraday pace this afternoon  Speculative players appear to be buying to open the weekly 8 24 195 strike call  betting on a break out above  195 by expiration at this Friday s close ",2018-08-20,Schaeffer's Investment Research,https://www.investing.com/analysis/options-traders-target-bigger-healthcare-gains-200339612,200339612
105231,326746,AGN,How Teva Stopped Falling And What s To Come,opinion,"Teva Pharma Industries  NYSE TEVA  is finally roaring back  and it could still have a way to go before finding a new plateau  It may not regain its old highs for years  but the bloodletting appears to be over  A combination of new FDA approvals for key generics  a successful restructuring program so far  and renewed confidence from Warren Buffett and Berkshire Hathaway  NYSE BRKa  have catapulted shares from lows at  10 85 to now trade over  25 for gains of 133  since bottoming 
Why could there still be room to run before shares start leveling off  We have to look at why the stock cratered so hard in the first place  The selling I believe was not set off by any one specific development  but mostly had to do with bad timing as a confluence of bearish news and developments overlapped one another causing a wave of selling  with the final plunge aided by margin calls and capitulation 
As Teva began to fall in 2015 2016  the chief concern was patent expiration and subsequent generic competition against Copaxone  its flagship multiple sclerosis drug  which in 2016 accounted for 20  of the generic giant s revenue  In 2016  patents that would have protected Copaxone from competition into 2030 were invalidated  increasing investor anxiety and accelerating the stock s fall 
At the same time that these patents were being invalidated  Teva s acquisition of Allergan s  NYSE AGN  generics unit for  40 5 billion was closing  miring Teva in enormous debt  just around the same time that generics pricing in the United States was taking a dive  The acquisition began to look like a giant generic mistake and Teva began to take up a persona non grata status in portfolios  Then  in 2017  the final nail in the coffin of Copaxone patent protection was delivered  That s when the stock finally bottomed 
The situation Teva is now in is the inverse of what happened in 2015 2016  Any isolated piece of bad news would have damaged the stock  but that it all happened in succession is what really cratered the shares  Now  good news is piling on in succession as Teva rockets back up 
First  new CEO K re Schultz stepped in  whose biggest job was arguably to stand up to the political pressure against Teva s restructuring plan  which involved taking Israel s crown jewel corporation and axing factories and thousands of workers  As a non Israeli  Schultz had a better shot at standing firm than a native Israeli  and did just that and pushed the plan through 
Now that its expected blockbuster migraine drug fremanezumab is on the verge of reaching market with a PDUFA date next month  the FDA having just approved a generic version of the Epipen  in great demand in the U S  considering recent pricing controversies  and Warren Buffett upping his stake  broadcasting confidence to Wall Street  it looks like the precipitous decline is finally over 
Another factor that may be affecting sentiment positively is the Trump Administration s health care plans  which include among other things directives to the FDA for quicker approvals of generic drugs in order to get healthcare costs downs  This  on net  should help Teva in the face of falling generics prices  for which the price declines may be over now with inflation picking back up generally 
What about debt  Teva still has a lot to pay back  but the debt situation is far from critical  60  of Teva s now  28 4 billion in debt is not due until 2023 or later  98  of that debt load is fixed rate  meaning Teva is not exposed to a rising rate environment 
As for Copaxone  sales will continue to decline  but fremanezumab revenues will slowly but surely be taking its place 
Teva may have trouble growing organically over the next few years until it pays off much of the debt holding it down  but in order for the stock price to recover it doesn t really have to grow that quickly  It just has to show that the worst is over  that it is improving its balance sheet and that it has stopped hemorrhaging  This doesn t mean it will catapult to old highs  but even getting back to its 200 week moving average would mean a 60  gain from here 
While Teva may not be a growth stock for quite a while yet  it can easily be a capital growth stock in the medium term 
Disclosure  No positions",2018-08-21,Joshua Paul,https://www.investing.com/analysis/how-teva-stopped-falling-and-whats-to-come-200339873,200339873
105232,326747,AGN,Is A Beat In Store For Editas  EDIT  This Earnings Season ,opinion,We expect Editas Medicine  Inc    NASDAQ EDIT   to beat estimates when it reports third quarter 2018 results early next month However  the company s earnings history has been dismal so far  having missed expectations in three quarters and surpassed in one with an average miss of 4 28   Last reported quarter  Editas came up with a negative surprise of 18 84  Shares of Editas have lost 19 6  so far this year  narrower than the  decrease of 19 8  Let s see  how things are shaping up for this quarter to be reported Factors to ConsiderEditas Medicine is a development stage genome editing biotech  which makes medicines to treat serious diseases using its proprietary genome editing platform based on CRISPR technology  Its lead pipeline candidate is EDIT 101 that uses CRISPR gene editing to treat Leber congenital amaurosis type 10  LCA10    a rare genetic illness that causes blindness  An Investigational New Drug  IND  application to begin clinical studies for EDIT 101 was expected to be filed in October 2018  However  the company has made no such announcement yet  An update is expected on third quarter conference call Pre clinical data on EDIT 101 presented in May this year showed that it was well tolerated in a study of non human primates  NHPs  when administered through a subretinal injection  Productive editing was achieved in NHPs regardless of pre existing or induced immunity to either AAV or Staphylococcus aureus Cas9 Editas is also pursuing the development of CRISPR candidates for eye diseases other than LCA10 including Usher Syndrome type 2A  USH2A  and the recurrent ocular Herpes Simplex Virus type 1  HSV 1   Data from pre clinical studies on these diseases has been positive  Editas also has CRISPR drugs in the pipeline to treat cancer  muscular dystrophy  alpha   1 antitrypsin deficiency and cystic fibrosis Editas has a strategic alliance and an option agreement with Allergan   NYSE AGN    under which the latter reserves its rights to license up to five of Editas  genome editing ocular programs  In July  Allergan exercised its option to develop and commercialize EDIT 101 globally  While Editas exercised its right to a profit sharing arrangement with Allergan under which  it will co develop and equally share the profits and losses from EDIT 101 in the United States  Also  Editas has the right to choose for co developing and co marketing another eye disease program in the United States  Moreover  the company has a collaboration and licensing deal with Juno Therapeutics  now part of Celgene  NASDAQ CELG   to use gene editing approaches including CRISPR Cas9 for developing engineered T cell medicines to treat cancer We expect management to provide more updates and detailed information on its pre clinical studies during the upcoming conference call Why a Likely Positive Surprise Our proven model clearly indicates that Editas is likely to beat estimates this to be reported quarter because it has the right combination of the two key ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for a probable positive surpriseEarnings ESP  Editas has an Earnings ESP of  12 90   representing the difference between the Most Accurate Estimate  loss of 63 cents per share  and the Zacks Consensus Estimate  loss of 72 cents   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Editas currently has a Zacks Rank  3  which increases the predictive power of ESP  Therefore  this combination of a positive ESP with a top Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Editas Medicine  Inc  Price and EPS Surprise   Other Stocks to ConsiderHere are some other biotech stocks worth considering as per our model  these too have the right combination of elements to beat on earnings this reporting season CRISPR Therapeutics AG   NASDAQ CRSP   is expected to release third quarter results on Nov 14  The company has an Earnings ESP of  3 53  and a Zacks Rank of 1  You can see  Spero Therapeutics  Inc    NASDAQ SPRO   has an Earnings ESP of  18 43  and a Zacks Rank  2  The company is expected to report third quarter results on Dec 13 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-editas-edit-this-earnings-season-200352470,200352470
105233,326748,AGN,Teva  TEVA  Q3 Earnings Beat  2018 EPS View Up  Shares Rise,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   reported third quarter 2018 earnings of 68 cents per share  which beat the Zacks Consensus Estimate of 55 cents per share  However  earnings per share declined 32  year over year Revenues came in at  4 53 billion  which missed consensus estimates of  4 58 billion  Sales declined 19   down 18  in constant currency terms  year over year Sales continue to be hurt by rapid erosion in sales of Teva s key multiple sclerosis injection  Copaxone  pricing erosion in the U S  generics market  divestiture of some non core assets  and discontinued business activities  Additional competition for Teva s largest product  Concerta authorized generic also hurt sales in the quarter Also  negative currency impact due to the strengthening of the dollar hurt sales and earnings in the quarter Teva Pharmaceutical Industries Ltd  Price and Consensus
    Segment DiscussionAs announced in November last year  Teva no longer reports two separate global groups for its two businesses   generics and specialty medicines  Instead  it reports under new segments based on three regions   North America  United States and Canada   Europe and International Markets North America segment sales were  2 27 billion  down 26  year over year due to pricing erosion in U S  generics market  lower sales of Copaxone as well as some other branded drugs and divestiture of some non core assets in the Women s Health business  In the United States  revenues declined 27  to  2 1 billion Copaxone posted sales of  463 million in North America  down 43  year over year due to generic competition for the 20 mg as well as the 40 mg formulation  In the United States  Copaxone recorded sales of  446 million Sales of other branded products Bendeka  Treanda  ProAir and Qvar all declined in the quarter The newest product in Teva s branded portfolio  Austedo  recorded sales of  62 million in the quarter in North America compared with  44 million in the previous quarter  Teva expects Austedo to record  200 million in revenues in 2018 In September  Teva gained FDA approval and immediately launched its anti calcitonin gene related peptide   CGRP   injection  Ajovy  fremanezumab  as a preventive treatment for migraine  Teva said it is seeing signs of a strong launch for Ajovy  An approval in Europe is expected in the first half of 2019 Please note that Amgen   NASDAQ AMGN   and Lilly s   NYSE LLY   CGRPs  Aimovig and Emgality were also approved this year Generic products revenues declined 25  to  922 million in the quarter due to price erosion in the U S business and increased competition for Concerta authorized generic However  on the call  the company said it is seeing signs of stabilization in U S  generic drug pricing  The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third quarter from second quarter levels due to optimization of its generics product portfolio as well as product launches  Teva  currently  commands 14  share of the U S  generic market Distribution revenues  which are generated by Anda  acquired from Allergan   NYSE AGN   in 2016  rose 13  in the quarter to  333 million The Europe segment recorded revenues of  1 21 billion  down 12   down 11  in constant currency terms  year over year due to loss of revenues from the closure of a distribution business in Hungary  divestiture of the women s health business and lower Copaxone revenues  which offset the positive impact of generic launches Generic products  including OTC products  revenues in Europe declined 3   1  on a constant currency basis  to  845 million due to lost revenues as a result of the termination of partnership with P G   PGT Healthcare  in July and price reductionsCopaxone sales declined 16  on a constant currency basis to  124 million due to price reductions  following the entry of generics Respiratory products sales in Europe segment rose 3   up 4  on a constant currency basis  to  93 million mainly due to the launch of Braltus in 2017 In the International Markets segment  sales declined 18  year over year to  726 million  However  in constant currency terms  sales declined 12  in this segment due to lower sales in Japan and Russia  the effect of the deconsolidation of subsidiaries in Venezuela and loss of revenues from the sale of the women s health business in these countries Generic products  including OTC  revenues declined 15  in constant currency terms to  498 million  Copaxone sales declined 2  to  14 million  Distribution revenues increased 4  in constant currency terms to  149 million in the quarterThe Other segment  API manufacturing business and certain contract manufacturing services  recorded revenues of  326 million  up 7  year over year  in constant currency terms due to improved API sales to third parties Profits DeclineAdjusted gross margin contracted 220 basis points  bps  to 50 9  in the quarter due to price impacts on Copaxone and Generics in the United States  However  gross margins slightly improved on a sequential basis Adjusted research   development expenses declined 33 8  from the year ago period to  243 million due to pipeline optimization  concluded phase III studies and resultant workforce reductions  Selling and marketing  S M  expenditure declined 14  from the year ago level to  678 million due to cost cutting and re structuring activities  Adjusted operating margin declined 180 bps to 24 4  in the quarter despite lower costs 2018 Earnings Outlook UppedTeva slightly raised the lower end of its full year sales guidance  However  it significantly raised its earnings guidance  following solid third quarter results and accelerated cost savings  The company also upped its free cash flow guidance The revenue guidance was tightened from a range of  18 5    19 0 billion to  18 6    19 0 billion  Meanwhile  the earnings guidance was raised from a band of  2 55 2 80 per share to  2 80 2 95 per share  Free cash flow guidance was raised to  3 6 3 8 billion from  3 2 3 4 billion Our TakeTeva s third quarter results were mixed as it beat expectations for earnings but missed the same for sales  However  the stock rose more than 15  in pre market trading on Thursday  as the company raised its earnings guidance significantly  which probably increased investors  hope of a possible turnaround  Importantly  the world s largest generic drugmaker s comments about stabilization of its U S  generics business was a boost Teva s shares have risen 21 4  this year so far against the  s decrease of 11 1    Teva is facing significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business and a massive debt load stemming from its 2016 acquisition of Allergan s generics business However  Teva has a new organizational structure in place  is closing plants  cutting down its generics portfolio  divesting non core assets  eliminating low value R D projects  and is reducing global workforce to revive growth  Teva is on track to meet its goal to save  3 billion by the end of 2019 from these initiatives with  1 8 billion already achieved in 2018 so far Its financial position seems more stable than before as it is regularly paying down debt  Its newest drugs  Austedo and Ajovy  could emerge as significant contributors to long term sales growth Currently  Teva has a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q3-earnings-beat-2018-eps-view-up-shares-rise-200354089,200354089
105234,326749,AGN,Drug Stocks To Post Earnings On Nov 5  MYL  NBIX  RARE  TARO,opinion,The drug biotech sector s performance in the third quarter reporting cycle so far has been mixed  While many bigwigs beat estimates for earnings  sales either missed estimates or remained in line  While most companies raised their earnings growth expectations  not many have increased their sales guidance According to the latest   for the Medical sector  76 7  of the sector s total market cap in the S P 500 index has released Q3 results  Total earnings for these Medical companies are up 11  from the year ago quarter on 7 2  increase in revenues  with 82 9  beating EPS estimates and 57 1  beating revenue estimates A few drug makers reported third quarter results last week  Pfizer   NYSE PFE   beat estimates for earnings  while recording in line sales  The company narrowed its earnings and sales expectations for the full year  Pfizer attributed the lowered sales outlook to weaker than expected revenues in the Essential Health segment due to continued shortages in the sterile injections business and currency headwinds Allergan   NYSE AGN   and Amgen   NASDAQ AMGN   delivered solid performance in the third quarter  beating estimates for both earnings and sales  while also raising their full year guidance  Sanofi   NYSE SNY   and Glaxo  GSK   both beat estimates for earnings and sales in the third quarter  Meanwhile  both the companies raised the lower end of their full year earnings growth guidance Here we have four pharma biotech companies  which are scheduled to release earnings on Nov 5  While Mylan  Neurocrine and Ultragenyx will release their third quarter 2018 results  Taro will release fiscal second qaurter results for the quarter ended Sep 30  2018  Let s see how things are shaping up for these announcements Mylan N V     NASDAQ MYL   The company s performance has been dismal so far  having missed earnings estimates in three of the last four quarters  The company reported average negative earnings surprise of 6 12  over the said time frame  In the last reported quarter  the company missed earnings estimates by 13 01  Mylan s stock has lost 23 3  in the year so far compared with the  decline of 5 9  Our proven model doesn t show that Mylan is likely to beat estimates this quarter  This is because the company has a Zacks Rank  3  Hold  and an Earnings ESP of  1 12   The Zacks Consensus Estimate for earnings in the third quarter is pegged at  1 17 per share  You can see  Concurrent with second quarter results  Mylan lowered its annual outlook as a result of the change in expected product launches and resizing of product opportunities in the United States  The restructuring in Morgantown also impacted guidance Mylan expects 2018 total revenues of  11 25  12 25 billion  down from the previous projection of  11 75  13 25 billion  The company anticipates adjusted earnings per share around  4 55  4 90  down from the earlier estimate of  5 20  5 60 While Mylan has one of the largest product portfolios among all generic pharmaceutical companies  the company has suffered a few setbacks in recent times  Mylan recently suffered a major setback as rival Teva Pharmaceutical Industries Ltd   NYSE TEVA  won the FDA approval for the first generic version of the former s EpiPen and EpiPen Jr  epinephrine  auto injector for the emergency treatment of allergic reactions  including those that are life threatening  anaphylaxis   in adults and pediatric patients   Read more   Neurocrine Biosciences  Inc    NASDAQ NBIX  In the last reported quarter  the company s earnings surpassed the Zacks Consensus Estimate by 61 11   However  Neurocrine s track record is mixed as it has topped estimates in two of the last four quarters  the average positive earnings surprise being 4 88  Neurocrine s shares have outperformed the industry so far this year  The stock has gained 44 9   against the  s decline of 3 9  Our proven model does not conclusively show an earnings beat for Neurocrine in the to be reported quarter  This is because the company has a Zacks Rank  3 and an Earnings ESP of  0 42   The Zacks Consensus Estimate for the third quarter is pegged at 48 cents per share Neurocrine is making great progress with the continued adoption of its lead drug Ingrezza  valbenazine  by physicians and patients for the treatment of adults with tardive dyskinesia  This trend is expected to continue in the third quarter   Ingrezza is also being evaluated in a phase IIb study in pediatric patients with Tourette syndrome  Top line data from this study are expected in late 2018 Orilissa  elagolix   being developed by the company in partnership with AbbVie  NYSE ABBV   was approved by the FDA in July 2018 to treat endometriosis pain in women  The drug will report sales for the first time in the third quarter The company s pipeline candidates include opicapone  being developed as an adjunctive therapy to levodopa DOPA decarboxylase inhibitors in Parkinson s disease patients  and Orilissa  elagolix  for uterine fibroidsand NBI 74788 for the treatment of congenital adrenal hyperplasia  CAH  The company is expected to provide updates on its pipeline candidates in the third quarter   Read more   Ultragenyx Pharmaceutical Inc    NASDAQ RARE  The biotechnology company s earnings surpassed the Zacks Consensus Estimate by 10 95   However  Ultragenyx s track record is mixed as it has topped estimates in two of the last four quarters and met in one  The average positive earnings surprise is 50 20  For this quarter  Ultragenyx has an of  0 43  and a Zacks Rank  3  indicating a likely positive surprise  The Zacks Consensus Estimate is pegged at a loss of  1 94 per share  You can uncover the best stocks to buy or sell before they re reported with our  Ultragenyx s revenues comprise only collaboration license revenues  and profit sharing and royalty revenues for its newly launched drug Crysvita  which was launched in the United States in April and in the EU in February  Meanwhile  Ultragenyx s product sales comprise only nominal sales for Crysvita in other regions and some from Mepsevii  Hence  investors  focus during the third quarter call will be on Ultragenyx s update The company has a number of products in its pipeline  It is also looking to expand the label of its lead drug  Crysvita  Crysvita is also being developed for the treatment of tumor induced osteomalacia  TIO    The 48 week data from the phase II TIO study are expected to be announced this year The company is expected to provide updates on its pipeline candidates during the third quarter conference call A lead pipeline candidate is synthetic triglyceride UX007  which is currently in a phase II study for the treatment of long chain fatty acid oxidation disorders  LC FAOD   In August 2018  the FDA accepted its most recent proposal to submit a new drug application  NDA  for UX007 based on existing data  The company expects to provide more details on timing  following a pre NDA meeting that is scheduled later in 2018  Ultragenyx s shares have increased 16 8  year to date against the  s decline of 16 2  Taro Pharmaceutical Industries Ltd    NYSE TARO  The company s earnings missed the Zacks Consensus Estimate by 26 61  in the last reported quarter  However  Taro s track record is mixed as it topped estimates in one of the last four quarters  the average positive earnings surprise being 8 55  The company has an Earnings ESP of 0 00  and a Zacks Rank  3  The Zacks Consensus Estimate for earnings is pegged at  1 96 per share Taro s shares have decreased 4 8  year to date compared with the  s decline of 3 9  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/drug-stocks-to-post-earnings-on-nov-5-myl-nbix-rare-taro-200354111,200354111
105235,326750,AGN,Pharma Stock Roundup  PFE  AGN Q3 Earnings  LLY  NVS Collaboration Deals In Focus,opinion,"It was another busy week for the pharma sector  marked by earnings of bigwigs like Pfizer   NYSE PFE    Allergan   NYSE AGN    Sanofi   NYSE SNY   and Glaxo   NYSE GSK    Merck   NYSE MRK   and AbbVie   NYSE ABBV   gained regulatory approvals for label expansion of their key cancer drugs  Eli Lilly   NYSE LLY    Pfizer and Sanofi announced collaboration deals Recap of the Week s Most Important StoriesEarnings  Pfizer while recording in line sales  The company narrowed its earnings as well as sales expectations for the full year  Pfizer attributed the lowered sales guidance to weaker than expected revenues in the Essential Health segment as a result of continued shortages in the sterile injections business  and currency headwinds Allergan delivered  in the third quarter  beating estimates for both earnings and sales while also raising its full year expectations  However  revenues declined year over year as some of its key blockbuster drugs lost exclusivity and are facing generic competition Sanofi and Glaxo beat estimates for earnings as well as sales in the third quarter  Both the companies raised the lower end of their full year earnings growth guidance Collaboration Divestiture Announcements  Lilly signed a deal with Dicerna Pharmaceuticals to help develop new medicines for the treatment of cardio metabolic  neurodegeneration disorders and pain using the latter s proprietary RNAi technology platform  RNAi is an emerging  technology for drug discovery attracting the attention of big drugmakers Per the deal  Lilly will make an upfront payment of  100 million to Dicerna as well as invest  100 million in the latter s stock  In addition  Dicerna is eligible to receive up to approximately  350 million for each development target and also commercialization milestones and royalties Two big drug giants  Pfizer and Novartis  came together to research on combination therapies of their early stage investigational candidates for the treatment of non alcoholic steatohepatitis  NASH   a fatty liver disease with no approved treatments at present  Pfizer has three candidates in clinical development with several others in pre clinical stage for NASH  Per the deal  one or more of Pfizer s three early stage candidates will be studied in combination with Novartis s tropifexor targeting different pathways in NASH Sanofi said it plans to collaborate with Denali Therapeutics to develop multiple molecules  which have the potential to treat neurologic and inflammatory diseases like multiple sclerosis  MS   amyotrophic lateral sclerosis  ALS   Alzheimer s disease  and systemic inflammatory diseases  For the deal  Sanofi will pay  125 million upfront payment and Denali Therapeutics will also be entitled to future milestone payments that could amount to more than  1 billion AstraZeneca announced an agreement to divest European rights to its acid reflux medicine  Nexium and worldwide rights  excluding the US and Japan  to arthritis pain reliever  Vimovo to Gr nenthal  The divestiture will allow AstraZeneca to focus on its core areas of Oncology  Cardiovascular  Renal   Metabolism and Respiratory  For the purchase  Gr nenthal will make upfront payments of  700 million and  150 million for Nexium and Vimovo  respectively  AstraZeneca will also be entitled to future milestones and sales related payments of up to  107 million  AstraZeneca will continue to market Nexium in markets outside EU Merck s Keytruda Gets FDA Nod for Difficult Lung Cancer  Merck received FDA approval for the label expansion of its blockbuster PD 1 inhibitor  Keytruda  in combination with chemotherapy  for first line treatment of metastatic squamous NSCLC   a difficult to treat lung cancer patient population  The supplemental biologics license application  sBLA  filing was based on data from the KEYNOTE 407 study We remind investors that data presented from this study stole the limelight at the annual meeting of the American Society of Clinical Oncology in June  Data from the study showed that the combination of Keytruda plus chemotherapy led to significant improvement in both overall survival  OS  and progression free survival regardless of tumor PD L1 expression status  The approval further strengthens Keytruda s position in the lung cancer market AbbVie Gets EU Approval for Venclexta and Rituxan Combo  AbbVie received European Commission s  EC  marketing approval for use of Venclexta in combination with Roche s MabThera  rituximab  for the treatment of patients with relapsed refractory chronic lymphocytic leukemia   CLL   who have received at least one prior therapy  Regulatory applications seeking approval for the combination use in this broader patient population were approved in the United States in June Label expansion for this indication should expand the patient population for Venclexta significantly and boost its commercial potential  The approval was based on positive data from the phase III MURANO study  which showed that the combination led to a profound improvement in progression free survival compared to Treanda plus Rituxan AbbVie also announced that a phase III study evaluating a Venclexta combo met the primary endpoint  The study  CLL14  was evaluating a combination of Venclexta plus Roche s Gazyva  obinutuzumab  as a first line therapy with a fixed duration of treatment in patients with chronic lymphocytic leukemia versus standard of care Gazyva plus chlorambucil   Data from the study demonstrated that patients in the Venclexta arm had superior progression free survival  PFS  compared to those in the standard of care arm  AbbVie is optimistic that the data may serve as the basis to expand into first line setting District Court Invalidates J J s Zytiga Patent  A New Jersey district court invalidated J J s patent  patent  438  related to Zytiga  opening the doors for generic launches  However  the court prohibited commercial launches of generic products before Oct 31  J J  NYSE JNJ  said it will appeal the court s decision  Several generic companies are looking to bring generic versions of 250 mg and or 500 mg tablets of Zytiga In a separate development  J J received FDA approval for the inclusion of cardiovascular outcomes data from the CANVAS program on the label of its diabetes drug  Invokana  This means the drug can be prescribed to reduce the risk of cardiovascular events like heart attack  stroke or cardiovascular death in adults with type II diabetes and established cardiovascular disease  The filing was based on data from a large CANVAS outcomes program  However  the label will include a warning about an increased risk of amputations  A similar label update was approved in the EU in September Glaxo Presents New HIV Data  Glaxo s HIV company  ViiV Healthcare announced 160 week data from the LATTE 2 phase IIb study evaluating the efficacy of a long lasting HIV injection in ART na ve HIV patients  Data from the study showed that the long acting  two drug  injectable regimen of cabotegravir and rilpivirine led to high rates of virologic response  long term durability of virologic response and good overall tolerability  In the study  the patients were administered cabotegravir rilpivirine either every eight weeks or every four weeks Glaxo also announced positive headline 48 week results from another study  FLAIR  evaluating the once monthly dose of the long lasting HIV injection  The study met the primary endpoint  showing similar efficacy of the once monthly regimen as a daily  oral three drug HIV pill in virally suppressed adults Glaxo is developing the long acting injectable dosing regimen to reduce the patients  number of annual doses from 365 to 12 The NYSE ARCA Pharmaceutical Index rose 2 2   in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
  

Here is how the seven major stocks performed in the last five trading sessions  All stocks were in the green this week except Lilly  which declined 0 1   Bristol Myers rose the most  5 9   in the last five trading sessions In the past six months  Lilly  LLY  has been the biggest gainer  38 2   while Bristol Myers recorded the lowest gain  1 3    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pfe-agn-q3-earnings-lly-nvs-collaboration-deals-in-focus-200353923,200353923
105236,326751,AGN,Ironwood  IRWD  Q3 Earnings   Revenues Miss  Shares Down,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   reported third quarter 2018 adjusted loss of 38 cents per share  wider than the Zacks Consensus Estimate of a loss of 14 cents and loss of 18 cents in the year ago period Total revenues in the quarter decreased 24 3  from the year ago period to  65 7 million mainly due to Linzess net sales adjustments and also missed the Zacks Consensus Estimate of  92 28 million Shares of the company fell 6 7  on Nov 7  following the earnings release  Moreover  a look at the company s share price movement shows that the stock has underperformed the  so far this year  Ironwood s shares have lost 20 5  during this period  while the industry decreased 2 7  Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess  linaclotide    generated U S  net sales of  204 8 million  up 7 3  year over year Please note that Ironwood and Allergan have an equal share in brand collaboration profits or losses for Linzess  Ironwood s share of net profits from sales of Linzess in the United States  included in collaborative revenues  was  52 3 million in the third quarter  down approximately 29  year over year The significant decline in sales was due to a  59 3 million negative adjustment related to Linzess sales over the last three fiscal years  2015  2016    2017   which was shared equally by Allergan and Ironwood  The negative adjustment  as calculated by Allergan  is the cumulative difference between previous gross to net estimates and actual subsequent payments made by Allergan  The difference was mainly associated with previous estimation of governmental and contractual rebates  Going forward  such adjustments will be done more frequently to avoid adjustment of a significant magnitude Sales of linaclotide active pharmaceutical ingredient added  10 9 million to revenues  including  9 5 million of sales to the company s Japanese partner  Astellas Pharma  The company also earned  1 9 million from linaclotide royalties  co promotion and other revenues According to data provided by IMS Health  Linzess prescriptions filled during the quarter were more than 830 000  up approximately 6  from the year ago period while volume of prescribed Linzess capsules increased about 12  in that period Zurampic and Duzallo  approved for uncontrolled gout  generated sales of  1 2 million in the quarter During the reported quarter  selling and administrative  SG A  expenses decreased 10 6  to  55 2 million  Research and development  R D  expenses were  46 8 million  up 26 2  from the year ago periodRestructuring UpdatesThe company remains on track to complete its separation into two publicly trading entities in first half 2019  In May  the company had announced its intention to split itself into two entities to achieve increased operational performance and strategic flexibility  One entity  which will continue with the current name  will focus on the commercial drugs and gastrointestinal   GI   pipeline development  The other entity will focus on the development of the Soluble Guanylate Cyclase pipeline for the treatment of serious and orphan diseases In August  Ironwood sent a notice of termination to AstraZeneca   NYSE AZN   for a license agreement related to lesinurad franchise which includes Zurampic and Duzallo  With this termination  Ironwood losses its rights to develop lesinurad based products in the United States  The company expects to save approximately  75 million to  100 million in operating expenses for the full year 2019 2018 Guidance ReiteratedIronwood maintained its guidance for 2018 operating expenses  Selling  general and administrative expense is expected to be in the range of  230 million to  250 million while R D expense is expected in the range of  160 million to  180 million Pipeline UpdatesLinzess is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation   CIC    Ironwood and Allergan are looking to broaden Linzess  label into additional symptoms and develop the drug as a non opioid  pain relieving agent in IBS patients In July  Ironwood and Allergan initiated a phase IIIb to evaluate a dose of 290 mcg of Linzess in multiple abdominal symptoms in addition to pain  including bloating and discomfort  in adult patients with irritable bowel syndrome with constipation  IBS C   Top line data from the study is expected by mid 2019 The companies anticipate to initiate a phase II study in the first quarter of 2019 to evaluate MD 7246  delayed release formulation of Linzess  for treating all subtypes of IBS  including IBS mixed and IBS with diarrhea In August  a label expansion of Linzess in the chronic constipation was approved in Japan  In China  Hong Kong and Macau  Ironwood has a marketing agreement with AstraZeneca for Linzess  The regulatory filing in China for IBS C is under review  The company expects the review to be completed by the end of 2018 The company is also developing three candidates   IW 3718  praliciguat and olinciguat  Ironwood is currently enrolling patients in a phase III study evaluating IW 3718 for treating gastroesophageal reflux disease and in a phase II study evaluating olinciguat in sickle cell disease  Data announced  along with the earnings release  from a phase II study evaluating olinciguat in achalasia showed expected pharmacokinetic and pharmacodynamic effects  However  Ironwood is keen on developing the candidate in sickle cell disease due to significant opportunity and has decided not to develop olinciguat further for achalasia as of now Two phase II studies to evaluate praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction  HFpEF  are currently enrolling patients  Top line data from both the studies are expected in the second half of 2019  In September  the FDA granted Fast Track designation to Praliciguat as a treatment for HFpEF However  the company has announced its intention to out license praliciguat to a global partner before progressing to phase III stage Our TakeThe company s performance this year has been dismal as its missed estimates for both earnings and sales in the first three quarters of the year  However  Linzess  prospects are encouraging due to strong demand trends and expansion of the drug in new patient population and geographic regions Meanwhile the prospect of the new Ironwood entity is high as it will turn profitable after the split and  its focus on encouraging gastrointestinal portfolio of commercial product and pipeline  However  the restructuring will unfavorably impact cash flow However  with a strong partner in Allergan and its  161 4 million in cash resources as of September end the company is likely to be able to meet its pipeline milestones and absorb the restructuring charges Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderIronwood currently carries a Zacks Rank  3  Hold   Vertex Pharmaceuticals Incorporated   NASDAQ VRTX   is a better ranked stock in the health care sector  carrying a Zacks Rank  2  Buy   You can see  Vertex s earnings per share estimates have moved up from  3 74 to  3 83 for 2018 in the past 30 days  The company delivered a positive earnings surprise in all the trailing four quarters with the average beat being 18 94   Share price of the company has increased 22 7  in a year s time Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-q3-earnings--revenues-miss-shares-down-200356898,200356898
105237,326752,AGN,Is Allergan  AGN  A Great Stock For Value Investors  ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Allergan plc   NYSE AGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Allergan has a trailing twelve months PE ratio of 9 1  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 8x  If we focus on the long term PE trend  Allergan s current PE level puts it below its midpoint over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE also compares favorably with the broader industry s trailing twelve months PE ratio  which stands at 8 8  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Allergan has a forward PE ratio  price relative to this year s earnings  of 9 6  which is tad higher than the current level  So  it is fair to expect an increase in the company s share price in the near term PEG RatioWhile earnings are certainly important  it is essential to know how much you are paying for the growth of earnings as well  One can easily do that with the PEG ratio  ratio of the P E to the expected future earnings growth rate   The PEG ratio gives a more complete picture of the valuation of a stock than the P E ratio Allergan s PEG ratio stands at just 1 2  compared with the Zacks Medical  Genetics industry average of 1 3  This suggests a decent undervalued trading relative to its earnings growth potential right now Broad Value OutlookIn aggregate  Allergan currently has a Value Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Allergan a solid choice for value investors What About the Stock Overall Though Allergan might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of C and a Momentum Score of B  This gives AGN a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen six estimates go higher in the past sixty days compared to eight lower  while the full year estimate has seen sixteen up and no down in the same time period This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has decreased by 0 5  in the past two months  while the full year estimate has increased by 1 2   You can see the consensus estimate trend and recent price action for the stock in the chart below Allergan plc Price and Consensus
    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineAllergan is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 26  of more than 250 industries  instills our confidence However  with a Zacks Rank  3 it is hard to get too excited about this company overall  In fact  over the past two years  the broader industry has clearly underperformed the market at large  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-18,Zacks Investment Research,https://www.investing.com/analysis/is-allergan-agn-a-great-stock-for-value-investors-200360631,200360631
105263,326778,AGN,David Tepper is long the market up to his eyeballs,news,Good morning  amidst headlines of doom  gloom  and confusion in Washington  billionaire hedge fund manager David Tepper is long   I don t think the market s cheap   he told CNBC Wednesday morning   but you can t be short in that kind of environment   And this environment  he says  is a stabilized China  a steady Japan  a growing US  and a calendar with no troubling macro events in sight  aside from the French election   Not one more regulation is happening and    you have tax cuts coming here  So unless there s a mess up in the administration    Unless that happens  nothing s going to get in the way until inflation starts picking up   When it does  the Fed will tighten  as by Tepper s estimation  it should have been doing more aggressively up to now   And risks  What risks  Tepper thinks the administration has gotten past starting a trade war with China  And while Trump s new immigration ban isn t palatable to him personally  he thinks it s fine for markets  He s hoping for peace with Mexico  Other than that    gravy  A few more key points from the interview  Tepper thinks it should be easy for Republicans to get tax reform through the legislature  He thinks Le Pen will with the French election  However  he thinks Macron could be a positive for the economy  Tepper went long pharmaceutical companies like Mylan  NASDAQ MYL  and Teva according to recent government filings  He said it was mostly a play on Allergan  NYSE AGN  and his belief that those stocks fell too far in the fall  He s also unsure on his Teva bet   Sometimes I think it s cheap and sometimes I look at it and I wonder why it s in my book    He s short bonds  long European equities   I may lose my behind     He thinks the boarder adjustment tax being floated by House Republicans could be good for the American economy as long as it s implemented over 5 years  It s not that complicated    and it doesn t necessarily mean that Americans pay more   Tepper is fully confident  Paul Ryan and his friends  will do this intelligently  He has an  interest  in Snap  and bought some in the IPO  but he wants the stock to go lower  Tepper has a dog named  Tepper described it as some kind of Yorkie Shitzu something    Sounds ferocious  All in all Tepper s super bullish  He even chastised everyone on the down   Everyone has to be on the negative side of life   Tepper complained to the Squawk Box crew ,2017-03-08,Business Insider,https://www.investing.com/news/stock-market-news/david-tepper-is-long-the-market-up-to-his-eyeballs-464629,464629
105264,326779,AGN,ValueAct boosts Valeant stake after Pershing exits,news,"By Michael Flaherty  Reuters    ValueAct Capital raised its stake in Valeant Pharmaceuticals International Inc  NYSE VRX   in a move that could provide a confidence boost to the drug company three days after its largest shareholder sold out of the stock   The show of faith came in contrast to Pershing Square  NYSE SQ  Capital Management  which exited its stake on Monday  suffering a more than  3 billion loss after spending 18 months trying to repair the company  ValueAct s disclosure on Thursday is another plot twist in a saga that began in the middle of 2015  when questions about Valeant s business practices sparked a series of news events and lawsuits that sent the stock into free fall  The stock is down 95 percent since its July 2015 peak  ValueAct s purchase of around  30 million worth of shares this week is a tiny fraction of the billions of dollars it once held in the company  Still  the move carried symbolic significance from a shareholder that has owned Valeant shares since 2006   ValueAct is signaling to the market that they think it is a positive factor that Pershing Square is no longer a shareholder   said activist hedge fund research and data provider  13DMonitor in a note on Thursday   There is no change in intent or purpose    In its filing on Thursday  ValueAct said the purchase this week boosts its holdings to 5 2 percent from 4 4 percent last quarter  The Canadian drugmaker s shares rose about 5 percent to  11 73 in extended trading on the news  Pershing became one of Valeant s biggest investors in 2015 when it sunk some  3 2 billion into the company  Pershing founder William Ackman played a major role in convincing Valeant s former CEO Mike  Pearson   LON PSON  to pursue a bid to buy botox maker Allergan Inc  NYSE AGN  in 2014  a deal that ultimately failed   With crisis seizing the company late in 2015  Pershing purchased more shares of Valeant  seized two board seats and became the company s most out spoken proponent   At the time  ValueAct  which had been selling down its once massive stake  pared its board presence to one seat  Ackman embarked on an effort to sell assets and regain investor confidence in the stock  Pearson was replaced last year with former Perrigo CEO Joseph Papa  But on Monday  Ackman called it quits on the effort  saying it was time to focus on other portfolio companies  The announcement sent the stock down more than 10 percent  and put the focus back on two of Valeant s largest hedge fund holders  ValueAct  and Paulson   Co  ValueAct helped install Pearson as CEO in 2008 and had at least one of its employees on the board since 2007  Pearson led the company on an acquisition spree that sent shares from the  20 range to  257 in 2015  before the stock went into a tailspin   
ValueAct  which currently has partner Robert Hale on the company s board  said on Thursday that it will continue to have discussions with officers of the company and directors to increase the company s value ",2017-03-17,Reuters,https://www.investing.com/news/stock-market-news/valueact-boosts-valeant-stake-after-pershing-exits-466826,466826
105265,326780,AGN,Ackman apologizes for Valeant losses  calls bet a mistake,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire hedge fund manager William Ackman has apologized to clients for betting on Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   telling them he was  deeply and profoundly sorry  for losing so much of their money on the investment  Ackman decided to sell his entire Valeant position earlier this month  suffering a roughly  4 billion loss since having bought the stake in early 2015   He called the investment a  huge mistake     My approach to mistakes is that I personally assume 100 percent of the responsibility on behalf of the firm   he wrote in the firm s annual letter released to clients on Tuesday evening and seen by Reuters on Wednesday  The 50 year old manager acknowledged the toll the bad bet has taken on his image and said he misjudged the management team in place when he bought the stock   We deeply regret this mistake  which has cost all of us a tremendous amount   he wrote  Thanks largely to Valeant s tumble  Ackman s hedge fund Pershing Square  NYSE SQ  Capital Management suffered back to back losses in 2015 and 2016 as his reputation as one of the hedge fund industry s most talented investors dimmed  Since launching the firm in 2004  Ackman has delivered a compound annual net return of 14 8 percent  He tends to take concentrated bets and often pushes management to perform better by urging spin offs or other measures  Nonetheless the board of Pershing Square Holdings  Ackman s publicly traded investment vehicle  decided after a review of his performance that he should continue to manage the investments  Anne Farlow  the chair  wrote in a separate letter  She welcomed Ackman s openness in analyzing what led to the Valeant failure  In his letter  Ackman laid some blame at the feet of Valeant s former management team  which he had thought was building the next Berkshire Hathaway  N BRKa   once of the most profitable companies in the country  Ackman met former Valeant Chief Executive Michael  Pearson   LON PSON  in 2014  when Pearson enlisted Ackman s help to try and buy Allergan  NYSE AGN  and Pershing Square bought up Allergan shares to try and push that company s management into selling to Valeant  Allergan ended up selling to a  Actavis   netting Ackman his best ever returns with his Pershing Square LP fund gaining 36 9 percent in 2014  Ackman fired Pearson in 2016  however  after he got a seat on Valeant s board   Prior management substantially overpaid for the company s largest acquisition   its acquisition of Salix   which occurred contemporaneously with the substantial majority of our investment in the company   Ackman wrote  
Pershing Square Holdings has swung to losses of 2 5 percent after starting the year with gains  but Ackman promised a quick recovery in the letter to clients ",2017-03-29,Reuters,"https://www.investing.com/news/stock-market-news/ackman-apologizes-for-valeant-losses,-calls-bet-a-mistake-469777",469777
105266,326781,AGN,Acorda Therapeutics to cut 20 percent of workforce,news," Reuters     Acorda Therapeutics  Inc  O ACOR  will cut nearly 20 percent of its workforce as part of a cost reduction plan  the company said on Wednesday  less than a week after losing certain patents for its multiple sclerosis  MS  drug  Ampyra 
The company  which had 597 employees as of Feb  20  said the job cuts are expected to result in cost savings of more than  21 million annually 
Acorda said the cost reductions would help the company focus on its two late stage studies for Parkinson s disease 
A federal judge in Delaware on Friday struck down key patents held by Acorda related to Ampyra  opening the doors for generic versions of the drug by companies including  Mylan Inc   O MYL  and Roxane Laboratories Inc 
Those companies had sought approval from the U S  Food and Drug Administration to sell a generic version of Ampyra  Acorda responded by suing them  seeking a court declaration that its patents on the drugs were valid 
A total of ten companies have sought to sell generic versions of Ampyra 
Acorda reached settlement agreements with seven of the generic companies  including Allergan plc  N AGN  and Par Pharmaceuticals 
Mylan  Roxane and Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  did not settle and challenged the validity of Acorda s patents in court 
Acorda said on Wednesday it would provide an updated 2017 earnings forecast during its first quarter earnings call ",2017-04-05,Reuters,https://www.investing.com/news/stock-market-news/acorda-therapeutics-to-cut-20-percent-of-workforce-471563,471563
105267,326782,AGN,Cloud software provider Okta surges 44 percent in debut,news, Reuters    Cloud software provider Okta Inc s  O OKTA  shares jumped as much as 44 percent in its debut on Friday  giving the tech unicorn a market capitalization of about  2 22 billion  The 11 million Class A share offering was priced at the top end of the expected price of  15  17  The company raised about  187 million   The San Francisco  California based company s shares opened at  23 56 and hit a high of  24 50 on the Nasdaq  Okta helps companies organize passwords and authenticate the identity of employees who log into work applications made by other software firms   The tech company has more than 3 100 customers  including Adobe Systems Inc  O ADBE    American Express   N AXP   LinkedIn Corp  NYSE LNKD  and Allergan  N AGN  among others  Okta is the latest in a string of cloud software IPOs that investors have warmly embraced  reflecting strong revenue growth and recurring subscription sales that offer greater predictability than many other tech stocks  Tech IPOs have showed signs of recovery this year  after a dull 2016  when just 20 technology companies went public   The number of U S  IPOs more than tripled in the first quarter  with the technology sector leading the issuance market  according to Thomson Reuters data   Snap Inc   N SNAP   the owner of the popular social media app Snapchat  grabbed attention when it went public early in March with a staggering valuation of  24 billion  Okta  backed by venture capital firms  including Sequoia Capital  Andreessen Horowitz  Greylock Partners and Khosla Ventures  follows the successful debuts this year of MuleSoft Inc  N MULE  and  Alteryx Inc   N AYX   Like these software providers  Okta is also not profitable  having posted a net loss of  83 5 million in the year ended Jan  31  2017  However  the company s revenue rose about 87 percent to  160 33 million  J P  Morgan  Goldman Sachs   Co  NYSE GS  and Allen   Co LLC are lead underwriters to the offering ,2017-04-07,Reuters,https://www.investing.com/news/stock-market-news/cloud-software-provider-okta-surges-44-percent-in-debut-472544,472544
105268,326783,AGN,Glaukos shares risk steep decline as rivals pressure  Barron s,news, Reuters    Shares of  Glaukos Corp   N GKOS  could fall 30 percent in the next year  as years of success by the medical device maker has attracted competition from larger companies that threaten its market share  according to the April 10 edition of Barron s  Glaukos shares have risen 150 percent to around  50 since June 2015  trading at 300 times expected earnings and 10 times forecast sales  the financial newspaper said   The San Clemente  California based company  which makes tiny titanium stents called iStents used to treat the progressive eye disease glaucoma  has had this market to itself in the United States   But new rivals  including  Novartis  AG s  S NOVN  Alcon unit and Allergan Plc  N AGN   are set to challenge its dominance and put pressure on pricing  Barron s said  Alcon  the world s largest eye care company  recently won approval for a competing product  while Glaukos is unlikely to have a new product on the market before the second half of next year  Barron s said    Although Glaukos dominates the stent market in minimally invasive glaucoma surgery  it is still a small company reliant on just one product for the foreseeable future  as bigger rivals emerge   the paper said   That s a prescription for disappointment  and a potentially steep stock price decline  ,2017-04-09,Reuters,https://www.investing.com/news/stock-market-news/glaukos-shares-risk-steep-decline-as-rivals-pressure:-barron's-472835,472835
105269,326784,AGN,Allergan and Novartis team up in NASH study,news,Allergan  AGN  and Novartis  NVS  0 3   will collaborate on a Phase 2b clinical trial assessing the former s cenicriviroc and the latter s Farnesoid X receptor  FXR  agonist in patients with non alcoholic steatohepatitis  NASH   Financial terms are not disclosed Cenicriviroc is a dual inhibitor of proteins called CCR2 and CCR5 that play key roles in inflammation and fibrosis FXR is a master regulator of carbohydrate and lipid metabolism  bile acid homeostasis  inflammation and fibrosis  FXR agonists reduce the expression of certain genes that control the synthesis of triglycerides in liver cells  They reduce liver steatosis  infiltration of liver cells with fat   lower the release of free fatty acids from fat tissue and reduce their uptake by the liver and improve tissues  responsiveness to insulin Previously  Allergan on a roll  buys another NASH therapy developer for  50M plus milestones  Sept  20  2016 ,2017-04-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-and-novartis-team-up-in-nash-study-475011,475011
105270,326785,AGN,NASH  The next untapped pharma market gives investors many options,news,"By Bill Berkrot  Reuters    Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH  a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020   The eventual market for the complex disease  formally known as Non alcoholic Steatohepatitis  is forecast to be  20 billion to  35 billion as populations with fatty diets increasingly fall victim to a condition with no approved treatments   Graphic  The growing threat of NASH drives deals    With intense competition and pricing pressure eroding sales of medicines for diabetes  rheumatoid arthritis and other lucrative disease categories  and an already crowded field for developmental cancer drugs  big pharma sees NASH as an enormous new market for future profit that will accelerate a wave of deal making  For a graphic  click   We are actively looking on the outside for opportunities    to complement our internal program   Morris Birnbaum  chief scientific officer for internal medicine for  Pfizer   N PFE   told Reuters   Pfizer currently has three early stage drugs in the clinic aiming to block or reverse fat accumulation in the liver   We believe that even though we re a bit behind  we still might come out with the best in class molecules   Birnbaum said  Bristol Myers Squibb  N BMY  also confirmed it is looking for additional assets to enhance its internally developed NASH drugs  It presented promising data for its lead NASH candidate at the big European liver meeting in Amsterdam that ended on Sunday    It s early days  but keep your seatbelts fastened   said Dr  Scott Friedman  dean for therapeutic discovery at Mt  Sinai Hospital in New York and one of the world s leading liver disease experts   Estimates for the prevalence of NASH in nations with fatty diets range from 5 to 20 percent of the population with up to 15 million potentially affected in the United States alone   Driven by the obesity and diabetes epidemics  the disease guarantees an enormous pool of patients for decades  making it a prime target for deals for promising therapies for NASH and its consequences   advanced fibrosis and liver destroying cirrhosis   The very early stages of many of the drugs  and the complicated nature of the disease itself  pose risks for drug developers and their investors alike   But the upside potential is still enticing to Raghuram Selvaraju  managing director and senior healthcare analyst at Rodman and Renshaw  He calls NASH one of the hottest spaces in the healthcare sector    We anticipate that there will be more transactions  more licensing deals from big pharma involving emerging biotechnology companies   he said  GILEAD A PIONEER  Just a few years ago  Gilead Sciences  O GILD  was the lone large drugmaker talking about NASH  It was undeterred after its most advanced anti fibrosis candidate failed  striking deals with two small companies to acquire additional NASH programs   Liver disease experts were impressed last year by Phase II data from a Gilead developed drug that demonstrated fibrosis regression after just six months   Allergan  N AGN  became a top NASH contender with its acquisition of Tobira Therapeutics and a deal with private Akarna Therapeutics on the same day last year   Other big drugmakers with licensing deals or options on future deals in the space include  Novartis   S NOVN   Merck   Co  N MRK   Bristol Myers and Johnson   Johnson  N JNJ    While many of the drugs in development are two to five years from reaching the market if they get that far  betting on the feverish deal activity gives investors a chance to profit near term  Many small companies developing drugs with a wide variety of approaches across the disease spectrum do not have partners  They include Intercept Pharmaceuticals  O ICPT   Galectin Therapeutics  O GALT   Genfit  PA GNFT  and Galmed Pharmaceuticals  O GLMD   all with a chance to be among the first to market  as well as Enanta Pharmaceuticals  O ENTA    Durect Corp   O DRRX  and little known U K  tradedTiziana Life Sciences  L TILST  with assets much earlier in development   Galectin  which expects key data in December  has commenced preliminary partnership discussions  its chief operating officer told Reuters  Len Yaffe  who runs the StockDoc Partners healthcare fund and has long followed the liver disease space  said investors with tolerance for risk could do well to buy shares in several small cap and micro cap companies with promising NASH drugs in early development  He said if any one has stellar data  or lands a deal  the payoff could be considerable   When Allergan announced the  1 7 billion deal for Tobira  for example  that company s shares jumped from under  5 to over  30  Yaffe  who had singled out Tobira to investors prior to its acquisition  said the Durect drug  looks incredibly promising as it relates to inflammation and fibrosis    Enanta has the advantage of cash flow from its hepatitis C partnership with AbbVie  N ABBV  to fund its NASH program    You want to bet on companies that can survive even if they don t get a partnership this year or next year   Selvaraju said  Enanta Chief Executive Jay Luly said companies in earlier stages of development may have an advantage over the first wave of experimental treatments as regulators  thinking on clinical trial goals and what makes an approvable product in such a new market evolves    When we get there  the development pathway could be not only more clearly defined  but more simplified   Luly said   MANY SHOTS ON GOAL  Drugmakers are taking a wide range of approaches to treat the complex disease  given multiple health issues among NASH patients that contribute to the liver damage  such as heart disease and diabetes   There are drugs targeting inflammation to prevent or reduce fibrotic scarring  Some address lipid regulation to reduce liver fat  while others attempt to directly halt or reverse fibrosis  And some companies are testing diabetes treatments to assess their ability to also improve NASH   The big sea change from two years ago   apart from an increased number of players   is a fairly rapid acceptance of the fact that we re going to be seeking combination therapies since it s a disease that involves multiple pathways   said Mt  Sinai s Friedman    In the end  whatever the mechanism is  it needs to yield decreased fibrosis   he said  noting that progressing fibrosis is what ultimately causes serious health consequences   The knowledge that multiple drugs will be needed for therapeutic combinations to treat NASH  and that most experimental drugs fail  are big drivers for deal activity  Drugmakers are looking to improve chances of success by amassing numerous experimental drugs for their NASH programs   Some experts said drugs that target late stage fibrosis and cirrhosis  where the risk of cancer and liver failure is highest  are likely to gain earliest acceptance from insurers   That fits the strategy of tiny Conatus Pharmaceuticals  O CNAT   whose shares more than doubled when it signed a  50 million collaboration deal with Novartis  Conatus is targeting end stage disease with the goal of preventing transplants   But given the millions of potential patients and expense of treating advanced disease  there should be incentive for insurers to embrace medicines that target earlier stage NASH as well   
 There s still a major role for drugs that work on the front end   said Dr  Arun Sanyal  a leading liver disease expert whose Virginia Commonwealth University lab discovered the compound being developed by Durect   One size will not fit all  ",2017-04-24,Reuters,https://www.investing.com/news/stock-market-news/nash:-the-next-untapped-pharma-market-gives-investors-many-options-476670,476670
105271,326786,AGN,Teva mulling sale of cancer portfolio to reduce debt  shares up 1  premarket,news,Bloomberg reports that Teva Pharmaceutical Industries  NYSE TEVA  is considering divesting its specialty cancer assets in order to trim debt  The oncology unit generated  1 14B in sales last year  down 5  Teva s debt  almost  36B at the end of 2016  jumped after its  40B acquisition of Allergan  NYSE AGN  s generics business last year  The company previously stated that it would not make any major strategic decisions until after a new CEO is on board Shares are up 1  premarket on light volume Now read  Why Teva Pharmaceuticals Has Significant Upside,2017-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/teva-mulling-sale-of-cancer-portfolio-to-reduce-debt;-shares-up-1-premarket-477533,477533
105272,326787,AGN,Pharma Stock Roundup  MRK Impresses At ASCO  LLY Gets FDA Nod For Olumiant,opinion,"This week was ruled by cancer data presentations at the annual meeting of the American Society of Clinical Oncology   ASCO   in Chicago by pharma bigwigs like Bristol Myers   NYSE BMY    Merck   NYSE MRK   and Roche   OTC RHHBY    among others  JAK inhibitors were in the news this week with Lilly   NYSE LLY   finally gaining FDA approval for its rheumatoid arthritis   RA   candidate Olumiant  baricitinib  in the United States while AbbVie   NYSE ABBV   presented positive top line data from its fifth late stage study on upadacitinib in RA Recap of the Week s Most Important StoriesUpdate from ASCO  Merck stole the show at ASCO after presenting data from several cancer studies of its PD L1 inhibitor  Keytruda  Key presentations were from two pivotal lung cancer trials  KEYNOTE 042 study evaluated Keytruda monotherapy in newly diagnosed lung cancer patients while  evaluated Keytruda in combination with chemotherapy in difficult to treat squamous non small cell lung cancer  NSCLC   Both the studies showed that treatment with Keytruda led to improved survival  Particularly  data from the KEYNOTE  407 study  which evaluated Keytruda in combination with chemotherapy for the first line treatment of metastatic squamous NSCLC was considered  practice changing  by investors Four and five years follow up data presented from two  showed that treatment with Keytruda led to long term survival benefit  Interim data from a cohort of a phase II study  KEYNOTE 158  evaluating Keytruda as a monotherapy in patients with previously treated advanced small cell lung cancer  SCLC  demonstrated encouraging response rates in the overall population of SCLC patients as well as in patients whose tumors express PD L1  Keytruda also demonstrated encouraging ORR in studies evaluating the Lenvima Keytruda combination in four different tumor types and Keytruda monotherapy for the first line treatment of advanced clear cell RCC Bristol Myers and Nektar Therapeutics  NKTR  presented preliminary data from a mid stage study evaluating NKTR 214 in combination with Bristol Myers PD L1 inhibitor  Opdivo in several tumor types  The response rates in melanoma and kidney cancer patients did not impress investors  resulting in a 42  drop in Nektar s stock on Monday    Read more   Bristol Myers also presented data on Opdivo at ASCO  In a late stage study evaluating Opdivo versus Yervoy in a broad range of patients with resected stage III or IV melanoma  Opdivo demonstrated sustained  superior recurrence free survival versus Yervoy  In another study  Opdivo plus chemotherapy showed improved PFS versus chemotherapy in first line lung cancer patients with PD L1 expression  1  Novartis  NVS  announced positive data from a combination study on breast cancer drug Kisqali and from two long term leukemia studies on Tasigna   Read more    Roche presented data from a late stage study  which showed that Tecentriq  atezolizumab  plus chemotherapy reduced the risk of disease worsening or death  PFS  by 29  in advanced squamous NSCLC patients versus chemotherapy alone AbbVie presented early data from a phase II study evaluating a combination of its cancer drugs Imbruvica plus Venclexta  venetoclax  for the first line treatment of patients with chronic lymphocytic leukemia  CLL   The data demonstrated high rates of responses in such patients  Also  interim data from a late stage study evaluating Imbruvica plus Roche s Rituxan in Waldenstr m s macroglobulinemia  a rare form of Non Hodgkin s lymphoma  showed that the combination significantly reduced the risk of disease progression or death by 80  compared to placebo plus Rituxan Pfizer   NYSE PFE    AstraZeneca and J J also made some cancer data presentations at the meeting Lilly Gets FDA Nod for Lower Dose of Olumiant  Eli Lilly and partner Incyte gained FDA approval for the lower dose of  2 mg  of the companies  JAK inhibitor  Olumiant  The FDA did not approve the higher dose  4 mg  and the drug s label was approved with a boxed warning stating risk of serious infections  malignancies and thrombosis  Olumiant is already marketed in Europe and Japan and generated sales of  32 2 million in the first quarter of 2018  In the United States  Lilly faced significant trouble in getting FDA nod for Olumiant  In April last year  the FDA had issued a complete response letter for the new drug application seeking approval of Olumiant  requesting additional information to determine the most appropriate doses  This year in April  an FDA advisory committee had recommended approval of the lower dose of the drug while not recommending the higher dose of 4 mg on inadequate safety profile to support an approval relative to its benefits   Read more    AbbVie s 5th Late Stage Upadacitinib Study Succeeds  AbbVie s oral JAK 1 selective inhibitor  upadacitinib  met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program  Top line data from the study showed thata significantly higher proportion of patients treated with upadacitinib in both 15 and 30 mg doses achieved superior responses compared to chemotherapy agent methotrexate  AbbVie plans to submit regulatory applications for upadacitinib in rheumatoid arthritis in the second half of the year    Read more   Allergan Under Activist Pressure to Split CEO Chairman Roles  Allergan   NYSE AGN   was under pressure this week after two hedge fund firms  Senator Investment Group and Appaloosa  disclosed a letter urging the company to engage in a management and board overhaul  The firms asked the pharmaceutical company to split its chairman and chief executive roles  both presently held by Brent Saunders  among other management changes  Appaloosa run by David Tepper and Senator Investment Group run by Douglas Silverman  suggested an outsider should be hired for either of the roles  The letter comes on the heels of Allergan s strategic plan announced last week to divest its women s health and infectious disease units  Allergan responded by saying that the board has been refreshed with the addition of three members in the last 16 months   Read more    Glaxo Completes Buyout of Novartis  Stake in Consumer Healthcare JV  Glaxo announced that it has completed its previously announced deal to buy out Novartis  36 5  stake in the Consumer HealthCare joint venture for  13 billion   9 2 billion  With the acquisition of Novartis  stake  Glaxo now has 100  ownership of its Consumer Healthcare unit  which includes products such as Sensodyne and Flonase  Glaxo and Novartis created the JV in 2015 as part of a three part transaction between the two companies by combining their consumer divisions Pfizer to Invest More in Venture Capital Arm    Pfizer plans to invest  600 million in its venture capital arm  Pfizer Ventures which will be invested in small biotechs and other emerging growth companies  About 150 million will be earmarked for companies involved in promising early stage neuroscience research   Read more   Meanwhile  Pfizer s regulatory applications for orally available PARP inhibitor  talazoparib  for metastatic breast cancer patients with an inherited BRCA mutation  were accepted for review by the FDA and the European Medicines Agency  In the United States  the new drug application  NDA  was granted priority review by the FDA with a decision accepted in December this year Top line results from talazoparib s registrational study  EMBRACA  in germline BRCA mutated breast cancer  presented in December 2017 demonstrated superiority of talazoparib over chemotherapy in improving progression free survival Roche s Haemophilia A Candidate Gets Priority Review  Roche s sBLA looking for label expansion of its drug  Hemlibra for people with haemophilia A without factor VIII inhibitors was granted priority review by the FDA  Hemlibra is presently marketed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors  With the FDA granting priority review  a decision is expected on Oct 14Separately  Roche s cancer drug Rituxan gained FDA approval for a new indication  moderate to severe pemphigus vulgaris  PV   a potentially life threatening diseaseThe NYSE ARCA Pharmaceutical Index rose 1 7  in the last five trading sessions 
 Large Cap Pharmaceuticals Industry 5YR   Return
 
 Here is how the seven major stocks performed in the last five trading sessions 
  All stocks were in the green last week except AstraZeneca  which declined 1 8   Merck rose the most  4 2   on ASCO strength In the past six months  Glaxo  GSK  has been the biggest gainer  15 4   while Bristol Myers declined the most  16 5    See the last pharma stock roundup here  Pharma Stock Roundup   What s Next in the Pharma World Watch out for FDA decisions on many pipeline drugs and line extensions of marketed products this month Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mrk-impresses-at-asco-lly-gets-fda-nod-for-olumiant-200323449,200323449
105273,326788,AGN,Amgen s  AMGN  Prolia Gets Label Expansion Approval In Europe,opinion,"Amgen   NASDAQ AMGN   announced that the European Commission   EC   has approved label expansion of its blockbuster drug  Prolia  The drug is now approved for the treatment of bone loss associated with long term systemic glucocorticoid therapy in adult patients at increased risk of fracture  This is also called glucocorticoid induced osteoporosis This is the third approved indication for Prolia in Europe  The approval is backed by increase in bone mineral density   BMD   achieved by the drug in a phase III study A similar line extension application received approval in the United States last month Prolia is presently marketed in Europe for the treatment of men and postmenopausal women with osteoporosis at high risk for fracture as well as to increase bone mass in men with prostate cancer receiving hormone ablation Amgen s shares have increased 6  this year so far against the  s decline of 6 9   The phase III study evaluated Prolia for improvement in BMD in patients receiving glucocorticoid treatment  compared to Allergan s   NYSE AGN   Actonel  risedronate   The study comprises two patient groups   one with patients on sustained glucocorticoid treatment  glucocorticoid continuing arm  and the second with patients initiating glucocorticoid therapy  glucocorticoid initiating arm   In both arms  Prolia demonstrated greater improvement in lumbar spine BMD in patients at one year and two years compared to Actonel  the study s primary endpoint Glucocorticoid induced osteoporosis is the most common form of secondary osteoporosis  Per the press release  30  to 40  of the patients receiving glucocorticoid treatment for the long term have shown vertebral fractures  Although the proportion of eligible patients is small  this line extension is likely to boost sales of the drug further Prolia is one of the major revenue sources for Amgen and is witnessing growth in market share in both the United States and internationally amid competition from generics of other drugs approved for osteoporosis  In the first quarter of 2018  the drug generated sales of almost half a billion dollars  up 16 5  year over year The drug faces competition from generics of other branded drugs including Eli Lilly s   NYSE LLY   Evista  alendronate   Merck s   NYSE MRK   Fosamax  raloxifene  and Novartis  Zometa  zoledronate  Amgen Inc  Price
    Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-06-10,Zacks Investment Research,https://www.investing.com/analysis/amgens-amgn-prolia-gets-label-expansion-approval-in-europe-200323986,200323986
105274,326789,AGN,Mylan  MYL   With Neulasta Approval  Focus Moves To Advair And Restasis ,opinion,"Mylan  NASDAQ MYL   With Neulasta Biosimilar Approval  Focus Moves to Advair and Restasis
June 12  2018
Over the last year  Mylan has faced a difficult generic environment  but has managed to offset the pressure with the launch of its generic Copaxone and a strong ex US business that has helped stabilize the business 
The key topics around Mylan are 
  Mylan s recently received approval of Fulphila  their Neulasta biosimilar  Analysts expect the drug to contribute to management s guidance and importantly  demonstrates the company s ability to bring complex generics and biosimilars to the market
  Investor focus now shifts to two upcoming  and sizable  opportunities  gAdvair on June 27  and gRestasis on July 31 
Neulasta Biosimilar Approval Demonstrates Ability to Bring Complex Generics to Market
Context  Neulasta is a branded drug that boosts white blood cells to help reduce infection rates from strong chemotherapy  The branded drug is owned by Amgen  NASDAQ AMGN  and generated about  4 billion in US sales over the last twelve months 

The drug is delivered through one of two methods  through a prefilled syringe  or through Onpro  an on body injector  also owned by Amgen  pictured below  
If administered by a prefilled syringe  the patient will need to travel to a cancer or oncology center to have the drug administered  Amgen estimates that 90  of patients live 150 miles or greater away from the hospital  meaning it s a significant chunk of time out of a patient s day  As a result  Onpro makes up roughly 60  of the franchise revenue  and the patients on Onpro are considered to be fairly sticky 
What happened  Mylan recently received approval for their Neulasta biosimilar  marketed as Fulphila  This was seen as a positive result  and sent the stock up 5  the next day  Of note  some concerns had arisen recently among investors after the company received a form 483  a list of observations during a factory inspection   Of note  the company received a CRL  complete response letter  last year  largely focused on qualitative observations at the facility  However  this was clearly not an issue for the company  Fulphila is the first biosimilar to Neulasta and therefore should enjoy some lead time and revenue benefits as the only generic available to patients 

Competition  Coherus BioSciences  NASDAQ CHRS  is seen as the only other manufacturer that has a chance of receiving FDA approval on their Neulasta biosimilar this year  The company received a CRL on their Neulasta biosimilar in June 2017  and recently refiled their application in May 2018  Coherus has an action date on November 3rd  and many investors expect Coherus to receive approval 
Beyond Coherus  Amneal Pharmaceuticals  NYSE AMRX  Adello are expecting a filing date at some point this year  and Sandoz Apotex are also expected to file some time in 2019  Given the difficulty in getting approval  Mylan  and potentially Coherus  could be the only competitors available on the market for a couple of years 
Financial impact  How much share will Fulphila take from Neulasta  Onpro becomes a significant consideration as it protects some of Amgen s Neulasta revenue  Mylan did note this January that they will be exploring the development of an Onpro like device  However  it will likely be some time until that comes out  In the meantime  Onpro provides some protection for Amgen against Fulphila given the convenience of its delivery  As noted previously  the Onpro saves patients the time of having to travel to a cancer center to have the shot administered  However  on the flip side  biosimilars are likely to get more favorable reimbursement  This can be a major factor as Neulasta shots cost over  6 000 on average  and patients will likely be willing to drive a further distance when the savings are of that magnitude 
In total  analysts are forecasting anywhere between  30 to  150 million in Fulphila revenue and  0 04    0 08 in EPS this year  taking into account a number of factors 
  5 10  market share  Drug availability for half the year  Onpro stickiness  Coherus potential launch near the end of the year  25 40  discount on pricing
Beyond 2018  many analysts expect revenue to grow to over  300 million in revenue in 2019  contributing EPS of  0 10 or more 
Focus Now Shifts to Advair and Restasis
With the approval of the Neulasta biosimilar  investors are now focused on the next two catalysts in 2018  Advair and Restasis  Management gave guidance for 2018 that implies a step up in sales and earnings  and the approval of these drugs would go a long way in derisking sales and earnings targets  Additionally  investors will be looking for any updates on Herceptin  which is expected to be a 2019 event 
Advair  Advair has an upcoming action date on June 27  Recall that numerous manufacturers have struggled to receive approval on an Advair generic  Mylan received a CRL in March of last year  Sandoz received a CRL in February this year  and Hikma Vectura  VEC  received a CRL in March 
On the positive side  competitor CRLs means that approval is not likely for them until late 2019 2020  If Mylan is able to get approval  they will likely enjoy a single generic market for a year or longer  On the negative side  the Advair opportunity has notably shrunk over the last year  GlaxoSmithKline  NYSE GSK   the owner of Advair  recently noted in April that payer negotiations had put pressure on pricing  and they now expect Advair sales to decline by 30  in 2018  This would put the opportunity at roughly  1 5 billion in branded sales   a significant decline from the  2 8 billion opportunity that Mylan had originally targeted in 2015  and the  2 2 billion sales generated in 2017 
Overall  analysts believe the drug could contribute  0 12    0 15 in EPS if the drug receives approval by mid 2018 
Restasis  Restasis has an action date on July 31st  Mylan has noted that they do not have any significant outstanding scientific issues  increasing the likelihood that they receive approval  Outside of Mylan  the competitive landscape is a bit more uncertain  as both TEVA and Akorn are pursuing the opportunity  but have not yet settled with Allergan  NYSE AGN   Analysts believe Restasis approval could contribute  0 05    0 10 in EPS this year  with potential for upside depending on the competitive landscape 
Herceptin  Investors generally see Herceptin as a 2019 event  as several companies have had issues with receiving approval for the biosimilar  Amgen and Pfizer  NYSE PFE  have both received CRLs this year   TEVA Celltrion still believe that they could get approval before the end of the year ",2018-06-13,The Non-Consensus,https://www.investing.com/analysis/mylan-with-neulasta-approval-focus-moves-to-advair-and-restasis-200324397,200324397
105275,326790,AGN,Allergan  AGN  Presents Positive Data On Glaucoma Candidate,opinion,Allergan PLC   NYSE AGN   announced positive top line results from a phase III study  evaluating its pipeline candidate Bimatoprost SR  Bimatoprost SR is Allergan s investigational implant  developed as the first sustained release drop free treatment option for lowering intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension The phase III study  n 594  compared Bimatoprost SR applied on patients with open angle glaucoma or ocular hypertension with timolol eye drops  The trial used two dosages of Bimatoprost SR administered in three cycles  Day 1  Week 16 and Week 32  compared with timolol eye drops  used twice daily for up to 20 months Data from the study showed that Bimatoprost SR reduced IOP by approximately 30  over the 12 week primary efficacy period  demonstrating non inferiority in case of timolol Well received by the patients  Bimatoprost SR showed potential for patients staying on treatment free for more than a year after the last implant was inserted In glaucoma patients  uncontrolled elevated IOP can lead to vision loss  In order to reduce elevated IOP  patients are prescribed eye drops  However  80  of glaucoma patients fails to use eye drops as prescribed  Bimatoprost SR  if approved  will provide such patients with an option of a drop free therapy and free them from daily eye drop regimens  Bimatoprost SR is designed to lower IOP for at least four months Allergan is expected to report additional data and results from a second phase III study with an identical design in the first half of 2019  A new drug application  NDA  filing to the FDA is also anticipated during the second half of 2019 We would like to remind investors that earlier this week  Allergan announced that its second anti CGRP candidate  atogepant  met its primary endpoint in a mid stage study  The CGP MD 01 study evaluated five doses of atogepant for the prevention of episodic migraine over 12 weeks  Atogepant achieved a reduction of statistical significance in monthly migraine probable migraine  MPM  headache  days from baseline for all doses Allergan s another oral anti CGRP acute migraine treatment  ubrogepant  has already shown positive results in two phase III studies  However  the migraine market is growing extremely competitive  In May  Amgen   NASDAQ AMGN   and its partner Novartis   NYSE NVS   received approval for commercializing their anti CGRP drug  Aimovig  for treating episodic migraine So far this year  shares of Allergan have increased 4  compared with the  rise of 2 4   Allergan currently carries a Zacks Rank  3  Hold   A better ranked stock in the large cap pharma sector is Eli Lilly and Company   NYSE LLY   with a Zacks Rank  2  Buy   You can see Eli Lilly s earnings per share estimates have been revised 5 7  upward for 2018 and 3  for 2019 in the last 60 days  The stock has inched up 1 5  year to date  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-presents-positive-data-on-glaucoma-candidate-200324991,200324991
105276,326791,AGN,Pharma Stock Roundup  LLY AZN Alzheimer s Drug Fails  MRK s Keytruda Wins Approvals,opinion,"Another Alzheimer s candidate failed in clinical studies this week  An independent data monitoring committee   IDMC   recommended Lilly   NYSE LLY   and AstraZeneca   NYSE AZN   to discontinue two studies on lanabecestat  Shares of Israel based small biotech  Galmed Pharmaceuticals Ltd    NASDAQ GLMD   rose after it announced positive data from a mid stage study on its NASH candidate Aramchol  Merck   NYSE MRK   gained FDA approval for two new indications of its blockbuster anti PD 1 therapy  Keytruda  While Glaxo s   NYSE GSK   late stage HIV studies met the primary endpoint  AbbVie   NYSE ABBV    Roche   OTC RHHBY   and AstraZeneca gained regulatory nods for label expansion of their key cancer drugs Recap of the Week s Most Important StoriesLilly AstraZeneca s Alzheimer s Candidate Fails  Lilly and AstraZeneca are discontinuing two late stage studies on their Alzheimer disease candidate  lanabecestat  on recommendation of the IDMC The IDMC said that the two studies   one in early Alzheimer s disease and the other in mild Alzheimer s disease dementia   were unlikely to meet the primary endpoints upon completion  leading to a decision to discontinue these studies on the oral beta secretase cleaving enzyme  BACE  inhibitor  The latest setback adds to a long list of failed treatment options for this deadly brain disease   Read more   Merck s Keytruda Gets FDA Nod for Two New Indications  Merck gained FDA s accelerated approval for two new indications for its blockbuster anti PD 1 therapy  Keytruda this week  These include third line treatment of adult as well as pediatric patients with primary mediastinal B cell lymphoma  PMBCL   a type of non Hodgkin lymphoma and second line treatment of recurrent or metastatic cervical cancer  These label expansion approvals should drive sales of Keytruda in the future quarters Also  Merck s regulatory application seeking approval for an expanded age indication of its HPV vaccine Gardasil was granted priority review by the FDA  Merck is looking to get Gardasil approved for women and men aged 27 to 45  The HPV vaccine is presently approved for men and women aged 9 to 26   Read more  Glaxo s GEMINI Studies on Two Drug HIV Regimen Succeed  Glaxo s two late stage studies testing its two drug HIV regimen of dolutegravir  Tivicay  and lamivudine showed non inferiority in HIV control to a standard three drug regimen regimen of dolutegravir plus tenofovir alafenamide fumarate and emtricitabine  The studies were conducted on treatment na ve HIV 1 infected adults   those who have not received prior antiviral therapy  Regulatory application to get the two drug regimen of dolutegravir and lamivudine approved is expected to be filed later this year In another positive news for Glaxo   of Glaxo s blockbuster respiratory drug  Advair was delayed again with a second complete response letter from the FDA Galmed Shares Hit the Roof as NASH Candidate Succeeds in Study  Galmed announced positive top line results from a mid stage study on its lead candidate  Aramchol  for the treatment of non alcoholic steatohepatitis  NASH   The study demonstrated that Aramchol was effective at reaching its primary endpoints Importantly  reduction in liver fat  as measured by magnetic resonance spectroscopy  was demonstrated in patients who had completed 52 weeks of treatment with Aramchol 400mg compared to placebo  These results strongly support the advancement of Aramchol to pivotal phase III studies  Shares of the company skyrocketed around 150  after this news was announced   Read more   Allergan s Anti CGRP Drug Meets Goal in Study  Allergan  NYSE AGN  announced that its second anti CGRP candidate  atogepant  in a mid stage study  The CGP MD 01 study evaluated 5 doses of atogepant for the prevention of episodic migraine over 12 weeks  Atogepant achieved a reduction of statistical significance in monthly migraine probable migraine   MPM   headache days from baseline for all doses Allergan s another oral anti CGRP acute migraine treatment  ubrogepant  has already shown positive results in two phase III studies Separately  Allergan announced from a phase III study on its pipeline candidate Bimatoprost SR  an investigational implant developed as the first sustained release drop free treatment option for lowering intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension  Data from the study showed that Bimatoprost SR reduced IOP by approximately 30  over the 12 week primary efficacy period  thereby demonstrating non inferiority to the study comparator  timolol eye drops AbbVie Roche Cancer Drugs Get FDA Nod for Combo Use  AbbVie and Roche announced  of their cancer drugs Venclexta and Rituxan  for previously treated chronic lymphocytic leukemia   CLL    The FDA approval was based on positive data from the phase III MURANO study of Venclexta plus Rituxan in relapse refractory CLL  Venclexta is jointly marketed by AbbVie and Roche s subsidiary Genentech in the United States and by AbbVie outside the United States Separately  Roche announced for its cancer drug  Avastin in combination with chemotherapy  carboplatin and paclitaxel  for the treatment for women with advanced ovarian cancer following initial surgery  With this latest approval  Avastin is now approved for six different types of cancer in the United States Tagrisso Gets EU Approval in First Line Setting  AstraZeneca s  AZN  lung cancer drug Tagrisso gained EU approval for the first line treatment of adult patients with metastatic NSCLC whose tumors have EGFR mutations  A similar label expansion application was approved in the United States in April  Until now  Tagrisso was approved in the United States  European Union  Japan and China as a second line treatment option for patients with EGFR mutation positive NSCLC  The label expansion in the first line setting should drive sales of Tagrisso higher in future quarters   Read more    J J Accepts Offer to Sell Diabetes Unit  J J formally accepted the binding offer it received in March of approximately  2 1 billion from a private equity firm  Platinum Equity  for its LifeScan diabetes device unit  The LifeScan unit makes blood glucose monitoring products and generated revenues of  1 5 billion last year  The transaction is expected to be closed by the end of the year   Read more   The NYSE ARCA Pharmaceutical Index rose 0 3  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions  In the last week  Pfizer  NYSE PFE  declined the most  0 9   while Glaxo generated the highest return  3   In the past six months too  Glaxo has been the biggest gainer  18 8   while Bristol Myers declined the most  14 0    See the last pharma stock roundup here  Pharma Stock Roundup   What s Next in the Pharma World Watch out for FDA decisions on several pipeline drugs and line extensions of marketed products this month Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-llyazn-alzheimers-drug-fails-mrks-keytruda-wins-approvals-200325388,200325388
105277,326792,AGN,Top Research Reports For UnitedHealth  Walmart   AT T ,opinion,"Tuesday  June 19  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including UnitedHealth  UNH   Walmart  NYSE WMT  and AT T  T   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
UnitedHealth s shares have outperformed the Zacks Medical Insurance industry year to date  up  15 6  vs   13 3    The Zacks analyst thinks the company s robust Government business and continued strong performance at Optum are driving long term growth  Its international business and strong capital position driving business investment are the other positives  
The company has been witnessing an increase in membership over the past many years  It again lifted its 2018 earnings guidance  buoying optimism among investors in the stock  The company has witnessed its 2018 estimate increase by 1 2  to  12 62 over the past 90 days  
However  membership loss in its fee based commercial as well as Brazilian businesses will contract the overall membership growth for UnitedHealth Group  Additionally  higher medical care ratio raises concern 
 You can   
Shares of Walmart have lost  16  in the last six months  underperforming the Zacks Supermarkets industry s  14 5  decline in the same time period  The Zacks analyst thinks Walmart is poised to gain from its strong e commerce initiatives  particularly expansion of online grocery delivery  This  along with efforts to drive brick and mortar sales should help the company maintain its sturdy U S  comps trend  
Walmart is also undertaking efforts to improve the performance of its International unit  by shifting focus from underperforming regions to profitable countries like India and China  To this end  the company s recent investment in Flipkart is however expected to dent the bottom line in the near term  
Further  investments related to the e commerce initiatives and a compelling pricing strategy have been hurting Walmart s gross margin  Nonetheless  the Flipkart deal bodes well for the long term  which along with focus on buyouts  alliances and improved delivery services should help Walmart stand firm against Amazon  NASDAQ AMZN  
 You can   
AT T s shares have decreased  11 4  in the last three months  underperforming the Zacks Wireless National industry s fall of  4 3   AT T is gearing up to launch the first standards based mobile 5G services to consumers in multiple U S  markets by the end of 2018  
The Zacks analyst thinks the company is likely to benefit from its long pending merger with Time Warner  Given the scale of both AT T and Times Warner  the merger is likely to reshape the industry dynamics  creating a media behemoth  The deal will allow the power packed combination of AT T s data and Time Warner s content  
However  AT T s profitability has been hurt with spectrum crunch in a saturated wireless market  In addition  the company s wireline division is struggling with persistent losses in access lines due to competitive pressure from voice over Internet protocol service providers and aggressive triple play offerings by cable firms  These are weighing on AT T s revenues and margins 
 You can   
Other noteworthy reports we are featuring today include NIKE  NKE   Thermo Fisher  TMO  and Anthem  ANTM  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly  and  reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
Strong Optum  Solid Balance Sheet Aids UnitedHealth  UNH 


E commerce Sales to Fuel Walmart  WMT   Soft Margins a Woe


Time Warner Deal   5G Launch Aid AT T  T   Access Line Ails


Featured Reports
Patheon Buyout Aids Thermo Fisher  TMO  Amid Rising Costs
The Zacks analyst is bullish on Thermo Fisher boosting top line and new capabilities through buyouts like Patheon and FEI  Rising operating costs for product development and marketing is a concern 

Increasing Membership Aids Anthem s  ANTM  Revenues
Per the Zacks analyst  a number of acquisitions  Medicaid expansion in the government segment have helped the company enhance its membership base 

Project Pipeline Aids Canadian Solar  CSIQ   Competition Hurts
Per the Zacks analyst  Canadian Solar s robust project pipeline across the globe helps the company to expand its footprint worldwide 

High IBG LLC Dependence to Hurt Interactive Brokers  IBKR 
Per the Zacks analyst  Interactive Brokers  dependence on IBG LLC will hurt financials if it fails to provide funds for taxes 

Allergan s  NYSE AGN  Key Drugs   Cost Cuts to Outweigh Generic Woes
Allergan faces generic competition for key drugs Namenda XR and Restasis in 2018  The Zacks analyst says that drugs like Botox Linzess  new drugs and cost cuts can shield it from potential sales drop 

Investments Put DICK S  DKS  on Growth Track  Sales Hurt
Per the Zacks analyst  DICK S Sporting s investments in e commerce  technology  Team Sports and private brands should boost market share 

High Inventory   Weak Pricing to Strain General Motors  NYSE GM  
Per the Zacks analyst  a high inventory level of passenger cars is pushing General Motors to cut production 

New Upgrades
Prudent Cost Control   Diversification Supports Goldman  GS 
Per the Zacks analyst  Goldman s efforts towards expense management are expected to aid bottom line expansion in the coming quarters  Further  business diversification is a favorable factor 

Acquisitions  Strong Balance Sheet Aids Total System  TSS 
Per the Zacks analyst  the acquisitions of NetSpend  TransFirst  Cayan  iMobile has driven inorganic growth  Its strong free cash flow provides immense investment opportunity 

International   Online Business Aid NIKE s  NKE  Performance
Per the Zacks analyst  NIKE is gaining from strength in international and NIKE Direct businesses  both posting double digit sales growth  This also drove 23 straight quarters of earnings beats 

New Downgrades
Omnicom  OMC  Grapples with Client Concentration Risk
The Zacks analyst is worried about Omnicom s dependence on a few big clients  Further  the company s reliance on information technology systems makes it vulnerable to cybersecurity risks 

Sluggish Enrollment Trend Weighs on Adtalem Global  ATGE 
Per the Zacks analyst  Adtalem Global s total enrollments have been sluggish for several quarters now  which is marring growth prospects 

DDR s  DDR  Profitability to Bear the Brunt of Divestitures
Per the Zacks analyst  DDR Corp  s aggressive asset disposition is likely to affect its earnings  Competition from e commerce remains a concern for the company ",2018-06-19,Zacks Investment Research,https://www.investing.com/analysis/top-research-reports-for-unitedhealth-walmart--att-200326156,200326156
105278,326793,AGN,Paratek s Antibiotic Candidate Gets FDA Committee Date,opinion,Paratek Pharmaceuticals  Inc    NASDAQ PRTK   announced that an FDA advisory committee will review the new drug application  NDA  for its lead antibiotic candidate  omadacycline  on Aug 8 The NDA  seeking approval for once daily  oral and intravenous  IV  dosing of omadacycline  was filed with the FDA in April this year  With the regulatory body granting priority review to the NDA  a decision from the FDA is expected in early October  The candidate is also under review in the EU  with a decision is expected in the second half of this year Omadacycline has been developed for the treatment of community acquired bacterial pneumonia  CABP  and acute bacterial skin plus skin structure infections  ABSSSI   The candidate enjoys Qualified Infectious Disease Product  QIDP  and Fast Track designations for treating CABP and ABSSSI The NDA was supported by data from three pivotal studies   two in ABSSSI and one in CABP  Omadacycline met primary endpoints in each of these trials and was generally safe and well tolerated during its evaluation process in both  Omadacycline is also being developed for the therapy of urinary tract infections Apart from omadacycline  Paratek s acne candidate  Seysara  is under review in the United States  It has been developed in partnership with Allergan plc   NYSE AGN   Shares of Paratek have plunged 40 2  year to date  underperforming the  decline of 5 8   Paratek currently carries a Zacks Rank  3  Hold   Better ranked stocks in the same sector include CRISPR Therapeutics AG   NASDAQ CRSP   and Genomic Health Inc   NASDAQ GHDX    both sporting a Zacks Rank  1  Strong Buy   You can see CRISPR Therapeutics  loss per share estimates has been narrowed by 7 8  for 2018 and 9  for 2019 in the last 60 days  The stock has skyrocketed 166 7  year to date Genomic Health s earnings estimates have been revised 46 9  upward for 2018 and 5 6  for 2019 in the past 60 days  The stock has soared 45 5  so far this year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-06-20,Zacks Investment Research,https://www.investing.com/analysis/parateks-antibiotic-candidate-gets-fda-committee-date-200326829,200326829
105279,326794,AGN,Allergan  Crucial Period Ahead For Company As Activist Pressure Mounts,opinion,"With Activist Pressure Mounting  Allergan  NYSE AGN  Will Need Positive Results from Upcoming Catalysts
Allergan is sitting at a crucial period in the company s history  The stock has declined by over 45  since its peak in 2015  and activist shareholders have begun to get more involved with public calls for board changes and a strategic plan 

Going forward  the company will see a number of important readouts and events that could determine the fate of the company  An important set of readouts will come from competitors for Botox Aesthetics  The readouts of these drugs and any earlier than expected entrance will put pressure on Botox Aesthetics s sales  which represented 9  of total sales  Additionally  the company will see several crucial readouts for a number of drugs in the pipeline over the coming months that will either make their future look more bright or more bleak  If the latter scenario plays out  activist calls for drastic changes will become louder 
Botox and Other Core Drugs Will Face Competition Soon
Botox Aesthetics will soon see branded competition enter the market  The first competitor that could potentially come to market is Evolus with DWP 450  In mid May  the company received a CRL related to its manufacturing processes  Evolus now has a new Spring 2019 target  but some investors believe that the drug could come to market as soon as October this year if all goes to plan 
Another competitor that investors are closely watching is Revance s RT002  Revance s Phase 3 trials showed a 6 month duration  which will likely prove to be a strong differentiating factor to Botox  which has a 3 4 month duration   Revance notes that they are on track to file by 1H19  with a potential launch in 2020 
Finally  Hugel is already on the market in Korea  and is expected to have a phase 3 readout in August  The company hopes to launch the drug in late 2019 
With a slew of competitors nearing a launch  there is headline risk that could put pressure on the stock as these drugs get closer to their launch  Investors are also debating the impact these launches could have on Botox growth  and whether consensus estimates are properly accounting for the impact of competitors in the market  Management believes that Botox Aesthetic can grow in the high single digits despite the competition  Currently  consensus estimates have growth for Botox Aesthetics slowing from 11  in 2018 to 8  in 2019 and 7  in 2020 

Beyond Botox Aesthetics  investors are also watching Botox Migraine and Restasis  Botox Migraine will face volatility as the CGRPs enter the market  with Amgen  NASDAQ AMGN  s Aimovig already launched and Eli Lilly Teva entering in 2H18   Restasis will face a number of generics from Mylan  NASDAQ MYL   Akorn Inc  NASDAQ AKRX   and Teva Pharma Industries Ltd ADR  NYSE TEVA   and management is planning on increased competition in 2H18  Any delays to competition could provide upside  while earlier launches or signs of traction would provide downside 
Several Upcoming Catalysts Could Determine Viability of Pipeline
The first set of crucial catalysts is expected to come from Allergan s ubrogepant  Recall that there are currently three competitor anti CGRPs  all injectables  that are about to enter the market for migraines  Allergan has two oral anti CGRPs in the pipeline  ubrogepant and atogepant  each with the potential to reach one billion in sales  Ubrogepant is a short acting drug targeting acute treatment  while atogepant is longer acting and targeting prophylaxis treatment 
Ubrogepant will have two readouts in 2H18 that will examine Ubrogepant s safety and efficacy  Efficacy has already been shown with two prior pivotal trials  with efficacy in line with other acute migraine treatments   and is therefore less of a concern  Safety however is more of a concern as one of the single dose trials showed signs of liver toxicity  Allergan is looking at a potential submission in 2019 and a launch in 2020  Patient readouts are expected in Sep Oct 2018  while the healthy volunteer trial is more broadly expected in 2H18 
The readouts could determine the likelihood of a 2020 launch for ubrogepant  Atogepant already received positive news earlier in June with a positive Phase 2b 3 readout that showed strong efficacy and safety results  The two drugs are increasingly looking more viable and could provide more upside and perceived value to Allergan s pipeline 
Another catalyst is expected to come from Allergan s abicipar  Abicipar is a drug for age related macular degeneration  AMD   Investors have largely written off abicipar after management noted that the first generation of the drug would have material inflammation  This would represent a large flaw given that competitor drugs from Regeneron s Eylea and Roche s Lucentis have much cleaner records  In fact  the inflammation signal  as well as the strong efficacy results for Eylea and Lucentis  were factors that led investors to believe that current management was making a mistake in pushing the trial forward 
However  while investors do not expect results to be strong  if Allergan is able to show lower inflammation signals  and strong efficacy  the stock could move higher given that consensus expectations are so low for abicipar  The market for AMD is estimated at  6  billion  and existing treatments are unpleasant intraocular injections  leaving room for a competitor with a longer duration  Readouts are expected within the next 1 2 months 
Allergan s third catalyst is Rapastinel  an IV injection for acute treatment of major treatment resistant depression  Rapastinel has shown the potential to have improved safety within the ketamine class  as Phase 2 results have shown no euphoria effects  The drug is in pivotal trials and management expects to have readouts in early 2019  Additionally  the drug has the potential to expand into suicidal ideation  which is a huge market and has potential for  2  billion in sales 

Source  Allergan 1Q18 Investor Presentation
Note  Red highlights are my own
Other pipeline drugs of interest among investors include Esmya  which has an upcoming PDUFA date in August  and bimatoprost SR  which just saw a positive phase 3 readout in June  
Beyond these drugs  Allergan will have several other upcoming events that could provide more clarity on the company s strategy and the current state of its pipeline  which is the subject of heavy debate among investors  The company will have an Aesthetics analyst meeting in mid September and a R D day in 4Q18 ",2018-07-16,The Non-Consensus,https://www.investing.com/analysis/allergan-crucial-period-ahead-for-company-as-activist-pressure-mounts-200331004,200331004
105280,326795,AGN,Allergan  Inflammation Is The Reason Investors Did Not React Well To Abicipar Resu,opinion,"Abicipar Results Appeared Positive But Stock Did Not React Well
On July 19th  Allergan  NYSE AGN  announced  seemingly  positive top line results from its two phase 3 trials for abicipar  Recall that abicipar is for patients with neovascular  wet  age related macular degeneration  AMD   Wet AMD is a condition in which abnormal blood vessels grow underneath the retina and macula  causing the retina and macula to bulge or lift  The bulging leads to significant vision distortion 
As I wrote recently  the abicipar readout was one of the key catalysts for the company over the next 6 9 months  Despite the seemingly positive results  the stock has actually moved down slightly over the last several days of trading  Why 

Investors are Worried about Ocular Inflammation
As I noted in that article  investors were worried about a prior inflammation signal in one of the phase 2 trials  and needed to see a lower inflammation signal to turn more positive on the drug  Ocular inflammation showed a 15  incident rate in both trials  which was actually higher than many investors anticipated 

Source  Allergan abicipar presentation
The drug will likely receive approval despite the inflammation  but the investor concern is focused primarily on commercialization  Recall that one of the key points of differentiation from competitor drugs Eylea and Lucentis is that abicipar could be the only drug approved for 12 week dosing  vs  4 weeks for Lucentis and 4 8 weeks for Eylea   This is a key point of differentiation given that the treatment is delivered via nasty ocular injections  But to many physicians  signs of inflammation would represent a significant risk to the patient  and would not outweigh the longer duration  This is especially true given that both Eylea and Lucentis show little to no inflammation  today  
As a result  attention now shifts to its phase 2 MAPLE study  which is examining a new reformulation that may reduce the inflammation rate  Management believes that they ve identified and removed the contaminating proteins that were leading to the inflammation  Some investors have voiced concerns that the study may require further clinical trials to receive approval  even with a reduce inflammation signal  The study has no comparator arm and consists of only 100 patients in an open label trial  all of which could potentially present issues with the FDA  The MAPLE study will have a readout in 1H19  and will be included in the company s BLA filing 
Note that on a conference call after the announcement  Allergan management stated that Lucentis had actually followed a somewhat similar path in reducing inflammation rates  According to Allergan  Lucentis saw higher inflammation rates during its phase 2 trial   30    slightly lower inflammation rates during its phase 3 trial   13    and then improved on its formulation and inflammation rate over time after launch  If true  these comments should lend credence to Allergan s approach and increase the odds of positive results from the MAPLE study  Regeneron responded by stating that Eylea s trials never saw inflammation rates as high as abicipar s  We will get a more definitive answer in 1H19 
Upcoming Competition Could Present Another Headwind
Even if the drug is approved and the reformulation is successful at reducing inflammation  there are still other competitive concerns on the horizon 
The first and most urgent concern is that Eylea  the market leader in wet AMD  has an upcoming PDUFA date of August 11 for a 12 week dosing schedule  With market leading traction  low rates of inflammation  and a potential 1 year advantage on abicipar  the drug could make it significantly harder for abicipar to take share within the market 
The second set of competition could come indirectly from biosimilars  Lucentis s US patent will expire in 2020  and several competitors are already in phase 3 trials  Competition here could come to market by 2020 in the US  and in Europe by 2022 
Abicipar Revenue Opportunity A Key Question  Will Need to Show Lower Inflammation Rates to be Competitive
As I detailed in my prior overview  Allergan is more broadly facing several headwinds in key franchises  including Botox and Restasis  With activist shareholder pressure mounting  the company has a number of catalysts that could determine whether the shareholders push harder for more drastic changes or stay the course with the current strategy 
Abicipar is one such catalyst  Abicipar s inflammation rates in the most recent readout did little to quell investor concerns  and focus will now shift to its MAPLE study readout  which should determine whether the company can achieve larger commercial success or not  This readout is expected in 1H19 
Note that even if the drug is able to show lower inflammation  there are still a number of other investor concerns  including whether they would need to have an additional phase 3 trial for approval  and upcoming competition  with Eylea s Aug  11 PDUFA date the most important date to watch  
However  given that the market for wet AMD is significant at  6 billion and growing  abicipar could still potentially turn into a  1  billion drug for Allergan if they are able to show safety levels in line with current drugs  Current estimates from analysts for abicipar range from  100 million to  500 million due to this key issue  but could turn higher on a positive readout from the MAPLE study ",2018-07-23,The Non-Consensus,https://www.investing.com/analysis/allergan-inflammation-is-the-reason-investors-did-not-react-well-to-abicipar-resu-200332379,200332379
105309,326824,AGN,Top 5 Things to Know in the Market on Wednesday,news,"Investing com   Here are the top five things you need to know in financial markets on Wednesday  February 8 
1  Euro hit by political woes  yen edges higher
The euro fell against the dollar for a third day on Wednesday as concerns over growing political risks in the euro zone drove its worst run of daily losses in nearly two months 
EUR USD slid 0 32  to 1 0643  the lowest level since January 30 
The yen edged higher against the dollar ahead of a visit by Japanese Prime Minister Shinzo Abe to the U S  later this week  where trade and currency issues are expected to be in the spotlight 
U S  President Donald Trump has accused Tokyo of using monetary policy to devalue its currency to boost exports 
2  Euro zone bond yields still rising
Bond yields in the euro area continued to rise  with the gap between French and Italian yield spreads over safe haven German bunds widening to multi year highs amid fears over the prospect of a Brexit or Trump style shock in France s presidential election 
The gap between France s 10 year bond yields and Germany s 10 year yields rose to 78 8 basis points  the highest since November 2012 
Greek borrowing costs also climbed as a fresh funding crisis loomed 
Yields on 10 year Greek bonds rose above 7 6   while the yield on the 2 year bond climbed above 10  to the highest level since mid 2016 
3  Global stocks mixed
U S  stock market futures pointed to a slightly higher open on Wall Street  as investors awaited fourth quarter earnings results from HBO parent company  Time Warner  Inc  NYSE TWX  and Allergan  NYSE AGN  ahead of the opening bell 
Whole Foods Market Inc  NASDAQ WFM  and Lions Gate Entertainment  NYSE LGFa  were to release their earnings reports after the market close 
European stock markets had a mixed morning as political tensions mounted 
In Asia  markets recovered from early losses to end mainly higher with the Shanghai Composite in China closing up 0 4  and Japan s Nikkei closing up 0 5  
4  Oil prices hit three week lows
Oil prices fell to three week lows on Wednesday extending falls from the previous session after an industry report showing an unexpectedly large U S  inventory build last week underlined concerns over a global supply glut 
Brent crude  the international benchmark for oil prices  was trading at  54 73 per barrel at 11 00 GMT  down 33 cents from the last close  U S  crude was down 45 cents at  51 72 a barrel 
Elsewhere in commodity markets  gold was trading at three month highs of  1 237 75 an ounce 
5  Bitcoin slumps as China holds talks with exchanges
Prices of web based digital currency Bitcoin  itBitUSD  slumped almost 2  on Wednesday following reports that China s central bank was holding talks with several domestic bitcoin exchanges 
The reports added to concerns that Chinese regulators will ramp up oversight of digital currency trading in what is a largely unregulated market ",2017-02-08,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-in-the-market-on-wednesday-458622,458622
105310,326825,AGN,Wall St  points to muted open with earnings  oil in focus,news,"Investing com   U S  stock markets pointed to a muted open on Wednesday morning  as investors eyed more corporate earnings while monitoring movements in oil prices 
In addition  headlines from Washington will continue to dictate market sentiment as traders focus on President Donald Trump for further details on his promises of tax reform  infrastructure spending and deregulation as well as trade policies 
The blue chip Dow futures dipped 8 points  or less than 0 1   at 6 45AM ET  11 45GMT   the S P 500 futures was flat  while the tech heavy Nasdaq 100 futures was little changed 
The S P 500 ended barely higher on Tuesday while the Nasdaq managed to scratch out a new record as gains in big tech names countered energy declines 
On the earnings front   Time Warner   NYSE TWX   Allergan  NYSE AGN   GlaxoSmithKline  NYSE GSK   Humana  NYSE HUM    Goodyear Tire   NASDAQ GT    Carlyle Group   NASDAQ CG  and  Owens Corning   NYSE OC  are among the major companies scheduled to report before the bell 
Whole Foods  NASDAQ WFM  reports after the bell  as does Prudential Financial  NYSE PRU  and Suncor Energy  NYSE SU  
Meanwhile  the U S  Energy Information Administration will release its official weekly oil supplies report at 10 30AM ET  15 30GMT  Wednesday  amid analyst expectations for a rise of 2 6 million barrels 
Oil prices sank to the lowest level in about three weeks after the American Petroleum Institute said that U S  oil inventories rose by a whopping 14 2 million barrels in the week ended February 3 
U S  crude fell 57 cents  or 1 1   to  51 59  while Brent slumped 44 cents to  54 62 a barrel 
Other than the EIA data  there are no other major economic reports or Federal Reserve speakers on tap Wednesday 
Elsewhere  European stock markets were slightly higher in mid morning trade  with Germany s DAX up 0 2   as earnings season continues to be the main focus for investors 
Earlier  in Asia  markets ended mostly higher  with the Shanghai Composite in China and the Nikkei in Japan both closing up about 0 5  
In the currency market  the dollar remained moderately higher against other major currencies as political uncertainty in the U S  and Europe continued to dominate market sentiment 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was up 0 2  at 100 55 in early trade  pulling away from last week s two month low of 99 19 ",2017-02-08,Investing.com,"https://www.investing.com/news/stock-market-news/wall-st.-points-to-muted-open-with-earnings,-oil-in-focus-458631",458631
105311,326826,AGN,Allergan Q4 earnings beat estimates  EPS  3 90 ,news,Investing com    NYSE Allergan  Wednesday reported fourth quarter earnings that beat estimates The maker of BOTOX posted a 16 1  rise in Q4 adjusted net income per share to  3 90 Net revenues in the quarter climbed 7 1  from a year earlier to  3 86 bn The pharmaceutical firm was expected to report EPS of  3 76 on revenues of  3 81 bn ,2017-02-08,Investing.com,https://www.investing.com/news/stock-market-news/allergan-q4-earnings-beat-estimates;-eps-$3.90-458642,458642
105312,326827,AGN,Allergan beats profit estimates  forecasts upbeat 2017,news, Reuters    Allergan Plc  N AGN  reported quarterly earnings and revenue that topped Wall Street estimates  as higher demand for Botox and eye treatment Restasis helped offset declines in its older drugs  and the company forecast 2017 revenue above expectations   The company s revenue rose 7 percent to  3 86 billion in the fourth quarter ended Dec  31  beating the average estimate of  3 77 billion  according to Thomson Reuters I B E S   The beat was also driven by demand for its constipation medicine Linzess that more than made up for declining sales of older drugs  such as its Alzheimer s dementia treatment Namenda and Asacol for ulcerative colitis  Chief Executive Brent Saunders  one of the industry s most active dealmakers  took the blame for the company s third quarter profit miss  citing unanticipated declines in sales of Allergan s older medicines  Allergan  which in September pledged to limit drug price increases to 10 percent  said it had raised the price of certain U S  branded products by 6 7 percent  on average  effective January  Net price increases on its U S  products averaged 4 8 percent in 2016  the company said  Net loss attributable to ordinary shareholders narrowed to  70 2 million  or 20 cents per share  in the fourth quarter ended Dec  31  from  700 5 million  or  1 78 per share  a year earlier   Excluding items  the company earned  3 90 per share  handily beating the average estimate by 14 cents   The Dublin based company also forecast on Wednesday adjusted earnings in the range of  15 80 per share to  16 30 per share on revenue of  15 50 billion to  15 80 billion for 2017   Analysts on average were expecting a profit of  16 01 per share and revenue of  15 37 billion   Allergan said last month it expected to achieve double digit adjusted earnings growth and mid single digit net revenue percentage growth in 2017  a forecast it called  realistic   The company s stock inched about 1 percent to  235 61 in light premarket trading on Wednesday ,2017-02-08,Reuters,https://www.investing.com/news/stock-market-news/allergan-revenue-up-7-percent-as-botox-offsets-drop-in-older-drug-sales-458637,458637
105313,326828,AGN,Wall St off as earnings digested  EIA data ahead ,news,Investing com   U S  stocks were lower early Wednesday as investors digested earnings reports The DJI was down 0 20  at 09 45 ET The S P 500 shed 0 25  The tech heavy Nasdaq composite lost 0 30  Oil was lower ahead of EIA data as the API reported a massive rise in U S  crude stocks The dollar gave up gains as the euro and other major currencies firmed  NYSE Time Warner  was up 0 43  at  96 64 after earnings beat forecasts  NYSE Allergan  gained 1 42  to  235 92 also after earnings topped estimates ,2017-02-08,Investing.com,"https://www.investing.com/news/stock-market-news/wall-st-off-as-earnings-digested,-eia-data-ahead-458687",458687
105314,326829,AGN,Drugmaker Stada confirms takeover bid from two companies,news," Reuters    German generic drugmaker Stada  DE STAGn  said it has received two offers for the acquisition of the company  one of which is private equity group Cinven Partners LLP  Cinven is offering a price of 56 euros per Stada share  Stada did not mention the name of the other bidder  The company said it is still weighing its options and says it is  not possible to foresee whether a takeover offer from Cinven or the other potential bidder will materialize   The Financial Times earlier reported that Stada had received an offer from Cinven for 58 euros per share  valuing the bid at 3 6 billion euros   3 83 billion    In August  the chief executive of Stada  Matthias Wiedenfels  under pressure from activist investors to reform the company s governance and replace board members  promised a more modern  dynamic approach to running the company   Stada steered clear of major merger deals last year as the generic drug industry began consolidating to cut costs  driven by larger players including Teva  TA TEVA  and Allergan  N AGN   
Stada had focused instead on branching out into branded consumer care and cosmetics products as well as diagnostics kits ",2017-02-12,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-stada-confirms-takeover-bid-from-two-companies-459453,459453
105315,326830,AGN,Teva seeks CEO with pharma background to lead recovery efforts,news,"By Tova Cohen TEL AVIV  Reuters    Teva Pharmaceutical Industries  TA TEVA  is seeking a new chief executive with deep drug industry experience  the Israel based company said on Monday as it looks to restore confidence after a series of missteps and the departure of CEO Erez Vigodman   Teva  the world s biggest generic drug maker  was left without a permanent chief last week after Vigodman  an industry outsider  stepped down following a string of costly acquisitions and delayed drug launches which sent its shares to their lowest in more than 10 years   We are here to fix what is not working  we will leave no stone unturned   interim CEO Yitzhak Peterburg said on Monday after the company reported higher than expected fourth quarter earnings  Its shares bounced 4 2 percent to  33 55 in early trade in New York  Teva s main focus in 2017 will be extracting benefits from its  40 5 billion acquisition of the  Actavis   NYSE AGN  generic drug business in August  implementing efficiency measures  generating cash and paying down debt  Peterburg said  Teva has already faced calls for management and structural changes  including a possible split into separate generic and branded medicine units   With the entire Teva team  I am conducting a thorough review of the business to find additional opportunities to enhance value   Peterburg said  He declined or say whether this could include breaking up the company  Investors have said Teva  which faces pricing pressure in its core generics business and recently lost protection on four of its patents for its key branded drug Copaxone for multiple sclerosis  must choose a new CEO with extensive pharmaceutical experience  DEEP EXPERIENCE   We want someone with deep and broad pharmaceutical experience     that can take Teva to the next level   Teva s new chairman  former Celgene  O CELG  CEO Sol Barer  said  noting he was personally involved in the search  Teva earned  1 38 per share excluding one time items in the fourth quarter  up from  1 28  Revenue grew 33 percent to  6 5 billion  primarily due to the inclusion of  630 million from the Actavis acquisition  Teva  N TEVA  had been forecast to earn  1 35 excluding one off items on revenue of  6 24 billion  according to Thomson Reuters I B E S   While today s results are likely to reassure investors following a turbulent past several months for Teva  execution over the longer term is required to alleviate investor concerns   Citi analyst Liav Abraham said  Global sales of Copaxone rose 6 percent in the quarter to  1 0 billion  Cash flow from operations fell 12 percent to  1 4 billion Teva reaffirmed its 2017 forecast of EPS between  4 90 and  5 30  on revenue of between  23 8 billion and  24 5 billion  Teva is  very committed  to this EPS range and will do what it takes to protect it  including additional cost cuts if necessary  Peterburg said  But the U S  launch of one or two generic competitors to Copaxone this month could lower 2017 revenue by between  1 billion and  1 3 billion and EPS by between 75 and 95 cents  Teva said  
It will pay an unchanged quarterly dividend of 34 cents per ordinary share and  17 50 per mandatory convertible preferred share  Teva has no plans to change its payout  Barer said ",2017-02-13,Reuters,https://www.investing.com/news/stock-market-news/teva-seeks-ceo-with-pharma-background-to-lead-recovery-efforts-459572,459572
105316,326831,AGN,Allergan to buy fat fighter Zeltiq Aesthetics for  2 48 billion,news,"By Michael Erman and Natalie Grover  Reuters    Botox maker Allergan  NYSE AGN  Plc  agreed to pay  2 48 billion in cash for Zeltiq Aesthetics Inc  adding a system that it says helps people slim down by freezing fat away to the company s line up of aesthetic products  Allergan said it would benefit from the cross selling opportunities for consumers of Zeltiq s CoolSculpting System  which uses cooling to kill fat cells  as well as customers of its own facial injectible products   Demand for both procedures is high and this is similar to pouring more gas on the fire   Allergan Chief Commercial Officer Bill Meury said on a call with investors  The Botox maker agreed to pay  56 50 per Zeltiq share  or a premium of 14 4 percent to the company s Friday close  Zeltiq s shares rose 12 8 percent to  55 72 in midday trading on Monday  Zeltiq s process was created after two scientists at Harvard University noticed that some children who ate popsicles got dimples in their cheeks  according to Zeltiq s website  They discovered that the popsicles were eliminating small pockets of fat cells  Insurers do not cover Zeltiq s CoolSculpting System  meaning the bulk of the company s more than  350 million in 2016 sales was paid directly by consumers  Allergan said it has been targeting so called  cash pay  businesses  which is a model it uses for some of its Botox sales and other aesthetic offerings  CoolSculpting is approved by the U S  Food and Drug Administration   Dublin based Allergan  led by its Chief Executive Brent Saunders  has struck a number of deals since its  160 billion merger with  Pfizer  Inc  NYSE PFE  collapsed in April  Those have included its  2 9 billion purchase of regenerative medicine business LifeCell Corp and the  1 5 billion acquisition of biotech company Vitae Pharmaceuticals   Earlier this month  Saunders set lofty expectations for its injection Kybella   used to diminish fat under the chin  leaving surrounding tissue largely unaffected   for 2017  and expressed an interest in continued deal making  In the three months ended Dec  31  total medical aesthetic product sales accounted for 28 percent of Allergan s net revenue  Allergan  which estimates that body contouring is a  4 billion market  said the transaction is expected to close in the second half of 2017  Shares of Allergan rose  1 27  or 0 5 percent  to  247 63 in midday trading on the New York Stock Exchange  
Moelis   Co is Allergan s financial adviser  while Debevoise   Plimpton LLP serve as legal counsel  Guggenheim Securities is Zeltiq s financial adviser  while Cooley LLP will provide legal advice ",2017-02-13,Reuters,https://www.investing.com/news/stock-market-news/allergan-agrees-to-buy-zeltiq-for-about-$2.48-billion-459551,459551
105317,326832,AGN,BioDelivery  BDSI  Q1 Earnings And Sales Beat Estimates,opinion,"BioDelivery Sciences International  Inc    NASDAQ BDSI   reported a loss of 18 cents per share for first quarter 2018  which was narrower than the Zacks Consensus Estimate of a loss of 23 cents  However  in the year ago quarter the company had recorded earnings of 87 cents per share BioDelivery s shares have underperformed the  this year so far  The stock has declined 40 7  during the period compared with an 11 4  decrease for the industry Revenues were  11 3 million in the reported quarter  down 61 7  from the year ago period  The top line beat the Zacks Consensus Estimate of  10 78 million by a slight margin The year over year decline in revenues was mainly due to the recognition of deferred revenues associated with the termination of a license agreement for Belbuca with Endo Pharmaceuticals  a subsidiary of Endo International Plc   NASDAQ ENDP   We remind investors that BioDelivery reacquired the worldwide rights to Belbuca in January 2017 from Endo  As a result of this reacquisition  the company started registering product revenues for Belbuca against royalties recorded previously Excluding the deferred revenues  total sales rose 9  year over year Quarter in DetailBioDelivery s opioid dependence drug  Bunavail  recorded  1 8 million sales in the quarter  down 43 8  year over year  However  revenues from the drug rose 5 9  sequentially BioDelivery s second marketed drug  Belbuca  for chronic pain  generated revenues of  8 0 million in the quarter  down 14 9  from the previous quarter  Sales rose 76  year over year Prescription volume for Belbuca expanded 9  sequentially and 55  year over year supported by improved managed care coverage and expansion of sales force  In the quarter  BioDelivery signed new contracts with Humana  NYSE HUM   ProCareRx  and CVS Caremark and improved coverage with UnitedHealthcare In the month of March  the company recorded an all time high in prescription volumes to more than 10 000 prescriptions  This marked an increase of nearly 20  from the previous high reached in January  Management seems confident that Belbuca will witness continued strong growth in 2018 Belbuca was made commercially available in Canada by BioDelivery s partner Purdue Pharma for severe pain in January 2018  which can drive sales further in the future quarters Research and development expenses declined 7  from the year ago period to  2 48 million  Selling  general and administrative expenses rose 1 9  year over year to  13 5 million in the quarter Other Updates Earlier this week  BioDelivery Sciences announced the appointment of Herm Cukier as its new chief operating officer  Cukier was until now serving as the senior vice president at Allergan   NYSE AGN   In February  BioDelivery entered into a settlement agreement with Teva Pharmaceuticals   NYSE TEVA    resolving its Belbuca patent litigation  Pursuant to this non exclusive license agreement  Teva will now be permitted to begin selling its generic version of Belbuca in the United States on Jul 23  2027 or earlier under certain circumstances 
 BioDelivery Sciences International  Inc  Price  Consensus and EPS Surprise
    
 BioDelivery currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/biodelivery-bdsi-q1-earnings-and-sales-beat-estimates-200315504,200315504
105318,326833,AGN,Amgen s Label Expansion Application For Prolia Gets FDA Nod,opinion,Amgen  Inc    NASDAQ AMGN   announced that the FDA has approved its supplemental Biologics License Application  sBLA  seeking label expansion for Prolia for the treatment glucocorticoid induced osteoporosis   GIOP   in men and women at high risk of fracture or those who have failed or are intolerant to other available osteoporosis therapy This is the fifth approved indication for Prolia  The approval is backed by increase in bone mineral density   BMD   achieved by the drug in a phase III study The drug is presently marketed in the United States for the treatment of postmenopausal women with osteoporosis at high risk for fracture as well as to increase bone mass in men with osteoporosis at high risk for fracture Shares of Amgen were up 0 1  in after market trading following the news  The company s shares have rallied 1 5  this year so far against the  s decline of 9 8  The phase III study evaluated Prolia for the treatment of GIOP patients in men and women at high risk of fracture or those who have failed or are intolerant to other available osteoporosis therapy compared to Allergan s   NYSE AGN   Actonel  risedronate   The study comprises two patient groups   one with patients who have received glucocorticoid treatment for less than three months prior to study enrollment  glucocorticoid initiating arm  and the second with patients who have received glucocorticoid treatment for at least three months  glucocorticoid continuing arm   In both the arms  the glucocorticoid treatment was continued for at least six months Data from the study showed that Prolia increased lumbar spine BMD by 3 8  compared with 0 8  by Actonel in glucocorticoid initiating arm  Lumbar spine BMD in patients treated with Prolia in glucocorticoid continuing arm increased 4 4  compared with 2 3  for Actonel Glucocorticoid induced osteoporosis is the most common form of secondary osteoporosis  This serious condition is presently treated with glucocorticoid treatment  which increases fracture risk within the first three months of treatment  Prolia can now cater to an expanded patient population and drive sales higher Prolia is a key revenue generator for Amgen and is witnessing market share gains in both the United States and internationally amid competition from generics of other drugs approved for osteoporosis  In 2017  the drug generated sales of  1 97 billion  up 20  year over year Prolia faces competition from several drugs  especially from generic versions of Eli Lilly s   NYSE LLY   Evista  alendronate   Merck s   NYSE MRK   Fosamax  raloxifene  and Novartis  Zometa  zoledronate  Amgen Inc  Price   Zacks Rank Amgen currently carries a Zacks Rank  3  Hold   You can  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-05-22,Zacks Investment Research,https://www.investing.com/analysis/amgens-label-expansion-application-for-prolia-gets-fda-nod-200318269,200318269
105319,326834,AGN,Allergan Stock Down Since Q1 Earnings Report  Here s Why,opinion,Shares of Allergan plc   NYSE AGN   have declined 4 4  since it reported its first quarter 2018 results on Apr 30  In fact  so far this year  Allergan s share price has declined 5 3   compared with the  s decline of 6 8  Allergan s first quarter 2018 results were strong as it beat expectations for both earnings and revenues  Earnings rose 11 6  year over year  driven by higher revenues and lower operating costs  Revenues increased 6  on an organic basis excluding the impact of M A and foreign exchange  Not only this  Allergan raised its earnings and sales guidance range for 2018 Also  this year  Allergan announced successful study results from two late stage studies on its anti CGRP acute migraine candidate  ubrogepant and a line extension study on Vraylar in bipolar I depression  Meanwhile  its anti infective drug  Avycaz gained FDA nod for a third indication in the United States  It gained EU approval for Mvasi  Allergan and partner Amgen s   NASDAQ AMGN   biosimilar version of Roche s   OTC RHHBY   cancer drug  Avastin Despite such strong quarterly performance and positive regulatory updates  shares of this pharma company continue to decline this year We believe this is because Allergan is facing loss of exclusivity for several of its key products and it will continue through 2018  This is what concerns analysts  While the first generic versions of Alzheimer s treatment Namenda XR and Estrace cream were launched in the first quarter  that of blockbuster dry eye drug  Restasis  Allergan s second best selling drug  is expected to be launched in the second quarter A generic version of Delzicol is also expected to be launched in early second quarter 2018  Allergan estimates that the products facing loss of exclusivity were worth 3 billion in 2017  Sales of these products are expected to decline significantly in 2018 with the introduction of generics On the first quarter conference call  Allergan management addressed this disconnect between its business performance and stock value  Allergan s CEO Brent Saunders said it is conducting a strategic review of its business  which can unlock shareholder value Management discussed several strategic options  which included incremental aggressive share buyback  divestiture of certain assets to concentrate more on key therapeutic areas  splitting the company and making smaller bolt on acquisitions  Allergan has hired multiple financial advisors to help evaluate the different options Regarding M A activity  Allergan said that though a large merger is unlikely  it may make product pipeline acquisitions that could strengthen its key areas of therapeutic focus  However  Saunders also said that splitting the company is not quite likely to be the outcome of the strategic review as it could prove time consuming  complicated and costly We need to wait and see if management s optimism surrounding these strategic options gets reflected in its share price  going forward Allergan currently carries a Zacks Rank  3  Hold  A better ranked drug biotech stock is Ligand Pharmaceuticals   NASDAQ LGND   with a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates increased 7 4  for 2018 and 8  for 2019 in the last 30 days  The company delivered a positive earnings surprise in all the trailing four quarters  with an average beat of 31 79   The company s shares have rallied 36 7  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-05-22,Zacks Investment Research,https://www.investing.com/analysis/allergan-stock-down-since-q1-earnings-report-heres-why-200318733,200318733
105320,326835,AGN,Allergan Recalls Taytulla Oral Contraceptives  Stock Down,opinion,Allergan plc   NYSE AGN   announced a nationwide recall of some sample packs of Taytulla softgel oral contraceptive capsules  1mg 20mcg   Allergan said that four non hormonal placebo pills were erroneously placed where the contraceptive capsules should have been  This instigated the recall following a physician report on the same Allergan warned that the four inactive pills raise the risk of unintended pregnancy and the patients who have concerns should consult a doctor Shares of Allergan were down almost 2  on Tuesday following the recall  In fact  so far this year  Allergan s share price has declined 7 7   compared with the  s decline of 5 8  Despite a strong first quarter performance and positive regulatory updates  shares of this pharma company continue to decline this year We believe that this is because Allergan is facing loss of exclusivity for several of its key products and this will continue through 2018 This is what concerns analysts  While the first generic versions of Alzheimer s treatment Namenda XR and Estrace cream were launched in the first quarter  that of blockbuster dry eye drug  Restasis  Allergan s second best selling drug  is expected to be launched in the second quarter A generic version of Delzicol is also expected to be launched in early second quarter 2018 Allergan estimates that the products facing loss of exclusivity wereworth 3 billion in 2017  Sales of these products are expected to decline significantly in 2018 with the introduction of generics On the first quarter conference call  management addressed this disconnect between its business performance and stock value  Allergan s CEO Brent Saunders said that the company is conducting a strategic review of its business  which can unlock shareholder value Allergan currently carries a Zacks Rank  3  Hold  Better ranked drug biotech stocks include Eli Lilly   Company   NYSE LLY    BioMarin Pharmaceutical  Inc    NASDAQ BMRN   and Ligand Pharmaceuticals   NASDAQ LGND    all with a Zacks Rank  2  Buy   You can see  Lilly s earnings estimates increased 5 7  for 2018 and 2 8  for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with an average beat of 8 20  BioMarin s earnings estimates rose 47 7  for 2018 and 19 1  for 2019 in the past 60 days  Shares of BioMarin have rallied 1 5  this year so far Ligand s earnings per share estimates increased 11 8  for 2018 and 8  for 2019 in the last 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with an average beat of 31 79   The company s shares have rallied 36 6  year to date Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-05-29,Zacks Investment Research,https://www.investing.com/analysis/allergan-recalls-taytulla-oral-contraceptives-stock-down-200320574,200320574
105321,326836,AGN,Why Is Allergan  AGN  Down 4 1  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Allergan plc   NYSE AGN    Shares have lost about 4 1  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is AGN due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Allergan Beats on Q1 Earnings   SalesAllergan s first quarter 2018 earnings came in at  3 74 per share  beating the Zacks Consensus Estimate of  3 36 as well as the guided range of  3 20  3 40  Earnings rose 11 6  year over year driven by higher revenues and lower operating costs Revenues came in at  3 67 billion  which marginally exceeded the Zacks Consensus Estimate of  3 59 billion as well as the guided range of  3 5 billion and  3 6 billion  Revenues rose 2 8  from the year ago period  On an organic basis  excluding the impact of M A and foreign exchange  sales grew 6  in the quarter Key products like Botox  Juv derm collection of fillers  Linzess and Lo Loestrin continued to do well in the quarter  However  lower sales of Namenda XR  Estrace  Minastrin and Asacol due to generic competition hurt first quarter sales by  200 million First quarter revenues also benefited from the addition of Alloderm from LifeCell  January 2017  and CoolSculpting body contouring system from Zeltiq  April 2017  acquisitions Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues increased 6 5  to  1 58 billion driven by continued strong performance of its facial aesthetics products  Botox and Juv derm collection of fillers In Facial Aesthetics  Botox  cosmetic  raked in sales of  196 7 million  up 7  year over year while Juv derm collection of fillers rose 2 5  to  122 8 million  However  sales of Botox  cosmetic  and Juv derm were hurt by unfavorable timing of promotional offers and year end physician rebate program in the quarter  However  Allergan is optimistic that their sales trends will normalize over the remainder of the year  On the call  Allergan said that sales for Botox  cosmetic  and Juv derm are expected to increase at double digit rates in 2018 In Eye Care  while Ozurdex sales rose 13 3  to  25 5 million  Restasis  sales decreased 17 2  to  255 8 million hurt by unfavorable trade buying patterns and lower selling price  Botox Therapeutic revenues were  358 5 million  up 16 1  driven by demand growth  In Plastic Surgery  breast implants sales increased 11 8   which contributed to the upside  In Medical Dermatology  Aczone sales plunged 60 6  in the reported quarter to  16 million due to generic pressure on the branded acne category and higher discounts to maintain formulary coverage and a generic launch of Aczone 5  LifeCell s Alloderm added  99 5 million while Zeltiq s CoolSculpting business added  87 1 million to sales in the quarter U S  General Medicine net revenues were down 9 1  year over year to  1 22 billion in the reported quarter with sales declining in the Diversified Brands  Central Nervous System  CNS  and Women s Health franchises  Anti Infectives sales rose 28 5  to  71 6 million and Gastrointestinal inched up 0 3  to  388 7 million Lower sales of Namenda XR  Estrace  Minastrin and Asacol due to generic competition hurt sales in this segment  which were partially offset by strong growth from Vraylar  Linzess and Lo Loestrin Linzess  sales rose 7 9  to  159 3 million  driven by strong demand  Lo Loestrin sales rose 14 8  to  114 6 million driven by higher average selling prices and increased demand Among the newer products  Namzaric  a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  33 4 million  less than  36 8 million in the previous quarter  Viberzi recorded sales of  35 9 million  also less than  42 9 million in the previous quarter  Vraylar sales were  84 4 million in the first quarter  lower than  87 7 in the previous quarter due to first quarter seasonality and unfavorable payer dynamics  However  Vraylar volume grew 11  on a sequential basis supported by demand growth Namenda XR sales slumped 66 8  to  40 5 million in the reported quarter due to generic competition following loss of exclusivity in February Estrace cream sales declined 91 3  to  6 4 million in the quarter Asacol Delzicol sales declined 33 7  to  38 2 million due to loss of exclusivity In the Women s Health segment  Minastrin 24 revenues plummeted 87 3  to  5 2 million in the quarter due to loss of exclusivity last March The International segment recorded net revenues of  864 million  up 17 2   up 9   excluding foreign exchange  from the year ago period  driven by growth in Medical Aesthetics  Botox  therapeutic  and Eye Care Profits RiseAdjusted gross margin declined 110 basis points  bps  in the quarter to 86 2  hurt by unfavorable product mix due to loss of exclusivity of higher margin products Adjusted operating income increased 8 7  to  1 76 billion in the first quarter  Adjusted operating margin rose 260 bps in the quarter to 47 9  due to lower operating costs Selling  general and administrative  SG A  expenses decreased 5 2  to  1 05 billion in the first quarter owing to a substantial reduction in selling and marketing spending from the successful execution of the restructuring program Research and development  R D  expenses also declined 9 7  to  355 8 million due to pipeline re prioritization Other DetailsIn the first quarter  Allergan paid down  3 6 billion in net debt and completed its  2 billion share repurchase program announced in September 2017 2018 OutlookAllergan raised its earnings and sales guidance range for 2018  A better than expected first quarter performance  lower share count and a delay in generic Restasis entry led to the increase in the guidance  A generic version of Restasis is now expected to be launched between May and July versus April to July expected previously  adding  80 million per month to the top line projections Allergan lifted its sales guidance to an approximate range of  15 15  15 35 billion compared with the earlier forecast of  15 0  15 3 billion Meanwhile  the company also raised its adjusted earnings expectation in the band of  15 65  16 25 per share from  15 25  16 00 guided earlier The company maintained the guidance range for adjusted tax rate  gross margin  SG A and R D costs Adjusted tax rate is still expected to be approximately 14  in 2018 Adjusted gross margin guidance is expected in the range of 85 5  and 86  which is lower than 2017 levels  Gross margins are expected to be hurt by loss of exclusivity of high margin products   Restasis  Estrace and Delzicol   and unfavorable product mix Adjusted R D expenses are expected to be approximately  1 5 billion while SG A spend is expected to be approximately  4 25 billion Operating margins in 2018 are expected to be in line with 2017 levels Share count in 2018 is expected to be approximately 345 million shares versus the prior guidance of 350 million shares attributable to the earlier completion of the buyback Strategic OptionsOn the call  Allergan said it is conducting a strategic review of its business due to the disconnect between its business performance and stock value  Management discussed several strategic options including incremental aggressive share buyback  divesting certain assets to concentrate more on key therapeutic areas  splitting the company and making smaller bolt on acquisitions  Regarding M A activity  Allergan said that though a large merger is unlikely  it may make product pipeline acquisitions that could strengthen its key areas of therapeutic focus  Allergan s CEO Brent Saunders also said that splitting the company is not quite likely to be the outcome of the strategic review as it could prove complicated and costlySecond Quarter 2018 OutlookIn second quarter 2018  revenues are anticipated between  3 85 billion and  4 0 billion while earnings per share are likely to be between  4 and  4 20 
On the call  Allergan clarified that first quarter earnings benefited from favorable timing of operating expenses  which will reverse in the remaining quarters of the year  This suggests that operating costs could be higher in the second quarter How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been 16 revisions higher for the current quarter compared to three lower  Last month  the consensus estimate has shifted by 5 3  due to these changes 
Allergan plc Price and Consensus
    VGM Scores
At this time  AGN has a great Growth Score of A  though it is lagging a bit on the momentum front with a B  Following the exact same course  the stock was also allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for growth investors than those looking for value and momentum 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising  Notably  AGN has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-29,Zacks Investment Research,https://www.investing.com/analysis/why-is-allergan-agn-down-41-since-its-last-earnings-report-200320560,200320560
105322,326837,AGN,Ironwood Pharmaceuticals  IRWD  Down 10 3  Since Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Ironwood Pharmaceuticals  Inc    NASDAQ IRWD    Shares have lost about 10 3  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is IRWD due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts Ironwood Incurs Loss in Q1  Announces RestructuringIronwood reported first quarter 2018 adjusted loss of 27 cents per share  which waswider than the Zacks Consensus Estimate of a loss of 16 cents  However  the company had reported adjusted loss of 33 cents in the year ago period Total revenues  collaborative revenue  in the quarter amounted to  69 2 million  up 32 7  from the year ago period  However  it missed the Zacks Consensus Estimate of  89 5 million The Quarter in DetailAs reported by partner Allergan  NYSE AGN   Linzess generated U S  net sales of  159 3 million  up 7 9  year over year Ironwood and Allergan equally share brand collaboration profits or losses  Ironwood s share of net profits from the sales of Linzess in the United States  included in collaborative revenues  was  61 2 million in the first quarter  up 23 7  year over year  Sales of linaclotide active pharmaceutical ingredient to the company s Japanese partner Astellas Pharma added  5 4 million to revenues Linzess witnessed continued strong demand growth year over year  According to data provided by IMS Health  Linzess prescriptions filled during the quarter were more than 764 000  up 9  from the year ago period  The drug s uptake continued to grow in 2018 following a strong performance in 2017 and it remained a market leader among branded prescription drugs Zurampic and Duzallo  approved for uncontrolled gout  generated sales of  0 6 millionDuring the reported quarter  selling and administrative  SG A  expenses increased 11 4  to  61 9 million and research and development  R D  expenses were  37 1 million  up 8 3  from the year ago period 2018 GuidanceIronwood expects to incur charges related to a restructuring initiative announced in May 2018  Hence  the company did not provide any financial guidance for the full year and plans to provide an update in the second quarter earnings release 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been two revisions lower for the current quarter  In the past month  the consensus estimate has shifted downward by 22 2  due to these changes 
Ironwood Pharmaceuticals  Inc  Price and Consensus   VGM Scores
At this time  IRWD has a subpar Growth Score of D  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate investors will probably be better served looking elsewhere 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  IRWD has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/ironwood-pharmaceuticals-irwd-down-103-since-earnings-report-can-it-rebound-200321002,200321002
105323,326838,AGN,Allergan Requests Shareholders To Veto Management Change,opinion,"Allergan plc   NYSE AGN   issued a statement in response to a letter from public shareholders from Appaloosa and Senator Investment Group of the company expressing disappointment on the recently announced strategic plan to divest the women s health and infectious disease units Activist investors Tepper from Appaloosa and Douglas Silverman from Senator Investment Group and have requested to split Brent Saunders  responsibilities  who is currently the chairman as well as the chief executive officer   CEO    They suggested recruiting a new chairman or CEO who is not from the company  replacement of two additional board members and changes to management of critical operating units  They are of the view that the company needs fresh ideas  They believe the above changes are required to drive returns or else share prices will continue to decline In its statement  the company stated that its board and management are open to inputs from all shareholders and considers the same while making decisions  They are focused on building a world class company and drive return for shareholders On its earnings call held in May  Allergan management discussed several strategic plans including divestment and share buybacks  The company recently concluded its strategic review and announced that it will focus on its leading four therapeutic areas   medical aesthetics  CNS  eye care and GI   and will divest the two units mentioned above  In January  the company cut jobs as part of a restructuring process Moreover  Allergan also mentioned that the board has been refreshed with the addition of three members in the last 16 months Meanwhile  the shareholders have rejected the proposal of splitting the role of Brent and appointment of an independent chairman during the annual general meeting held in May So far this year  Allergan s share price has declined 7  compared with the  s decline of 6 4  
We note that Allergan recorded strong earnings in the first quarter and also announced successful results from clinical studies  However  its shares are declining as several of its key products are facing loss of exclusivity  which may have an unfavorable impact on the top line Restasis  a major revenue contributor  is facing stiff competition with the launch of Shire plc s   NASDAQ SHPG   dry eye disease drug Xiidra last year  Its sales have declined more than 17  in the first quarter  A generic version of the drug may also be launched by mid 2018  Meanwhile  Synergy Pharmaceuticals Inc  s   NASDAQ SGYP   Trulance  which was approved for chronic idiopathic constipation last year is expected to increase competition for Linzess  Several companies are looking to bring generic version of the drug in the market  Moreover  in January  Mylan   NASDAQ MYL   launched the generic version of Estrace vaginal cream  which saw sales erosion of more than 90  in the first quarter The company estimated that the products losing exclusivity were worth  3 billion in 2017  We expect a significant decline in revenues from these products Allergan plc Price
    Allergan currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-05,Zacks Investment Research,https://www.investing.com/analysis/allergan-requests-shareholders-to-veto-management-change-200322616,200322616
105342,326857,AGN,Investors see Biogen CEO choice as friendly to potential takeover,news,"By Bill Berkrot and Carl O Donnell NEW YORK  Reuters    The surprise selection of Michel Vounatsos to run Biogen Inc  O BIIB  signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains  and likely keeps the U S  biotech in play as a takeover target  Vounatsos joined Biogen as chief commercial officer in April after 20 years leading various commercial operations at Merck   Co  N MRK   Three months later  Biogen CEO George Scangos said he would step down  initiating a search for his successor that concluded with Monday s announcement that Vounatsos would take the helm Jan  6  Biogen shares rose more than 2 percent on Tuesday as investors viewed the choice of an internal CEO candidate as keeping alive a potential takeover of the company  Biogen has been subject of takeover speculation since August  when the Wall Street Journal reported it had received early stage overtures from several bidders  including Allergan Plc  N AGN  and Merck    The same strategic value of the assets are still there and the company is the same as it was last week  They still have the theoretical potential of being a target for players like Merck or  Pfizer   N PFE    RBC Capital Markets analyst Michael Yee said   While Biogen is still focused on producing treatments for devastating illnesses with few treatments  including Alzheimer s and Parkinson s  Vounatsos is being tasked with a more careful approach to how the company spends on development  and to make the most out of its existing flagship portfolio of multiple sclerosis treatments  Vounatsos stressed this goal during a call with Wall Street analysts on Tuesday  saying  we will not leave a stone unturned in order to continue to grow this franchise   After several years of impressive share price and earnings growth under Scangos  Biogen hit a major bump in the road in mid 2015  when its most important growth driver  the oral MS drug Tecfidera  badly missed sales estimates  That forced the company to lower its earnings forecasts and subsequently announce a reorganization and spin off of its hemophilia business  Slowing growth of its MS drugs and fears of potential U S  curbs on drug pricing that hit the entire biotech sector put additional pressure on Biogen shares  Vounatsos said he would be assessing company execution and resource allocation decisions and let Wall Street know in the first half of 2017 whether he will  validate or slightly alter the path forward   Cowen and Co analyst Eric Schmidt said many people had assumed Biogen would choose another leader with a scientific pedigree to maintain its traditional culture  Scangos  a scientist by trade  went on to head research for Bayer AG s  DE BAYGn  pharmaceutical division and led its biotechnology unit before becoming CEO of a discovery stage biotech  Exelixis Inc   O EXEL     The board seems to be of the opinion that Biogen has matured into a complex commercial organization  and that protecting and growing the company s  11 billion revenue base is now the most important priority   Schmidt said  THE CONTENDERS Speculation about internal CEO candidates had centered on two highly regarded executives with longer Biogen tenure   Chief Financial Officer Paul Clancy and Chief Medical Officer Al Sandrock   Some investors were hoping to see an outside candidate chosen to bring a fresh perspective to the company  although that would also likely send a clear message that Biogen intended to remain independent   Many investors were looking for more of a deal oriented CEO or an external executive who has already been in a CEO role    Barclays   LON BARC  analyst Geoff Meacham said in a note  calling Vounatsos  a safe choice   Vounatsos said he would be looking for deals to help fill out all stages of the drug development pipeline  While he has yet to oversee a major new drug launch at Biogen  typically the best way to judge performance of a chief commercial officer  one is in the offing  Biogen is widely expected to get U S  approval in coming months for the first drug that would treat spinal muscular atrophy  the leading genetic cause of death in infants   The drug  Spinraza  is seen as a breakthrough therapy and forecast to become a multibillion dollar product if approved for all SMA patients  And then there is aducanumab  the experimental Alzheimer s disease drug considered potentially the most valuable pipeline asset in biotechnology  and one that highlights Biogen s current very high risk  very high reward strategy  The drug has shown early promise  But it is at least a few years from reaching the market and could well fail  as over 100 previous attempts to develop an effective Alzheimer s treatment have already   
If it succeeds Biogen  or any company that buys Biogen  will own one of the great cash cows in pharmaceutical history ",2016-12-20,Reuters,https://www.investing.com/news/stock-market-news/investors-see-biogen-ceo-choice-as-friendly-to-potential-takeover-449033,449033
105343,326858,AGN,Pharma company executives debate drug pricing increases,news,"By Deena Beasley SAN FRANCISCO  Reuters    Grappling with a backlash against high U S  prescription drug prices  more pharmaceutical companies are pledging to limit annual increases to under 10 percent   but the tactic is doing little to salve critics  including President elect Donald Trump  who on Wednesday said drugmakers are  getting away with murder   The pharmaceutical industry is typically reluctant to talk about U S  drug prices  generally the highest in the world due to a combination of market fragmentation and free market policies  But recent high profile price hikes by Mylan NV  O MYL   Turing Pharmaceuticals and Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  have raised the ire of consumers and lawmakers    AbbVie Inc   N ABBV  on Wednesday became the third global drugmaker to publicly promise to cap annual price increases at under 10 percent  following earlier pledges by Allergan Plc  N AGN  and  Novo Nordisk  A S  CO NOVOb   Allergan last week raised the price of two dozen of its drugs by between 7 percent and 9 5 percent   I do think that the industry is off to a good start in terms of good behavior   Allergan Chief Executive Officer Brent Saunders told investors here this week during J P  Morgan s annual healthcare conference  the largest industry meeting of the year  Mylan s six fold increase in the price of the EpiPen allergy treatment over less than a decade put the company front and center last year in the heated debate  Prices for four of the nation s top 10 drugs increased more than 100 percent since 2011  Reuters found  Mylan Chief Executive Officer Heather Bresch  answering questions at the conference  said capping price increases for brand name drugs below 10 percent  is not the right solution   noting that raising prices by 9 percent still adds a whopping  33 billion to the nation s annual prescription drug bill   The pricing model has got to change   she said   If anybody is walking away from this conference thinking it s business as usual  that s a mistake   Other executives said future pricing power will likely hinge more on evidence that a particular drug is cost effective   I think we will see a bigger trend of outcomes based pricing   said Joseph Jimenez  chief executive officer at  Novartis  AG  S NOVN   referring to studies showing how a drug can improve patient lives while cutting costs  The Swiss drugmaker recently struck deals with two U S  insurers for its heart failure drug Entresto under which payments are calculated based on any proven reduction patient admissions to the hospital  not on the number of pills consumed  European regulators already require companies to demonstrate the cost effectiveness of new therapies   We already design studies to incorporate health economics for ex U S  regulators   Perry Sternberg head of U S  commercial operations at  Shire  Plc  L SHP  told Reuters in an interview   It is data that is going to become more and more important   It can be difficult to measure how patients fare on specific drugs  since results depend on patients following doctors orders  but drugmakers acknowledge that advances in technology are offering new ways to solve some of those issues  Derica Rice  chief financial officer at Eli Lilly   Co  N LLY   said in an interview that the drugmaker is  trying to find creative solutions    Drugmakers point out that prescription drugs account for only around 15 percent of U S  healthcare costs and say other aspects of the healthcare system should be targeted for savings  But those sectors  including hospitals and physicians  have been undergoing an evolution for several years now away from a traditional  fee for service  system toward a focus on quality  rather than quantity  of care  
 We have fewer tools to manage pharmaceutical costs   said Steven  Pearson   LON PSON   president of the Institute for Clinical and Economic Review  a non profit organization that evaluates new medicines   We still pay fee for pill  ",2017-01-12,Reuters,https://www.investing.com/news/stock-market-news/pharma-company-executives-debate-drug-pricing-increases-452850,452850
105344,326859,AGN,Allergan to pay  15 million over failing to disclose merger talks,news,"By Sarah N  Lynch WASHINGTON  Reuters    A unit of Botox maker Allergan Plc  N AGN  will pay a  15 million penalty and admit to wrongdoing  after U S  regulators on Tuesday accused the unit of failing to disclose 2014 merger talks with  Actavis   the U S  Securities and Exchange Commission said  In a statement on Tuesday  the SEC said that the disclosure failures occurred in the months after the company received a tender offer from Valeant Pharmaceuticals  NYSE VRX  International  TO VRX  and co bidder Pershing Square  NYSE SQ  Capital Management  the hedge fund run by Bill Ackman  Allergan resisted a seven month long hostile pursuit by Ackman and Valeant  and in November 2014 announced it had accepted a  66 billion takeover bid from Actavis  According to the SEC  Allergan previously told investors that Valeant s bid was inadequate and that it was not in merger talks   In fact  the SEC said Allergan did have merger talks with an unnamed North Carolina company that it never disclosed  After those failed  the SEC said  Allergan did not provide timely disclosures about its talks with Actavis  In a statement  Allergan Plc spokesman Mark Marmur said the company s wholly owned subsidiary  Allergan Inc  agreed as part of the settlement not to engage in future violations and that the SEC had not accused the subsidiary of any intentional wrongdoing  
He added that the SEC had not charged the parent company and that the filings at issue pre dated Allergan s acquisition by Actavis ",2017-01-17,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-pay-$15-million-over-failing-to-disclose-merger-talks-453756,453756
105345,326860,AGN,Europe s oncologists back biosimilar versions of cancer drugs,news, Reuters    Europe s leading association of oncologists has thrown its weight behind cheaper copycat versions of biotech cancer drugs that have lost patent protection  saying they are effective and affordable   Off patent chemical medicines have for decades been copied with precision and sold as cheap generic versions  but drug regulators have only over recent years embraced copycat versions of complex biological drugs  known as biosimilars  Even though biotech drugs  which are proteins made from genetically modified cells  cannot be exactly replicated  biosimilars have been shown to be equivalent in terms of effectiveness and side effects    Biosimilars are must have weaponry in financially sustaining healthcare systems on a global scale as well as significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world   ESMO President Professor Fortunato Ciardiello said in a statement  ESMO added that price discounts for biosimilars of 20 to 40 percent could be reached in Europe  with potential savings for healthcare systems of 50 100 billion euros   53  107 billion  by 2020   Europe has been in the lead over the United States in opening up regulatory pathways for biosimilars   The first biosimilar versions of cancer drugs are expected to reach the market in Europe this year  with  Amgen Inc   NASDAQ AMGN  and Allergan  NYSE AGN  Plc seeking EU approval of their version of Roche Holding  SIX ROG  AG s blockbuster cancer treatment Avastin   Biosimilars are an excellent opportunity to have good  valid drug options that improve the sustainability and affordability of cancer treatment in various countries   ESMO said  also publishing a paper with recommendations on how doctors should handle them     1   0 9359 euros ,2017-01-18,Reuters,https://www.investing.com/news/general-news/europe's-oncologists-back-biosimilar-versions-of-cancer-drugs-453961,453961
105346,326861,AGN,U S  FTC reaches pay for delay settlement with Endo,news,"By Toni Clarke WASHINGTON  Reuters    Endo International Plc  O ENDP  said on Monday it had reached a proposed settlement with U S  anti trust regulators under which it will not pay rivals to delay the introduction of generic competitors to its medications  The Federal Trade Commission had alleged Endo paid Impax Laboratories Inc  O IPXL  to delay the introduction of a generic version of its painkiller Opana ER  The agency also alleged Endo paid Watson Laboratories Inc to delay introduction of a generic version of its Lidoderm pain treatment  The proposed settlement must be ratified by a court  Endo said it is not required to make any monetary payment to the FTC and made no admission of liability  It said the settlement is  consistent with the company s position that the Lidoderm and Opana ER settlements fully complied with the law both at the time they were executed and today   Watson and Impax were also named in the FTC s lawsuit  which alleges the companies illegally blocked access to low cost alternatives to Endo s products  The complaint against those companies remains outstanding  
Watson  which was formerly owned by Allergan Plc  N AGN   is now owned by Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   Teva and Allergan declined to comment  A spokesman for Impax was not immediately reachable ",2017-01-23,Reuters,"https://www.investing.com/news/stock-market-news/ftc-settles-pay-for-delay-lawsuit,-files-two-related-complaints-455106",455106
105347,326862,AGN,Teva CEO exits amid crisis of confidence at drugmaker,news,"By Tova Cohen and Steven Scheer TEL AVIV  Reuters    The chief executive of Teva Pharmaceutical Industries  TA TEVA  has stepped down  leaving new management to overhaul the world s biggest maker of generic drugs and restore confidence after a series of missteps sent its shares plummeting  Teva  Israel s largest company  said on Monday Chief Executive Erez Vigodman was departing immediately and would be replaced on an interim basis by Chairman Yitzhak Peterburg  A string of questionable and costly acquisitions  along with delayed drug launches  has prompted calls for a management overhaul and structural changes   such as a spin off of its branded drugs businesses   to restore investor confidence  Investors say Teva  which faces pricing pressure in its core generics business and recently lost patent protection on its key branded drug Copaxone for multiple sclerosis  must choose a new CEO with extensive pharmaceutical experience   The new boss needs to set a clear strategy  said Eldad Tamir  head of investment house Tamir Fishman  whose funds have slashed holdings in Teva by 90 percent in the past two years   Is it the biggest generics company or is there an understanding that generics is hitting a glass ceiling and it should do other stuff   such as investing more in branded drugs  he said   Compounding the challenge for Teva  U S  President Donald Trump has pledged to crack down on drug prices  Tal Levi  buyside analyst for Israeli investment house Halman Aldubi  said Teva needed to manage cash flow better and deliver the hoped for synergies from its acquisition last year of the  Actavis   NYSE AGN  generics business  Teva s New York listed shares  N TEVA   which hit  72 in July 2015  tumbled to a 10 year low of  32 20 last week after a U S  court found Copaxone patents to be invalid  The drug accounted for almost a fifth of Teva s revenue last year  Teva shares traded down 1 7 percent in Tel Aviv on Tuesday following Vigodman s departure  which comes after the head of Teva s generics business  Siggi Olafsson  left  The New York listed stock was down 2 5 percent in pre market trading   Vigodman joined Teva in 2014 after his success at rejuvenating an ailing Israeli agrochemicals firm earned him a reputation as a turnaround specialist and dealmaker   But a series of stumbles have dismayed investors  Vigodman embarked on a costly buying spree that culminated in the acquisition of Actavis for  40 5 billion  a price many investors believe was too high  Teva is now saddled with nearly  36 billion in debt  similar to its market value  making it very difficult to raise new equity  Tamir said  A  2 3 billion deal for Mexican drugmaker Rimsa has led to both sides suing each other  And in December Teva agreed to pay more than  519 million to settle U S  criminal and civil allegations that it bribed overseas officials to gain business  Last month  Teva provided a 2017 revenue and profit forecast below Wall Street s estimates  THOROUGH REVIEW  Interim leader Peterburg  who will work alongside Teva s new chairman  former Celgene  O CELG  CEO Sol Barer  said he would conduct a  thorough review  of Teva s business while the company searches for a permanent CEO   RBC Capital Markets analyst Randall Stanicky said it was unclear what this entailed and whether asset sales could be on the agenda   We find it interesting that Teva would pursue a review before naming a permanent CEO  which may be suggestive of further close involvement of the board and broader management team   Stanicky said  Some investors have told Reuters they would like to see Teva spin off its speciality drug business  This might please U S  activist investors as it could give a short term boost to the stock  said Levi  whose firm Halman Aldubi has been slowly raising its Teva stake in the past month   But Israeli institutions are long term investors  I m not sure making a short term profit is a good idea for the Israeli market and Teva   he said  Bernstein analyst Ronny Gal  in a video to clients  called Peterburg  a good caretaker CEO  but clearly not a candidate to run the company long term   
Prior to rejoining Teva s board of directors in 2012  Peterburg led the company s research and development efforts as head of global branded products  from 2010 until October 2011 ",2017-02-07,Reuters,"https://www.investing.com/news/stock-market-news/teva-names-interim-ceo,-new-chairman-as-vigodman-steps-down-458291",458291
105348,326863,AGN,Can Allergan  AGN  Keep The Earnings Streak Alive In Q1 ,opinion,"We expect Allergan plc   NYSE AGN   to beat expectations when it reports first quarter 2018 results on Apr 30  before market open  Last quarter  the company delivered a positive earnings surprise of 2 78  Allergan s share price has declined 2 3  this year so far  compared with the  s decline of 5 8  Allergan s earnings performance has been strong  with the company beating expectations in each of the past four quarters  The average positive earnings surprise over the last four quarters is 1 81  Allergan plc Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderOn the fourth quarter 2017 conference call  the company guided first quarter 2018 revenues  between  3 5 billion and  3 6 billion while earnings per share are expected to be between  3 20 and  3 40  These numbers indicate the lowest revenue and earnings quarter for the year In the fourth quarter of 2017  the favorable timing of physician rebating program benefited sales of Allergan s facial aesthetics products  This benefit was absent in the first quarter of 2018  which will hurt revenues  As such  the company expects first quarter revenue growth rate to be somewhat lower than the annual 2018 growth rate  Also  generic competition for Estrace and Namenda XR will hurt sales sharply in the first quarter While a generic version of Namenda XR was launched by Indian company  Lupin in February that of Estrace cream was launched by Mylan   NASDAQ MYL   in January Allergan expects a generic version of Restasis  its second best selling drug  to be launched between April and July of 2018  Meanwhile  a generic version of Delzicol is expected to be launched in early second quarter 2018 Investor focus on the call will be on management s comments on the potential impact of generic competition on key growth drivers  Restasis and Namenda XR  The Zacks Consensus Estimate for Restasis is  295 million Nonetheless  Allergan s established products like Botox  Linzess  Lo Loestrin and Juv derm collection of fillers and new products like Juv derm collection of fillers should support sales in Q1  The Zacks Consensus Estimate for Botox is  771 million In fact  recent label expansions for Botox  FDA approval for forehead line treatment  and Vraylar  FDA approval for maintenance treatment of schizophrenia  and Avycaz  FDA approval for HABP VABP  should add to sales of these drugs in Q1  Meanwhile  the addition of Alloderm from LifeCell  January 2017  and CoolSculpting body contouring system from Zeltiq  April 2017  acquisitions should continue to support the top line in the quarter However  we believe sales erosion of Aczone due to generic pressure on the branded acne category and loss of exclusivity  LOE   mainly from Asacol HD and Minastrin 24  will continue to hurt the top line We remind investors that on the Q4 call  the company had said that it does not expect any significant M A activities in 2018  Allergan expects to reevaluate its M A strategy in the second half of the year once it gets through the LOEs  An update is expected at the upcoming conference call Earnings WhispersOur proven model shows that Allergan is likely to beat on earnings because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate   3 37 per share  and the Zacks Consensus Estimate   3 36 per share  is  0 14   This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Allergan has a Zacks Rank  3  The combination of Allergan s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderHere are some large cap health care stocks worth considering per our model  These also have the right combination of elements to beat on earnings this time around Bristol Myers Squibb Company   NYSE BMY   has an Earnings ESP of  0 82  and a Zacks Rank of 2  The company is scheduled to report first quarter earnings on Apr 26  You can see  Pfizer  Inc    NYSE PFE   is also slated to announce financial figures on May 1  The company has an Earnings ESP of  1 36  and is also a Zacks  2 Ranked stock Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-23,Zacks Investment Research,https://www.investing.com/analysis/can-allergan-agn-keep-the-earnings-streak-alive-in-q1-200308374,200308374
105349,326864,AGN,Allergan  AGN  Q1 Earnings Beat Estimates  Sales Up Y Y,opinion,Allergan plc s   NYSE AGN   first quarter 2018 earnings came in at  3 74 per share  beating the Zacks Consensus Estimate of  3 36 by 11 3   The bottom line also rose 11 6  year over year  driven by higher revenues and lower operating costs  Earnings also surpassed the previously expected range of  3 20  3 40 Revenues generated  3 67 billion  which marginally exceeded the Zacks Consensus Estimate of  3 59 billion by 2 2   The top line also rose 2 8  from the year ago period  Revenues also surpassed the past projection between  3 5 billion and  3 6 billion Key products like Botox and Juv derm collection of fillers and new products like Vraylar  Viberzi and Namzaric did well in the quarter under review  However  sales erosion of Namenda XR and Aczone and loss of exclusivity  mainly from Asacol HD and Minastrin  hurt the top line First quarter revenues also benefited from the addition of Alloderm from LifeCell  January 2017  and CoolSculpting body contouring system from ZELTIQ  April 2017  acquisitions Shares of Allergan increased almost 4  on Apr 30 in pre market trading  The stock has lost 3 1  so far this year  outperforming the  s decline of 6 1   Segment DiscussionThe company reports revenues under three segments  namely U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues increased 6 5  to  1 58 billion  driven by a consistently strong performance of its facial aesthetics products  Botox and Juv derm Collection of fillers Botox  cosmetic  raked in sales of  196 7 million  up 7  year over year   Botox Therapeutic revenues were  358 5 million  up 16 1   In addition  Juv derm Collection of fillers rose 2 5  to  122 8 million  In Eye Care  though Ozurdex sales increased 13 3  to  25 5  blockbuster dry eye drug  Restasis  sales decreased 17 2  to  255 8 million  In Plastic Surgery  breast implants sales increased 11 8   which contributed to the upside  In Medical Dermatology  Aczone sales plunged 60 6  in the reported quarter to  16 million LifeCell s Alloderm added  99 5 million while ZELTIQ s CoolSculpting business added  87 1 million to sales in the first quarter U S  General Medicine net revenues were down 9 1  year over year to  1 22 billion in the reported quarter with sales declining in the Diversified Brands  Central Nervous System  CNS  and Women s Health franchises  Anti Infectives sales rose 28 5  to  71 6 million and Gastrointestinal inched up 0 3  to  388 7 million Established products like Linzess and Lo Loestrin as well as new products like Namzaric  Viberzi and Vraylar did well in the first quarter  Linzess  sales rose 7 9  to  159 3 million  driven by strong demand  Lo Loestrin sales rose 14 8  to  114 6 million  backed by strong demand trends Among the newer products  Namzaric  a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  33 4 million  up 41 5  compared with the year ago figure  Viberzi recorded sales of  35 9 million  up 14  year over year Namenda XR sales slumped 66 8  to  40 5 million in the reported quarter due to loss of patent exclusivity for Namenda XR this February Asacol Delzicol sales declined 33 7  to  38 2 million due to a reduction in demand for Ascaol HD  following the launch of an authorized generic in August 2016 In the Women s Health segment  Minastrin 24 revenues plummeted 87 3  to  5 2 million in the quarter due to loss of exclusivity last March The International segment logged net revenues of  864 million  up 17 2  from the year ago period  driven by growth in Facial Aesthetics  Botox  therapeutic   Eye Care and the addition of CoolSculpting Selling  general and administrative  SG A  expenses decreased 5 2  to  1 05 billion in the first quarter owing to a substantial reduction in selling and marketing spending including the impact of previous restructurings Research and development  R D  expenses also declined 9 7  to  355 8 million due to reprioritization of R D programs 2018 Outlook RaisedAllergan lifted its sales guidance in the approximate range of  15 15  15 35 billion compared with the former forecast of  15 0  15 3 billion  The Zacks Consensus Estimate for the metric in the current year is pegged at  15 22 billion Meanwhile  the company also raised its adjusted earnings expectation in the band of  15 65  16 25 per share from  15 25  16  guided earlier  The consensus mark for the metric in the current year was pegged at  15 22 per share The company however  continues to estimate adjusted tax rate at approximately 14  in 2018 Q218 ViewIn second quarter 2018  revenues are anticipated between  3 85 billion and  4 billion while earnings per share are likely to be between  4 and  4 20  While the Zacks Consensus Estimate for revenue in the second quarter is pegged at  3 59 billion  the consensus mark for earnings was pegged at  3 36 per share during the same period Migraine Candidate Succeeds in Second Phase III StudyAllergan also announced results from the second of two pivotal phase III studies  evaluating its migraine candidate  ubrogepant  The ACHIEVE II trial evaluated the efficacy  safety and tolerability of orally administered ubrogepant across two doses  25 mg and 50 mg  compared with placebo in a single migraine attack in adults Data from the study demonstrated that a  significant greater percentage of patients  treated with ubrogepant under both dosages  25 mg and 50 mg  was free from pain at 2 hours after the initial dose as compared to those treated with placebo  Also  the 50 mg dose showed a statistically significant greater percentage of ubrogepant patients achieving absence of the  most bothersome migraine associated symptom  at 2 hours after the initial dose in comparison to patients treated with placebo  The company expects to submit a regulatory application for ubrogepant to the FDA in 2019 Allergan plc Price  Consensus and EPS Surprise    Zacks Rank   Key PicksAllergan carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated   NASDAQ LGND    Infinity Pharmaceuticals  Inc    NASDAQ INFI   and OncoMed Pharmaceuticals  Inc    NASDAQ OMED    each sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved north from  3 92 to  4 40 for 2018 and from  4 75 to  5 32 for 2019 in the last 60 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has surged 42 6  over a year Infinity s loss per share estimates have narrowed from  1 69 to 74 cents for 2018 and from 94 cents to 66 cents for 2019 in the last 60 days  The company pulled off a positive surprise in three of the last four quarters with an average beat of 7 87  OncoMed s loss per share estimates have narrowed from  1 29 to 96 cents for 2018 and from  1 31 to  1 13 for 2019 in the last 60 days  The company came up with a positive surprise in three of the trailing four quarters with an average beat of 57 23  The Hottest Tech Mega Trend of All      Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-29,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-q1-earnings-beat-estimates-sales-up-yy-200311083,200311083
105350,326865,AGN,Ironwood  IRWD  Incurs Loss In Q1  Announces Restructuring,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   reported first quarter 2018 adjusted loss of 27 cents per share  wider than the Zacks Consensus Estimate of a loss of 16 cents  However  the company had reported adjusted loss of 33 cents in the year ago period Total revenues  collaborative revenue  in the quarter amounted to  69 2 million  up 32 7  from the year ago period  and missed the Zacks Consensus Estimate of  89 5 million Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess  linaclotide    generated U S  net sales of  159 3 million  up 7 9  year over year Please note that Ironwood and Allergan have an equal share in brand collaboration profits or losses  Ironwood s share of net profits from the sales of Linzess in the United States  included in collaborative revenues  was  61 2 million in the first quarter  up 23 7  year over year  Sales of linaclotide active pharmaceutical ingredient to the company s Japanese partner Astellas Pharma added  5 4 million to revenues According to data provided by IMS Health  Linzess prescriptions filled during the quarter were more than 764 000  up 9  from the year ago period  The drug s uptake continued to grow in 2018 following a strong performance in 2017 and it remained a market leader among branded prescription drugs In January  Ironwood and Allergan settled a patent litigation related to an abbreviated new drug application of Sun Pharmaceutical Industries  seeking approval of a generic version of Linzess  Per the settlement agreement  Sun Pharmaceuticals will be allowed to market an authorized generic version from Feb 1  2031 Zurampic and Duzallo  approved for uncontrolled gout  generated sales of  0 6 million in the quarter  Duzallo was launched in October 2017 as an oral treatment for hyperuricemia associated with gout During the reported quarter  selling and administrative  SG A  expenses increased 11 4  to  61 9 million  Research and development  R D  expenses were  37 1 million  up 8 3  from the year ago periodRestructuring InitiativeIn a separate press release  Ironwood announced its intent to split the company into two separate entities  One entity  which will continue with the current name  will focus on the three commercial drugs and gastrointestinal   GI   pipeline development  The other entity will focus on the development of the Soluble Guanylate Cyclase pipeline for the treatment of serious and orphan diseases The company expects to achieve increased operational performance and strategic flexibility following the completion of the restructuring process The separation is expected to close in the first half of 2019 2018 GuidanceIronwood expects to incur charges related to its restructuring initiative  Hence  the company did not provide any financial guidance for the full year and plans to provide an update in the second quarter earnings release Pipeline UpdatesLinzess is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  and chronic idiopathic constipation   CIC    Ironwood and Allergan are looking to broaden Linzess  label into additional symptoms and develop the drug as a non opioid  pain relieving agent in IBS patients A phase III study to evaluate Linzess in additional abdominal symptoms is expected to start in mid 2018  The companies are also in discussion with the FDA to start a phase IIb study to evaluate a delayed release formulation of linaclotide for treating all subtypes of IBS  including IBS mixed and IBS with diarrhea A label expansion of Linzess in the chronic constipation indication is under review in Japan  In China  Hong Kong and Macau  Ironwood has an agreement with AstraZeneca plc   NYSE AZN   for Linzess  The regulatory filing in China for IBS C is under review  The company expects the review to be completed in the first half of 2018 The company is also developing three candidates   IW 3718  Praliciguat  IW 1973  and Olinciguat  IW 1701    for gastroesophageal reflux disease  diabetic nephropathy and sickle cell disease  respectively  Ironwood expects to advance IW 3718 in phase III studies in the third quarter of 2018  Two phase II studies to evaluate Praliciguat in diabetic nephropathy and heart failure are currently enrolling patients Our TakeThe company s first quarter loss was wider than estimated and sales also missed expectations  However  the stock was up 3 2  on May 1 on restructuring news  The prospect of the new Ironwood with its sole focus on marketed drugs and GI pipeline is more attractive with lower potential R D costs A look at the company s share price movement shows that the stock has outperformed the  this year so far  Ironwood s shares have gained 24 7  during this period  while the industry declined 3 4  Ironwood is focused on expanding Linzess  label and its geography  Linzess  sales growth is expected to continue in 2018  which will boost the top line  A potential approval in China will further boost sales of the drug Meanwhile  we expect the new Ironwood to be able to be turn profitable faster as revenues grow and operating expenses decline after restructuring Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Key PickIronwood currently carries a Zacks Rank  3  Hold   Ligand Pharmaceuticals Incorporated   NASDAQ LGND   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can  Ligand s earnings per share estimates moved up from  4 20 to  4 43 for 2018 and remained stable at  5 32 for 2019 in the last 30 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has increased 14 6  in a year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-incurs-loss-in-q1-announces-restructuring-200312070,200312070
105351,326866,AGN,What To Watch When Teva Reports Q1 2018 Earnings On Thursday,opinion,"Reports Thursday  May 3  before the open
Revenue Expectation   16 89B  EPS   2 31

When Teva Pharmaceutical Industries  NYSE TEVA  reports earnings for its first quarter on May 4  don t expect fireworks  Kare Schultz  the CEO who took the helm of the generic and specialty medicine manufacturer this past November  has been very upfront about the company s dismal growth prospects in the near term  His strategy  to dampen investor expectations while he works on a massive belt tightening campaign  has so far played out in his favor 

Teva shares have gained more than 50  so far during his still new tenure  attracting interest from the world s most successful value investor  Warren Buffett  whose Berkshire Hathaway Inc   NYSE BRKa  initiated a new position worth about  365 million in Teva  to become its tenth largest shareholder  But that initial euphoria may evaporate quickly if Schultz fails to show the market that his restructuring plan  which involves cutting about 25  of the company s workforce  is moving ahead as originally planned 
Slippery Downward Slope  Complex Problems
Teva s shares have been on a slippery slope during the past three years as the company s  41 billion acquisition of Allergan s  NYSE AGN  generics unit failed to improve sales  The deal went sour at a time when the company lost its monopoly on Copaxone  the multiple sclerosis injection that at one point generated half of Teva s profits 
In February  Teva said it won t be able to charge as much as expected for new medicines amid escalating pressure on prices in the U S  Sales this year may decline as much as 18  to  18 3 billion  about  1 billion less than analysts had estimated 
Another key detail to look for in Teva s earnings call is how well Schultz s efforts to manage this drug maker s precarious debt load are succeeding  Teva has more than  17 billion of debt due over the next five years  In a recent  4 5 billion 10 year bond sale  the company was successful in extending its maturities  However  it had to offer interest rates that junk borrowers pay 
It s clear there s no quick fix for Teva s complex problems  especially when the U S  pharmaceutical industry is going through drastic changes  ranging from accelerated Food and Drug Administration  FDA  approval of competing medicines to government regulation that limits drug prices 
Bottom Line
Any positive surprise on the earning front should be enough to produce a powerful rally in Teva s stock  now that investors have almost written off any hope for recovery in 2018  That scenario  however  puts more pressure on Schultz to deliver quickly ",2018-05-03,Haris Anwar/Investing.com,https://www.investing.com/analysis/what-to-watch-when-teva-reports-q1-2018-earnings-on-thursday-200312121,200312121
105352,326867,AGN,Teva  TEVA  Up On Q1 Earnings   Sales Beat  Rise In Guidance,opinion,"Israel based Teva Pharmaceutical Industries Ltd    NYSE TEVA   is a global pharmaceutical company with a strong presence in the generics as well as branded markets  The company s branded products include Copaxone  multiple sclerosis   Azilect  Parkinson s disease  and respiratory products like ProAir and Qvar   Moreover  the company has several candidates in its pipeline  which are in different stages of development mainly for the treatment of pain and asthma In early Aug 2016  Teva acquired Allergan s generics business   Actavis  NYSE AGN  Generics and in Oct 2016 it acquired the latter s Anda Inc   the 4th largest distributor of generic pharmaceuticals in the U S Teva is facing significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from new generic launches and a massive debt load Teva s earnings surpassed expectations in only one of the last four quarters  met the same in one and missed expectations in the remaining two  resulting in an average positive surprise of 0 49  Currently  TEVA has a Zacks Rank  4  Sell   but that could definitely change following the company s earnings report which was just released  You can see  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Teva s first quarter earnings came in at 94 cents per share  which massively beat consensus estimate of 68 cents Revenues Beat  Teva posted revenues of  5 1 billion  which beat consensus estimates of  4 8 million  However  sales declined 10  year over year Key Statistics  As announced in November last year  Teva no longer reports two separate global groups for its two businesses   generics and specialty medicines  Instead  Teva now reports under new segments based on three regions  North America  Europe and Growth Markets North America segment sales were  2 5 billion  down 22  year over year due to pricing erosion in U S  generics market  lower sales of its blockbuster multiple sclerosis drug  Copaxone due to generic competition and divesture of some non core assets in the Women s Health business  Lead branded product  Copaxone  posted U S  sales of  476 million  down 40  year over year due to generic competition for the 20 mg as well as the 40 mg formulation The Europe segment recorded revenues of  1 44 billion  up 8  year over year  However  in constant currency terms  sales declined 6   In the Growth Markets  sales were flat in constant currency terms 2018 Outlook Up  Teva raised its 2018 sales and earnings guidance  The revenue outlook was raised from a range of  18 3    18 8 billion to a range of  18 5    19 0 billion  Meanwhile  the earnings guidance was raised from a band of  2 25  2 50 per share to  2 40 2 65 per share Share Price Impact  Shares were up more than 7  in pre market trading on the guidance increase Check back later for our full write up on this TEVA earnings report later Teva Pharmaceutical Industries Ltd  Price and Consensus
    5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-up-on-q1-earnings--sales-beat-rise-in-guidance-200312359,200312359
105353,326868,AGN,Pharma Stock Roundup  Mixed Q1 For MRK  PFE  FDA Nod For Kymriah s 2nd Indication,opinion,"First quarter results of pharma bigwigs like Pfizer   NYSE PFE    Merck   NYSE MRK   and Allergan   NYSE AGN   stole the limelight this week  Other than that  Novartis   NYSE NVS   gained FDA approval for the second indication of its CAR T therapy  Kymriah  While AbbVie   NYSE ABBV   submitted a regulatory application in the EU for its psoriasis candidate  risankizumab  Merck s PD L1 inhibitor  Keytruda gained FDA s Priority Review status for yet another label expansion application 
Recap of the Week s Most Important Stories
Mixed Q1 Results for Merck   Pfizer  Both the pharma giants beat estimates for earnings but missed the same for sales  While Pfizer re affirmed its previously issued guidance for 2018  Merck raised its outlook for both earnings and sales  Both the companies witnessed a relatively weaker top line performance in the quarter 
For Merck  strong sales of Keytruda  Gardasil and Bridion were partially offset by lower sales of other key therapies   RotaTeq  Zepatier and Zostavax  Meanwhile  loss of market exclusivity for several drugs also hurt the top line 
While for Pfizer  the top line was hurt by decline in sales of key drugs like Lyrica  Prevnar 13 Prevenar 13  and Enbrel  loss of exclusivity for some products like Viagra and Pristiq and continued supply shortages in legacy Hospira products 
Allergan beat estimates for both earnings and revenues in the first quarter of 2018 and raised its 2018 guidance for both earnings and sales 
Novartis  Kymriah Gets FDA Approval for Second Indication  Novartis  supplemental Biologics License Application  sBLA  looking to get its CAR T therapy Kymriah approved for the second indication was granted approval by the FDA  With the latest approval  Kymriah suspension has been approved for intravenous infusion for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma after two or more lines of systemic therapy including diffuse large B cell lymphoma  DLBCL   high grade B cell lymphoma and DLBCL arising from follicular lymphoma 
Kymriah was the first CAR T therapy to obtain FDA approval in August 2017 for the treatment of patients up to 25 years of age with B cell precursor ALL that is refractory or in second or later relapse 
Separately  Novartis announced that the FDA has given a complete response letter to its BLA for its proposed biosimilar version of Roche s cancer drug  Rituxan 
Merck s Keytruda in News  Merck s supplemental Biologics License Application  sBLA  looking to get overall survival data from the phase III KEYNOTE 189 study included on the label of the PD L1 inhibitor  Keytruda was granted priority review by the FDA  The FDA will give its decision on Sep 23  2018 
The study evaluated Keytruda  in combination with Lilly s Alimta  pemetrexed  and platinum chemotherapy  cisplatin or carboplatin  for the first line treatment of patients with metastatic non squamous NSCLC regardless of PD L1 expression  The combination treatment improved overall survival regardless of PD L1 expression including in patients whose tumors tested negative for PD L1 
Notably  in May 2017  this combination therapy was granted an accelerated approval by the FDA for the aforementioned indication  The approval was based on tumor response rate and PFS data from the KEYNOTE 021 study  Hence  the positive readouts from the KEYNOTE 189 confirmatory study will help the company gain continued approval for the combo therapy  which should support uptake and sales 
Merck also announced interim data from another pivotal lung cancer study on Keytruda  which met a pre specified secondary endpoint of overall response rate  ORR  in an early cohort of participants  The phase 3 KEYNOTE 407 study evaluated Keytruda in combination with carboplatin paclitaxel or nab paclitaxel for the first line treatment of metastatic squamous NSCLC 
AbbVie Submits Application for Psoriasis Candidate in EU  AbbVie submitted a marketing application to the European regulatory authorities for investigational interleukin 23  IL 23  inhibitor  risankizumab for the treatment of moderate to severe plaque psoriasis  The Marketing Authorization Application  MAA  is supported by data from four pivotal phase III studies  Data from these studies have shown that more than half of the patients receiving risankizumab achieved complete skin clearance at one year 
Meanwhile  AbbVie also announced commencement of a self tender offer for up to  7 5 billion of its common stock at a price not less than  99 00 per share and not more than  114 00 per share 
United Therapeutics to Acquire SteadyMed  United Therapeutics Corporation   NASDAQ UTHR   announced a definitive merger agreement with SteadyMed Ltd  per which United Therapeutics will acquire the latter for  216 million including contingent payments  With the deal  United Therapeutics will add SteadyMed s drug device pipeline product  Trevyent for pulmonary arterial hypertension  PAH  patients to its portfolio  The product could have posed competition to United Therapeutics  RemoSynch implantable pump  which is under review in the United States 
Trevyent is a single use  pre filled pump that has been developed by SteadyMed to deliver a two day supply of treprostinil subcutaneously using SteadyMed s PatchPump technology to treat PAH  Though SteadyMed received a refuse to file letter from the FDA for want of further information  SteadyMed intends to resubmit its NDA by the end of 2018 
Allergan s Ubrogepant Succeeds in 2nd Phase III Study  Allergan announced that the second of two pivotal phase III studies evaluating its oral anti CGRP acute migraine treatment ubrogepant met its co primary endpoints  The phase III data showed ubrogepant displaying strong efficacy and a clean side effect profile 
The ACHIEVE II study evaluated the efficacy and safety of orally administered ubrogepant  25 mg and 50 mg  for treating a single migraine attack of moderate to severe headache intensity 
The study data demonstrated that a  significant greater percentage of patients  treated with ubrogepant  at both the doses  were free from pain at two hours after the initial dose as compared to those treated with placebo  Also  a statistically significant greater percentage of ubrogepant patients taking the 50 mg dose experienced absence of the  most bothersome migraine associated symptom     either photophobia  phonophobia or nausea    at two hours after the initial dose compared to those treated with placebo  However  the 25 mg dose failed to demonstrate statistical significance in this endpoint 
J J Seeks Label Expansion of PAH Drug  J J s   NYSE JNJ   Actelion submitted a supplemental New Drug Application  sNDA  to the FDA seeking approval for a label expansion of its PAH drug  Opsumit  macitentan  to include treatment of patients with chronic thromboembolic pulmonary hypertension  CTEPH  
Also  J J announced a definitive agreement to acquire private biotech  BeneVir Biopharm  BeneVir  which makes oncolytic immunotherapies utilizing its proprietary  T Stealth Oncolytic Virus Platform and has potential in the treatment of solid tumors
The NYSE ARCA Pharmaceutical Index declined 2 5  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return


 Here is how the seven major stocks performed in the last five trading sessions 

All stocks declined last week except AstraZeneca  which rose 1 4   Pfizer declined the most  5 7   
In the last six months  Glaxo was the biggest gainer  9 6    while Bristol Myers declined the most  16 6   
 See the last pharma stock roundup here  Pharma Stock Roundup   
What s Next in the Pharma World 
Watch out for pipeline and regulatory updates 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-04,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mixed-q1-for-mrk-pfe-fda-nod-for-kymriahs-2nd-indication-200313312,200313312
105354,326869,AGN,Teva  TEVA  Stock Dips Despite Q1 Earnings   Sales Beat ,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   reported first quarter 2018 earnings of 94 cents per share  which beat the Zacks Consensus Estimate of 68 cents per share  However  earnings per share declined 11 3  year over year Revenues came in at  5 1 billion  which also beat the consensus estimate of  4 8 billion  However  sales declined 10  year over year  down 15  excluding impact of currency  Sales were hurt by increased pricing erosion in the U S  generics market and rapid erosion in sales of Teva s key multiple sclerosis injection  Copaxone and divesture of some non core assets  Segment DiscussionAs announced in November last year  Teva no longer reports two separate global groups for its two businesses   generics and specialty medicines  Instead  it reports under new segments based on three regions   North America  Europe and Growth Markets North America segment sales were  2 5 billion  down 22  year over year due to pricing erosion in U S  generics market  lower sales of Copaxone and divestiture of some non core assets in the Women s Health business  In the United States  revenues declined 23  to  2 4 billion Lead branded product  Copaxone  posted sales of  476 million in North America  down 40  year over year due to generic competition for the 20 mg as well as the 40 mg formulation Glatopa  a generic version of Copaxone 20 mg  is being marketed by Momenta and Sandoz   Novartis    NYSE NVS   generic arm   since 2015 while Mylan   NASDAQ MYL   launched its version of the 20 mg formulation in October 2017  In the same month  in a major blow to Teva  Mylan launched  at risk  its generic version of the 40 mg thrice weekly formulation  much earlier than expected With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  there has been rapid erosion in sales of Copaxone  Moreover  a second generic version of the 40 mg formulation  Glatopa  was launched by Sandoz in February this year  much earlier than its scheduled launch in April On the call  Teva said that despite Mylan s introduction of a 40 mg generic  Copaxone still commands around 85  of volumes in the 40 mg market  However  Teva had to decrease the price of Copaxone by increasing rebates in connection with the generic competition   The lower pricing helped it maintain its volume share  However  Teva expects tougher competition as the year progresses  which could exert some further pressure on pricing Sales of other branded products Bendeka  Treanda  ProAir and Qvar increased in the quarter The newest product in Teva s branded portfolio  Austedo  recorded sales of  30 million in North America Austedo  SD 809  was approved and launched in April 2017 for the treatment of chorea associated with Huntington s disease and for the second indication  tardive dyskinesia  in the United States in August Generic products revenues declined 23  to  1 1 billion in the quarter due to lower volumes and price erosion  Significant competitive and pricing pressure is hurting the U S  generics industry  The consolidation of customers in the industry has increased the ability to negotiate lower prices for generic drugs  Teva launched 10 generic products in the first quarterDistribution revenues  which are generated by Anda  rose 12  in the quarter to  331 million In August 2016  Teva acquired Allergan s   NYSE AGN   generics business   Actavis Generics   and Allergan s Anda Inc   the fourth largest distributor of generic pharmaceuticals  in October 2016 The Europe segment recorded revenues of  1 44 billion  up 8  year over year  However  in constant currency terms  sales declined 6  due to loss of revenues from the closure of a distribution business in Hungary and divestiture of the women s health business Generic products  including OTC products  revenues in Europe rose 2  on a constant currency basis to  997 million due to new product launches and volume growth in OTC  partially offset by price decline  Copaxone sales declined 13  on a constant currency basis to  153 million due to price reductions following the entry of generics In the Growth Markets  sales rose 4   However  in constant currency terms  sales were flat in this segment as higher sales in Israel  Japan and Russia were partially offset by the effect of the deconsolidation of subsidiaries in Venezuela and loss of revenues from the sale of the women s health business in these countries  While Generic products  including OTC  revenues declined 3  in constant currency terms to  488 million  Copaxone sales declined 24  to  16 million The Other segment  API manufacturing business and certain contract manufacturing services  recorded revenues of  342 million  down 8  year over year due to lower API sales to third parties Profits DeclineAdjusted gross margin contracted 460 basis points  bps  to 52 3  in the quarter due to lower profitability in the North America segment  Adjusted research   development expenses declined 31  from the year ago period to  289 million due to pipeline optimization  Selling and marketing  S M  expenditure declined 20  from the year ago level to  715 million due to cost cutting and re structuring activities  Adjusted operating margin declined 40 bps to 28 3  in the quarter despite lower costs 2018 Outlook UppedTeva raised its 2018 sales and earnings guidance following the first quarter beat  The revenue outlook was raised from a range of  18 3    18 8 billion to a range of  18 5    19 0 billion  The earnings guidance was raised from a band of  2 25  2 50 per share to  2 40 2 65 per share U S  Generics sales are expected to decline roughly 20  from 2017 levels to approximately  4 billion in 2018 hurt by ongoing price erosion Costs are expected to decline  1 5 billion in 2018 as a result of the company s cost savings initiatives Free cash flow guidance was raised to  3 0 3 2 billion from  2 6 2 8 billion Delay in FDA Approval of Migraine CandidateAlong with the earnings release  the company said it does not expect to get FDA approval for its pipeline candidate  fremanezumab for the prevention of chronic episodic migraine on its PDUFA date in June  It said it expects a pre approval inspection to take place soon  Teva expects fremanezumab to be approved and launched before the end of this year We remind investors that in January  Teva s partner Celltrion received an FDA warning letter for a facility in South Korea  following an inspection of the fill finish side of the facility  This facility manufactures API for fremanezumab  In EU  a regulatory application for fremanezumab is under review Please note that Lilly and Amgen  NASDAQ AMGN  are also on track to launch a new migraine treatment this year Our TakeTeva beat expectations for both earnings and sales in the first quarter and also raised its full year outlook for both the metrics  However  Teva s stock declined more than 4  since the earnings release Teva s shares have declined 5 9  this year so far compared with the  s decline of 12 4  The Israel based generic drug maker had a tough 2017 as it faced significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from generic launches and a massive debt load of more than  30 billion   Mylan s earlier than expected launch of the first generic version of the 40 mg strength of Copaxone was a major setback for Teva Teva divested some non core assets last year  mainly in the Women s Health business  to cut its significant debt load  The company also has a new organizational structure in place  is closing plants  cutting down its generics portfolio  eliminating low value R D projects  and aims to cut its global workforce by more than 25  over the next two years as part of a restructuring plan it revealed in December last year  Teva is progressing well on these re structuring activities and still expects to save almost  3 billion by the end of 2019 from these initiatives  Despite the progress on the restructuring activities and the fact that its financial position seems more stable than before  we believe Teva has a long way to go before gaining stability Teva Pharmaceutical Industries Ltd  Price  Consensus and EPS Surprise
    Teva carries a Zacks Rank  4  Sell  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-07,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-stock-dips-despite-q1-earnings--sales-beat-200313747,200313747
105355,326870,AGN,BioDelivery Sciences  BDSI  Q1 Earnings  What To Expect ,opinion,"We expect BioDelivery Sciences International  Inc    NASDAQ BDSI   to beat estimates when it reports first quarter 2018 results on May 10  In the last reported quarter  the company delivered a negative earnings surprise of 31 82  BioDelivery s shares have underperformed the  this year so far  The stock has declined 37 3  during the period compared with a 12 3  decrease for the industry BioDelivery s earnings history has been a mixed bag with the company surpassing expectations in two of the last four quarters and missing in the other two  It delivered an average beat of 127 29   BioDelivery Sciences International  Inc  Price and EPS Surprise
     
Let s see how things are shaping up for this announcement Factors to ConsiderBioDelivery s key products include Belbuca  chronic pain  and Bunavail  opioid dependence  Bunavail s sales performance has been lackluster so far  However  BioDelivery is working on improving Bunavail s performance  The company has reduced the number of sales territories and is focusing on the most growth oriented territories to improve Bunavail s profits The company is also focusing on securing new or improved positioning on other managed care contracts either on an exclusive or preferred status  Bunavail sales growth remained unchanged sequentially in the fourth quarter of 2017  With a reduced cost structure combined with growth opportunities  it remains to be seen if sales of the drug improve in the first quarter Belbuca s start has also been slower than expected due to pain market pressure  We remind investors that BioDelivery had reacquired worldwide rights to Belbuca in January from Endo Pharmaceuticals  a subsidiary of Endo International  As a result of this reacquisition  the company started recording product revenues for Belbuca against royalties recorded previously The prescription volumes for Belbuca have shown improvement in the past couple of quarters following the re acquisition  Sales of Belbuca improved sequentially in the fourth quarter of 2017  We believe this positive trend will continue through 2018  Belbuca was made commercially available in Canada for severe pain in January 2018  which should support further sales growth of the drug Earlier this week  BioDelivery Sciences announced the appointment of Herm Cukier as its new chief operating officer  Cukier was until now serving as the senior vice president at Allergan   NYSE AGN    He will be introduced on BioDelivery s first quarter conference call Earnings WhispersOur proven model shows that the stock is likely to beat on earnings this quarter as it has the right combination of the two key ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for this to happen Zacks ESP  BioDelivery has an Earnings ESP of  8 70   representing the difference between the Most Accurate estimate of a loss of 21 cents and the Zacks Consensus Estimate of a loss of 23 cents  This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  BioDelivery has a Zacks Rank  3  The combination of BioDelivery s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks That Warrant a LookHere are some other health care stocks with the right combination of elements to beat estimates this time around Paratek Pharmaceuticals  Inc    NASDAQ PRTK   has an Earnings ESP of  7 31  and currently carries a Zacks Rank  3  The company is scheduled to release first quarter results on May 9 Keryx Biopharmaceuticals  Inc    NASDAQ KERX   has an Earnings ESP of  11 69  and currently carries a Zacks Rank  3  The company is scheduled to release first quarter results on May 10 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-07,Zacks Investment Research,https://www.investing.com/analysis/biodelivery-sciences-bdsi-q1-earnings-what-to-expect-200314206,200314206
105369,326884,AGN,Hedge funds slow to adjust champagne tastes to beer budgets,news,"By Lawrence Delevingne NEW YORK  Reuters    Hedge funds have struggled of late to keep up their reputation as the sports cars of the investment world  often overtaken in the race for returns by the public buses of portfolios  index funds  But the proverbial Ferraris of investing   paid big to beat the market or protect from its gyrations   have so far shown little sign of curtailing their lavish spending on compensation  offices and employee perks  Hedge fund operators still work out of trophy offices in Manhattan s Plaza district  Greenwich  Connecticut or London s Mayfair  They are keeping the free lunch and snacks  ski and beach junkets  and even in house yoga  And they continue to lavish portfolio managers with multi million dollar pay  all in the face of poor performance and declining fees   These guys aren t living in reality   said Brad Balter  chief executive of Boston based hedge fund investor Balter Capital Management  A critic of the industry s extravagant ways and a longtime proponent of lower cost mutual fund like hedge funds  or liquid alternatives  Balter said many high spending hedge funds will eventually have to change their ways and become more like their more humble mutual fund cousins in terms of compensation  perks and other costs   But there are few signs of dramatic change   PAY RAISE  Many hedge funds have underperformed the equities market this year  with stock pickers burned by losing bets on Valeant Pharmaceuticals  TO VRX   Allergan  N AGN  and  Home Depot   N HD   among others  while macroeconomic managers have struggled to trade their way through global political and economic uncertainty   But the average portfolio manager at a firm running more than  4 billion with middling performance   up about 1 percent year to date   is expected to make an average of  2 23 million this year  That is up from  2 21 million in 2015 and down from  2 42 million in 2014  according to 2017 Glocap Hedge Fund Compensation Report   Top executives stand to make far more  The average wealth gain for the highest earning 25 hedge fund managers in 2015 was  517 6 million  according to a ranking by industry publication Alpha  Five firm founders   Ken Griffin  James Simons  Ray Dalio  David Tepper and Israel Englander   made at least  1 billion  By comparison  the average mutual fund portfolio manager  regardless of size or performance  is expected to make  634 000 in 2016  according to Glocap  up from  630 000 in 2015    Even if performance is down  managers still understand the need to pay big for top talent to avoid losing the very people who will help them generate returns   said Peter Friedman  chief executive of Integra Advisors  a recruitment firm that focuses on quantitative investing  FEE CUTS  There are some small signs of a reckoning  Poor recent performance of late and predictions by McKinsey   Co and others of tepid returns for years to come   because of low interest rates  slow economic growth and more   have caused a small but high profile group of clients to revolt   Investors have pulled some  51 billion out of the approximately  3 trillion hedge fund industry over the first three quarters of 2016  according to data tracker HFR  on pace for the biggest drop since the financial crisis of 2008 and its immediate aftermath   For those staying put  clients are demanding steep reductions to the classic fee model of 2 percent of assets and 20 percent of investment gains  A handful of major firms have acquiesced  including Brevan Howard Asset Management  Caxton Associates and Och Ziff Capital Management Group  N OZM    Many new managers are launching their firms with fees closer to 1 5 percent of assets and 15 percent of gains  including so called  hurdles  that prevent charging for performance before beating a benchmark   FREE STUFF Even so  there is little evidence so far of substantial changes to spending habits  according to recent conversations with more than two dozen industry participants    Citadel  PDT Partners and Bridgewater all still provide copious free food for employees  Citadel has produced modest gains in its main funds this year while Bridgewater is down slightly in its flagship hedge fund  Performance for PDT was unavailable  Decadent parties remain a perennial favorite  Balyasny Asset Management flew employees and their guests for a weekend at the Fontainebleau Miami Beach hotel last November for its annual business conference and holiday party event dubbed  BAM Bash   The 2014 version of the same party in New York City featured pop star Taio Cruz and acrobatic performers  BAM funds have produced modest gains this year   Renaissance Technologies still flies staff and their families for an all expenses paid vacation weekend  This autumn the destination was a resort in Florida  And Two Sigma rented out the Intrepid Sea  Air   Space Museum in New York for its 2015 holiday party  the venue in 2014 was the nearby American Museum of Natural History  Hedge fund offices continue to dazzle  even if returns do not  Och Ziff Capital Management  which has suffered investor withdrawals due to a foreign bribery scandal and mediocre performance  works in the  200 per square foot Solow Building in Manhattan  one of the city s most expensive office towers   Two Sigma s lower Manhattan office features spaces for playing games  recording music and working out   including fitness boot camps  meditation and same day gym laundry service  D E  Shaw   Co s sleek midtown Manhattan headquarters feature nap pods  a gym  game room and back up childcare   D E  Shaw  Two Sigma and Renaissance use computer driven investment models  which means they compete for talent not just with other hedge funds but also top technology companies known for extensive employee perks  such as Alphabet Inc s Google  O GOOGL  and  Facebook Inc   O FB   Like many so called quants  all three firms have produced strong returns of late    While costs are certainly being scrutinized  the fact that the environment is becoming more favorable to delivering performance means that talent has to be retained   said Jack Inglis  chief executive of hedge fund lobbying group Alternative Investment Management Association  For that reason  he said  it makes no sense to yank perks or other relatively modest budget items  SOME CRACKS To be sure  some firms are making cuts  Highland Capital Management slashed its conference budget in half  even though its public Global Allocation Fund is up more than 20 percent this year  It also recently traded its Solow Building outpost for less pricey space in the Times Square  NYSE SQ  Tower in New York  Brevan Howard  which has performed poorly this year  told employees to use their personal phones for company business and tightened its rules on travel  Several hedge fund marketers  who drum up new customers for funds  said they planned to engage in conference freeloading  hanging around the venue of an event without entering  and meeting with clients after hours  thereby avoiding the price of a ticket  which can cost between  5 000 and  15 000 per person  Pershing Square  whose public fund is down 18 3 percent this year through mid November  is soon moving into new offices that are 40 percent less expensive  There is one flourish in the planned Hell s Kitchen  Midtown Manhattan space  a tennis court on the roof   Other hedge funds are postponing real estate decisions this year  according to Ben Friedland  an executive vice president at CBRE  pointing to a more than 50 percent yearly decline in new leases signed by financial services firms  and a relatively high proportion of them renewing short term contracts   Many firms are choosing to punt   said Friedland  Robert Olman  founder of recruitment firm Alpha Search Advisory Partners  said firms are becoming more cost conscious given that performances fees are not yielding much    Twenty percent is not adding up to a lot these days   Olman said   So they are watching every dollar   SOUL SEARCHING In some sign of change  a few large and relatively successful firms have announced restructuring efforts  Ray Dalio s Bridgewater  the world s largest hedge fund manager with 1 700 employees and more than  150 billion under management  said in September it was planning  significant changes to people  processes and technologies   to address a surge in staff numbers that led to its non investment divisions becoming  bloated  inefficient  and bureaucratic    Billionaire hedge fund manager Paul Tudor Jones laid off roughly five dozen employees in August  or about 15 percent of his Tudor Investment Corp workforce  Pershing Square cut 10 percent of its staff in June when founder and head Bill Ackman laid off eight lower level employees  And Daniel Och s Och Ziff has seen its headcount decline by about 17 percent this year  a combination of layoffs and departures  Others have closed foreign offices  including TPG Axon Capital and Hutchin Hill Capital  or shut down altogether  including Perry Capital and Nevsky Capital   Lisa Baird  a hedge fund specialist at Heidrick   Struggles  said the executive search firm is now getting more inquiries related to restructuring  The discussions with clients include the issue of whether pay for some roles is too high  given lower salaries for similar roles outside of the hedge fund industry   There has definitely been a premium paid by hedge funds for many roles   Baird said   That is coming into question with the squeeze on fees   For now though  most thoughts of big changes have not translated into action   Anthony Keizner  a partner at recruitment firm Odyssey Search Partners  said many fund managers know changes could be necessary  but it is hard to be among the first the make a big shift given the potential for loss of talent   
 I ve heard people say  Maybe we re the frog in the boiling water scenario   we don t realize yet we should be changing   ",2016-11-23,Reuters,https://www.investing.com/news/stock-market-news/hedge-funds-slow-to-adjust-champagne-tastes-to-beer-budgets-442621,442621
105370,326885,AGN,U S  Treasury presses on with rule opposing serial tax inversions,news,"WASHINGTON  Reuters    Despite Republican plans to scale back federal regulation next year  the U S  Treasury is moving to finalize a controversial rule intended to make it harder for American companies to avoid U S  taxes by redomiciling abroad  The rule  issued as temporary regulations in April  has been challenged in federal court after it helped scuttle a planned  160 billion merger between Ireland based Allergan Plc  N AGN  and U S  drugmaker  Pfizer  Inc  N PFE   Known as the  serial inverter  rule  the regulations aim to prevent non U S  companies from engaging in multiple merger deals called tax inversions that allow their U S  partners to rebase in low tax countries  if only on paper   Treasury continues to work to finalize these regulations   a Treasury spokeswoman said on Monday  The administration finalized another set of anti inversion regulations last month  Business lobbyists believe the serial inverter rule could be made final before year end  With Republican Donald Trump in the White House and Republicans in control of both chambers of Congress next year  corporations hope to see regulations rolled back sharply  
House of Representatives Republican leader Kevin McCarthy called on federal agencies this month to stop issuing new regulations  Earlier in the year  House Republicans asked the Treasury not to proceed further with anti inversion regulations ",2016-11-28,Reuters,https://www.investing.com/news/stock-market-news/u.s.-treasury-presses-on-with-rule-opposing-serial-tax-inversions-444091,444091
105371,326886,AGN,Allergan CEO expects drug industry to face pricing heat from Trump,news,"By Ransdell Pierson  Reuters    U S  President elect Donald Trump could be more critical of drugmakers and their price increases than the industry expects  Allergan Inc  NYSE AGN  Chief Executive Brent Saunders said on Thursday  Saunders  speaking at the annual Forbes Healthcare Summit in New York  predicted Trump could be a  more vicious tweeter  against the drug industry than his former Democratic rival Hillary Clinton had been during the campaign  Clinton s tweets committing to a crackdown on exorbitant price increases weighed heavily on pharmaceutical shares  Shares of the Nasdaq Biotechnology Index plunged almost 5 percent on Sept  21  2015 when Clinton tweeted her outrage over a 50 fold price increase for an HIV drug sold by Turing Pharmaceuticals   Biotech stocks took another hit on Aug  24  when Clinton tweeted that there was no justification for recent big price increases for Mylan  NASDAQ MYL  NV s EpiPens that treat life threatening allergic reactions   Pharma shares jumped in the days after Trump s election as investors expressed relief that Clinton s proposed price controls were off the table  though they have since given up most of those gains  Saunders on Thursday said drugmakers should not expect Trump or Congress to be any less critical of price increases after Trump takes office in January    I worry today that the pharmaceutical industry has a very false sense of security because of the Trump Administration and a Republican controlled Congress   Saunders said   
He said Americans are rightly angry about price increases  and the industry needs to police itself or face government repercussions ",2016-12-01,Reuters,https://www.investing.com/news/stock-market-news/allergan-ceo-expects-drug-industry-to-face-pricing-heat-from-trump-445034,445034
105372,326887,AGN,Ex Attorney Yang being considered for SEC chair  source,news,By Steve Holland and Sarah N  Lynch NEW YORK WASHINGTON  Reuters    Former U S  Attorney Debra Wong Yang is being considered to chair the Securities and Exchange Commission in the Trump administration  a source familiar with the situation said on Tuesday  Yang is a partner at Gibson Dunn   Crutcher in Los Angeles where she represents corporate defendants in white collar crime investigations and compliance matters  Previously  Yang served as the first female Asian American U S  attorney  She was appointed to the Central District of California by Republican President George W  Bush in 2002 and left in 2006 to join Gibson Dunn  Yang is a longtime friend of Republican New Jersey Governor Chris Christie  and donated to his presidential campaign   If tapped  she would become the second consecutive former federal prosecutor to lead the SEC   Its current chair  Mary Jo White  previously served as U S  attorney for the Southern District of New York  Yang did not respond to a call or an email requesting comment  and it is not clear if she is the leading contender for the top SEC job  Other names that have been floating around include former SEC Commissioner Paul Atkins  who is helping oversee the transition for financial regulation  and Ralph Ferrara  a former SEC general counsel who is also on the transition team  Unlike Atkins or Ferrara  Yang is not considered to be as deeply steeped in securities regulatory policy matters  Yang has represented a variety of corporate clients and also previously served as a Justice Department appointed monitor for a medical device company   Currently  she is representing Allergan  NYSE AGN  Plc in a lawsuit filed last month against a company called Amazon  NASDAQ AMZN  Medica for trademark infringement  false advertising and unfair competition related to its selling Botox with foreign labels to U S  doctors  She has also represented Uber Technologies Inc in a class action lawsuit to force the company to pay its drivers overtime and minimum wage  Yang was among the Gibson Dunn attorneys who were hired to conduct an outside investigation into the  Bridgegate  scandal  Their March 2014 report exonerated Christie  finding that he had no involvement in the decision to close lanes on the George Washington Bridge linking New Jersey and New York City   Two of Christie s former close associates  Bridget Kelly  his deputy chief of staff  and Bill Baroni  the former deputy executive director of the Port Authority of New York and New Jersey  were convicted for their roles in the scandal last month   During their trial  former Port Authority official David Wildstein  who previously pleaded guilty for his involvement  testified that he and Baroni had in fact discussed the lane closures with Christie   Christie has not been charged with wrongoing  Defense attorneys in the case and local media in New Jersey have raised questions about the independence of Gibson Dunn s investigation  citing Yang s personal friendship with Christie and efforts to raise money for his campaign ,2016-12-06,Reuters,https://www.investing.com/news/politics-news/ex-attorney-yang-being-considered-for-sec-chair:-source-446055,446055
105373,326888,AGN,Biotech stocks slide after Trump says  I m going to bring down drug prices,news,"Drug companies expecting less pressure on price increases under a Donald Trump administration might need to rethink their strategy 
In an interview with Time magazine the president elect offered his thoughts on the drug prices 
 I m going to bring down drug prices  I don t like what s happened with drug prices  
The comments sent drugmaker shares reeling  with the Nasdaq biotech index was down about 3 7  on Wednesday morning 
Drug stocks  in the wake of Trump s election last month  with biotechnology stocks rallying 13 3   Investors had been skittish about what a Hillary Clinton presidency would mean for regulation of drug development and pricing
  and she often sent drugmakers  stocks falling with her comments on Twitter 
Until now  Trump had not been this explicit about his stance on the issue  even as politicians including Bernie Sanders and Hillary Clinton repeatedly attacked drug companies over the rate of price hikes 

But it s not totally unexpected either  Just last week the CEO of Allergan  NYSE AGN   a major drugmaker that has pledged to cap the rate of price increases  warned that drug pricing is a populist issue and populism was central to Trump s campaign 
 I worry today that pharma has a false sense of relief or security   Brent Saunders   It wouldn t be completely surprising  he said  to see Trump tweeting opposition to the next  
Prior to his comments in Time  Trump had mentioned placing an emphasis on advancing research and development and reforming the Food and Drug Administration to get more new drugs approved  at a faster pace ",2016-12-07,Business Insider,https://www.investing.com/news/stock-market-news/biotech-stocks-slide-after-trump-says-'im-going-to-bring-down-drug-prices-446259,446259
105374,326889,AGN,U S  says Allergan s Forest units to pay  38 million to settle kickback allegations,news,"WASHINGTON  Reuters    Allergan  NYSE AGN  PLC s Forest Laboratories and Forest Pharmaceuticals units will pay  38 million to settle U S  charges that it paid physicians to prescribe three medications  the U S  Justice Department said on Thursday  
In a statement  the department said the alleged kickbacks involved the companies  blood pressure hypertension drug Bystolic  fibromyalgia medication Savella and the Alzheimer s disease product Namend ",2016-12-15,Reuters,https://www.investing.com/news/stock-market-news/u.s.-says-allergan's-forest-units-to-pay-$38-million-to-settle-kickback-allegations-448111,448111
105375,326890,AGN,U S  states sue Mylan  Teva  others for fixing drug prices,news,By Diane Bartz and Sarah N  Lynch WASHINGTON  Reuters    Two years after high generic drug prices became a public controversy  legal cases are starting to land  Twenty states filed a lawsuit Thursday against Mylan NV  O MYL   Teva Pharmaceuticals  TA TEVA  and four other generic drug makers  saying they conspired over steak dinners and  girls nights out  on pricing of two common generic drugs  according to a copy of the complaint  The civil lawsuit  led by antitrust investigators in Connecticut  comes one day after the U S  Department of Justice filed criminal charges against two generic drug industry executives  alleging that they colluded to fix prices and split up market share   nL4N1E94KE  Taken together  the cases are part of a broader generic drug pricing probe that remains under way at the state and federal level  as well as in the U S  Congress  In 2014  media reports of sharply rising drug prices led to Congressional hearings    We believe that this is the tip of the iceberg   Connecticut Attorney General George Jepsen told Reuters in an interview   Price fixing in the generic industry is widespread and pervasive  and it involves many other drugs and a number of other companies   Both of the Justice Department defendants are expected to plead guilty  It is typical for the department to file one lawsuit about an ongoing issue and use evidence from those defendants to build subsequent cases against others  Several companies have publicly disclosed receiving subpoenas from the Justice Department related to generic drug pricing issues  Among them  Mylan  Allergan  N AGN   which later sold its generic business to Teva  Lannett Co  N LCI   Impax Laboratories   Par Pharmaceuticals  which is owned by Endo Pharmaceuticals  O ENDO   Sun Pharmaceutical Industries  Taro Pharmaceuticals Ltd and Mayne Pharma Group  AX MYX   FROM  20 TO  1 849 IN SEVEN MONTHS The drugs involved in Thursday s lawsuit include the delayed release version of a common antibiotic  doxycycline hyclate  and glyburide  an older drug used to treat diabetes  Doxycycline  for example  rose from  20 for 500 tablets to  1 849 between October 2013 and May 2014  according to Senator Amy Klobuchar  a Minnesota Democrat who had been pressing for action on high drug prices  The lawsuit  filed in the U S  District Court for the District of Connecticut  names Heritage Pharmaceuticals Inc as a  ring leader  of the price manipulation  and also lists Mayne Pharma  AX MYX    Aurobindo Pharma   NS ARBN  and Citron Pharma LLC as participants  The two executives charged in Wednesday s Justice Deparment filing were from Heritage  According to the complaint  Heritage  Teva  Aurobindo and Citron conspired to raise prices on glyburide  Heritage  Mylan and Mayne conspired to allocate and divide the market for doxycycline  Heritage  part of India s Emcure Pharmaceuticals  referred back to its Wednesday comment  which blamed the former executives for the price fixing  and said they had been terminated   Mylan denied the charge   To date  we know of no evidence that Mylan participated in price fixing   spokeswoman Nina Devlin said by email  Teva spokeswoman Denise Bradley said the company has  not found evidence that would give rise to any civil or criminal liability   The other three companies had no immediate comment  The lawsuit alleges that drug companies either set prices or allocated markets to prop up prices  Employees knew the conduct was illegal and either deleted emails or made efforts to avoid communicating in writing  the lawsuit alleges  The attorneys general asked the court to order the companies to disgorge ill gotten gains  which were not defined  pay attorneys  fees and stop collusion   The states  complaint names but does not individually charge former Heritage CEO Jeffrey Glazer and former Heritage Vice President of Commercial Operations Jason Malek  the two men charged a day earlier by the Justice Department  The states  suit puts Glazer and Malek at the center of the alleged schemes   nL4N1E94KE  The names of the other individuals referenced in the states  lawsuit and the content of their text messages and other communications are redacted  Some of the alleged collusion occurred at industry conferences and dinners  the complaint said  Female sales representatives gathered for a  Girls Night Out  where they discussed sensitive information  the complaint says   In one case  it says that Mylan agreed to  walk away  from one large national wholesaler and one large pharmacy to allow Heritage to win business   Malek  it says  was in charge of communicating with Teva  and he was able to reach a deal to raise prices on glyburide  the suit alleges  Connecticut s Jepsen said Assistant Attorney General Joseph Nielsen was prompted to investigate by a 2014 article about rising generic drug prices  In September of this year  he said  Connecticut began pitching other states to join the lawsuit   To date  the other states that have joined include Delaware  Florida  Hawaii  Idaho  Iowa  Kansas  Kentucky  Louisiana  Maine  Maryland  Massachusetts  Minnesota  Nevada  New York  North Dakota  Ohio  Pennsylvania  Virginia and Washington   Jepsen said he expects more to sign onto the case ,2016-12-15,Reuters,"https://www.investing.com/news/stock-market-news/u.s.-state-ags-sue-six-cos,-including-mylan,-teva,-over-drug-pricing-448068",448068
105376,326891,AGN,Allergan to buy Acelity s tissue unit LifeCell for  2 9 billion,news," Reuters    Drugmaker Allergan  NYSE AGN  Plc said on Tuesday it would buy LifeCell  a regenerative medicine unit owned by privately held Acelity LP Inc  for  2 9 billion in cash  bringing the number of deals it has made this year to an even dozen  LifeCell makes regenerative tissue products that are commonly used in breast reconstruction procedures and complex hernia surgeries to provide soft tissue support  The products will support Allergan s portfolio of medical aesthetics  breast implants and tissue expanders  the company said  Allergan Chief Executive Brent Saunders has described the company s acquisition strategy as being one of  stepping stones   Allergan s deal to sell itself last year to  Pfizer  Inc  NYSE PFE  for  160 billion was dropped due to a change in tax law  Allergan  best known for its Botox product  said Lifecell s 2016 sales are expected to be  450 million and grow at a mid single digit rate  It expects the deal to close in the first half of 2017  Dublin based Allergan  which was created through the combination of  Actavis  and Allergan  earlier this year sold its generics business to Teva Pharmaceutical Industries  NYSE TEVA   freeing up cash for deals  Allergan has agreed to 12 deals this year  including the  1 7 billion acquisition of Tobira Therapeutics Inc  maker of an experimental treatment for fatty liver disease  and  639 million acquiring Vitae  maker of an experimental drug to treat psoriasis  
Allergan shares fell 1 2 percent to  190 17 ",2016-12-20,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-buy-acelity's-unit-lifecell-for-$2.9-billion-448910,448910
105377,326892,AGN,Biotech Stock Roundup   PTGX Down  VRNA Up  AMGN s Repatha Gets Positive Opinion ,opinion,"It was a week that saw Protagonist stock crashing on news of discontinuation of a phase IIb study  Amgen s Reptha getting a positive CHMP opinion  Verona Pharma stock rallying on positive top line data from COPD study and the FDA accepting sBLA for Bristol Myers  Opdivo 
Recap of the Past Week s Most Important Stories
Protagonist Plummets on Study Results  Shares of Protagonist Therapeutics   NASDAQ PTGX   plummeted on announcement of the discontinuation of phase IIb study   PROPEL   on its ulcerative colitis   UC   candidate  PTG 100  The company decided to discontinue the study as a planned interim analysis of PROPEL study by an independent Data Monitoring Committee determined that the study will not be able to achieve its primary endpoint of clinical remission 
The interim analysis was done on data from first 65 patients who had completed the 12 week treatment with PTG 100  The total patient population of the study was 240  The company has notified that it will stop further treatment of patients currently in the study  Protagonist has also postponed its decision to initiate a phase II III on PTG 100 in patients with chronic pouchitis  as it awaits full review of the interim data from the PROPEL study  Read more   
Amgen s Repatha Gets Positive CHMP Opinion  Amgen   NASDAQ AMGN   announced that the Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency   EMA   rendered a positive opinion on the company s regulatory application seeking approval to include data from the cardiovascular outcomes study  FOURIER  on the European label of its PCSK9 inhibitor  Repatha 
The application seeks for a new indication in the Repatha label for adults with established atherosclerotic cardiovascular disease  myocardial infarction  stroke or peripheral arterial disease  to reduce cardiovascular risk by lowering LDL C levels  Concurrently  the CHMP gave a positive opinion for the marketing authorization to Amgen and Allergan s   NYSE AGN    ABP 980  a biosimilar of Roche s oncology drug Herceptin  
The biosimilar has been recommended for approval for the treatment of the same three types of cancer   HER2 positive metastatic breast cancer  HER2 positive early breast cancer and HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction   Read more   
Verona Pharma Surges on Study Results  Shares of Verona Pharma plc   NASDAQ VRNA   surged following positive top line data from its phase IIb study evaluating pipeline candidate  RPL554   RPL554  a first in class  inhaled  dual inhibitor is being evaluated as a maintenance treatment for chronic obstructive pulmonary disease   COPD    The study met its primary endpoint as RPL554 demonstrated clinically and statistically significant improvements in lung function at all dose levels 
Additionally  secondary endpoints were also met and support the potential clinical benefits of RPL554 for the treatment of COPD  The positive results from the study support the progression of RPL554 into later stage development as an inhaled treatment for COPD patients  Verona Pharma doesn t have any approved product in its portfolio and the successful development and commercialization of the drug will significantly boost results 
Bristol Myers  Opdivo sbLA Accepted by the FDA  The FDA accepted Bristol Myers Squibb Company s   NYSE BMY   supplemental Biologics License Application  sBLA  for blockbuster drug Opdivo in combination with Yervoy for the treatment of adults with microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  metastatic colorectal cancer  mCRC  that has progressed following treatment with a fluoropyrimidine  oxaliplatin  and irinotecan  The agency has also granted the application priority review and set an action date of Jul 10  2018  The combination is already approved for a variety of oncology indications 
Seattle Genetics Gets Breakthrough Therapy Designation for Enfortumab  Seattle Genetics  Inc    NASDAQ SGEN   and partner Astellas Pharma Inc  announced that the FDA has granted Breakthrough Therapy Designation to antibody drug conjugate   ADC   enfortumab vedotin  for the treatment of patients suffering from locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors   CPI    The candidate is being studied in a pivotal clinical trial  EV 201  NCT03219333   as monotherapy in this patient setting and in an early phase clinical trial in combination with CPI therapy  EV 103  NCT03288545   Both companies are also evaluating enfortumab vedotin in other solid tumors  including ovarian and non small cell lung carcinoma 
Biohaven Pharma Plunges Despite Positive Trial  Biohaven Pharmaceutical Holding Company Ltd   s   NYSE BHVN   shares plunged significantly despite the company announcing positive top line results from two phase III trials  BHV3000 301 and BHV3000 302  on migraine candidate rimegepant  formerly known as BHV 3000   Rimegepant is an oral CGRP receptor antagonist which is being evaluated for the acute treatment of migraine  CGRP receptor antagonists represent a novel class of drug candidates for the treatment of migraine 
The results were statistically significant and clinically meaningful across multiple outcome measures as the candidate met the co primary efficacy endpoints of superiority to placebo  at two hours post dose  on pain freedom and freedom from the most bothersome symptom  The company is on schedule to submit an NDA for rimegepant in 2019  However  the investors were not much impressed with the data when compared to rival Allergan s migraine candidate ubrogepant Medical   Biomedical and Genetics Industry 5YR   Return

The NASDAQ Biotechnology Index lost 4 98  over the last five trading sessions  Among major biotech stocks  Biogen  NASDAQ BIIB  lost 14 5    Over the last six months  Celgene  NASDAQ CELG  lost 39 98  while Vertex gained 7 56   see the last biotech stock roundup here    

 
What s Next in the Biotech World 
Stay tuned for more regulatory and pipeline updates 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-03-28,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup--ptgx-down-vrna-up-amgns-repatha-gets-positive-opinion-200301587,200301587
105378,326893,AGN,Allergan s Vraylar Meets Endpoints In Bipolar I Phase III,opinion,Allergan plc   NYSE AGN   and Hungary based partner Gedeon Richter Plc  have announced positive top line results from the third pivotal study  evaluating the companies  schizophrenia drug Vraylar  cariprazine  for an expanded indication  Both entities are looking to get Vraylar approved for the treatment of adults with major depressive episodes related to bipolar I disorder Notably  Vraylar is already approved in the United States and the EU for the acute therapy of manic or mixed episodes associated with bipolar I disorder as well as for schizophrenia  Additionally  the FDA approved the drug in November 2017 for an expanded use as a maintenance therapy for treatment of schizophrenia Shares of Allergan have inched up 0 7  this year so far against the  s decrease of 5 9   The phase III  RGH MD 53  study was investigating two doses of Vraylar  1 5 mg and 3 mg  in 493 adult patients with major depressive episodes associated with bipolar I disorder  bipolar I depression  compared with placebo  The study met its primary as well as secondary endpoints Though Vraylar s 1 5 mg dosage showed a significantly greater improvement than placebo on the Montgomery Asberg Depression Rating Scale  MADRS  from baseline to week 6  the 3 mg dose failed to reach statistical significance  However  the drug was generally well tolerated in the trial  We also note that around 5  of the total patients  under Vraylar treatment  discontinued the trial due to adverse events in comparison to 3  treated with placebo We remind investors that last December  Allergan and Gedeon produced positive top line results from the second pivotal phase III  RGH MD 54  program  examining Vraylar for treatment of bipolar I depression  This study also met its primary endpoint Based on the above reported data  the company is planning to submit regulatory applications to the FDA in the second half of 2018 Allergan has a licensing agreement with Gideon Richter  a Hungarian multinational pharmaceutical and biotechnology company  to co develop and market Vraylar in the United States as well as Canada The schizophrenia drug performed well in 2017  recording sales of  287 8 million compared with  94 3 million in 2016  It is likely to be a key driver of Allergan s top line in 2018 Per National Alliance of Mental Illness  bipolar disorder is one of the most common mental diseases and the third most frequent cause of hospitalization in the United States for both youth and adults aged between 18 and 44 years  Moreover  2 6  of adults in the country are affected with bipolar disorder  Hence  approval of the drug for the expanded indication will provide the company with access to a wider patient population base suffering bipolar issues Other players in the bipolar disorder and schizophrenia treatment market include AstraZeneca plc s   NYSE AZN   Seroquel XR  Johnson   Johnson s   NYSE JNJ   Risperdal Consta and Alkermes plc s   NASDAQ ALKS   Aristada Allergan plc Price    Zacks RankAllergan carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-04-03,Zacks Investment Research,https://www.investing.com/analysis/allergans-vraylar-meets-endpoints-in-bipolar-i-phase-iii-200303077,200303077
105379,326894,AGN,Paratek s  PRTK  NDAs For Omadacycline Get Priority Review,opinion,"Paratek Pharmaceuticals  Inc    NASDAQ PRTK   announced that the FDA has accepted two new drug applications  NDAs   seeking approval of its antibiotic candidate  omadacycline  The NDAs were granted priority review  thus speeding up the review process  A decision is expected in October 2018 The NDAs are seeking approval of once daily oral and intravenous   IV   dosing of omadacycline for treating community acquired bacterial pneumonia   CABP   and acute bacterial skin and skin structure infections   ABSSSI   The candidate already enjoys Qualified Infectious Disease Product and Fast Track designation for both the indications Shares of the company were up almost 3  in after market trading on Apr 4  However  Paratek s shares have declined 25 7  so far this year  underperforming the  s decline of 7 4  in the said period The NDAs submitted included positive data from phase III program evaluating omadacycline in ABSSSI and CABP patients  The candidate was also well tolerated In April 2017  Paratek had announced non inferiority of omadacycline to Bayer s   OTC BAYRY   CABP drug  Avelox  in a phase III study The chief medical officer of Paratek stated that resistance to antibiotics is on the rise  increasing the need for new antibiotics Paratek is also planning to file a marketing authorization in the European Union for omadacycline in similar indications The candidate is also being developed for the treatment of urinary tract infections However  there are approved therapies available for the treatment of CABP and ABSSSI  which includes Allergan plc s   NYSE AGN   Teflaro  Moreover  Nabriva Therapeutics plc   NASDAQ NBRV   is evaluating its antibiotic candidate lefamulin in late stage studies in CABP and ABSSSI Apart from omadacycline  Paratek s acne candidate  Seysara  is under review in the United States Paratek Pharmaceuticals  Inc  Price
    Zacks RankParatek has a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-04,Zacks Investment Research,https://www.investing.com/analysis/parateks-prtk-ndas-for-omadacycline-get-priority-review-200303460,200303460
105380,326895,AGN,FDA Refuses Alkermes Depression Drug Review  4 Stocks In Focus ,opinion,"The FDA s refusal to review Alkermes plc s   NASDAQ ALKS   depression candidate ALKS 5461 this week was a major setback for the company  The decision sent Alkermes  stock tumbling more than 21  
ALKS 5461  a once daily oral medication has been developed for the adjunctivetreatment of major depressive disorder   MDD   in patients  who have not responded to standard antidepressant therapies 
The FDA refused to review the candidate stating that the new drug application   NDA   did not have enough evidence that the oral medication will work  The FDAwas of the opinion that additional studies should be conducted to ascertain the drug s effectiveness for the proposed indication 
It goes without saying that unexpected pipeline setbacks like these  shift investors  focus to companies that market or are developing drugs for the treatment of depression  Alkermes  latest pipeline setback has shifted investors  focus to this market 
 Depression and Types 
Depression is a medical condition that affects the brain  Individuals with depression feel melancholic and have intricacy in enjoying routine activities  Factors such as stress and brain chemistry are the most common causes of depression  It can also be genetic 
There are different forms of depression such as persistent depressive disorder  perinatal depression disorder  psychotic depression  seasonal affective disorder and bipolar depression  Psychotic depression  persistent depressive disorder and bipolar disorder are the most severe forms of depression  
According to WHO as of May 30  2016  an estimated 350 million people worldwide are affected by depression and have been seen to carry suicidal tendencies  Thus  there rose a pressing need to develop drugs for this condition  Known as antidepressants  these drugs are instrumental in identifying the signs and symptoms of the ailment 
Several pharma and biotech companies are involved in developing and selling of anti depressantdrugs 
4 Stocks in Focus
Let us look at some of the companies that are actively pursuing the development of treatment for various types of depression 
Allergan plc   NYSE AGN    This Zacks Rank  3  Hold  stock  looks well positioned in the depression market  The company has quite a few products in its portfolio including Vraylar  schizophrenia and bipolar I disorder   Viibryd  major depressive disorder  and Saphris  bipolar I disorder   These drugs are also in several label expansion studies  Earlier this week  Allergan announced that a pivotal study evaluating Vraylar for the treatment of adults with major depressive episodes associated with bipolar I disorder  bipolar I depression  met the primary endpoint 
Moreover  Allergan moved rapastinel  its NMDA receptor modulator  into phase III development for major depressive disorder  Rapastinel  a potentially game changing treatment  is expected to be launched in 2021  The drug is expected to generate revenues of  1  2 billion  Rapastinel was granted breakthrough therapy status for adjunction major depressive disorder by the FDA in 2016 
Allergan is also evaluating its flagship product  Botox  for the treatment of major depressive disorder  Allergan has outperformed the  year to date  The company s shares have moved up 1 7  against the industry decline of 4 7  

Johnson   Johnson   NYSE JNJ    Healthcare giant  J J has a strong presence in the neuroscience segment  which is one of its core therapeutic areas  While the company has products like Risperdal Consta  schizophrenia and bipolar I disorder  in its portfolio  one of the most promising candidates in J J s pipeline is esketamine  an investigational antidepressant medication with blockbuster potential  Esketamine  an NMDA receptor antagonist  which has a novel mechanism of action  got breakthrough therapy designation from the FDA for major depressive disorder with imminent risk for suicide in 2016  Esketamine has been granted breakthrough therapy designation for treatment resistant depression and a regulatory application for this indication in the United States is expected to be filed this year 
J J  a Zacks Rank  2  Buy  stock  has underperformed the industry year to date  The company s stock has lost 6 7  compared with the  decline of 3 3   You can see  

Eli Lilly and Company   NYSE LLY    The pharmaceutical giant Lilly s major drug Cymbalta is used for the treatment of major depressive disorder  generalized anxiety disorder  fibromyalgia and neuropathic pain The neuroscience portfolio of Lilly includes drugs like Prozac for the treatment of major depressive disorder  obsessive compulsive disorder  bulimia nervosa  and panic disorder  Zyprexa for the treatment of schizophrenia  acute mixed or manic episodes associated with bipolar I disorder  and bipolar maintenance 
Lilly  a Zacks Rank  2 stock  has underperformed the industry  The company s shares have declined 6 9  compared with the  sdecline of 3 2  

Sage Therapeutics  Inc    NASDAQ SAGE    Sage is another company working on the development of CNS treatments  The company s portfolio includes novel pipeline candidates targeting critical CNS receptor systems  GABA and NMDA  The company s lead program  brexanolone  SAGE 547   is in late stage development for super refractory status epilepticus  a rare and severe seizure disorder  as well as for postpartum depression   PPD    Brexanolone has been granted breakthrough therapy designation in the United States and PRIority MEdicines designation in the EU for the treatment of postpartum depression 
SAGE 217 is scheduled to move into a phase II placebo controlled study for four therapeutic indications   MDD  PPD  essential tremorand Parkinson s disease 
Sage  a Zacks Rank  3 stock  underperformed the  year to date  The company s shares have lost 11 2  compared with the industry s decline of 1 1  

Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-04,Zacks Investment Research,https://www.investing.com/analysis/fda-refuses-alkermes-depression-drug-review-4-stocks-in-focus-200303458,200303458
105381,326896,AGN,3 Biotech Pharmaceutical Picks For Second Half Of 2018,opinion,"Looking ahead to the second half of 2018  three top biotech   pharmaceutical companies  Allergan  NYSE AGN   Pfizer  NYSE PFE   and Johnson   Johnson  NYSE JNJ  are poised to make big moves to the upside  One of the reasons we like these three companies is that they have limited to no exposure to opioids  which carry significant legal and regulatory risk for other drug companies   President Trump has declared opioid abuse a  public health emergency  and has vowed concerted efforts to address drug addiction and opioid abuse through education and prevention  treatment and recovery  and law enforcement and interdiction 
 Culpability for the worst drug epidemic in American history is shifting to other parts of the opioid industrial complex  the pharmaceutical companies and distributors   explains according to Jayen Madia  who helps manage the  15 billion investment portfolio of AXIS Capital  AXS   a Bermuda based insurance and reinsurance company  As Head of Risk Assets  Jayen Madia oversees a diverse set of assets  including private credit  private equity  and real estate  globally 
Allergan and Johnson   Johnson do not sell or market opiates  Pfizer markets just one opioid called Embeda  which is not a big seller and already carries a  black box  warning 
Allergan
Allergan is a global pharmaceutical company headquartered in Dublin  Ireland  The company focuses on developing  manufacturing  and commercializing pharmaceuticals  devices  and biologic products  Allergan focuses its products on diseases and conditions affecting the central nervous system  eyes  gastroenterology  women s health  urology  anti infective therapeutic categories  as well as medical aesthetics and dermatology 
Allergan s Stock Price And Performance
As of March 2018  Allergan s share price was  159 48 USD  Allergan s stock prices have fallen dramatically since its all time high in 2015  shares are down by 50  since that period of time due to fears over the competitive landscape surrounding Botox  Allergan s leading treatment  and the upcoming patent exclusivity expiration of its dry eye drug Restasis  However  the company s shares are estimated to grow over 35  in 2018  While Botox is being threatened by competitors  Barron s indicates that research from Cowen Inc  shows that Botox has a 70  market share       and sales are growing at roughly double digit rates despite the emergence of discount priced competition  
Another area of growth for Allergan is its CoolSculpting technology acquired in connection with its 2017 acquisition of Zeltiq Aesthetics Inc   CoolSculpting is a non surgical  clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology   explains Dr  Edward Fruitman  the Medical Director and founder of Trifecta Med Spa in New York City  recognized by Allergan as one of the top providers in the United States   CoolSculpting recently received FDA clearance for improved appearance of lax tissue in conjunction with submental fat  or double chin  treatments  This will be another strong catalyst for growth  
Pfizer
Pfizer is a global pharmaceutical company committed to bringing therapies to improve people s lives  The Pfizer portfolio is heavy on medications and vaccines  as well as some consumer health products 
Pfizer s Stock Price And Performance
As of March 2018  Pfizer s stock shares were down over 4 78   settling at  34 49 per share  However  based on trading volumes  Pfizer is one of the most active stocks on the market today  Analysts predict that Pfizer will grow at a rate of 6 94  over the next five years  However  as Stock News Gazette points out  Pfizer s high growth rate may not translate to value for its investors due to an overinvestment on pipeline projects that offer a low return 
Pfizer has attempted to sell its consumer healthcare business  which includes products like Advil and Chapstick  The company began shopping around the idea in late 2017 in the hopes to earn  20 billion  however  no one s biting  GlaxoSmithKline was considered a frontrunner to purchase the consumer health line  but dropped out of the bidding in late March 2018  Speculation rests on Nestle  Proctor   Gamble  or Abbott Labs acquiring Pfizer s consumer health line  Analysts say that Pfizer is holding tight to the  20 billion price for the consumer health line  if they aren t able to achieve that price  there is additional speculation that Pfizer could spin off their consumer health business into a separate entity called Zoetis  according to Pfizer CFO Frank D Amelio 
Johnson   Johnson
Johnson   Johnson has been in business for over 130 years  creating a variety of medical and consumer health products for customers around the globe  Johnson   Johnson is seeking to capitalize on its core products  while also expected to make some acquisitions in 2018  Johnson   Johnson s pharmaceutical arm focuses on immunology  infectious diseases and vaccines  neuroscience  cardiovascular and metabolism  oncology  and pulmonary arterial hypertension 
Johnson   Johnson s Stock Price And Performance
As of March 2018  Johnson   Johnson s share price was  125 89  The company is one of the largest pharmaceutical and health companies based in the United States  with 2017 sales at  76 5 billion  Investors consider Johnson   Johnson a stable company  with a diversified portfolio and a solid growth outlook in 2018  Johnson   Johnson is a company with consistent growth  and its pharmaceutical division is anticipated to drive growth throughout 2018  For example  the drug Darzalex has performed at an 18  revenue growth rate  and the momentum from its oncology unit is also contributing to the company s overall growth ",2018-04-10,David Ben Melech,https://www.investing.com/analysis/3-top-biotech-and-pharmaceutical-picks-for-second-half-of-2018-200304451,200304451
105382,326897,AGN,FDA Prolongs Review Date For AbbVie Endometriosis Candidate,opinion,AbbVie Inc    NYSE ABBV   and partner Neurocrine Biosciences announced that the FDA has extended the review period of marketing application for the companies  pipeline candidate  elagolix  by three months  As a result  the regulatory body will now announce its decision by the third quarter of 2018 instead of the previously anticipated second quarter 2018 timeline AbbVie is looking to get elagolix approved as an oral medicine for pain management associated with endometriosis Last September  the FDA accepted AbbVie s new drug application  NDA  for elagolix and subsequently  granted priority review status in October  However  the regulatory body requested for an extended time frame to review additional information  provided by AbbVie along with its NDA pertaining to liver function test results Notably  management showed confidence in the company s data provided to the FDA and continues to work with the regulatory body to bring elagolix to the U S  market We remind investors that the NDA filing was supported by positive results from two replicate pivotal phase III trials  evaluating elagolix for the aforementioned indication  The detailed data from the study  presented last October  showed that treatment with elagolix resulted in statistically significant reductions in menstrual and non menstrual pelvic pain associated with endometriosis compared with placebo Data from the studies also demonstrated superiority as compared to placebo in alleviating pelvic pain  non menstrual pelvic pain and painful intercourse associated with endometriosis Endometriosis affects an estimated one in 10 women of reproductive age and is associated with pain symptoms  At present  there is no cure for the disease  The pain associated with it is currently managed with oral contraceptives  progestins  danazol  NSAIDS  opioids and GnRH agonists  Many medicines are not specifically indicated for treating endometriosis  If approved  elagolix will be the first option for patients in need of an additional treatment to apprehend the disease AbbVie s share price has surged 45 4  in a year  comparing favorably with the  s 7 5  gain  Meanwhile  Elagolix is also being evaluated in two phase III programs for preventing heavy menstrual bleeding in premenopausal women with uterine fibroids Importantly  another pharma company Allergan   NYSE AGN   also has a pipeline candidate  ulipristal acetate  in its portfolio  which is currently under evaluation for treatment of uterine fibroids  Here too  the FDA in February requested to extend the review period of the company s NDA for the candidate to August 2018 AbbVie Inc  Price    Zacks Rank   Key PicksAbbVie carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated   NASDAQ LGND   and Infinity Pharmaceuticals  Inc    NASDAQ INFI    both sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved up from  3 78 to  4 20 for 2018 and from  4 75 to  5 32 for 2019 in the last 60 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has soared 54 6  over a year Infinity s loss per share estimates narrowed from  1 07 to 74 cents for 2018 and from 83 cents to 66 cents for 2019 in the last 30 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 7 87  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/fda-prolongs-review-date-for-abbvie-endometriosis-candidate-200304756,200304756
105383,326898,AGN,Why Is Allergan  AGN  Stock Falling Today ,opinion,"Allergan   NYSE AGN   shares have fallen 5 8  on the day  while Shire plc   NASDAQ SHPG   is up 3 4  so far  These fluctuations come in light of a  50 billion dollar acquisition deal for Shire that is now taking a competitive turn 
Shire is a pharmaceutical company responsible for the manufacturing of ADHD medications such as Adderall  On Thursday Takeda Pharmaceutical Co    OTC TKPYY    a Japanese company  saw its  60 billion cash and stock buyout offer rejected by Shire  The offer was priced at  66 16 a share  a 50  premium to Shire s stock price from late March 
In conjunction with the third rejected offer from Takeda  Allergan  a company famous for making Botox  has announced it would consider producing an offer for the drug maker  Following the announcement  Allergen shares immediately began to drop  most likely due to investor concern that the company will overpay to overtake Shire 
In contrast  Shire share prices began to take off today  This comes as a result of increased investor confidence  facilitated by the mega pharmaceutical fight for the company  and the hopes of a high buyout as a result 
Takeda  in order to bounce back from this rejection  needs to find a means of acquiring a much greater capacity of wealth if it wishes to purchase Shire  which currently holds a higher market valuation  and compete with Allergan 
Riding this wave of media spotlight has helped raise share prices 7 9  at peak trading on the day  and unlike Allergan and Takeda  Shire s earnings outlook in the short term is seemingly positive  regardless of this deal 
Currently Shire holds a  B  grade for Growth  and a  B  grade for Value based in our Style Scores system 
Shire s P E of 10 7  P B of 1 4  and P S of 3 3 all come in at discounts to their respective industry averages and help show why the stock leaves investors with a strong value option  And if this buyout goes well  this could only be more of a discounted purchase  assuming the investor gets in now 
The company s growth prospects look strong as well  A debt equity ratio of 0 5 shows that Shire is financially sound  and a cash flow of  22 71 per share compared to the   0 51 industry average helps show investors the financial stability of the company in an unstable industry 
This being said  Shire is expected to witness EPS growth of a modest 8 35  on an annualized basis over the next three to five years  Analyst estimate revisions point to a negative trend as well  Although all current quarter EPS estimates  3  in the past 60 days have been positive  current year EPS estimates within the same time range  6  are at a 100  agreement to the downside  This is why the pharmaceutical company currently holds a Zacks Rank  4  Sell  
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/why-is-allergan-agn-stock-falling-today-200307103,200307103
105384,326899,AGN,Amgen  AMGN  To Report Q1 Earnings  Is A Beat In The Cards ,opinion,"We expect biotech major Amgen Inc    NASDAQ AMGN   to beat expectations when it reports first quarter 2018 results on Apr 24  after market close  Amgen delivered a negative earnings surprise of 4 93  in the last quarter Amgen shares have declined 0 6  in the past year  Still  this compares favorably with the 8 4  decrease registered by the during this period Amgen s performance has been modest  with the company delivering a positive surprise in three out of the trailing four quarters  The average earnings beat over the last four quarters is 2 93  Amgen Inc  Price and EPS Surprise
    Let s see how things are shaping up for the company this quarter Factors at PlayThe first quarter usually generates the lowest product sales for Amgen Amgen s newer products like Prolia  Kyprolis  Xgeva and Blincyto are likely to perform well backed by higher demand  This will make up for lower sales of mature brands like Enbrel  Aranesp  Epogen  Neulasta and Neupogen due to competitive pressure In 2017 and early 2018  Amgen gained FDA approval to include overall survival data in the labels for Kyprolis and Blincyto  which may reflect in first quarter sales of these drugs  In January  Xgeva gained FDA approval for the prevention of skeletal related events in patients with multiple myeloma  The label extension can boost sales of the drug Neulasta demand is being hurt by competition from PD 1s and other new cancer therapiesNeupogen sales are also being hurt by biosimilar competition in the United States  mainly from Zarxio  Sandoz s biosimilar version of NeupogenWe expect Neulasta and Neupogen first quarter sales to be hurt by competitive dynamics  Neulasta and Epogen are expected to start facing biosimilar competition in the United States this year  Also  Sensipar sales are likely to decline sharply the soon to be reported quarter as the drug lost patent exclusivity in March 2018 Enbrel sales are expected to be hurt by increased pricing and competitive pressure  Enbrel is one of the main drivers of Amgen s revenues On the fourth quarter conference call  Amgen said that sales of Enbrel in the first quarter are expected to be the lowest in 2018  representing approximately 20  of full year sales  Also Repatha sales in the first quarter are expected to be relatively flat sequentially hurt by insurance verifications and patient out of pocket costs  Also investors will be keen to know if sales of Repatha have improved with the inclusion of FOURIER outcomes data on its label Amgen and partner Allergan s   NYSE AGN   biosimilar version of Roche s cancer drug Avastin  Mvasi was approved in EU in January  which should boost first quarter sales of the drug Investor focus on the call will be on management s comments on the preparations for the potential launch of migraine candidate  Aimovig  The FDA is expected to give its decision on Aimovig biologics license application  BLA  in mid May Meanwhile  higher investments to support product launches is likely to result in higher SG A costs in the to be reported quarter Earnings WhispersOur proven model shows that Amgen is likely to beat on earnings because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate   3 34 per share  and the Zacks Consensus Estimate   3 23 per share  is  3 34   This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Amgen has a Zacks Rank  3  The combination of Amgen s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderBiotech stocks that have both a positive ESP and a favorable Zacks Rank include Alexion Pharmaceuticals  Inc    NASDAQ ALXN    scheduled to release results on Apr 26  has an Earnings ESP of  2 09  and a Zacks Rank  2  You can see  Celgene Corporation   NASDAQ CELG   has an Earnings ESP of  0 63  and a Zacks Rank  3  The company is scheduled to release results on May 4 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/amgen-amgn-to-report-q1-earnings-is-a-beat-in-the-cards-200307477,200307477
105385,326900,AGN,Pharma Stock Roundup  NVS  JNJ Q1 Sales   Earnings Top  MRK   BMY Active At AACR,opinion,"This week was ruled by cancer data presentations by drug companies at the annual meeting of the American Association for Cancer Research  AACR  in Chicago  Other than that  J J   NYSE JNJ   and Novartis   NYSE NVS   kicked off 2018 pharma earnings on a strong note  beating the Zacks Consensus Estimate for both earnings and sales in the first quarter of 2018 Recap of the Week s Most Important StoriesJ J Beats on Q1 Earnings  Raises Sales Guidance  J J s first quarter 2018 earnings came in at  2 06 per share while sales were  20 billion  Both the numbers increased 12 6  year over year  Though quite a few key products in J J s portfolio like Remicade and Concerta faced generic competition  we believe that new products like plaque psoriasis drug  Tremfya  guselkumab   cancer drugs  Darzalex  Imbruvica and Zytiga  currency tailwinds and contribution from acquisitions helped J J deliver strong sales and profit in the first quarter of the year and led it to raise the sales outlook for the whole year   Read more    Novartis  first quarter earnings came in at  1 28 per share  which beat the Zacks Consensus Estimate of  1 25  Revenues increased 10  year over year to  12 7 billion and beat the Zacks Consensus Estimate of  12 3 billion  Strong performance of key drugs Cosentyx and Entresto led to the impressive performance in the quarter  Novartis re iterated the previously issued guidance for 2018   Read more    Merck Presents Successful Keytruda Data  At AACR  Merck   NYSE MRK   presented full data from the pivotal KEYNOTE 189 study  which evaluated Keytruda  in combination with Alimta  pemetrexed  and platinum chemotherapy  cisplatin or carboplatin  for the first line treatment of patients with metastatic non squamous NSCLC regardless of PD L1 expression  The data showed that the Keytruda combo significantly improved overall survival  reducing the risk of death by half  51   compared to chemotherapy alone In January  Merck had announced that the study met both its primary endpoints  progression free survival  PFS  and OS  co primary endpoint  Notably  in May 2017  this combination therapy was granted an accelerated approval by the FDA for the aforementioned indication  The approval was based on tumor response rate and PFS data from the KEYNOTE 021 study  Hence  the positive readouts from the KEYNOTE 189 confirmatory study will help the company gain continued approval for the combo therapy  which should support uptake and sales    Read more    Merck also presented updated data from the phase III EORTC1325 KEYNOTE 054 study  which evaluated Keytruda monotherapy in high risk stage III melanoma patients in the adjuvant setting  Data from the study demonstrated that as an adjuvant treatment  Keytruda increased recurrence free survival   RFS    reducing the risk of disease recurrence or death by 43  over placebo after surgery in such patients   Read more    Separately  Merck and AstraZeneca   NYSE AZN   announced final overall survival   OS   data from a phase III study evaluating PARP inhibitor  Lynparza  in metastatic breast cancer at the AACR  The median OS was 19 3 months in the Lynparza arm  compared to 17 1  for chemotherapy Bristol Myers s Opdivo in Focus  Bristol Myers   NYSE BMY   presented initial results from the phase III study  CheckMate 227  which evaluated a combination of its PD L1 inhibitor Opdivo plus Yervoy for the first line treatment of advanced NSCLC in patients with high tumor mutational burden  The initial results showed that the one year PFS rate was more than triple with the combination versus chemotherapy  43  vs  13    However  while the results were encouraging  investors were disappointed as Merck s Keytruda seemed to have fared better than Opdivo and Yervoy combination   Read more    Opdivo also demonstrated a statistically significant overall survival  primary endpoint  benefit compared to chemotherapy in a late stage study  CheckMate 078  evaluating it in a predominantly Chinese population with previously treated non small cell lung cancer  Opdivo reduced the risk of death by 32  versus chemotherapy   Read more    In another development  Opdivo was approved in combination with Yervoy for the treatment of intermediate  and poor risk advanced renal cell carcinoma in previously untreated patients  Also  Bristol Myers  supplemental Biologics License Application  sBLA  to expand the use of Opdivo monotherapy to previously treated patients with small cell lung cancer  SCLC  was granted priority review by the FDA  The FDA is expected to give its decision on Aug 16  2018  Separately  Bristol Myers struck a collaboration with Illumina  NASDAQ ILMN   Inc  to develop and commercialize companion diagnostics for Bristol Myers  oncology immunotherapies Bristol Myers also inked a deal with Johnson   Johnson for the development and commercialization of Bristol Myers  factor XIa  FXIa  inhibitor  BMS 986177 for the prevention and treatment of major thrombotic conditions  Both companies are expected to advance BMS 986177 into phase II trials in the second half of 2018 Roche s Hemlibra Gets BTD for New Indication  Swiss pharma giant Roche s   OTC RHHBY   haemophilia drug  Hemlibra was granted breakthrough therapy designation by the FDA for the treatment of haemophilia A without factor VIII inhibitors based on positive data from the phase III HAVEN 3 study Hemlibra  emicizumab  was approved for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors in EU in February and in the United States in November last year  It has been successfully launched in the United States   Read more    Shire Agrees to Sell Oncology Unit  Shire announced a definitive agreement to sell its Oncology business to French company  Servier for  2 4 billion  The Dublin  Ireland drug giant plans to return the proceeds from the sale to its shareholders through a share buyback  Japan s Takeda considered taking over Shire and the latter s oncology business was one the key areas of interest to Takeda   Read More     Shire  however  on Thursday  rejected Takeda s third offer of 46 50 pounds per share as well saying that it undervalued Shire s growth prospects and pipeline Meanwhile  Allergan   NYSE AGN   issued a press release on the same day saying that it is in the  early stages of considering a possible offer for Shire    However  later in the day  it issued another press release saying it does not intend to make an offer for Shire Bayer  DE BAYGN  Sells Stake to Singapore s Temasek  Germany s Bayer has struck a deal to sell its 3 6  stake to Singapore s investment company Temasek for total gross proceeds of 3 billion euro  With the latest purchase  Temasek will own approximately 4  of Bayer s stock  The equity sale raises funds for Bayer s upcoming merger with seed maker Monsanto Company  NYSE MON  AstraZeneca s Tagrisso Gets FDA Nod in First Line Setting  AstraZeneca s lung cancer drug Tagrisso gained FDA approval for the first line treatment of adult patients with metastatic NSCLC whose tumors have EGFR mutations  The sNDA was based on data from the phase III FLAURA study A similar label expansion application is under review in the EU  Until now  Tagrisso was approved in the United States  European Union  Japan and China as a second line treatment option for patients with EGFR mutation positive NSCLC   Read more    The NYSE ARCA Pharmaceutical Index declined 1 3  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions While Merck was the biggest gainer last week  rising 3 3   Bristol Myers declined 12 3  In the last six months  AstraZeneca has been the biggest gainer  3    while Bristol Myers declined the most  19    See the last pharma stock roundup here  Pharma Stock Roundup    What s Next in the Pharma World Watch out for first quarter 2018 earnings results from several drug giants and other pipeline and regulatory updates Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-04-19,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-nvs-jnj-q1-sales--earnings-top-mrk--bmy-active-at-aacr-200307476,200307476
105386,326901,AGN,Shire  SHPG  Turns Down Takeda s Third Buyout Proposition,opinion,Shire plc   NASDAQ SHPG   announced that it has rejected the Japanese company Takeda Pharmaceutical s third offer to acquire it in a cash stock deal for 46 50 pounds per share or around  63 billion  The offer comprised 17 75 pounds in cash and 28 75 pounds worth of new Takeda shares Notably  Shire had earlier rejected two low priced offers from Takeda stating that the latter continues to undervalue its growth and pipeline prospects  However  per the companies  discussions between the Japanese entity and the Dublin  Ireland based drug giant are still on Notably  on Thursday Apr 19  Botox maker Allergan   NYSE AGN   announced that it is mulling over an offer to buy Shire  However  later in the day  it issued another press release informing that it abandons the plan to make an acquisition proposal for Shire We remind investors that the first proposition tendered by Takeda late last month  was priced at 44 pounds per share  Subsequently  Takeda put forward a second proposal of 45 50 pounds per share in the second week of this month  which saw a marginal increase from the first offer  However  both were turned down by Shire In order to recover from this refusal  Takeda needs to find a new means to purchase Shire  accompanied with much greater market valuation and the power to compete with the likes of Allergan among others Shares of Shire have gained 5 2  so far this year versus the  s decline of 1 7   We remind investors that on Monday Apr 16  Shire announced a definitive agreement to sell its oncology business to the French company Servier  for  2 4 billion Importantly  Shire has initiated the sale of this segment as part of its long term strategy to focus on rare disease leadership  The company plans to return the proceeds from this divestment to its shareholders through a share buyback The company also looks to dispose other non strategic assets as part of the strategy Demand for companies with rare disease drugs in their portfolio or pipeline candidates are rising  This is evident from the billion dollar deals signed this year  Novartis   NYSE NVS   is acquiring AveXis for  8 7 billion while Sanofi   NYSE SNY   has spent nearly  16 billion to boost its rare blood disorder pipeline Shire plc Price    Zacks RankShire carries a Zacks Rank  4  Sell  You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-04-20,Zacks Investment Research,https://www.investing.com/analysis/shire-shpg-turns-down-takedas-third-buyout-proposition-200307367,200307367
105399,326914,AGN,Impax Labs Q3 falls short of consensus  impairment charge and softer guidance sinks shares  down 24 ,news,Impax Laboratories  IPXL  23 6   Q3 results   M   Total Revenues  227 9   3 1    Generic Product Sales  175 3   3 0   Net Income   179 3    600 8    Non GAAP Net Income  EPS   2 51    612 2    Non GAAP EPS  0 37   7 5    Cash Flow Ops  9 mo    97 8   178 6   The results were impacted by a  251M non cash impairment charge related to lower than expected contract prices for products acquired from Teva Pharmaceutical Industries  TEVA  3 2   and affiliates of Allergan  AGN  6 7   Consensus view was non GAAP EPS of  0 39 on revenues of  234 8M 2016 Guidance  Total Revenues   840M   855M from  900M   940M  Non GAAP EPS   1 10   1 20 from  1 57   1 70 Previously  Impax Labs acquires portfolio of generic products from Teva for  586M  June 21 ,2016-11-09,Seeking Alpha,"https://www.investing.com/news/stock-market-news/impax-labs-q3-falls-short-of-consensus;-impairment-charge-and-softer-guidance-sinks-shares,-down-24-439267",439267
105400,326915,AGN,Reuters  Pfizer weighs consumer health exit,news,Pfizer   NYSE PFE  is evaluating a potential sale or spinoff of its consumer health division that could value the unit at as much as  14B  Reuters reports An exit from the business  which includes Chapstick and Advil  would be one of Pfizer s biggest corporate moves since abandoning a  160B deal to buy Allergan  NYSE AGN  earlier this year ,2016-11-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/reuters:-pfizer-weighs-consumer-health-exit-439402,439402
105401,326916,AGN,Allergan launches softgel oral contraceptive,news,Allergan  AGN  1 8   announces the availability of TAYTULLA  norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules   1mg 20 mcg  an oral contraceptive in a softgel capsule for the prevention of pregnancy  the only oral contraceptive in this formulation In clinical studies  TAYTULLA was 99 9  effective in preventing pregnancy when no backup contraception was used ,2016-11-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-launches-softgel-oral-contraceptive-439580,439580
105402,326917,AGN,Trump presidency could prove a salve for pharma merger deals,news,"By Carl O Donnell NEW YORK  Reuters    Biotechnology companies  whose U S  shares soared Wednesday after Republican Donald Trump s presidential election  may soon see another benefit  an uptick in biotech M A   A potential influx of foreign cash and improved stock valuations under the Trump administration would likely boost dealmaking in the industry  which has been anemic ever since political rhetoric against high drug prices picked up late last year  industry analysts and investment bankers said  That could mean renewed interest in some prime targets of takeover speculation  from cancer drug specialists like Tesaro Inc  O TSRO  to rare diseases firms like  Sarepta  Therapeutics Inc  O SRPT   according to several healthcare investors interviewed by Reuters  It could also throw a lifeline to smaller biotech firms  which on average have only 11 months of cash left to finance their research  according to Thomson Reuters data  and have been hesitant to try to raise money during a weak equities market   Despite a few headline grabbing deals  such as  Pfizer  Inc s  N PFE   14 billion acquisition of cancer drugmaker Medivation Inc in August  overall life sciences dealmaking is down 65 percent from the same period last year  according to Thomson Reuters data   Indeed  the biggest mergers and acquisitions news this year was Pfizer s failed bid to buy Allergan Inc  N AGN  for  160 billion  which was shot down by U S  regulators in April  Investment bankers attribute the slowdown to weak biotech stock prices  which have traded down as much as 30 percent after Democratic presidential candidate Hillary Clinton vowed to act against pharmaceutical  price gouging  late last year   Sector stocks are still valued more than 25 percent below their 2015 peak  and potential acquisition targets have stood firm against suitors who tried to take advantage of the drop   There s been a gap between what acquirers and shareholders are willing to pay for a biotech company and what the company s board thinks it s worth   said one investment banker  who asked not to be named because he was not authorized to talk to media   A VOCAL CRITIC The weak M A environment has persisted despite pharmaceutical companies  need to expand in fast growing areas of drug development  from oncology to neurology  and to sell off business units that are not a good strategic fit   Although Trump has said that runaway drug price inflation must be addressed  Clinton was much more vocal in calling out particular companies  including Valeant Pharmaceuticals  NYSE VRX  International  TO VRX  and Mylan NV  O MYL  for what she deemed  outrageous  price hikes  The Nasdaq Biotech Index rallied around 9 percent on Wednesday on news that Trump had won the election  The index rose another 1 5 percent on Thursday   In another potential tailwind for biotech deals  Trump has said that he plans to work with Congress to allow U S  companies to pay a lower tax rate when bringing back overseas cash  Pfizer would be one of the biggest beneficiaries  with more than  80 billion in funds overseas that Chief Executive Ian Read would like to repatriate  Read has said that Pfizer s appetite for deals  remains firm   and that he would consider deals of all sizes   The pace of biotech M A  could accelerate if changes in the tax code support this trend by facilitating the repatriation of cash  trapped  overseas for bigger biopharma companies   said Adnan Butt  an analyst at RBC Capital Markets   It may take several months before any benefits to dealmaking are felt  as companies and investment banks assess Trump s new policies as president before committing to large deals  That has not caused big pharma to shy away from dealmaking completely  however  Pfizer is in the early stages of reviewing a potential sale or spin off of its consumer healthcare business  which could be worth over  14 billion  Reuters reported on Wednesday   Meanwhile  cash strapped Valeant is in advanced talks to sell its gastro intestinal business  which could be worth as much as  10 billion  according to media reports   
Representatives for Tesaro and Sarepta Therapeutics were not immediately available to comment ",2016-11-11,Reuters,https://www.investing.com/news/stock-market-news/trump-presidency-could-prove-a-salve-for-pharma-merger-deals-439845,439845
105403,326918,AGN,Aerie s  AERI  Q4 Loss Wider On Higher Operating Expenses,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   posted fourth quarter 2017 loss of  1 38 per share  wider than the Zacks Consensus Estimate of a loss of  1 29 and the year ago loss of 72 cents Aerie Pharmaceuticals  Inc  Price and Consensus
     
Quarter in DetailIn December 2017  Aerie s lead drug Rhopressa was approved by the FDA for the reduction of elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension  This approval came two months ahead of the scheduled Prescription Drug User Fee Act date of Feb 28  2018 In the reported quarter  research and development expenses more than doubled to  38 1 million  General and administrative expenses surged 51 5  to  22 2 million  Also  higher operating expenses in the reported quarter reflect increased activities associated with the expansion of employee base to support operational growth and preparatory activities associated with the Rhopressa commercialization efforts apart from a  24 8 million research and development expense related to the Envisia asset acquisition For 2017  loss per share came in at  3 37  wider than the Zacks Consensus Estimate of a loss of  3 27 Pipeline UpdatesAerie currently evaluates its second candidate  Roclatan  a once daily  quadruple action fixed dose combination of Rhopressa and Xalatan  The NDA for Roclatan is expected to be filed in second quarter 2018   The company has initiated a phase III trial  Mercury 3  in the third quarter of 2017 to prepare for regulatory submission in Europe  It will be a non inferiority trial comparing Roclatan with prescribed fixed dose combination of Ganfort Meanwhile  Aerie plans to launch the drug Rhopressa in mid second quarter 2018  The company has hired all regional sales directors and district managers as well as more than 30 of an expected 100 territory managers The company expects to gain preferred formulary coverage for the majority of commercial payers for Rhopressa by late 2018 with most of the Medicare Part D coverage expected to commence in 2019 OutlookAerie expects Rhopress revenues in the range of  20 million to  30 million in 2018 Our TakeA wider than expected loss in the fourth quarter was due to higher operating expenses Aerie received a significant boost with the approval of lead drug Rhopressa  The FDA nod came ahead of the PDUFA date in February  This regulatory agency approval will significantly boost Aerie s prospects as glaucoma is one of the largest segments in the global ophthalmic market  Aerie s share price has outperformed the industry over the last 12 months  The stock has gained 6 8  versus the  s decline of 0 09  However  Aerie faces a stiff competition from established  branded and generic pharmaceutical companies  drugs such as Novartis    NYSE NVS   Simbrinza and Travtan  and Allergan s   NYSE AGN   Lumigan as well as products of other smaller biotechnology and pharmaceutical giants  Valeant Pharmaceutical s   NYSE VRX   Vyzulta was recently approved for an open angle glaucoma or ocular hypertension  Rhopressa will confront a tough time in gaining market share due to competition from these products Zacks RankAerie carries a Zacks Rank  3  Hold   You can see   The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/aeries-aeri-q4-loss-wider-on-higher-operating-expenses-200295330,200295330
105404,326919,AGN,Allergan divests surgical scaffold product line,news,Privately held Sofregen Medical acquires Allergan s  AGN  3 3   SERI Surgical Scaffold product line for an undisclosed sum  Polaris Partners financed the deal SERI is a silk based scaffold that provides soft tissue support in plastic and reconstructive surgical procedures  It has been used on over 10K procedures requiring surgical mesh ,2016-11-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/allergan-divests-surgical-scaffold-product-line-440007,440007
105405,326920,AGN,Pharmaceutical Industry Outlook   March 2018,opinion,"The year 2017 was rewarding for pharma and biotech stocks  with the sector witnessing some positive developments that led to a much awaited recovery 
The NYSE ARCA Pharmaceutical Index gained 11 8   while the Nasdaq Biotechnology Index was up 18 7  in 2017  This is in sharp contrast to 2016  which was tough for pharma and biotech stocks following criticisms about rising drug prices 
A key reason for the sector s improved performance was the willingness of investors to look beyond the drug pricing controversy and focus on fundamentals instead  Although the drug pricing controversy will remain a headline risk  investors seem more comfortable with the issue 
Moreover  a significantly higher number of FDA approvals in 2017 restored investor confidence in the sector  The approval of the first gene cell therapy last year was a major breakthrough 
Though the sector was off to a strong start in 2018  it has been struggling recently with the NYSE ARCA Pharmaceutical Index and Nasdaq Biotechnology Index down 1 8  and 2 8  year to date  respectively  probably on broader market correction  Also  the mention of high drug prices by President Trump in his State of the Union address dampened investor sentiment  However  the sector is largely expected to rebound as the year progresses 
New product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals  continued strong performance from key products  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending are some of the factors that should keep the sector on track in 2018  A faster drug approval process and the proposed removal of outdated regulations that push up costs and slow down innovation should also provide benefits 
Hopes of more mergers and acquisitions  M As  have also gone up with the tax reform in place and big players on the lookout for companies with innovative pipelines technology  There has already been quite a bit of M A buzz this year about potential deals  Sanofi  PA SASY   SNY  and Celgene  CELG  have already announced two deals each 
However  headwinds include drug pricing scrutiny  pricing pressure  increasing competition  the growing presence of biosimilars  generic competition  a slowdown in the growth of legacy products  concerns regarding Amazon s interest in entering the healthcare arena and major pipeline setbacks 
We are discussing some factors in details here 
Mergers and Acquisitions  M As  on the Rise
The year started off with expectations that M A activity would pick up  The new tax law  which cuts corporate tax rate from 35  to 21  and encourages companies to bring back huge cash held overseas at a one time tax rate of 10   is expected to spur merger activity this year 
This was held true with biotech pharma M A activity already starting to gather steam  Sanofi  earlier this year  announced deals to buy Belgian biotech company  Ablynx and haemophilia focused biotech  Bioverativ  BIVV   Celgene also announced deals to buy Juno Therapeutics  Inc   JUNO   which focuses on the development of CAR T therapies and Impact Biomedicines  which will add a late stage JAK2 kinase inhibitor  to Celgene s pipeline 
Merck  MRK  recently announced that it has proposed to buy Australian oncolytic immunotherapies maker Viralytics Ltd  to strengthen its presence in the fast growing immuno oncology market 
In fact  most big pharma CEOs believe the tax cuts will place American companies on a level playing field as they can compete better with their foreign counterparts  which operate in better tax environments 
Meanwhile  in licensing deals continue to be popular with several big companies tying up with smaller and mid sized players with promising mid to late stage pipeline candidates or interesting technology  These deals make sense for both sides    the larger companies are able to boost their pipelines with promising candidates while the smaller ones gain access to a non dilutive source of funds that allows them to continue investing in those pipelines 
Some companies that often find themselves on the acquisition radar include Exelixis  Incyte  BioMarin and TESARO  among others 
Divesting Non Core Business Segments and Restructuring
Another trend being witnessed is the divestment of non core business segments  Companies like UCB  Novartis  NVS   Teva  TEVA   Sanofi  Valeant  Glaxo  GSK  and AstraZeneca  AZN  have all been a part of this trend  Pfizer  PFE   which has already divested several of its business segments  is currently looking at strategic options for its Consumer Healthcare business  Teva divested many non core assets last year  mainly in the women s health portfolio  to support repayment of debt 
The monetization of non core assets allows these companies to focus on their key areas of expertise and utilize the sale proceeds for returning value to shareholders in the form of share buybacks and dividends  Smaller companies have also been monetizing assets to raise money for pipeline development 
Restructuring activities are also gaining momentum as large companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 
New Products Should Pick Up Pace
Highly awaited new products launched over the last couple of years should contribute significantly to revenues  Key new products include Ibrance  cancer   Cosentyx  psoriasis   Repatha and Praluent  PCSK9 inhibitors   Cotellic  advanced melanoma   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Tecentriq  urothelial cancer  and Taltz  moderate to severe plaque psoriasis   among others  The FDA also expanded the label of cancer drugs like Lynparza  Opdivo  Kyprolis  Imbruvica and Xalkori 
Competitive Threat from Biosimilars on the Rise
While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the United States for several years  With the FDA approving the first biosimilar in the United States  Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened 
Seven biosimilar applications have been approved by the FDA to date in the United States  These include  other than Zarxio  Sandoz s Erelzi  biosimilar version of Amgen  AMGN  Pfizer s Enbrel   Amgen s Amjevita  biosimilar to AbbVie s Humira  and Mvasi  biosimilar of Roche s Avastin   Pfizer and Celltrion s Inflectra and Ixifi  both are biosimilars of Merck J J s Remicade  
And then there is Lilly and Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway  Also  last December  Sanofi gained FDA approval for Admelog  insulin lispro injection   technically a follow on biologic version of Lilly s  LLY  Humalog Admelog wasthe first follow on Humalog product to be approved by the FDA 
Biosimilars should cut healthcare costs and provide a large number of patients with access to the much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014 2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen and Remicade biosimilars alone represent potential savings of more than  22 billion 
Apart from Amgen  Novartis and Pfizer  companies like Biogen  NASDAQ BIIB   Merck and Allergan  NYSE AGN  are targeting the highly lucrative biosimilars market  Pfizer  PFE  is a Zacks Rank  2  Buy  stock  You can see  
How did the Sector Perform in Q4 
AbbVie  Allergan  Novartis  Bristol Myers  AstraZeneca  Glaxo  Lilly and Pfizer all beat estimates for both earnings and sales in the fourth quarter  While AbbVie and Lilly raised their previously issued earnings expectations for 2018  Pfizer provided an upbeat outlook for the year  Allergan expects lower revenues and earnings in this year than 2017 as it faces generic competition to Restasis 
J J and Merck issued mixed results as they beat estimates for earnings while missed the same for sales 
Sanofi s fourth quarter 2017 results were below expectations as it missed expectations for both earnings and sales  However  Sanofi expects to return to growth in 2018 
Overall  the sector performed quite well in the fourth quarter and looks optimistic for further growth in 2018 
Importantly  at their conference calls  most companies discussed plans to invest in capital expenditures  products pipeline and in licensing or acquisition deals on expectation of an improved cash position following the tax reform 
Zacks Industry Rank
Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  Large Cap Pharmaceuticals  Biomedical and Genetics  Drugs and Generic Drugs 
We put our 265 industries into two groups  the top half  i e  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank  
Over the last 10 years  using a one week rebalance  the top half beat the bottom half by a factor of more than 2 to 1 
Currently  the Zacks Large Cap Pharmaceuticals sector is at the top 41  while the Zacks Biomedical and Genetics as well as the Zacks Drug sectors are at the bottom 28  and 24   respectively  The Zacks Generic Drugs sector  which is facing intense pricing competition  is at the bottom 17   Overall  factors like pricing and competitive pressures and slowdown in sales of legacy products are weighing on these stocks 
Click here to know more  About 
Earnings Trends 
As of Feb 28  2018  470 S P 500 members in the Medical industry  accounting for 94  of the index s total market capitalization  reported results  according to the latest  
If we look at the overall results of the Medical industry  earnings growth was 8 5  in the December quarter  Total revenues rose 6 1  in the quarter  The sector racked up an earnings beat ratio  the percentage of companies coming out with positive surprises  of 85 4  and a revenue beat ration of 87 5  in the December quarter 
Earnings and revenues for the March quarter are expected to rise 8 2  and 6 3   respectively 
Valuation Suggests Upside Potential
Going by the price to earnings multiple  which is often used to value drug stocks  the pharmaceutical industry looks poised for growth at this point  The industry is currently trading at 17 33 x forward 12 month consensus EPS estimate  slightly below the S P 500 P E multiple of 18 85  leaving room for upside 
Moreover  when compared to the industry s own performance over the last five years  it can be seen that the current multiple is below the industry high of 19 01  Keeping these numbers in mind  the current level seems to represent an attractive entry point 
Conclusion
While 2017 was strong  2018 is expected to be another important year for the drug biotech sector as these companies continue to invest in the pipeline  build their global business and support new product growth  In preparation for 2018  many of these companies have accelerated their cost saving initiatives to enable investment in new products and defend existing products to optimize long  and short term growth 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/pharmaceutical-industry-outlook--march-2018-200296459,200296459
105406,326921,AGN,Some hedge funds bet big on health insurers before Trump vote,news,"By Svea Herbst Bayliss NEW YORK  Reuters    Healthcare stocks  including insurers  have jumped since Donald Trump won the U S  presidential election last week and some hedge fund managers may see further gains in after making new bets in the sector in the third quarter  Billionaire investor Daniel Loeb s Third Point portfolio invested in insurer  Humana Inc   NYSE HUM  during the third quarter  according to the latest 13F hedge fund filings with the U S  Securities and Exchange Commission  Loeb s hedge fund bought 1 4 million shares of Humana  John Paulson s Paulson   Co   whose investments have been followed closely ever since his successful bet against the housing market  also took a new position in Humana  buying 79 500 shares  Pointstate Capital put on a new position as well  buying 991 622 shares   At Glenview Capital Management  where Humana was already the biggest investment  the firm raised its holdings by 9 0 percent  Diamond Hill Capital  Samlyn Capital  P  Schoenfeld Asset Management and Clovis Capital Management also made new bets on the insurer  although they were far smaller  according to regulatory filings that show what U S  stocks investment managers owned on Sept  30  Over the last six weeks  Humana has been one of the sector s best performers  boasting a 12 16 percent gain since Sept  30  Since January  the stock has gained 11 percent  handily outperforming the S P 500 s 6 percent gain  Some insurers including UnitedHealth Group Inc  NYSE UNH  and Anthem Inc had said they are losing money on the healthcare exchanges created by President Barack Obama s Affordable Care Act  With Donald Trump vowing to overturn the law  UnitedHealth and Anthem have also posted strong gains since the end of the third quarter  Anthem has climbed 10 5 percent in the last six weeks with UnitedHealth gaining 9 percent and  Aetna Inc   NYSE AET  posting a 7 5 percent rise  Glenview Capital boosted its Anthem bet by 41 percent while Hotchkis   Wiley Capital Management and Cornerstone Advisors Inc also each raised their stakes  Vulcan Value Partners and Two Sigma Investments increased their bets on UnitedHealth  Most investment managers released their 13 F filings on Monday and while the information is backward looking  it is watched closely by investors for hints of upcoming trends  The filings also reveal which managers made moves  identifying by name the investors who may have been behind big gyrations  Not all investors stuck with the health insurers  however  with a good number trimming their investments in the run up to the U S  election on November 8  With most polls calling for Hillary Clinton to win the White House  some investors were concerned she could impose greater regulation on drug companies and curb their price hikes  Hedge fund Adage trimmed its bet on Humana but held onto 1 1 million shares  Arrowgrass Capital Partners cut its bet by nearly half but still owned 1 9 million shares  And Farallon Capital Management  founded by Tom Steyer  cut its position by 45 percent to 382 000 shares  Similarly  shares of Valeant Pharmaceuticals  NYSE VRX   which drew Clinton s ire during the campaign for enormous price hikes  continue to drop in the last weeks amid fears about its debt load  Mutual fund powerhouse Fidelity Investments cut its Valeant stake by more than half   But with Trump heading to the White House in January  a number of investors said healthcare stocks  which had been undervalued  could now be poised for robust gains  Since the end of September  biotech company Celgene  NASDAQ CELG   whose blockbuster cancer drug Revlimid helped boost earnings  has gained 15 4 percent  making it the sector s top performer  Two Sigma boosted its investment by 200 percent to own 177 million shares   
Carl Icahn  the activist investor  sold most of his shares in Allergan  NYSE AGN  Plc just a few months after  Pfizer   NYSE PFE  walked away from a plan to merge with the company  Even in the second quarter  a number of investors had trimmed their holdings in Allergan  Viking Global Investors  one of those that trimmed in the second quarter  now exited in the third quarter  selling 1 9 million shares ",2016-11-14,Reuters,https://www.investing.com/news/stock-market-news/some-hedge-funds-bet-big-on-health-insurers-before-trump-vote-440665,440665
105407,326922,AGN,Large cap movers showing heavy relative volume,news,Gaining on triple or more their normal volume Advance Auto  AAP  15 5  BBVA  MC BBVA   BBVA  1 1  Eni  E  1 9   Global Payments   GPN  2 9  JD com  JD  13 3  Visa  V  1 3  Sliding on triple of more their normal volume Allergan  AGN  2 9   Home Depot   HD  2 7  Nokia  HE NOKIA   NOK  4 3  Teva Pharmaceutical  TEVA  6 5  ,2016-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/large-cap-movers-showing-heavy-relative-volume-441015,441015
105408,326923,AGN,Why Is Allergan  AGN  Down 10 1  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Allergan plc   NYSE AGN    Shares have lost about 10 1  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is AGN due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts Allergan Beats Q4 Earnings   SalesAllergan s fourth quarter 2017 earnings came in at  4 86 per share  beating the Zacks Consensus Estimate of  4 74 by 2 3   Earnings rose 24 6  year over year driven by higher revenues and lower R D costs and lower share count  which offset the impact of lower gross margins and higher SG A spend Revenues came in at  4 33 billion  which beat the Zacks Consensus Estimate of  4 28 billion by 1 2   Revenues rose 12  from the year ago period Key products like Botox and Juv derm collection of fillers and new products like Vraylar  Viberzi and Namzaric did well in the quarter  However  sales erosion of Namenda XR and Aczone and loss of exclusivity  mainly from Asacol HD and Minastrin  hurt the top line Fourth quarter revenues also benefited from the addition of Alloderm from LifeCell  January 2017  and CoolSculpting body contouring system from ZELTIQ  April 2017  acquisitionsSegment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues increased 19 8  to  1 88 billion driven by continued strong performance of its facial aesthetics products  Botox and Juv derm Collection of fillers Botox  cosmetic  raked in sales of  228 4 million  up 14 5    Botox Therapeutic revenues were  367 2 million  up 17 1   In addition  Juv derm Collection of fillers rose 14 7  to  139 5 million  In Eye Care  Ozurdex sales increased 16 8  to  26 4 million while Restasis  sales rose 1 8  to  400 3 million  In Plastic Surgery  breast implants sales increased 21 5  to  69 million  which contributed to the upside  In Medical Dermatology  Aczone sales declined 37 9  in the quarter to  38 million due to generic pressure on the branded acne category and higher discounts for formulary coverage LifeCell s Alloderm added  97 9 million while ZELTIQ s CoolSculpting business added  94 4 million to sales in the fourth quarter U S  General Medicine net revenues were flat at  1 5 billion in the reported quarter with sales declining in the Diversified Brands and Women s Health franchises  Anti Infectives sales rose 14 8  to  66 6 million  Gastrointestinal rose 2  to  453 2 million and Central Nervous System sales rose 2 9  to  349 million Established products like Linzess and Lo Loestrin as well as new products like Namzaric  Viberzi and Vraylar did well in the quarter  Linzess  sales rose 12 2  in the quarter to  194 8 million  driven by strong demand  Lo Loestrin sales rose 17 7  to  126 5 million backed by strong demand trends and higher selling prices Among the newer products  Namzaric  a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  36 8 million  almost flat with  37 million in the previous quarter  Viberzi recorded sales of  42 9 million  higher than  40 9 million in the previous quarter  Vraylar sales were  87 7 million in the fourth quarter  higher than  80 2 in the previous quarter driven by demand growth Namenda XR sales declined 30 7  year over year to  97 8 million in the quarter due to lower demand and generic pressure Asacol Delzicol sales declined 32  to  42 8 million due to a reduction in demand for Ascaol HD  following the launch of an authorized generic in August 2016 as well as lower demand for Delzicol In the Women s Health segment  Minastrin 24 revenues declined 93 2  to  5 3 million in the quarter due to loss of exclusivity in March last year The International segment recorded net revenues of  915 9 million  up 16 8  from the year ago period  driven by growth in Facial Aesthetics  Botox  therapeutic   Eye Care and the addition of CoolSculpting Profits RiseAdjusted operating income increased 16 4  to  2 17 billion in the fourth quarter  Adjusted operating margin rose 190 basis points in the quarter to 50 3  quarter due to improved operating leverage and lower R D costs Selling  general and administrative  SG A  expenses rose 6 2  to  1 13 billion in the quarter  primarily due to costs related to acquisitions  R D expenses declined 4 7  to  405 7 million due to cost control and reprioritization of R D programs 2017 ResultsFull year 2017 sales of  15 94 billion beat the Zacks Consensus Estimate of  15 89 billion  Revenues were within the guidance of 15 875 billion to  16 025 billion  Sales rose 9 4  year over year Adjusted earnings for 2017 were  16 35 per share  which beat the Zacks Consensus Estimate of  16 27 per share and were within the guided range of  16 15  16 45  Earnings rose 21  year over year 2018 OutlookIn 2018  Allergan expects lower revenues and earnings than 2018 as it faces generic competition to Restasis Allergan maintained its previously issued total sales guidance in the range of approximately  15 0 billion    15 3 billion assuming the generic Restasis is launched between April and July of 2018 Meanwhile  the company said that it expects adjusted earnings in the range of  15 25    16 00 per share in 2018  In January  Allergan had said that it expected earnings of at least  15 25 per share in 2018 Adjusted tax rate is expected to be approximately 14  in 2018 Adjusted gross margin guidance is expected in the range of 85 5  and 86  which is lower than 2017 levels  Gross margins are expected to be hurt by loss of exclusivity of high margin products   Restasis  Estrace and Delzicol  and unfavorable product mix Adjusted R D expenses are expected to be approximately  1 5 billion while SG A spend is expected to be approximately  4 25 billion Operating margins in 2018 are expected to be in line to slightly below 2017 levels On the call  the company said that it does not expect any significant M A activities in 2018  Allergan expects to reevaluate its M A strategy in the second half of the year once it gets through the LOEs First Quarter 2018 OutlookIn the first quarter 2018  revenues are expected to be between  3 5 billion and  3 6 billion while earnings per share are expected to be between  3 20 and  3 40  These numbers represent the lowest revenue and earnings quarter for the year In the fourth quarter of 2017  the favorable timing of physician rebating program benefited sales of Allergan s facial aesthetics products  This benefit will be missing in the first quarter of 2018  As such  the company expects first quarter revenue growth rate to be somewhat lower than the annual 2018 growth rate  Also  generic competition for Estrace and Namenda XR will hurt sales sharply in the first quarter 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision higher for the current quarter compared to four lower 
Allergan plc Price and Consensus
    VGM Scores
At this time  AGN has a nice Growth Score of B  though it is lagging a bit on the momentum front with a C  Following the exact same course  the stock was also allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for growth investors than those looking for value and momentum 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Interestingly  AGN has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-allergan-agn-down-101-since-its-last-earnings-report-200296659,200296659
105409,326924,AGN,Amgen submits BLA in U S  for Avastin biosimilar,news,Amgen  NASDAQ AMGN  and development partner Allergan plc  NYSE AGN  announce the submission of a Biologics License Application  BLA  to the FDA seeking approval of a biosimilar to Roche s  OTCQX RHHBY  cancer med Avastin  bevacizumab   The biosimilar  ABP 215  is the most advanced of the four oncology biosimilars that the companies are collaborating on under their December 2011 agreement Under the terms of the partnership  Amgen has primary responsibility for developing  manufacturing and initially commercializing the products ,2016-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/amgen-submits-bla-in-u.s.-for-avastin-biosimilar-441110,441110
105410,326925,AGN,Short interest in Valeant rising,news,Barron s reports that S3 Partners research chief Ihor Dusaniwsky says short sellers are regaining their mojo with Valeant Pharmaceuticals  VRX  0 2   as various government investigations continue to dog the company This month  short interest has climbed to  626M  up 18  from October s  532M  Short interest peaked at  2 5B during Valeant s pursuit of Allergan  AGN  2 1   but dropped to  1 2B by the end of 2015 He adds that VRX remains at General Collateral levels  cheapest to borrow  and there are plenty of shares available for bears ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/short-interest-in-valeant-rising-442329,442329
105411,326926,AGN,Pharma Stocks Weighed Down By Competition  Generic Pressure,opinion,"While the drug pricing issue is no longer a major headwind for pharma and biotech stocks  it will nevertheless remain a headline risk until the Trump administration comes out with a policy for controlling drug prices  The sector  previously a Wall Street favorite  was hit hard by political rhetoric and increasing media and public focus on the high prices of drugs  With the drug pricing controversy gaining steam since September 2015  companies like Valeant saw their share prices plunge 
According to the April 2017 Kaiser Health Tracking poll  six in 10 Americans believe that affordability of prescription drugs should be the top priority for the President and Congress  The focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 
Some of the options favored by the public for drug price control include getting drug companies to reduce prices of medication for people on Medicare  making it easier for generics to enter the market  and requiring drug companies to provide information on how drug prices are set 
Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing treatments to market and the need to invest in R D to develop additional treatments 
Biosimilars a Key Headwind
Another challenge being faced by the sector is the recent entry of biosimilar competition in the United States  While a relatively new area  the market for biosimilars is huge and highly lucrative  with several blockbuster biologics slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments 
According to research released by the IMS Institute for Healthcare Informatics last year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the United States through 2020  The report further says that by 2020  biosimilars will start competing with biologics that have annual sales of  50 billion 
Biosimilars are also gaining acceptance across formularies  Although there is still low visibility on how well biosimilars will perform or how much of the market they will be able to capture  the focus on making expensive drugs more affordable and formulary coverage for biosimilars could very well make it challenging for innovator companies to hold on to market share for their blockbuster drugs 
Generics Pose a Threat
Quite a few of the big players in the drug industry are looking at loss of patent protection for major blockbuster drugs  Pfizer s  PFE  Pristiq and Viagra  Merck s  MRK  Vytorin  Sanofi s  SNY  Renagel  Lilly s Strattera  Axiron and Effient are some key drugs  which started to face generic competition in the United States in 2017  The launch of a generic version of Teva s 40 mg formulation of blockbuster multiple sclerosis drug  Copaxone in October last year significantly hit the company s sales and profits  Some other key drugs expected to face generic biosimilar competition in 2018 include Glaxo s  GSK  Advair  Amgen s  AMGN  Neulasta  Epogen and Sensipar  Lilly s  LLY  Cialis  Allergan s  AGN  Namenda XR and Restasis  among others 
With generics and biosimilars breathing down their necks  many of these companies are looking toward new products to pick up pace and make up for lost sales  However  relatively newer products like Amgen s Repatha and Sanofi Regeneron s Praluent have yet to ramp up significantly  With efforts on to control drug prices  the FDA is focusing on speeding up the generic drug approval process  especially for third  fourth or fifth generics  which is leading to rapid erosion of branded drug sales 
Slowdown in Sales of Mature Products
Several companies like Amgen are facing a slowdown in sales of mature products while new product sales have yet to pick up significantly  Many of these companies are also facing loss of patent protection  which means generics or biosimilars  as the case may be  could enter the market soon and lead to price erosion 
Pricing Pressure to Hit Sales
While concerns regarding the drug pricing issue may have taken a backseat for the time being  pharma and biotech companies remain wary of increasing scrutiny of drug prices  Moreover  with increasing competition in the market and the entry of innovative treatments  pricing pressure is expected to hit sales 
Regulatory Setbacks
Although the FDA surpassed 2016 s tally of new drug approvals in 2017  a few companies failed to gain approval for their drugs last year and were issued complete response letters  CRLs  by the agency  A CRL is issued by the FDA to inform the company that its application will not be approved in its present form  There could be several reasons for the same including insufficient data to support approval as well as manufacturing issues 
Some of the companies that are facing a delay in getting their drugs approved include Mylan  NASDAQ MYL   biosimilar version of Amgen s Neulasta   Lilly  Olumiant for rheumatoid arthritis   Amgen and UCB  Evenity for the treatment of postmenopausal women with osteoporosis  
UCB SA  UCBJF  is a Zacks Rank  2  Buy  stock  You can see  
Stocks to Avoid
As concerns regarding pricing pressure  slowdown in legacy product sales and biosimilar competition continue to keep the sector volatile  it would be prudent to stay away from stocks that have not been able to win analysts  confidence and carry an unfavorable Zacks Rank 
Companies like AstraZeneca  AZN   Bayer  DE BAYGN   BAYRY  Dr  Reddy s Laboratories Ltd   RDY   Teva Pharmaceuticals  TEVA  and Adamas Pharmaceuticals  Inc   ADMS  are all Sell ranked stocks  While AstraZeneca  Bayer and Adamas Pharmaceuticals are Zacks Rank  4  Sell  stocks  Teva and Dr  Reddy s carry a Zacks Rank  5  Strong Sell   To know more about this sector  check out our latest  ",2018-03-09,Zacks Investment Research,https://www.investing.com/analysis/pharma-stocks-weighed-down-by-competition-generic-pressure-200296982,200296982
105412,326927,AGN,Top Analyst Reports For Lockheed Martin  Allergan   Barclays,opinion,"Tuesday  March 13  2018
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Lockheed Martin  LMT   Allergan  NYSE AGN  and Barclays  LON BARC   BCS   These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Lockheed Martin s shares have gained  24 3  over the last year  underperforming the Zacks Aerospace Defense sector  which has gained  47 3  over the same period  However  Lockheed Martin  being the largest defense contractor in the world  experiences strong demand for high end military equipment in both domestic as well as overseas markets  
The Sikorsky takeover has proved to be beneficial for the company  in terms of substantial contract wins for production of newly designed choppers as well as maintenance of the existing one  In fact  strong order growth has been a primary growth driver for this company  Lockheed Martin continues to be a strong cash generator  helping it to take important cash deployment decisions  
However  the F 35 program  despite being a prime defense project for the U S  government  has been facing criticism for being overly expensive for past few years  The company also faces intense competition for its broad portfolio of products and services in both domestic and international markets 
 You can   
Shares of Allergan have lost  3 2  year to date  marginally underperforming the Zacks Generic Drugs industry  which has declined  3 0  over the same period  Allergan boasts dominant growth franchises across several therapeutic areas  
Key products like Botox and Linzess and new products such as Viberzi  Namzaric and Vraylar support sales  Allergan also boasts a strong branded pipeline with meaningful data readouts expected in 2018  Biosimilars also represent significant opportunity  
However  while the Zacks analyst remains optimistic about the company s growth prospects  Allergan faces potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis  Also  competition for key growth drivers  Restasis and Linzess  is an investor concern  Nonetheless  in late 2017  Allergan announced cost cutting initiatives to protect it from potential revenue declines 
 You can   
Barclays s shares have outperformed the Zacks Foreign Banks industry over the last six months  with BCS shares up  17 7  vs   5 1  gain for the industry  The company has surpassed expectations for earnings in only one of the trailing four quarters  The bank s fourth quarter 2017 results reflected a slight improvement in revenues and lower expenses  
However  the Zacks analyst thinks restructuring and business simplifying efforts have ended successfully and will likely continue to result in decrease in expenses  Also  driven by these efforts  the company intends to enhance capital deployment activities as profitability improves going forward  
The bank has been facing pressure on revenues owing to weak capital market performance  low interest rates and uncertainty related to Brexit  Further  litigation matters remain a near term concern 
 You can   
Other noteworthy reports we are featuring today include Constellation Brands  STZ   Sun Life Financial  SLF  and Southwest Airlines  LUV  
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 
Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys 

Mark Vickery
Senior Editor
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly  and  reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Per the Zacks analyst  Nektar has a strong pipeline  with many updates lined up 


Per the Zacks analyst  solid investment plan helps Entergy in modernizing its grids and offering reliable services to its customers 


Per the Zacks analyst  digital and wealth initiatives in Canada  sales momentum in Asia  scaling and integration of U S  operations  and strong asset management businesses bodes well for Sun Life 


The Zacks analyst believes that the Popeyes Louisiana Kitchen buyout has accelerated Restaurant Brands  global unit development and aided in cutting costs 


The Zacks analyst likes Apache s promising Alpine High discovery with strong economics and top tier returns but is concerned over operational issues in North Sea that resulted in lower production 


The Zacks analyst likes the company s efforts to reward shareholders  The increase in passenger revenues are encouraging too 


Per the Zacks analyst  buyout of Finland based salvage auto auction company AVK will help Copart expand its operations in the Europe s Nordic region 

New Upgrades

Per the Zacks analyst  Ciena s diversified product portfolio is helping it to expand its customer base  High growth in Asia Pacific  especially in India  is a key driver 


The Zacks analyst thinks that improving performance in the Pacific Northwest and New Zealand timber segment will enable Rayonier to enjoy better pricing power 


Per the Zacks analyst  Agilent benefits from an expanding product portfolio  end market strength and robust performance in China and Europe 

New Downgrades

Per the Zacks analyst  Cures Act related reimbursement issues will continue to mar BioScrip s topline performance through 2021  Non core business mix contraction continues to hamper sales growth 


Per the Zacks analyst  tepid performance of Philips  Connected Care   Health Informatics business due to postponement of large orders in health informatics is weighing on the company s bottom line 


Per the Zacks analyst  softness in Constellation Brands  wine and spirits business is impacting overall sales  Going forward  the segment s results are likely to be hurt by slowdown in the industry ",2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/top-analyst-reports-for-lockheed-martin-allergan--barclays-200297842,200297842
105413,326928,AGN,AbbVie s Uterine Fibroids Candidate Succeeds In Phase III ,opinion,AbbVie   NYSE ABBV   and partner Neurocrine Biosciences announced that the second of the two pivotal phase III studies evaluating its pipeline candidate  elagolix uterine fibroids  met the primary endpoint  AbbVie is looking to get elagolix approved as an oral medicine for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids Elagolix is already under review in the United States for management of endometriosis with associated pain AbbVie s shares have increased more than 1  on Mar 13  following the news release  Moreover  so far this year  AbbVie s share price has increased 24 5   comparing favorably with a gain of 0 5  recorded by the  Coming back to the latest release  data from the phase III ELARIS UF II  M12 817  study demonstrated that elagolix  in combination with low dose add back therapy  reduced heavy menstrual bleeding in 76 2  of women with uterine fibroids compared with 10 1  in placebo at month six  The safety profile of the candidate was also found to be consistent with the first phase III study  ELARIS UF I  results  The study met its secondary endpoints as well  Data from the ELARIS UF II study will support regulatory submissions for elagolix for the aforementioned indication Note that  positive top line data from the first phase III ELARIS UF I study were announced in February 2018  This study also met the primary endpoints Per the company s press release  uterine fibroid affects around 20 80  of women by age 50  Out of them  25  may experience symptoms such as heavy menstrual bleeding  painful periods  vaginal bleeding at times other than menstruation and anemia  At present  there are limited non surgical treatment options for women suffering from the disease  Uterine fibroid is currently managed with oral contraceptives  progestins and GnRH agonists  Many of these medicines are not specifically indicated for the treatment of uterine fibroid  Hence  approval of the candidate will provide the company access to patients who are in need of an additional treatment option to apprehend the disease Meanwhile  pharma company Allergan   NYSE AGN   also has a pipeline candidate  ulipristal acetate  in its portfolio which is being evaluated for treatment of uterine fibroids  It might be the first oral treatment to hit the market  as it is under review in the United States with a response expected from the regulatory agency in August 2018 AbbVie Inc  Price   Zacks Rank   Key PicksAbbVie carries a Zacks Rank  2  Buy   Other top ranked stocks in the health care sector are Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    While Regeneron sports a Zacks Rank  1  Strong Buy   Ligand holds a Zacks Rank  2  Buy   You can see  Regeneron s earnings per share estimates have moved up from  17 02 to  18 68 and from  20 29 to  21 60 for 2018 and 2019  respectively  in the last 60 days  The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9 15  Ligand s earnings per share estimates have moved up from  3 78 to  4 20 for 2018 and from  4 75 to  5 32 for 2019 in the last 30 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has surged 65 8  over a year Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/abbvies-uterine-fibroids-candidate-succeeds-in-phase-iii-200298158,200298158
105414,326929,AGN,Amgen s Repatha Gains CHMP Nod To Include Outcomes Data,opinion,Biotech major Amgen Inc    NASDAQ AMGN   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive recommendation to its regulatory application seeking approval to include data from the cardiovascular outcomes study  FOURIER  on the European label of its PCSK9 inhibitor  Repatha With the label expansion application  Amgen is looking to get Repatha approved to prevent heart attacks  strokes and coronary revascularizations in adults with established atherosclerotic cardiovascular disease in Europe Though Amgen s shares have declined 1 8  so far this year  it is still better than the 5 7  decrease registered by the  The FOURIER outcomes data is already included in the U S  label of Repatha  following FDA approval in December last year Data from the phase III FOURIER study presented last year had revealed significant reduction in myocardial infarctions and strokes on treatment with Repatha compared with the current best therapy alone Repatha significantly reduced risk of hard MACE  heart attack  stroke or cardiovascular death  by 20  compared to the standard treatment with statin therapy  For individual components  risks of heart attack  stroke and coronary revascularization were reduced by 27   21  and 22   respectively Uptake of Repatha  which gained FDA approval in August 2015  has not been encouraging so far due to pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   also faced similar issues with their PCSK9 inhibitor  Praluent  The priority for Amgen right now is to improve patient access to Repatha The outcomes data  FOURIER  is the key to the commercial success of Repatha as it would broaden the use of the drug  With the cardiovascular indication approved to be included in Repatha s label  patient access to Repatha is expected to improve However  some analysts believe that though data from the study looks good  it is not very clear if payers will be willing to improve access to Repatha based on this data In a separate press release  Amgen and partner Allergan   NYSE AGN   announced that the CHMP has also given a positive opinion recommending marketing authorization for ABP 980  their biosimilar version of Roche s cancer drug  Herceptin  Amgen Allergan are looking to get ABP 980 approved in the EU for the same cancer indications as the reference product  including HER2 positive metastatic breast cancer  HER2 positive early breast cancer and HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction The companies  application to get biosimilar Herceptin approved in the United States is under review with a decision from the FDA expected in May Meanwhile  Amgen and Allergan s Mvasi  a biosimilar version of Roche s another cancer drug Avastin  was approved in the United States in September last year and in the EU early this year Amgen carries a Zacks Rank  3  Hold   You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-03-25,Zacks Investment Research,https://www.investing.com/analysis/amgens-repatha-gains-chmp-nod-to-include-outcomes-data-200300681,200300681
105435,326950,AGN,Allergan  AGN  To Report Q4 Earnings  What s In The Cards ,opinion,"Allergan plc   NYSE AGN   will report fourth quarter and full year 2017 earnings on Feb 6  before the market opens  Last quarter  the company delivered a positive earnings surprise of 2 22  
Allergan s share price has declined 21 4  in the past year while the witnessed a decline of 22 9  

Allergan s earnings performance has been strong  with the company beating expectations in each of the past four quarters  The average positive earnings surprise over the last four quarters is 1 95  Allergan PLC  Price and EPS Surprise
 

   Let s see how things are shaping up for this announcement 
Factors to Consider
Allergan s established products like Botox  Linzess  Lo Loestrin and Restasis and new products like Vraylar and Namzaric should support sales in the fourth quarter  In fact  label expansions for Botox  FDA approval for forehead line treatment  and Vraylar  FDA approval for maintenance treatment of schizophrenia  are likely to boost sales of these drugs in the fourth quarter  However  we believe sales erosion from Namenda XR due to lower demand and loss of exclusivity  mainly from Asacol HD and Minastrin  will again hurt the top line  The Zacks Consensus Estimate for Botox  Linzess and Namenda XR are pegged at  837 million   206 million and  103 million  respectively 
In third quarter  some new products like Viberzi and Kybella performed below expectations  It remains to be seen if sales of these products rise this time around
The addition of Alloderm from LifeCell  January 2017  and CoolSculpting body contouring system from ZELTIQ  April 2017  is expected to support the top line in the quarter 
Higher promotional expenses for key products  increased costs to support an advancing pipeline and the acquisition of lower margin LifeCell and ZELTIQ can put pressure on Allergan s margins 
Investor focus will be on management s comments on the impact of new competition for key growth drivers  Restasis and Linzess  We remind investors that on the third quarter call  Allergan said that it will refrain from any M A activities for the next few months until its gets a better handle on the Restasis situation  Allergan is facing potential loss of exclusivity for Restasis  its second best selling product  In October 2017  a Texas federal district court invalidated four of the six patents covering Restasis  potentially opening doors for early generic competition  Though Restasis patents are scheduled to expire in August 2024  a generic version may be launched in the second quarter of 2018 
Also  the company said that a split of the company is not in the cards at the moment  An update on these strategies is expected on the fourth quarter call 
We expect management to also comment on the cost saving and restructuring program it announced earlier this year  In the regulatory filing  Allergan said it is laying off over 1 000 employees to protect it from potential revenue declines  Allergan also said that it plans to eliminate an additional 400 open positions  While the company estimates to incur costs of approximately  125 million  the job cuts and other cost savings measures are expected to save operating costs between  300 and  400 this year  Also  the majority of the costs  primarily due to severance  will be reflected in the fourth quarter results 
Also  investors expect management to comment on the weaker than expected sales outlook for 2018  which Allergan announced in early January 
Earnings Whispers
Our proven model does not conclusively show that Allergan is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  The Most Accurate estimate stands at  4 75  while the Zacks Consensus Estimate is pegged lower at  4 74  This results in an Earnings ESP of  0 19   You can uncover the best stocks to buy or sell before they re reported with our 
Zacks Rank  Allergan has a Zacks Rank  4  Sell   We caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Some stocks in the biotech pharma sector that have a positive Earnings ESP and a favorable Zacks Rank are 
Alexion Pharmaceuticals  Inc    NASDAQ ALXN   with an Earnings ESP of  3 45  and a Zacks Rank  3  The company is scheduled to release results on Feb 8  You can see  
Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  2 66  and a Zacks Rank  3  The company is scheduled to release results on Feb 1 
Astrazeneca  LON AZN  PLC   NYSE AZN   is slated to announce financial figures on Feb 2  The company has an Earnings ESP of  1 87  and is a Zacks  3 Ranked stock 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-31,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-to-report-q4-earnings-whats-in-the-cards-200286112,200286112
105436,326951,AGN,Allergan s Anti Infective Drug Avycaz Receives Third FDA Nod,opinion,Allergan plc   NYSE AGN   announced that the FDA has approved a label expansion of its anti infective drug  Avycaz  ceftazidime and avibactam   With this nod  the drug is now approved for treatment of patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia  HABP VABP  due to gram negative bacteria  This approval marks the third therapeutic indication for the drug in the United States Notably  Avycaz is marketed for treatment of complicated urinary tract infections  cUTI   including pyelonephritis  caused by designated susceptible pathogens consisting of certain Enterobacteriaceae and Pseudomonas aeruginosa  Avycaz is also indicated for curing adult patients with complicated intra abdominal infections  cIAI  in combination with metronidazole We remind investors that the company s supplemental New Drug Application  sNDA  for Avycaz was accepted by the FDA under priority review in October 2017 based on a preceding Qualified Infectious Disease Product designation for the aforementioned indication Importantly  Avycaz is the first gram negative antibiotic approved in the United States to treat HABP VABP in over 15 years Allergan s shares have lost 22 2  in a year s time  outperforming the  s decline of 24 4   The approval was based on non inferiority data from a pivotal phase III REPROVE study  evaluating the safety and efficacy of Avycaz on adult patients with HABP VABP  The trial met its primary endpoints and showed that the drug was non inferior to meropenem  a broad spectrum antibiotic  in reducing death risks irrespective of the cause The drug also showed in vitro  study in controlled environment outside human body  activity against certain gram negative bacteria causing HABP VABP Significantly  Avycaz is jointly marketed by Allergan and Pfizer   NYSE PFE    While Allergan has commercialization rights to Avycaz in North America  rights to the rest of the world are owned by Pfizer Avycaz raked in sales of  42 7 million in the nine months ending Sep 30  2017  up 58 7  from the year ago figure  The FDA approval for the expanded patient population should improve its commercial potential Per the company s press release  HABP VABP is the second most common type of nosocomial  hospital originated  infection in the United States  mainly in the intensive care unit  Hence  the potential market opportunity for Avycaz is huge in the country Apart from Avycaz  Allergan s anti infectives portfolio comprises antibiotics namely Teflaro and Dalvance Allergan PLC  Price    Zacks Rank   Key PicksAllergan carries a Zacks Rank  4  Sell  Two better ranked stocks in the health care sector are XOMA Corporation   NASDAQ XOMA   and Exelixis  Inc    NASDAQ EXEL    both carrying a Zacks Rank  2  Buy   You can see  XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 624 9  in the last 12 months Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company delivered a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has soared 64 1  in a year s time Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ,2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/allergans-antiinfective-drug-avycaz-receives-third-fda-nod-200286469,200286469
105437,326952,AGN,Teva Completes Sale Of Women s Health Segment For  703M,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that it has completed the divestment of its global women s health business to privately held private equity firm  CVC Capital Partners  The deal was closed for  703 million in cash 
The divested portfolio includes products across contraception  fertility  menopause and osteoporosis categories  The drugs in the portfolio include Ovaleap  Zoely  Seasonique  Colpotrophine and Actonel  which are sold outside the United States  These products will now be sold by Theramex  a women s health unit previously held by Teva 
The sale is part of Teva s planned divestment of specialty products in women s health 
We remind investors that Teva had signed a definitive agreement for this sale with CVC Capital Partners in September 2017  Moreover  the company also signed another definitive agreement with Foundation Consumer Healthcare for the sale of its Plan B One Step and brands of emergency contraception 
CVC Capital Partners has appointed Anish Mehta  former head of International Business Development at Allergan   NYSE AGN    as Theramex s chief executive officer 
In a separate SEC filing  Teva reported that it has entered into a settlement agreement with Allergan  jointly dismissing the working capital dispute arbitration  Allergan will pay Teva  700 million as part of the settlement 
Teva s shares rose 3 8  on Feb 1  following the news  However  shares of the company have declined 38 5  in the past year  underperforming the  s decline of 24 9   Teva s decline can be attributed to industry pressure  generic competition for its blockbuster drug  Copaxone  and a massive debt load 

 
Teva also suffered a another setback in October 2017 as Mylan   NASDAQ MYL   launched its generic version of the 40 mg formulation of Copaxone  much earlier than expected 
In order to combat these challenges  Teva has divested some non core assets to cut its significant debt load and aims to cut its global workforce by more than 25  over the next two years Teva Pharmaceutical Industries Limited Price
 

   Zacks Rank   Stocks to Consider
Teva carries a Zacks Rank  4  Sell  
Zoetis Inc    NYSE ZTS   is a better ranked health care stock  carrying a Zacks Rank  2  Buy   You can see  
Zoetis  earnings per share estimates have increased from  2 72 to  2 94 for 2018 over the last 30 days  The company delivered a positive earnings surprise in the trailing four quarters with an average beat of 2 32  
Breaking News  Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved 
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-02,Zacks Investment Research,https://www.investing.com/analysis/teva-completes-sale-of-womens-health-segment-for-703m-200286606,200286606
105438,326953,AGN,Teva  TEVA  Q4 Earnings   Sales Beat  2018 View Disappoints,opinion,"Israel based Teva Pharmaceutical Industries Ltd    NYSE TEVA   is a global pharmaceutical company with a strong presence in the generics as well as branded markets  The company s branded products include Copaxone  multiple sclerosis   Azilect  Parkinson s disease  and respiratory products like ProAir and Qvar   Moreover  the company has several candidates in its pipeline  which are in different stages of development mainly for the treatment of pain and asthma In early Aug 2016  Teva acquired Allergan s generics business   Actavis  NYSE AGN  Generics and in Oct 2016 it acquired the latter s Anda Inc   the 4th largest distributor of generic pharmaceuticals in the U S Teva is facing significant challenges including generic competition for Copaxone  pricing erosion in the U S  generics business  lower than expected contribution from new generic launches and a massive debt load Teva s earnings have surpassed expectations in only one of the last four quarters  met the same in one and missed expectations in the remaining two  resulting in an average negative surprise of 2 66   Estimates have gone down over the past seven days Currently  TEVA has a Zacks Rank  4  Sell   but that could definitely change following the company s earnings report which was just released  You can see  Teva Pharmaceutical Industries Limited Price and Consensus
    We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Teva s fourth quarter earnings came in at 93 cents per share  which beat Zacks consensus estimate of 81 cents per share Revenues Beat  Teva posted revenues of  5 46 billion  which beat consensus estimates of  5 42 million  However  sales declined 16  year over year Key Statistics  Generic segment sales were  3 1 billion  down 16  year over year while Specialty segment sales were  1 8 billion  down 19  Lead branded product  multiple sclerosis drug Copaxone  posted worldwide sales of  821 million  down 19  due to generic competition Glatopa  a generic version of Copaxone 20 mg  is being marketed by Momenta and Sandoz since 2015 while Mylan  NASDAQ MYL  launched its version of the 20 mg formulation in Oct 2017  In Oct 2017  in a major blow to Teva  Mylan launched  at risk  its generic version of the 40 mg thrice weekly formulation  much earlier than expected  With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  there has been a rapid erosion in sales of Copaxone 2018 Outlook Below Expectations  Teva expects revenues in a range of  18 3    18 8 billion which fell short of the Zacks Consensus Estimate of  19 17 billion  The company expects earnings in a band of  2 25  2 50 per share in 2018 which also fell short of the Zacks Consensus Estimate of  2 93 per share Share Price Impact  Shares were down more than 11  in pre market trading Check back later for our full write up on this TEVA earnings report later Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q4-earnings--sales-beat-2018-view-disappoints-200288430,200288430
105439,326954,AGN,Teva  TEVA  Q4 Earnings Top  Stock Tanks On Weak 2018 View,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   reported fourth quarter 2017 earnings of 93 cents per share  which beat the Zacks Consensus Estimate of 81 cents per share and came ahead of the guided range of 70 cents 80 cents  However  earnings per share declined 32  year over year Revenues were  5 46 billion  which marginally beat the consensus estimate of  5 42 billion  However  sales declined 16  year over year  down 12  excluding impact of currency  Sales were hurt by increased pricing erosion and volume declines in the U S  Generics unit and rapid erosion in sales of Copaxone   Teva s blockbuster multiple sclerosis injection   in the Specialty segment Segment DiscussionTeva revised its segment structure following the Actavis acquisition  The Generics segment now includes revenues from the OTC business as well as the API business Generic Medicines segment revenues were  3 1 billion  down 16  year over year Revenues from the U S  generics business declined 15  to  1 2 billion due to significant competitive and pricing pressure in the generics industry  The ongoing consolidation of customers in the generics industry led to increasing price erosion and decreasing volume  The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs  Accelerated FDA approval of additional generic versions of competing off patent medicines  increased competition for Concerta authorized generic  and stringent government regulations also hurt sales European generic revenues were  1 1 billion  flat year over year  However  sales declined 8  in local currency terms from the year ago period mainly due to absence of revenues from the generic business of Actavis in the United Kingdom  which was divested in January 2017 Rest of the world  ROW  generic revenues declined 31  to  864 million in the quarter  On a local currency basis  sales rose 2  mainly due to higher sales in Russia and Israel API revenues were flat at  181 million  OTC revenues were down 46  to  217 million  up 9  in local currency terms  Specialty Medicines revenues were  1 8 billion  down 19  from the year ago period due to lower sales of its central nervous system  CNS  products and divesture of some non core assets in the Women s Health business  Among Teva s various therapeutic areas  CNS sales declined 21  to  984 million due to lower sales of Copaxone Sales of respiratory products declined 10  to  293 million  oncology product sales rose 6  to  283 million  and women s health business recorded a 44  decrease in revenues to  68 million  Other specialty revenues declined 32  to  167 million Worldwide revenues of Copaxone declined 19  to  821 million mainly due to lower sales in the United States  Sales declined 25  in the United States to  622 million mainly due to the generic competition  which resulted in higher rebates and lower volumes Glatopa  a generic version of Copaxone 20 mg  is being marketed by Momenta   NASDAQ MNTA   and Sandoz   Novartis  generic arm   since 2015 while Mylan   NASDAQ MYL   launched its version of the 20 mg formulation in October 2017  In the same month  in a major blow to Teva  Mylan launched  at risk  its generic version of the 40 mg thrice weekly formulation  much earlier than expected  With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  there has been rapid erosion in sales of Copaxone  Moreover  a second generic version of the 40 mg formulation is expected to be launched in April this year Ex U S  sales of Copaxone were flat on a local currency basis at  199 million Among other products  Azilect sales declined 55  to  40 million as a generic version of the drug was launched in the United States in 2017  ProAir declined 27  to  102 million and QVAR declined 47  to  61 million  both hurt by negative net pricing effects  Combined Treanda and Bendeka revenues rose 5  to  157 millionThe Other segment  distribution and other activities  recorded revenues of  550 million  down 4  year over year as the company sold off some distribution businesses Profits DeclineAdjusted gross margin contracted 720 basis points  bps  to 52 2  in the quarter  Research   development expenses declined almost 40  from the year ago period to  310 million  Selling and marketing  S M  expenditure declined 28  from the year ago level to  791 million  Adjusted operating income declined 29  to  1 4 billion in the quarter despite lower costs 2017 ResultsFull year 2017 sales of  22 4 billion beat the Zacks Consensus Estimate of  22 3 billion and also came ahead of the guided range of  22 2    22 3 billion  Sales rose 2  year over year  gaining from the inclusion of Actavis Generics revenues Teva acquired Allergan s   NYSE AGN   generics segment  Actavis Generics and also its U S  generic distribution business  Anda  in 2016Adjusted earnings for 2017 were  4 01 per share  which beat the Zacks Consensus Estimate of  3 84 per share and exceeded the guided range of  3 77  3 88 per share  Earnings declined 22  year over year 2018 Outlook Below ExpectationsTeva expects revenues in the range of  18 3    18 8 billion  which fell short of the current Zacks Consensus Estimate of  19 17 billion  The company expects earnings in the band of  2 25  2 50 per share in 2018  also short of the current Zacks Consensus Estimate of  2 93 per share In 2018  Teva expects Copaxone to generate sales of  1 8 billion globally  significantly lower than  3 8 billion in 2017 as the franchise continues to erode U S  Generics sales are expected to decline roughly 20  from 2017 levels to approximately  4 billion in 2018 hurt by ongoing price erosion and generic Concerta  Also  ProAir franchise is expected to see generic competition during the second half of 2018 Costs are expected to decline  1 8 billion in 2018 Our TakeThough Teva beat expectations for both earnings and sales in the fourth quarter  its stock crashed more than 10  on Thursday  as the company issued a weak outlook for 2018  wherein it expects sales and profits to decline further this year Teva s shares have slumped 42 1  in the past year compared with the  s decline of 29 3  The Israel based generic drug maker had a tough 2017 as it faced significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from generic launches and a massive debt load of more than  32 billion   Mylan s earlier than expected launch of the first generic version of the 40 mg strength of Copaxone was a major setback for Teva Teva divested some non core assets  mainly in the Women s Health business  to cut its significant debt load  The company also has a new organizational structure in place  is closing plants  cutting down its generics portfolio  eliminating low value R D projects  and aims to cut its global workforce by more than 25  over the next two years as part of a restructuring plan it revealed in December  Though the company expects to save almost  3 billion by the end of 2019from these restructuring initiatives  a clear path to growth is not visible These efforts might not be enough to revive the company s fortunes during this challenging period  especially as it faces erosion of its largest product  Copaxone  Other than that  divestures and pricing pressure in the U S  generic business will continue to hurt the top line in 2018 Teva carries a Zacks Rank  4  Sell  Teva Pharmaceutical Industries Limited Price  Consensus and EPS Surprise    You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q4-earnings-top-stock-tanks-on-weak-2018-view-200289014,200289014
105440,326955,AGN,Bayer exploring sale of dermatology business  Bloomberg,news," Reuters    German chemicals and crop pesticides firm  Bayer AG   DE BAYGn  is exploring the sale of its dermatology business to push forward its deal with  Monsanto  Co  N MON   Bloomberg reported  citing sources  Bayer is working with JPMorgan Chase   Co  N JPM  on the sale  which could fetch more than 1 billion euros   1 12 billion   the report said     Bayer said on Monday it was willing to offer more than  65 billion  a 2 percent increase on its previous offer for the world s largest seeds company Monsanto  The dermatology business could attract interest from existing makers of skincare products including Nestle SA s  S NESN  Galderma  Allergan Plc  N AGN  and  Almirall SA   MC ALM   as well as private equity firms  according to the Bloomberg report   
Bayer and J P  Morgan were not immediately available for comment ",2016-09-08,Reuters,https://www.investing.com/news/stock-market-news/bayer-exploring-sale-of-dermatology-business:-bloomberg-425123,425123
105441,326956,AGN,Allergan to buy Tobira in push for NASH treatments,news," Reuters    Allergan Plc  N AGN  said it would buy Tobira Therapeutics Inc  O TBRA  in a deal worth up to  1 7 billion  about 19 times the company s current value  to get a leg up in the race to develop therapies for NASH  an incurable fatty liver disease  Allergan s offer of  28 35 per Tobira share upfront is nearly a whopping 500 percent premium to the stock s close on Monday  which gave Tobira a market capitalization of about  89 million  Dublin based Allergan said Tobira shareholders could get up to  49 84 per share contingent on the company achieving certain milestones  Tobira s shares surged 575 percent to  32 premarket on Tuesday  Allergan s shares were off 0 4 percent  This is the latest in a string of deals orchestrated by Brent Saunders  Allergan s chief executive and a seasoned dealmaker  About 30 percent of people in the United States suffer from fatty liver diseases such as NASH  nonalcoholic steatohepatitis  due to obesity  diabetes and over indulgent lifestyles  according to the American Liver Foundation  NASH  which occurs in up to 5 percent of Americans  is a silent liver disease that resembles alcoholic liver disease  but occurs in people who drink little or no alcohol  There are no approved medicines for NASH  Without treatment  sufferers can develop advanced damage  including the scarring known as fibrosis  cirrhosis  which destroys liver function  and even cancer  Other major contenders in the race to develop a drug to treat NASH include  Intercept Pharmaceuticals Inc   O ICPT  and  Genfit SA   PA GNFT   who have drugs in late stage development  Conatus Pharmaceuticals Inc s  O CNAT  treatment is in mid stage development  
Covington   Burling are Allergan s lead legal counsel  Centerview Partners and Citi are Tobira s financial advisers  while Skadden  Arps  Slate  Meagher   Flom LLP and Gunderson Dettmer Stough Villeneuve Franklin   Hachigian  LLP are its legal counsel ",2016-09-20,Reuters,https://www.investing.com/news/stock-market-news/allergan-to-buy-tobira-in-push-for-nash-treatments-427284,427284
105442,326957,AGN,Allergan pays top dollar for  stepping stones  from neurology to dermatology,news,"By Carl O Donnell  Reuters    Allergan Plc  N AGN  CEO Brent Saunders calls them  stepping stones    small  bolt on acquisitions  as opposed to the mega deals common in the drug industry  And they re expected to boost dealmaking in sectors ranging from neurology to skin care  Allergan s agreement on Tuesday to acquire liver drug developer Tobira Therapeutics Inc  O TBRA  for  1 7 billion may seem trivial compared to the proposed  160 billion deal Allergan crafted last year to sell itself to  Pfizer  Inc  N PFE   But that deal was torpedoed in April by the U S  Treasury s latest curbs on tax inversions  Now the company  domiciled in Ireland  is taking a new tack  preparing to spend a war chest of more than  20 billion on stepping stone deals   The small deals are aimed at filling gaps in its core therapeutic areas  which range from the central nervous system and gastrointestinal diseases  to dermatology and eye care  Allergan has added four other small companies to its portfolio this year  three of which sold for less than  100 million upfront  plus performance payments  Two  ForSight Vision and Retrosense Therapeutics  treat eye disorders  The others  Topokine Therapeutics and  Vitae Pharmaceuticals Inc    O VTAE   focus on dermatology   Allergan agreed to acquire Vitae last week for  639 million  The fact that Allergan is paying top dollar for some of these companies   including a nearly 600 percent premium for Tobira  excluding performance payments   has investors and dealmakers speculating about the company s next stepping stone  Logical acquisition targets for Allergan would include Acadia Pharmaceuticals Inc  O ACAD   a maker of treatments for Parkinson s disease  Intra Cellular Therapies Inc  O ITCI   a developer of psychiatric medications  Neurocrine Biosciences Inc  O NBIX   which focuses on neurology and women s health  and  Dermira  Inc  O DERM   a dermatology company  according to investment bankers and industry investors   In an interview with Reuters  Saunders declined to comment on any specific companies that Allergan may want to acquire next  But he said that stepping stones will play a key role in helping the company continue to meet its ambitious annual revenue growth target of 10 percent for years to come    I needed to do big deals to get where we are  but the strategic vision was always to get to a point where we could use stepping stones   Saunders said   Allergan has relied heavily on M A because it views inventing its own drugs in house as too risky  Saunders  46  has attempted or executed mergers and acquisitions totaling more than  300 billion in the last three years   Allergan now has the money to embark on a major acquisition spree thanks to the sale of its generic drug portfolio to Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   Allergan received  33 4 billion in cash and  5 1 billion in Teva stock last month as a result of that deal   While Allergan has pledged to spend some of those dollars on share buybacks  it will still have cash reserves of more than  20 billion it can spend on deals   Allergan wants to build out its central nervous system franchise  which is one of the largest in the industry and treats diseases including Alzheimer s  depression  migraines and schizophrenia  Saunders said   He added that he would like to branch out into other types of neurological treatments  including multiple sclerosis  attention deficit hyperactivity disorder and Parkinson s disease   One of Allergan s successful endeavors in the central nervous system space  its Namenda Alzheimer s franchise  took a hit over the past year after one of its key drugs  Namenda IR  lost patent protection  Namenda IR generated more than  500 million in 2015   Allergan is hoping that a ramp up of its newly commercialized anti psychotic drug  Vraylar  can help offset that decline  BOTOX AS A GATEWAY DRUG Saunders said he also is optimistic about opportunities in dermatology and eye care  adding that he would be open to a medium sized deal to build out its opthalmic products   In dermatology  Allergan has the world s biggest franchise by sales  largely due to its flagship drug  Botox  for wrinkle smoothing  Last year  in a stepping stone acquisition  Allergan bought a publicly traded dermatology company called Kythera for  2 1 billion  and it has been ramping up sales of its key drug  Kybella  which treats double chins   There s definitely potential for more deals like that in dermatology   said Randall Stanicky  an analyst at RBC Capital Markets   Botox is a gateway product into the entire world of aesthetics   In the interview  Saunders left open the possibility of a transformative acquisition or merger for Allergan  which has a market capitalization of  95 billion  He said a company with a cutting edge treatment that reversed Alzheimer s was an example of the type of big deal Allergan would consider making   Biogen Inc  N BIIB  and Eli Lilly and Co  N LLY  both have late stage drugs that promise to reverse the effects of the degenerative neurological disease  Biogen and Eli Lilly have market capitalizations of  65 billion and  86 billion  respectively  
Reuters reported in August that Allergan had held informal conversations with some members of Biogen s board before deciding against any acquisition offer ",2016-09-20,Reuters,https://www.investing.com/news/stock-market-news/allergan-pays-top-dollar-for-'stepping-stones'-from-neurology-to-dermatology-427325,427325
105443,326958,AGN,Wall Street ends flat with Fed  BOJ up next,news,"By Lewis Krauskopf  Reuters    Wall Street ended little changed on Tuesday as healthcare gains countered declines in energy shares  a day before highly anticipated outcomes of monetary policy meetings in the United States and Japan  Though the Federal Reserve is not expected to raise rates on Wednesday  investors will comb the U S  central bank s statement for any clues about whether it will hike in coming months  The Bank of Japan is expected to further ease its ultra loose policies  according to a Reuters poll of economists   Not many think the Fed is going to hike tomorrow  but whether they change the language to get a little more hawkish  there s been conversation around that   said Walter Todd  chief investment officer at Greenwood Capital in Greenwood  South Carolina    The Bank of Japan is a whole other issue unto itself     Given the level of uncertainty around those two meetings  I just think people are kind of biding their time   The Dow Jones industrial average  DJI  rose 9 79 points  or 0 05 percent  to 18 129 96  the S P 500  SPX  gained 0 64 points  or 0 03 percent  to 2 139 76 and the Nasdaq Composite  IXIC  added 6 33 points  or 0 12 percent  to 5 241 35  Traders are projecting an 18 percent chance that the Fed will raise rates on Wednesday  but the probability rises to 60 percent for a hike at its December meeting  according to the CME FedWatch website  A report on Tuesday showed U S  housing starts fell more than expected in August   It would seem at this point that  with all the recent economic data coming in just a little bit soft  that any move by the  Fed  would be a pretty nasty surprise   said Eric Kuby  chief investment officer at North Star Investment Management in Chicago  The healthcare sector  SPXHC  was the best performing major S P sector  rising 0 4 percent   Allergan  N AGN  said it would pay up to  1 7 billion to buy Tobira Therapeutics  O TBRA   which is developing therapies for NASH  an incurable fatty liver disease  Tobira shares soared more than 700 percent  while Allergan  NYSE AGN pa  shares fell 2 7 percent  Shares of Gilead Sciences  O GILD   which is also developing drugs for NASH  rose 3 5 percent and gave the biggest boost to the S P and the Nasdaq    Wells Fargo   N WFC  shares rose 1 2 percent after the bank s chief executive weathered criticism as he testified before a U S  Senate panel  Energy shares  SPNY  were the worst performing group  falling 0 8 percent  Exxon  N XOM  fell 1 5 percent  A Wall Street Journal report said the U S  Securities and Exchange Commission is investigating how the oil major valued its assets in the wake of the plunge in oil prices  FedEx  N FDX  shares rose more than 1 percent in extended trading after the package delivery company reported results  About 5 8 billion shares changed hands on U S  exchanges  below the 6 7 billion daily average for the past 20 trading days  according to Thomson Reuters data  Declining issues outnumbered advancing ones on the NYSE by a 1 28 to 1 ratio  on Nasdaq  a 1 10 to 1 ratio favored decliners  
The S P 500 posted 3 new 52 week highs and 4 new lows  the Nasdaq Composite recorded 77 new highs and 33 new lows ",2016-09-20,Reuters,https://www.investing.com/news/stock-market-news/wall-street-set-to-open-higher-as-investors-await-fed-meet-427293,427293
105444,326959,AGN,Pfizer abandons plan to split into two companies,news,"By Caroline Humer and Ransdell Pierson  Reuters    U S  drugmaker  Pfizer  Inc  N PFE   which has been considering a split into two companies for more than two years  said on Monday it would not do so because the move would not create any shareholder value  Pfizer said a split would not boost cash flow or better position the businesses competitively  It would also disrupt operations  have inherent costs and fail to deliver any tax efficiencies  the company said  Pfizer will keep its low growth generics and patent protected branded medicines separate  giving it the option to split later if  factors materially change at some point in the future   Pfizer said the decision would not affect its 2016 financial forecast  Its shares fell 1 5 percent to  33 75 in morning trading  amid a 1 percent decline in the ARCA Pharmaceutical Index of large drugmakers  DRG   The move follows the collapse of Pfizer s planned  160 billion acquisition of Irish drugmaker Allergan Inc  N AGN  after a change in U S  law negated the tax benefits for companies moving corporate headquarters to overseas locales through acquisitions  Investors were expecting the company to step back from the split  Sanford Bernstein analyst Tim Anderson said in a research note    The company seems likely to leave open its option for a future split up  but more immediately it may continue hunting for M A targets   Anderson wrote  Pfizer began openly planning for a possible split in early 2014  saying it would operate the businesses as separate divisions and track their progress for three years before reaching a decision  In August  it said it would decide by year end  Pfizer said the sum of the parts analysis showed no benefit to shareholders  and that tax costs and business disruptions were factors it considered   The company had considered the move largely because its patent protected medicines routinely enjoyed sales growth while demand for its generics usually declined  But the  15 billion purchase of Hospira a year ago has bolstered Pfizer s wide array of generics  which the company calls  essential products   Hospira makes generic injectable hospital products and biosimilars  which are cheaper versions of the world s leading biotech drugs   Annual sales of Pfizer s generic portfolio should grow by a single digit percentage rate in coming years  JPMorgan  NYSE JPM  analyst Chris Schott said in a research note  He forecast a 3 percent rise in the company s overall annual sales through 2020  resulting in 8 percent earnings growth  Investors shifted their focus to whether Pfizer would split after the company terminated the Allergan deal in April  In August  Pfizer said it was buying  Medivation  Inc  O MDVN  for  14 billion to get access to blockbuster prostate cancer drug Xtandi for its growing oncology roster  
That deal illustrates a shift in Pfizer s mergers and acquisitions strategy from lowering taxes  which was the rationale behind the failed Allergan bid  to strengthening its lineup of branded drugs  especially lucrative cancer treatments ",2016-09-26,Reuters,https://www.investing.com/news/stock-market-news/pfizer-says-not-to-split-into-two-428439,428439
105445,326960,AGN,U S  targets corporate tax reduction strategy with new regulation,news,"By David Morgan WASHINGTON  Reuters    The Obama administration  in its latest bid to prevent American companies from minimizing U S  taxes by rebasing abroad  issued final rules on Thursday to combat a key tax reduction technique known as earnings stripping  Six months after proposing the regulations  the U S  Treasury made good on its pledge to move swiftly against corporate tax inversions by rolling out the new final rule  despite opposition from business groups and from Republicans in Congress who demanded a delay only last week   For years  this administration consistently has called for comprehensive business tax reform to fix our broken tax system   Treasury Secretary Jack Lew told reporters   In the absence of congressional action  however  it is Treasury s responsibility to use our authority to protect the tax base   Business lobbyists said the rules would likely be challenged in court  Tax inversions occur when a U S  company is acquired by a smaller foreign business from a low tax country and adopts its domicile to reduce the combined firm s overall U S  tax burden  Inversions have occurred since the 1980s  but a new wave in recent years prompted the Treasury to take a series of actions including Thursday s final regulations  which were unveiled in April as part of a package that led to the collapse of a  160 billion merger deal between U S  drugmaker  Pfizer  Inc  N PFE  and Ireland s Allergan Plc  N AGN   Treasury also imposed a temporary rule in April to prevent foreign companies from engaging in serial inversions  That is expected to be finalized later this year   Earnings stripping occurs when the U S  subsidiary of a newly inverted company avoids taxes on domestic operations by sending them overseas as tax deductable interest payments   The newly finalized regulations would reclassify some forms of debt as equity  changing tax exempt interest payments into dividends that are taxed  Business groups including the U S  Chamber of Commerce have warned that the regulations could harm the cash management operations of U S  based multinationals and pose damaging unintended consequences for a range of businesses by creating mountains of red tape  But Treasury officials said the final rules addressed those concerns by granting exemptions for regulated financial and insurance firms  cash pooling  short term debt  transactions between the foreign units of U S  companies  stock acquisitions for employee compensation plans and other operations  
The regulation also relaxed requirements for companies to document intercompany loans and delayed the documentation deadline for a year to Jan  1  2018 ",2016-10-13,Reuters,https://www.investing.com/news/stock-market-news/u.s.-treasury-issues-final-inversion-rules-on-earnings-stripping-432327,432327
105446,326961,AGN,Allergan revenue rises 4 4 percent  company expands buyback,news, Reuters    Allergan Plc  N AGN  reported a 4 4 percent rise in quarterly revenue  lifted by higher demand for key products such as Botox and Restatis eye drops  and the company expanded its share buyback program by  5 billion to  15 billion   Net revenue rose to  3 62 billion from  3 47 billion in the third quarter ended Sept  30  The company also initiated a regular quarterly cash dividend of 70 cents per share  payable in the first quarter of 2017   Chief Executive Brent Saunders has orchestrated a string of acquisitions since the Dublin based drugmaker s planned  160 billion merger with  Pfizer  Inc  N PFE  collapsed in April  due to new U S  tax regulations ,2016-11-02,Reuters,https://www.investing.com/news/stock-market-news/allergan-revenue-rises-4.4-percent;-company-expands-buyback-436755,436755
105447,326962,AGN,S P 500 ends down for seventh straight session,news,"By Lewis Krauskopf  Reuters    The S P 500 ended lower on Wednesday for a seventh straight session  its longest such streak in five years  as the Federal Reserve signaled it could hike interest rates in December and the uncertain U S  election continued to cloud the market s outlook  The U S  central bank held interest rates steady  but said the economy had gained steam and job gains remained solid  expressing more optimism that inflation was moving toward its 2 percent target  The decision was broadly in line with expectations of investors  who have been discounting a hike at this meeting but generally bracing for one in December  It was the last Fed decision before next week s presidential election between Democrat Hillary Clinton and Republican Donald Trump  a race that has rattled markets as it has appeared to grow closer in the past week   With the Fed meeting  basically they just teed it up for an increase in December  so there was really nothing unusual     This market right now is more on the election and any technical indicators   said Alan Lancz  president of investment advisory firm Alan B  Lancz   Associates in Toledo  Ohio   The Dow Jones industrial average  DJI  fell 77 46 points  or 0 43 percent  to 17 959 64  the S P 500  SPX  lost 13 78 points  or 0 65 percent  to 2 097 94 and the Nasdaq Composite  IXIC  dropped 48 01 points  or 0 93 percent  to 5 105 57  The S P 500 closed below 2 100 for the first time since July 7   Any material drift from there might bring on further weakness and technical selling   Lancz said   We re getting in an area now where the market needs to see some support   In another negative technical sign for the market  the combined number of 52 week lows on the NYSE and Nasdaq jumped to the most since June and significantly outpaced the number of new highs  The Fed s increasing confidence that prices were moving higher was reflected in its view that  inflation has increased somewhat since earlier this year  and the removal of its previous reference to inflation remaining low in the near term  In September  Fed Chair Janet Yellen said that a move before year s end was likely as long as U S  employment and inflation continue to strengthen   The market may be wondering if there s enough evidence of a stronger economy to warrant a rate hike versus a belief that Chair Yellen needs to replenish her toolkit in the event of a weakening economic backdrop   said Quincy Krosby  market strategist at Prudential Financial  NYSE PRU  in Newark  New Jersey  The biggest sector decliners were utilities  SPLRCU   real estate  and telecommunications  SPLRCL  companies  which are high dividend paying groups thought to be vulnerable in rising rate environments   Energy  SPNY  fell 1 percent as oil prices fell  In earnings news  Allergan  N AGN  shares fell 5 2 percent after the drugmaker s disappointing results  More than 8 billion shares changed hands in U S  exchanges  above the 6 5 billion daily average over the last 20 sessions  Declining issues outnumbered advancing ones on the NYSE by a 3 23 to 1 ratio  on Nasdaq  a 2 82 to 1 ratio favored decliners  
The S P 500 posted 2 new 52 week highs and 11 new lows  the Nasdaq Composite recorded 19 new highs and 154 new lows ",2016-11-02,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-flat-as-election-race-tightens-436778,436778
105448,326963,AGN,Biotechs love Trump  many ahead premarket,news,Biotechs and Big Pharma look like they will jump out of the blocks this morning  Most leading names are up premarket Sampling   NASDAQ AMGN   4    NASDAQ GILD   2    NASDAQ REGN   3    NASDAQ BIIB   4    NASDAQ VRTX   2    NASDAQ CELG   3    NYSE BMY   2    NYSE PFE   5    NYSE MRK   2    NYSE AZN   1    NYSE GSK   1    NYSE JNJ   2    NYSE ABBV   4    NYSE LLY   3    NYSE NVS   3    NYSE AGN   4    NASDAQ TEVA    6 ,2016-11-09,Seeking Alpha,"https://www.investing.com/news/stock-market-news/biotechs-love-trump,-many-ahead-premarket-439138",439138
105470,326985,AGN,Allergan To Cut Jobs Amid Loss Of Exclusivity For Key Drugs,opinion,"Allergan plc   NYSE AGN    in a regulatory filing  announced that it is laying off over 1 000 employees as part of a cost saving and restructuring program to protect it from potential revenue declines 
Allergan said the job cuts will impact employees in commercial functions that revolve around products and categories already facing or will face loss of exclusivity  Allergan also said that it plans to eliminate an additional 400 open positions 
While the company estimates to incur costs of approximately  125 million  the job cuts and other cost savings measures are expected to save operating costs between  300 and  400 this year  Also  the majority of the costs  primarily due to severance  will be recorded in the fourth quarter 
Allergan currently employs more than 18 000 people 
The job cuts come at a time when Allergan is facing potential loss of exclusivity for several of its key products in 2018 including Alzheimer s treatment  Namenda XR and blockbuster dry eye drug  Restasis  which is expected to hurt sales 
Allergan is adopting different ways of protecting Restasis  its second best selling drug  from generic competition  Restasis recorded sales of  1 06 billion in the first nine months of 2017 
Allergan came under fire for entering into an agreement with the Saint Regis Mohawk Tribe under which the latter obtained the rights to six patents covering Restasis and Allergan was granted exclusive licenses to Restasis products  Lawmakers questioned the unconventional move adopted by the company to protect Restasis from generic competition  The deal with the Tribe has raised concerns that it will curb generic competition in the pharmaceutical industry and discourage generic drug makers from making cheaper versions of expensive drugs 
However  in October 2017  a Texas federal district court invalidated four of the six patents covering Restasis  potentially opening doors for early generic competition  Though Restasis patents are scheduled to expire in August 2024  a generic version may be launched as early as mid 2018 
Also  this year  Allergan faces loss of patent exclusivity for Estrace vaginal cream and ulcerative colitis drug Delzicol  Last week  Mylan   NASDAQ MYL   launched the first generic version for Estrace cream 
Also  new competition for key growth drivers  Restasis and Linzess  is an investor concern  Shire s   NASDAQ SHPG   dry eye disease drug Xiidra  launched last year  is posing strong competition for Restasis  Meanwhile  Synergy Pharmaceuticals Inc  s   NASDAQ SGYP   Trulance  plecanatide  was launched last yearfor chronic idiopathic constipation  which could pose competition to Allergan s Linzess 
In the past year  Allergan s shares have declined 22 9  compared with the  s decline of 26 8  

 
The job cuts are aimed to save some dollars at a time when Allergan is facing competitive and generic pressure related to some of its highest revenue generating products 
Allergan carries a Zacks Rank  4  Sell  
You can see 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-to-cut-jobs-amid-loss-of-exclusivity-for-key-drugs-200277749,200277749
105471,326986,AGN,Key Biosimilar Approvals In 2017  Progress Report ,opinion,"The biosimilar space was in focus in 2017 on key FDA approvals Biosimilars contain a version of the active substance of an already approved original biological drug  Development of biosimilars is technically more challenging than the development of generic drugs as the former requires clinical studies in patients and are engineered to match the reference drug in quality  safety and efficacy  Due to the complex nature of the product  the development and the regulatory pathway of biosimilars differ significantly from that of generics  A biosimilar is usually less expensive than the branded drug  Thus  the market for the same is highly lucrative  With the acceleration in approvals of biosimilars  the market has thus attracted a lot many players which are witnessing rapid growth  Here we go through the progress report for 2017 Merck   Co   Inc    NYSE MRK   launched Reneflexis  a biosimilar version of Remicade  infliximab   in the United States in July 2017 after approval in April  The FDA also granted tentative approval for Lusduna Nexvue  the biosimilar version of Lantus  basal insulin in a pre filled dosing device  Merck currently carries a Zacks Rank  3  Hold   You can see  Remicade has been seeing intense competition in the biosimilars space of late  We note that Pfizer  Inc    NYSE PFE   supplies Inflectra  a biosimilar version of Remicade  Pfizer is a strong player in the biosimilars market  In December 2017  Pfizer got FDA approval for another of its Remicade s biosimilar  Ixifi  as a treatment for rheumatoid arthritis  Crohn s disease  pediatric Crohn s disease  ulcerative colitis  ankylosing spondylitis  psoriatic arthritis and plaque psoriasis  The company has a portfolio of three marketed biosimilar medicines outside the United States  including Inflectra  Retacrit  epoetin zeta  and Nivestim  filgrastim  along with a strong pipeline of 13 distinct biosimilar molecules in various stages of development  Pfizer currently carries a Zacks Rank  3 Generic leader Mylan NV   NASDAQ MYL   is also exploring the biosimilars market   that has the potential to grow to  20 billion by 2020  Early last December  Mylan and partner Biocon Ltd  announced the FDA approval of Ogivri  trastuzumab dkst   a biosimilar version of Herceptin  trastuzumab   Ogivri has been approved for all indications included in the label of the reference product  Herceptin  including the treatment of HER2 overexpressing breast cancer and metastatic stomach cancer  Ogivri is the first FDA approved biosimilar of Herceptin and the first biosimilar from Mylan and Biocon s joint portfolio  Mylan currently carries a Zacks Rank  3 Meanwhile  Amgen Inc    NASDAQ AMGN   and Allergan plc    NYSE AGN   won FDA approval for the biosimilar version of Avastin in September 2017 for the treatment of multiple types of cancer  We note that Mvasi is the first biosimilar approved in the United States for the treatment of cancer  Amgen s biosimilar version of Humir  Amjevita  is already approved by the FDA and will be launched in the United States on Jan 31  2023  after the company resolved litigation with the AbbVie  Inc    NYSE ABBV   The companies have also submitted a BLA to the FDA for ABP 980  a biosimilar candidate to Herceptin in July 2017  We note that the companies are collaborating on four oncology biosimilars  including ABP 980  which is the second to be submitted for FDA approval  The companies also submitted a Marketing Authorization Application to the European Medicines Agency for the candidate in 2017  We note that Amgen has a total of 10 biosimilars in its pipeline  two of which have been approved by the FDA  Amgen currently carries a Zacks Rank  3 Boehringer Ingelheim s Cyltezo  adalimumab adbm   another biosimilar of Humira  was also approved by the FDA in August 2017  
Medical   Generic Drugs Industry 5YR   ReturnConclusionOwing to the slew of FDA approvals  we expect investors to remain focused on this space in the near future Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/key-biosimilar-approvals-in-2017-progress-report-200277958,200277958
105472,326987,AGN,Pharma Stock Roundup  Allergan Announces Job Cuts  Pfizer Inks Deals,opinion,"The week has been pretty slow with key announcements including Allergan s   NYSE AGN   job cut announcement and Pfizer s   NYSE PFE   collaboration agreements with companies like Sangamo and Arvinas Recap of the Week s Most Important StoriesAllergan Announces Job Cuts  At the time of announcing third quarter results in November  Allergan had said that it would have to look at cost reduction in order to deal with the impact of loss of exclusivity   LOE   on key products including Restasis  This week  the company announced a cost cutting and restructuring program which will lead to the elimination of more than 1 000 currently filled positions  primarily in commercial and other functions  About 400 open positions will also be eliminated  Restructuring costs of about  125 million  primarily due to severance  will be recorded mostly in the fourth quarter of 2017 with overall operating expense savings expected in the range of  300 to  400 million compared to 2017  The company expects to achieve additional cost reductions through non headcount spending rationalization  Read more    Pfizer in Protein Degradation Deal with Arvinas  Pfizer has agreed to shell out up to  830 million to private biotech company  Arvinas  which is focused on creating a new class of drugs based on protein degradation  The companies announced a research collaboration and license agreement for the discovery and development of drug candidates using Arvinas  proprietary PROTAC  PROteolysis TArgeting Chimeras  platform  a novel technology that is used for the creation of small molecule therapeutics aimed at degrading disease causing cellular proteins The multi year agreement  which covers different therapeutic areas  will see Arvinas drive discovery efforts  while Pfizer will be responsible for the clinical development and commercialization of any products resulting from this collaboration The  830 million covers upfront and milestone payments that depend on the achievement of specified preclinical  clinical and commercial milestones  The deal terms include tiered royalties as well Protein degradation is an area that has been attracting the interest of large cap companies   Arvinas has an agreement with Roche   OTC RHHBY   as well Pfizer Sangamo Sign Another Collaboration Agreement  Pfizer has signed another collaboration agreement with Sangamo for the development of a potential gene therapy using zinc finger protein transcription factors  ZFP TFs  for the treatment of amyotrophic lateral sclerosis   ALS   and frontotemporal lobar degeneration   FTLD   linked to mutations of the C9ORF72 gene  The agreement will see Pfizer shelling out an upfront payment of  12 million as well as milestone payments worth up to  150 million plus tiered royalties on net sales While Sangamo will be responsible for the development of ZFP TF candidates  Pfizer will be operationally and financially responsible for subsequent research  development  manufacturing and commercialization for the C9ORF72 ZFP TF program and other resulting products Sangamo and Pfizer already have a collaboration agreement that was announced last year for the development and commercialization of gene therapy products for hemophilia A  including SB 525  Read more    Pfizer is a Zacks Rank  3  Hold  stock   you can see   The company s stock is up 9 5  over the last one year  compared to the 15  rally of the  it belongs to Roche MacroGenics Ink Deal  Roche and clinical stage biopharma company  MacroGenics  are collaborating on the discovery and development of innovative monoclonal antibody based therapeutics for the treatment of cancer  as well as several autoimmune disorders and infectious diseases  The companies  respective platforms  including MacroGenics  DART platform and Roche s CrossMAb and DutaFab technologies  will be used for the selection of a bispecific format and lead pipeline candidate  Roche will be responsible for further development and commercialization of any such pipeline candidate The deal will see Roche making an upfront payment of  10 million plus up to  370 million on the achievement of milestones and royalties on future sales Mylan   Partner to Start Eylea Biosimilar Study in 1H18  Mylan   NASDAQ MYL   and partner Momenta announced that they intend to start a pivotal study for M710  a proposed biosimilar to Regeneron s blockbuster eye drug  Eylea  aflibercept   A vascular endothelial growth factor   VEGF   inhibitor  Eylea is indicated for the treatment of neovascular  wet  age related macular degeneration  macular edema following retinal vein occlusion  diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema  The study is scheduled to commence in the first half of 2018 in patients with diabetic macular edema  Eylea is the flagship product at Regeneron with global sales coming in at  4 3 billion in the first nine months of 2017  Read more    Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index was up 1 4  over the last four trading sessions  Among major stocks  AstraZeneca   NYSE AZN   was up 4 1   Over the last six months  Pfizer was up 11 5  while GlaxoSmithKline   NYSE GSK   declined 11 3   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for updates and outlooks that will be provided by several companies next week at the 36th Annual J P  Morgan Healthcare Conference Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-01-05,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-allergan-announces-job-cuts-pfizer-inks-deals-200277873,200277873
105473,326988,AGN,Allergan s  AGN  Sales Guidance For 2018 Lower Than Expected,opinion,Allergan plc   NYSE AGN   announced a weaker than expected sales outlook for 2018as it faces potential loss of exclusivity for some of its key products in 2018 Allergan expects total sales in the range of approximately  15 0 billion    15 3 billion  which falls short of the Zacks Consensus Estimate of  15 76 billion  Meanwhile  the company said that it expects adjusted earnings of at least  15 25 per share  Though not directly comparable  the earnings projection also appears short of the Zacks Consensus Estimate of  15 98 per share Allergan is facing potential loss of exclusivity for several of its key products in 2018 including Alzheimer s treatment  Namenda XR and blockbuster dry eye drug  Restasis  In the latest press release  the company said that it expects a generic version of Namenda XR to be launched in early first quarter while that of Restasis  Allergan s second best selling drug  is not expected to be launched prior to the second quarter We remind investors that in October 2017  a Texas federal district court invalidated four of the six patents covering Restasis  The patent loss opened doors for early generic competition for Restasis whose patents were scheduled to expire in August 2024  Please note that no generic version of Restasis has been approved yet We also remind investors that on the third quarter earnings call  Allergan had said that if a generic version of Restasis is launched in mid 2018  adjusted earnings per share would be no less than  16  Also  the company said that if a generic enters the market on Jan 1  2018  adjusted earnings per share will be more than  15 per share Also  this year  Allergan faces loss of patent exclusivity for Estrace vaginal cream and ulcerative colitis drug  Delzicol  In December last year  Mylan   NASDAQ MYL   launched the first generic version for Estrace cream while a generic version of Delzicol is expected to be launched in early second quarter Last week  Allergan  in a regulatory filing  announced that it is laying off over 1 000 employees as part of a cost saving and restructuring program  In the latest press release  Allergan said its cost reduction efforts should reduce  operating  expenses  by   300  million  to   400  million  in  2018 from  2017 Also  new competition for key growth drivers  Restasis and Linzess  is an investor concern  Shire s   NASDAQ SHPG   dry eye disease drug  Xiidra  launched last year  is posing strong competition for Restasis  Meanwhile  Synergy Pharmaceuticals Inc  s   NASDAQ SGYP   Trulance  plecanatide  was launched last year for chronic idiopathic constipation  which could pose competition to Allergan s  Linzess In the past year  Allergan s shares have declined 22 5  compared with the  sdecline of 25 5  Allergan also provided some other updates along with issuing 2018 outlook  The company said that the impact of the tax reforms will be broadly neutral to its adjusted effective tax rate over time with a moderate increase in the 2018 rate from 2017 levels  Allergan guided an adjusted tax rate of approximately 15  in 2018 Under the new  2 billion share buyback plan announced in September last year  Allergan said it has already bought back approximately 20  of the authorized amount in the three months ended December 2017  Also  the company said it plans to sell its remaining stake in Teva securities this year Allergan carries a Zacks Rank  4  Sell  You can see Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/allergans-agn-sales-guidance-for-2018-lower-than-expected-200278903,200278903
105474,326989,AGN,Will Amgen  AMGN  Continue To Tread Growth Path This Year ,opinion,"Amgen  Inc  s   NASDAQ AMGN   stock was up 19  in 2017  which compared favorably with a gain of 2 8  recorded by the  Last year s share price surge was supported by a series of positive news including promising data from several pivotal studies and rapid progress with its pipeline and line extensions The positive trend is likely to continue this year as well What Backed the Stock s Rally in 2017 A few new products were approved last year  While the FDA approved Mvasi    Amgen and Allergan s   NYSE AGN   biosimilar version of Roche s   OTC RHHBY   cancer drug  Avastin   and Parsabiv for secondary hyperparathyroidism  sHPT   EU approved Amgevita  Amgen s biosimilar version of Humira Amgen also gained approval for several line extensions   FDA approval to include a new indication   risk reduction of major cardiovascular events data   on Repatha s labeland overall survival datafrom the TOWER study on leukemia drug Blincyto s label  approval for arefined indication for metastatic colorectal cancerdrug Vectibix and EU approval for a pediatric formulation of Mimparafor secondary hyperparathyroidism  sHPT  The line extensions can expand the eligible patient populations of these drugs and drive their sales higher in future quarters In 2017  Amgen made several data presentations from studies evaluating line extensions on key marketed products  Repatha and Kyprolis  both with blockbuster potential   and other studies on its pipeline candidates  tezepelumab asthma  and Evenity osteoporosis Factors Likely to Support the Stock in 2018With several pivotal data readouts and regulatory milestones expected in 2018  the bullish run of the stock is likely to continue This year  Amgen expects regulatory approval for pipeline candidates  Aimovig erenumab prevention of episodic and chronic migraine  and Evenity and label expansion for Prolia and Kyprolis  This month  Amgen already received FDA approval for an expanded patient population for Xgeva   multiple myeloma patients  In the biosimilars portfolio  Amgen expects EU approval for Mvasi and FDA EU approval for the biosimilar version of Roche s other cancer drug  Herceptin Also  Amgen s newer drugs   Prolia  Xgeva  Vectibix  Nplate and Sensipar   are performing well  a trend expected to continue next year  which should drive sales  Sales of other newer products like Kyprolis  Repatha and Blincyto are expected to pick up in 2018 as they were approved forlabel expansions last year Besides this  Amgen s restructuring plan is making it leaner and more cost efficient which should lend support to the bottom line Though Amgen faces some challenges  given the presenceof biosimilar competition  slowdown in sales of mature drugs  mainly its blockbuster drug Enbrel  the positives are expected to outweigh the headwinds 
Amgen markets Enbrel in partnership with Pfizer  Inc    NYSE PFE  Amgen carries a Zacks Rank  3  Hold   You can see    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/will-amgen-amgn-continue-to-tread-growth-path-this-year-200280744,200280744
105475,326990,AGN,Teva s Trisenox Gets FDA Approval As First Line Treatment,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that the FDA has approved the label expansion of Trisenox injection to include first line treatment of acute promyelocytic leukemia   APL   patients in combination with tretinoin The eligible APL patients should have t 15 17  translocation or PML RAR alpha gene expression Trisenox is currently approved for a similar indication in patients who are refractory relapsed to retinoid and anthracycline chemotherapy The drug is already approved in the EU as both first line and second line treatment for this indication Teva s shares have declined 35  in the past year  underperforming the  s decline of 19  in that period According to the company  Trisenox  in combination with retinoic acid  can increase survival rates  dramatically reduce the risk of relapse  and help avoid chemotherapy related side effects in low to intermediate risk APL patients  It has been seen in clinical studies that Trisenox  in combination with retinoic acid  can lead to a 99  overall survival rate with almost no relapse after more than four years  50 months  of median follow up Teva s oncology portfolio includes five drugs  which performed well in the third quarter of 2017  It registered year over year growth of 12  to reach  302 million  The label expansion of Trisenox is expected to further boost the portfolio s performance in the coming quarters However  Teva is facing headwinds due to pricing pressure in the generics industry  Also  the approval of Mylan s   NASDAQ MYL   generic version of its key drug  Copaxone  in October last year had a negative impact on its fourth quarter revenue guidance Moreover  the Israeli firm is also facing a huge debt load  which swelled with the acquisition of Allergan s   NYSE AGN   generic division in 2016 In a bid to get rid of its problems  the company brought in a new chief executive officer   CEO    Kare Schultz  who had played an instrumental role in the turnaround of Denmark s H  Lundbeck A S  which was struggling with a string of losses  He also worked as the chief operating officer of another Denmark based drug giant  Novo Nordisk  CO NOVOb  A S   NYSE NVO   The new CEO announced restructuring plans in December 2017 in order to reduce cost and improve business performance  profitability  cash flow generation and productivity  Teva has announced to cut about 14 000 job cuts  more than 25  of the company s global workforce  over the next two years with the majority expected in 2018  The company will also shut down many of its offices and R D facilities around the globe and divest the assets  The moves are expected to reduce its  16 1 billion cost base  estimated for 2017  by  3 billion at the end of 2019 Teva Pharmaceutical Industries Limited Price
    Zacks RankTeva carries a Zacks Rank  4  Sell  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-15,Zacks Investment Research,https://www.investing.com/analysis/tevas-trisenox-gets-fda-approval-as-firstline-treatment-200280738,200280738
105476,326991,AGN,Cancer Space Update  Label Expansions  Data Readouts In Focus,opinion,"After a couple of quiet weeks  the cancer space witnessed some activity with FDA actions on label expansion and positive data readouts on major drugs from several companies  Meanwhile  a biosimilar for a blockbuster cancer drug received approval in Europe  A new drug was also granted approval for the treatment of leukemia Amgen  Inc  s   NASDAQ AMGN   multiple myeloma drug  Kyprolis  received FDA nod to include overall survival   OS   data from the head to head ENDEAVOR study on its label  The first CAR T therapy to receive approval  Novartis AG s   NYSE NVS   Kymriah  got a boost as the FDA accepted a supplemental Biologics License Application  sBLA  seeking label expansion in diffuse large B cell lymphoma   DLBCL    Moreover  AstraZeneca s   NYSE AZN   Lynparza got the FDA nod for label expansion in metastatic breast cancer  Teva Pharmaceutical  NYSE TEVA  also announced   in first line setting  in combination with tretinoin Moreover  Amgen and partner Allergan   NYSE AGN   announced the approval of Mvasi  a biosimilar version of Roche s   OTC RHHBY   blockbuster cancer drug  Avastin in Europe Data readouts included encouraging data on Merck s   NYSE MRK   Keytruda from confirmatory phase III lung cancer study and Exelixis  Inc  s   NASDAQ EXEL   Cabometyx from phase III hepatocellular carcinoma study  Apart from these  BioLineRx Ltd   NASDAQ BLRX   also announced  from a phase IIa COMBAT study in pancreatic cancer on its lead pipeline candidate  BL 8040  Partial data from the study showed that BL 8040 as a monotherapy is safe and well  tolerated in patients with the given indication Let s see the news in details Amgen s Kyprolis Gets a Label Update  Avastin s Biosimilar Approved  The FDA approved a regulatory application to include OS data from ENDEAVOR study on the label of Kyprolis  The FDA s decision came much earlier than expected  It was initially expected in April  A similar application is under review in Europe   Read more   Amgen Inc  Price
    Novartis s CAR T therapy sBLA Accepted by the FDA  Novartis announced that the FDA has accepted and granted priority review to its sBLA seeking label expansion of its CAR T therapy  Kymriah  A potential approval will expand the drug s access to patients with relapsed or refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant   Read more   Novartis AG Price
    AstraZeneca Announced Label Expansion of Lynparza in Breast Cancer  AstraZeneca s PARP inhibiting ovarian cancer treatment  Lynparza  was granted label expansion in the United States to include metastatic breast cancer indication  Lynparza became the first PARP inhibitor approved for treating metastatic breast cancer  The expanded label will certainly boost the drug s prospects and give it an advantage over other two PARP inhibitors  which are only approved for ovarian cancer   Read more   Astrazeneca  LON AZN  PLC Price
    Merck s Keytruda Impressive in Phase III Lung Cancer Study  Merck shares got a boost on Jan 16  following the announcement that Keytruda in combination with Lilly s Alimta and carboplatin achieved dual primary endpoints in a confirmatory phase III KEYNOTE 189 study  The study was evaluating the combination for the treatment of metastatic non squamous non small cell lung cancer  NSCLC  in first line setting  The data was reported much earlier than anticipated  in February 2019   The combination was granted accelerated approval in May 2017 for the aforementioned indication   Read more   Merck   Company  Inc  Price
    Exelixis  Cabometyx Positive in Phase III Carcinoma Study  Exelixis  along with partner Ipsen  announced data from pivotal phase III CELESTIAL study of Cabometyx  Data from the study evaluating the drug in advanced hepatocellular carcinoma showed that it achieved significant OS benefit in patients who have received prior treatment  The median OS achieved by the drug was 10 2 months versus 8 2 months for placebo   Read more   Exelixis  Inc  Price
    Apart from these  Gilead announced this week that it has entered into a collaboration agreement with Pfizer  NYSE PFE  to develop its CAR T therapy  Yesacrta  in combination with the latter s utomilumab  in patients with refractory large B cell lymphoma Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/cancer-space-update-label-expansions-data-readouts-in-focus-200281911,200281911
105477,326992,AGN,Amgen Allergan s Avastin Biosimilar Secures EU Approval,opinion,Amgen  Inc    NASDAQ AMGN   and partner Allergan   NYSE AGN   announced that the European Commission has granted marketing approval to its biosimilar version of Roche s   OTC RHHBY   blockbuster cancer drug  Avastin  bevacizumab   Mvasi  The drug was approved in the United States in September Mvasi is approved in the EU for the treatment of multiple types of cancer  Note that Mvasi is the first bevacizumab biosimilar to be approved in the European Union The approval was in line with expectations considering the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency s  EMA  had rendered a positive opinion for the approval of Mvasi in November The approval was supported by a comprehensive data package that demonstrated similarity of Mvasi with bevacizumab Amgen has collaborated with Allergan for the worldwide development and commercialization of four oncology antibody biosimilar medicines  Other than Mvasi  Amgen Allergan s portfolio also includes biosimilar versions of Herceptin  under review in the United States and EU  and Rituxan  in late stage studies Overall  Amgen has 10 biosimilars in its pipeline including biosimilar versions of Johnson and Johnson Merck s Remicade and Alexion s Soliris  Amgen s biosimilar version of Abbvie s   NYSE ABBV   blockbuster rheumatoid arthritis drug Humira  Amjevita  was approved by the FDA in September 2016 and in the EU  trade name  Amgevita  in March 2017 for the same indications as Humira Amjevita is the first biosimilar version of Humira to be approved by the FDA as well as Amgen s first biosimilar medicine to be approved  Per a settlement agreement with AbbVie  Amgen will begin selling Amjevita in most countries in the EU this year and in the United States from January 2023 Amgen s biosimilar opportunity is likely to translate into annual revenues of more than  3 billion  Amgen has also partnered Daiichi Sankyo for the commercialization of nine biosimilars in Japan In the past year  Amgen s shares have returned 21 3  compared with 4 2  increase registered by the   Amgen carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/amgenallergans-avastin-biosimilar-secures-eu-approval-200281905,200281905
105478,326993,AGN,Amgen s Migraine Drug Hits Primary Endpoint In Phase IIIb,opinion,Amgen   NASDAQ AMGN   announced that its fully human monoclonal antibody  Aimovig  erenumab   met all primary and secondary endpoints in a unique phase IIIb study for prevention of patients with episodic migraine  who have failed multiple prior preventive treatments Notably  Aimovig is the only investigational therapy designed to selectively block the calcitonin gene related peptide  CGRP  receptor  which plays a significant role in migraine activation Aimovig is under review in both the United States and the EU for prevention of both episodic and chronic migraine  A decision from the FDA is expected on May 17  2018 Moreover  shares of the company are up 25 8  in a year  comparing favorably with the  s an increase of 8 6   The phase IIIb LIBERTY study was designed to evaluate the efficacy and safety of Aimovig in a broad spectrum of migraine patients ranging from those without a preventive treatment as well as those  who have tried and failed such therapies Results from the study demonstrated that at least 50  of patients achieved reduction of monthly migraine  days from the baseline over the last four weeks compared with placebo  the primary endpoint of the study  Data from the trial also showed consistent efficacy  safety and tolerability of Aimovig across a wider spectrum of migraine patients including those with complicated cases We remind investors that Amgen developed Aimovig in collaboration with Novartis   NYSE NVS    The companies have now agreed to combine capabilities to co commercialize the candidate in the United States  Incidentally  Amgen retains its exclusive commercialization rights in Japan  Novartis  which retains its existing commercialization rights in rest of the world  has exclusive rights to commercialize Aimovig in Canada under the expanded deal Per the World Health Organization  migraine is one of the most debilitating illnesses  Approximately 10 million Americans  daily activities are affected by frequency or severity of migraine  Around 3 5 million subjects are undergoing a preventive therapy  of which  80  discontinues the treatment within a year  Hence  approval of Aimovig will provide the company a much needed access to a huge patient population in the United States  who are in need of additional curative options to apprehend the disease However  several companies including Teva Pharmaceutical Industries Limited   NYSE TEVA   and Allergan   NYSE AGN   among others are also developing migraine treatments targeting CGRP Amgen Inc  Price    Zacks RankAmgen carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-01-22,Zacks Investment Research,https://www.investing.com/analysis/amgens-migraine-drug-hits-primary-endpoint-in-phase-iiib-200282680,200282680
105479,326994,AGN,Teva says Allergan deal to close  any time   expects U S  antitrust clearance,news,"By Caroline Humer and Tova Cohen NEW YORK TEL AVIV  Reuters    Teva Pharmaceutical Industries Ltd  TA TEVA  said on Wednesday it expected its  40 billion deal to buy Allergan  NYSE AGN pa  Plc s  N AGN  generics business to close  at any time   even as the companies extended the deadline for completing the transaction to October to allow more time for the U S  antitrust review  The deal was announced more than a year ago and had been expected to wrap up last month  but it has taken longer as the companies have arranged sales of more drugs than anticipated to clear the antitrust regulators   We expect the closing of the     generics deal at any time now   Teva Chief Executive Officer Erez Vigodman said during a conference call with analysts to discuss the Israeli drugmaker s financial outlook  The deal closing is contingent on clearance from the U S  Federal Trade Commission  FTC   the antitrust regulator reviewing the deal  which the companies said they expect at any time  After it clears that hurdle  it will take another 10 days to close on the sale  Vigodman said  A spokeswoman for the FTC declined to comment  Teva shares  N TEVA  rose 2 95 percent to  54 01 in late morning trading in New York  and Allergan gained 1 96 percent to  244 42  Allergan also said in a regulatory filing earlier on Wednesday that the companies had amended their sale agreement to extend the deadline by three months into late October  As the review has continued into July  it has raised the likelihood of the companies missing the deadline later this month  As recently as May  Allergan CEO Brent Saunders had said he expected the deal to close within weeks  But in an emailed statement on Wednesday  the company backed Teva s view of the timing on the closing and an Allergan spokesman said that approval was  imminent   The filing said Allergan is now planning to exclude two products  Actonel and Carafate  from the sale  Teva has also agreed to sell some groups of drugs to third parties as it tries to get clearance from the FTC  In June  it announced a  652 million sale to Australia s Mayne Pharma Group Ltd  AX MYX    During the conference call on Wednesday  Teva said it expects to sell about  2 9 billion in assets in 2016  Teva also said that it expected the Allergan generics business  which Allergan put up for sale after it merged with  Actavis   to contribute  1 9 billion to net income in 2017   
Teva gave an outlook that forecast 2016 revenue of  22 billion to  22 5 billion and adjusted earnings of  5 20 to  5 40 per share  It provided an outlook through 2019 that included the new assets ",2016-07-13,Reuters,"https://www.investing.com/news/stock-market-news/teva-says-allergan-deal-to-close-'any-time',-expects-u.s.-antitrust-clearance-414152",414152
105480,326995,AGN,Wall St  falls as weak auto sales spur growth jitters,news,"By Chuck Mikolajczak NEW YORK  Reuters    Wall Street stocks fell on Tuesday  with each of the major indexes notching their worst day in about a month as economic data and weaker than expected auto sales spurred concerns about growth  Shares of Ford  N F  and General Motors  N GM  dropped more than 4 percent each after the two major U S  automakers reported July vehicle sales slightly below expectations  The automakers  declines pulled the S P consumer discretionary sector  SPLRCD  down 1 5 percent as the worst  performing of the 10 major S P groups   Data showed U S  consumer spending rose more than expected in June as households bought a range of goods and services  However  personal income rose only 0 2 percent  missing estimates of 0 3 percent  while inflation remained below the Federal Reserve s 2 percent target  That could keep the central bank on a cautious path to hiking interest rates    People are starting to see that things aren t quite as rosy as they might have thought in the month of July with that big run up   said Peter Jankovskis  co chief investment officer at OakBrook Investments LLC in Lisle  Illinois  The S P 500 climbed 3 6 percent in July  its best month since March   Another drop in U S  crude  CLc1  below  40 a barrel also weighed on sentiment  as the commodity settled down 1 4 percent at  39 51    Pfizer   N PFE   was the biggest percentage decliner on the Dow  after the largest U S  drugmaker reported better than expected quarterly results but revenue from its branded patent protected medicines was disappointing   The Dow Jones industrial average  DJI  fell 90 74 points  or 0 49 percent  to 18 313 77  the S P 500  SPX  lost 13 81 points  or 0 64 percent  to 2 157 03 and the Nasdaq Composite  IXIC  dropped 46 46 points  or 0 9 percent  to 5 137 73  CVS  N CVS  jumped more than 5 percent to  98 57 after the drugstore chain operator s quarterly profit beat estimates  Of the 353 companies in the S P 500 that have reported earnings through Tuesday morning  71 percent have topped analyst expectations  according to Thomson Reuters data  Earnings for the second quarter are expected to show a decline of 2 6 percent  an improvement from the expected 4 5 percent decline on July 1   Equities pared early losses after a report in the Wall Street Journal that biotechnology giant Biogen Inc  O BIIB  has drawn takeover interest from drug companies  including Merck   Co Inc  N MRK  and Allergan Plc  N AGN   Biogen shares surged 9 4 percent to  330 11 and the Nasdaq biotechnology index  NBI  climbed 0 2 percent after falling as much as 1 8 percent   Declining issues outnumbered advancing ones on the NYSE by a 3 35 to 1 ratio  on Nasdaq  a 2 97 to 1 ratio favored decliners  The S P 500 posted 14 new 52 week highs and 1 new low  the Nasdaq Composite recorded 54 new highs and 38 new lows   
About 7 45 billion shares changed hands on U S  exchanges  compared with the 6 64 billion daily average over the last 20 sessions ",2016-08-02,Reuters,https://www.investing.com/news/stock-market-news/futures-lower-ahead-of-economic-data-417975,417975
105481,326996,AGN,Biogen not pursuing a sale  source,news,By Greg Roumeliotis  Reuters    U S  biotechnology company Biogen Inc  O BIIB  has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers  according to a person familiar with the matter   While some of Biogen s peers have approached individual board directors of the company over time  nothing has been presented to Biogen s board for consideration recently  the person said on Wednesday  One reason that no formal offer has materialized is that Biogen values its portfolio of neurology drugs highly  and would expect any proposal to come with a significant premium  the person added  The Wall Street Journal reported on Tuesday  citing sources  that Allergan Plc  N AGN  and Merck   Co Inc  N MRK  had sounded out Biogen on the possibility of a takeover  Merck expressed more of an interest in Biogen than Allergan  but this did not result in any offer  the source said  The source asked not to be identified because Biogen s deliberations are confidential  Biogen  Allergan and Merck offered no comment  Cambridge  Massachusetts based Biogen has a market value of  70 billion  The company s  11 billion in annual revenue comes primarily from its multiple sclerosis portfolio  about  4 billion of which may be subject to generic competition in coming years  Earlier this week  Biogen said it would develop and commercialize an experimental genetic muscle disorder drug called nusinersen after an interim analysis of late stage data showed patients experienced statistically significant improvement  Facing slowing growth of its flagship multiple sclerosis drug Tecfidera  Biogen last year embarked on a sweeping restructuring program to focus on core areas  such as neurology  with high risk  potentially high reward experimental treatments for Alzheimer s disease  among others  Last month  the company s chief executive  George Scangos  announced plans to step down once a successor is named  Meanwhile  Allergan recently announced the closing of a deal to sell its generics business to Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  for more than  40 billion  providing Allergan with a substantial war chest that could be deployed for acquisitions  In April  Allergan  which is based in Dublin  Ireland  terminated its planned merger with U S  based rival  Pfizer  Inc  N PFE  after new U S  Treasury rules reduced the tax benefits of the deal   In earnings calls  Merck  based in Kenilworth  New Jersey  has expressed an interest in growing aggressively through deals  calling business development  a top priority   In 2015  it closed an acquisition of Cubist Pharmaceuticals for  9 5 billion ,2016-08-04,Reuters,https://www.investing.com/news/stock-market-news/biogen-not-pursuing-a-sale:-source-418441,418441
105482,326997,AGN,Allergan s cash use plan  pipeline could add to share run,news,"By Lewis Krauskopf NEW YORK  Reuters    Four months after the collapse of its deal to be bought by  Pfizer   N PFE   Allergan plc  N AGN  has a  33 billion war chest  a pipeline of experimental drugs that some investors view as undervalued and optimistic shareholders scooping up its shares  Whether the stock s recent rebound continues could rest on how wisely the drugmaker deploys that money  Wall Street could get a glimpse of Allergan s plans when it reports second quarter results on Monday   A lot of the strategic focus is going to be on what they do with this cash infusion   said Kevin Kedra  an analyst with Gabelli   Co  One possibility is Allergan strikes a major purchase of its own  It was reported this week to be interested in buying Biogen  O BIIB   which has a market value around  70 billion   While some analysts say the company does not need to strike such a sizable deal  they are bracing for some level of deal making  along with share buybacks and the paydown of debt  Allergan s newfound cash bounty stems from the sale of its generic drugs business to Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA    Helped in part by the sale  which closed on Tuesday after some doubts it would win U S  antitrust approval  Allergan shares have climbed 10 percent since the end of June  topping a 3 5 percent rise for the NYSE Arca Pharmaceutical index  DRG  of large and specialty drugmakers  They have rebounded about 30 percent since sinking to a two year low at the start of May and traded at midday on Thursday at  255 02  up  2 49  or 0 99 percent  on the New York Stock Exchange  Even after bouncing back  the shares remain down almost 20 percent for 2016  hurt after the Pfizer deal fell apart in April over new U S  tax rules  Led by deal making Chief Executive Officer Brent Saunders and armed with its top selling Botox drug  known for smoothing wrinkles  Allergan s earnings per share are expected to rise 14 percent on average annually through 2019 on annual revenue growth of 8 7 percent  according to Thomson Reuters I B E S  With the recent rebound  the shares are trading at about 15 8 times earnings estimates for the next 12 months  That is slightly pricier than their three year average of 15 3 times  but well below valuations for shares of other pharmaceutical companies with strong growth expectations  such as Bristol Myers Squibb  N BMY  and Eli Lilly  N LLY   To merit a higher valuation  Allergan must improve its pipeline of experimental medicines  said Guggenheim Securities analyst Louise Chen  who rates the stock  neutral    They are going to need some sort of biotech assets or something that is going to be a bigger hook for people than what they currently have   Chen said  Other analysts and investors tout the company s current pipeline and say it is not fully represented in the stock  Drugs for uterine fibroids  dry eye  major depressive disorder and migraines are among those  not getting the credit they deserve  for their potential  said Brian Turner  principal at Allergan shareholder Levin Capital Strategies  
 They already have an existing pipeline   Turner said   The growth will be there  So they don t need to do anything transformative  ",2016-08-04,Reuters,"https://www.investing.com/news/stock-market-news/allergan's-cash-use-plan,-pipeline-could-add-to-share-run-418560",418560
105483,326998,AGN,Business groups sue over new U S  limit on tax driven foreign buyouts,news,"By David Ingram and David Morgan
NEW YORK WASHINGTON  Reuters    Two business groups sued the Obama administration on Thursday over a crackdown on U S  companies that try to reduce their U S  taxes by rebasing abroad in a process known as inversion 
The U S  Chamber of Commerce and the Texas Association of Business filed a lawsuit in Texas federal court that said a regulation from the U S  Treasury Department in April exceeded what the law allows the department to do 
The lawsuit was the first to challenge a rule on inversion  The deals are legal  but have drawn criticism from some politicians who say U S  companies that do them are avoiding their tax obligations  A wave of inversions largely ended after Treasury moved against the deals 
The rule targeted by the lawsuit is aimed at transactions involving non U S  companies  such as Ireland based drugmaker Allergan Plc  N AGN  that have grown through a series of acquisitions 
It helped scuttle what had been a planned  160 billion combination of Allergan and U S  drugmaker  Pfizer  Inc  N PFE  in what would have been the largest inversion ever 
 Treasury and the IRS ignored the clear limits of a statute  and simply rewrote the law unilaterally  This is not the way government is supposed to work in America   Tom Donohue  head of the chamber  a business lobbying group  said in a statement 
A Treasury spokeswoman said in a statement that its action was based on strong policy interests and clear legal authority  It said the department would continue to defend the regulations to slow the erosion of the U S  corporate tax base 
UPHILL BATTLE
Lawyers with expertise in tax law have said such a lawsuit would face an uphill battle against Treasury  which has a strong record in court  The 1867 Anti Injunction Act says that  in general  no legal challenge can be brought against a tax until it is assessed  So the administration of President Barack Obama could argue that the law bars a lawsuit for now 
 I would be quite surprised if this case survived the obvious defense by the Justice Department that this is an attempt to short circuit the regular course of tax collections   said Edward Kleinbard  a law professor at the University of Southern California 
The chamber and the Texas Association of Business argue  though  that the Treasury and the tax collecting Internal Revenue Service must still follow a different law  the Administrative Procedure Act  APA   That law spells out the process agencies must follow before they impose regulations 
According to the lawsuit  the Treasury rule violated the APA because Treasury lacked authority to act  its rule was arbitrary and capricious  and it did not permit public notice and comment 
Allergan and Pfizer are not parties to the lawsuit  but the lawsuits cites their failed merger as an example of the harm done by the rule 
Representatives of the companies declined to comment on the litigation 
Pfizer is a member of the chamber and the Texas Association of Business  Allergan is a member of the chamber and the Greater Waco Chamber of Commerce  which in turn is a member of the Texas group  the lawsuit said 
The two drug companies  would actively explore merger opportunities  if the rule were set aside  the lawsuit said 
DOZENS OF DEALS
Dozens of U S  companies have done inversions since 1983  when the first such deal was completed  Treasury has periodically moved to curb the flow of deals because inversions erode the U S  corporate income tax base 
Treasury unveiled a package of rules in April meant to further discourage the deals  which typically involve a U S  multinational buying a smaller company in a foreign country with lower corporate taxes and then rebasing there  if only on paper 
Inverting U S  companies usually leave their core U S  operations at home  transferring only their legal tax domicile to the home country of the acquired company  Recent popular destinations for the deals are Ireland  Britain and Canada 
Fast food chain Burger King inverted to Canada last year  medical technology group  Medtronic   N MDT  to Ireland in 2014  drug maker  Mylan Inc   O MYL  to The Netherlands that same year 
The lawsuit challenges a specific rule that imposed a three year limit on foreign companies such as Allergan bulking up on U S  assets to avoid ownership thresholds for a later inversion 
In April  Treasury defended its regulation in a statement that said it was  not consistent with the purposes  of federal law to permit a foreign company to bulk up so quickly and then enter into another inversion 
Texas federal courts have been a friendly venue for groups suing the Obama administration  A judge there blocked the president s proposed overhaul of immigration 
More litigation is expected in the months ahead as Treasury moves to finalize another anti inversions rule targeting  earnings stripping   a tax avoiding practice in which a foreign parent lends money to a U S  unit  which sends U S  profits back as partially U S  tax deductible interest 

Republicans  and at times Obama  have pushed for a comprehensive tax code overhaul that would fully address inversions  but Washington for decades has lacked the political will to tackle such a complex project ",2016-08-04,Reuters,https://www.investing.com/news/stock-market-news/business-groups-sue-over-new-u.s.-limit-on-tax-driven-foreign-buyouts-418554,418554
105484,326999,AGN,Pfizer boosts cancer drug roster with  14 billion Medivation deal,news,"By Ransdell Pierson and Ankur Banerjee  Reuters     Pfizer  Inc  N PFE   beating out numerous other bidders  said it agreed to buy U S  cancer drug company  Medivation  Inc  O MDVN  for  14 billion in cash  adding its blockbuster prostate cancer drug Xtandi to the company s growing oncology roster  Medivation shares jumped nearly 20 percent to close at  80 42  just shy of the offer price of  81 50 per share  Shares of Pfizer  the largest U S  drugmaker  were down 0 4 percent at  34 84   The offer is a 55 percent premium to Sanofi SA s  PA SASY  initial bid to buy Medivation for  52 50 per share in April  which pushed the San Francisco based company to put itself up for sale  It represents a 118 percent increase since Reuters reported on March 30 that Medivation had hired JP Morgan to handle interest from companies in a potential acquisition   The planned purchase of Medivation  with its  2 2 billion a year Xtandi  is the latest in a number of deals by large drugmakers willing to pay top dollar for cancer drugs that are more effective than standard  older treatments  Perhaps the most notable example is AbbVie Inc s  N ABBV   21 billion purchase last year of Pharmacyclics  The deal gave AbbVie shared ownership with Johnson   Johnson  N JNJ  in the blockbuster leukemia drug Imbruvica  Analysts predicted the deal would not raise antitrust concerns because Pfizer does not currently sell a prostate cancer drug aside from generics   Pfizer said its earnings would increase immediately after buying Medivation  The deal comes four months after Pfizer and Ireland based Allergan Plc  N AGN  scrapped their  160 billion merger  Pfizer has since bought Anacor Pharmaceuticals Inc in a  5 2 billion deal to add an eczema gel to its portfolio  The Medivation deal illustrates a shift in Pfizer s M A strategy from lowering taxes   the rationale behind the failed Allergan tax inversion deal   to strengthening its lineup of branded drugs  especially lucrative cancer treatments  Pfizer  in a conference call with analysts  said it still plans to decide by year end whether to split into separate companies selling either low growth generics or patent protected brand medicines    The Medivation deal increases the likelihood of a split   said SunTrust Robinson Humphrey analyst John Boris  But  he said  Pfizer would likely first try to buy other drugmakers or their best assets in order to further strengthen its branded drug portfolio  A year ago  Pfizer paid  15 billion for Hospira  which sells generic hospital products and is developing biosimilars meant to compete with big selling injectable biotech drugs  That deal was seen by Wall Street as a way of bolstering its generic drugs ahead of potentially divesting the business   Pfizer s biggest growth driver is a new breast cancer drug called Ibrance  The company is also trying to catch up with Merck   Co  N MRK  and Bristol Myers Squibb Co  N BMY  in developing immuno oncology drugs that work by taking the brakes off the immune system to fight cancers  Pfizer Chief Executive Ian Read told analysts the Medivation deal was mainly driven by the desire to obtain Xtandi  although he expressed high hopes for talazoparib and pidilizumab  experimental Medivation drugs for breast cancer and lymphoma  respectively  Xtandi generated U S  net sales of  330 3 million in the second quarter  Japanese drugmaker Astellas Pharma Inc  T 4503  owns the rights to sell Xtandi outside the United States  where it generated sales of  240 million in the period  Read said Xtandi  which was approved four years ago to treat men who had failed to benefit from prostate cancer treatments  could capture far greater sales if it is eventually approved for earlier use and is prescribed by urologists   The product is just at the beginning of its growth cycle   Read predicted  Some analysts  including BMO s Alex Arfaei  said Pfizer appeared to be overpaying for Medivation  But Piper Jaffray analyst Richard Purkiss said the price is not excessive given Xtandi s potential for earlier treatment in coming years  Reuters had reported that Pfizer  Merck   Celgene Corp   O CELG  and  Gilead Sciences Inc   O GILD  had submitted expressions of interest to buy Medivation    Given the already very high price being discussed  the difficult public relationship between Medivation and Sanofi     we see a higher bid as very unlikely  but not impossible   RBC Capital Partners wrote in a client note ahead of the announcement   Sanofi said while it recognized the potential strategic benefits of a combination with Medivation  it was a  disciplined acquirer and remained committed to acting in the best interests of Sanofi shareholders    Pfizer said the deal was approved by boards of both companies and should be completed in the third or fourth quarter  Shares of other cancer drug companies  including  Incyte Corp   O INCY  and Seattle Genetics  O SGEN   also rose on Monday  as investors speculated about more dealmaking in the sector   Pfizer s financial advisers were Guggenheim Securities and Centerview Partners  with Ropes   Gray LLP providing legal counsel   
J P  Morgan Securities and Evercore were Medivation s financial advisers  while Cooley LLP and Wachtell  Lipton  Rosen   Katz served as its legal advisers ",2016-08-22,Reuters,https://www.investing.com/news/stock-market-news/pfizer-nears-$14-billion-deal-for-medivation-421532,421532
105507,327022,AGN,Revance s Neuromodulator Injection Positive In Phase III,opinion,Revance Therapeutics  Inc    NASDAQ RVNC   shares surged more than 33  on Dec 5 after the company announced positive top line results from two pivotal phase III studies  evaluating its next generation neuromodulator  RT002  daxibotulinumtoxin   for reducing wrinkles that lies between the brows  glabellar lines  Both the phase III studies  SAKURA 1 and SAKURA 2  met their primary and secondary endpoints  demonstrating highly statistically significant improvement in severity of glabellar lines with RT002 against placebo  Data from the study showed that RT002 delivered substantial reduction in severity of glabellar lines for a long acting duration of six months  The candidate was generally well tolerated in both the trials Notably  the duration achieved by RT002 in treating glabellar lines is better than any other marketed neuromodulators which demonstrates a duration of three four months  It is important to note that Allergan s   NYSE AGN   shares dropped almost 2  following the news release as RT002 is considered a potential threat to the company s lead drug  Botox  which is marketed for the same indication  RT002 has a longer duration compared with Allergan s Botox of five months Revance s shares have significantly outperformed the industry year to date  The stock has soared 66 4  compared with the  s gain of 0 9  in the same time frame Notably  the company is conducting a long term safety trial  SAKURA 3  on RT002 that already enrolled more than 2 500 patients across 66 sites in the United States and Canada  The study is expected to complete in the second half of 2018  If the study is successful  plans are afoot to submit regulatory applications to the FDA in the first half of 2019 with a potential launch in 2020  Per the company  RT002 will be the first neuromodulator with a long acting duration of six months  if approved Per the data from Global Industry Analysts  the global aesthetic market represented revenues of about  1 6 billion in 2016 for treatments with neuromodulators  Moreover  patients and physicians consider the effect of treatment duration as the most significant component for any injectable neuromodulator  Hence  approval of the candidate is expected to cater to the hugely unmet needs of patients preferring longer duration for treatment of glabellar lines We remind investors that RT002 is also being evaluated in other clinical programs for different indications  Revance plans to initiate a phase III study on RT002 for treating cervical dystonia  a neurological muscle movement disorder  in 2018  RT002 was recently granted an orphan drug designation for cervical dystonia indication in the United States  Moreover  it also plans to release results from a phase II study  evaluating RT002 for management of plantar fasciitis by this year end Revance Therapeutics  Inc  Price   Zacks Rank   Key PicksRevance carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Corcept Therapeutics Incorporated   NASDAQ CORT   and Achillion Pharmaceuticals  Inc    NASDAQ ACHN    each carrying a Zacks Rank  2  Buy   You can see  Corcept s earnings per share estimates have moved up from 77 cents to 88 cents for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 14 32   Share price of the company has skyrocketed 127 3  year to date Achillion s loss per share estimates has narrowed from 66 cents to 63 cents for 2017 and from 75 cents to 67 cents for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the trailing four quarters with an average beat of 4 51  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-12-06,Zacks Investment Research,https://www.investing.com/analysis/revances-neuromodulator-injection-positive-in-phase-iii-200271123,200271123
105508,327023,AGN,Roche s Avastin Gets Full FDA Approval For Brain Cancer,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   member  Genentech announced that the FDA has converted accelerated approval for Avastin  received in May 2009  for previously treated glioblastoma  most aggressive form of brain cancer  to full approval 
The full approval was based on data from the phase III EORTC 26101study in which Avastin based treatment increased the time to disease progression or death compared to chemotherapy alone  The study  however  did not meet the primary endpoint as there was no significant increase in overall survival with Avastin based treatment 
However  it showed that patients were able to completely stop intake of corticosteroids while on treatment in the Avastin arm compared to the control arm  The evidence from the study  which showed that Avastin treatment delayed disease progression and reduced the need for corticosteroids  led to the conversion of the provisional approval to a full one 
Apart from the recent approval  the drug is already approved in the United States  for various indications that include  first  or second line treatment of metastatic colorectal cancer  advanced nonsquamous non small cell lung cancer  NSCLC   metastatic kidney cancer and advanced cervical cancer and recurrent ovarian cancer 
So far this year  shares of the company have increased 8 4  compared with the  s gain of 15  

However  the drug has been facing competition and has been witnessing declining sales  In September 2017  Amgen   NASDAQ AMGN   and its partner Allergan   NYSE AGN   announced that the FDA approved their biosimilar version of Avastin for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer  The biosimilar to be marketed by the trade name Mvasi is the first cancer biosimilar approved in the United States  It is also the first biosimilar for Avastin in the same country 
Zacks Rank   Stocks to Consider
Roche carries a Zacks Rank  4  Sell   A top ranked health care stock in the same space is Johnson and Johnson   NYSE JNJ   sporting a Zacks Rank  2  Buy   You can see  
Johnson and Johnson s earnings per share estimates have moved up from  7 18 to  7 28 for 2017 and from  7 72 to  7 85 for 2018  over the last 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters  with an average beat of 3 12   The share price of the company has increased 21 2  year to date 
Wall Street s Next Amazon  NASDAQ AMZN  
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-12-06,Zacks Investment Research,https://www.investing.com/analysis/roches-avastin-gets-full-fda-approval-for-brain-cancer-200271122,200271122
105509,327024,AGN,S P Ends Skid As Tech Rallies Again,opinion,"The tech sector had another positive performance on Thursday  giving the NASDAQ the best showing of the major indices and helping the S P break its four session losing skid  The NASDAQ jumped 0 54  today to 6812 8  while the S P increased 0 29  to 2637  The Dow also advanced 0 29  to 24 211 5 
	Apparently  the market wasn t too concerned about a government shutdown on Friday  which was prescient since both houses of Congress passed a temporary spending bill after the close to keep things running until December 22  And for the most part  the mood is optimistic that the House and Senate will be able to get some kind of tax reform to President Trump s desk perhaps by the end of the year  So the most immediate event on the schedule now is tomorrow s Government Employment Situation report Insider Trader made the biggest splash in the portfolios on Thursday as Tracey sold one stock for a profit and then bought a pharmaceutical company that recently had two insider buys  Learn all about these moves in the highlights section below  along with some excerpts from other commentaries Today s Portfolio Highlights Insider Trader  The Trading Window Period for the next earnings season is still open  so the portfolio continues to see a lot of insider activity  Tracey added a pharmaceutical giant on Thursday  but first she cashed in on Raytheon  RTN   Shares of the defense contractor grinded to another new high recently  and the editor thought this was a good time to secure a 7 3  return 
	The new buy is Allergan  NYSE AGN   whose claim to fame is Botox  Shares recently got shellacked on positive news for a potential competitor to its  1 product  The stock is now down 22  year to date  However  the CEO and a director both bought shares of their own company this week in a classic  insider buying  move  Basically  these people think that their company is oversold right now  Tracey added AGN on Thursday with a 10  allocation  Read the complete commentary for more on today s moves Counterstrike   Stocks grinded higher today  confirming the important Fibonacci levels in the S P that I referred to yesterday  The S P closed 0 29  higher  while the Nasdaq gained 0 54   While the S P still looks very bullish  the 61 8  short set up in the Nasdaq held today  Targets are still in place at 6200 in the Nasdaq futures 
	 The divergence between the two indices is somewhat maddening  On one hand we have the S P which looks like it can go back to all time highs like it typically does  On the other hand  we have the tech heavy Nasdaq that looks like it will test its 50 day moving average 
	 It s hard to determine which index to trust  my gut says the larger of the two is where we should focus  In any regards  these Fibs should be monitored      Jeremy MullinLarge Cap Trader   On Thursday  the Nasdaq outpaced its Large Cap index peers  sporting a gain of 0 7  intraday  The Dow Transports were rallying today too  sending the Dow Jones Transportation Average higher by  1 1  
	 The S P500 was up  0 4  when I check in at midday 
	 I have not sold a Tech stock  and I am not going to  I think this was a very natural and healthy correction  The bottom line with the market these days  and it comes thru very clear when I work with the Zacks Industry Rank system  Semis are not getting replaced by sentiment    by growth ier names  industries or plays    anytime soon 
	 As long as the publicly traded  very liquid stock markets get the tailwind of global risks sinking down  and traders chase the stronger growth plays first and foremost  a green bid will remain on those stocks      John Blank
	All the Best 
	Jim Giaquinto
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-12-07,Zacks Investment Research,https://www.investing.com/analysis/sp-ends-skid-as-tech-rallies-again-200271565,200271565
105510,327025,AGN,Allergan Inks Deal To Buy Texas Based Repros Therapeutics,opinion,"Irish pharma giant Allergan plc   NYSE AGN   has recently inked a definitive agreement to acquire a Texas based development stage biopharmaceutical company  Repros Therapeutics   NASDAQ RPRX    Repros is focused on developing new drugs to treat hormonal and reproductive system disorders 
Shares of Allergan have declined 18 2  this year so far  comparing favorably with the  s decrease of 28 1   Although Repros  shares plunged 49 7  so far this year  the same jumped more than 40  following the news on Dec 12 

 
Pursuant to the agreement  Allergan will execute the acquisition through its subsidiary for a cash tender offer of  0 67 per share of Repros  common stock  The closing of the transaction is subject to customary closing conditions  Repros anticipates completion of the buyout during the first quarter of 2018 
Notably  the agreement will add two late stage candidates  Proellex and enclomiphene  to Allergan s pipeline  Repros plans to initiate a phase III study on Proellex for treatment of uterine fibroid  On one hand  the company currently evaluates Proellex  a selective progesterone modulator  SPRM   in a phase IIb study for uterine fibroids by vaginal delivery  On the other  enclomiphene is under evaluation for treating low testosterone levels in overweight men  Notably  the company had submitted regulatory applications to the European Medicines Agency  EMA  in September 2016  subsequently accepted by the regulatory body 
On a positive note  addition of these candidates would boost Allergan s pipeline and that bodes well for the company s long term growth 
We remind investors that acquisitions form an integral part of Allergan s expansion strategy as the company completed four major takeovers  Arrow  Specifar  Actavis Group and Warner Chilcott  apart from the Forest and Allergan Inc  deals in the past few years  This year so far  Allergan has burgeoned its medical aesthetics business into regenerative medicine and body sculpting through the accretive acquisitions of LifeCell and ZELTIQ  respectively 
These buyouts not only provided Allergan with operational expertise but also aided the company to enhance its commercial presence and fortified its foothold in the key markets Allergan PLC  Price

   Zacks Rank   Key Picks
Allergan carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Corcept Therapeutics Inc    NASDAQ CORT   and Achillion Pharmaceuticals  Inc    NASDAQ ACHN    both carrying a Zacks Rank  2  Buy   You can see  
Corcept s earnings per share estimates have moved up from 77 cents to 88 cents for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 14 32   Share price of the company has skyrocketed 136 4  year to date 
Estimates for Achillion s loss per share have narrowed from 66 cents to 63 cents for 2017 and from 75 cents to 67 cents for 2018 over the last 60 days  The company surpassed expectations in two of the last four quarters with an average positive surprise of 4 51  
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/allergan-inks-deal-to-buy-texasbased-repros-therapeutics-200272981,200272981
105511,327026,AGN,Aerie  AERI  Gets Early FDA Approval For Lead Drug Rhopressa ,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced that the FDA has approved its lead candidate  Rhopressa  netarsudil ophthalmic solution  0 02  for the lowering of elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension The news comes as a significant boost for Aerie given that the company had no approved products in its portfolio  The FDA approval comes two months ahead of the scheduled Prescription Drug User Fee Act goal date of Feb 28  2018 Aerie plans to hire a sales force of 100 representatives in the first quarter of 2018 and plans to launch the drug by mid 2018 An approval was in the cards as the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa s approval in October 2017  Members of the committee unanimously agreed that the trials support the efficacy of netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension  In addition  majority of the members agreed that the Rhopressa s efficacy outweigh safety risks The news will surely relieve investors  In October 2016  Aerie withdrew its NDA for Rhopressa in the United States which was submitted in the third quarter of 2016  A third party manufacturing facility in Tampa  FL  not being ready for pre approval inspection led to the withdrawal  The contract drug product manufacturer had previously informed Aerie and the FDA that it will be prepared for the inspection in January 2017 but then delayed it further  The manufacturer clarified that the delay is not a result of any new finding but the additional time needed to complete the validation of new equipment Glaucoma is one of the largest segments in the global ophthalmic market  According to the National Eye Institute  it has been estimated that more than 2 7 million individuals in the United States suffer from glaucoma  This number is expected to reach 4 3 million by 2030   Aerie s share price has increased 15 4  in the last six months as against the  s 2 1  rally However  Aerie faces stiff competition from established branded and generic pharmaceutical companies  such as Novartis    NYSE NVS   Simbrinza and Travtan  and Allergan s   NYSE AGN   Lumigan  as well as other smaller biotechnology and pharmaceutical companies  Valeant Pharmaceutical s  VRX  Vyzulta was recently approved for open angle glaucoma or ocular hypertension  Rhopressa will face a tough time in gaining market share due to competition from these products Meanwhile  Aerie s second product candidate  Roclatan  netarsudil latanoprost ophthalmic solution  0 02  0 005   which is a fixed dose combination of Rhopressa and latanoprost  achieved its primary efficacy endpoint in two phase III registration trials  named Mercury 1 and Mercury 2  and also achieved successful 12 month safety and efficacy results in Mercury 1  The company expects to submit its NDA for Roclatan in the second quarter of 2018 
Zacks Rank                                             
Aerie currently carries a Zacks Rank  4  Sell  
You can see  
Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-gets-early-fda-approval-for-lead-drug-rhopressa-200274369,200274369
105512,327027,AGN,Teva s Migraine Candidate Gets Priority Review From FDA,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   announced that the FDA has accepted its biologics license application  BLA  seeking approval for its monoclonal antibody candidate  fremanezumab  as a preventive treatment for migraine  With the FDA granting priority review designation to the BLA  a decision from the FDA is expected in mid 2018  Teva looks to launch fremanezumab next year The BLA submission was supported by positive data from two phase III studies under HALO program  which evaluated the candidate in patients with episodic migraine   EM   and chronic migraine   CM   Fremanezumab is also being evaluated in late stage studies  ENFORCE  for the prevention of chronic and episodic cluster headache  In the latest press release  the company also said the FDA has granted fast track designation for fremanezumab for the prevention of cluster headache  In addition  recently a phase II clinical program in post traumatic headache has also been initiated Meanwhile  Teva s restructuring plan announced last week  which aims to lay off more than 25  of its global workforce and shut down some plants  has resulted in massive protests and strikes in Israel by employees as well as the country s main public sector labor union  The strikes briefly shut down the Ben Gurion airport  banks  stock exchange and government offices on Sunday  Teva is one of Israel s biggest employers Last month  Teva s new chief executive officer  Kare Schultz announced a new organizational and leadership structure to save costs and increase productivity  The organizational changes included the departure of heads of three divisions Teva s shares have slumped 48 9  so far this year compared with the  s decline of 26 1  Teva is facing significant challenges in the form of generic competition for its largest branded drug  Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from new generic launches and a massive debt load The U S  generics industry is facing significant competitive and pricing pressure  which is hurting the company s topline Meanwhile  Teva s blockbuster multiple sclerosis drug  Copaxone s sales have been declining for quite some time now  In October  in a major blow to Teva  Mylan   NASDAQ MYL   launched  at risk  its generic version of the 40 mg formulation  much earlier than expected  Meanwhile  Glatopa  a generic version of Copaxone 20 mg  is marketed by Momenta and Sandoz  Novartis    NYSE NVS   generic arm  since 2015 while Mylan also launched its version of the 20 mg formulation in October  With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  Copaxone sales are expected to erode rapidly Additionally  the company s debt burden increased as a result of the  40 5 billion acquisition of Allergan s   NYSE AGN   generic unit  Allergan Generics in 2016  With nearly  35 billion in debt  the company s borrowing costs have increased significantly  which is hurting profits In order to combat these challenges  Teva has divested some non core assets to cut its significant debt load  It remains to see if the latest corporate shake up  planned layoffs and divestures are enough to revive the company s fortunes during this challenging period  especially as it faces erosion of its largest product  Copaxone Teva carries a Zacks Rank  4  Sell  You can see  Zacks Editor in Chief Goes   All In   on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/tevas-migraine-candidate-gets-priority-review-from-fda-200274448,200274448
105513,327028,AGN,Allergan s Vraylar Positive For Bipolar Disease In Phase III,opinion,Allergan plc   NYSE AGN    along with partner Gedeon Richter  announced positive top line results from a second pivotal phase III study on its schizophrenia drug Vraylar The study evaluated Vraylar  cariprazine  for treatment of adult patients with major depressive episodes associated with bipolar I disorder  bipolar I depression  Notably  Vraylar is already approved in the United States and the EU for the acute treatment of manic or mixed episodes associated with bipolar I disorder as well as for schizophrenia  Additionally  the FDA approved the drug last month for an expanded use as a maintenance therapy for treatment of schizophrenia Shares of Allergan have declined 18 6  this year so far  comparing favorably with the  s decrease of 26  The phase III  RGH MD 54  study was investigating two doses of Vraylar  1 5 mg and 3 mg  in a total of 488 patients with bipolar I depression  The study met its primary endpoints and showed a significant improvement in patients compared with placebo  The drug was generally well tolerated in the study  However  we also note that of the total number of patients  around 5 0  being treated with Vraylar discontinued the trial due to adverse events in comparison to 2 5  treated with placebo Based on the above reported data  the company is planning to submit regulatory applications to the FDA in the second half of 2018 Significantly  Allergan has a licensing agreement with Gideon Richter  a Hungarian multinational pharmaceutical and biotechnology company  to co develop and market Vraylar in the United States as well as Canada Vraylar has performed well in the first nine months of 2017  recording sales of  200 1 million compared with  51 1 million  registered in the same period a year ago  The drug is likely to be a key driver of Allergan s top line in 2018 Per National Alliance of Mental Illness  bipolar disorder is one of the most common mental diseases and the third most common cause of hospitalization in the United States for both youth and adults aged between 18 and 44 years  Moreover  2 6  of adults in the country live with bipolar disorder  Hence  approval of the drug for the expanded indication will provide the company with access to a wider patient population base with bipolar issues Other players in the bipolar disorder and schizophrenia treatment market include AstraZeneca plc s   NYSE AZN   Seroquel XR  Johnson   Johnson s   NYSE JNJ   Risperdal Consta and Alkermes plc s   NASDAQ ALKS   Aristada Allergan PLC  Price   Zacks RankAllergan carries a Zacks Rank  3  Hold   You can see  Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/allergans-vraylar-positive-for-bipolar-disease-in-phase-iii-200274429,200274429
105514,327029,AGN,Allergan Paratek s Acne Candidate NDA Filing Accepted By FDA,opinion,Allergan plc   NYSE AGN   along with partner Paratek Pharmaceuticals   NASDAQ PRTK   announced that its new drug application  NDA  for its investigational  once daily  Seysara  sarecycline  has been accepted for review by the FDA for treatment of patients aged nine years and above with moderate to severe acne vulgaris  The company expects a response from the FDA in the second half of 2018 A look at Allergan s share price movement so far this year shows that the stock has outperformed the   Though the stock has lost 21 1   the industry has decreased 27 9   Also shares of Paratek were up 15 2  during the period Allergan completed its NDA submission for Seysara in October  based on positive data from two phase III  n 2002  studies   SC1401 and SC1402   respectively  The trials met the primary endpoints and revealed that patients treated with Seysara  1 5 mg kg  demonstrated a statistically significant improvement in acne severity compared with placebo at week 12 Notably  Allergan owns the rights for development and commercialization of Seysara in the United States while Paratek retains the rights in the ex U S  markets Among other players conducting trials on candidates in the same space  Foamix Pharmaceuticals Ltd    NASDAQ FOMX   is developing FMX101 in late stage studies for treating moderate to severe acne We remind investors that Allergan has more than 55 projects in mid to late stage development  The company has extended its R D pipeline to adjacent categories like NASH  Parkinson s disease and gene therapy with many promising phase II III programs on development track Allergan also boasts a strong branded pipeline with meaningful data read outs expected next year Allergan PLC  Price   Zacks Rank   Key PickAllergan carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Corcept Therapeutics Incorporated   NASDAQ CORT   carrying a Zacks Rank  2  Buy   You can see  Corcept s earnings per share estimates have moved up from 78 cents to 88 cents for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 14 32   Share price of the company has skyrocketed 117 7  year to date Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/allerganparateks-acne-candidate-nda-filing-accepted-by-fda-200275074,200275074
105515,327030,AGN,Global stocks climb along with oil  yen retreats again ,news,"By Lewis Krauskopf NEW YORK  Reuters    World stock markets rallied on Tuesday as oil prices climbed and companies reported solid earnings  while the yen again retreated against the dollar  MSCI s broad gauge of global stocks  MIWD00000PUS  climbed 0 9 percent  on pace for its best session in three weeks  The U S  benchmark S P 500 gained 0 9 percent and the pan European FTSEurofirst 300  FTEU3  index advanced 0 8 percent  The yen fell against the dollar for a second day as a key Japanese economic adviser reiterated that the country was prepared to intervene in currency markets  But against a basket of currencies  the dollar was little changed  helping to steady oil and other commodities denominated in the greenback   The Dow Jones industrial average  DJI  was rising 172 68 points  or 0 98 percent  at 17 878 59  the S P 500  SPX  was gaining 18 28 points  or 0 89 percent  at 2 076 97 and the Nasdaq Composite  IXIC  was adding 31 65 points  or 0 67 percent  at 4 781 86   I d probably say it s the currency fluctuations that are influencing the market in the short term   said Walter Todd  chief investment officer at Greenwood Capital Associates in Greenwood  South Carolina  Allergan  N AGN  shares propped up the S P 500 after the U S  pharmaceutical company posted strong earnings  Results from  Credit Suisse   S CSGN  and jewelry maker  Pandora   CO PNDORA  helped the European index   The market has been resilient and has offered the opportunity for the buyers of the pullback to capitalize on it and that s why we re seeing a move back into equities   said Andre Bakhos  managing director at Janlyn Capital LLC in Bernardsville  New Jersey  Greek shares  ATG  hit their highest level in 2016 after euro zone finance ministers offered to grant Greece some debt relief  with the move causing Greek 10 year bond yields  to fall below 8 percent for the first time since early December  The yen slid 0 7 percent against the dollar as risk appetite improved for a second straight session  undermining traditional safe havens such as the Japanese currency  Repeated verbal warnings from Japan over the weekend and on Tuesday saying it was prepared to step in to weaken the currency has also held off investors  Oil prices rose as supply disruptions of 2 5 million barrels per day in Canada and elsewhere offset concerns about growing record high U S  crude stockpiles   U S  crude  CLc1  gained 2 percent to 444 30 a barrel  while benchmark Brent crude  LCOc1  rose 3 2 percent to  45 03 a barrel  Oil prices have recovered some ground after touching 12 year lows earlier in 2016  U S  Treasuries were steady before the government was due to sell  24 billion in three year notes  
Benchmark 10 year notes  US10YT RR  gained 1 32 in price on Tuesday to yield 1 7578 percent  down from 1 76 percent on Monday ",2016-05-10,Reuters,https://www.investing.com/news/stock-market-news/asian-stocks-at-two-month-lows-as-oil-weighs;-dollar-up-400944,400944
105516,327031,AGN,Pfizer to buy Anacor in  5 2 billion deal for access to eczema gel,news,"By Amrutha Penumudi  Reuters     Pfizer  Inc  N PFE  is buying Anacor Pharmaceuticals Inc  O ANAC  in a  5 2 billion deal to add an eczema gel to its portfolio  just a month after the U S  drug major scrapped plans to acquire Allergan Plc  N AGN    Anacor shares surged as much as 56 percent to  99 94 on Monday  above the offer price of  99 25 per share in cash  The net of cash deal value assumes conversion of Anacor s outstanding convertible notes  the companies said in a statement  The deal hints at a shift in Pfizer s M A strategy from lowering taxes   the rationale behind its  160 billion bid for Dublin based Allergan   to strengthening its drugs portfolio ahead of a decision on selling or spinning off its generic medicines business by late 2016   The recent pullback in valuations of biotech firms could stimulate Pfizer s appetite for deals  analysts said  The company is also reported to be in talks to buy cancer drug maker  Medivation  Inc  O MDVN    The equity value of the Anacor deal is  4 45 billion  based on the company s outstanding fully diluted shares as of March 31  Anacor stock had fallen 43 percent this year to Friday s close   The acquisition will give Pfizer access to a non steroidal topical gel  crisaborole  which is currently under review by the U S  Food and Drug Administration for the treatment of mild to moderate eczema   Pfizer said it believed crisaborole had the potential to reach or exceed peak sales of  2 billion  In the past 15 years  there have been no new molecules approved for eczema   or atopic dermatitis   a common  relapsing  inflammatory skin disorder that affects 18 25 million people in the United States   SURPRISE BUYER Some analysts said they had expected Anacor to be acquired by Allergan  which has a stronger presence in the dermatology market  or by  Novartis  AG s  S NOVN  Sandoz unit  which sells Anacor s toenail fungus drug in the United States  Wedbush analyst David Nierengarten  however  said that Pfizer was strong in primary care and pediatric treatments  the target markets for crisaborole  He said other bids were possible  given that the  180 8 million termination fee was relatively low for a deal this size   Pfizer s current inflammation and immunology drugs portfolio includes Enbrel and Xeljanz  which target auto immune diseases  Enbrel  marketed by the company outside North America  lost patent protection in Europe last year  The U S  patents for the drug  sold in the country by  Amgen Inc   O AMGN   are set to expire in 2028   
Centerview Partners and Guggenheim Securities advised Pfizer advisers and Citi advised Anacor  Wachtel Lipton Rosen   Katz was Pfizer s legal adviser  while Davis Polk   Wardwell LLP advised Anacor ",2016-05-16,Reuters,https://www.investing.com/news/stock-market-news/pfizer-to-buy-anacor-pharma-in-$5.2-billion-deal-402223,402223
105517,327032,AGN,Investors made bets on Allergan just weeks before deal collapsed,news,"BOSTON  Reuters    Hedge funds  including Baupost Group  Davidson Kempner Capital Management and Magnetar Financial  made investments in Allergan Plc  N AGN  during the first quarter  betting that the company would become the world s biggest drug maker  Seth Klarman s Baupost Group bought 1 7 million shares during the first three months of 2016  while Davidson Kempner bought 833 099 shares and Magnetar bought 775 453 shares  Similarly  Eton Park Capital and Maverick Capital nearly doubled the stakes their firms already owned  Eric Mindich s Eton Park bought 926 504 shares and Lee Ainslie s Maverick Capital bought 730 432 shares  Adage Capital Partners nearly doubled its holdings  buying 547 759 shares to hold 1 2 million shares  The investments came weeks after Allergan agreed with rival  Pfizer  Inc  N PFE  in November to a merger that was valued at more than  150 billion  But their bet that the two companies would become the world s biggest pharmaceutical company was wrong as the deal collapsed in early April and Allergan s stock dropped  The merger derailed due to U S  Treasury action to curb inversions or where companies move abroad to cut taxes  Some investors trimmed their Allergan stakes in the first quarter  Viking Global Investors cut it by 18 percent to own 4 8 million shares at the end of the quarter  
Senator Investment Group cut its position by more than half when it sold 875 000 shares and Third Point trimmed its holding by selling 400 000 shares to own 5 million  Jana Partners cut its stake by 718 000 shares to 447 000 shares and Omega Advisors cut its stake by about 221 000 shares to 561 000 shares   Hoplite Capital cut its stake by roughly half to own 299 825 shares ",2016-05-17,Reuters,https://www.investing.com/news/stock-market-news/investors-made-bets-on-allergan-just-weeks-before-deal-collapsed-402352,402352
105518,327033,AGN,Carl Icahn acquires  large position  in Allergan  backs CEO,news," Reuters    Billionaire investor Carl Icahn said on Tuesday he had acquired a  large position  in Botox maker Allergan Plc  N AGN  and that he was very supportive of Chief Executive Officer Brent Saunders  Shares of Allergan rose 1 3 percent to  238 79 in early trading  Icahn  who did not disclose details of the stake  said in a statement on his website that he was confident in Saunders  ability to enhance value for all Allergan shareholders   Saunders became CEO of Allergan after it was bought by  Actavis   where he had been CEO  and then changed its name  Saunders had moved into the top spot at Actavis from the CEO job at Forest Labs  which Actavis acquired  Icahn had a Forest Labs stake and was agitating for change when the company s long time management ceded control and Saunders took the CEO job in 2013  Icahn said he sold the Forest position when the company changed hands  Allergan is near to closing the sale of its generic business to Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA   Once that happens  Saunders has said the company will be able to make acquisitions of more than  1 billion  Allergan needs to pay off more debt before it will make even bigger deals  he has said  The move comes a few months after Allergan s plans to be bought by  Pfizer   N PFE  fell apart  In that so called  inversion  deal  Pfizer would have moved its headquarter to Dublin  where Allergan is based  in order to lower the taxes it pays in the United States  Icahn  who launched a  150 million political action committee advocating tax reform to eliminate such deals  had said the Pfizer Allergan tie up would result in the loss of the country s 10th largest company to Ireland  
The government effectively blocked that deal by issuing new tax rules that made it less favorable ",2016-05-31,Reuters,https://www.investing.com/news/stock-market-news/carl-icahn-acquires-'large-position'-in-allergan-405528,405528
105519,327034,AGN,U S  stocks down after data  oil moves higher on Cushing draw,news,"Investing com   With the exception of minimal gains in the technological index  Wall Street traded lower on Tuesday as economic reports showed conflicting data on the U S  consumer  markets ratcheted down expectations for a Federal Reserve  Fed  hike at the next meeting in June and West Texas continued to struggle with the  50 psychological level 
At 16 30GMT or 12 30ET  the Dow 30 lost 90 points  or 0 50   the S P 500 fell 5 points  or 0 23   while the tech heavy NASDAQ Composite inched up 3 points  or 0 07  
Investors returned from the Memorial Day holiday with caution on Tuesday  perhaps reticent to push stocks higher as they awaited the publication of the employment report due on Friday 
Economic reports released on Tuesday showed a mix picture with both April s personal spending and real personal consumption rising more than expected 
However  according to The Conference Board  consumer confidence fell for a second straight month in May  calling in to question that the positive start to the second quarter shown in the biggest gain in consumer spending in the last seven years may have already begun to falter 
Increases in housing prices for March managed to beat expectations as the firming labor market and low mortgage rates spurred new buyers 
Further  the core PCE index  a favorite gauge of the Fed to monitor inflation  edged up 0 2  from the previous month at an annualized rate of 1 6   settling in line with consensus forecasts 
After the string of data  Fed fund futures were pricing the odds of a June hike at 21   compared to the 28  registered at the prior close  The probability for July increase also inched down  but remained above the 50  threshold at 58  
In oil markets  crude got a boost from a report from industry research group Genscape showed that supplies at the Cushing  Oklahoma delivery point for U S  crude fell last week  but West Texas  hitting an intraday high of  50 09  seemed unable to hold above the  50 psychological level 
Gains were limited by low expectations for any meaningful agreement being made by the meeting of major oil producers later this week  The Organization of the Petroleum Exporting Countries will meet on Thursday in Vienna although no dramatic announcement on a production cut is expected 
In other bearish news for black gold  Iraq plans to ship 5 million extra barrels of crude in June  Saudi Arabia  Kuwait  Iran and the United Arab Emirates are also planning to increase supplies later this year 
U S  crude futures gained 1 16  to  49 90 by 16 32GMT  or 12 32ET  while Brent oil traded up 0 73  to  50 73 
In company news   Verizon Communications  Inc  NYSE VZ  was up 0 7  after the blue chip reached an agreement with unions to include 1 400 new jobs along with salary increases in order to end a nearly seven week strike 
 Sodastream International  Ltd  NASDAQ SODA  gained more than 4  after announcing its new Beer Bar which allows consumers to make home crafted beer using sparkling water and a beer concentrate 
Allergan Plc  NYSE AGN  gained almost 1  as multimillionaire activist Carl Ichan admitted to having taken a  large position  in the maker of Botox 
In light earnings news   Medtronic  PLC  NYSE MDT  fell more than 1  after the medical products makers gave a weak forward guidance  while in Europe  Volkswagen  DE VOWG p  lost 2 6  as the German car maker reported a 19 3  decline in profit for the first quarter  missing analyst forecasts for a 17  drop ",2016-05-31,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-down-after-data;-oil-moves-higher-on-cushing-draw-405578,405578
105520,327035,AGN,Independence of compliance reviews is questioned in drug firm settlements,news,"By Sarah N  Lynch
WASHINGTON  Reuters    Some major U S  drug companies have hired their own auditors to perform compliance reviews mandated in government settlements over alleged civil violations  such as paying kickbacks or off label drug promotion  according to federal records reviewed by Reuters 
Third party compliance reviews are playing an increasingly large role in helping the government ensure companies fulfill their obligations in federal settlements 
But unlike the Justice Department or the Securities and Exchange Commission  the Department of Health and Human Services inspector general does not prohibit companies from hiring firms with whom they have existing business ties 
Some lawmakers and legal experts say that practice creates conflicts of interest and could impair outside reviewers  independence 
 If the goal of this whole thing is to have an energetic and independent reviewer ferreting out mistakes and potential fraud within the company  do not put them under the financial thumb of the people who have millions of dollars at stake in keeping the audit work   said Kevin Outterson  a professor of health and corporate law at Boston University 
Several large drug makers   including Novartis  GlaxoSmithKline  Merck  NYSE MRK   Sanofi  PA SASY  and  Allergan Inc   NYSE AGN pa     have relied on their existing or previous auditors  PricewaterhouseCoopers  PwC  or Ernst   Young  EY   to also serve as compliance reviewers  according to corporate filings and a list of reviewers 
The health agency s inspector general provided the list of reviewers hired by drug companies in response to a Reuters Freedom of Information Act request 
The inspector general typically settles civil claims through the use of a  corporate integrity agreement  mandating various reforms 
These five year deals often require the hiring of an independent compliance consultant known as an  independent review organization   which is tasked with reviewing internal policies and data  such as payments to doctors 
In exchange  the inspector general s office agrees not to exclude a company from participating in Medicaid and Medicare 
Susan Gillin  an attorney in the inspector general s office  said she agreed that  theoretically  a potential conflict of interest exists  
But she said her agency has not observed any problems with weak oversight by auditors serving in dual roles  Such arrangements are allowed  she said  as long as the firm is not involved in corporate management or advising on policies it will also review 
 We have very few repeat parties to corporate integrity agreements   she said 
While some companies have had multiple settlements over the years  they typically cover different alleged violations  or conduct committed by companies that  between settlements  became part of a different firm through an acquisition  Gillin said 
Spokespeople for Novartis  Merck  GlaxoSmithKline and Sanofi all said they disclosed their business relationships to the inspector general  which reviewed them  A spokesman for Allergan Plc  said the arrangement predated the company s acquisition by  Actavis   NYSE AGN  in March 2015 
Executives at PwC and Ernst   Young told Reuters they believe their dual work auditing and conducting compliance reviews are not in conflict and that they comply with all applicable regulations 
The compliance reviewers  are independent in fact and in appearance   said EY Vice Chair Ron Hauben 
Nancy Beacham  a partner at PwC  said the firm adheres to federal standards for all public company auditing engagements 
 We abide by the rules of what we can and cannot do   she said 
BIG CONTRACTS AT STAKE
Some legal experts who see a conflict in the dual role say it can be exacerbated by the fact that accounting firms are generally paid more for their audit work than for these sorts of compliance reviews 
For example  prior to Allergan Inc s acquisition by Actavis in March 2015  the company disclosed that in fiscal year 2012  it paid Ernst   Young more than  5 million in audit fees  compared with more than  440 000 it paid the firm for compliance work performed under the corporate integrity agreement 
 Work with a major company is an important contract  and an established contractor isn t going to be independent   said Brandon Garrett  a professor at the University of Virginia School of Law 
Senate Judiciary Chairman Charles Grassley  an Iowa Republican  said such arrangements could weaken enforcement 
 If the firms enforcing the agreements aren t independent   he told Reuters in a statement  that  defeats the purpose of the agreements  
While some companies hire their auditors as reviewers  the majority of the more than two dozen public companies reviewed by Reuters that have or had corporate integrity agreements   such as  Pfizer   NYSE PFE   CVS Caremark and Eli Lilly   do not hire their own auditors and instead opt for consulting or law firms 
HISTORY OF VIOLATIONS
Pricewaterhouse s current dual clients for audits and compliance reviews include Novartis and Merck  according to the list provided by the health agency s inspector general 
GlaxoSmithKline previously engaged its auditor  PwC  for a compliance review which ended in 2012 
EY currently performs dual work for Sanofi and it previously did dual work for Allergan Inc  prior to its acquisition 
GlaxoSmithKine  Novartis and Merck have all been involved in multiple settlements with the U S  government since 1991 to resolve a range of criminal and civil claims  according to a recent report by the nonprofit watchdog Public Citizen 
GlaxoSmithKline has paid nearly  8 billion in federal fines between 1991 and 2015   the most of any drugmaker  according to the Public Citizen report 
A GlaxoSmithKline spokeswoman said the company has greatly improved its compliance by taking steps such as eliminating payments to doctors who speak on the company s behalf and ending sales incentives based on prescription volumes 
Novartis  in 2010  settled civil charges of paying kickbacks to doctors who spoke at corporate events  and signed a corporate integrity agreement 
The company now faces another civil lawsuit filed by federal and state prosecutors  which alleges that kickbacks to doctors continued for nearly a year after it signed its 2010 corporate integrity agreement with the health agency s inspector general 
Novartis has sought to dismiss the case  saying it makes  sweeping  allegations of a  decade long  nationwide fraudulent scheme based on just fifteen doctors  ",2016-06-02,Reuters,https://www.investing.com/news/stock-market-news/independence-of-compliance-reviews-is-questioned-in-drug-firm-settlements-406067,406067
105545,327060,AGN,Orexigen  OREX  Q3 Loss Narrower Than Expected  Stock Up,opinion,"Orexigen Therapeutics  Inc   NASDAQ OREX   reported net loss of  1 35 per share for the third quarter of 2017  which was narrower than the Zacks Consensus Estimate of a loss of  2 13  The company had reported earnings of  1 12 in the year ago period mainly due to a non cash settlement gain of  80 2 million  which was recorded as deferred revenues previously Quarterly revenues of approximately  18 9 million were significantly higher than  7 million in the year ago quarter  The top line improvement was primarily attributed to higher Contrave sales  Orexigen s shares were up 8  in after market trading on Nov 13  presumably on impressive Contrave sales  Year to date  the stock is up 1 1   underperforming the  s gain of 1 5  Quarterly DetailsIn the third quarter  U S  net sales of Contrave  Orexigen s weight management drug  were  17 8 million  Product sales to global partners and milestone income amounted to  1 1 million IMS Health s prescription data recorded 208 397 total prescriptions for Contrave filled this quarter  an increase of 26  from the year ago period R D expenses increased 9 9  from the year ago period to  5 8 million  General and administrative expenses were  30 4 million  down 13 5  from the year ago period due to lower costs associated with commercializing Contrave in the United States Subsequent to the quarter  in November  the company signed an agreement with Merck  NYSE MRK  KGaA  for the commercialization of Contrave in Latin America including Brazil and Mexico  Merck KGaA will also be responsible for regulatory activities and will own marketing authorization in the region Meanwhile  the United States District Court for the District of Delaware s favorable ruling in a paragraph IV litigation related to Contrave s patents was a major relief for Orexigen  Actavis  NYSE AGN  Laboratories  a subsidiary of Teva Pharmaceutical Industries Limited   NYSE TEVA    had filed an abbreviated new drug application seeking approval for the generic version of Contrave prior to the expiration of its U S  patents  The ruling confirmed the exclusivity of Contrave through 2030 2017 OutlookThe company tightened its net sales expectation in the United States to the range of  70 million to  80 million  previously  75 million to  85 million  as shipments from wholesalers have been consistently lower than prescription volumes  The company expects ex U S  sales to be in the range of  10 million to  15 million  The company expects its operating expense to be in the range of  185 million to  200 million  Cash balance at the end of the year is expected to be in the range of  40 million to  50 million Our TakeOrexigen achieved impressive sales growth for Contrave in the first nine months of 2017  With the U S  District court ruling maintaining Contrave s exclusivity through 2030 and Orexigen focused on entering into agreements for commercialization of Contrave in several geographies  we expect the drug to continue its performance going forward Orexigen has also adopted a targeted approach for ramping up Contrave sales after reacquisition of the U S  rights last year  The company has benefited from this commercial strategy  We expect this strategy to continue to have a fruitful impact in the coming quarters Orexigen Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderOrexigen carries a Zacks Rank  3  Hold  Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   is a better ranked health care stock  sporting a Zacks Rank  1  Strong Buy   You can see  Sucampo s earnings per share estimates have increased from  1 01 to  1 11 for 2017 and from  1 06 to  1 21 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15 63  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/orexigen-orex-q3-loss-narrower-than-expected-stock-up-200264914,200264914
105546,327061,AGN,Top 4 Inexpensive Healthcare Mutual Funds For 2018,opinion,The overall demand for new innovative medical products and services has continued to rise due to an ageing population   This increase in demand for new drugs  therapies  and medical instruments is expected to be a long term growth driver for the Healthcare sector   Innovations by medical devices companies  drug makers  and improvements in new technology have been the driving force behind the Healthcare sector over the past several quarters  The sector s participants typically have a solid balance sheet  improving revenues  and tend to return cash to shareholders via dividends   The debate about the future of the Affordable Care Act still exists  and is currently acting as a headwind  but the overall view of the sector is that it is undervalued   Further  both the biotech and pharmaceutical industries ability to innovate with new drugs and therapies has enabled them to generate sustainable cash flows which makes them attractive investments   Finding the Righ Funds  To capitalize on the growing healthcare sector  we utilized the  to identify the best funds with specific characteristics   First  the fund had to have a Zacks Rank  1  Strong Buy  or  2  Buy  rating   Second  they had to have an  beow 1 2  with no  Third the fund had to have significant exposure to stocks in the healthcare sector   Lastly  they had to have a history of success with a 1 year total return above  15  The PicksDelaware Healthcare I     a Zacks Rank  1  Strong Buy  seeks maximum long term capital growth through capital appreciation  Normally  the Fund will invest at least 80  of its assets in the equity securities of healthcare companies  meaning companies that develop  produce or distribute products or services Cost Specifics  There is no minimal investment  it has a 0 85  management fee with a total expense ratio of 1 13    Performance and Management  YTD return  30 5   1 year return  24 5   3 year return  12 7   and 5 year return  20 6    The fund is managed by Liu Er Chen  who is both a CFA  and M D  and holds the title of SVP   Mr  Chen also has a M B A  in management from Columbia Business School Top Holdings  As of the most recent filings  the top five positions were held in MorphoSys AG  Chugan Pharma  Amgen  NASDAQ AMGN   Eli Lilly and Sanofi  PA SASY  SA   Fidelity Select Healthcare     a Zacks Rank  2  Buy  seeks capital appreciation  The fund normally invests its 80  of assets in common stocks of companies principally engaged in the design  manufacture  or sale of products or services used for or in connection with health care or medicine  Dividends and capital gains are declared in April and December every year Cost Specifics  There is a  2 500 minimal investment  it has a 0 55  management fee with a total expense ratio of 0 73    Performance and Management  YTD return  25 8   1 year return  15 3   3 year return  9 0   and 5 year return  19 7    The fund is co managed by Justin Segalini  and Eddie Yoon   Top Holdings  As of the most recent filings  the top five positions were held in Amgen  UnitedHealth Group  NYSE UNH   Allergan  NYSE AGN   Boston Scientific  NYSE BSX   and Becton Dickinson and Co   Hartford Healthcare Fund HLS IA     a Zacks Rank  2  Buy  is a stock fund that invests in health care  a sector that is experiencing innovations and breakthroughs across multiple subsectors  The fund s objective seeks long term growth of capital   Cost Specifics  There is no minimal investment  it has a 0 84  management fee with a total expense ratio of 0 89    Performance and Management  YTD return  24 1   1 year return  18 1   3 year return  12 9   and 5 year return  19 7    The fund is managed by Jean Hynes  CFA Senior Managing Director  who holds a BA in economics from Wellesley College   Top Holdings  As of the most recent filings  the top five positions were held in UnitedHealth Group  Medtronic  NYSE MDT   Bristol Myers Squibb  Celgene Corp  NASDAQ CELG   and Allergan   Prudential  LON PRU  Jennison Health Sciences Fund     a Zacks Rank  2  Buy   seeks long term capital appreciation  The Fund invests primarily in equity related securities of U S  firms engaged in the following industries  hospitals  nursing and residential care  health and medical insurance carriers  pharmaceutical and medicine companies  and medical equipment firms Cost Specifics  There is no minimal investment  it has a 0 72  management fee with a total expense ratio of 0 86    Performance and Management  YTD return  28 8   1 year return  21 6   3 year return  10 6   and 5 year return  18 6    The fund is co managed by David Chan and Debra Netschert   David holds a CFA  and is the managing director   He also holds a M B A  from Columbia University   Debra is a managing director who holds a MS from Boston University   Top Holdings  As of the most recent filings  the top five positions were held in UnitedHealth Group  Medtronic  Bristol Myers Squibb  Celgene Corp  and Allergan ,2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/top-4-inexpensive-healthcare-mutual-funds-for-2018-200265142,200265142
105547,327062,AGN,Allergan s Vraylar Gets FDA Nod For Maintenance Therapy,opinion,"Allergan plc   NYSE AGN   announced that the FDA has approved its supplemental New Drug Application  sNDA  for label expansion of its schizophrenia capsule  Vraylar  cariprazine   for maintenance treatment 
Notably  Vraylar is already approved in the United States for acute treatment of schizophrenia and bipolar disorder  It is also approved in Europe for the given indication 
Shares of Allergan have declined 16 9  this year so far  comparing favorably with the  s decrease of 31 5  

The FDA approval was based on new data from a 72 week study in the prevention of relapse in adult patients with schizophrenia  Data from the study demonstrated that long term treatment with Vraylar delayed time to relapse compared with placebo over the course of up to 72 Weeks 
Significantly  Vraylar has performed above expectations in 2016  recording sales of  94 3 million in the year  The drug is likely to be a key driver of Allergan s top line growth in 2017 
Per the company s press release  approximately 2 4 million people are affected by schizophrenia in the United States  Also  the disease relapses in 60 70  patients within a year if no maintenance treatment is taken  Hence  Vraylar s label expansion as a maintenance therapy will cater to the hugely unmet need of patients  requiring a long term treatment option for the disease 
Other players in the bipolar disorder and schizophrenia treatment market are AstraZeneca plc s   NYSE AZN   Seroquel XR  Johnson   Johnson s   NYSE JNJ   Risperdal Consta and Alkermes plc s   NASDAQ ALKS   Aristada Allergan PLC  Price

   Zacks Rank
Allergan carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/allergans-vraylar-gets-fda-nod-for-maintenance-therapy-200265131,200265131
105548,327063,AGN,Biotech Stock Roundup  Dynavax Vaccine Gets FDA Nod  Loxo Inks Deal With Bayer,opinion,"With just a handful of biotech companies left to report third quarter results  focus is back on regulatory and pipeline updates  Among major news this week  Dynavax Technologies   NASDAQ DVAX   finally gained FDA approval for its hepatitis B vaccine while Loxo Oncology   NASDAQ LOXO   was in the news for its collaboration agreement with Bayer  DE BAYGN  Recap of the Week s Most Important StoriesLoxo down despite Bayer Deal worth Up To  1 55 Billion  Loxo  which is focused on the development of highly selective medicines for patients with genetically defined cancers  saw its shares lose ground despite the announcement of a collaboration agreement with Bayer that could be worth up to  1 55 billion  The companies are collaborating for the global development and commercialization of Loxo s highly selective TRK inhibitors  larotrectinib and LOXO 195  for patients with TRK fusion cancers The agreement terms include a  400 million upfront payment  Loxo could receive another  450 million on the achievement of certain regulatory and commercial milestones and an additional  200 million for milestones related to LOXO 195  Development costs will be split equally by the companies  The companies will co promote in the United States while Loxo will receive tiered  double digit royalties on net sales  and sales milestones totaling  475 million for ex U S  territories  Larotrectinib is scheduled to be filed for FDA approval in late 2017 early 2018 Loxo s shares were down 4 1  on the news with the investment community expressing disappointment about the sharing of profits in the United States as well as the absence of an outright acquisition deal FDA Nod for Dynavax Hepatitis B Vaccine  It turned out to be third time lucky for Dynavax with the company finally gaining FDA approval for its hepatitis B vaccine  Heplisav B  The regulatory action makes Heplisav B the first new hepatitis B vaccine in the United States in more than 25 years and the only two dose hepatitis B vaccine for adults Hepatitis B  a highly infectious and potentially deadly virus  affects a wide range of adults in the United States with infections on the rise given the absence of any cures  However  hepatitis B can be prevented through vaccination Heplisav B is the first FDA approved product for Dynavax and the company expects to launch the vaccine in the first quarter of 2018 Achillion Slips on Secondary Offering News  Achillion Pharmaceuticals  Inc    NASDAQ ACHN   was down 4 2  on news that one of its shareholders  Johnson   Johnson  NYSE JNJ  Innovation JJDC  Inc    JJDC    is selling the whole of its equity positon in Achillion  approximately 18 4 million shares   Achillion will not receive any part of the proceeds from the offering We remind investors that Achillion had an agreement with Johnson   Johnson s Janssen Pharmaceuticals for hepatitis C virus   HCV   treatments  At the time of announcing the HCV agreement in May 2015  J J and Achillion had also announced an equity transaction under which JJDC would invest  225 million in Achillion and get approximately 18 4 million newly issued and unregistered shares  Achillion s shares were down significantly when the company had announced the termination of the HCV agreement in September 2017  Read more    Year to date  Achillion s shares are down 10 7  compared to the  1 5  rally Zymeworks Inks Deal with J J Company  Zymeworks Inc    NYSE ZYME    a clinical stage biopharmaceutical company  announced a licensing agreement with Janssen Biotech  a J J company  for the development and commercialization of next generation bispecific antibody therapeutics Under the deal  Janssen will get a worldwide  royalty bearing license to research  develop  and commercialize up to six bispecific antibodies using Zymeworks  Azymetric and EFECT platforms  Zymeworks is entitled to an upfront payment of  50 million plus up to  282 million in development milestones and up to  1 12 billion in commercial milestone payments  as well as tiered royalties on potential sales Janssen also has the option to add two more bispecific programs to the deal which would mean additional money for Zymeworks The deal is a boost for Zymeworks which already has partnership agreements with several other large companies like Merck  NYSE MRK   Lilly  Celgene  NASDAQ CELG   Glaxo and Daiichi Sankyo  Including the J J deal  Zymeworks has the potential to earn milestones worth a total of  5 5 billion from all these agreements Zymeworks is a Zacks Rank  2  Buy  stock  You can see  CHMP Positive on Amgen Drugs  Amgen   NASDAQ AMGN   and partner Allergan  NYSE AGN  got a positive opinion from the European Union Committee for Medicinal Products for Human Use   CHMP   for ABP 215  their biosimilar version of Roche s blockbuster cancer drug  Avastin  bevacizumab   ABP 215 is already approved in the United States under the trade name  Mvasi Amgen also got a positive opinion from the CHMP for its efforts to expand the use of Nplate in pediatric patients with chronic immune thrombocytopenic purpura  Read more    
CHMP Positive on Vertex s Orkambi Label Expansion  Vertex   NASDAQ VRTX   also got a positive opinion from the CHMP for the label expansion of its cystic fibrosis   CF   drug  Orkambi for use in children with CF in the 6 11 years age group with two copies of the F508del mutation  Approval for this age group would expand the targeted patient population by about 3 400 patients  A decision should be out within three months  Orkambi  which is already approved for this age group in the United States  is expected to bring in revenues of  1 29 billion    1 32 billion in 2017  Meanwhile  the company expects to seek regulatory approval for the use of Orkambi in children with CF in the two to five years age group who have two copies of the F508del mutation in the first quarter of 2018  Read more    Performance
Medical   Biomedical and Genetics Industry 5YR   ReturnThe NASDAQ Biotechnology Index declined 2 5  over the last four trading sessions  Among major biotech stocks  Regeneron lost 7 3  while Alexion was down 4 7   Over the last six months  Vertex was up 27 2  while Celgene was down 16 9   See the last biotech stock roundup here    
What s Next in the Biotech World Clinical stage company  Ultragenyx Pharmaceutical Inc    NASDAQ RARE    could well gain FDA approval for its first product this week with the FDA expected to give a response on November 16 about the approval status of vestronidase alpha or rhGUS for mucopolysaccharidosis 7  MPS 7  also known as Sly syndrome   About 200 patients across the world are afflicted by this disease  which is one of the rarest forms of MPS  Currently  there are no approved treatments for MPS 7 The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-dynavax-vaccine-gets-fda-nod-loxo-inks-deal-with-bayer-200265416,200265416
105549,327064,AGN,Redhill Biopharma  Successful Phase II With Bekinda For IBS D  ,opinion,"In October 2017  Redhill Biopharma Ltd  NASDAQ RDHL  announced that one of its core assets  BEKINDA  significantly alleviated symptoms of patients with diarrhoea predominant irritable bowel syndrome  IBS D  in a Phase II trial  Although not comparable directly  the data look good in relation to two other recent drugs  Viberzi and Xifaxan  which had combined sales of  382m in 2016 after the launch in 2015 for this indication  We have increased our success probability for BEKINDA in IBS D and now value RedHill at  449m or  21 1 ADS 

BEKINDA  Primary endpoint met in Phase II trial
BEKINDA  formerly RHB 102  is a once daily  oral formulation of ondansetron  The Phase II trial was a randomised  two arm study that enrolled 126 patients split 60 40 to receive either BEKINDA 12mg or a placebo for eight weeks  The primary endpoint was stool consistency compared to the baseline  as per the FDA guidance definition  54 7  of patients in the active arm responded to treatment compared to 35 3  in the placebo group  This is a significant difference of 19 4  and compares well with other recent drugs approved for IBS D   Viberzi  eluxadoline  Allergan  NYSE AGN   and Xifaxan  rifaximin  Valeant   for which the respective percentage rates were 13 5  and 10 5   noting the limitations of making comparisons across different trials   Both Viberzi and Xifaxan were approved for IBS D in 2015 and in 2016 had solid sales of  93m and  289m  respectively  in IBS D  EvaluatePharma  
To read the entire report Please click on the pdf File Below ",2017-11-27,Edison,https://www.investing.com/analysis/successful-phase-ii-with-bekinda-for-ibsd-200268314,200268314
105550,327065,AGN,Teva s New CEO Re Shuffles Senior Management  Stock Up 7 ,opinion,Teva Pharmaceutical Industries Limited s   NYSE TEVA   new chief executive officer  Kare Schultz announced a new organizational and leadership structure to save costs and increase productivity  The organizational changes that include the departure of heads of three divisions will be effective immediately Shares of Teva rose 7 6  on Monday  However  shares have slumped 59 6  so far this year compared with the  s decline of 30 3  The Israeli drugmaker will no longer have two separate global groups for its two businesses   generics and specialty medicines  Instead  Teva will now operate through three regions  North America  Europe and Growth Markets   which will include generics  specialty  and over the counter  OTC  medicines The Generic R D and Specialty R D organizations will be combined into one consolidated Global R D unit   It will be headed by Dr  Hafrun Fridriksdottir  who was until now serving as President of Global Generics R D  A Marketing   Portfolio function has been formed that will take care of the interface between regions  R D and operations However  Schultz  who joined Teva on Nov 1  made no mention of the workforce reductions  rumors of which have been doing the rounds lately  Last week  an Israeli newspaper published a report  which stated that Teva will cut its U S  workforce by  tens of percents  and its Israeli workforce by 20 25    However  the company did say that it is working on a detailed restructuring plan  details of which will be shared next month The Israeli newspaper report also said its current head of R D and chief scientific officer  Michael Hayden will be removed  In the latest press release  Teva confirmed the rumor stating that Hayden will retire at the end of this year along with Dr  Rob Koremans and Dipankar Bhattacharjee  head of its Specialty Medicines and Generic Medicine groups  respectively  Teva also announced some top leadership changes including Michael McClellan as executive vice president and chief financial officer  effective immediately Teva is facing significant challenges in the form of generic competition for its largest branded drug   Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from new generic launches and a massive debt load The U S  generics industry is facing significant competitive and pricing pressure  which affects the company s top line performance  An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry  The challenges in the U S  generics market are expected to continue through the rest of this year and probably in the next Teva s blockbuster multiple sclerosis drug  Copaxone s sales have been declining for quite some time now  Last month  in a major blow to Teva  Mylan   NASDAQ MYL   launched  at risk  its generic version of the 40 mg formulation  much earlier than expected  Meanwhile  Glatopa  a generic version of Copaxone 20 mg  is marketed by Momenta and Sandoz  Novartis    NYSE NVS   generic arm  since 2015 while Mylan launched its version of the 20 mg formulation last month  With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  Copaxone sales are expected to erode rapidly Additionally  the company s debt burden accrued as a result of the  40 5 billion acquisition of Allergan s   NYSE AGN   generic unit  Allergan Generics in 2016  With nearly  35 billion in debt  the company s borrowing costs have increased significantly  which is hurting profits In order to combat these challenges  Teva has divested some non core assets to cut its significant debt load  It remains to see if the latest corporate shake up  rumored layoffs and divestures are enough to revive the company s fortunes during this challenging period  especially as it faces erosion of its largest product  Copaxone Teva carries a Zacks Rank  5  Strong Sell  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-11-27,Zacks Investment Research,https://www.investing.com/analysis/tevas-new-ceo-reshuffles-senior-management-stock-up-7-200268773,200268773
105551,327066,AGN,Ironwood Succeeds In Diabetic Hypertension Phase II Study,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   announced encouraging top line data from a phase IIa study  evaluating its lead soluble guanylate cyclase  sGC  stimulator candidate  IW 1973  in patients with type II diabetes with hypertension The candidate reduced blood pressure and improved metabolic parameters like fasting plasma glucose and cholesterol in diabetic hypertensionpatients compared to baseline Shares of the company were up 0 9  in pre market trading following the news  However  it was down 6 2  at the close of trade on Monday following broader market pressures  In fact  Ironwood s shares have fallen 10 2  in the past six months  underperforming the  s gain of 0 4  in that period The sGC candidate was evaluated in two separate phase IIa studies in diabetic patients with hypertension  One study evaluated two dosing regimens   once daily 40 mg for 14 days and 20 mg daily two times for first seven days  followed by once daily 40 mg for the next seven days  The other one was a dose escalating study Data from the studies showed that IW 1973 reduced blood pressure by 6 3 mmHg from baseline against 1 6 mmHg for placebo  Moreover  the candidate reduced fasting glucose and cholesterol levels by 32 5 mg dL and 24 7 mg dL  respectively  from baseline The patient population treated with IW 1973 kept their existing treatment regimen intact  The treatment regimens included separate medications for hypertension and diabetes  The encouraging results achieved by the candidate may pave the way for a potential single medication for treating both the diseases  The candidate will also be able to treat other metabolic abnormalities like high cholesterol and serum lipid levels Apart from these two studies  Ironwood is also developing the candidate in phase II studies for treating diabetic nephropathy and heart failure with preserved ejection fraction Along with pipeline progress  Ironwood s key marketed product  Linzess  is also growing on the back of broad payer access and continued demand  However  Ironwood shares its brand collaboration profits or losses equally with Allergan plc   NYSE AGN     Meanwhile  a potential approval to Synergy Pharmaceuticals Inc  s   NASDAQ SGYP   supplemental new drug application in January next year seeking approval for label expansion of Trulance in irritable bowel syndrome with constipation will increase competition Ironwood Pharmaceuticals  Inc  Price
    Zacks Rank   Stock to ConsiderIronwood carries a Zacks Rank  3  Hold  Corcept Therapeutics Incorporated   NASDAQ CORT   is a better ranked health care stock  carrying a Zacks Rank  2  Buy   You can see  Corcept s earnings per share estimates have increased from 45 cents to 47 cents for 2017 and from 77 cents to 88 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 14 32   The company s stock is up 129 8  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/ironwood-succeeds-in-diabetic-hypertension-phase-ii-study-200270613,200270613
105552,327067,AGN,AstraZeneca s COPD Drug Succeeds In Label Expansion Study,opinion,AstraZeneca   NYSE AZN   announced positive top line data from a phase IV study evaluating its marketed drug  Tudorza Pressair  aclidinium bromide 400 mg  twice daily   for an expanded indication The phase IV ASCENT was conducted to expand the label Tudorza to include patients with chronic obstructive pulmonary disease   COPD   with cardiovascular risk factors  The post marketing requirement  PMR  study was requested by the FDA and was conducted on a total of 3630 patients  The study met its both primary efficacy and safety endpoints  Data from the study demonstrated that treatment with Tudorza led to a statistically significant reduction in the annual rate of moderate or severe COPD exacerbations compared with placebo Notably  Tudorza is a long acting muscarinic antagonist  LAMA  which is also marketed under the brand name Eklira and Bretaris for treatment of COPD in more than 50 countries globally including the United States AstraZeneca s shares have outperformed the industry year to date  The stock has rallied 17 7  compared with the  s gain of 15 5  in the same time frame A full evaluation of the ASCENT data is underway and further results will be presented at a forthcoming medical meeting  Based on positive ASCENT data AstraZeneca expects to submit a supplemental new drug application  NDA  to the FDA to expand the label of Tudorza The potential label expansion of Tudorza will provide the company with access to a wider patient population base suffering from COPD We remind investors that in March 2015  AstraZeneca acquired the rights to Allergan s   NYSE AGN   branded respiratory business  which added Tudorza in its portfolio In April  the company entered into a strategic collaboration with Circassia Pharmaceuticals Plc for development and commercialization of Tudorza and another COPD drug Duaklir in the United States AstraZeneca s COPD products in the market include Symbicort  Pulmicort et al  Sales of its respiratory portfolio have declined 5  in the first nine months of the year due to pricing pressure and competition in the United States and the EU Importantly  the company s promising respiratory treatments in the pipeline include tralokinumab in phase III studies for severe asthma and PT010  also in phase III studies for treating COPD  AstraZeneca expects to launch four new respiratory medicines between 2017 and 2020 It remains to be seen if these candidates can improve the company s respiratory sales upon approval Per the company s press release  COPD is a progressive serious lung disease  commonly found to affect approximately 329 million people worldwide  Moreover  cardiovascular risks are seen to have the biggest effect on patients with COPD  representing a significant need for such therapies Astrazeneca  LON AZN  PLC Price   Zacks Rank   Key PicksAstraZeneca carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Corcept Therapeutics Incorporated   NASDAQ CORT   and Achillion Pharmaceuticals  Inc    NASDAQ ACHN    both carrying a Zacks Rank  2  Buy   You can see  Corcept s earnings per share estimates have moved up from 77 cents to 88 cents for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 14 32   Share price of the company has skyrocketed 129 8  year to date Achillion s loss per share estimates has narrowed from 66 cents to 63 cents for 2017 and from 75 cents to 67 cents for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the trailing four quarters with an average beat of 4 51  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-copd-drug-succeeds-in-label-expansion-study-200270593,200270593
105553,327068,AGN,Here s Why Sarepta Stock Is Up More Than 70  In 6 Months,opinion,"Shares of Sarepta Therapeutics  Inc    NASDAQ SRPT   have been rising for the past six months  The biotech company s stock has rallied 72 4   significantly outperforming the 0 6  rise of the  in this period 
The company has only one marketed product in its portfolio  Exondys 51  which received accelerated approval last year in September  The drug is approved for treating patients with Duchenne muscular dystrophy   DMD    a rare genetic disorder affecting children  who have confirmed mutation of the DMD gene susceptible to exon 51 skipping The company has progressed well with the commercialization of Exondys 51 and development of pipeline candidates in the past six monthsExondys 51 Picks Up WellCombined sales of the drug in these two quarters were  81 million  with sales increasing 31 4  sequentially in the third quarter  Sarepta has increased its revenue guidance for the fiscal in its second and third quarter results due to impressive adoption of Exondys 51 among patients  The company expects to end the year with total sales in the range of  150 million to  155 million  indicating sequential growth of 15  25  in the fourth quarter In July  Sarepta had launched a Managed Access Program in Europe and Americas to increase the reach of the drug In July 2017  Sarepta settled an ongoing global patent litigation with BioMarin Pharmaceutical Inc    NASDAQ BMRN   regarding the exclusive license on a patent pertaining to exon skipping technology used in DMD therapies  The settlement removes a major overhang for Sarepta as BioMarin has granted global exclusive rights to its DMD patent estate for Exondys 51 and all future exon skipping products to Sarepta Pipeline ProgressSarepta is looking to build its DMD pipeline beyond Exondys 51 by developing other exon skipping treatments Sarepta s lead candidate  golodirsen  has demonstrated 100  response rate with 10 7 times increase in mean dystrophin protein from baseline in DMD patients in a phase I II study  The data were reported in September 2017 We remind investors that Exondys 51 had achieved nearly three times increase in mean dystrophin protein from baseline  The better efficacy shown by golodirsen in dystrophin production has increased investors skepticism about its potential to become a new and better treatment option for DMD patients Sarepta has also entered into a gene therapy research collaboration with French Muscular Dystrophy Association  Genethon to gain access to the latter s micro dystrophin gene therapy that is capable of targeting majority of DMD patients Meanwhile  in June  the company appointed Douglas Ingram as its new president and CEO  Ingram has extensive experience in leading a biotech company as he had worked in various capacities at Allergan plc   NYSE AGN    It remains to be seen how Ingram uses his expertise to help Sarepta achieve its potential Sarepta Therapeutics  Inc  Price
    Zacks Rank   Key PickSarepta carries a Zacks Rank  2  Buy  Corcept Therapeutics Incorporated   NASDAQ CORT   is another health care stock  carrying the same rank as Sarepta  You can see  Corcept s earnings per share estimates have increased from 45 cents to 47 cents for 2017 and from 77 cents to 88 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 14 32   The company s stock is up 129 8  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/heres-why-sarepta-stock-is-up-more-than-70-in-6-months-200270576,200270576
105554,327069,AGN,Tax rules that killed Allergan Pfizer deal may be hard to challenge,news,By David Ingram  Reuters    U S  tax rules are more difficult to sue over than other regulations that emanate from Washington  presenting a challenge to anyone considering a lawsuit over an Obama administration plan to discourage deals known as inversions  tax lawyers say  Business trade groups have frequently gone to court since President Barack Obama took office in 2009 to try to block rules about the environment  health or labor unions  but taxes are different because of a law that generally bars suits until a tax is assessed  the lawyers said in interviews this week  The U S  Treasury Department unveiled a package of measures on Monday designed to counter a wave of tax evading acquisitions in which U S  corporations move offshore  largely for tax benefits  The measures have already felled the  160 billion merger of U S  drugmaker  Pfizer  Inc  N PFE  and Ireland based Allegan Plc  N AGN    nL3N17936X   It was not clear whether either company or anyone else would sue the Treasury Department  The companies did not immediately respond to requests for comment about a potential lawsuit   The head of the largest U S  business lobbying group  U S  Chamber of Commerce President Tom Donohue  floated the possibility on Wednesday when he told CNBC that he had asked people   What is the scope of their authority  and is it something you d sue about   Donohue said  though  that a potential lawsuit would take a long time and corporations would need to deal with the regulations  for a while   A Chamber spokeswoman  Blair Holmes  said later in an email that it was too early to decide about a possible lawsuit  Another trade group chief  Organization for International Investment President Nancy McLernon  also would not rule out a legal challenge  Treasury Department staff had taken steps to ensure their plan had a strong basis in law and believed that their authority to act was clear  a spokeswoman said  One huge advantage for the government is procedural  An 1867 law called the Anti Injunction Act says that in general no legal challenge can be brought against a tax until it is assessed  In 2011 and 2012  the law threatened to derail lawsuits against Obama s healthcare overhaul  Under the act s bar  a company such as Pfizer would need to move forward with a merger  file a tax return  and then be assessed by the Internal Revenue Service before it could sue  lawyers said  and it is not clear whether shareholders could stomach the uncertainty for so long   For better or worse  there really aren t timely ways of challenging a tax regulation like this   said Edward Kleinbard  a professor who specializes in tax law at the University of Southern California  Patrick Smith  a tax lawyer in Washington who is a partner at the law firm Ivins  Phillips   Barker  wrote in a tax journal last year that the courts could be open to a faster  more aggressive alternative  He said any business contemplating an inversion might be able to sue in federal district court under the Administrative Procedure Act  as someone would sue over other regulations  Such an approach is untested  however   It s novel thinking that s basically unchartered territory   Smith said  Beyond procedural hurdles  a plaintiff would face a steep climb trying to argue that the Treasury Department exceeded its legal authority  tax lawyers said  For one set of proposed regulations aimed at a practice known as earnings stripping  the Treasury Department is relying on a section of the tax code enacted in 1969  Congress intended the section to give the department broad authority  according to research by Steven Rosenthal  a senior fellow at the Urban Brookings Tax Policy Center  although a plaintiff could try to argue the opposite  Another question would be whether temporary regulations issued on Monday addressing serial acquisitions by a non U S  company would   in the case of Allergan  NYSE AGN pa    be unlawfully retroactive  Tax lawyers said  though  that the government could reasonably argue that the rules apply only to a deal that has not closed  such as the Allergan Pfizer merger   As with all regulations  federal agencies have some leeway to make reasonable interpretations of the law  lawyers said   In the past  the courts have tended to give significant deference to Treasury on how to interpret and apply their code   said Adam Rosenzweig  a law professor at Washington University in St  Louis ,2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/tax-rules-that-killed-allergan-pfizer-deal-may-be-hard-to-challenge-393848,393848
105555,327070,AGN,White House  Congress would have most impact on fighting tax avoidance,news,"ABOARD AIR FORCE ONE  Reuters    The White House said on Thursday that the best way for the government to fight tax avoidance would be for Congress to take action after the U S  Treasury Department issued major new rules on tax inversions on Monday   I know that if they are working on any future actions the most impactful thing we could do is if Congress took some action here   White House spokesman Eric Schultz told reporters when asked if the Treasury Department would issue more regulations on tax avoidance   U S  drug maker  Pfizer  Inc  N PFE  agreed on Tuesday to terminate its  160 billion agreement to acquire Allergan Plc  N AGN  in a victory for the Obama administration s push to stop tax dodging mergers  
 Story corrects quote to reflect spokesman saying Congress would have most impact on countering tax avoidance  not that Treasury is working on more action  ",2016-04-07,Reuters,https://www.investing.com/news/politics-news/white-house:-treasury-working-on-more-steps-to-counter-tax-avoidance-394134,394134
105556,327071,AGN,Exclusive  Pfizer approaches Medivation about potential takeover   sources ,news,"By Lauren Hirsch and Carl O Donnell  Reuters     Pfizer  Inc  N PFE  has approached U S  cancer drug maker  Medivation  Inc  O MDVN  to express interest in an acquisition  raising the possibility of a bid rivaling a  9 3 billion offer by Sanofi SA  PA SASY   people familiar with the matter said on Tuesday  Pfizer s approach comes less than a week after Sanofi went public with its  52 50 per share cash offer  complaining that Medivation refused to engage  Medivation subsequently rejected the offer as too low  Its shares closed on Tuesday at  57 52  Medivation has not yet decided whether it should engage with Pfizer in negotiations and is in discussions with its financial and legal advisers  the people said  There is no certainty that Pfizer will press ahead with a bid  they added  Sanofi currently has no plans to raise its offer and is waiting for Medivation to launch an auction to sell itself before it makes any new bid  some of the people said   The sources asked not to be identified because the matter is not public  Medivation  Sanofi and Pfizer declined to comment  Based in San Francisco  Medivation is best known for its oncology drug Xtandi  which treats prostate cancer   For Pfizer  a deal with Medivation would mark another attempt at building scale in patented drugs after it scrapped its  160 billion acquisition of Dublin based Allergan Plc  N AGN  last month   The breakdown came days after the U S  Treasury issued new rules that weighed on Pfizer s ability to slash its tax bill by using the deal to redomicile in Ireland  Earlier on Tuesday  Pfizer Chief Executive Ian Read said in an interview with Reuters that he would consider another merger of any size  as long as the deal makes sense  He did not comment on Medivation  Sanofi is vying for Medivation in an attempt to expand in the lucrative oncology sector  as it struggles to compensate for declining revenues from a key diabetes drug that recently lost patent protection   Sanofi s unsolicited approach for Medivation has echoes of its bid for rare disease drug maker Genzyme in 2011  It took Sanofi nine months to overcome Genzyme s resistance  It also offered Genzyme shareholders so called contingent value rights  which offered them additional payments if the acquired company was able to achieve certain performance milestones   
Using contingent value rights in the case of Medivation may be more challenging for Sanofi  given its lackluster track record in cancer drugs  However  Sanofi has no plans to use contingent value rights in any new offer  according to the sources ",2016-05-03,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-pfizer-approaches-medivation-about-potential-takeover---sources-399651,399651
105557,327072,AGN,Biotech stock swoon sparks buyout interest  investor,news,"By Lewis Krauskopf NEW YORK  Reuters    A brutal start to the year for biotech stocks could pave the way for more deal making in the sector  with premiums of potentially 50 percent to 100 percent above depressed share prices  according to a top healthcare investor  The Nasdaq Biotechnology index  NBI  fell 23 percent in the first three months of 2016  its worst quarterly performance since 2002  and remains down one third from its all time high last July  Drug pricing practices in the United States and setbacks for a few promising experimental drugs have taken a toll on shares  Andy Acker  a portfolio manager at Janus Capital Group who helps oversee  7 billion in healthcare assets  says the sell off led to a steep discount to the sector s value  especially at a time of major innovation in developing treatments for cancer  heart disease and other illnesses that affect millions  In the wake of the declines  large pharmaceutical and biotech companies appear ready to resume deal making   Buyers are starting to get interested   Acker said in an interview this week   Last week   AbbVie Inc   N ABBV  said it would spend  5 8 billion for privately held Stemcentrx  which is developing a lung cancer treatment  while France s Sanofi SA  PA SASY  went public with a  9 3 billion offer for cancer drug maker  Medivation  Inc  O MDVN   Janus was the 10th biggest investor in Medivation as of the end of the year  according to Thomson Reuters data  and Acker said multiple bidders could be interested in the company   Reuters  citing people familiar with the matter  reported late on Tuesday that  Pfizer  Inc  N PFE  had approached Medivation to express interest in an acquisition  The U S  government s derailment of Pfizer s  160 billion acquisition of Allergan Plc  N AGN  last month has raised expectations that both drugmakers will now seek smaller transactions  Allergan will be flush with cash if its  40 billion sale of its generics unit to Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  wins U S  antitrust approval  One potential target for Allergan  Acker said  is  Ironwood Pharmaceuticals  Inc  O IRWD   which is partnering with Allergan on an irritable bowel syndrome medicine  Another possibility is Anacor Pharmaceuticals Inc  O ANAC   which is developing a nonsteroidal topical ointment for eczema  Acker said   As of the end of the year  Janus was Ironwood s third biggest shareholder and Anacor s ninth biggest  Janus is also a major investor in Allergan  Acker co manages the Janus Global Life Sciences Fund  which has returned 19 35 percent a year on average over the past five years  beating 90 percent of peers  according to Morningstar   He said additional deals could take time because sellers may be reluctant to accept a buyout based on depressed prices  But takeovers eventually could be consummated at premiums of 50 percent to 100 percent above where target company shares bottomed recently  Biotech investors would welcome such deals  which could help boost valuations for rivals to a buyout target  Investor concerns about whether the winner of this year s U S  presidential election will take steps to curb drug costs are likely to weigh  Acker said   
 There will be some uncertainty through the election   Acker said ",2016-05-04,Reuters,https://www.investing.com/news/stock-market-news/biotech-stock-swoon-sparks-buyout-interest:-investor-399778,399778
105558,327073,AGN,Higher health stocks and falling oil leave S P 500 flat,news,"By Noel Randewich  Reuters    Wall Street ended mixed on Monday after a rally in Allergan  NYSE AGN pa  Plc and other healthcare companies offset a decline in energy shares  Five of 10 S P sectors ended higher  led by the health sector s  SPXHC  1 13 percent increase  while energy  SPNY  and materials sectors  SPLRCM  both tumbled 1 25 percent  Allergan  N AGN  surged 5 98 percent  Teva Pharmaceutical Industries Ltd  TA TEVA   N TEVA  said it still expected its  40 5 billion acquisition of Allergan s generic drug business to close in June   Chevron  Corp  N CVX  fell 1 48 percent as U S  crude prices dropped 2 8 percent and traders assessed the impact of wildfires on Canada s oil output and a build in inventory   A bigger than expected drop in China s imports and exports in April pointed to weak demand in the world s second biggest economy and weighed on materials stocks   Caterpillar   N CAT  dropped 3 52 percent  weighing the most on the Dow industrials  Investors remain cautious about corporate earnings  With first quarter reports almost all in  earnings at S P 500 companies  on average  fell 5 5 percent while revenue was down 1 9 percent  according to Thomson Reuters I B E S   I would give this earnings season a C or C   While most of the companies were able to step over a greatly reduced bar of expectations  overall sales growth remains disappointing   said Alan Gayle  senior investment strategist at RidgeWorth Investments in Atlanta  which has  50 billion in assets under management  The Dow Jones industrial average  DJI  ended down 0 2 percent at 17 705 91 points while the S P 500  SPX  edged up 0 08 percent to 2 058 69  The Nasdaq Composite  IXIC  added 0 3 percent to 4 750 21  helped by a 2 45 percent rally in the Nasdaq biotech index  NBI   After the bell  solar panel company SolarCity  O SCTY   co founded by technology billionaire Elon Musk  offered a first quarter report that disappointed investors  sending its stock down 13 percent  During the session   Krispy Kreme Doughnuts Inc   N KKD  jumped 24 32 percent to after agreeing to be taken private for  1 35 billion   That made investors hungry for other restaurant stocks  including  Kona Grill   O KONA   up 8 18 percent  and Pollo Loco  O LOCO   up 5 02 percent  Shares of Lending Club Corp  N LC  tumbled 34 93 percent  The chief executive officer of the world s biggest online lending platform resigned following an internal probe   Wayfair Inc   N W  jumped 10 17 percent after the online furniture retailer reported first quarter sales that beat analysts  estimates  Declining issues outnumbered advancing ones on the New York Stock Exchange by 1 594 to 1 407  On the Nasdaq  1 486 issues rose and 1 322 fell  The S P 500 index showed 33 new 52 week highs and four new lows  while the Nasdaq recorded 47 new highs and 53 new lows  
About 6 8 billion shares changed hands on U S  exchanges  below the 7 2 billion daily average for the past 20 trading days  according to Thomson Reuters data ",2016-05-09,Reuters,https://www.investing.com/news/stock-market-news/wall-street-opens-flat-as-oil-prices-surrender-gains-400812,400812
105578,327093,AGN,Teva  TEVA  Q3 Earnings Miss  Cuts 2017 View  Stock Falls,opinion,"Israel based Teva Pharmaceutical Industries Ltd    NYSE TEVA   is a global pharmaceutical company with a strong presence in the generics as well as branded markets  The company s branded products include Copaxone  multiple sclerosis   Azilect  Parkinson s disease  and respiratory products like ProAir and Qvar   Moreover  the company has several candidates in its pipeline which are in different stages of development In early Aug 2016  Teva acquired Allergan s generics business   Actavis  NYSE AGN  Generics and in Oct 2016 it acquired the latter s Anda Inc   the 4th largest distributor of generic pharmaceuticals in the U S Teva s earnings have surpassed expectations in only one of the last four quarters  met the same in one and missed expectations in the remaining two  resulting in an average negative surprise of 1 66   Estimate movement has been mostly downward over the past 30 days Currently  TEVA has a Zacks Rank  5  Sell   but that could definitely change following the company s earnings report which was just released  You can see  We have highlighted some of the key stats from this just revealed announcement below Earnings Miss  Teva s third quarter earnings came in at  1 00 per share  which missed Zacks consensus estimate of  1 05 per share Revenues In Line  Teva posted revenues of  5 61 billion  in line with the consensus estimates  Sales increased 1  year over year Sales in the quarter were hurt by increased pricing erosion and volume declines in the U S  Generics unit  ongoing political turmoil in Venezuela and loss of exclusivity in the Specialty segment in the quarter Key Statistics  Generic segment sales were  3 billion  down 8  year over year while Specialty segment sales were  2 03 billion  down 1  Lead branded product  multiple sclerosis drug Copaxone  posted worldwide sales of  987 million  down 7  due to generic competition Glatopa  a generic version of Copaxone 20 mg  is being marketed by Momenta and Sandoz since 2015 while Mylan  NASDAQ MYL  launched its version of the 20 mg formulation last month  Last month  Mylan also launched  at risk  its generic version of the 40 mg formulation  much earlier than expected Slashes 2017 Outlook  Teva lowered its 2017 sales and earnings outlook  for the second time this year  Teva now expects revenues in a range of  22 2    22 3 billion as against  22 8    23 2 billion expected previously  The company expects earnings in a band of  3 77  3 88 per share in 2017 significantly lower than  4 30  4 50 per share expected previously Share Price Impact  Shares were down more than 6  in pre market trading Check back later for our full write up on this TEVA earnings report later Teva Pharmaceutical Industries Limited Price and EPS Surprise
    Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-q3-earnings-miss-cuts-2017-view-stock-falls-200257896,200257896
105579,327094,AGN,Teva  TEVA  Stock Plunges 20  On Q3 Earnings Miss   View Cut,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   reported third quarter 2017 earnings of  1 00 per share  which missed the Zacks Consensus Estimate of  1 05 per share by 4 8  and declined 24  year over year Revenues of  5 61 billion were in line with the Zacks Consensus Estimate  Sales increased 1  year over year  up 4  excluding impact of currency   mainly due to the inclusion of an extra month of revenues from Actavis acquisition compared with the third quarter of last year Teva acquired Allergan s   NYSE AGN   generics segment  Actavis Generics and also its U S  generic distribution business  Anda  Inc  last year Excluding the benefit from the Actavis generics acquisition  the core sales performance was below expectations  Sales in the quarter were hurt by increased pricing erosion and volume declines in the U S  Generics unit  ongoing political turmoil in Venezuela and loss of exclusivity in the Specialty segment in the quarter Segment DiscussionFrom the fourth quarter of 2016  Teva revised its segment structure following the Actavis acquisition  The Generics segment now includes revenues from the OTC business as well as the API business Generic Medicines segment revenues were  3 billion  down 8  year over year Revenues from the U S  generics business declined 9  to  1 2 billion due to significant competitive and pricing pressure in the generics industry  The ongoing consolidation of customers in the generics industry has led to increasing price erosion and decreasing volume  The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs  Moreover  accelerated FDA approvals of additional generic versions of competing off patent medicines and increased competition for Concerta authorized generic  also hurt sales European generic revenues were  985 million  up 6   1  in local currency  from the year ago period  This was due to the inclusion of three months revenues from the generic business of Actavis versus two month in the year ago quarter Rest of the world  ROW  generic revenues declined 18  to  843 million in the quarter  On a local currency basis  sales rose 5  mainly due to the inclusion of revenues from Actavis API revenues declined 10  to  171 million  OTC revenues were down 22  to  306 million  up 15  in local currency terms  Specialty Medicines revenues were  2 03 billion  down 1  from the year ago period due to lower sales of its central nervous system  CNS  products  Among Teva s various therapeutic areas  CNS sales declined 12  to  1 15 billion due to lower sales of multiple sclerosis drug  Copaxone  Teva s lead branded product Sales of respiratory products rose 30  to  351 million  oncology product sales rose 12  to  302 million  and women s health business recorded a 9  increase in revenues to  119 million  Other specialty revenues rose 18  to  116 million Worldwide revenues of Copaxone declined 7  to  987 million mainly due to lower sales in the United States  Sales declined 8  in the United States to  802 million due to lower volumes of the 20 mg formulation and negative net pricing effects despite the 7 9  price increase taken in January Glatopa  a generic version of Copaxone 20 mg  is being marketed by Momenta and Sandoz  Novartis    NYSE NVS   generic arm  since 2015 while Mylan   NASDAQ MYL   launched its version of the 20 mg formulation last month  In a major blow to Teva  last month  Mylan also launched its generic version of the 40 mg thrice weekly  3TW   three times a week  formulation   much earlier than expected  The 40 mg formulation of Copaxone accounted for more than 85  of total Copaxone scrips in the United States at the end of the reported quarter Ex U S  sales of Copaxone declined 1  to  185 million Among other products  Azilect sales declined 64  to  36 million as a generic version of the drug was launched in the United States this year  ProAir rose 31  to  155 million  combined Treanda and Bendeka revenues declined 21  to  181 million and QVAR declined 1  to  95 million The Other segment  distribution and other activities  recorded revenues of  569 million  up 122 2  year over year  The segment mainly gained from the inclusion of distribution revenues from Anda Profits DeclineAdjusted gross margin contracted 800 basis points  bps  to 53  in the quarter due to the addition of the low margin Anda distribution business and low margins in both the Generic Medicines and Specialty Medicines segments  Research   development expenses declined 6 2  from the year ago period to  381 million  Selling and marketing  S M  expenditure declined 9 4  from the year ago level to  805 million  Adjusted operating margin declined 600 bps in the quarter to 26 2   despite lower costs 2017 Outlook SlashedTeva lowered its 2017 sales and earnings outlook for the second time this year  Teva now expects revenues in the range of  22 2    22 3 billion compared with  22 8    23 2 billion expected previously  The company expects earnings in the band of  3 77  3 88 per share in 2017  significantly lower than  4 30  4 50 per share expected previouslyIncreased price erosion and volume declines in the U S Generics market  lower than expected contribution from new generic launches in the United States and the accelerated erosion in Copaxone sales following the earlier than expected launch of the 40 mg generic resulted in the guidance cut With the entry of the generic version of the 40 mg formulation and a second generic version of the 20 mg formulation  Teva estimates a negative impact of at least 30 cents per share on fourth quarter earnings  higher than Teva s previous assumption of 25 cents Meanwhile many other filers  including Momenta are also looking to get approval for their generic versions of the 40 mg formulation  which if approved  will erode sales further Teva now expects new product launches to contribute  400 million to revenues compared with  500 million expected previously Our TakeAmid already lowered expectations  Teva s disappointing third quarter results and the slash in outlook led to a sharp decline in share price Shares declined almost 20  on Thursday  hitting a 52 week low of  10 85  In fact  shares have slumped 69  so far this year compared with the  s decline of 31 4  Teva s branded drug pipeline is progressing decently and it has also divested some non core assets  mainly in the Women s Health business  including Paragard and Plan B One Step contraceptives  to cut its significant debt load  However  it might not be enough to revive the company s fortunes during this challenging period  particularly as it faces erosion of its largest product  Copaxone It will be interesting to see how its new chief executive officer  K re Schultz  guides the Israel based generic drug maker to post a turnaround Teva carries a Zacks Rank  5  Strong Sell  Teva Pharmaceutical Industries Limited Price  Consensus and EPS Surprise
    You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-03,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-stock-plunges-20-on-q3-earnings-miss--view-cut-200258144,200258144
105580,327095,AGN,Ironwood  IRWD  Beats Estimates In Q3 Earnings  Stock Up,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   reported third quarter 2017 adjusted loss of 18 cents per share  narrower than the Zacks Consensus Estimate of a loss of 23 cents and  flat year over year Total revenues  collaborative revenues  in the quarter amounted to  86 8 million  up 31 3  from the year ago period and beat the Zacks Consensus Estimate of  68 5 million Ironwood s shares gained 2 09  on Nov 2  In fact  a look at the company s share price movement shows that the stock has underperformed the  this year so far  Ironwood s shares have lost 0 8  during this period  while the industry registered a decrease of 0 2  The Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess   generated U S  net sales of  190 9 million  up 16  year over year Please note that Ironwood and Allergan have an equal share in brand collaboration profits or losses  Ironwood s share of the net profits from the sales of Linzess in the United States  included in collaborative revenues  was  63 4 million in the third quarter  up 26 6  year over year According to data provided by IMS Health  Linzess prescriptions filled during the quarter were more than 780 000  up 13  from the year ago period During the reported quarter  selling and administrative  SG A  expenses increased 37 3  to  61 8 million  Research and development  R D  expenses were  37 1 million  down 1 2  from the year ago period Zurampic  approved for uncontrolled gout  generated sales of  0 7 million in the quarter  Zurampic prescriptions filled during the quarter were 2066  higher than 1500 prescriptions filled in the previous quarter In August  the FDA approved Duzallo as an oral treatment for hyperuricemia associated with gout in patients  The drug was launched in October  With this approval  Duzallo became the first dual mechanism treatment for patients with uncontrolled gout Pipeline UpdatesLinzess is currently approved in the United States for the treatment of adults with irritable bowel syndrome with constipation  IBS C  290 mcg  and chronic idiopathic constipation  CIC  145 mcg   72 mcg   Ironwood and Allergan are looking to broaden Linzess  label into additional symptoms and develop the drug as non opioid  pain relieving agent in IBS patients  A phase III study to evaluate Linzess in additional symptoms is expected to start in 2018 The company is planning to advance delayed release 2 formulations of Linzess and will stop the development of delayed release 1 Ironwood s partner in Japan  Astellas Pharma submitted a supplemental new drug application Japan in September for label expansion of Linzess in chronic constipation  In China  Hong Kong and Macau  Ironwood has an agreement with AstraZeneca plc   NYSE AZN   for Linzess  The regulatory filing is under review in China for IBS C  The company expects the review to be completed in the first quarter of 2018 In July  Ironwood reported positive data on IW 3718 from a phase IIb study conducted in patients with uncontrolled GERD  The study met its primary endpoint  The results demonstrated that an oral dose of IW 3718  1500 mg  administered twice daily in combination with a proton pump inhibitor   PPI   significantly reduced heartburn severity in patients when compared to PPI alone The company is also developing two candidates   IW 1973 and IW 1701   for diabetic nephropathy and sickle cell disease  respectively 2017 Guidance The company expects to use less than  110 million for operations in 2017  previously  100 million   The company  however  maintained its R D expenses and SG A expenses guidance for 2017 in the range of  145  160 million and  235  250 million  respectively Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock To ConsiderIronwood currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is Agenus Inc    NASDAQ AGEN    carrying a Zacks Rank  2  Buy   You can see  Agenus  loss estimates remained stable at  1 17 for 2017 and narrowed from  1 40 to  1 36 for 2018 over the last 30 days  The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 4 27  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-03,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-beats-estimates-in-q3-earnings-stock-up-200258185,200258185
105581,327096,AGN,Pharma Stock Roundup  Pfizer  Teva s Q3 Earnings  Novartis Seeks New Indication For Kymriah ,opinion,"Major pharma companies like Pfizer   NYSE PFE    Teva Pharmaceutical Industries Limited   NYSE TEVA    Sanofi  PA SASY   Read more     Allergan  NYSE AGN   Read more    and Novo Nordisk  CO NOVOb   Read more    reported third quarter results last week Recap of the Week s Most Important StoriesWhy Did Teva s Shares Plunge after Q3 Earnings  Teva s shares plunged 19 9  following the release of third quarter results  While the company missed on earnings  revenues were in line with expectations  However  the key reason for the stock s poor performance was the lowered outlook with the company facing huge revenue erosion with its key branded drug  Copaxone  facing generic competition for the 40 mg formulation as well  This development alone is expected to hit 2017 earnings by 30 cents per share  Meanwhile  the Generics business continues to face headwinds with price erosion remaining a major challenge  Read more         Key Takeaways from Pfizer s Q3 Conference Call  Pfizer s third quarter earnings surpassed expectations and resulted in the company raising its earnings outlook for the year  Read more     The company said that key brands including Ibrance and Eliquis globally and Xtandi  Lyrica  Xeljanz and Chantix in the United States continue to perform well However  the company is facing supply shortages for products from the legacy Hospira portfolio mainly due to capacity constraints and technical issues  At the time of acquiring Hospira  completed in September 2015   Pfizer had expected that it would take up to a couple of years to integrate the manufacturing plants and resolve the majority of the supply chain issues  On the third quarter call  the company said that it expects to make substantial progress in 2018 toward cutting down the sterile injectable shortages Regarding Inflectra  Pfizer s biosimilar version of J J s Remicade  the company said that penetration in the United States continues to be slower than expected due to the exclusionary contracting of Remicade by J J  We remind investors that Pfizer has filed a lawsuit in the U S  District Court against J J related to providing patient and physician access to lower cost biosimilars  Read more    Pfizer also provided an insight on the expected impact of loss of exclusivities  LOEs  in the next few years  While LOEs are expected to affect revenues by about  2 billion in each of the next three years  this will go down to approximately  1 billion in 2021 and will not be more than  500 million from 2022 through 2025 As far as near term pipeline and regulatory updates are concerned  Pfizer expects a decision from the FDA for its type II diabetes drug  ertugliflozin  in December  Meanwhile  top line results on PARP inhibitor  talazoparib  from the phase III EMBRACA study will read out by year end  The study is evaluating talazoparib versus standard of care chemotherapy in patients with germline BRCA positive metastatic breast cancer Data on PD L1 inhibitor Bavencio plus Pfizer s 4 1BB agent in patients who have not been previously treated with an immune checkpoint inhibitor is also due later this year  Pfizer is also looking to submit an application with the FDA for lorlatinib  its next generation ALK inhibitor for the treatment of ALK positive metastatic non small cell lung cancer  by year end Pfizer has gained 9 4  year to date  compared to the 15 4  rally of the  it belongs to Novartis Seeks Label Expansion for Kymriah  Novartis   NYSE NVS   is looking to expand the label of Kymriah  the first CAR T therapy to gain FDA approval  The company is seeking FDA approval for the use of Kymriah for the treatment of adult patients with relapsed or refractory  r r  diffuse large B cell lymphoma  DLBCL  who are ineligible for autologous stem cell transplant   ASCT    Novartis has Breakthrough Therapy designation for r r DLBCL  DLBCL is the most common form of non Hodgkin lymphoma   NHL    r r DLBCL is a highly aggressive and difficult to treat non Hodgkin lymphoma that is fatal in almost 40  of patients due to relapsed or refractory disease  Kymriah is currently approved for patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia   ALL   that is refractory or has relapsed at least twice  Approval for the r r DLBCL indication would expand the patient population for Kymriah though Gilead already has a presence in this area with its CAR T therapy Yescarta being approved for the treatment of adult patients with certain types of large B cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment Novartis also announced its intention to acquire Advanced Accelerator Applications to strengthen its presence in oncology  Read more    FDA Approves AstraZeneca s Blood Cancer Drug  AstraZeneca   NYSE AZN   gained accelerated FDA approval for its BTK inhibitor  Calquence  acalabrutinib   for adult patients with previously treated mantle cell lymphoma  an aggressive type of blood cancer that is usually diagnosed at an advanced stage and associated with a high relapse rate  We note that AbbVie s Imbruvica is also approved for this patient population AstraZeneca also expanded its clinical trial collaboration with Incyte   the companies will evaluate the efficacy and safety of Incyte s investigational selective IDO1 enzyme inhibitor  epacadostat  in combination with AstraZeneca s PD L1 inhibitor  Imfinzi  compared to Imfinzi alone in early lung cancer Meanwhile  AstraZeneca said that its IL 13 human monoclonal antibody  tralokinumab  failed to achieve the primary endpoint in a late stage study for severe  uncontrolled asthma  Top line results from another late stage study showed that tralokinumab failed to achieve a statistically significant reduction in oral corticosteroid   OCS   use  the primary endpoint  when added to the standard of care  in patients dependent on OCS FDA Nod for J J Drug Label Expansion  The FDA also granted approval to a new dosage  10 mg once daily  of Johnson   Johnson s Xarelto  The 10 mg formulation is approved for use in reducing the continued risk for recurrent venous thromboembolism   VTE   after completion of at least six months of initial anticoagulation therapy  Johnson   Johnson  NYSE JNJ  is a Zacks Rank  2  Buy  stock   you can see  Valeant Gets FDA Nod for Vyzulta and PDUFA Date for IDP 118  Valeant Pharmaceuticals International  Inc  s   NYSE VRX   Vyzulta  latanoprostene bunod ophthalmic solution  0 024   also gained FDA approval for the reduction of intraocular pressure   IOP   in patients with open angle glaucoma or ocular hypertension  The company also announced that the FDA has accepted its regulatory application for IDP 118  halobetasol propionate and tazarotene  lotion  an investigational topical treatment for plaque psoriasis  A response from the FDA regarding the approval status of the treatment is expected by Jun 18  2018 Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index declined marginally this week  Among major stocks  Bristol Myers Squibb   NYSE BMY   was up 3 8  while Merck   NYSE MRK   was down 3 7   Over the last six months  J J was up 15 1  while Merck declined 10 6   See the last pharma stock roundup here    
What s Next in the Pharma World Quite a few small and mid cap pharma companies are yet to report results  Moreover  Bristol Myers should get a response from the FDA regarding label expansion of its blockbuster drug  Sprycel  for use in the treatment of children with Ph  chronic phase   CP   chronic myeloid leukemia   CML    The company is also seeking approval for a powder for oral suspension   PFOS   formulation of Sprycel  A response from the agency is expected on November 9 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-11-05,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pfizer-tevas-q3-earnings-novartis-seeks-new-indication-for-kymriah-200258505,200258505
105582,327097,AGN,Key Predictions For Q3 Earnings Reports Of PBYI  XON  LGND,opinion,The third quarter reporting cycle is drawing to a close  Quarterly results have been strong  Overall  the beat percentage is in line with the recent quarters but growth rates have been particularly impressive  Also  the estimate revision trend for Q4 has been mostly favorable As of Nov 3  2017  406 S P 500 members  accounting for 85 4  of the index s total market capitalization  have reported results  according to the  Total earnings of these 406 index members are up 7 5  from the year ago quarter on 6 3  improvement in revenues  The beat ratio is 73 9  for earnings and 66 7  for revenues Per the report  total earnings of S P 500 companies in Q3 are expected to grow 6 5  year over year on 5 6  higher revenues Please note that the broader Medical sector  includes drug  biotech as well as Medical Device companies  is expected to record year over year growth of 4 6  in revenues and 6 5  in earnings in Q3 Among the big biotech pharma companies that reported this week  generic maker Mylan   NASDAQ MYL   missed estimates for both earnings and sales in Q3 due to lower EpiPen sales  Among the ones that reported last week  Pfizer   NYSE PFE   and Allergan   NYSE AGN   beat earnings expectations while revenues came in line  Zoetis   NYSE ZTS   beat expectations for both earnings and sales  While Pfizer and Zoetis raised their earnings guidance  Allergan increased only the upper end of its earnings outlook Here we have three small biotech pharma companies that are set to report third quarter results on Nov 9  Let s see how things are shaping up for this quarter Puma Biotechnology  Inc    NASDAQ PBYI  Puma Biotech  which is scheduled to release earnings after market close  delivered a positive surprise of 34 29  last quarter  The company s earnings track record has been good so far  It has delivered an average positive surprise of 39 46  in the last four quarters For this quarter  Puma has an  of  18 47  and a Zacks Rank  3  Hold   indicating a likely positive surprise  The Zacks Consensus Estimate is pegged at a loss of  2 75 per share  You can uncover the best stocks to buy or sell before they re reported with our  Puma Biotechnology s only marketed product  Nerlynx  neratinib  was launched for the treatment of HER2 positive breast cancer in August  So Q3 is the first quarter in which Puma will record sales for Nerlynx   Read More   Intrexon Corporation   NYSE XON  Intrexon is also scheduled to announce results after market close  Last quarter  the company delivered a positive earnings surprise of 23 81   In the trailing four quarters  it missed expectations twice  surpassed estimates once while meeting the same in the other  resulting in an average negative surprise of 0 57  The company has an Earnings ESP of  13 64  and a Zacks Rank  4  Sell   The Zacks Consensus Estimate is pegged at a loss of 22 cents per share Investor focus is expected to be on Intrexon s pipeline on the conference call  The company is developing several candidates in partnership with other companies   Read More  Ligand Pharmaceuticals Inc    NASDAQ LGND  Ligand is expected to report after market close  Ligand s earnings history has been a mixed bag with the company surpassing estimates in two of the last four quarters and missing the same in the other two  It also delivered a trailing four quarter average positive surprise of 6 19   Last quarter  the company came up with a positive earnings surprise of 67 50  The company has an Earnings ESP of  15  and a Zacks Rank  1  Strong Buy  You can see  The Zacks Consensus Estimate for earnings is pegged at 60 cents per share We expect investor focus to remain on the company s updates regarding partnerships and major pipeline assets on the third quarter conference call   Read More   Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/key-predictions-for-q3-earnings-reports-of-pbyi-xon-lgnd-200263549,200263549
105583,327098,AGN,Amgen Gets Positive CHMP Opinion To Expand Nplate s Label,opinion,Amgen  Inc    NASDAQ AMGN   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive opinion to expand the label of Nplate to include the pediatric population Nplate is presently marketed for the treatment of chronic immune thrombocytopenic purpura  ITP    an autoimmune disease characterized by low platelet count   in adults  Amgen is looking to get Nplate approved for use in pediatric patients  one year of age and older  who are refractory to other treatments like corticosteroids and immunoglobulin The positive opinion was based on five studies demonstrating that Nplate reduces the rates of bleeding in children with this rare blood disorder Amgen s shares have rallied 17 8  this year so far  better than the  s growth of 2 3  In a separate press release  Amgen and partner Allergan   NYSE AGN   announced that the CHMP has rendered a positive opinion for the marketing application of its biosimilar version of Roche s   OTC RHHBY   cancer drug Avastin  ABP 215  According to the companies  this may be the first bevacizumab biosimilar  which has been recommended for approval in the EUThe Avastin biosimlar was approved in the United States in September and will be marketed by the trade name of Mvasi We remind investors that Amgen and Allergan have collaborated for the worldwide development and commercialization of four oncology antibody biosimilar medicines including Roche s Avastin  Herceptin and Ritixan In fact  Amgen has 10 biosimilars in its pipeline  Its biosimilar version of Abbvie s   NYSE ABBV   rheumatoid arthritis drug Humira  Amjevita  was approved by the FDA last year and in the EU in March this year for the same indications  However  per a settlement with AbbVie  Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023Currently  Amgen has a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-11-12,Zacks Investment Research,https://www.investing.com/analysis/amgen-gets-positive-chmp-opinion-to-expand-nplates-label-200264539,200264539
105584,327099,AGN,A Flash Resolution To Bearish Divergence,opinion,"AT40   48 1  of stocks are trading above their respective 40 day moving averages  DMAs AT200   54 9  of stocks are trading above their respective 200DMAsVIX   11 3  a new all time low  Short term Trading Call  cautiously bullish
Commentary It was by the slimmest of margins  but the S P 500  via SPDR S P 500  NYSE SPY   finally ended a week with a loss  After 8 straight weeks of gains  the index closed the last week with a 0 2  loss as Friday slipped by 0 1  

The S P 500  SPY  survived a dip on Thursday  but slipped again on Friday  The uptrending 20 day moving average  DMA  is just barely holding as support 
For a hot minute  the dip on Thursday looked like the resolution of the bearish divergence which revealed the narrowing of the latest rally  The day looked very similar to a resolution from two weeks prior  but this time around the buyers were even more successful at erasing the losses with a same day reversal  Unlike the dip from two weeks ago  the next day did not deliver buying follow through  Interestingly  the trading placed the volatility index  the VIX  right back to where it was two weeks ago with a gain of 7 5  on the day and 24  for the week 

The volatility index  the VIX  came alive this week and actually fought off the automatic volatility faders 
The iShares Russell 2000 ETF  NYSE IWM  became the highlight of the narrowing rally  IWM has declined almost steadily since its last closing all time high 5 weeks ago  Critically  IWM spent the last three days struggling to hold onto its 50DMA support 

The iShares Russell 2000 ETF  IWM  is cooling off from a sharp rally off the August low  The 50DMA line of support has so far halted the slide 
Financials also contributed to the resolution of bearish divergence by buckling this past week off a 10 year high  Like IWM  the Financial Select Sector SPDR ETF  NYSE XLF  has its 50DMA creating a critical support line  I am watching closely for a buy the dip opportunity to load up on a new tranche of call options 

The Financial Select Sector SPDR ETF  XLF  sold off sharply from its 10 year high  Will its 50DMA hold as support 
AT40  T2108   the percentage of stocks trading above their respective 40DMAs  closed the week at 48 1  and a 2 month low  Its steady 5 week decline from overbought conditions closely matches the decline in IWM  AT200  T2107   the percentage of stocks trading above their respective 200DMAs  also peaked in early October but has declined much less sharply  AT200 declined from 60 8  to 54 9   This gentle slope helps explain why the major indices have yet to produce a major dip during the narrowing of the rally  While I was looking for the rally to start broadening last week  I am now thinking the current trends will continue absent a catalyst to produce significant buying interest 
STOCK CHART REVIEWS
Caterpillar  NYSE CAT  CAT inspired industrials two weeks ago with a major post earnings gap up to a new all time high  Buyers have yet to follow through on the excitement  On Thursday  CAT gapped down to a post earnings low  I added to an existing call option as one of my few dip buys in anticipation of a downside resolution of the previous bearish divergence  CAT rallied off uptrending 20DMA support on Friday 
Caterpillar  CAT  fell from its primary uptrend through its upper Bollinger Band  BB  channel  The post earnings gap up is starting to look like a blow off top  but the stock has a chance for repair at its uptrending 20DMA support 
Blue Apron Holdings Inc  NYSE APRN I took a small chance on APRN  It completely failed  This company really should never have gone public  Bankruptcy anyone  The chart says it all 
Blue Apron  APRN  looks like it cooked itself  The post IPO slide resumed after a disastrous earnings report 
AMC Entertainment Holdings Inc  NYSE AMC I was hopeful for AMC  This now looks like a 2018 recovery story  The stock ended the week at a new all time low 

AMC Entertainment Holding  AMC  hit a new all time low  A positive catalyst now looks some time away 
Impinj Inc  NASDAQ PI  This is a bottom fishing play that is working out very well so far  Earnings were extremely disappointing for the second report in a row  I think the steepness of the sell offs are the release of overly inflated expectations  Using   I bought PI after it closed at a post earnings high  My optimistic upside target is around  30 where the downtrending 20DMA is headed 

Impinj  PI  is a stock breaking down  Can the current post earnings recovery mark the beginnings of a sustainable bottom 
DexCom Inc  NASDAQ DXCM  DXCM also triggered a bottom fishing buy  but it quickly started sliding again after that  The lows held and a post earnings gap up seem to confirm a bottom in the making  I wrote about the DXCM play in    

A bottoming seems underway for DexCom  DXCM  as earnings help to propel the stock to a fresh post Abbott news high 
Teva Pharma Industries Ltd ADR  NYSE TEVA  The pain is unending for TEVA  I dove back into this one WITHOUT the confirmation that comes with the bottom fishing rules because I thought I had fundamental reasons for taking the risk  The chart below speaks volumes  TEVA is likely also helping to drag stakeholder Allergan  NYSE AGN  lower and lower 

Teva Pharmaceuticals  TEVA  continues a mighty struggle  The stock nows sits at a 17  year low 
Tableau Software  NYSE DATA  DATA is one strange stock  Ever since a massive post earnings collapse in February  2016  subsequent earnings have produced big moves  Sometimes the stock sold off post earnings only to turn right around and rally to new heights  Ahead of its latest earnings  DATA sat at a near double for the year  This optimism was apparently misplaced for the latest report as the stock gapped down below 50DMA support post earnings for a 10  loss  It now trades right around where it did right after the previous earnings report  I tried a pre earnings play that failed and reached for a play on a bottom after buyers started showing up  A new post earnings low would be very bearish for the stock 

Tableau Software  DATA  closed below 50DMa support for the first time since April 
El Pollo Loco Holdings Inc  NASDAQ LOCO  LOCO joined the carnage infecting so many casual dining plays  If not for the widespread malaise  I would have held onto my shares as part of my second swing through the chicken trade  Buyers are already creeping back into the stock  so I am watching closely for a post earnings closing high to buy 

El Pollo Loco Holdings  LOCO  suffered a second poor earnings report in a row  The stock now trades back at the all time lows hit two years ago Red Robin Gourmet Burgers Inc  NASDAQ RRGB  RRGB is a poster child for the carnage in casual dining  The stock collapsed 29  toward its low for the year on what was an awful earnings report  The company completely reset expectations by guiding down Q4 EPS to  0 45  0 60 vs   1 00 analyst  consensus   The only thing going for RRGB now is the 45 2  short position  The longer the stock fails to make fresh post earnings lows  the more likely nervous bears will start covering  and presumably take profits   I LOVE the turkey burgers and  now bottomless  sweet potato fries  I wish I could love the stock similarly 

Red Robin Gourmet Burgers  RRGB  suffered a devastating and very bearish double breakdown through 50 and 200DMA supports 
Zynga Inc  NASDAQ ZNGA  Two months ago  I pointed out the breakout for Zynga  ZNGA   I held onto my shares and braced myself for earnings  I felt like a genius as the stock soared to a new 3 1 2 year high  Unfortunately  the sellers stepped in soon thereafter and took profits back down to the current consolidation range  I now sit and wait for the next positive catalyst 

Zynga  ZNGA  is on a very extended  two stage  consolidation  The three major moving averages support future upside 
United States Steel Corporation  NYSE X  The recovery in U S  Steel continued with a big gap up from earnings after market October 31  The move kept intact the steady uptrend in the 50DMA  The move also  stranded  a bunch of sellers who panicked ahead of earnings and created a 50DMA breakdown  This island  also known as an abandoned baby bottom  serves as a very clear line in the sand for a higher bottom in U S  Steel  With the 50 and 200DMAs converging as well  X maintains a bullish look 

U S  Steel  X  survived another earnings report by returning to a bullish position above its 50 and 200DMAs
 Above the 40  uses the percentage of stocks trading above their respective 40 day moving averages  DMAs  to assess the technical health of the stock market and to identify extremes in market sentiment that are likely to reverse  Abbreviated as AT40  Above the 40 is an alternative label for  T2108  which was created by Worden  Learn more about T2108 on my T2108 Resource Page  AT200  or T2107  measures the percentage of stocks trading above their respective 200DMAs 
Active AT40  T2108  periods  Day  432 over 20   Day  246 over 30   Day  46 over 40   overperiod   Day  2 under 50   underperiod   Day  13 under 60   Day  20 under 70 
Daily AT40  T2108 

Black line  AT40  T2108     measured on the right 
Red line  Overbought threshold  70    Blue line  Oversold threshold  20  
Weekly AT40  T2108 

Be careful out there 
Full disclosure  long AMC  long APRN  long CAT calls  long DATA calls  long DXCM  long PI  long TEVA calls  long ZNGA",2017-11-13,Dr. Duru,https://www.investing.com/analysis/a-flash-resolution-to-bearish-divergence-200264379,200264379
105585,327100,AGN,Deja vu for Paulson as Allergan loss hurts U S  hedge funds,news,"By Svea Herbst Bayliss and Lawrence Delevingne BOSTON NEW YORK  Reuters    For hedge fund titan John Paulson  history may be repeating itself   The billionaire investor lost an estimated  258 million on Tuesday when the share price of drug company Allergan Plc  N AGN  tumbled nearly 15 percent on speculation new tax rules would scuttle its merger with  Pfizer  Inc   N PFE   Research firm Symmetric io calculated the hypothetical loss based on publicly disclosed stock holdings as of Dec  31  2015  That estimated decline comes after Paulson lost money  in late 2014 when his Advantage fund dropped 13 6 percent in October of that year after U S  pharmaceutical company  AbbVie Inc   N ABBV  backed out of a planned deal with Irish drug maker  Shire  Plc  L SHP  after new tax rules made the deal less lucrative for the companies  Merger arbitrage specialists such as the  18 billion Paulson   Co bet on the outcome of mergers  Paulson s bet that the Allergan deal would go ahead has been rattled by the new tax rules  which were unveiled on Monday  Reuters reported on Tuesday that Pfizer was leaning toward abandoning its  160 billion agreement to buy Botox maker Allergan  Paulson  who made his reputation on bets against the U S  housing market and said recently in a video interview how critical it was to stay the course in investing  did not comment  The Paulson Partners fund  which bets on corporate events such as mergers  is down 7 7 percent in 2016 through February  according to a person familiar with the returns  The Paulson Advantage Plus Fund lost 11 24 percent in the first two months of the year  More recent figures were not available   Paulson is not the only fund that got burned  Symmetric io estimated that hedge funds in total lost  3 billion on Allergan on Tuesday  Research from Goldman Sachs  NYSE GS  shows that 80 hedge funds counted Allergan as one of their top 10 holdings at the end of the fourth quarter  making the company one of the most popular stocks in the hedge fund industry  The pain appears to have been particularly acute for four large hedge fund firms  Viking Global Investors  Paulson   Co  Third Point and Pentwater Capital Management each lost more than  200 million on Tuesday  the Symmetric io data show  according to year end holding disclosures   It is possible that positions have since changed  The firms mentioned either declined to comment or did not respond to a request for comment  Less than a year ago  Daniel Loeb s Third Point invested with Allergan and praised the company s management team  including Chief Executive Brent Saunders  In a July 2015 letter to clients  Loeb was particularly happy to hear Saunders talk about the opportunity for a transformational transaction  That was after Allergan had already merged with  Actavis  but before the Pfizer deal was announced late last year  The risk of the deal being scuttled also hurt players who had made smaller bets on Allergan   
Scott Ferguson who runs Sachem Head Capital Management  is invested with Allergan and lost an estimated  78 million on paper  according to Symmetric io  Ferguson was not available to comment  Similarly  Keith Meister s Corvex Management lost an estimated  33 6 million  while Philippe Laffont s Coatue Management lost an estimated  38 4 million  the Symmetric io data show  The firms were not immediately available to comment ",2016-04-05,Reuters,https://www.investing.com/news/stock-market-news/deja-vu-for-paulson-as-allergan-loss-hurts-u.s.-hedge-funds-393723,393723
105586,327101,AGN,Obama s inversion curbs kill Pfizer s  160 billion Allergan deal,news,"By Caroline Humer and Ransdell Pierson NEW YORK  Reuters    U S  drug maker  Pfizer  Inc  NYSE PFE  agreed on Tuesday to terminate its  160 billion agreement to acquire Botox maker Allergan  NYSE AGN pa  Plc  in a major victory to U S  President Barack Obama s drive to stop tax dodging corporate mergers  The decision to end the biggest tax  inversion  ever attempted  which would have seen Pfizer slash its tax bill by redomiciling to Ireland where Allergan is registered  came a day after the U S  Treasury unveiled new rules to curb inversions  While these new rules did not name Pfizer and Allergan  one of their provisions targeted a specific feature of their merger  Allergan s previous history as a major acquirer of other companies  The subsequent demise of the deal allows Obama to claim a big win during his last year in office  Earlier on Tuesday  Obama called global tax avoidance a  huge problem  and urged Congress to take action to stop U S  companies from tax avoiding corporate  inversions   which lower companies tax bills by redomiciling overseas   While the Treasury Department s actions will make it more difficult    to exploit this particular corporate inversions loophole  only Congress can close it for good   Obama said  Pfizer and Allergan will announce the termination of their deal on Wednesday  a source familiar with the matter said  asking not to be identified ahead of any official statement  Pfizer and Allergan declined to comment  Pfizer was concerned that any tweaks to salvage the inversion might have provoked new rules by the U S  Treasury  and so was leaning earlier on Tuesday to end the deal  a source had earlier told Reuters  Pfizer will have to pay Allergan up to  400 million for its expenses as a result of terminating the deal  according to their merger agreement  Pfizer shares had ended trading in New York on Tuesday up 2 percent on hopes the company would walk away or renegotiate the deal in its favor  Allergan shares closed down 14 8 percent to their lowest level since October 2014   Several U S  presidential candidates  including Republican Donald Trump and Democrats Hillary Clinton and Bernie Sanders  have seized on the issue in their campaigns   We have so many companies leaving  it is disgraceful   Trump told reporters as he greeted voters in Waukesha  Wisconsin on Tuesday  Clinton and Sanders both expressed support for Treasury s plan   Besides Pfizer Allergan  other pending inversion deals that have not yet closed include the proposed  16 5 billion merger of  Johnson Controls  Inc  NYSE JCI  with Ireland based Tyco International Plc  Waste Connections Inc s  2 67 billion deal with Canada s Progressive Waste Solutions Ltd  and IHS Inc s  13 billion acquisition of London based Markit Ltd  In all these cases  the shares of the target companies fell only slightly  Johnson Controls and Tyco said they would respond after conducting a review of the new rules   Waste Connections and Progressive Waste Solutions said they expected the rules would impact less than 3 percent of the combined adjusted free cash flow in their first year after the deal   IHS and Markit said they believed the rules would not affect their adjusted effective tax rate guidance of a low to mid twenties percentage range  THREE YEAR RULE Under previous rules which still apply  Allergan shareholders needed to own at least 40 percent of the combined company for the two companies to enjoy the full tax benefits of an inversion  and more than 20 percent to have any inversion benefit at all  But a new  three year look back rule  issued by the Treasury on Monday made this much harder for Allergan  and appeared to take aim directly at it because of how the company was put together   The new rule does not allow stock accumulated through a foreign company s U S  deals in the last three years to count towards the book value needed to meet the inversion threshold  This weighed on Allergan heavily because of its significant deals in this timeframe  These include the  66 billion merger of Allergan and  Actavis   NYSE AGN  Plc  the  25 billion purchase of Forest Laboratories and the  5 billion takeover of Warner Chilcott    The serial acquisition portion of the regulations will cause Pfizer to be treated as an  expatriated entity   under the terms of its existing deal with Allergan    Robert Willens  a corporate tax and accounting analyst  wrote in a note  SHEDDING GENERICS In a second change to the rules  the Treasury also said it would seek to limit a practice known as earnings stripping that is often undertaken following  but not limited to  an inversion  The new Treasury rules would restrict related party debt for U S  subsidiaries in dealings that do not finance new investment in the United States   Without Allergan s new  fast growing medicines  Pfizer may need to look for other companies with attractive products  such as U S  drugmakers Biogen  NASDAQ BIIB  Inc  Regeneron Pharmaceuticals Inc  NASDAQ REGN  and  AbbVie Inc   NYSE ABBV   said Raghuram Selvaraju  managing director of brokerage H C  Wainwright  Pfizer had planned to make a decision by 2016 whether to split off its hundreds of generic medicines  but delayed the decision until 2019 after announcing its merger with Allergan  Morningstar analyst Damien Conover had said the decision could be moved to late 2017 or 2018 if the deal with Allergan collapsed   Pfizer  which announced the deal in November  had said its tax rate would drop to about 17 or 18 percent after the deal  from around 25 percent  That would have represented more than  1 billion in annual cost savings   The deal s collapse is also a blow to the investment banks involved  Guggenheim Partners LLC   Goldman Sachs Group  Inc  NYSE GS   Centerview Partners Holdings LLC and Moelis   Co stood to share  94 million in fees advising Pfizer had the deal closed  while Allergan would have paid its advisors  JPMorgan Chase   Co  NYSE JPM  and  Morgan Stanley   NYSE MS    142 million in total  according to the latest estimates by Freeman   Co LLC  Bankers may now get paid only 10 percent of these amounts  according to Freeman  This is not the first time a tightening of the U S  inversion rules have caused a merger to unravel  U S  pharmaceutical company AbbVie abandoned its  55 billion takeover of Ireland domiciled peer  Shire  Plc  LON SHP  after the Obama administration cracked down on inversions in 2014  AbbVie had to pay Shire a  1 6 billion break up fee  
 This story has been refiled to remove extraneous apostrophe in first paragraph ",2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/u.s.-treasury-rules-put-pfizer-allergan-deal-in-question-393611,393611
105587,327102,AGN,Wall Street set for higher open as oil rebounds,news,"By Abhiram Nandakumar  Reuters    U S  stocks were set to open higher on Wednesday as oil rose and investors awaited the release of minutes from the Federal Reserve s March meeting on monetary policy  U S  crude rose more than 2 percent on renewed hopes of a deal by producers to freeze output and cut a global glut   O R  Investors will parse the minutes to gain insight into the Fed s thinking on the economy and interest rates  The market has been grappling with mixed signals from central bank officials  with some supporting an aggressive plan to raise rates  while Fed Chair Janet Yellen has taken a cautious stance  Adding to the uncertainty was a barrage of mixed data suggesting a recovering U S  economy could still be susceptible to risks from a weak global economy   The market is back to its original conundrum  which is  where is the growth     said Kevin Caron  market strategist at Stifel  Nicolaus   Co in Florham Park  New Jersey  Caron  who expects the stock market to remain choppy  said there were still some lingering concerns about global growth and weak expectations for corporate earnings  Several Fed officials are slated to speak on Wednesday  including Cleveland Fed President Loretta Mester and St  Louis Fed President James Bullard  Both are voting members of the rate setting Federal Open Market Committee  At 8 23 a m  ET  1223 GMT   Dow e minis  1YMc1  were up 21 points  or 0 12 percent  with 27 335 contracts changing hands  S P 500 e minis  ESc1  were up 2 5 points  or 0 12 percent  with 211 275 contracts traded  Nasdaq 100 e minis  NQc1  were up 6 points  or 0 13 percent  on volume of 25 563 contracts Wall Street fell sharply on Tuesday as investors booked profits from a recent rally  leaving the S P 500 flat for 2016  A recent rally   sparked by rising oil  strength in the economy and a cautious Fed   helped stocks recover from a steep selloff that had sent the S P 500 down more than 10 percent earlier this year  Cisco  O CSCO  shares were up 1 1 percent at  27 89 after JP Morgan raised its rating on the stock to neutral  Allergan  N AGN  fell 2 1 percent to  231 48  continuing its slide for a second day  after new rules aimed at curbing tax inversions effectively killed its  160 billion merger with  Pfizer   N PFE   Pfizer shares rose 1 6 percent to  31 86  
 Monsanto   N MON  fell 1 4 percent to  85 46 after the seed company reported a 25 percent fall in quarterly profit ",2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/futures-higher-as-oil-recovers;-fed-minutes-awaited-393789,393789
105588,327103,AGN,Pfizer  Allergan scrap  160 billion deal after U S  tax rule change,news,"By Caroline Humer and Ankur Banerjee  Reuters    U S  drugmaker  Pfizer  Inc  N PFE  and Ireland based Allergan Plc  N AGN  walked away from their  160 billion merger on Wednesday  a major win for President Barack Obama  who has been pushing to curb deals in which companies move overseas to cut taxes  Pfizer said the decision was driven by new U S  Treasury rules aimed at such deals  called inversions  The merger would have allowed New York based Pfizer to cut its tax bill by an estimated  1 billion annually by domiciling in Ireland  where tax rates are lower  While the new Treasury rules did not name Pfizer and Allergan  one of the provisions targeted a specific feature of their merger   Allergan s history as a major acquirer of other companies  Allergan Chief Executive Brent Saunders said on CNBC television that the new Treasury rule would not stop the company from doing other stock based acquisitions as soon as this fall  The new Treasury rule takes into account the past three years of a company s deals   It really looked like they did a very fine job at constructing a temporary rule to stop this deal and obviously it was successful   Saunders said  Saunders said that he would stay to run the standalone company with a focus on both deals and research and development  Allergan will also move ahead with plans for its  40 5 billion sale of its generic drug business to Israel s Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA   It expects the transaction to close by June  With the deal behind it  Pfizer said it would decide this year about whether to split off its hundreds of generic medicines into a separate business  It had put off making that decision until 2019 after announcing its deal with Allergan last November  Pfizer will pay Allergan  150 million to reimburse expenses from its deal  Shares of Allergan  which fell 15 percent on Tuesday  were up 3 3 percent at  244 38 at mid afternoon  Pfizer rose 4 7 percent to  32 84   Pfizer has new products coming and plenty of money that it could put to work with acquisitions  though not on the scale of Allergan  said Les Funtleyder  healthcare portfolio manager at E Squared Asset Management in New York  which holds Pfizer shares  It is not clear that Pfizer should definitely split into two  he said   It is true that these larger companies are a little unwieldy to manage   Funtleyder said   but there are plenty of strategies to keep them together and increase shareholder value    The decision to call off the deal came in part because Pfizer was concerned that any tweaks to salvage its deal with Allergan might have provoked new rules by the Treasury  a source familiar with the situation told Reuters on Tuesday  Obama on Tuesday called global tax avoidance a  huge problem  and urged Congress to take action to stop U S  companies from deals that allow it  
U S  inversion rules have unraveled other mergers  U S  drugmaker  AbbVie Inc   N ABBV  abandoned its  55 billion takeover of Ireland domiciled peer  Shire  Plc  L SHP  in 2014 after the Obama administration cracked down on inversions  AbbVie had to pay Shire a  1 6 billion break up fee ",2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/pfizer-and-allergan-scrap-$160-billion-'inversion'-deal-393780,393780
105589,327104,AGN,Oil  healthcare boost stocks  dollar weak after minutes,news,"By Chuck Mikolajczak NEW YORK  Reuters    Global equity markets posted solid gains on Wednesday  aided by a climb in oil prices and a surge in healthcare stocks  while the U S  dollar hit a fresh 17 month low against the yen after the minutes from the latest Federal Reserve meeting  Stocks on Wall Street and in Europe bounced from declines of more than 1 percent in the prior session  led by energy and healthcare sectors   Pfizer   N PFE  and Allergan  N AGN  scrapped their  160 billion merger deal  fuelling speculation on where the two companies may look to for acquisitions  The healthcare sectors  SPXHC   SXDP   were the top performing groups in both the United States and Europe  with each up more than 2 percent   Federal Reserve policymakers debated last month whether an interest rate hike would be needed in April  though a consensus emerged that risks from a global economic slowdown warranted a cautious approach  After the minutes traders added slightly to bets that the Fed will raise rates earlier than December  the timing that had been expected before the release   The minutes were a little more hawkish than the tone that we ve heard from  Fed Chair Janet  Yellen post FOMC meeting  but that was to be expected somewhat in my view   said Scott Smith  senior market analyst at Cambridge global Payments in Toronto  The Dow Jones industrial average  DJI  rose 112 73 points  or 0 64 percent  to 17 716 05  the S P 500  SPX  gained 21 5 points  or 1 05 percent  to 2 066 67 and the Nasdaq Composite  IXIC  added 76 78 points  or 1 59 percent  to 4 920 72  MSCI s index of world shares  MIWD00000PUS  rose 0 89 percent  The pan European FTSEurofirst 300 share index  FTEU3  closed up 0 76 percent after suffering its biggest drop in nearly a month on Tuesday  The dollar continued to weaken against the yen after the Fed minutes  with earlier comments from Japanese Prime Minister Shinzo Abe that countries should avoid trying to weaken currencies with  arbitrary intervention  also weighing on the greenback  The dollar was down 0 53 percent  at 109 73 yen after hitting 109 31  its lowest since October 2014  The dollar index  DXY   which measures the greenback against a basket of six major currencies  was last down 0 16 percent at 94 477   But as for much of the last year  oil continued to have an outsized influence on most of the market moves   Crude prices extended their rebound  U S  inventories unexpectedly fell from record highs last week as refineries continued to hike output and imports fell  Investors also gauged the possibility of an output freeze by producers  Russian sources told Reuters that Russia believed  45 to  50 per barrel was an acceptable price for the oil market to re balance and said there were now discussions on how long to freeze production and how to monitor it  Brent crude futures  LCOc1  jumped 5 2 percent to settle at  39 84 per barrel  off a one month low of  37 27 hit on Tuesday  while U S  crude futures  CLc1  surged 5 18 percent to settle at  37 75  the biggest percentage gain since March 16  
In bond markets  U S  Treasury yields reached session highs after the Fed minutes with the benchmark 10 year Treasury yield  US10YT RR  reaching a session high of 1 774 percent  It was last down 8 32 in price to yield 1 7549 percent ",2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/asia-stocks-at-three-week-lows-as-china-worries-grow;-oil-up-393719,393719
105590,327105,AGN,Wall Street rises with healthcare  oil rallies,news,"By Caroline Valetkevitch  Reuters    U S  stocks jumped on Wednesday  bolstered by gains in healthcare shares after the collapse of the  160 billion merger of  Pfizer  and Allergan  NYSE AGN pa   and by a rise in energy shares  Minutes from the most recent Federal Reserve meeting suggested the Fed was unlikely to raise interest rates before June   U S  drugmaker Pfizer Inc  N PFE  and Ireland based Allergan Plc  N AGN  called off their merger after new U S  Treasury rules aimed at curbing tax cutting inversion deals   News of the merger s breakup boosted the healthcare sector on hopes that the pharmaceutical giants could turn to smaller targets   The S P healthcare index  SPXHC  gained 2 7 percent  while the Nasdaq Biotech Index  NBI  jumped 6 percent  Shares of Pfizer rose 5 percent to  32 93 and gave the biggest boost to the S P 500  while Allergan was up 3 5 percent at  244 74   I guess the feeling is Pfizer will now look for a new target   said Stephen Massocca  chief investment officer  Wedbush Equity Management LLC in San Francisco  But  he said   the rally in healthcare is a little counter intuitive  given the political climate seems to be negative for big pharma right now   The Dow Jones industrial average  DJI  was up 112 73 points  or 0 64 percent  to 17 716 05  the S P 500  SPX  had gained 21 49 points  or 1 05 percent  to 2 066 66 and the Nasdaq Composite  IXIC  had added 76 78 points  or 1 59 percent  to 4 920 72  Crude oil jumped after data showed an unexpected draw in U S  stockpiles last week  boosting shares of energy companies  The S P 500 energy index  SPNY  rose 2 1 percent  The day s rally  which included gains in all but two sectors  followed two days of declines in the S P 500  The index had rallied 13 percent in the previous seven weeks  thanks to stabilizing oil prices and reduced concerns about China s economy   Investors will soon turn their attention to first quarter S P 500 earnings  which are estimated to be down 7 4 percent from a year ago  according to Thomson Reuters data  Some strategists see further gains in the market if companies are able to handily beat such low earnings expectations  Federal Reserve policymakers debated whether they might hike rates in April but  a number  of them argued headwinds to growth would probably persist  with many arguing they should be cautious about raising rates   I don t think there was anything particularly surprising there  We knew from earlier comments immediately following  the meeting  that there was some dissension   Massocca said  About 6 9 billion shares changed hands on U S  exchanges  below the 7 2 billion daily average for the past 20 trading days  according to Thomson Reuters data  Advancing issues outnumbered declining ones on the NYSE by 2 286 to 734  for a 3 11 to 1 ratio on the upside  on the Nasdaq  2 003 issues rose and 789 fell for a 2 54 to 1 ratio favoring advancers  
The S P 500 posted 12 new 52 week highs and no new lows  the Nasdaq recorded 35 new highs and 21 new lows ",2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/wall-st.-opens-higher-ahead-of-fed-minutes-393805,393805
105609,327124,AGN,Conatus Entrusts Keith W  Marshall With Key Management Roles,opinion,Conatus Pharmaceuticals Inc    NASDAQ CNAT   announced the appointment of Keith W  Marshall as executive vice president  chief operating officer and chief financial officer Notably  Marshall has over fifteen years of experience in finance  operations and business advisory roles  Also  he was an agent on private placements for private biotechnology companies and an advisor to buyers and sellers in biotechnology as well as pharmaceutical company transactions Therefore  the company is banking on Marshall s contributions as it aims at completing its four ongoing phase IIb studies for its lead candidate  emricasan  besides expanding its pipeline Meanwhile  Conatus is focusing on its efforts to develop emricasan  In January 2016  the company started ENCORE NF study under the ENCORE program for potential improvements in fibrosis and steatohepatitis in patients with fibrosis caused by Nonalcoholic steatohepatitis  NASH   Top line data is expected in the first half of 2019 In May 2017  Conatus also initiated another study  ENCORE LF  It is a phase IIb trial  studying EMRI monotherapy on patients with decompensated NASH cirrhosis  Top line data from the study is expected in 2019  Going forward  the company plans to initiate a new study   ENCORE XT   a planned extension study in patients who completed the ENCORE PH or ENCORE LF studies with continued monitoring for efficacy  safety  clinical outcomes and health related quality of life In fact  the ENCORE studies are being conducted to provide clinically relevant efficacy  dosing  and safety data to support the initial registration of emricasan for chronic administration in patients with NASH cirrhosis and potentially support future label expansion In December 2016  Conatus signed an exclusive option  collaboration and license agreement with Novartis   NYSE NVS   for the worldwide development and commercialization of emricasan  which is a positive  This strategic agreement with Novartis not only lends expertise to Conatus but will also provide the company with much needed funds for the development of emricasan Yet  Conatus has had its share of pipeline setbacks  In 2008  the FDA had placed a clinical hold on emricasan while it was being developed by Pfizer   NYSE PFE   due to a preclinical observation  However  the clinical hold was lifted in 2013 Currently  several studies on emricasan are ongoing with data readouts scheduled over next couple of years  Also  stiff competition remains a threat  In fact  several companies like Allergan   NYSE AGN    Intercept Pharmaceuticals  Galectin Therapeutics and Enanta Pharmaceuticals are working on developing treatments for NASH Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/conatus-entrusts-keith-w-marshall-with-key-management-roles-200219815,200219815
105610,327125,AGN,Company News For Oct 19  2017,opinion,Shares of Fogo De Chao Inc   NASDAQ FOGO   tanked 7 5  after the company expects adjusted earnings of 77 cents to 80 cents a share for the year  lower than analysts  expectations of 91 cents Shares of Abbott Laboratories   NYSE ABT   gained 1 3  after the company reported third quarter earnings per share of 66 cents  ahead of the Zacks Consensus Estimate by a penny Allergan plc s   NYSE AGN   shares slumped 5 3  after a Texas district court judge ruled against the company in a patent lawsuit Shares of Electronic Arts Inc    NASDAQ EA   declined 2 4  on news that the company is closing the unit that was working on a coming  Star Wars  videogame,2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-oct-19-2017-200219803,200219803
105611,327126,AGN,Will Allergan Reward Shareholders ,opinion,"Allergan  NYSE AGN  has been a painful ride for investors  Starting last year when the proposed merger with Pfizer  NYSE PFE  fell through  Allergan has fallen  As of this writing  shares are trading at  186 and nearing their 52 week low 
But the interesting thing about Allergan is that it has a lot going for it and most analysts agree  In this post  I will show you all of the great things going on with this company and what might be some of the things holding the stock back 
Things Going Right For Allergan
Looking first at earnings  the company reported earnings per share of  4 02 which beast estimates by  0 10  Revenues came in at  4 billion  also beating estimates  this time by  70 million  This was an increase of 9  
And this growth isn t expected to slow  Analysts expect earnings growth of 13  over the next 5 years 
What is fueling this growth  First are the drugs Botox and Juvederm  Both are seeing increases in sales and these 2 treatments only account for around 10  market share in their respective segments  In other words  there is a lot of room for future growth 
In addition to these  Allergan has 6 drugs in its pipeline that are getting rave reviews and if they pass through clinical trials  are expected to be revenue machines 
Here are the 6 drugs 

Ubrogepant  treatment for migraines
Atogepant  treatment for migraines
Rapastinel  treatment for depression
ESMYA  treatment for uterine fibroids
Relamorelin  treatment for diabetic gastroparesis
Ceniciviroc  treatment for HIV infection
Abicipar  treatment for macular degeneration

Next up is international sales growth  During its recent earnings report  international sales are up over 16   with China leading the way with growth of 61   Most analysts agree that this speed of international growth should continue 
Finally  Allergan has decided to institute a share buyback program of  2 billion and has raised revenue guidance for the remainder of 2017  Add to this some analysts have a price target of  275 per share  which leaves a lot of room for price appreciation 
The Case Against Allergan
With such a great outlook  what are some things that could potentially be holding the stock price back  There are a few things  and here they are in no particular order 
Debt  the company has over  30 billion of debt on the books  I m not sure why this would be a major factor now as most investors ignored it when merger talks were happening with Pfizer  But since that deal fell through  the focus has been on the large amount of debt  Maybe is it because Allergan seems to have no interest in paying it off quickly 
Slowing sales  some of the drugs the company has on the market are seeing declines in sales  These are outweighed by the great performance of other drugs it is selling  And since drugs in the pipeline are not a guaranteed revenue stream until they actually come to market  investors can t assume the declining sales will be further hidden by newer  hot selling drugs 
So Should You Invest In Allergan 
Personally  I don t understand why investors are beating this stock down so much  The company has a great outlook and the negatives that are potentially weighing it down are not the biggest of concerns  At these levels  I would be investing in this stock 
If analysts are right and the stock hits its target of  275  you are making a ton of money  And even if it doesn t hit that target  there is still tremendous upside potential for this stock 
This author has no positions in any stock mentioned and does not plan to open any positions in any stocks mentioned for at least 72 hours after publication of this article ",2017-10-19,Modest Money,https://www.investing.com/analysis/will-allergan-reward-shareholders-200219875,200219875
105612,327127,AGN,Pharma Stock Roundup  Beat   Raise Quarter From J J  Allergan Hit By Restasis Ruling,opinion,"Johnson   Johnson   NYSE JNJ   kicked off third quarter earnings season for the pharmaceutical sector on a strong note with the company beating on both earnings and revenues  While focus remained on J J s strong earnings results  companies like Allergan   NYSE AGN   were also in the news regarding patent litigation    Recap of the Week s Most Important StoriesJ J Q3 Results Impress  Raises Outlook  J J s Q3 earnings results were strong with the company beating on both earnings and revenues  All three segments  Consumer  Medical Devices and Pharmaceuticals  did well with oncology recording robust growth  Results included contribution from pulmonary hypertension products which became a part of the company s portfolio following its acquisition of Actelion  Based on solid third quarter results  J J raised its outlook for the year as well  Read more    The company has gained 23 3  year to date  compared to the 20 6  rally of the  it belongs to Sanofi s Dupixent Tops in Allergic Inflammatory Disease Study  Sanofi  PA SASY  and partner Regeneron Pharmaceuticals announced positive phase II results on Dupixent  dupilumab  in adults with active moderate to severe eosinophilic esophagitis  a chronic  allergic inflammatory disease  Patients receiving Dupixent weekly reported a significant improvement in the ability to swallow versus placebo  Read more    The market could be huge for Dupixent if it gains timely approval given the lack of any FDA approved treatments  Dupixent has orphan drug status in the United States for this indication 
Dupixent  which has blockbuster potential  is currently approved for eczema and is being evaluated for additional indications apart from eosinophilic esophagitis  In fact  last month  the companies had announced positive top line data from a late stage study on Dupixent for uncontrolled persistent asthma   Regeneron and Sanofi are also collaborating with Aimmune Therapeutics  a clinical stage company focused on the development of treatments for potentially life threatening food allergies  Under the clinical collaboration  Aimmune s AR101 will be evaluated with adjunctive Dupixent in peanut allergic patients in a mid stage study that is scheduled to commence next year  The study will be sponsored by Regeneron while Aimmune will provide clinical supply of AR101 and food challenge materials Data on Merck s Keytruda  Priority Review for Lynparza sNDA  Merck   NYSE MRK   presented updated overall survival   OS   data on its anti PD 1 therapy  Keytruda  for the first line treatment of patients suffering from metastatic non small cell lung cancer with high levels of PD L1  The company said that the additional six months of available data continued to show a reduction in the risk of death by 37  for Keytruda compared to chemotherapy  Keytruda more than doubled median OS compared to chemotherapy after two years of follow up Keytruda is a key product in Merck s portfolio with the drug bringing in sales of  1 5 billion in the first half of 2017 Merck and partner AstraZeneca also announced that they have been granted priority review by the FDA for their supplemental New Drug Application  sNDA  for the use of PARP inhibitor Lynparza tablets in patients with gBRCA  HER2 negative metastatic breast cancer   MBC   who have been previously treated with chemotherapy either in the neoadjuvant  adjuvant or metastatic settings  A response from the agency is expected in the first quarter of 2018 Novo Nordisk  CO NOVOb  Diabetes Drug Gets FDA Panel Support  Novo Nordisk   NYSE NVO   got a boost with an FDA advisory panel  the Endocrinologic and Metabolic Drugs Advisory Committee  voting unanimously  16 0  in favor of approving once weekly semaglutide for use in type II diabetes patients  Given the favorable vote  chances of gaining FDA approval look pretty high  On its second quarter call  Novo Nordisk had said that it expects a decision from the FDA by year end  Semaglutide s approval would be a major positive for the company with the drug expected to be a key growth driver Novo Nordisk is a Zacks Rank  2  Buy  stock   you can see  Priority Review for BMY Drug Label Expansion  Bristol Myers Squibb Company s   NYSE BMY   immuno oncology therapy  Opdivo  has been granted priority review by the FDA for label expansion into the treatment of melanoma patients who are at high risk of disease recurrence following complete surgical resection  Opdivo  one of the prioritized brands in Bristol Myers  portfolio  brought in sales of  2 3 billion in the first half of 2017  Read more    Adverse Ruling for Allergan in Restasis Patent Litigation  Allergan continues to make headlines related to its blockbuster eye drug  Restasis  This time round  the company announced that it has received an adverse ruling from the U S  District Court for the Eastern District of Texas regarding four patents covering the drug  The court found the patents to be invalid  Allergan intends to appeal the ruling and said that the FDA is yet to approve any generic version of the drug  However  ophthalmology focused company  Imprimis Pharmaceuticals  announced that it is working on making lower cost alternatives to Restasis available  The company said that initial prescriptions will be 99 cents for a one month supply while refills will start at  79 per month  including shipping According to Allergan  the Restasis patents are scheduled to expire on Aug 27  2024  Allergan  which entered into a settlement agreement with a generic challenger recently  InnoPharma   has been adopting different ways to protect Restasis from generic competition  The company came under fire for entering into an agreement with the Saint Regis Mohawk Tribe  with lawmakers questioning the unconventional move adopted by the company to protect the drug from generic competition  Restasis is Allergan s second best selling drug bringing in sales of almost  1 5 billion in 2016  Lawmakers pointed out that the sovereign status of Native American tribes would make any patent challenges lengthy and complex as tribes may be immune from the legal claims made by generic drug makers to challenge patents  The deal has basically raised concerns that it will curb generic competition in the pharmaceutical industry and discourage generic drugmakers from making cheaper copy cat versions of expensive drugs Impax to Combine with Amneal  Specialty pharma company Impax Laboratories   NASDAQ IPXL   will be merging with privately held generic company Amneal Pharmaceuticals in an all stock transaction  With this merger  the combined company will have high value generic product pipelines and a growing specialty business  The deal is expected to boost Impax s stand alone earnings per share in the first 12 months and generate double digit revenue and earnings per share growth over the three years following the close of the transaction  Annual cost synergies of about  200 million are expected to be achieved within three years  The merger is expected to go through in the first half of 2018  Read more    Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index was up 1  this week with the sector reacting positively to J J s Q3 results  Among major stocks  J J was up 3 8  while Bristol Myers declined 1   Over the last six months  Bristol Myers was up 23 2   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for earnings results from companies like Novartis  Eli Lilly   NYSE LLY   and Bristol Myers among others in the coming week Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-20,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-beat--raise-quarter-from-jj-allergan-hit-by-restasis-ruling-200220056,200220056
105613,327128,AGN,Pharma Stock Roundup  Lilly Tops On All Fronts  Mixed Results From Bristol Myers,opinion,"Major pharma companies like Eli Lilly   NYSE LLY    Bristol Myers Squibb   NYSE BMY    GlaxoSmithKline plc   NYSE GSK   and Novartis  Read more    reported third quarter results this week  While it was a  beat and raise  quarter for Lilly  Bristol Myers s results were mixed Recap of the Week s Most Important StoriesLilly Tops Expectations  Mulls Options for Animal Health Segment  Lilly s third quarter results were better than expected with the company beating on both the top  and bottom line and raising its outlook for the year reflecting uptake trends for new pharmaceutical products The company also announced that it is exploring strategic alternatives for its Animal Health business  Elanco Animal Health  with an update expected by mid 2018  The company is weighing options like an initial public offering  merger  sale  or retention of the business  The segment brought in revenues of  2 3 billion so far in 2017  Read more     Lilly is a Zacks Rank  2  Buy  stock   you can see  Mixed Quarter for BMY  It was a mixed quarter for Bristol Myers with the company missing on earnings but surpassing revenue expectations  Opdivo s performance remained strong despite the presence of increasing competition with sales growing 38  to  1 3 billion  Eliquis also performed well  The company said that business development remains a top priority while it expects to buy back shares worth an additional  250 million by year end  Read more     The company has gained 4 3  year to date  compared to the 16 1  rally of the  it belongs to Sanofi  PA SASY  Files Patent Infringement Lawsuit against Mylan for Lantus  French drugmaker  Sanofi   NYSE SNY   has filed a patent infringement suit against Mylan   NASDAQ MYL   for Lantus and Lantus SoloStar  The lawsuit  filed in the United States District Court for the District of New Jersey  alleges infringement of 18 patents  Although Sanofi s diabetes product sales are under immense pressure  the Lantus franchise remains a major contributor to the top line  Earlier this year in August  Sanofi had filed a patent infringement suit against Merck alleging infringement of two patents related to Lantus products Interest Increases in Pfizer s Consumer Healthcare Business  Ever since Pfizer   NYSE PFE   announced that it is exploring strategic options for its Consumer Healthcare business  including a full or partial separation via a spin off or sale  quite a few companies have been rumored to be interested in striking a deal  This week  British pharma major  Glaxo  was asked on its third quarter call about its interest in acquiring Pfizer s Consumer Healthcare business   Glaxo s own Consumer segment has been witnessing a material slowdown in global growth across key categories with factors like pricing pressure  increasing competition and tougher emerging markets weighing on performance  Read more    Meanwhile  according to a Reuters article  Pfizer expects to start the auction process for its consumer healthcare business in November  According to sources  possible bidders apart from Glaxo and Reckitt Benckiser could include names like Procter   Gamble  Sanofi  Johnson   Johnson  NYSE JNJ  and Nestle PerformanceThe NYSE ARCA Pharmaceutical Index declined 3 7  this week  Among major stocks  Glaxo declined 10 9  mainly reflecting concerns about the company s dividend payouts especially if it strikes a deal for Pfizer s Consumer Healthcare business  Over the last six months  J J was up 16 3   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for earnings results from companies like Merck   NYSE MRK   and Pfizer Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-27,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-lilly-tops-on-all-fronts-mixed-results-from-bristolmyers-200221468,200221468
105614,327129,AGN,Is Aerie  AERI  Poised For A Beat This Earnings Season ,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   is expected report third quarter 2017 results on Nov 1  Last quarter  the company reported a narrowed than expected loss 
In fact  Aerie s performance over the last four quarters has been decent  The company reported a narrower than expected loss in three of the trailing four quarters while posting wider than expected loss in the remaining one  with an average positive surprise of 0 64  

 
Aerie s share price has increased 40 8  year to date as against the  s 5 6  decline  Earlier in the month  Aerie s stock price surged on positive news for its lead drug  Rhopressa 
Why a Likely Positive Surprise 
Our proven model indicates Aerie to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen which is the case here 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 61   This is because both the Most Accurate estimate stands at a loss of 61 cents and the Zacks Consensus Estimate is pegged at a loss of 62 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Aerie has a Zacks Rank  3  which is favorable  The combination of a Zacks Rank  3 and a positive ESP indicates a likely positive surprise  Note that we caution against stocks with Zacks Ranks  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing a negative estimate revision 
Factors at Play
With no approved product in its portfolio  Aerie depends heavily on its late stage candidates   Rhopressa and Roclatan  Hence  we expect investor focus on pipeline updates 
Aerie s lead candidate  Rhopressa  a once daily formulation for lowering intraocular pressure  IOP  is being evaluated in patients suffering from open angle glaucoma and ocular hypertension  On Oct 13  the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa s approval  The members of the committee unanimously agreed that the trials support the efficacy of netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension 
In addition  majority of the members agreed that the Rhopressa s efficacy outweigh safety risks 
The FDA has set a Prescription Drug User Fee Act date of Feb 28  2018  We note that the FDA is not bound by the Advisory Committee s guidance  but takes its advice into consideration when reviewing drugs 
Apart from Rhopressa  Aerie is also evaluating Roclatan  Aerie initiated a phase III study   Mercury 3 in Europe for its other pipeline candidate Roclatan 0 02  0 005   Roclatan is a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  is being evaluated to lower IOP in patients with glaucoma or ocular hypertension  The company plans to submit its NDA for the same in the first half of 2018 
The trial is a non inferiority trial comparing Roclatan to prescribed fixed dose combination of Ganfort  a combination of the bimatoprost along with timolol   marketed by Allergan plc   NYSE AGN   in Europe 
We expect investors to focus on further pipeline updates on the call  Cash burn for the year is projected at  110 million  up from  100 million due to further pipeline development Aerie Pharmaceuticals  Inc  Price and EPS Surprise
 

   Stock to Consider
Here is one another health care stock that you may want to consider  as our model shows that this too has the right combination of elements to post an earnings beat this quarter 
Clovis Oncology  Inc    NASDAQ CLVS   has an Earnings ESP of  2 01  and a Zacks Rank  2  The company is scheduled to release results on Nov 1   You can see  
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/is-aerie-aeri-poised-for-a-beat-this-earnings-season-200257151,200257151
105615,327130,AGN,Allergan reports higher than expected fourth quarter revenue,news," Reuters    Allergan Plc  N AGN   which is being bought by  Pfizer  Inc  N PFE   reported better than expected revenue  helped by strong performance in its U S  brands segment  which sells products like Botox and Restasis eye drops  Allergan said revenue from its U S  brands rose 38 percent to about  2 5 billion in the quarter ended Dec  31  accounting for 58 7 percent of the total revenue  The Dublin based company posted a net loss of  700 5 million  or  1 78 per share  compared with a loss of  732 9 million  or  3 34 per share  GAAP results were impacted by acquisition related expenses  the company said  Excluding special items  Allergan earned  3 41 per share  while analysts were expecting a profit of  3 34 per share  according to Thomson Reuters I B E S  Revenue rose about 74 percent to  4 20 billion in the quarter  beating analysts  average estimate of  4 19 billion  
The company also issued 2016 adjusted revenue forecast of about  17 billion  slightly shy of the analysts  average estimate of  17 66 billion ",2016-02-22,Reuters,https://www.investing.com/news/stock-market-news/allergan-reports-higher-than-expected-q4-revenue-385799,385799
105616,327131,AGN,Exclusive  Teva set to win EU okay for  40 5 billion Allergan deal   sources,news,"By Foo Yun Chee BRUSSELS  Reuters    Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA  is expected to win EU antitrust approval for its  40 5 billion bid for Allergan s  N AGN  generics unit after agreeing to sell off some of its products to appease regulators  three people familiar with the matter said on Wednesday  Teva  the world s biggest generic drugsmaker  will divest some drugs already on the market and others in the pipeline to address competition concerns by the European Commission  the people said  The package includes products from both Teva and Allergan  NYSE AGN pa   Other sources had previously told Reuters that assets worth about  1 billion in the United States  Europe and the Middle East would be sold in order to secure the green light from regulators  Teva will gain bigger economies of scale  a crucial element in the low margin generic drugs business  with the deal  the largest in Israel s corporate history  The Commission  which is scheduled to decide on the case on Thursday  and Teva declined to comment  The deal  which requires U S  approval  has triggered a warning from the American Antitrust Institute that a more concentrated generic market usually comes with higher prices  The think tank also said divestments may not be enough to ensure competition in the market in a letter to the U S  Federal Trade Commission in January  
Dublin based Botox maker Allergan in turn is to be acquired by  Pfizer  Inc  N PFE  in a  160 billion deal creating the world s largest drugmaker ",2016-03-09,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-teva-set-to-win-eu-okay-for-$40.5-billion-allergan-deal---sources-388978,388978
105617,327132,AGN,New U S  inversion rules threaten Pfizer Allergan deal,news,By Lindsay Dunsmuir and Carl O Donnell WASHINGTON NEW YORK  Reuters    The U S  Treasury Department took new steps on Monday to curb tax avoiding corporate  inversions   with the pending  160 billion merger of  Pfizer  Inc  NYSE PFE  and Allergan  NYSE AGN pa  Plc seen as a potential casualty  The changes  less than a year before President Barack Obama ends his term  follow sharp political criticism of Pfizer s and Allergan s merger  which would be the largest inversion deal ever  While the rules did not single out this deal  one of the provisions takes aim directly at it  Shares of Dublin based Allergan fell 22 percent in after market trading  while shares of New York based Pfizer rose 3 percent  The companies said they were reviewing the Treasury Department s notice   Prior to completing any review  we won t speculate on any potential impact   the companies said in a joint statement  The federal government has grappled with a wave of inversions in recent years as U S  companies have sought to slash their tax bills by redomiciling overseas  though their core operations and management usually remain in the United States even as they claim a new tax home  Several U S  presidential candidates  including Republican Donald Trump and Democrat Hillary Clinton  have seized on the issue in their campaigns  Obama  a Democrat  has called repeatedly for action by the Republican controlled U S  Congress on inversions  but lawmakers have done little  He repeated his appeal to Congress on Monday and said he welcomed the Treasury s action  The Treasury said in a statement it will impose a three year limit on foreign companies bulking up on U S  assets to avoid ownership limits for a later inversion deal   In simple words  Allergan s key deals in the prior 36 months won t be counted  as far as meeting the inversion threshold is concerned  when doing the ownership math for the Pfizer Allergan deal   Evercore analyst Umer Raffat wrote in a note   These deals include the  66 billion merger of Allergan Plc and  Actavis   NYSE AGN  Plc  the  25 billion purchase of Forest Laboratories and the  5 billion takeover of Warner Chilcott   The real issue is not so much what Allergan may prove or disprove  or whether Treasury overstepped its authority  The real question is whether Pfizer reads today s regulations as reason enough to not continue to pursue the deal   Raffat wrote  Under the agreement between Pfizer and Allergan  either party may terminate the deal if an adverse change in U S  law would cause the combined company to be treated as a U S  domestic corporation for federal income tax purposes  The terminating party would have to pay the other company up to  400 million for its expenses  according to the merger agreement  LEW SAYS LEGISLATION STILL NEEDED Treasury also said it is proposing rules to tackle a practice known as earnings stripping that is often undertaken following an inversion  Earnings stripping covers a range of financial dealings that shrink the taxable U S  profits of multinationals  A common strategy is to load up the U S  unit of a redomiciled foreign company with debt and then shift U S  profits to the new lower tax foreign jurisdiction through interest payments  The new Treasury rules would restrict related party debt for U S  subsidiaries in dealings that do not finance new investment in the United States  As part of these proposed regulations  the Internal Revenue Service would also be able to divide debt instruments into part debt and part equity  Treasury said  Treasury Secretary Jack Lew said the new actions would  further rein in  inversions  while he repeated his call that only legislation in Congress could prevent such deals  But at least one business group  the Organization for International Investment  which advocates for foreign based companies  condemned the new rules   Treasury s action would increase the cost of investing and expanding across the United States for all foreign companies and put at risk more than 12 million American workers that are supported by foreign direct investment in the United States   Nancy McLemon  the group s chief executive  said in a statement  Such tax avoidance schemes have long been a thorn in Treasury s side  The proposed deal between Pfizer and Allergan  which would create the world s largest drugmaker  prompted renewed scrutiny  Pfizer plans to redomicile in Ireland  where Allergan is based  and the companies expect to complete their merger in the second half of this year  Last November  following the announcement of the Allergan Pfizer deal  Treasury clamped down on inversions by limiting a U S  acquirer s ability to set up a new foreign parent in a third country and to  stuff  assets into a foreign parent to meet post inversion ownership limits  On Treasury s latest steps  Senator Charles Schumer of New York  who has been a co sponsor of legislation to curb inversions  said in a statement   These regulations will make potential inverters and foreign acquirers think twice before making the leap  and those bad actors should be on notice that we intend to clamp down even further    This story has been refiled to correct syntax in headline  It was earlier refiled to add dropped word  Pfizer  in paragraph 3 ,2016-04-04,Reuters,https://www.investing.com/news/stock-market-news/new-u.s.-inversion-rules-threaten-pfizer-allergan-deal-393459,393459
105618,327133,AGN,Top 5 Things to Know In the Market on Tuesday,news,"Investing com   Here are the top five things you need to know in financial markets on Tuesday  April 5 
1  Dollar tumbles to 17 month low against the yen
The dollar fell to its lowest level in 17 months against the safe haven yen on Tuesday  prompting speculation over a possible intervention to halt the appreciation of the Japanese currency 
USD JPY hit lows of 110 30  the weakest level since October 31  2014 and was last at 110 38 by 9 56GMT  or 5 56AM ET  off 0 86  for the day  The pair has fallen more than 8  so far this year 
The yen s gains fueled speculation over how much higher the currency can climb before Japanese officials act to weaken the currency 
2  Oil sinks to 4 week lows
Oil prices extended losses from the prior session on Tuesday  falling to fresh four week lows as investors are starting to doubt whether there will be an agreement between top oil producers of a coordinated freeze at a meeting in Doha  set to take place on April 17 
U S  crude was down 24 cents  or 0 67   to  35 46 a barrel  while Brent shed 31 cents  or 0 82   at  37 38 
3  Global stock markets slammed
European stocks were deep in negative territory on Tuesday  with Germany s DAX down more than 2 5   as a decline in oil prices weighed on investor sentiment and dragged down resource companies 
Meanwhile  U S  stock futures pointed to a sharply lower open  with the Dow futures falling more than 120 points  amid mixed messages from Federal Reserve policymakers on the outlook for U S  interest rate rises and as market players awaited service sector data due later in the session 
Earlier  markets in Asia closed mostly lower following losses in U S  equities overnight amid fresh declines in oil prices 
4  Allergan  NYSE AGN pa  shares plummet 20  in pre market
Shares of Allergan Plc  NYSE AGN  plunged 22 5  to  215 00 ahead of the opening bell  following news of the U S  Treasury Department s new steps to curb tax avoiding inversion deals in which a U S  company reincorporates overseas after the purchase of a foreign company 
Dublin based Allergan has agreed to be bought by  Pfizer   NYSE PFE  in the biggest inversion deal ever  Shares of Pfizer were up 2 9  at  31 62 in pre market trading 
5  Central bank roundup  India  Australia
The Reserve Bank of India cut its benchmark interest rate by 25 basis points to 6 5   the lowest since January 2011  in a widely anticipated move  The RBI hinted at another rate cut later this year if inflation trends stay benign 
Elsewhere  Australia s central bank left interest rates at a record low 2 0   where they have been for nearly a year  citing evidence of continued growth at home despite an unhelpful rise in the local dollar ",2016-04-05,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-in-the-market-on-tuesday-393549,393549
105619,327134,AGN,Dow futures tumble 100 points on global economy concern  oil slips,news,"Investing com   Wall Street futures pointed to a lower open on Tuesday as concern over global economy dampened investor sentiment and traders eyed another leg down in oil to fresh four week lows 
The blue chip Dow futures fell 114 points  or 0 66   by 10 57AM GMT  or 6 57AM ET  the S P 500 futures dropped 16 points  or 0 75   while the tech heavy Nasdaq 100 futures lost 26 points  or 0 58  
U S  futures followed European stock markets down on Tuesday after International Monetary Fund  IMF  chief Christine Lagarde urged global policymakers to act and prepare contingency measures in case downside risks to the global economy materialize 
Lagarde appeared to attempt to minimize the alarmist tendency at her lecture in Frankfurt  assuring listeners that the recovery continued and insisting that the world was not in crisis 
 The not so good news is that the recovery remains too slow  too fragile  and risks to its durability are increasing   she said 
Also taking a toll on risk appetite  crude continued to slide amid growing doubts that the April 17 meeting of major oil producers in Doha will lead to any concrete measures to solve the global supply glut 
Market players looked ahead to fresh weekly information on U S  stockpiles of crude that are expected to reach new record highs  The American Petroleum Institute will release its inventories report later in the day  while Wednesday s government report could show crude stockpiles rose by 3 3 million barrels in the week ended April 
In the meantime  U S  crude futures slipped 0 14  to  35 65 by 10 58AM GMT  or 6 58AM ET  while Brent oil lost 0 29  to  37 58 
Additionally  while waiting for the appearance of Federal Reserve  Fed  chair Janet Yellen on Thursday  markets digested new remarks from Chicago Fed president Charles Evans who stated on Tuesday that financial markets were more pessimistic in their expectations than the U S  central bank and repeated his call for two rate hikes this year 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was up 0 14  at 94 72  still close to last week s five and a half month low of 94 30 
On the macro front  investors will gauge activity in the U S  services sector in March  along with the Job Openings and Labor Turnover Summary report  JOLTS  for February at 14 00GMT  or 10 00AM ET 
Markets will also eye the February trade deficit data which will be reported at 12 30GMT or 8 30AM ET 
In company news  Allergan Plc  NYSE AGN  tumbled more than 20  in the pre market as new U S  inversion rules threatened to derail its merger with  Pfizer   NYSE PFE   The Dow Jones component rose more than 3  
Darden Restaurants Inc  NYSE DRI  is scheduled to report earnings ",2016-04-05,Investing.com,https://www.investing.com/news/stock-market-news/dow-futures-tumble-100-points-on-global-economy-concern;-oil-slips-393562,393562
105620,327135,AGN,Exclusive  Pfizer leaning toward abandoning deal with Allergan   source,news,By Pamela Barbaglia  Reuters    Drugmaker  Pfizer  Inc  N PFE  is leaning toward abandoning its  160 billion agreement to buy Allergan Plc  N AGN  in light of the U S  Treasury s new measures to curb such tax evading deals  a source familiar with the situation said on Tuesday  The discussions between the two companies and their lawyers are set to continue for the remainder of Tuesday and no final decision has been made  the source said  speaking on condition of anonymity   However  Pfizer is not willing to change the terms of its deal with Allergan which  under the new tax rules  would no longer benefit from the move to Ireland  the source said  Pfizer and Allergan declined to comment  The U S  Treasury Department took new steps on Monday to curb tax driven corporate inversions whereby companies seek to slash their tax bills by redomiciling overseas  though their core operations and management usually remain in the United States even as they claim a new tax home  Pfizer is concerned U S  President Barack Obama s administration could change the rules again to thwart a deal  The source said the company s lawyers have presented alternative ways for the two companies to salvage the inversion but there was little appetite for it   Pfizer is aware that the Treasury will keep ruling against any solution it can come up with   he said  One of the main hurdles to the deal was Treasury s decision impose a three year limit on foreign companies bulking up on U S  assets to avoid ownership limits for a later inversion deal  This means Allergan s latest deals    which include the  66 billion merger of Allergan Plc and  Actavis  Plc  the  25 billion purchase of Forest Laboratories and the  5 billion takeover of Warner Chilcott   will not be counted and the business will fail to meet the ownership math for the deal  The source said the new rules came as a surprise as Pfizer was confident of delivering on its  160 billion proposed merger with Allergan  He said the management was rather expecting the Treasury to rule against inversions toward the end of last year when the two companies were looking at ways to bypass the existing law  Pfizer and Allergan have always had an exit strategy in place  the source said  The two drugmakers agreed that either party may terminate the deal if an adverse change in U S  law would cause the combined company to be treated as a U S  domestic corporation for federal income tax purposes  The terminating party would have to pay the other company up to  400 million for its expenses  according to the merger agreement  Pfizer s Chief Executive Ian Read has tirelessly worked to find a merger partner and redomicile the business in Europe since dropping a takeover bid for British drugmaker AstraZeneca  L AZN  in 2014  The source said Read firmly believes in the industrial logic of a deal with Allergan and the tax savings that the combined entity would achieve  but he has been put off by the Treasury s latest measures and is unwilling to fight a legal battle with the U S  authorities ,2016-04-05,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-pfizer-leaning-toward-abandoning-deal-with-allergan---source-393657,393657
105631,327146,AGN,United Natural  UNFI  Approves New  200M Share Buyback Plan ,opinion,"United Natural Foods  Inc    NASDAQ UNFI   has recently approved the authorization of a new  200 million share buyback plan in a bid to boost shareholder value  However  the number and value of shares along with time to repurchase them will be decided by the company  alongside depending on various factors As of Sep 14  2017  United Natural had roughly 50 6 million outstanding shares  which are to be bought back according to the applicable securities laws Notably  the company will repurchase shares with cash from operations and borrowings from its credit facility in addition to the available cash funds Apart from United Natural  Allergan plc   NYSE AGN   and Autobytel Inc    NASDAQ ABTL   have recently sanctioned stock repurchase program to reward shareholders  While Allergan authorized a fresh  2 billion share repurchase program  Autobytel approved to repurchase additional  3 million of its common stock United Natural s PerformanceWe note that United Natural has been gaining from increased consumer preference for natural and organic brands  in spite of the ongoing industry challenges  Such headwinds include stiff competition  aggressive promotional spending and tight margins Recently  United Natural reported fourth quarter fiscal 2017 results  wherein earnings surpassed the Zacks Consensus Estimate  while revenues lagged  In fact  the company s top line has missed estimates for 11 consecutive quarters now Nevertheless  management expects net sales for fiscal 2018 in the range of  9 6  9 8 billion  signifying an increase of 3 8 5 8  over the net sales of fiscal 2017  Also  earnings are envisioned in the band of  2 67 to  2 77 per share  The Zacks Consensus Estimate  which has moved up by 6 cents in the last 30 days  is currently pegged at  2 70 for fiscal 2018 
Moreover  acquisitions have been one of the primary growth drivers for United Natural in the past few years  Such acquisitions have aided the company to expand distribution network  footprint and customer base in key markets  along with the launch of new brands  Also  management remains focused on reducing operating expenses and enhancing operating efficiency 
Consequently  this Zacks Rank  3  Hold  company s shares have rallied 13 4  in the past month  as against the  s decline of 2 3   Currently  the industry is placed at the bottom 32   175 out of 256  of the Zacks classified industries 
We believe that the latest share buyback program would significantly boost the stock and shareholder return  reflecting the company s healthy balance sheet and free cash flow A better ranked stock in the same industry includes McCormick and Company  Inc    NYSE MKC    which has a long term earnings growth rate of 9 4  and sports a Zacks Rank  1  Strong Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/united-natural-unfi-approves-new-200m-share-buyback-plan-200217822,200217822
105632,327147,AGN,Allergan s Uterine Fibroids Candidate s NDA Accepted By FDA,opinion,"Allergan plc   NYSE AGN   announced that the FDA has accepted the new drug application  NDA  for its pipeline candidate  ulipristal acetate  Allergan is looking to get ulipristal acetate approved for the treatment of abnormal uterine bleeding from fibroids in that organ  The company expects the FDA to give its decision in the first half of 2018  Once approved  ulipristal acetate will be the first once daily non surgical oral treatment option approved for the condition 
Allergan s shares have declined 1 2  compared with the  s decline of 20 4  

 
There are other companies that have pipeline candidates being evaluated for uterine fibroids  In July 2017  Bayer Aktiengesellschaft   OTC BAYRY   is evaluating vilaprisan in women suffering from uterine fibroids and in July initiated a phase III study ASTEROID for the same 
AbbVie Inc    NYSE ABBV   along with Neurocrine Biosciences  Inc  is evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids  In April this year  the companies announced positive results from a phase IIb study which showed that elagolix met its primary endpoint by significantly reducing the number of heavy bleeding days rapidly within the assessment period of six months from the baseline in comparison to a placebo  utilizing the alkaline hematin method Allergan PLC  Price

    
Zacks Rank   Stock to Consider
Currently  Allergan carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is ACADIA Pharmaceuticals Inc   NASDAQ ACAD   carrying a Zacks Rank  2  Buy   You can see  
Over the last 60 days  ACADIA s loss per share estimates narrowed from  2 63 to  2 52 for 2017 and from  1 92 to  1 85 for 2018  The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 7 97   Year to date  the share price of the company has climbed 27 9  Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-11,Zacks Investment Research,https://www.investing.com/analysis/allergans-uterine-fibroids-candidates-nda-accepted-by-fda-200218217,200218217
105633,327148,AGN,Morgan Stanley names Collins to global healthcare banking co head role  memo,news,"By Mike Stone and Olivia Oran  Reuters     Morgan Stanley   N MS  named John Collins as the co head of its global healthcare banking group  according to an internal memo on Wednesday  He replaces Clint Gartin  who will become chairman of investment banking   A veteran mergers and acquisitions banker  Collins most recently served as global operations officer in the investment banking division   Collins started his career at Morgan Stanley in 1990 as an analyst and was promoted to managing director in 2004  He left to join Moelis   Co  N MC  in 2010 before rejoining Morgan Stanley in 2013   Collins will work alongside healthcare banking co head Michele Colocci and will focus on building out the firm s global client base  He will start at his new role in January   Gartin joined Morgan Stanley in 1981 and became a managing director in 1991  He has held a number of roles within the firm  including chief administrative officer of investment banking and most recently  vice chairman of investment banking and global co head of healthcare   A Morgan Stanley spokeswoman confirmed the contents of the memo  
Morgan Stanley ranks No  2  both in the United States and globally  in the M A advisory league tables  The healthcare group has advised on high profile deals recently including  Pfizer  Inc s  N PFE   160 billion deal for Allergan PLC  N AGN  and  Shire  PLC s  L SHP  and Perrigo Company PLC s  N PRGO  successful defense against a  31 billion hostile takeover attempt by Mylan NV  O MYL  ",2015-12-02,Reuters,https://www.investing.com/news/stock-market-news/morgan-stanley-names-collins-to-global-healthcare-banking-co-head-role:-memo-374159,374159
105636,327151,AGN,Ardelyx IBS C Candidate Succeeds In Pivotal Study  Stock Up,opinion,"Ardelyx  Inc    NASDAQ ARDX   announced meeting the primary endpoint in a second phase III study   T3MPO 2   evaluating tenapanor in patients with irritable bowel syndrome with constipation  IBS C   Based on the positive top line data from this study as well as previously completed T3MPO 1 study  the company is planning to file a new drug application   NDA   in the second half of 2018 Ardelyx s stock surged more than 36  in after market trading on Wednesday  following the announcement  However  shares of the company are down 62  so far this year  significantly underperforming the  s gain of 0 7  in the period Data from the T3MPO 2 study showed that the candidate achieved the primary endpoint and all secondary endpoint with statistical significance  The candidate reduced abdominal pain by 30  in greater number of patients compared to placebo  36 5  vs  23 7   and increased one or more complete spontaneous bowel movements  CSBM  in the same week for at least six weeks in the 12 week treatment period  The improvements were consistent over the 26 weeks of study In May  the company had announced positive data from the first phase III study  T3MPO 1  on tenapanor for the same indication  Meanwhile  another phase III study  T3MPO 3  is evaluating the candidate in this indication where patients are treated for up to one year  The study is expected to be complete by 2017  Data from this study will also be included in the NDA Ardelyx is currently focusing on finding a collaboration partner to expand its reach through successful commercialization The candidate is also being evaluated in a phase III study in hyperphosphatemia in patients who are suffering from end stage renal disease and are on dialysis IBS C is a gastrointestinal disorder in which patients suffer from significant abdominal pain and constipation  Ardelyx estimates 11 million patients with IBS C in the United States However  there are other companies marketing or developing drugs for the treatment of IBS C in the United States  Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   along with its partner Allergan plc   NYSE AGN   markets Linzess for IBS C  Synergy Pharmaceuticals Inc  s   NASDAQ SGYP   is developing its chronic idiopathic constipation drug Trulance for the treatment of IBS C with an application for label expansion under review  A decision for Trulance is expected in January next year Ardelyx  Inc  Price and Consensus
    Ardelyx carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-11,Zacks Investment Research,https://www.investing.com/analysis/ardelyx-ibsc-candidate-succeeds-in-pivotal-study-stock-up-200218504,200218504
105637,327152,AGN,Non Alcoholic Steatohepatitis 2017 Progress Update,opinion,"Big time investors of late have been investing a substantial portion of their R D sources for the treatment of Non Alcoholic Steatohepatitis  NASH   The market for NASH is poised to witness rapid growth unlike other lucrative but saturated markets like cancer 
A chronic liver disease  NASH is caused by excessive fat accumulation in the liver which in turn is known as steatosis  NASH is known to affect up to 15 million people in the United Stated and could lead inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  It is expected to be the leading cause for liver transplantation by 2020  Notably  it is currently the leading cause of liver transplants for people under 50 in the United States 
NASH patients are also known to be affected by obesity and type II diabetes  The disease is prevalent in European countries along with developing countries  The market for this disease is projected around  20  35 billion  With no treatments currently approved for this disease  the market opportunity is significant 
Let us take a look at the companies whose candidates are being evaluated at present for the treatment of NASH 
Intercept Pharmaceuticials  Inc    NASDAQ ICPT   is presently evaluating lead drug Ocaliva  The drug is already approved in the United States for the treatment of primary biliary cholangitis  PBC  with an inadequate response to or intolerant to the standard of care  UDCA  The company currently has an ongoing phase III trial  REGENERATE  in non cirrhotic NASH patients with liver fibrosis and top line data from interim analysis is expected in the first half of 2019 
The company also completed a phase II trial  CONTROL  to evaluate the lipid metabolic effects of Ocaliva and cholesterol management effects of concomitant statin administration in NASH patients  The company also plans to initiate a phase III trial in NASH patients with cirrhosis in the second half of 2017  Given the success of the phase II trial  we expect Intercept to be one of the first companies to obtain an approval for NASH 
Biotech bigwig Gilead Sciences Inc    NASDAQ GILD   also has quite a few programs for patients diagnosed with NASH along with advanced fibrosis  These include selonsertib  ASK 1 inhibitor  phase III   GS 9674  FXR agonist  phase II  and GS 0976  ACC inhibitor  phase II   The company plans to initiate combination studies with three agents in 2017 
Given the increasing competition in once lucrative hepatitis C market  Gilead is looking to diversify its portfolio and foray into emerging fields of CAR T therapy and NASH  The company earlier acquired Phenex s farnesoid X receptor program comprising small molecule FXR agonists for the treatment of liver diseases including NASH 
Another major player in the biotech space  Bristol Myers Squibb Company   NYSE BMY   has a mid stage candidate in the NASH space  BMS 986036  an investigational pegylated analogue of human fibroblast growth factor 21  FGF21   a key regulator of metabolism  in patients with biopsy confirmed NASH  F1 F3  achieved its primary endpoint of significant reduction in liver fat versus placebo in April  The company was entitled the rights to research  develop and commercialize BMS 986036 from Ambrx  Inc 
Swiss major Novartis Inc    NYSE NVS   entered into a clinical trial agreement with Allergan plc   NYSE AGN   to conduct a phase IIb study in April  involving the combination of a Novartis FXR agonist and Allergan s cenicriviroc for the treatment of NASH  The company has a collaboration and license agreement with Conatus Pharmaceuticals Inc    NASDAQ CNAT   for the global development and commercialization of emricasan for patients with decompensated liver cirrhosis caused by NASH Medical   Biomedical and Genetics Industry 5YR   Return 
Bottom Line 
Given the potential in the market  there are many other big pharma and biotech companies having pipeline candidates for the treatment of NASH  We expect a lot of activity in the space going forward  A potential approval of any drug for NASH will attract more players 
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-12,Zacks Investment Research,https://www.investing.com/analysis/nonalcoholic-steatohepatitis-2017-progress-update-200218533,200218533
105638,327153,AGN,Pharma Industry Outlook   October 2017,opinion,"Pharma Sector Makes a Strong Recovery in 2017
As we head toward the end of 2017  the pharma and biotech sectors have bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 14 8   while the Nasdaq Biotechnology Index is up 26 9   This is in sharp contrast to 2016  which was a tough year for pharma and biotech stocks with the sector facing a lot of criticism for rising drug prices 
While drug pricing was a key reason for the sector s underperformance last year  it was not the only challenge for the sector  2016 was also disappointing from an R D perspective with a fewer number of drugs managing to gain FDA approval  There were some high profile pipeline failures as well  Other factors like mixed results  slower than expected new product launches and increasing competition also weighed on the sector 
However  the sector has rebounded nicely this year  New product sales ramping up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms and cash repatriation should also work in its favor 
Moreover  investors now seem more comfortable with the drug pricing scenario and are focusing more on the fundamentals of the sector  Although the drug pricing issue will remain a headwind  expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected 
Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  FDA Commissioner Scott Gottlieb said that the agency is working on a plan to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies 
Valuation Suggests Upside Potential
Going by the price to earnings multiple  which is often used to value drug stocks  the pharmaceutical industry looks pretty attractive at this point  The industry is currently trading at 15 6x forward 12 month consensus EPS estimate  below the S P 500 P E multiple of 18 2  leaving room for upside  Moreover  when compared to the industry s own performance over the last five years  it can be seen that the current multiple is below the industry high of 18 1  Keeping these numbers in mind  the current level seems to represent an attractive entry point 
So what are the factors that could drive the sector  First and foremost  this is an industry that will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong pipelines  innovative treatments  impressive results  and increased health care spending should support growth  Trump s pro business stand is also expected to benefit the sector 
A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also provide benefits 
But as we said earlier  drug pricing will remain a headline risk  Other challenges for the sector include the growing presence of biosimilars  generic competition  a slowdown in the growth of legacy products and high profile pipeline setbacks 
What About Mergers and Acquisitions  M As  
The year started off with expectations that M A activity would pick up  but this did not happen  Although several small deals were announced  big ticket M A activity was more or less limited  Johnson   Johnson s  30 billion acquisition of Actelion and Gilead s  GILD   11 9 billion acquisition of Kite were the major M A news this year  while a few bolt on deals were announced by other companies 
The sector will receive an additional boost if more M A deals are announced  though companies are likely to adopt a  wait and see  stance as they await more clarity on the drug pricing situation and tax reforms  Another major deterrent could be high valuations with companies remaining wary of bidding wars leading to over priced deals 
Meanwhile  in licensing deals continue to be popular with several big companies tying up with smaller and mid sized players with promising mid to late stage pipeline candidates or interesting technology  These deals make sense for both sides    the larger companies are able to boost their pipelines with promising candidates while the smaller ones gain access to a non dilutive source of funds that allows them to continue investing in those pipelines 
Some companies that often find themselves on the acquisition radar include names like Exelixis  Incyte and TESARO  among others 
Divesting Non Core Business Segments and Restructuring
Another trend being witnessed is the divestment of non core business segments  Companies like UCB  Novartis  Teva  TEVA   Sanofi  PA SASY   Valeant  Glaxo and AstraZeneca have all been a part of this trend  Pfizer  NYSE PFE   PFE   which has already divested several of its business segments  is currently looking at strategic options for its Consumer Healthcare business  The monetization of non core assets allows these companies to focus on their key areas of expertise and to utilize the sale proceeds for returning value to shareholders in the form of share buybacks and dividends  Smaller companies have also been monetizing assets to raise money for pipeline development 
Restructuring activities are also gaining momentum as large companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 
New Products Should Pick Up Pace
Highly awaited new products launched over the last couple of years should contribute significantly to revenues  Key new products include Ibrance  cancer   Cosentyx  psoriasis   PCSK9 inhibitors   Repatha and Praluent  Cotellic  advanced melanoma   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Tecentriq  urothelial cancer  and Taltz  moderate to severe plaque psoriasis   among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 
Competitive Threat from Biosimilars on the Rise
With the FDA approving the first biosimilar in the United States  Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the United States  The second biosimilar to gain approval in the United States was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade 
This was followed by the FDA approval of biotech giant Amgen s  AMGN  Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  AbbVie s Humira  adalimumab   which is used for a wide range of inflammatory diseases 
And then there is Lilly and Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway  Basaglar was found to be sufficiently similar to Sanofi s Lantus to scientifically justify reliance  and to establish its safety and efficacy for the approved uses 
Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen and Remicade biosimilars alone represent potential savings of more than  22 billion 
Apart from Amgen  Novartis and Pfizer  companies like Biogen  NASDAQ BIIB  and Allergan  NYSE AGN  are targeting the highly lucrative biosimilars market  While all these companies are Zacks Rank  3  Hold  stocks  you can see  
What to Expect from the Sector in Q3 Earnings Season 
A look at consensus earnings expectations for the Medical sector from the Zacks  report for the third quarter earnings season shows that earnings will grow 0 8  from the year ago period on revenue growth of 4 7   This compares to Q2 earnings growth of 7  and revenue growth of 4 4   The Medical sector is one of the few Zacks sectors that have consistently recorded growth over the last few quarters 
While new products should start contributing significantly and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  challenges remain in the form of currency headwinds  additional competition  pricing pressure  slowdown in growth of mature products and loss of exclusivity for certain key drugs 
Zacks Industry Rank
Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  Large Cap Pharmaceuticals  Biomedical and Genetics  Drugs and Generic Drugs 
We put our 265 industries into two groups  the top half  i e  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank  
Over the last 10 years  using a one week rebalance  the top half beat the bottom half by a factor of more than 2 to 1 
Currently  the Zacks Large Cap Pharmaceuticals sector is at the bottom 38  while the Zacks Biomedical and Genetics as well as the Zacks Drug sectors are at the bottom 40   The Zacks Generic Drugs sector  which is facing intense pricing competition  is at the bottom 27   Overall  factors like pricing pressure and slowdown in sales of legacy products are weighing on these stocks 
Click here to know more  About 
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/pharma-industry-outlook--october-2017-200219150,200219150
105639,327154,AGN,Zacks Industry Outlook Highlights  Gilead  Teva  Pfizer And Amgen,opinion,For Immediate ReleaseChicago  IL   October 17  2017   Today  Zacks Equity Research discusses the Industry  Pharmaceuticals  Part 1  including Gilead  Nasdaq   NASDAQ GILD        Teva  NYSE   NYSE TEVA        Pfizer  NYSE   NYSE PFE       and Amgen  Nasdaq   NASDAQ AMGN       Industry  Pharmaceuticals  Part 1Link  Pharma Sector Makes a Strong Recovery in 2017As we head toward the end of 2017  the pharma and biotech sectors have bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 14 8   while the Nasdaq Biotechnology Index is up 26 9   This is in sharp contrast to 2016  which was a tough year for pharma and biotech stocks with the sector facing a lot of criticism for rising drug prices While drug pricing was a key reason for the sector s underperformance last year  it was not the only challenge for the sector  2016 was also disappointing from an R D perspective with a fewer number of drugs managing to gain FDA approval  There were some high profile pipeline failures as well  Other factors like mixed results  slower than expected new product launches and increasing competition also weighed on the sector However  the sector has rebounded nicely this year  New product sales ramping up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms and cash repatriation should also work in its favor Moreover  investors now seem more comfortable with the drug pricing scenario and are focusing more on the fundamentals of the sector  Although the drug pricing issue will remain a headwind  expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  FDA Commissioner Scott Gottlieb said that the agency is working on a plan to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies Valuation Suggests Upside PotentialGoing by the price to earnings multiple  which is often used to value drug stocks  the pharmaceutical industry looks pretty attractive at this point  The industry is currently trading at 15 6x forward 12 month consensus EPS estimate  below the S P 500 P E multiple of 18 2  leaving room for upside  Moreover  when compared to the industry s own performance over the last five years  it can be seen that the current multiple is below the industry high of 18 1  Keeping these numbers in mind  the current level seems to represent an attractive entry point So what are the factors that could drive the sector  First and foremost  this is an industry that will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong pipelines  innovative treatments  impressive results  and increased health care spending should support growth  Trump s pro business stand is also expected to benefit the sector A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also provide benefits But as we said earlier  drug pricing will remain a headline risk  Other challenges for the sector include the growing presence of biosimilars  generic competition  a slowdown in the growth of legacy products and high profile pipeline setbacks What About Mergers and Acquisitions  M As  The year started off with expectations that M A activity would pick up  but this did not happen  Although several small deals were announced  big ticket M A activity was more or less limited  Johnson   Johnson s  30 billion acquisition of Actelion and Gilead s Nasdaq       11 9 billion acquisition of Kite were the major M A news this year  while a few bolt on deals were announced by other companies The sector will receive an additional boost if more M A deals are announced  though companies are likely to adopt a  wait and see  stance as they await more clarity on the drug pricing situation and tax reforms  Another major deterrent could be high valuations with companies remaining wary of bidding wars leading to over priced deals Meanwhile  in licensing deals continue to be popular with several big companies tying up with smaller and mid sized players with promising mid to late stage pipeline candidates or interesting technology  These deals make sense for both sides    the larger companies are able to boost their pipelines with promising candidates while the smaller ones gain access to a non dilutive source of funds that allows them to continue investing in those pipelines Some companies that often find themselves on the acquisition radar include names like Exelixis  Incyte and TESARO  among others Divesting Non Core Business Segments and RestructuringAnother trend being witnessed is the divestment of non core business segments  Companies like UCB  Novartis  Teva  NYSE       Sanofi  PA SASY   Valeant  Glaxo and AstraZeneca have all been a part of this trend  Pfizer  NYSE       which has already divested several of its business segments  is currently looking at strategic options for its Consumer Healthcare business  The monetization of non core assets allows these companies to focus on their key areas of expertise and to utilize the sale proceeds for returning value to shareholders in the form of share buybacks and dividends  Smaller companies have also been monetizing assets to raise money for pipeline development Restructuring activities are also gaining momentum as large companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile New Products Should Pick Up PaceHighly awaited new products launched over the last couple of years should contribute significantly to revenues  Key new products include Ibrance  cancer   Cosentyx  psoriasis   PCSK9 inhibitors   Repatha and Praluent  Cotellic  advanced melanoma   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Tecentriq  urothelial cancer  and Taltz  moderate to severe plaque psoriasis   among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori Competitive Threat from Biosimilars on the RiseWith the FDA approving the first biosimilar in the United States  Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the United States  The second biosimilar to gain approval in the United States was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade This was followed by the FDA approval of biotech giant Amgen s Nasdaq      Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  AbbVie s Humira  adalimumab   which is used for a wide range of inflammatory diseases And then there is Lilly and Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway  Basaglar was found to be sufficiently similar to Sanofi s Lantus to scientifically justify reliance  and to establish its safety and efficacy for the approved uses Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen and Remicade biosimilars alone represent potential savings of more than  22 billion Apart from Amgen  Novartis and Pfizer  companies like Biogen  NASDAQ BIIB  and Allergan  NYSE AGN  are targeting the highly lucrative biosimilars market  While all these companies are Zacks Rank  3  Hold  stocks  you can see  Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-gilead-teva-pfizer-and-amgen-200219247,200219247
105640,327155,AGN,Allergan  AGN  Loses Restasis Patent Lawsuit  Shares Fall,opinion,"Allergan plc   NYSE AGN   announced that a Texas federal district court invalidated four of the six patents covering Restasis  Allergan s second bestselling drug  This potentially opens the doors for early generic competition  Shares of the company fell almost 3 5  in response on Monday 
The company is disappointed with the court s ruling and is planning to appeal against it  However  if this ruling is upheld even after the appeal  it will negatively impact Restasis sales  The invalidated patents   111   048   930 and  191   which are listed in the Orange Book were set to expire in Aug 27  2024 
Restasis is approved for the treatment of chronic dry eye 
Allegan s shares have outperformed the  so far this year  While the company s stock fell 5 6   the industry was down 23 5  in that period 

In 2015  Allergan had filed patent infringement lawsuits against a group of generic drug manufacturers which include Teva Pharma   NYSE TEVA   and Mylan   NASDAQ MYL   among others  The companies are seeking approval for generic versions of Restasis in the United States  Meanwhile  last week  Allergan settled with InnoPharma  granting the latter the right to market generic Restasis beginning Feb 24  2024 
Moreover  in a bid to dismiss inter partes review for Restasis  Allergan signed an agreement last month with Saint Regis Mohawk Tribe  to gain sovereign immunity  However  court litigation is out of the purview of sovereign immunity  This unconventional move by the company has been questioned by many lawmakers and was criticized by generic manufacturers  Such deals to gain sovereign immunity will make the launch of generics a lengthy and complex legal process  curbing competition 
Restasis generated  676 4 million in sales worldwide in the first the six months of 2017  The FDA s approval to Shire PLC s   NASDAQ SHPG   Xiidra last year has already increased competition for the drug  Any earlier than expected generic entry following the invalidation of these patents will further increase competition Allergan PLC  Price and Consensus
 

   Allergan carries a Zacks Rank  4  Sell  
You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-loses-restasis-patent-lawsuit-shares-fall-200219410,200219410
105641,327156,AGN,Teva divesting  1 billion in assets to clear Allergan deal,news,"By Carl O Donnell  Reuters    Teva Pharmaceutical  N TEVA  Industries Ltd  TA TEVA  is in the process of divesting about  1 billion worth of assets to address antitrust concerns over its deal to buy Allergan  N AGN pa  Plc s  N AGN  generic drugs business  people familiar with the matter said  Teva agreed in July to purchase Allergan s generics unit for  40 5 billion in cash and stock  establishing the Israeli company as the largest manufacturer of generic drugs at a time when pharmaceutical benefits managers and insurers are putting increased pressure on drug prices  While small by comparison  a successful divestiture will help ensure that the deal with Allergan is completed as scheduled by the first quarter of 2016  also allowing Allergan to merge with  Pfizer  Inc  N PFE  and create the world s largest drugmaker  Pfizer s  160 billion acquisition of Allergan  the largest healthcare merger of all time  is contingent upon Allegan completing the sale of its generic drugs business to Teva  That deal is expected is to close in the second half of 2016  The assets that Teva is divesting span the United States  Europe and the Middle East  and will be sold in a series of processes that are expected to be completed in early 2016  the sources said   Teva expects to complete its U S  divestitures by January  and has received offers from a number of generic pharmaceutical companies  one of the sources added   
The sources asked not to be identified because the matter is confidential  Teva was not immediately available for comment   The deal between Teva and Allergan has been seen as a potential source of antitrust concern due to the overlap in the two companies  drug portfolios  Shortly before the deal  Allergan received a subpoena from the antitrust division of the Department of Justice related to the pricing of its generic products ",2015-12-03,Reuters,https://www.investing.com/news/stock-market-news/teva-divesting-$1-billion-in-assets-to-clear-allergan-deal:-sources-374312,374312
105642,327157,AGN,Morgan Stanley names Collins to global healthcare banking co head role  memo,news," This December 2 story was corrected to change Morgan Stanley s North American ranking from No  2 to No  3  By Mike Stone and Olivia Oran  Reuters     Morgan Stanley   N MS  named John Collins as the co head of its global healthcare banking group  according to an internal memo on Wednesday  He replaces Clint Gartin  who will become chairman of investment banking   A veteran mergers and acquisitions banker  Collins most recently served as global operations officer in the investment banking division   Collins started his career at Morgan Stanley in 1990 as an analyst and was promoted to managing director in 2004  He left to join Moelis   Co  N MC  in 2010 before rejoining Morgan Stanley in 2013   Collins will work alongside healthcare banking co head Michele Colocci and will focus on building out the firm s global client base  He will start at his new role in January   Gartin joined Morgan Stanley in 1981 and became a managing director in 1991  He has held a number of roles within the firm  including chief administrative officer of investment banking and most recently  vice chairman of investment banking and global co head of healthcare   A Morgan Stanley spokeswoman confirmed the contents of the memo  
Morgan Stanley ranks No  2  both in the United States and globally  in the M A advisory league tables  The healthcare group has advised on high profile deals recently including  Pfizer  Inc s  N PFE   160 billion deal for Allergan PLC  N AGN  and  Shire  PLC s  L SHP  and Perrigo Company PLC s  N PRGO  successful defense against a  31 billion hostile takeover attempt by Mylan NV  O MYL  ",2015-12-07,Reuters,https://www.investing.com/news/stock-market-news/morgan-stanley-names-collins-to-global-healthcare-banking-co-head-role:-memo-374864,374864
105643,327158,AGN,Pfizer  Allergan say combined drug pipeline  underappreciated ,news,"By Ransdell Pierson NEW YORK  Reuters    The research chiefs of betrothed drugmakers  Pfizer  Inc  N PFE  and Allergan  N AGN  say the proposed combination of their experimental drugs deserves more credit  including potential blockbuster treatments for schizophrenia and depression  Pfizer agreed in November to buy Botox maker Allergan for  160 billion in a transaction meant to slash Pfizer s tax rate and achieve other cost savings  The tax inversion deal would shift Pfizer s headquarters to Dublin and is slated to close in the second half of 2016  Industry regulators and U S  lawmakers have criticized the deal for its reliance on financial engineering  But more recently  company executives have said medical benefits of bringing together their drugs in development have been  underappreciated  and some healthcare analysts are making the case that combining the two research programs will yield sales and earnings ahead of Wall Street expectations   There has been a lot of attention on financial aspects of the deal  but there has been an underestimation of the Allergan pipeline   Pfizer research chief Mikael Dolsten told Reuters in a recent interview  Dolsten told Reuters that Allergan s depression treatment rapastinel  which has shown promise of treating symptoms within hours rather than weeks required for standard treatments  could be  transformational  if it succeeds in late stage trials  Further studies of Vraylar  a treatment for schizophrenia and bipolar disorder approved in September  could show it has  unique  ability to treat negative symptoms of schizophrenia  such as social withdrawal and slowed movement  Dolsten said   Relamorelin  potentially the first new treatment in decades for delayed emptying of food from the stomach  is another big opportunity  he said  Allergan has predicted peak annual sales of up to  2 billion for rapastinel and up to  1 billion each for Vraylar  relamorelin  an experimental treatment for uterine fibroids called Esmya and Allergan s recently approved Viberzi treatment for irritable bowel syndrome   It expects potential annual sales of up to  2 billion each for experimental treatments for migraine headaches and for a leading cause of blindness called macular degeneration   The forecasts have largely fallen on deaf ears  said  Credit Suisse   VX CSGN  analyst Vamil Divan    Right now there are almost no expectations for Allergan s pipeline   Divan said   Even if they get just a few billion dollars out of these products  that would be more than people give them credit for   Pfizer expects a modest lift to its earnings in 2018 from the planned purchase of Allergan  a boost of 10 percent in 2019 and a high teens percentage boost in 2020  Divan said he expects Allergan s pipeline to add a few extra percentage points of sales and earnings growth in all three of those time periods   We have 70 products in mid  to late stage trials  but I think our pipeline is under recognized   David Nicholson  research head for Allergan s branded products  said in an interview  He attributed the lack of visibility to the rapid series of acquisitions and deals that created the present day Allergan  folding in the portfolios of large drugmakers such as Forest Laboratories and  Actavis     It takes time for people to realize these are all part of one company s pipeline   said Nicholson  Nomura analyst Shibani Malhotra said less than 20 percent of Allergan sales are from outside the United States  and that Botox and other Allergan products could eventually get a surprisingly strong boost from 70 new international markets that Pfizer will open up  including Japan   The biggest advantage for Allergan would be in leveraging Pfizer s global sales forces   Malhotra said  Pfizer Chief Executive Ian Read is slated to lead the combined company  with Allergan s younger Chief Executive Brent Saunders serving as president and chief operating officer  Nicholson  in a presentation on Tuesday with Read  Saunders and Dolsten at the annual JP Morgan Healthcare Conference in San Francisco  said Allergan s pipeline deserves far more credit  as does Pfizer s array of immuno oncology drugs  
 When we put these pipelines together   other  companies better watch out  ",2016-01-12,Reuters,"https://www.investing.com/news/stock-market-news/pfizer,-allergan-say-combined-drug-pipeline-'underappreciated'-379813",379813
105644,327159,AGN,Pfizer weighing sale of Hospira s pump business  Bloomberg,news," Reuters    Drugmaker  Pfizer  Inc  N PFE  is thinking about selling hospital products maker Hospira s infusion pump business for about  2 billion  Bloomberg reported  citing people familiar with the matter  Talks are said to be at an early stage  Bloomberg reported on Wednesday     Pfizer closed its  15 billion acquisition of  Hospira   N HSP   which makes biosimilars and generic versions of injectable drugs  in September   A Pfizer spokeswoman declined to comment   Infusion pumps are computerized and are designed to deliver medications directly into patients  bloodstreams   
In November  Pfizer said it would buy Botox maker Allergan Plc  N AGN  in a deal worth  160 billion  which would create the world s largest drugmaker ",2016-01-13,Reuters,https://www.investing.com/news/stock-market-news/pfizer-weighing-sale-of-hospira's-pump-business:-bloomberg-380011,380011
105645,327160,AGN,Johnson Controls to buy Ireland based Tyco for  16 5 billion,news,"By Greg Roumeliotis and Bernie Woodall  Reuters     Johnson Controls  Inc  N JCI   a U S  maker of car batteries and heating and ventilation equipment  agreed to acquire Ireland based peer Tyco International Plc  N TYC  in a  16 5 billion deal that will lower its tax bill  the companies said on Monday   By moving its headquarters to Cork  Ireland  Johnson Controls would become the latest major U S  company to carry out a so called tax inversion after drug giant  Pfizer  Inc  N PFE  structured such a deal with Irish peer Allergan Plc  N AGN  last November  While the tax benefits are not as profound as is the case of Pfizer s deal with Allergan  the news was enough to stir controversy among politicians in a U S  presidential election year   I have a detailed and targeted plan to immediately put a stop to inversions and invest in the U S   block deals like Johnson Controls and Tyco  and place an  exit tax  on corporations that leave the country to lower their tax bill   Democratic Presidential candidate Hillary Clinton said in a statement  Vermont Senator Bernie Sanders  Clinton s opponent for the Democratic Presidential nomination  also criticized the deal  calling it a disaster for American taxpayers  Others saw it as an opportunity to also highlight what they argue are the weaknesses of the U S  tax system   Absent comprehensive tax reform that includes shifting to a territorial tax system with base erosion protections  Congress ought to examine viable bipartisan solutions that will effectively target and combat inversions and not tip the balance to tax driven foreign acquisitions of U S  firms   said U S  Senate Finance Committee Chairman Orrin Hatch  a prominent Republican  The merger will combine Johnson Controls  commercial buildings business with Tyco s fire security offerings  accelerating Johnson Controls  transformation following its decision to spin off its automotive parts unit   Milwaukee based Johnson Controls has a market value  22 5 billion  while Cork  Ireland based Tyco  which specializes in fire protection systems is valued at  14 2 billion  The deal will create savings of at least  500 million in the first three years  the companies said  They expect to save an additional  150 million a year through tax synergies   The move would be consistent with Johnson Control s strategy of transforming from an auto supplier into a multi industry leader   UBS analyst Colin Langan said in a client note  Johnson Controls  shares ended trading in New York on Monday down 3 9 percent at  34 21  while Tyco s shares ended up 11 6 percent at  34 15  Tyco was ahead of many big U S  industrial companies in seeking tax relief by moving its legal residence offshore  The company moved its headquarters to Bermuda from Exeter  New Hampshire in 2007  then to Switzerland in 2009  and to Cork in 2014  Tyco said in 2014 that its move to Cork was tax neutral and that it occurred because of Swiss laws capping executive pay and tighter immigration rules  TREASURY THRESHOLD Johnson Controls  shareholders will own about 56 percent of the combined company  with Tyco shareholders owning the remainder  thanks in part to a cash consideration of about  3 9 billion that Johnson Controls shareholders will receive  Keeping Johnson Controls  shareholders ownership of the combined company below 60 percent was important for the company because the latest U S  Treasury rules  in a bid to limit inversions  placed some restrictions on deals that cross this threshold   The cash consideration is supplied by Tyco very much with the tax inversion in mind  This way you can engage unrestricted in strategies that free up your undistributed foreign earnings   said Robert Willens  a corporate tax and accounting consultant  The new company  Johnson Controls Plc  will be initially headed by Johnson Controls Chief Executive Alex Molinaroli and will continue to trade on the New York Stock Exchange  After 18 months  Tyco s George Oliver will become CEO and Molinaroli will become executive chair for one year  after which Oliver will become chairman and CEO  Johnson Controls has been preparing to spin off its automotive seating and interiors business and said on Monday the spinoff was on track for early first fiscal quarter of 2017  Shares of Johnson Controls have lost more than a quarter of their value since the start of 2015  while Tyco s shares have fallen over 30 percent  Tyco was broken up into three companies after turnaround expert Edward Breen took the helm from former CEO Dennis Kozlowski  who was convicted in 2005 of grand larceny  securities fraud and other charges  Under Breen  Tyco spun off its electronics and healthcare businesses in 2007  He expanded Tyco s security business with the  1 9 billion acquisition of Broadview Security in 2010  In 2012  Tyco was again broken up into three pieces   one selling valves and controls for the energy market that merged with  Pentair  Inc  N PNR   while its commercial fire and security businesses combined into  New Tyco  and traded under Tyco s symbol  The third piece consisted of the ADT North American residential security business  now  ADT Corp   N ADT   Breen is CEO of U S  chemical giant DuPont  N DD   which last month agreed to combine with Dow Chemical  N DD  in a  120 billion merger  Tax savings were seen as a primary driver of that deal   
Centerview Partners and  Barclays   L BARC  were financial advisers to Johnson Controls  while Lazard and Goldman Sachs  N GS  advised Tyco   Citigroup  Inc  N C  provided financing for the transaction ",2016-01-25,Reuters,https://www.investing.com/news/stock-market-news/johnson-controls-to-merge-with-tyco-381548,381548
105646,327161,AGN,J J profit beats forecasts  helped by lower taxes  cost cuts,news,"By Ransdell Pierson  Reuters    Johnson   Johnson  N JNJ  on Tuesday reported higher than expected quarterly earnings  helped by cost cuts and lower taxes  and gave a 2016 profit outlook slightly above Wall Street s  Shares of the diversified healthcare company rose almost 5 percent to  101 18 as investors shrugged off fourth quarter sales and a 2016 revenue outlook that were both below analysts  estimates  Edward Jones analyst Ashtyn Evans said investors were cheered by J J s vow to make more of its medical devices market leaders and to launch 30 new devices this year  including a new insulin pump   It s an optimistic outlook  but the market is reacting to that   said Evans  who noted that company devices in recent quarters have been the company s slowest growing business  Device sales fell 3 3 percent to  6 43 billion in the fourth quarter  J J last week said it would cut about 3 000 jobs within the struggling unit over the next two years to generate annual cost savings of up to  1 billion and to focus on priority areas like artificial knees and devices for trauma surgery  The strong U S  dollar  which hurts the value of sales outside the United States  weighed heavily on J J s fourth quarter results  and analysts said J J would probably rely on more cost cuts in 2016 to meet its profit forecast  The company said it expects earnings of  6 43 to  6 58 per share for 2016  excluding special items   Wall Street analysts forecast earnings of  6 38 per share  J J forecast 2016 sales at  70 8 billion to  71 5 billion  Analysts on average were expecting  71 88 billion  In a conference call with analysts  Chief Executive Officer Alex Gorsky said the company was interested in dealmaking within its main consumer  medical device and pharmaceuticals segments to boost longer term results  although it believes valuations of potential acquisition targets were inflated in 2015   We will continue to be very active in the M A area   Gorsky said  noting that J J in recent years had derived about half its revenue from acquired products   The company has pursued fairly small  tuck in  acquisitions in recent years as some other large healthcare companies struck big deals  most notably  Pfizer  Inc s  N PFE  planned  160 billion acquisition of Allergan Inc  N AGN   J J s fourth quarter sales fell 2 4 percent to  17 81 billion  below the analysts  average estimate of  17 88 billion  But sales would have risen 4 4 percent if not for the stronger dollar   Prescription drug sales rose 0 8 percent to  8 06 billion  buoyed by demand for arthritis drug Remicade and psoriasis treatment Stelara  Sales of consumer brands  which include its Tylenol painkiller and Neutrogena skin care products  were hit especially hard by the stronger dollar  falling 7 9 percent to  3 32 billion  Fourth quarter net income rose about 28 percent to  3 22 billion  or  1 15 per share  from a year earlier  when it took special charges of about  1 4 billion  Excluding restructuring charges and other items  J J earned  1 44 per share  topping analysts  average estimate of  1 42   J J is the first major U S  drugmaker to announce quarterly earnings   
Investors on Tuesday also focused on comments from Republican presidential front runner Donald Trump that the U S  Medicare insurance program for the elderly and disabled could reap huge savings by negotiating with drugmakers ",2016-01-26,Reuters,"https://www.investing.com/news/stock-market-news/j-amp;j-profit-beats-forecasts,-helped-by-lower-taxes,-cost-cuts-381758",381758
105647,327162,AGN,Pfizer 2016 forecasts disappoint  shares fall,news," Reuters    U S  drugmaker  Pfizer  Inc  N PFE  on Tuesday forecast 2016 revenue and earnings below analysts  estimates  largely because of the strong dollar  The company s shares fell 1 5 percent to  29 70 even though soaring Prevnar pneumonia vaccine sales led to a stronger than expected fourth quarter  Pfizer  which plans to buy Botox maker Allergan Inc  N AGN  later this year in a  160 billion deal  said it expected earnings of  2 20 to  2 30 per share in 2016  That would not be much different from  2 20 reported for 2015 and below Wall Street forecasts of  2 36  Evercore ISI analyst Mark Schoenebaum said Pfizer attributed its cautious 2016 forecast largely to the stronger dollar  which hurts the value of sales outside the United States   Pfizer forecast 2016 revenue of  49 billion to  51 billion  up from  48 9 billion in 2015 but shy of Wall Street expectations of  52 49 billion  The company s forecasts do not include the planned purchase of Allergan in the second half of the year   Revenue rose 7 percent to  14 05 billion in the fourth quarter  ahead of the average analyst estimate of  13 56 billion  according to Thomson Reuters I B E S   Global vaccine revenue rose 45 percent to  1 92 billion  with sales of Prevnar 13 doubling in the United States  Pfizer said Prevnar benefited from increased use by adults and the timing of government purchases of the product for children   Pfizer s net income fell to  613 million  or 10 cents per share  from  1 23 billion  or 19 cents per share  a year earlier  Excluding special items  the company earned 53 cents per share  topping the analysts  average estimate of 52 cents   Pfizer said on Nov  23 that it would buy Allergan to slash its U S  tax bill and obtain faster growing medicines   The combined company would be based in Dublin and have an expected tax rate of 17 percent to 18 percent by 2017  well below Pfizer s current corporate tax rate of about 25 percent   
Allergan shares are trading at about a 17 percent discount to their value under the all stock deal as some investors still fear the U S  government could stop the tax inversion deal ",2016-02-02,Reuters,https://www.investing.com/news/stock-market-news/pfizer-revenue-rises-as-pneumonia-vaccine-sales-jump-382858,382858
105648,327163,AGN,Aerie  AERI  Up On FDA Review Committee Result For Rhopressa,opinion,"Shares of Aerie Pharmaceuticals  Inc    NASDAQ AERI   have moved up 15 8  in the last one week on positive news for its lead drug  Rhopressa 

In fact  Aerie s stock has surged 71 4  year to date  compared with the  s gain of 3 4  
On Oct 13  the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa s approval  The members of the committee unanimously agreed that the trials support the efficacy of netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension 
In addition  majority of the members agreed that the Rhopressa s efficacy outweigh safety risks 
The FDA has set a Prescription Drug User Fee Act date of Feb 28  2018  We note that the FDA is not bound by the Advisory Committee s guidance  but takes its advice into consideration when reviewing drugs 
Rhopressa is designed to lower intraocular pressure   IOP  in patients through novel mechanisms of action   MOAs   The company believes that Rhopressa represents the first new MOAs for lowering IOP in patients with glaucoma in over 20 years 
A potential approval of the drug will significantly boost Aerie s growth prospects   However  Rhopressa is expected to face tough competion from established branded and generic drugs like such as Novartis AG s   NYSE NVS   Simbrinza and Travtan  and Allergan plc s   NYSE AGN   Lumigan  as well as other smaller biotechnology and pharmaceutical companies 
Meanwhile  Aerie initiated a phase III study   Mercury 3 in Europe for its other pipeline candidate Roclatan 0 02  0 005   Roclatan is a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  is being evaluated to lower IOP in patients with glaucoma or ocular hypertension  The company plans to submit its NDA for the same in the first half of 2018 
Zacks Rank 
Aerie currently carries a Zacks Rank  4  Sell  
You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-up-on-fda-review-committee-result-for-rhopressa-200219407,200219407
105649,327164,AGN,Teva offers EU concessions over Allergan generics deal   EU,news,"By Foo Yun Chee BRUSSELS  Reuters    Teva Pharmaceutical  N TEVA  Industries Ltd  TA TEVA  has offered concessions to allay antitrust concerns over its  40 5 billion bid for Allergan s  N AGN  generics unit  European Union regulators said on Friday   Commitments have been submitted and the new legal deadline is set on 10 March   European Commission spokesman Ricardo Cardoso said in an email  without providing details  Acquiring the  Actavis  generic business would strengthen Teva s position as the world s largest generics drugmaker  The company was not immediately available for comment  Teva plans to sell about  1 billion worth of assets in the United States  Europe and the Middle East to resolve antitrust concerns  people familiar with the matter have told Reuters  The deal also needs U S  regulatory approval  Earlier this month  the American Antitrust Institute flagged competitive concerns about the deal to the U S  Federal Trade Commission  
Dublin based Botox maker Allergan  N AGN pa  in turn is to be acquired by  Pfizer  Inc  N PFE  which would slash the latter s tax rate once it moves its headquarters to Dublin ",2016-02-19,Reuters,https://www.investing.com/news/stock-market-news/teva-offers-eu-concessions-over-allergan-generics-deal---eu-385492,385492
105672,327187,AGN,Allergan Authorizes New  2B Share Buyback Plan  Stock Up,opinion,"In an effort to reward shareholders  the board of directors of Allergan  NYSE AGN plc   NYSE AZN   has sanctioned a new stock repurchase program  thereby allowing the company to buy back shares worth up to  2 billion 
The company also reiterated its commitment to increase quarterly cash dividend annually 
The company retained its previous target to pay down  3 75 billion of debt in 2018  These announcements reflect the company s strategy to develop a strong future cash flow position and investment grade ratings by reducing its debt burden  Notably  Allergan has been prudent in paying down debt  The company repaid debt of almost  10 billion in 2016 and  2 6 billion in the first half of 2017 
The company has also reaffirmed financial guidance for third quarter 2017 and FY17 which it previously issued in August earlier  Allergan expects total revenue in the range of  15 85  16 05 billion for 2017  Adjusted earnings per share are expected in the range of  16 05  16 45 during the same period 
Allergan s shares were up almost 4  after the company announced the buyback of shares along with the reaffirmation of financial guidance and a hike in quarterly cash dividend  Also  shares have nudged up 0 8  so far this year against the 20 9  decrease of the  during the period 

We remind investors that the company has recently completed a share buyback of  15 billion including a  10 billion accelerated share repurchase  It bought back shares from a portion of the net proceeds it generated from divestiture of its generics business to Teva Pharmaceutical   NYSE TEVA    last August 
In a separate press release  Allergan announced retirement of Executive Vice President  EVP  and Chief Financial Officer  CFO   Tessa Hilado  However  the company stressed that Hilado will continue in her current role until a replacement is found  The organization has already initiated a search for a new CFO Allergan PLC  Price

   Zacks Rank   Stocks to Consider
Allergan currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates reduced from  1 46 to  1 29 for 2017 and from  1 41 to  1 26 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
ACADIA s loss per share estimates narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
Can Hackers Put Money INTO Your Portfolio 
Earlier this month  credit bureau Equifax  NYSE EFX  announced a massive data breach affecting 2 out of every 3 Americans  The cybersecurity industry is expanding quickly in response to this and similar events  But some stocks are better investments than others 
Zacks has just released Cybersecurity  An Investor s Guide to help Zacks com readers make the most of the  170 billion per year investment opportunity created by hackers and other threats  It reveals 4 stocks worth looking into right away ",2017-09-26,Zacks Investment Research,https://www.investing.com/analysis/allergan-authorizes-new-2b-share-buyback-plan-stock-up-200215539,200215539
105673,327188,AGN,Pharma Stock Roundup  J J Drug Gets CRL  Label Expansion For Merck And BMY Drugs,opinion,"Key highlights in the pharma sector include a complete response letter   CRL   from the FDA for Johnson   Johnson s   NYSE JNJ   investigational rheumatoid arthritis   RA   treatment and FDA approval for Merck s   NYSE MRK   and Bristol Myers Squibb s   NYSE BMY   cancer drugs Recap of the Week s Most Important StoriesCRL for J J RA Drug  J J s Janssen Biotech got a CRL from the FDA for sirukumab for the treatment of moderately to severely active RA  The agency has asked for additional data on the safety of sirukumab  This does not come as a surprise considering the investigational treatment failed to get the support of an FDA advisory panel last month  Given the safety concerns raised by the panel  the request for additional data was more or less expected  J J intends to meet with the agency to determine the requirements for gaining approval for the IL 6 inhibitor Meanwhile  the company has submitted a new drug application   NDA   for the first darunavir based single tablet regimen for the treatment of HIV  Approval would make this combination the only complete regimen with the potential to deliver the advantages of a single table regimen with the high genetic barrier to resistance of darunavir and the demonstrated safety profile of TAF Another FDA Nod for Merck s Keytruda  Merck s anti PD 1 therapy  Keytruda  has gained FDA approval for yet another indication  The cancer therapy  which is already available for a wide range of indications  can now be used in previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction  GEJ  adenocarcinoma whose tumors express PD L1  This marks the tenth new indication for Keytruda over a three year period Keytruda is a key product in Merck s portfolio with the drug bringing in sales of  1 5 billion in the first half of 2017  The company is working on expanding the label of the drug which is currently in more than 550 studies covering a wide range of cancers and treatment settings  Read more    Merck is a Zacks Rank  3  Hold  stock  You can see  Allergan Announces Share Buy Back  CFO Departure  Allergan   NYSE AGN   continues to work on returning capital to its shareholders with the company announcing its intention to buy back shares worth  2 billion  This comes shortly after the company completed a  15 billion share buyback program  Allergan also reaffirmed its commitment to increase its cash dividend every year while reiterating its commitment to maintaining investment grade credit ratings and paying down  3 75 billion of debt in 2018 The company also announced the departure of Tessa Hilado  executive vice president and chief financial officer   CFO    who will be retiring from the company once a successor is appointed Bristol Myers  Opdivo Gets Another Approval  Bristol Myers also gained approval for another indication for its immune oncology therapy  Opdivo  With the latest approval  Opdivo can now be used for the treatment of hepatocellular carcinoma patients previously treated with Nexavar  sorafenib   This makes Opdivo the first and only immuno oncology agent to be approved for this patient population  Read more    The company also gained approval in Japan for the use of Opdivo for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy  Gastric cancer is highly prevalent in Asian countries and is the second most commonly diagnosed cancer in Japan Bristol Myers also entered into a clinical trial collaboration with AbbVie under which a combination of Opdivo and AbbVie s investigational antibody drug conjugate ABBV 399 will be evaluated in c met overexpressing non small cell lung cancer  NSCLC  Bristol Myers stock has gained 8 1  year to date  compared to the 17 1  rally of the  it belongs to Priority Review for Aradigm Drug  Aradigm got priority review for Linhaliq for the treatment of non cystic fibrosis bronchiectasis  NCFBE  patients with chronic infections with pseudomonas aeruginosa  P  aeruginosa   A response from the agency regarding the approval status of the drug should be out by Jan 26  2018  NCFBE  a severe  chronic and rare disease  affects more than 150 000 people in the United States and over 200 000 people in Europe  With no drug currently approved for the treatment of this condition  there is significant unmet need  Aradigm s shares were up 32 8  on the news Performance
Large Cap Pharmaceuticals Industry 5YR   Return
The NYSE ARCA Pharmaceutical Index is down 0 1  so far this week  Among major stocks  Lilly   NYSE LLY   is up 0 9  while Pfizer   NYSE PFE   is down 1 3   Over the last six months  Bristol Myers was up 14 7  while Glaxo   NYSE GSK   declined 1 6   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for the usual pipeline and regulatory updates Can Hackers Put Money INTO Your Portfolio Earlier this month  credit bureau Equifax  NYSE EFX  announced a massive data breach affecting 2 out of every 3 Americans  The cybersecurity industry is expanding quickly in response to this and similar events  But some stocks are better investments than others Zacks has just released Cybersecurity  An Investor s Guide to help Zacks com readers make the most of the  170 billion per year investment opportunity created by hackers and other threats  It reveals 4 stocks worth looking into right away ",2017-09-26,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-jj-drug-gets-crl-label-expansion-for-merck-and-bmy-drugs-200215479,200215479
105674,327189,AGN,Allergan  AGN  Pipeline   New Drugs To Counter Generic Woes ,opinion,We issued an updated research report on Allergan plc   NYSE AGN   on Sep 26 Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions  In 2017 so far  through the accretive acquisitions of LifeCell and ZELTIQ  Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting  respectively Allergan sold its generics business in Aug 2016 and the Anda distribution business to Teva Pharmaceuticals   NYSE TEVA   in Oct 2016  Following the closure of the Teva deal  Allergan can now focus on the branded segment and is using the proceeds to buy back shares  pay down debt and pursue additional deals Key products like Botox and Linzess and new products such as Viberzi and Vraylar are supporting sales growth at Allergan  In fact  at the second quarter conference call  Allergan raised its previously issued earnings and sales guidance for 2017  following a strong first half performance and solid outlook for the rest of the year Allergan also boasts a strong branded pipeline with meaningful data read outs in the next few months  The company has more than 65 projects in mid to late stage development including six key phase III programs  This year  Allergan is extending its R D pipeline to adjacent categories like NASH  Parkinson s disease  and gene therapy with many promising phase II III programs in development  Allergan has nine product launches planned for 2017 Biosimilars also represent significant opportunity  Allergan and Amgen  Inc    NASDAQ AMGN   have a collaboration agreement for the worldwide development and commercialization of biosimilar versions of Roche s   OTC RHHBY   cancer drugs  Avastin  Herceptin and Rituxan  The biosimilar version of Avastin  to be marketed by the trade name of Mvasi  received FDA approval this month  making it the first cancer biosimilar to get FDA nod However  while we remain optimistic about the company s growth prospects  it is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio Meanwhile  new competition for key growth drivers  Restasis and Linzess  is an investor concern  Shire s dry eye disease drug Xiidra  launched last year  poses strong competition for Restasis  Meanwhile  Synergy s Trulance  plecanatide  was launched in the second quarter for CIC  which could pose competition to Linzess Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-28,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-pipeline--new-drugs-to-counter-generic-woes-200216201,200216201
105675,327190,AGN,Allergan s SNDA For Anti Infective Avycaz Accepted By FDA,opinion,"Allergan plc   NYSE AGN   announced that a supplemental New Drug Application  sNDA  for its anti infective drug  Avycaz  has been accepted and granted priority review by the FDA We remind investors that Avycaz is currently approved for the treatment of complicated urinary tract infections   cUTI    including pyelonephritis  The drug  in combination with metronidazole  is approved for treating complicated intra abdominal infections   cIAI   The company is looking to get the label of the drug expanded to include hospital acquired bacterial pneumonia ventilator associated bacterial pneumonia  HABP VABP   A decision from the FDA is expected in first quarter 2018 Allergan shares are up 0 5  so far this year  outperforming the  s decline of 19 8  in the same period The sNDA submission was based on non inferiority data from a pivotal REPROVE study  which evaluated safety and efficacy of Avycaz in adult patients with HABP VABP  The study showed that Avycaz was non inferior to meropenem in reducing death irrespective of cause The drug also showed in vitro  study in controlled environment outside human body  activity against certain gram negative bacteria  which causes HABP VABP We remind investors that the FDA issued a refusal to file letter last month to the sNDA for Vraylar to expand its label to include negative symptoms associated with schizophrenia However  boosting its generic portfolio  the company received approval in September for the biosimilar version of Roche Holding  SIX ROG  AG s   OTC RHHBY   cancer drug  Avastin for the treatment of five types of cancer Allergan PLC  Price and Consensus
    Zacks Rank   Stocks to ConsiderAllergan carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Biogen Inc    NASDAQ BIIB    While Regeneron sports a Zacks Rank  1  Strong Buy   Biogen carries a Zacks Rank  2  Buy   You can see  Regeneron s earnings per share estimates have increased from  13 84 to  14 99 for 2017 and from  15 79 to  16 65 for 2018 over the last 60 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 25 9  year to date Biogen s earnings per share estimates have moved up from  21 37 to  21 42 for 2017 and from  23 11 to  23 23 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 6 41   The share price of the company has increased 11 5  year to date Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/allergans-snda-for-antiinfective-avycaz-accepted-by-fda-200216820,200216820
105676,327191,AGN,Allergan s Botox Gets FDA Nod For Forehead Line Treatment,opinion,Allergan plc   NYSE AGN   announced that the FDA has approved its Botox Cosmetic product for a third indication   temporary improvement of moderate to severe forehead lines in appearance  associated with frontalis muscle activity in adults So far this year  Allergan s share price has slipped 0 1  compared with the  s decline of 19 8  Approved for therapeutic and aesthetic use  Botox is a key top line driver for Allergan  Its cosmetic indications include improvement in appearance of glabellar lines  frown lines between the brows  and severe crow s feet  This latest FDA approval makes Botox Cosmetic the only neurotoxin treatment approved for three facial aesthetic treatments   forehead lines  crow s feet wrinkles at the outer corner of eyes and glabellar lines Botox s therapeutic diseases include overactive bladder  cervical dystonia  chronic migraine and strabismus among others The drug generated  1 53 billion sales in the first half of 2017  an increase of 12 7  year over year  driven by strong demand trends  The latest label expansion approval for forehead line treatment  which enjoys a pent up demand  should drive the sales further We remind investors that Botox became a part of Allergan s portfolio following the March 2015  77 billion acquisition of Allergan Inc  Having previously commanded a strong presence in the generics market  Allergan with the merger has found place on the top 10 list of world wide pharma companies based on sales  Later  Allergan sold its generics business as well as the Anda distribution arm to Teva Pharmaceutical Industries Ltd    NYSE TEVA   in 2016  However  in April 2016  Pfizer  Inc    NYSE PFE   had terminated an agreement to combine with Allergan Allergan carries a Zacks Rank  3  Hold   You can see Stocks to ConsiderA better ranked biotech drug stock is Biogen  Inc    NASDAQ BIIB   with a Zacks Rank  2  Buy  Biogen has seen the Zacks Consensus Estimate for current year earnings being revised 4 5  upward for 2017 and 2 3  for 2018 over the past 90 days  Shares of the company have rallied 11 9  this year Can Hackers Put Money INTO Your Portfolio Earlier this month  credit bureau Equifax  NYSE EFX  announced a massive data breach affecting 2 out of every 3 Americans  The cybersecurity industry is expanding quickly in response to this and similar events  But some stocks are better investments than others Zacks has just released Cybersecurity  An Investor s Guide to help Zacks com readers make the most of the  170 billion per year investment opportunity created by hackers and other threats  It reveals 4 stocks worth looking into right away ,2017-10-03,Zacks Investment Research,https://www.investing.com/analysis/allergans-botox-gets-fda-nod-for-forehead-line-treatment-200216967,200216967
105677,327192,AGN,Teva Shares Plummet After Mylan s Copaxone Generic Gets FDA Approval,opinion,"Shares of Teva Pharmaceuticals   NYSE TEVA   opened more than 13  lower on Wednesday  plunging close to their 52 week low in the process  The struggling Israeli pharma firm  which has faced significant pressure to reduce its debt load  is sliding once again this time because of a brand new competitor 
Indeed  the big news rocking the pharmaceutical world today is that Mylan   NASDAQ MYL   another major drugmaker wrapped up in its own chaos over the past year or so has received FDA approval to sell a generic version of Teva s multiple sclerosis drug Copaxone 
Mylan said that it wants to quickly introduce a slew of new generics to the market in an effort to curb rising drug costs  Today s approval will certainly help the company s top line  but it will also be the first step in this new plan which should contribute to Mylan s ongoing efforts to regain public trust after being embroiled in its EpiPen price hike scandal 
Shares of Mylan opened about 15  higher and touched a nearly two month high of  38 14  Teva  on the other hand  plummeted to  16 33 per share and is now down more than 54  on the year 
Mylan had missed out on approval of a Copaxone generic twice this year  and company management was recently forced to lower its earnings forecast due to a delay in launching key drugs  In a note this morning  Wells Fargo  NYSE WFC  analysts said the new generic should add 13 cents per share to Mylan s quarterly earnings  so long as the FDA grants the company a 180 day exclusivity period 
For Teva  this new competition could have serious consequences  as Copaxone generated more than  1 billion in sales in the second quarter alone 
 The ongoing challenges to its generics business and that with FDA approval of Mylan s generic of Copaxone  earnings cash flow are likely to affected   Jefferies analyst David Steinberg wrote in a note    Although Copaxone  has been a strong contributor to cash flow over the last two decades  growing generic competition to this franchise has been an overhang on TEVA shares in recent years  
Fresh generic competition from Mylan only adds to Teva s growing list of problems  Over the past few months  the Israeli firm has been desperately scrambling to ramp up assets in an effort to preserve its credit rating and cut its mounting debt 
After completing its deal to buy Allergan s   NYSE AGN   generics division last year  Teva s debt pile swelled to a whopping  35 billion  In August  on the same day that the company reported lackluster Q2 earnings  slashed its full year outlook  and cut its dividend by 75   Teva CEO Yitzhak Peterburg said that asset sales will likely generate at least  2 billion  well above that  1 billion level that was previously forecasted 
For now  Teva remains a Zacks Rank  3  Hold   However  the company will need to improve performance in its own generics unit and pare down its debt quickly if it wants to lift share prices anytime soon 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
Can Hackers Put Money INTO Your Portfolio 
Just last month  credit bureau Equifax  NYSE EFX  announced a massive data breach affecting 2 out of every 3 Americans  The cybersecurity industry is expanding quickly in response to this and similar events  But some stocks are better investments than others 
Zacks has just released Cybersecurity  An Investor s Guide to help Zacks com readers make the most of the  170 billion per year investment opportunity created by hackers and other threats  It reveals 4 stocks worth looking into right away ",2017-10-03,Zacks Investment Research,https://www.investing.com/analysis/teva-shares-plummet-after-mylans-copaxone-generic-gets-fda-approval-200217028,200217028
105678,327193,AGN,Pharma Stock Roundup  Mylan Up  Teva Down On Copaxone News  Lawmakers Question Allergan Deal ,opinion,"This week  companies like Allergan   NYSE AGN    Teva   NYSE TEVA   and Mylan   NASDAQ MYL   were in the limelight  While Mylan and Teva were in the news related to the FDA approval of Mylan s generic versions of Teva s top selling branded drug  Copaxone  Allergan is under fire for its agreement with the Saint Regis Mohawk Tribe for Restasis Recap of the Week s Most Important StoriesAllergan s Restasis Deal under Fire  Allergan s deal with the Saint Regis Mohawk Tribe  announced early in September  has come under fire with lawmakers questioning the unconventional move adopted by the company to protect its blockbuster eye drug  Restasis  from generic competition  Under the terms of the deal  Allergan transferred six patents related to Restasis to the Tribe while being granted exclusive licenses to the patents  In return  Allergan will pay  13 75 million upon execution of the agreement as well as annual royalties of  15 million Restasis is Allergan s second best selling drug bringing in sales of almost  1 5 billion in 2016  While one of the original patents on the drug s active ingredient was set to expire in 2014  Allergan filed additional patents extending protection to 2024 Lawmakers pointed out that the sovereign status of Native American tribes would make any patent challenges lengthy and complex as tribes may be immune from the legal claims made by generic drug makers to challenge patents  In fact  the Tribe is filing to dismiss the ongoing inter partes review   IPR   of the Restasis patents based on their sovereign immunity from IPR challenges The deal has basically raised concerns that it will curb generic competition in the pharmaceutical industry and discourage generic drugmakers from making cheaper copy cat versions of expensive drugs Allergan has been asked by the Committee on Oversight and Government Reform to provide certain documents and information about the deal by Oct 17  2017 Mylan s Gain  Teva s Loss  In a major development  Mylan gained FDA approval for its generic version of Teva s top selling branded drug  Copaxone  for multiple sclerosis  Mylan gained approval for the 40 mg  thrice weekly  dosage as well as the once daily 20 mg formulation  With Mylan being among the first applicants to challenge the 40 mg patent  the company could  therefore  enjoy 180 days of exclusivity though a formal communication from the FDA regarding the same is yet to come  Mylan has launched both products  According to QuintilesIMS  brand sales for the 20 mg and 40 mg doses were approximately  700 million and  3 64 billion  respectively  for the 12 months ending Jul 31  2017  Mylan also gained approval for the 40 mg dose in the EU While the FDA approval of generic Copaxone is a big boost for Mylan  it is a major blow for Teva which is currently facing a whole lot of challenges  Teva issued a statement saying that the launch of the 40 mg formulation before the final resolution of pending patent infringement lawsuits with Mylan will be treated as an  at risk  launch which means Mylan would have to pay significant damages if the court upholds the patents protecting the drug The entry of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  Sandoz and Momenta have been on the market for quite a while with Glatopa  a generic version of the 20 mg dose  is expected to cut Teva s 4Q earnings by at least 25 cents per share  Additional details should be out when the company announces third quarter results on November 2  The entry of generic Copaxone just adds to the existing list of problems being faced by Teva  Read more    Novo Nordisk  CO NOVOb  Gets FDA Approval for Fiasp  Novo Nordisk   NYSE NVO    which has a strong presence in the diabetes market  provided some regulatory updates on its diabetes franchise  The company gained FDA approval for Fiasp  a fast acting mealtime insulin  for the treatment of adults with diabetes  The approval process was not exactly smooth with the company receiving a complete response letter last year when the agency had asked for additional information related to the assay for the immunogenicity and clinical pharmacology data  Read more    Meanwhile  the European Medicines Agency s   EMA   Committee for Medicinal Products for Human Use   CHMP   endorsed the company s plan to update the EU label of Tresiba to include results from the DEVOTE study showing a significant reduction in the risk of severe hypoglycemia Novo Nordisk is a Zacks Rank  2  Buy  stock   you can see  Sanofi Regeneron Score a Win in PCSK9 Inhibitor Litigation  Sanofi   NYSE SNY   and partner Regeneron got a major boost with the U S  Court of Appeals for the Federal Circuit ordering a new trial related to Amgen s claims regarding patents for PCSK9 inhibitors  The court also vacated the permanent injunction in the lawsuit which means Sanofi and Regeneron can continue selling their PCSK9 inhibitor  Praluent  in the United States Favorable Court Ruling for Lilly  Another company that got a positive ruling on the patent front is Eli Lilly and Company   NYSE LLY    The company said that the Patent Trial and Appeal Board of the U S  Patent and Trademark Office   PTO   ruled in its favor regarding the vitamin regimen patent for cancer therapy  Alimta  pemetrexed for injection   If the patent is upheld  Alimta will be safe from generic competition until May 2022  This decision has removed an overhang on the shares  Alimta brought in sales of more than a billion dollars in the first half of 2017 This week  Lilly also gained FDA approval for a new cancer treatment  Verzenio  for use in women with HR   HER2  advanced breast cancer Lilly has gained 19 2  year to date  compared to the 17 9  rally of the  it belongs to Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index gained 1 9  so far this week  Among major stocks  Lilly is up 3 1   Over the last six months  Bristol Myers was up 21 8  while Glaxo   NYSE GSK   declined 0 7   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for the usual pipeline and regulatory updates 4 Stocks to Watch after the Massive Equifax  NYSE EFX  HackCybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans  But which stocks are the best buy candidates right now  And what does the future hold for the cybersecurity industry Equifax is just the most recent victim  Computer hacking and identity theft are more common than ever  Zacks has just released Cybersecurity  An Investor s Guide to inform Zacks com readers about this  170 billion year space  More importantly  it highlights 4 cybersecurity picks with strong profit potential ",2017-10-05,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mylan-up-teva-down-on-copaxone-news-lawmakers-question-allergan-deal-200217461,200217461
105679,327194,AGN,Exclusive  Pfizer  Allergan CEOs agree on combined company roles   sources,news," Reuters     Pfizer  Inc  N PFE  and Allergan Inc  N AGN  chief executives have agreed on the roles they would assume in a combined company  removing one of the last hurdles to the largest ever healthcare merger  people familiar with the matter said  Pfizer CEO Ian Read will be CEO of the combined company  while Allergan CEO Brent Saunders will have another very senior role  the people said on Friday  without providing more details   
The sources asked not to be identified because the negotiations are confidential  Pfizer declined to comment while Allergan did not immediately respond to a request for comment ",2015-11-20,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-pfizer,-allergan-ceos-agree-on-combined-company-roles---sources-372317",372317
105680,327195,AGN,Euro and commodities skid  Asia stocks mixed,news,"By Wayne Cole SYDNEY  Reuters    The euro sagged to a seven month trough on Monday as the prospect of more policy easing in Europe benefited the U S  dollar  while activity in Asian shares was crimped by a holiday in Japan  The strength of the dollar also combined with worries about Chinese demand to clobber commodity prices again  sending copper to its lowest in over six years  Financial spreadbetters expect European stocks to open mixed  with Britain s FTSE 100  FTSE  about 0 4 percent lower  while Germany s DAX  GDAXI  and France s CAC 40  FCHI  start the day about 0 05 percent and 0 04 percent higher  respectively   The head of the European Central Bank  Mario Draghi  last week offered the strongest hint yet that the ECB will unveil fresh stimulus measures at its Dec  3 policy meeting  The contrast with the U S  Federal Reserve could not be more stark as it seems destined to lift rates in December for the first time in a decade  underpinning the dollar  The impact was clear in bond markets where yields on two year German debt hit their lowest ever at negative 38 basis points  while U S  yields were at their highest since mid 2010  As a result the premium offered by U S  paper yawned out to 130 basis points  the fattest since 2006  The drag from negative yields pulled the euro down to  1 0613   breaching the recent low of  1 0615  It also peeled off to 130 52 yen  EURJPY    again the lowest since April  before bouncing back to 130 74   Against a basket of currencies  DXY  the dollar firmed 0 3 percent to 99 881  while also rising to 123 19 yen   Equities were quieter  with MSCI s broadest index of Asia Pacific shares outside Japan  MIAPJ0000PUS  off 0 2 percent  South Korea s main index  KS11  gained 0 7 percent while Australian stocks  AXJO  added 0 4 percent  Wall Street could find support from news of another blockbuster merger  Sources told Reuters that  Pfizer  Inc  N PFE  was due to secure formal board approval for its acquisition of Allergan Plc  N AGN  for more than  150 billion  creating the world s biggest drug maker  The E Mini contract on the S P 500  ESc1  was little changed at 2 089 25 on Monday  The Dow  DJI  ended Friday up 0 51 percent  while the S P 500  SPX  added 0 38 percent and the Nasdaq  IXIC  0 62 percent  The S P 500 boasted its best week in almost a year  while Europe s main stock index enjoyed its strongest week in a month    Interestingly  markets are treating the prospects of policy divergence reasonably well   said Jo Masters  a senior economist at Australia and New Zealand Bank   But with two of the world s major central banks about to head on divergent policy paths  can such smooth sailing continue over the months ahead   they wondered   Increased policy tension is likely to mean that volatility remains elevated   The strength of the dollar kept commodity prices under pressure  Gold  hovered around  1 070 56 an ounce having touched its lowest level in nearly six years  Copper  slipped to a fresh six and a half year low  as traders bet metals prices had further to fall given China s slowing factory demand   MET L  
Oil prices sank again with U S  crude  CLc1  off  1 05 at  40 85 a barrel  while Brent  LCOc1  lost 69 cents to  43 97 O R  ",2015-11-23,Reuters,"https://www.investing.com/news/stock-market-news/euro-and-commodities-skid,-asia-stocks-mixed-372488",372488
105681,327196,AGN,Top 5 Things to Know Today,news,"Investing com   Here are the top five things you need to know today in financial markets 
1  Global shares fall as commodities plunge
Global stock markets slumped on Monday as steep declines in oil and metal prices spooked investors 
Asian stocks ended mostly lower in holiday thinned trade as soft commodity prices weighed  Markets in Japan remained closed for Labor Thanksgiving day 
In Europe  equities traded lower  as commodity producers led declines 
Meanwhile  U S  stock futures were down 0 2   suggesting a weak opening on Wall Street later in the day 
2  Oil tumbles more than  1 on global oversupply fears
Oil prices plunged on Monday  as oversupply concerns remained a factor for oil markets  U S  crude was last down  1 23  or 2 92   to  40 67 a barrel  while Brent sank 83 cents  or 1 86   to  43 84 a barrel 
The oil market has been on the defensive in recent months amid uncertainty about how quickly the global glut of crude is set to shrink 
3  Metals struggle near multi year lows
Gold  silver and copper traded at levels not seen in more than five years on Monday as expectations of higher interest rates in the U S   a broadly stronger U S  dollar and slower global economic growth  especially in China  weighed 
4  Euro slides to 7 month lows on ECB easing prospects
The euro fell to the lowest level in seven months against the dollar on Monday amid heightened expectations that the European Central Bank will scale up its monetary easing program next month  EUR USD hit lows of 1 0600  the weakest since April 15 and was last at 1 0623  down 0 2  
Upbeat euro zone private sector survey data failed to ease jitters over growth prospects for the region 
5   Pfizer  set to buy Allergan  N AGN pa  for more than  150 billion
Pfizer secured formal board approval on Sunday for its acquisition of Allergan for more than  150 billion in a deal that will create the world s biggest drug maker  The deal  the largest ever in the healthcare sector  will be announced on Monday 
Allergan  N AGN  shares were up 5 6  in premarket trade  while Pfizer  N PFE  tacked on 0 87  ",2015-11-23,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-know-today-372520,372520
105682,327197,AGN,5 things to know today ,news,"Investing com  
Global shares fall Global stock markets slumped on Monday as steep declines in oil and metal prices spooked investors 
Oil tumbles more than  1 Oil prices plunged  weighed down by the stronger dollar and ongoing concerns that global supply is outstripping demand 
Metals near multi year lowsGold  silver and copper traded at more than 5 year lows as prospects for higher US interest rates and the strong dollar weighed 
Euro slides to 7 month lowsThe euro fell to 7 month lows on heightened expectations that the European Central Bank will scale up monetary easing next month 
  Pfizer  set to buy Allergan  N AGN pa Pfizer  N PFE  is set to acquire Botox maker Allergan  N AGN  in a deal worth more than  150 billion that will create the world s largest drug maker ",2015-11-23,Investing.com,https://www.investing.com/news/economy-news/5-things-to-know-today-372536,372536
105683,327198,AGN,Democratic candidate Sanders condemns Pfizer Allergan deal as  disaster ,news,"WASHINGTON  Reuters    Democratic presidential candidate Bernie Sanders condemned the  Pfizer  Inc  N PFE  acquisition of Allergan Plc  N AGN  on Monday and urged the Obama administration to block the deal  Pfizer said it would buy Botox maker Allergan in a record breaking deal worth  160 billion to cut its U S  tax bill by moving its headquarters to Ireland  
 The Pfizer Allergan merger would be a disaster for American consumers who already pay the highest prices in the world for prescription drugs   Sanders said in a statement ",2015-11-23,Reuters,https://www.investing.com/news/politics-news/democratic-candidate-sanders-condemns-pfizer-allergan-deal-as-'disaster'-372577,372577
105684,327199,AGN,Pfizer to buy Allergan in  160 billion deal,news,"By Ransdell Pierson and Bill Berkrot NEW YORK  Reuters     Pfizer  Inc  N PFE  on Monday said it would buy Botox maker Allergan  N AGN pa  Plc in a deal worth  160 billion to slash its U S  tax bill  rekindling a fierce political debate over the financial maneuver  The acquisition  which would shift Pfizer s headquarters to Ireland  would be the biggest ever tax inversion  The news prompted Democratic presidential front runner Hillary Clinton to promise to propose measures to prevent the increasingly popular and controversial practice aimed at helping U S  companies lower their taxes by re incorporating overseas   Shares of Allergan and Pfizer fell more than 2 percent as investors learned the merger  which would create the world s largest drugmaker  would bring lower cost savings than they had hoped  It also would delay a decision by Pfizer on whether it would sell off its division consisting of products facing generic competition   U S  President Barack Obama has called inversions unpatriotic and has tried to crack down on the practice   Senator Bernie Sanders  another Democratic candidate for president  called on the Obama administration to stop the deal  which  would allow another major American corporation to hide its profits overseas    Congress also must pass real tax reform that demands that profitable corporations pay their fair share of taxes   Sanders said   To avoid potential restrictions  the transaction was structured as smaller  Dublin based Allergan buying Pfizer  although the combined company will be known as Pfizer Plc and continue to be led by Chief Executive Officer Ian Read  The U S  Treasury  concerned about losing billions in tax revenue  has been taking steps to limit the benefits of tax inversion deals  but it admitted last week that it would take legislation from Congress to stop such moves  The Allergan acquisition will delay New York based Pfizer s decision on whether to sell off its lower margin unit by two years  until late 2018  the company said  The deal enhances offerings from both Pfizer s faster growing branded products business  with additions like Botox  and its older established products unit  Still  investors had been hoping Pfizer would sell off the lower margin business in 2017  a move now put off by the time required to integrate Allergan    The only thing I d really say I m disappointed about is Pfizer s postponing their break up   said Gabelli Funds portfolio manager Jeff Jonas  He called the delay decision  pretty conservative and a little late    Others were disappointed by other aspects of the deal  including the projected cost savings  and a lack of details on potentially increased share buybacks   Synergies of  2 billion plus in the third year are less than the  4 billion we had estimated in year 1   said Cowen and Co analyst Steve Scala  On a conference call with analysts  Pfizer said the merger would give it enhanced access to its tens of billions of dollars parked overseas and allow for more share buybacks  dividend payments and business development  The combined company would have annual sales of about  64 billion  It was not immediately clear how many jobs would be lost as a result of the deal  which is expected to close in the second half of 2016  TAX SAVINGS Allergan CEO Brent Saunders will become president and chief operating officer of the combined company  with oversight of all commercial businesses   Read  who has long sought to slash Pfizer s U S  tax rate  said the deal would help put the company on  on a more competitive footing  with overseas based rivals   The company had estimated it would pay about 25 percent in corporate taxes this year  compared with about 15 percent for Allergan  Pfizer Chief Financial Officer Frank D Amelio said he expected a combined tax rate of 17 percent to 18 percent by 2017  The deal comes some 18 months after the failure of Read s initial attempt at an inversion  a  118 billion bid to acquire Britain based AstraZeneca Plc that ran into stiff opposition from that company s management and UK politicians  Saunders said the combination would provide access to about 70 additional worldwide markets for Allergan products  such as Botox wrinkle treatment  Alzheimer s drug Namenda and dry eye medication Restasis  For 166 year old Pfizer  Allergan would be the fourth huge acquisition over the last 15 years   one for each of the last 4 CEOs   following purchases of Warner Lambert  Pharmacia and Wyeth  This also caps a record year for healthcare mergers and acquisitions  taking their cumulative value in 2015 to more than  600 billion    They include prior big deals involving Saunders  such as the  70 5 billion acquisition of Allergan by  Actavis   N AGN   which then took the Allergan name  and an agreement to sell that company s huge portfolio of generic drugs to Teva Pharmaceutical Industries  N TEVA  for  40 5 billion  Allergan and Pfizer estimated their merger would increase earnings per share by 10 percent  excluding special items  in 2019 and add by a high teens percentage rate in 2020   The deal values Allergan shares at  363 63 each  about 16 percent more than their closing price of  312 46 on Friday  Pfizer shareholders would control of 56 percent of the combined company  The record breaking deal includes  8 billion in debt  Pfizer said  Allergan shareholders would receive 11 3 shares in the combined entity for each of their shares  Pfizer stockholders can get cash or one share of the combined company for each of their shares  but the aggregate amount of cash must range from  6 billion to  12 billion  Plans call for four current directors of Allergan  including Saunders and Executive Chairman Paul Bisaro  to join Pfizer s 11 member board  the companies said  Reports that the companies were in talks emerged a month ago  Pfizer was advised by Guggenheim Securities  Goldman Sachs   Co  N GS   Centerview Partners and Moelis   Co  Its legal advisers are Wachtell  Lipton  Rosen   Katz  Skadden  Arps  Slate  Meagher   Flom LLP and A   L Goodbody   
Allergan was advised by J P  Morgan   Morgan Stanley   N MS  and Cleary Gottlieb Steen   Hamilton LLP  Latham   Watkins LLP and Arthur Cox are its legal advisers ",2015-11-23,Reuters,https://www.investing.com/news/stock-market-news/pfizer-set-to-buy-allergan-for-more-than-$150-billion-372456,372456
105685,327200,AGN,U S  stocks slightly lower as Health Care  Energy rally loses steam,news,"Investing com    U S  stocks closed slightly lower on Monday on a volatile day of trading  as a rally in the health care and energy sectors faded late in the session 
Investors reacted to a major merger in the pharmaceutical industry after  Pfizer  Inc  N PFE  acquired Allergan Plc  N AGN  in a  160 billion  the biggest deal ever in the healthcare sector  The merger allows Pfizer to move its corporate headquarters to Dublin  the home of Allergan  to slash its corporate tax rate from 25 to 17   The deal also comes in the wake of an announcement from the U S  Department of the Treasury last week to take additional actions to deter U S  multi national corporations from engaging in tax inversion strategies by acquiring a smaller competitor in order to relocate to the company s home country 
The Dow Jones Industrial Average lost 31 13 or 0 17  to 17 792 68  while the NASDAQ Composite index fell 2 44 or 0 05  to 5 102 48  erasing some of their gains from late last week  The S P 500 Composite index also lost 2 58 or 0 12  to 2 086 59  as six of 10 sectors closed in the red  Stocks in the Utilities  Telecommunications and Technology sectors lagged  each falling by more than 0 50  on the session 
The top performer on the Dow was  Home Depot  Inc  N HD   which gained 2 25 or 1 73  to 132 46 after topping analyst expectations with its third quarter results  Last week  Home Depot  N HD  reported stronger than expected revenues after comparative store sales surged 7 3  on the quarter  Pfizer closed as the worst performer on the Dow after falling 0 89 or 2 77  to 31 29 
The biggest gainer on the NASDAQ was  Autodesk Inc   O ADSK  which rose 2 08 or 3 44  to 62 63  Last week  Autodesk  O ADSK  announced that it will open a new 60 000 square office in Toronto  one which will become the software giant s largest office in the world  The worst performer was VimpelCom  O VIP   which fell 0 27 or 7 14  to 3 45  Shares in the Russian telecom company are still down more than 35  this year 
The top performer on the S P 500 was  Tyson Foods  Inc  N TSN   which soared 4 27 or 9 77  to 47 92 after the largest meat processor in the U S  reported stronger than expected revenues last quarter  The worst performer was CONSOL Energy Inc  N CNX   which fell 0 57 or 7 24  to 7 30  Earlier on Monday U S  crude futures closed slightly lower  paring gains from earlier in the session after Saudi Arabia hinted it could agree to cut crude prices when OPEC meets next week 
Shares in  Chipotle Mexican Grill Inc   N CMG  rose 23 69 or 4 42  to 559 88  one session after suffering its worst day in three years when the Centers for Disease Control reported that the Mexican restaurant chain s E  Coli outbreak had spread to six U S  states 
On the New York Stock Exchange  advancing issues outnumbered declining ones by a 1 565 to 1 490 margin ",2015-11-23,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-slightly-lower-as-health-care,-energy-rally-loses-steam-372623",372623
105686,327201,AGN,Wall Street falls after strong week  Pfizer and Allergan drag,news,"By Sinead Carew  Reuters    U S  stock indexes closed slightly lower in a quiet trading day on Wall Street after last week s strong gains  while a big healthcare deal failed to impress investors on Monday  Pfizer s  N PFE  announcement of what is expected to be the biggest ever healthcare deal pushed its shares down 2 6 percent making it one of the biggest drags on the S P  Target company Allergan  N AGN  closed 3 4 percent lower after the  160 billion deal announcement   Today was a dull day unless you re involved in  Pfizer  or Allergan  Away from that  it s kind of aimless   said Brian Fenske  head of sales trading at ITG in New York   Nobody was panicking when the market was going lower  It wasn t really on heavy volume   The Dow Jones industrial average  DJI  fell 31 13 points  or 0 17 percent  to 17 792 68  the S P 500  SPX  lost 2 58 points  or 0 12 percent  to 2 086 59 and the Nasdaq Composite  IXIC  dropped 2 44 points  or 0 05 percent  to 5 102 48   Disappointment in the Pfizer  Allergan deal was driven by weaker than hoped for projected savings from the complex deal  antitrust issues  along with a possible delay in Pfizer s plan to split into two companies  according to analysts  A few days ahead of the U S  Thanksgiving holiday  when markets are closed and traders take time off  about 6 18 billion shares changed hands on U S  exchanges  below the 7 2 billion average for the 20 sessions  according to Reuters data  After a week when the S P 500 had its best performance of the year  investors were unimpressed by Monday s economic data and some were concerned that economic growth may be slower than expected  said Stephen Massocca  Chief Investment Officer of Wedbush Equity Management LLC in San Francisco   We had a very large rally last week and it s not surprising to see the market correct after that   said Massocca  U S  home resales fell in October as a persistent shortage of properties limited choice for potential buyers and pushed up prices  suggesting some softening in the housing market recovery after strong gains early this year   A separate report showed Markit s Purchasing Managers Index hit a 25 month low in early November  highlighting continued weakness in the factory sector  S P utilities were the worst performer with a 1 percent decline  followed by telecommunications services   Those sectors tend to be affected by expectations for a U S  Federal Reserve hike in interest rates   The staples  was the strongest  led by a 10 2 percent increase in shares of  Tyson Foods   N TSN  to  48 09 after its quarterly sales beat estimates   The energy sector  rose 0 7 percent  as crude prices were volatile after Saudi Arabia agreed to cooperate with other oil producers to stabilize prices but traders worried about a global supply glut and signs of rising U S  stockpiles  Advancing issues outnumbered decliners 1 581 to 1 466  for a 1 08 to 1 ratio  on the Nasdaq  1 566 issues rose and 1 236 fell  a 1 27 to 1 ratio favoring advancers  
The S P 500 posted 25 new 52 week highs and 4 lows  the Nasdaq recorded 77 new highs and 77 lows ",2015-11-23,Reuters,https://www.investing.com/news/stock-market-news/indexes-set-to-open-little-changed;-commodities-hit-372549,372549
105687,327202,AGN,Asian shares wobble  dollar close to eight month peak,news,"By Lisa Twaronite and Hideyuki Sano TOKYO  Reuters    Asian shares struggled on Tuesday after a healthcare mega merger failed to impress Wall Street  while the dollar took a breather from its run to eight month highs on rising convictions that the Federal Reserve will raise interest rates next month  MSCI s broadest index of Asia Pacific shares outside Japan  MIAPJ0000PUS  wavered in and out of positive territory  and was last down 0 2 percent  Japan s Nikkei  N225  dipped about 0 1 percent after a long weekend  Markets were closed for a national holiday on Monday   We re post Japan Inc earnings now and the focus is back on China where local brokers are talking about market reforms  many of which have direct market impacts  which is important because China is a policy driven market   said Gavin Parry  managing director of Parry International Trading    There s also a continued focus on the U S  Federal Reserve  with a lot of sell side banter about quantifying what level of rate increase brokers are expecting   he said  Chinese shares dropped  with the blue chip CSI300 index  of the largest listed companies in Shanghai and Shenzhen down 1 2 percent and the Shanghai Composite Index  down 1 percent  On Monday  Wall Street edged down as Pfizer s  N PFE  plan to buy Allergan Plc  N AGN  in a  160 billion deal quickly drew criticism from politicians as a tax dodge   Investors may feel that even if this deal comes through  this will become the last of this sort   said Yoshinori Shigemi  global market strategist at JPMorgan  N JPM  Asset  Markets showed no immediate reaction to a worldwide travel alert issued by the U S  State Department  that warned U S  citizens of the risks of travelling because of what it described as  increased terrorist threats   The dollar index  which tracks the U S  unit against six major rival currencies  edged down about 0 1 percent to 99 683  after it rose to an 8 month high of 100 00   DXY  overnight  within sight of its 12 year peak of 100 39 touched on March 13  Whether the dollar can rise above that peak could depend on the pace of the Fed s rate hikes next year  Markets are currently pricing in two more rate hikes next year after a likely December move  In contrast to the Fed  the European Central Bank is widely expected to add stimulus next week  including deepening its already negative interest rates that make banks pay  not receive  interest on their deposits at the central bank  The euro edged up slightly to  1 0637   after falling to a 7 month low of  1 0592 in U S  trade on Monday  Precious metals were under pressure  Spot gold  edged up about 0 1 percent to  1 070 40 an ounce but remained not far above last week s near six year low  Silver  also touched six year lows overnight  while platinum  dipped to a fresh seven year low on Tuesday  Base metals were also pressured  suffering from concerns about slowing demand from China  Copper   which has fallen more than 12 percent so far this month  stood at  4 463 per tonne  down about 0 6 percent and not far from a 6 1 2 year low of  4 443 50 hit on Monday  But crude prices won a reprieve after Saudi Arabia pledged to work toward oil price stability  
U S  crude futures  CLc1  were off earlier highs but still up 0 5 percent at  41 95 per barrel  up from a three month low of  38 99 hit on Friday  Brent  LCOc1  added 0 5 percent to  45 03 ",2015-11-23,Reuters,"https://www.investing.com/news/stock-market-news/asian-shares-wobble,-dollar-close-to-eight-month-peak-372648",372648
105705,327220,AGN,Key FDA Regulatory Events To Watch Out For In Sep 2017,opinion,"The FDA  which approved 22 novel drugs last year  has given its approval to 31 drugs so far in 2017 including five in August  Key approvals this year include Gilead s Vosevi  hepatitis C virus   Puma s Nerlynx  to reduce the risk of breast cancer returning   J J s Tremfya  moderate to severe plaque psoriasis   Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s multiple sclerosis treatment  Ocrevus  Regeneron and Sanofi s eczema treatment  Dupixent  Tesaro s PARP inhibitor  Zejula  and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Some of these drugs have blockbuster potential 
A recent landmark approval was that of Novartis  Kymriah  making it the first gene therapy in the United States  This marks the beginning of a new era for the treatment of cancer and other serious and life threatening diseases 
With the drug development process being lengthy and time consuming and requiring the utilization of a lot of funds and resources  key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts  Here is a look at a few important regulatory events scheduled for the month of September 
Will the FDA Follow the Advisory Panel Vote for Mylan s Herceptin Biosimilar Mylan NV   NASDAQ MYL   should hear from the FDA soon about the approval status of its biosimilar version of Roche s blockbuster drug  Herceptin  trastuzumab   The company and its partner  Biocon Ltd  got a favorable vote  16 0  from the FDA s Oncologic Drugs Advisory Committee   ODAC   in July for the biosimilar  Herceptin is approved for a wide range of indications including HER2  breast cancer in the metastatic and adjuvant settings Earlier this year  Mylan had entered into a global settlement agreement with Roche s Genentech  and F  Hoffmann La Roche Ltd  for Herceptin  trastuzumab   under which Mylan got global licenses  excluding Japan  Brazil and Mexico  for its trastuzumab product  Mylan could well be the first to launch a biosimilar version of Herceptin in the United States  Approval would boost investor sentiment for the company which has lost 17 3  year to date versus the 17 9  decline of its  
FDA Advisory Panels to Discuss Glaxo  Pfizer   PTC Therapeutics DrugsQuite a few FDA advisory panel meetings are scheduled for this month  The FDA s Vaccines and Related Biological Products Committee  VRBPAC  will be meeting on Sep 13 to discuss the safety and effectiveness of GlaxoSmithKline plc s   NYSE GSK   Shingrix  Glaxo is looking to get the non live  recombinant vaccine approved for the prevention of herpes zoster  shingles  in people who are 50 years old or above  Shingles  a common and potentially serious condition  can cause lasting pain and other complications such as scarring or visual impairment Then on Sep 19  the FDA s ODAC will be meeting to discuss the supplemental new drug application  sNDA  submitted by Pfizer   NYSE PFE   for its cancer drug  Sutent  Pfizer is looking to expand Sutent s label for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma   RCC   following nephrectomy  surgical removal of the cancer containing kidney   The FDA is expected to render a final decision regarding the label expansion in Jan 2018  Sutent brought in sales of  529 million in the first half of 2017 Later this month  on Sep 28  the FDA s Peripheral and Central Nervous System Drugs Advisory Committee will discuss PTC Therapeutics    NASDAQ PTCT   new drug application   NDA   for Translarna  ataluren  for the treatment of patients with dystrophinopathy due to a nonsense mutation in the dystrophin gene  Translarna is already approved outside the United States  The FDA is expected to give a response regarding the approval status of the drug by Oct 24  2017 Will the FDA Grant Approval to Amgen Allergan s Avastin Biosimilar Amgen   NASDAQ AMGN   and Allergan  NYSE AGN  are also expecting a decision from the FDA for their biosimilar version of Roche s cancer drug  Avastin  bevacizumab   With the companies getting a favorable vote from an FDA advisory panel   ODAC   recently  chances of gaining approval on the FDA action date of Sep 14 look good  Shares of Amgen have gained 22 2  year to date  significantly outperforming the  rally of 15 9  
Merck  Bristol Myers Seek Label ExpansionMerck   NYSE MRK   is looking to expand the label of its anti PD 1 therapy  Keytruda  for use in the treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma  Keytruda is under priority review for this indication with a response expected on Sep 22  Keytruda  which brought in sales of  1 5 billion in the first half of 2017  is a key product in Merck s portfolio and is being evaluated for a wide range of indications  Merck has gained 8 4  year to date versus the 12 3  growth of its  
Bristol Myers Squibb Company   NYSE BMY   is also looking to expand the label of its PD 1 inhibitor  Opdivo  Opdivo is under priority review for use in patients with hepatocellular carcinoma   HCC   after prior treatment with Nexavar  sorafenib   The FDA is expected to give a response on Sep 24  2017  Opdivo  one of the prioritized brands in Bristol Myers  portfolio  brought in sales of  2 3 billion in the first half of 2017  Bristol Myers has gained 2 5  year to date versus the 12 3  growth of its  
Will the FDA Approve J J s Plivensia Johnson   Johnson s investigational rheumatoid arthritis   RA   treatment  Plivensia  sirukumab   an IL 6 inhibitor  is under FDA review with a response expected on Sep 23  However  early in August  Plivensia failed to get the support of the FDA s Arthritis Advisory Committee on safety concerns  J J is looking to get Plivensia approved for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or are intolerant to one or more disease modifying anti rheumatic drugs  DMARDs   RA is a common  chronic  life long  autoimmune disease that affects about 1 3 million people in the United States  Although the FDA is not required to do so  it usually follows the advice of its advisory panels  Considering the safety concerns raised by the panel  it s quite likely that the agency will ask for additional information before granting approval  Shares of J J have gained 13 7  year to date  outperforming the  rally 
Neos Therapeutics is also awaiting a decision this month for NT 0201  its amphetamine XR liquid suspension product candidate for attention deficit hyperactive disorder   ADHD    Approval on Sep 15  2017 would allow the company to go ahead with its plans to launch the product in Jan 2018 Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-09-04,Zacks Investment Research,https://www.investing.com/analysis/key-fda-regulatory-events-to-watch-out-for-in-sep-2017-200211354,200211354
105706,327221,AGN,Allergan  AGN  Down 8 3  Since Earnings Report  Can It Rebound ,opinion,"About a month has gone by since the last earnings report for Allergan PLC   NYSE AGN    Shares have lost about 8 3  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers 
Allergan Beats Q2 Earnings   Sales TopAllergan s second quarter 2017 earnings came in at  4 02 per share  beating the Zacks Consensus Estimate of  3 95 by 1 8   Earnings rose 20  year over year driven by higher revenues  lower share count and interest expense  which offset lower gross margins and higher tax rates Revenues came in at  4 01 billion  up 8 8  from the year ago period  and beat the Zacks Consensus Estimate of  3 95 billion by 1 4  While key products like Botox and new products like Vraylar  Namzaric and Viberzi did well in the quarter  sales were once again hurt by sales erosion from Namenda XR and loss of exclusivity  mainly from Asacol HD and Minastrin  Also  lower sales of Restasis and Aczone hurt the top line Second quarter revenues  however  gained from the addition of Alloderm from LifeCell  Jan 2017  and CoolSculpting body contouring system from ZELTIQ  Apr 2017  acquisitions Segment DiscussionAllergan reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues increased 15 2  to  1 72 billion driven by strong growth in Botox and the addition of LifeCell s Alloderm and ZELTIQ s CoolSculpting businesses  Botox  cosmetic  raked in sales of  210 3 million  up 10 7    Botox Therapeutic revenues were  346 9 million  up 17 2   In addition  Juv derm Collection of fillers rose 7 3  and Ozurdex sales increased 15 8   which contributed to the upside  Alloderm added  84 6 million while CoolSculpting added  78 9 million to sales in the second quarter Importantly  Restasis sales declined 9 4  to  336 4 million in the quarter due to unfavorable trade buying patterns  The company expects stable Restasis revenues this year U S  General Medicine net revenue declined 1 5  to  1 43 billion in the reported quarter with sales declining in the Diversified Brands  Women s Health  and the Gastrointestinal franchises  Anti Infectives sales rose 7 4  to  67 8 million while Central Nervous System sales rose 9 2  to  346 6 million Established products like Linzess and Lo Loestrin as well as new products like Viberzi  Namzaric and Vraylar did well in the quarter  Linzess  sales rose 11 5  in the quarter to  167 8 million  driven by strong demand and continued OTC conversion   Lo Loestrin sales rose 11 9  to  113 0 million backed by strong prescription growth However  lower Namenda XR sales hurt the performance of the CNS franchise  Namenda XR sales declined 28 7  to  118 7 million in the quarter due to lower demand  lower pricing and shift of promotional efforts to Namzaric  The company does not expect a generic version of Namenda XR to be launched until first quarter of 2018  delayed from the prior expectation of fourth quarter of 2017  Also  Allergan does not expect any generic version of Estrace Cream to be launched this year Namzaric  a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  33 4 million compared with  23 6 million in the previous quarter  Continued conversion from Namenda XR and higher demand following an expanded label with new dosages pulled up sales of Namzaric Asacol Delzicol sales declined 61 9  to  45 6 million due to a generic competition for Ascaol HD  following the launch of an authorized generic in Aug 2016 as well as lower demand for Delzicol In the Women s Health segment  Minastrin 24 revenues declined 86 3  to  11 4 million in the quarter due to loss of exclusivity in Mar 2017 The International segment recorded net revenue of  858 8 million  up 16 2   excluding currency impact  from the year ago period  driven by growth in Facial Aesthetics  Botox Therapeutic and the addition of LifeCell and CoolSculpting Profits DeclineAdjusted operating income increased 16  to  1 9 billion in the second quarter  Adjusted operating margins  however  declined 330 basis points in the quarter to 47 1  quarter due to higher operating expenses and the addition of lower margin LifeCell and ZELTIQ acquisitions Selling  general and administrative  SG A  expenses rose 17 1  to  1 22 billion in the quarter  primarily due to higher foreign exchange transactional losses  costs related to acquisitions and promotional expenses for key products  R D expenses increased 14 2  to  393 9 million to support an advancing pipeline 2017 OutlookThe company raised its previously issued earnings and sales guidance for 2017 following a strong first half performance and solid outlook for the rest of the year Allergan expects total revenue in the range of  15 85 billion to  16 05 billion compared with  15 8 billion to  16 0 billion previously  Currency headwinds are now not expected to hurt revenues versus a negative impact of approximately  100 million expected previously The company said that revenues are expected to be the highest in the fourth quarter  mainly driven by seasonality and formulary coverage dynamics  while third quarter revenues are expected to be at similar levels to the second quarter Adjusted earnings per share are expected in the range of  16 05  16 45 compared with  15 85  16 35 previously  Adjusted earnings guidance continues to reflect strong double digit growth in the range of 17  to 22  Adjusted gross margin is expected between 86 5  and 87  slightly more than 86  and 87  expected previously due to higher than expected gross margins in the first half  Second half gross margins are expected to be lower than the first half R D expenses are expected to be approximately  1 6 billion  maintained   SG A spend is expected between  4 5 billion to  4 6 billion compared with  4 45 billion and  4 55 billion previously  Meanwhile  SG A and R D expenses are expected to be higher in the third quarter versus the fourth quarter  Higher promotional activities given the timing of new launches and continued strong promotion for key brands is expected to lead to higher sales and marketing costs in the third quarter 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed a downward trend in fresh estimates  There have been four revisions higher for the current quarter compared to eight lower Allergan PLC  Price and Consensus    VGM Scores
At this time  the stock has a subpar Growth Score of C  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for value investors than growth and momentum investors 
Outlook
Estimates have been broadly trending downward for the stock  The magnitude of this revision also indicates a downward shift  Notably  the stock has a Zacks Rank  3  Hold   We are looking for an inline return from the stock in the next few months ",2017-09-04,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-down-83-since-earnings-report-can-it-rebound-200211394,200211394
105707,327222,AGN,Aerie Initiates Phase III Study For Ophthalmic Drug Roclatan,opinion,Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced the initiation of phase III study  Mercury 3 in Europe for its pipeline candidate Roclatan 0 02  0 005   Roclatan is a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  iis being evaluated to lower intraocular pressure  IOP  in patients with glaucoma or ocular hypertension Aerie s stock has surged 51 8  year to date  compared with the  gain of 10 2  The company is conducting Mercury 3 to facilitate regulatory filings and commercialization in Europe and is not necessary for approval in the United States  The company expects 500 patients to enroll in the study  The study will be a two arm  six month safety trial that and it will provide a 90 day interim efficacy readout  The study will compare Roclatan for non inferiority to prescribed fixed dose combination that is Ganfort  a combination of the bimatoprost along with timolol   marketed by Allergan   NYSE AGN   in Europe  The study will be conducted mainly in the United Kingdom  France  Germany  Italy  Spain  and Belgium  The topline 90 day efficacy data is expected by early 2019 We remind investors that  the company reported positive 12 month safety results in July 2017 from Mercury 1 phase III study and positive  top line  90 day efficacy and safety data from the second phase III study  Mercury 2 in May 2017  Aerie expects to submit a new drug appication  NDA  for Roclatan to FDA in the first half of 2018 Apart from Roclatan  Aerie is also evaluating Rhopressa  which is designed to lower IOP in patients through novel mechanisms of action  MOAs  to treat patients with glaucoma or ocular hypertension  On Feb 28  the company resubmitted its NDA for Rhopressa  and expects a standard review period of 12 months  The company also expects to start a clinical study for Rhopressa later in 2017 to address the Japanese market Aerie Pharmaceuticals  Inc  Price    Zacks Rank   Stocks to ConsiderAerie currently carries a Zacks Rank  3  Hold   A better ranked stock in health care sector includes Alexion Pharmaceuticals  Inc    NASDAQ ALXN   sporting a Zacks Rank  1  Strong Buy   You can see  Alexion Pharmaceuticals  earnings per share estimates have moved up from  5 32 to  5 61 for 2017 and from  6 53 to  6 92 for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 11 12   The share price of the company has increased 18 7  year to date One Simple Trading Idea Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-09-06,Zacks Investment Research,https://www.investing.com/analysis/aerie-initiates-phase-iii-study-for-ophthalmic-drug-roclatan-200211936,200211936
105708,327223,AGN,AstraZeneca Sells Remaining Rights To Its Anaesthetics Drugs,opinion,AstraZeneca  plc   NYSE AZN   announced that it has entered into an agreement to dispose theremaining rights to its anaesthetics medicines  to Aspen Global Incorporated  AGI   the Mauritian subsidiary of the Aspen Group  for an upfront consideration of  555 million We remind investors that AstraZeneca had divested the commercialization rights to its anaesthetic medicines outside the U S  markets to AGI  per a collaboration agreement signed in June 2016 With the new deal  AGI will acquire remaining rights to the intellectual property and manufacturing know how related to AstraZeneca s anaesthetic medicines comprising of Diprivan  EMLA  Xylocaine Xylocard Xyloproct  Marcaine  Naropin  Carbocaine and Citanest Meanwhile  AstraZeneca will continue to manufacture and supply the medicines to AGI for the next five years  Also  the company will be entitled to sales based milestone payments of up to  211 million from Sep 1  2017 to Nov 30  2019  However  under the new agreement  AGI will not pay any royalties to AstraZeneca  which was a condition in the older agreement Notably  the new deal is expected to close in the fourth quarter of 2017 So far this year  AstraZeneca s shares have gained 19 5   comparing favorably with the  s growth of 16  AstraZeneca has been regularly divesting non core assets or marketing rights to some treatments so that it can focus its resources on three main therapy areas including oncology and respiratory In June 2017  the company sold the global rights of migraine treatment drug Zomig outside Japan to Gr nenthal  a German pharmaceutical company In March  it sold the U S  commercialization rights to its inhaled respiratory medicines   Tudorza and Duaklir   for COPD to Circassia Pharmaceuticals  Also  it entered into a deal with Sanofi s  SNY  vaccines unit Sanofi  PA SASY  Pasteur for the development and commercialization of MEDI8897 for the prevention of respiratory syncytial virus  RSV  associated illness in newborns and infants in the same month Again  in February  it entered into an agreement with TerSera Therapeutics selling commercial rights to Zoladex in the United States and Canada Last year  AstraZeneca divested the outside U S  rights to Rhinocort Aqua  a nasal spray indicated for allergic and non allergic rhinitis to an affiliate of Johnson   Johnson   NYSE JNJ    the global rights to develop and commercialize its experimental Crohn s disease drug   MEDI2070 to Allergan plc   NYSE AGN    and the U S  rights to the branded as well as authorized generic verison of its beta blocker heart medicine   Toprol XL   to Aralez Pharmaceuticals  Inc    NASDAQ ARLZ   AstraZeneca currently carries a Zacks Rank  3  Hold  You can see  5 Trades Could Profit   Big League   from Trump Policies  If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-09-13,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-sells-remaining-rights-to-its-anaesthetics-drugs-200213316,200213316
105709,327224,AGN,Biosimilar 2017 Progress Report  Stocks In Focus,opinion,"The biosimilar space remains in the spotlight as a number of regulatory decisions are pending  While generic drugs are follow on versions of chemically synthesized molecules  biosimilars contain a version of the active substance of an already approved original biological drug 
Development of biosimilars is technically challenging than the development of generic drugs as the former requires clinical studies in patients and are engineered to match the reference drug in quality  safety and efficacy  Due to the complex nature of the product  the development and the regulatory pathway of biosimilars differ significantly from that of generics 
A biosimilar is usually less expensive than the branded drug  Thus the market for the same remains highly lucrative  With the acceleration in approvals of biosimilars  the market has thus attracted a lot of players which is witnessing rapid growth  Here are a few latest developments from this space 
Leading the biosimilar space is Novartis AG s   NYSE NVS   generic arm Sandoz  which is a strong player in the biosimilar market with five marketed biosimilars  Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent used to treat anemia  and filgrastim for neutropenia under the brand names Zarzio outside the United States and Zarxio in the United States   
The company plans to launch five major oncology and immunology biosimilars between 2017 and 2020  This includes a biosimilar version of Rituxan  rituximab   which was approved by the European Commission in June 2017  marketed as Rixathon  
Recently  the FDA accepted its Biologics License Application  BLA  for a proposed biosimilar version of Rituxan  In August 2016  Sandoz s Erelzi  a biosimilar version of Amgen  Inc  s   NASDAQ AMGN   blockbuster drug Enbrel gained approval in the United States for five indications  Erelzi was also approved by the European Commission in 2017 
In May 2017  the European Medicines Agency also accepted the company s Marketing Authorization Applications for biosimilar versions of Humira  adalimumab  and Remicade  infliximab  for review  Novartis currently carries a Zacks Rank  3  Hold   
You can see  
Generic leader Mylan NV   NASDAQ MYL   is also exploring the world of biosimilars  a market that has the potential to grow to  20 billion in 2020  The FDA recently notified Mylan and partner Biocon that the target action date for a biosimilar version of Herceptin  trastuzumab  has been extended to Dec 3  2017 
A decision from the FDA was expected by Sep 3 but the FDA extended the review period due to review of some of the clarificatory information submitted to the agency as part of the application review process  We note that the Biocon partnership includes six biosimilar programs such as biosimilar versions of Herceptin  Neulasta  Humira  Avastin  Enbrel and Neupogen and three insulin analogs  Lantus  Humalog and NovoLog  
Mylan has a collaboration agreement with Momenta Pharmaceuticals  Inc    NASDAQ MNTA   to develop  manufacture and commercialize up to six of Momenta s current biosimilar candidates  including Momenta s biosimilar candidate  Orencia  abatacept   Mylan currently carries a Zacks Rank  5  Strong Sell  
Meanwhile  Amgen and Allergan plc    NYSE AGN   have also submitted a BLA to the FDA for ABP 980  a biosimilar candidate to Herceptin in Jul 2017  We note that both the companies are collaborating on four oncology biosimilars  including ABP 980 which is the second to be submitted for FDA approval 
Both companies have also submitted a Marketing Authorization Application to the European Medicines Agency for the candidate earlier in 2017  We note that Amgen has a total of 10 biosimilars in its pipeline  one of which has been approved by the FDA  
In March 2017  the European Commission granted marketing authorization to Amgevita  a biosimilar version of Humira in all available indications  The companies have an important event lined up as the FDA is expected to give a decision on the approval of ABP 215  a biosimilar version of Avastin shortly  Amgen currently carries a Zacks Rank  3  Hold  
Last month  biotech major Biogen  Inc    NASDAQ BIIB   announced that the European Commission granted a marketing authorization for Imraldi  a biosimilar version of Humira  This is the third anti TNF biosimilar from Biogen to receive a marketing authorization in the European Union following the approval of Benepali  a biosimilar of Enbrel and Flixabi  infliximab   a biosimilar version of Remicade  Biogen currently carries a Zacks Rank  3  Hold  
In July 2017  Merck   Co   Inc    NYSE MRK   launched Reneflexis  a biosimilar version of Remicade in the United States which was approved by the FDA in April  The FDA also granted tentative approval for Lusduna Nexvue  the biosimilar version of Lantus  basal insulin in a pre filled dosing device  Merck currently carries a Zacks Rank  3  Hold  Medical Sector 5YR   Return
 


Conclusion Given the fact that so much is happening in this space  we expect investor focus on upcoming approval dates 
5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course  Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-14,Zacks Investment Research,https://www.investing.com/analysis/biosimilar-2017-progress-report-stocks-in-focus-200213360,200213360
105710,327225,AGN,Amgen Allergan s Avastin Biosimilar Secures FDA Approval,opinion,Amgen   NASDAQ AMGN   and partner Allergan   NYSE AGN   announced that the FDA approved their biosimilar version of Roche s   OTC RHHBY   cancer drug  Avastin  bevacizumab   for treatment of five types of cancers including lung cancer  colorectal cancer  glioblastoma  renal cell carcinoma and cervix cancer  The biosimilar will be marketed by the trade name Mvasi Mvasi is the first cancer biosimilar approved in the United States  It is also the first bevacizumab biosimilar in the country  Notably  Amgen has also submitted regulatory applications for the same in the EU We remind investors that in July  the FDA s Oncologic Drugs Advisory Committee had unanimously voted to recommend approval of Mvasi Amgen s shares have outperformed the  so far this year  The stock has plunged 29 6  versus the broader industry s 15 4  rally The approval was supported by a comprehensive data package that demonstrated similarity of Mvasi with bevacizumab  Data also included results from a phase III comparative efficacy  safety and immunogenicity study  confirming no clinically meaningful difference between Mvasi and the reference product Amgen and Allergan are also developing biosimilar versions of Roche s Herceptin  ABP 980   under review in the United States and the EU  and Rituxan  ABP 798 in phase III  Amgen s biosimilar version of AbbVie s Humira Amjevita  was approved by the FDA in September last year  However  Amjevita has not been launched yet due to an ongoing litigation  Others under development include Amgen s biosimilar versions of Alexion s Soliris  Lilly s Erbitux and Johnson and Johnson   NYSE JNJ   Merck s Remicade  Interestingly  biosimilar endeavors offer a lucrative opportunity of annual revenues worth  3 billion above for Amgen  The company has also collaborated with Japan s Daiichi Sankyo for commercialization of nine biosimilars in Japan With accelerating approvals of biosimilars  a number of pharmaceutical and biotech companies are working on to bringing biosimilars in the market   Though many biosimilars are marketed in the EU  very few are available in the United States  Last November  Pfizer  NYSE PFE  had launched Inflectra  a biosimilar version of Remicade  Sandoz also markets Zarxio  the first biosimilar to be approved in the United States  The product is in turn a biosimilar of Amgen s Neupogen  In July 2016  Merck  NYSE MRK  had launched Reneflexis  a biosimilar version of Remicade in the United States In August last year  Sandoz had gained an FDA approval for Erelzi  a biosimilar version of Amgen s Enbrel  However  the product is on hold due to ongoing litigation and is yet to be unveiled in the United States Amgen Inc  Price   Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside   Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-14,Zacks Investment Research,https://www.investing.com/analysis/amgenallergans-avastin-biosimilar-secures-fda-approval-200213524,200213524
105711,327226,AGN,Should Value Investors Consider Allergan Plc  AGN  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Allergan plc   NYSE AGN   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Allergan has a trailing twelve months PE ratio of 15 2  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 3  If we focus on the stock s long term PE trend  the current level puts Allergan s current PE ratio somewhat below its midpoint  which is 18 3  over the past five years Further  the stock s PE also compares favorably with the sector s trailing twelve months PE ratio  which stands at 20 5  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Allergan has a forward PE ratio  price relative to this year s earnings  of just 13 8  so it is fair to say that a slightly more value oriented path may be ahead for Allergan s stock in the near term too P CF RatioAn often overlooked ratio that can still be a great indicator of value is the price cash flow metric  This ratio doesn t take amortization and depreciation into account  so can give a more accurate picture of the financial health in a business  This is a preferred metric to some valuation investors because cash flows are  a  generally less prone to manipulation by the company s management and  b  are less affected by variation in accounting policies between different companies The ratio is generally applied to find out whether a company s stock is overpriced or underpriced with reference to its cash flows generation potential compared with its competitors  However  it is not commonly used for cross industry comparison  as the average price to cash flow ratio varies from industry to industry In this case  Allergan s P CF ratio of 3 9 is significantly lower than the industry average of 14 8  which indicates that the stock is somewhat undervalued in this respect Broad Value OutlookIn aggregate  Allergan currently has a Value Style Score of B  putting it into the top 40  of all stocks we cover from this look  This makes AGN a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Allergan is just 1 1  a level that is considerably lower than the industry average of 1 8  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  AGN is a solid choice on the value front from multiple angles What About the Stock Overall Though Allergan might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of A and a Momentum score of A  This gives JWN a VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen six estimates go higher in the past sixty days and six lower  while the full year estimate has seen eleven upward and one downward revisions in the same time period This has had a noticeable impact on the consensus estimate  as the current quarter consensus estimate has dipped about 0 7  in the past two months  while the full year estimate has inched up 0 8   You can see the consensus estimate trend and recent price action for the stock in the chart below Allergan PLC  Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineAllergan is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  bottom 6  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates  analyst sentiment and broader factors to turn favorable in this name first  but once that happen  this stock could be a compelling pick 4 Promising Stock Picks to Keep an Eye On With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ,2017-09-18,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-allergan-plc-agn-stock-now-200214158,200214158
105712,327227,AGN,How Is The Age Related Macular Degeneration Space Faring Now ,opinion,"The Age Related Macular Degeneration  AMD  space has been in the spotlight of late due to a number of developments  Earlier in the month  Swiss pharma company Roche Holdings AG   OTC RHHBY   suffered a setback when its ophthalmology candidate  lampalizumab  failed to achieve the primary endpoint in late stage studies  The candidate was being evaluated for the treatment of geographic atrophy  GA   an advanced form of AMD   Lampalizumab did not reduce mean change in GA lesion area compared to sham treatment for 1 year  48 weeks  Last month  Ophthotech Corporation   NASDAQ OPHT   also announced disappointing results from a phase III study  OPH1004  The study evaluated its pipeline candidate Fovista  an anti PDGF therapy  in combination with Regeneron Pharmaceuticals  Inc  s   NASDAQ REGN   Eylea  aflibercept  or Roche s Avastin  bevacizumab  for the treatment of wet AMD AMD and its TypesAMD is a disorder of the central portion of the retina  known as the macula  which might lead to blindness  There are two forms of AMD   dry AMD and wet AMD  Dry AMD can lead to wet AMD  GA is a progressive and irreversible form of AMD Per American Academy of Ophthalmology  dry AMD occurs when parts of the macula get thinner with age and tiny clumps of protein grow  Although dry AMD is the most common form of AMD  there are no approved therapies in the United States and Europe to treat this condition On the other hand  wet AMD occurs when new  abnormal blood vessels grow under the retina  which in turn leak blood or other fluids  scarring of the macula  Anti VEGF drugs help in treating wet AMD by reducing the number of abnormal blood vessels in the retina apart from laser therapy Drugs AvailableA number of drugs have been made available to treat this disorder  The leading among them is Regeneron s Eylea   The drug is approved for the treatment of wet AMD  diabetic macular edema  DME   macular edema following retinal vein occlusion among others  Sales of the drug in the United States came in at  3 3 billion in 2016  up from  2 7 billion in 2015 which highlights the huge market potential of this indication  Regeneron currently carries a Zacks Rank  1  Strong Buy   You can see Novartis AG s   NYSE NVS   Roche s Lucentis is also an anti VEGF therapy approved for various ocular indications  which includes neovascular age related macular degeneration  visual impairment due to DME among others  Novartis currently carries a Zacks Rank  3  Hold  Roche s Avastin is also used for wet AMD  Roche currently carries a Zacks Rank  3  Pipeline CandidatesGiven the huge potential of the market  several companies have a host of candidates lined up in their pipelines  Novartis is developing RTH258  brolucizumab  for wet AMD  The candidate is expected to pose competition to Eylea  Earlier in 2017  Novartis released positive data on RTH258  The candidate met the primary and key secondary endpoints in two phase III studies  HAWK and HARRIER  However  Novartis expects to complete the pharmacokinetic study with the final manufacturing process to enable filing in 2018  Hence  the candidate is not likely to hit markets before 2019 giving Eylea a breather Allergan plc   NYSE AGN   is also developing Abicipar pegol  anti VEGF A DARPin  for wet AMD and related conditions   The company also has other candidates like bimatoprost SR  brimonidine SR for dry AMD  Allergan currently carries a Zacks Rank  3 Meanwhile  Ophthotech is also developing Zimura in combination with an anti VEGF drug for the treatment of wet AMD in treatment na ve patients   Ophthotech currently carries a Zacks Rank  3  Medical Sector 5YR   ReturnBottom LineGiven the potential in the AMD market  and the number of companies developing treatments for the same  we expect investors to keep an eye on new approvals 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-09-20,Zacks Investment Research,https://www.investing.com/analysis/how-is-the-agerelated-macular-degeneration-space-faring-now-200214736,200214736
105713,327228,AGN,Allergan s  AGN  Vraylar Gets RTF From FDA  New Data For CVC,opinion,Allergan plc   NYSE AGN   announced that the FDA has issued a refusal to file  RTF  letter to its supplemental New Drug Application  sNDA  for Vraylar  cariprazine   The company is looking to get Vraylar s label expanded to include new data  which supports the drug s use as a maintenance treatment Vraylar is presently approved in Europe for treatment of schizophrenia Allergan s share price is down 2 5  this year so far  comparing favorably with the  s decrease of 22 3  The FDA said that the sNDA was not sufficiently complete to allow a substantive review  The company plans to meet the FDA officials to understand what additional information will be required We remind investors that earlier in March  the FDA had accepted the company s sNDA for Vraylar  The sNDA was based on data from a phase III study  evaluating Vraylar for maintenance of efficacy in adults with schizophrenia  Data from the study showed that Vraylar has significantly delayed the time to relapse compared with placebo  Also  relapse occurred in nearly twice as many placebo patients  47 5   in comparison to those treated with Vraylar Vraylar has performed above expectations in 2016  recording sales of  94 3 million in the year  The drug is likely to be a key driver of Allergan s top line growth in 2017 Other players in the bipolar disorder and schizophrenia treatment market include AstraZeneca plc s   NYSE AZN   Seroquel XR  Johnson   Johnson s   NYSE JNJ   Risperdal Consta and Alkermes plc s   NASDAQ ALKS   Aristada In a separate press release  Allergan announced new data from the CENTAUR phase IIb study  evaluating its pipeline candidate cenicriviroc  CVC  for treating liver fibrosis in adult patients with NASH These phase IIb data supports continued development of cenicriviroc  CVC  in the ongoing phase III AURORA study evaluating the safety and efficacy of the candidate for liver fibrosis in adult patients with NASH The CENTAUR study demonstrated no significant difference in fibrosis improvement being observed between CVC and placebo in the second year for patients administered with CVC for a couple of years  Some patients switched over to CVC in year two after remaining on placebo for a year  20  of such patients receiving CVC achieved the combined endpoint of reduction in fibrosis by at least one stage with no worsening of NASH  This find lies in straight comparison to 13  of those remaining on placebo Allergan PLC  Price   Zacks RankAllergan currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-09-24,Zacks Investment Research,https://www.investing.com/analysis/allergans-agn-vraylar-gets-rtf-from-fda-new-data-for-cvc-200215232,200215232
105714,327229,AGN,Allergan CEO Saunders warms up to drug discovery ,news,"By Ransdell Pierson and Bill Berkrot NEW YORK  Reuters    Brenton Saunders  the whiz kid pharmaceutical executive with a reputation for being wary of the costs of early stage drug development  says he s open to new ideas from outside and is now warming up to investing in drug discovery if it makes sense for his company  That could ease concern that if Allergan  N AGN pa  Inc s  N AGN   friendly  talks with  Pfizer  Inc  N PFE  end in a merger  the combined company may not remain one of the world s largest inventors of new medicines   I practice a very open minded management structure and learn new things all the time that change my opinion   Saunders  45  said in a phone interview with Reuters from an Allergan discovery lab   For instance  when  Actavis  and Allergan merged  we didn t have any discovery capabilities  but we assessed Allergan s discovery capabilities in ophthalmology and aesthetic medicine and recognize they added a lot of value  Not only have we kept them  we ve invested in them   While sources close to the ongoing negotiations stress that no decision on Saunders  role has been taken yet  the possibility of Pfizer being led or influenced by an executive who has not overseen the full development  from discovery to approval  of a single drug raises concerns among many industry insiders  Pfizer refused to comment on Saunders  role in any potential deal with Allergan  Pfizer board member Dennis Ausiello  chief of medicine at Massachusetts General Hospital in Boston  said in an interview that Pfizer would not be Pfizer without drug discovery   Innovation is at the heart and core of the business  and discovery is at the heart and core of innovation   Ausiello said  also acknowledging that acquisitions also have an important role to play in Pfizer s drug development strategy  The New York based company sees one or more additional new product launches each year through 2022 and plans to have 10 new immuno oncology drugs in clinical testing by next year  Saunders has said that drug discovery is too inherently risky and costly  and called the idea that big pharma players need to do it a  fallacy   He prefers to license or acquire medicines that have already been shepherded through the riskiest stages of their development by other companies  That s in contrast to Ian Read  Pfizer s 62 year old CEO  When Read took over Pfizer in 2010  he declared reigniting a moribund research engine that had produced no important new medicines in a decade as one of his most important tasks  Since then  Read can claim credit for the regulatory approval of 10 new medicines  including breast cancer drug Ibrance  which analysts forecast will eventually generate  5 billion a year  and Trumenba  a meningitis vaccine  both products of Pfizer labs  Some Pfizer insiders don t see Saunders as a good match for the 166 year old company  whose expected revenue of  48 billion this year is about three times as much as Allergan s   Saunders is not going to come to Pfizer and get religion on the need for drug discovery  I would doubt that would happen   John Lamattina  who served as Pfizer s research chief between 2003 and 2007  said in an interview  Saunders declined to discuss any future role he might assume  He said he believed he would in fact be able to fit in with a company that has discovery culture   I believe as an executive of any company  it s your job to invest in things you do better than your competition and reassess things you don t do better   he said in the interview  TOP NOTCH EXPERTISE In his meteoric career  Saunders has lead Bausch   Lomb  Forest Laboratories and Actavis  which took the Allergan name after acquiring the Botox maker this year  all in the past five years  While his faith in drug discovery credentials may be questioned  he is highly regarded among his peers as a CEO with top notch operational expertise  A protege of industry veteran Fred Hassan  who fixed Pharmacia and sold it to Pfizer  Saunders is credited with helping turn around struggling Schering Plough and then leading its integration with Merck   Co  N MRK   When Actavis acquired Forest  Actavis CEO Paul Bisaro replaced himself with Saunders  who had previously sold Bausch   Lomb to Valeant Pharmaceuticals  N VRX  International Inc  TO VRX   In a recent interview  Bisaro called Saunders the best young CEO in the industry   It just didn t make any sense to let him get away   said Bisaro  who remained as executive chairman  To be sure  Saunders has also shown a determination to move away from commoditized offerings  Last July  just four month after Actavis acquired Allergan  Saunders agreed to sell Allergan s generic drugs portfolio to Teva Pharmaceutical  N TEVA  Industries Ltd  TA TEVA  for  40 5 billion  Despite their different backgrounds  Read may see Saunders  skill set as complementary to his  some industry experts said  Raghuram Selvaraju  healthcare analyst with Rodman   Renshaw  said he believes Read would even be willing to cede his title to Saunders and become executive chairman   Ian s main concern is to get lower taxes for Pfizer through an inversion  He would rather be able to say he pulled this tax inversion off  and now I m going to let Brent crack the whip and wield the axe   Selvaraju said  referring to the many job cuts that typically follow large mergers  Saunders said he has known Read for many years  from the time they both sat on the board of PhRMA  the largest U S  trade group for the pharmaceutical industry  He declined to comment further on his relationship with him in light of the ongoing deal talks   
 The story was refiled to correct  protege   not  portage  in the 16th paragraph ",2015-11-06,Reuters,https://www.investing.com/news/stock-market-news/allergan-ceo-saunders-warms-up-to-drug-discovery-370059,370059
105715,327230,AGN, Democrat targets corporate tax avoidance deals in U S  Congress,news,"By Susan Cornwell WASHINGTON  Reuters    Tax driven  inversion  deals that let companies flee the U S  tax system by relocating abroad  if only on paper  would be curbed under legislation introduced in Congress  as  Pfizer  Inc  N PFE  pursues such a deal with rival Allergan Plc  N AGN   Wisconsin Democratic Representative Mark Pocan s bills likely have little chance of advancing in the Republican run Congress  But they represent renewed concern about the transactions  A wave of them peaked in September 2014 when a Treasury Department crackdown slowed  but did not halt them  The possible Pfizer Allergan deal helps to  highlight what can go on   Pocan  a small business owner  said in an interview on Monday  If Congress is going to pursue tax reform  closing such loopholes should be part of the conversation  he said  In an inversion  a U S  company typically buys a foreign company and then relocates to its home country in an effort to cut the combined company s overall taxes  Relocations of this sort usually only involve paperwork  leaving core operations such as executive management and research in the United States  One of Pocan s bills would tax all of a U S  company s profits  foreign and domestic  at the same time and the same rate  At present  only domestic profits are taxed immediately  Tax on foreign profits may be deferred indefinitely   The other bill would discourage  earnings stripping   which can be facilitated by inversions  This practice involves shifting profits earned in the United States out of the country and into a lower tax jurisdiction  New York based Pfizer and Dublin based Allergan said late last month that they have not reached an agreement and declined to give details on their proposed combination  Bills resembling Pocan s introduced last year made no headway  Lawmakers were widely seen as unlikely to tackle major tax code changes before the 2016 presidential election  Still  some Democrats have been scolding Pfizer since it said it was in friendly merger talks with Allergan to create what would be the world s biggest drug company  Sources have told Reuters that Pfizer is discussing a tax inversion  
Pocan said another reason for re introducing his legislation now was to remind the Treasury that it also could do more to curb tax avoidance schemes   That is what we are kind of waiting for  And we thought putting this out there might help remind them that we re still watching   he said ",2015-11-09,Reuters,https://www.investing.com/news/stock-market-news/democrat-targets-corporate-tax-avoidance-deals-in-u.s.-congress-370472,370472
105716,327231,AGN,Valeant  Ackman must face U S  insider trading lawsuit,news,"By Jonathan Stempel  Reuters    A U S  judge said Valeant Pharmaceuticals International Inc  TO VRX   N VRX  and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in  Allergan Inc   N AGN pa  before making an unsuccessful takeover bid for the maker of Botox  In a Nov  9 decision  U S  District Judge David Carter in Santa Ana  California  rejected arguments by Valeant  Ackman and Ackman s Pershing Square Capital Management that the lawsuit should be dismissed because their activity was not fraudulent  The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before the defendants on April 22  2014 announced an unsolicited  51 billion bid for Allergan  Pershing had by then quietly amassed a 9 7 percent stake in Allergan  which soared in value after the bid was announced  Investors said Pershing bought those shares knowing that Valeant was preparing a bid that could  and later did  become hostile  Valeant and Ackman said there was no intent to defraud  and that they breached no duties by sharing information before the takeover bid became public  But the judge  without ruling on the merits  found  serious questions  as to whether  substantial steps  had been taken toward a possible hostile bid  which would have required Valeant to disclose more or Ackman to stop his buying   Plaintiffs must plead defendants knew they were in possession of material nonpublic information at the time of the trade and that they acted with the intent to deceive  manipulate  or defraud   Carter wrote   Plaintiffs have alleged both elements   Valeant spokeswoman Laurie Little said the Laval  Quebec company was disappointed with the decision  and believes it complied with securities laws   We look forward to presenting evidence to establish that we did nothing improper   she added  Michael Shipley  a lawyer for Pershing and Ackman  declined to comment  Allergan is not a defendant  The lead plaintiffs are the State Teachers Retirement System of Ohio  the Iowa Public Employees Retirement System  and Allergan employee Patrick Johnson  court papers show  Their lawyers did not immediately respond to requests for comment  Allergan was bought in March by Dublin based  Actavis  Plc for about  70 5 billion  the combined company announced at the time  Actavis was renamed Allergan Plc  N AGN   The next month  Allergan dropped its own lawsuit accusing Valeant and Pershing of insider trading  Pershing remains a large shareholder in Valeant  whose shares have tumbled in recent months over concerns about its financial practices and drug pricing  
The case is In re  Allergan Inc Proxy Violation Securities Litigation  U S  District Court  Central District of California  No  14 02004 ",2015-11-11,Reuters,"https://www.investing.com/news/stock-market-news/valeant,-ackman-must-face-u.s.-insider-trading-lawsuit-370866",370866
105717,327232,AGN,Pfizer Allergan deal refocuses market on U S  tax inversion rules  ,news,"By Kevin Drawbaugh WASHINGTON  Reuters     Pfizer  Inc s  N PFE  buyout bid for Allergan Plc  N AGN  has financial markets on edge over a possible new move by the U S  Treasury Department against tax inversion deals  but the outlook for any such steps was still unclear on Friday   For months  Treasury has offered no fresh guidance on the inversion issue  leaving tax experts to speculate about what could come next  Inversions typically involve a U S  multinational buying a smaller foreign rival and relocating to its home country  if only on paper  to escape U S  taxation   Allergan shares fell 2 3 percent on Thursday afternoon amid reports that Treasury might move to block its deal with Pfizer   Possible steps the government might take include tightening the rules on two strategies related to inversions  tax experts said   earnings stripping  and  skinny down  distributions   Treasury took several actions in September 2014 to reduce the tax benefits available to companies that have inverted  while also making new inversions more difficult to do and less potentially rewarding  The moves stemmed a wave of inversions  but not before Minnesota medical technology group  Medtronic   N MDT  reincorporated in Ireland   At the time  Treasury and the Internal Revenue Service said they were weighing further actions  On Friday  a Treasury spokeswoman offered more of the same language    The Treasury Department and the IRS expect to issue additional guidance to further limit inversion transactions   said the statement from late last year   That guidance said Treasury was looking at ways  to address strategies that avoid U S  tax on U S  operations by shifting or  stripping  U S  source earnings to lower tax jurisdictions  including through intercompany debt    Because U S  corporations don t disclose what they pay in income taxes  it s hard to estimate how much revenue has been lost to inversions or could be lost in the future  A congressional committee estimated in May 2014 that legislation then being debated to largely slam the door on inversions would raise almost  20 billion from 2015 through 2024  That legislation was never adopted   Tighter earnings stripping rules would curtail a key attraction of inversions  but Treasury has struggled to write such a rule within the constraints of present law  experts said  Fresh legislation from Congress on inversions  despite occasional rhetoric to the contrary from lawmakers on Capitol Hill  is regarded as unlikely before the 2016 elections    The rhetoric is heating up over Pfizer  but I don t see anything immediate on the horizon   said Edmund Outslay  a tax accounting professor at Michigan State University  Nor  he said  did he expect Treasury to act on its own   Corporate tax law consultant Robert Willens said a tighter earnings stripping rule from Treasury was unlikely without action from Congress  But  he said  Treasury could harden its existing rule on  skinny down  restructuring strategies meant to circumvent existing inversion rules   No two inversions are identical  but the goal is usually for a U S  company to do just enough to satisfy Treasury and IRS requirements for treatment as a foreign entity  while avoiding the actual transfer abroad of core management and research   
To be recognized as a foreign entity under U S  law  one key hurdle is to ensure that the original U S  shareholders own less than 60 percent of the combined company  One way to do that is through  skinny down  share buybacks or other distributions that shrink the size of the U S  company going into the inversion  Treasury likely could tighten that rule  perhaps by extending the time limit on covered transactions  without accompanying legislation from Congress  experts said   I think that s where they ll focus their attention   Willens said ",2015-11-13,Reuters,https://www.investing.com/news/stock-market-news/pfizer-allergan-deal-refocuses-market-on-u.s.-tax-inversion-rules-371262,371262
105718,327233,AGN,How Pfizer has shifted U S  profits overseas for years,news,By Tom Bergin and Kevin Drawbaugh RINGASKIDDY  Ireland  Reuters    Drugmaker Pfizer s  N PFE  plans to take over Allergan  N AGN  have faced a political backlash in the United States over fears a deal would lead to the company shifting its headquarters and taxable profits to Ireland  However a Reuters examination of corporate filings in Europe  patent databases and other information shows the company has for over a decade been shifting profits generated by American scientists and patients overseas   to a subsidiary based in the rolling hills of County Cork    Pfizer  and Allergan are in talks to create the world s biggest drug company by market value and analysts expect a deal would likely involve Pfizer  inverting   or reversing into the smaller  Irish registered Allergan  Ireland s tax rate is 12 5 percent  a fraction of the 35 to 40 percent levied in the United States   President Barack Obama has described inversions as unpatriotic and last year changed some tax rules to make inverting less attractive  Allergan investors fear the U S  treasury department may scupper a deal with additional measures   Yet any such actions would already be too late to stop New York based Pfizer from reporting in Ireland profits tied to its U S  activities  Pfizer has used transactions between companies within its group to allow an Irish subsidiary based in Ringaskiddy   Pfizer Ireland Pharmaceuticals   to buy the rights to patents developed in the United States and then use them to make drugs which are sold back to U S  affiliates   Even though the Irish and other overseas units pay  3 2 billion a year in royalties to use such patent rights  the higher prices at which Pfizer in the United States imports manufactured drugs from affiliates means almost all the profits from these drugs are reported overseas  Drugs which were discovered in the United States  manufactured in Ringaskiddy and sold back to the United States include anti cholesterol treatment Lipitor   the best selling prescription drug of all time   and epilepsy drug Lyrica  which generated revenue of over  5 billion last year for Pfizer  Pfizer s actions are entirely lawful and all companies seek to manage their tax bills down  The drugmaker said the prices it used for its inter subsidiary transactions were fair and that its business structure was motivated primarily by a desire for operational efficiency rather than tax minimization    Pfizer fully complies with all applicable accounting and tax laws in the jurisdictions in which we operate and pays all taxes due   spokeswoman Joan Campion said   Jerry Buttimer  a member of the Irish parliament in whose constituency Ringaskiddy lies  said there was nothing wrong or unusual in companies seeking to reduce their tax bills   All companies will do what is in the best interest of its operations and shareholders   he said   But Ed Kleinbard  Professor of law at the University of Southern California said the company s arrangements reflected  aggressive tax planning  and it seemed  from the outside  to be almost as capable in tax planning as pharmacology    This is a company that is investing heavily in tax research  as well as pharmaceutical research   he joked   IRISH PROFITS Pfizer Ireland Pharmaceuticals is at the center of the drug company s tax minimizing structure   It is registered at a two story 1970s era office block on the road into Ringaskiddy  a hamlet with two pubs and several factories operated by major drug manufacturers  a reflection of Irish government policy over the decades to create jobs in the area   Pfizer licenses the rights to drugs developed in the United States and in other countries like Britain  to Pfizer Ireland Pharmaceuticals  according to accounts filed by the Dutch and Belgian parents of Pfizer s Irish units   A manufacturing facility on the 200 acre Ringaskiddy site  which is bordered by green fields on one side and Cork Harbour on the other  produces active ingredients for drugs  based on formulas discovered by overseas affiliates   It currently makes the active ingredients for Lipitor  anti impotence drug Viagra  anti lung cancer drug Xalkori and Ibrance  which fights breast cancer  Pfizer also operates other factories across Ireland  and smaller operations in Singapore and Puerto Rico   The compounds pass through a series of Irish companies which  like Pfizer Ireland Pharmaceuticals  have unlimited status meaning they do not have to publish accounts  a requirement of similar sized limited companies in Ireland   Reuters pieced together the Irish subsidiary s activities over the past 11 years from notes in the accounts of affiliates such as UK registered Pfizer Ltd  Belgian registered Pfizer Research and Development Company NV and CP Pharmaceuticals International CV  the tax exempt Dutch partnership through which Pfizer owns its overseas activities  including the Irish operations   It also examined patent and public health databases and spoke to three company executives  Pfizer does have manufacturing plants in the United States but filings for its overseas units show non U S  companies supply over 80 percent of U S  sales   Those sales generate margins of around 40 percent for Pfizer s overseas arm   earning it over  17 billion in 2013  However  Pfizer has reported losses on its U S  business in each of the past five years   Pfizer said it follows the  arm s length  tax principle when conducting inter company sales and purchases  This says companies should transact with affiliates at the same prices unconnected companies would   However  academics say it is very hard to judge whether inter company sales of unique products like patented chemicals  for which there is no independent open market  are conducted at prices that independent companies would agree to use    The current arm s length rules are always difficult to enforce because of the lack of a comparable price  in the drugs industry    said Edmund Outslay  tax accounting professor  Eli Broad College of Business at Michigan State University   U S  COSTS  Many of Pfizer s group costs like research  debt and top management are mostly borne in the United States  despite non U S  operations accounting for over 60 percent of global sales and 50 percent of hard assets like plants and property   For example  Pfizer has  30 40 billion in long term debt but only  12 million of it is borne by the overseas arm  filings for CP Pharmaceuticals International show   The company said the practice of borrowing in the United States reflected lender preferences rather than any attempt to shift profits  It added that it was natural for a U S  company to bear a big share of its overhead costs in the United States   But academics and campaigners are skeptical   Pfizer maximizes the deductions it takes in the U S  and maximizes the income it shifts to low tax jurisdictions   Outslay said   Pfizer denies its allocation of costs is an intentional ploy to cut taxes   While it manages to report most of the profits generated by U S  activity overseas  if it wants to take the overseas profits home  to pay dividends or fund buybacks  it has to pay the difference between the tax paid on the money   around 12 5 percent   and the U S  tax rate   Of  16 billion of U S  income taxes Pfizer has paid since 2009  almost all reflects payments in relation to such remitting of profits from overseas subsidiaries  a Reuters analysis of group filings shows  Even including this tax on remitted earnings  the amount of cash Pfizer pays in overall income taxes as a share of its profits is lower than rivals like Britain s GlaxoSmithKline  L GSK   Denmark s  Novo Nordisk   CO NOVOb  and Paris based Sanofi  PA SASY    To avoid having to pay the tax due when cash is repatriated  Pfizer keeps most of its foreign earnings overseas and  indeed  much of it stays in Ireland   In the capital  an office building near the mouth of the Liffey in Ringsend houses Pfizer s Dublin Treasury Centre  which the company says is responsible for treasury operations outside the United States and for helping manage Pfizer s offshore pile of cash on which no U S  tax has been paid  According to a presentation given by one of its staff last year  this unit overseas a cash mountain approaching  50 billion   But if Pfizer does complete an inversion  the practice of stockpiling foreign profits in Dublin may no longer be necessary  That s because as an Irish headquartered group it would be free to use its cash for dividends without incurring additional U S  tax ,2015-11-16,Reuters,https://www.investing.com/news/stock-market-news/how-pfizer-has-shifted-u.s.-profits-overseas-for-years-371495,371495
105719,327234,AGN,Pfizer discussing Allergan offer at  370  380 per share  source,news," Reuters     Pfizer  Inc  N PFE  is in talks to acquire Allergan Plc  N AGN  for  370  380 per share  according to a person familiar with the matter  valuing the potential deal at around  150 billion  the healthcare sector s biggest  Talks between the sides have accelerated  though the U S  Treasury s announcement on the tightening of the rules for tax inversions has made timing more uncertain and a deal is not imminent  the source said  asking not to be identified because the matter is confidential  
Pfizer declined to comment  while Allergan did not respond to a request for comment ",2015-11-18,Reuters,https://www.investing.com/news/stock-market-news/pfizer-discussing-allergan-offer-at-$370-$380-per-share:-source-371971,371971
105720,327235,AGN,Pfizer Allergan talks accelerate amid new inversion clamp down,news,"By Greg Roumeliotis and Kevin Drawbaugh NEW YORK WASHINGTON  Reuters     Pfizer  Inc s  N PFE  talks to acquire Allergan Plc  N AGN  in a  150 billion deal that would see the U S  drug giant redomicile in Ireland accelerated on Wednesday  as the U S  Treasury prepared to clamp down further on such tax inversions  Pfizer is negotiating a price of  370 to  380 for each Allergan share  a person familiar with the discussions said  asking not to be identified because the talks are confidential  Allergan shares ended trading on Wednesday at  310 8 per share  While negotiations have made progress in recent days  an agreement is not imminent and its timing remains uncertain following the Treasury s disclosure that it would seek to tighten the rules on inversions  the source added  Inversions typically involve a U S  multinational buying a smaller foreign competitor and relocating to its home country  if only on paper  to escape U S  taxation  Ireland is a common destination  Management usually stays in the United States    Later this week  we intend to issue additional targeted guidance to deter and reduce further the economic benefits of corporate inversions   according to a letter from the Treasury seen by Reuters  Pfizer was not named in the letter  which was signed by Treasury Secretary Jack Lew and addressed to four senior lawmakers  U S  Senators Ron Wyden and Orrin Hatch  and Representatives Kevin Brady and Sander Levin  All four serve on the Senate and House tax committees   We have no further comment beyond what is in the letter  at this time   a Treasury spokesman said  Pfizer and Allergan also declined to comment  Levin said in a statement   The fact that American companies  including Pfizer  continue to pursue inversions makes clear that additional steps are needed to stop this trend   Noting that Treasury can only do so much on its own  Levin urged Congress to  get off the sidelines and take action to change the law to stop these tax motivated inversions   As a wave of inversions peaked in September 2014  Treasury took several regulatory actions to reduce the tax benefits of inverting  while also making new deals more difficult  That slowed deal flow but did not stop it entirely  For months tax experts have speculated about what could come next from Treasury  Possible steps might include tightening the rules on two strategies related to inversions  tax experts said  so called  earnings stripping  and  skinny down  distributions  Earnings stripping rules combat shifting of U S  profits out of the country to low tax jurisdictions  Treasury has struggled to write new rules on this under present law  said tax experts  Rules targeting skinny down distributions are meant to keep U S  companies from shrinking their operations ahead of inversions to evade standards for minimum levels of foreign ownership in inverted companies  A combination of Dublin based Allergan with New York based Pfizer would follow an unprecedented wave of consolidation in the pharmaceutical industry as companies seek access to new drugs and increased leverage on pricing  Apart from tax considerations  a deal would give Pfizer access to Allergan s dominance in the aesthetics and ophthalmology markets  and displace Johnson   Johnson  N JNJ  as the world s biggest healthcare group  
Bloomberg News first reported on the price that Pfizer and Allergan were discussing ",2015-11-19,Reuters,https://www.investing.com/news/stock-market-news/treasury-dept.-to-tighten-corporate-tax-inversion-rules-371948,371948
105721,327236,AGN,Pfizer  Allergan in final stage of merger talks  CNBC,news," Reuters     Pfizer  Inc  N PFE  and Allergan Plc  N AGN  are in final stages of talks over an all stock deal  CNBC tweeted  citing sources  Reuters reported on Wednesday that Pfizer s talks to acquire Allergan had accelerated  as the U S  Treasury prepares to clamp down further on tax inversions  Pfizer will offer more than 11 shares for each Allergan share held  CNBC said on Thursday The offer would value Allergan at at least  366 41 per share  or a total of more than  144 billion  The deal would result Pfizer to domicile in Ireland  The Treasury this week will clamp down further on tax avoiding  inversion  deals done by U S  companies with foreign rivals  according to a letter obtained by Reuters on Wednesday  
Pfizer shares were down 1 6 percent in early trading  while Allergan s were down 1 8 percent ",2015-11-19,Reuters,"https://www.investing.com/news/stock-market-news/pfizer,-allergan-in-final-stage-of-merger-talks:-cnbc-372083",372083
105722,327237,AGN,Exclusive  Pfizer negotiating 2 3 percent Allergan break up fee   sources,news,"By Greg Roumeliotis and Pamela Barbaglia  Reuters     Pfizer  Inc  N PFE  is negotiating a 2 3 percent break up fee with Allergan Plc  N AGN  that would be in line with most deals  people familiar with the matter said  a sign of confidence that such a merger could overcome regulatory hurdles   The break up fee  to be paid by Pfizer if it were to walk away from Allergan  would come out to  3 billion to  4 5 billion based on a  150 billion deal value  That would make it one of the highest ever break up fees in dollar terms  However  break up fees are set in relation to the target company s size  One of the people familiar said a 2 3 percent fee would be at the lower end of similar transactions   One of the main regulatory concerns about a Pfizer Allergan merger pertains to the domicile of the combined company  U S  based Pfizer could move its headquarters to Ireland  where Allergan is based  to take advantage of lower tax rates  So called tax inversions have driven other merger deals  but the U S  Treasury is planning to clamp down on them   When the Treasury last tightened the rules on inversions in 2014  Chicago based drugmaker  AbbVie Inc   N ABBV  paid a break up fee of close to  1 7 billion to peer  Shire  Plc  L SHP  to abandon its  55 billion merger agreement that would have seen it redomicile in Ireland  The largest beak up fee ever agreed was  10 billion  and involved  Verizon Communications  Inc s  N VZ   130 billion deal in 2013 to acquire  Vodafone  Group Plc s  L VOD  45 percent stake in Verizon Wireless  The biggest break up fee that has been paid was for  4 billion  when AT T Inc s  N T   39 billion deal to acquire T Mobile US Inc  O TMUS  was opposed by regulators in 2011  The sources  who asked not to be identified because the negotiations are confidential  cautioned that the break up fee and other aspects of Pfizer s deal with Allergan have not been finalized  and that the companies were still waiting for the Treasury to unveil its updated rules on inversions  Pfizer and Allergan both declined to comment  Pfizer is negotiating  370 to  380 for each Allergan share  a person familiar with the discussions said on Wednesday  Allergan shares closed at  302 05  down 2 8 percent  illustrating that investors are still worried about the deal s prospects  Pfizer shares ended down 3 percent at  32 29   We struggle to see what the Treasury can do to specifically curb a Pfizer Allergan combination  however  we also acknowledge that the political noise surrounding the redomicile of Pfizer   one of the largest pharma companies in the U S    will likely only increase with the announcement of a merger  and likely constitutes the most material hurdle to consummation of transaction of this nature    Citigroup   N C  analysts wrote in a note on Wednesday  As a wave of inversions peaked in September 2014  Treasury took several regulatory actions to reduce the tax benefits of inverting  while also making new deals more difficult  That slowed deal flow but did not stop it entirely  For months tax experts have speculated about what could come next from Treasury  Possible steps might include tightening the rules on two strategies related to inversions  tax experts said  so called  earnings stripping  and  skinny down  distributions  Earnings stripping rules combat shifting of U S  profits out of the country to low tax jurisdictions  Treasury has struggled to write new rules on this under present law  said tax experts  
Rules targeting skinny down distributions are meant to keep U S  companies from shrinking their operations ahead of inversions to evade standards for minimum levels of foreign ownership in inverted companies ",2015-11-20,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-pfizer-negotiating-2-3-percent-allergan-break-up-fee---sources-372112,372112
105746,327261,AGN,Allergan Signals Higher Prices Potentially Ahead For Teva,opinion,"Teva Pharma Industries Ltd ADR  NYSE TEVA  lost 24  last Thursday after reporting disappointing earnings  From the Seeking Alpha transcript of the conference call 

 All of us at Teva understand the frustration and disappointment our shareholders are feeling 
In our U S  Generics business  we experienced accelerated price erosion and decreased volume  mainly due to customer consolidation  greater competition as a result of an increase in generic drug approval by the FDA  and some new product launches that were either delayed this quarter or got subjected to more competition  
 we expect to have no contribution from our businesses in Venezuela to earnings in the last two quarters of 2017  

To fix the issues 

  we are focusing on streamlining our businesses to meaningfully reduce our cost base We recently concluded a full review of our specialty R D pipeline with the assistance of an experienced outside adviser in order to rationalize and focus our pipeline assets and maximize return on investment  We are also in the final stages of engaging world class consulting firm to support our U S  Generics business  We like the full potential of these assets in light of the evolving environment 
 our board has authorized a reduction in our cash dividend by 75  to  0 085  This reduction represents approximately  260 million of cash per quarter  

Investors clearly had no patience for any of this news  After three full days of non stop selling and a devastating downgrade from Morgan Stanley going from equal to under weight  TEVA has lost a stomach churning 40 5  since its earnings 

The on going weakness in Teva Pharmaceuticals  TEVA  accelerated into a 40 5  post earnings loss 
The U S  generics business is part of Teva s troubles  A massive  40 5B deal Teva closed with Allergan  NYSE AGN  exactly two years ago sits right in the middle of those troubles  At the time  TEVA traded at an all time high and its ultimate peak 
TEVA is down a stomach churning 74 2  from that point  I note the irony because AGN still trades around the same price it had at the time of the deal s announcement  Moreover  AGN came out of the deal with a 10  ownership in TEVA  Allergan s stock is down slightly in sympathy with TEVA s woes 

Allergan  AGN  is caught up in the TEVA mix with its 10  stake  The stock is facing down a critical test of support at its 50 day moving average  DMA  
In a timely appearance  Allergan CEO and Chairman Brent Saunders appeared  to talk about the business and its recent earnings report  At the beginning of the discussion  Saunders made it clear that selling AGN because of its TEVA stake made no sense  AGN holds 10  of TEVA worth  a couple of billion dollars  while AGN has  several billion dollars in cash  
AGN promised the market from the start of its deal with TEVA that the TEVA holding was not a long term investment  The lock up on the shares expired just a few days ago  but AGN plans to sell its stake in a  responsible way  over the next several quarters  My ears perked up when Saunders claimed that selling TEVA at current prices  doesn t make much sense   That was all I need to hear to sense a potential trading opportunity 
Firstly  after three days of heavy selling  TEVA is due for a large relief bounce  a lot of weak hands likely shook themselves out in this relentless selling  A relief bounce should also be due to the extent investors panicked out the stock to get ahead of AGN s sales  Now we know the AGN overhang is at higher prices  As with most of these rebound trades  I am initially targeting a return to the lower Bollinger Band   BB  which is now around  22 25 
It is possible that generics competitor Mylan  NASDAQ MYL  is also an opportunity  Mylan completes the irony of TEVA s current troubles as TEVA made a last hour switch from pursuing MYL to AGN two years ago  Fast forward to today  and MYL sold off in sympathy with TEVA s woes  Morgan Stanley added a downgrade to MYL for good measure 
While   I still have my eye on  to CEO Heather M  Bresch if she can drive earnings per share to  6 00 by March  2018  MYL is right on the edge with guidance of  5 15 to  5 55 for fiscal year  FY  2017  Second quarter earnings before the market opens on Wednesday  August 9th will have to be good just to fight back the recent selling 
The announcement will have to be downright fantastic to suggest the company might still hit the  6 00 EPS target  MYL must explain that the depths of TEVA s woes are company specific  In other words  MYL could experience a post earnings surge  With MYL Jan 2018  35 call options costing a mere  1 70 or so  I find the risk reward very attractive to start accumulating ahead of earnings  If MYL manages to disappoint post earnings anyway  I will be looking to accumulate shares for holding into March  2018 
Mylan  MYL  has suffered mightily thanks to Teva Pharmaceuticals and Morgan Stanley  NYSE MS   Can the company redeem itself with this week s earnings news 
Be careful out there 
Full disclosure  no positions  yet ",2017-08-08,Dr. Duru,https://www.investing.com/analysis/allergan-signals-higher-prices-potentially-ahead-for-teva-pharmaceutical-200205904,200205904
105747,327262,AGN,Teva Plunges To 10 Year Low  Credit Rating In Jeopardy,opinion,"Shares of Teva Pharmaceuticals   NYSE TEVA    a favorite for investors chasing large dividend yields  fell more than 4 4  and hit a 10 year intraday low on Wednesday  Just says after the company reported sluggish Q2 earnings  investors are continuing to ditch the stock amid reports that Teva is desperately trying to sell off assets 
According to sources cited by   Teva is looking to ramp up asset sales in an effort to preserve its credit rating and cut its mounting debt  The report claims that Medis  an Iceland based generic drug manufacturer  is one of the Teva units on the table 
Bloomberg also claimed that Teva is considering the sale of its respiratory treatment assets  although the publication s anonymous sources said that a decision to sell has not been finalized and considerations are still at an early stage 
 Teva is looking at every opportunity to focus our business and streamline operations processes and structure   the company said in a statement   Beyond this update  Teva is not in a position to comment on market speculation  
Teva is under increasing pressure to reduce its debt load  which has swelled to a whopping  35 billion following its acquisition of Allergan s   NYSE AGN   generics division  Any new asset sales would come in addition to the pending offloading of Teva s women s health and European cancer and pain treatment units 
Just last week  on the same day that the company  lackluster Q2 earnings  slashed its full year outlook  and cut its dividend by 75   Teva CEO Yitzhak Peterburg said that asset sales will likely generate at least  2 billion  well above that  1 billion level that was previously forecasted 
Also last week  Moody s said that Teva s debt reduction has been slower than expected and lowered its credit rating  Moody s hasn t been the only analyst firm to question Teva recently  as Morgan Stanley s David Risinger also chimed in this week 
 We believe that Teva s disappointing generic business performance will take more time to improve given a combination of the generic industry s intensifying secular challenges and Teva s own difficulty in executing on its pipeline   Risinger said in a note 
Risinger downgraded Teva to  underweight  and cut its price target to  16  which would represent a further 8 5  slide from Wednesday s close 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-09,Zacks Investment Research,https://www.investing.com/analysis/teva-plunges-to-10year-low-credit-rating-in-jeopardy-200206379,200206379
105748,327263,AGN,ACADIA Pharmaceuticals Shares Surge Up On Better Than Expected Results,opinion,"ACADIA Pharmaceuticals Inc  NASDAQ ACAD 
ACADIA Pharmaceuticals Inc   ACAD   a a biopharmaceutical company yesterday reported their second quarter 2017 financial results 
The company reported second quarter earnings of a loss of  0 55 per share which fell beat analyst expectations of a loss of  0 71 per share 
ACADIA reported second quarter revenues of  30 5 million which beat analyst expectations of  19 6 million 
ACADIA Pharmaceuticals Inc  CEO s Comments

 Our commercial efforts continue to drive strong financial performance with solid market uptake for NUPLAZID in patients with Parkinson s disease psychosis   said Steve Davis  ACADIA s President and Chief Executive Officer   Following positive data from our Phase II study in Alzheimer s disease psychosis and recently completed End of Phase II meeting with the FDA  we are excited to start our Phase III program in the next couple of months   

ACAD Technical Analysis

ACAD opened trading yesterday at  30 53 which was down from the previous day s trading close of  30 57  ACAD closed trading yesterday at  29 54 and spiked up after market to  33 40  equivalent to a 13  increase from the closing price  Taking a look at the daily chart we can see the last time ACAD traded above these levels we have to go back to May 1st when it traded at  34 41 
Taking a closer look at the daily chart we can see that before the spike up ACAD had been in an overall downward trend dating back to February 27th when it traded at  39 85  ACAD has a of 96 million shares and traded 1 23 times the normal daily trading on Tuesday 
For trading purposes  I would like to see ACAD open trading on Wednesday above  32 and if it does I would be looking to take a long position at the bell  My  would be  0 25 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
ACADIA Pharmaceuticals Inc   incorporated on January 16  1997  is a biopharmaceutical company  The Company is focused on the development and commercialization of medicines for central nervous system  CNS  disorders 
The Company s lead drug candidate  NUPLAZID  pimavanserin   is used for the treatment of hallucinations and delusions associated with Parkinson s disease psychosis  PD Psychosis   NUPLAZID is a selective serotonin inverse agonist  SSIA   preferentially targeting 5 HT2A receptors 
The Company is conducting a Phase II trial  referred to as the SERENE Study  designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer s disease  AD  Agitation 
It is also conducting a Phase III  six week  randomized  double blind  placebo controlled  multi center  outpatient study  referred to as the ENHANCE 1 study  designed to examine the use of pimavanserin in patients with schizophrenia 
It is conducting a Phase II  26 week  randomized  double blind  placebo controlled  multi center study  referred to as the ADVANCE study  designed to examine the use of pimavanserin in patients with schizophrenia  having predominant negative symptoms 
It is also conducting a Phase II  10 week  randomized  double blind  placebo controlled  multi center study  referred to as the CLARITY study  designed to examine the use of pimavanserin in patients with major depressive disorder  having an inadequate response to standard antidepressant therapy with either a selective serotonin reuptake inhibitor  SSRI  or a serotonin norepinephrine reuptake inhibitor  SNRI  
The Company competes with Eisai Inc   Pfizer Inc   NYSE PFE   Actavis  NYSE AGN  plc  Otsuka Pharmaceutical Co   Ltd   Sunovion Pharmaceuticals Inc  and Eli Lilly ",2017-08-10,Warrior Trading,https://www.investing.com/analysis/acadia-pharmaceuticals-acad-stock--shares-surge-up-on-better-than-ex-200206409,200206409
105749,327264,AGN,Are Amgen s New Drugs Doing Well Enough To Drive Sales ,opinion,"We issued an updated research report on Amgen  Inc    NASDAQ AMGN   on Aug 14 The leading biotech beat estimates on both earnings   sales in the second quarter  the results of which were announced on Jul 25  While Amgen slightly tightened the sales guidance  it raised the earnings outlook backed by its strong performance in the first half Amgen s newer drugs   Prolia  Xgeva Kyprolis Vectibix  Nplate and Sensipar   are all performing well backed by strong demand Amgen is also progressing with its pipeline including biosimilar drugs  Important pipeline candidates include Aimovig erenumab  prevention of migraine   under review in the U S    CNP520  BACE inhibitor for Alzheimer s disease   phase III  and omecamtiv mecarbil  heart failure   phase III  Amgen has 10 biosimilars in its pipeline  The company has collaborated with Allergan plc   NYSE AGN   for the worldwide development and commercialization of three oncology antibody biosimilar medicines   Roche s Herceptin  Avastin and Rituxan However  the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products  Volume growth of new products may not be enough to offset the lost sales due to the decline in mature brands like Enbrel  Epogen  Neulasta and Neupogen due to competitive pressure While Neulasta sales are being hurt by competition from PD 1s and other new cancer therapies  Neupogen sales are going down due to biosimilar competition in the U S  from Zarxio  Zarxio is Sandoz s  Novartis AG s   NYSE NVS   generic arm  biosimilar version of Neupogen  which was launched in the U S  in Sep 2015The company expects Neulasta and Neupogen sales to continue to be hurt by competitive dynamic through the rest of 2017  Meanwhile  Neulasta and Epogen could start facing biosimilar competition next year Also the softness in Enbrel s sales due to stiff competitive pressure is a key cause of concern  Pricing pressure and stiff competition are hurting sales of Enbrel  one of the main drivers of Amgen s revenues this year Meanwhile  uptake of Amgen s PCSK9 inhibitor  Repatha  which gained FDA approval in Aug 2015  has not been very encouraging so far due to pricing and re imbursement issues payer restrictions  Sanofi   NYSE SNY   and partner Regeneron Pharmaceuticals also faced similar issues with their PCSK9 inhibitor  Praluent In the second quarter  however  the company did notice some improving share trends for the drug  following the presentation of the outcomes study  FOURIER  data in March this year  The data showed significant reduction in myocardial infarctions and strokes  The company filed regulatory applications in both the U S  and EU to include FOURIER data on Repatha s label in Jun 2017 with a FDA decision expected on Dec 2  2017 Lastly  Amgen has had its share of pipeline setbacks  The latest being the complete response letter  CRL  received from the FDA for Evenity romosozumab  osteoporosis in postmenopausal women at increased risk for fracture  in July  following the heart related safety issue that emerged from the otherwise successful ARCH results  The FDA asked for safety and efficacy data from two pivotal phase III studies   ARCH and BRIDGE   to be included in the original application  which was filed only on the basis of the pivotal FRAME study   This will lead to a delay in the drug s approval Amgen Inc  Price and Consensus
    Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/are-amgens-new-drugs-doing-well-enough-to-drive-sales-200207354,200207354
105750,327265,AGN,Teva Stock Is Getting Destroyed  Is Now The Time To Buy  ,opinion,"Teva Pharma Industries Ltd ADR  NYSE TEVA  has been a darling for investors in the generic drug sector  Even as recently as last year  investors were eager to see the growth of the company and along with it  the stock price  But then second quarter earnings were reported and Teva stock price hit the fan as they say 
Teva stock price has since cratered 45  since earnings were released and there is no sign of the price coming back  So should investors  particularly value investors take a look at Teva 
In this post  we will look at Teva stock and see whether or not there is a value play here or if you are better served putting your investing dollars elsewhere 
Teva Stock Drops After Earnings
Just looking at the raw numbers  the earnings Teva reported don t appear to be terrible  Revenue came in at  5 69 billion  missing by  40 million  But this was an increase of 13   Earnings per share also missed estimates by  0 05  coming in at  1 02 
But a closer look shows the full picture  Net income was down 20   Cash flow was down 23   Then executives pulled the plug  They slashed earnings estimates for the full year and  
So what exactly happened 
The Issues With Teva Stock
There are a handful of issues at play here when it comes to Teva stock  First  management is partly to blame  When Teva bought Actavis Generics from Allergan  NYSE AGN   they touted the added revenue and the cost savings that would come  Unfortunately  they drank too much of their own potion and really had no chance of meeting expectations 
But the issues don t end there  Here are other issues Teva is facing 
Consolidation  many of Teva s customers are consolidating  which is lowering the revenue the company plans to earn in the future 
Competition  there is more competition for generic drugs  This is leading to cost cutting and lowering potential revenue 
Decline in specialty drugs  many of Teva s specialty drugs have experienced a year over year sales decline and there is no sign of sales picking up any time soon 
Slower to market  a handful of the drugs in the pipeline are being delayed which is putting added pressure on the company and Teva stock price 
Increase in debt  the debt burden of Teva has now eclipsed  35 billion  which puts pressure on earnings
Search for CEO  the company is still searching for a permanent CEO  so the company is in a sense meandering along until a new leader takes over 
And then there is the issue with Allergen  When Teva bought Acatvis Generics  part of the deal was in stock  So Allergen became the largest shareholder of Teva stock  At the time of the deal  there was a restriction on when Allergen could sell their shares 
That holding period has now passed  And with Teva stock price down 50  from when Allergen bought it  only one wonders if they want to cut ties now with the troubled generic drug maker 
Is There A Value Play 
The question is  is there any reason for a value investor to invest in Teva  At this point  I can t think of one  The reason being is that there is nothing in the immediate horizon that will cause the stock price to jump 
If anything  the stock price will trade in a small range for some time  Over the long term however  Teva does have some things going for it  They have 5 new drugs on the horizon that can add to the bottom line 
But in the meantime  the company needs to find a permanent CEO and start to work on reducing its debt load  They have started some cost saving initiatives by   but this will only put a dent in the issues with Teva 
I would hold off on investing in Teva for a few months and re evaluate how things are progressing  Keys will be earnings for the third quarter and full year to see if the company is making headway on increasing earnings and revenues 
If it can quickly turn things around  Allergen will likely continue to hold on to its shares hoping to earn some losses back  which would take away the downward pressure and fears that they will sell everything and drive the stock price lower 
This author has no positions in any stock mentioned and does not plan to open any positions in any stocks mentioned for at least 72 hours after publication of this article ",2017-08-16,Modest Money,https://www.investing.com/analysis/teva-stock-is-getting-destroyed-is-now-the-time-to-buy-200207412,200207412
105751,327266,AGN,Shire Files Marketing Application For Lifitegrast In Europe,opinion,"Shire plc   NASDAQ SHPG   announced that it has submitted a Marketing Authorization Application  MAA  for lifitegrast for the treatment of dry eye disease in Europe  In fact  the application has been validated by the UK as the Reference Member State  involved in the Decentralized Procedure  DCP  
If approved  lifitegrast will be the first and only treatment among a new class of drugs  Consequently  it will give a significant boost to Shire s efforts to build an ophthalmology unit  Notably  the MAA for the drug was supported by data from five clinical trials  including 2 500 patients 
Shares of the company have declined 13 3  compared with the Zacks classified  fall of 2 4  on a year to date basis 

It is to be noted that Lifitegras was launched in August 2016 in the U S  under the brand name Xiidra   In fact  Shire received a major boost when the FDA approved its Xiidra 5   a twice daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease  DED  in adults   
Per the company  Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition  Approximately 16 million adults in the U S  are diagnosed with dry eye disease  underscoring significant need for treatments in this field  Xiidra also strongly competes with Allergan plc s   NYSE AGN   eye care drug Restasis 
Meanwhile  the company has a deep pipeline in ophthalmology comprising early   mid  and late stage candidates gained through organic growth and strategic acquisitions  Also  it remains committed to continued innovation in ophthalmics  where there are opportunities to address unmet need  and improve the lives of patients Shire PLC Price

   Zacks Rank   Stocks to Consider
Shire currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Alexion Pharmaceuticals  Inc    NASDAQ ALXN   and Sanofi   NYSE SNY    While Alexion sports a Zacks Rank  1  Strong Buy   Sanofi holds a Zacks Rank  2  Buy   You can see  
Alexion Pharmaceuticals  earnings per share estimates have moved up from  4 55 to  4 77 for 2017 and from  5 49 to  6 43 for 2018 over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 12 26   The share price of the company has increased 10 6  year to date 
Sanofi s earnings per share estimates have increased from  3 20 to  3 31 for 2017 and from  3 36 to  3 38 for 2018 over last 30 days  The company pulled off positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10   The share price of the company has increased 18 3  year to date 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/shire-files-marketing-application-for-lifitegrast-in-europe-200207703,200207703
105752,327267,AGN,3 Top Healthcare Mutual Funds For Bipartisan Reform,opinion,Even with the uncertainty of the Affordable Care Act s  ACA  future  the Healthcare sector has been one of the top performing segments in 2017   Currently there are two plans in motion with Republicans attempting one more time to repeal the act  and a second plan more geared at a bipartisan solution  Committee meetings are expected to start next month in attempts to find a middle ground between both political parties to fix several parts of the ACA   The hearings are supported by both Republican chairman of the Health  Education  Labor  and Pensions Committee member Senator Lamar Alexander of Tennessee  and the committee s top Democrat Senator Patty Murray of Washington State   These two Senators have cooperated with each other on a few other pieces of legislation    A bipartisan solution seems to marry the best ideas from each party and would most likely help both the consumer and businesses alike   What we looked for    To capitalize on the healthcare sector  we utilized the  to identify the best funds with specific characteristics   First  the fund had to have a   Strong Buy rating   Second  they had to have an  below 1 2 with no    Third the fund had to have significant exposure to stocks in the healthcare sector   Lastly  they had to have a history of success  and be maintained by a top fund manager The PicksFidelity Select Medical Equipment   Systems    fund s objective is to seek capital appreciation  Normally the fund invests at least 80  of assets in common stocks of companies principally engaged in research  development  manufacture  distribution  supply  or sale of medical equipment and devices and related technologies  The fund offers dividends and capital gains twice a year in April and December Cost Specifics  The minimal investment is  2 500  it has a 0 55  management fee  and the total expense ratio is 0 76   Performance and Management  YTD return  24 3   1 year  12 9   5 year  22 4   10 year  13 7    FSMEX has been managed by Edward Yoon since 2007 who has been a research analyst and portfolio manager at Fidelity since 2006   Mr  Yoon has a BA in business economics from Brown University   Top Holdings  As of the most recent filings  the top five positions were held in Medtronic  NYSE MDT  PLC  Boston Scientific  NYSE BSX   Becton  Dickerson and Co   Intuitive Surgical  NASDAQ ISRG   and Danaher Corp  NYSE DHR  Hartford Healthcare HLS Fund Class IA    is a stock fund that invests in health care  a sector that is experiencing innovations and breakthroughs across multiple subsectors  The fund s objective seeks long term growth of capital   Cost Specifics  There is no minimal investment associated with this fund  but it does have a 0 84  management fee with a total expense ratio of 0 89   Performance and Management  The YTD return is  22 5   1 year  13 2   5 year  20 6   and 10 year  12 8    HIAHX is currently team managed which is led by  Robert Deresiewicz  a biotechnology analyst with an MBA from Harvard  And Ann Gallo  a global industry analyst with an MS from the Massachusetts Institute of Technology   Top Holdings  As of the most recent filing the top 5 positions consisted of United Health Group  Medtronic  Allergan  NYSE AGN   Celgene  NASDAQ CELG   Bristol Myers Squibb   Fidelity Select Health Care    fund s objective is to seek capital appreciation  The fund normally invests its 80  of assets in common stocks of companies principally engaged in the design  manufacture  or sale of products or services used for or in connection with health care or medicine  Dividends and capital gains are declared in April and December every year Cost Specifics   The minimal investment is  2 500  it has a management fee of 0 55   and has a total expense ratio of 0 73 Performance and Management  The YTD return is  22 3   1 year  9 8   5 year  21 1   and 10 year  13 5    FSPHX is currently team managed and led by Yolanda Strock  the sector leader of the Health Care Equity Research group   She has an MBA from Duke University  a B S  from University of Pennsylvania  Warton   and a B A from the University of Pennsylvania   Top Holdings   As of the most recent filing the top 5 positions were in Amgen  NASDAQ AMGN   Allergan  United Healthcare Group  Boston Scientific  and Medtronic   Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/3-top-healthcare-mutual-funds-for-bipartisan-reform-200210239,200210239
105753,327268,AGN,Why Is Ironwood  IRWD  Down 4 1  Since The Last Earnings Report ,opinion,"About a month has gone by since the last earnings report for Ironwood Pharmaceuticals  Inc    NASDAQ IRWD    Shares have lost about 4 1  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts Ironwood Second Quarter Loss Wider than Expected  Sales MissIronwood reported second quarter 2017 adjusted loss of 28 cents per share  wider than both the Zacks Consensus Estimate of a loss of 23 cents and the year ago loss of 16 cents Total revenue  collaborative revenue  in the quarter amounted to  65 1 million  up 19 7  from the year ago period but below the Zacks Consensus Estimate of  68 5 million The Quarter in DetailLinzess generated U S  net sales of  167 8 million  as reported by partner Allergan  NYSE AGN   up 11 5  year over year Ironwood and Allergan equally share brand collaboration profits or losses  Ironwood s share of the net profits from the sales of Linzess in the U S   included in collaborative revenues  was  43 8 million in the second quarter  up 11  year over year but down 13  sequentially Lower inventory hurt sales of Linzess in the quarter  Management is uncertain whether this trend will persist through the rest of the year However  Linzess witnessed continued strong demand growth year over year  According to data provided by IMS Health  Linzess prescriptions filled during the quarter crossed 750 000  up 15  from the year ago period  Total Linzess volume growth included a 19  increase in capsules due to an increase in the number of prescriptions for the 90 count bottle Zurampic raked in sales of  0 5 million in the quarter  Zurampic prescriptions filled during the quarter were 1500  higher than 900 prescriptions filled in the previous quarter  The uptake of the drug has been slow and management expects sales to be nominal in 2017 as it works on educating physicians and patients as well as secure payer access During the reported quarter  selling and administrative  SG A  expenses increased 56 5  to  57 8 million primarily due to investments to support the launch of Zurampic Research and development  R D  expenses were  37 3 million  up 17 9  from the year ago period due to costs associated with pipeline development 2017 Guidance MaintainedThe company now expects to use less than  100 million for operations in 2017  much higher than 2016 levels  given a full year of commercial expenses related to the launch of Zurampic and to support the launch of Duzallo and pipeline advancement R D expenses and SG A expenses are expected in a range of  145  160 million and  235  250 million  respectively Total marketing and sales expenses for Linzess are still expected to be around  250  280 million 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed a downward trend in fresh estimates  There have been three revisions lower for the current quarter  In the past month  the consensus estimate has shifted lower by 20 5  due to these changes 
Ironwood Pharmaceuticals  Inc  Price and Consensus
    VGM Scores
At this time  Ironwood s stock has a subpar Growth Score of D  though it is lagging a bit on the momentum front with an F  Following the exact same course  the stock was allocated a grade of F on the value side  putting it in the bottom 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate investors will probably be better served looking elsewhere 
Outlook
Estimates have been broadly trending downward for the stock  The magnitude of this revision also indicates a downward shift  It s no surprise that the stock has a Zacks Rank  4  Sell   We expect below average returns from the stock in the next few months ",2017-09-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-ironwood-irwd-down-41-since-the-last-earnings-report-200211364,200211364
105754,327269,AGN,Democrats take aim at drug prices  prompting sharp drops in biotech stocks,news,"By Ransdell Pierson and Bill Berkrot  Reuters    Democratic lawmakers on Monday attacked  massive  price increases of two heart drugs by Canada s Valeant  fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U S  drug prices  All 18 Democratic members of the House of Representatives Committee on Oversight and Government Reform urged their chairman to subpoena Valeant Pharmaceuticals International Inc  TO VRX   N VRX  and force it to provide documents relating to price increases of 212 percent for Isuprel and 525 percent for Nitropress  Valeant boosted the prices immediately after buying the heart drugs last February  Shares of Valeant tumbled 16 5 percent on the New York Stock Exchange  and other pharmaceutical company shares also slid  Investors are worried that the drug industry faces a moment of reckoning for steep price hikes for both new and older medicines  Shares of many pharmaceutical companies have slumped since 2016 Democratic presidential hopeful Hillary Clinton last week proposed ways for the government to prevent  profiteering  by the industry  The slump in Valeant shares on Monday hit hedge funds run by activist investors Bill Ackman  John Paulson and Jeffrey Ubben  Ackman s fund  Pershing Square Capital Management  owns nearly 5 76 percent of Valeant  which partnered with Ackman last year in a failed bid to acquire Botox maker Allergan Plc  N AGN    The Nasdaq Biotech Index  NBI  sank 6 percent  while the ARCA Pharmaceuticals Index of large drugmakers dropped 3 5 percent   AbbVie Inc   N ABBV   Eli Lilly   Co  N LLY  and  Gilead Sciences Inc   O GILD  were among the hardest hit  The Democratic House members also urged panel Chairman Jason Chaffetz  a Republican  to invite Valeant Chief Executive Michael  Pearson   LONDON PSON  to testify at a hearing next week  That would put Pearson in the same hot seat as Martin Shkreli  chief executive of privately held Turing Pharmaceuticals  who has already been called to testify  Chaffetz said Monday evening that he had not yet read the letter from the Democrats   I m going to take a look at it  but I haven t yet read it   he told Reuters outside the Capitol  Tiny Turing has been widely criticized for a price hike of more than 5 000 percent for its Daraprim treatment for a dangerous parasitic infection  to  750 per pill from the original price of  13 50  Turing said last week that it roll back the price  but only said that it would be below  750  Clinton on Monday called on Turing to roll back the price to the original  13 50 per pill   It just makes people more nervous that you are going to see Michael Pearson sitting next to Martin Shkreli   said Evercore ISI analyst Umer Raffat  Pearson has built Valeant into one of the world s largest drugmakers through a series of acquisitions  His business model has featured price hikes and deep cuts in research spending  Officials at Valeant could not be immediately reached for comment on the requests for a subpoena   A BIG FLUSH  U S  biotech stock valuations have been falling since they peaked in mid July    The sector was overvalued and today we re seeing a big flush   said Len Yaffe  portfolio manager of the StockDoc Partners healthcare fund  He said the decline was exacerbated by trading in exchange traded funds  which hold a basket of stocks and tend to track a particular stock index   We re seeing the negative side of investing in ETFs    Clinton last week unveiled a plan that includes a  250 monthly cap on out of pocket costs for prescription drugs  It would allow the Medicare plan for the elderly to negotiate drug pricing and permit Americans to buy drugs more cheaply from other countries  On Monday  she suggested in a Facebook  NASDAQ FB  posting that large drugmakers should help increase competition among generic drugs by investing in their production when there is only one manufacturer   Industry experts are skeptical that Clinton  if elected  could overcome tremendous Republican opposition to such measures in Congress  But her high profile focus on the issue is expected to embolden efforts by health insurers  doctors  groups and others to pressure drugmakers  
  Stock  selling hasn t really stopped since Hillary Clinton made her comments last week   said Jeff Jonas  a portfolio manager with Gabelli funds   The Democratic committee members would certainly continue that trend that Hillary started  ",2015-09-28,Reuters,https://www.investing.com/news/politics-news/house-democrats-take-aim-at-price-hikes-for-valeant-drugs;-shares-drop-363580,363580
105755,327270,AGN,Valeant shares plunge on short seller scrutiny of pharmacy ties,news,"By Caroline Humer
NEW YORK  Reuters    Shares of Valeant Pharmaceuticals International Inc  TO VRX   N VRX  plunged as much as 30 percent after an influential short seller accused the company of fraud  saying it used its relationship with specialty pharmacies to inflate revenue 
The report by Citron Research  a short selling firm run by Andrew Left  said Wednesday that Valeant s previously undisclosed relationship is a sign of a cover up  Valeant spokeswoman Laurie Little was not immediately available for comment 
The Citron Research report hit shares hard shortly after 10 a m  EDT in New York trading  The shares were last trading down  41 62 at  105 12  representing a major loss for billionaire Bill Ackman  who holds a 5 7 percent stake in Valeant 
Shares of some key competitors  including Allergan Inc  N AGN   Endo International Plc  O ENDP  and  Mallinckrodt  Plc  N MNK  also fell sharply 
Citron alleged that Valeant was using specialty pharmacies   include Philidor and R O Pharmacy Inc   to create  phantom sales  of its products or pushing more product through distribution channels than sales would warrant  and to avoid scrutiny from auditors 
 Citron believes the whole thing is a fraud to create invoices to deceive the auditors and book revenue   the note said 
Valeant has been under fire for several weeks over its practice of raising drug prices sharply once it acquires new medications  Last week  it disclosed that it was under investigation by federal prosecutors in New York and Massachusetts 
The government requested information on pricing and on programs that help patients cover their out of pocket expenses for Valeant s drugs  Those drugs are often distributed by specialty pharmacies 
On Monday  during a conference call with investors  Valeant defended its pricing and declined to comment on the federal investigations  saying it was cooperating with authorities 
But the company disclosed new information about its dealing with two pharmacies  which distribute specialty drugs to patients  including that it had purchased an option to acquire Philidor and was already consolidating its results 
Len Yaffe  an investor at StocDoc Partners  who is short on Valeant  said that he is not yet sure of what to make of Citron s claims  He said the notion that Valeant would need to resort to phantom sales to juice revenues heightens existing widespread concerns about the company s ability to produce growth in an increasingly hostile pricing environment 
Valeant s stock took a significant hit in late September in response to criticism from Democratic presidential candidate Hillary Clinton about rising drug prices and media reports of its particularly steep price increases 
Independent Canadian equity research firm Veritas said it saw significant unquantifiable risks overhanging Valeant 
Analyst Dimitry Khmelnitsky sees Valeant at risk of losing its  secret sauce  that made it a darling of many investors due to the pullback in its share price  Valeant has traditionally used its highly valued shares to pursue accretive acquisitions and tack on debt 

The selloff on Wednesday knocked off  15 billion in market capitalization from Valeant  which was valued as high as  90 billion in early August  It has since lost more than half of its value ",2015-10-21,Reuters,https://www.investing.com/news/stock-market-news/valeant-shares-plunge-on-short-seller-scrutiny-of-pharmacy-ties-367296,367296
105756,327271,AGN,Specialty pharmacies in spotlight as Valeant ties questioned ,news,"By Deena Beasley LOS ANGELES  Reuters    Investor concerns over accounting practices at Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  have put a spotlight on the little known and fast growing specialty pharmacy industry   Shares of Valeant fell 19 percent on Wednesday after influential short seller Citron Research accused the company of using specialty pharmacies  through a network led by its partner Philidor Rx Services  to inflate its revenue  an allegation the drugmaker denied  Specialty pharmacies are designed to deliver medications with unique handling  storage and distribution requirements  often for patients with complex conditions such as cancer  multiple sclerosis or rheumatoid arthritis  They can provide more detailed guidance for patients on how to take the drugs  Specialty drugs are often expensive  sometimes priced at over  100 000 a year  The industry has been growing quickly as drugmakers shift research and sales efforts to more complex medications  Pembroke Consulting estimated early this year that the number of accredited specialty pharmacies would jump by nearly 100 to a total of 250 in 2015  In the past  drugmakers were directly involved in distribution of their products  Merck   Co  N MRK   for example  owned a pharmacy service company known as Medco  But it spun off that business in 2003  partly due to concerns over potential conflicts of interest   Medco was later acquired by Express Scripts Holding Co  O ESRX   which is now the largest U S  pharmacy benefits manager   A New York Times report earlier this week said that Valeant worked with Philidor Rx Services  based in Hatboro  Pennsylvania  to increase sales  and prices  for treatments that don t meet the specialty criterion  including drugs for acne and toenail fungus  and that regular pharmacies may not prescribe   The same day  Valeant disclosed that a growing percentage of its revenue is coming from products dispensed through specialty pharmacies  and that it had purchased an option to acquire Philidor  Valeant is Philidor s main customer    We find specialty pharmacies improve patients  access to medicines at an affordable price  and help ensure physicians are able to prescribe the medications they believe most appropriate for their patients   Valeant Chief Executive Michael  Pearson   L PSON  told investors on a conference call   He said that for many of the company s skin products  Philidor and other specialty pharmacies fill a customer s prescription before reimbursement is worked out with an insurer  and that Valeant only recognizes revenue from the products once the drug reaches a patient   Pearson also described how Valeant s relationship with another specialty pharmacy  R O Pharmacy LLC of Camarillo  California  turned sour  Valeant said it had shipped  69 million worth of medications at wholesale prices to R O  and that the pharmacy  is currently improperly holding significant amounts it receives  from insurers   R O has sued Valeant in California over its efforts to claim the money  saying it has no contractual relationship with the drugmaker  Representatives of R O declined to comment  Citron alleged that R O and Philidor may actually be the same company  and that the two were used by Valeant to create phantom accounts to inflate revenue  In a statement  Philidor said R O is part of its network of affiliated pharmacies and that it provides services to those partners including call center functions  help with insurance claims  technical support and  certain management services     Philidor does not currently have a direct equity ownership in R O Pharmacy or the affiliated pharmacies  but does have a contractual right to acquire the pharmacies now or in the future subject to regulatory approval   the statement said   Scott Knoer  chief pharmacy officer at the Cleveland Clinic  said the web of relationships raises concern  Cleveland Clinic and other hospitals have been hit financially by Valeant price increases on heart drugs Isuprel and Nitropress    There would be an inherent conflict of interest if a specialty pharmacy is owned by someone making the drug   Knoer said   There could be pressure on the pharmacy to start patients on the drug  or continue patients on it  or not stop them  as warranted  While concerns over Valeant s ties to its specialty pharmacies hit rival stocks on Wednesday  both Allergan Plc  N AGN  and Endo International Plc  O ENDP  were quick to say their businesses did not operate in the same manner   
Allergan said about 3 percent of its U S  sales of branded drugs are distributed through specialty pharmacies  most of which are specialty products that require careful handling  Endo said it uses specialty pharmacies mainly for branded products that need to be administered by doctors  and that drugs distributed through this channel represent about 3 percent of the company s projected total revenue for 2015  It said any specialty pharmacies that it works with are fully independent of the company ",2015-10-22,Reuters,https://www.investing.com/news/stock-market-news/specialty-pharmacies-in-spotlight-as-valeant-ties-questioned-367418,367418
105757,327272,AGN,Wall St  slips on tech results  chances of Fed hike,news,"By Lewis Krauskopf  Reuters    U S  stocks ended slightly lower on Thursday as the market digested disappointing tech earnings reports and the potential for an interest rate hike in December  The Federal Reserve  which kept rates unchanged at its policy meeting that ended Wednesday  downplayed concerns about global growth and indicated confidence in the U S  job market s recovery  Stocks had jumped on Wednesday following the Fed statement and  after a strong run from the end of September  were due for a  reprieve   said Jason Ware  chief investment officer at Albion Financial  in Salt Lake City   I would just say that we had a big move and this is a bit of a cooling pause the next day   Ware said  The three indexes are on track for their best month in four years  S P utilities   which tend to do worse when interest rates are rising  were the worst performing S P sector  off 0 6 percent   The Dow Jones industrial average  DJI  fell 23 72 points  or 0 13 percent  to 17 755 8  the S P 500  SPX  lost 0 94 points  or 0 04 percent  to 2 089 41 and the Nasdaq Composite  IXIC  dropped 21 42 points  or 0 42 percent  to 5 074 27  The three indexes recovered much of the day s losses late in the session  After the bell  U S  listed shares of Valeant Pharmaceuticals  N VRX   TO VRX  fell 11 5 percent to  98 63  extending losses from the regular session  when it dropped 4 7 percent to end at  111 50  Express Scripts Holding Co  O ESRX  and CVS Health Corp  N CVS  said they had dropped Philidor Rx  a specialty pharmacy used by Valeant  from their networks in a sign the fall out from the drugmaker s connection with the specialty pharmacy is spreading  Also after the close  shares of LinkedIn  N LNKD  jumped 12 4 percent to  244 as it reported earnings and revenue that beat analysts  expectations  The S P healthcare sector ended the session up 0 4 percent  making it the top performing sector  as Allergan s shares  N AGN  shot up 6 percent to  304 38  The Botox maker confirmed it was in buyout talks with  Pfizer   N PFE   Pfizer dropped 1 9 percent   Sixty percent of the S P 500 companies have reported quarterly results so far  Analysts now expect overall third quarter profit to decline a modest 1 7 percent  compared with the 4 2 percent drop forecast on Oct  1  according to Thomson Reuters data   NXP Semiconductors   O NXPI  sank 19 7 percent to  73 after its bleak forecast  The slide took down other chipmakers  with the broader semiconductor index  SOX  down 3 percent   F5 Networks Inc   O FFIV  shares fell 9 3 percent to  110 08 after a disappointing outlook  making it the biggest percentage loser in the S P 500 technology index    Declining issues outnumbered advancing ones on the NYSE by 1 852 to 1 185  for a 1 56 to 1 ratio on the downside  on the Nasdaq  1 820 issues fell and 959 advanced for a 1 90 to 1 ratio favoring decliners  The S P 500 posted 28 new 52 week highs and 6 lows  the Nasdaq recorded 102 new highs and 76 new lows   
About 7 billion shares changed hands on U S  exchanges  about even with the 7 1 billion daily average for the past 20 trading days  according to Thomson Reuters data ",2015-10-29,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-lower-as-december-rate-hike-back-on-the-table-368651,368651
105758,327273,AGN,Exclusive  Guggenheim  JPMorgan clinch key roles in Pfizer Allergan talks,news,"By Greg Roumeliotis and Pamela Barbaglia NEW YORK LONDON  Reuters    Investment banks Guggenheim Partners LLC and JPMorgan Chase   Co  N JPM  have secured key roles in  Pfizer  Inc s  N PFE  merger negotiations with Allergan Plc  N AGN   according to people familiar with the matter  in what would be the biggest ever deal in the pharmaceutical sector   Guggenheim is advising Pfizer alongside  Goldman Sachs Group  Inc  N GS   while JPMorgan is advising Allergan alongside  Morgan Stanley   N MS   the people said on Monday  Other investment banks are also vying to secure roles  the people added  The sources asked not to be identified because the financial advisory roles are not yet public  JPMorgan and Morgan Stanley declined to comment  while Pfizer  Allergan  Guggenheim and Goldman Sachs did not immediately respond to requests for comment  Banks advising Allergan stand to collectively earn between  140 million and  180 million  while banks advising Pfizer could make between  80 million and  100 million in total  depending on the purchase price  according to estimates by consultancy Freeman   Co   Pfizer  the No  1 U S  drugmaker  and Botox maker Allergan disclosed last week they were in friendly talks to merge  Pfizer and Allergan have market capitalizations of  215 billion and  122 billion respectively   
The deal  which is several weeks away from an agreement  would potentially set up Pfizer to take advantage of Ireland s lower tax rates  where Allergan is domiciled  according to the sources ",2015-11-02,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-guggenheim,-jpmorgan-clinch-key-roles-in-pfizer-allergan-talks-369274",369274
105759,327274,AGN,Pfizer Allergan deal would set up U S  company for a split,news,"By Bill Berkrot and Ransdell Pierson  Reuters    A  Pfizer  Inc  N PFE  merger with Ireland based Allergan  N AGN   in addition to providing tax benefits  would bolster the U S  drugmaker s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent  Many Wall Street analysts believe Pfizer will decide to split late next year  after compiling three years of financial data treating its  established products  division  which sells generic medicines  and its  innovative  patent protected medicines unit  as if they were separate companies   Such a split would dramatically boost the company s profitability  because in patents drugs command much higher prices that rise every year  as opposed to off patent medicines  that become commoditized and their prices decline   This would be the creation of two companies really  not one huge  350 billion Pfizer   Andy Summers  co portfolio manager at Janus Capital Group  said of the likely Pfizer split post merger  Janus is the 11th largest Allergan shareholder with about 6 5 million shares  according to Thomson Reuters data   Pfizer s  15 billion purchase earlier this year of hospital products maker  Hospira   N HSP   which sells generic injectable drugs and is developing biosimilar versions of top selling biotech medicines  was widely seen as a move to make the established products business more attractive ahead of a sale  A combination with Allergan would add lucrative product lines to Pfizer s core innovative business  including aesthetics such as anti wrinkle treatment Botox and facial fillers  and opthalmology and neurology brands   At a business review on Wednesday  Allergan highlighted some of its more promising new medicines  including Viberzi for irritable bowel syndrome  which the company believes will be a  1 billion drug  Allergan could also contribute somewhat to established products as well  notably the Alzheimer s treatment Namenda  which was not included in the  40 5 billion agreement to sell Allergan s huge portfolio of generic drugs to Teva Pharmaceutical Industries  N TEVA   The deal is expected to close early next year  Oliver Pursche  chief executive of Bruderman Asset Management  which holds Pfizer shares in client portfolios  said a combination with Allergan  certainly gives Pfizer more flexibility in terms of how it wants to execute that strategy  of splitting the company    It makes it more of a growth company   VACCINES A GROWTH DRIVER Pfizer has annual sales of about  48 billion  with about  27 billion from patent protected drugs  vaccines and consumer products  It gets about  21 billion from the established products  which consist of older medicines that now face competition from cheap generics  including the cholesterol fighter Lipitor  once the world s top selling prescription medicine  Allergan  which was created in its current form in March following its merger with  Actavis   expects revenue of more than  8 billion in the second half of 2015  not including the generic drugs it is selling to Teva   All of Brent s growth areas at Allergan would stay at the growth company   said Janus s Summers  referring to Allergan CEO Brent Saunders  Revenue from Pfizer s established products fell 9 percent in 2014  creating a drag on overall growth  That has only worsened this year with the impact of the strong dollar on overseas sales  The unit s sales were down 16 percent in the third quarter  In contrast  businesses Pfizer would keep were up 13 percent for the quarter  with vaccines the biggest growth driver led by its current top seller  Prevnar 13  used to prevent pneumonia  Pfizer s new breast cancer drug Ibrance will also be a big driver of future growth  with some analysts forecasting eventual annual sales in excess of  5 billion  With its huge name recognition  Botox would be a crown jewel addition to the innovative drug lineup  which includes Viagra and nerve pain treatment Lyrica   Botox has about  2 4 billion a year in sales  much of it a cash business that does not require reimbursements from payers  It also has approvals for medical uses  such as for overactive bladder and chronic migraine  Allergan on Wednesday said the drug has a lot of room to grow  as it undergoes tests for a dozen new uses  including as a treatment for atrial fibrillation  a potentially dangerous irregular heart rhythm   Botox is a growing market  so that is a benefit   Pursche said   
Allergan currently has some 30 000 employees  but it is too early to know how many would lose their jobs if the deal goes through ",2015-11-06,Reuters,https://www.investing.com/news/stock-market-news/pfizer-allergan-deal-would-set-up-u.s.-company-for-a-split-370000,370000
105760,327275,AGN,After big spending and hard lobbying  Pfizer eyes new tax home,news,"By Susan Cornwell and Diane Bartz WASHINGTON  Reuters     Pfizer  Chief Executive Ian Read  who has been lobbying Congress regularly for a corporate tax cut  is trying for the second time in as many years to do a deal with a foreign company that could produce the savings he has been unable to extract from Washington  Pfizer Inc  N PFE   which is pursuing a deal for Dublin based Allergan Plc  N AGN   was one of the top spenders among pharmaceutical companies lobbying the U S  government in 2014  according to data from the Center for Responsive Politics  But while Read has convinced some U S  lawmakers that a U S  corporate tax rate of 35 percent puts them at disadvantage to global rivals  having no tax reform on the near horizon has propelled the largest U S  drugmaker into pursuing a tax cutting merger overseas  people close to Pfizer said   Ian Reed has been very active    in telling Congress the risk of having an anti competitive tax structure   said a source close to the company  who asked not to be named because she was not authorized to discuss the matter publicly   Ian has been to Washington  had meetings in New York  he s been to the White House  he s been on the Hill  in the last two years it s got be seven or eight times  just on encouraging tax reform   Pfizer and Allergan said last week that they were in friendly merger talks to create what would be the world s biggest drug company  While no other details were available  Pfizer is discussing a tax inversion  in which U S  companies relocate overseas to take advantage of lower tax rates abroad  sources have told Reuters      The talks come a year after Pfizer failed to buy British drugmaker AstraZeneca Plc  L AZN  over a disagreement on price  That deal also would have allowed Pfizer to reincorporate in Britain and pay a significantly lower corporate tax  While the latest merger move has sparked fresh inquiry into the controversial tax maneuver  lobbyists and analysts said it s unlikely that either the Obama administration or Congress would throw up serious obstacles  With the 2016 presidential election just one year away  bipartisan agreement in Congress on a subject as controversial and complicated as corporate tax reform seems unlikely   Between now and then I think it is next to impossible   said Grover Norquist  president of Americans for Tax Reform  a taxpayer advocacy group  But legislation to close the loopholes on inversion  something many Democrats would like  is seen as an even longer shot in the currently Republican dominated Congress  People close to Pfizer stressed that Pfizer s interest in Allergan is driven by the latter s portfolio of products that include wrinkle treatment Botox and Restasis dry eye treatment  But inversion is also an important element in Pfizer s considerations  the sources said   It would make no sense for a company to want to penalize the shareholders of an acquired company  of a merged company  by being taxed at the higher rate  in a country where the tax rates are higher   the source close to the company said  POLITICAL CALENDAR Pfizer spent  9 49 million on lobbying in 2014 and  10 1 million on lobbying in 2013  according to the Center for Responsive Politics   This makes it a top pharmaceutical spender along with Amgen  O AMGN   which spent  8 56 million in 2014  Eli Lilly  N LLY   which spent  8 2 million that year  and  Novartis  AG  VX NOVN   which spent  6 54 million  Pfizer lobbies on a variety of topics and does not break down how much they lobby on tax reform specifically  Among those representing Pfizer s tax interests is Ken Kies  one of Washington s top tax lobbyists  Read has made a few converts from traipsing up to the Hill to complain   I ve talked to him a number of times   Republican Senator Rob Portman  of Ohio  said of Read   I sympathize with his policy analysis  I agree with him that it s stupid for us to put our companies in this situation    and for us to    you know  blame the companies rather than blaming ourselves    is a copout   Portman told Reuters  With its latest maneuver  Pfizer appears to have stopped waiting for Congress to act   
 I don t think they are giving up  I think they are just dealing with the world as it is    Investment in cures and patients don t follow a political calendar  they follow a scientific calendar   the source close to the company said ",2015-11-06,Reuters,"https://www.investing.com/news/stock-market-news/after-big-spending-and-hard-lobbying,-pfizer-eyes-new-tax-home-370007",370007
105782,327297,AGN,Mylan s Biosimilar Herceptin Gets FDA Advisory Committee Nod,opinion,"Mylan N V    NASDAQ MYL   and partner  Biocon Ltd  announced that the FDA Oncologic Drugs Advisory Committee  ODAC  unanimously recommended approval of its biosimilarversion of Roche s   OTC RHHBY   breast cancer drug Herceptin  trastuzumab  In fact  the FDA s ODAC voted 16 to 0 in favor of biosimilar candidate  which has been developed to treat HER2 positive breast cancer that is a more aggressive form of the disease Notably  shares of Mylan inched up about 0 41  following the news release  However  the company has outperformed the Zacks categorized  industry in the year so far  with the stock gaining 2 8  against the industry s decline of 0 3  Meanwhile  the data presented to ODAC included results that showed that the proposed biosimilar trastuzumab is highly similar to Herceptin  in line with the FDA s assessment provided in the pre meeting briefing documents  Per ODAC  there is no clinically meaningful difference between Mylan s biosimilar candidate and Herceptin in terms of safety  purity and potency Biosimilar trastuzumab is also under review by regulatory authorities in Australia  Canada  Europe and several emerging markets While this is good news for Mylan  it is a blow for Roche because Herceptin is one of its key drugs  Last week  another biosimilar of Roche was put under review by the ODAC  Amgen   NASDAQ AMGN   and its partner  Allergan plc    NYSE AGN   announced that the supplemental biologics license application  sBLA  for its candidate  ABP 215  a biosimilar to Roche s another cancer  drug Avastin  will also be reviewed by ODAC   Both Herceptin and AVastin are key drugs for Roche and biosimiar versions of these drugs  once approved  will hurt the sales of the drugs  Mylan N V  Price and Consensus
    Zacks RankMylan currently sports a Zacks Rank  1  Strong Buy   You can see   Today s Stocks from Zacks  Hottest Strategies                                                                                             It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively                And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-07-16,Zacks Investment Research,https://www.investing.com/analysis/mylan's-biosimilar-herceptin-gets-fda-advisory-committee-nod-200201597,200201597
105783,327298,AGN,Paratek Antibiotic Candidate s Phase III Data Favorable,opinion,Paratek Pharmaceuticals  Inc    NASDAQ PRTK   announced positive results from a phase III study  OASIS 2  comparing its antibiotic candidate omadacycline to Pfizer Inc  s   NYSE PFE   Zyvox for the treatment of acute bacterial skin and skin structure infections  ABSSSI  The study met the key primary and secondary endpoints and Paratek Pharma looks set to file a new drug application  NDA  with the FDA in the first half of 2018  Shares were up more than 5  in after hours trading The OASIS 2 study evaluated the efficacy and safety of an oral once daily dose of omadacycline against a twice daily dose of Zyvox The study met the FDA specified primary efficacy endpoint of statistical non inferiority  NI  at early clinical response  ECR   48 to 72 hours after the first dose of the drug in the study  The ECR for omadacycline was found to be 87 5  compared to 82 5  for Zyvox Additionally  the study met statistical NI in European Medicines Agency specified co primary endpoints for post treatment evaluation  PTE   The clinical success rates in modified intent to treat population for the omadacycline and Zyvox arms were 84 2  and 80 8   respectively  The rates were 97 9  for omadacycline versus 95 5  in Zyvox arm in the clinically evaluable populations We remind investors that omadacycline has now shown positive results in three phase III studies  namely OASIS 2  OASIS 1 and OPTIC studies The OASIS 2 study data shows that omadacycline can be prescribed as an oral only dosing regimen in the outpatient setting  This is expected to reduce the need for hospital admission for the treatment of ABSSSI Data from OASIS 1 announced last year showed that the candidate met the FDA specified primary efficacy endpoint of ECR  The ECR for omadacycline was found to be 84 8  compared to 85 5  in the Zyvox arm Data from the OPTIC study announced in Apr 2017 demonstrated statistical non inferiority of omadacycline to Bayer AG s   OTC BAYRY   Avelox for the treatment of adults with community acquired bacterial pneumonia  CABP  at ECR of 72 120 hours after initiation of therapy  It was also found to be statistically non inferior to Avelox in the post treatment evaluation Paratek intends to present results from these studies along with data for the secondary endpoints at an upcoming scientific congress The NDA for omadacycline will be for the treatment of both ABSSSI and CABP and will include data from all three studies  We note that omadacycline enjoys Fast Track status in the U S The company also intends to file for FDA approval for another pipeline candidate  sarecycline  for the treatment of acne  in the second half of the year  Paratek is developing this candidate along with Allergan plc   NYSE AGN   and announced positive results in the first quarter of 2017  The study met its primary endpoint The positive developments have pushed up Paratek s share price by 62  so far this year  It outperformed the Zacks classified  industry  which increased 8 7  in the same period Zacks RankParatek currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/paratek-antibiotic-candidate's-phase-iii-data-favorable-200201838,200201838
105784,327299,AGN,Allergan  AGN  Beats Q2 Earnings   Sales  Shares Down,opinion,"Dublin  Ireland based Allergan plc   NYSE AGN   is engaged in the development  manufacturing  marketing  sale and distribution of branded pharmaceuticals and select over the counter products Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering  Having completed the acquisition of companies like Durata and Forest  Allergan acquired Botox maker  Allergan Inc   in Mar 2015  With this acquisition  Allergan  which was previously known for its strong presence in the generics market  finds itself in the company of the top 10 pharmaceutical companies across the world based on sales In 2017 so far  through the accretive acquisitions of LifeCell and ZELTIQ  Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting  respectively Allergan sold its generics and Anda distribution business to Teva in Aug and Oct 2016  respectively Allergan s earnings performance has been mixed so far  with the company beating expectations in three of the past four quarters and missing on one occasion  The average negative earnings surprise over the last four quarters is 0 27  Currently  Allergan has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Allergan s second quarter earnings of  4 02 per share were above our consensus estimate of  3 95 per share Revenues Beat  Revenues also beat expectations  Revenues came in at  4 01 billion  up 8 8  from the year ago period  and also beat the Zacks Consensus Estimate of  3 95 billion by 1  2017 Outlook Up  The company raised its previously issued earnings and sales guidance for 2017 Allergan expects total revenue in the range of  15 85 billion to  16 05 billion compared with  15 8 billion to  16 0 billion previously  Currency headwinds are now not expected to hurt revenues versus a negative impact of approximately  100 million expected previously Adjusted earnings are expected in the range of  16 05  16 45 compared with  15 85  16 35 per share previously Share Price Impact  Shares declined more than 2  in pre market trading Allergan PLC  Price and Consensus
    Check back later for our full write up on this AGN earnings report later More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-02,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-beats-q2-earnings--sales-shares-down-200205006,200205006
105785,327300,AGN,Allergan  AGN  Q2 Earnings   Sales Top  Restasis Sales Down,opinion,Allergan plc s   NYSE AGN   second quarter 2017 earnings came in at  4 02 per share  beating the Zacks Consensus Estimate of  3 95 by 1 8   Earnings rose 20  year over year driven by higher revenues and operating profitsRevenues came in at  4 01 billion  up 8 8  from the year ago period  and beat the Zacks Consensus Estimate of  3 95 billion by 1  While key products like Botox and new products like Vraylar  Namzaric and Viberzi did well in the quarter  sales were once again hurt by sales erosion from Namenda XR and loss of exclusivity  mainly from Asacol HD and Minastrin  Also  lower sales of key dry eye disease drug  Restasis hurt the top line Second quarter revenues  however  gained from the addition of Alloderm from LifeCell  Jan 2017  and CoolSculpting body contouring system from ZELTIQ  Apr 2017  acquisitions Adjusted operating income increased 16  to  1 9 billion in the quarter Selling  general and administrative  SG A  expenses rose 17 1  to  1 22 billion in the quarter  primarily due to higher promotional spend to support new product launches  R D expenses increased 14 2  to  393 9 million to support an advancing pipeline Segment DiscussionThe company reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues increased 15 2  to  1 72 billion driven by strong growth in Botox and the addition of LifeCell s Alloderm and ZELTIQ s CoolSculpting businesses  Botox  cosmetic  raked in sales of  210 3 million  up 10 7    Botox Therapeutic revenues were  346 9 million  up 17 2   In addition  Juv derm Collection of fillers rose 7 3  and Ozurdex sales increased 15 8   which contributed to the upside  Alloderm added  84 6 million while CoolSculpting added  78 9 million to sales in the second quarter Importantly  Restasis sales declined 9 4  to  336 4 million in the quarter due to unfavorable trade buying patterns  We remind investors that Shire plc   NASDAQ SHPG   launched its dry eye disease drug  Xiidra last year  There have been investor concerns about Xiidra posing strong competition for Restasis  The company expects stable Restasis revenues this year U S  General Medicine net revenue declined 1 5  to  1 43 billion in the reported quarter with sales declining in the Diversified Brands  Women s Health  and the Gastrointestinal franchises  Anti Infectives sales rose 7 4  to  67 8 million while Central Nervous System sales rose 9 2  to  346 6 million Established products like Linzess and Lo Loestrin as well as new products like Viberzi  Namzaric and Vraylar did well in the quarter  Linzess  sales rose 11 5  in the quarter to  167 8 million  driven by strong demand and continued OTC conversion However  lower Namenda XR sales hurt the performance of the CNS franchise  Namenda XR sales declined 28 7  to  118 7 million in the quarter due to lower demand  lower pricing and shift of promotional efforts to Namzaric  The company does not expect a generic version of Namenda XR to be launched until first quarter of 2018  delayed from the prior expectation of fourth quarter of 2017  Also  Allergan does not expect any generic version of Estrace Cream to be launched this year Namzaric  a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  33 4 million compared with  23 6 million in the previous quarter Asacol Delzicol sales declined 61 9  to  45 6 million due to a reduction in demand for Ascaol HD  following the launch of an authorized generic in Aug 2016 as well as lower demand for Delzicol In the Women s Health segment  Minastrin 24 revenues declined 86 3  to  11 4 million in the quarter due to loss of exclusivity in Mar 2017 The International segment recorded net revenue of  858 8 million  up 16 2  from the year ago period  driven by growth in Facial Aesthetics  Botox Therapeutic and the addition of LifeCell and CoolSculpting 2017 Outlook UpThe company raised its previously issued earnings and sales guidance for 2017 Allergan expects total revenue in the range of  15 85 billion to  16 05 billion compared with  15 8 billion to  16 0 billion previously  Currency headwinds are now not expected to hurt revenues versus a negative impact of approximately  100 million expected previously Adjusted earnings per share are expected in the range of  16 05  16 45 compared with  15 85  16 35 previously Adjusted gross margin is expected between 86 5  and 87   R D expenses are expected to be approximately  1 6 billion  maintained   SG A spend is expected between  4 5 billion to  4 6 billion compared to  4 45 billion and  4 55 billion previously Our TakeAllergan did fairly well in beating estimates for both earnings and sales in the second quarter  The company also raised its 2017 outlook  Shares were down slightly in pre market trading  However  so far this year  Allergan s share price is up 19 2  against the  s decline of 1 9  Allergan is reshaping its portfolio through strategic acquisitions  The drugmaker sold its generics and Anda distribution business to Teva Pharmaceutical Industries Limited   NYSE TEVA   in Aug and Oct 2016  respectively in order to focus on its branded segment Allergan also boasts a strong branded pipeline with nine product launches planned for 2017  Allergan is extending its R D pipeline to adjacent categories like NASH  Parkinson s disease  and gene therapy with many promising phase II III programs in development We are also encouraged by Allergan s focus on building its biosimilars pipeline  Allergan has a collaboration agreement with Amgen  Inc    NASDAQ AMGN   for the worldwide development and commercialization of three oncology antibody biosimilars  which include biosimilars of Roche s cancer drugs Herceptin and Avastin However  generic competition for legacy brands like Namenda IR XR and Asacol HD as well as new competition for key growth drivers  Restasis and Linzess  is an investor concern Allergan carries a Zacks Rank  3  Hold   You can see More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ,2017-08-02,Zacks Investment Research,https://www.investing.com/analysis/allergan-agn-q2-earnings--sales-top-restasis-sales-down-200205147,200205147
105786,327301,AGN,Teva Q2 Earnings Lag   17 View   Dividend Cut  Stock Slumps,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   reported second quarter 2017 earnings of 99 cents per share  including equity compensation expenses   which missed the Zacks Consensus Estimate of  1 06 per share by 6 6   The year ago adjusted earnings were  1 22 per share Revenues of  5 69 billion missed the Zacks Consensus Estimate of  5 85 billion by 2 8   Sales  however  increased 13  year over year  up 17  excluding impact of currency   mainly due to the inclusion of revenues from Allergan plc s   NYSE AGN   generics segment  Actavis Generics  including AndaTeva acquired Actavis Generics in Aug 2016 and also Allegan s U S  generic distribution business Anda  Inc  in Oct 2016 Excluding the benefit from the Actavis generics acquisition  the core sales performance was below expectations  Sales in the quarter were hurt by increased pricing erosion in the U S  Generics unit  ongoing political turmoil in Venezuela and loss of exclusivity in the Specialty segment in the quarter Segment DiscussionBeginning in the fourth quarter of 2016  Teva revised its segment structure following the Actavis acquisition  The Generics segment now includes revenues from the OTC business as well as the API business Generic Medicines segment revenues rose 20  to  3 08 billion  mainly attributable to the inclusion of revenues from the Actavis generics business Revenues from the U S  generics business rose 45  to  1 3 billion due to the inclusion of revenues from the generic business of Actavis European generic revenues were  957 million  up 24   28  in local currency  from the year ago period  This was due to the inclusion of revenues from the generic business of Actavis Rest of the world  ROW  generic revenues declined 7  to  831 million in the quarter  On a local currency basis  sales rose 13  mainly due to the inclusion of revenues from Actavis API revenues declined 1  to  204 million  OTC revenues rose 6  to  283 million  up 40  in local currency terms  Excluding the benefit from the Actavis generics acquisition  the core sales performance of the segment was poor due to accelerated U S  generic drug price erosion and decreased volumes  Meanwhile  delays in the launch of some new generic drugs and increased competition for some others also hurt sales in the segment The U S  generics industry is facing significant competitive and pricing pressure  An increase in FDA generic drug approvals and ongoing customer consolidation is resulting in additional competitive pressure in the generics industry The drug price erosion is expected to accelerate in the second half of this year  Teva said that the price erosion in the U S  generics business is expected to be in the high single digits range in 2017 Specialty Medicines revenues declined 9  from the year ago period to  2 1 billion due to lower sales of its central nervous system  CNS  and oncology products  Among Teva s various therapeutic areas  CNS sales declined 18  to  1 16 billion due to lower sales of multiple sclerosis drug  Copaxone  Teva s lead branded product Sales of respiratory products rose 3  to  322 million  oncology product sales declined 16  to  280 million  and women s health business recorded a 2  decline in revenues to  115 million  Other specialty revenues rose 107  to  190 million Worldwide revenues of Copaxone declined 10  to  1 billion  Sales in the U S  declined 12  to  843 million due to lower volumes of the 20 mg formulation  which is facing generic competition and negative net pricing effects despite the 7 9  price increase taken in January  In Jun 2015  Novartis AG s   NYSE NVS   generic arm  Sandoz launched Glatopa  a once daily generic version of 20 mg formulation of Copaxone Ex U S  sales of Copaxone declined 3  to  180 million The 40 mg thrice weekly  3TW   three times a week  formulation of Copaxone accounted for more than 85  of total Copaxone scrips in the U S  at the end of the reported quarter  We note that Teva is facing patent challenges for the 40 mg formulation Companies like Mylan N V    NASDAQ MYL   and Momenta Pharmaceuticals are looking to get approval for their generic versions of the 40 mg thrice weekly formulation of Copaxone  In late January  Teva suffered a major setback with the U S  District Court for the District of Delaware invalidating four of the five Orange Book patents protecting Copaxone 40 mg  Teva intends to appeal against the decision  However  generic versions of the 40 mg formulation have not been launched yet  The FDA approval of Momenta s generic version of Copaxone has been delayed owing to manufacturing issues Teva does not expect any generic competition for Copaxone 40 mg this year  However  the company said that in case  a generic version was launched for a full quarter this year  it will hurt earnings by 20   25 cents Among other products  Azilect sales declined 69  to  34 million as a generic version of the drug was launched in the U S  ProAir declined 9  to  123 million  combined Treanda and Bendeka revenues declined 21  to  163 million and QVAR declined 8  to  107 million The Other segment  distribution and other activities  recorded revenues of  543 million  up 158 6   The segment mainly gained from the inclusion of distribution revenues from Anda Profits DeclineAdjusted gross margin contracted 570 basis points  bps  to 56 8  in the quarter due to the addition of the low margin Anda distribution business and low margins in the Generic Medicines segment  Gross margin rose in the Specialty segment  Research   development expenses increased 21 6  from the year ago period to  450 million  Selling and marketing  S M  expenditure was up 1  from the year ago level to  906 million  Adjusted operating margin  excluding equity compensation expense  declined 330 bps in the quarter to 28 1  2017 Outlook SlashedTeva slashed its previously issued 2017 sales and earnings guidance  Increased price erosion in the U S Generics market  delays in generic launches in the U S and greater instability in the Venezuela market led to the cut in guidance The revenue guidance was cut to a range of  22 8  23 2 billion from  23 8  24 5 billion  Earnings are expected in the band of  4 30    4 50  much lower than  4 90  5 30 per share expected previously Teva expects continued sales erosion for Copaxone in 2017 due to increased competition Management said that the Venezuelan business is not expected to contribute anything to earnings in the last two quarters of 2017 Dividend CutTeva announced a 75  cut in dividend for the second quarter to 8 5 cents per share from 34 cents per share paid in the first quarter Our TakeTeva s second quarter earnings and sales were dismal as the U S  generics industry continues to face significant competitive and pricing pressure  The Israel based generic drug maker also slashed its 2017 earnings and sales outlook to reflect the challenging environment in the U S  Generics business and Venezuela devaluation  The U S  generic industry pressure is expected to persist and management expects lower revenue and profits in U S  Generics in 2018 and potentially 2019 The major cut in dividend   to help pay down debt and invest in business   was a big disappointment  Also  the company did not provide any update on a new chief executive officer  CEO  saying  this is a process we are not going to rush    Teva s CEO  Erez Vigodman  had stepped down in February this year  Teva s Chief Financial Officer Eyal Desheh  also retired in June Shares declined 24  on Thursday  hitting a 52 week low of  23 33 per share  In fact  shares have slumped 34 5  so far this year compared with the  sdecline of 1 9  Teva carries a Zacks Rank  3  Hold   You can see  Teva Pharmaceutical Industries Limited Price  Consensus and EPS Surprise    Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/teva-q2-earnings-lag-17-view--dividend-cut-stock-slumps-200205422,200205422
105787,327302,AGN,Ironwood  IRWD  Q2 Loss Widens  Revenues Miss  Stock Up,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   reported second quarter 2017 adjusted loss of 28 cents per share  wider than both the Zacks Consensus Estimate of a loss of 23 cents and the year ago loss of 16 cents Total revenue  collaborative revenue  in the quarter amounted to  65 1 million  up 19 7  from the year ago period but below the Zacks Consensus Estimate of  68 5 million Ironwood s shares gained 2 16  in afterhours trading on Aug 3 on positive pipeline updates  In fact  a look at the company s share price movement shows that the stock has outperformed the  this year so far  Ironwood s shares have gained 8 8  during this period  while the industry registered an increase of 0 9  The Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess   generated U S  net sales of  167 8 million  up 11 5  year over year Please note that Ironwood and Allergan have an equal share in brand collaboration profits or losses  Ironwood s share of the net profits from the sales of Linzess in the U S   included in collaborative revenues  was  43 8 million in the second quarter  up 11  year over year According to data provided by IMS Health  Linzess prescriptions filled during the quarter crossed 750 000  up 15  from the year ago period During the reported quarter  selling and administrative  SG A  expenses increased 56 5  to  57 8 million  and research and development  R D  expenses were  37 3 million  up 17 9  from the year ago periodZurampic  Ironwood s second commercial product for the treatment of uncontrolled gout  was launched in Oct 2016 Zurampic raked in sales of  0 5 million in the quarter  Zurampic prescriptions filled during the quarter were 1500  higher than 900 prescriptions filled in the previous quarter Pipeline UpdatesLinzess is currently approved in the U S  for the treatment of adults with irritable bowel syndrome with constipation  IBS C  290 mcg  and chronic idiopathic constipation  CIC  145 mcg   72 mcg   Ironwood and Allergan are looking to broaden Linzess  label by expanding the targeted patient population and gaining approval for additional indications  The partners are also developing a delayed release version of Linzess for IBS C and non constipated subtypes of IBS Ironwood has a partnership with Astellas Pharma to market Linzess in Japan  Astellas is looking to submit regulatory application for label expansion in chronic constipation with the Japanese regulatory authorityIn China  Hong Kong and Macau  Ironwood has an agreement with AstraZeneca plc   NYSE AZN   for Linzess  The regulatory filing is under review in China for IBS C  The company expects the review to be completed in the first quarter of 2018 This year  Ironwood expects to launch Duzallo  the fixed dose combination of Zurampic and allopurinol  The new drug application for Duzallo is under review in the U S  The FDA s decision is expected in the second half of 2017 and the drug is expected to be launched in late 2017  If approved  Duzallo would become the first dual mechanism treatment for patients with uncontrolled gout 2017 Guidance MaintainedThe company continues to expect to use less than  100 million for operations in 2017  This is however much higher than the 2016 levels  This is due to the full year of commercial expenses related to the launch of Zurampic and to support the potential launch of Duzallo and pipeline advancement The company also maintained its R D expenses and SG A expenses guidance for 2017 in the range of  145  160 million and  235  250 million  respectively Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderIronwood currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is Summit Therapeutics PLC   NASDAQ SMMT    carrying a Zacks Rank  2  Buy   You can see  Summit s loss estimates narrowed from  2 36 to 32 cents for 2017 over the last 30 days  The company delivered positive earnings surprise in each of the four trailing quarters with an average beat of 25 55   Its share price is up 66 4  so far this year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/ironwood-irwd-q2-loss-widens-revenues-miss-stock-up-200205400,200205400
105788,327303,AGN,Pharma Stock Roundup  Mixed 2Q Results From Pfizer  Bristol Myers Announces IO Deals,opinion,"This week  companies like Pfizer   NYSE PFE    Allergan   NYSE AGN   and Teva   NYSE TEVA   reported second quarter results  While Pfizer reported a mixed quarter  Allergan topped expectations  Teva  however  had a tough quarter  Meanwhile  Bristol Myers   NYSE BMY   announced immune oncology  IO  focused deals including an acquisition Recap of the Week s Most Important StoriesA Look at Q2 Earnings Results  Big companies like Pfizer  Allergan and Teva reported second quarter results this week  Pfizer surpassed earnings estimates but missed on revenues raising concerns about the company s top line growth prospects  While Prevnar and Enbrel sales declined during the quarter  Pfizer is facing two key loss of exclusivities  LOEs  in the U S     Viagra later this year and Lyrica at the end of 2018  Read more    Meanwhile  Allergan topped both earnings and sales estimates and raised its outlook as well  Read more    Teva s shares fell 24  on a dismal quarter with the company missing on earnings and sales reflecting the performance of the U S  generics business and the continued deterioration in Venezuela  The generics business was hit by accelerated price erosion and lower volume mainly due to customer consolidation  higher competition  and delayed new product launches  Teva lowered its outlook for the year and slashed its dividend as well  The company also expects to exit 45 markets across the globe by year end and will be cutting its headcount by about 7 000 since the closing of the Actavis Generics business deal  Teva has lost 34 5  of its value year to date versus the 7 6  decline of its  J J  AbbVie Drug Gets FDA Nod for cGVHD  Johnson   Johnson   NYSE JNJ   and AbbVie s BTK inhibitor Imbruvica gained FDA approval for its first non cancer indication    chronic graft versus host disease  cGVHD  in adults after failure of one or more systemic lines of therapy  This makes Imbruvica the first and only approved treatment for this patient population  This marks the sixth indication for Imbruvica in the U S  J J stock has gained 15 8  year to date  outperforming the 10 9  rally of the  it belongs to Bristol Myers in Acquisition Deal Worth Up to  2 3B  Bristol Myers announced that it will be acquiring IFM Therapeutics  a venture backed biotech company working on treatments that modulate novel targets in the innate immune system to treat cancer  autoimmunity and inflammatory disorders With this acquisition  Bristol Myers will gain full rights to IFM s preclinical STING  stimulator of interferon genes  and NLRP3 agonist programs that are focused on cancer  The STING agonist program includes a lead asset while the NLRP3 agonist program includes a potential first in class pipeline candidate This acquisition  scheduled to close in the third quarter  will strengthen Bristol Myers  immune oncology  IO  pipeline  The deal will see Bristol Myers shelling out  300 million upfront while additional payments of up to  1 01 billion will be made for each of the first products from the two programs on the achievement of certain milestones Additional milestone payments could be made for further products resulting from these programs Bristol Myers signed another IO focused deal this week    the company signed a clinical collaboration agreement with Clovis Oncology under which its immunotherapy Opdivo will be evaluated in combination with Clovis  PARP inhibitor Rubraca in mid  and late stage studies for different types of tumors Meanwhile  Opdivo s label was expanded in the U S  this week for the treatment of adult and pediatric  12 years and older  patients with microsatellite instability high  MSI H  or mismatch repair deficient  dMMR  metastatic colorectal cancer  mCRC  that has progressed following treatment with a fluoropyrimidine  oxaliplatin  and irinotecan  Accelerated approval was granted on the basis of overall response rate  ORR  and duration of response However  we note that Merck s Keytruda gained approval earlier this year for patients with MSI H or dMMR in a wider patient population    Merck s label includes patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options as well as colorectal cancer patients whose disease has progressed following treatment with certain chemotherapy drugs J J RA Drug Fails to Get FDA Advisory Panel Support  J J s investigational rheumatoid arthritis  RA  treatment  Plivensia  sirukumab   an IL 6 inhibitor  failed to get the support of the FDA s Arthritis Advisory Committee on safety concerns  The company is looking to get Plivensia approved for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or are intolerant to one or more disease modifying anti rheumatic drugs  DMARDs   RA is a common  chronic  life long  autoimmune disease that affects about 1 3 million people in the U S  Although the FDA is not required to do so  it usually follows the advice of its advisory panels  Considering the safety concerns raised by the panel  the agency could well ask for additional information before granting approval Pfizer Drug Gets Advisory Panel Support  Pfizer s supplemental new drug applications  sNDAs  for its JAK inhibitor  Xeljanz  5 mg twice daily  and Xeljanz XR  11 mg once daily   for the treatment of adult patients with active psoriatic arthritis  PsA   got the support of the FDA s Arthritis Advisory Committee  The advisory panel voted 10 to 1 in favor of approving the proposed dose of Xeljanz for the PsA indication  A decision from the FDA should be out by Dec 2017  Xeljanz  currently approved for RA  brought in sales of  587 million in the first half of 2017 Priority Review for AstraZeneca BTK Inhibitor  AstraZeneca s   NYSE AZN   investigational BTK inhibitor  acalabrutinib  was granted priority review by the FDA  The company is looking to get the drug approved for use in patients with relapsed refractory mantle cell lymphoma  MCL  who have received at least one prior therapy  A response from the agency is expected in the first quarter of 2018  Acalabrutinib was also given Breakthrough Therapy Designation  BTD  for this indication AstraZeneca s Imfinzi also got BTD this week for the treatment of patients with locally advanced  unresectable non small cell lung cancer  NSCLC  whose disease has not progressed following platinum based chemoradiation therapy Positive Data on Lilly Migraine Drug  Lilly   NYSE LLY   presented late stage data on its investigational migraine drug  lasmiditan  saying that it met the primary endpoint as well as key secondary endpoints  The results were consistent with results presented from an earlier late stage study  Lilly expects to file for FDA approval in the second half of 2018 Lilly is a Zacks Rank  2  Buy  stock  You can see  Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index declined 0 6  over the last four trading sessions  Among major stocks  Pfizer was up 1 8  while Lilly lost 1 4   Over the last six months  J J was up 18 9  while AstraZeneca gained 12 3   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for the usual pipeline and regulatory updates Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-08-04,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-mixed-2q-results-from-pfizer-bristolmyers-announces-io-deals-200205341,200205341
105789,327304,AGN,VIVUS  VVUS  Q2 Loss In Line With Estimates  Sales Down Y Y,opinion,"VIVUS Inc    NASDAQ VVUS   reported a loss of 13 cents per share in the second quarter of 2017  which was wider than a loss of 11 cents in the year ago period  However  the loss was in line with the Zacks Consensus Estimate VIVUS  Inc  Price  Consensus and EPS Surprise
    Quarterly revenues decreased 18 5  to  11 2 million from the year ago period Shares of the biotech company fell more than 8  on Friday on dismal revenue numbers  In fact  so far this year  VIVUS shares have underperformed the   The stock fell 11 3  during the period  while the industry witnessed a gain of 8 9  Quarter in DetailThe company s weight management drug Qsymia generated net product sales of  8 5 million  down 33 2  from the year ago period due to reduction in Qsymia inventory by wholesalers and change in revenue recognition methodology Supply and royalty revenues from Stendra Spedra were  2 7 million  up 163 8  from the year ago period due to an increase in supply revenues as a number of orders placed by commercialization partners in this quarter were better than the year ago period General and administrative expense was  11 6 million  down 22 4  year over year mainly attributable to cost control initiatives undertaken by the company  Research and development expense decreased almost 7 5  to  1 million in the reported quarter due to cost savings efforts related to Qsymia regulatory requirements  partially offset by development of tacrolimus for the treatment of pulmonary arterial hypertension  PAH  Subsequent to the quarter in Jul 2017  the company announced that it has entered into a settlement agreement with Actavis  NYSE AGN  Laboratories  a subsidiary of generic company Teva Pharmaceutical Industries Limited   NYSE TEVA    thereby resolving a three year old patent litigation related to the launch of generic versions of its weight management drug  Qsymia In Jan 2017  VIVUS acquired exclusive  worldwide rights for the development and commercialization of tacrolimus and ascomycin from Selten Pharma  Inc  for the treatment of PAH and related vascular diseases  It also reacquired the commercial rights to Stendra in Africa  the Middle East  Turkey and the Commonwealth of Independent States  including Russia from Sanofi   NYSE SNY   in March Zacks Rank   Key PicksVIVUS carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Aduro Biotech  Inc    NASDAQ ADRO    which carries a Zacks Rank  2  Buy   You can see  Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 36 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 2 53   The company s shares are up 7 4  so far this year 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-06,Zacks Investment Research,https://www.investing.com/analysis/vivus-vvus-q2-loss-in-line-with-estimates-sales-down-yy-200205679,200205679
105790,327305,AGN,3 things to watch this morning,news,"1  China stocks plunge 8 5   biggest one day drop since February 2007
The Shanghai Composite tumbled 8 5  on Monday  the biggest one day drop since February 2007  on weak industrial profits and amid reports that government buying of stocks and securities has slowed 
Equity markets in China plunged sharply earlier this month  forcing policymakers to intervene and provide measures to boost liquidity and calm investors 
2  U S  durable goods data in focus
The U S  is to release data on durable goods orders at 8 30AM ET  The report is expected to show that orders for durable goods rose 3 0  in June  while core orders inched up 0 5  
Investors awaited the outcome of the Federal Reserve s two day monetary policy meeting due to begin on Tuesday to see if policymakers will give any indication on the timing of a rate lift off 
3  Teva to buy Allergan  NYSE AGN pa  Generics for  40 5 billion
Israeli drug maker Teva Pharmaceuticals  ARCA TEVA  agreed to acquire the generic drug division of Allergan in a cash plus stock deal valued at  40 5 billion  it announced on Monday 
Allergan will receive  33 75 billion in cash and shares in Teva valued at  6 75 billion  giving it a 10  stake in the enlarged company  according to a statement from the Israeli company 
The Israeli drug maker added that it has withdrawn its cash and stock proposal for rival Mylan 
U S  listed shares of Teva surged 11 8  in pre market trade  Allergan  NYSE AGN  rose 5 5   while Mylan  NASDAQ MYL  shares slumped 11 9  ",2015-07-27,Investing.com,https://www.investing.com/news/economy-news/3-things-to-watch-this-morning-353059,353059
105791,327306,AGN,U S  pre market top movers of the day   Teva  Allergan  Mylan,news,"Investing com   U S  stock futures pointed to a lower open on Monday  as sentiment soured after China stocks suffered their biggest one day drop since 2007 
During early morning hours in New York  the blue chip Dow futures lost 101 points  or 0 58   the S P 500 futures declined 11 points  or 0 53   while the tech heavy Nasdaq 100 futures slumped 31 points  or 0 68  
The Shanghai Composite tumbled more than 8  on Monday  the biggest one day drop since February 2007  on weak industrial profits and amid reports that government buying of stocks and securities has slowed 
Equity markets in China plunged sharply earlier this month  forcing policymakers to intervene and provide measures to boost liquidity and calm investors 
The U S  is to release data on durable goods orders at 8 30AM ET  The report is expected to show that orders for durable goods rose 3 0  in June  while core orders inched up 0 5  
Investors awaited the outcome of the Federal Reserve s two day monetary policy meeting due to begin on Tuesday to see if policymakers will give any indication on the timing of a rate lift off 
In deal news  Israeli drug maker Teva Pharmaceuticals  ARCA TEVA  agreed to acquire the generic drug division of Allergan  NYSE AGN  in a cash plus stock deal valued at  40 5 billion  it announced on Monday 
Allergan will receive  33 75 billion in cash and shares in Teva valued at  6 75 billion  giving it a 10  stake in the enlarged company  according to a statement from the Israeli company 
The Israeli drug maker added that it has withdrawn its cash and stock proposal for rival Mylan  NASDAQ MYL  
U S  listed shares of Teva surged 14 1  in pre market trade  Allergan rose 10 3   while Mylan shares tumbled 11 6   Meanwhile  Perrigo  NYSE PRGO  shares tacked on 3 4  after Mylan reaffirmed its interest in the company 
Stay up to date on the latest pre market news and movers by visiting   ",2015-07-27,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-pre-market-top-movers-of-the-day---teva,-allergan,-mylan-353064",353064
105792,327307,AGN,Teva to buy Allergan generic business for  40 5 billion  drops Mylan bid,news,"By Tova Cohen and Steven Scheer
TEL AVIV  Reuters    Israel s Teva Pharmaceutical Industries  ARCA TEVA  will pay  40 5 billion in cash and stock for Allergan  NYSE AGN pa  s generic drugs business  solidifying Teva s position as the world s No  1 maker of generics while freeing Allergan to focus on branded drugs  paying down debt and potential  transformational  acquisitions 
The deal  the largest in Israel s corporate history  allows Teva stronger economies of scale  crucial in the low margin generic drugs business  Teva  which dropped its hostile pursuit of Mylan  NASDAQ MYL   will likely have to sell off some drugs to allay antitrust concerns 
 Allergan s business is more high end  than Mylan   It s a more interesting business     a profitable business and it s well managed   said Gilad Alper  an analyst at brokerage Excellence Nessuah 
Allergan  known for its Botox anti wrinkle treatment  became the third largest generic drugmaker in the United States after combining with  Actavis   NYSE AGN  in March  It is seen as a better fit than Mylan because it will improve Teva s distribution channels and access to profitable injectable drugs 
Pressure has been growing on Teva Chief Executive Erez Vigodman to find new revenue sources to combat generic competition for its branded multiple sclerosis drug Copaxone  Copaxone accounts for about half of Teva s profit 
Allergan CEO Brent Saunders  who led Actavis  purchase of Forest Laboratories and then Allergan  said the company will use the  36 billion in net proceeds from the generics sale to help fund further large acquisitions 
 We can accelerate our timing on transformational M A   Saunders said during a conference call  He cited aesthetics  eye care  central nervous system disorders and gastrointestinal therapies as areas for potential future deals  Wall Street analysts speculated that possible targets include Biogen  NASDAQ BIIB  Inc   Amgen Inc   NASDAQ AMGN  and  AbbVie Inc   NYSE ABBV  
The healthcare sector has seen an unprecedented wave of deals since early 2014  from large drugmakers buying up smaller rivals  to consolidation among makers of generic medicines and tie ups between insurers 
Global healthcare M A reached  398 5 billion as of July 23  up 80 percent on a year ago  according to Thomson Reuters data 
HIGHLY COMPETITIVE
Teva shares  which had been weighed down by the Mylan uncertainty  rose 13 percent in New York trading on Monday  Allergan shares gained 7 2 percent and Mylan shares slid 14 4 percent 
Mylan had used a poison pill style defense to fight a  40 billion takeover by Teva  arguing that a deal was  without sound industrial logic or cultural fit  and would face regulatory hurdles  The company said on Monday it would continue efforts to buy Perrigo  whose shares were up 3 8 percent 
Teva may need to sell a large number of assets to satisfy antitrust authorities about the Allergan transaction  according to two antitrust attorneys who handle pharmaceutical deals 
 But if you look at the total size of the deal  that s going to be a tiny fraction   one of the lawyers said 
It may also be harder to find buyers for those drugs given the consolidation already seen in the generics sector  they said  The U S  Federal Trade Commission requires buyers for proposed divestitures before it will approve a deal 
Teva said it has identified asset sales needed for the deal to pass muster with U S  and UK antitrust regulators  and that the number was less than what had been anticipated in a combination with Mylan 
CULTURAL FIT
Teva said it had approached Allergan a year ago but did not generate interest  It then went after Mylan  which repeatedly rebuffed its offers  and only turned its attention back to Allergan earlier this month  In June 2014  Vigodman hired Sigurdur Olafsson  former head of Actavis s generic drug business  to fill a similar role at Teva 
 My sense always was that Mylan was Teva s Plan B   said Benny Landa  an industrialist who led an investor bid last year to shake up Teva s board  calling the deal  brilliant  
Teva will pay  33 75 billion in cash and  6 75 billion in shares  representing a 10 percent stake in the Israel based company  Teva said  It expects the deal to close in the first quarter of 2016 
Vigodman said the combined company will have proforma revenue of  26 billion and earnings before interest  tax  depreciation and amortization of  9 5 billion in 2016 
 This acquisition reinforces our strategy  accelerates growth and diversifies revenues both by product and geographically  supporting our new business model   he said 
Teva  which will gain a portfolio of more than 1 000 products  forecast a double digit boost to adjusted earnings per share in 2016 and a more than 20 percent benefit in years two and three after closing the deal 
It expects cost synergies and tax savings of  1 4 billion annually by the third anniversary from efficiencies in operations  manufacturing  and sales and marketing 
It also expects the acquisition to generate free cash flow of  6 5 billion in 2016 and increased free cash flow in subsequent years  This means Teva will be able to pursue acquisitions to expand its portfolio in both specialty pharmaceuticals and generics 

J P  Morgan is acting as financial advisor to Allergan and Latham   Watkins LLP is serving as Allergan s lead legal advisor   Barclays   LONDON BARC  and Greenhill   Co are serving as financial advisors to Teva  Sullivan   Cromwell LLP and Tulchinsky Stern Marciano Cohen Levitski   Co are serving as legal counsel to Teva ",2015-07-27,Reuters,https://www.investing.com/news/stock-market-news/teva-to-buy-allergan-generic-drug-business-for-$40.5-billion-353058,353058
105793,327308,AGN,Wall Street drops as China stock slump stokes growth fears,news,"By Noel Randewich  Reuters    Wall Street sank on Monday  with the Nasdaq losing almost 1 percent after the steepest decline in Chinese stocks in eight years increased concerns that cooling growth in the world s No  2 economy could hurt China s trading partners  The Dow Jones industrial average finished at its lowest level since February  and the S P 500 chalked up a five session losing streak for the first time since January  In addition  480 stocks hit 52 week lows on the New York Stock Exchange  the most in one day since Oct  15   After Chinese stocks plunged more than 8 percent  the country s top securities regulator said Beijing would keep buying shares to stabilize the market as an unprecedented rescue plan already in place appeared to sputter  Commodity prices resumed a downward spiral  with the Thomson Reuters CRB commodities index  TRJCRB  hitting a six year low and oil a four month low   It s hard to assess whether China single handedly can deep six the market   said Chuck Carlson  chief executive at Horizon Investment Services in Hammond  Indiana   A significant slowdown in China impacts not just the U S  but global players as well   The Dow Jones industrial average  DJI  fell 0 73 percent to end at 17 440 59 points  The S P 500  SPX  lost 0 58 percent to end at 2 067 64  The Nasdaq Composite  IXIC  dropped 0 96 percent to 5 039 78  Nine of the 10 major S P 500 sectors were lower  led by a 1 35 percent fall in the energy index   With second quarter reports well under way  analysts expect overall earnings of S P 500 companies to dip 0 3 percent and revenue to decline 3 9 percent  according to Thomson Reuters data  Such results could inflate already relatively pricey valuations  The S P 500 is trading near 16 9 times forward 12 month earnings  above the 10 year median of 14 7 times  according to StarMine data   Valuations are a concern right now   said Randy Frederick  managing director of trading and derivatives for  Charles Schwab   NYSE SCHW  in Austin  Texas   We really need to see corporate revenue growth   The main event for U S  markets this week is likely to be the two day U S  Federal Reserve meeting beginning on Tuesday  the last policy meeting before September  which still looms as the first possible date for an interest rate increase  Teva Pharmaceutical s  N TEVA  shares jumped 16 41 percent to a record high of  72 00 after the company agreed to buy Allergan s  N AGN  generic drug business for  40 5 billion  giving up on its bid to buy Mylan  O MYL   Allergan  NYSE AGN pa  rose 6 09 percent while Mylan fell 14 51 percent  Fiat Chrysler  N FCAU  fell 4 88 percent after a U S  auto safety watchdog announced a  105 million fine against the automaker over lapses in safety recalls  On the NYSE  2 73 stocks fell for every one that rose  On the Nasdaq  decliners outnumbered gainers 2 47 to 1  The S P 500 index posted three new 52 week highs and 58 lows  the Nasdaq Composite saw 21 new highs and 246 lows  
Some 7 3 billion shares changed hands on U S  exchanges  above the daily average of 6 6 billion so far this month ",2015-07-27,Reuters,https://www.investing.com/news/stock-market-news/u.s.-stock-futures-slump-after-china-market-selloff-resumes-353066,353066
105794,327309,AGN,Hikma to buy Boehringer s U S  generics unit for  2 65 billion,news, Reuters     Hikma Pharmaceuticals  Plc  L HIK  said it would buy German drugmaker Boehringer Ingelheim s U S  specialty generic drugs business for about  2 65 billion in cash and stock to bolster its presence in the United States  Hikma said it will pay about  1 18 billion in cash and issue 40 million new Hikma shares  or about 16 71 per cent of its issued share capital  for Boehringer s Roxane Laboratories Inc and Boehringer Ingelheim Roxane Inc on closing of the deal  The Jordanian company  which makes and markets branded and non branded generics and injectable drugs  said the deal would make it the sixth biggest U S  generics provider   Shares in the company rose 8 percent to 2 253 pence in early trading on Tuesday  The stock has lost about 13 percent since its inclusion in Britain s benchmark FTSE 100  FTSE  equity index in March  The transaction is the latest in a string of deals in the generics sector  where economies of scale are important because of the highly competitive nature of the market  Israel s Teva Pharmaceutical  ARCA TEVA  Industries  TA TEVA  agreed on Monday to pay  40 5 billion for Allergan s  N AGN  generic drugs business  solidifying Teva s position as the world s No  1 maker of generics  Hikma s new acquisition follows from its purchase of Boehringer s U S  generic injectable drugs business and manufacturing operations in Ohio last year  The United States accounted for more than half of Hikma s 2014 revenue  The generics division is its smallest  accounting for about 15 percent of revenue  Hikma said the deal valuation was based on an agreed issue price for the new Hikma shares of 23 50 pounds per share and an exchange rate of 1 56 dollars to the pound  It has also agreed to make milestone payments of up to  125 million  Hikma said it expects the deal to add to adjusted earnings per share in 2016 and  very strongly  to adjusted EPS thereafter  Bloomberg had reported last month that Hikma was one of the bidders for Roxane    ,2015-07-28,Reuters,https://www.investing.com/news/stock-market-news/hikma-to-buy-boehringer's-u.s.-generics-unit-for-$2.65-billion-353198,353198
105795,327310,AGN,Mylan CEO says does not  have to  buy Perrigo  has other options,news,By Bill Berkrot NEW YORK  Reuters    Generic drugmaker Mylan Inc s  O MYL  chief executive said on Thursday that acquiring  Perrigo Co   N PRGO  was not a must and that it had other options should Perrigo successfully fend off Mylan s  34 billion hostile offer    There are alternatives to Perrigo  We believe Perrigo is the right first step  We like Perrigo  but we don t have to have Perrigo   CEO Heather Bresch said during a conference call with Wall Street analysts to discuss quarterly results  We ve been actively looking at many targets out there   she said  Bresch made it clear that getting the Perrigo deal done remains the company s top priority  but said there are many ways to grow the business and attain its goal of becoming a leading consolidator in the generic drugs industry   Perrigo accelerates that for us   she said   We believe there s a lot of different assets that can get us there  There are things for sale all over the globe   Bresch mentioned U S  products that would increase a drug dosage form or add a therapeutic category  smaller bolt on acquisitions that could enhance the infrastructure it has in place  assets in Europe that would complement the business it acquired from  Abbott Laboratories   NYSE ABT  that enabled Mylan to reincorporate in the Netherlands  and other lines of over the counter products  Mylan  which since April had been actively fighting a takeover attempt by larger rival Teva Pharmaceutical  ARCA TEVA  Industries  TA TEVA   got its wish to remain independent when Teva last week decided instead to buy Allergan s  N AGN  generics business for  40 5 billion   By acquiring Ireland based Perrigo  Mylan would pick up over the counter consumer products  a line of generic topical medicines and animal health treatments  Mylan shares were down 46 cents  or 0 8 percent  at  54 14 on Nasdaq ,2015-08-06,Reuters,"https://www.investing.com/news/stock-market-news/mylan-ceo-says-has-other-options,-doesn't-'have-to'-buy-perrigo-354825",354825
105796,327311,AGN,Ackman s Pershing Square hedge fund drops 9 2 percent in August,news,"By Svea Herbst Bayliss and Richard Valdmanis BOSTON  Reuters    Hedge fund mogul William Ackman  one of last year s best performers  joined a string of high profile managers in reporting deep losses for August as global markets tumbled amid fears over slower growth in China  Ackman s Pershing Square Capital Management  which makes concentrated bets on a small number of stocks  told clients on Wednesday that its Pershing Square LP fund fell 7 7 percent last month  leaving it flat on the year with a 0 06 percent gain  The firm s Pershing Square Holdings portfolio dropped 9 2 percent  and is now down 0 1 percent for the year  erasing a 10 percent gain it had at the end of July  two sources familiar with the numbers said  Last year the fund gained 40 percent  beating the Standard   Poor s 13 7 percent gain  Ackman warned investors in a letter last week that tumbling markets had wiped out gains  The decline moderated slightly when the market rebounded some late last week   The shift of fortunes shows how much market volatility  sparked by sharp declines in Chinese stock prices  has hurt the world s most prominent investors  Although some investors  like managers  grumbled about August s rout  several said hedge funds were largely still beating the broader market  The Standard   Poor s 500 fell 6 percent in August while the average hedge fund lost 2 2 percent  data from Hedge Fund Research show  Leon Cooperman s Omega Advisors closed the month with a 6 percent loss  while Dan Benton s Andor Capital  which invests heavily in technology stocks  fell 4 5 percent  investors said  Viking Global Investors dropped 2 1 percent in August but is still up 7 4 percent for the year  a person who saw the number said  On Monday  David Einhorn  who runs Greenlight Capital  and Daniel Loeb  who leads Third Point  said they each lost roughly 5 percent last month  while Barry Rosenstein s Jana Partners fell 4 3 percent  Greenlight is now down nearly 14 percent for the year  one of the industry s most high profile losses  Activist investors such as Ackman and Rosenstein are seen as being especially vulnerable to market downturns since many of their investments involve buying undervalued stocks and holding them while trying to persuade corporations to unlock value  Clifton Robbins s Blue Harbour Group  which also tends to invest in activist situations  fell 2 56 percent last month and Scott Ferguson s Sachem Head Capital guided investors that its returns would be off roughly 2 percent  investors said  
There were also winners  Investors said Visium Asset Management s Balance Fund inched up 0 57 percent last month  gaining 11 2 percent for the year  The HG Vora Special Opportunities fund is up 8 percent for the year after rising 0 20 percent in August  Newcomer Clearfield Capital  which counts Ackman among its investors  was flat on the month and is flat on the year  people familiar with the funds  returns said    with additional reporting by Lawrence Delevingne in New York  Editing by Chris Reese  Andrew Hay and Ken Wills ",2015-09-02,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-hedge-fund-drops-9.2-percent-in-august-359826,359826
105797,327312,AGN,Allergan forecasts second half revenue above  8 billion,news," Reuters    Drugmaker Allergan Plc  N AGN  said it expected revenue to be greater than  8 billion in the second half to reflect the divesture of its global generics business to Teva Pharmaceuticals Industries Ltd  TA TEVA   N TEVA    
The company said it intends to report its global generics business as discontinued operations in the third quarter ",2015-09-28,Reuters,https://www.investing.com/news/stock-market-news/allergan-forecasts-second-half-revenue-above-$8-billion-363610,363610
105819,327334,AGN,Outline Of Parnassus Fund  PARNX ,opinion,"Parnassus Fund     seeks long term growth of capital  The fund uses a contrarian investment strategy  investing in stocks that are out of favor with the financial community and are  therefore  undervalued  The fund invests 15  of its total assets in foreign securities and up to 5  in warrants  The fund invests 5  of its total assets in community development loan fund  such as those that provide financing for small business and for low and moderate income housing 

	This Large Value product has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 3  5 year benchmarks  3 year 9 9  and 5 year 17 2   To see how this fund performed compared in its category  and other  1 and  2 Ranked Mutual Funds   

	PARNX s performance  as of the last filing  when compared to funds in its category was in the top 12  over the past 1 year  and in the top 20  over the past 3 years and in the top 2  over the past 5 years 

	Parnassus Fund  as of the last filing  allocates its fund in top three major groups  in Large Growth  Large Value and Small Growth  Further  as of the last filing  Motorola Solutions Inc  NYSE MSI   Allergan  NYSE AGN  Plc and Intl Business Machines Co were the top holdings for PARNX 

	This Zacks Rank  2  Buy  was incepted in December 1984 and is managed by   PARNX carries an expense ratio of 0 86  and requires a minimal initial investment of  2 000 

Want key mutual fund info delivered straight to your inbox  

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/outline-of-parnassus-fund-(parnx)-200197787,200197787
105820,327335,AGN,Better Days Ahead For The Pharma Sector ,opinion,"We are halfway through 2017 and the pharma and biotech sector has bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 12 9  while the NASDAQ Biotechnology Index is up 17 2   This is in sharp contrast to 2016 which was a tough year for pharma and biotech stocks  with the sector facing a lot of criticism for rising drug prices  While shares rallied post election in November on hopes that drug pricing would not be a key focus area under a Trump presidency  it turned out to be short lived following the President s views regarding drug pricing Drug pricing was not the only headwind last year  2016 was also disappointing from an R D perspective with a fewer number of drugs managing to gain FDA approval  There were some high profile pipeline failures as well  Other factors that weighed on the sector include mixed results  slower than expected new product launches and increasing competition However  the sector has fared better this year  New product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from legacy products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms and cash repatriation would support a recovery as well Importantly  investors now seem to be more comfortable with the drug pricing scenario and are willing to look at the fundamentals of the sector  Although the drug pricing issue will remain a headwind this year as well  expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected   Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  FDA Commissioner Scott Gottlieb recently said that the agency is working on a plan to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies Valuation Suggests Upside PotentialGoing by the current price to earnings multiple  which is often used to value drug stocks  the pharmaceutical industry looks pretty attractive at this point  The industry is currently trading at a P E multiple of 15 8  below the S P 500 P E multiple of 18 3  leaving room for upside  Moreover  when compared to the industry s own performance over the last year  it can be seen that the current multiple is below the industry high of 17  Keeping these numbers in mind  the current level seems to represent an attractive entry point So what are the factors that could drive the sector  First and foremost  this is an industry that will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong pipelines  innovative treatments  impressive results  and increased health care spending should support growth  Trump s pro business stand is also expected to benefit the sector  Major companies should gain from Trump s proposed tax plan and proposal to repatriate corporate profits held offshore at a one time tax rate A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also work in favor of the sector On the other hand  drug pricing will remain a headline risk  The growing presence of biosimilars  a slowdown in growth of legacy products and high profile pipeline setbacks are also challenges for the sector 
M As to Pick Pace in 2017 While there were not too many acquisitions in 2016  expectations are that M A activities will pick up this year  But this year too  there has been limited M A activity with Johnson   Johnson s     30 billion acquisition of Actelion being the major M A news this year while a few bolt on deals were announced by other companies  However  expectations are high that M As will increase as the year progresses    potential tax reform and cash repatriation are expected to lead to a boost in this area Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals  with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash  Companies like Exelixis  Incyte    and TESARO have often been considered attractive acquisition targets by industry watchers Streamlining OperationsAnother trend being witnessed is the divestment of non core business segments  Companies like Pfizer  NYSE PFE      UCB  Novartis     Sanofi  PA SASY   Valeant  Glaxo and AstraZeneca    have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise  Smaller companies have also been monetizing assets to utilize the money for pipeline development Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile New Products Should Pick PaceHighly awaited new products that gained approval over the last couple of years should contribute significantly to revenues  Key new products include Ibrance  cancer   Cosentyx  psoriasis   PCSK9 inhibitors    Repatha and Praluent  Cotellic  advanced melanoma   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Tecentriq  urothelial cancer   and Taltz  moderate to severe plaque psoriasis   among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori Biosimilars A Competitive ThreatWith the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S  The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  AbbVie s Humira  adalimumab   which is used for a wide range of inflammatory diseases 
And then there is Lilly    and Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway    Basaglar was found to be sufficiently similar to Sanofi s Lantus to scientifically justify reliance  and to establish its safety and efficacy for the approved uses Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion Apart from Amgen  NASDAQ AMGN   Novartis and Pfizer  companies like Biogen  NASDAQ BIIB     and Allergan  NYSE AGN  are targeting the highly lucrative biosimilars market  While all these companies are Zacks Rank  3  Hold  stocks  you can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here What to Expect from the Sector in Q2 Earnings Season A look at consensus earnings expectations for the Medical sector from the Zacks Earnings Trends report for the second quarter earnings season shows earnings will decline 1  from the year ago period while revenues will grow 3 7   This compares to Q1 earnings growth of 5 5  and revenue growth of 5 7  While new products should start contributing significantly and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  challenges remain in the form of currency headwinds  additional competition  slowdown in growth of mature products and loss of exclusivity for certain key drugs Zacks Industry RankWithin the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative  The Zacks Industry Rank for Large Cap Pharmaceuticals is  43   196 for Medical Generic Drugs   163 for Medical Biomedical and Genetics and  171 for Medical Drugs  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Positive for Large Cap Pharmaceuticals  Neutral for Medical Drugs and Medical Biomedical and Genetics and Negative for Medical Generic Drugs Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/better-days-ahead-for-the-pharma-sector-200198087,200198087
105821,327336,AGN,Zacks Industry Outlook Highlights  Johnson   Johnson  Incyte  Pfizer  Novartis And AstraZeneca,opinion,"For Immediate Release

	Chicago  IL   June 29  2017   Today  Zacks Equity Research discusses the Industry  Pharmaceuticals  including Johnson   Johnson  NYSE JNJ   NYSE        Incyte  NASDAQ         Pfizer  NYSE PFE   NYSE         Novartis  NYSE        and AstraZeneca  NYSE        

	Industry  Pharmaceuticals

	Link  

Better Days Ahead for the Pharma Sector 

	We are halfway through 2017 and the pharma and biotech sector has bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 12 9  while the NASDAQ Biotechnology Index is up 17 2   This is in sharp contrast to 2016 which was a tough year for pharma and biotech stocks  with the sector facing a lot of criticism for rising drug prices  While shares rallied post election in November on hopes that drug pricing would not be a key focus area under a Trump presidency  it turned out to be short lived following the President s views regarding drug pricing 

	Drug pricing was not the only headwind last year  2016 was also disappointing from an R D perspective with a fewer number of drugs managing to gain FDA approval  There were some high profile pipeline failures as well  Other factors that weighed on the sector include mixed results  slower than expected new product launches and increasing competition 

	However  the sector has fared better this year  New product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from legacy products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms and cash repatriation would support a recovery as well 

	Importantly  investors now seem to be more comfortable with the drug pricing scenario and are willing to look at the fundamentals of the sector  Although the drug pricing issue will remain a headwind this year as well  expectations are that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected 

	Deregulation and increased competition seem to be some of the ways that will be used to control drug prices  FDA Commissioner Scott Gottlieb recently said that the agency is working on a plan to lower healthcare costs by speeding up the development of next generation treatments  especially for rare diseases or targeted cancer therapies 

Valuation Suggests Upside Potential

	Going by the current price to earnings multiple  which is often used to value drug stocks  the pharmaceutical industry looks pretty attractive at this point  The industry is currently trading at a P E multiple of 15 8  below the S P 500 P E multiple of 18 3  leaving room for upside  Moreover  when compared to the industry s own performance over the last year  it can be seen that the current multiple is below the industry high of 17  Keeping these numbers in mind  the current level seems to represent an attractive entry point 

	So what are the factors that could drive the sector  First and foremost  this is an industry that will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong pipelines  innovative treatments  impressive results  and increased health care spending should support growth  Trump s pro business stand is also expected to benefit the sector  Major companies should gain from Trump s proposed tax plan and proposal to repatriate corporate profits held offshore at a one time tax rate 

	A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also work in favor of the sector 

	On the other hand  drug pricing will remain a headline risk  The growing presence of biosimilars  a slowdown in growth of legacy products and high profile pipeline setbacks are also challenges for the sector 

M As to Pick Pace in 2017 

	While there were not too many acquisitions in 2016  expectations are that M A activities will pick up this year  But this year too  there has been limited M A activity with Johnson   Johnson s  NYSE        30 billion acquisition of Actelion being the major M A news this year while a few bolt on deals were announced by other companies  However  expectations are high that M As will increase as the year progresses    potential tax reform and cash repatriation are expected to lead to a boost in this area 

	Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals  with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash  Companies like Exelixis  Incyte  NASDAQ        and TESARO have often been considered attractive acquisition targets by industry watchers 

Streamlining Operations

	Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  NYSE         UCB  Novartis  NYSE         Sanofi  PA SASY   Valeant  Glaxo and AstraZeneca  NYSE        have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise  Smaller companies have also been monetizing assets to utilize the money for pipeline development 

	Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 

New Products Should Pick Pace

	Highly awaited new products that gained approval over the last couple of years should contribute significantly to revenues  Key new products include Ibrance  cancer   Cosentyx  psoriasis   PCSK9 inhibitors    Repatha and Praluent  Cotellic  advanced melanoma   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Tecentriq  urothelial cancer   and Taltz  moderate to severe plaque psoriasis   among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 

Biosimilars A Competitive Threat

	With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S  The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade 

	This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  AbbVie s Humira  adalimumab   which is used for a wide range of inflammatory diseases 

	And then there is Lilly and Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway    Basaglar was found to be sufficiently similar to Sanofi s Lantus to scientifically justify reliance  and to establish its safety and efficacy for the approved uses 

	Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion 

	Apart from Amgen  NASDAQ AMGN   Novartis and Pfizer  companies like Biogen  NASDAQ BIIB  and Allergan  NYSE AGN  are targeting the highly lucrative biosimilars market  While all these companies are Zacks Rank  3  Hold  stocks  you can see   

What to Expect from the Sector in Q2 Earnings Season 

	A look at consensus earnings expectations for the Medical sector from the Zacks  report for the second quarter earnings season shows earnings will decline 1  from the year ago period while revenues will grow 3 7   This compares to Q1 earnings growth of 5 5  and revenue growth of 5 7  

	While new products should start contributing significantly and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  challenges remain in the form of currency headwinds  additional competition  slowdown in growth of mature products and loss of exclusivity for certain key drugs 

Zacks Industry Rank

	Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs 

	We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry 

	As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative  

	The Zacks Industry Rank for Large Cap Pharmaceuticals is  43   196 for Medical Generic Drugs   163 for Medical Biomedical and Genetics and  171 for Medical Drugs  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Positive for Large Cap Pharmaceuticals  Neutral for Medical Drugs and Medical Biomedical and Genetics and Negative for Medical Generic Drugs 

Today s Stocks from Zacks  Hottest Strategies

	It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 

	And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-28,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-johnson---johnson,-incyte,-pfizer,-novartis-and-astrazeneca-200198263",200198263
105822,327337,AGN,Sarepta Appoints Ex Allergan Executive As CEO And President,opinion,Sarepta Therapeutics  Inc    NASDAQ SRPT   announced the appointment of Douglas S  Ingram as the new chief executive officer  CEO   He will also serve as the company s president and will also be a member of the board of directors Ingram has a cumulative experience of more than 20 years as an executive leader in the field of life sciences  No wonder  this played an instrumental role in his selection for the job  Most recently  Ingram served as president and chief executive officer of Chase Pharmaceuticals  which was acquired by Allergan  plc   NYSE AGN   in late 2016 Shares of Sarepta were up 2 5  on Wednesday following the announcement of the news  This year  Sarepta s shares have surged 23 4  so far while the Zacks classified  industry has gained 8 8  Prior to the acquisition of Allergan by Actavis  plc in 2015  Ingram served the company in various capacities including its president Sarepta s first marketed drug Exondys 51 was launched last year in the U S  Also  a marketing application is under review in the EU  Ingram s near term priorities include successful commercialization of Exondys 51 Ingram will also focus on the development of other candidates in the pipeline and various research collaborations to maintain Sarepta s leadership position in the treatment of Duchenne muscular dystrophy  DMD   The company currently has collaboration with Catabasis Pharmaceuticals  Inc    NASDAQ CATB   to explore a combination drug treatment approach for DMD Ingram will replace Sarepta s present CEO  Edward M  Kaye who  in April this year  informed the company of his intention to resign on Sep 20  upon the completion of his term Sarepta Therapeutics  Inc  Price and Consensus   Zacks Rank   Key PickSarepta Therapeutics carries a Zacks Rank  2  Buy   Another stock to consider in the health care sector is Regeneron Pharmaceuticals  Inc    NASDAQ REGN    sporting a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10  over the last 60 days  The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0 45   Regeneron s shares have surged 39 8  so far this year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/sarepta-appoints-ex-allergan-executive-as-ceo-and-president-200198309,200198309
105823,327338,AGN,M As  Rich Pipelines   Catalyst Rich 2017 To Drive Pharma Stocks,opinion,"Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs  a changing competitive scenario and mixed results  the sector s fundamentals remain strong    innovation  mergers and acquisitions  M As   product approvals and positive data flow should act as catalysts M As to Pick Pace Expectations are high that the pharma sector will witness an increase in M As as the year progresses    potential tax reform and cash repatriation are expected to lead to a boost in this area  While so far  not too many deals have been announced  we could see several M A agreements being announced in the coming quarters though companies are wary of bidding wars leading to over priced deals Big players like Sanofi  PA SASY  have expressed an interest in pursuing M A deals  Allergan  NYSE AGN  has also been very active on the acquisition and deal making front  Industry bellwether Johnson   Johnson  NYSE JNJ  recently acquired Actelion for approximately  30 billion  While some of these companies are looking to replace sales of blockbuster products that are facing loss of patent exclusivity  others are looking to build their pipelines both through acquisitions as well as licensing agreements Companies with innovative technologies and pipelines are highly sought after  Niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology and multiple sclerosis are in demand  Treatments for orphan diseases are also much sought after with quite a few deals being signed in these areas Innovative Pipelines   Catalyst Rich 2017Pharma and biotech companies continue to work on bringing innovative new treatments to market  and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in important therapeutic areas like immuno oncology  Alzheimer s  hepatitis C virus  HCV   central nervous system disorders  and immunology inflammation Among these  immuno oncology has been attracting a lot of interest as these therapies have the potential to change the treatment paradigm for cancer    they basically use the natural capability of the patient s own immune system to fight the disease  Major players in this field include Bristol Myers     Novartis  AstraZeneca  Merck    and Roche Deals targeting immuno oncology are being inked by companies like Pfizer  NYSE PFE      Merck KGaA  Bristol Myers  AstraZeneca and Incyte  Companies like Kite    are also advancing in this area  Interest in PARP inhibitors has also increased considerably as they could well be the next major class of therapeutics in oncology According to IMSQuintiles  68 new cancer drugs were approved for 22 indications from 2011 to 2016 while worldwide costs for cancer therapeutics and supportive care drugs shot up from  91 billion in 2012 to  113 billion in 2016  More than 600 molecules are in late stage development with the majority being targeted therapy 
New Product Sales Should Ramp UpSales of products that gained approval over the last two years as well as line extensions should ramp up and boost growth  New products with blockbuster potential include Amgen s PCSK9 inhibitor  Repatha  Novartis  psoriasis treatment  Cosentyx  and Pfizer s cancer treatment  Ibrance  Cancer treatments like Kyprolis  Keytruda  and Imbruvica should also bring in more sales thanks to label expansions The FDA approved 22 new drugs in 2016 including Zinplava  c  difficile infection   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Epclusa  HCV   Ocaliva  rare  chronic liver disease   Zinbryta  multiple sclerosis   Tecentriq  urothelial cancer   Venclexta  chronic lymphocytic leukemia in patients with a specific chromosomal abnormality   Taltz  moderate to severe plaque psoriasis   Cinqair  severe asthma  and Zepatier  HCV  among others  The agency also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori Faster Drug Approval ProcessAt a meeting with pharma majors earlier this year  President Trump spoke about speeding up the FDA approval process  Last year  the number of new drug approvals slipped to 22  well below the 45 approvals in 2015 and 41 in 2014  The President said that the FDA will be streamlined and the drug approval process will be much faster  The recently signed 21st Century Cures Act is a step in this direction With the passing of this Act  expectations are that there will be more innovation in the sector and  maybe  a surge in new drug approvals  Some of the key drugs currently under FDA review with decisions expected in the next few months include Celgene s enasidenib  relapsed or refractory acute myeloid leukemia   Puma s neratinib  breast cancer   Kite s axicabtagene ciloleucel  cancer  and Teva s SD 809  tardive dyskinesia  among others Meanwhile  the agency is working on streamlining the development process for drugs for rare diseases as well as for targeted cancer therapies  The FDA is also working on clearing up a backlog of orphan drug applications So far in 2017  the FDA has given its nod to 23 new drugs  already surpassing last year s total tally of 22  Among this year s approvals  drugs like Kevzara  adult rheumatoid arthritis  and Dupixent  eczema  have blockbuster potential According to the IMSQuintiles report  the late phase R D pipeline for the industry indicates that there should be about 40 45 new brand launches every year through 2021 Stock PicksAlthough the sector may face some volatility due to the drug pricing issue  pipeline success in innovative and important therapeutic areas  cost cutting  share buybacks  new products  increased pipeline visibility and appropriate utilization of cash should help restore investor confidence in this sector Here are a few stocks that look well positioned and carry a favorable Zacks Rank     1  Strong Buy  or  2  Buy   You can see  
Sanofi  SNY   French pharma giant  Sanofi  has a strong presence in several markets including diabetes  cardiovascular  rare disorders  vaccines and consumer healthcare  The company  which had recorded a decline in share price last year  has outperformed the Zacks categorized  industry this year with shares gaining 21 9  YTD Although Sanofi s diabetes segment will remain under pressure in 2017  the company got a boost this year with the FDA approval of two drugs with blockbuster potential    eczema treatment  Dupixent  and rheumatoid arthritis treatment  Kevzara  As the pipeline continues to deliver and new product sales ramp up  this Zacks Rank  2 stock could well be poised for a turnaround Regeneron Pharmaceuticals  Inc   REGN   Tarrytown  NY based Regeneron s key growth driver eye drug  Eylea  continues to perform well  The company has been working on diversifying its portfolio and gained FDA approval for two drugs this year    Dupixent  moderate to severe atopic dermatitis  and Kevzara  moderately to severely active rheumatoid arthritis   Both have blockbuster potential with Dupixent already off to a strong start  The company also has a strong pipeline  Regeneron  a Zacks Rank  1 stock  has outperformed the Zacks categorized  industry with shares gaining 36 8  YTD  Estimated earnings growth for the current year is 27 4  Sangamo Therapeutics  Inc   SGMO   Richmond  CA based Sangamo is a clinical stage company focused on translating ground breaking science into genomic therapies based on its platform technologies in genome editing  gene therapy  gene regulation and cell therapy  The company got a shot in the arm recently with Pfizer signing a deal for the development and commercialization of gene therapy programs for hemophilia A  This deal bodes well for the long term prospects of the company  Shares of this Zacks Rank  2 stock are up a whopping 185 3  YTD All said and done  the pharma sector s fundamentals remain strong    robust pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth  To know more about this sector  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-29,Zacks Investment Research,"https://www.investing.com/analysis/m-as,-rich-pipelines---catalyst-rich-2017-to-drive-pharma-stocks-200198383",200198383
105824,327339,AGN,Alkermes Presents Phase III Data On Schizophrenia Candidate,opinion,Alkermes plc   NASDAQ ALKS   announced positive preliminary top line results from a phase III study  ENLIGHTEN 1  evaluating its schizophrenia candidate  ALKS 3831  It is a supportive study in the broad clinical development program  ENLIGTHEN on ALKS 3831 We note that ALKS 3831 is a once daily  oral atypical antipsychotic drug candidate designed to be a broad spectrum treatment for schizophrenia Alkermes  share price increased 4 3  year to date  underperforming the Zacks classified  industry s gain of 6 4  ENLIGHTEN 1 study is assessing the antipsychotic efficacy of ALKS 3831 compared with placebo over four weeks in patients with acute exacerbation of schizophrenia  The study also includes a comparator arm of Eli Lilly and Company s   NYSE LLY   Zyprexa  olanzapine   an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities  including significant weight gain The study met its primary endpoint  demonstrating statistically significant reductions in Positive and Negative Syndrome Scale  PANSS  scores versus placebo from the baseline   The candidate showed improvements similar to Zyprexa Moreover  ALKS 3831 showed similar weight gain and metabolic side effects commonly associated with the use of Zyprexa The company is conducting another phase III study  ENLIGHTEN 2  evaluating weight gain with ALKS 3831 compared with Zyprexda  The data from the study is expected in 2018  A favorable weight and metabolic profile compared to Zyprexa will make the candidate a potential treatment for schizophrenia Per the press release  the chronic  severe and disabling brain disorder  schizophrenia affects approximately 2 4 million adults in the U S We note that the market for schizophrenia is highly competitive with the presence of drugs from large cap pharma companies including Johnson   Johnson s   NYSE JNJ   Invega Sustenna and Risperdal Consta  and Allergan plc s   NYSE AGN   Vraylar  A few other companies are also developing their candidates for this indication Alkermes PLC Price and Consensus   Alkermes carries a Zacks Rank  4  Sell  You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-02,Zacks Investment Research,https://www.investing.com/analysis/alkermes-presents-phase-iii-data-on-schizophrenia-candidate-200198918,200198918
105825,327340,AGN,Lilly Gets Favorable Ruling In Alimta Patent Lawsuit In UK,opinion,Eli Lilly and Company   NYSE LLY   announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker  Actavis related to its key cancer drug  Alimta  pemetrexed disodium  Per the court s verdict  alternative salt forms of Alimta launched by Actavis  now a part of Teva Pharmaceutical Industries Limited   NYSE TEVA    directly infringes the vitamin regimen patent of Alimta in the UK  France  Italy and Spain prior to expiry in Jun 2021  Teva bought Actavis  Allergan plc s   NYSE AGN   generic business in Aug 2016 Shares were up around 1  on Friday  Lilly s share price has risen 11 9  so far this year  slightly better than an11 1  increase witnessed by the Zacks classified industry We remind investors that in Feb 2016  the UK High Court ruled that a generic version of Alimta proposed by Actavis will not infringe the vitamin regimen patent in the UK  France  Italy and Spain  given that it is diluted only with dextrose solution  In Jun 2015  the UK Court of Appeal had said that Lilly s patent would be indirectly infringed by the sale of certain alternative salt forms of pemetrexed with the instructions to dilute them with saline solution  In the latest ruling  the UK Supreme Court has affirmed this finding by the UK Court of Appeal  The full judgment will be published on Wednesday Following the decision by the U K  Appellate court  Actavis launched generic pemetrexed Armisarte in the EU  at risk  The latest announcement by the UK Supreme Court implies that Actavis  generic pemetrexed products infringe the patent  regardless of the diluent used in reconstitution or dilution We remind investors that in Sep 2015  a U S  district court also ruled in favor of Lilly on the validity of the vitamin regimen patent and in Jan 2017  a U S  Appellate court confirmed the lower court s decision While the compound patent covering Alimta in the U S expired in Jan 2017  the vitamin regimen patent will remain valid till Jun 2021  plus pediatric exclusivity expiring in 2022   if Alimta s patent is ultimately upheld through all the remaining challenges  The compound patent has already expired in major European countries and Japan in Dec 2015 A number of generic manufacturers including Teva and Sandoz  the generic arm of Novartis AG   NYSE NVS   are seeking approvals in various countries to market generic forms of Alimta prior to the expiration of its vitamin regimen patents We note that Alimta is one of the top revenue grossers at Lilly and a longer commercial life for Alimta would provide top line support as several products in Lilly s portfolio are already facing patent expiration Alimta sales  however  declined 13  year over year to  489 9 million in the last reported quarter   first quarter of 2017  reflecting lower demand in the U S  due to competitive pressure mainly from immuno oncology agents  Outside the U S   sales of Alimta were hurt by loss of exclusivity in several countries and lower realized prices The entry of generic competition for Alimta following the loss of effective patent protection will cause a rapid decline in revenues for the product Lilly has a Zacks Rank  4  Sell  You can see  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-09,Zacks Investment Research,https://www.investing.com/analysis/lilly-gets-favorable-ruling-in-alimta-patent-lawsuit-in-uk-200200044,200200044
105826,327341,AGN,AstraZeneca to carve out antibiotic R D into separate firm,news,By Ben Hirschler LONDON  Reuters    Drugmaker AstraZeneca  L AZN  has decided to carve out its early stage antibiotic research by creating a stand alone subsidiary company  as it sharpens its focus on other therapy areas  Chief Executive Pascal Soriot said last year he was looking to partner or sell its anti infective business  which is no longer viewed as a core area for the British drugmaker  AstraZeneca said in an emailed statement it would invest  40 million in the new antibiotic company  which will include early stage products such as a drug in Phase II for gonorrhea  The move will impact approximately 95 employees based in Waltham  Massachusetts  The new structure has no impact on anti infective products already on the market  including Merrem  Zinforo  Fluenz Flumist and Synagis  It also does not affect Avycaz  a new antibiotic approved this week from Actavis  N ACT   which was co developed with AstraZeneca  Antibiotics have fallen out of favor in the past decade among many Big Pharma companies  because of their typically low margins  The industry has focused instead on more profitable areas  like cancer  More recently some companies have started coming back to the space  given the demand for novel medicines that can fight drug resistant superbugs  with Merc  NYSE MRK k   Co  N MRK  agreeing to buy Cubist for  8 4 billion in December  But AstraZeneca prefers to deploy its resources on its three priority areas of oncology  cardiovascular and metabolic diseases  and respiratory and inflammation  The decision to carve out early stage antibiotics fits with Soriot s aim of doing more so called  externalization   involving the sale of non core drugs  both to increase the company s focus and generate additional income to see it through a tough period of patient expiries on older drugs  Last year it struck a partnership deal worth up to  500 million for Alzheimer s treatment with Eli Lilly  N LLY   which could be a model for further transactions ,2015-02-27,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-to-carve-out-antibiotic-r-amp;d-into-separate-firm-329991,329991
105827,327342,AGN,Fidelity cuts Google stake by nearly a third amid shift to cheaper searches,news," Reuters    One of  Google Inc   NASDAQ GOOGL  s largest investors has cut its exposure to the company by nearly a third over the past several months amid worries about a shift to cheaper searches on mobile phones  The  107 billion Fidelity Contrafund cut its stake in Google to 5 2 percent of net assets as of Jan  31  from 7 3 percent of net assets as of June 30   The firm continued to do phenomenally innovative things  but it is fighting a shift away from desktop search to less expensive searches on mobile phones   Fidelity Investments portfolio manager Will Danoff said in Contrafund s annual report  released on Feb  28th  Danoff is considered one of the best stock pickers in the mutual fund industry  with Contrafund producing an average annual total return of 9 9 percent over the past 10 years  That s nearly 2 percentage points better than the benchmark S P 500 s average annual return of 7 99 percent during the same period  according to Morningstar Inc   Still  in 2014  Google weighed down Contrafund s performance  along with a number of other large cap funds with big positions in the stock  Danoff turned in one of his most disappointing performances of the past decade as Contrafund s 2014 total return of 9 56 percent lagged the S P 500 s 13 69 percent advance   
 In the strong performing health care sector  I could have done a much better job with surging biotechnology stocks   Danoff said in the annual report for investors   Notable mistakes included not owning enough Amgen  NASDAQ AMGN   a biotech firm that made excellent advances  and avoiding index stock Allergan  NYSE AGN   the specialty drug company that announced plans to be acquired by  Actavis   NYSE ACT   ",2015-03-02,Reuters,https://www.investing.com/news/technology-news/large-google-investor-cuts-stake-amid-shift-to-cheaper-searches-330434,330434
105828,327343,AGN,Exclusive  Ackman s Pershing Square makes  3 3 billion bet on Valeant,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman has purchased a five percent stake in Valeant Pharmaceuticals  TO VRX   N VRX   his hedge fund said on Monday  making him the Canadian drug company s fifth largest stakeholder  Ackman s  20 billion Pershing Square Capital Management hedge fund began building up the  3 3 billion stake  only months after its vocal effort to help Valeant buy Botox maker Allergan  N AGN  failed  a source familiar with the investment told Reuters  The source  who asked not to be named  said the fund would take a passive approach to Valeant  instead of pressuring it to change management or pursue strategic options  as it does with most of its investments  Valeant spokeswoman Laurie Little said  we have a good working relationship with Pershing Square and welcome them as shareholders   Valeant shares were up nearly 2 5 percent at  203 64 on the New York Stock Exchange on Monday  The drug maker s Toronto listed shares gained about 2 4 percent to C 256 52  Known as one of corporate America s noisiest agitators  Ackman was the top performer in the realm of large hedge fund managers last year with a 40 percent return  His Pershing Square has notched big wins at railway firm Canadian Pacific  TO CP  and shopping mall operator  General Growth Properties   N GGP   and also made money with its Allergan stake  Valeant sought Ackman s help in early 2014 to buy Allergan  leaving the hedge fund to spend roughly  4 billion to build its 9 7 percent stake in the Botox maker  But Allergan rejected Valeant s overtures  sued the hedge fund and instead sold itself to rival  Actavis   NYSE ACT  in November  While working with Valeant on the takeover bid  Ackman could not buy Valeant shares  All restrictions fell away when the deal fell through  leaving him able to buy in  paying just under  200 per share initially  the source said  Last month  Valeant bought Salix Pharmaceuticals for  14 5 billion  pushing its share price up further   Some investment industry sources had speculated that Ackman would press for a deal between Valeant and animal health company Zoetis  N ZTS   in which Ackman has a  2 billion stake and a Pershing Square partner on the board  But the source said Pershing Square would take a passive approach because Ackman had faith in Valeant s management  including its chief executive officer  Michael  Pearson   LONDON PSON   who has slashed costs  cut the company s tax rate by moving it to Canada and turned it into a serial acquirer during his seven years as CEO  Pershing Square confirmed on Monday that its various funds had bought more than 16 4 million shares of Valeant  representing 4 9 percent of the company  It said that Valeant now made up 16 9 percent of Pershing Square Holdings  AS PSH   a fund that was publicly listed last year   
The options on the U S  listed shares of Valeant were unusually busy over the last two weeks with average daily volume of about 15 000 contracts  more than twice the average for the last 200 days  according to Trade Alert data  Bets on the shares rising above  210 by April 17 were the most active with more than 16 000 contracts traded over the last two weeks ",2015-03-09,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-makes-$3.3-billion-bet-on-valeant-331528,331528
105829,327344,AGN,Actavis says Allergan s Pyott won t join new company s board,news,"NEW YORK  Reuters     Actavis  Plc  N ACT  said on Tuesday that  Allergan Inc  s  N AGN  top executive David Pyott will not join the combined company s board of directors after all  Pyott  who had run Allergan since 1998 before agreeing to the company s purchase by Actavis last year  had previously said he was considering a role on the board  Actavis closed on its  70 billion purchase of the Botox maker on Tuesday   I am excited for the opportunity to pursue new interests  including my work with a few public company boards  several universities in the U S  and the UK and ophthalmic charities whose goals are to improve eye health in emerging markets   Pyott said in a statement  
Actavis  which plans to change its name to Allergan  said its newly configured board would have 12 members including two from Allergan s existing board  Michael Gallagher and Peter McDonnell ",2015-03-17,Reuters,https://www.investing.com/news/stock-market-news/actavis-says-allergan's-pyott-won't-join-new-company's-board-332782,332782
105830,327345,AGN,Generic drugmaker Teva makes  40 billion offer for rival Mylan,news,"By Tova Cohen and Caroline Humer TEL AVIV NEW YORK  Reuters    Teva Pharmaceutical Industries  ARCA TEVA  Ltd on Tuesday made an unsolicited  40 billion offer for smaller rival Mylan  NASDAQ MYL  NV  a bold bid for growth as its lucrative Copaxone drug faces generic competition   The offer followed weeks of speculation that Israel based Teva  the world s largest generic drugmaker  would soon target Mylan  Shares of Mylan traded below the offer price of  82 in cash and stock  evidence of investor scepticism that Teva can win over the company  which has set up a defense that includes a poison pill  Analysts agreed that Teva would need to sweeten its bid to the  90 per share range  S P Capital IQ analyst Jeffrey Loo said a viable offer would be  92  about 22 times Mylan s 2015 expected earnings   If they raise their bid  they will have more Mylan shareholders pressuring management to come to the table   Loo said  He suggested Teva would need to increase the cash component of the offer  which is now at 50 percent  Mylan has yet to respond publicly  The company is pursuing an unsolicited   29 billion bid for  Perrigo Co   NYSE PRGO  Plc  a major producer of over the counter medicines  in an apparent attempt to stave off interest from Teva   Perrigo has not yet responded to that offer  saying it would consult its board  but a source familiar with the matter said the company was set to reject Mylan s bid as soon as this week  Mylan Executive Chairman Robert Coury said last week that the company had studied the potential for a deal with Teva and concluded that such a combination  is without sound industrial logic or cultural fit   and would attract antitrust scrutiny  Teva said its offer should be more attractive to Mylan shareholders than the proposed purchase of Perrigo  representing a 48 percent premium to the company s share price before speculation of a deal surfaced on March 10   Pressure has been growing on Teva for new revenue sources as multiple sclerosis drug Copaxone starts to face generic competition this year   Teva said the purchase would help it to expand its offering of harder to produce medical products  such as soft gel caps  topical and inhalant technologies and injectables  and increase its portfolio of specialty pharmaceuticals  The acquisition would create an entity with more than  30 billion in annual revenue  add to earnings in the first year and eventually generate  2 billion in annual savings  Teva said  It expects that a transaction could close by the end of 2015 and pledged a quick response  including selling assets if necessary  to ease any regulatory concerns  Mylan shares were up 8 9 percent at  74 12 in afternoon Nasdaq trading  while Teva rose 2 0 percent to  64 55 on the New York Stock Exchange  Perrigo fell 2 2 percent to  193 79  HEALTHCARE DEAL FRENZY A Teva Mylan deal would be the second largest healthcare transaction in the last 12 months  following generic drugmaker  Actavis   NYSE ACT  Plc s  66 billion purchase of Botox maker Allergan  NYSE AGN   The wave of consolidation has also included  AbbVie Inc   NYSE ABBV  s proposed purchase of Pharmacyclics and Valeant Pharmaceuticals  NYSE VRX   deal for Salix  Generic drugmakers are looking to get bigger and gain access to product lines with higher profit margins  while traditional pharmaceutical companies have tried to add novel treatments for cancer and rare diseases   Teva Chief Executive Officer Erez Vigodman said the companies should meet to address Mylan s concerns  In a letter to Coury  he said a deal would create  an organization with the scale and reach to excel in the current environment  which I know you appreciate   A turnaround specialist  Vigodman joined Teva last year  tasked with cutting costs and improving profits under pressure from rising competition  In February  he said the company was ready to return to making acquisitions  A Mylan purchase would be the largest deal in Israeli history  Mylan recently moved its headquarters from the United States to the Netherlands  where corporate taxes are lower and where it could take advantage of Dutch anti takeover provisions that can dilute shares by granting a call option to a foundation set up for this purpose   In early April  Mylan said it had entered into such a call option agreement  Sanford Bernstein analyst Aaron Gal said in a research note that Perrigo was likely to reject Mylan but might then start negotiating with the company  That would push Mylan to campaign to win shareholder support for its purchase  At the same time  Teva will start its own campaign to publicly convince Mylan shareholders of the merits of its offer  Mylan is likely to demand a higher price  shared management and maybe some employee job protection  he said   
 Barclays   LONDON BARC  and Greenhill   Co Inc are advising Teva  whose lawyers are Kirkland   Ellis LLP  Tulchinsky Stern Marciano Cohen Levitski   Co  De Brauw Blackstone  NYSE BX  Westbroek N V  and Loyens   Loeff N V ",2015-04-21,Reuters,https://www.investing.com/news/stock-market-news/teva-makes-$82-per-share-offer-for-mylan-338127,338127
105831,327346,AGN,Greenlight s Einhorn slams oil frackers at Sohn conference,news,"By Svea Herbst Bayliss  Jessica Toonkel and Ashley Lau NEW YORK  Reuters    Billionaire hedge fund manager David Einhorn  who often moves a stock simply by speaking its name  on Monday kicked off the year s most prominent investment conference by laying out a case against oil frackers  arguing these companies drill  lots and lots of holes  and burn through plenty of cash  Einhorn  who often unveils short bets against companies at these events  cited Pioneer Natural Resources Co as a particular offender at the 20th annual Sohn Investment Conference   We call it the motherfracker   he said  prompting investors to kick the share price down as much as 5 3 percent  The company should trade closer to  78 a share  he said  not the  166 50 the stock is trading at now   Pioneer is burning cash and its reserves are not growing   said Einhorn  who runs  11 billion Greenlight Capital  adding  Pioneer ought to stop touting estimates based on stale pricing   The company is losing 20 cents of present value for every dollar it invests  Pioneer shares closed Monday at  168 33 a share  down 1 88 percent  Einhorn also mentioned EOG Resources Inc  NYSE EOG   which he called the  father fracker   Concho Resources  Whiting Petroleum Corp and Continental Resources Inc  Last year Einhorn unveiled a short bet against athenahealth Inc at a previous Sohn conference and was the first to underscore problems at Lehman Brothers months before the investment bank filed for bankruptcy  Einhorn was one of the few investors at the conference who unveiled a short bet  as most other investors put forth ideas that investors can buy and hold  Leon Cooperman and David Tepper talked about markets and sought to soothe investors fearful that the long running equities bull market might be over  Tepper  founder of Appaloosa Management  shocked markets a year ago by warning that investors should not be too long in the stock market  On Monday  he said that investors should not be  too long bonds  not too short stocks  and warned that investors should be careful with commodity investments  Investors at this conference  even the billionaires  are told to keep it short and talk no more than 15 minutes  Tepper who didn t use all of his time joked that he would sell some of his unused minutes to Bill Ackman  who is known for speaking at a breakneck pace to race through dozens and dozen of slides  Cooperman  who runs Omega Advisors and has long been saying the stock market would continue to climb  stuck by his bullish outlook  saying the stock market can still end higher this year   If there is a bubble out there  it is not in the stock market   Cooperman said  adding it may be in the fixed income market  He pitched a handful of U S  based companies including  Google Inc   NASDAQ GOOGL   Dow Chemical Co  Priceline Group Inc and drugmaker  Actavis   NYSE ACT  Plc  Picking up on the pharmaceutical industry theme  Larry Robbins  who runs Glenview Capital Management  touted  AbbVie Inc   NYSE ABBV   saying the stock price could double  The company s price is relatively cheap and management is disciplined  Robbins said   Even though AbbVie called off a planned  55 billion takeover of Shire late last year  industry analysts are still holding out forecasts that the breakneck pace of mergers and acquisitions in the pharmaceutical industry will continue  The company could be taken over or it could be the one taking over someone else  Robbins said  Ackman  founder and chief executive of Pershing Square Capital Management LP  talked about his most recent addition to the portfolio  Canadian pharmaceutical company Valeant Pharmaceuticals International Inc  NYSE VRX   which he called  massively undervalued   He said companies that buy up others at a steady pace are often misunderstood and said Valeant  which announced plans to buy Salix earlier this year  is an early stage Berkshire Hathaway  NYSE BRKa   referring to Warren Buffett s company  Keith Meister  a former Carl Icahn lieutenant who now runs  8 billion Corvex Management  focused on fast food restaurant chain Yum Brands  saying his firm is one of the five largest investors and that the company is Corvex s second biggest investment ever  On Friday Daniel Loeb s Third Point said it had taken a significant stake in Yum  Meister said Yum should spin off its China business  allowing a fully independent China company that appeals to the nation s large middle class  He said Yum s share could trade at least at  130  compared with the current price of  92 25  after the company spins off the China operation  
A Yum spokeswoman said the company welcomes input from shareholders in trying to enhance shareholder value and added  In any event  our focus is to get our China business back on track    with additional reporting by Sam Forgione in New York  Editing by Steve Orlofsky and Jennifer Ablan ",2015-05-04,Reuters,"https://www.investing.com/news/stock-market-news/greenlight's-einhorn-slams-oil-frackers,-meister-touts-yum-at-sohn-340170",340170
105832,327347,AGN,Canada s Valeant approaches to buy Zoetis  WSJ,news," Reuters    Canada based drugmaker Valeant Pharmaceuticals International Inc  TO VRX   N VRX  has approached to buy  Zoetis Inc   N ZTS   an animal health company  the Wall Street Journal reported  Shares of Zoetis  whose pipeline includes medicines and vaccines for pets and livestock  were up 2 percent at  56 65 in extended trading   The company  spun off from  Pfizer  Inc  N PFE  in 2013  was valued at  24 85 billion as of Thursday s close  according to Thomson Reuters data  Both Valeant and Zoetis spokesperson declined to comment  It was not clear what Zoetis s reaction to the preliminary approach was  if any  or whether it was open to a sale  the Journal reported  citing people familiar with the matter     Zoetis  the world s largest animal health company  has been cutting costs and said last month it planned to cut up to a quarter of its workforce and exit nearly 40 percent of its manufacturing plants  The decision came a month after Bill Ackman s Pershing Square  Zoetis s biggest shareholder  and Sachem Head Group seated their second nominee on the company s 11 member board in exchange for not soliciting takeover offers  Valeant  which lost a bid to buy Botox maker Allergan Inc  N AGN  in November  is often criticized for a growth plan that is driven by acquisitions and cost cutting  
Shares of Laval  Quebec based Valeant closed at C 287 79 on the Toronto Stock Exchange  after rising 73 percent this year  while Zoetis shares closed at  55 38 on the NYSE on Thursday ",2015-06-25,Reuters,https://www.investing.com/news/stock-market-news/valeant-offers-to-buy-zoetis:-wsj-348295,348295
105833,327348,AGN,As Christie eyes White House  New Jersey wants jobs,news,By Hilary Russ NEW YORK  Reuters    New Jersey Governor Chris Christie s second in command gave her pitch to a small crowd at a Philadelphia biotechnology convention in June with her signature move  giving out her cell phone number    Please consider picking up the phone   Lieutenant Governor Kim Guadagno said  a plea for attendees from companies large and small to give the state a chance  Her phone rang immediately   Ahh   she groaned  recognizing the caller s area code   Now  no one from New Jersey  I want the guys that aren t already here in New Jersey    The crowd laughed  but Guadagno s frequently used gambit is part of the state s bid to catch up to other parts of the country   When the 2007 2008 recession hit  other states identified the Eastern Seaboard state as a soft target for poaching jobs  with companies ripe for the plucking because of high taxes and labor costs  With Christie announcing his U S  presidential election bid on Tuesday  New Jersey s economic woes could hinder his ability to get voters on board with his proposals nationally  Christie s political action committee did not immediately respond to a request for comment The state s unemployment rate of 6 5 percent exceeds the national average by a full percentage point  and more people are moving out of New Jersey than any other  Its credit rating has been downgraded nine times since Christie took office   Officials  economists and consultants hired to advise on where to locate corporate real estate or a company say there is no simple explanation for New Jersey s sluggish economy  but add that other states have done more to attract business    The recession forced a lot of companies to look at the cost of doing business  Everybody looks at New Jersey and says   Wow  there are lots of companies there  we d like to come pick them off    said Christopher Lloyd  a Richmond  Virginia based site selection specialist for McGuireWoods Consulting  In an interview  Guadagno defended the administration  noting the decline in the state s unemployment rate from 9 8 percent the month that she and Christie took office in January 2010 to the current 6 5 percent   Still  on the night back in June that Guadagno pitched to investors in Philadelphia  she was scheduled to attend a dinner with a number of handpicked companies  so that we can start  one at a time if we have to  to debunk the myth that New Jersey s a hard to do business in state   THE MEDICINE CHEST New Jersey has also been hit with losses in its key pharmaceutical industry as more companies elected to move into urban environments  rather than suburban locales that attracted young families to the state in the 1980s  Swiss drugmaker Roche had its U S  base in Nutley for more than 80 years before a 2009 merger with Genentech that moved the combined headquarters to San Francisco  It shuttered the Nutley campus in 2012  costing New Jersey about 1 000 jobs   Roche planned a clinical research center on the U S  East Coast with 240 people  but picked a Manhattan site created by Alexandria Real Estate Equities  which creates urban campuses for pharmaceutical  technology and biotech companies  The New York site gives young people the lifestyle not available in suburbia  It also put Roche in close contact with other companies  hospitals and universities for quicker collaborations for drug development   They  New Jersey  were the leaders in this country  but they didn t recognize the fundamental change in the industry  the expiration of patents of big pharma and the nature of collaborations and innovations   Joel Marcus  Alexandria s founder  chief executive and chairman  told Reuters   Between 2008 and 2013  New Jersey  long considered the  medicine chest of the world   saw pharmaceutical jobs decline by 17 percent  according to state data  Nationally  the industry also shrank  though not as much  Last Friday  Bristol Myers Squibb announced that it would open a new research site at Alexandria s center in Cambridge  Massachusetts  pulling with it employees from Connecticut and some from New Jersey   State chief economist James Wooster said in an April report that New Jersey s economic recovery was  sluggish by any standard   as the manufacturing  financial services and information sectors have continued to lose jobs since the recession   In 2014  Atlantic City hemorrhaged jobs as a result of several casino closures  In January  Mercedes Benz said it would move its U S  headquarters to Atlanta  taking 1 000 jobs  Overall job growth is expected to lag the nation through at least 2022  according to state data  It hasn t all been bad news  Some companies  including Amazon com  NASDAQ AMZN  and Destination Maternity Corp have been lured into New Jersey  Others decided to stay and expand  including  Actavis  Inc  NYSE AGN   AILC UL   Sandoz Inc and Burlington Coat Factory  Since February 2010  New Jersey s recessionary low point  186 000 private jobs have been created  To respond to the changes in biotech and pharmaceuticals  the administration restructured some of its best colleges  including Christie s merger of most of the University of Medicine and Dentistry of New Jersey into Rutgers University  to make it easier to do clinical trials  In 2013  the state streamlined its tax incentive program  which had been overly complex and outdated  The program requires companies to certify they have made capital investments and created or preserved jobs before receiving incentives  Since then  New Jersey has approved  2 2 billion in subsidies but so far only given out  603 500   Those will start ramping up over the course of the next couple years  and I think that we re going to have great growth   said Michele Brown  CEO of Choose New Jersey  a private nonprofit touting the state s attributes  one of several officials with Guadagno at the Philadelphia biotech convention  Guadagno is counting on these incentives to boost employment  Christie will have to hope voters hear a similar message   If I can get a seat at your table  if I can sit down and tell you what the tax credits are  what the incentives are  how this partnership you re looking at right here works very hard to make sure you get an answer  you may not always get the answer that you want  but you get an answer in a timely fashion  then companies are at least going to look at us   she said ,2015-06-30,Reuters,"https://www.investing.com/news/politics-news/as-christie-eyes-white-house,-new-jersey-wants-jobs-348939",348939
105834,327349,AGN,Teva nears deal for Allergan s generic drugs unit  source,news,"By Greg Roumeliotis  Reuters    Teva Pharmaceutical  ARCA TEVA  Industries Ltd  TA TEVA  is in advanced talks to buy Allergan  NYSE AGN pa  Plc s  N AGN  generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV  O MYL   according to a person familiar with the matter  Jerusalem based Teva  which has offered to buy Mylan for  40 billion  is now close to an agreement to acquire Dublin based Allergan s generic drugs unit for between  40 billion and  45 billion  the person said on Saturday  A deal could be announced as early as next week  the person said  cautioning that negotiations had not yet been completed and asking not to be identified because the discussions are confidential  Teva and Allergan representatives did not respond to requests for comment  Large drug makers are trying to realign their operations to focus on a small number of leading businesses  while smaller specialty and generic producers are seeking larger scale  Allergan s branded drugs business makes products such as Botox and Alzheimer s drug Namenda  Its generics business makes up about a third of the company s total revenue  A successful deal with Allergan would give Teva  which has a market capitalization of  60 billion  a much bigger footprint in the generic drugs sector  It would also offer opportunities for significant cost synergies and tax savings  Last year   Actavis  Plc outbid Canadian drugmaker Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  and activist investor William Ackman to merge with Allergan and adopt its name  Allergan now has a market capitalization of  121 billion  Teva s bid for Mylan took a hit earlier this week when the latter s independent Dutch foundation exercised a call option allowing it to buy 50 percent of Mylan s total issued and outstanding capital  giving it temporary control of half the company  The foundation  known as Stichting  opposes Teva s bid  arguing that a Teva takeover would likely lead to job losses at Mylan and reduce access to cheap generic medicines in emerging markets  Mylan for its part is pressing on with a  34 billion hostile bid for  Perrigo Co  Plc  N PRGO   Were Teva to clinch a deal with Allergan for its generic drug business and drop its bid for Mylan  this would likely strengthen the hand of Mylan s management in its campaign to buy Perrigo   
The Wall Street Journal first reported that Teva was in advanced talks to acquire Allergan s generic drug unit ",2015-07-25,Reuters,https://www.investing.com/news/stock-market-news/teva-nears-deal-for-allergan's-generic-drugs-unit:-source-352944,352944
105835,327350,AGN,Teva to buy Allergan s generic drug unit for  40 5 billion,news,"Investing com   Israeli drug maker Teva Pharmaceuticals  ARCA TEVA  agreed to acquire the generic drug division of Allergan  NYSE AGN  in a cash plus stock deal valued at  40 5 billion  it announced on Monday 
Allergan will receive  33 75 billion in cash and shares in Teva valued at  6 75 billion  giving it a 10  stake in the enlarged company  according to a statement from the Israeli company 
Teva  already the world s biggest seller of generic medicines  said the acquisition reinforces its strategy in the generics industry 
 This strategic acquisition brings together two leading generics businesses with complementary strengths  brands and cultures  providing patients with more affordable access to quality medicines  and creating significant financial benefits for Teva stockholders   the company said in a statement 
The Israeli drug maker added that it has withdrawn its cash and stock proposal for rival Mylan  NASDAQ MYL  
Teva will host a conference call and live webcast at 8 00AM ET to discuss the announcement 
U S  listed shares of Teva surged 11 8  in pre market trade  Meanwhile  Allergan rose 5 5  premarket in New York  while Mylan  NASDAQ MYL  shares slumped 11 9  
U S  stock market futures pointed to a lower open  The Dow futures indicated a loss of 0 25   the S P 500 futures pointed to a drop of 0 2   while Nasdaq 100 futures dipped 0 35  ",2015-07-27,Investing.com,https://www.investing.com/news/stock-market-news/teva-to-buy-allergan's-generic-drug-unit-for-$40.5-billion-353053,353053
105847,327362,AGN,Valeant  VRX  Decides To Extend Stay On Xifaxan s ANDA  ,opinion,"Valeant Pharmaceuticals International  Inc    NYSE VRX   and Actavis  NYSE AGN  Laboratories  Inc   which is now a part of Teva Pharmaceuticals Inc    NYSE TEVA   announced that both the companies have agreed to stay outstanding litigation and extend the 30 month stay regarding the latter s Abbreviated New Drug application  ANDA  for a generic version of Xifaxan  rifaximin  550 mg tablets  The mutual decision was taken at Actavis  request We note that Valeant initiated the litigation against Actavis in Mar 2016  Additionally  Valeant filed a Citizen Petition with the FDA in Oct 2016  requesting changes to previously recommended standards for approval of generic versions of Xifaxan Thereafter  in Mar 2017  the FDA answered the Citizen Petition and issued its revised draft guidance regarding the recommended standards for approval of ANDAs for generic versions of Xifaxan As a result  legal action is stayed through April 30  2018 and cannot be lifted prior to Oct  31  2017  In addition  all currently scheduled litigation activities  including the January 2018 trial date  have been indefinitely removed from the court docket  The court has ordered  that Actavis  30 month regulatory stay shall be extended from Aug  12  2018 until no earlier than Feb  12  2019 and could be longer if the litigation stay lasts for more than 6 months Xifaxan was added to Valeant s portfolio through the Salix acquisition  The drug is approved for irritable bowel syndrome  The company recruited and launched a new primary care sales force for Xifaxan which should boost the weak sales somewhat  A potential generic entry will impact sales After a tumultuous period  Valeant started a rebuilding process with its new CEO  Joseph C  Papa  Even though it is still early to comment on the rebuilding process  but the company s efforts to sell non core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters We note that the shares of Valeant have underperformed the Zacks classified  industry in the last year  The stock lost 48 7  as compared to the industry s gain of 14 5  
Zacks Rank   Key Picks
Valeant currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS    and Aeglea BioTherapeutics   NASDAQ AGLE    While VIVUS and MEI Pharma sport a Zacks Rank  1  Strong Buy   Aeglea carries a Zacks Rank  2  Buy   You can see  
VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  
Aeglea s loss per share estimates narrowed from  3 64 to  2 48 for 2017  over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20 75  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-05-18,Zacks Investment Research,https://www.investing.com/analysis/valeant-(vrx)-decides-to-extend-stay-on-xifaxan's-anda-200190271,200190271
105848,327363,AGN,Amgen  AMGN  Submits BLA To FDA For Migraine Drug Erenumab,opinion,Amgen Inc    NASDAQ AMGN   recently announced the submission of a biologics license application  BLA  to the FDA for its pipeline candidate erenumab  AMG 334  for the prevention of migraine Shares of Amgen have outperformed the Zacks classified  industry so far this year  The stock has gained 8  during the period  while the broader industry witnessed an increase of 1 1  The BLA submission was supported by positive data from pivotal studies in patients with episodic and chronic migraine  The studies were designed to assess the drug s safety and efficacy in migraine prevention  In Sep 2016  the company announced positive top line data from the first pivotal phase III study  ARISE  on erenumab for the prevention of episodic migraine  Meanwhile  the candidate is being evaluated in a second phase III episodic migraine study  STRIVE   assessing both 70 mg and 140 mg doses for 24 weeks  In Nov 2016  the company announced positive top line data from the study Moreover in Jun 2016  positive data from a phase II study for the prevention of chronic migraine were also announced  Results from the studies will be presented at American Headache Society in Boston in June We remind investors that Amgen is developing erenumab in collaboration with Novartis AG   NYSE NVS    The companies are focused on the development and commercialization of the treatments for migraine and Alzheimer s disease  For the migraine program  Amgen retains commercialization rights in Japan  while Novartis has rights in Europe  Canada and Rest of World We note that several companies  including Teva Pharmaceutical Industries Limited   NYSE TEVA   and Allergan plc   NYSE AGN    are developing migraine treatments targeting CGRP Per the company s press release  around 10 million people in the U S  are affected by migraine  Among them  approximately 3 5 million of these patients are currently on a preventive therapy with 80  of them likely to discontinue the treatment within one year  Thus  approval of the drug will address the huge unmet need faced by patients suffering from the disease in the U S Amgen Inc  Price   Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-05-18,Zacks Investment Research,https://www.investing.com/analysis/amgen-(amgn)-submits-bla-to-fda-for-migraine-drug-erenumab-200190250,200190250
105849,327364,AGN,Aerie s Ophthalmic Candidate Positive In Registration Trial ,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced positive primary efficacy results of the 90 day phase III registration trial   Mercury 2   for its pipeline candidate Roclatan 

We note that Aerie has outperformed the Zacks classified industry in the last 12 months  The stock has rallied 144 9  during this period  compared with the industry s 12 5  gain 
We note that Aerie is evaluating Roclatan  a once daily  quadruple action fixed dose combination of its lead candidate Rhopressa and Pfizer s   NYSE PFE   Xalatan 
The results of the trial were consistent with the Mercury 1 trial which was a phase III registration trial that reported top line efficacy findings in Sep 2016 
The data from the trial showed that Mercury 2 achieved its primary efficacy endpoint of demonstrating statistical superiority over each of its components   Rhopressa  netarsudil ophthalmic solution  0 02   and Xalatan  all of which were dosed once daily in the evening 
The data also showed that the IOP lowering effect of Roclatan was 1 to 3 mmHg  millimeters of mercury  greater than monotherapy with either Xalatan or Rhopressa throughout the duration of the study 
The study evaluated patients with maximum baseline intraocular pressures  IOPs  ranging from above 20 to below 36 mmHg 
As a result  the company now expects to submit its NDA for Roclatan in the first half of 2018 
Moreover  the data from the trial showed relatively low discontinuation rates for the 90 day Mercury 2 trial of 9 8  and 10 6  for Roclatan and Rhopressa respectively 
The company also expects to commence a trial  Mercury 3  in mid 2017  in Europe to support filings there  The trial will be a non inferiority trial comparing Roclatan to prescribed fixed dose combination of Ganfort  a combination of the bimatoprost along with timolol   marketed by Allergan   NYSE AGN   in Europe 
Last week  Aerie announced that it has received notification from the FDA about the completion of the initial 60 day review of the NDA for Rhopressa  The FDA determined that the application is sufficiently complete and can undergo a substantive review  Concurrently  the Prescription Drug User Fee Act  PDUFA  goal date for the completion of the FDA s review has been set on Feb 28  2018 
A potential approval and successful commercialization will boost the company s growth prospects in the global ophthalmic market significantly 
Zacks Rank   Key Pick
Aerie currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters  with an average beat of 233 69  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana   Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-05-25,Zacks Investment Research,https://www.investing.com/analysis/aerie's-ophthalmic-candidate-positive-in-registration-trial-200191500,200191500
105850,327365,AGN,Alkermes Gets FDA Nod For Two Month Dose Of Aristada,opinion,Alkermes plc   NASDAQ ALKS   announced that the FDA has approved two month Aristada  aripiprazole lauroxil  extended release injectable suspension for the treatment of schizophrenia  The new two month dose is expected to be available in mid June Alkermes  share price increased 6 1  year to date outperforming the Zacks classified  industry s gain of 1 7  Consequently  Aristada  is now approved in four doses and and three dosing duration options  441 mg  662 mg or 882 mg once monthly  882 mg once every six weeks and 1064 mg once every two months  As a result  Aristada provides a number of options to help clinicians tailor treatment to the individual needs of their patients   The drug was originally approved in Oct 2015 We note Aristada posted sales of  18 million in the first quarter of 2017  up compared with  5 6 million in the first quarter of 2016  Aristada is growing impressively in a long acting injectable  LAI  market  evident from its improvement in the double digits However  in Mar 2017  Allergan plc   NYSE AGN   announced that its supplemental New Drug Application  sNDA  Vraylar has been accepted for review by the FDA  Allergan is looking to get Vraylar s label expanded to include new data  which supports the drug s use as a maintenance treatment Alkermes PLC Price    Zacks Rank and Stocks to ConsiderAlkermes carries a Zacks Rank  3  Hold   Better ranked stocks in the health care sector includes VIVUS  Inc    NASDAQ VVUS   and MEI Pharma  Inc    NASDAQ MEIP    both sporting a Zacks Rank  1  Strong Buy   You can see  VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 30 days  The company posted positive earnings surprises in the trailing four quarters  with an average beat of 233 69  MEI Pharma s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 in the last 30 days  The company posted positive earnings surprises in three of the four preceding quarters  with an average beat of 66 56  3 Stocks to Ride a 588  Revenue ExplosionAt Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ,2017-06-06,Zacks Investment Research,https://www.investing.com/analysis/alkermes-gets-fda-nod-for-two-month-dose-of-aristada-200193800,200193800
105851,327366,AGN,Allergan To Buy Keller Funnel  Boost Plastic Surgery Unit,opinion,Allergan plc   NYSE AGN   announced a deal to acquire privately held medical device company Keller Medical  Inc  which makes Keller Funnel  for an undisclosed amount These novel plastic funnels are used in breast augmentation or reconstruction procedures  They are designed to improve breast implantation and reduce the risks of implant contamination during procedures by minimizing surgeon and patient contact  The acquisition is a strategic fit for Allergan s plastic surgery and regenerative medicine business Allergan s share price is up 8 6  this year so far against the Zacks classified industry s decline of 7  Acquisitions form an integral part of Allergan s expansion strategy  In 2017 so far  through the accretive acquisitions of LifeCell and ZELTIQ  Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting  respectively Last year  Allergan made a string of buyouts  The Tobira Therapeutics acquisition added global rights to Tobira s lead pipeline candidates Cenicriviroc  CVC  and Evogliptin  which are highly differentiated compounds being developed to treat the multi factorial elements of NASH  including inflammation  metabolic syndromes and fibrosis  These reinforce Allergan s commitment to this growing space  Allergan also bought privately held Akarna Therapeutics whose lead product candidate AKN 083  a preclinical stage FXR agonist  is also being evaluated for the treatment of NASH Through the acquisition of clinical stage biotech company  Vitae Allergan boosted its dermatology pipeline  Allergan also bought private clinical stage biotechnology companies  RetroSense Therapeutics and ForSight VISION 5  which strengthened its eye care pipeline  Allergan also acquired Chase Pharmaceuticals Corporation that focuses on the development of treatments for Alzheimer s disease Separately  Allergan and partner Amgen  Inc    NASDAQ AMGN   announced that the FDA s Oncologic Drugs Advisory Committee will review its regulatory application for biosimilar version of Roche Holding  SIX ROG  AG s   OTC RHHBY   cancer drug Avastin on Jul 13  The candidate is under review in the U S  and EU  Other than Avastin  the companies are also developing biosimilar versions of Roche s other cancer drugs Herceptin and Rituxan under a joint Amgen Allergan label Allergan carries a Zacks Rank  3  Hold   You can see A better ranked stock in the pharma sector is Aquinox Pharmaceuticals  Inc    NASDAQ AQXP   with a Zacks Rank  2  Buy  Loss estimates for Aquinox s full year have narrowed by almost 6  in the past 30 days  The average earnings surprise over the past four quarters is 8 50  3 Top Picks to Ride the Hottest Tech Trend Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ,2017-06-07,Zacks Investment Research,"https://www.investing.com/analysis/allergan-to-buy-keller-funnel,-boost-plastic-surgery-unit-200194079",200194079
105852,327367,AGN,5 Reasons Why You Should Invest In AstraZeneca  AZN  In 2017,opinion,"London based pharma giant  AstraZeneca plc   NYSE AZN   has a strong product portfolio and is one of the key players in the global cardiovascular market AstraZeneca carries a Zacks Rank  2  Buy   You can see  Here we discuss five key factors that indicate that the time is ripe to invest in the stock Rising Estimates   Share Price  AstraZeneca s earnings estimates for 2017 went up 2 8  while that for 2018 moved up 4 4  in the past 60 days  Its earnings performance has also been pretty impressive  with the company reporting positive surprises consistently  The average earnings beat over the last four quarters is 142 6  Shares of AstraZeneca have risen 26 7  this year so far  while the Zacks classified industry increased 11 4   This comes after a decline of almost 20  in 2016 New Drugs Going Strong  AstraZeneca s newly launched drugs are contributing to its top line  thereby easing the impact of genericization on legacy products  New drugs like Lynparza  ovarian cancer   Farxiga Forxiga  type II diabetes  Movantik Moventig  opioid induced constipation  and Tagrisso  lung cancer  are off to an encouraging start  AstraZeneca is looking for further label expansions for these drugs Trends of better diagnosis  improved access and favorable patient dynamics should bode well for the company s established products across its portfolios  Meanwhile  the company is working on driving sales of Brilinta  cardiovascular  sales  which has been doing well  Brilinta enjoys a leading position in the U S  branded oral anti platelet market Deep Pipeline and Strategic Deals  AstraZeneca is also working on bolstering its pipeline and is looking at suitable acquisitions  In addition to acquisitions  the company is pursuing co development deals with companies like Nektar Therapeutics   NASDAQ NKTR    Eli Lilly   Company   NYSE LLY    Ionis  Allergan plc   NYSE AGN    Merck  NYSE MRK  and Valeant to boost its pipeline This year  the company expects to launch four new products   Imfinzi durvalumab  multiple cancers  approved in the U S  for urothelial carcinoma   Qtern  saxagliptin Forxiga fixed combination  approved in the U S   EU    Bevespi  already launched  and benralizumab  asthma  under review in the U S  AstraZeneca has a promising and diversified late stage pipeline that includes immuno oncology candidates  Immuno oncology is a therapeutic area  which is presently attracting a lot of interest and represents huge commercial potential  The company s target is to launch at least six new oncology medicines by 2020 with three already launched since 2014 An interesting candidate in the company s immuno oncology pipeline is Imfinzi  durvalumab   It is being evaluated for multiple cancers  either alone or in combination with other regimens   including phase III trials in first line urothelial cancer  non small cell lung cancer  small cell lung cancer and head and neck squamous cell carcinoma among othersOther promising candidates in late stage development or under regulatory review include ZS 9  hyperkalemia   roxadustat  anemia in patients with chronic kidney disease  and AZD3293  Alzheimer s disease  News Rich Year So Far  This year so far has been news rich for AstraZeneca  In May  it received positive CHMP opinion for plaque psoriasis candidate  brodalumab  gained the first approval for Imfinzi  durvalumab  for urothelial carcinoma and announced positive lung cancer data from late stage studies  In April  its EGFR inhibitor Tagrisso s conditional approval was converted to full approval in both the U S  and EU In March  it announced positive Lynpraza data from a phase III study evaluating the drug as a maintenance monotherapy in patients with germline BRCA mutated  gBRCA   platinum sensitive  relapsed ovarian cancer  Later  in the same month  the regulatory application for label expansion for the maintenance indication was also granted priority review by the FDA  In February  AstraZeneca gained FDA approval for Qtern  diabetes  and also presented positive breast cancer data on Lynpraza The company expects a lot of activity on the regulatory and pipeline front through the rest of the year including U S  regulatory decisions for benralizumab and pivotal data for systemic lupus erythematosus candidate anifrolumab and for durvalumab from lung cancer studies If the decisions data are positive  the share price uptick should continue Aggressive Cost Cutting Initiatives  AstraZeneca intends to drive operational efficiency and reduce the impact of genericization on its key products by trimming its cost structure  In 2016  SG A cost declined 9  thanks to efficiency savings in sales and marketing operations as well as a reduction in general administration areas  These actions included a major reduction in the sales and head office structure in U S  marketing  By the end of 2018  these restructuring initiatives are expected to generate net annualized benefits of about  1 1 billion  Streamlining operations  along with its focus on R D  will benefit the company in the long run ConclusionMany key drugs in AstraZeneca s portfolio are facing generic competition in the U S  Its diabetes franchise also facing stiff competition  Nonetheless  we believe that its new drugs  cost cutting initiatives  rapid pipeline progress  and accretive deals acquisitions will keep the stock afloat this year Astrazeneca  LON AZN  PLC Price and Consensus
    Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legalIgnited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-why-you-should-invest-in-astrazeneca-(azn)-in-2017-200196396,200196396
105853,327368,AGN,Top Stock Reports For Oracle  Allergan   Abbott ,opinion,"Friday June 23 2017
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 12 major stocks  including Oracle     Allergan  NYSE AGN      and Abbott    These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Buy rated Oracle shares have outperformed the Zacks Technology Sector year to date  gaining  33 1  vs   15 4   The company s offerings in SaaS and PaaS have gained significant momentum in the past few quarters  which improves the company s competitive position in the red hot cloud space  particularly against salesforce com and Workday  The Zacks analyst likes the company s growing cloud market share and sees the positive momentum in this area as a notable top line growth driver  Moreover  Oracle continues to win new customers in HCM  ERP and CX  However  high investments in IaaS will affect gross margin expansion in the near term  Further  a strong U S  dollar remains a headwind 
 You can 
Shares of Allergan have gained  17 1  year to date  outperforming the Zacks Medical Generic Drugs industry  which has increased  0 3  over the same period  The Zacks analyst likes products like Botox and Linzess as well as new products  which are supporting sales growth  With the closing of the Teva deal  Allergan can now focus on the branded segment and is using the proceeds to buy back shares  pay down debt and pursue additional deals  Biosimilars also represent a significant opportunity  However  Allergan faces generic threats for legacy brands like Namenda IR as well as patent challenges for some of the other products in its branded portfolio  Also new competition for key growth drivers  Restasis and Linzess  is an investor concern 
 You can  
Abbott s shares have outperformed the Zacks Medical sector in the year to date period  the stock is up  28 1  vs   14 3  gain for the sector  on the back of greater appreciation for the company s strategic repositioning through acquisitions divestitures  A case in point is the St  Jude Medical buyout that complements the company cardiovascular devices business  Recently  Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging  All in all  market participants like management s strategic focus on core therapeutic areas  On the flip side  the analyst identifies weakness in the nutrition business in China and sluggish growth in the Venezuelan market as areas of concern 
 You can  
Other noteworthy reports we are featuring today include Adobe     Alexion    and Valero    
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500  

Brian Hamilton
Investment Research Coordinator
Note  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read









Featured Reports

Alexion s blockbuster drug  Soliris  continues to perform while Kanuma lagged expectations  Per the Zacks analyst  the successful development of ALXN1210 will boost growth prospects significantly 


While the covering analyst likes Valero s diversified refinery base and high dividend yield  its rise in expenses following heavy maintenance activities limits upside 


Per the Zacks analyst  Fioptics internet and video subscriber gain is a major positive for Cincinnati Bell  However  loss in local access lines  heavy capital expenses and legal woes raises concerns 


The Zacks analyst thinks CME Group s  NASDAQ CME  focus on expansion of its derivative product lines will continue to drive growth 


Per the covering analyst  Lululemon is capable of driving impressive sales growth by focusing on eCommerce and investing in innovation 

New Upgrades

Per the Zacks analyst  organic growth remained a key strength at M T Bank  as reflected by rising loans and deposits aiding revenue growth  Further  easing of margin pressure is a favorable factor 


With Adobe delivering strong Q2 results  the covering analyst believes that the company s strong position in creative cloud market and continued innovation will continue to drive growth going forward 

New Downgrades

Per the Zacks analyst  John Wiley   Sons  top line is likely to be hurt as it continues to face weak demand for printed books  Evidently  revenues for publishing declined 7  in fiscal 2017 


The covering analyst believes gross margin compression due to rising land and construction costs can keep the housing momentum in check  Lennar s gross margin declined 160 bps year over year in Q2 ",2017-06-23,Zacks Investment Research,"https://www.investing.com/analysis/top-stock-reports-for-oracle,-allergan---abbott-200197260",200197260
105854,327369,AGN,AstraZeneca not only game in town for deal hungry Pfizer,news,"By Pamela Barbaglia and Sophie Sassard LONDON  Reuters    Pfizer  N PFE  appears unlikely to make a fresh bid for AstraZeneca  L AZN  in 12 days time  when an enforced cooling off period ends  and the U S  drugmaker is now weighing other less risky targets 
People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U S  investment bank ahead of Nov  26  when it is allowed to renew its pursuit of AstraZeneca under UK takeover rules 
This includes a close analysis of the benefits of a tax saving deal to buy Dublin based generic drugmaker Actavis  N ACT   which has a market value of around  64 billion against AstraZeneca s  94 billion 
 I am pretty sure that no one at AstraZeneca is ready to agree a friendly deal   said a banker who met with the British company recently and has insights into Pfizer s strategy 
 The hurdles are now getting bigger and bigger  A deal would take longer and would be more expensive  In that context  Actavis is becoming more attractive  although it would not be a great story   he added  explaining Actavis would not offer the same synergies and opportunities in oncology as AstraZeneca 
Pfizer s Chief Executive Ian Read told analysts in October that the company remained interested in lowering its tax bill  despite a U S  clampdown on companies using so called inversion deals to move their tax base overseas 
 We still believe that on a case by case basis there is meaningful value to be had from inversions   Read said 
AstraZeneca Chief Executive Pascal Soriot  however  said last week that the risks of inversion deals had increased markedly since the U S  rules changes  as evidenced by the collapse of AbbVie s  N ABBV   55 billion plan to buy Shire  L SHP  
Many investors agree with that reading 
 I would not put it  the chance of a new Pfizer bid for AstraZeneca  at more than a 20 30 percent probability   said Norbert Janisch  portfolio manager at Raiffeisen Capital Management in Vienna  which is a shareholder in AstraZeneca 
DEAL HUNGRY
AstraZeneca has been buoyed recently by progress with new drugs but its shares  which are trading 25 percent above the level before news of Pfizer s interest emerged in April  still contain a takeover premium 
The political difficulties of staging what would be the biggest ever foreign takeover of a British company also remain considerable  with a general election in May 2015 that the opposition Labour party  which opposed Pfizer s earlier bid  could well win 
It all means Pfizer would  once again  have to try for a friendly deal  and analysts doubt AstraZeneca s board would come to the table for less than 60 pounds a share  against 47 pounds at present 
Pfizer s problem is that the tax advantages of buying AstraZeneca are now considerably less than in May  when its 55 pounds a share offer was rejected 
The U S  group s need for a deal remains  however  given its vulnerability to cheaper generics and its relatively weak line up of experimental medicines  which is spurring Read and his lieutenants to look at other options 
 The truth is that Pfizer has never stopped looking at targets in Europe after the AstraZeneca debacle   said one banker familiar with Pfizer s strategy 

AstraZeneca  meanwhile  plans to set out its stall at a Nov  18 investor day  This will include an update on experimental drugs in the hot research area of cancer immunotherapy  which involves boosting the immune system to fight tumours 
 Additional reporting by Anjuli Davies and Carolyn Cohn  Editing by Ben Hirschler and Mark Potter ",2014-11-14,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-not-only-game-in-town-for-deal-hungry-pfizer-316789,316789
105855,327370,AGN,Allergan  Actavis near deal  may be announced as early as Monday  WSJ,news,"NEW YORK  Reuters    Allergan Inc  N AGN  is near making a friendly deal with Actavis Plc  N ACT   the Wall Street Journal reported on Sunday  citing people familiar with the matter 

The boards of the two companies are expected to meet to review a cash and stock deal  and an agreement could be announced as early as Monday  according to the report 
 Reporting by Caroline Valetkevitch  Editing by Jeffrey Benkoe ",2014-11-16,Reuters,"https://www.investing.com/news/stock-market-news/allergan,-actavis-near-deal;-may-be-announced-as-early-as-monday:-wsj-316951",316951
105856,327371,AGN,Ackman supports Allergan s  66 billion sale to Actavis,news," Reuters    Activist investor William Ackman said on Tuesday he supports the  66 billion deal in which Actavis PLC will buy Allergan Inc and will withdraw his request for an Allergan special shareholder meeting 
Ackman  who had been fighting alongside Valeant Pharmaceuticals International Inc for control of Allergan  had called for the Allergan meeting to vote out board members and force the company to the table to consider their joint offer  The meeting is scheduled for Dec  18 
 We congratulate Actavis and Allergan on their announced transaction  As a result of the deal  we are withdrawing our special meeting request   Ackman said in an e mailed statement 
Ackman s comments come after Actavis said on Monday it would pay  219 per share for Allergan  billions more than Valeant was willing to pay  Ackman  who owns nearly 10 percent of Allergan  had paper gains of more than  2 3 billion based on that price 

CNBC reported earlier that Ackman will meet with executives from Actavis later this week 
 Reporting by Caroline Humer  editing by Gunna Dickson ",2014-11-18,Reuters,https://www.investing.com/news/stock-market-news/ackman-supports-allergan's-$66-billion-sale-to-actavis-317220,317220
105858,327373,AGN,Allergan Continues To Focus On Acquisitions And Branded Unit,opinion,We issued an updated research report on Allergan plc   NYSE AGN   on Jun 23 Acquisitions form an integral part of Allergan s expansion strategy  Allergan is reshaping its portfolio through strategic acquisitions  With the Allergan  Inc  acquisition  the company finds itself among the top 10 pharma companies worldwide based on sales  Last year  Allergan sold its generics business and the Anda distribution business to Teva Pharmaceutical Industries Limited   NYSE TEVA    With the closing of the Teva deal  Allergan has become a  branded biopharmaceutical leader   As a result  it can now focus on the branded segment and is using the proceeds to buy back shares  pay down debt and pursue additional deals In 2017 so far  through the accretive acquisitions of LifeCell and ZELTIQ  Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting  respectively  Allergan made a string of buyouts last year as well Meanwhile  key products like Botox and Linzess and new products like Viberzi and Vraylar backed by strong demand are supporting sales growth Allergan also boasts a strong pipeline with nine product launches planned in 2017  In 2016  Allergan launched over 10 new products  including  Vraylar  Viberzi  Kybella  and Namzaric  This year  Allergan is extending its R D pipeline to adjacent categories like NASH  Parkinson s disease  and gene therapy with many promising phase II III programs in development Biosimilars also represent significant opportunity  Allergan has a collaboration agreement with Amgen  Inc    NASDAQ AMGN   for the worldwide development and commercialization of three oncology antibody biosimilars  which include biosimilars of Roche Holding  SIX ROG  AG s   OTC RHHBY   cancer drugs Herceptin and Avastin While we remain optimistic about the company s growth prospects  Allergan is facing patent challenges for quite a few of its products including Generess Fe  Namenda XR and Asacol Delzicol and Minastrin 24  In 2017  key Namenda franchise sales will continue to erode especially with the expected entry of a generic version of Namenda XR in the fourth quarter of 2017 Meanwhile  competition for key growth drivers  Restasis and Linzess  is an investor concern  Shire s dry eye disease drug Xiidra  launched last year  is posing strong competition for Restasis  Meanwhile  Synergy s Trulance  plecanatide  received FDA approval in Jan 2017 for CIC  which could pose competition to Linzess Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-25,Zacks Investment Research,https://www.investing.com/analysis/allergan-continues-to-focus-on-acquisitions-and-branded-unit-200197508,200197508
105859,327374,AGN,Japanese shares lose steam  Asian shares slip,news,"By Hideyuki Sano TOKYO  Reuters    Japanese shares gave up early gains on Wednesday as investors booked profits after Prime Minister Shinzo Abe delayed a tax hike and said he would call a snap election to seek a fresh mandate for his economic policies 
Asian shares slipped to a three week low as resource shares were hit by fall in oil and other commodity prices and as Chinese shares lost momentum as investors continued to take profits after Monday s launch of the landmark Hong Kong Shanghai trading link 
Japan s Nikkei  N225  erased earlier gains to stand flat by midday  showing little reaction after the Bank of Japan maintained its policy as expected after a surprise easing last month 
 Considering the current economic conditions  postponing the consumption tax would be positive for stocks   Ryota Sakagami  chief strategist at SMBC Nikko Securities  said in report 
Abe s tax hike delay by 18 months is expected to help the world s third biggest economy  which unexpectedly slipped back into a recession in the June September quarter after an earlier sales tax increase clobbered consumption 
 But the ruling party bloc is likely to reduce their seats  Their victory is unlikely to create hopes for big changes  So we do not anticipate the type of boom in Japanese stocks we saw after election in 2005 and 2012   Sakagami added 
Few expect Abe s Liberal Democratic Party and its smaller ally to lose their majority  but financial markets and analysts are now contemplating the possibility that the ruling bloc might fare less well than initially anticipated 
Investors are now looking to what BOJ Governor Haruhiko Kuroda would say about the country s slide into recession and Abe s decision to delay the tax hike   something Kuroda has said is not advisable  Kuroda will hold a news conference at 0630 GMT  1 30 a m  EST  
The BOJ stunned markets last month by expanding its monetary easing program to preempt a slowdown in inflation 
The Japanese yen hit a seven year low  weighed by the BOJ s extremely loose policy and weak economic data 
The dollar rose as high as 117 31 yen  high last seen in 2007  and last stood at 117 27 yen USD JPY  The euro also hit a six year high of 146 81 yen  EUR JPY  
The euro held firm against the dollar at  1 2530  after German analyst and investor sentiment rose unexpectedly in November for the first time in almost a year 
The ZEW index surpassed even the most bullish forecast  raising hopes of an improvement in Europe s biggest economy after it dodged recession in the third quarter 
The upbeat data also helped European shares to close at a seven week high while Wall Street shares inched up as the healthcare sector benefited from the takeover of Allergan Inc  N AGN  by Actavis  N ACT  
The Australian dollar tumbled as the price of iron ore   IO62 CNI SI   Australia s top export earner  slipped to its lowest in five years at  72 10 a metric ton  1 1023 tons  
Later in the day  the U S  Federal Reserve will release the minutes of its last policy meeting  which markets will watch for any clues on when the Fed will start raising rates 
U S  debt yields dipped on Tuesday as benign wholesale inflation figures cemented the view that the Fed can afford to wait for an extended period before raising rates 
The 10 year U S  10 year yield stood at 2 320 percent  US10YT RR  in early Asia  after having dipped about 2 5 basis points on Tuesday 
One major reason inflation is subdued in the United States   and elsewhere   is because of falling oil prices over the last five months  partly on oversupply concerns as U S  shale oil production has increased 
Oil prices were depressed near four year lows after two straight days of falls so far this week as traders looked to whether the OPEC will agree on an output cut at its Nov  27 meeting 

U S  crude futures stood at  74 29 per barrel  near last week s low of  73 25  having fallen more than 31 percent in the last five months 
 Editing by Shri Navaratnam   Kim Coghill ",2014-11-18,Reuters,"https://www.investing.com/news/stock-market-news/japanese-stocks-rise-on-recovery-hopes,-boj-meet-in-focus-317260",317260
105862,327377,AGN,Exclusive  Valeant to drop deal making in near term to cut debt  boost stock ,news,"By Nadia Damouni  Olivia Oran and Rod Nickel  NEW YORK WINNIPEG  Reuters    Valeant Pharmaceuticals International Inc  TO VRX  is abandoning its growth by acquisitions strategy for the time being to try to reduce debt  boost its stock price and one day return to its traditional deal making in a stronger position  people familiar with the matter told Reuters   After spending  19 billion on 40 acquisitions since 2008  the Canadian drugmaker is regrouping after failing last month to acquire Botox maker Allergan Inc  N AGN   they said   The new strategy  targeted for the next two to three quarters  may surprise some investors accustomed to Valeant s usual way of doing business  Speculation about Valeant s next takeover target has driven up shares in generic drugmaker Mylan Inc  O MYL   medical device maker Cooper Companies  N COO  and Teva Pharmaceutical Industries Ltd  TA TEVA    Valeant does not rule out pursuing deals where appropriate  but it is focused on its ability to pay down debt or buy back shares  said spokeswoman Laurie Little    The silver lining that has come out of the Allergan situation is that we have already reported one relatively clean quarter   said Little   By delivering several more clean quarters over the next several months  we will clearly show the strength of our base business    By clean quarter  Little was referring to the absence of one time acquisition costs that frequently appear on Valeant s balance sheet   Valeant has more than  16 3 billion of debt as of September 30 and is rated Ba3 by Moody s  the third level of junk status  Improving its credit rating will help it pay for acquisitions down the road  the sources said  In fending off Valeant s cash and stock bid  Allergan repeatedly questioned the financial strength of its unwanted suitor  In the end  it agreed to a  66 billion buyout by generics maker Actavis Plc   Valeant said last month it would spend up to  2 billion buying back senior notes  shares and other securities   Over the next two to three quarters  Valeant also aims to sell more of its new products  which includes toenail fungus drug Jublia  athlete s foot product Luzu  acne treatment Onexton and a new line of Bausch and Lomb Ultra contact lenses   Valeant has little choice but to put big acquisitions on hold because they have little cash and their stock is  poor currency  after losing Allergan  said Vicki Bryan  analyst at Gimme Credit  an independent research service on corporate bonds  Valeant s pipeline of new products isn t as strong as other companies   and if it spends more on research and marketing  profit margins may narrow  Bryan said    Reactive  strategy  is way more expensive than proactive   she said   Glenn Greenberg  managing director of Brave Warrior Advisors  a Valeant shareholder  said Jublia and B L Ultra together have estimated sales of  1 billion and could contribute profits of  2 50 a share   Valeant s strategy persuaded San Francisco based hedge fund ValueAct Capital to return to Valeant s board in September after a hiatus of several months  ValueAct CEO Jeff Ubben told Reuters that Valeant s  stand alone business plan is exciting  and is the main reason we rejoined the board    Valeant has  been built around quality assets that can grow organically  and a decentralized management style that empowers performance to deliver high levels of profitability   he said  ValueAct owned 5 7 percent of Valeant as of Sept  30   In August  at the height of Valeant s pursuit of Allergan  Ubben questioned whether the Canadian drugmaker could afford a protracted takeover battle   The loss of Allergan after a seven month pursuit was a setback for Chief Executive Mike Pearson  who aims to make Valeant one of the world s top five pharmaceutical companies by the end of 2016  Valeant lost bids for drugmaker Cephalon and ophthalmology drugmaker Ista Pharmaceuticals in recent years   Sources close to Valeant say that the company has been disciplined by not overpaying for acquisitions  Still  some investors who had watched Valeant s market valuation rise from  1 billion in 2008 to more than  48 billion today said much of the company s mystique faded during the protracted takeover battle with Allergan   
Now  Valeant  needs to show that this is a sound business and that their fundamentals are strong   said Alex Arfaei  an analyst at BMO Capital   If you go from one hostile deal to another  you are creating the impression that you re desperate  Valeant certainly has some strong signs of growth and is anything but desperate      Additional reporting by Jessica Toonkel in New York  Editing by Michele Gershberg and John Pickering ",2014-12-09,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-valeant-to-drop-deal-making-in-near-term-to-cut-debt,-boost-stock-319520",319520
105863,327378,AGN,Exclusive  Express Scripts presses for more drug savings with coverage list ,news,"By Deena Beasley  LOS ANGELES  Reuters    Express Scripts  O ESRX   the largest manager of prescription drug plans for U S  employers  is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year   On Monday  Express Scripts said it lined up a cheaper price for AbbVie Inc s  N ABBV  newly approved hepatitis C treatment and  in most cases  will no longer cover Gilead Sciences Inc s  O GILD   rival treatments after trying for nearly a year to win a deeper discount   The move threatens to undermine profits at Gilead  and was viewed by Wall Street as a sign that other major biotechnology players  including Amgen Inc  O AMGN  and Biogen Inc  O BIIB   will face steeper U S  pricing pressure from insurers  Other drugmakers without potentially transformative new products  such as Shire Plc  L SHP   Novo Nordisk  VX NOVN  and Theravance Inc  O THRX   may also be particularly vulnerable  analysts said  Neither Shire  Novo Nordisk nor Theravance responded to requests for comment   Express Scripts will further expand the number of medicines it won t cover for 2016  including treatments for common illnesses such as diabetes  pulmonary hypertension and arthritis  said Chief Medical Officer Dr Steve Miller  in an interview earlier this month  In some cases  Express Scripts could drop coverage for newer specialty medicines in the biotechnology field  he said  The timing on specific drugs will depend on when new competing drugs with similar clinical benefits are approved for the U S  market   Express Scripts first began excluding drugs from its largest national reimbursement list for 2014  with 44 medications  and increased that number to 66 for 2015   The prospect of having their drugs dropped from Express Scripts  biggest  formulary  list of covered medicines has prompted some leading pharmaceutical makers to discount their prices  Miller said   Express Scripts is acting on behalf of clients who need to rein in healthcare costs  and estimates that the move has so far saved such employers more than  1 billion in annual spending  Miller said   Employers  are by necessity asking us to take a more aggressive stance because the affordability of their benefits is really at risk   Miller said   We are going to be opportunistic  in looking for savings in the future   Gilead shares dropped more than 14 percent in Monday trading to  92 90  Shares in Amgen  Biogen and Celgene CELG O fell more than 2 percent   CVS HEALTH  The second largest U S  pharmacy benefits manager  CVS Health Corp  N CVS   has said it will exclude 95 prescription products from its reimbursement list next year  up from 72 in 2014  It expects the practice will save its plan sponsors over  3 5 billion between 2012 and 2015   The drugs most under scrutiny include more expensive   me too  products  in categories where several drugmakers compete for similar patients  Both Novo Nordisk and Sanofi SA  PA SASY  are developing slightly longer lasting insulins   Amgen  AbbVie and Johnson   Johnson  N JNJ   respectively sell Enbrel  Humira and Remicade   all rheumatoid arthritis drugs that work in a similar way  Companies like Teva Pharmaceuticals Industries  N TEVA  and Actavis  N ACT  want to switch patients to more expensive versions of their multiple sclerosis and Alzheimer s drugs  respectively  before the arrival of cheap generic competitors   The effect is already being felt by such Big Pharma players as AstraZeneca Plc  L AZN  and Sanofi  Both companies warned recently that the need to offer U S  price discounts on some of their biggest brand name medicines will hurt 2015 sales   Insurers are pushing back against prices in other categories  including blood thinners and even HIV drugs and multiple sclerosis treatments  where there are multiple options for doctors and patients  observers said    The extent of this becoming a broader problem is tied to whether we get great new drugs for things like asthma   high cholesterol   Alzheimer s and cancer   said Sanford Bernstein analyst Ronny Gal   If there is a limited pool of money and a bunch of new drugs  the pressure on older drugs will increase       DIMINISHING RETURNS  In recent years  the introduction of far cheaper generic versions of medicines like Pfizer Inc s  N PFE  Lipitor to reduce cholesterol and Merck   Co s  N MRK  asthma drug Singulair helped insurers save on reimbursement costs  But that wave of patent expiries has slowed considerably   In the meantime  a new crop of novel  and in some cases  highly effective treatments for cancer and hepatitis C are costing them tens of billions of dollars more to reimburse   The influx of generics  allowed the system to actually see drug price deflation   said Asher Anolic  manager of Fidelity s Select Pharmaceuticals Portfolio   At the same time  others are launching innovative new drugs     Based on those dynamics I get more concerned  Where is the give in the system  It s on the legacy products    Anolic said his Fidelity fund focuses on drugmakers with highly differentiated portfolios of treatments  Its top holdings as of Sept 30 included Actavis  AbbVie  Novartis AG  VX NOVN  and Bristol Myers Squibb Co  N BMY     When you look at the industry as a whole  we will probably see less profitability   said Nils Behnke  a partner at consulting firm Bain   Co   Mid sized companies with a broader portfolio of little products   me too  products   they will have a hard time    Murray Aitken  vice president at healthcare information company IMS Health  N IMS   estimates that 2014 spending on new and innovative brand name drugs will total about  20 billion compared with about  3 billion in 2012   Industry executives say newer health plans  whether purchased by individual consumers or offered through an employer  will further accelerate efforts to limit drug prices because they require patients to pay a higher share of prescription costs   Pharmacy benefits companies like Express Scripts say they will cover an excluded medicine if that specific treatment is deemed medically necessary for a patient  Some groups have expressed concern that patient care might be compromised   The Pharmaceutical Research and Manufacturers of America  a leading drug industry trade group  said such practices hurt patients by limiting access to a range of appropriate medicines and potentially discriminating against certain conditions   But insurers say that the high price of new drugs set by manufacturers has already deterred some patients from following doctor s orders   
 Plan sponsors  because of the rapid rise in cost  are many times having to ask the consumer to pay more  for their medicines  said Express Scripts  Miller   If you can t afford your healthcare  you don t take it      Reporting by Deena Beasley  Editing by Michele Gershberg and John Pickering ",2014-12-23,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-express-scripts-presses-for-more-drug-savings-with-coverage-list-321293,321293
105865,327380,AGN,How the Actavis deal upended Allergan No  2 s CEO ambitions,news,"By Olivia Oran and Nadia Damouni NEW YORK  Reuters    For two decades  Allergan Inc  N AGN  president Doug Ingram labored to transform the Botox maker from a sleepy eye care upstart to a global aesthetics giant  He was just a few months away from getting the top job when a merger deal with Actavis Plc  N ACT  in November thwarted his ambitions  Ingram has now accepted an advisory role to facilitate the merger and will soon be looking for a job outside the combined company  Allergan s derailed succession plans  disclosed by Ingram and other top executives in interviews with Reuters  underscore how corporate mergers can leave even some of the industry s top executives in the cold  To be sure  Ingram has many options  While he is currently focused on helping Allergan and Actavis with their integration  he has already received interest from other healthcare companies as well as private equity firms  he said in an interview  declining to name them    The merger  is bittersweet for me personally  We had a really exciting vision for this company and people were very much behind me   Ingram said   Ingram will get more than  26 million in cash  stock and benefits as a payout for the merger  a regulatory filing shows  His total compensation in 2013 was  3 6 million  Ingram focused on running Allergan s core business over the last year while 61 year old CEO David Pyott  who was preparing for his retirement  served as Allergan s public face and met with investors to defend the company from a hostile bid from Valeant Pharmaceuticals International Inc  TO VRX    Ingram also spearheaded  475 million in cost cuts for calendar 2015  He also helped create the company s European operations and led a landmark free speech lawsuit that challenged U S  policy on drug promotion    He has to be on everybody s dance card if you are looking for a CEO of a substantial  complicated  global company   Pyott said about Ingram   Here is a person that was very ready to take over   A serial marathon runner known for sending out e mails at 3 a m   Ingram is a sociable executive who keeps a guitar in his office and likes to jam with his colleagues  often to the tune of Led Zeppelin s  Stairway to Heaven   Ingram s status as a key Allergan insider  pivotal to the success of the  66 billion deal with Actavis  was reaffirmed just last week  in a one on one dinner with Actavis CEO Brent Saunders  Saunders had flown to California for a three day round of meetings with Allergan  Included in his agenda was meeting Ingram  who picked up Saunders from his hotel in his white Tesla and drove to steak and seafood restaurant Mastro s in Orange County to discuss integration strategy  Ingram joined Allergan in 1996 as its chief litigation counsel after spending six years as a corporate lawyer   He quickly rose the ranks  yet despite his internal success  Ingram is little known to the investor community   
 Doug has been a vital part of the company s strategy and success   said Matthew Maletta  Allergan s associate general counsel who has worked with Ingram since 2001   I have been a stockholder in Allergan forever and I would buy more if Doug was getting the CEO job  ",2015-02-03,Reuters,https://www.investing.com/news/stock-market-news/how-the-actavis-deal-upended-allergan-no.-2's-ceo-ambitions-326372,326372
105871,327386,AGN,AstraZeneca to buy Actavis lung drugs as earnings fall short,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca  L AZN  said on Thursday it would buy Actavis   N ACT  branded respiratory drug business in the United States and Canada for an initial  600 million as it reported disappointing fourth quarter earnings  AstraZeneca  which is seeking such deals to drive growth  will also pay another  100 million after Actavis agreed to changes in ongoing collaborations between the two firms  Britain s second biggest drugmaker said 2015 sales would decline by a mid single digit percent at constant exchange rates  But adjusted or  core  earnings per share  EPS  are forecast to increase by a low single digit percent this year  due to lower spending and plans to find partners on certain projects   We ll behave as a biotech company would when it comes to products that are not core   Chief Executive Pascal Soriot told reporters  citing a recent Alzheimer s deal with Eli Lilly  N LLY  as a model for future cost sharing   The weak quarterly results knocked the shares back 1 9 percent by 1110 GMT  6 10 a m  EST   Citi analyst Andrew Baum said AstraZeneca appeared to have  kitchen sinked  the quarter  or taken a deliberate hit to earnings by bringing forward some drug development costs  Deutsche s Mark Clark said this should help secure 2015 profits  The group  which fended off a  118 billion bid by Pfizer  N PFE  last year  saw sales in the fourth quarter fall 2 percent to  6 68 billion  generating core earnings down 38 percent at 76 cents a share  Industry analysts had on average forecast sales of  6 79 billion and earnings of 82 cents  according to Thomson Reuters  Buying the Actavis respiratory drugs builds on AstraZeneca s acquisition of Almirall s  MC ALM  lung drugs last July and gives it global rights to inhaled medicines containing aclidinium  which helps open airways  Actavis had owned North American rights under an earlier agreement with Almirall  Respiratory is a key therapeutic area for AstraZeneca  which has predicted a 75 percent jump in annual sales to  45 billion by 2023   We are on track to return to growth by 2017 and are well positioned to deliver our long term goals   Soriot said  AstraZeneca s promising cancer drugs have won over many investors but it faces near term profit pressure from loss of exclusivity on older drugs  with the arrival of generic copies of heartburn and ulcer medicine Nexium in the United States a big challenge in 2015   
After reporting core 2014 EPS of  4 28  Soriot and his team have good reason to ensure earnings hold up this year  since management incentives only vest fully if earnings remain at or above  4 20 ",2015-02-05,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-to-buy-actavis-lung-drugs-as-earnings-fall-short-326676,326676
105875,327390,AGN,Allergan  AGN  Beats Q1 Earnings Estimates  Ups 2017 View ,opinion,"Allergan plc s   NYSE AGN   first quarter 2017 earnings came in at  3 35 per share  beating the Zacks Consensus Estimate of  3 32 by 0 9   Earnings rose 12  year over year  Revenues came in at  3 57 billion  up 5 1  from the year ago period  and beat the Zacks Consensus Estimate of  3 53 billion by 1 2  First quarter revenues gained from the addition of two months of revenues from the LifeCell acquisition  which closed in Jan 2017 While key products like Botox  Lo Loestrin and Linzess and new products like Vraylar and Viberzi did well in the quarter  established products like Namenda IR XR  Asacol HD and Minastrin 24 witnessed declining sales due to loss of exclusivity Meanwhile  sales were slightly hurt by change in U S  wholesale buying patterns and normal seasonality in the first quarterAdjusted operating income declined 7  in the quarter due to higher operating expenses Quarterly DetailsThe company reports revenues under three segments   U S  General Medicine  U S  Specialized Therapeutics and International U S  Specialized Therapeutics  net revenues increased 14  to  1 48 billion driven by strong growth in Facial Aesthetics  Botox Therapeutic and the addition of Alloderm  Products like Botox  cosmetic  and Restasis raked in sales of  183 8 million  up 11   and  308 8 million  up 3    respectively  Botox Therapeutic revenues were  308 8 million  up 13   In addition  Juv derm Collection of fillers rose 17   Kybella rose 34  and Ozurdex sales increased 16   which contributed to the upside U S  General Medicine net revenues declined 7  to  1 35 billion in the reported quarter with sales declining in four out of five sub segments   Central Nervous System  Diversified Brands  Women s Health  and the Gastrointestinal franchise  Anti Infectives sales rose 8 2  to  55 7 million Established products like Linzess and Lo Loestrin as well as new products like Viberzi and Vraylar did well in the quarter  Linzess  sales rose 8  in the quarter to  147 6 million  driven by strong demand and continued OTC conversion  which offset the negative impact of trade buying patterns However  lower Namenda IR and XR sales hurt the performance of the CNS franchise  Namenda IR sales plunged 90 2  in the quarter  On the other hand  Namenda XR sales declined 30  to  122 0 million in the quarter due to lower demand  unfavorable trade buying patterns and shift of promotional efforts to Namzaric Namzaric  a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  23 6 million compared with  19 5 million in the previous quarter  Asacol Delzicol sales declined 46  due to a reduction in demand for Ascaol HD  following the launch of an authorized generic in Aug 2016 as well as lower demand for Delzicol In the Women s Health segment  Minastrin 24 revenues declined 48  to  41 1 million in the quarter due to loss of exclusivity in Mar 2017 The International segment recorded net revenues of  737 3 million  up 10  from the year ago period driven by growth in Facial Aesthetics 2017 Outlook UpThe company raised its previously issued earnings and sales guidance for 2017 to reflect contribution from the ZELTIQ Aesthetics  which Allergan agreed to buy in February this year Allergan expects total revenue in the range of  15 8 billion to  16 0 billion for 2017 compared with  15 5 billion to  15 8 billion previously  Currency headwinds are expected to hurt revenues by  100 million Adjusted earnings are expected in the range of  15 85  16 35 compared with  15 80  16 30 per share previously The company expects stable Restasis revenues  while Namenda franchise sales will continue to erode in 2017  especially with the expected entry of a generic version of Namenda XR in the fourth quarter of 2017 Adjusted gross margins are expected between 86  and 87   R D expenses are expected to be approximately  1 6 billion compared with  1 45 billion to  1 55 billion expected previously  SG A spend is expected between  4 45 and  4 55 billion compared with  4 3 billion and  4 4 billion previously Our TakeIn a seasonally soft first quarter  Allergan did fairly well in beating estimates for both earnings and sales  Meanwhile  the company raised its 2017 outlook  driving shares up around 1 3  in pre market trading  In fact  Allergan s share price is up 14 7  this year so far against the Zacks classified industry s decline of 2 1  Allergan is reshaping its portfolio through strategic acquisitions  The drugmaker sold its generics and Anda distribution business to Teva Pharmaceutical Industries Limited   NYSE TEVA   in Aug and Oct 2016  respectively With the closing of the Teva deal  Allergan has become a  branded biopharmaceutical leader   As a result  it can now focus on the branded segment and is using the proceeds to buy back shares  pay down debt and pursue additional deals  It also boasts a strong pipeline with nine product launches planned in 2017 We are also encouraged by Allergan s focus on building its branded and biosimilars pipeline  Allergan has a collaboration agreement with Amgen  Inc    NASDAQ AMGN   for the worldwide development and commercialization of three oncology antibody biosimilars  which include biosimilars of Roche Holding  SIX ROG  AG s   OTC RHHBY   cancer drugs Herceptin and Avastin Allergan PLC  Price  Consensus and EPS Surprise
    Allergan carries a Zacks Rank  3  Hold   You can see  
Zacks  Best Private Investment Ideas                                                                                                                                                                                                                                                            While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors",2017-05-08,Zacks Investment Research,"https://www.investing.com/analysis/allergan-(agn)-beats-q1-earnings-estimates,-ups-2017-view-200188071",200188071
105877,327392,AGN,Impax  IPXL  Q1 Earnings Miss  Stock Up On Cost Savings Plan ,opinion,Impax Laboratories Inc     NASDAQ IPXL   posted first quarter 2017 adjusted earnings of 11 cents per share  missing the Zacks Consensus Estimate of 12 cents  Earnings were down 74 4  from 43 cents in the year ago period due to lower revenues and higher costs  Total revenue decreased 18 2  year over year to  184 4 million due to a decline in Generic division sales Moreover  revenues were below the Zacks Consensus Estimate of  190 7 million in the reported quarter  However  despite the miss  Impax s share price increased more than 16 5  as it announced a restructuring plan that raised its annual cost savings target  In fact  year to date  Impax shares are up 24 9   while the Zacks classified  industry declined 4 9  Cost Savings PlanIn its effort to save costs  Impax has initiated several processes to improve efficiencies and margins  and focus on growth opportunities  The company has consolidated its generics R D and manufacturing and packing operation in the U S  to its Hayward  CA facility  Also  the company closed its manufacturing and R D site at Middlesex  NJ As part of the strategic restructuring  the company has already ceased manufacturing in Taiwan and a decision on the sale or closure of the unit is yet to be taken The company is also modifying its generic portfolio so as to eliminate low value products and streamline operations The company expects the above actions to save annualized costs to the tune of  85 million  All these initiatives are projected to save a total of  130 million by the end of 2019  However  the company expects a one time charge of  65 million to fully achieve its cost saving goals Quarter in DetailDuring the reported quarter  Impax Generic division revenues declined 21 1  from the year ago quarter to  134 1 million  The decline in revenues was due to decreased sales of Voltaren Gel  diclofenac gel   metaxalone  fenofibrate and mixed amphetamine salts ER as a result of increased competition and pricing pressure  However  the decline was partially offset by increased sales of epinephrine auto injector  oxymorphone ER and products acquired from Teva Pharmaceuticals Industries Ltd    NYSE TEVA   and affiliates of Allergan plc   NYSE AGN   However  the company s generic business showed improved margins The Impax Specialty Pharma division recorded revenues of  50 3 million  down 9 3  year over year  largely due to lower sales of Zomig and the anthelmintic products franchise Adjusted research and development  R D  expenses grew 16 6  to  21 8 million in the reported quarter Adjusted selling  general and administrative expenses  SG A  increased 9 2  to  47 5 million Sanofi   NYSE SNY   has filed a suit for patent infringement against Impax s abbreviated new drug application  ANDA  for the generic version of the former s multiple sclerosis drug  Aubagio Also  the company reduced its outstanding debt and is focused on saving costs 2017 OutlookThe company expects its full year adjusted earnings to be in the range of 55 cents to 70 cents per share The company expects adjusted gross margin in the range of 47  to 49  Adjusted research and development expenses  including patent litigation expenses  across the generic and brand divisions are forecast to be in the range of  90 million to  95 million Adjusted selling  general and administrative expenses are expected to be in the range of  190 million to  195 million Our TakeDuring the first quarter  some of the company s generic products faced aggressive competition and pricing pressure  which impacted its revenues and profitability  The headwinds in the generic segment are likely to continue through 2017  However  we are positive on its cost cutting initiatives Impax Laboratories  Inc  Price  Consensus and EPS Surprise   Zacks Rank Impax currently carries a Zacks Rank  3  Hold   You can see  The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-05-10,Zacks Investment Research,"https://www.investing.com/analysis/impax-(ipxl)-q1-earnings-miss,-stock-up-on-cost-savings-plan-200188598",200188598
105878,327393,AGN,Teva  TEVA  Q1 Earnings In Line  Sales Lag As Copaxone Falls,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   reported first quarter 2017 earnings of  1 03 per share  including equity compensation expenses   which was in line with the Zacks Consensus Estimate  The year ago adjusted earnings were  1 18 per share Revenues of  5 63 billion missed the Zacks Consensus Estimate of  5 80 billion by 3   Sales  however  increased 17  year over year  up 22  excluding impact of currency   mainly due to the inclusion of revenues of Allergan plc s   NYSE AGN   generics segment  Actavis Generics  which was acquired in Aug 2016  While sales in the Generics segment rose  the same declined in the Specialty unit The generic drug maker also acquired Allegan s U S  generic distribution business Anda  Inc  in Oct 2016 Segment DiscussionBeginning in the fourth quarter of 2016  Teva revised its segment structure following the Actavis acquisition  The Generics segment now includes revenues from the OTC business Generic Medicines segment revenues rose 24  to  3 06 billion  mainly due to the inclusion of revenues from the Actavis generics business Revenues from the U S  generics business rose 41  to  1 4 billion due to the inclusion of revenues from the generic business of Actavis European generic revenues were  988 million  up 25   31  in local currency  from the year ago period  This was due to the inclusion of revenues from the generic business of Actavis Rest of the world  ROW  generic revenues were flat at  689 million in the quarter  On a local currency basis  sales rose 27  boosted by Teva s new Japanese business venture with Takeda  which began operations in April last year and the inclusion of revenues from Actavis API revenues were flat at  197 million  OTC revenues declined 10  to  264 million  up 25  in local currency terms  At the call  the company said that the U S  generic industry is facing challenges owing to an increase in generic drug approvals by the FDA resulting in competitive pressure and ongoing consolidation of key customers  The company informed that net price erosion in the U S  generics business was 7  in the quarter Specialty Medicines revenues declined 6  from the year ago period to  2 02 billion due to lower sales of its central nervous system  CNS  and respiratory products Among Teva s various therapeutic areas  CNS sales declined 14  to  1 14 billion due to lower sales of multiple sclerosis drug Copaxone  Teva s lead branded product Sales of respiratory products declined 17  to  304 million  oncology product sales rose 1  to  270 million  and women s health business recorded a 13  increase in revenues to  124 million  Other specialty revenues rose 116  to  184 million Worldwide revenues of Copaxone declined 4  to  970 million  Sales in the U S  declined 5  to  782 million as the 7 9  price increase taken in January was offset by lower volumes of the 20 mg formulation  which has started facing generic competition  In Jun 2015  Novartis AG s   NYSE NVS   generic arm  Sandoz launched Glatopa  a once daily generic version of 20 mg formulation of Copaxone Ex U S  sales of Copaxone rose 2  to  188 million due to higher volumes The 40 mg thrice weekly  3TW   three times a week  formulation of Copaxone accounted for 85  of total Copaxone scrips in the U S  at the end of the reported quarter  higher than 84  in the previous quarter  We note that Teva is facing patent challenges for the 40 mg formulation Companies like Mylan N V    NASDAQ MYL   and Momenta Pharmaceuticals are looking to get approval for their generic versions of the 40 mg thrice weekly formulation of Copaxone  In late January  Teva suffered a major setback with the U S  District Court for the District of Delaware invalidating four of the five Orange Book patents protecting Copaxone 40 mg  Teva intends to appeal against the decision  However  generic versions of the 40 mg formulation have not been launched yet  The FDA approval of Momenta s generic version of Copaxone has been delayed owing to manufacturing issues Among other products  Azilect sales declined 47  to  60 million as a generic version of the drug was launched in the U S   in January this year Nuvigil plunged 83  to  17 million due to loss of exclusivity  ProAir declined 30  to  121 million  Treanda and Bendeka rose 1  to  157 million and QVAR declined 27  to  98 million The Other segment  distribution and other activities  recorded revenues of  552 million  up 176   The segment mainly gained from the inclusion of distribution revenues from Anda Profits DeclineAdjusted gross margin contracted 590 basis points  bps  to 56 8  in the quarter due to the addition of the low margin Anda distribution business  Gross margin declined in both the Specialty and Generics segments  Research   development expenses increased 17 5  from the year ago period to  457 million  Selling and marketing  S M  expenditure was up 10 5  from the year ago level to  907 million  Adjusted operating margin  excluding equity compensation expense  declined 290 bps in the quarter to 28 8  Maintains 2017 OutlookTeva maintained its 2017 sales and earnings guidance issued previously  Teva expects revenues in the range of  23 8  24 5 billion and earnings in the band of  4 90  5 30 per share in 2017 Teva expects continued sales erosion for Copaxone in 2017 due to increased competition  Challenges in the U S Generics market and greater instability in the Venezuela market will also put pressure on the top line Our TakeTeva s first quarter earnings and sales were soft and it reiterated its 2017 guidance Once again  sales and profits in the first quarter were driven by inorganic growth related mostly to the Actavis acquisition and the joint venture with Takeda in Japan  The core business fails to witness any real growth as the U S  generics industry continues to face significant competitive and pricing pressure Encouragingly  Teva said it expects to realize cost savings of approximately  1 5 billion by the end of 2017  an increase of  200 million from previous expectations  It paid down debt worth  1 2 billion during the quarter from  35 8 billion at year end 2016 to  34 6 billion at the end of the first quarter Meanwhile  the company also said it will sell certain non core assets  including the global women s health business and the European oncology and pain divisions to cut debt  Shares rose more than 2  on Thursday  However  Teva s shares have lost 11 7  so far this year compared with the Zacks classified industry s decline of 4 9  Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline  We are encouraged by the recent approval and launch of Austedo for the treatment of Huntington s disease However  headwinds remain in the form of generic competition for Copaxone  new competition for branded products  generic pricing and competitive pressure  a higher cost base and debt level and the sudden departure of its chief executive officer  CEO    Teva continues to search for a permanent CEO  which remains the company s  highest priority  Teva Pharmaceutical Industries Limited Price  Consensus and EPS Surprise
    Teva carries a Zacks Rank  3  Hold   You can see  Sell These Stocks  Now  Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-12,Zacks Investment Research,"https://www.investing.com/analysis/teva-(teva)-q1-earnings-in-line,-sales-lag-as-copaxone-falls-200188834",200188834
105880,327395,AGN,Pharma Stock Roundup  Mylan  Teva Q1 Earnings  Roche Drug Misses In Pivotal Study,opinion,"This week  companies like Mylan   NASDAQ MYL    Allergan  NYSE AGN  and Teva   NYSE TEVA   reported earnings results  The spotlight also remained on Roche   OTC RHHBY   which saw its immuno oncology drug fail in a pivotal study   Recap of the Week s Most Important StoriesA Look at Earnings Results  Mylan  Allergan and Teva all reported first quarter results this week  While Mylan topped earnings estimates  it missed on sales with EpiPen being impacted by increased competition and the presence of a lower priced authorized generic   Read more     Teva s sales also fell short of expectations  Read more     The company continues its search for a permanent CEO and has decided to divest its global Women s Health business as well as the Oncology and Pain business in Europe  Teva expects to generate  1 billion from the sale of these businesses as well as additional assets  Meanwhile  Allergan delivered a  beat and raise  quarter  Read more    Setback for Roche as Tecentriq Fails in Pivotal Study  Swiss pharma giant  Roche  was hit by results from a pivotal study  IMvigor211  on its immuno oncology drug  Tecentriq  a PD L1 inhibitor  Tecentriq failed to meet the primary endpoint of overall survival  OS  in the study conducted in second line bladder cancer patients  Tecentriq had gained accelerated FDA approval for this indication based on duration of response and tumor response rate and IMvigor211 was being conducted to serve as a confirmatory study to support full approval  With results falling short  the drug s conditional approval for this indication could be at stake though Tecentriq also gained accelerated approval for the first line patient population Meanwhile  other checkpoint inhibitors that gained accelerated approval for this indication based on duration of response will also feel the heat until confirmatory data is out  In this regard  we note that Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  met the primary endpoint of OS in a phase III study    the data has been submitted for FDA review with a response from the agency expected by Jun 14  2017 So far in 2017  Roche has outperformed the Zacks categorized  industry with shares gaining 16 6  while the industry is up 7 7   Roche is a Zacks Rank  3  Hold  stock    you can see  Label Expansion for Merck s Keytruda  Merck got a boost with the FDA granting accelerated approval to Keytruda for use in combination with Alimta  pemetrexed  and carboplatin  pem carbo   a commonly used chemo regimen  for the first line treatment of metastatic nonsquamous non small cell lung cancer  NSCLC   irrespective of PD L1 expression Novartis  Kisqali Co Pack Gets FDA Nod  Swiss drugmaker Novartis gained FDA approval for a combination pack of two of its breast cancer drugs    the company said that the Kisqali Femara Co Pack can be used for the treatment of HR  HER2  advanced or metastatic breast cancer in postmenopausal women  The convenience of obtaining a full 28 day cycle of the two medicines in one package with a single prescription and co pay could well provide Novartis with a convenience edge  The company said that the pack is priced at the same cost as Kisqali alone  Kisqali is among Novartis  most recent product launches Another Approval for Pfizer Merck KGaA s Bavencio  The FDA granted accelerated approval to Pfizer   NYSE PFE   and Merck KGaA s immunotherapy drug  Bavencio  for a second indication  The drug has been approved for urothelial carcinoma  an aggressive disease with a high rate of recurrence  Bavencio was approved earlier this year for metastatic Merkel cell carcinoma  mMCC   a rare and aggressive skin cancer Pfizer Boosts Gene Therapy Portfolio with Sangamo Deal  In an attempt to boost its rare diseases and gene therapy pipeline  Pfizer has entered into an exclusive  worldwide collaboration and license agreement with Sangamo for the development and commercialization of gene therapy programs for hemophilia A  The deal covers SB 525  one of Sangamo s four lead pipeline candidates  which is expected to enter the clinic this quarter  The agreement under which Pfizer will pool its expertise in rare disease  gene therapy  and hemophilia with Sangamo s deep knowledge in genomic therapies will see Sangamo getting an upfront payment of  70 million  Sangamo could get milestone payments of up to  475 million  including up to  300 million related to SB 525 and up to  175 million for additional hemophilia A gene therapy candidates that may be developed under the collaboration  Tiered double digit royalties on net sales also form a part of the deal This is not the first time that Pfizer has signed a gene therapy focused deal  Last year  the company had acquired Bamboo Therapeutics  a privately held biotech company focused on developing gene therapies for the treatment of patients with certain rare diseases AstraZeneca Provides Data on Imfinzi   Asthma Drug  AstraZeneca s   NYSE AZN   investigational asthma drug  tralokinumab  failed to meet the primary endpoint of a significant reduction in the annual asthma exacerbation rate  AAER  in the overall population of severe  uncontrolled asthma patients  in the first of two pivotal studies The company  however  noted that a clinically relevant reduction in AAER was observed in a sub population of patients with an elevated biomarker associated with increased IL 13 activity  This sub group of patients will now be the focus for the second ongoing pivotal study  Results from the second study are expected in the second half of the year Meanwhile  the company said that Imfinzi met a primary endpoint in a study being conducted in patients with locally advanced  unresectable NSCLC  The planned interim analysis also showed that Imfinzi has a favorable benefit risk profile Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index was down slightly  0 40   over the last four trading sessions  AstraZeneca was up 2 2  while Lilly s shares slipped 2 8   Over the last six months  AstraZeneca was up 11 3  while Bristol Myers was down 2 2   See the last pharma stock roundup here    What s Next in the Pharma World Watch out for an update from Johnson   Johnson   NYSE JNJ   regarding its Pharmaceutical businesses next week Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-12,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-mylan,-teva-q1-earnings,-roche-drug-misses-in-pivotal-study-200188793",200188793
105881,327396,AGN,Teva  TEVA  Launches Glumetza Generic  Inks Deal With Otsuka,opinion,Teva Pharmaceutical Industries Ltd   NYSE TEVA   announced the launch of a generic version of Valeant Pharmaceuticals International  Inc  s   NYSE VRX   diabetes drug  Glumetza  in the U S  The drug will be available in 500 mg and 1000 mg tablets Teva s shares have underperformed the Zacks classified  industry so far this year  Shares of the company lost 10 9   while the industry registered a decrease of 4 1  As per IMS data  Glumetza recorded sales of  1 03 billion in one year ended Mar 2017  However  Lupin Pharmaceuticals Inc   the U S  subsidiary of Indian pharma major   Lupin Limited   has been marketing a generic version of Glumetza since Feb 2016 We remind investors that Teva is strengthening its generic business through acquisitions and developing generics of complex  high quality products  With the acquisition of Allergan plc s   NYSE AGN   generic business   Actavis Generics   last year  Teva has the largest portfolio of FDA approved generic products in the market Otsuka AgreementIn a separate press release  Teva declared entering into an agreement with Japan based global healthcare company  Otsuka Pharmaceutical  to exclusively develop and commercialize Teva s investigational drug candidate   fremanezumab   in Japan  The candidate is an anti calcitonin gene related peptide  CGRP  subcutaneous injection being developed for the prevention of episodic and chronic migraine Phase IIb global studies conducted by Teva showed that fremanezumab significantly reduced the number of monthly cumulative headache hours for chronic migraine and the number of migraine days for episodic migraine compared to baseline Otsuka will pay Teva an upfront payment of  50 million  The pharmaceutical company will further pay Teva on reaching various milestones of filing and regulatory approvals in Japan  and achieving specified revenue targets  Otsuka will be responsible in conducting and funding future clinical trials of fremanezumab in Japan Notably  Eli Lilly and Company   NYSE LLY   had recently announced positive data from phase III studies of its anti CGRP candidate  galcanezumab  for the same indications and is expected to submit a Biologics License Application  BLA  to the FDA in the second half of 2017 Zacks RankTeva currently carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-05-15,Zacks Investment Research,"https://www.investing.com/analysis/teva-(teva)-launches-glumetza-generic,-inks-deal-with-otsuka-200189486",200189486
105882,327397,AGN,Aerie s  AERI  Rhopressa NDA Sufficient For FDA Review,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced that it has received notification from the FDA about the completion of the initial 60 day review of the new drug application  NDA  for Rhopressa  The FDA determined that the application is sufficiently complete and can undergo a substantive review  Concurrently  the Prescription Drug User Fee Act  PDUFA  goal date for the completion of the FDA s review has been set on Feb 28  2018 

We note that Aerie has outperformed the Zacks classified  industry in the last 12 months  In fact  the stock rallied 191 4  during this period  compared with the industry s 17 2  gain 
The acceptance indicates that the FDA has not identified any potential review issues  The FDA is currently planning to hold an advisory committee 
We note that Rhopressa is Aerie s lead candidate  Rhopressa is a once daily formulation for intraocular pressure  IOP  in patients suffering from open angle glaucoma and ocular hypertension  Aerie filed a NDA for the drug in the U S  in Sep 2016  However  in Oct 2016  the company withdrew the NDA due to the failure of a third party manufacturing facility not ready for pre approval inspection  The company resubmitted its NDA in Feb 2017 
Hence  a potential approval and successful commercialization will boost the company s growth prospects in the global ophthalmic market significantly 
Currently  Rhopressa is being evaluated in two phase III registration studies   the Rocket 4 study  six month data expected in the second quarter of 2017   designed to gain adequate safety data for regulatory filings in EU and the Rocket 3 study  a 12 month  safety only study for regulatory filings in Canada  Aerie expects to submit regulatory application for Rhopressa in the EU in the second half of 2017 
Apart from Rhopressa  Aerie is evaluating Roclatan  a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  The company expects top line 90 day efficacy and safety data from the second phase III clinical trial  Mercury 2  for Roclatan 0 02  0 005   in the second quarter of 2017  Data from Mercury 1 is expected in the third quarter of 2017  If Mercury 1 and Mercury 2 are successful  the NDA for Roclatan is expected to be filed in late 2017 or early 2018 
The company also expects to commence a trial  Mercury 3  in mid 2017  in Europe to support filings there  The trial will be a non inferiority trial comparing Roclatan to prescribed fixed dose combination of Ganfort  a combination of the bimatoprost along with timolol   marketed by Allergan   NYSE AGN   in Europe 
Zacks Rank   Key Pick
Aerie currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the last 60 days  The company posted positive earnings surprises in all of the four trailing quarters  with an average beat of 233 69  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-16,Zacks Investment Research,https://www.investing.com/analysis/aerie's-(aeri)-rhopressa-nda-sufficient-for-fda-review-200189578,200189578
105883,327398,AGN,Editas Medicine Shares Tumble Down On Poor Q1 Earning Results,opinion,"Editas Medicine Inc  NASDAQ EDIT 
Editas Medicine  Inc   EDIT   a genome editing company yesterday reported their first quarter 2017 financial results  The company reported a first quarter loss of  31 1 million 
EDIT reported first quarter adjusted earnings of a loss of  0 85  which fell short of analyst expectations of a loss of  0 62 per share  EDIT reported first quarter revenues of  682 000 
Editas Medicine  Inc  CEO s Comments

 We made outstanding progress this quarter building our business for the long term  including forming a strategic alliance with Allergan  NYSE AGN  in ocular diseases  cementing our unmatched intellectual property position with a favorable USPTO decision  and doubling our cash runway   said Katrine Bosley  President and Chief Executive Officer of Editas Medicine    These achievements represent significant strides forward in positioning Editas Medicine to execute our vision to build a company that pioneers a broad new category of genomic medicines   

EDIT Technical Analysis

Editas Medicine Chart
EDIT opened trading yesterday at  20 02 which was up from the previous day s trading close of  19 29  EDIT closed trading yesterday at  20 01 and crashed down after market to  18 88  equivalent to a 6  decrease from the closing price 
Taking a look at the daily chart we can see the last time EDIT traded below these levels we have to go back to May 11th when it traded at  18 51  It s higher priced than the usual penny stocks that I trade but there could still be plenty of opportunity for a trade here 
Taking a closer look at the daily chart we can see that before the spike down EDIT had already been in an overall downward trend dating back to February 21st when it traded at  27 27  EDIT has a float of 20 59 million shares and traded below the normal daily trading volume on Monday 
For trading purposes  I would like to see EDIT open trading on Tuesday below  19 25 and if it does I would be looking to take a short position at the bell  My  would be  0 20 from my entry position fearing anything more than that and the stock would start to fill in the gap down 
Company Profile
Editas Medicine  Inc  operates as a genome editing company  It focuses on treating patients with genetically defined diseases by correcting their disease causing genes  It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments 
Editas Medicine  Inc  has a collaboration and license agreement with Juno Therapeutics  Inc  for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors  and collaboration  option  and license agreement with Adverum Biotechnologies  Inc  to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases 
The company was formerly known as Gengine  Inc  and changed its name to Editas Medicine Inc  in November 2013  Editas Medicine  Inc  was founded in 2013 and is based in Cambridge  Massachusetts ",2017-05-16,Warrior Trading,"https://www.investing.com/analysis/editas-medicine,-inc.-$edit-stock-shares-tumble-down-on-poor-q1-earn-200189428",200189428
105884,327399,AGN,Cardiome  CRME  Q1 Loss Wider Than Expected  Sales Miss,opinion,Cardiome Pharma Corp    NASDAQ CRME   reported loss of 20 cents per share in first quarter of 2017  Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year ago loss of 9 cents  The wider loss can primarily be attributed to a decrease in revenues and an increase in selling  general and administration expenses in the quarter   So far this year  Cardiome s shares have significantly outperformed Zacks classified  industry  The company s shares have gained 23 9  while the industry registered an increase of 8 1  Quarterly revenues plunged 26 8  year over year to  5 2 million  Reported revenues also missed the Zacks Consensus Estimate of  7 million  The decrease in revenues was due to the timing of distributor sales  In the year ago quarter  the company recorded revenues of  1 7 million from an annual order to a distributor Quarter in DetailNet revenue for the quarter included product and royalty revenues of  5 2 million  down 26   and licensing and other fees of  0 05 million  down 2 1   Cardiome s selling  general and administrative  SG A  expenses were up 30 2  to  8 2 million  This was due to expansion of the company s direct sales force in Europe related to the launch of Xydalba and the initiation of a Canadian sales force In the first quarter of 2017  the company reported gross margin of 68 5  compared with 79 9  a year ago  The drop in gross margin resulted from customer mix  as a significant portion of the company s sales in the first quarter was through distributor lower margins Moreover  during the same period the company launched Xydalba in France  The drug is already approved in the EU for the treatment of acute bacterial skin and skin structure infections  ABSSSI  in adults  The company licensed Xydalba from Allergan plc   NYSE AGN   in the second quarter of 2016 to commercialize it in U S  and the rest of the world 2017 GuidanceThe company expects revenues in the range of  28  30 million in 2017  The company anticipates a one year dip in Aggrastat revenues due to global inventory management issues in Middle East  Aggrastat is indicated for use in patients with acute coronary syndrome  which are commercially available in markets outside the U S Cardiome Pharma Corporation Price  Consensus and EPS Surprise    Zacks Rank   Key PicksCardiome currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Aeglea BioTherapeutics   NASDAQ AGLE   and VIVUS  Inc    NASDAQ VVUS    While Aeglea carries a Zacks Rank  2  Buy   VIVUS sports a Zacks Rank  1  Strong Buy   You can see  Aeglea s loss per share estimates narrowed from  3 64 to  2 48 for 2017  over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20 75  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-16,Zacks Investment Research,"https://www.investing.com/analysis/cardiome-(crme)-q1-loss-wider-than-expected,-sales-miss-200189744",200189744
105886,327401,AGN,Allergan s Irritable Bowel Drug Viberzi Approved In Canada,opinion,Allergan plc   NYSE AGN   announced that Health Canada has approved Viberzi  eluxadoline  for the treatment of adults suffering with irritable bowel syndrome with diarrhea IBS D   The drug is marketed in the U S  and Europe as a twice daily  oral treatment A look at the company s share price movement shows that the stock has outperformed the Zacks classified  industry this year so far  Allergan s shares gained 6 9  during this period  while the industry registered a decrease of 5 2  The approval from Health Canada is based on results from two phase III clinical trials evaluating Viberzi over 26 and 52 weeks for a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50  of the days from weeks one through 12 and from weeks one through 26  The data from the two pivotal studies published in the New England Journal of Medicine showed a significant reduction in abdominal pain and diarrhea in one to four weeks when treated with Viberzi  The patients experienced sustained relief over the period of the study Approximately 2 million adults in Canada are estimated to be affected by IBS D  As per one gastroenterologist in Toronto  the treatment options that are currently available are not satisfactory for many patients as they continue to experience irritations  Hence  Viberzi has significant opportunity for growth Viberzi put up a robust performance in 2016 with sales of  93 3 million  However  Valeant Pharmaceuticals International  Inc    NYSE VRX   sells Xifaxan for the same indication Meanwhile  Allergan already markets another irritable bowel syndrome drug  Linzess  The company along with its partner  Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   markets Linzess for the treatment of irritable bowel syndrome with constipation  IBS C   Allergan is evaluating Linzess for better treatment of IBS C by targeted delivery through delayed release However  competition in the IBS C market has intensified with the FDA approval of Synergy Pharmaceuticals Inc  s   NASDAQ SGYP   Trulance for the same indication in Jan 2017 Allergan PLC  Price   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-16,Zacks Investment Research,https://www.investing.com/analysis/allergan's-irritable-bowel-drug-viberzi-approved-in-canada-200189742,200189742
105887,327402,AGN,AbbVie Down On Humira Patent Loss  Is More Damage In Store ,opinion,AbbVie Inc  s   NYSE ABBV   shares declined more than 2  on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug  Humira to small biotech Coherus BioSciences  Inc    NASDAQ CHRS   So far this year  AbbVie s share price has increased 4 4   comparing unfavorably with a gain of 9 4  recorded by the Zacks classified industry Coherus announced on Wednesday that it received a favourable ruling on an inter partes review  IPR  challenge to AbbVie s dosing patent  135 for Humira  The Patent Trial and Appeal Board  PTAB  of the US Patent and Trademark office ruled to invalidate Humira s  135 patent  which covers the method of treating rheumatoid arthritis with subcutaneous doses of Humira 40mg bi weekly Coherus is looking to get approval for a biosimilar version of Humira  Its shares shot up almost 8  on Wednesday Patent  135  which expires in Jun 2022  faces two additional IPR challenges from Boehringer Ingelheim  with rulings expected by early July The PTAB ruling did not come as a surprise as it was broadly expected  The investment community generally believes that AbbVie has a robust intellectual property  IP  portfolio beyond the  135 patent  which should preclude biosimilars from the U S  market until 2022  Sales should continue to remain strong until then However  another group of investors comment that though the PTAB ruling was a minor hit for AbbVie  it still increases the chance of a biosimilar Humira launch earlier than expected Humira is key driver of Amgen s revenues  accounting for more than 60  of its total sales  The product continues to see strong growth in the dermatology and gastroenterology markets  Growing awareness  favorable clinical data  additional indications and expansion into new markets like China and Japan is helping the product contribute consistently to AbbVie s top line  The company expects Humira to bring in total sales of more than  18 billion in 2020 However  several companies including Amgen  Inc    NASDAQ AMGN   Allergan plc   NYSE AGN   and Samsung  KS 005930  Bioepis are working on biosimilar versions of Humira  Amgen s biosimilar version of Humira  Amjevita  was approved by the FDA in Sep 2016 and in the EU  trade name  Amgevita  in Mar 2017 for the same indications as Humira  However  Amgen is not expected to launch the drug at risk amid litigation The entry of biosimilars will have a huge impact on the company s financials AbbVie carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/abbvie-down-on-humira-patent-loss:-is-more-damage-in-store-200189974,200189974
105894,327409,AGN,Irish Drugmaker Actavis In Talks To Buy Forest Labs For  25B,news,"By    Actavis PLC  NYSE ACT  is in advanced talks to buy out competing drug maker Forest Labs  NYSE FRX  in a whopping  25 billion deal expected to be announced early Tuesday  according to media reports 
The acquisition of New York based Forest Labs  which had a market capitalization of  19 3 billion as of Friday  would add a range of generic drugs including Alzheimer s drug Namenda  and blood pressure pill  Bystolic  to Actavis  product line up  On Feb  14  Actavis had a market value of  33 4 billion 

Dublin based Actavis has made deals worth  14 4 billion over the last three years and reportedly uses the mergers and acquisitions route to grow inorganically  a Bloomberg report said  citing Ori Hershkovitz  a partner at Sphera Funds Management Ltd in Tel Aviv 
 They have promised the market that they would do a large amount of deals to keep the accretion alive  If you can t do a large amount of R D  there s only one way to grow and that s through M A   Hershkovitz said  according to Bloomberg 
The transaction has not been confirmed by either company but the speculated  25 billion deal value is more than seven times Forest Labs  estimated sales for 2014  according to Bloomberg  
In October  the company bought New Jersey based Warner Chilcott Plc  for  9 2 billion to expand into the women s health segment 
Forest Labs  stock  which closed 1 49 percent up on Friday was trading 23 27 percent up in pre market trading Tuesday ",2014-02-18,International Business Times,https://www.investing.com/news/stock-market-news/irish-drugmaker-actavis-in-talks-to-buy-forest-labs-for-$25b-266840,266840
105895,327410,AGN,European stocks remain mostly higher after inflation data  Dax up 0 03 ,news,"Investing com   European stocks remained mostly higher on Monday  after the release of euro zone inflation data added to speculation the European Central Bank could announce fresh stimulus measures  while sustained expectations for a similar move in China continued to support 
During European afternoon trade  the DJ Euro Stoxx 50 edged 0 11  higher  France s CAC 40 eased 0 08   while Germany s DAX inched up 0 03  
Eurostat said the annual rate of consumer inflation slowed to 0 5  this month from 0 7  in February  falling to the lowest level since November 2009 and undershooting expectations for a reading of 0 6   The ECB targets an inflation rate of just under 2  
The report showed that core inflation rose 0 8  in March  in line with forecasts  but down from 1 0  in February 
Global equities also remained supported after Chinese premier Li Keqiang said Friday the country has policies in place to support economic growth  The remarks eased concerns over recent signs of a slowdown in the world s second largest economy 
Financial stocks were broadly higher  as French lender Societe Generale  SOGN PAR  added 0 17   while Germany s Deutsche Bank  DBKGn XETRA  and Commerzbank  CBKG XETRA  climbed 0 59  and 1 76  
Among peripheral lenders  Italy s Unicredit  CRDI MILAN  and Intesa Sanpaolo  ISP MILAN  surged 2 07  and 2 41  respectively  while Spanish bank Banco Santander  SAN MADRID  advanced 0 67  
Elsewhere  Novartis  NOVN SIX  surged 2 83  after the company ended a drug trial early as the results showed patients treated with it lived longer without being hospitalized for heart failure than those who received standard treatment 
German telecommunication service provider Drillisch  DRIG XETRA  saw shares rally 2 74  after Chief Executive Officer Paschalis Choulidis said the company may pay a special dividend or buy back shares if it doesn t make acquisitions by 2015 
In London  commodity heavy FTSE 100 added 0 18   still supported by gains in the mining sector 
Shares in Bhp Billiton  BLT LSE  climbed 0 48  and Vedanta Resources  VED LSE  jumped 1 12   while rival Rio Tinto  RIO LSE  rallied 1 96  
Financial stocks also remained mostly higher  as Lloyds Banking  LLOY LSE  climbed 0 50  and Barclays  BARC LSE  gained 0 59   while the Royal Bank of Scotland  RBS LSE  advanced 1 16   HSBC Holdings  HSBA LSE  continued to underperform on the other hand  sliding 0 49  
On the downside  biotech group Shire  SHP LSE  tumbled 1 26  after a U S  federal court of appeals on Friday reversed lower court finding that a competing product from Actavis  NYSE ACT  infringed a Shire patent 
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 33  rise  S P 500 futures signaled a 0 35  gain  while the Nasdaq 100 futures indicated a 0 42  climb 
Also Monday  official data showed that German retail sales rose 1 3  in February  confounding expectations for a 0 5  fall  Retail sales in January were revised down to a 1 7  rise from a previously estimated 2 5  increase ",2014-03-31,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-remain-mostly-higher-after-inflation-data;-dax-up-0.03-274691,274691
105896,327411,AGN,Forest Labs Buys Furiex Pharma For  1 46B,news,"By     Reuters    Forest Laboratories Inc  NYSE FRX  said it would buy Furiex Pharmaceuticals Inc  FURX O  for up to  1 46 billion including milestone payments to access Furiex s promising treatment for irritable bowel syndrome 
This is the latest in a series of healthcare deals and offers that have been structured to either gain scale or build up expertise in specific disease areas 
Forest  which itself is being acquired by Actavis Inc  NYSE ACT   said it expected Furiex s eluxadoline to be  very complementary  to its own bowel drug Linzess 
Eluxadoline  which is being developed for treating symptoms of diarrhea predominant irritable bowel syndrome  significantly alleviated symptoms of the disease in two large late stage trials in February 
Furiex is on track to submit a marketing application for eluxadoline by the end of the third quarter of 2014 
Forest will pay about  95 per share in cash to Furiex shareholders and up to  30 per share in a contingent value right  that would be dependent on the drug achieving certain designations given by the U S  Food and Drug Administration following the drug s approval 
Furiex s shares were up 28 percent at  102 50 in premarket trading 
Forest said it expected the Furiex deal to close in the second or third quarter of 2014 and said it would not affect the timing of the Forest Actavis acquisition 
Generic drugmaker Actavis said in February that it would buy Forest for about  25 billion to gain higher margin  branded treatments for Alzheimer s  hypertension and other disorders 
Forest said it would sell Furiex s royalties on diabetes drug alogliptin and premature ejaculation treatment Priligy to New York based Royalty Pharma for about  415 million upon successful completion of its acquisition of Furiex 
Furiex was advised by BofA Merrill Lynch  Credit Suisse  Kirkland   Ellis LLP and Wyrick Robbins Yates   Ponton LLP 
Covington   Burling LLP was Forest s legal counsel  while Royalty Pharma was advised by Goodwin Procter LLP ",2014-04-28,International Business Times,https://www.investing.com/news/stock-market-news/forest-labs-buys-furiex-pharma-for-$1.46b-280004,280004
105897,327412,AGN,AstraZeneca buys Almirall lung drugs for up to  2 1 billion,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca  L AZN  took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to  2 1 billion for the rights to Spanish group Almirall s  MC ALM  lung drugs 
The British drugmaker  which resisted a  118 billion takeover attempt by Pfizer  N PFE  in May  said it would pay an initial  875 million and up to  1 22 billion more if the drugs meet development and sales targets 
The tie up boosts a key therapeutic area for AstraZeneca  whose Chief Executive Pascal Soriot is determined to show his company has a strong independent future 
Soriot also struck a clinical trial collaboration with Japan s Kyowa Hakko Kirin  T 4151  for a study that will evaluate a combination of the two companies  drugs in cancer   another important field for AstraZeneca 
For Almirall  the deal with AstraZeneca is a notable win  giving it extra resources to increase its focus on dermatology  The company is a local success story whose shares have strongly outperformed the Spanish market in the past three years 
AstraZeneca will have the right to develop and commercialise Almirall s existing lung drugs   including its recently launched treatment Eklira or aclidinium   as well as its pipeline of experimental therapies 
Almirall Sofotec  an Almirall subsidiary focused on making devices for delivering drugs to the lungs  including the Genuair inhaler  will also transfer to AstraZeneca 
Importantly  the deal gives AstraZeneca access to revenues from a drug already on the market  in Eklira  helping its sales immediately as it struggles with a wave of patent expiries on its own blockbuster medicines 
Eklira sales are expected to reach  535 million by 2018  according to consensus forecasts collected by Thomson Reuters  although much of that will be sold via Actavis  N ACT   which has U S  rights to the drug after acquiring Almirall s marketing partner Forest Laboratories 
AstraZeneca expects the transaction  which will be paid for from existing cash reserves and using short term credit facilities  to be neutral to core earnings per share in 2015 and accretive from 2016  It is set to close by the end of 2014 and will not affect AstraZeneca s current year financial outlook 
Mick Cooper  an analyst at Edison Investment Research  said the agreement with Almirall was a  smart deal  that would help build up AstraZeneca s respiratory business  which is already doing well as its Symbicort drug wins business from GlaxoSmithKline s  L GSK  Advair 
 Its respiratory franchise has considerable momentum at the moment and this agreement fills in the gaps in the portfolio   he said 
FAMILY CONTROL
Almirall said the deal would boost its earnings immediately and shares in the Barcelona based group  which was advised by Rothschild  jumped 8 percent by 1045 GMT 
Some analysts expressed surprise at Almirall s decision  since respiratory accounts for 30 percent of its sales  ahead of dermatology  its next largest franchise with 27 percent 
But it was always going to be difficult for it to compete against industry heavyweights in the respiratory field  given the need for large clinical trials and heavy marketing spend 
Instead  Almirall will now become a specialist company  focused on dermatology  and is likely to seek small acquisitions and licensing deals to build up this remaining business  according to one person familiar with the firm s thinking 
Despite a wave of takeovers now sweeping the pharmaceuticals sector  Almirall is unlikely to become a takeover target any time soon  since it is two thirds owned by the Gallardo family  which is keen to retain control 
Analysts at Jefferies said AstraZeneca s decision to buy the entire respiratory franchise wiped out concerns about Almirall s so called LAMA LABA lung drug combination in the United States  where regulators have asked for more clinical trial data 
AstraZeneca shares were 1 percent higher  outperforming a 0 5 percent gain in the European drugs sector  
It positions AstraZeneca more strongly in a battle to develop next generation treatments for asthma and chronic lung disease caused by smoking  where it is up against big hitting rivals like GSK and Novartis  VX NOVN  
AstraZeneca already raised its bet on respiratory medicine last year by buying U S  based Pearl Therapeutics for up to  1 15 billion 
The two companies said a  significant  number of Almirall employees would transfer to AstraZeneca 
AstraZeneca will report second quarter results on Thursday  when it will seek to prove its financial resilience after its decision to reject Pfizer s takeover advances 

Pfizer on Tuesday left investors guessing whether it would renew its pursuit of its British rival  as it presented results  but said it was still considering big deals 
 Additional reporting by Anjuli Davies  Editing by Tom Pfeiffer and Jane Merriman ",2014-07-30,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-buys-almirall-lung-drugs-for-up-to-$2.1-billion-299105,299105
105898,327413,AGN,Actavis in buyout talks with Salix  CNBC,news," Reuters    Actavis Plc  N ACT  is in buyout talks with Salix Pharmaceuticals Ltd  O SLXP   CNBC reported on Wednesday   Allergan Inc  N AGN  has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals Inc  TO VRX    Allergan has questioned the sustainability of Valeant s growth and business model and  opaque  financial disclosures   Valeant said on Wednesday that such concerns were  completely unfounded     In the third quarter  we expect our results to be better than consensus on revenue  and better than the guidance we provided in our second quarter earnings call for Cash EPS  organic growth  restructuring charges and adjusted cash flow from operations   Valeant Chief Executive Michael Pearson said in a letter to Allergan s board   
 This story corrects the first paragraph and headline to say Actavis is in buyout talks with Salix  not Allergan in buyout talks with Actavis  Adds second paragraph to say Allergan has been in talks with Salix after approach from Valeant     Reporting by Vidya L Nathan  Editing by Saumyadeb Chakrabarty ",2014-09-24,Reuters,https://www.investing.com/news/stock-market-news/allergan-in-buyout-talks-with-actavis:-cnbc-310612,310612
105899,327414,AGN,Exclusive  Actavis plans new merger approach for Allergan   sources,news,"By Nadia Damouni and Soyoung Kim  NEW YORK  Reuters    Actavis Plc  N ACT  plans to approach Allergan Inc  N AGN  again about a potential merger  as the Botox maker warms up to the possibility of a sale  people familiar with the matter said on Tuesday   Allergan  which has repeatedly rejected offers from Valeant Pharmaceuticals International Inc  TO VRX   would consider a takeover proposal that values the company at above  200 per share  some of these people said   Actavis  which held informal conversations with Allergan in recent months about a possible combination  would like to take a hard look at buying the company and could reach out to its management team as soon as this week to reiterate its interest  one of the sources said   There has been no formal engagement between the two companies yet  the sources said  asking not to be named because the matter is not public   Actavis  new overture would come as Valeant and its partner William Ackman plan to boost their offer by about  15 per share  valuing Allergan at more than  190 per share  according to a separate person familiar with the matter   Valeant had initially intended to announce a higher bid after reporting what it expects to be blow out earnings on Oct  20  the person said  adding that the timing and amount of the bump could still change   Allergan  while fighting off Valeant s advances  did not reach out to other alternative buyers and instead focused on identifying opportunities for revenue growth and cost cuts internally  But it is aware of competing interest from other drugmakers  particularly from Actavis  the sources said   The emergence of Actavis as a serious rival suitor adds another twist to the months long takeover battle between Valeant and Allergan  The Canadian drugmaker s bid already has attracted controversy because it is backed by activist investor Ackman  leading to a legal challenge from Allergan which has accused the two parties of insider trading   Shares of Allergan ended 1 7 percent higher at  186 20 on the New York Stock Exchange after rising more than 3 percent on the news  valuing the company at more than  55 billion  Actavis closed at  243 39 for a market capitalization of roughly  64 billion   Shares of Valeant fell 2 5 percent  putting the value of its existing cash and stock offer for Allergan at  175 94 per share  or  52 8 billion based on shares outstanding   Valeant expects its shares to rise substantially when it announces earnings in the coming weeks  potentially making its newly increased offer worth well above  195 per share and close to  200  one person familiar with the matter said   Analysts have an average price target of around  200 per share for Allergan  with the price ranging from  174 to  240 per share  according to a Thomson Reuters poll of 16 analysts   Representatives for Allergan and Actavis declined to comment   Actavis  continued pursuit of Allergan comes as the takeover target faces a Dec  18 special shareholder meeting  at which top Allergan investor Ackman s Pershing Square Capital Management hopes to replace a majority of the company s board   Pershing Square has teamed up with Valeant to pursue a takeover of Allergan  and is hoping to install new board members who could be more receptive to a takeover by the Canadian drugmaker   Actavis  which regularly reviews potential acquisitions  considers Allergan as the best opportunity currently and is hoping to engage in friendly discussions  the sources said   Industry executives have said Actavis would be a better cultural fit for Allergan because the companies  respective chief executives  Brent Saunders and David Pyott  believe in focusing on research and development  while Valeant CEO Mike Pearson is known for cost cutting   A large part of Allergan s business is ophthalmology  an area that Saunders is familiar with after serving as CEO of Bausch   Lomb  Valeant acquired Bausch   Lomb last year   DEFENSIVE ACQUISITION UNLIKELY  Valeant and Pershing Square offered to buy Allergan on April 22 but Allergan has said the offer undervalued the company  Since then Allergan has announced cost cuts and said it was looking for acquisitions while trying to persuade shareholders they were better off remaining independent   But the possibility of Allergan making a potentially large acquisition has faced significant opposition from shareholders who feared such a deal would make the company too big and expensive for Valeant   Allergan had held on and off discussions with Salix Pharmaceuticals Ltd  O SLXP  about buying the drugmaker for more than  10 billion in cash  people familiar with the matter said previously  A cash takeover would not have required a shareholder vote and could have put Allergan out of Valeant s reach   
Those discussions stalled in part because Allergan considered Salix s valuation as high  and while the company continues to look at other deal opportunities  the likelihood of it striking a big acquisition before the Dec  18 shareholder meeting is low  the sources said     Reporting by Soyoung Kim and Nadia Damouni  additional reporting by Caroline Humer  Editing by Richard Chang  Lisa Shumaker and Stephen Coates ",2014-10-08,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-actavis-plans-new-merger-approach-for-allergan---sources-312180,312180
105900,327415,AGN,Exclusive  Top Actavis holder  Fidelity  adds Allergan holdings  sources,news,"By Soyoung Kim and Tim McLaughlin  NEW YORK BOSTON  Reuters    Fidelity Investments  the largest shareholder in Actavis Plc  N ACT   has increased its holdings in takeover target Allergan  N AGN  in recent months and would be supportive of a potential merger between the two drugmakers  according to people familiar with the matter   The Boston based investment firm  which collectively owned 3 88 million Allergan shares through several of its funds as of end June  had added roughly 2 million shares by the end of August  according to Thomson Reuters data based on Fidelity s monthly filings   The additions would likely make Fidelity the No 8 shareholder in Allergan  according to Thomson Reuters data  assuming there was no significant changing of hands in the company s top 10 shareholder base  Fidelity is currently Actavis  top shareholder with a 6 3 percent stake  according to Thomson Reuters data   Fidelity would be open to taking Actavis  shares if the drugmaker comes up with a rival bid using its own stock as currency  the sources said  asking not to be named because they are not authorized to speak to the media  The fund managers also like Allergan s standalone business plan  the sources added   Revelations of Fidelity s increased holdings in Allergan come days after Reuters reported that Actavis was planning to make a new approach to the Botox maker about a merger  potentially challenging Valeant Pharmaceuticals Inc s  TO VRX   N VRX  unsolicited bid for Allergan   Boosting its Allergan ownership also contrasts with Fidelity s recently reduced bets in Valeant  Two of Fidelity s top stock pickers unloaded most of their holdings in Valeant after the Canadian drugmaker in April unveiled its bid for Allergan  which has marked one of 2014 s most contentious takeover battles   Some Fidelity fund managers are reluctant to support Valeant s cash and stock proposal in part because they have questions about the value of Valeant s stock  according to the people familiar with the matter   Allergan Chief Executive David Pyott has regularly cast doubts on the value and sustainability of Valeant stock  saying the rival s share performance has been driven by financial engineering and  unsustainable  price increases   Allergan declined to comment  Representatives for Fidelity also declined to comment   Several analysts said in research notes this week that Allergan shareholders would prefer a competitive offer from Actavis over Valeant s bid    Based on our discussions with investors  we believe fundamental investors who own Allergan    are inherently more comfortable with the Actavis business model than the Valeant model   BernsteinResearch analysts said in a Wednesday note    Exchanging Allergan shares for Actavis shares would not force many of them to sell  as they might with Valeant position    Industry executives say Actavis would be a better cultural fit for Allergan because the companies  respective chief executives  Brent Saunders and David Pyott  believe in focusing on research and development  while Valeant CEO Mike Pearson is known for cost cutting   To be sure  Valeant still has a powerful ally  Hedge fund manager William Ackman has amassed a 9 7 percent stake in Allergan to make him the company s largest shareholder  and has teamed up with Valeant to pursue a joint bid   T Rowe Price  the second largest shareholder in Allergan with a stake of near 5 4 percent  is also Valeant s No 3 investor with a 4 9 percent stake  and would likely benefit from a combination between the two companies   Ackman has secured investors who collectively own more than 35 percent of Allergan shares  including his position  to call for a special shareholder meeting on Dec  18  at which he hopes to replace majority of the company s board   The prospect of a bidding war  as well as Allergan s own improving performance  has driven its shares to all time highs this week  with the stock trading at  187 55 on the New York Stock Exchange  well above Valeant s offer   On Thursday  Allergan lifted its third quarter profit estimate and said the updated forecast showed that Valeant s takeover offer undervalued the company   
Shares of Valeant have come under pressure  however  as doubts increase about whether its bid will succeed  The stock fell 2 8 percent to  122 35 on the New York Stock Exchange on Thursday  valuing its Allergan bid at  173 55 per share  or just below  52 billion     Reporting by Soyoung Kim in New York and Tim McLaughlin in Boston  additional reporting by Jessica Toonkel and Nadia Damouni  Editing by Alden Bentley ",2014-10-10,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-top-actavis-holder,-fidelity,-adds-allergan-holdings--sources-312536",312536
105901,327416,AGN,Exclusive  Allergan shareholder Paulson   Co urges deal with Shire   sources,news,"By Olivia Oran  Reuters    Allergan Inc  N AGN  shareholder Paulson   Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc  L SHP  as an alternative to a deal with hostile bidder Valeant Pharmaceuticals  TO VRX   according to two people familiar with the matter 
 The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire  the sources said  The deal would not be structured as a so called tax inversion  the people said 
It was not immediately clear whether Allergan would pursue such a deal  Allergan and Paulson declined to comment 
The move by Paulson  Allergan s third largest shareholder  comes as AbbVie s  N ABBV   54 billion deal to buy Shire is close to unraveling after the U S  government changed the rules governing tax inversions 
Shareholders including Paulson are looking at alternative strategies for Allergan as it tries to fend off a deal from Valeant  Some large Allergan shareholders have said they would prefer a deal with drugmaker Actavis Plc  N ACT  to a tie up with Shire 
Actavis plans to approach Allergan again about a potential merger  people previously told Reuters 
Paulson was also pushing behind the scenes for a deal between Allergan and Valeant earlier this summer  sources previously told Reuters  It remains unclear if the fund is still in favor of that 

Valeant might raise its bid for Allergan and would not abandon its pursuit ahead of a Dec  18 special meeting  Michael Pearson  CEO of the Laval  Quebec based company  said on Monday 
 Reporting by Olivia Oran in New York  Additional reporting by Nadia Damouni and Jessica Toonkel  Editing by Chizu Nomiyama and Lisa Von Ahn ",2014-10-20,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-allergan-shareholder-paulson--amp;-co-urges-deal-with-shire---sources-313598,313598
105902,327417,AGN,Allergan in discussions with another party after approach,news," Reuters    Allergan Inc  N AGN  on Thursday said that it is currently in discussions with another party that a source familiar with the situation identified as Actavis Inc  N ACT   just days after the company disclosed that it had been approached 
The discussions about a potential merger transaction could lead to  negotiations   Allergan said in a regulatory filing with the Securities and Exchange Commission related to its Dec  18 meeting with shareholders 
Allergan is fighting a  54 billion hostile takeover by Valeant Pharmaceuticals International  TO VRX  and Pershing Square Capital Management  saying that Allergan s growth will be diminished and that Valeant will cut costs too deeply 

Allergan had been holding off on talks with Actavis because it was waiting for a California judge to decide on its request for an injunction to stop William Ackman  head of Pershing Square  from voting at the shareholder meeting  a second source familiar with the situation previously told Reuters  The judge cleared the path for Ackman to vote his shares earlier this week by ordering Valeant and Pershing to add disclosures to their proxy filing  which the companies said they would 
 Reporting by Caroline Humer  Editing by Alden Bentley ",2014-11-06,Reuters,https://www.investing.com/news/stock-market-news/allergan-in-discussions-with-another-party-after-approach-315761,315761
105909,327424,AGN,5 Major Drug Stocks Likely To Beat Q1 Earnings Estimates,opinion,"Pharma and biotech stocks had a difficult 2016 fraught with headwinds mainly related to drug pricing issues  Though the drug pricing issues still persist  the industry has nonetheless picked up backed by strong results  FDA approvals  success of new products and significant contributions from established drugs Also  healthcare merger and acquisition activity continues to gather steam  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Merger and acquisitions  especially small bolt on acquisitions as well as aggressive in licensing activities and collaborations are expected to increase going forward  This is expected to act as a huge catalyst for biotech stocks  There has also been some talk about speeding up the FDA approval process  which should bode well for the long term growth of the sector The Zacks classified Drugs industry has gained 3 3  this year so far  after declining 16 3  last year  A similar trend was witnessed in the share price movement of companies like Lilly  Celgene  NASDAQ CELG   Vertex Allergan  NYSE AGN   Amgen  all of which are in the green this year after a decline last year  Meanwhile  the SPDR S P Pharmaceuticals ETF  NYSE XPH  index has risen 8 0  this year so far after declining 23 7  last year   However  the sector does have its share of challenges like high profile pipeline setbacks  generic biosimilar competition for key drugs and slowdown in sales of some mature products  Nonetheless  it is still a good sector to invest in How to Pick Likely Q1 WinnersGiven the enormity of the healthcare space  selecting stocks that have the potential to beat estimates could appear to be quite daunting  But our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    and a positive    More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their upcoming earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70    You can uncover the best stocks to buy or sell before they re reported with our  
Here are five healthcare stocks that are poised to beat estimates in the first quarter according to our methodology Our first pick is the bellwether of healthcare companies  Johnson   Johnson  NYSE JNJ      which has a solid presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Brunswick  NJ based company has a Zacks Rank  3  Hold  and an Earnings ESP of  0 57   The Zacks Consensus Estimate for the first quarter is  1 77 per share  The company has been seen to consistently beat earnings expectations  In fact  Johnson   Johnson s earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 2 43  J J is expected to report results on Apr 18Our next choice is biotech major  Amgen Inc  NASDAQ AMGN       With a Zacks Rank  3  the stock carries an Earnings ESP of  0 67   The Zacks Consensus Estimate for the first quarter is pegged at  3 00 per share  This Thousand Oaks  CA based company has a pretty impressive track record with the company beating earnings estimates consistently  The average earnings surprise over the four trailing quarters is 7 38  Amgen is expected to announce results on Apr 26 Large cap pharma stock  Bristol Myers Squibb Company  NYSE BMY     too has an impressive track record with the company consistently beating earnings expectations  The company s earnings surpassed expectations in three of the last four quarters  with an average positive surprise of 7 26   This New York based company carries a Zacks Rank  3 and has an Earnings ESP of  1 35   It looks poised to beat expectations in the first quarter as well  The Zacks Consensus Estimate for the same is pegged at 74 cents per share Bristol Myers is scheduled to report results on Apr 27 Another well known name in the pharmaceuticals market  Eli Lilly   Company    makes it to our list of likely outperformers in the first quarter by virtue of its Zacks Rank  2 and an Earnings ESP of  1 04   The Zacks Consensus Estimate is pegged at 96 cents per share  You can see  
Lilly is scheduled to report its results on Apr 25     United Therapeutics     a biotechnology company is another solid bet  This Zacks Rank  3 stock currently carries an Earnings ESP of  5 37   This Silver Spring  MD based company registered an average positive earnings surprise of 15 39  over the trailing four quarters United Therapeutics is expected to release results on Apr 27  with the current Zacks Consensus Estimate for the first quarter pegged at  3 54 per share Bottom Line  Challenges in the form of competitive and pricing pressure will continue to remain in the healthcare sector  However  a number of companies in the space are seeing improvements in their financial results  Picking some outperformers from the space  backed by a solid Zacks Rank and a positive Zacks Earnings ESP  could lead investors to gain from this earnings season The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/5-major-drug-stocks-likely-to-beat-q1-earnings-estimates-200183187,200183187
105910,327425,AGN,Allergan  AGN  Collaborates With Novartis To Treat NASH,opinion,Allergan plc   NYSE AGN   entered into a collaboration with Novartis AG   NYSE NVS   to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc  CVC  and Novartis lead Fxr agonist to treat non alcoholic steatohepatitis  NASH  A look at Allergan s year to date share price movement shows that the company has outperformed the Zacks classified  industry  Specifically  the stock gained 11 6  so far this year against a 3 4  decline for the industry NASH is the progressive form of non alcoholic fatty liver disease  NAFLD   which occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage  The inflammation can cause fibrosis of the liver and eventually lead to many complications  Allergan is developing CVC as a once daily orally administered immunomodulator that blocks chemokine receptors in inflammatory and fibrogenic pathways Other than CVC  it is developing evogliptin and AGN 242266 programs  targeting different mechanisms for the treatment of this multi factorial NASH disease With no treatments currently approved for this disease  the market opportunity is significant  With Intercept Pharmaceuticals  Inc  s   NASDAQ ICPT   Ocaliva  Conatus Pharmaceuticals Inc  s   NASDAQ CNAT   emricasan and Galmed Pharmaceuticals s Aramchol  several companies are working on developing treatments for NASH In a separate press release  a generic drug company Argentum Pharmaceuticals LLC  which was engaged in a patent dispute over Allergan s eye drug  Restasis  announced that it has reached a settlement  The agreement grants Argentum the right to market a generic version of Restasis before the expiry of the patent  The drug was approved by the FDA in 2002 to treat dry eye Currently  Allergan carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-04-18,Zacks Investment Research,https://www.investing.com/analysis/allergan-(agn)-collaborates-with-novartis-to-treat-nash-200183700,200183700
105912,327427,AGN,Pharma Stock Roundup  J J Slips On Mixed Q1  Lilly Hit By FDA CRL,opinion,"Johnson   Johnson   NYSE JNJ   kicked off the first quarter earnings season for the pharma sector this week  Meanwhile  Lilly   NYSE LLY   was also in the news with the company receiving a complete response letter  CRL  for its experimental rheumatoid arthritis  RA  treatment  baricitinib Recap of the Week s Most Important StoriesJ J Down on Mixed Q1 Results  Industry bellwether J J posted mixed Q1 results this week with the company surpassing earnings expectations but missing on revenues  Shares were down 3 1  leaving the investment community jittery about how the rest of the sector would perform  Read more    CRL for Lilly s RA Drug  FDA Wants More Data  Lilly and partner Incyte were in for a major disappointment with the FDA issuing a CRL for their experimental RA treatment  baricitinib  The agency told the companies that it is unable to approve baricitinib  a once daily oral medication for the treatment of moderate to severe RA  in its current form  What is concerning is that the agency has asked for additional clinical data to determine the most appropriate doses as well as to further characterize safety concerns across treatment arms  This means delayed approval timelines and additional costs depending on the studies that may need to be conducted  Lilly and Incyte said that they were not in agreement with the FDA and the timing for resubmission would be based on further discussions with the agency We note that baricitinib was approved in the EU under the trade name Olumiant in Feb 2017  Read more    BTD for Novartis CAR T Drug  Swiss pharma giant Novartis   NYSE NVS   got a second Breakthrough Therapy designation  BTD  for its experimental CAR T therapy  CTL019  The company got BTD for the treatment of adults with relapsed and refractory  r r  diffuse large B cell lymphoma  DLBCL   who have failed two or more prior therapies  According to the American Society of Clinical Oncology  DLBCL is the most common form of lymphoma accounting for about 30  of all non Hodgkin lymphoma cases  The company expects to file for FDA approval of this indication by year end Novartis had previously got BTD designation for the treatment of r r B cell acute lymphoblastic leukemia  ALL  in pediatric and young adult patients  CTL019 is currently under priority review in the U S  for this indication  Read more    Developments on the NASH Front  Novartis and Allergan   NYSE AGN   entered into a clinical trial agreement to conduct a phase IIb study on Novartis  FXR agonist and Allergan s cenicriviroc  CVC  for the treatment of NASH  non alcoholic steatohepatitis  Read more     Allergan has also signed up with TARGET PharmaSolutions  a clinical data company focused on real world evidence  on its TARGET NASH study  The aim of the five year longitudinal observational study is to help facilitate a greater understanding of the impact of NASH and future treatment options Meanwhile  Bristol Myers   NYSE BMY   announced a collaboration agreement with Danish company  Nordic Bioscience  for the development of biomarker technology that would help in the diagnosis and monitoring of fibrotic diseases including NASH  Read more    NASH is an increasingly common  progressive form of fatty liver disease which is becoming a significant and growing health issue given the rising obesity epidemic  With no treatments currently approved for this disease  the market opportunity is significant  Several companies are working on developing treatments for NASH    the market could be worth billions of dollars and many companies are hoping to cash in on this opportunity Nivalis Alpine in Merger Agreement  Nivalis and privately held biotech company  Alpine Immune Sciences  Inc   entered into a merger agreement with the deal slated to close in the third quarter  The combined company with a novel protein based discovery platform will be focused on inflammation and immuno oncology  Nivalis  which suffered a huge setback with disappointing mid stage data on its lead pipeline candidate  cavosonstat   had decided to wind down its research and development activities while evaluating strategic alternatives  The combined company will have about  90 million in cash and equivalents and expects to commence an early stage study on a dual ICOS CD28 antagonist engineered for use in autoimmune and inflammatory diseases in the second half of 2018 Pipeline and Regulatory Updates from Roche  Roche   OTC RHHBY   had quite a few pipeline and regulatory updates including label expansion for two drugs  The FDA granted approval for the use of Lucentis for the monthly treatment of withal forms of diabetic retinopathy  the leading cause of blindness among working age adults in the country  This makes Lucentis the first and only FDA approved medicine to treat diabetic retinopathy in people who have been diagnosed with or without diabetic macular edema  DME  Roche also got FDA approval for the use of its first cancer immunotherapy Tecentriq in an additional type of advanced bladder cancer  Tecentriq  which gained FDA approval last year  can now be used for the first line treatment of people with locally advanced or metastatic urothelial carcinoma  mUC  not eligible for cisplatin chemotherapy  The label expansion will increase the patient population for Tecentriq  This is the third approval for Tecentriq in less than a year in the U S Roche also announced positive interim results on emicizumab from a late stage study in children with hemophilia A  Results showed a clinically meaningful reduction in the number of bleeds over time Roche has outperformed the Zacks categorized  industry year to date with shares gaining 11 3   compared to the industry gain of 4  Sanofi  PA SASY   Regeneron Face Patent Infringement Lawsuit for Dupixent  Sanofi   NYSE SNY   and partner Regeneron are facing a patent infringement lawsuit filed by Amgen s Immunex Corporation related to their recently approved eczema treatment  Dupixent  We note that Sanofi and Regeneron had already filed a lawsuit prior to the approval of Dupixent seeking a court order that their drug does not infringe a patent held by Amgen  NASDAQ AMGN   The lawsuit was a proactive move by the companies to prevent Amgen from initiating a patent infringement lawsuit like it had related to Sanofi and Regeneron s PCSK9 inhibitor Praluent  Sanofi is a Zacks Rank  2  Buy  stock  You can see  Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index dipped slightly  0 82   over the last four trading sessions  Among major pharma stocks  Lilly lost 4 6  with the shares reflecting the impact of the CRL while Bristol Myers was up 1 2   Over the last six months  Bristol Myers gained 6 1  while AstraZeneca was down 3 6   See the last pharma roundup here    
What s Next in the Pharma World First quarter earnings season has started and quite a few pharma companies are scheduled to report next week  Companies like Lilly  Novartis  Sanofi and Bristol Myers will all be reporting results in the coming days Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-21,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-j-j-slips-on-mixed-q1,-lilly-hit-by-fda-crl-200184242",200184242
105914,327429,AGN,Novartis Tops Q1 Earnings  Cosentyx  Entresto Boost Sales,opinion,"Novartis AG   NYSE NVS   reported first quarter 2017 core earnings of  1 13 per share  beating the Zacks Consensus Estimate of  1 10 but it was lower than the year ago figure of  1 17 Novartis AG Price and EPS Surprise

   Revenues declined 1  to  11 5 billion  roughly in line with the Zacks Consensus Estimate as volume growth was offset by the negative impact of generic competition 
A look at Novartis  share price movement in the last three months shows that the stock underperformed the Zacks classified  industry  Its shares gained 3 8  compared with 6 7  gain for the industry 

All growth rates mentioned below are on a year over year basis and at constant exchange rates 
The Quarter in Detail
Novartis operates under three segments  Innovative Medicines  Pharmaceuticals   Alcon  Ophthalmology unit  and Sandoz  Generics  
The Innovative Medicines division recorded sales of  7 7 billion  up 2   Generic competition and pricing pressure impacted sales at the segment  primarily due to the entry of generics for Gleevec in the U S  Nevertheless  growth products   Cosentyx  Entresto  Promacta Revolade  Jakavi  Tafinlar   Mekinist and Gilenya boosted sales 
Psoriasis Cosentyx sales surged 136  on the back of strong growth in its three approved indications while Entresto too had solid first quarter as sales benefited from continued access improvements  increased investment in the U S  as well as additional launches in Europe  Oncology franchise grew 7  driven mainly by Promacta Revolade  Jakavi  Tafinlar   Mekinist and Tasigna  
Sales at the Sandoz division were  2 4 billion  up 1  as volume growth was offset by price erosion  Biopharmaceuticals sales grew 30  to  274 million mainly driven by Zarxio and Glatopa 20mg in the U S 
Sales at the Alcon division were  1 4 billion  up 1   Vision care sales were up 4  fueled by strong performance of the daily contact lens portfolio  including continued double digit growth of Dailies Total1 globally  However  surgical sales were down due to competitive pressure in intraocular lenses  IOLs  
2017 Outlook Reiterated
Novartis expects net sales to be broadly in line with the 2016 levels after including the impact of continued genericization of Gleevec Glivec in the U S  and Europe  The impact of generic competition on sales is expected to be approximately  2 5 billion in 2017 
Pipeline Update
Novartis  pipeline progress has been encouraging  The company received FDA s approval for Kisqali  ribociclib  formerly LEE011  in combination with an aromatase inhibitor for treatment of postmenopausal women with HR  HER2  advanced or metastatic breast cancer 
The combination of Tafinlar   Mekinist received EU approval to treat patients with advanced or metastatic NSCLC whose tumors express the BRAF V600 mutation  In addition  Votubia dispersible tablets were approved by the EC as an adjunctive treatment for patients whose refractory partial onset seizures are associated with TSC 
Meanwhile  the biosimilar versions of Amgen s   NASDAQ AMGN   Enbrel  etanercept  and Roche s   OTC RHHBY   MabThera Rituxan received positive opinions from the CHMP in EU 
On the other hand  CTL019 was granted priority review by the FDA  in pediatric and young adult patients with acute lymphoblastic leukemia  CTL019 is an investigational CAR T cell therapy  The FDA has also granted Breakthrough Therapy designation to CTL019 for the treatment of adult patients with r r diffuse large B cell lymphoma 
Additionally  Zykadia was granted Priority Review in the U S  for use as a first line treatment for patients with metastatic NSCLC with an ALK mutation and breakthrough therapy designation in this indication for patients with brain metastases 
Novartis expects to submit an application for BAF312  siponimod  for the treatment of relapsing multiple sclerosis  RMS  in 2018 as per discussions with regulatory authorities 
On the other hand  a phase III trial on RLX030  serelaxin  did not meet its primary endpoints 
Novartis also entered into a clinical trial agreement with Allergan   NYSE AGN   to conduct a phase IIb study  involving the combination of a Novartis FXR agonist and Allergan s cenicriviroc  CVC  for the treatment of non alcoholic steatohepatitis  NASH  
Our Take
Novartis first quarter results were encouraging as the company beat earnings estimates while sales were in line with expectations 
Earlier in 2017  Novartis announced that it is mulling strategic options for Alcon which includes retaining the business separation via capital market transactions such as a spin off or an initial public offering   Given its dismal performance  Alcon seems to be a laggard for quite some time now  The company will throw more light on its plans for Alcon toward the end of 2017 
On a positive note  growth drivers like Cosentyx and Entresto  more than offset the impact of generic erosion  mainly due to Glivec  Cosentyx hit blockbuster status in 2016  The recent approval of Kisqali in the U S  and priority review status for CTL019 also bodes well for the company s portfolio  We are also impressed by the company s efforts to strengthen its biosimilars portfolio 
Zacks Rank
Novartis currently carries a Zacks Rank  5  Strong Sell   You can see  
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-25,Zacks Investment Research,"https://www.investing.com/analysis/novartis-tops-q1-earnings:-cosentyx,-entresto-boost-sales-200185102",200185102
105916,327431,AGN,Aerie  AERI  Posts Wider Than Expected Q1 Loss  Expenses Up,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   posted first quarter 2017 loss of 76 cents per share  including stock based compensation   wider than the Zacks Consensus Estimate of a loss of 74 cents but narrower than the year ago loss of 85 cents 
Being a development stage company  Aerie has not generated any revenues from product sales yet 

We note that Aerie outperformed the Zacks classified  industry in the last six months  In fact  the stock rallied 25 9  during this period  compared with a gain of 13 8  for the industry 
Quarter in Detail
In the reported quarter  research and development expenses declined 11  to  9 8 million as the company completed trials in the U S  General and administrative expenses increased 47 7  to  14 5 million  The higher operating expenses in the reported quarter were due to expansion of the employee base to support the growth of operations and commercialization preparatory activities  including commercial manufacturing costs for Rhopressa 
Pipeline Update
The company resubmitted new drug application  NDA  for lead candidate Rhopressa 0 02  on Feb 28 and expects a review period of 12 months  We note that Aerie withdrew the Rhopressa NDA filed in September as a third party manufacturing facility in Tampa  FL was not ready for pre approval inspection by the FDA  The company initiated preparations to bring a second contract manufacturer online in 2018 
The company reported encouraging six month top line safety and efficacy results from the phase III trial  ROCKET 4  on Rhopressa  The trial is being conducted to provide adequate safety data for European regulatory filings  Rocket 4 has been successfully completed for submission to the European regulatory authorities 
Apart from Rhopressa  Aerie is evaluating Roclatan  a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  The company expects top line 90 day efficacy and safety data from the second phase III clinical trial  Mercury 2  for Roclatan 0 02  0 005   in second quarter 2017  Data from Mercury 1 is expected in third quarter 2017  If Mercury 1 and Mercury 2 are successful  the NDA for Roclatan is expected to be filed in late 2017 or early 2018 
The company also expects to commence a trial  Mercury 3  in mid 2017  in Europe to support filings there  The trial will be a non inferiority trial comparing Roclatan to prescribed fixed dose combination of Ganfort  a combination of the bimatoprost along with timolol   marketed by Allergan   NYSE AGN   in Europe 
Our Take
The wider than expected loss in the first quarter was disappointing  Nevertheless  we are encouraged by the company s efforts in developing its pipeline candidates  With a number of upcoming data readouts lined up for the upcoming quarters  we expect investors to remain focused on further updates by the company 
Zacks Rank   Key Pick
Aerie currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Infinity Pharmaceuticals  Inc    NASDAQ INFI   which currently carries a Zacks Rank  1  Strong Buy   You can see  
Infinity  loss estimates narrowed to  1 03 from  1 43 for 2017 over the past 60 days  The company recorded a positive earnings surprise in three of the last four quarters  the average being 36 64  Its share price increased 43 7  year to date 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-05-03,Zacks Investment Research,"https://www.investing.com/analysis/aerie-(aeri)-posts-wider-than-expected-q1-loss,-expenses-up-200186926",200186926
105917,327432,AGN,What s In The Cards For Allergan  AGN  This Earnings Season ,opinion,"Allergan plc    NYSE AGN   will report first quarter 2017 earnings on May 9  before the market opens  Last quarter  the company delivered a positive earnings surprise of 2 90  Allergan s share price is up 16 1  this year so far  outperforming the 1  decline witnessed by the Zacks classified industry Allergan s earnings performance has been mixed so far  with the company beating expectations in three of the past four quarters and missing on one occasion  The average negative earnings surprise over the last four quarters is 0 08  Let s see how things are shaping up for this announcement Factors to ConsiderWhile Allergan s revenues should be driven by new product launches  international growth and growth from key established products like Botox  Linzess  Restasis  earnings growth will be driven by revenues and operating expense management The performance of new products like Avycaz  treatment for adult patients with complicated intra abdominal and urinary tract infections   Vraylar  bipolar I disorder and schizophrenia   Kybella  double chin reduction  and Viberzi  adults suffering from irritable bowel syndrome with diarrhea  will also be in focus  Viberzi  and Vraylar did well in the past two quarters and we expect the trend to continue in the to be reported quarter as well However  Namenda IR is facing generic competition  which will continue to hurt sales of the drug  Meanwhile  Namenda XR sales also declined in the previous quarter due to lower demand and shift of promotional efforts to Namzaric is a once daily  fixed dose combination of Namenda XR and Aricept  We do not expect the trend to reverse this quarter  Meanwhile  investors will be interested to hear about Namzaric s performance in the quarter  Asacol Delzicol sales will also continue to be hurt by reduction in demand for Ascaol HD following the launch of an authorized generic in Aug 2016 Meanwhile  the LifeCell acquisition  which closed in February this year  should support the top line For the first quarter  the company expects revenues of approximately  3 5 billion  which includes two months of LifeCell revenues  This quarter will record the lowest revenues this year  Sales are expected to be hurt by an anticipated change in U S  wholesale buying patterns and normal seasonality in the first quarter Earnings WhispersOur proven model does not conclusively show that Allergan is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Most Accurate estimate stands at  3 28  while the Zacks Consensus Estimate is pegged higher at  3 32  This results in an Earnings ESP of  1 21   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Allergan s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Allergan PLC  Price and EPS Surprise
    
Stocks to ConsiderStocks in the pharma sector that have both a positive ESP and a favorable Zacks Rank are Editas Medicine  Inc    NASDAQ EDIT    which is expected to release on May 15  has an Earnings ESP of  32 26  and a Zacks Rank  3  You can see  ImmunoGen  Inc    NASDAQ IMGN   with an Earnings ESP of  2 78  and a Zacks Rank  3  The company is scheduled to release results on May 5 FIBROGEN INC   NASDAQ FGEN   with an Earnings ESP of  23 81  and a Zacks Rank  3  The company is scheduled to release results on May 9 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-03,Zacks Investment Research,https://www.investing.com/analysis/what's-in-the-cards-for-allergan-(agn)-this-earnings-season-200187130,200187130
105919,327434,AGN,Teva Pharmaceutical  TEVA  Q1 Earnings  What s In The Cards ,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   is scheduled to report first quarter 2017 earnings on May 11  before the market opens  Last quarter  the company delivered a positive earnings surprise of 3 03  This generic drug maker s shares have lost 14 1  so far this year compared with the Zacks classified  industry s decline of 2 1  Teva s earnings have surpassed expectations in three of the last four quarters and met the same in the remaining one  delivering an average positive surprise of 3 35  Let s see how things are shaping up for this announcement Factors to ConsiderWe believe that the inclusion of sales from Actavis  NYSE AGN  Generics acquisition should continue to pull up Teva s sales However  Teva s generic segment could continue seeing weakness  The segment will remain under pressure due to pricing erosion as well as the absence of important product launches Meanwhile  in the branded segment  sales of blockbuster multiple sclerosis  MS  treatment Copaxone should continue to erode due to increased competition  Glatopa  a generic version of Copaxone 20 mg  entered the market in Jun 2015  Teva is also facing patent challenges for the 40 mg thrice weekly formulation of Copaxone  Companies like Mylan N V    NASDAQ MYL   and Momenta are looking to get approval for their generic versions of the 40 mg thrice weekly formulation of Copaxone  Teva suffered a major setback in Jan 2017 with the U S  District Court for the District of Delaware invalidating four out of five Orange Book patents for Copaxone 40 mg  Teva intends to appeal against the decision  There is uncertainty regarding the timing of the generic launch of Copaxone 40mg  It is possible that certain competitors may receive FDA approval and launch before the appeal decision is out Meanwhile  Azilect revenues should decline this quarter as a generic version of Azilect was launched in the U S   in January this year Teva continues to focus on its cost reduction program  which should give its profits a boost In April  Teva announced FDA approval of SD 809 for the treatment of chorea associated with Huntington disease  HD   The tablets will be marketed by the trade name of Austedo  We expect management to update on the commercialization plans for the new drug at the conference call At the fourth quarter conference call  Peterburg had said that a thorough review of the business is being conducted  Teva has also begun a comprehensive search for a new CEO with significant pharmaceutical experience  We expect an update on the CEO search at the conference call Earnings WhispersOur proven model does not conclusively show that Teva is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is  4 85  as the Most Accurate estimate stands at 98 cents while the Zacks Consensus Estimate is pegged higher at  1 03 per share  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Teva s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderTeva Pharmaceutical Industries Limited Price  Consensus and EPS Surprise
    Some stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are Expected to release results on May 15  Editas Medicine  Inc    NASDAQ EDIT   has an Earnings ESP of 32 26  and a Zacks Rank  3  You can see  Ionis Pharmaceuticals  Inc    NASDAQ IONS   has an Earnings ESP of  250 0  and a Zacks Rank  3  The company is scheduled to release results on May 9 Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-07,Zacks Investment Research,https://www.investing.com/analysis/teva-pharmaceutical-(teva)-q1-earnings:-what's-in-the-cards-200187747,200187747
105920,327435,AGN,The Top Earnings Charts To Start The Week ,opinion,"The earnings party isn t over yet 
While most of the S P 500 has reported  there are still hundreds of companies expected to report earnings this week  including many mid and small cap companies 
Also on tap are the retailers  which has been one of the most maligned industries  Will they show a turnaround 
The week starts off with two well known retailers  including the largest online only home goods retailer 
These companies all have great earnings track records  Can they do it again this quarter 
The Top Earnings Charts to Start the Week1     Allergan   NYSE AGN    the maker of Botox and Latisse  has a great record of beating with just two misses in the last 5 years 2     Aon   NYSE AON   has a fantastic chart as shares are hitting new highs going into the earnings report  It also has a great surprise record with just 1 miss in 5 years 3     Blue Buffalo Pet Products   NASDAQ BUFF   hasn t missed since its 2015 IPO  It s in the hot area of all natural pet food but shares have been choppy 4     Wayfair   NYSE W   has only missed one time in the last 5 years but shares are stuck in a narrow trading range  Could this be the quarter that sends the shares into the breakout 5     Party City   NYSE PRTY   isn t an apparel retailer  but investors are still jittery  It has missed twice since the 2015 IPO  Are Americans still shopping for and hosting parties 
Want to Learn How to Trade Options 
If you want more guidance on the options trades this earnings season  Dave Bartosiak takes you through the trades on  
Travel giant Priceline  PCLN  is reporting this week  Shares are at all time highs 
What does Dave think about the options trade 
Watch below to find out 

Join him for all of the options trading action this earnings season  Don t miss a single trade 
Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them                                                                                       
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-05-08,Zacks Investment Research,https://www.investing.com/analysis/the-top-earnings-charts-to-start-the-week-200187826,200187826
105921,327436,AGN,Ironwood  IRWD  Q1 Loss Wider Than Expected  Sales Miss,opinion,Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   reported first quarter 2017 adjusted loss of 33 cents per share  significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year ago loss of 8 cents  Total revenue  collaborative revenues  in the quarter amounted to  52 2 million  down 20 9  from the year ago period and also below the Zacks Consensus Estimate of  72 million  In the last year quarter  the company received a milestone payment of  15 million from Astellas for the development of Linzess to treat adults with IBS C in Japan Ironwood s shares lost 1  on May 8  2017  following the earnings release  A look at the company s share price movement shows that the stock has underperformed the Zacks classified  industry this year so far  Ironwood s shares gained 2 9  during this period  while the industry registered an increase of 5 4  The Quarter in DetailAs reported by partner Allergan plc   NYSE AGN    Ironwood s key marketed product   Linzess   generated U S  net sales of  147 6 million  down 15  sequentially but up 7 7  year over Please note that Ironwood and Allergan have an equal share in brand collaboration profits or losses  Ironwood s share of the net profits from the sales of Linzess in the U S   included in collaborative revenues  was  49 5 million in the first quarter  down 21 2  sequentially According to data provided by IMS Health  Linzess prescriptions filled during the quarter crossed 700 000  up 17  from the year ago period Differences in trade buying patterns  which resulted in destocking of approximately  20 million in inventory during the first quarter  drove sales and prescription growth of Linzess During the reported quarter  selling and administrative  SG A  expenses increased 53 6  to  55 6 million  primarily due to investments for the launch of Zurampic Research and development  R D  expenses were  33 7 million  up 6  from the year ago period due to costs associated with pipeline development Other UpdatesLinzess is currently approved in the U S  for the treatment of adults with irritable bowel syndrome with constipation  IBS C  290 mcg  and chronic idiopathic constipation  CIC  145 mcg   Ironwood and Allergan are looking to broaden Linzess  label by expanding the targeted patient population and gaining approval for additional indications This January  the FDA approved a 72 mcg dose of Linzess for the treatment of adults with CIC  The new dose was introduced in Mar 2017  Approval for this lower dose strength would boost prescriptions in the large  heterogeneous adult CIC patient population  In Dec 2016  Ironwood announced positive top line data from a phase IIb study evaluating a colonic formulation of Linzess  Data from the study showed that the colonic formulation led to improvements in pain relief over Linzess  supporting the advancement of the colonic formulation to phase III development in 2017 Allergan has a deal with Astellas for Linzess in Japan  In China  Hong Kong and Macau  Ironwood has an agreement with AstraZeneca plc   NYSE AZN   for Linzess  The drug received approval for IBS C indication in Japan in Dec 2016 and was subsequently launched in Mar 2017  Furthermore  a regulatory filing has been submitted in China for IBS C  The company expects the review to be completed in the first quarter of 2018 Zurampic  Ironwood s second commercial product for the treatment of uncontrolled gout  was launched in Oct 2016 Zurampic raked in sales of  0 3 million in the quarter  Zurampic prescriptions filled during the quarter were 900  higher than 371 prescriptions filled in the previous quarter  At the call  management said that it expects slow uptake of the drug in 2017  The company also expects sales to be nominal as it works on educating physicians and patients as well as secure payer access This year  Ironwood expects to launch Duzallo  the fixed dose combination of Zurampic and allopurinol  The new drug application for Duzallo was accepted by the FDA for review in January this year  The PDUFA date is in the second half of 2017 and the drug is expected to be launched in late 2017  If approved  Duzallo would become the first dual mechanism treatment for patients with uncontrolled gout 2017 GuidanceThe company continues to expect to use less than  100 million for operations in 2017  much higher than the 2016 levels  This is due to the full year of commercial expenses related to the launch of Zurampic and to support the launch of Duzallo and pipeline advancement The company also maintained its R D expenses and SG A expenses guidance for 2017 in the range of  145  160 million and  235  250 million  respectively Ironwood Pharmaceuticals  Inc  Price  Consensus and EPS Surprise    Zacks Rank   Key PicksIronwood currently carries a Zacks Rank  3  Hold   A better ranked stocks in the health care sector is VIVUS  Inc    NASDAQ VVUS    which sports a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-05-08,Zacks Investment Research,"https://www.investing.com/analysis/ironwood-(irwd)-q1-loss-wider-than-expected,-sales-miss-200187989",200187989
105935,327450,AGN,Orexo  The Highs And Lows Of 2016 ,opinion,"Orexo AB  ST ORX  made significant progress in 2016 towards becoming a sustainable speciality pharma company  with continued Zubsolv revenue growth contributing to a first full year of profitability  Key achievements included the ex US global Mundipharma licence deal for Zubsolv  EMA filing in Q4   and the first large exclusive Medicaid FFS contract in Maryland  Despite this  and ahead of major newsflow in 2017  IP infringement litigation remains a stock overhang with Orexo trading near 52 week lows  We believe the market s view of Zubsolv s prospects is too pessimistic  Our new assumptions  updated for evolving market dynamics  generate a SEK3 16bn or SEK91 share valuation  vs SEK4 54bn or SEK131 share  

FY16 operational review
FY16 delivered the Mundipharma deal and Europe filing  potential approval Q417   completion of the RESOLV study  approval of the lowest Zubsolv dose strength and grant of two new patents  Disproportionate share of growth with C275 physicians is being captured by Zubsolv as new legislation is implemented  The outcome of the first IP challenge precludes Actavis  NYSE AGN  from generic launch pre 2019  Orexo has appealed the invalidity of the  330 patent  ruling late 2017 early 2018  ",2017-02-21,Edison,https://www.investing.com/analysis/orexo---the-highs-and-lows-of-2016-200176402,200176402
105936,327451,AGN,The Zacks Analyst Blog Highlights  IBM  Allergan  Chubb  DISH Network And HP,opinion,"For Immediate Release

	Chicago  IL   February 27  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include IBM  NYSE          Allergan  NYSE AGN   NYSE          Chubb  NYSE CB   NYSE         DISH Network  NASDAQ          and HP Inc   NYSE         

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Friday s Analyst Blog  

Top Research Reports for Monday  IBM  AGN  CB

	Today s Research Daily features new research reports on 16 major stocks  including IBM  NYSE          Allergan  NYSE         and Chubb  NYSE        

IBM  shares have turned around over the last one year  up  35 1  vs   22 6  for the Zacks Technology sector  on greater appreciation for the company s outlook  The Zacks analyst likes IBM s strategic growth initiatives  including its Big Data   business analytics  cloud computing  mobile and social business  The recent better than expected Q4 earnings report has helped sentiment as well 

	The company s cloud based products continue to win customers like Chubb  In addition  tuck in acquisitions will lead to incremental revenues  strengthening its technology leadership and resulting in a more favorable mix of business   You can   

Allergan  shares have gained  28 6  over the last three months  outperforming the Zacks Medical Generic Drugs industry  which has increased  10 9  over the same period  Allergan reported strong fourth quarter results  wherein both earnings and sales beat estimates  Also  the company s 2017 sales outlook was above expectations  The Zacks analyst likes products like Botox and Linzess as well as new products  which are supporting sales growth 

	With the closing of the Teva deal  Allergan can now focus on the branded segment and is using the proceeds to buy back shares  pay down debt and pursue additional deals  However  Allergan faces generic threats for legacy brands like Namenda IR XR and Asacol HD   You can   

Chubb  shares have outperformed the Zacks Property  Casualty and Title industry over the last three months  gaining  9 8  vs  7 4   Chubb s fourth quarter earnings outperformed expectations and also improved year over year on higher net premiums written and investment income  Its inorganic growth story seems impressive and should help it achieve higher long term ROE 

	A strong capital position helps Chubb to engage in shareholder friendly moves and invest in strategic initiatives that drive growth  However  the company s exposure to cat loss and escalating expenses are headwinds  The recent uptrend in long term interest rates is beneficial to Chubb and others in its space   You can   

	Other noteworthy reports we are featuring today include DISH Network  NASDAQ          and HP Inc   NYSE         

Today s Long Term Buys   Sells
	Today you can gain access to the best long term trades unearthed by Zacks Research  These moves have double and triple digit profit potential and are rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information  

	Today  Zacks is promoting its   Buy   stock recommendations    

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  













	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-02-26,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-ibm,-allergan,-chubb,-dish-network-and-hp-200177192",200177192
105937,327452,AGN,Pharma Industry Outlook   February March 2017,opinion,"There is no doubt that 2016 was a tough year for pharma and biotech stocks  with the sector facing a lot of criticism for rising drug prices  Although shares did rally post election in November on hopes that drug pricing would not be a key focus area under a Trump presidency  the rally turned out to be short lived following the President s views regarding drug pricing  Trump made it clear that he does not like what happened to drug prices and he will bring them down 
Not just drug pricing  2016 was also disappointing from an R D perspective with a fewer number drugs managing to gain FDA approval  There were some high profile pipeline failures as well  Other factors that weighed on the sector include mixed results  slower than expected new product launches and increasing competition 
The impact of these issues resulted in the NASDAQ Biotechnology Index declining 19 1  in 2016 while the NYSE ARCA Pharmaceutical Index fell 9 7  
Is the Sector Set for a Rebound in 2017 
So far in 2017 the sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5 1  while the NASDAQ Biotechnology Index is up 7 3   New product sales ramp up  R D success and innovation  strong results  FDA approvals and continued strong performance from legacy products are some of the factors that could contribute to a sustained recovery in the sector  Tax reforms as well as cash repatriation would support a recovery as well 
Valuation Looks Slightly Stretched 
Going by the current price to earnings multiple  which is often used to value drug stocks  the pharmaceutical industry doesn t look attractive at this point  The industry is currently trading at a P E multiple of 18 69 which is close to the S P 500 P E multiple of 18 71  Moreover  when compared to the industry s own performance over the last year  it can be seen that the multiple is close to the industry high of 20 01  So investors might not be keen to pay more premium to invest in this industry 
Drug Pricing Will Remain a Concern
Drug pricing  which was a key source of concern last year  will remain a headline risk in 2017 as well  Right now  there is low visibility on how this issue will play out  While it is clear that the government intends to address the drug pricing issue  there is no clarity on what steps will be taken 
Will M As Pick Pace in 2017 
While there were not too many acquisitions in 2016  expectations are that M A activities will pick up this year  So far in 2017  there has been limited M A activity with Johnson   Johnson  NYSE JNJ   JNJ  announcing its intention to acquire Actelion for  30 billion and a few bolt on deals being announced by other companies  However  expectations are high that M As will increase as the year progresses    potential tax reform and cash repatriation are expected to lead to a boost in this area    
Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals  with most of them finding it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 
Divestment of Non Core Assets   Restructuring Activities
Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  NYSE PFE   PFE   UCB  Novartis  Sanofi  PA SASY   Valeant  Glaxo  GSK  and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise 
Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 
New Products Should Gain Traction
Highly awaited new products that gained approval over the last couple of years should contribute significantly to revenues  Key new products include Ibrance  cancer   Cosentyx  psoriasis   PCSK9 inhibitors   Repatha and Praluent  Cotellic  advanced melanoma   Lartruvo  soft tissue carcinoma   Exondys 51  Duchenne muscular dystrophy   Tecentriq  urothelial cancer   and Taltz  moderate to severe plaque psoriasis   among others  The FDA also expanded the label of cancer drugs like Kyprolis  Imbruvica and Xalkori 
Biosimilars Gaining Importance
With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s  AMGN  blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S  The second biosimilar to gain approval in the U S  was Pfizer and Celltrion s Inflectra  infliximab dyyb  with the reference product being Remicade 
This was followed by the FDA approval of biotech giant Amgen s Amjevita  adalimumab atto   Amjevita is approved for use in all eligible indications of the reference product  AbbVie Humira  adalimumab   which is used for a wide range of inflammatory diseases 
And then there is Lilly  LLY  and Boehringer Ingelheim s Basaglar  which while technically not approved as a biosimilar  is a  follow on  insulin glargine product approved through an abbreviated approval pathway    Basaglar was found to be sufficiently similar to Sanofi s Lantus to scientifically justify reliance  and to establish its safety and efficacy for the approved uses 
Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion 
Apart from Novartis and Pfizer  companies like Merck  MRK   Amgen  Biogen  NASDAQ BIIB  and Allergan  NYSE AGN   AGN  are targeting the highly lucrative biosimilars market  While all these companies are Zacks Rank  3  Hold  stocks  you can see  
How Did the Sector Fare in Q4 Earnings Season 
As of Feb 17  2017  83 3  of the Medical sector had reported results with earnings growing 4 8  on revenue growth of 5 3  from the year ago period  While the earnings beat ratio was 80   the revenue beat ratio was 53 3   Medical is one of the standout sectors among the 16 Zacks sectors 
Meanwhile  a look at consensus earnings expectations from the Zacks  report shows that the Medical sector will deliver earnings growth of 5 5  and revenue growth of 5 4  in 2017 
While new products should start contributing significantly and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  challenges remain in the form of currency headwinds  additional competition  slowdown in growth of mature products and loss of exclusivity for certain key drugs 
Zacks Industry Rank
Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs 
We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry 
As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative  
The Zacks Industry Rank for Large Cap Pharmaceuticals is  169   196 for Medical Generic Drugs   156 for Medical Biomedical and Genetics and  103 for Medical Drugs  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Neutral for Large Cap Pharmaceuticals  Medical Drugs and Medical Biomedical and Genetics while Negative for Medical Generic Drugs 
8 Stocks with Huge Profit Potential
Just released  Driverless Cars  Your Roadmap to Mega Profits Today  In this latest Special Report  Zacks  Aggressive Growth Strategist Brian Bolan explores a full blown technological breakthrough in the making   autonomous cars  He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon ",2017-02-27,Zacks Investment Research,https://www.investing.com/analysis/pharma-industry-outlook---february-march-2017-200177137,200177137
105938,327453,AGN,Paratek Pharmaceuticals Shares Shoot Up Positive Late Stage Study,opinion,"Paratek Pharmaceuticals Inc  NASDAQ PRTK 
Paratek Pharmaceuticals  Inc   PRTK   a clinical stage biopharmaceutical company yesterday announced positive top line results from its phase 3 study of Omadacycline  Omadacycline is used to treat skin  respiratory and other infections  The drug has already received fast track status by the FDA and is hoping to secure FDA approval for the treatment by first quarter 2018 
Paratek Pharmaceuticals  Inc  CEO s Comments

 This successful study demonstrates the potential of omadacycline to treat community acquired bacterial pneumonia  a significant and serious health issue   said Michael Bigham  Chairman and Chief Executive Officer at Paratek   This Phase 3 study in pneumonia along with our previously announced successful Phase 3 study in skin infections satisfy the regulatory filing requirements of our special protocol assessment with the FDA  We look forward to sharing these data with the FDA and EMA  Our plan is to submit our NDA in the U S  as early as the first quarter of 2018 with an EMA submission later in 2018   

PRTK Technical Analysis

PRTK opened trading yesterday at  19 25 which was exactly the same as the previous day s trading close  Shares closed trading yesterday at  18 60 and spiked up after market to  24 70  equivalent to a 33  increase from the closing price  Taking a look at the daily chart we can see that the last time PRTK traded above these levels we have to go back to September 24th  2015 when it traded at  25 83 
Taking a closer look at the daily chart we can see that before the spike up PRTK had already been in an overall upward trend dating back to November 1st  2016 when it traded at  10 40  PRTK has a float of 18 02 million shares and traded 4 23 times the normal daily trading volume on Monday 
For trading purposes  I would like to see PRTK open trading on Friday above  22 50 and if it does I would be looking to take a long position at the bell especially if it trades below the lower   My stop loss would be  0 30 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
Paratek Pharmaceuticals  Inc   a clinical stage biopharmaceutical company  focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States 
Its lead product candidates include omadacycline  a broad spectrum  intravenous  and oral antibiotic  which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections  ABSSSI   community acquired bacterial pneumonia  CABP   urinary tract infections  and other community acquired bacterial infections  and Sarecycline  a tetracycline derived compound that is in Phase III clinical trial for the treatment of acne and rosacea 
The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP 
It has collaborative research and license agreement with Allergan  NYSE AGN  plc to research  develop  and commercialize tetracycline products  license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases  or medical conditions  and license agreement with Shin Nippon Biomedical Laboratories Ltd  to develop TO 2070 for the treatment of acute migraine 
The company also has a cooperative research and development agreement with the U S  Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases  Paratek Pharmaceuticals  Inc  was founded in 1996 and is headquartered in Boston  Massachusetts ",2017-04-04,Warrior Trading,"https://www.investing.com/analysis/paratek-pharmaceuticals,-inc.-$prtk-stock-|-shares-shoot-up-positive-200181255",200181255
105957,327472,AGN,Moody s  Outlook For Global Pharmaceuticals Stable Despite Growing Anger,opinion,"Moody s expects global pharmaceuticals to be stable in 2017  as cost pressures neutralize gains from rising demand  and modest price increases in U S  offset single digit declines in rest of the world and despite growing anger over  The outlook for the medical device industry and for profit  was also rated stable 
Healthcare will account for a larger share of GDP in most countries  as demographics  including aging populations  continue to drive rising demand for pharmaceuticals  notably in emerging markets  However  the growth is creating severe budgetary pressures in most parts of the world  and pricing scrutiny in the U S  creates  
Still  successful product launches in oncology and other complex diseases  and ongoing cost reduction programs will help drive earnings growth of 2  3    the ratings agency said 
A potential repeal of Obamacare   as pledged by president elect Donald Trump   is seen as negative for two of the three segments  While hospitals would be adversely affected by the expected rise in the number of uninsured  the devices industry would face increased pricing pressure  The outlook for pharmaceuticals was seen to be stable  as reduced fees would be offset by modestly lower drug volumes 
Pfizer  NYSE PFE  rated A1 stable among global pharmaceuticals
Among top pharmaceutical companies  Pfizer was rated A1 stable based on its scale and diversity  with low single digit growth driven by the cancer drug Ibrance  Astrazeneca s  NYSE AZN   A3 stable  sustainable growth will depend on successful launches from late stage pipeline as patent expirations subside  while Allergan  NYSE AGN   Baa3 stable  faces a drag on account of larger shareholder payouts  Valeant  B3 negative  is expected to face  significant pricing pressure  on PBM formularies   very high financial leverage  and  unresolved legal exposures  
Emerging markets and introduction of new products  particularly in cardiology and orthopedics are key drivers for the medical devices industry  Among top device makers  Abbott was rated A2 with review for possible downgrade because of regulatory challenges in pending St Jude Medical Inc  NYSE STJ  and Alere Inc  NYSE ALR  acquisitions  besides limited free cash flow  Zimmer Biomet Holdings Inc  NYSE ZBH   Baa3 negative  was cited for LDR Holding Corp  acquisition delay and supply chain problems  Boston Scientific  NYSE BSX   Baa2 stable  is expected to bolster top line growth via new product launches while litigation risks remain on account of IRS tax dispute and pelvic mesh cases 
Earnings at for profit hospital chains are estimated to grow between 2 5  and 3 0   with increasing costs from higher wages and pharmaceutical prices a drag  Assuming the Affordable Care Act is not repealed  bad debts will rise on account of cuts in deductibles and co payments  Moody s expects the company to accelerate development of new reimbursement models and changes in healthcare delivery methods 
HCA  Ba2 stable   the largest for profit hospital system by revenue  is expected to outpace peers in EBITDA growth and cash flow performance  Community Health Systems Inc  NYSE CYH   B2 negative  faces declining EBIDTA  challenges from shifts to smaller  rural markets after Quorom Health spinoff and other planned divestitures  and has only limited opportunity for improvement  Moody s expects review of strategic alternatives to cause  near term uncertainty  
Tenet Healthcare  NYSE THC  Corp   B2 negative  suffers from  very high leverage  with limited opportunity for meaningful improvement  Its USPI acquisition was seen as indication of  interest in outpatient services beyond existing hospital markets  and joint ventures revealing a  growing strategy of partnering with not for profit hospitals  ",2016-12-15,ValueWalk,https://www.investing.com/analysis/moodys:-outlook-for-global-pharmaceuticals-stable-despite-growing-anger-200169796,200169796
105958,327473,AGN,Opening Bell  Range Bound Markets Today  And Through The Week,opinion,"by Eli Wright
Global markets have mostly been trading sideways during the second half of December as a holiday induced calm descended on markets  With many exchanges still closed today for Christmas Boxing Day  the trend should extend into New Year celebrations at the beginning of next week  Markets in Australia  New Zealand  Canada  Britain  and Hong Kong are all closed 
Asia Pacific shares have been the most active over the past two weeks  trading within a three percent range   and dropping lower to end last week  as indicated in the chart below comparing the Dow  S P 500  NASDAQ Composite  MSCI Europe and FTSE Asia Pacific indexes over the past two months 


Overnight in Asia  however  major indices were up  the Shanghai Composite rose 0 17  to 3 115 33  while the Nikkei edged 0 03  higher  to 19 403 06  The Hang Seng was closed for Christmas 
European markets have fluctuated within a small  two percent range for the past two weeks  In early trading  the DAX is up 0 16  to 11 468 50 while the Stoxx 50 is 0 09  higher  at 3 277  The FTSE is closed until tomorrow 
US markets have been the most tightly range bound for the past two weeks  with the Dow  NASDAQ  and S P 500 all within an approximate span of     one percent  That doesn t appear to be changing today  In pre market trading  the S P is up just 0 01  while the NASDAQ is up 0 02   The Dow is 0 03  lower 
US Treasury yields moved sideways last week in narrow ranges as well  Yield for the 2 year bond note is currently at 1 218   the 10 year yield is at 2 553   and the 30 year yield is 3 132   With the yield arrow currently pointing up for all three of these Treasury Bonds  technical indicators  chart below  favor additional near term increases  The 2 year note especially is currently at levels previously seen in 2008 

Despite the recent uptick  bond yields are still at historically low levels 
Forex
Much like the equity markets  currency trading has also tailed off during the holiday period  The range for USD JPY has grown smaller with each passing day  The pair is currently trading at 117 30 
Once this period of consolidation ends  the US dollar will likely resume its bullish trajectory versus the yen and move towards 118 again 

The British pound has been struggling since the Fed raised rates  Currently at  1 2276  it could fall further still when its current consolidation phase completes  The next downside target is  1 2182  upside target is  1 241 

The euro has weakened yet more since the US election  it s fallen off approximately six and a half cents  Divergent monetary policy should continue to weigh on the single currency 
Much like the yen and GBP  once FX trading picks up after the holidays  more downward movement for the EUR is likely  Many analysts expect EUR USD to reach parity  possibly as early as the beginning of next year  One analyst even makes the case for a lower low  Indeed  with most EUR USD crashes since 2008 experiencing 20  25  declines  a downside correction from the most recent high of  1 16 would land the euro squarely in the  0 85  0 95 area 

Thus far today  the dollar has made small gains against a basket of currencies  The US Dollar Index currently sits at 103 02 
Amongst the major currencies today  only the Aussie has gained against the greenback  as of this writing 

Commodities
Gold is up one percent this morning  to  1 145 45  However  it s been in a straight downward decline for the past seven weeks straight 
The precious metal has endured seven consecutive  bearish weeks previously the last time from June 22 August 3  2015 when prices were approximately  1 090 ounce  This current bearish downleg  however  is unique in that each week the yellow metal experienced a lower close than the week before  At this point  a move toward  1 080  1 050 is not out of the question  An upside move could see gold rise to  1 170 

Oil is currently trading at  53 35  a level not seen since July  2015  Brent is up  trading at  56 10 
Last month  for the first time in eight years  OPEC actually behaved like a cartel  and promised to cut oil production by 1 2 billion bpd  Selected non OPEC nations joined the agreement several days later  The deal is slated to take effect at the beginning of the New Year and extend through the first half of 2017  If the nations that agreed to the deal can actually comply by limiting production  this arrangement could potentially keep oil prices buoyed until the US s  the peak demand period for the commodity 
On occasion markets will react to breaking news  particularly when it relates to oil  but traders appear to be unfazed by the latest out of Russia  where yesterday it was announced that a 2017 production increase should be expected  As Russian Deputy Energy Minister Kirill Molodtsov  

 Supposedly 253 5  million tons of oil are expected to be exported from Russia  this year  which is 4 8 percent more than in 2015  In 2017  we will have a little more than this  

Stocks
On Sunday we covered weekly sector performance  as well as the biggest gainers and losers on the S P  In this post we ll focus just on Friday s close  The S P gained 0 11  on the day  rising to 2 263 79  but Health Care companies were the real winners  led by the biotechnology sector which jumped 1 08  

Source  Fidelity com
The biggest gainers within the sector were Vertex Pharmaceuticals  NASDAQ VRTX  and Endo International  NASDAQ ENDP  which both jumped approximately 3 18   followed by Allergan  NYSE AGN  which rose 2 62   and Regeneron  NASDAQ REGN   which finished the day up 2 52  
Still  none of these stocks had a good 2016  YTD  Regeneron has fallen 30   Allergan has dropped 36   Vertex is down 15 34   and Endo has plummeted more than 73    the biggest decline of any company in the Health Care index 

Merck   Co  NYSE MRK  was the only Health Care stock that fell on Friday  edging 0 03  lower  to  59 56  Ironically  in contrast to Friday s Health Care gainers listed above  Merck is actually up 12 76  year to date ",2016-12-27,Investing.com,https://www.investing.com/analysis/opening-bell:-range-bound-markets-are-the-story-of-the-day-200170843,200170843
105959,327474,AGN,These Pharma Stocks Could Make You Sick,opinion,"We spend a lot of time highlighting sectors and industries that are outperforming the broader market and garnering plenty of bullish headlines  but it s just as important to identify lagging market niches for long only investors to avoid and short oriented traders to target 
After Tuesday s rally  there are only a couple of industry groups that are actually falling so far in 2017  as the below table shows 

Source  Faraday Research
Down Groups
Banking stocks  regional and general  are essentially unchanged on the year as the yield curve is roughly flat since January 1  That leaves Retail  Food and Beverage  and Pharmaceutical stocks as the only industries that are trading down by more than 1  so far this year  The first two are tied to the consumer and based on the recent improvements in consumer confidence figures  these stocks will likely need a run of persistently below expectation economic data to fall much further relative to the overall market 
The underperformance in Pharmaceutical stocks has an obvious culprit  a few weeks ago  then President elect Donald Trump noted in his first news conference that the pharmaceutical industry was  getting away with murder  and that  Pharma has a lot of lobbies  a lot of lobbyists and a lot of power  And there s very little bidding on drugs   Based on this rhetoric and the potential for new regulations on the industry  one of the few that may actually face increasing regulation under the Trump administration   we believe that pharmaceuticals will continue to face major headwinds in the coming months  As a possible counterpoint  It s worth noting that Trump s Health Czar nominee  Tom Price  has previous connections to  Big Pharma  and may be more lenient than some bears fear 
Longs To Avoid
Among the large cap pharmaceutical names we track  Allergan  NYSE AGN   Gilead Sciences  NASDAQ GILD   Eli Lilly  NYSE LLY   Bristol Myers Squibb  NYSE BMY  and Amgen  NASDAQ AMGN  are showing the worst long term momentum according to our proprietary measures  These are some names that long only investors may want to avoid and short biased traders may want to focus on    at least until the sector shows signs of bottoming out ",2017-01-24,Matthew Weller,https://www.investing.com/analysis/these-pharma-stocks-could-make-you-sick-200173462,200173462
105960,327475,AGN,5 Stocks Report Earnings Today  WFM  YUM  GRUB  AGN  IRBT,opinion,"Whole Foods Market Inc  NASDAQ WFM   Supermarkets faced a slew of headwinds in 2016 including stiff competition  food price deflation and waning store traffic  The combination of these factors made it difficult for high end grocery stores like Whole Foods    to re establish its footing  As a result the stock danced sideways for nearly 12 months on a number of mixed earnings reports  Moving forward  the company remains dedicated to revamping its pricing strategy with a focus on value offerings to meet changing spending behavior  The introduction of its lower price point  365  chain promises to help Whole Foods reach said goal 
The new stores come equipped with innovative technology  a modern look that appeals to millennials and most importantly lower prices  a concept that once escaped the Whole Foods brand  Many of its initiatives intend to stave off competition from traditional supermarkets like Kroger  NYSE KR  and non traditional ones like Amazon  NASDAQ AMZN   Walmart  NYSE WMT  and Costco  NASDAQ COST  
Yum  Brands  NYSE YUM   During the fourth quarter Yum Brands    completed the spin off of Yum China  creating two independent publicly traded entities  Yum China contributed meaningfully to the top line in previous quarters and for that reason year over year comparisons will look skewed  As for Yum Brands  Wednesday s report puts the spotlight on KFC  Taco Bell and Pizza Hut to persevere through the changing spending habits 
Various digital initiatives such as mobile ordering along with the frequent menu updates  that often include healthier items  aim to boost comps  That said  a number of near term headwinds post a legitimate threat to financial performance  including weak currency translation  volatile consumer spending  and macroeconomic uncertainty 
Grubhub Inc  NYSE GRUB   Strong marketing efforts and ongoing initiatives to improve delivery networks helps Grubhub    gain traction in areas outside of major cities and also strengthens its competitive advantage  While the company holds an advantage in the space  the business model requires huge volumes to generate meaningful profits 
If Grubhub is unable to secure more volume on a sound pricing strategy  this will put pressure on financial performance  Meanwhile  competition continues to emerge from the most likely sources  including threats from Amazon and Uber 
Allergan  NYSE AGN   Revenue for the quarter is predicated on new product launches  international growth and progression of established products like Botox  Earnings  on the other hand  will reflect operating expense management and a lower share count  Analysts expect new products like Viberzi and Vraylar to maintain the upward trend started during the third quarter 
On the downside  a slew of Allergan s    legacy products face threats from genericization  a problem that continues to hurt sales in the pharmaceutical space  The handful of acquisitions Allergan made during the quarter should offset some of the lost sales from generic competition 
iRobot Corporation  NASDAQ IRBT   iRobot s    line of cleaning products continues to gain traction on the back of a steadily improving consumer spending environment  Analysts believe strategic marketing initiatives coupled with new product launches and international expansion will support strong results moving forward  But the company still faces several near term threats  including currency headwinds  slowing demand and macroeconomic uncertainty ",2017-02-08,Estimize,https://www.investing.com/analysis/5-stocks-to-watch-that-report-earnings-tomorrow-200175007,200175007
105961,327476,AGN,Opening Bell  Uncertainty Rules Directionless Markets,opinion,"by Eli Wright
In the face of ongoing global political and economic uncertainty  as well as falling oil prices after yesterday s API weekly crude oil stock release showed a bigger than expected build in inventories  traders appear to be playing it safe  Neither bulls nor bears can be said to definitively hold the reins right now  Of course  this could also be the calm before the next storm 
The Dollar Index is up a scant 0 15  this morning  back over the 100 mark  albeit barely  at 100 40  equity markets are mixed  and gold has dipped lower 
Overnight in Asia  the Nikkei rose 0 45  to 18 996  the Shanghai Composite gained 0 46  to 3 167 45  and the Hang Seng moved 0 82  higher  to 23 524 
In Europe  the FTSE is 0 25  lower  at 7 168 75  the DAX is up 0 05   at 11 555  and the Stoxx 50  is 0 06  higher  at 3 236 50 
Wall Street indices pared gains yesterday after the Department of Commerce reported that the US recorded a  502B trade deficit in 2016  the   Though the Dow reached an intraday record high of 20 155 35  it closed lower at 20 090 29  for a daily gain of 0 19   The NASDAQ also notched a midday record of 5 196 27  but it ended the day at 5 185 88  up 0 35   The S P 500 eked out a 0 02  gain  closing at 2 293 08  it s still hovering near its record high  the benchmark 2 300 
Technical charts echo the current market malaise  the recent spate of indecisive candles culminating in yesterday s doji stars indicate a lack of clear direction for traders 

Indeed  since the US election on November 8  there have been only two days where the S P moved more than one percent  In both cases  it pushed higher  As Bespoke Investment Group   it s been more than 80 days since the S P last saw a decline of more than one percent 

Source  Bespoke Investment Group
Given these conditions  traders might very well react strongly to decisive market changes in either direction  if markets go markedly higher  profit taking would certainly occur  conversely  a greater than 1  drop could see traders using the opportunity to enter new positions  For now though  despite the uncertainty  there are those who advise not betting against the S P 500 just yet 
In pre market trading  the major US indices are mixed  the Dow is 0 15  higher  the NASDAQ is flat  and the S P is down 0 12  
Looking at US Treasurys  2  and 30 year yields are flat at 1 169  and 3 019  respectively  while the 10 year yield has increased to 2 397  
Forex
The euro is down 0 15  against the dollar this morning  trading at 1 0663  The single currency continues to be pressured by anxiety surrounding upcoming elections in the Netherlands  France  Germany  and other EU nations  as well as by a deadlock among  regarding the current terms of the Greek bailout  EU lenders want more austerity measures  while the IMF disagrees 
The USD is also higher against the Japanese yen  up 0 06   at 112 47  Further upside exists for the pair at 113 72  However  we might not see any big moves until Friday  when President Trump meets with Japan s Prime Minister Shinzo Abe 
The New Zealand Dollar is flat at 0 73  ahead of the Reserve Bank of New Zealand s Interest Rate Decision 
Bitcoin is down 0 5   to  1 047 as China s central bank called in several of the country s exchanges for closed door meetings  On the upside  the crypto currency is currently only seven percent off its recent high of  1 135 reached on January 4 and it could challenge that mark again before traders decide whether to take profits or look to further gains 

The digital currency could also receive a boost if  next month  the SEC decides in favor of a rule adjustment that would pave the way for the  to trade on the Bats Global Markets exchange 
Commodities
Many analysts expected OPEC s production cuts to boost the price of oil  but crude has been moving lower since yesterday  it s down 0 81   to  51 75  ahead of today s EIA weekly crude inventory data  The forecast calls for an increase of 2 529M 
Brent is also trading lower  down 0 54   to 54 76 
Natural gas rose 2 3  yesterday  to  3 13  but it s down 0 26  today  to  3 122  Gas prices often fluctuate based on short term weather forecasts  Approximately 50  of US homes rely on gas for heating and with predictions calling for mostly warmer than usual temperatures for the rest of the winter in significant parts of the US  prices could continue to fall  NatGas s next level of support can be found at  2 843 
Gold is down 0 25   at  1 233 55  but the precious metal is still close to three month highs and could move higher to  1 260 
Stocks
More than 150 companies report earnings today  including 
Media and entertainment giant Time Warner  NYSE TWX  which is expected to report Q4 2016 earnings per share of  1 19 on  7 71 billion in revenue 
Fast food restaurant operator Yum  Brands  NYSE YUM   which owns and licenses Pizza Hut  KFC  and Taco Bell among others  is slated to report Q4 2016 earnings  with expected EPS of  0 74 on revenue of  4 11 billion 
Natural and organic foods supermarket chain Whole Foods  NASDAQ WFM  is expected to announce Q1 2017 earnings per share of  0 39 on revenue of  4 98 billion 
Goodyear Tire   Rubber  NASDAQ GT  is expected to report Q4 2016 EPS of  0 87 on  3 93 billion in revenue 
Two telecom and internet service providers also report  Level 3 Communications  NYSE LVLT  expects Q4 2016 EPS of  0 44 on revenue of  2 07B while CenturyLink  NYSE CTL  expects Q4 2016 EPS of  0 57 on revenue of  4 32B
Four pharma giants report on Q4 2016  Sanofi  NYSE SNY  expects EPS of  0 66 on revenue of  10 3B  GlaxoSmithKline  NYSE GSK  expects EPS of  0 64 on revenue of  9 23B  Allergan  NYSE AGN  expects EPS of  3 76 on revenue of  3 81B  and Mylan  NASDAQ MYL  expects EPS of  1 42 on revenue of  3 22B
President Trump continues to wield a heavy hand in the markets  yesterday Big Pharma was jolted after White House Press Secretary Sean Spicer clarified Trump s position on drug pricing during a  by saying the president was  absolutely  in favor of programs like Medicare negotiating lower drug prices 
The S P s pharmaceutical sector fell 0 31  in the aftermath 

Source  Fidelity com
Among the losers  Endo  NASDAQ ENDP  fell 4 15   Merck  NYSE MRK  dropped 1 14   Mallinckrodt  NYSE MNK  declined 0 89   Vertex Pharmaceuticals  NASDAQ VRTX  finished down 0 66   and Pfizer  NYSE PFE  closed 0 47  lower ",2017-02-08,Investing.com,"https://www.investing.com/analysis/opening-bell:-traders-stay-cautious-as-usd,-equities-edge-higher-200175039",200175039
105962,327477,AGN,SPY Remains In Tight  Choppy Range,opinion,"Morning Notes
US Futures are pointing slightly higher this morning while European stocks also trade higher  yet gains were muted after German December industrial production fell sharply lower by the most in 8 years  Asian stocks closed mostly lower 
Technicals

The SPDR S P 500  NYSE SPY  remains in a tight  choppy range making for a lack of follow through in the majority of stocks  Support will lie at the low of yesterday s range at  228 72  followed by  228 54   228 46   228 10  and  226 82  Resistance will lie at the high of yesterday s range at  229 66  followed by record highs at  229 71 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  
  Others On Watch  
Microchip Technology Incorporated  NASDAQ MCHP 
Gilead Sciences Inc  NASDAQ GILD 
Economic Calendar
10 30 EIA Weekly Petroleum Status Report
Notable Earnings Before OpenAlaska Air Group Inc  NYSE ALK    EPS Est   1 40 Allergan  NYSE AGN    EPS Est   3 76The Goodyear Tire   Rubber Company  NASDAQ GT    EPS Est   0 87Grubhub Inc  NYSE GRUB    EPS Est   0 25 Humana  NYSE HUM    EPS Est   2 05Time Warner Inc  NYSE TWX    EPS Est   1 19 
Notable Earnings After Close Whole Foods Market  NASDAQ WFM    EPS Est   0 39iRobot Corporation  NASDAQ IRBT    EPS Est   0 41",2017-02-09,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-list-2-8-2017-200175135,200175135
105979,327494,AGN,Amgen s Migraine Drug Hits Primary Endpoint In STRIVE Study,opinion,"Amgen  Inc    NASDAQ AMGN   announced top line data from a phase III study  STRIVE   which showed that its calcitonin gene related peptide  CGRP  receptor  erenumab  significantly reduced monthly migraine days in patients with episodic migraine Erenumab is being evaluated in two phase III studies for the prevention of episodic migraine and in phase II studies for chronic migraine STRIVE  n 955   a global randomized  double blind  placebo controlled study  is the second of the phase III studies for episodic migraine to report results this year  Under STRIVE  patients were randomized to receive either placebo  or one of two erenumab doses   70 mg or 140 mg   subcutaneously  once monthly for six months AMGEN INC Price and Consensus
    Patients enrolled in STRIVE were experiencing an average of 8 3 migraine days per month  at baseline  The study met the primary endpoint  Patients who were treated with either 70 mg or 140 mg erenumab experienced a statistically significant 3 2 and 3 7 days reduction  respectively  from baseline in monthly migraine days compared to a 1 8 day reduction for those receiving placebo at 24 weeks  In addition  the safety profile of erenumab was found to be similar to placebo and consistent with the previously reported studies Positive top line data from the first episodic migraine study  ARISE  were presented in September  Data showed that patients  when treated with erenumab  70 mg   experienced a statistically significant 2 9 day reduction from baseline in monthly migraine days  in comparison to a 1 8 day reduction in the placebo arm at 12 weeks  thereby meeting the primary endpoint of the study Earlier this year  positive data from a phase II study on erenumab for the prevention of chronic migraine were also announced Management believes that data from the above studies can support regulatory filings which are expected in 2017 Amgen is co developing erenumab with Novartis AG   NYSE NVS    We note that several companies  including Teva Pharmaceutical Industries Limited   NYSE TEVA   and Allergan plc   NYSE AGN   among others  are developing migraine treatments targeting CGRP Amgen currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top Investment Ideas for Long Term Profit How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-16,Zacks Investment Research,https://www.investing.com/analysis/amgen's-migraine-drug-hits-primary-endpoint-in-strive-study-200165280,200165280
105980,327495,AGN,Spectrum  SPPI  Gets CRL For Bladder Cancer Drug In U S ,opinion,"Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   announced that it has received a Complete Response Letter  CRL  from the FDA for its New Drug Application  NDA  for Qapzola  apaziquone  The company was looking to get Qapzola approved for the immediate intravesical instillation  post transurethral resection of bladder tumors  post TURBT  in patients with non muscle invasive bladder cancer  NMIBC  Consequently  Spectrum has stopped enrolling patients in the ongoing phase III program on Qapzola and is currently conducting a new smaller study on the candidate  following discussions with the FDA Note that this September  the FDA s Oncologic Drugs Advisory Committee  ODAC  voted against the approval of Qapzola  The ODAC stated that Qapzola failed to demonstrate a substantial evidence of a treatment effect in comparison with placebo We remind investors that Spectrum reacquired global development and commercialization rights to Qapzola in the U S   Europe and other territories from Allergan plc   NYSE AGN   under an amended collaboration agreement in 2013 The unfavorable response from the FDA is highly disappointing  Considering the lack of FDA approved treatments for post TURBT instillation in patients with NMIBC  there exists significant unmet for new treatment options Although Spectrum s product portfolio currently comprises six marketed products  the company has been unable to generate substantial revenues for most of them  Therefore  approval of pipeline candidates is crucial for the company Encouragingly though  Spectrum s shares were unaffected by the announcement Going forward  investor focus is expected to remain on further updates by the company on Qapzola SPECTRUM PHARMA Price
    Zacks Rank   Key PicksSpectrum currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Vanda Pharmaceuticals  Inc    NASDAQ VNDA   and Cambrex Corp    NYSE CBM    Both the stocks currently sport a Zacks Rank  1  Strong Buy   You can see  Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016 over the last 60 days  while its earnings estimates increased from 16 cents to 17 cents for 2017  The company posted a positive earnings surprise in three of the last four quarters with an average beat of 56 65  Cambrex s earnings estimates increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19 78  Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-11-21,Zacks Investment Research,https://www.investing.com/analysis/spectrum-(sppi)-gets-crl-for-bladder-cancer-drug-in-u.s.-200165839,200165839
105981,327496,AGN,Allergan Acquires Chase Pharma  Expands CNS Portfolio,opinion,"Allergan plc   NYSE AGN   announced that it has acquired Chase Pharmaceuticals Corporation  a clinical stage biopharmaceutical company that focuses on the development of treatments for Alzheimer s disease As per the terms of the agreement  Allergan provided an upfront payment of  125 million and is eligible to receive additional potential regulatory and sales milestone payments related to Chase s lead candidate  CPC 201 CPC 201  a combination of Aricept  donepezil  and solifenacin  is anticipated to enter a phase III study in 2017  based on feedback from the FDA from the recently completed end of phase II meeting We are encouraged by the company s efforts in expanding its CNS portfolio  Per data provided by Allergan in its press release  an estimated 45 million people are living with dementia across the world  Alzheimer s disease accounts for 60  to 70  of dementia cases The market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched  We note that AstraZeneca PLC   NYSE AZN    in collaboration with Eli Lilly and Company   NYSE LLY   is currently evaluating their experimental Alzheimer s disease treatment candidate  AZD3293  in a phase III study  AZD3293 has a fast track status in the U S Meanwhile  in a separate press release  Allergan announced that its XEN Glaucoma Treatment System  comprising XEN45 gel stent and XEN injector  has received FDA clearance  It is indicated for the management of refractory glaucomas  where previous surgical treatment has failed  or in patients with primary open angle glaucoma  and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy The company anticipates launching the XEN Glaucoma Treatment System in the U S  early next year   We note that XEN enjoys the CE mark in the EU and is indicated for the reduction of intraocular pressure in patients with primary open angle glaucoma who have failed previous medical treatments According to information provided by the company in its press release  60 5 million people were living with glaucoma in 2010  Moreover  the company expects the number of people suffering from glaucoma to increase to nearly 80 million by 2020 due to the growing aged population ALLERGAN PLC Price
    Allergan currently carries a Zacks Rank  3  Hold  Stock to ConsiderVanda Pharmaceuticals  Inc    NASDAQ VNDA   is a better ranked stock in the health care sector  with a Zacks Rank  1  Strong Buy   You can see  Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016 over the last 60 days  while its earnings estimates increased from 16 cents to 17 cents for 2017  The company posted a positive earnings surprise in three of the last four quarters  with an average beat of 56 65   Its share price has surged 80  year to date Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-23,Zacks Investment Research,"https://www.investing.com/analysis/allergan-acquires-chase-pharma,-expands-cns-portfolio-200166321",200166321
105982,327497,AGN,Pharma Stock Roundup  Lilly Alzheimer s Drug Fails  J J In Acquisition Talks With ALIOF,opinion,"The big news last week was the high profile failure of Lilly s   NYSE LLY   investigational Alzheimer s disease drug  solanezumab  While the news dented Lilly s shares with the stock touching a 52 week low  other companies involved in developing Alzheimer s disease treatments were also not spared  The development setback just goes to show how a single company s R D setback can impact the entire sector Meanwhile  does Johnson   Johnson s   NYSE JNJ   interest in acquiring Actelion   OTC ALIOF   imply the beginning of increased merger and acquisition  M A  activity in the pharma and biotech sector Recap of the Week s Most Important StoriesLilly Stumbles in Phase III for Alzheimer s Drug  Lilly s shares tumbled following the release of highly awaited data on its experimental Alzheimer s disease  AD  treatment  solanezumab  from a late stage study  The candidate was being investigated to see whether it can slow the progression of memory problems associated with amyloid  a protein that forms plaques in the brains of people with Alzheimer s  Solanezumab failed to meet the primary endpoint in the study that was conducted in patients with mild dementia due to AD  Lilly said that while results directionally favored solanezumab  the magnitudes of treatment differences were small  With this latest failure  Lilly has decided to drop the development of solanezumab and will be taking a charge of about 9 cents per share in the fourth quarter  Read more    Allergan Boosts Alzheimer s Disease Efforts with Chase Pharma Acquisition  Even though Lilly and other companies have faced setbacks in their development efforts for Alzheimer s disease treatments  pharma and biotech stocks remain committed to this therapeutic area  In fact  last week  Allergan   NYSE AGN   acquired Chase Pharmaceuticals  a clinical stage biopharma company whose lead pipeline candidate is being evaluated for Alzheimer s disease  CPC 201 is slated to move into a pivotal study next year  Read more    J J Eyes Actelion  Companies in Preliminary Talks  Shortly after rumors surfaced about acquisition talks  Johnson   Johnson and Actelion both confirmed the same and said that they are in preliminary talks regarding a potential deal  Switzerland based Actelion  which saw its shares surging 19 8  to a market cap of more than  19 billion  is focused on the discovery  development and commercialization of drugs for diseases with significant unmet medical needs  The company has a strong presence in the pulmonary arterial hypertension  PAH  market though Tracleer could start facing generic competition in the U S  from the first quarter of 2017  However  Actelion has been working on extending its core PAH franchise and has also been diversifying its pipeline into new therapeutic areas like multiple sclerosis  lupus  insomnia  Fabry s disease  specialty cardiovascular disorders and Clostridium difficile associated diarrhea among others AstraZeneca s Durvalumab Partial Clinical Hold Lifted  The FDA lifted the partial clinical hold on AstraZeneca s   NYSE AZN   durvalumab for head and neck squamous cell carcinoma  HNSCC  less than a month after it was placed  With the lifting of the hold  new patients can be enrolled in the studies evaluating durvalumab as monotherapy and in combination with tremelimumab or other potential medicines The FDA had placed the hold based on AstraZeneca s decision to pause enrolment of new HNSCC patients while a detailed analysis of adverse events related to bleeding observed in a couple of phase III studies was being conducted  Read more  AstraZeneca    Opdivo Label Expanded in the EU  Bristol Myers    NYSE BMY   immuno oncology drug  Opdivo  got a new indication added to its label with the  European Commission approving the drug for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma  cHL  after autologous stem cell transplant and treatment with Adcetris  This is the sixth EU approval for Opdivo in four distinct cancer types in less than two years  According to Bristol Myers  about 12 200 new cases and 2 600 deaths occurred in 2012 due to Hodgkin lymphoma  Read more     Bristol Myers is a Zacks Rank  3  Hold  stock  You can see  Performance
Large Cap Pharmaceuticals Industry Price IndexThe NYSE ARCA Pharmaceutical Index declined 0 7  over the last four trading days with Lilly falling 9 9  on the solanezumab setback  We note that Lilly has underperformed the Zacks categorized Large Cap Pharmaceuticals industry year to date  Meanwhile  Glaxo s shares were up almost 2  over the last four trading days Over the last six months  Merck   NYSE MRK   gained almost 10  while Bristol Myers declined 19 4   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for the usual pipeline and regulatory news as well as an update on the J J Actelion acquisition talks  Moreover  several companies including J J will be present at the annual meeting of the American Society of Hematology  ASH  with data Where Do Zacks  Investment Ideas Come From You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research   ",2016-11-27,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-lilly-alzheimer's-drug-fails,-j-j-in-acquisition-talks-with-aliof-200166850",200166850
105984,327499,AGN,Top Research Reports For Alphabet  Deere   Bristol Myers,opinion,"Monday  November 28 2016
Today s Research Daily features new research reports on 16 major stocks  including Bristol Myers  BMY   Google  GOOGL  and Deere  DE  
Bristol Myers shares have underperformed the broader market as well as the large cap pharma group this year  though the stock has turned around a bit since the election  Concerns about generic competition for several of its key products  particularly the HCV franchise  remain a major headwind for the stock  These issues notwithstanding  the analyst points out in the updated research reprot issued today Bristol Myers  efforts to develop its pipeline and strengthen its product portfolio  primarily through acquisitions and deals  An operating model focused on accelerating pipeline development and streamlining infrastructure bodes well for growth   You can  
Google s parent Alphabet  NASDAQ GOOGL  shares continued to lag the Tech sector as well as the broader market this year  but the company remains well positioned for the long run given its dominant share in a competitive  fast growing search market  The analyst discusses the pros   cons of investing in Alphabet shares at present in the updated research report issued today  On the positive side  the analyst points out the company s focus on innovation  strategic acquisitions and Android OS should continue to generate strong cash flows  Its diversification strategy is also positive  but requires significant investment and involves uncertain payback periods  particularly since these efforts are at the cutting edge of technology  Additionally  growing competition and legal hassles could intensify with Brexit   You can  
Buy rated Deere shares have surged 36  over the year  handily beating the broader market as well as the farming machinery industry  The analyst emphasizes that the company has benefited from the proper execution of its operating plans  disciplined cost management as well as its broad product portfolio  It stands firm on its commitment to reduce structural costs through indirect and direct material cost reduction  reduced headcount and other initiatives  Increase in construction spending  improvement in political conditions in Brazil and positive conditions in India is likely to lead to better results   You can  
Other noteworthy reports we are featuring today include Halliburton  NYSE HAL   Allergan  NYSE AGN  and American Airlines  AAL  
Confidential  Best Trades from Zacks Research Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand  He is now prepared to pass them along to you  Today Steve is also opening up Zacks  7 Best Stocks for October  2016 free of charge  From 220 Zacks Rank  1 Strong Buys  this Special tabs 7 for immediate breakout    
Sheraz Mian
Director of Research
Note  If you want an email notification each time Sheraz publishes a new article  please  
Today s Must Read









Featured Reports

The Zacks analyst believes that with the sale of the generics business to Teva  Allergan can now focus on the branded segment 


The covering analyst believes that massive improvement on the cost front due to significantly low quarterly expenses led the company to beat third quarter earnings estimates   


Though positive on American Airlines  bullish view on unit revenues in Q4  the Zacks analyst expects recent labor deals to hurt the company s near term earnings 


The covering analyst stresses that Jacobs intends to grow on contract wins  greater operational efficacy and lower costs  amid challenging market conditions 


The Zacks analyst believes that the quality of earnings was strong as is evident from improvement in underlying auto margins and strong results for homeowners  business despite high catastrophe loss


The Zacks analyst believes that Regency s decent Q3 result depicts same property NOI growth  Its deal to buy Equity One would boost its portfolio quality  


Though Garmin s aviation business remains lumpy  the Zacks analyst believes that the company s solutions remain popular among both Original Equipment Manufacturers and after market customers 

New Upgrades

Halliburton s effective cost management and improved utilization on the back of growing North American rig count has made the Zacks analyst turn bullish on the oilfield services behemoth 


As per the covering analyst  State Street remains on track to boost efficiencies through its restructuring plans  Also  the company s revenues will benefit from GE Asset Management acquisition  


The Zacks analyst believes American Water Works is well poised to benefit from its consistent investments aimed at strengthening infrastructure and making strategic acquisitions 

New Downgrades

The Zacks analyst believes that Chunghwa Telecom s disappointing outlook for 2016 should be a concern for investors


The covering analyst thinks low exposure to international markets and high level of inventory are concerns  Also  deep focus on premium items is detrimental to sales in a soft consumer environment 


The Zacks analyst thinks pressure on investment management fees amid muted AUM growth along with impact of new regulations continue to pose concerns ",2016-11-28,Zacks Investment Research,"https://www.investing.com/analysis/top-research-reports-for-alphabet,-deere---bristol-myers-200167027",200167027
105986,327501,AGN,Orexo  Worst Case Scenario Averted ,opinion,"The court ruling upholding the validity of the Orexo AB  ST ORX   996 Zubsolv patent precludes Actavis  NYSE AGN  from launching a generic before September 2019  Orexo has 30 days to decide whether to appeal the court decision that a second patent   330 with 2032 expiry  is invalid  A worst case scenario allowing imminent launch of Actavis generic s  has been averted  Zubsolv s IP portfolio includes two additional patents   900 and  421  that extend to 2032  which coupled with the prospect of an appeal on  330  means that significant hurdles remain ahead of Actavis generic launch 

Multi layer IP strategy for Zubsolv
Actavis is the only company to file ANDAs for generic Zubsolv to date  The recent ruling relates to the June 2016 court hearing concerning the first ANDA  filed 2014 covering Zubsolv 1 4mg and 5 7mg   the court decision upheld the validity of the 8 454 996 US patent but found 8 940 330 invalid  Since the first ANDA filing  the FDA has approved four further Zubsolv dose strengths and two new patents have been issued  9 259 421 and 9 439 900   Actavis s second ANDA was filed in 2015  Orexo responded by initiating two additional infringement suits  The first suit has an October 2017 trial date  the second  related to  421  is pending a court date 
To read the entire report Please click on the pdf File Below",2016-11-28,Edison,https://www.investing.com/analysis/orexo---worst-case-scenario-averted-200166794,200166794
105987,327502,AGN,Amgen Allergan File For EU Approval Of Avastin Biosimilar,opinion,Amgen Inc    NASDAQ AMGN    along with partner Allergan plc    NYSE AGN    announced the submission of a Marketing Authorization Application  MAA  to the European Medicines Agency  EMA  for ABP 215  their biosimilar version of Roche Holding  SIX ROG  AG s   OTC RHHBY   cancer drug Avastin  bevacizumab   ABP 215 is the most advanced oncology biosimilar candidate in Amgen s pipeline Amgen shares gained 3 5  in the past one month  comparing favorably with an increase of 3 1  for the Zacks classified Medical Biomed Genetic Market Last month  the companies filed a Biologics License Application  BLA  to the FDA for ABP 215 Note that Amgen has a collaboration agreement with Allergan for the worldwide development and commercialization of the former s oncology antibody biosimilar medicines The MAA submission was based on data from a phase III comparative efficacy  safety and immunogenicity study  which evaluated adult patients with non squamous non small cell lung cancer  NSCLC   The study confirmed no clinically meaningful difference between ABP 215 and bevacizumab in terms of efficacy  safety and immunogenicity We note that Amgen has a total of nine biosimilar candidates in its portfolio  which includes Amjevita  a biosimilar version of AbbVie Inc  s   NYSE ABBV   Humira  Amjevita was approved by the FDA this September  Those currently under development include the biosimilar versions of Roche s Rituxan  Eli Lilly s Erbitux  and Johnson and Johnson Merck s Remicade  Amgen has also tied up with Daiichi Sankyo for the commercialization of nine biosimilars in Japan  The company plans to launch the first biosimilar in 2017  followed by four others through 2019  subject to successful approval According to sources  the market for biosimilars can grow to  20 billion in 2020  Not surprisingly  competition in this space is intensifying with the number of pharmaceutical and biotech companies working on biosimilars growing by the day AMGEN INC Price    Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ,2016-12-04,Zacks Investment Research,https://www.investing.com/analysis/amgen-allergan-file-for-eu-approval-of-avastin-biosimilar-200168245,200168245
105990,327505,AGN,Here s Why Teva Pharmaceutical s  TEVA  Stock Is Down Today,opinion,"Shares of Teva Pharmaceutical Industries   NYSE TEVA   slipped over 5 8  in morning trading Tuesday after the company announced a change in upper level management  Teva is replacing the chief executive of its global generics group  Siggi Olafsson  with Dipankar Bhattacharjee  the current chief of its European generics group 
Going Through Changes
Bhattacharjee  who has served as CEO of Teva Generics Europe since 2013  will take over immediately  while Olafsson will step down and remain active in the company until retiring at the end of the first quarter of 2017 
Teva s generic medicines business has already undergone significant changes this year  as the company purchased Allergan s   NYSE AGN   Actavis generics group back in August  Nevertheless  heading into Tuesday  shares of TEVA were down nearly 45  on the year  The company has struggled with lagging revenues  and the entire generics industry has felt the pressure of a Justice Department probe 
Recent Challenges
Teva recently reported its third quarter financial results  and although its earnings came in a penny higher than the Zacks Consensus Estimate  quarterly revenues missed expectations by nearly  300 million  The company also cut its outlook for the remainder of 2016  Also read    
Investors have also been weary as the Department of Justice  DoJ  looks ready to file price collusion charges against several companies engaged in the generic drugs business  The DoJ investigation has been ongoing for several years and covers more than 12 companies and about 24 drugs 
Companies that have reportedly received subpoenas include Teva  Mylan   NASDAQ MYL    Impax Laboratories   NASDAQ IPXL    and Endo International   NASDAQ ENDP    among others 
Bottom Line
It s interesting to see Teva s stock sliding today  as some investors might think a changeup at the top is exactly what the company needs right now  However  it s safe to say that most investors aren t responding positively to what is a new batch of uncertainty thrown into an already volatile situation 
Stocks that Aren t in the News  Yet 
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015 with a stellar average gain of  26  per year ",2016-12-06,Zacks Investment Research,https://www.investing.com/analysis/here's-why-teva-pharmaceutical's-(teva)-stock-is-down-today-200168464,200168464
105991,327506,AGN,Biotech Stock Roundup  Actelion Remains In M A Spotlight  ASH Data In Focus,opinion,"Several companies like Celgene  Read more     Alexion  Read more     Juno and Kite   NASDAQ KITE   were present at the annual meeting of the American Society of Hematology  ASH  with data on approved and pipeline products Meanwhile  Switzerland based Actelion   OTC ALIOF   continued to be a part of acquisition chatter with Sanofi  PA SASY  now rumored to be interested in the company Recap of the Week s Most Important StoriesIs Sanofi Planning to Come Up with an Offer for Actelion  Actelion  which had confirmed that it is in discussions with Johnson   Johnson  NYSE JNJ   could well receive an offer from French pharma giant  Sanofi  according to a Bloomberg article  Per sources  Sanofi is apparently considering a counterbid for Actelion and is weighing its options  The company is yet to decide whether it will approach Actelion with a formal offer Meanwhile  according to sources  J J has hiked its offer though Actelion is reportedly not interested in a complete takeover  We note that Actelion has often been considered an attractive takeover target mainly due to its rare disease portfolio  In addition to holding a strong position in the pulmonary arterial hypertension  PAH  market  Actelion s portfolio also has treatments approved in certain countries for specialist diseases like type I Gaucher disease  Niemann Pick type C disease  digital ulcers in patients suffering from systemic sclerosis  and mycosis fungoides type cutaneous T cell lymphoma  Actelion has consistently outperformed the Zacks categorized Medical Biomedical Genetics industry year to date  YTD  with Actelion gaining 50 3  while the Zacks categorized Medical Biomedical Genetics industry declined 25 4  AbbVie at ASH  Gets Orphan Drug Status for Immunology Drug  AbbVie   NYSE ABBV   was present at ASH with data on its cancer drug  Imbruvica  The company presented positive mid stage data from a study in chronic graft versus host disease  cGVHD  patients showing that Imbruvica has the potential to be evaluated for non cancer ailments  Imbruvica has orphan drug status as well as breakthrough therapy designation in the U S  for this indication 
AbbVie also announced safety and efficacy findings on Imbruvica from a phase II study in patients with relapsed refractory  R R  marginal zone lymphoma  MZL  with a 48  overall response rate being observed  AbbVie is currently seeking FDA approval for this slow growing form of non Hodgkin s lymphoma for which no specifically indicated treatments or standards of care are available in the U S 
AbbVie also presented data supporting the use of Imbruvica combination therapy for relapsed refractory diffuse large B cell lymphoma  DLBCL  and first line follicular lymphoma  FL     two of the most common types of non Hodgkin s lymphoma  Moreover  a 5 year analysis of Imbruvica data for chronic lymphocytic leukemia small lymphocytic lymphoma showed that 89  of patients achieved complete or partial response while long term RESONATE 2 follow up data showed lasting efficacy  Read more    Meanwhile  AbbVie continues to work on strengthening its presence in cancer and entered into 5 year collaborations with the Robert H  Lurie Comprehensive Cancer Center of Northwestern University as well as the Johns Hopkins University School of Medicine to work in several areas of oncology research including lung  colorectal  breast  prostate and hematological cancer Among non cancer updates  AbbVie s investigational immunology treatment  risankizumab  got orphan drug status in the U S  for Crohn s disease in pediatric patients  Read more    Amgen Files for Avastin Biosimilar  Amgen   NASDAQ AMGN   and partner Allergan  NYSE AGN  have submitted a regulatory application to the European Medicines Agency  EMA  seeking approval for ABP 215  a biosimilar version of Roche s multi billion dollar cancer drug  Avastin  bevacizumab   According to the companies  this may be the first bevacizumab biosimilar application to be submitted to the EMA  Read more     Amgen has performed better than the Zacks categorized Medical Biomedical Genetics industry YTD with its shares declining 10 6  compared to the Zacks categorized Medical Biomedical Genetics industry decline of 25 4  
Agios Stumbles on Data  Agios   NASDAQ AGIO   presented new data on a couple of pipeline candidates  AG 348 and AG 519  at ASH  Although data looked positive at first glance  the AG 348 results fell short of investor expectations while the drug related cholestatic hepatitis serious adverse event for the 300 mg dose of AG 519 left investors jittery  Shares were down 12 4   Both molecules are being evaluated for PK deficiency  a rare  potentially debilitating  congenital anemia  Agios has been underperforming the Zacks categorized Medical Products industry    while the Zacks categorized Medical Products industry declined 1 4  YTD  Agios declined 25 1  during this period Kite Starts Rolling BLA Submission for CAR T Therapy  Kite has started the rolling submission of its BLA for its CAR T therapy KTE C19  axicabtagene ciloleucel  in the U S  The company said that it expects to complete the submission by Mar 2017  Timely approval would allow the company to launch the product as early as 2017  Kite is looking to get the CAR T treatment approved for use in patients with relapsed refractory aggressive B cell non Hodgkin lymphoma  NHL  who are ineligible for autologous stem cell transplant  ASCT   The company has breakthrough designation for the candidate  Kite was also present at ASH with data on KTE C19  Read more     Kite has outperformed the Zacks categorized Medical Biomedical Genetics industry with shares declining 17 1  compared to the industry decline of 25 4  Performance
Medical   Biomedical and Genetics Industry Price IndexThe NASDAQ Biotechnology Index declined 2 1  over the last five trading days  All major biotech stocks were down with Vertex   NASDAQ VRTX   losing 8 8   Vertex has been underperforming the Zacks categorized Medical Biomedical Genetics industry YTD with the stock being affected for a major part of the year by political rhetoric regarding rising drug prices  Over the last six months  Celgene   NASDAQ CELG   was up 9 1  while Alexion lost 19 9   See the last biotech stock roundup here     Celgene is a Zacks Rank  2  Buy  stock  You can see  
What s Next in the Biotech World Watch out for the usual pipeline and regulatory updates from biotech companies Zacks  Best Investment Ideas for Long Term ProfitToday you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ",2016-12-06,Zacks Investment Research,"https://www.investing.com/analysis/biotech-stock-roundup:-actelion-remains-in-m-a-spotlight,-ash-data-in-focus-200168646",200168646
105995,327510,AGN,Teva Copaxone EU Label To Omit Pregnancy Contraindication,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU  The latest label update will improve the safety and tolerability profile of the multiple sclerosis drug The positive outcome was received through a variation report issued by the UK Medicines and Healthcare Products Regulatory Agency  However  the new label does recommend avoiding the drug during pregnancy unless its treatment benefits outweigh its risks On Monday  Teva announced the appointment of Dipankar Bhattacharjee to succeed Sigurdur  Siggi  Olafsson as President and Chief Executive Officer  CEO  of the global generic medicine group  Siggi is stepping down from the post of the CEO and he is due to retire at the end of the first quarter of 2017  Bhattacharjee  on the other hand  has been the CEO of Teva Generics Europe since 2013  Shares of Teva dropped more than 5  on Tuesday as Siggi s departure took the investment community by surprise In fact  Teva s share price has declined 46 6  so far this year  comparing unfavorably with the Zacks classified Generic Drugs industry s 38 3  decline For Teva  2016 has been a transitional year as it is working on the integration of Actavis Generics   Allergan plc s   NYSE AGN   generics business acquired in August   and is progressing with its branded pipeline  The Actavis Generics acquisition will help the company strengthen its position in the key generic markets  Teva is also looking to strengthen its biosimilar pipeline Meanwhile  Teva intends to accelerate growth platforms  protect and expand core franchises  expand its global presence  pursue strategic deals  and reduce the cost base  However  headwinds remain in the form of generic competition for Copaxone  as well as new competition for branded products  We note that Teva is facing patent challenges for the 40 mg formulation of Copaxone  Last June  Novartis AG s   NYSE NVS   generic arm  Sandoz  and partner Momenta Pharmaceuticals  Inc    NASDAQ MNTA   launched Glatopa  the once daily generic version of Copaxone 20 mg Teva carries a Zacks Rank  3  Hold   You can see  TEVA PHARM ADR Price and Consensus
    Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-12-06,Zacks Investment Research,https://www.investing.com/analysis/teva-copaxone-eu-label-to-omit-pregnancy-contraindication-200168631,200168631
106019,327534,AGN,Xbrane  Price Beating Products For Major Markets ,opinion,"Xbrane Biopharma s  ST XBRANE  first product offering will be Spherotide  the first generic formulation of the prostate cancer GnRH agonist triptorelin  sales  446m  made by Xbrane s Italian subsidiary  First sales are likely to be in Iran from 2017  Bigger sales could be generated by a biosimilar of Lucentis  Xlucane  produced at a low cost using a proprietary process  Xlucane might be marketed in the US from 2021  a year after patent expiry  and from patent expiry in Europe in 2022  Lucentis sales worldwide are about  3 6bn 
Prostate cancer   a  500m generic opportunity
Triptorelin  branded as Decapeptyl  total sales 2015   446m   Ipsen sales  334m plus Allergan  NYSE AGN  and Ferring  is indicated for advanced  non metastatic prostate cancer  It also treats Endometriosis  Triptorelin is one of a well established class that down regulate GnRH receptors  all brands are off patent  Most sales are of three month depot formations  continuity of dosing is crucial  The leaders are goserelin  Zoladex  AstraZeneca sales 2015   816m  and leuprolide  Lupron Abbive   826m   Generic depot formulations been very difficult to make  Spherotide is produced in Xbrane s Italian subsidiary  acquired in September 2015  Initial sales are planned to Iran in 2017  Xbrane estimates this market as worth  30m  It is awaiting GMP approval to ship a SEK7m order  A recent Chinese SEK70m deal should yield SEK17m cash in Q117  Clinical trials will be required for approval elsewhere  EU and US applications are planned in 2018  There is no clinical data 
To read the entire report Please click on the pdf File Below",2016-11-10,Edison,https://www.investing.com/analysis/xbrane---price-beating-products-for-major-markets-200163854,200163854
106020,327535,AGN,Pharma Stock Roundup  Pharma Stocks Rally On Trump Win  Pfizer To Divest Consumer Unit ,opinion,"Although some big names like AstraZeneca   NYSE AZN   and Mylan   NASDAQ MYL   reported Q3 results this week  earnings reports were overshadowed by the run up to the Presidential election and the surprise win of Donald Trump  In fact  the pharma sector responded favorably to Trump s victory on hopes that there will be fewer drug pricing headwinds considering Trump was not as vocal as Hillary Clinton about rising drug prices and excessive price hikes  Trump s pro business stand is also expected to benefit the sector  Major pharma companies should gain from Trump s proposed tax plan and proposal to repatriate corporate profits held offshore at a one time tax rate of 10  Recap of the Week s Most Important StoriesCrestor Generics Hit AstraZeneca Revenues  AstraZeneca s third quarter results were mixed with the company beating on earnings but falling short on revenues  In addition to cost management  earnings benefited from a non recurring inter government tax agreement as well  Shares were down following the release of Q3 results with sales being impacted by the genericization of Crestor  AstraZeneca also said that it was not likely to seek approval for its experimental immuno oncology treatment  durvalumab  for second line head and neck squamous cell carcinoma  HNSCC  based on the phase II HAWK study  The single arm study was initially designed as a potential fast to market opportunity for the second line indication but the company s changed plans were based on the recent changes in the HNSCC landscape including the approval of Merck s   NYSE MRK   Keytruda for this patient population  Moreover  durvalumab was placed on partial clinical hold by the FDA in late October for HNSCC Valeant Q3 Results Disappoint  Valeant   NYSE VRX   reported disappointing Q3 results missing both earnings and revenue estimates  Valeant also slashed its outlook for 2016  Read more     The company is facing several headwinds apart from the drug pricing issue and ongoing investigations into its pricing policy  Generic competition for some products  soft performance of the dermatology business  a 3 month delay in the FDA action date for brodalumab  severe psoriasis   quality challenges related to manufacturing issues  Valeant got a warning letter for its Rochester  NY site from the FDA   product recalls  and back orders are some of the issues being faced by the company  Moreover  B L international is facing challenges in Europe due to weakness in Poland and the Middle East  especially Turkey and Egypt  Not surprisingly  earnings estimates for Valeant are seeing downward revisions following the release of Q3 results Is Pfizer Contemplating Sale of Consumer Healthcare Unit  According to a Reuters article  Pfizer   NYSE PFE   is considering the sale or spin off of its consumer health segment for as much as  14 billion  The company s consumer healthcare segment  which brought in sales of  2 5 billion in the first nine months of 2016  is known for products like Advil  Centrum and Chapstick among others We remind investors that earlier this year  Pfizer had decided against splitting up its business  However  on the third quarter call on being asked about the consumer business  CEO Read had said that the company evaluates all its businesses and subjects them to tests to see whether they are worth more inside or outside Pfizer Meanwhile  Pfizer was also in the news for the EU approval of Ibrance for a specific type of breast cancer  This makes Ibrance the first medicine in a  new class of anti cancer treatments  CDK 4 6 inhibitors  to be approved in Europe and also the first new medicine to be approved for the treatment of women with this particular type of metastatic breast cancer in the first line setting in almost 10 years  Ibrance is one of the most promising new products in Pfizer s portfolio and EU approval was expected considering the CHMP had issued a positive opinion in September  Ibrance sales were  1 5 billion in the first nine months of 2016 Pfizer is a Zacks Rank  3  Hold  stock  You can see  Mylan   Partner Biocon File Herceptin Biosimilar  Mylan  which missed Q3 estimates  Read more     announced the submission of a regulatory application for a biosimilar version of Roche s   OTC RHHBY   Herceptin  trastuzumab  in the U S  This is Mylan s first FDA biosimilar submission  and the company believes it has the potential to be the first to seek approval for a biosimilar version of Herceptin in the U S Bristol Myers Provides Updates on Opdivo  Signs Deal with Nitto  Bristol Myers   NYSE BMY   came out with several updates this week  The company gained FDA approval for its immuno oncology treatment Opdivo for use in head and neck cancer Opdivo also met the primary endpoint in a late stage study for unresectable advanced or recurrent gastric cancer refractory to  or intolerant of  standard therapy  This is good news for the company as Opdivo is the first and only immuno oncology agent to demonstrate overall survival advantage in this patient population The company also announced a 5 year research collaboration with Johns Hopkins University for the identification of mechanisms of response and resistance in patients whose cancer is being treated with checkpoint inhibitor based immunotherapies  including Opdivo monotherapy  or Opdivo in combination with Yervoy or other investigational immunotherapies A clinical trial agreement was also signed with Infinity for Opdivo plus Infinity s IPI 549 in patients with advanced solid tumors The company has also signed an exclusive worldwide license agreement with Nitto Denko for the development and commercialization of Nitto s investigational siRNA molecules targeting heat shock protein 47  HSP47  in vitamin A containing formulations  The collaboration includes Nitto s lead asset ND L02 s0201  currently in early stage development for the treatment of advanced liver fibrosis The agreement will see Bristol Myers shelling out  100 million upfront and making subsequent payments in the form of clinical and regulatory milestone payments  royalties  sales based milestone payments as well as option exercise payments for lung and other organ fibrosis  This deal once again shows pharma s interest in developing treatments for fibrotic diseases and to develop therapies for patients living with advanced non alcoholic steatohepatitis  NASH  and cirrhosis due to NASH Performance
Large Cap Pharmaceuticals Industry Price Index
The NYSE ARCA Pharmaceutical Index recorded a gain of 7 6  over the last five trading days reflecting a positive response to Trump s win  Moreover  Proposition 61  California s ballot measure to ensure that the State of California is able to negotiate with drug companies for drug prices that do not exceed the price paid for the same drugs by the U S  Department of Veterans Affairs  was shot down by voters Among major pharma stocks  both Pfizer and Bristol Myers shot up more than 12  while AstraZeneca was down slightly on Q3 results  Over the last six months  Bristol Myers declined 20 8  while Merck was up 18 8   See the last pharma stock roundup here    
What s Next in the Pharma World Companies like Bristol Myers will be showcasing data at the annual meeting of the American College of Rheumatology  ACR  and the Association of Rheumatology Health Professionals  ARHP  in the coming days  Bristol Myers will also be presenting data along with Pfizer on Eliquis at the American Heart Association  AHA  Scientific Sessions 2016 Now See Our Private Investment IdeasWhile the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-11-10,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-pharma-stocks-rally-on-trump-win,-pfizer-to-divest-consumer-unit-200164131",200164131
106021,327536,AGN,Drug Stocks  Q3 Earnings To Watch On Nov 14  ARGS  AST,opinion,With 89  of the S P 500 members having already reported their results  the Q3 reporting cycle is soon to wrap up  Though earnings and revenue growth for the reported index members is still low  an improvement over other recent periods is palpable  In fact  it is being said that the  This is corroborated by the Q3 performance of the index members  Of the 445 S P 500 companies that have reported as of Nov 9  72 8  topped earnings expectations while 55 3  surpassed revenue estimates  Total earnings for these index members were up 4  from the year ago quarter on a 2 7  improvement in revenues This is on track to be the first quarter to see positive earnings growth after five quarters of back to back declines Several sectors are witnessing earnings and revenue growth this quarter and Medical is one of them  Our  shows that 88 7  of the companies in the Medical sector have reported results so far  with earnings growing 6 4  on 7 4  higher revenues  The blended beat  which represents the percentage of companies that have beaten both earnings and revenue estimates  stands at 42 6  The earnings picture for both the pharma and the biotech sectors is a mixed bag of beats and misses  Pharma giants such as Johnson   Johnson   NYSE JNJ    Merck  NYSE MRK    Co   Inc   and Bristol Myers Squibb Company  NYSE BMY  surpassed both earnings and revenue expectations  and raised their outlook for the year  Meanwhile  Allergan  NYSE AGN  plc and Pfizer Inc    NYSE PFE   lagged on both the fronts and trimmed their 2016 earnings guidance Meanwhile  in the biotech sector  Celgene Corporation   NASDAQ CELG   and Amgen Inc    NASDAQ AMGN   topped earnings and revenue estimates  and raised their expectations for 2016  whereas sector behemoth Gilead Sciences Inc    NASDAQ GILD   missed on earnings and barely surpassed revenue estimates  keeping its outlook unchanged for the year Several mid  and small sized pharma and biotech companies are yet to report Q3 results  Let s take a sneak peek at two such companies  both of which are scheduled to report Q3 results on Nov 14 Headquartered in Durham  NC  Argos Therapeutics Inc    NASDAQ ARGS   is an immuno oncology company focused on the development and commercialization of immunotherapies using the Arcelis technology platform  The most advanced candidate in the company s pipeline  AGS 003  is being evaluated for the treatment of metastatic renal cell carcinoma and non small cell lung cancer ARGOS THERAPEUT Price and EPS Surprise    Argos  track record has been far from encouraging with the company missing estimates in three of the trailing four quarters  bringing the average negative surprise to 5 66   This Zacks Rank  3  Hold  stock has an  of 0 00  for the third quarter  making it difficult to predict a positive surprise You can uncover the best stocks to buy or sell before they re reported with our Asterias Biotherapeutics  Inc    NYSE AST   is developing proprietary cell therapy programs based on its immunotherapy and pluripotent stem cell platform technologies  Currently  the company is focused on the advancement of its three pipeline candidates   AST OPC1  AST VAC1 and AST VAC2   across neurology and oncology ASTERIAS BIOTHR Price and EPS Surprise    This Fremont  CA based biotechnology company has a dismal track record  The company has missed expectations in three of the trailing four quarters with an average negative surprise of 30 64   This Zacks Rank  3 stock has an ESP of 0 00   once again making a surprise prediction difficult this quarter  You can see  Confidential from ZacksThis week  Zacks researchers have named 7 other stocks that look to break out even sooner than today s Bull of the Day  You can see these time sensitive tickers free  and access additional trades that are not available to the public ,2016-11-11,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks'-q3-earnings-to-watch-on-nov-14:-args,-ast-200164187",200164187
106022,327537,AGN,5 Reasons To Buy 5 Low P E Biotech ETFs ,opinion,"With Trump winning the U S  presidential election  the biotech and pharma sectors have regained their lost ground  Since Clinton   who has long been vocal against the price gouging issue in the pharma sector   is no more threat to the sector  pharma and biotech stocks should get a break from controversies  at least for some time 
As a result  biotech ETFs soared in the last five trading sessions  as of November 10  2016   returning in the range of 15 8 26   read    
An end to the price gouging issue is perhaps the key driver of the latest biotech rally  However  four other factors elaborated below may also have been instrumental in setting biotech and pharma stocks northbound for the days to come  read    
Cheaper Valuation 
The sector  which has long been an investors  favorite and saw an enormous run from late 2011 till summer 2015  has lost its luster from the year to date look  The risk off sentiments prevalent in the early part of 2016 hit this high beta high growth area  As a result  despite rebounding massively in recent times  the biotech ETF SPDR S P Biotech ETF  is off about 6  this year  as of November 10  2016   read  
Investors should also note that such a steep sell off brought down the once sizzling hot biotech space to a calmer valuation  XBI has a P E ratio of 16 56 times versus SPDR S P 500 ETF  NYSE SPY  s   AX SPY   P E of 17 73 
Same was the case for pharma ETFs which are off 7 8 18  so far this year  But SPDR S P Pharmaceuticals ETF   HN XPH   has a P E of 12 92 times  though other pharma ETFs are still richly valued  If we look at the overall medical sector  P E ratio of the S P 500 stands at  times for next year while the medical sector s is at 15 4 times  as per the Earnings Trends issued on November 9  2016 
Earnings Picture 
Now it is time to look at the earnings picture  The medical sector has logged 6 3  earnings growth in Q3 on 7 3  higher revenues  Notably  so far  revenue growth is the second highest in the 16 major sectors classified under the S P 500 index 
Lower Corporate Taxes in the Cards 
As per an article published on   corporate tax reform and cash access may facilitate biotech stocks and ETFs ahead  In his campaign  Trump indicated that he will reduce corporate tax to 15  and provide a one time repatriation holiday of 10   This lower tax rate would do wonders for big biotech companies like Biogen  NASDAQ BIIB  which can see EPS rising by about 10   as per the article 
Smaller cap biotech firms would be especially benefited as they are so cash stripped that their present cash holdings can fund just 11 months of research  as per Reuters 
Wave of Mergers   Acquisitions 
This new found source of cash would help several biotech companies to indulge in merger and acquisition activities  In any case  the space was known for inorganic growth  Although Allergan Plc   NYSE AGN   announced back to back takeover deals in late September and Pfizer Inc   NYSE PFE   announced its  14 billion acquisition of cancer drugmaker Medivation in August  deals have cooled down  off 65  year over year  in the sector lately  read    
 see  renewed interest in some prime targets of takeover speculation  from cancer drug specialists like Tesaro to rare diseases firms like Sarepta Therapeutics   Moreover  the sector s valuation is subdued at present  opening door for acquisitions at cheaper prices 
ETFs to Buy
We suggest buying low P E biotech ETFs at this moment to make the most of the election induced surge 
SPDR S P Biotech ETF    P E 16 56 times
BioShares Biotechnology Products Fund    P E 18 03 times
VanEck Vectors Biotech ETF   CM BBH     P E 18 08 times
ALPS Medical Breakthroughs ETF    P E 19 36 times
First Trust NYSE Arca Biotechnology Index Fund   LON FBT     P E 19 99 times
Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-11-13,Zacks Investment Research,https://www.investing.com/analysis/5-reasons-to-buy-5-low-p-e-biotech-etfs-200164542,200164542
106023,327538,AGN,AstraZeneca s Symbicort Positive In Pediatric Asthma Study,opinion,"AstraZeneca PLC   NYSE AZN   announced phase III study results for its well known product for asthma  Symbicort  The study showed that the drug improves lung function in pediatric asthma patients aged six to twelve years  Results from CHASE 3 phase III study evaluated Symbicort  budesonide formoterol fumarate dihydrate  Inhalation Aerosol 80 4 5 micrograms versus budesonide 80 micrograms  in pediatric patients 
The CHASE 3 study was conducted by the company after FDA asked for  additional data on budesonide and formoterol  particularly regarding the impact of different doses  in pediatric asthma patients between six and twelve years of age 
AstraZeneca has been making significant progress with its pipeline  Promising pipeline candidates dealing with asthma include benralizumab for asthma and chronic obstructive pulmonary disease  COPD  and tralokinumab for asthma and atopic dermatitis 
AstraZeneca is working on bolstering its pipeline and is looking for suitable acquisitions and deals  In order to strengthen its respiratory portfolio  AstraZeneca acquired rights to Allergan plc s   NYSE AGN   branded respiratory business in the U S  and Canada in Mar 2015 
In May 2016  AstraZeneca acquired Takeda Pharmaceutical Company Limited s   OTC TKPYY   core respiratory business  thereby gaining global rights to Daliresp Daxas
In Feb 2014  AstraZeneca boosted its diabetes portfolio by acquiring Bristol Myers Squibb Company s   NYSE BMY   global diabetes business 
Last week the company reported its third quarter 2016 results with core earnings of  1 32 per American Depositary Share  comfortably beating the Zacks Consensus Estimate of 48 cents ASTRAZENECA PLC Price
 

   AstraZeneca currently carries a Zacks Rank  3  Hold   You can see the  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-14,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca's-symbicort-positive-in-pediatric-asthma-study-200164564,200164564
106025,327540,AGN,5 Stocks To Watch That Report Earnings Tomorrow,opinion,"Teva Pharmaceutical  NYSE TEVA   Teva is in a position of strength heading into its third quarter report thanks to the results of the election and a continued shift towards generics  Teva recently purchased Allergan s generics brand for  500 million and Actavis Generics  NYSE AGN  in August   both of which are expected to help support top line growth moving forward  Analysts expected revenue to grow by 24  this quarter as it strengthens its position in the generic market  Teva is also seeing traction in its branded segment which features speaclity products such as Copaxane for use in treating multiple sclerosis  Weakness in international generic markets  particularly in the EU  will put partially offset the positive initiatives of the quarter 
Agilent Technologies  NYSE A  Agilent broad portfolio of products ranging from forensics to pharmaceuticals have performed remarkably well in recent quarters  In the second quarter the company delivered better than expected performance which featured 11  growth on the bottom line and 3  on the top  The company s three core reporting segments were up between 4  to 8  and helped deliver results above its previous guidance range  Agilent s continued focus on high growth markets through product launches are considered positives for moving forward 
JD Com  NASDAQ JD   Shares are trading down 27  this year on the back of decelerating revenue growth and plummeting profitability  JD com operates in a highly concetrated Chinese ecommerce space that is currently dominated by Alibaba and its subsidiares  That said  JD is proving that it can compete in this environment as it continued to see active users and order fulfillment growth  Consistent market initiatives have been placed to ensure long term growth and increase brand awareness  Meanwhile  a strategic product mix and expanded fulfillment capabilities are helping to drive traffic trends and support the top line  JD recently launched its commercial drone delivery service during China s annual Single s Day shopping event  Additional efforts like this will help close the gap between Alibaba  NYSE BABA  and hopefully propel the stock higher 
Home Depot  NYSE HD   Low interest rates and a bounceback in the housing market have led to robust earnings in recent quarters  Not only does Home Depot benefit from an increase in new home sales  but as home prices stay high  consumers tend to invest heavily into their properties  Strong job growth has also supported this ongoing trend  allowing consumers to spend on home improvement projects  In the second quarter the home improvement retailer posted a 4 7  increase in comparable sales and 5 4  in United States stores  The company should continue to deliver encouraging results but faces a number of near term headwinds including intense competition and significant international exposure  Besides Lowe s  consumers are starting to look towards online retailers like Amazon for their home improvement needs  This shift to e commerce could have a lasting impact on Home Depot if it is not taken seriously in the immediate future 
Dick s Sporting Goods Inc  NYSE DKS   Dick s has been gaining strength in recent quarters despite a pullback from apparel brands like Nike and Under Armour  Its efforts to expand online capabilities along with strategic marketing and merchandising have helped drive traffic trends and sales  Dick s has also benefited from a consolidation in the industry following the bankruptcy of Sports Authority stores  Dick s now owns the intellectual property and much of the branding of the former retailer  Tomorrow s report is forecasted to maintain its current trajectory but will more importantly shed some light on the pivotal holiday season to be reported in early 2017 ",2016-11-14,Estimize,https://www.investing.com/analysis/5-stocks-to-watch-that-report-earnings-tomorrow-200164605,200164605
106029,327544,AGN,Teva  TEVA  Q3 Earnings Top But Revenues Lag Estimates,opinion,"Israel based Teva Pharmaceutical Industries Limited   NYSE TEVA   is a global pharmaceutical company with a strong presence in the generics as well as branded markets  Teva s main branded products include Copaxone  multiple sclerosis  and Azilect  Parkinson s disease   Besides this  Teva s branded product portfolio consists of respiratory products like ProAir  a short acting beta agonist for the treatment of bronchial spasms and exercise induced bronchospasm  and Qvar  an inhaled corticosteroid for long term control of chronic bronchial asthma Moreover  the company has several candidates in its pipeline  Earlier this week  Teva completed its acquisition of Allergan s generics business  Actavis  NYSE AGN  Generics   The company also acquired Allergan s Anda Inc   the 4th largest distributor of generic pharmaceuticals in the U S   for  500 million in Oct 2016 Teva s earnings track record has been good with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 3 75  TEVA PHARM ADR Price and EPS Surprise
    Currently  TEVA has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  TEVA s third quarter earnings came in at  1 28 per share  beating consensus estimates of  1 27 Revenues  Teva posted revenues of  5 6 billion  missing consensus estimates of  6 billion Key Stats  Currency fluctuations cut third quarter revenues by about  188 million  Lead branded product  Copaxone  posted worldwide sales of  1 1 billion  down 2  2016 Outlook  Teva has lowered its guidance for 2016  The company now expects revenues in the range of  21 6  21 9 billion  previous guidance   22 0 22 5 billion  and earnings in the range of  5 10  5 20  previously   5 20 5 40  per share  The Zacks Consensus Estimate for 2016 revenue and earnings are  22 31 billion and  5 17 per share and  respectively Check back later for our full write up on this TEVA earnings report later Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2016-11-14,Zacks Investment Research,https://www.investing.com/analysis/teva-(teva)-q3-earnings-top-but-revenues-lag-estimates-200164738,200164738
106030,327545,AGN,Amgen Files For Avastin Biosimilar  Repatha Data Positive ,opinion,Amgen Inc    NASDAQ AMGN    along with its partner Allergan plc    NYSE AGN    announced the submission of a Biologics License Application  BLA  to the FDA for its biosimilar version of Roche Holding  SIX ROG  AG s   OTC RHHBY   Avastin  bevacizumab   ABP 215 ABP 215 is the most advanced oncology biosimilar in Amgen s pipeline  The company has a total of nine biosimilar candidates in its portfolio  of which Amjevita  a biosimilar version of AbbVie Inc  s   NYSE ABBV   Humira was approved by the FDA this September  The ones under development include biosimilar versions of Roche s Rituxan  Eli Lilly s Erbitux  and Johnson and Johnson Merck s Remicade  Amgen has also tied up with Daiichi Sankyo for the commercialization of nine biosimilars in Japan Note that Amgen has a collaboration agreement with Allergan for the worldwide development and commercialization of the former s oncology antibody biosimilar medicines In a separate press release  Amgen announced that it has presented detailed results of the GLAGOV trial at the American Heart Association  AHA  meeting  which were simultaneously published in the Journal of the American Medical Association GLAGOV is a multicenter  double blinded  randomized  placebo controlled phase III study  which evaluated the effect of Repatha  a PCSK9 inhibitor  on patients with coronary artery disease  CAD  who were already treated with optimized statin therapy  as measured by intravascular ultrasound imaging  IVUS   Top line results of the study were announced in September The phase III study  n 968   in which patients were given either monthly Repatha 420 mg or placebo subcutaneous injections  showed that Repatha modifies the underlying process of atherosclerosis  a major cause of cardiovascular disease The study met the primary as well as the secondary endpoint  The primary endpoint was change in percentage of atheroma volume  PAV  from baseline to week 78 as measured by IVUS The study results demonstrated that adding Repatha to optimized statin therapy resulted in statistically significant regression of atherosclerosis in patients with CAD  Nearly two thirds of patients on Repatha experienced a reduction in plaque burden Patients in the Repatha arm experienced a 0 95  decrease in PAV from baseline  compared with an increase of 0 05  from baseline in patients receiving optimized statin therapy plus placebo  Moreover  patients in the Repatha arm experienced a mean decrease in normalized total atheroma volume  TAV   a measure of plaque volume  compared to placebo We note that Repatha is indicated in adults with primary hypercholesterolaemia  heterozygous familial and non familial  or mixed dyslipidaemia  as an adjunct to diet Repatha holds the potential to treat patients who are unable to maintain acceptable levels of LDL cholesterol  A phase III cardiovascular outcomes study  FOURIER  on Repatha is currently ongoing with top line data expected in the first quarter of 2017 AMGEN INC Price    Zacks RankAmgen currently carries a Zacks Rank  3  Hold   You can see  The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ,2016-11-15,Zacks Investment Research,https://www.investing.com/analysis/amgen-files-for-avastin-biosimilar;-repatha-data-positive-200164971,200164971
106036,327551,AGN,6 Things You Need To Know About Teva s  TEVA  Q3 Earnings ,opinion,"Israel based Teva Pharmaceutical Industries Limited   NYSE TEVA   reported third quarter results yesterday  With the company missing revenue estimates and lowering its outlook for the year  shares were down 8 4  Here is a look at some key points from the company s conference call Generics Segment Hit by Pricing  Lack of Major Product Launches  Competition  Teva has a strong presence in the generics market with a major part of its revenues being derived from this segment  Although third quarter revenues included  887 million from the Actavis  NYSE AGN  Generics acquisition  the generics segment s performance fell short of expectations The company reported a slight decline in the legacy generics business mainly due to loss of exclusivity and increased competition for the generic versions of Pulmicort  Nexium and Xeloda and lack of significant new product launches  Teva said that new product launches were affected by delays in product approvals  patent related decisions and quality challenges faced by third party suppliers These factors are likely to continue impacting the fourth quarter as well with major product launches now expected in 2017 and 2018 though fourth quarter sales should benefit from a full quarter s contribution from the Actavis Generics business Meanwhile  the U S  business witnessed higher than expected price erosion  approximately 7   in the third quarter  The company said that this was due to increased price pressure on certain divested products  Teva said that it continues to expect price erosion in the U S  in the mid single digit range  the same as other companies like Mylan NV   NASDAQ MYL   Guidance Lowered  Teva lowered its 2016 outlook for both earnings and sales  The company now expects earnings of  5 10    5 20 per share on net sales of  21 6 billion    21 9 billion  At the time of releasing second quarter results  Teva had guided towards earnings of  5 20    5 40 per share and revenues of  22 0 billion    22 5 billion  Teva said that it does not expect any significantly large product launch in the fourth quarter as well No Significant Deals for Now  Teva provided some insight into its capital allocation plans on the call  The company  which has been pretty active on the acquisition front  said that it will be focusing on unlocking value from integration  developing internal products  and repaying debt  The company plans to drop all the projects that do not add value or move the needle over time  Where deals are concerned  Teva will be looking at tuck in deals instead of significant ones Thoughts on DoJ Probe on Generic Drugmakers  Generic drugmakers were in the news earlier this month following a Bloomberg article which said that the Department of Justice  DoJ  could file price collusion charges against these companies by year end  According to the article  the DoJ investigation  which started a couple of years back  covers more than 12 companies and about 24 drugs  A grand jury is examining whether some of the executives colluded with each other to raise prices  On the third quarter call  Teva s CEO said that they are not aware of any fact that will give rise to an exposure to Teva with respect to the investigation  520 Million Set Aside for Settlement of FCPA Investigations  Teva is setting aside  520 million related to the settlement of U S  Foreign Corrupt Practices Act  FCPA  investigations into conduct in three countries  Russia  Mexico and Ukraine  from 2007 2013  The company is in advanced discussions with the DoJ and the SEC to settle the investigations Rimsa Issues  Teva is in litigation with the former owners of Rimsa  a Mexico based pharmaceutical manufacturing and distribution company that was acquired by Teva in Mar 2016  Teva said that it has uncovered evidence of systematic information manipulation regarding brand development and manufacturing and claimed that these violations were concealed during the due diligence process  The company said that it has implemented a full remediation plan to address the identified issues and expects to realize the opportunities presented by the Mexican market over time Bottom LineWith the completion of the Actavis Generics and Anda acquisitions  2017 will be an important year for Teva  Moreover  there should be more clarity on the Copaxone 40 mg generics situation  As far as the generics business is concerned  the company said that it needs new product launches worth  500 million    600 million every year to maintain mid single digit growth in the U S  business  Teva has more than 300 ANDAs pending at the FDA with the company expecting to launch more than 60 of those in 2017 depending on regulatory approvals  patent infringement decisions  and other factors 
TEVA PHARM ADR Price  Consensus and EPS Surprise   Teva is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the healthcare sector include companies like Bayer  DE BAYGN  AG   OTC BAYRY   and Mallinckrodt plc   NYSE MNK    Both companies have positive earnings track records  While the average earnings beat for Bayer over the last four quarters is 2 33   Mallinckrodt s average earnings beat over the last four quarters is 11 88   Bayer and Mallinckrodt are Zacks Rank  2  Buy  stocks  You can see  
The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ",2016-11-15,Zacks Investment Research,https://www.investing.com/analysis/6-things-you-need-to-know-about-teva's-(teva)-q3-earnings-200165048,200165048
106050,327565,AGN,Can Allergan  AGN  Keep The Earnings Streak Alive In Q3 ,opinion,"Allergan plc   NYSE AGN   will be reporting third quarter 2016 earnings on Nov 2  before market open  Last quarter  the company delivered a positive earnings surprise of 2 13  Allergan s performance has been pretty impressive  with consistent positive surprises  The average earnings beat over the last four quarters is 3 44  ALLERGAN PLC Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderAllergan s top as well as bottom line should continue to be propelled by acquisitions  particularly that of Botox maker Allergan Inc  NYSE AGN pa   Botox Migraine  Namenda XR  and Vraylar should continue to drive growth  Linzess and Viberzi should also perform well However  Namenda IR is facing generic competition  Investors will be interested to hear about Namzaric s performance  Namzaric was launched in the second quarter of 2015 and is expected to reduce the impact of the Jul 2015 entry of Namenda IR generics The performance of new products like Avycaz  treatment for adult patients with complicated intra abdominal and urinary tract infections   Vraylar  bipolar I disorder and schizophrenia   Kybella  double chin reduction  and Viberzi  adults suffering from irritable bowel syndrome with diarrhea  will also be in focus Allergan sold its generics and Anda distribution business to Teva Pharmaceutical Industries Limited   NYSE TEVA   in August and October  respectively  Both these business lines will be treated as discontinued operations Importantly  on the second quarter conference call  management had said that while the Anda divesture will hurt second half revenues by  100 million  contribution from new product launches will be greater in the second half  typical to pharma seasonality Earnings WhispersOur proven model does not conclusively show that Allergan is likely to beat on earnings this quarter  That is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Most Accurate estimate stands at  3 55 while the Zacks Consensus Estimate is pegged higher at  3 60  So  the Earnings ESP is  1 39   Please check our that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Allergan s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are Ariad Pharmaceuticals Inc    NASDAQ ARIA   is expected to release results on Nov 1  The company has an Earnings ESP of 5 26  and a Zacks Rank  1  You can see  Shire plc   NASDAQ SHPG   with an Earnings ESP of  1 26  and a Zacks Rank  2  The company is scheduled to release results on Nov 1 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-26,Zacks Investment Research,https://www.investing.com/analysis/can-allergan-(agn)-keep-the-earnings-streak-alive-in-q3-200161185,200161185
106053,327568,AGN,Nivalis  NVLS  Q3 Earnings Preview  Can The Stock Surprise ,opinion,Nivalis Therapeutics  Inc    NASDAQ NVLS   is expected to report third quarter 2016 results on Nov 7  Last quarter  the company posted a negative surprise of 5 77   Let s see how things are shaping up for this announcement Nivalis  performance has been disappointing so far  Over the four trailing quarters  the company s earnings have missed expectations on three occasions and met the same once  bringing the average negative earnings surprise to 9 59  NIVALIS THERAPT Price and EPS Surprise    Factors at PlayNivalis  a development stage pharmaceutical company  is focused on the discovery  development and commercialization of treatments for cystic fibrosis  CF   With no approved product in its portfolio at the moment  Nivalis does not generate any revenue yet  In this scenario  investor focus will be on the company s progress with regard to its lead candidate  Cavosonstat  N91115  On Jul 2016  the company announced the completion of enrollment in a phase II study evaluating Cavosonstat for the treatment of patients with CF who have two copies of the F508del mutation  in combination with Vertex Pharmaceuticals Inc  s   NASDAQ VRTX   Orkambi  Top line data should be out by the end of this year During the quarter  May 2016   Nivalis dosed the first patient in another phase II study on Cavosonstat  This proof of concept study is being conducted to evaluate the effect of Cavosonstat as add on therapy to Vertex s Kalydeco in adults who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein  Data from the study are expected in the first half of 2017 Meanwhile  Nivalis is expected to see a sequential rise in operating expenses due to continued investment in the development of Cavosonstat and other factors Earnings WhispersOur proven model does not conclusively show that Nivalis is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  However  that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 59 cents Please check our  that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Though Nivalis  Zacks Rank  3 increases the predictive power of the ESP  its 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a couple of health care stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter Ariad Pharmaceuticals Inc    NASDAQ ARIA   is expected to report earnings on Nov 1 The company has an Earnings ESP of  5 26  and a Zacks Rank  2  You can see Allergan plc   NYSE AGN   has an Earnings ESP of  0 56  and a Zacks Rank  3  The company is scheduled to report third quarter results on Nov 2 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-30,Zacks Investment Research,https://www.investing.com/analysis/nivalis-(nvls)-q3-earnings-preview:-can-the-stock-surprise-200161733,200161733
106054,327569,AGN,5 Things To Watch When Pfizer Reports Earnings On Tuesday,opinion,"by Clement Thibault
Pfizer Inc  NYSE PFE   the global biopharmaceutical company which discovers  develops and manufactures healthcare products  will report Q3 2016 earnings on Tuesday November 1st  before the market opens 


1  Earnings and revenue
Pfizer is expected to report earnings of  0 49 per share alongside  13 03 billion in revenue  Year over year  this would represent growth of about 7 2  in revenue 

2  Breaking Up Is Hard To Do
Over the past few years  Pfizer reorganized its lines of business into two segments  Essential Health  under which most of its legacy drugs such as Lipitor and Viagra operate  and Innovative Health which focuses primarily on new drug development and is currently the fastest growing PFE segment  One of the key strategic decisions Pfizer management made during the past quarter was not to spin off the Innovative Health division into a separate company 
The decision was announced on September 26th after the company spent almost four years  evaluating its options  much to the chagrin of Wall Street analysts who thought that the combined value of two separate companies would be bigger than Pfizer s valuation is today  This is certainly a conservative approach by Pfizer  and will likely hamper Innovative Health s growth  though it will generate a more robust cash flow 

3  Legacy Drugs
Pfizer s two most lucrative drugs last quarter were Prevenar 13 and Lyrica 
Prevenar 13 is a one time vaccine for the prevention of the thirteen most common forms of pneumococcal pneumonia  On its own  Prevenar 13 brought in  1 25 billion just during the last quarter It was first introduced at the end of 2009 in Europe for infants and young children  rolled out to the US in 2010 and in 2013 was approved for use in 120 countries worldwide  At the same time it was approved for non vaccinated children and adolescents as well as adults aged 50 plus  Going forward however  sales of Prevenar 13 are expected to slow given its already extended reach  but the recent approval of the drug for adults aged 18 49 should steady sales for a while 
Lyrica  Pfizer s second biggest blockbuster drug  also brought in a total of  1 25 billion  Lyrica is an anti epileptic drug  slowing down the impulses in the brain that cause seizures  It s also used to treat neuropathic pain  fibromyalgia and certain anxiety disorders  Its revenue is stable and expected to grow in the single digits over the next two years  until the expiration of the Pfizer owned patent on the drug in December 2018 
Pfizer has eight additional major drugs which are each expected to generate a billion dollars in revenue this year  Because patents protect drugs from being copied for a total of 20 years  revenue from any blockbuster drug has a limited lifespan  Thus  for the investor  aside from current revenue generators the upcoming pipeline is as important as if not more important than existing drugs 
4  Building a Healthy Pipeline
Because patents only protect new drugs from copycat products for a total of 20 years  revenue from any blockbuster introduction has a limited lifespan  Thus  for the investor  along with current revenue generators  it s critical to be aware of what a pharmaceutical company also has in its R D pipeline 
In order to keep its top line from stagnating  Pfizer is currently working on two fronts  First  the company invests about  7 billion annually in research and development  with the aim of creating its next best seller 
Ibrance was introduced in early 2015 for treatment of ER   HER2 metastatic breast cancer  Since its initial introduction it s been expanded for use with additional patient populations  Pfizer is also currently working to receive approvals for expansion to other forms of cancer  such as pancreatic cancer  as well  Ibrance is already on pace to make almost a billion dollars this year  but if Pfizer s expansion plans succeed  new markets will open for the drug with additional revenue sources emerging 
Perhaps more significant  Pfizer continues to make strategic acquisitions as an additional way to increase or expand their drug pipelines  At the end of 2015  Pfizer attempted a  160 billion merger with Ireland based Allergan NYSE AGN  which was ultimately scrapped because of changes to US tax rules which made the deal less appealing for the US based pharmaceuticals giant  The deal s cancellation freed up funds for smaller acquisitions 
On September 27th  Pfizer acquired Medivation for  14 billion dollars  This allows Pfizer to add Xtandi  a prostate cancer drug  to its oncological lineup  The Medivation acquisition also brings another important potential drug to the PFE portfolio   Talazoparib   which blocks an enzyme that s integral to cancer cell development  A number of companies such as AstraZeneca  NYSE AZN  and AbbVie  NYSE ABBV  are also working on similar drugs  Talazoparib trials are scheduled to end during June 2017  Though there s no guarantee this new drug will become a blockbuster  chances are good that it might  But even if it doesn t  this sort of acquisition expands Pfizer s offering and its future capabilities 

5  Handsome Dividend
As a result of the drop in Pfizer s stock price over the last few months when it fell from  37 in July to trade around  32 today Pfizer s dividend is worth considering  Over the past four quarters the declared dividend has been 30 cents per quarter  or  1 2 dollars annually  for a yield of 3 75  
Though Pfizer cut its dividend back in 2009 by 50   from 32 cents per quarter to 16 cents  in order to help finance the  68 billion acquisition of Wyeth at that time  the company has been slowly but steadly growing it back  and has regularly increased its payout for the past seven years 
Pfizer s next ex dividend date is November 8th  and it is expected to grow its dividend again by two or three cents  Given expected GAAP earnings of  0 49 and non GAAP earnings of  0 62 for the company this quarter  the payout ceiling is not stretched in any way  In today s yield starved world  a safe and growing dividend from an industry that s always going to be necessary is worth a second look 
Conclusion
Pfizer s P E ratio of 28 is 20  higher than the industry average  which comes in at around 23  Solely by that measure Pfizer would be considered expensive  although its dividend would prevent it from being categorized as totally overpriced  However  when considering different measures such as the Price to Book  where Pfizer compares favorably to peers such as Merck  NYSE MRK  and Eli Lilly  NYSE LLY   with a ratio of 3 to the industry s 3 5  it s obvious there s more to Pfizer than just immediate earnings  Its Free Cash Flow  for example  is a massive  13 billion TTM  33  more than Merck  and its Price to FCF ratio of 15 is less than half the industry average 
Even with its higher P E Pfizer should still be considered a safe investment  And its prospects  especially its oncology portfolio  appear solid enough for yield starved investors to consider the stock  Its recent share price tumble provides a dual opportunity to lock in an attractive dividend yield while potentially returning value on the price itself ",2016-10-31,Clement Thibault/Investing.com ,https://www.investing.com/analysis/5-things-to-watch-when-pfizer-reports-earnings-on-tuesday-200161604,200161604
106056,327571,AGN,AVEO Pharmaceuticals  AVEO  Q3 Earnings  What s In Store ,opinion,"AVEO Pharmaceuticals  Inc   NASDAQ AVEO   is expected to report third quarter 2016 results this month  The company has an impressive track record for the last four reported quarters  While it has beaten estimates on three occasions  it met expectations in one with an average positive surprise of 57 14  In the last reported quarter  AVEO posted a positive surprise of 7 14  results were in line with expectations  Let s see how things are shaping up for this quarter Factors at PlayAVEO  a development stage biopharmaceutical company  is focused on the development of treatments targeting cancer and other areas of unmet medical need  The company has an interesting pipeline with the most advanced candidate being tivozanib Tivozanib is currently under review in the EU for the first line treatment of renal cell carcinoma  RCC   The regulatory application was submitted by AVEO s partner  EUSA Pharma During the quarter  AVEO initiated a phase I II study  TiNivo  evaluating tivozanib in combination with Bristol Myers Squibb Company s   NYSE BMY   Opdivo  nivolumab  for the treatment of advanced RCC  The phase I study will evaluate escalating doses of tivozanib  in combination with Opdivo  in patients with advanced RCC  It will be followed by an expansion phase II cohort at the established combination dose We note that a pivotal phase III  TIVO 3  study comparing tivozanib to Nexavar  sorafenib  for the third line treatment of patients with refractory RCC is currently underway Apart from tivozanib  AVEO has several early  and mid stage candidates in its pipeline including ficlatuzumab  phase II completed   non small cell lung cancer  and AV 203  phase I completed   advanced solid tumors  among others  The company has collaborations with several companies for the development of its pipeline candidates The company depends entirely on collaboration revenues  and milestone and other payments for its top line  Therefore  the top line may vary on a quarterly basis depending mainly on the timing of these payments Investors  focus should remain on tivozanib s progress and other pipeline related updates AVEO PHARMACEUT Price and EPS Surprise
    What Our Model IndicatesOur proven model does not conclusively show that AVEO is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is pegged at 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 12 cents  Please check our  that enables you to find stocks that are expected to come out with earnings surprises Zacks Rank Though AVEO has a favorable Zacks Rank  3  Hold   an ESP of 0 00  makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a Look Here are a couple of health care stocks that you may want to consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter Allergan plc   NYSE AGN   has an Earnings ESP of  0 56  and a Zacks Rank  3  The company is scheduled to report third quarter results on Nov 2 Infinity Pharmaceuticals  Inc    NASDAQ INFI   is scheduled to report third quarter results on Nov 7  It has an Earnings ESP of  5 81  and sports a Zacks Rank  1  You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/aveo-pharmaceuticals-(aveo)-q3-earnings:-what's-in-store-200162011,200162011
106062,327577,AGN,Allergan  AGN  Lags Q3 Earnings  Cuts View  Ups Buyback,opinion,"Allergan  NYSE AGN pa  plc s   NYSE AGN   third quarter 2016 earnings came in at  3 32 per share  missing the Zacks Consensus Estimate of  3 57 by 7   Earnings declined 2 6  from the year ago period and almost 1  sequentially  Lower revenues  and higher research and development and selling and marketing costs hurt earnings in the quarter Revenues came in at  3 62 billion  up 4 4  from the year ago period  but short of the Zacks Consensus Estimate of  3 70 billion Quarterly DetailsThe drugmaker sold its generics and Anda distribution business to Teva Pharmaceutical Industries Limited   NYSE TEVA   in Aug and Oct 2016  respectively  Both these business lines were treated as discontinued operations Continuing operations include the U S  General Medicine  U S  Specialized Therapeutics and International business segments U S  Specialized Therapeutics net revenues increased 12  to  1 45 billion driven by strong growth in Eye Care  Facial Aesthetics and Neuroscience  Products like Botox and Restasis raked in sales of  174 5 million  up 10   and  356 4 million  up 14    respectively  While Botox sales were driven by continued strong demand for the product  Restasis benefited from continued strong promotional efforts U S  General Medicine net revenues fell 4  to  1 49 billion in the reported quarter due to a decline in Central Nervous System and Established Brands revenues that was partially offset by strong growth in Gastroenterology and Women s Health Strong growth was put up by established products like Linzess  Lo Loestrin  Estrace Cream  Minastrin 24  and new products like Viberzi  Dalvance and Vraylar  However  lower Namenda IR and XR sales hurt the performance of the CNS franchise  Namenda XR sales declined 32  to  146 9 million in the quarter due to lower demand and selling price  Namzaric a once daily  fixed dose combination of Namenda XR and Aricept  recorded sales of  14 9 million compared with  12 8 million in the previous quarter  Namzaric was launched in the second quarter of 2015 to reduce the impact of the Jul 2015 entry of Namenda IR generics  Asacol Delzicol sales declined 49   also hurt by generic competition in the quarter The International segment recorded net revenues of  697 8 million  up 6  from the year ago period  Its growth was driven by Eye Care  Facial Aesthetics and Botox revenues 2016 Outlook LoweredAllergan lowered its revenue and earnings guidance  The company expects total net revenues in the range of  14 45 billion to  14 65 billion  Previously  Allergan had anticipated total net revenues in the range of  14 65 billion to  14 90 billion Allergan expects earnings in the range of  13 30  13 50 compared with  13 75 to  14 20 per share projected previously  The Zacks Consensus Estimate for earnings and sales stand at  13 93 per share and  14 73 billion  respectively  for 2016  While research and development spend is still expected to be about  1 5 billion  selling  general and administrative expenses are expected to be around  4 billion Allergan completed its  5 billion share buyback program in the quarter  ahead of the year end scheduled  We note that the company had announced a share buyback program of up to  10 billion at the time of releasing first quarter results Importantly  the board expanded the share repurchase authorization to  15 billion including a  10 billion accelerated share repurchase  ASR  program  The company also announced that it is initiating a regular quarterly cash dividend of 70 cents per share  payable from the first quarter of 2017 Our TakeAllergan s third quarter results were weak  with the company missing estimates for both earnings and sales  However  the  10 billion ASR and the new dividend boosted investors  confidence  pushing the share price up more than 1  in pre market trading  With the closing of the Teva deal  the company s restructured and simplified business is encouraging We are also encouraged by Allergan s focus on building its branded and biosimilars pipeline  Allergan has a collaboration agreement with Amgen  Inc    NASDAQ AMGN   for the worldwide development and commercialization of oncology antibody biosimilars  Allergan and Amgen are developing biosimilar versions of Roche Holding  SIX ROG  AG s   OTC RHHBY   cancer drugs Herceptin andAvastin Moreover  the divestment of the generics business should allow the company to focus on its target areas ALLERGAN PLC Price  Consensus and EPS Surprise
    Allergan carries a Zacks Rank  3  Hold   You can see  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/allergan-(agn)-lags-q3-earnings,-cuts-view,-ups-buyback-200162270",200162270
106064,327579,AGN,Drug Stocks To Watch For Earnings On Nov 4  REGN   More,opinion,"The bulk of the Q3 earnings season is over  with 364 S P 500 members  as of Nov 2    accounting for 72 6  of the index s total market capitalization   having already reported results  according to the latest  While total earnings for these index members were up 1 6  from the year ago quarter  revenues were also up 1 6  year over year  The beat ratio was 72 3  for earnings and 54 7  for revenues Notably  the ongoing reporting cycle is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S P 500 index  However  though the third quarter reporting cycle saw numerous positive surprises and stability in current quarter  Q4 2016  estimates in the beginning  these two attributes have started losing ground this week  Positive surprises  particularly on the revenue side  have become harder to come by and Q4 estimates are moving down This change was reflected in the results of pharmaceutical companies as well  Though quite a few of the large cap pharma companies posted better than expected third quarter results last week  three large pharma companies that have reported so far this week   Allergan  NYSE AGN pa  plc s   NYSE AGN    Gilead Sciences Inc    NASDAQ GILD   and Pfizer Inc    NYSE PFE     announced softer than expected Q3 results  While Allergan and Pfizer missed estimates for both earnings and sales  Gilead managed to beat sales expectations marginally but missed earnings estimates Two more companies from the healthcare sector are set to report their third quarter results on Nov 4  Let s see how things are shaping up for their respective announcements Regeneron Pharmaceuticals  Inc    NASDAQ REGN   Regeneron posted a positive surprise of 21 97  last reported  The company s performance has been mixed so far  In the last four quarters  it surpassed earnings estimates on two occasions and missed the same twice  Overall  the company has recorded an average negative earnings surprise of 2 04  REGENERON PHARM Price and EPS Surprise
    Regeneron s key growth driver  Eylea  should continue to perform well in the third quarter of 2016 and contribute meaningfully to the top line  Apart from Eylea  investor focus will remain on the performance of the PCSK9 inhibitor  Praluent   Read More    
 The Zacks Consensus Estimate for the quarter is pegged at  2 27 per share  The company has a Zacks Rank  3  Hold  and an  of 0 00   Please check our  that enables you find stocks that are expected to come out with earnings surprises Lion Biotechnologies  Inc    NASDAQ LBIO   Last quarter  the company delivered a negative earnings surprise of 21 05   Lion Biotechnologies had a mixed track record over the last four quarters  The company surpassed expectations twice  missed once and delivered in line results in the other quarter  with the average positive earnings surprise being 9 52  LION BIOTECH Price and EPS Surprise
    The Zacks Consensus Estimate for the quarter is pegged at a loss of 18 cents per share  The company has an Earnings ESP of 0 00  and a Zacks Rank  3  You can see  Confidential from ZacksThis week  Zacks researchers have named 7 other stocks that look to break out even sooner than today s Bull of the Day  You can see these time sensitive tickers free  and access additional trades that are not available to the public ",2016-11-02,Zacks Investment Research,https://www.investing.com/analysis/drug-stocks-to-watch-for-earnings-on-nov-4;-regn---more-200162583,200162583
106065,327580,AGN,Pharma Stock Roundup  Pfizer  Allergan Q3 Results Fall Short  Insulin Drugmakers Under Pricing Pressure,opinion,"This week  key earnings updates came from companies like Pfizer   NYSE PFE   and Allergan   NYSE AGN   while pharma stocks remained under drug pricing pressure with lawmakers questioning the prices of insulin drugs Recap of the Week s Most Important StoriesPfizer  Allergan Disappoint in Q3  Pfizer s third quarter results were disappointing with the company missing on both earnings and revenues  The company also announced that it will be dropping the development of its late stage PCSK9 inhibitor  bococizumab    this decision was based on the emerging clinical profile as well as the market landscape  Read more    Meanwhile  Allergan s third quarter results were also disappointing    the company  which had surpassed expectations in each of the first two quarters of 2016  missed earnings as well as revenue expectations in the third quarter  Read more      Generic Stocks in Trouble   Last week  several companies with a presence in the generic segment saw their share prices slide following a Bloomberg article that the Department of Justice  DoJ  could file price collusion charges against these companies by year end  According to the article  the DoJ investigation started a couple of years back and covers more than 12 companies and about 24 drugs  A grand jury is examining whether some of the executives colluded with each other to raise prices  Companies like Lannett  Impax and Endo were among stocks that were hit hard by the news  Other companies with a presence in the generics market also saw their shares slide Insulin Drugmakers Feel the Pricing Pressure  Insulin drugmakers like Lilly   NYSE LLY   and Novo Nordisk  CO NOVOb  are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs  Moreover  Sen  Sanders and Rep  Cummings have asked the Justice Department and the Federal Trade Commission  FTC  to investigate potential collusion among pharmaceutical companies that manufacture diabetes products According to the lawmakers  insulin medication prices have tripled between 2002 and 2013  from  231 to  736 per year per patient  As per information provided in the letter to the DoJ and the FTC  the price of Sanofi s Lantus shot up 168  from 2010 to 2014 while that of Lilly s Humalog shot up 103  and that of Merck s   NYSE MRK   Januvia and Janumet by 75  each  Merck is a Zacks Rank  2  Buy  stock  You can see  Novartis Breast Cancer Treatment Gets Priority Review  Novartis    NYSE NVS   experimental breast cancer treatment  LEE011  ribociclib  was granted Priority Review by the FDA for the first line treatment of postmenopausal women with HR  HER2  advanced or metastatic breast cancer in combination with Femara  letrozole   LEE011 plus Femara was shown to reduce the risk of progression or death by 44  compared to Femara alone  The candidate is also being reviewed by the European Medicines Agency  EMA  Astellas to Acquire Ganymed  Strengthen Cancer Pipeline  Astellas Pharma announced that it will be acquiring Germany based Ganymed Pharmaceuticals AG  a biopharmaceutical company focused on the development of a new class of immunotherapeutic cancer drugs called ideal monoclonal antibodies  IMABs  The acquisition could see Astellas shelling out up to  1 282 billion including  422 million for 100  of the equity in Ganymed  The balance would be payable on the achievement of milestones related to the development of IMAB362  which is being evaluated for cancer  a key focus areas as well as growth driver for Astellas  IMAB362 has orphan drug status in the U S  and Europe for gastric and pancreatic cancer Performance
Large Cap Pharmaceuticals Industry Price IndexPfizer s shares declined 6 0  reflecting the disappointing earnings report  The NYSE ARCA Pharmaceutical Index declined 2 3  over the last five trading days  Over the last six months  Bristol Myers   NYSE BMY   declined 27 9  while Merck was up 7 3   See the last pharma stock roundup here    
What s Next in the Pharma World Companies like Mylan  NASDAQ MYL   Endo and AstraZeneca   NYSE AZN   will be reporting earnings results in the coming days  Moreover  a decision from the FDA regarding Bristol Myers  Opdivo for head and neck cancer should be out by Nov 11 
Now See Our Private Investment IdeasWhile the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-11-06,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-pfizer,-allergan-q3-results-fall-short,-insulin-drugmakers-under-pricing-pressure-200163171",200163171
106067,327582,AGN,Buy Healthcare Stocks Now  That All Depends On The Election,opinion,"It is  regrettably  impossible to separate market strategy from the presidential campaign as we approach the Final Days  of the campaign  Of the campaign  It won t be The End of Days no matter who wins and who loses   Bear with me as we wend our way through the opinionated land mines here   
Many voters and investors have been disgusted by Donald Trump s inability to focus on the Big Issues rather than trying to sell us the blather that he is some kind of Boy Scout  And many have been disgusted  but not surprised  by the revelations now in plain view on Wikileaks of the greed and double dealing of Hillary Clinton as she claws her way to reach the presidency  It seems strange that Wall Street didn t at least get a little bit of the jitters  But  then  what am  I saying  It s Wall Street  and they ll only be chagrined if they find their funding failed to buy them the candidate with their interests uppermost in mind 
 We ve all seen  the Real Donald    regrettably  what you see is what you get   but if you are of a curious bent  you might also want to see some of what Hillary Clinton s thoughts  and her staff s  are  by viewing the actual e mails   
I sent a note recently to our clients reading in part 

    The market is steady because 76  of the volume is institutional Wall Street traders  pension funds  etc  No one  except the trial lawyers  of course  has contributed more to Hillary Clinton s campaign than Wall Street so it makes sense that they are cautiously optimistic that they ll get a win for their money 
 But what if  What if they are wrong and Donald Trump actually wins  I expect Wall Street will sell  sell  sell and I want to be ready if that happens  We re now marking time  in securities that are liquid and provide income   just in case   If Ms  Clinton wins  the rally is likely to be underwhelming since most institutional money is already in the market  If Mr  Trump wins  we want to be there to pick the newly low hanging fruit  We ll see  

If you d like to see my logic in thinking this might just happen  whether you agree or not  you are welcome to visit my new national and global affairs blog and look at the most recent entry   Election 2016   You ll find it at  
So the first Wednesday in November could prove to be a real yawner  or it could see a 500 point move  or moves  in one  or more  directions  I maintain this is no time to become overly fearful or overly excited about a particular sector or security but  rather  a time to do research and have cash ready to pounce upon any irrational over reaction 
How  specifically  might the market landscape change based upon which of the two least popular most voted for candidates becomes the next chief executive of our country 
In thinking about this  we may  thankfully  leave the realm of character and personality  and may consider instead the likely policy changes each candidate might pursue upon their election 
I have always made money buying the best gas and oil companies  along with their contractors and equipment suppliers  when they are really out of favor  I d like to be able to do so again 
But if Ms  Clinton ascends to the office  I may have to wait a while longer to buy them  as cheap may well become cheaper  She will likely advocate continuing subsidies for more solar and wind companies  The current administration s subsidization of solar and other renewable energy in the U S  has totaled just under  200 billion the past 5 years  These subsidies have done little to increase the contribution of solar power to the grid as it is still expected to comprise just 0 6 percent of electricity generation this year 
These subsidies haven t done much to generate power  they have  however  increased the money sloshing around for  pay for play  favoritism  I imagine a Clinton presidency would continue the current policy of support for massive federally funded projects  I would also want to consider that horizontal fracturing might be outlawed  and offshore and onshore drilling sharply curtailed  The Saudis would pay dearly to see such a scenario 
If Mr  Trump is elected  who knows what will happen  He has exhibited a mercurial bent since the campaigning began  and long before   But I believe he believes his own promise to put Americans back to work in real jobs again and therefore it is likely that we would see a resurgence in American gas and oil exploration and production  along with continued renewables research  in order to make America as energy independent as possible while creating those jobs  This might not please Saudi Arabia quite as much  In this case  I would look to move into the best domestic gas   oil companies immediately  buying those most currently depressed with the best prospects for success   Indeed we have already begun nibbling at Southwestern Energy  NYSE SWN  
In terms of another favored sector of mine  the banking  insurance and brokerage industries  we know that Ms  Clinton at least  says  she favors more regulation and wants to expand the long arm of Dodd Frank even more intrusively  Given the funding she has received from Wall Street  we might take her instinct for more and more regulation and contrast it with the biggest firms  desire to see less regulation  It will be interesting to see which wins out  her public platform or private promises 
Mr  Trump  on the other hand  says he would shrink the reach of Dodd Frank  but still believes that financial regulation of the biggest and baddest is necessary  For those who want to see the stock market as a Big Casino  a vote for Ms  Clinton would likely be a vote for keeping low rates for longer  For those who would rather save than spend  an increase in rates would be most welcome  Mr  Trump is likely to appoint a Fed Chair focused on normalization of rates shortly after he enters the office 
Looking at another of my favorite sectors  healthcare  Ms  Clinton is a rock solid advocate of the Affordable Care Act  Obamacare   She believes more government intervention is the solution to its current ills and has said larger subsidies supported by taxpayers are necessary to make certain that everyone is covered  regardless of lifestyle  medical history  or personal provision for care 
Managed care companies and hospitals would certainly like to see this  though Ms  Clinton s belief is that firms that do the research  clinical trials  etc   like biotech and pharmaceutical companies  are merely price gougers  These firms are unlikely to do well in a Clinton presidency 
Mr  Trump has vowed to repeal Obamacare and shift more responsibility as well as funding to the states  Without Obamacare  the number of insured enrollees may drop or rise  if the individual states do a better job of working with their own health care providers and insurers 
Under either president  I think healthcare firms have been hammered down enough over the past year  down 9 06    more than any other sector  that smart selections among the various sub sectors are likely to be profitable as long as we think as investors  not traders  months  not weeks 

Since health care has been so bloodied and battered this year  I m considering placing a preliminary toe in the water  Here are two of my favorites 
An Opportunity in Generic Drug Firms 
According to the Generic Pharmaceutical Association  generic drugs account for 88 percent of prescriptions dispensed in the U S A  The industry has been consolidating over the past few years  led by Israel based Teva  NYSE TEVA   which made a  40 5 billion acquisition of Actavis from previous parent Allergan  NYSE AGN  just two months ago 
But now these purveyors of cheaper versions of patented drugs coming off patent protection have a new problem  U S  prosecutors have just announced a comprehensive criminal investigation into suspected price collusion among some of the major generics manufacturers  The investigation began about two years ago and has now gone to a grand jury  The grand jury is being asked to decide if there is enough evidence that some senior executives agreed to raise prices on certain drugs to pursue formal charges  About two dozen generic drugs seem to be part of the inquiry  Firms receiving subpoenas include Mylan  NASDAQ MYL   Teva  Allergan  Lannett Com  NYSE LCI  and seven others 
The DoJ must believe they have good reason to pursue  this isn t just a civil case where the perpetrators  companies are fined  penalizing mostly the shareholders  This one is a criminal investigation  which means they have had to gather enough evidence to get warrants from a judge and to ensure compulsory discovery of evidence  There is  apparently  a carrot offered along with this stick   an amnesty program for those willing to cooperate with the investigation 
It s likely that the first charges could be filed as early as next month  As the biggest generics firm  Teva in particular may be on the hot seat  In May  Allergan received a DOJ subpoena requesting information about its generics business  As a result of its recent acquisition of Actavis  Allergan s potential liability has been transferred to Teva 
This bombshell created panic selling of all these firms last week  yet there is no indication looking at the history of such investigations that  a  criminal charges are actually warranted   b  that they will successfully prosecute and  c  that the fines and other punishments would be enough to warrant the nearly 10  selloff in TEVA shares 
Without trying to second guess the DoJ s motives or the strength of its case  I view the opportunity to nibble at TEVA shares anytime I can get them below  40 a share a gift  While price fixing schemes have been a top priority of the Antitrust Division  each company must still be presumed innocent until proven guilty 
Even if charges are successfully filed and some firms found guilty  I don t think the best of these generics manufacturers will go much lower than they already have  Let s take a closer look at Teva as well as a non generic  Novo Nordisk  NYSE NVO  

Teva Pharmaceutical Industries
We owned Israel headquartered TEVA in our Growth   Value Portfolio years ago before the healthcare sector went into  first  a fearful reaction anticipating what the passage of Obamacare might do to these shares  then a full fledged rout as the reality of how bad those effects would be  Here s what I like anew about TEVA at these prices 
First  they are the biggest fish in this rather large and growing pond  Acquiring Actavis  and selling off some other UK and Irish holdings in order to get EU approval for the Actavis deal  may bite them in the short term if there was any price fixing before the takeover but long term  the buy solidifies TEVA s  1 position worldwide 
Second  no matter what the short term results are of the DoJ probe  let s be realistic  generic drugs  at 88  of all prescriptions filled  are part of the solution to rising healthcare costs  not part of the problem  As the biggest in the business  TEVA has the research depth  manufacturing prowess  and economies of scale to outperform the rest of the generics marketplace  Their chart below shows where TEVA sees the coming growth in the generics market   and has positioned itself to dovetail perfectly with these trends 

Next  it is important to understand that TEVA s expansive and cutting edge research laboratories allow them to be more nimble than its many competitors  more often than not they will be the  first to file  when a popular or important drug goes off patent  In the U S  alone  TEVA has more than 300 current generic filings with the FDA  the majority of which are so called  1st Wave  opportunities while an additional third are even more coveted  first to file  generics 
The FDA has made its view on first to file generics clear  indicating that it considers such applications  public health priorities  that are deemed important because they are  increasing patient access   These filings the FDA tries to provide a decision on within just 15 months  TEVA is targeting 80 new generic applications in the USA for 2017 
Part of TEVA s strength comes from the integration of their various pieces  This company is not  just  a quick and capable generics manufacturer  They also have developed their own specialty pharmaceuticals that  ironically  they must defend against their fellow generics makers as well 
In fact  TEVA currently gets almost 50  of its revenue from its Specialty Pharma business and the biggest chunk of that comes from the company s MS drug Copaxone  A number of competitors are clamoring to create their own generic version of Copaxone  Even if they were to succeed  however  it is unlikely TEVA would face generic competition until at least sometime in 2018  It will take that long  after a court decision is rendered  for competitors to get their own product FDA approved  By then I think that TEVA s other products in their Specialty Pharma pipeline  like their joint venture with Regeneron  NASDAQ REGN  for a promising osteoarthritis and chronic back pain drug  will have come to the fore 
This research and development capability allows TEVA to understand first hand the process of ethical drug development and to see their world from both sides of the fence 
Finally  TEVA sets itself apart by what they have dubbed  New Therapeutic Entities   NTEs  by which they create entirely new treatment modalities based on existing drugs  An example 
A subsidiary of Johnson   Johnson  NYSE JNJ  makes Risperidone  used to treat schizophrenia  bipolar mania  and autism  Schizophrenia affects more than 20 million people  Antipsychotics like Risperidone are generally effective for the treatment of schizophrenia  however 75  of patients are non adherent to treatment within 2 years  The economic burden of relapses and re hospitalizations in US alone is north of  62 billion 
The reason for non adherence is likely because it is too difficult to keep up with given current modalities  Current treatments require that the patient visit their doctor or clinic every two weeks  where 17 reconstitution steps are needed to prepare an injection  which must be delivered intramuscularly  TEVA s response  They are currently developing Resperidone LTI  Long Acting Injectible  which allows extended release of the drug which lasts 3 months  requires minimal reconstitution to create in the doctor s office and is delivered subcutaneously rather than via intramuscular injection 
Taking steps like this that could save up to  60 billion  just in the USA alone   which is why I continue to believe that the healthcare sector is worthy of our investment dollars 
P S  I don t have the medical knowledge to comment on each and every twist and turn in FDA filings and relative merits of various drugs or claims and challenges to or by TEVA and its competitors  But if you are particularly interested in this level of detail  Vivian Lewis  editor of  offers a subscription based daily blog featuring dozens of foreign based securities  She follows TEVA  and many others  on a far more frequent basis than anyone I know 
And Now  the Non Generic Health Care Company
Credit where credit is due  Vivian Lewis and I have both owned and recommended TEVA for many years  she continuously and I only when I felt it offered particularly compelling value  But Novo Nordisk has piqued my interest because of her devotion to and analysis of the company and its future prospects  All research that follows is solely my own responsibility  however 
Novo Nordisk is a multinational company headquartered in Bagsvaerd  Denmark  a suburb just outside Copenhagen  that employs more than 42 000 employees in 75 countries around the globe  NVO is the  1 obesity and diabetes care company on the planet  Their other areas of expertise and revenue include hemophilia  growth hormone therapy  and hormone replacement therapy  but diabetes care still comprises more than 80  of NVO s annual revenues 
The reason why Novo has sold off to its 52 week low most recently is mostly that Bernie Sanders and some others in Congress are asking for a DoJ investigation into price fixing of insulin prices by a number of insulin makers  I m not sure why the  1 company would want to collude with its lesser rivals  but then one never knows whether these bombastic diatribes have any evidence behind them or whether they are purely for political grandstanding 
Please note that there is no ongoing investigation that we know of  it is merely the threat from some members of Congress that  in light of Mr  Sanders and Ms  Clinton s portrayal of all health care sector firms as bogeymen  has sent stock prices of the entire industry down 
Certainly the reason wasn t that sales and earnings are in trouble  they were both up this quarter  The company did  however  caution that the expected revenues and earnings  in the various local currencies they do business in  to be lower in the coming quarter  More likely  Novo s shift to greater R D spending rather than resting on their laurels with current products has some analysts concerned  as analysts always are  about the next 12 weeks  They should be  Novo is taking a giant step forward that may cost them in the short term 
Managed care providers and others in the prescribing and paying chain are simply not willing to pay a penny more for drugs that barely improve efficacy  They are looking for leapfrog improvements  Novo s response has been to apply a much higher threshold for new diabetes products and to heighten its focus on related medical issues like cardiovascular disease and chronic kidney disease 
As part of this change  NVO is dropping any further research into their oral insulin project  which they now describe as  not commercially viable in the increasingly challenging payer environment   Instead  they have redoubled their efforts in the much more promising Oral GLP 1 diabetes treatment  We know that obesity management can be used to delay or even prevent pre diabetes and type 2 diabetes  However  it s often simply not possible for the obese to lose weight on their own through diet and exercise  Novo s GLP 1 medications  including oral semaglutide  have been shown to be effective at aiding in weight loss  This alone could be a serious contributor to Novo s new revenue stream  Not to mention that oral GLP 1 has shown very early signs of possibly being effective in treating both cardiovascular and Alzheimer s diseases 
Add to this Novo s FDA approval this year for its new long lasting insulin Tresiba  That puts Novo yet another step ahead of its nearest competitor  The company has filed for regulatory approval of faster acting insulin in the US and the EU for the treatment of type 1 and 2 diabetes as well as for Xultophy  which lowers blood sugar  Milestones like these continue to lengthen the distance between Novo and its competitors and indicate a bright future 
The risks are there  of course  but Novo seems to have understood the risks and taken steps to address them  Those risks include a stagnant pricing posture for current insulin as more biosimilars come to market  lower margins on oral insulin  the need to secure higher capability treatments  and the usual political kerfuffles every time a drug company saves the nation billions in healthcare expense and actually expects to be compensated fairly for their time and expertise 
I see Novo s risks as either known and being dealt with or  in other cases  of short term interest only  The only thing that keeps me from buying both TEVA and NVO with both hands is the chance of a landslide victory by Ms  Clinton that also gives control of both the House and Senate to those who share her beliefs  Many of these Congresspersons think a single payer government health care plan reliant upon government R D  shunting aside the contributions of for profit competitors  is best for the nation 
Even then  I think TEVA and NVO will do quite nicely beyond US borders  Still  I m holding fire for the most part  While I m happy to own either of these fine companies at their current prices  I ll be even happier if I can buy them for less  The odds of a stacked Senate and a stacked house are remote  but just in case   
The reason I prefaced my remarks about these two fine firms with a political analysis of what might result for them is because   you re darn right  politics affects our investing decisions  Let s just hope they don t muck it up too badly 
In summary  if Mr  Trump should pull off a win  I would expect everything in the U S  markets to plunge briefly as Wall Street realizes their bull has been gored  As a result I m holding off buying  hoping for an even better entry point  until Wednesday  November 9 anyway  But I do believe that some energy and many financials are the best place to be in the longer run after the election  with healthcare added if the House and Senate remain independent bodies from the executive branch  Even so  I will be a buyer of TEVA below 35 and NVO below 30 
What I will buy right now  today  are three floating rate mutual funds  Whoever gains the presidency  rates will rise  After considerable research  I conclude that Federated Floating Rate  FFRSX  T  Rowe Floating Rate  PRFRX  and Lord Abbott Floating Rate  LFRAX  are the best in the sector  with Invesco Dynamic Credit  NYSE VTA  and First Trust Senior Loan  NASDAQ FTSL  the two best ETFs  I have seen nothing to convince me that  passive investing  via ETFs performs better in down markets than active intelligent investing  so I suggest the mutual funds most highly  We are now buying all three mutual funds for ourselves and our clients who seek income 
Disclaimer  I do not know your personal financial situation  so this is not  personalized  investment advice  I encourage you to do your own due diligence on issues I discuss to see if they might be of value in your own investing 
Past performance is no guarantee of future results  Our many years of success might have been just dumb luck  Often  my articles expand upon recent communiqu s to our clients  If you wish further information regarding our services  please contact us at inquire stanfordwealth com   or contact me directly at joe stanfordwealth com ",2016-11-07,Joseph L. Shaefer,https://www.investing.com/analysis/buy-healthcare-stocks-now-that-all-depends-on-the-election-200163060,200163060
106069,327584,AGN,Teva  TEVA   Can It Keep The Earnings Streak Alive In Q3 ,opinion,"Teva Pharmaceutical Industries Ltd    NYSE TEVA   will be reporting third quarter 2016 earnings on Nov 15  before market open  Last quarter  the company delivered a positive earnings surprise of 5 93  The generic drug maker has been consistently beating earnings expectations  The company s earnings surpassed expectations in three of the last four quarters  with an average positive surprise of 3 75  TEVA PHARM ADR Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderTeva s generic segment could continue seeing weakness  In the first and second quarters  generic segment revenues declined 17  and 7   respectively  Revenues from U S  generics declined more than 30  in both the quarters reflecting loss of exclusivity for the generic versions of Nexium and Pulmicort In the third quarter  important launches were that of generic versions of Cubicin and Gleevec in the U S  which can provide some sales support The EU generics segment will remain under pressure with sales being affected by macro economic conditions and healthcare reforms However  Teva s position in the generics market should strengthen with the completion of the acquisition of Allergan plc s   NYSE AGN   generics segment    Actavis Generics in August and its U S  generic distribution business Anda  Inc  in October With the closing of this deal  Teva now has commercial presence in 80 markets  including a top three leadership position in more than 40 markets and global leadership in all key global markets  The combined pending ANDAs are about 338 including 115 FTFs and Teva now has a significantly improved platform in the EU and ROW  Meanwhile  Allergan s Anda business will be a natural fit in Teva s business model Teva expects to achieve  1 4 billion in operational and tax synergies by the end of 2019 through this deal which is expected to boost 2017 EPS by about 17  and 2019 EPS by 19  Meanwhile  in the branded segment  specialty products and Copaxane should continue to do well Investors will remain focused on the Copaxone franchise s performance considering the 20 mg version of the multiple sclerosis treatment that is facing generic competition in the form of Glatopa  Investors will also be interested in the performance of newly launched products like Bendeka and Cinqair Teva continues to focus on its cost reduction program which should pull up profits Earnings WhispersOur proven model does not conclusively show that Teva is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is  0 79  as the Most Accurate estimate stands at  1 26 per share while the Zacks Consensus Estimate is pegged higher at  1 27 per share Zacks Rank T eva s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter AveXis  Inc    NASDAQ AVXS   is scheduled to release results on Nov 10  The company has an Earnings ESP of 11 43  and a Zacks Rank  2  You can see  Global Blood Therapeutics  Inc    NASDAQ GBT   with an Earnings ESP of  16 95  and a Zacks Rank  2  The company is expected to release results on Nov 10 Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-11-08,Zacks Investment Research,https://www.investing.com/analysis/teva-(teva):-can-it-keep-the-earnings-streak-alive-in-q3-200163708,200163708
106095,327610,AGN,5 Stock Picks Ahead Of World Mental Health Day,opinion,"World Mental Health Day is observed every year on Oct 10    this year  the theme is  psychological first aid   which covers both psychological and social support  According to information provided by the National Alliance on Mental Illness  about one in five adults in the U S  or 43 8 million people experience mental illness in a given year and approximately 1 in 25 adults in the U S  or 10 million people experience a serious mental illness in a given year that substantially interferes with or limits one or more major life activities Given these statistics  it is not surprising that several pharma and biotech companies are involved in developing and selling drugs that target mental health disorders which include a wide range of conditions like attention deficit hyperactivity disorder  ADHD   anxiety disorders  bipolar disorder  depression  eating disorders and schizophrenia among others The market potential for drugs targeting mental health disorders is huge  In fact  due to the social stigma and ignorance associated with such conditions  a large part of the market remains untapped as people don t seek treatment or are unaware of their symptoms 
5 Stocks to ConsiderAhead of World Mental Health Day  let us look at some of the companies which are actively pursuing the development of treatments for various types of mental illnesses To guide investors to the right picks  we highlight 5 stocks that carry a favorable Zacks Rank   Zacks Rank  1  Strong Buy  or  2  Buy  or  3  Hold   You can see  The Zacks Rank is a reliable tool that helps you to trade with confidence regardless of your trading style and risk tolerance  To learn more about how you can use this proven system for market beating gains  visit  First on our list is Zacks Rank  1 stock GW Pharmaceuticals plc   NASDAQ GWPH   which is working on the development of plant derived cannabinoid therapeutics  The company s proprietary cannabinoid product platform targets a broad range of disease areas including schizophrenia which affects about 1 1  of the adult population in the U S   as per the National Institute of Mental Health  While GW Pharma has been more in the news for its progress with the development of Epidiolex  childhood onset epilepsy   the company has an experimental schizophrenia treatment in its pipeline   GWP42003  GW Pharma has completed a mid stage study on the candidate which demonstrated positive proof of concept  The candidate showed notable anti psychotic effects as well as demonstrated the ability to reduce the characteristic movement disorders induced by currently available anti psychotic agents  Shares of this UK based stock  which has been witnessing positive estimate revisions  are up 94 4  year to date  YTD  
GW PHARMA ADR Price and Consensus   Shire plc   NASDAQ SHPG   is well known for its ADHD offerings including Vyvanse  Adderall XR and Intuniv even though some of these products are facing generic competition  The company s neuroscience division delivered sales of  2 5 billion in 2015 and continues to perform well driven by its strong presence in the ADHD market  Shire is working on developing new treatment options for the growing adult ADHD market  The company expects to re submit its regulatory filing for SHP465 in the U S  and is hoping to gain approval in the second quarter of 2017 followed by product launch in the second half of 2017  The company believes that SHP465 has the potential to address a segment of the adult ADHD market that still has unmet needs for non residual control  Shire s share of the U S  ADHD prescription market in Dec 2015 was 16 7   compared to 16 2  in Dec 2014  Shire also has a presence in the binge eating disorder  BED  market with Vyvanse being approved for the treatment of moderate to severe BED in adults  According to information provided by Shire  BED is the most common eating disorder in the U S   affecting about 2 8 million adults  Shire  a Zacks Rank  3 stock  has a strong earnings track record with the company beating expectations in each of the last four quarters with an average surprise of 8 41  
SHIRE PLC ADR Price and Consensus   Healthcare giant  Johnson   Johnson   NYSE JNJ   also has a strong presence in the neuroscience segment  which is one of its core therapeutic areas  In addition to Concerta for ADHD  the company has products like Risperdal Consta  schizophrenia and bipolar I disorder  and Invega Sustenna Trinza  schizophrenia  in its portfolio Meanwhile  one of the most promising candidates in J J s pipeline is esketamine  an investigational antidepressant medication with blockbuster potential  Esketamine recently got breakthrough therapy designation from the FDA for major depressive disorder with imminent risk for suicide  According to the National Institute of Mental Health  in 2015 about 16 1 million adults in the U S  had at least one major depressive episode in the past year  FDA approval would make esketamine one of the first new approaches to treat major depressive disorder in the last 50 years  Esketamine has breakthrough therapy designation for treatment resistant depression as well J J  a Zacks Rank  3 stock  has a good earnings track record having surpassed expectations in each of the last four quarters  The company s shares are up 18 2  YTD 
JOHNSON   JOHNS Price and Consensus   Specialty pharma company  Supernus Pharmaceuticals  Inc    NASDAQ SUPN    is developing several candidates in psychiatry to address large unmet medical needs and market opportunities  SPN 810 is currently in a couple of late stage studies for impulsive aggression in ADHD patients in the 6 12 years age group  If all goes well  the company expects to launch the product in 2019  SPN 810 has the potential to be developed for other indications like autism and bipolar disorder Supernus has another experimental ADHD treatment in its portfolio  SPN 812  for the 6 12 years age group  Data from an ongoing phase IIb study are expected by early 2017  According to research and consulting firm GlobalData  the ADHD market across the U S   France  Germany  Italy  Spain  the UK  and Japan  is set to grow at a CAGR of 8 5  from approximately  6 1 billion in 2014 to  13 9 billion by 2024  Growth will be driven by the launch of new products with convenient oral formulations or less frequent dosing  growing awareness and higher treatment rates Supernus  a Zacks Rank  2 stock has an impressive earnings track record with an average surprise of 117 95  over the last four quarters 
SUPERNUS PHARMA Price and Consensus
   Allergan  NYSE AGN pa  plc   NYSE AGN    a Zacks Rank  3 stock  also looks well positioned in the mental health disorder market  The company has quite a few products in its portfolio targeting this market including Vraylar  schizophrenia and bipolar I disorder   Viibryd  major depressive disorder  and Saphris  bipolar I disorder   Moreover  the company is evaluating flagship product Botox for major depressive disorder and intends to move rapastinel into phase III development for adjunctive major depressive disorder this year  Rapastinel was given breakthrough therapy designation earlier this year for this indication 
ALLERGAN PLC Price and Consensus   Confidential  Zacks  Best Investment Ideas  Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-06,Zacks Investment Research,https://www.investing.com/analysis/5-stock-picks-ahead-of-world-mental-health-day-200157710,200157710
106096,327611,AGN,Repros  Secondary Hypogonadism Drug Under Review In EU,opinion,Repros Therapeutics Inc    NASDAQ RPRX   announced that the European Medicines Agency has accepted for review its marketing authorization application for enclomiphene  The company is looking to get enclomiphene approved for the treatment of secondary hypogonadism Repros expects to receive day 120 questions related to the application by the end of Jan 2017 We remind investors that Repros  efforts to gain approval for enclomiphene in the U S  for the treatment of secondary hypogonadism had suffered a setback with the FDA issuing a complete response letter in Dec 2015  Currently  the company is conducting a proof of concept phase II study  ZA 205  on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with routine diet and exercise regimen  Six month interim data from this study were reported in Aug 2016 Repros plans to participate as a sponsor in the upcoming FDA s Bone  Reproductive and Urologic Drugs Advisory Committee meeting  The meeting is scheduled for Dec 6  2016  The committee intends to discuss appropriate clinical trial design features  including acceptable endpoints for establishing clinical benefit  for drugs that are intended to treat secondary hypogonadism while preserving or improving testicular function  including spermatogenesis REPROS THERAPEU Price   Meanwhile  Repros has made significant progress with its pipeline so far  which includes Proellex  The company plans to hold discussion with the FDA regarding the prospects of advancing the candidate into phase III studies for the treatment of women struggling with painful menstruation  In addition  Proellex is being evaluated for the treatment of uterine fibroids The latest development on the regulatory front raises optimism  Considering that Repros has no approved product in its portfolio at the moment  enclomiphene s approval will be a huge boost for the company Investor focus is expected to remain on the upcoming FDA advisory panel meeting as well on EU updates on the candidate Currently available treatments for hypogonadism in the market include AbbVie Inc  s   NYSE ABBV   AndroGel  Endo International plc s   NASDAQ ENDP   Testim and Allergan  NYSE AGN pa  plc s   NYSE AGN   Androderm Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-09,Zacks Investment Research,https://www.investing.com/analysis/repros'-secondary-hypogonadism-drug-under-review-in-eu-200157999,200157999
106097,327612,AGN,Allergan Gets Priority Review For Avycaz Label Expansion,opinion,"Allergan  NYSE AGN pa  plc   NYSE AGN   announced that its supplemental new drug application for antibiotic Avycaz  ceftazidime and avibactam  ex U S  trade name  Zavicefta   has been accepted for review by the FDA  Allergan is looking to include data from a phase III study in Avycaz s existing label  The phase III study had evaluated Avycaz in patients with complicated urinary tract infections  cUTI   including pyelonephritis  due to designated susceptible pathogens We note that the FDA has granted priority review status to the company s regulatory application based on a prior Qualified Infectious Disease Product designation for the product  As a result  the company expects a response to be out in the first quarter of 2017 We remind investors that Avycaz was approved in the U S  in Feb 2015 for the treatment of adult patients with complicated intra abdominal infections  cIAI   in combination with metronidazole  as well as for cUTI  including pyelonephritis  caused by designated susceptible bacteria  including certain Enterobacteriaceae and Pseudomonas aeruginosa 
ALLERGAN PLC Price
    In Jun 2016  Avycaz s label was updated to include data from the phase III cIAI study  The study evaluated the safety and efficacy of Avycaz in combination with metronidazole  for the treatment of cIAI  It also included data from a subset of patients with infections caused by ceftazidime nonsusceptible pathogens and another with pathogens producing certain extended spectrum beta lactamases Avycaz raked in sales of  22 1 million in the first half of 2016  Apart from Avycaz  Allergan s anti infectives portfolio also consists of antibiotics like Teflaro and Dalvance We note that Avycaz is being developed by Allergan in collaboration with AstraZeneca plc   NYSE AZN    While Allergan has commercialization rights to Avycaz in North America  rights to rest of the world are owned by AstraZeneca Allergan divested its generics business to Teva Pharmaceutical Industries Ltd   NYSE TEVA   in Aug 2016  The company has been working on expanding and strengthening its branded business Allergan currently carries a Zacks Rank  3  Hold  A Stock to ConsiderA better ranked stock in the health care sector is Amarin Corporation plc   NASDAQ AMRN    sporting a Zacks Rank  1  Strong Buy   You can see Amarin s loss estimates narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days  The company s share price has rallied 65 2  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,https://www.investing.com/analysis/allergan-gets-priority-review-for-avycaz-label-expansion-200158673,200158673
106098,327613,AGN,Pharma Stock Roundup  Mylan In EpiPen Medicaid Settlement  ESMO Data In Focus,opinion,"Mylan   NASDAQ MYL   was in the news again with the company agreeing to a settlement related to Medicaid rebate classification for EpiPen  Meanwhile  several pharma companies were present at the congress of the European Society for Medical Oncology  ESMO  with data on their cancer treatments Recap of the Week s Most Important StoriesMylan Settles with DoJ for EpiPen  Mylan has agreed to pay  465 million to the U S  Department of Justice  DoJ  and other government agencies to settle the investigation into the classification of its life saving combination product  EpiPen Auto Injector and EpiPen Jr Auto Injector  for purposes of the Medicaid Drug Rebate Program  While shares were up with the settlement agreement being announced  concerns remain about ongoing investigations and continued political  public and media focus on drug pricing  Mylan said that it received a document request from the Division of Enforcement at the Securities and Exchange Commission  SEC  seeking communications with the CMS and documents regarding Mylan products sold and related to the Medicaid Drug Rebate Program  and any related complaints  Mylan has cut its earnings outlook for 2016 and expects to report third quarter results on Nov 9  Read more    UK Court Ruling Unfavorable for Pfizer  Pfizer   NYSE PFE   got an unfavorable decision in the Court of Appeal in the UK for its blockbuster drug  Lyrica  The Court upheld the decision of the High Court that found that the patent covering Lyrica for pain is not infringed by Actavis  NYSE AGN  and patent claims directed generally to pain and neuropathic pain are invalid  Pfizer intends to appeal the decision to the Supreme Court  Lyrica brought in worldwide sales of  4 8 billion in 2015 and  2 5 billion in the first half of 2016 Meanwhile  Pfizer was at ESMO with data on Inlyta and Sutent  Data from a phase Ib study evaluating a combination of Inlyta and Merck s Keytruda provided additional support for novel immunotherapy combinations in renal cell carcinoma  RCC   Preliminary results from another study combining Inlyta with Merck KGaA s avelumab suggested evidence of anti tumor activity for this combination  Both combinations are currently in late stage studies for first line advanced RCC Pfizer also presented data on Sutent from a late stage study evaluating the drug in an adjuvant setting in patients at high risk for recurrence after surgical resection of RCC  Results showed that Sutent extended disease free survival  DFS  by more than a year compared to placebo  resulting in an overall risk reduction of 24   Pfizer is in discussions with regulatory authorities regarding the next steps Roche s Tecentriq Lung Cancer Data Looks Good  Roche   OTC RHHBY   presented data on its PD L1 inhibitor  Tecentriq  at ESMO  Results from a phase III study showed that Tecentriq demonstrated significant survival advantage compared to chemotherapy regardless of PD L1 status in a specific type of lung cancer  Patients on Tecentriq lived 4 2 months longer than those treated with docetaxel chemotherapy  Tecentriq is currently under FDA review for a lung cancer indication and could gain approval for the label expansion shortly as the agency is expected to respond by Oct 19 Merck Presents Keytruda Data at ESMO  Merck   NYSE MRK   was also present at ESMO with data on Keytruda from different studies  The company reported positive data on Keytruda for front line bladder cancer   overall response rate was 24  in patients with and without PD L1 expression  Meanwhile  results from KEYNOTE 024  which evaluated squamous and non squamous non small cell lung cancer  NSCLC  patients whose tumors expressed high levels of PD L1  showed that Keytruda led to a 50  reduction in the risk of disease progression or death and a 40  reduction in the risk of death compared to platinum doublet  the current standard of care  Median progression free survival  PFS  for Keytruda was 10 3 months compared to 6 0 months for chemotherapy Keytruda  which posted sales of  563 million in the first half of 2016  is in more than 350 studies across more than 30 tumor types  Keytruda is currently under FDA review for the first line treatment of patients with advanced NSCLC whose tumors express PD L1  with a target action date of Dec 24  2016  Merck is a Zacks Rank  2  Buy  stock  You can see  Bristol Myers at ESMO  Bristol Myers   NYSE BMY   presented data on Opdivo at ESMO from several studies including updated data from CheckMate 057 and  017    results showed that previously treated metastatic NSCLC patients had tripled the duration of response with Opdivo compared to those treated with docetaxel  with a minimum follow up of two years  Data was also presented on Yervoy Performance
Large Cap Pharmaceuticals Industry Price IndexAll major pharma stocks lost some ground over the last five trading days with the NYSE ARCA Pharmaceutical Index declining 2 2   Bristol Myers and AstraZeneca   NYSE AZN   declined 8 7  and 4 4   respectively  Over the last six months  Bristol Myers declined 25 7  while Merck was up 11 7   See the last pharma stock roundup here    
What s Next in the Pharma World Johnson   Johnson s   NYSE JNJ   earnings results will be in focus with the company slated to release results on Oct 18  A decision from the FDA regarding Roche s Tecentriq for a lung cancer indication should also be out by Oct 19 Confidential  Zacks  Best Investment Ideas  Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-13,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-mylan-in-epipen-medicaid-settlement,-esmo-data-in-focus-200158869",200158869
106099,327614,AGN,Allergan  AGN  Gains Rights To RTGel From UroGen Pharma ,opinion,"Ireland based Allergan  NYSE AGN pa  plc   NYSE AGN   has gained worldwide rights to RTGel delivery system technology for use with neurotoxins from privately held pharma company UroGen Pharma  for an upfront payment of  17 5 million RTGel technology was developed by New York based UroGen to promote ease of delivery into and retention of drugs in body cavities  including the bladder while preventing their rapid excretion  RTGel takes a liquid form at lower temperatures and converts into gel when heated  This special technology when formulated with an active drug  may improve efficacy of treatment of patients suffering from Overactive Bladder  OAB  For patients suffering from OAB  a neurotoxin injection into the bladder is considered as a successful therapeutic option  Botox is a reputed neurotoxin ALLERGAN PLC Price
    Other than the upfront payment  Allergan will also be entitled to the development and commercial milestones as well as royalties on net sales This agreement is going to set milestones for patients suffering from OAB and related conditions  According to the company s press release  over 30 million people in the U S and over 200 million worldwide suffer from OAB  The unison of Botox and RTGel will deliver innovative and meaningful treatments for the disease Currently  Allergan carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include Bioblast Pharma Ltd    NASDAQ ORPN    Geron Corporation   NASDAQ GERN    Exelixis  Inc    NASDAQ EXEL    All the companies sport a Zacks Rank  1  Strong Buy   You can see the  Bioblast Pharma recorded positive earnings surprises in each of the last four quarters with an average beat of 51 66   The loss estimates for 2016 and 2017 have narrowed down over the past 60 days Geron has an average positive surprise of 20 78  for the last four quarters Exelixis has an average positive surprise of 9 10  for the trailing four quarters  Its share price has jumped more than 100  year to date  The loss estimates for 2016 and 2017 have narrowed down over the past 60 days Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-16,Zacks Investment Research,https://www.investing.com/analysis/allergan-(agn)-gains-rights-to-rtgel-from-urogen-pharma-200159187,200159187
106100,327615,AGN,The Zacks Analyst Blog Highlights  Mylan  Pfizer  Roche  Merck And Bristol Myers,opinion,"For Immediate Release

	Chicago  IL   October 17  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Mylan  NASDAQ MYL   NASDAQ     Pfizer  NYSE PFE   NYSE       Roche  OTCMKTS      Merck  NYSE MRK   NYSE     and Bristol Myers  NYSE      

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Friday s Analyst Blog  

Pharma Stock Roundup  Mylan in EpiPen Settlement  ESMO Data in Focus

	Mylan  NASDAQ      was in the news again with the company agreeing to a settlement related to Medicaid rebate classification for EpiPen  Meanwhile  several pharma companies were present at the congress of the European Society for Medical Oncology  ESMO  with data on their cancer treatments 

Recap of the Week s Most Important StoriesMylan Settles with DoJ for EpiPen   Mylan has agreed to pay  465 million to the U S  Department of Justice  DoJ  and other government agencies to settle the investigation into the classification of its life saving combination product  EpiPen Auto Injector and EpiPen Jr Auto Injector  for purposes of the Medicaid Drug Rebate Program  While shares were up with the settlement agreement being announced  concerns remain about ongoing investigations and continued political  public and media focus on drug pricing  Mylan said that it received a document request from the Division of Enforcement at the Securities and Exchange Commission  SEC  seeking communications with the CMS and documents regarding Mylan products sold and related to the Medicaid Drug Rebate Program  and any related complaints  Mylan has cut its earnings outlook for 2016 and expects to report third quarter results on Nov 9  Read more     UK Court Ruling Unfavorable for Pfizer   Pfizer  NYSE      got an unfavorable decision in the Court of Appeal in the UK for its blockbuster drug  Lyrica  The Court upheld the decision of the High Court that found that the patent covering Lyrica for pain is not infringed by Actavis  NYSE AGN  and patent claims directed generally to pain and neuropathic pain are invalid  Pfizer intends to appeal the decision to the Supreme Court  Lyrica brought in worldwide sales of  4 8 billion in 2015 and  2 5 billion in the first half of 2016 
	Meanwhile  Pfizer was at ESMO with data on Inlyta and Sutent  Data from a phase Ib study evaluating a combination of Inlyta and Merck s Keytruda provided additional support for novel immunotherapy combinations in renal cell carcinoma  RCC   Preliminary results from another study combining Inlyta with Merck KGaA s avelumab suggested evidence of anti tumor activity for this combination  Both combinations are currently in late stage studies for first line advanced RCC 
	Pfizer also presented data on Sutent from a late stage study evaluating the drug in an adjuvant setting in patients at high risk for recurrence after surgical resection of RCC  Results showed that Sutent extended disease free survival  DFS  by more than a year compared to placebo  resulting in an overall risk reduction of 24   Pfizer is in discussions with regulatory authorities regarding the next steps Roche s Tecentriq Lung Cancer Data Looks Good   Roche  OTCMKTS       presented data on its PD L1 inhibitor  Tecentriq  at ESMO  Results from a phase III study showed that Tecentriq demonstrated significant survival advantage compared to chemotherapy regardless of PD L1 status in a specific type of lung cancer  Patients on Tecentriq lived 4 2 months longer than those treated with docetaxel chemotherapy  Tecentriq is currently under FDA review for a lung cancer indication and could gain approval for the label expansion shortly as the agency is expected to respond by Oct 19 Merck Presents Keytruda Data at ESMO   Merck  NYSE      was also present at ESMO with data on Keytruda from different studies  The company reported positive data on Keytruda for front line bladder cancer   overall response rate was 24  in patients with and without PD L1 expression  Meanwhile  results from KEYNOTE 024  which evaluated squamous and non squamous non small cell lung cancer  NSCLC  patients whose tumors expressed high levels of PD L1  showed that Keytruda led to a 50  reduction in the risk of disease progression or death and a 40  reduction in the risk of death compared to platinum doublet  the current standard of care  Median progression free survival  PFS  for Keytruda was 10 3 months compared to 6 0 months for chemotherapy 
	Keytruda  which posted sales of  563 million in the first half of 2016  is in more than 350 studies across more than 30 tumor types  Keytruda is currently under FDA review for the first line treatment of patients with advanced NSCLC whose tumors express PD L1  with a target action date of Dec 24  2016  Merck is a Zacks Rank  2  Buy  stock  You can see   Bristol Myers at ESMO   Bristol Myers  NYSE      presented data on Opdivo at ESMO from several studies including updated data from CheckMate 057 and  017    results showed that previously treated metastatic NSCLC patients had tripled the duration of response with Opdivo compared to those treated with docetaxel  with a minimum follow up of two years  Data was also presented on Yervoy 

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-16,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-mylan,-pfizer,-roche,-merck-and-bristol-myers-200159161",200159161
106101,327616,AGN,Allergan  AGN  Brings Juvederm Voluma XC To U S  Market,opinion,"Allergan  NYSE AGN pa  plc  NYSE AGN   announced that it has launched Juv derm Voluma XC in the U S  The product is a new addition to the Juv derm range of fillers for lip augmentation and for correcting perioral rhytids  or  lipstick lines   in adults aged 21 and above In one year of clinical trials  the Juv derm Voluma XC injections were found to be effective in augmenting lip fullness and softening fine lines around the mouth  Perioral lines  which are otherwise difficult to treat  have been a concern for aesthetically oriented patients for a long time  Juv derm Voluma XC is formulated with Vycross  a type of dermal filler which gives smoother  more comfortable and natural looking and longer lasting appearance Per the American Society of Plastic Surgeons  ASPS   the usage of soft tissue fillers was the most rapidly growing cosmetic minimally invasive procedure in 2015  With the launch of Juv derm Voluma XC in the market the need of a number of physicians and patients will be addressed  Since the product has minimal side effects which eases within a month of application  the product is expected to generate decent sales for Allergan ALLERGAN PLC Price
    Allergan has been on an acquisition spree this month  Last week  it announced a definitive deal to acquire Tobira Therapeutics  Inc    NASDAQ TBRA    a clinical stage biotechnology company focused on making drugs to treat non alcoholic steatohepatitis  NASH  and other liver diseases at a massive premium of 500   On the same day  Allergan also announced that it has bought the privately held Akarna Therapeutics for  50M in upfront cash plus unspecified milestones  Akarna Therapeutics  lead product candidate AKN 083  a preclinical stage FXR agonist  is also being evaluated for the treatment of NASH In September  Allergan announced that it will be acquiring the clinical stage biotech company  Vitae Pharmaceuticals  Inc    NASDAQ VTAE    for approximately  639 million  The acquisition  scheduled to close in the fourth quarter of 2016  will boost Allergan s dermatology pipeline  Allergan also announced the acquisition of RetroSense Therapeutics  a privately held  clinical stage biotechnology company  which will add the latter s lead gene therapy development program RST 001 to Allergan s eye care pipeline Meanwhile  the company sold its generics business to Teva Pharmaceutical Industries Ltd   NYSE TEVA   in Aug 2016 
Allergan currently carries a Zacks Rank  3  Hold   You can see the  
Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-18,Zacks Investment Research,https://www.investing.com/analysis/allergan-(agn)-brings-juvederm-voluma-xc-to-u.s.-market-200159580,200159580
106102,327617,AGN,Allergan s Nocturia Drug Gets FDA Advisory Committee s Nod,opinion,"Allergan  NYSE AGN pa  plc   NYSE AGN   and partner Serenity Pharmaceuticals announced that the FDA s Advisory Committee of Bone  Reproductive and Urologic Drugs recommended approval for its pipeline candidate SER120  desmopressin nasal spray  for the treatment of nocturia Nocturia is a very common yet under diagnosed urological disorder in adults  Patients suffering from this disease need to wake and empty their bladders at least twice every night  The Committee voted 14 4 in favor of the candidate s benefit risk profile Although the FDA takes the recommendations of its advisory committee into account while reviewing applications  it is not bound to follow the same  A decision from the FDA is expected in the fourth quarter of this year ALLERGAN PLC Price
    Allergan has recently been on an acquisition spree  Last month  it announced a definitive deal to acquire Tobira Therapeutics  Inc    NASDAQ TBRA    a clinical stage biotechnology company focused on making drugs to treat non alcoholic steatohepatitis  NASH  and other liver diseases at a massive premium of 500  The deal is expected to close at 2016 end   On the same day  Allergan also announced that it has bought the privately held Akarna Therapeutics for  50M in upfront cash plus unspecified milestones  Akarna Therapeutics  lead product candidate AKN 083  a preclinical stage FXR agonist  is also being evaluated for the treatment of NASH In September  Allergan announced that it will be acquiring the clinical stage biotech company  Vitae Pharmaceuticals  Inc    NASDAQ VTAE    for approximately  639 million  The acquisition  scheduled to close in the fourth quarter of 2016  will boost Allergan s dermatology pipeline  Allergan also announced the acquisition of RetroSense Therapeutics  a privately held  clinical stage biotechnology company  which will add the latter s lead gene therapy development program RST 001 to Allergan s eye care pipeline Meanwhile  the company sold its generics business to Teva Pharmaceutical Industries Ltd   NYSE TEVA   in August Allergan currently carries a Zacks Rank  3  Hold   You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-20,Zacks Investment Research,https://www.investing.com/analysis/allergan's-nocturia-drug-gets-fda-advisory-committee's-nod-200160023,200160023
106122,327637,AGN,Allergan Buys NASH Therapy Maker Tobira At Huge Premium,opinion,"Allergan  NYSE AGN pa  plc   NYSE AGN   announced a definitive deal to acquire Tobira Therapeutics  Inc    NASDAQ TBRA   for a total potential consideration of around  1 7 billion Tobira is a clinical stage biotechnology company focused on making drugs to treat non alcoholic steatohepatitis  NASH  and other liver diseases ALLERGAN PLC Price
    What is Allergan Paying The acquisition comes at a steep price  Allergan will pay  28 35 per share upfront for all the outstanding shares of Tobira common stock  plus one Contingent Value Right  CVR  to receive up to  49 84 per share in future payments  based on the successful completion of certain development  regulatory and commercial milestones related to Tobira s lead pipeline candidates The upfront payment of  28 35 alone represents a stunning premium of around 500  to Tobira s Monday s closing price of  4 74  Shares of Tobira rose more than 700  after the acquisition was announced Is the Massive Premium Justified The acquisition will add global rights to Tobira s lead pipeline candidates Cenicriviroc  CVC  and Evogliptin  thereby expanding Allergan s gastroenterology pipeline Incidentally  CVC and Evogliptin are highly differentiated compounds  which are being developed to treat the multi factorial elements of NASH  including inflammation  metabolic syndromes and fibrosis thereby reinforcing Allergan s commitment to the NASH space Notably  NASH  a severe type of liver disease  occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage  leading to liver fibrosis  and eventually cirrhosis  liver cancer or liver failure  At present  no approved therapies are available for patients suffering from NASH  According to the company s press release  NASH is the fastest growing cause of liver cancer and liver transplant in the U S   thus representing significant unmet need CVC is a first in class oral CCR2 5 phase III inhibitor impacting liver inflammation and fibrosis  The candidate demonstrated a clinically and statistically significant improvement in fibrosis of at least one stage without worsening NASH after one year of treatment   one of the two secondary endpoints   in the phase IIb CENTAUR study However  we remind investors that CVC failed to meet the primary endpoint of a two point reduction in the NAFLD Activity Score as well as the second secondary endpoint in the CENTAUR study   Results from CENTAUR were announced in July The other candidate  Evogliptin is in a phase I study which is evaluating the oral DPP 4  Dipeptidyl peptidase 4  inhibitor as a potential treatment for NASH in combination with CVC impacting the metabolic element of the disease While ultimately the NASH market holds great potential  Allergan s generosity has raised some eyebrows  which is reflected in the 2 5  decline in the company s shares on Tuesday The transaction is expected to close by the end of the year  if the necessary approvals are obtained  The boards of directors of both the companies have approved the merger Also Buys Akarna Therapeutics On the same day  Allergan also announced that it has bought privately held Akarna Therapeutics for  50M in upfront cash plus unspecified milestones  Its lead product candidate AKN 083  a preclinical stage FXR agonist  is also being evaluated for the treatment of NASH   thus making the acquisition highly complementary to the Tobira buyout Allergan joins Gilead Sciences Inc    NASDAQ GILD   and Intercept Pharmaceuticals  Inc    NASDAQ ICPT   which are also developing therapies for the treatment of NASH Allergan  one of the largest and fastest growing drugmakers  has a Zacks Rank  3  Hold   You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-21,Zacks Investment Research,https://www.investing.com/analysis/allergan-buys-nash-therapy-maker-tobira-at-huge-premium-200154700,200154700
106123,327638,AGN,5 Biotech Stocks To Watch As Interest In NASH Increases,opinion,"The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH  a common but often  silent  liver disease  Interest in NASH has gone up with Allergan plc   NYSE AGN   announcing a couple of deals targeting this disease area earlier this week  The company announced two back to back deals   one with clinical stage biopharma company  Tobira  worth up to  1 695 billion and the other with privately held biopharma company Akarna for an up front payment of  50 million plus additional payments on the achievement of certain milestones  Both Tobira and Akarna are focused on developing treatments for NASH NASH Represents Significant Commercial OpportunityNASH is an increasingly common  progressive form of fatty liver disease which is becoming a significant and growing health issue given the rising obesity epidemic  Patients who have diabetes  high cholesterol or high triglycerides are often diagnosed with the disease  which is expected to become the leading cause of liver transplant and liver cancer  By 2020  NASH is expected to become the leading indication for liver transplant ahead of chronic hepatitis C and alcoholic liver disease With no treatments currently approved for this disease  the market opportunity is significant  Several companies are working on developing treatments for NASH   the market could be worth billions of dollars and many companies are hoping to cash in on this opportunity  According to a Newsweek article  analysts predict that the market for a NASH drug could reach  35 billion or more by 2025 NASH Stocks in FocusWith Allergan willing to shell out as much as up to  1 695 billion for Tobira  the market is rife with speculation that more acquisition deals will be announced in this space  In such a scenario  it would make sense to focus on these 5 stocks that are working on bringing NASH treatments to market  All these stocks saw their share prices increase following the Allergan Tobira announcement New York based Intercept Pharmaceuticals  Inc    NASDAQ ICPT   is focused on the development and commercialization of novel therapeutics to treat non viral  progressive liver diseases  While the Zacks Rank  3  Hold  stock gained FDA approval for its first product Ocaliva  OCA  an FXR agonist  earlier this year for primary biliary cholangitis  the main potential for the product lies in NASH  Intercept has a broad and comprehensive plan for evaluating Ocaliva for NASH with a late stage study ongoing  Ocaliva got breakthrough therapy designation for Ocaliva for the treatment of NASH with liver fibrosis in Jan 2015  Intercept s shares are up 7 4  so far this week 
INTERCEPT PHARM Price and Consensus   San Diego  CA based Conatus Pharmaceuticals Inc    NASDAQ CNAT   is another company focused on the development and commercialization of novel medicines to treat liver disease  The company s lead pipeline candidate  emricasan  an orally active pan caspase protease inhibitor   is in a phase IIb study in patients with NASH fibrosis  The Zacks Rank  3 stock has fast track status in the U S  for emricasan for the treatment of NASH cirrhosis  The company has several studies planned covering different types of NASH patient populations  Conatus  shares are up 25  so far this week 
CONATUS PHARMA Price and Consensus   Norcross  GA based Galectin Therapeutics  Inc    NASDAQ GALT   is a clinical stage company focused on bringing new therapies for fibrotic disease and cancer to market  The company  which is targeting late stage NASH  expects to report top line data from a phase II study being conducted on its lead drug candidate  GR MD 02  in NASH patients with advanced fibrosis  stage 3  by the end of this month  GR MD 02  which targets galectin 3 protein  has fast track status in the U S  for NASH with hepatic fibrosis  This Zacks Rank  2  Buy  company s shares are up 52 9  so far this week on the market buzz regarding NASH and takeover speculation 
GALECTIN THERAP Price and Consensus   Watertown  MA based Enanta Pharmaceuticals  Inc    NASDAQ ENTA   is looking to move its FXR agonist  EDP 305  into clinical studies this year  The Zacks Rank  3 biotech company saw its shares gaining almost 8  so far this week  You can see  
ENANTA PHARMA Price and Consensus   Israel based Galmed Pharmaceuticals Ltd    NASDAQ GLMD    a clinical stage company  is evaluating Aramchol in a phase IIb study in patients with NASH  who are overweight or obese  and who are pre diabetic or type II diabetic  Aramchol also enjoys fast track status in the U S  Shares of this Zacks Rank  3 stock are up 26 1  so far this week 
GALMED PHARMA Price and Consensus
   And it s not just small or mid sized companies that are working on bringing NASH treatments to market    big players like Gilead  Merck  NYSE MRK  and AstraZeneca are some of the companies that have struck deals for adding NASH candidates to their pipeline  More deals are likely to follow given the lack of approved treatments and the prevalence of  9 to15 million NASH patients in the U S  of whom about 20  could develop cirrhosis 
Now See Our Private Investment IdeasWhile the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-09-21,Zacks Investment Research,https://www.investing.com/analysis/5-biotech-stocks-to-watch-as-interest-in-nash-increases-200155023,200155023
106124,327639,AGN,Is Galectin The Next Takeover Target For The Biotech World ,opinion,"Shares of Galectin Therapeutics  Inc    NASDAQ GALT   were up almost 36  on Wednesday It is being speculated that Galectin could be the next takeover target in the biotech world after Allergan  NYSE AGN pa  plc s   NYSE AGN   highly expensive definitive deal to acquire Tobira Therapeutics  Inc    NASDAQ TBRA   was announced on Tuesday Allergan has agreed to buy Tobira  a clinical stage biotechnology company focused on making drugs to treat non alcoholic steatohepatitis  NASH  and other liver diseases  for a total potential consideration of around  1 7 billion Importantly  the purchase consideration includes an upfront payment of  28 35 alone  which represented a stunning premium of around 500  to Tobira s Monday s closing price of  4 74  Shares of Tobira rose more than 700  after the acquisition was announced Like Tobira  Galectin is also a promising player in the NASH space  It is focusing on making therapies that target galectin proteins for the treatment of fibrotic liver disease as well as cancer  Its lead pipeline candidate  GR MD 02 is in two phase II trials in subjects with NASH  While the NASH   CX trial  n 290  is evaluating the efficacy of GR MD 02 in patients with NASH with cirrhosis  the NASH   FX trial is evaluating the candidate in NASH patients with advanced fibrosis  stage 3   Top line data from the NASH   FX trial is due to be released this month Preclinical data in animals have shown that GR MD 02 has robust treatment effects in reversing liver fibrosis and cirrhosis NASH  a severe type of liver disease  occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage  leading to liver fibrosis or scarring of the liver  and eventually cirrhosis  liver cancer or liver failure  At present  no approved therapies are available for patients suffering from NASH  liver fibrosis  or cirrhosis  for which liver transplant is the only treatment available  According to a press release issued by Galectin  it is estimated that by 2025 the worldwide market for NASH treatments could approach  35 billion  Thus  the NASH market holds great potential  bringing small companies like Galectin in focus as acquisition targets GALECTIN THERAP Price
    Other companies that are also developing therapies for the treatment of NASH include Gilead Sciences Inc    NASDAQ GILD   and Intercept Pharmaceuticals Galectin has a Zacks Rank  2  Buy   You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-22,Zacks Investment Research,https://www.investing.com/analysis/is-galectin-the-next-takeover-target-for-the-biotech-world-200154940,200154940
106125,327640,AGN,Amgen s Biosimilar Of Abbvie s Humira Gets FDA Approval,opinion,"Amgen  Inc    NASDAQ AMGN   today announced the approval of Amjevita  adalimumab atto   a biosimilar version to AbbVie Inc  s   NYSE ABBV   rheumatoid arthritis  RA  drug Humira Amjevita has been approved for the same indications that Humira is being used for   including rheumatoid arthritis  RA   juvenile idiopathic arthritis  JIA   psoriatic arthritis  PsA   ankylosing spondylitis  AS   adult Crohn s disease  CD   ulcerative colitis  UC   plaque psoriasis  PsO    all in specific patient populations  The U S  sales of Humira were about  8 4 billion in 2015 We remind investors that in July  the FDA s Arthritis Advisory Committee voted in favor of an approval of Amjevita The approval of Amjevita is based on positive data from two phase III studies comparing the safety  efficacy and immunogenicity of Amjevita with Humira in patients with moderate to severe RA and moderate to severe plaque psoriasis  The studies met their primary endpoints Amjevita is the first biosimilar version of Humira to be approved by the FDA as well as Amgen s first biosimilar medicine to be approved AMGEN INC Price
    Amgen is exploring the world of biosimilars and expects to launch five such new products between 2017 and 2019  The biosimilars opportunity represents annual revenues of more than  3 billion for Amgen  The company also has a partnership with Allergan  NYSE AGN pa   Inc    NYSE AGN   for the worldwide development and commercialization of oncology antibody biosimilar medicines Other than Amjevita  other candidates being developed include biosimilar versions of Roche s Avastin  ABP 215   Herceptin  ABP 980  breast cancer  and Rituxan  ABP 798   Eli Lilly and Company s   NYSE LLY   Erbitux  ABP 494   and Johnson   Johnson Merck s Remicade  ABP 710  Amgen has also tied up with Daiichi Sankyo for the commercialization of nine biosimilars in Japan  including biosimilars of Humira  Avastin and Herceptin The approval of Amjevita would be a huge boost for Amgen which itself is facing biosimilar threats for quite a few of its key drugs  Anemia drug Aranesp faces competition in Europe from biosimilars marketed by companies like Pfizer  NYSE PFE  and Novartis  Biosimilars are also starting to have a negative impact on sales of its key products like Neupogen and Neulasta in the EU  In August this year  Novartis  generic arm  Sandoz received FDA approval for a biosimilar version of Amgen s blockbuster RA drug Enbrel Both Amgen and AbbVie are Zacks Rank  3  Hold  stocks  You can see the  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-26,Zacks Investment Research,https://www.investing.com/analysis/amgen's-biosimilar-of-abbvie's-humira-gets-fda-approval-200155467,200155467
106126,327641,AGN,Pfizer  PFE  To Stay Together As A Single Company After All,opinion,"Drug maker Pfizer  Inc    NYSE PFE   has finally decided not to split its two segments   Innovative Health  IH  and Essential Health  EH    into two publicly traded companies For years  the company has been facing pressure from investors and analysts alike to split into two separate companies in hopes of driving growth  In April  Pfizer said it would come up with a decision by the year end  following the termination of its planned  160 billion merger with Allergan plc   NYSE AGN   However  per Pfizer s management  a recent analysis has showed that it was already favorbaly positioned to maximize shareholder value in its current form Pfizer reorganized its reporting segments to IH and EH from the second quarter onward  While the IH business includes the new products  EH covers legacy brands  branded generics  generic sterile injectable products  biosimilars and infusion systems Pfizer s management asserted that both the IH and EH units have delivered strong results over the past three years as well as the first half of 2016  While IH sales witnessed growth of 18   EH revenues jumped 22  on an operational basis  excluding the impact of foreign exchange  in the first half of 2016  While the Sep 2015 Hospira acquisition boosted sales at the EH segment  the IH unit gained from strong performance of key new drugs like breast cancer drug  Ibrance  Strong performance of both the segments met one of the key criteria for keeping the two units together   their ability to compete on a standalone basis Also  management said that a separation at this juncture would improve neither its cash flow generation ability nor the competitive edge of the businesses  Moreover  it could result in operational disturbance while raising costs  without resulting in any incremental tax efficiencies Management believes that new products like Eliquis  Xeljanz  Xalkori and Ibrance  the Jun 2016 acquisition of Anacor  as well as the pending  14 billion acquisition of cancer focused biopharma company  Medivation  Inc    NASDAQ MDVN    will boost sales at the IH segment  going forward  On the other hand  EH is expected to return to sustainable growth over the next few years driven by sterile injectable and biosimilar capabilities acquired from the Hospira deal and expected growth in the emerging markets Instead  Pfizer is expected to buy more companies in the future  which will add key branded products to help offset at least some impact of increasing generic threats  Pfizer s top line is presently under pressure due to generic competition for several of its products Shares of Pfizer fell around 2  on the news PFIZER INC Price
    Pfizer has a Zacks Rank  3  Hold   A stock worth considering in the large cap healthcare sector is Eli Lilly and Company   NYSE LLY    which carries a Zacks Rank  2  Buy   You can see the  Eli Lilly has delivered an average four quarter positive earnings surprise of 4 31   Its earnings estimate for 2016 has risen 0 6   while that for 2017 increased over 2  over the last 60 days Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-26,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-to-stay-together-as-a-single-company-after-all-200155819,200155819
106127,327642,AGN,Amgen  AMGN  Migraine Drug Hits Phase III Primary Endpoint,opinion,"Amgen Inc    NASDAQ AMGN   announced positive top line data from a phase III study  ARISE  on calcitonin gene related peptide  CGRP  receptor  erenumab  AMG 334   for the prevention of episodic migraine 
The multi center  randomized  12 week  double blind  placebo controlled study evaluated the safety and efficacy of erenumab in patients with episodic migraine  Data showed that patients  when treated with erenumab  70 mg   experienced a statistically significant 2 9 day reduction from baseline in monthly migraine days  in comparison to a 1 8 day reduction in the placebo arm at 12 weeks  thereby meeting the primary endpoint of the study  In addition  the safety profile of erenumab was found to be similar to placebo and consistent with previously reported studies 
Currently  additional analyses of these data are in progress and expected to be submitted at a future medical conference and for publication 
AMGEN INC Price   Earlier this year  positive data from a phase II study on erenumab for the prevention of chronic migraine were also announced  Meanwhile  the candidate is also being evaluated in a second phase III episodic migraine study  STRIVE   assessing both 70 mg and 140 mg doses for 24 weeks  The study is anticipated to be completed by the end of this year 
We note that  Amgen is developing erenumab in collaboration with Novartis AG   NYSE NVS    focused on the development and commercialization of treatments for migraine and Alzheimer s disease  For the migraine program  Amgen owns commercialization rights in the U S   Canada and Japan  while Novartis has rights in Europe and Rest of World 
We note that several companies  including Teva Pharmaceutical Industries Limited   NYSE TEVA   and Allergan plc   NYSE AGN   among others  are developing migraine treatments targeting CGRP 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-29,Zacks Investment Research,https://www.investing.com/analysis/amgen-(amgn)-migraine-drug-hits-phase-iii-primary-endpoint-200156486,200156486
106128,327643,AGN,Biotech Mergers Run The Show  5 Small Cap Stocks For Q4,opinion,"Healthcare merger and acquisition activity has gathered steam over the past few years  A few big mergers in the recent past include that of Pfizer  Inc    NYSE PFE   and Wyeth  Pfizer and Hospira  Novartis AG   NYSE NVS   and Alcon  Sanofi   NYSE SNY   and Genzyme  Roche Holding  SIX ROG  AG   OTC RHHBY   and Genentech  and AstraZeneca PLC   NYSE AZN   and MedImmune  Consolidation helps large pharma companies gain more pricing power while simultaneously curbing competition 
Last November  Pfizer announced that it would acquire Allergan  NYSE AGN pa   Plc   NYSE AGN   for  160 billion  However  this deal fell apart in Apr 2016 due to the new U S  tax inversion rules 
There has been a flurry of mergers and acquisitions in the healthcare space this year too  In August  Pfizer announced the acquisition of oncology focused Medivation  Inc    NASDAQ MDVN   for approximately  14 billion  The deal is expected to close this year  This was preceded by the buyout of Anacor in Jun 2016 
Also in June  Shire plc  acquired Baxalta to brace its rare disease portfolio further  while Aegerion Pharmaceuticals  and QLT Inc   entered into a definitive merger agreement to form a new company  Novelion Therapeutics Inc 
In April  Abbott Laboratories   NYSE ABT   announced plans to buy St  Jude Medical Inc    NYSE STJ   in a move to bolster its share in the cardiovascular device market  In fact  the month of September probably saw higher merger acquisition activity this year  Horizon Pharma plc  announced plans to buy California based Raptor Pharmaceuticals Corp    This acquisition  slated to close in the fourth quarter  is likely to strengthen Horizon s orphan business in the U S  and expand it in Europe and key important markets 
After months of negotiations  German pharmaceutical maker  Bayer  DE BAYGN  AG   OTC BAYRY   last month announced a definitive merger agreement to acquire Monsanto Company  NYSE MON   in an all cash deal worth  66 billion 
Allergan announced a string of small bolt on acquisitions last month  It announced a definitive deal to acquire Tobira Therapeutics  Inc    a clinical stage biotechnology company focused on drugs to treat non alcoholic steatohepatitis  NASH  and other liver diseases at a massive premium of 500   Also  Allergan said it will be acquiring clinical stage biotech company  Vitae  to boost its dermatology pipeline 
Last month  Allergan also bought privately held Akarna Therapeutics to add the latter s lead product candidate AKN 083  a preclinical stage FXR agonist  being evaluated for the treatment of NASH  Allergan also added the lead gene therapy development program RST 001 of privately held  clinical stage biotechnology company RetroSense Therapeutics to its eye care pipeline last month 
In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing  mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time Small biotech companies are open to such deals as most of them find it challenging to raise cash  thereby facing difficulty in surviving and continuing with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash 
Merger and acquisitions  especially small bolt on acquisitions  as well as aggressive in licensing activities and collaborations are expected to increase  going forward  This in turn puts the spotlight on small cap biotech stocks 
Biotech companies with new therapies or interesting pipeline candidates can be strong takeover targets 
Here we have narrowed down the list of choices by focusing on five stocks with a favorable Zacks Rank of  1  Strong Buy  or  2  Buy   Also  these are small cap biotech companies with a market cap of less than  1 billion  These stocks are well positioned in today s market environment and could see considerable upside riding on the aforementioned trends 
VIVUS Inc    NASDAQ VVUS  
Mountain View  CA based VIVUS  Inc  focuses on developing compounds to treat obesity  sleep apnea  diabetes and sexual health  VIVUS  key product  Qsymia  targets the highly lucrative obesity market with huge commercial potential 
VIVUS delivered positive earnings surprises in three of the past four quarters  with an average beat of 39 88   Its loss estimates for 2016 and 2017 have narrowed over the past 60 days  The company s share price has increased 13  year to date  Currently  VIVUS sports a Zacks Rank  1  You can see  
Geron Corporation   NASDAQ GERN  
Menlo Park  CA based biopharmaceutical company  Geron Corporation focuses on the development of first in class therapeutic products for the treatment of cancer  Geron s product development programs are based on its patented core technology  telomerase  which represents significant commercial opportunity  The successful development of products that target telomeres could very well change the treatment paradigm for several diseases including oncology  which represents huge commercial potential 
Geron  which carries a Zacks Rank  1  delivered positive earnings surprises in each of the past four quarters  with an average beat of 20 78   Its loss estimates for 2016 have narrowed from 26 cents to 24 cents in the past 60 days 
Achillion Pharmaceuticals  Inc    NASDAQ ACHN  
Achillion Pharmaceuticals is a development stage company  focused on the development of potent and specific complement factor D inhibitors for rare and other diseases  Achillion has out licensed its HCV portfolio to Janssen  a Johnson   Johnson   NYSE JNJ   company 
Currently  Achillion holds Zacks Rank  1  It delivered positive earnings surprises in all the past four quarters  with an average beat of 364 79   Its loss estimates for 2016 have narrowed from 66 cents to 62 cents in the past 60 days 
 Anika Therapeutics Inc 
Anika Therapeutics makes therapeutic products and devices that promote the repair  protection and healing of bone  cartilage and soft tissues  Its products are based on hyaluronic acid  a naturally occurring  biocompatible polymer found in the body  The stock carries a Zacks Rank  1 
Anika Therapeutics  earnings estimates for 2016 and 2017 have increased a respective 9 5  and 11 5  over the last 60 days  The company recorded a positive earnings surprise in each of the last four quarters  with an average beat of 42 19   Its share price has jumped 25  year to date 
ANI Pharmaceuticals  Inc  
This Zacks Rank  2 specialty pharmaceutical company witnessed an increase of 9 5  and 4 7  in its earnings estimates for 2016 and 2017  respectively  in the last 60 days  It surpassed earnings estimates twice in the last four quarters  bringing the average positive surprise to 46 85   The company s share price has surged 50 6  year to date 
Now See Our Private Investment Ideas
While the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-10-04,Zacks Investment Research,https://www.investing.com/analysis/biotech-mergers-run-the-show:-5-small-cap-stocks-for-q4-200157064,200157064
106157,327672,AGN,Top Research Reports For August 19  2016,opinion,"Friday  August 19  2016
We are featuring 16 research reports in today s Research Daily  including reports on Verizon  VZ   Comcast  NASDAQ CMCSA  and Teva Pharmaceutical  NYSE TEVA  
Verizon shares have been weak lately  but they continued to benefit from investors  great demand for yield  it provides a juicy dividend  currently yiedling in excess of 4    But Verizon is more than safe and stable dividend  They are actively investing into related spaces that add to their core telecom leadership  The move into online content delivery  mobile video and online advertising  with the recent Yahoo  NASDAQ YHOO  deal as part of that strategy   Youcan  
Comcast s continued momentum  the stock is up 20  year to date  reflects the strength in its Cable business and significant improvement in the NBC Universal segment  The deals to acquire DreamWorks Animation and Icontrol Networks bode well and should help fend off competition  Also  Comcast is investing heavily in its theme park business  The company has forayed into the over the top video delivery market with the launch of its Internet TV service  Stream    You can  
Teva Pharmaceutical shares have struggled this year as a result of investors  concerns on the generic drug maker s pipeline and stiff competitive pressures in the space  These issues notwithstanding  the analyst likes the Actavis  NYSE AGN  Generics acquisition  which will help the company strengthen its position in key generic markets  Teva continues to progress with its branded and generics drugs pipeline and is also looking to strengthen its biosimilar pipeline   You can    
You can find all of today s stock research reports 
Today s Private Buys   Sells from Zacks ResearchWhile we share the above news with the public  our sensitive recommendations are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors  
Sheraz Mian
Director of Research
Note  Sheraz Mian regularly provides earnings analysis on Zacks com and appears frequently in the print and electronic media  His weekly earnings related articles include  and   He also provides weekly commentary to subscribers and manages the  and portfolios  
If you want an email notification each time Sheraz publishes a new article  please 

Today s Must Read









Featured Reports

Zoetis  Q2 results were strong with a beat on both fronts  The Zacks analyst believes that the raised outlook for 2016 is achievable on the back of a diversified product portfolio 


The covering analyst believes Eversource Energy s consistent investment in growth projects and cost saving initiatives will boost its performance 


While positive on the earnings beat  the Zacks analyst is concerned about the revenue miss and expects top line struggles to continue due to prevalent headwinds like foreign exchange issues 


According to the covering analyst  robust omni channel growth drove DICK S Sporting s second quarter fiscal 2016 results that also led to a raised outlook  


The Zacks analyst thinks AvalonBay remains well poised to gain from higher demand of household formation and favorable demographics  Yet  high deliveries in a number of its markets raise woes 


Sun Life s bottom line beat expectations but net income declined on segmental weaknesses  Yet  the company expects bottom line growth of 8   10  and ROE of 12    14  over the medium term 


The Zacks analyst believes higher sales and RCI productivity gains drove robust second quarter results  

New Upgrades

According to the Zacks analyst  SM Energy s initiative to improve asset quality in view of improving commodity prices is likely to help it in enhancing future growth potential as well as margins 


The covering analyst appreciates Nabors  cost reduction initiatives especially when the drilling business scenario is not favorable and is expected to deteriorate further 


The Zacks analyst is encouraged by the company s narrower than expected loss per share and sales beat in second quarter fiscal 2016  alongside its robust sales outlook  which drove estimates up

New Downgrades

The Zacks analyst is concerned about weak prices and sustained pressure on the company s acetyl margins  Acetyl demand remains weak in China given the sluggish economic conditions 


According to the covering analyst  reduced performance outlook resulting from low fuel surcharge revenues is cause for concern  despite introduction of asset light transportation models   


The Zacks analyst remains concerned about Lowe s dismal performance in the second quarter of 2016 and subdued earnings outlook  However  expected sales growth of 10  provides some cushion to the stock",2016-08-18,Zacks Investment Research,"https://www.investing.com/analysis/top-research-reports-for-august-19,-2016-200149016",200149016
106158,327673,AGN,Cempra s Application For Pneumonia Drug Validated In EU,opinion,"Cempra  Inc    NASDAQ CEMP   announced that the European Medicines Agency  EMA  has validated its marketing authorization application  MAA  for the oral capsule and intravenous  IV  formulations of pipeline candidate solithromycin  for the treatment of community acquired bacterial pneumonia  CABP  
CABP is commonly known as community acquired pneumonia  CAP  in the EU  As per the information provided by the company  upon approval  solithromycin would be the first new oral and IV antibiotic available in the EU in more than 15 years  According to the European Respiratory Society  ERS   more than 3 000 000 cases of CAP are diagnosed annually  resulting in approximately 1 000 000 hospitalizations 
Since the EMA has validated the application  the submission is deemed to be complete and the formal review process will start shortly  The EMA s Committee for Medicinal Products for Human Use  CHMP  will start the assessment of solithromycin under a centralized review procedure followed by the European Commission CEMPRA INC Price
 

   A potential approval and successful commercialization will significantly boost Cempra s growth prospects as the company does not have any approved product in its portfolio yet  It is developing solithromycin in oral capsules  IV and suspension formulations  Solithera  solithromycin  is one of the two lead product candidates at Cempra 
The company also has a new drug application for solithromycin for the treatment of CABP under review in the U S  Meanwhile  the company is evaluating solithromycin is in a phase III study for the treatment of uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia 
We note that Allergan s   NYSE AGN   Teflaro is also approved for the treatment of CABP 
Another candidate in Cempra s pipeline is Taksta  which is being evaluated in a phase III study for the treatment of patients with acute bacterial skin and skin structure infections 
Cempra currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Pacira Pharmaceuticals  Inc    NASDAQ PCRX   and Corcept Therapeutics Inc    NASDAQ CORT    Both the stocks sport a Zacks Rank  1  Strong Buy  ",2016-08-24,Zacks Investment Research,https://www.investing.com/analysis/cempra's-application-for-pneumonia-drug-validated-in-eu-200149858,200149858
106159,327674,AGN,Your Complete Guide To The Generic Drug Industry ,opinion,"On Monday  embattled drugmaker Mylan NV   NASDAQ MYL   announced that it will launch a generic version of the EpiPen at a 50  discount to the branded version as the company continues to respond to widespread criticism surrounding the pricing structure of the popular allergy medication 
Mylan s new generic EpiPen not only offers patients a more affordable treatment option  but it also adds to the company s massive generics portfolio  Regardless of the recent criticism the company has faced  Mylan s generics business is one of the largest in a very competitive global industry  also read    
With the spotlight on Mylan and the oftentimes absurd price hikes that have become commonplace in today s pharmaceutical industry  some attention has to be given to generic drug manufacturers that attempt to offer medications at lower costs to the consumer  also read    
With that said  sometimes it feels like the generic drug industry exists in the shadows  with new options sprouting out from seemingly nowhere and making a major impact on the overall pharmaceuticals market  Today we ll take a look at how generics are developed and how they affect the drug industry today 
Same Standards 
Generic drugs are defined by the   FDA  as being equivalent to the brand name product in dosage  strength  route of administration  quality  performance  and intended use  Generics are required to have the same active ingredients as their branded counterparts  although they do not need to contain the same inactive ingredients 
A potential generic drug manufacturer is required to prove that its drug is bioequivalent to the brand name drug  A wide range of bioequivalence data is collected and reviewed by the FDA during the approval process  For instance  after a patient takes the generic drug  they will be tested to see whether the same levels of the drug are found in their bloodstream 
The FDA also regulates the manufacturing and distribution of generic drugs  All related quality standards must be met in this regard  and many generic drugs are actually made in the same manufacturing plants as the brand name versions to help meet this guideline 
Patent Patience
When a pharmaceutical company is developing an original drug  it can apply for a patent that gives it the exclusive right to distribute that chemical compound for a specific time period  after which generic drug manufacturers can seek approval to manufacturer a non brand version 
In the United States  the latest major update to this regulatory process came with the Patient Protection and Affordable Care Act more commonly known as Obamacare in 2010  Obamacare established an exclusivity period of 12 years for drug patents  with the ability to extend that period only if significant updates or improvements are made to the drug 
Drugmakers oftent attempt to extend their exclusivity periods with a number of different strategies  In a process that critics call  Evergreening   pharmaceutical companies will typically try a variety of moves  including aggressive litigation and minor tweaks to a drug s inactive ingredients  in an attempt to delay generic competition 
Once a drug s exclusive period has expired  a wannabe generic manufacturer can file an Appreciated New Drug Application  ANDA  with the FDA to seek approval for their product  The ANDA looks at a wide variety of factors  including the quality standards mentioned above 
Once a generic drug s ANDA is approved  it can hit the market and is available to all patients who need the medicine  Generic drugs appeal to customers because they are typically significantly less costly than name brand drugs  as generic manufacturers have significantly less operating costs than other pharmaceutical companies 
It s important to keep in mind that generic manufacturers do not need to replicate the drug s original tests  and most generic businesses do not spend much money on marketing and promotion  which means the company s overhead remains lower  In 2010  the FDA found that FDA approved generics saved about  158 billion in that year alone 
Tickers to Watch
Of course  as an investor you re probably most interested in which companies operating in this sphere are publicly traded  As mentioned before  Mylan is one of the world s leading players in generics  while Teva Pharmaceuticals   NYSE TEVA   is the largest generic drug manufacturer in the world  especially after its recent  40 5 billion acquisition of Allergan s   NYSE AGN   generics business 
Other notable stocks to watch in the industry include Amphastar   NASDAQ AMPH    currently a Zacks Rank  1  Strong Buy   Axogen Corp    NASDAQ AXGN    currently a Zacks Rank  2  Buy   Akorn Inc    NASDAQ AKRX    a leading supplier of therapies used in ophthalmology and other specialty areas  Perrigo   NYSE PRGO    which has a deep portfolio of generic sprays  ointments  and injectables  and Novartis   NYSE NVS    which operates its generic business through its Sandoz subsidiary 
ETF focused investors can also check out the VanEck Vectors Generic Drug ETF   which tracks companies that derive a significant portion of their revenues from generics or have the potential to derive a significant portion of their revenues from generics 
Complicated Competition 
At this point  you might be asking   If generic drugs are equally effective and cheaper  why would anyone ever opt for a name brand drug   Well  first remember our exclusivity windows  Plenty of pharmaceutical companies are cashing in on name brand drugs that have no generic alternative right now 
For those drugs that do have a generic versus name brand competition  the answer lies in the subtle differences of humans  All drugs have to operate within blood concentration thresholds  and some patients can notice the subtle differences or even react negatively to whatever the pill capsule is made out of  With some diseases  the range of safe concentration levels is incredibly narrow  which could make switching from name brand to generic dangerous 
In most cases  however  generic drugs are completely safe and more affordable than their name brand counterparts  For more coverage on drug prices  check out the latest episode of the  where Mylan s recent scandal was the first segment 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-29,Zacks Investment Research,https://www.investing.com/analysis/your-complete-guide-to-the-generic-drug-industry-200150651,200150651
106160,327675,AGN,Pharma Round Up  Mylan s Antitrust Probe  Allergan Limits Drug Price Hikes,opinion,"On Tuesday  New York Attorney General Eric Schneiderman opened an investigation into Mylan NV   NASDAQ MYL   that focuses on the drugmaker s contracts with local school districts to purchase its EpiPens 
In a statement  Schneiderman said  No child s life should be put at risk because a parent  school or health care provider cannot afford a simple  life saving device because of a drug maker s anticompetitive practices  
According to   the probe will be broad  but one of the main focus points is whether or not its EpiPens4School program  which offered a significant discount on the drug  locked schools into anti competitive contracts 
Last month  the pharma leader drew widespread criticism after it was discovered that the company increased the price of EpiPens over 400  over the last several years  To put that in perspective  the drug cost  57 a shot when Mylan acquired it in 2007  and now  a two pack of EpiPens costs more than  600 
Shortly afterwards  Mylan  it would take several steps to make the lifesaving allergy treatment more affordable to patients 
Allergan CEO Pledges Limit on Drug Price Increase
Also on Tuesday  healthcare giant Allergan Inc  NYSE AGN pa   s   NYSE AGN   CEO Brett Saunders has offered a promise to limit price hikes on the drugs it sells  writing in a  that  I understand the public outcry and add my voice to the condemnation of these behaviors  
Saunders argues that there is a  long standing unwritten social contract  between patients  physicians  policy makers  and the greater public  and  Those who have taken aggressive or predatory price increases have violated this social contract  
While not explicitly naming names  it s pretty clear he is referring to Martin Shkreli and Turing Pharmaceuticals  Valeant   NYSE VRX    and Mylan s recent EpiPen controversy 
Allergan s pricing pledge is significant  as it opposes the common practice taken by fellow biotech and pharmaceutical companies  raising drug prices two to three times every year  This usually means that drug costs can significantly exceed the annual inflation rate 
 For our industry to remain a vibrant and important part of the healthcare ecosystem  Allergan commits to this social contract and I encourage others to formulate their own self policing actions   Saunders continues 
 
Interested in IPOs  Check out the special edition of Zacks Friday Finish Line  where Editor Maddy Johnson and Ryan McQueeney interview Kathleen Smith of Renaissance Capital about the IPO market in the second half of 2016 ",2016-09-06,Zacks Investment Research,"https://www.investing.com/analysis/pharma-round-up:-mylan's-antitrust-probe,-allergan-limits-drug-price-hikes-200152053",200152053
106161,327676,AGN,Allergan Takes Over RetroSense  Boosts Eye Care Pipeline,opinion,"Allergan plc   NYSE AGN   has acquired RetroSense Therapeutics  a privately held  clinical stage biotechnology company  which will add the latter s lead gene therapy development program RST 001 to its eye care pipeline RST 001 is being developed for the treatment of the eye disease  retinitis pigmentosa  RP   The candidate  presently in phase I IIa trials  also enjoys an orphan drug designation by FDA Substantially all of the assets of RetroSense were acquired by Allergan for an upfront payment of  60 million as well as future regulatory and commercialization milestone payments related to RST 001 ALLERGAN PLC Price
    Retinitis pigmentosa is a group of rare inherited genetic disorders  which can lead to central vision loss and blindness in many cases  According to information provided by Allergan in its press release  approximately 100 000 people in the U S  have the disorder  creating a significant need for new treatment options RST 001 is first in class gene therapy application of optogenetics  a therapeutic approach which can be a breakthrough treatment option across a host of retinal conditions  including RP  Allergan management feels this potentially revolutionary technology can be highly complementary to its innovative eye care development programs Acquisitions form an integral part of Allergan s expansion strategy as the company completed four major acquisitions  Arrow  Specifar  Actavis Group and Warner Chilcott  apart from the Forest and Allergan Inc  NYSE AGN pa   deals in the past few years Last month  Allergan announced that it will acquire ForSight VISION5 for an upfront payment of  95 million as well as launch milestone payments related to ForSight s lead development program With this acquisition  slated to close in 60 days  Allergan will add ForSight s lead development program  a peri ocular ring designed for extended drug delivery and reducing elevated intraocular pressure  IOP  in glaucoma patients  to its pipeline Zacks Rank and Stocks to ConsiderAllergan  one of the largest and fastest growing drugmakers  has a Zacks Rank  3  Hold  Some better ranked stocks in the healthcare sector include Amphastar Pharmaceuticals  Inc    NASDAQ AMPH    AxoGen  Inc    NASDAQ AXGN   and Mallinckrodt Public Limited Company   NYSE MNK    While Amphastar Pharmaceuticals has a Zacks Rank  1  Strong Buy   AxoGen and Mallinckrodt have a Zacks Rank  2  Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-06,Zacks Investment Research,https://www.investing.com/analysis/allergan-takes-over-retrosense;-boosts-eye-care-pipeline-200152198,200152198
106162,327677,AGN,Bayer Finally Buys Monsanto  Inflation Vanishes,opinion,Wednesday  September 14  2016It was a long time coming  but St  Louis based agribusiness giant Monsanto   NYSE MON   has agreed to be purchased by German Big Pharma staple Bayer   OTC BAYRY   for  66 billion in cash  This amounts to  128 per share  a 21  premium from Monsanto s closing price Tuesday  Bayer has been pursuing the seed and pesticide maker since last spring at least  and this is the biggest pure acquisition of 2016 so far Combining a pharmaceuticals manufacturer with a pesticide and food engineering major does have synergies on a very large scale   Monsanto s technologies  including GMOs  which augment the chemical makeup of food products   appear to be directly relatable to biopharma pursuits of the drug maker  or so it would stand to reason  Bayer expects the acquisition to add to core profits in the first year after the deal closes Allergan   NYSE AGN   has also made an acquisition  announced this morning  for small cap dermatology focused Vitae Pharma   NASDAQ VTAE   for  639 million  Allergan looks toward Vitae s promising psoriasis treatment adding to its stable of treatments for auto immune deficiencies  While this may seem like a minor deal at first  if you re a holder of Vitae shares your day started off great   the buyout at  21 per share marks a jump of 157  overnight Inflation  What Inflation Import and Export Prices both sank into negative territory in August  Import prices reached  0 2   a notch lower than expected and down from July s  unchanged   0 1   Year over year  Import prices are down 2 2   exactly as expected  Exports fell to  0 8  for August  and are at  2 4  year over year Much of this has to do with beleaguered oil prices  but not all of it  The non petroleum read is still 0 9   with capital goods unchanged  Perhaps this is the work of a stronger dollar In any case  we are not seeing inflation rear up anywhere with numbers like these  and this plays toward dovish sentiments that counter the firming of the rate hike chorus among Fed Reserve presidents  Thus  if these numbers are indicative of a lesser likelihood of an interest rate hike by the Fed next week  we expect to see a near term market rally To this end  we are currently seeing S P 500 futures up 4 25 points  the dow up 28 and the Nasdaq at 15 5  These numbers are all higher than prior to the Import and Export numbers Mark VickerySenior Editor,2016-09-13,Zacks Investment Research,"https://www.investing.com/analysis/bayer-finally-buys-monsanto,-inflation-vanishes-200153506",200153506
106163,327678,AGN,Why Did Tobira Therapeutics  TBRA  Stock Skyrocket 720  Today ,opinion,"On Tuesday  shares of Tobira Therapeutics Inc    NASDAQ TBRA   skyrocketed  up over 720  in late afternoon trading after the company announced it would be acquired by Allergan   NYSE AGN   in a deal worth up to  1 7 billion 
Allergan is set to acquire Tobira for an upfront payment of  28 35 per share in cash  and up to  49 84 per share in Contingent Value Rights  CVRs  in the case of any successful completion of certain commercial  development  and regulatory milestones 
 With this acquisition  Allergan will now have one of the strongest portfolios of development stage programs for the treatment of NASH  with Cenicriviroc as the cornerstone  We will continue to look for differentiated development stage assets that can bolster this position and enhance our commitment to innovation in this disease   Allergan CEO Brent Sanders said in a statement announcing the deal 
The acquisition will add Cenicriviroc  CVC  and Evogliptin to Allergan s portfolio  which are two differentiated  complementary development programs for the treatment of non alcoholic steatohepatitis  NASH  
 I am extremely excited to see Tobira and Allergan come together   said Laurent Fischer  M D   Chief Executive Officer  Tobira Therapeutics   The combination of our team s innovation in the NASH space and the infrastructure  development expertise and world class ability of Allergan to market medicines will enable us to more rapidly develop and commercialize needed medications for patients suffering from NASH and other serious fibrotic diseases around the world  
Tobira is a clinical stage biopharmaceutical company that focuses on developing and commercializing therapies for NASH and other liver diseases  Investors can expect the transaction to close at the end of 2016 ",2016-09-20,Zacks Investment Research,https://www.investing.com/analysis/why-did-tobira-therapeutics-(tbra)-stock-skyrocket-720-today-200154586,200154586
106164,327679,AGN,Biotech ETFs In Focus On Tobira Therapeutics  Massive Gain ,opinion,"Tuesday was quite eventful for the biotech space  with Allergan  NYSE AGN pa  Plc   NYSE AGN   announcing back to back takeover deals within a short span of time  The drug maker announced the  1 695 billion acquisition of Tobira Therapeutics   AX TBR  A   which is into developing therapies for a fatty liver disease  before the market opened on September 20  2016  After   Allergan unveiled another deal worth  50 million to acquire Akarna Therapeutics Ltd   which is also into the same treatment  read    
Investors should note that a premium as high as 498  to Tobira s closing stock price just the day before points to the Allergan s urgencyfor this deal Tobira Therapeutics  shares were up 720 9  on Tuesday following the announcement of the deal 
Other Recent Allergan Deals
Allergan is in the mood for acquisitions  A week ago  the company announced the  639 million acquisition of Vitae Pharmaceuticals to strengthen its   Plus  in early September  Allergan purchased ophthalmology  RetroSense Therapeutics LLC for  60 million to boost its eye care suite 
Back to Tobira 
Per the deal  Allergan will pay  28 35 a share in cash upfront and up to  49 84 if Tobira meets certain sales and regulatory targets  going by   Also  Bloomberg noted that  the lower price values Tobira at about  533 million based on the number of shares outstanding  almost six times its market capitalization of  89 million as of Monday s close    even if the liver drug maker doesn t hit the goals  
And if Tobira fulfils the conditions  the premium to the deal would simply skyrocket  Allergan also said Akarna s investigational treatment for NASH or non alcoholic steatohepatitis is complementary to Tobira s therapies  going by an article published in the  
Market Impact 
All this explains why Tobira shares saw a 22 times higher volumes on Tuesday than regular trading  Not only this  the news acted as a beacon for the entire biotech space  
The move indicates the growing need for therapeutic push for NASH  which is a severe fatty liver condition  This is why  developing NASH treatments including Intercept PharmaceuticalsInc    NASDAQ ICPT    Galmed PharmaceuticalsLtd    NASDAQ GLMD     Conatus PharmaceuticalsInc    NASDAQ CNAT   tacked on considerable gains on the day  ICPT  GLMD and CNAT were up about 8 5   25 4  and 19 4  respectively 
Plus  the Tobira deal hints at the bright prospect of small scale biopharmaceutical companies which could be lucrative targets of big acquirers  read    
ETF Impact 
Most of the biotech ETFs were in the green on September 20 with BioShares Biotechnology Clinical Trials   MZ BBC   BioShares Biotechnology Products  and ALPS Medical Breakthroughs ETF   SI SBIO   deserving special mention as these funds include several clinical stage biotech companies  Notably  BBC  BBP and SBIO were up 2 2   2  and over 1 9  on September 20  respectively 
SPDR S P BiotechETF   which gives exposure to mainly small cap biotech companies  added about 2 5  on September 20  The leading biotech fund iShares Nasdaq Biotech ETF  was up over 1 4  on that day  see  here  
Want more information on the world of ETFs  Make sure to check out the podcast below where we discuss the investing landscape with Kevin O Leary and Connor O Brien of O Shares Investments 

Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-09-20,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-in-focus-on-tobira-therapeutics'-massive-gain-200154797,200154797
106188,327703,AGN,Is This Pharma Play Best In Class ,opinion,"As the bull market pushes past its seventh year and stock market averages triple in value off their great recession lows  it can become increasingly difficult to find good companies trading at reasonable values  As Buffett famously said   You can buy a good company  but at a bad price it can still turn into a bad investment   The S P 500 currently trades at 17x forward earnings and 19x TTM earnings  While this isn t bubble territory when factoring in generational lows in the risk free rates  it s far from cheap 

Which brings me to Gilead Sciences  NASDAQ GILD   which is trading at 7x forward and TTM earnings  5 year average is 21x  and 3 9x sales  5 year average is 7x  for a company that has grown revenue at an average annual pace of 32  for the last 5  and 10 year period and earnings at a pace of 40  50  annually for the same period  chart above   The company also displays operating and gross margins well above the industry average 
Now there are always two sides to every trade and the bears are looking at the overhead potential of drug pricing reform and more specifically at what other generic drugs may cut into Gilead s future revenue and earnings growth potential  While nothing is certain  it s usually a good idea to buy good companies with a margin of safety  In this case we have a solid company with good competitive advantages  exemplary management and revenue growth that exceeds even Amazon s  NASDAQ AMZN   trading at a fraction of its historical average 

Taking a look at the weekly chart  GILD looks to have a confluence of support between the  82 50  84 range with the 200 week MA just below 

Next  take a look at the entire biotech sector chart  Here we see that the whole sector has been under pressure since the 2015 highs  down 40   The sector appears to be stabilizing and a break above  289 would bode well for all those beaten down biotech names like Gilead  Regeneron  NASDAQ REGN  and Allergan  NYSE AGN  
Gilead Sciences reports earnings after the market closes on Monday  The street is looking for earnings of  3 10 share on  7 95 billion in revenue  The bar appears to have been set quite low for the quarter  and  for that matter  the future as well ",2016-07-25,Michael Gouvalaris,https://www.investing.com/analysis/gilead-sciences-inc.-(gild):-best-buy-in-the-market-200143887,200143887
106189,327704,AGN,Teva  TEVA   Stock Likely To Beat On Earnings In Q2 Again ,opinion,Teva Pharmaceutical Industries Limited   NYSE TEVA   is scheduled to report its second quarter 2016 earnings results on Aug 4  before the opening bell  Teva s first quarter earnings surpassed expectations  Let s see how things are shaping up for this announcement Factors at PlayLast month  Teva had provided its long term outlook and had also raised its earnings outlook for the second quarter to  1 19    1 22 per share from the earlier guidance of  1 16    1 20 per share  Meanwhile  second quarter revenues are expected in the range of  4 9    5 0 billion  up from the previous guidance of  4 8    4 9 billion Teva s generic segment could continue seeing some weakness as in the first quarter when generic segment revenues declined 17   Revenues from the U S  generics business had declined 32  reflecting loss of exclusivity for the generic versions of Nexium and Pulmicort  Lack of any important generic launches during the second quarter will also impact the performance of this segment As far as pricing erosion in the generics segment is concerned  Teva said that it did not see any change with the environment remaining stable The EU generics segment will remain under pressure with sales being affected by macro economic conditions and healthcare reforms However  Teva s position in the generics market should strengthen with the completion of the acquisition of Allergan  NYSE AGN pa  plc s   NYSE AGN   generics segment    Actavis Generics  The company received U S  Federal Trade Commission  FTC  approval for the acquisition with the deal slated to close this week Once the deal goes through  Teva will have about 338 product registrations pending FDA approval and will hold the leading position in first to file opportunities with about 115 pending ANDAs in the U S  Moreover  the company will have a commercial presence across 80 markets  including a top three leadership position in over 40 markets Teva expects to achieve  1 4 billion in operational and tax synergies by the end of 2019 through this deal which is expected to boost 2017 EPS by about 17  and 2019 EPS by 19  Meanwhile  in the branded segment  Teva mentioned a slight sequential improvement in its specialty products   Copaxone  Azilect  as well as Nuvigil Investors will remain focused on the Copaxone franchise s performance considering the 20 mg version of the multiple sclerosis treatment is facing generic competition in the form of Glatopa  Teva has guided towards Copaxone sales of about  4 billion in 2016 and an erosion of between  200 million    300 million every year from this level until 2019  Investors will also be interested in the performance of recently launched products like Bendeka and Cinqair Teva continues to focus on its cost reduction program  Results should also benefit from lower financing costs for the Actavis Generics deal Surprise HistoryTeva s performance has been strong with the company reporting positive earnings surprises in three of the last four quarters  The average earnings surprise over the last four quarters is a positive 4 56  TEVA PHARM ADR Price and EPS Surprise   Earnings Whispers Our proven model shows that Teva is likely to beat earnings this quarter because it has the right combination of two key ingredients Positive Zacks ESP  Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  2 56   The Most Accurate estimate is  1 20 per share while the Zacks Consensus Estimate for Teva is  1 17 per share Zacks Rank  3  Hold   The combination of Zacks Rank  3 and earnings ESP of  2 56  makes us very confident in looking for a positive earnings beat on Aug 4 Stocks That Warrant a LookThe Earnings ESP for Raptor Pharmaceuticals Corp    NASDAQ RPTP   is  11 11  and it carries a Zacks Rank  3  The company will be reporting second quarter results on Aug 4 Bio Techne Corp    NASDAQ TECH   has an Earnings ESP of  1 14  and carries a Zacks Rank  3  It is expected to report fourth quarter fiscal 2016 results on Aug 4 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-08-02,Zacks Investment Research,https://www.investing.com/analysis/teva-(teva):-stock-likely-to-beat-on-earnings-in-q2-again-200145660,200145660
106190,327705,AGN,Allergan Lowered To Buy At Vetr Inc,opinion,"Allergan PLC  NYSE AGN  was downgraded by  from a  strong buy  rating to a  buy  rating in a research report issued to clients and investors on Tuesday   reports  They presently have a  276 34 price target on the stock  Vetr s price objective suggests a potential upside of 10 21  from the company s previous close 
In other Allergan PLC news  Director Nesli Basgoz sold 459 shares of the firm s stock in a transaction that occurred on Wednesday  May 11th  The shares were sold at an average price of  225 10  for a total value of  103 320 90  Following the completion of the transaction  the director now owns 5 242 shares of the company s stock  valued at approximately  1 179 974 20  The sale was disclosed in a filing with the Securities   Exchange Commission  which is accessible through   Also  CFO Maria Teresa Hilado purchased 661 shares of the firm s stock in a transaction on Thursday  June 2nd  The stock was acquired at an average cost of  241 57 per share  with a total value of  159 677 77  Following the transaction  the chief financial officer now directly owns 11 957 shares in the company  valued at  2 888 452 49  The disclosure for this purchase can be found  
AGN has been the topic of several other reports  JPMorgan Chase  reaffirmed an  overweight  rating on shares of Allergan PLC in a research report on Friday  May 13th  Credit Suisse  SIX CSGN  Credit Suisse Group AG began coverage on shares of Allergan PLC in a research note on Monday  July 25th  They set an  outperform  rating and a  327 00 target price on the stock 
Zacks Investment Research lowered shares of Allergan PLC from a  buy  rating to a  hold  rating in a research note on Tuesday  July 26th  Leerink Swann lowered their target price on shares of Allergan PLC from  340 00 to  272 00 and set an  outperform  rating on the stock in a research note on Wednesday  April 6th 
Finally  Deutsche Bank reissued a  buy  rating on shares of Allergan PLC in a research note on Monday  April 18th  Six equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company  The stock presently has an average rating of  Buy  and a consensus price target of  308 30 
Shares of Allergan PLC  NYSE AGN  traded down 1 61  during midday trading on Tuesday  reaching  250 75  The company had a trading volume of 3 601 333 shares  Allergan PLC has a 52 week low of  195 50 and a 52 week high of  339 00  The firm has a market capitalization of  99 19 billion and a price to earnings ratio of 22 44  The stock has a 50 day moving average of  240 30 and a 200 day moving average of  252 64 
Allergan PLC  NYSE AGN  last announced its quarterly earnings results on Tuesday  May 10th  The company reported  3 04 earnings per share for the quarter  topping the consensus estimate of  3 03 by  0 01  The company had revenue of  3 80 billion for the quarter  compared to analyst estimates of  3 97 billion  The firm s quarterly revenue was up 48 1  on a year over year basis  On average  analysts anticipate that Allergan PLC will post  14 17 earnings per share for the current year 
A number of institutional investors have modified their holdings of AGN  Pure Financial Advisors Inc  boosted its position in shares of Allergan PLC by 0 4  in the second quarter  Pure Financial Advisors Inc  now owns 2 596 shares of the company s stock valued at  600 000 after buying an additional 10 shares in the last quarter  YHB Investment Advisors Inc  boosted its position in shares of Allergan PLC by 0 4  in the second quarter  YHB Investment Advisors Inc  now owns 4 899 shares of the company s stock valued at  1 132 000 after buying an additional 18 shares in the last quarter  Kistler Tiffany Companies LLC boosted its position in shares of Allergan PLC by 2 2  in the second quarter  Kistler Tiffany Companies LLC now owns 920 shares of the company s stock valued at  213 000 after buying an additional 20 shares in the last quarter  Miracle Mile Advisors LLC boosted its position in shares of Allergan PLC by 0 4  in the second quarter  Miracle Mile Advisors LLC now owns 4 860 shares of the company s stock valued at  1 200 000 after buying an additional 20 shares in the last quarter  Finally  Twin Capital Management Inc  boosted its position in shares of Allergan PLC by 0 6  in the fourth quarter  Twin Capital Management Inc  now owns 4 379 shares of the company s stock valued at  1 368 000 after buying an additional 26 shares in the last quarter 
Allergan  Inc is a multi specialty healthcare company  The Company focuses on developing and commercializing pharmaceuticals  biologics  medical devices and over the counter  OTC  products  It discovers  develops and commercializes a range of products for the ophthalmic  neurological  medical aesthetics  medical dermatology  breast aesthetics  urological and other specialty markets ",2016-08-03,MarketBeat.com,https://www.investing.com/analysis/allergan-plc-(agn)-lowered-to-buy-at-vetr-inc-200145740,200145740
106191,327706,AGN,5 Drug Stocks Reporting Q2 Earnings On Aug 8  AGN   More,opinion,As the Q2 earnings cycle draws to a close  the overall picture that has emerged does not appear as grim as we feared  As per our  report  approximately 414 S P 500 members  accounting for 85 2  of the index s market capitalization  have reported quarterly results so far  wherein earnings have declined 4 5  on 1 0  lower revenues  Despite bleak year over year comparisons  a whopping 70 3  beat on bottom line estimates while 51 9  were able to top revenue expectations The second quarter is still on track to be the fifth quarter in a row to record negative earnings growth and estimates for the third quarter are still moving south  although the magnitude of the fall has declined considerably  In fact  the fourth quarter is predicted to see a return to growth  which will continue into 2017  This could be reason enough for investor optimism for now How did the Medical Sector Perform Medical is one of the few sectors that were poised to record positive earnings growth this quarter  braving a challenging business environment fraught with headwinds like unfavorable currency movements and biosimilars  Based on the quarterly results of 84 6  members that have released quarterly earnings as of yet  the sector has clearly exceeded expectations  Average earnings in the sector recorded 6 3  growth on 9 8  higher revenues  resulting in a blended beat of 77 3   Bigwigs like Johnson   Johnson   NYSE JNJ   and Novartis AG   NYSE NVS   were able to beat expectations comfortably while many upped their annual outlooks in anticipation of a year over year better second half Quite a few companies are slated to report results next week  Let s take a look at five companies in the Medical sector  all of which are scheduled to make earnings announcements on Aug 8 Allergan plc   NYSE AGN   is scheduled to report second quarter 2016 results before the opening bell on Aug 8  Both of Allergan s top and bottom line should continue to be driven by its acquisition of Botox maker Allergan Inc  NYSE AGN pa   and other such strategic deals  The company has an impressive track record so far  having beaten estimates in three of the four trailing quarters and meeting the same once  bringing the positive earnings surprise to 2 90   However  Allergan s current Zacks Rank  3  Hold  and an  of  1 49  makes surprise difficult for this quarter  Read more   ALLERGAN PLC Price and EPS Surprise   Endo International plc   NASDAQ ENDP   is scheduled to report second quarter 2016 on Aug 8  While the company s strategy of divesting its underperforming assets was encouraging  its 2016 outlook was quite a disappointment  Nevertheless  the company has an impressive track record of having beaten expectations in all of the last four quarters with an average earnings beat of 4 5   However  Endo s current Zacks Rank  3  Hold  and an Earnings ESP of 0 00  makes surprise difficult for this quarter  Read more  ENDO INTL PLC Price and EPS Surprise   Kite Pharma  Inc    NASDAQ KITE   is scheduled to report second quarter 2016 results on Aug 8  after the market closes  This clinical stage biopharmaceutical company focused primarily on the development and commercialization of immune oncology drugs that harness the power of a patient s own immune system to target and kill cancer cells  Kite s performance over the last four quarters has been mixed with the company surpassing expectations twice and lagging the same twice  Overall  the company posted an average earnings surprise of  4 80  over the past four quarters  However  Kite s current Zacks Rank  3  Hold  and an Earnings ESP of 0 00  makes surprise difficult for this quarter  Read more   KITE PHARMA INC Price and EPS Surprise   Horizon Pharma plc   NASDAQ HZNP   is scheduled to report second quarter 2016 results on Aug 8  before the opening bell  The biopharmaceutical company markets nine drugs through its orphan  primary care and rheumatology business units  The company s growth by acquisition strategy to expand and diversify its portfolio is quite encouraging  However  Horizon Pharma s performance has been dismal so far  with the company missing earnings estimates twice in the trailing four quarters and surpassing once  Nevertheless  the company has maintained an average positive earnings surprise of 4 46   Horizon Pharma currently carries a Zacks Rank  3  which when combined with a 0 00  Earnings ESP makes surprise prediction difficult  Read more   HORIZON PHARMA Price and EPS Surprise   Ultragenyx Pharmaceutical Inc    NASDAQ RARE   is scheduled to report second quarter results on Aug 8  This clinical stage biopharmaceutical company focuses on drugs for the treatment of rare and ultra rare diseases  specifically serious  debilitating genetic diseases  The company s performance has been dismal so far  having missed earnings estimates in all of the past four quarters  bringing the average negative earnings surprise to 21 90   For the second quarter  the company currently carries a Zacks Rank  3  which when combined with its ESP of  2 04   makes earnings beat unlikely ULTRAGENYX PHAR Price and EPS Surprise  ,2016-08-04,Zacks Investment Research,https://www.investing.com/analysis/5-drug-stocks-reporting-q2-earnings-on-aug-8:-agn---more-200146373,200146373
106192,327707,AGN,Allergan  AGN  Beats On Q2 Earnings  Misses On Revenues,opinion,"Dublin  Ireland based Allergan plc   NYSE AGN   is engaged in the development  manufacturing  marketing  sale and distribution of branded  biosimilar and over the counter pharmaceutical products 
Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering  Having completed the acquisition of companies like Durata and Forest  Allergan acquired Botox maker  Allergan Inc  NYSE AGN pa    in Mar 2015  With this acquisition  Allergan  which was previously known for its strong presence in the generics market  finds itself in the company of the top 10 pharmaceutical companies across the world based on sales Meanwhile  earlier this month  Allergan divested its generics business to Teva and also signed an agreement to sell its Anda distribution segment  Allergan has been treating its generics business as discontinued operations and will treat the Anda distribution segment as discontinued operations from the second quarter of 2016 In the trailing four quarters  Allergan posted an average positive earnings surprise of 2 90   In fact  it beat earnings estimates on three occasions  while posting in line results in one Currently  Allergan has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Allergan s second quarter earnings of  3 35 per share were above our consensus estimate of  3 28 per share Revenues Fall Short  Revenues  however  missed expectations  Allergan posted revenues of  3 68 billion  compared to our consensus estimate of  4 14 billion Key Stats  Branded products like Botox  Restasis and Namenda XR brought in sales of  189 9 million   371 3 million and  166 5 million  respectively Revises 2016 Outlook  Allergan updated its guidance for 2016  The updated guidance excludes the impact of Anda from net revenues and expenses  Allergan expects total net revenues in the range of  14 65 billion to  14 90 billion in 2016  Previously  Allergan had anticipated total net revenues of about  17 billion  The Zacks Consensus Estimate for revenues is currently  16 62 billion  Branded net revenues are expected in the range of  14 75 billion to  15 billion in 2016  Previously  branded net revenues were expected to be approximately  15 billion in 2016 Allergan expects earnings in the range of  13 75 to  14 20 per share in 2016  The Zacks Consensus Estimate for earnings is currently  14 01 per share Check back later for our full write up on this AGN earnings report later Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-07,Zacks Investment Research,"https://www.investing.com/analysis/allergan-(agn)-beats-on-q2-earnings,-misses-on-revenues-200146718",200146718
106193,327708,AGN,Orexo  Margins  Maryland And Mundipharma ,opinion,"Orexo s  ST ORX  Q216 results pointed to positive Zubsolv momentum with evidence of net revenue growth  improving margins and encouraging market access developments  Financial discipline contributed to a Q216 SEK12 1m operating profit and a second successive quarter of positive operating cash flow  The new Maryland FFS Medicaid agreement should help boost Zubsolv s penetration into the public market segment and ongoing expansion in US prescribing rights will be a key growth driver longer term  Ex US  the recent Mundipharma licensing deal provides access to the global opioid dependence market  In the near term  however  uncertainty due to the ongoing Actavis  NYSE AGN  litigation weighs on the current share price 

Positive developments for Zubsolv and the US market
The Maryland FFS agreement makes Zubsolv the exclusive preferred product on the Maryland state formulary from July  The HHS increase of the patient cap  to 275 from 100  and Congress passage of the Comprehensive Addiction and Recovery Act 2016  enactment into law is pending presidential signature  means that legislative changes to increase access to treatment become increasingly tangible 
To read the entire report Please click on the pdf File Below",2016-08-10,Edison,"https://www.investing.com/analysis/orexo---margins,-maryland-and-mundipharma-200147109",200147109
106194,327709,AGN,Allergan To Buy ForSight VISION5  Boost Glaucoma Pipeline,opinion,Late last week  Allergan  NYSE AGN pa  plc   NYSE AGN   announced that it will be acquiring a privately held  clinical stage biotechnology company focused on eye care  ForSight VISION5 will be acquired by Allergan for an upfront payment of  95 million as well as a launch milestone payment related to ForSight s lead development program Acquisition to Boost Allergan s Glaucoma SegmentWith this acquisition  slated to close in 60 days  Allergan will add ForSight s lead development program  a peri ocular ring designed for extended drug delivery and reducing elevated intraocular pressure  IOP  in glaucoma patients  to its pipeline Data from a randomized  controlled phase II study comparing the ring to twice daily timolol eye drops showed that a single administration of the ring provided sustained reduction in IOP for six months  with a reduction of 4 6 mmHg at the study s primary endpoint of 12 weeks   About 90  of subjects retained inserts in both eyes for 6 months without clinician assistance With glaucoma expected to be a leading cause of vision loss across the world  there is significant need for new treatment options  Information provided by the Bright Focus Foundation indicates that glaucoma may impact more than 80 million people across the world by 2020 According to information provided by Allergan in its press release  while eye drops are currently used to lower elevated IOP  almost 50  of glaucoma patients may stop refilling their prescriptions after six months  usually because of difficulty in using drops The ring  if developed successfully  will provide an alternate treatment option to patients  It rests on the surface of the eye and is inserted by an ophthalmologist or optometrist  and releases medication  bimatoprost  over several months to lower elevated IOP in glaucoma and ocular hypertensive patients   Our TakeThe deal is in line with Allergan s efforts to strengthen its branded product portfolio  Allergan  which previously had a strong presence in the generics market  divested its Actavis Generics segment to Teva Pharmaceutical Industries Limited   NYSE TEVA   earlier this month and also agreed to sell its Anda  Inc  distribution business to Teva Allergan has a pretty strong presence in the eye care market with products like Restasis  Lumigan  Combigan  and Ozurdex in its portfolio  Within the glaucoma segment  the company recently launched XEN Gel Stent  a minimally invasive procedure to lower IOP  in 10 international markets and is looking to gain FDA approval next year  Other players in the eye care segment include Novartis AG   NYSE NVS   Meanwhile  Allergan was recently in the news as being interested in acquiring biotech major Biogen  Inc    NASDAQ BIIB    However  on the second quarter call  the company said that it is not looking at and is not focused on any large transformational M A ALLERGAN PLC Price  ,2016-08-14,Zacks Investment Research,"https://www.investing.com/analysis/allergan-to-buy-forsight-vision5,-boost-glaucoma-pipeline-200148018",200148018
106195,327710,AGN,Why Is Time  TIME  Stock Popping Today ,opinion,"On Monday  shares of magazine publisher Time Inc    NYSE TIME   are popping  up over 6  in late morning trading after Jana Partners LLC  a New York based hedge fund  announced a new  5 million share position in the media company 
Jana Partners also acquired a new stake in online travel booking company Expedia Inc    NASDAQ EXPE    as well as announced it has exited Pfizer Inc    NYSE PFE   and Allergan Plc   NYSE AGN   in the second quarter 
The fund is sometimes referred to as an activist hedge fund  despite most of its investments not being categorized as activist  but its few activist campaigns often attract a lot of attention  According to   Jana Partners has recently targeted companies including Computer Sciences Corp    NYSE CSC    ConAgra Foods Inc    NYSE CAG    Hertz Global Holdings Inc    and PetSmart Inc 
Time  who publishes Time Magazine  People Magazine  Fortune  and Sports Illustrated  among many others  needed a boost after reporting   Adjusted EPS of 22 cents beat our consensus estimate but fell 18 5  year over year  Total revenues of  769 million  however  lagged way behind the Zacks estimate and decreased 0 5  year over year 
Time is currently sits at a  3  Hold  on the Zacks Rank  and year to date  TIME stock is down 12 89  APPLE INC Price  Consensus and EPS Surprise  ",2016-08-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-time-(time)-stock-popping-today-200148030,200148030
106211,327726,AGN,Impax  IPXL  Stock Declines On Deal To Buy Generic Products,opinion,"Impax Laboratories  Inc    NASDAQ IPXL   entered into definitive agreements with Teva Pharmaceutical Industries Ltd    NYSE TEVA   and Allergan plc   NYSE AGN   related to the acquisition of  several generic products across solid oral  inhalable  injectable and topical dosage forms as well as the return of Impax s rights to its pending abbreviated new drug application  ANDA  for the generic version of Concerta  methylphenidate hydrochloride   The deal will see Impax shelling out  586 million Once the deal closes  potentially by the end of this month  Impax will add 18 generic products to its portfolio including 15 currently marketed products  one yet to be launched but approved generic product  one pending ANDA and one in development  The portfolio also includes two approved strengths and 1 pipeline strength of currently marketed products Meanwhile  Impax will regain full commercial rights to its pending ANDA for the Concerta generic that was previously partnered with Teva 
Immediately Accretive to EarningsImpax updated its financial guidance for 2016 and said that the deal will be immediately accretive to earnings  The updated guidance includes the impact of the deal  current prescription trends  pricing levels  inventory levels  and the anticipated timing of future product launches and events Impax expects to launch 12 to 14 generic products this year including 6 to 8 new generic product approvals The addition of the 15 marketed products is currently expected to boost second half 2016 revenues by about  80 million and is expected to offset the revenue decline from recent competition for Impax s diclofenac sodium gel and metaxalone products While the company continues to expect revenue growth of at least 15  in 2016  earnings are now expected to grow at least 20   up from the earlier guidance of earnings growth of at least 10   Gross margins are now expected in the low 50  range compared to the earlier guidance of approximately 50   Impax maintained its R D and SG A guidance of  100 million    105 million  about 10  of revenues  and  200 million    210 million  about 20    21  of revenues   respectively However  interest expense is now expected to be about  20 million instead of the previously guided  12 million Why Did the Shares Decline Despite the raised earnings outlook for 2016  Impax s shares declined 11 5  following the announcement of the deal reflecting investor concerns regarding the lack of visibility on the products covered by the deal as well as concern regarding the performance of the existing business especially accelerated pricing erosion for key generic products   diclofenac sodium gel and metaxalone IMPAX LABORATRS Price   However  we note that the deal is expected to expand Impax s portfolio of difficult to manufacture or limited competition products  According to IMS Health  the pending and development pipeline programs are estimated to represent U S  brand and generic sales of about  3 1 billion for the 12 months ending Mar 2016  Meanwhile  the to be acquired marketed generic products generated sales of about  150 million in 2015 
Impax is a Zacks Rank  3  Hold  stock  Amphastar Pharmaceuticals  Inc    NASDAQ AMPH   is a better ranked stock in the generics segment with a Zacks Rank  1  Strong Buy  ",2016-06-21,Zacks Investment Research,https://www.investing.com/analysis/impax-(ipxl)-stock-declines-on-deal-to-buy-generic-products-200137527,200137527
106212,327727,AGN,Allergan  AGN  Gets FDA Nod For Avycaz Label Expansion,opinion,Allergan  NYSE AGN pa  plc   NYSE AGN   announced that the FDA has expanded the label of its antibiotic  Avycaz  The label now includes phase III data on Avycaz plus metronidazole for the treatment of complicated intra abdominal infections  cIAI  caused by designated susceptible microorganisms  The label has also been updated to include phase III data from a subset of patients with infections due to ceftazidime nonsusceptible  CAZ NS  pathogens  as well as a subset of patients who had pathogens producing certain extended spectrum beta lactamases  ESBLs  Allergan  which is selling its generics business to Teva Pharmaceutical Industries Limited   NYSE TEVA   for net cash equity proceeds of about  36 billion  is working on expanding and strengthening its branded business  The company has more than 70 projects in mid to late stage development and is also working on expanding the labels of existing products Earlier this month  the FDA had accepted for review a supplemental New Drug Application  sNDA  for the 72 mcg dose of Linzess for use in the treatment of adults with chronic idiopathic constipation  CIC   A response from the agency should be out early next year Meanwhile  interesting pipeline candidates include abicipar  age related macular degeneration   rapastinel  depression   ubrogepant  migraine   XEN45  glaucoma  and tavilermide  dry eye  among others Although the termination of the combination agreement with Pfizer  Inc    NYSE PFE   was disappointing  we remain optimistic about the stand alone company s growth prospects  We expect Allergan to continue pursuing tuck in acquisitions and buying R D assets Allergan is a Zacks Rank  3  Hold  stock  Amphastar Pharmaceuticals  Inc    NASDAQ AMPH   is a better ranked stock in the healthcare sector with a Zacks Rank  1  Strong Buy   Pfizer is also a Zacks Rank  1 stock Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-23,Zacks Investment Research,https://www.investing.com/analysis/allergan-(agn)-gets-fda-nod-for-avycaz-label-expansion-200138078,200138078
106213,327728,AGN,Why Pfizer  PFE  Is A Great Stock To Buy For The Long Run,opinion,"Pfizer   NYSE PFE   is one of the largest pharmaceutical companies out there   With a market cap above  200 billion  many may think that the company doesn t have much more room to grow its share price  but what s not to love   The company has a solid dividend  great fundamentals  and a wide array of household drug brands which drive sizable profits for the company   For the reasons above  Pfizer deserves a spot in your portfolio for the long run 
Dividends
Pfizer has increased its quarterly dividend payout per share by 87 5  since 2009   From that year onwards  PFE has consistently raised its quarterly dividend by  0 02 per share every year   When looking at the company s cash flows  it is clear that Pfizer can easily afford to increase its current dividend payout substantially   The yield is pretty attractive  and it stands at about 3 5  right now   If you load up on this stock  your dividend yield stands to increase as Pfizer continues to raise its cash payout to shareholders over time 
Fundamentally Sound Investment
While revenues have decreased by a notable margin since 2013  the company is still churning out sales at a high level   2015 revenues came out to about  48 8 billion  and the company had high expectations going into fiscal 2016  posting sales guidance in a range from  49  51 billion   After Q1 of 2016 though  Pfizer raised its guidance even higher  and it now expects revenues to fall between  51 billion and  53 billion this year 
Pfizer has bought back over  20 billion in stock over the last three fiscal years  and this has helped to concentrate share value for investors   PFE also has close to  20 billion in cash on its balance sheet  and this will help the company in staying liquid and utilizing its investing power going forward   What s really great about Pfizer is its ability to consistently beat investor expectations over time   The chart below does a nice job of showing how good things happen to those who consistently top earnings expectations 
Promising Outlook
Pfizer is expected to experience some headwinds because of patents from some of its name brand drugs which are expected to expire over the next few years   While this is an area of concern worth analyzing  it should be noted that the company does have 30 projects in phase 3  as of February 2  2016   the last trial step before seeking drug approval from the FDA 
Pfizer has been known for its attempts to grow and realize synergies through making successful acquisitions   Pfizer s 2009 acquisition of Wyeth  a fellow drug maker  has been paying off nicely for the pharmaceutical giant  and  4 billion in savings have been realized so far   Wyeth helps to boost Pfizer s revenues  and its strong presence in the vaccines and consumer health products industries helps Pfizer in diversifying its sales  
Pfizer expects to see  1 billion in annual cost synergies by 2018 as a result of the Hospira acquisition   Hospira was acquired in September of 2015  and the company is a leading provider of injectable drugs   Hospira is a global leader in biosimilars  and the company also specializes in utilizing infusion technologies  Hospira has its hands in these industries  each of which are expected to see significant growth over the mid to long term 
Last month  Anacor   NASDAQ ANAC   agreed to be bought by Pfizer for  5 2 billion   PFE pursued the acquisition so that it could gain access to Anacor s non steroidal topical gel which treats eczema  a condition which up to 25 million people in the US suffer from 
If Pfizer continues to stay aggressive with regards to pursuing value adding growth opportunities  it stands to realize even more synergies and profitability over time  
Bottom Line
Pfizer seems to be making all of the right moves to pursue more growth for the long run   While shareholders are disappointed that the Allergan   NYSE AGN   merger couldn t happen  they still have a lot to be thankful for   They are invested in a company which provides them with income  share buybacks  robust revenues  profitability  and most importantly  a strive towards expanding a wide pipeline of drugs  products  and services for the broader pharmaceutical industry   Pfizer is the biggest pharmaceutical company in the US  and from the moves it is making  it stands extend its lead as the largest player in its industry 
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-24,Zacks Investment Research,https://www.investing.com/analysis/why-pfizer-(pfe)-is-a-great-stock-to-buy-for-the-long-run-200137919,200137919
106214,327729,AGN,Teva s Cinqaero Gets Positive CHMP View  Decision In 2H16,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   announced that Cinqaero  reslizumab   which is under review for use as an add on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment  got a positive opinion from the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  We note that Cinqaero gained FDA approval in late Mar 2016 where it was launched under the trade name Cinqair  With the CHMP issuing a positive opinion  we believe the candidate will gain EU approval  potentially in the second half of the year Teva has several programs ranging from phase I to registration stage in its pipeline with many of these focused on the central nervous system  CNS  and respiratory fields  As far as other therapeutic areas like women s health and oncology are concerned  Teva is focusing on market ready products or late stage candidates to maximize sustainable profitability Meanwhile  Teva is looking to strengthen its generics business and is set to acquire Allergan  NYSE AGN pa  plc s   NYSE AGN   generics business for  40 5 billion  Once this deal closes  potentially by the end of this month  Teva will expand its presence as well as portfolio significantly Teva is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the medical sector include Pfizer  Inc    NYSE PFE   and Amphastar Pharmaceuticals  Inc    NASDAQ AMPH    both Zacks Rank  1  Strong Buy  stocks ,2016-06-27,Zacks Investment Research,"https://www.investing.com/analysis/teva's-cinqaero-gets-positive-chmp-view,-decision-in-2h16-200138474",200138474
106215,327730,AGN,AstraZeneca Skin Drug  Tralokinumab  Rights Licensed To LEO,opinion,AstraZeneca plc   NYSE AZN   signed an agreement with LEO Pharma A S for the worldwide development and commercialization of tralokinumab for skin diseases   atopic dermatitis and any future additional dermatology indications Financial TermsAstraZeneca will get an upfront payment of  115 million from LEO Pharma and could get up to  1 billion in commercially related milestones as well as mid teen tiered percentage royalties on product sales Tralokinumab has completed a phase IIb study for the treatment of patients with atopic dermatitis and is in late stage development for patients with severe asthma  Under the terms of the deal  AstraZeneca retains all rights to tralokinumab in respiratory disease and any other non dermatology indications Announces Brodalumab Deal As Well for EuropeAstraZeneca also announced that it will be terminating its licensing agreement with Valeant Pharmaceuticals International  Inc    NYSE VRX   for the development and commercialization of brodalumab in Europe     AstraZeneca has instead signed up with LEO Pharma which will get an exclusive license to brodalumab in Europe  Brodalumab is under regulatory review for patients with moderate to severe plaque and in development for psoriatic arthritis We note that AstraZeneca previously had a co development and commercialization agreement with Amgen Inc    NASDAQ AMGN   for brodalumab  However  Amgen had terminated that deal based on events of suicidal ideation and behavior in the brodalumab program  which Amgen felt would likely lead to restrictive labeling  Amgen will  however  continue to receive a low single digit inventor royalty The deals with LEO Pharma support AstraZeneca s strategic focus on three main therapy areas  Respiratory  Inflammation and Autoimmunity  Cardiovascular and Metabolic disease and Oncology  The company said that it does not expect these agreements to impact its guidance for 2016  On its first quarter call  the company had said that it continues to expect both total revenue and core earnings to decline in the low to mid single digit percentage range in 2016 One of its key drugs  Crestor  started facing generic competition from May 2016 with Allergan plc   NYSE AGN   launching a generic ,2016-07-05,Zacks Investment Research,"https://www.investing.com/analysis/astrazeneca-skin-drug,-tralokinumab,-rights-licensed-to-leo-200140347",200140347
106216,327731,AGN,Teva Returns MPC Rights ,opinion,"Teva Pharma Industries  NYSE TEVA  has relinquished all rights to cardiovascular applications of Mesoblast s  NASDAQ MESO  mesenchymal precursor cell  MPC  technology  as it focuses on its core CNS and respiratory interests  Mesoblast will seek a new partner with a cardiovascular focus at the appropriate time  It has entered an A 120m   US 90m  equity finance facility with Kentgrove Capital to fund the ongoing Phase III CHF trial and a 600 patient confirmatory trial  estimated cost  US 90m   and has brought forward the interim futility analysis to Q117  We have revised our development timelines and lower our valuation to A 1 8bn from A 2 8bn  A 4 67 from A 7 36 per share  

Near Term Costs But Future Opportunities
Management confirmed that neither Mesoblast nor Teva saw efficacy data following the recent positive interim safety review of the Phase III CHF trial  so we attribute Teva s withdrawal to a commitment to tightening its focus as it prepares to integrate its Allergan  NYSE AGN pa  Generics  NYSE AGN  acquisition  rather than knowledge of the likely trial outcome 
To read the entire report Please click on the pdf File Below",2016-07-08,Edison,https://www.investing.com/analysis/mesoblast---teva-returns-rights-to-cardiovascular-programme-200140726,200140726
106217,327732,AGN,Why Are Allergan  AGN  And Teva Pharma  TEVA  Stocks Up Today ,opinion,"On Wednesday  shares of Allergan Plc   NYSE AGN   and Teva Pharmaceuticals Industries Ltd   NYSE TEVA   are both on the rise  up around 2  and 3   respectively  in morning trading after Teva CEO Erez Vigodman said it expects its  40 5 billion acquisition of Allergan s generics business to close any day 
However  the companies have extended the deadline for finishing the transaction to October in roder to allow more time for U S  antitrust approval 
Mr  Vigodman said in a conference call with analysts that  We expect the closing of the     generics deal at any time now  
According to    Vigodman s comments came after Allergan said in a regulatory filing on Wednesday morning that the companies had amended their sale agreement to extend the deadline by three months into late October   The company is also now planning to not include two products from the sale  Actonel and Carafate  The filing also disclosed that Teva will reduce the cash it will pay by  221 million 
TEVA stock is also up today after it increased its Q2 forecast  The company now expects adjusted earnings between  1 19  1 20 per share  up from previous estimates of  1 16  1 20 per share  Teva also raised its revenue projections for the second quarter  with revenues now expected between  4 8 billion  5 billion versus previous estimates of  4 8 billion  4 9 billion ",2016-07-12,Zacks Investment Research,https://www.investing.com/analysis/why-are-allergan-(agn)-and-teva-pharma-(teva)-stocks-up-today-200141648,200141648
106239,327754,AGN,Teva s  TEVA  Stock Gains On Q1 Earnings   Revenue Beat,opinion,Teva Pharmaceutical Industries Ltd  s   NYSE TEVA   shares were up more than 5  with the company announcing better than expected first quarter 2016 results  While earnings came in at  1 20 per share  well above the Zacks Consensus Estimate of  1 13  revenues were  4 81 billion  surpassing the Zacks Consensus Estimate of  4 75 billion However  both revenues  down 3 5   and earnings  down 11 8   declined from the year ago period  Currency fluctuations had a negative impact of  107 million on total revenues Quarter in DetailGeneric segment revenues declined 17  to  2 2 billion  Revenues from the U S  generics business declined 32  to  976 million reflecting loss of exclusivity for the generic versions of Nexium and Pulmicort European generic revenues continued to decline with sales coming in at  671 million  down 1  from the year ago period Specialty medicines revenues grew 10  from the year ago period to  2 2 billion reflecting higher sales of CNS  up 8  to  1 3 billion  and respiratory products  up 38  to  366 million   Oncology product sales grew 2  to  268 million while Azilect increased 6  to  113 million Worldwide Copaxone revenues grew 9  to  1 billion  While sales in the U S  increased 12  to  821 million  ex U S  sales slipped 4  to  185 million  U S  sales benefited from higher net pricing including a 7 9  price increase taken in Jan 2016   The 40 mg thrice weekly  3TW   three times a week  formulation accounted for more than 81  of total Copaxone scrips in the U S In Jun 2015  Sandoz  Novartis    NYSE NVS   generic arm  had launched Glatopa  its once daily generic version of Copaxone 20 mg Teva said that at the end of the first quarter  U S  market share for the Copaxone products in terms of new and total prescriptions was 28 1  and 29 8   respectively The women s health business recorded revenues of  110 million  down 15  API revenues increased 25  to  197 million Research   Development expense increased 14 3  from the year ago period to  375 million  Meanwhile  Selling and Marketing  S M  expenditures declined 9 6  from the year ago period to  821 million Provides Second Quarter 2016 OutlookThe company provided its outlook for the second quarter of 2016   while earnings are expected in the range of  1 16    1 20 per share   1 32    1 36 per share excluding the impact of the Dec 2015 equity offerings   revenues are expected in the range of  4 7  4 9 billion  The Zacks Consensus Estimate for second quarter 2016 earnings and revenue are  1 21 per share and  5 45 billion  respectively Guidance includes the impact of the Rimsa acquisition and the Teva Takeda business venture  but not of the Actavis  NYSE AGN  Generics acquisition The company will provide its outlook for 2016 in August once the Actavis Generics acquisition is completed    Teva expects the deal to go through by June  The company will provide guidance for 2017 and 2018 in September Teva said that it continues to expect cost synergies and tax savings of approximately  1 4 billion annually  mostly achievable by the third anniversary of the closing of the Actavis Generics transaction  This includes the assumption that about  1 1 billion of net global revenue will be divested Our TakeTeva s first quarter results were strong with the company beating on earnings and revenues  Strength in the specialty business helped offset weakness in the generics segment that didn t see any major launches during the quarter  2016 is a transition year for Teva as it works on the integration of Actavis Generics and progresses with its branded pipeline  The company has quite a few important regulatory and development updates lined up this year Teva has also earmarked  3 billion    5 billion for potential branded drug deals in 2016  The company is also looking to strengthen its biosimilar pipeline Meanwhile  the Actavis Generics acquisition will help the company strengthen its position in key generic markets Some well ranked stocks with a presence in the generics market include Amphastar Pharmaceuticals  Inc    NASDAQ AMPH   and Akorn  Inc    NASDAQ AKRX    While Amphastar is a Zacks Rank  1  Strong Buy  stock  Akorn holds a Zacks Rank  2  Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-10,Zacks Investment Research,https://www.investing.com/analysis/teva's-(teva)-stock-gains-on-q1-earnings---revenue-beat-200129030,200129030
106240,327755,AGN,Biotech ETFs Soar On Pfizer Anacor Deal  SBIO  XBI In Lead,opinion,"The largest U S  drug maker Pfizer    NYSE PFE    struck a deal to acquire the skin drug maker Anacor Pharmaceuticals    NASDAQ ANAC    for  5 2 billion  Pfizer entered into this deal after the  160 billion megamerger with Botox maker Allergan    NYSE AGN    was scrapped due to the new tax inversion rules  read    
Under the terms of the deal  Pfizer will pay  99 25 per share in cash through a cash tender offer  reflecting a 55  premium over Anacor s closing stock price on May 13  The acquisition  expected to be completed in the third quarter of this year  has already been approved by the board of directors of both companies and is seeking approval from shareholders and regulators  The transaction will be slightly dilutive to Pfizer earnings in 2017 but accretive from the start of 2018 
The deal will allow Pfizer to gain control exclusively over Anacor s flagship asset   crisaborole   an experimental nonsteroidal topical gel treatment of mild to moderate atopic dermatitis known as eczema  In phase 3 clinical trials  crisaborole reported strong results and was accepted for FDA review to treat mild to moderate atopic dermatitis in children and adults in March  If approved on January 7  2017  Pfizer expects the drug to generate annual sales of  2 billion  The buyout will bolster its inflammation and immunology drug business and add a new stream of revenue growth to Pfizer s innovate business 
About 18 25 million people in the U S  have the chronic inflammatory skin disorder  which causes inflammation and itching often in skin folds with symptoms lasting for two weeks or more  It is particularly common in infants and children  And as no drug has been approved for the illness over the last 15 years  this new Anacor drug could make a huge difference Market Impact
With the potential to dominate the atopic dermatitis market  ANAC soared 57 2  on the day to finish above the  100 per share mark  while its crushed its average volume figures  as more than 17 3 million shares moved hands compared to just 1 4 million on average  read    

The news also bolstered biotech ETFs  especially the ones that focus on small caps  In particular  ALPS Medical Breakthroughs ETF    was the biggest winner from the news  rising 5 4  on the day  followed by 4 5  gains for SPDR S P Biotech ETF     Both funds have a Zacks ETF Rank of 3 or  Hold  rating SBIO in Focus
This fund targets companies with one or more drugs in Phase II or Phase III FDA clinical trials by tracking the Poliwogg Medical Breakthroughs Index  It is a small cap centric fund  having amassed  114 9 million in its asset base  The product holds 95 stocks in its basket with Anacor taking the top spot at 5 1   It charges 50 bps in fees per year from investors and trades in average daily volume of around 86 000 shares XBI in Focus
This fund tracks the S P Biotechnology Select Industry Index and provides equal weight exposure across 90 stocks  suggesting no concentration issue and huge diversification benefits  The product has a definite tilt toward small cap securities  as mid and large caps account for a combined 31  share  ANAC occupies the twelfth position in the fund s basket with 2  of the total assets  With AUM of  1 7 billion and average daily volume of 6 5 million shares  XBI is extremely liquid and an easily traded fund  It charges a relatively low fee of 35 bps a year for the exposure  see    
Bottom Line

Investors should note that these two ETFs clearly outpaced the other products in the biotech space in the last trading session  This is especially true as the other popular names in the biotech space such as iShares Nasdaq Biotechnology ETF     First Trust NYSE Arca Biotechnology Index Fund     Market Vectors Biotech ETF    and PowerShares Dynamic Biotechnology   Genome Portfolio    added 3 1   2 8   1 9  and 2 2   respectively  on the day  This is because these products have little or no exposure to Anacor Pharmaceuticals ",2016-05-16,Zacks Investment Research,"https://www.investing.com/analysis/biotech-etfs-soar-on-pfizer-anacor-deal:-sbio,-xbi-in-lead-200130507",200130507
106241,327756,AGN,Pfizer To Buy Anacor  Add Eczema Treatment To Portfolio,opinion,Pfizer Inc    NYSE PFE   announced that it will be acquiring biopharmaceutical company  Anacor Pharmaceuticals  Inc    NASDAQ ANAC    for  99 25 per share or a total of about  5 2 billion  assuming the conversion of Anacor s outstanding convertible notes   Anacor s shares shot up more than 57  on the news With this acquisition  slated to close in the third quarter  Pfizer will add experimental eczema treatment  crisaborole  to its pipeline  Crisaborole is currently under FDA review for the treatment of mild to moderate atopic dermatitis  eczema  with a response expected by Jan 7  2017 Apart from crisaborole  Pfizer will gain rights to Kerydin  a topical treatment for onychomycosis  toenail fungus  distributed and commercialized by Sandoz in the U S These products should fit well in Pfizer s innovative business and is in line with the company s strategic focus on Inflammation and Immunology Pfizer estimates crisaborole has peak sales potential of at least  2 billion  According to information provided by the company in its press release  atopic dermatitis affects about 18 to 25 million people in the U S  including 8    18  of infants and children With no new molecular entities being approved for atopic dermatitis in the last 15 years  crisaborole could gain share rapidly on commercialization  Pfizer is well positioned to maximize crisaborole s commercial potential given its strong presence in the inflammation and immunology market thanks to products like Enbrel and Xeljanz  But the market could get crowded as quite a few companies are working on bringing eczema treatments to market Pfizer maintained its guidance for 2016 but expects the deal to be slightly dilutive to 2017 earnings and accretive thereafter Pfizer s announcement comes a few weeks after the company terminated its  160 billion merger agreement with Ireland based Allergan plc   NYSE AGN    Ever since that deal was terminated  expectations were high that Pfizer would announce a string of deals  In fact  the company is currently rumored to be interested in buying oncology focused Medivation  Inc    NASDAQ MDVN   Pfizer is a Zacks Rank  2  Buy  stock  A better ranked stock in the healthcare sector is Bristol Myers Squibb Company   NYSE BMY    a Zacks Rank  1  Strong Buy  stock Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-17,Zacks Investment Research,"https://www.investing.com/analysis/pfizer-to-buy-anacor,-add-eczema-treatment-to-portfolio-200130372",200130372
106242,327757,AGN,Carl Icahn Discloses Large Position In Allergan  AGN ,opinion,"Activist investor Carl Icahn disclosed a  large position  in Allergan   NYSE AGN   Tuesday morning  Shares of the Ireland based drug maker  which recently had its massive merger with Pfizer   NYSE PFE   blocked by government regulators  popped nearly 3  in premarket trading after the announcement 
According to a statement on his   Icahn  who notoriously advocates for management and strategy changes in companies he holds positions in  is very supportive of Allergan CEO Brent Saunders 
 We were instrumental in bringing Brent on board as the new CEO of Forest Labs a few years ago and worked cooperatively and constructively with him to help increase value for all Forest shareholders    We have every confidence in Brent s ability to enhance value for all Allergan shareholders   said Icahn 
The entire statement was brief and did not disclose how large Icahn s stake is  nor did it discuss what  if any  changes he wants to see the company make  In an interview with   an Allergan spokesperson said that the company recognizes Icahn s position and  has no reason to believe that this investment was made for purposes of influencing the actions of management or control of the company  
 We welcome all investors who recognize the value of our business  The Company is grateful for the confidence of our investors  whether they are new holders or have been long term investors   spokesman Mark Marmur said 
Icahn s announcement comes less than two months after new government regulations halted the company s merger with Pfizer  The  160 billion deal was stymied by the Obama administration s tougher rules on inversion  a business practice wherein a company will merge with a foreign rival to benefit from lower tax rates 
Following Allergan s pre market pop  the stock has dropped back down and is currently up about 0 60  on the day ",2016-05-31,Zacks Investment Research,https://www.investing.com/analysis/carl-icahn-discloses-large-position-in-allergan-(agn)-200133171,200133171
106243,327758,AGN,Synergy Climbs On Takeover Chatter,opinion,"Synergy Pharmaceuticals  NASDAQ SGYP  is having an incredible day in the market today as chatter with regard to a coming takeover is reborn  The big question is    Will a takeover happen  While this question is still yet to be answered  I believe that regardless of takeover possibilities  the stock is screaming  BUY ME   Today  we ll talk about the takeover chatter and how realistic the concept is  what we re seeing in the market as a result  and why the stock is a buy in my opinion  regardless of a takeover 
Takeover Chatter Is Reborn Surrounding SGYP
The idea of a company coming in and acquiring Synergy Pharmaceuticals is nothing new  In fact  just weeks ago we heard that Allergan  NYSE AGN  was currently in advanced talks with regard to acquiring the company  At the time  the stock climbed dramatically  However  over the past few weeks  the chatter has died down to silence 
Well  that s not the case anymore  Once again  investors seem to be talking about a takeover happening  and happening soon  Now the big question is    Is this realistic  In my opinion  the answer is yes  The reality is that Allergan was very close to a deal to acquire SGYP weeks ago  In fact  at the time  StreetInsider reported that a deal could be announced within a week  While there was no deal announced  that doesn t mean that a deal is an acquisition 
The reality is that at this point  SGYP is an acquisition waiting to happen  The company has made all the right moves  and recently submitted an NDA to the United States Food and Drug Administration  which was indeed accepted  If a company wants to get their hands on what Synergy Pharmaceuticals has done  they re going to want to do it before the FDA decision  At the end of the day  Plecanatide data was overwhelmingly positive and will likely lead to an approval  If a company waits to acquire SGYP until after the FDA s response in January  they re likely going to pay a hefty sum 
So  yes  an acquisition is on the table and a very real possibility at the moment  Will it happen  Only time will tell 
How The Market Is Reacting To The News
As investors  we know that the news moves the market  Any time there is positive news surrounding a publicly traded company  we can expect to see gains in the value of the company  In this particular case  while there isn t much news  the chatter surrounding SGYP is overwhelmingly positive  After all  nothing seems to get investors more excited than the concept of an acquisition  As a result  the stock is climbing in the market today  Currently  12 07   Synergy Pharmaceuticals stock is trading at  4 19 per share after a gain of  0 35 per share or 9 11  thus far today 
What We Can Expect To See Moving Forward
Moving forward  I have an overwhelmingly bullish opinion of what we can expect to see from SGYP  First and foremost  an acquisition is incredibly likely at this point  and will demand a very high premium  So  there s quite a bit of opportunity there alone 
However  I would take a bullish stance on Synergy Pharmaceuticals even if there wasn t an acquisition on the table  The reality is that the company has done incredible things with Plecanatide  Based on the results I ve read  I couldn t see the FDA not approving this treatment for chronic idiopathic constipation  Not to mention  the company is currently in the midst of Phase 3 studies on the treatment for the irritable bowel syndrome with constipation indication  The previous studies in this indication were overwhelmingly positive as well 
Based only on what we know to be fact   NDA with the FDA  promising results in the indication  new indication being studied  and solid financial and management to back it up   I d expect to see further growth in the value of the stock  The fact that an acquisition is on the table is just icing on the cake 
What Do You Think ",2016-06-07,Joshua Rodriguez,https://www.investing.com/analysis/synergy-climbs-on-takeover-chatter-200134551,200134551
106244,327759,AGN,Orexigen Stock Gains More Than 50  On Markman Hearing,opinion,Orexigen Therapeutics  Inc  s   NASDAQ OREX   shares shot up 51 6  on a favorable Markman hearing in the company s patent infringement lawsuit against Actavis  NYSE AGN   In the Markman ruling  Judge Richard G  Andrews adopted Orexigen s proposed constructions for most of the disputed claim terms Actavis is looking to market a generic version of Orexigen s obesity treatment  Contrave  Orexigen had received a Paragraph IV notice in Apr 2015 in which certain Orange Book listed patents protecting Contrave were challenged A patent infringement lawsuit was filed within the stipulated time period to ensure that Actavis  regulatory application for its generic Contrave cannot be granted final FDA approval until 30 months from the date of receipt of the notice letter or a favorable District Court ruling  whichever occurs first With Contrave being the only marketed product in Orexigen s portfolio  the earlier than expected entry of generics would be a major setback for the company Orexigen is currently working on growing sales of the product  Following the acquisition of U S  rights  the company is looking to adopt a targeted approach in growing Contrave sales  Orexigen will focus on differentiating Contrave from generic amphetamines and will work on improving the gross to net ratio through managed care and pharmacy discount strategies  Contrave should benefit from a more targeted sales effort  The company is planning a third quarter relaunch and expects Contrave to achieve market share of 10    11  by 2018  Orexigen is hiring 160 sales reps to promote the product The obesity market has quite a few other branded treatments including VIVUS Inc  s   NASDAQ VVUS   Qsymia and Arena Pharmaceuticals  Inc  s   NASDAQ ARNA   Belviq Orexigen is a Zacks Rank  4  Sell  stock  Some better ranked stocks in the health care sector include Retrophin  Inc    NASDAQ RTRX   and Arena  While Retrophin is a Zacks Rank  1  Strong Buy  stock  Arena is a Zacks Rank  2  Buy  stock Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/orexigen-stock-gains-more-than-50-on-markman-hearing-200135016,200135016
106245,327760,AGN,Ironwood Allergan s Linzess SNDA Accepted For FDA Review ,opinion,"Ironwood Pharmaceuticals  Inc    NASDAQ IRWD   and Allergan plc   NYSE AGN   announced that their supplemental New Drug Application  sNDA  for the 72 mcg dose of Linzess for use in the treatment of adults with chronic idiopathic constipation  CIC  has been accepted for review by the FDA  The FDA is expected to respond early next year  Approval of this dosage would provide patients with an additional treatment option  Currently  Linzess is approved by the FDA for the treatment of adults with CIC as a 145 mcg capsule to be taken once daily  Additionally  it is approved for the treatment of adults with irritable bowel syndrome with constipation  IBS C  as a 290 mcg capsule to be taken once daily According to information provided by the company in its press release  CIC is estimated to affect about 35 million adult Americans  According to a web based survey commissioned by Ironwood and Allergan  it was found that only 12  of adult CIC sufferers are diagnosed medically  Moreover  very few prescription treatments are currently available for this condition During the first quarter  impressive growth was observed in LInzess  with U S  net sales jumping 44  on a year over year basis and commercial margins expanding to 55  
Ironwood has an agreement with AstraZeneca plc   NYSE AZN   for the development and commercialization of Linzess in China  Hong Kong and Macau  Ironwood and AstraZeneca filed for marketing approval with the China Food and Drug Administration in Dec 2015  to market Linzess in China 
Ironwood is a Zacks Rank  3  Hold  stock  A better ranked stock in the health care sector is Juniper Pharmaceuticals  Inc    NASDAQ JNP    carrying a Zacks Rank  1  Strong Buy  ",2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/ironwood-allergan's-linzess-snda-accepted-for-fda-review-200135351,200135351
106249,327764,AGN,Paratek Reports Positive Phase III Data On Antibiotic Drug,opinion,"Paratek Pharmaceuticals  Inc    NASDAQ PRTK   announced positive results from a phase III study  OASIS  comparing its antibiotic candidate omadacycline to Pfizer Inc  s   NYSE PFE   Zyvox for the treatment of acute bacterial skin and skin structure infections  ABSSSI  
The OASIS study evaluated the efficacy and safety of an intravenous to oral once daily dose of omadacycline against a twice daily dose of Zyvox 
Results showed that the study met the FDA specified primary efficacy endpoint of early clinical response  ECR   The ECR for omadacycline was found to be 84 8  as compared to Zyvox which stood at 85 5   Additionally  the study met two European Medicines Agency specified co primary efficacy endpoints for post treatment evaluation  The candidate was found to be safe and well tolerated 
Paratek intends to present results from this study along with data for the secondary endpoints at an upcoming scientific congress 
Apart from ABSSSI  Paratek is also conducting additional studies on omadacycline for other indications  The company expects to announce top line data from a phase III study comparing omadacycline to Bayer  DE BAYGN  AG s   OTC BAYRY   Avelox for the treatment of community acquired bacterial pneumonia  CABP  as early as the third quarter of 2017  Last month  Paratek initiated a phase Ib study on omadacycline for the treatment of urinary tract infections 
Paratek plans to submit a new drug application for omadacycline for the treatment of both ABSSSI and CABP in the first half of 2018  We note that omadacycline enjoys Fast Track status in the U S 
Other than omadacycline  another advanced candidate in the company s pipeline is sarecycline  It is currently in phase III studies for the treatment of moderate to severe acne vulgaris  While Allergan plc   NYSE AGN   has development and commercialization rights to sarecycline in the U S   all ex U S  rights are with Paratek 
Paratek is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Pfizer  sporting a Zacks Rank  1  Strong Buy  and Bayer  carrying a Zacks Rank  2  Buy  ",2016-06-16,Zacks Investment Research,https://www.investing.com/analysis/paratek-reports-positive-phase-iii-data-on-antibiotic-drug-200136671,200136671
106251,327766,AGN,Allergan Glaucoma Gel Stent Filing Accepted For FDA Review,opinion,"Allergan  NYSE AGN pa  plc   NYSE AGN   announced that FDA has accepted its 510 k  Premarket Notification Application for the XEN Glaucoma Treatment System  comprising XEN45 gel stent and XEN injector  for review  XEN45 gel stent is a minimally invasive  implantable  cross  linked gelatin shunt used to reduce intraocular pressure associated with refractory glaucoma We note that  XEN45 enjoys the CE mark in the EU and is indicated for the reduction of intraocular pressure in patients with primary open angle glaucoma who have failed previous medical treatments According to information provided by the company in its press release  60 5 million people were living with glaucoma in 2010  Moreover  the company expects the number of people suffering from glaucoma to increase to nearly 80 million by 2020 due to the growing aged population 
With the Allergan  Inc  acquisition  Allergan  which was previously known for its strong presence in the generics market  finds itself in the company of the top 10 pharma companies across the world based on sales  Allergan has been actively pursuing acquisitions to expand its presence in the branded market  The sale of its generics business to Teva will allow Allergan to focus on its branded segment 
Allergan currently has a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Bristol Myers Squibb Company   NYSE BMY   and Amphastar Pharmaceuticals  Inc    NASDAQ AMPH     both sporting a Zacks Rank  1  Strong Buy  and Teligent  Inc    NASDAQ TLGT   carrying a Zacks Rank  2  Buy  ",2016-06-17,Zacks Investment Research,https://www.investing.com/analysis/allergan-glaucoma-gel-stent-filing-accepted-for-fda-review-200136504,200136504
106286,327801,AGN,Danger Zone  Compensation Committees And Shareholder Value,opinion,"When executives  compensation incentives are not aligned with creating shareholder value  you risk having executives whose goals are not aligned with investors  The consequences of such misalignment are behavior like what we are seeing with Valeant Pharmaceuticals International Inc  NYSE VRX   whose stock is down 74  YTD and whose internal controls may get a   The primary culprit for this kind of misalignment is the compensation committee  They are responsible for designing  approving and recommending to the Board of Directors the executive compensation plans for companies  They make the rules that the executives play by 
We know that Valeant is not the only company with misaligned executive incentives  There are many others  many of which have already been put in the Danger Zone and some who will go into the Danger Zone soon  This week  however  compensation committees land in the Danger Zone because of the role they play in creating the problems that lead to shareholder value destruction 
Here s How Non GAAP Performance Goals Misalign Executive Behavior
From a recent  by Valeant 

 The tone at the top of the organization and the performance based environment at the company  where challenging targets were set and achieving those targets was a key performance indication  may have been contributing factors resulting in the company s improper revenue recognition  

The  tone at the top  wasn t simply a performance based environment that led to issues  All executives should strive to achieve certain  performance goals   The problem comes from what type of performance was emphasized  in particular  achieving non GAAP targets that fail to reflect actual business operations  In   the goals for achieving cash and or stock bonuses at VRX ranged from 
Total shareholder return
Revenue growth
 Do at least one significant deal that creates substantial shareholder value 
 Cash EPS    Valeant s term for non GAAP EPS
None of these goals lead to generating the cash flows Valeant needs to pay its debt holders  In reality  they are straw men for corporate performance with no real connection to the economics of the business  The result of these misaligned goals manifests in a major divergence between real cash flows and Valeant s  cash   i e  fake  earnings 
Figure 1  Executives Grow  Cash  Earnings At Expense of Real Cash Flows

Sources  New Constructs  LLC and company filings
From 2010 to the trailing twelve months  Valeant grew  cash  earnings from  421 million to  3 55 billion  At the same time  free cash flow was positive only once  and  cumulatively is   38 4 billion 
Of all the goals  the worst for shareholders is  ironically   Do at least one significant deal that creates substantial shareholder value  because there was no accountability for the amount management would pay for acquisitions  As a result  executives could exploit the hi lo fallacy to boost earnings while gouging profits 
The only thing worse than a bad rule is not enforcing the rules  Valeant executives got paid for the Allergan  NYSE AGN  deal even though Valeant failed to actually acquire Allergan  a deal that would not have created shareholder value even if it had gone through  
Essentially  executives received the  significant deal  bonus with an  A for effort  note attached  In total  14 3 million was paid under the annual cash incentive program in 2014 and total compensation across five executives totaled  122 9 million  Compare this with 2013  when four executives were paid  only   23 8 million 
In hindsight  what happened at Valeant almost looks inevitable given the misalignment of their performance goals and creating shareholder value 
Compensation Committees Fail Across The Board
VRX s  tone at the top  admission may be rare  as only four other companies have used such language from 2010 2015 in their Internal Controls of Financial Reporting opinions  We cover four of these five companies  and each of them receives a Dangerous rating and has for quite some time  However  compensation committee s creating a misalignment of interests is widespread and often surfaces in companies that land in the Danger Zone  Since 2014  53 out of 69 companies placed in the Danger Zone have executive compensation plans directly related to non GAAP metrics  A sampling of these metrics include 
Adjusted EBITDA
Adjusted operating income
Adjusted Net Income
Core Sales Growth
Normalized Gross Margin
Non GAAP Net Revenues
Total Bookings
Customer Satisfaction
  Of Customers
Club Openings
 Financial Operations Efficiency 
Dollar retention
Manufacturing Cash Flow
Adjusted Free Cash Flow
Organic Net Revenue Growth
The large number of Danger Zone companies with poor executive pay plans is no coincidence  If compensation committees set goals misaligned with shareholder interests  it is only natural for executives to focus more on what their best interests  i e  pay  instead of shareholders  interests  i e  real cash flow  This divergence of interests expands over time as executive s efforts to compensate themselves at the expense of shareholders compound over the years  Figure 2 shows the five worst performing Danger Zone picks since 2014 
Figure 2  Worst Performing Danger Zone Stocks Since 2014

Sources  New Constructs  LLC and company filings
Navistar  NYSE NAV  pays executives based on adjusted EBITDA margin and revenue growth  Men s Wearhouse  NYSE TLRD  paid executives for meeting EBIT growth  excluding the Jos  A Bank acquisition  Valeant Pharmaceuticals  NYSE VRX  compensation committee emphasized  Cash  EPS and revenue growth  Universal Technical Institute  NYSE UTI  incentivized executives to meet EBIT  graduate placement  and completion rate goals while Twitter  NYSE TWTR  pay was solely at management discretion  with 99  of pay tied to equity based compensation 
Unfortunately  only four of the 69 Danger Zone companies referenced above include return on invested capital  ROIC  in their executive compensation plans  ROIC is a metric that has been  to create shareholder value    and  we believe  should be the first are foremost measure for executive compensation 
Misaligned Compensation Undermines the Integrity of the Capital Markets
We believe that the purpose of the capital markets is to allocate capital to its most efficient use  The best way to quantify  the most efficient use  is through ROIC  which measures the return of cash flow per dollar of capital invested  When compensation committee s align incentives with goals that fail to create true value  they undermine the integrity of capital markets  Investors must trust the agents of capital  i e   executives  to focus on earning the highest return per dollar invested  and thereby growing shareholder value  When this trust is broken  through misaligned incentives  Pandora s box is opened to any number of untrustworthy actions 
Worse yet  misaligned incentives tend to attract executives that are more likely to misbehave  Truly good managers will naturally want to maximize shareholder value  That is their purpose  not maximizing non GAAP EPS for a few quarters to get the big annual bonus  This short term focus mirrors the compensation and mindset of hedge fund managers  who can earn massive performance bonuses for outperforming in any given year  With the ability to earn hundreds of millions in compensation in just a few short years  executives can  and will  take actions with little regard to the future  If events take a turn for the worse  as in the case of Valeant  executives can ride off with little fear of losing the large compensation they received during their tenure as  
Investors Need To Be Aware of Poor Executive Compensation
It s a known fact that   One of the top reasons for manipulation is to meet bonus targets  which makes transparency and details on executive compensation material information to investors  We include a compensation analysis in each of our Danger Zone reports  it is important to note that the risk of a Valeant type episode exists for every company with misaligned executive compensation  Sometimes  the risk is more obvious  such as the case of Jarden Corporation  NYSE JAH   whose entire business model was built upon growing  adjusted EPS   Adjusted EPS was also the main determinant of executive pay  While growing adjusted EPS  the company s economic earnings remained negative and were only getting worse 
Other firms  such as Qlik Technologies  NASDAQ QLIK   have larger issues such as deteriorating margins and little competitive advantage  By itself  focusing on non GAAP metrics is no more a red flag than normal  However  alarms go off when the compensation committee states in the  
 Over the past three years  we have increased our emphasis on non GAAP operating profit and we now reward our executive officers for over performance of this key financial measure  
Not surprisingly  Qlik s GAAP net income  net operating profit after tax  NOPAT   ROIC  and economic earnings have declined as the company has focused more on non GAAP metrics  Figure 3 below shows the disconnect between true profits and non GAAP net income 
Figure 3  Qlik s Non GAAP Illusion

Sources  New Constructs  LLC and company filings
Another company we ve exposed for their egregious use of non GAAP metrics is Demandware  NYSE DWRE   The compensation committee at Demandware has aligned executive interests with non GAAP EBITDA and dollar renewal percentage  Figure 4 shows that non GAAP net income has grown from   1 million in 2012 to  11 million in 2015 while economic earnings have declined from   16 million to   55 million 
Figure 4  Demandware s Non GAAP Nonsense

Sources  New Constructs  LLC and company filings
Compensation Committee s Lack Accountability
At the end of the day  compensation committee s need to be held accountable  Currently  members of the committee are tightly tied to executives  In the case of Jarden  we noted in our Danger Zone report that the three largest recipients of a bonus tied to a non GAAP metric also held seats on the Board of Directors  The group that was supposed to protect the interest of shareholders was instead comprised of executives that can vote to give themselves larger bonuses  That is not how corporate governance should work 
It is clear that many compensation committees are failing shareholders  We will continue to find these companies and highlight them in the Danger Zone so our clients can make more informed investment decisions 
Disclosure  David Trainer and Kyle Guske II receive no compensation to write about any specific stock  style  or theme ",2016-04-14,David Trainer,https://www.investing.com/analysis/danger-zone:-compensation-committees-200125028,200125028
106287,327802,AGN,Misaligned Incentives That Led To Valeant Disaster Go Unaddressed,opinion,"Valeant Pharmaceuticals  NYSE VRX  finds itself back in the news this week  as Centerbridge Partners  a large holder of VRX bonds  of its intentions to call a default as a result of VRX s failure to file its annual report on time 
As   the company was getting traction in convincing debt holders to push the deadline back to May 31 But  with the new deadline came certain restrictions  which  as we highlighted in our February 29   would shut down the strategy that helped executives pump the stock to nosebleed heights 
What does Centerbridge know that no one else knows  Why are they pushing back on the concessions other debt holders seemed to be accepting 
Misaligned Compensation Incentives That Led To Disaster Remain Unchanged
We think Centerbridge understands that investing in VRX is not a good bet until Valeant s leadership fully addresses the serious corporate governance flaws that are the source of the problems at the company 
Executive compensation plans that pay executives for non GAAP metrics like Valeant s misalign executive incentives with investors  best interests  By paying executives for performance that does not generate real cash flows  Valeant s board of directors created the misalignment that precipitated the executive behavior that got the company into so much trouble in the first place  This misalignment is the fact that Valeant executives get paid big bucks for meeting non GAAP performance metrics while running the business into the ground and leaving investors holding the bag 
Until this misalignment is resolved and Valeant executives  interests are aligned with investors  how can we be sure that their behavior will not revert to what got them in this situation in the first place 
Responsibility for Proper Corporate Governance Begins with the Compensation Committee
We recently pointed out the  and how the structure of executive compensation can create inherent conflicts of interest between executives and shareholders  In many ways  Valeant is the poster child for how wrong things can go when executives  interests are misaligned  We specifically identified problems at Valeant  problems that can t be fixed with an annual filing  In a recent  by Valeant  the company noted 

 The tone at the top of the organization and the performance based environment at the company  where challenging targets were set and achieving those targets was a key performance indication  may have been contributing factors resulting in the company s improper revenue recognition  

This tone at the top starts with the incentives management is given in regards to performance  In Valeant s case  the following were goals management needed to achieve to receive cash and or stock bonuses  
Total shareholder return
Revenue growth
 Do at least one significant deal that creates substantial shareholder value 
 Cash EPS    Valeant s term for non GAAP EPS
None of these goals lead to generating the cash flows Valeant needs to pay its debt holders  even if there is no default  In reality  they are straw men for corporate performance measurement with no real connection to the economics of the business 
Of all the goals  the worst for shareholders is  ironically   Do at least one significant deal that creates substantial shareholder value  because there was no accountability for the amount management would pay for acquisitions  Lack of accountability directly led to the debt load   30 4 billion in 2014  including off balance sheet debt  Valeant is saddled with and increasing default risks 
A bad rule turns even worse when it is not enforced  Valeant executives got paid for the Allergan  NYSE AGN  deal even though Valeant failed to actually acquire Allergan  a deal that would not have created shareholder value even if it had gone through  
Essentially  executives received the  significant deal  bonus with an  A for effort  note attached  In total  14 3 million was paid under the annual cash incentive program in 2014 and total compensation across five executives totaled  122 9 million  Compare this with 2013  when four executives were paid  only   23 8 million 
Fund Holders Face Risks As Well
Shareholders aren t the only investors watching investment in Valeant dwindle away as executives receive massive bonuses  Fund holders in ETFs or mutual funds that have large allocations to VRX pose similar risks  risks we covered in more detail in our report      Funds have cut holdings in VRX since the fallout  but many still allocate significantly to the stock  Unfortunately  most fund research does not analyze the holdings of a fund  even though the performance of holdings equals the performance of a fund  Our predictive ratings for ETFs give investors a different perspective as they are based on the quality of a fund s holdings  Figure 1 shows the eight ETFs and mutual funds that allocate significantly to VRX and could pose a risk to investors  portfolio 
Figure 1  Funds With Exposure To and Risk of Decline from Holding VRX

Sources  New Constructs  LLC and company filings
Since the 40  decline in VRX in mid March  investors in Sequoia Fund  SEQUX  have seen the importance of analyzing holdings prior to placing capital in a fund  On March 23  Robert Goldfarb  from his position managing Sequoia  a position he held since 1980  Only a week later  Morningstar lowered its analyst rating to Bronze from Gold  a move which can be tracked to large fund outflows  Perhaps more alarming was Morningstar s Gold rating on SEQUX  a sign that only reinforces why investors need independent fund research  In total  SEQUX is down 11  year to date while the S P 500 is up 1  
Stock Remains Overvalued  Even After Multiple Declines
All in all  VRX is down 51  since our Danger Zone report in late February  For investors hoping for a rebound  even after such a drastic decline  the stock is still overvalued 
In order to justify its current price of  31 share  the company would need to grow NOPAT by 15  compounded annually for the next 5 years  In this scenario  Valeant would be generating  18 billion in revenue  more than double its 2014 revenue  and greater than greater than Bristol Myers Squibb s  BMY  2015 revenue 
Even in an ideal scenario  in which Valeant focuses on internal growth and not destructive acquisitions  which as noted above  it may not even be allowed to undergo  VRX still has significant downside  If Valeant can grow NOPAT by 8  compounded annually for the next decade  the stock is worth  25 share today   a 19  downside 
Disclosure  David Trainer and Kyle Guske II receive no compensation to write about any specific stock  style  or theme ",2016-04-14,David Trainer,https://www.investing.com/analysis/misaligned-incentives-that-led-to-valeant-disaster-go-unaddressed-200125029,200125029
106288,327803,AGN,Corporate Taxes Are Out Of Sync  Discouraging U S  Job Growth,opinion,"On April 4  the Treasury Department issued new regulations directed at corporate inversions    in which a U S  parented multinational changes its tax residence in order to reduce its tax burden through a number of different strategies  Last Monday s new rules were the Obama administration s third round of efforts to obstruct inversions  following others from 2014 and 2015 
These are the toughest yet  surprising analysts and observers with their stringency  Some critics charged that the new regs were aimed specifically at a nascent mega tie up between U S  based Pfizer  NYSE  NYSE PFE  and Ireland based Allergan  NYSE AGN   which as of this writing have market capitalizations of about  200 billion and  95 billion  respectively  both have declined sharply in share price since the new regulations were announced   The administration denied this accusation  saying   The Treasury Department is not focused on a specific transaction  it s focused on specific loopholes  
Nevertheless  the new rules did indeed lead PFE and AGN to scrap their prospective deal  Some other deals currently in the works    such as those between U S  based Johnson Controls  NYSE JCI  and Ireland based Tyco International NYSE TYC     are likely to go ahead because they do not fall afoul of the most aggressive changes  which train their fire closely on  serial inverters  
 Serial Inverters  Under Fire
Those changes hinge on the existing rules governing inversions  which place a size threshold on a foreign acquirer relative to its U S  acquisition target  The agency notes 

 Some foreign companies may avoid  the tax code s existing curbs on inversions by acquiring multiple American companies over a short window of time    thereby enabling the foreign company to complete another  potentially larger  acquisition of an American company to which  existing rules  will not apply  Over a relatively short period of time  a significant portion of a foreign acquirer s size may be attributable to the assets of these recently acquired American companies 
 It is not consistent with the purposes of  the existing rules  to permit a foreign company  including a recent inverter  to increase in its size in order to avoid the inversion threshold under current law for a subsequent acquisition of an American company  For the purposes of computing the ownership percentage when determining if an acquisition is treated as an inversion under current law  today s action excludes stock of the foreign company attributable to assets acquired from an American company within three years prior to the signing date of the latest acquisition  

It was that final sentence that was the death knell of the PFE AGN tie up  since AGN has increased rapidly in size through acquisitions over the past three years  With those acquisitions excluded  the deal would yield no benefits 
The other new rules are aimed at  earnings stripping   in which after an inversion  a foreign parent company can use internal financial engineering to reduce the tax burden of its U S  subsidiary 
The Big Picture  A Broken U S  Corporate Tax Code Suppresses Growth and Job Creation
Last October  after the second wave of Treasury s new rules  we wrote about the negative effects of the U S  corporate tax system  and noted that as long as the system s perverse incentives remained unaddressed  phenomena such as corporate inversions would be inevitable  In fact  it could get worse  We wrote 

 Human economic actors will respond to incentives  and will act rationally within a system to maximize the value of their assets  Where there is an opportunity for tax arbitrage    by effectively moving income from high tax to low tax jurisdictions    and economic actors have the capacity to take advantage of that arbitrage  they will  Can rules or legislation stop the process  We doubt it  Incrementally  the effect will be to redouble the efforts of tax engineers to locate and exploit opportunities for arbitrage  If inversion deals are discouraged while the basic drivers that make them happen remain unaddressed  a simpler process will happen as U S  companies are just bought by foreign companies  For individual firms such deals can make good sense under the current U S  tax regime    even though on a macro level  they lead to the erosion of the U S  tax base and the incremental migration of good  highly skilled jobs abroad  

Yes  Treasury could stop the PFE AGN deal    and others like it    from going forward  But it will not stop the bleed of growth and high quality jobs that results from an ineffective and punitive corporate tax policy 
Further  the continued issuance of jerry rigged regulations contributes to an environment of uncertainty for business  in which future planning is derailed by the fear that unexpected new regulations will make those plans fruitless   Even though AGN and PFE were not that far along in the process  they had still spent millions pursuing the potential merger  
 What Is To Be Done 
The solution is straightforward  as we noted in October  but it is a political solution that neither U S  party shows signs of being interested in 

 Most member states of the OECD have acclimated themselves to an environment in which business is global  While the U S  and a few other members maintain a worldwide taxation system    in which the profits of their domestic companies are subject to tax no matter where they are earned    most have gone to territorial systems where only domestic earnings are taxed  The most obvious solution is for the U S  to move in the direction of a properly managed territorial tax system  rather than a worldwide one  but even that will produce perverse incentives and distortions unless the effective U S  corporate tax rate is transparently lowered to be more in line with OECD peers  

Further  the revelations of shadowy offshore tax haven activities in the leaked  Panama papers  should reinforce our awareness of this fact  when people are denied legitimate avenues for reducing their tax burdens to levels deemed reasonable by most global jurisdictions  more of them will resort to illegal means  This is not to excuse such behavior    far from it  But it is to observe  realistically  that the heart of the matter is the tax code    and that trying to achieve compliance with a fundamentally flawed tax code without reforming it will ultimately create far more and far bigger problems than it solves 
Investment implications   The U S  corporate tax code needs to be overhauled  and the top rate  the highest among developed nations  needs to come down  Corporate inversions    in which U S  companies reduce their U S  tax burdens by acquiring a foreign firm and redomiciling themselves in a lower tax jurisdiction    result in great part from this high tax rate  and curbing inversions does not solve the problem  The U S  needs economic growth and high quality jobs  Both of those are delivered by U S  businesses that have confidence about the regulatory environment  and can compete on a fair playing field with companies from other national tax jurisdictions  The Department of the Treasury has issued tough new regulations to stop inversions  but these regulations can ultimately only worsen the perverse incentives that result from a U S  corporate tax system that is completely out of step with its peers in the OECD  Absent tax reform  actions such as last week s new Treasury rules will only increase the perception that government is the adversary of business  creating unexpected roadblocks for business planning and strategy  And they will do nothing to stop the bleed of growth and high quality jobs that results from an ineffective and punitive corporate tax policy ",2016-04-15,Tim Shirata,"https://www.investing.com/analysis/u.s.-corporate-taxes-are-out-of-sync-with-the-rest-of-the-world,-which-200125181",200125181
106289,327804,AGN,Teva  TEVA  Q1 Earnings  Will The Stock Deliver A Surprise ,opinion,"Teva Pharmaceutical Industries Limited   NYSE TEVA   is scheduled to report its first quarter 2016 earnings results on May 9  before the opening bell  Teva s fourth quarter earnings were in line with expectations  Let s see how things are shaping up for this announcement Factors at PlayAt the time of announcing fourth quarter results  Teva had guided towards first quarter revenues of  4 7 billion    4 9 billion  First quarter revenues will continue to be impacted by exchange rates  Meanwhile  earnings are expected in the range of  1 16    1 20 per share Teva s generic segment could continue seeing some weakness as in the fourth quarter when generic segment revenues declined 9   Revenues from the U S  generics business had declined 15  reflecting a decline in sales of the generic versions of Lovaza  Pulmicort  and Xeloda  During the first quarter  Teva launched its generic version of Ortho Tri Cyclen Lo and another dosage strength of its generic version of Pulmicort Respules The EU generics segment will remain under pressure with sales being affected by macro economic conditions  currency fluctuations and healthcare reforms However  Teva s position in the generics market should strengthen with the completion of the acquisition of Allergan s   NYSE AGN   generics segment Meanwhile  in the branded segment  investors will remain focused on the Copaxone franchise s performance considering the 20 mg version of the multiple sclerosis treatment is facing generic competition in the form of Glatopa Teva continues to focus on its cost reduction program Surprise HistoryTeva s performance has been strong with the company reporting positive earnings surprises in three of the last four quarters  The average earnings surprise over the last four quarters is a positive 5 44  
Earnings Whispers Our proven model does not conclusively show that Teva is likely to beat estimates this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP  Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 77   The Most Accurate estimate is  1 15 per share while the Zacks Consensus Estimate for Teva is  1 13 per share Zacks Rank  4  Sell   The combination of Zacks Rank  4 and earnings ESP of  1 77  makes it difficult to conclusively show that Teva is likely to beat estimates this quarter Stocks That Warrant a LookHere are a few health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter The Earnings ESP for Chiasma  Inc    NASDAQ CHMA   is  4 76  and it carries a Zacks Rank  3  The company is expected to release first quarter results on May 11 Jazz Pharmaceuticals   NASDAQ JAZZ   has an Earnings ESP of  6 11  and carries a Zacks Rank  3  It will be reporting first quarter results on May 10 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/teva-(teva)-q1-earnings:-will-the-stock-deliver-a-surprise-200128299,200128299
106290,327805,AGN,Specialty Pharma Stocks To Report Q1 On May 10  AGN  IPXL,opinion,"A major part of the first quarter earnings season is over with results from 87  of the S P 500 members already out  While Q1 earnings season has come to an end for 6 of the 16 Zacks sectors  the Retail sector stands out as it is the only one at this stage that has more than 50  of its reports still to come Meanwhile  a look at overall Q1 results shows that growth was more or less non existent though actual results were better than expected with several companies coming out with positive surprises for both earnings as well as revenues According to our weekly  report  Q1 will be the 4th quarter in a row of earnings declines for the index However  Medical is one of the sectors witnessing earnings and revenue growth in the first quarter  Our Q1 scorecard shows that 92 5  of the Medical sector has reported results with earnings growth of 8 1  and revenue growth of 10   Most of the remaining Medical stocks including several specialty pharma companies like Allergan plc   NYSE AGN   and Impax Laboratories Inc    NASDAQ IPXL   will be reporting results this week Let s see how these specialty pharma stocks are poised ahead of the scheduled announcements Dublin  Ireland based Allergan is scheduled to report first quarter 2016 results before the opening bell on May 10  This Zacks Rank  3  Hold  stock s track record is decent with the company beating earnings estimates in three of the last four quarters  However  the combination of Zacks Rank  3 and  of  1 00  makes it difficult to conclusively show that Allergan is likely to beat estimates this quarter  While Allergan s top as well as bottom line should continue to be driven by the acquisition of Botox maker Allergan Inc  NYSE AGN pa   as well as other acquisitions  Namenda IR is facing generic competition  Read more    Allergan is looking to complete the sale of its generics business to Teva Pharmaceutical Industries Ltd    NYSE TEVA   in June  On the first quarter call  Allergan intends to provide an update on its plans to simplify company operations post the close of the Teva transaction 
Impax  which has a presence in both the generics and branded markets  is also scheduled to report first quarter 2016 results on May 10  before the market opens This Zacks Rank  3 stock has a mixed track record with the company beating earnings estimates in two of the last four quarters and missing in the other two  However  our proven model shows that Impax is likely to beat earnings because it has the right combination of two key ingredients   Earnings ESP of  8 89  and Zacks Rank  3 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-08,Zacks Investment Research,"https://www.investing.com/analysis/specialty-pharma-stocks-to-report-q1-on-may-10:-agn,-ipxl-200128856",200128856
106291,327806,AGN,Allergan  AGN  Beats On Q1 Earnings  Revenues Miss,opinion,Dublin  Ireland based Allergan plc   NYSE AGN   is engaged in the development  manufacturing  marketing  sale and distribution of branded  biosimilar and over the counter  OTC  pharmaceutical products Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering  Having completed the acquisition of companies like Durata and Forest  Allergan acquired Botox maker  Allergan Inc  NYSE AGN pa    in Mar 2015  With this acquisition  Allergan  which was previously known for its strong presence in the generics market  finds itself in the company of the top 10 pharmaceutical companies across the world based on sales Meanwhile  Allergan expects to complete the sale of its generics business to Teva by Jun 2016  Allergan is treating its generics business as discontinued operations from the third quarter of 2015 In the trailing four quarters  Allergan posted an average positive earnings surprise of 5 48   In fact  it beat earnings estimates on three occasions  while posting in line results in one Currently  Allergan has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Allergan s first quarter earnings of  3 04 per share were above our consensus estimate of  2 99 per share Revenues Fall Short  Revenues  however  missed expectations  Allergan posted revenues of  3 79 billion  compared to our consensus estimate of  3 96 billion Key Stats  Branded products like Botox  Restasis and Namenda XR brought in sales of  637 5 million   313 7 million and  173 1 million  respectively 2016 Outlook  For 2016  Allergan continues to expect total net revenues from continuing operations of about  17 billion  The Zacks Consensus Estimate for revenues is currently  16 95 billion  Branded net revenues are expected to be approximately  15 billion in 2016 Announces Share Buyback Program  Allergan also announced a new share buyback program of up to  10 billion  The buyback will start only after the closing of the Teva deal Check back later for our full write up on this AGN earnings report later Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-09,Zacks Investment Research,"https://www.investing.com/analysis/allergan-(agn)-beats-on-q1-earnings,-revenues-miss-200129143",200129143
106292,327807,AGN,Key Morning Earnings For May 10  AGN  DF  TAST,opinion,"As  the last of the companies to report are posting their earnings results  On Tuesday  three big names in the food and pharmaceuticals industries reported their quarterly earnings before the bell  Let s take a look 
Allergan  NYSE AGN pa  Plc    NYSE AGN  
The Dublin  Ireland based pharmaceutical developer reported Q1 earnings per share of  3 04  excluding  2 57 from non recurring items   surpassing the Zacks Consensus Estimate of  2 99 per share  Revenues of  3 79 billion  however lagged slightly behind our consensus estimate of  3 96 billion and decreased 10 4  year over year 
Allergan s branded products like Botox  Restasis and Namenda XR brought in sales of  637 5 million   313 7 million and  173 1 million  respectively  The company reiterated its 2016 outlook  with total net revenues expected to be roughly  17 billion 
Dean Foods Co    NYSE DF  
Dean Foods  one of the country s leading processor and distributor of milk and other dairy products  reported strong Q1 results  Adjusted earnings per share came in at  0 45  excluding  0 02 from non recurring items   beating the Zacks Consensus Estimate of  0 38 per share and marking the fifth consecutive quarter of year over year growth 
Revenues of  1 878 billion just edged past the consensus estimate of  1 876 billion but declined 8 4  year over year  Management expects second quarter 2016 adjusted earnings to range from  0 32  0 40 cents a share 
Carrols Restaurant Group  Inc    NASDAQ TAST  
The largest Burger King franchisee posted impressive results for its first quarter  Earnings per share of  0 05 beat the Zacks Consensus Estimate of a loss of   0 08 per share and increased 118 5  year over year  Revenues of  222 5 million also topped our consensus estimate of  216 2 million and rose 15 2  year over year 
Comparable restaurant sales came in at 5 7  over the year ago level  As a result  Carrols has updated their 2016 guidance  with total restaurant sales expected to be in the range of  935 960 million  previously  930 955 million  including a comparable restaurant sales increase of 2  4  ",2016-05-10,Zacks Investment Research,"https://www.investing.com/analysis/key-morning-earnings-for-may-10:-agn,-df,-tast-200129155",200129155
106319,327834,AGN,My Top 3 Fabulous Pharma Stocks ,opinion,"Introduction
I am a fervent believer that investment decisions should be made based on the relative merits of each individual investment under consideration  However  my anecdotal observations and experience suggests that many investors do not embrace that approach  This is especially true regarding investment decisions on common stocks  Instead of focusing on the opportunities and valuations available from select individual businesses  many investors are obsessed  and I allege blinded by generalized views or beliefs about the overall market and or the economy 
For example  in a recent article  I postulated about reasons why carefully selected growth stocks might benefit retired investors under certain circumstances  In the article I presented a few examples of high quality fast growing businesses that I considered fairly valued based on their earnings growth rates  Unfortunately  and as I expected might happen  a comment made in the article rejected my carefully selected growth stock research candidates based on what I believe are misguided views about the market in general  The comment is included in its entirety as follows 
 I like growth stocks but not when the market is at all time highs and way overpriced as it is now  Just for example  the Russell 2000 is at a P E of 40 and P B of 4   hardly compelling valuations 
Many growth stocks should be sold short here and that is what I am doing  When the market tanks  soon  I will close out my shorts and go long on some of the growth stocks I like 
Making a decision on buying a stock without looking at its relative valuation and that of the market is a dangerous proposition and one I am not interested in  
To clarify my position  I offer the following elaboration and critique regarding why I found this comment concerning  First of all  the reference that the P E ratio and price to book ratio of the Russell 2000 were at all time high valuations was not relevant to the valuations of the individual research candidates I presented  Each of the companies I presented was offered because I believed their valuations were in alignment with their past  present  and most importantly  their future earnings potential  The valuation of the Russell 2000 was therefore irrelevant 
The second paragraph also offered a generalized view of growth stocks and suggested that they should be sold short  But again  I don t believe this statement relates specifically to the candidates I offered in the article  Then the bold prediction was made that the market would tank soon  which of course  is impossible to accurately forecast  However  the comment also indicated that this could be timed to perfection by closing out shorts and then investing in growth stocks that were favored  Again  I contend that this is impossible to time or predict 
Finally  the comment suggested that buying a stock without looking at its relative valuation and that of the market was a dangerous proposition  Of course  I vigorously agree that investors should evaluate the valuation of the company  but only based on its specific fundamental merits  regardless of the valuation of the overall market  I elaborated on my belief that it s a market of stocks and not a stock market in a recent article  
The Pharma Sector Powerful Demographic Forces Support Growth Potential
Therefore  I was motivated to offer this follow up article on growth stocks for retirement portfolios by offering three attractive looking growth stock research candidates in the Pharma sector  Thanks to the demographic forces of an aging population  I contend that the Pharma sector offers enormous growth potential that is independent of the general economy or the stock market 
As I indicated in my previous article on the appropriateness of growth stocks in retirement portfolios  they are not necessarily a good fit for every retired investor  However  for those investors at or near retirement that are interested in adding some growth  I offer the following three Pharma growth stock opportunities that I am personally researching  Most importantly  my initial review indicates that each of these candidates are reasonably valued based on their respective future growth opportunities 
Three Fabulous Pharma Growth Stocks
Two of the following three Pharma growth stocks were originally previewed in my previous article  In this article I have added a third Pharma research candidate in what follows is my reasoning as to why I consider these attractive growth opportunities based on my preliminary research  Perhaps readers of this article that have more information or familiarity with any of these companies will help the rest of us by sharing their knowledge 
Actavis plc  NYSE ACT 

Actavis  my first research candidate  is well positioned to serve the growing pharmaceutical needs of our aging population  The company offers both branded and generic pharmaceuticals worldwide 

Short business description courtesy of S P Capital IQ 


 Actavis plc  a specialty pharmaceutical company  develops  manufactures  markets  and distributes generic  branded generic  branded  biosimilar  and over the counter  OTC  pharmaceutical products  It operates in three segments  North American Brands  North American Generics and International  and Anda Distribution 

The North American Brands segment provides patented and off patent trademarked pharmaceutical products primarily under the Dalvance  Bystolic  Canasa  Carafate  Daliresp  Fetzima  Linzess  Namenda  Namenda XR  Saphris  Teflaro  Viibryd  Actonel  Asacol HD  Atelvia  Delzicol  Doryx  Estrace Cream  Enablex  Lo Loestrin Fe  and Minastrin 24 Fe brands 

The North American Generics and International segment develops  manufactures  and sells generic  branded generic  and OTC pharmaceutical products 

The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies  pharmacy chains and buying groups  and physician s offices 

The company also develops and out licenses generic pharmaceutical products primarily in Europe through its third party business  and provides products in women s health  gastroenterology  urology  and dermatology areas 

The company sells its generic and brand pharmaceutical products primarily to drug wholesalers  retailers  and distributors  including national retail drug and food store chains  hospitals  clinics  mail order retailers  government agencies  and managed healthcare providers 

It has a collaboration agreements with Amgen  NASDAQ AMGN   Inc  to develop and commercialize biosimilar versions of Herceptin  Avastin  Rituxan Mab Thera  and Erbitux  Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation  Sanofi Aventis U S  LLC  and Trevena for the development of TRV027  Actavis plc was founded in 1983 and is headquartered in Parsippany  New Jersey  


Both demographics and acquisitions have stimulated accelerating earnings growth since 2011  Nevertheless  Actavis trades at P E ratio that is less than its historical earnings growth achievement  However  the normal P E ratio has moderately expanded as a result of extraordinary growth in 2013 and 2014 



Importantly  Actavis has also generated cash flow growth that is aligned with its historical earnings growth  Consequently  the company has ample resources to continue funding research and development and its reasonable 36  debt to capital ratio is well covered 



Growth in earnings and cash flow since 2010 has resulted in significant total returns for Actavis shareholders  Returns have significantly out performed the general market  which is extraordinary when you consider that this timeframe has produced one of the best returns for the S P 500 in recent history  The stock market has nothing to do with the results that Actavis achieved 



Looking to the near to intermediate time future  leading analysts continue to expect earnings growth in excess of 20  per annum for this fiscal year and next  The company s current P E ratio is in alignment with this near term forecast growth  Consequently  the company offers double digit return potential over the next couple of years 



The following analyst scorecard summarizes analysts  accuracy when making earnings forecasts one year and two year forward  This provides additional confidence that Actavis might meet earnings forecasts for the next two years 



Analysts also provide 3 5 year earnings estimates  The consensus of 9 analysts expects long term  3 5 years  earnings growth to average slightly less than 15  per annum  This lower long term forecast offers a potential negative to this company s ability to generate double digit returns longer term  Although this is still a high earnings growth rate  the company s current P E ratio would indicate higher than optimum current valuation over the longer term 



The following slides provide additional insight into the growth opportunities for Actavis  For a more comprehensive review of the full presentation  follow this link 









Valeant Pharmaceuticals International  NYSE VRX 

Valeant Pharmaceuticals is also well positioned to serve the growing pharmaceutical needs of our aging population  However  this candidate offers additional diversification due to the specific markets that it serves 

Short business description courtesy of S P Capital IQ 


 Valeant Pharmaceuticals International  Inc  develops  manufactures  and markets pharmaceuticals  over the counter products  and medical devices worldwide 

The company offers Solodyn to treat red and pus filled pimples of acne in patients  as well as Ziana  Acanya  Atralin  Retin  A Micro  and ONEXTON gel  Wellbutrin XL for major depressive disorder in adults  Jublia for onychomycosis of the toenails  Xenazine for chorea  Targretin for Cutaneous T Cell Lymphoma  Arestin  a subgingival sustained release antibiotic  and PROVENGE for the treatment of prostate cancer  It also provides Zovirax  an antiviral for recurrent herpes labialis and initial genital herpes  Syprine to treat patients with Wilson s disease  Elidel to treat atopic dermatitis  Prolensa for inflammation and pain following cataract surgery  Duromine  a weight loss drug  and Lotemax gel for post operative inflammation and pain 

In addition  the company offers PreserVision  an antioxidant eye vitamin and mineral supplement  CeraVe to rebuild and repair the skin barrier  ReNu Multiplus to lubricate and rewet soft contact lenses  Biotrue for healthy contact lens wear  Ocuvite  a lutein eye vitamin and mineral supplement  cleansing solution for gas permeable contact lenses  Artelac to treat dry eyes  AntiGrippin for acute respiratory and respiratory viral diseases  and influenza  and Bedoyecta  a vitamin B complex product 

Further  it provides SofLens daily disposable contact lenses  PureVision  a contact lens  various ophthalmic surgical products  Biotrue ONEday lens  medical device systems for aesthetic applications  and Bausch   Lomb Ultra  a contact lens 

Additionally  the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions  Cardizem CD to treat hypertension and angina  and Latanoprost for the treatment of glaucoma  Valeant Pharmaceuticals International  Inc  was founded in 1983 and is headquartered in Laval  Canada  


Valeant Pharmaceuticals represents a second example of accelerating earnings growth since 2010  Even though the company has experienced P E ratio expansion thus far in 2015  I believe the company is still soundly valued based on earnings potential 



The biggest negative I find with this candidate is its high debt to capital ratio of 79   However  accelerating cash flow generation supports the company s ability to service the debt  and as we will see with the follow up slide presentation  the company is committed to reducing its debt moving forward 



Once again we see an example of extraordinary historical performance as a result of strong operating results  The total return potential from investing in growth stocks is powerful and significant  and not related to general stock market returns 



On a short to intermediate term basis  Valeant may be moderately overvalued  However  thanks to the power of compounding  the company still offers the potential for total returns exceeding 20  per annum out to 2017 



Once again the analyst scorecard summary indicates a high success rate for analyst forecasts made one year and two years prior to actuals  Consequently  this provides some evidence that current forecasts may be reasonable and accurate 



In contrast to what we saw with Actavis  long term  3 5 year  analyst forecasts are strong at over 20  per annum on average  Consequently  from a long term total return perspective  Valeant may be the strongest choice  However  that higher future return is somewhat less appealing based on the company s current debt load 



The following slides summarize the opportunity in front of Valeant  Note the discussions on cash flows and the balance sheet on the last slide  For a more comprehensive review of the full presentation   









Celgene Corporation  NASDAQ CELG 

Although my final candidate  Celgene  has the lowest historical growth since 2010 of the three  it has also had the most consistent double digit growth over a longer period of time  Consequently  although recent performance has been moderately lower than my first two examples  this is my favorite candidate of the three 

Short business description courtesy of S P Capital IQ 

 Celgene Corporation  a biopharmaceutical company  discovers  develops  and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally 
It markets REVLIMID  an oral immunomodulatory drug for multiple myeloma  myelodysplastic syndromes  MDS   and mantle cell lymphoma  ABRAXANE  a solvent free chemotherapy product to treat breast  non small cell lung  pancreatic  and gastric cancers  POMALYST IMNOVID for the treatment of multiple myeloma  and VIDAZA  a pyrimidine nucleoside analog to treat intermediate 2 and high risk MDS  and chronic myelomonocytic leukemia  as well as acute myeloid leukemia  AML  
The company s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum  OTEZLA for psoriatic arthritis  psoriasis  and ankylosing spondylitis  ISTODAX to treat cutaneous and peripheral T cell lymphoma  and FOCALIN  FOCALIN XR  and RITALIN LA products 
Its clinical stage products comprise oral anti inflammatory agents targeting PDE4  an intracellular enzyme that modulates the production of multiple pro inflammatory and anti inflammatory mediators  CC 122 and CC 220 to treat hematological and solid tumor cancers  and inflammation and immunology diseases  cellular therapies  such as PDA 001 and PDA 002 for Crohn s and peripheral arterial diseases  CC 486 to treat MDS  AML  and solid tumors  Sotatercept and luspatercept for the treatment of anemia  and CC 223 and CC 115 for lymphomas  hepatocellular  and prostate cancers 
The company has collaborative agreements with Novartis Pharma AG  Acceleron Pharma  Agios Pharmaceuticals  Inc   Epizyme Inc   Sutro Biopharma  Inc   bluebird bio  Inc   FORMA Therapeutics Holdings  LLC  MorphoSys AG  Acetylon Pharmaceuticals  Inc   OncoMed Pharmaceuticals  Inc   and NantBioScience  Inc  Celgene Corporation was founded in 1980 and is headquartered in Summit  New Jersey  


As previously mentioned  I favor the consistent growth that this company has historically achieved  But more importantly  and as we shall soon see  expectations are for future growth to continue at or above its historical achievements 



Celgene s debt to capital ratio is reasonable at 46  and supported by strong and accelerating cash flow growth 



Although historical performance since 2010 has been lower than my first two candidates  it is still extraordinary when compared to the average company 



Since we cannot invest in the past  only the future  the future growth expectations of Celgene are the primary reason I favor it over the other two candidates  Importantly  it appears that Celgene is soundly valued based on earnings growth estimates exceeding 25  over the next two years 

The one year forward and two year forward analyst scorecard for Celgene is also encouraging  The company has met or exceeded analyst estimates over 70  of the time 



Regarding longer term 3 5 year growth  Celgene is expected to grow faster than the previous candidates  Given this company s consistent historical record  I believe the potential for total annualized returns exceeding 20  are well defined 

The following slides illustrate the important and large opportunities that Celgene serves  For a more comprehensive review of the full presentation   









Summary and Conclusions

The three Pharma companies presented in this article offer intriguing potential for above average future long term earnings growth  Importantly  based on that earnings growth potential  each of them appear soundly valued at current levels  However and perhaps most importantly  their growth potential is  for the most part  independent of the overall economy  Each of these companies possess unique characteristics supported by the powerful demographic trend of an aging population 

Consequently  I believe it s worth putting concerns about the market or economy aside  and focusing instead on the opportunities that each of these big Pharma growth stocks offer  Finally  I remind the reader that I have not personally completed my research and due diligence  Therefore  I suggest that further comprehensive research and due diligence should be conducted  On the other hand  the long term total return potential of each of these candidates seems worthy of that effort 

Disclosure  No position at the time of writing  To get a free more detailed perspective on these three Pharma stocks  follow this direct link to a video on my site  and watch and listen to me analyze these companies out loud via the  fundamentals analyzer software tool 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2015-06-09,Chuck Carnevale,https://www.investing.com/analysis/my-top-3-fabulous-pharma-stocks-254386,254386
106320,327835,AGN,Weak GDP Keeps Market Flat,opinion,"U S  benchmarks edged lower on Thursday as the market reacted to weaker than expected U S  GDP and pending home sales reports  At the same time  the Federal Reserve hinted at December as a possible time frame for an interest rate hike  adding downward pressure on the stock market  According the most recent GDP report  the U S  economy slowed down to an annual growth rate of 1 5  after posting a 3 9  growth rate in the previous quarter  Concern over U S  economic health was further amplified with a second consecutive drop in pending home sales in September  Jobless claims rose slightly  however they remained at historically low levels  Investors remained cautious during the trading session  as shown by the low trade volume and tight ranges assets moved within  After Thursday s Federal Reserve announcements  market participants are expecting a 50  chance for a rate hike in December  according to the FedWatch tool by CME Group  O CME   The Standard and Poor s 500 remained virtually flat with a 0 04  decline to trade at 2 089 41  Out of the index s ten sectors  five remained in the red  Of the positive sectors  energy and healthcare posted the strongest gains  The energy sector was aided by rising energy costs while the healthcare sector rebounded amid talks of a merger between pharmaceutical giants Allergan Plc  N AGN  and Pfizer Inc  N PFE   The Dow Jones Industrial Average fell 23 71 points  or 0 13   to trade at 17 755 8 and the Nasdaq Composite shed 21 42 points  or 0 42   to trade at 5 074 27  Despite recent declines  Wall Street s main indexes are on track for a monthly gain of almost 9  in October  their biggest monthly gain since late 2011 
Crude Oil is on its way to close its fourth consecutive month below a price point of  50 a barrel  Currently  crude oil is trading at  45 6 a barrel after falling 46 cents  The current global supply glut isn t showing any signs of relief for energy related companies who ve posted around  19 billion in write downs within one week  Iraq  OPEC s second largest producer  is currently producing at rate of more than four million barrels a day  At the same time  U S  crude stockpiles have risen for a fifth straight week  as supplies remain around 100 million barrels higher than the running five year average  While crude oil prices rose above  50 a barrel earlier this month  OPEC has opted to move above its production quota in an effort to maintain its market share  According to the International Energy Agency  surplus supplies will remain in place until at least the middle of next year 
This week s major economic data releases conclude with today s Japanese inflation  employment and interest rate decisions  The last main release for the week is Eurozone unemployment later today ",2015-10-30,OptionsClick,https://www.investing.com/analysis/weak-gdp-keeps-market-flat-269747,269747
106321,327836,AGN,Alexza Pharmaceuticals  New Opportunity ,opinion,"Regaining US Adasuve rights  new opportunity Alexza  O ALXA  and Teva  N TEVA  have reached an agreement whereby Alexza will reacquire the US commercial rights for Adasuve  with a projected target completion date of 1 January 2016  US sales since the March 2014 launch have been tepid  Teva derived product revenue to Alexza was under  3m  and recent developments at Teva  ie Actavis  N AGN  acquisition  may have deprioritized Adasuve s position within the firm  While Teva s Adasuve relinquishment may reflect a reduced long term sales outlook  the process may actually help facilitate Alexza s ongoing strategic review  An outright sale or royalty agreement for Alexza s entire interest in Adasuve may be more straightforward once US rights are regained 

In September 2015  Alexza retained an investment bank to examine strategic options  including asset sales or a business combination  to enhance shareholder value and lower the cost of capital for advancing pipeline projects including AZ 007  Staccato zaleplon   Alexza also secured a  5m loan from EU partner Ferrer to maintain sufficient liquidity to complete the review and secure a deal 
To Read the Entire Report Please Click on the pdf File Below",2015-11-03,Edison,https://www.investing.com/analysis/alexza-pharmaceuticals-270083,270083
106322,327837,AGN,Will Pfizer Propel Allergan To Strong Q4 Earnings ,opinion,"Allergan  N AGN pa  Health Care   Pharmaceuticals   Reports February 22  Before Market Opens
Key Takeaways
The Estimize consensus is calling for EPS of  3 47  a resounding 10 cents higher than Wall Street  and revenue expectations of  4 21 billion  roughly  85 million greater than the Street
In late 2015  Allergance announced a merger with Pfizer valued at roughly  160 billion
Allergan plans to expand its branded segment which has caused it to sells its generics business to Teva Pharma Industries Ltd  N TEVA 
Drug and pharmaceutical manufacturer  Allergan is scheduled to report fourth quarter earnings February 22  before the market opens  The company is coming off a better than expected third quarter but the bigger news was the  160 billion merger with pharma giant  Pfizer Inc  N PFE   Consequently  share prices rose 20 60  this past year with expectations at an all time high when the company reports on Monday  The Estimize consensus is calling for EPS of  3 47  a resounding 10 cents higher than Wall Street  and revenue expectations of  4 21 billion  roughly  85 million greater than the Street  Compared to Q4 2014 this represents a projected decline on the bottom line by 11  and increase in sales of 4   Despite some wins for Allergan  the Estimize community has been bearish on earnings  revising EPS and revenue estimates down 8  and 7  in the past 3 months  respectively  Since the announced merger  Allergan has not provided guidance for the remainder of fiscal 2015 nor fiscal 2016  The proposed merger is a win win for both companies  Allergan will now have the leverage to expand its branded segment while Pfizer finds a legal home in tax friendly Ireland  Allergan s growth strategy has primarily focused on expanding its branded segment through acquisitions and developing the pipeline  In order to accomplish this  Allergan decided to sell its generics business to Teva  Once the deal closes in FQ1 2016  Teva will acquire Allergan s legacy business Actavis  N AGN  global generics  This opens up Allergan to focus solely on branded products  with more than 70 projects currently in mid to late stage development  Pfizer should help streamline this process with operational expertise and capabilities needed to support Allergan s long term investment  In the meantime  the merger brings on several concerns including risks in the integration process and setbacks in the pipeline 
Do you think AGN can beat estimates ",2016-02-21,Estimize,https://www.investing.com/analysis/will-pfizer-propel-allergan-to-strong-q4-earnings-200118926,200118926
106323,327838,AGN,Tarnished Pharma Sector Can Still Shine  3 Stocks To Consider ,opinion,"by Clement Thibault
Big pharma is perhaps one of the world s most scrutinized business sectors  Its main goal is a bit of a conundrum create and provide drugs that maintain health and cure diseases  while at the same time profit from the entire costly enterprise  The challenge involved in balancing the two seemingly polar aspects of business and health is tricky  Sometimes they complement each other well  for example when a new blockbuster drug is developed and approved for common illnesses such as leukemia or chronic liver disease  both of which have new blockbusters scheduled to be released in 2016  by AbbVie  NYSE ABBV  and Intercept Pharmaceuticals  NASDAQ ICPT  respectively  and the medication s developers see their profits skyrocket 
But blockbuster drugs are harder to come by these days  and the expiration of patents often opens the door for cheaper  generic medication substitutes  badly hurting profits of the companies developing the new drugs  For this reason  some pharmaceutical companies have been engaging in a different kind of business model 
Of course  the best news from the pharmaceutical industry is another FDA approval triumph  but lately  pharma industry news has been rather bad  Back in August 2015  Turing Pharmaceuticals  then CEO Martin Shkreli decided to raise the price of Daraprim  a drug used to treat toxoplasmosis   after Turing acquired the medication  A  covering the sudden price hike sparked public outrage and numerous debates regarding the commercialization of healthcare and profit taking off lifesaving medicines and the seriously ill population that can t live without them 
Shkerli isn t alone  Valeant Pharmaceuticals  NYSE VRX  also came under fire for the same practice during September 2015 price gauging  Leaders of the Democratic Party have called for a subpoena of the company s records  in order to examine its price setting processes  and on September 21  Democratic presidential candidate Hillary Clinton  calling the practice  outrageous   That one tweet kicked off a bad week for the Dow Jones Pharmaceuticals Index  as it lost 8 5  between September 21st and September 28th 

Valeant Pharmaceuticals soon discovered that not all publicity is good publicity  The company s share price has lost over 74  from its high of  263 81 in August  It currently trades at  61 31  This past Monday  the company acknowledged a U S regulatory probe of its business related to fraudulent practices and misleading investors 

If these stories can teach us anything  it s that all that glitters is not necessarily gold  even and maybe especially in the pharma sector  Still  there s a deal brewing in the sector that we believe is already creating opportunities for savvy market players 
In late 2015  Allergan  NYSE AGN  agreed to an acquisition in principle by Pfizer  NYSE PFE   It s a much criticized mega pharmaceutical deal  but it continues to move forward 
The criticism stems from the view some have that by acquiring Ireland based Allergan  and moving business operations to that lower tax country  Pfizer s U S tax bill will be seriously cut via a loophole called tax inversion  President Obama referred to the tax loophole as unpatriotic and presidential candidates Clinton and Trump have also sounded off on the deal 

According to the terms of the deal  Allergan shares are priced at  333 24 a share  However  Allergan shares are currently trading at  288 67  potentially rewarding buyers today with a 15  return in the future 
The price discount reflects concerns of intervention by the U S Treasury which could block the deal in order not to lose the tax revenue  Still  the deal is expected to go through in the second half of 2016  and provide new markets for the merged mega company  which is set to become one of the world s largest companies  with a combined value of over  300 billion 
This is an exciting investments opportunity both in the short and long term  The quasi immediate return of price per share profits is enhanced by a larger  combined drug pipeline  The two companies claim to have over 100 drugs in mid to late stage development  in altogether different markets 
While Pfizer is focusing its development efforts on treatments for cancer  heart disease  and more conventional illnesses  Allergan is mostly focused on specialty markets such as cosmetics and dermatology  The merger will therefore not cannibalize sales of either company s list  which is both good and surprising news for the two big pharma companies 

Teva Pharma Industries  NYSE TEVA  is another beneficiary of the Allergan Pfizer deal  The Israeli company  valued at  57 5B  is set to acquire Allergan s generic drugs division for  40 5B  which would strengthen Teva s position as the world s largest manufacturer of generic drugs 
With a TTM EPS of 5 42  the company today trades at a P E ratio of 10 2  following a bad start to the year when the company s shares slid by 15   Teva s revenue has fallen YoY  and analysts expect Teva to post a small growth number in 2016  with an EPS expectation of  5 49  hence the discount price 
Its sclerosis drug Copaxone  which accounts for 20 percent of its revenue  is now facing competition from Novartis  NYSE NVS   and is another source of worries for the company and its shareholders  However  2017 and beyond should be brighter for the drug maker  with growth expected to continue at about 7  annually 
Moreover  the company  a free cash flow of 20 to 25 billion according to CEO Erez Vigodman  allowing it to continue making moves to cement its position in the pharmaceutical industry  With its standing as market leader strengthened within the generic drug market and a relatively low P E  Teva should be near the top of your list if you have the patience to wait a bit for larger gains down the road ",2016-03-07,Clement Thibault/Investing.com ,https://www.investing.com/analysis/tarnished-pharma-sector-can-still-shine;-3-stocks-to-consider-200120645,200120645
106324,327839,AGN,Allergan s Inversion Headache,opinion,"This pharmaceutical is having an incredibly hard day in the market today    and for good reason  The company is the center of actions made by the U S  Treasury as well as the IRS  Today  we ll talk about those actions  why they are hitting AGN so hard  and what we can expect to see moving forward 
US Treasury And IRS Make Moves Hurt AGN
Allergan s  NYSE AGN  latest problem stems from moves made by the United States Treasury as well as the IRS  These agencies have issued temporary restrictions as well as proposed regulations to further reduce the benefit of and limit the number of corporate tax inversions  This is a major hit to AGN as the company is the product of several acquisitions and  ultimately  tax inversions to reduce costs in a big way for the company  However  the biggest effect of this action is likely an issue with the agreement between AGN and Pfizer  NYSE PFE   The truth is that  by limiting inversions  the merger between AGN and PFE will likely have incredibly high costs  Recently  BMO Capital analyst Alex Arfaei gave his opinion with regard to this issue  and he said it much better than I could 

Under current law  an inverted company is subject to potential adverse tax consequences if the shareholders of the former U S  parent  in this case current PFE shareholders  end up owning at least 60  of the shares of the new foreign parent  Therefore  we believe that the tax benefits of the PFE   AGN merger will likely be significantly diminished based on the Treasury s recent actions  If Pfizer is not able to invert and repatriate its ex U S  cash in a tax efficient manner to repurchase a significant portion of the 4 7Bn new shares it will be issuing to buy AGN  then we doubt that the current deal structure  and implied valuation for AGN  would make sense for PFE shareholders  If Pfizer still chooses to pursue Allergan for other strategic reasons  e g  to setup a split  our initial view is that the deal structure needs to be significantly revised 

Market Reaction
We all know that the news moves the market and  unfortunately  the news that was released late yesterday was incredibly bad for AGN  As a result  we re seeing a big reaction in the market today  Currently  10 11   the stock is trading at  232 50 per share after a loss of  45 05 per share or 16 23  thus far today 
What To Expect
Moving forward  things are incredibly uncertain at the moment  In the short term  Allergan is likely to see some struggles as the company s deal with Pfizer is likely to go down the tubes  Even if it ends up that the deal will continue forward  chances are that we will see big changes  and the pie won t be as sweet for the company  As a result  we re likely to see further declines in the short run  However  in the long run  I have an incredibly bullish opinion of what we can expect to see from AGN  The reality is that the company has a long line of incredible products  not to mention the prospective products it is working on  With strong products  strong management  a strong team  and a decent amount of money to keep the ball rolling  I m expecting to see long run gains out of AGN however this plays out ",2016-04-05,Joshua Rodriguez,https://www.investing.com/analysis/allergan's-inversion-headache-200124063,200124063
106325,327840,AGN,Waiting For Earnings,opinion,"Four weeks of corporate earnings are about to hit the market like an Arctic wind  As you brace yourself for the data  you will note that while stock prices have lifted into earnings season  expectations are still on ice  The strong U S  dollar versus a year ago  combined with weak bank earnings and very weak energy earnings  have done their job to lift negative preannouncements to recent highs and keep optimism in check  With investors not overweight risk  and the pain trade looking higher  a few well placed earnings beats or signs of optimism could cause a stampede into stocks  We are always a bit anxious going into earnings season  but it feels a bit more on edge this quarter with the Fed now looking determined to delay on interest rate increases  The other cross winds to keep an eye on right now are the weakening U S  dollar  which will help future earnings comparisons  and the rising interest in Emerging Market currencies  debt and equities  after 6 years of underperformance   Good luck with your earnings season 

The spike in negative preannouncements keeping expectations in check 

 FactSet  94 S P 500 cos  have issued negative EPS guidance for Q1  second highest total in 10 yrs  

Looking at where the markets interest lies  Gold Mining stocks  NYSE GDX  continue to be in demand with solid buying volumes 

International Treasury Bonds  NYSE BWX  also remain a focused area due to the weak U S  dollar and flight to a safety trade with overseas assets 

About that weakening U S  dollar 2014 levels look to be in store which would be welcome to global commodity players  as well as U S multinational earnings 



Besides U S  dollars  the market also dislikes Bank Stocks  NYSE KBE  

Trading revenues stink  Net Interest Margins stink  Credit will only deteriorate  Regulation continues to get worse  the Government continues to block announced M A and Factset is looking for Q1 EPS to fall 8 5   Does anyone see light at the end of this tunnel 

Speaking of M A   350b  in deals now canceled with the Pfizer  NYSE PFE  Allergan  NYSE AGN  deal sent back 


Trends in the Asset Management industry continue to amaze 
A striking 18 Morningstar 500 funds suffered outflows of at least 40  of assets under management in the trailing 12 months ended February 2016  61 shed 25  or more  and 168 had outflows of 10  or more 


If a Mutual Fund company wanted to get rid of all of its customers and financial advisors  I would recommend pay in kind for all redemptions 

When Tom Bentley tried to pull his money from a mutual fund troubled by its large stake in Valeant Pharmaceuticals International Inc  NYSE VRX    he instead received shares in a Springfield  Mo  auto parts retailer 
Sequoia Fund Inc  sent the retired computer hardware engineer about 5  of his money in cash and the rest was stock in one company O Reilly Automotive Inc  Mr  Bentley said he sold the shares as soon as they appeared in his account on April 7  but they had already dropped in value 
 It has been pretty horrendous   Mr  Bentley said 
Typically  mutual fund investors expect cash instead of stock when they ask for their money back  But investors seeking to pull large sums from Sequoia are getting a combination  according to people familiar with the matter 


If you have NFL clients  make certain that they are maxing out their 401 k  program  If you have other pro athlete clients  check to see if their league 401 k  is as lucrative 

The NFL has one of the best 401 k  programs in the country  according to Kerney  Players are automatically enrolled  and can put in up to  18 000 a year  unless they re a rookie or on a practice squad   And the league will put in two dollars for every dollar a player puts in   up to  13 000  So a player can set aside  44 000 a year in the plan   18 000    26 000  


 A great chart on U S  assets and liabilities from JPMorgan 







I bet that your elementary schooler will not need a driver s license  But don t only listen to me  read what the former Corp VP of R D and Planning at General Motors  NYSE GM  thinks 

 Driverless vehicles are not a fairy tale   Burns said at the AIC on Tuesday   I absolutely believe driverless vehicles are real  
Combined with the rise of electric engines and ride sharing services  driverless cars will eventually change the auto industry in profound ways  Imagine the end of driving  the internal combustion engine  car dealers  car ownership  and the car insurance industry as we know it 
Burns  who studied safety issues like distracted drivers while at GM  said autonomous cars have the potential to reduce accidents by as much as 94 percent  using integrated sensors  lasers  radars and cameras to make driving decisions and communicate with other vehicles 
 This is what we do with aircraft today   Burns said 
  


Op Ed of the Week 

 GE has been in business for 124 years  and we ve never been a big hit with socialists  We create wealth and jobs  instead of just calling for them in speeches  We take risks  invest  innovate and produce in ways that today sustain 125 000 U S  jobs   Jeff Immelt  GE
  




The information presented here is for informational purposes only  and this document is not to be construed as an offer to sell  or the solicitation of an offer to buy  securities  Some investments are not suitable for all investors  and there can be no assurance that any investment strategy will be successful  The hyperlinks included in this message provide direct access to other Internet resources  including Web sites  While we believe this information to be from reliable sources  361 Capital is not responsible for the accuracy or content of information contained in these sites  Although we make every effort to ensure these links are accurate  up to date and relevant  we cannot take responsibility for pages maintained by external providers  The views expressed by these external providers on their own Web pages or on external sites they link to are not necessarily those of 361 Capital ",2016-04-12,Blaine Rollins,https://www.investing.com/analysis/waiting-for-earnings-200124747,200124747
106354,327869,AGN,Looking Ahead of Wall Street  Salix Pharmaceuticals  Receptos  Tetraphas,opinion,A handful of bio pharmaceutical stocks are announcing their financial results for the final quarter of 2014 this week  What should investors watch for Salix Pharmaceuticals Ltd  NASDAQ SLXP  Salix Pharmaceuticals is scheduled to announce its fourth quarter 2014 financial results on Monday  March 2nd  after market close  The company is expected to post a loss of   0 29 a share  down from  0 93 earnings per share the same quarter last year Salix faced inventory issues in November when supply levels for its irritable bowel syndrome drug  Xifaxan  and other drugs were higher than it had previously guided  forcing the company to cut its full year earnings forecast  With that said  Salix stated it will try to return inventory levels to levels attained three months ago for all its drugs by the end of 2015  This indicates that 2015 will bring little to no growth  if not losses However  Salix Pharmaceuticals stock jumped 35  in January as speculation of a merger and acquisition began circulating  By February  Valeant Pharmaceuticals  NYSE VRX  International Inc  NYSE VRX   announced that it acquired Salix for  10 1 billion  or about  160 per share On average  the top analyst consensus for Salix Pharmaceuticals on is Hold Receptos Inc  NASDAQ RCPT  Receptos is set to announce its fourth quarter and year end financial results on Tuesday  March 3rd  after market close  The company is expected to post a loss of   1 08 a share  down from a loss of   0 86 a share year over year Receptos is known for developing therapies for treating immune and metabolic diseases  The company s leading drug is RPC1063  which is an oral supplement that was tested in Phase 2 and 3 clinical trials to treat relapsing multiple sclerosis  RMS  and ulcerative colitis  UC   RPC 1063 is also currently in a Phase 2 trial of treating inflammatory bowel disease  IBD  The company said recently that RPC1063 met primary endpoints in a Phase II trial as a treatment for colitis  A Phase III study in colitis and a Phase II study in Crohn s disease are expected in 2015 Since September 2014  Recepto s shares have increased 155  due to its ongoing positive results from RPC1063 On average  the top analyst consensus for Receptos on is Strong Buy Tetraphase Pharmaceuticals Inc  NASDAQ TTPH  Tetraphase is poised to announce its fourth quarter and full year 2014 financial results on March 5th after market close  The company is expected to post a loss of   0 60 per share  down from a loss of   0 49 per share the same quarter a year prior In December 2014  Tetraphase revealed that its new antibiotic  Eravacyline  proved to be successful in a late stage study  Eravacycline is meant to treat infections caused by gram negative bacteria  a type of antibiotic resistant pathogens mostly knows as superbugs  Tetraphase is seeking to apply for U S  regulatory approval of the drug by the end of 2015 If approved  the drug will compete with a variety of new superbug fighting antibiotics  including drugs from Cubist Pharmaceuticals  Actavis  NYSE ACT  Plc and AstraZeneca Plc On average  the top analyst consensus for Tetraphase on is Strong Buy ,2015-03-02,Carly Forster,"https://www.investing.com/analysis/looking-ahead-of-wall-street:-salix-pharmaceuticals,-receptos,-tetraphas-243553",243553
106355,327870,AGN,Weekend Update  March 6  2015,opinion,"   VIX a rally above weekly mid Cycle resistance at 14 26 and Short term resistance at 15 77 put the VIX on a buy signal  SPX sell signal  A rally above Long term resistance at 16 77 and the Cycle Top resistance at 18 99 may put the VIX into high gear  
SPX has its first weekly loss since January 

SPX gave up all of its gains for 2015 as it reversed down to weekly Short term support at 2061 06  A further decline beneath that level confirms the reversal and beneath Long term support at 2000 05 puts the uptrend in jeopardy  The next decline may not be saved at Long term support as the last one did on January 29 
 Bloomberg     U S  stocks fell  with benchmark indexes tumbling the most in two months  as better than forecast jobs data fueled speculation the Federal Reserve is moving closer to raising interest rates 
The Standard   Poor s 500 Index fell 1 4 percent  the most since Jan  5  to 2 071 26 at 4 p m  in New York  The equity gauge lost 1 8 percent for the week 
 Investors are looking and focusing entirely on what the Federal Reserve will do in the coming months   Chad Morganlander  a money manager at St  Louis based Stifel  Nicolaus   Co   which oversees about  170 billion  said by telephone   Effectively good news in this data point supports the notion that they will raise rates in the not too distant future  That scotches the speculative fervor within the equity market  
NDX meets the upper trendline 

NDX tested the upper trendline of its trading channel on Monday but retreated into the week end The Composite Index managed to cross above its former high of 5000 00 for two days  but did not close above it 
 ZeroHedge  In the aftermath of Marc Cuban s op ed from two days ago  that the current second tech bubble is worse than the first dot com bubble of 2000  there has been much anguish by those deeply invested  on margin  in  bio tech stocks  to demonstrate that the Nasdaq at 5000  or Biotechs trading at 50x or 5000xP E  is perfectly normal and the global central banks   13 trillion in liquidity has nothing to do with it  Of course  the answer who is right and wrong on this issue will not be revealed until after the current bubble pops 
Luckily  there are some very clear clues 
Yield gives up all support 

The High Yield Index declined through the entire cluster of Model support levels  leaving the Cup with Handle formation the next target  The Cup with Handle formation has a very high probability of success The mainstream press has no idea what might be coming 
 NYTimes  Actavis Inc  NYSE ACT  is showcasing the value of being barely investment grade  The company  a drug maker that has been making many acquisitions  attracted huge demand this week for  21 billion of bonds it is selling at a mere notch above junk status  They yield less than a bigger and higher rated debt issue that Verizon did in 2013  Buyers of top tier debt can t help but keep looking further downward  Fears of deflation  government bond buying  slow growth and a lack of alternatives are squeezing interest rates in developed countries  Germany  for example  persuaded investors to pay for the privilege of lending to it for five years  The United States bond markets are a bit less desperate  The government here is paying 2 09 percent for 10 year debt That has left corporate issuers in a sweet spot  especially those edging toward junk  When Verizon issued  49 billion of debt rated BBB plus  it caused a stampede  There was more than  100 billion of demand for a yield of 2 25 percentage points over 10 year Treasuries  or a rate of about 5 2 percent at the time 
The euro pushes lower 

The euro broke below its Wave  3  low and is pushing lower  It anticipates its next Master Cycle low  Wave 5  momentarily  which may surprise the short sellers  The discussion now is   How far below parity will the euro go  
 TheGuardian  The pound has hit a seven year high against the euro  bringing cheer for British holidaymakers but underscoring fears about the fragile European single currency as markets prepare for a flood of emergency electronic cash 
The euro sank to  1 387 against the pound and also sold off sharply against the dollar before next week s launch of a  1 1tn stimulus programme in the eurozone  The European Central Bank is to start pumping  60bn a month into the euro economy as the first phase in its quantitative easing programme  The scheme is intended to help get the eurozone back on the path to sustained growth 
Euro Stoxx 50 is challenging its Broadening Top 

The Euro Stoxx 50 Index appears to be challenging the upper trendline of its Orthodox Broadening Top  This may be a case of  Buy the rumor and sell the news  The Cycles Model now suggests the top is only days away 
 Bloomberg     European stocks are already enjoying their strongest start to a year in more than two decades  Citigroup  NYSE C  says there s still further to go 
European stocks will surge another 14 percent this year  Jonathan Stubbs  the bank s head of Europe and U K  equity strategy  wrote in a note dated March 5  Citigroup boosted its 2015 forecast for the Stoxx Europe 600 Index to 450 from 400  The benchmark gauge already rallied 15 percent in 2015 to a seven year high 
The yen may make a deeper low 

The yen appears poised to make a deeper low  A sideways consolidation often leads to a continuation of the trend and it is down  This may last just a few more weeks at most  but if so  may decline as far as 78 00 
 Bloomberg     Japan s small and medium sized companies aren t feeling the benefits of Prime Minister Shinzo Abe s reflationary policies  said the leader of a labor group that s fighting for pay increases 
The decline in the yen  which has slumped 29 percent since Abe took office in December 2012  is squeezing these companies through higher import costs  said Yukio Manaka  the president of the Japanese Association of Metal  Machinery and Manufacturing Workers 
 We are seeing raw material costs skyrocket because of the yen s depreciation  putting pressure on business performance   Manaka  59  said at a briefing in Tokyo on March 4 
The Nikkei Average appears to lose momentum 

The Nikkei appears to be losing upward momentum as it approaches its 6 year anniversary of the March 9  2009 low  It may continue rising to its anniversary  but the risk of a reversal is mounting  The Orthodox Broadening Top agrees with that outcome  since it represents a market that is out of control and has a highly emotional public participation  This may be the start of a dramatic decline that may be imminently due 
 JapanTimes  The Nikkei 225 average on Friday rewrote its highest closing level in 14 years and 10 months  boosted by purchases on persistent hopes for fund flows into global stock markets 
The key market gauge surged 219 16 points  or 1 17 percent  to close at 18 971 00  the best finish since April 19  2000 
The Topix gained 17 12 points  or 1 12 percent  to end at 1 540 84 
The TSE opened higher after the European Central Bank on Thursday announced details of its quantitative monetary easing 
A wide range of issues attracted purchases on the back of heightened hopes that more investment money will flow into stock markets around the world  with the Nikkei average coming within striking distance of 19 000 
U S  Dollar heading higher  but may reverse abruptly 

The US dollar appears to be in need of finishing Minor wave 5 before reversing back down  The rally may stop at 100 00  but seems to be targeting 101 40  This has been an extended rally and the Cycle is getting stretched  It s time for caution here 
 WSJ  The dollar pushed to an 11 year high against the euro on Friday  after a strong U S  jobs report solidified market expectations for the Federal Reserve to raise interest rates around midyear 
The euro fell to  1 0839 in late afternoon trading in New York  its lowest level against the dollar since Sept  4  2003  The euro recovered slightly to end the session down 1 7  at  1 0843 in its largest one day decline in six weeks 
The U S  economy added 295 000 jobs and the unemployment rate ticked down to 5 5  in February  according to the Labor Department  Economists had predicted 240 000 jobs were created last month and the unemployment rate would fall to 5 6  
USB in a shake out 

The Long Bond is doing a shake out of weaker hands in Wave  4  Since the end of January liquidity has been rotating out of bonds and into stocks and commodities as the Cycle inverted  The decline appears to be targeting weekly Long term support  currently at 143 60  Once accomplished  the rally in bonds may continue through mid year 
The Bond Vigilantes are back 
 WSJ  U S  government bonds suffered the biggest one day selloff since November 2013 as a solid U S  employment report stoked fears that the Federal Reserve may raise interest rates in June 
Investors including hedge funds and portfolio managers shed holdings as they are worried that higher official interest rates from the central bank would undermine the value of outstanding bonds  Traders said the selloff reminded them of the  taper tantrum  during the summer of 2013 when the bond market was rattled by concerns of a pullback in the Fed s bond buying monetary stimulus 
 The selloff is seriously ugly and quite bloody   said Christopher Sullivan  who oversees  2 45 billion as chief investment officer at the United Nations Federal Credit Union   The U S  economy is poised to continue to be on an upward slope  A rate increase in June cannot be ruled out  
Gold breaks down 

Gold broke down beneath its January 2 low and appears to be capable of declining to or beneath its Cup with Handle formation  If so  the decline may last through the end of March 
 WSJ  Gold prices saw their sharpest drop in more than a year Friday  after data showing strong U S  job growth last month bolstered the case for the Federal Reserve to raise interest rates around the middle of 2015 
Gold for April delivery  the most actively traded contract  fell 2 7  to  1 164 30 a troy ounce on the Comex division of the New York Mercantile Exchange  That was the lowest settlement for the most active gold contract since Nov  13  2014  and the biggest drop for gold prices since December 2013 
For the year  prices are down 1 7   below the Dec  31 settlement of  1 184 10 for the first time 
Crude may be ready to rejoin the decline 

Crude appears to be st up to rejoin the decline  The shakeout attempt ran out of gas  There may be a mid month pause in the decline  but it appears capable of running through the month of March before another correction may be due 
 ZeroHedge  Don t look now  but the sharp slide in crude prices may be leading the proverbial sheep to slaughter  Investors have piled into the market s largest crude ETF over the last several months sending the number of shares outstanding to the highest level since 2009  We suspect many of these  investors  might be unaware that they re currently staring down the most severe decoupling between second  and first  month contracts in four years 
 normal  knife catching BTFD ers piled into USO for the bounce   
Shanghai Index completing a reversal pattern 

The Shanghai Index fell back below weekly Short term support resistance at 3255 80 this week  confirming the retracement and resumption of the decline  The Shanghai Index may be in a panic decline that could last into May  The index had its final ramp on Monday and has been in decline since  Volatility is on the rise in China  despite massive liquidity injections 
 ZeroHedge  You wouldn t know it if you looked at the price of oil  but arguably the world s largest economy just unloaded a kitchen sink of fears  warnings  and downgrades on its economy  the most notable being 
 CHINA SETS 2015 GDP GROWTH TARGET AT ABOUT 7   from 7 5  in 2014 
In a report to be delivered to the government tonight  Premier Li Keqiang warned China may face more economic difficulties in 2015 vs 2014 and downward economic pressure is still growing  despite Western  analysts  proclaiming China fixed   The currency is weakening on the news and AsiaPac stocks are lower and as Chinese stocks open lower  despite hints at more easing   millions of newly minted  can t lose  Chinese investors begin to worry 
The Banking Index spiked  but no new high 

  BKX spiked higher today  but couldn t change its bearish outlook  This is the index that will lead equities and commodities in their next decline  The Cycles Model now implies that the next decline may last through mid April  Could this be a waterfall event 
 ArmstrongEconomics  The biggest problem we have with central banks is that they are run by academics with ZERO real world experience  This applies not just at the Fed  but most central banks with the lone exception of Bank of China  The greatest danger this presents is that the money center banks manipulate the central bankers during states of financial panic and they who are so frightened  they will do whatever the money center banks tell them
In the USA  there is nobody who would investigate the dark corners of the Federal Reserve being manipulated by the NY bankers who walk of water without ice  However  the system is much more open in Britain where the bankers do not control the courts as they do in New York City  Consequently  the Bank of England  BoE  is now being investigated by the Serious Fraud Office  SFO  for being  too  friendly with the money center banks during the crisis of 2008 
 ZeroHedge  Not  contained   Just six short months ago  the 2Y bonds of Austria s bank bank   HETA Asset Resolution AG   were trading well above par as the world and his mom reached for yield   6   in all the wrong places  Today  following the  spectacular development  over the weekend that the bank will be wound down due to the discovery of an  8 5bn  hole  in its balance sheet  the 2Y HETA bonds are trading below 50c on the dollar  at a yield of 54    This is indeed Austria s  Lehman  moment as for the first time in the new European  bail in  era  senior debt is getting a massive haircut 
 TheEconomist  BANKS are yet again in trouble not pure investment banks such as Lehman Brothers  or mortgage specialists such as Northern Rock  but a handful of huge global  network  banks  These lumbering giants are the woolly mammoths of finance  and if they cannot improve their performance they deserve a similarly grievous fate 
 ZeroHedge  For the first time in public  though practically the entire world assumed it  an official from The IMF has admitted that the various Greek bailouts were not for The Greeks at all     They gave money to save German and French banks  not Greece   Paolo Batista  one of the Executive Directors of International Monetary Fund told Greek private Alpha TV on Tuesday  As KeepTalkingGreece reports  Batista then went on to strongly criticized not only the euro zone and the European Central Bank but also the IMF and the Fund s managing Director Christine Lagarde for defending Europe much too much   ",2015-03-08,Anthony M. Cherniawski,"https://www.investing.com/analysis/weekend-update-march-6,-2015-244258",244258
106356,327871,AGN,Pharma Stock Outlook  Let s Make A Deal,opinion,Pharmaceutical Stock Outlook  Acquisitions   Deals in Focus  2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions  M As  and licensing agreements are concerned  While tax inversion deals were being actively pursued earlier  these cross border deals lost their luster considering new rules imposed by the Treasury Department Deal Making Frenzy Showing No Signs of Slowing Down Nevertheless  M As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down  AbbVie s  NYSE ABBV   21 billion acquisition agreement with Pharmacyclics Inc  NASDAQ PCYC  is one of the biggest deals to be announced in recent times  The deal goes to show that lofty valuations will not deter large companies from pursuing acquisitions to boost their pipelines and product portfolios  Other major deals include the ones involving Actavis  NYSE ACT    Allergan  NYSE AGN    Shire Plc  NASDAQ SHPG   NPS Pharmaceuticals  Endo  NASDAQ ENDP    Auxilium  and Pfizer  NYSE PFE   Hospira  NYSE HSP   Salix Pharmaceuticals Ltd  NASDAQ SLXP is currently being wooed by both Valeant Pharmaceuticals  NYSE VRX  and Endo  Meanwhile  we expect small bolt on acquisitions to continue  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals   most of these companies find it challenging to raise cash  thereby making it difficult for them to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense for them to seek deals with pharma companies sitting on huge piles of cash  We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics  Therapeutic areas attracting a lot of interest include central nervous system disorders  diabetes and immunology inflammation  The hepatitis C virus  HCV  market is also attracting a lot of attention  Another lucrative area is immuno oncology as these therapies have the potential to change the treatment paradigm for cancer    they basically use the natural capability of the patient s own immune system to fight the cancer  Major players in this field include Bristol Myers Squibb Company  NYSE BMY   Astrazeneca Plc  NYSE AZN   Merck  NYSE MRK  and Roche Holding Ltd  OTC RHHBY   Deals targeting immuno oncology are being inked by companies like Pfizer Inc  NYSE PFE   Merck KGaA PK  OTC MKGAY   Bristol Myers  AstraZeneca and Incyte  NASDAQ INCY   Another trend witnessed recently is the divestment of non core business segments  Companies like Pfizer  Abbott Laboratories  NYSE ABT   UCB  Novartis AG  BA NVS   Glaxosmithkline  NYSE GSK  and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise  Restructuring activities are also gaining momentum as large pharma companies look to cut costs and streamline operations  Most of these companies like Allergan  Merck  Novartis  Eli Lilly and Company  NYSE LLY   Shire and Sanofi  PARIS SASY  are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile  Products with Blockbuster Potential Gain Approval Several important product approvals as well as label expansions were gained last year  Gilead strengthened its position in the HCV market further with its combination treatment  Harvoni  gaining FDA approval  Harvoni is expected to bring in multi billion dollar sales for Gilead  The highly lucrative obesity market got a new player with Orexigen Therapeutics Inc  NASDAQ OREX  Contrave gaining FDA approval  Meanwhile  it proved to be third time lucky for MannKind Corporation  NASDAQ MNKD  with the company finally gaining approval for diabetes product  Afrezza  The FDA also said yes to Celgene  NASDAQ CELG  s blockbuster hopeful Otezla and Amgen  NASDAQ AMGN  s leukemia drug  Blincyto  Products like Medivation s  NASDAQ MDVN  Xtandi and Pharmacyclics  Imbruvica gained label expansions  Other highly anticipated treatments like Opdivo  metastatic melanoma   Viekira  HCV   Esbriet  idiopathic pulmonary fibrosis   Keytruda  melanoma   Orbactiv and Dalvance  skin infections   and Zydelig  blood cancer  were among the 41 new molecular entities  NMEs  and Biologics License Applications  BLAs  approved last year  Meanwhile  so far in 2015  the FDA has approved 9 NMEs and BLAs Biosimilars Gaining Focus With the FDA approving the first biosimilar in the U S   Zarxio  a biosimilar version of Amgen s blockbuster drug  Neupogen   the floodgates have opened  While biosimilars have been available in the EU for quite a while  there was no regulatory pathway for biosimilars in the U S  Biosimilars should cut healthcare costs and provide a large number of patients with access to much needed biologic treatments  According to information provided by Express Scripts  NASDAQ ESRX   about  250 billion could be saved in the next decade  2014   2024  if biosimilars for 11 products including Neupogen  Avastin  Epogen  Humira  Neulasta  Remicade and Rituxan are approved  According to the company  Neupogen biosimilars alone represent potential savings of about  5 7 billion  However  at present  there is low visibility on the pricing of biosimilars in the U S  Unlike generics  which are sometimes priced at even a 90  discount to the branded drug  biosimilars are usually sold at a 20  30  discount to the price of the reference drug  So  it could be a while before biosimilar sales actually pick up and meet industry expectations  Apart from Novartis  companies like Merck  Amgen  Hospira  NYSE HSP   Biogen Idec Inc  NASDAQ BIIB  and Actavis are targeting the highly lucrative biosimilars market  Meanwhile  emerging markets remain focus areas with companies like Mylan  NASDAQ MYL   Pfizer  Merck  Eli Lilly  Glaxo and Sanofi all looking to expand their presence in India  China  Brazil and other emerging markets  However  while higher demand for medicines  government initiatives for healthcare  new patient population and increasing use of generics should help drive demand  we point out that emerging markets are also not immune to genericization Earnings Trends The Q4 earnings season is over for the medical sector  While the earnings  beat ratio   percentage of companies coming out with positive surprises  was 81 1   the revenue  beat ratio  was 69 8   Total earnings grew 23 9  compared to 15 5  in 3Q  while total revenue grew 11 9  in the quarter compared to 12 1  in 3Q  Looking at consensus earnings expectations for 1Q  earnings are expected to grow 10 5  and revenues 9   While results will be affected by negative currency movement  new products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  Overall  2015 earnings are expected to grow 9 7  and revenues 9 6   For a detailed look at the earnings outlook for the Medical and other sectors  please check our  report Zacks Industry Rank Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs  We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  To learn more  visit    As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative   The Zacks Industry Rank for large cap pharma is  192  med biomed gene is  75  med drugs is  106  while med generic drugs is  95  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Positive for med biomed gene  Neutral for med generic drugs and med drugs and Negative for large cap pharma stocks OPPORTUNITIES While EU austerity measures  negative currency impact and pricing pressure remain headwinds  the pharma industry is out of the worst of its genericization phase  Many companies  which had faced generic headwinds in the last couple of years  should continue to see a sustained improvement in results this year  Cost cutting  downsizing  emerging markets and new products should support growth  Among pharma stocks  companies like Salix and Valeant carry favorable Zacks Ranks  Valeant  a Zacks Rank  2  Buy  stock  has been in the news given its acquisition strategy  After failing to acquire Allergan  Valeant is currently looking to acquire Salix  a Zacks Rank  1  Strong Buy  stock  In the biotech space  we are positive on ISIS Pharmaceuticals Inc  NASDAQ ISIS   Geron Corporation  NASDAQ GERN   Acorda Therapeutics Inc  NASDAQ ACOR  and Osiris Therapeutics Inc  NASDAQ OSIR  among others  While Acorda is a Zacks Rank  1  Strong Buy  stock  the others carry a Zacks Rank  2  Among generic companies  Akorn Inc  NASDAQ AKRX  and Actavis look well positioned  While Akorn is a Zacks Rank  1 stock  Actavis carries a Zacks Rank  2  With the upcoming Allergan acquisition  Actavis  which was previously known for its strong presence in the generics market  will find itself in the company of the top 10 pharmaceutical companies across the world based on sales WEAKNESSES We recommend avoiding names that offer little growth or opportunity for a take out  These include companies which are developing drugs that are likely to face regulatory hurdles  Large cap pharma companies that currently carry a Zacks Rank  4  Sell  include Sanofi  Bayer  OTC BAYRY   Novartis  Novo Nordisk B  NYSE NVO  and Roche  Among biotech stocks  companies like Regeneron  NASDAQ REGN   Arena  NASDAQ ARNA   Puma  NYSE PBYI  and Alkermes plc  NASDAQ ALKS  are Zacks Rank  4 stocks ,2015-03-18,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-outlook:-let's-make-a-deal-245340,245340
106357,327872,AGN,Select Stocks Are Rocking  ADXS  SHAK  EGRX  ACT,opinion," I had to pick myself up and get on with it  do it all over again  only even better this time   Sam WaltonA weak start to the day that shook out a lot of traders but our stocks resumed strength and I m very happy about it I continue to see some super gains in the stocks I ve selected for myself and members including Advaxis Inc  NASDAQ ADXS  who keeps on trucking  Shake Shack Inc  NYSE SHAK   Eagle Pharm  NASDAQ EGRX  and now Actavis Inc  NYSE ACT  are doing great as well from very recent buy points I really only have 3 more stocks I m interested in here although several others are breaking out and should do well but I am already pretty heavy and only have room for 3 more good sized positions 

SPDR S P 500  ARCA SPY  is holding really well here near highs and as long as we remain above the 207 50 area we are just resting for a breakout higher as I ve been talking about here for the past week or more Let s see how it goes but so far  so good and I m heavy in stocks and should be all in very shortly I can t stress enough how good the next couple of months could be so if you ve ever though about joining my real time service this is the best time I ve seen in a long time I hope you had a great day and the rest of your week is even better ",2015-04-15,Warren Bevan,https://www.investing.com/analysis/select-stocks-are-rocking-248482,248482
106358,327873,AGN,Analysts Disagree Over Significance of Akorn  Inc s Financial Errors,opinion,"Akorn Inc  NASDAQ AKRX  announced on Friday that it will have to restate financials from 2014 due to accounting errors  Akorn warned that their financial reports for 2014  filed by KMPG  should not be relied upon  Though the pharmaceutical company affirmed its 2015 earnings per share guidance  the stock fell by more than 20  on Monday following the announcement 
Akorn identified the 2014 accounting missteps when reviewing financials for the first quarter of 2015  The miscalculations stemmed from understatements of rebates and other sales allowances  Though the company is still determining the exact impact of the miscalculations  initial estimates believe the errors resulted in a  20 million to  35 million overstatement of net revenue and pre tax income for the full year 2014 Consequently  Akorn warned investors that it does not expect to file its quarterly report by the SEC deadline  However  Akorn affirmed guidance for 2015 earnings  expecting to post adjusted diluted EPS between  1 88 and  1 98 
On April 27  Akorn announced recent executive appointments including Randall Pollard who was appointed Corporate Controller  In this role  Pollard will oversee all accounting and financial reporting 
Analysts weighed in on the impact the flawed accounting will have on the pharmaceutical company 
On Monday  analyst  reaffirmed a Buy rating on Akorn  though he did not provide a price target  Steinberg does not think the accounting errors will have a significant impact on the stock  He has rated Akorn once before on April 20  when he set a  56 price target for the stock  He was bullish on Akorn because he believed its clobetasol cream was more successful than that of Actavis  NYSE ACT  s 
Since David Steinberg has only rated Akorn once before on April 20  he has a 100  success rate recommending the stock with a  1  average return  Overall  David Steinberg has an 81  success rate recommending stocks with a  24 5  average return per rating 
Separately  analyst  of Piper Jaffray downgraded Akorn from Overweight to Neutral with a price target of  53  Amsellem commented   Though management does not believe the accounting issues will impact 1Q15 results  and it is sticking with its 2015 guidance  there is in our view far too large of a credibility gap to simply take those statements at face value   Amsellem believes the company has lost credibility to the point that Akorn must replace its CFO 
David Amsellem has rated Akorn four times since July 2012  earning a 67  success rate recommending the company with a  25  average return per AKRX rating  Overall  Amsellem has an 80  success rate recommending stocks with a  23 7  average return per recommendation 
On average  the top analyst recommendation for Akorn on is Hold ",2015-04-28,Sarah Roden,"https://www.investing.com/analysis/analysts-disagree-over-significance-of-akorn,-incs-financial-errors-249895",249895
106383,327898,AGN,2 Stocks To Profit From As Corporate America Rushes Abroad,opinion,"Whenever Corporate America faces off with Washington lawmakers  one outcome is usually guaranteed Fireworks 
And the latest conflict   following a statement from President Obama and the Democrats last Thursday   is quickly shaping up to be a true battle royale  Be warned   This new policy not only demonstrates Washington s  Regulate Everything  culture  it also threatens the financial well being of America s corporations   and  in turn  your own wealth 
The Urge to  Invert 
These days  much of the sparks between Corporate America and Washington concern Uncle Sam sticking his grubby hands in the corporate cookie jar  and making off with obscene amounts of tax revenue 
Stifled by America s excessive taxation policies  a slew of companies have essentially expatriated from the United States in a process known as  corporate inversion  
It s a technique where companies restructure their businesses abroad  in hopes of reducing their tax burden  This includes re incorporating under a wholly owned international subsidiary  or simply buying a foreign company outright 
With their tax domicile then based in that country  the Internal Revenue Service can t touch their earnings 
The technique itself is nothing new  The first inversion deal was done in 1982  but the trend has set a record pace recently  as U S  companies   particularly healthcare and biotechs   divert overseas  as they battle for any competitive advantage they can get 
Those who ve done so are already reaping rewards  For example  Ireland has proved particularly popular 
New Jersey based Actavis  NYSE ACT  acquired Dublin s Warner Chilcott  NASDAQ  WCRX  in an  8 5 billion deal  and promptly  inverted  its business to tax friendly Ireland 
Chicago s AbbVie Inc   NYSE ABBV   recently just closed a deal with another Dublin based firm  Shire plc  NASDAQ SHPG  
Global medical device leader  Medtronic  NYSE MDT   shelled out  42 9 billion to buy Covidien plc  NYSE COV   which is based in Massachusetts  but incorporated in Ireland 
This year alone  we ve seen nine inversion deals finalized  Take that  Washington 
But as you d expect  politicians are eager to stop this practice  In fact  just last week  President Obama outlined his intention to close a loophole that allows companies to avoid U S  taxes by basing themselves abroad 
More specifically  Obama is supporting Democrat led anti inversion bills that would see companies with half their business in the United States be considered U S  domiciled for tax purposes  Quoted on Reuters  a White House official stated   We can t afford to wait to reform our tax code to deal with inversion   while claiming that inversion deals would cost the United States an estimated  17 billion in lost tax revenue over the next decade 
Of course  there s no guarantee that a bill will pass  But while the loophole still exists   and even amid Washington s attempts to close it   there s little sign of the trend slowing  U S  companies still want to get deals done to reap tax benefits while they still can   And naturally  they hope that a bill doesn t pass  
So which companies are ripe for the picking 
Inversion Investment  1  Bajan Bucks
If you re in the healthcare or biotech sector  and seeking a generous tax break  Barbados is a top destination 
Barbados is revered as one of the world s most corporate friendly tax havens  boasting 14 very favorable tax treaties with various countries   including the United States 
And it doesn t get much better than Concordia Healthcare Corp   TO  CXR   Why  Well  for a start  the firm is based in Toronto   which  in itself  makes the company an attractive proposition for American companies looking to  invert  
Second  it pulls in a large chunk of revenue from its Barbados based subsidiary  Concordia Pharmaceuticals  All told  Concordia Healthcare sports a blended tax rate in the single digits 
In fact  Concordia was close to finalizing an inversion deal with an undisclosed U S  firm in early 2014  But issues over the valuation ended the conversation 
This not only makes CXR an attractive corporate investment  but also a good option for retail investors  as it won t settle for anything less than its intrinsic value  And who can blame it  After going public as recently as January  Concordia s stock has surged from  7 80 to  36 70   a 370  surge 
As the inversion trend continues  Concordia remains a compelling target 
Inversion Investment  2  The Luck of the Irish
As I mentioned earlier  Ireland is a very popular place for corporate inversions 
Indeed  on July 14  Israeli newspaper  Globes  reported that Dublin based Perrigo plc  NYSE PRGO   which manufactures generic and over the counter drugs  had hired a team of investment bankers to help it consider a potential buyout 
The potential suitor  None other than  64 billion behemoth  Abbott Laboratories  NYSE ABT   Abbott is a well established worldwide manufacturer and distributor of healthcare products  with a segment of its business devoted to pharmaceuticals 
Perrigo shares shot up nearly 10  on the news 
Some argue that Perrigo isn t the right move for Abbott  But amid that debate  one thing remains undisputed  Perrigo is a prime takeover target 
Jefferies analyst  David Steinberg  notes that  Perrigo is an attractive candidate for certain strategic buyers  due to its durable  highly cash flow generative business model  
I agree  Over the last five years  Perrigo boasts a free cash flow  FCF  growth rate of 20 7  
But it s even more attractive when you consider the 10 year FCF growth rate of 25   This proves the company s ability to consistently generate money for expanding its business  paying down debt  and offering its  0 42 annual dividend per share 
And the fact that Perrigo operates in Ireland   a feat it accomplished through an inversion buyout of Elan Corporation   merely sweetens the deal  Why 
Because Ireland offers an extremely low corporate tax rate of only 12 5   It s a primary reason why AbbVie recently purchased Shire  The inversion deal will reportedly save AbbVie  8 billion in taxes 
In  Lew  of it All 
You can see why Washington isn t too thrilled with this recent surge in expatriation  All told  the future potential losses are massive 
According to Goldman Sachs  GS   United States faces nearly  40 billion loss of pre tax income from 2014 inversion deals alone 
U S  Treasury Secretary  Jack Lew  has urged Congress to crack down on foreign merger deals  citing  economic patriotism  as the main reason 
Give me a break 
My guess is that companies would choose being rich over being patriotic 
The Obama administration shares that concern  as it hustles to push through new legislation that will close the loophole and retroactively eliminate the tax breaks for most of this year s inversion deals 
We ll see how its efforts turn out  In the meantime  get in on the companies I mentioned while the getting s good ",2014-07-28,Marty Biancuzzo,https://www.investing.com/analysis/2-stocks-to-profit-from-as-corporate-america-rushes-abroad-220818,220818
106384,327899,AGN,Bullish Investors Jockey For Position As If Correction Is Over,opinion,"As many investors enjoy the final weeks of summer  some optimistic bulls seem to be positioning themselves well ahead of Labor Day in anticipation of a fall rally  Indeed  last week s action was impressive  After only a mere 4  correction  investors continued to brush off the disturbing violence both at home and abroad  and they took the minor pullback as their next buying opportunity  But was that really all the pullback we re going to get this year  I doubt it  But I also believe that nothing short of a major Black Swan event can send this market into a deep correction 
In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 
Market overview 
Looking at the ten U S  business sectors  Technology  Utilities  and Healthcare each had a good week last week and are still the leaders year to date  while Energy fell back a tad  Notably  Basic Materials continues to show new life and is pulling away from the pack at the lower end of the performance scale    Industrial  Financial  Consumer Goods Staples  Consumer Services Discretionary  and Telecommunications 
U S  Treasuries continue to enjoy strong demand  even while the Fed continues to taper its bond buying activity  The U S  10 Year yield fell even further last week  closing Friday at 2 34   and the 30 Year last checked in at 3 13   Again  the strength in Treasuries is reflects global investors seeking the relative safety of the U S   given all the global turmoil  as well as an expectation that the Fed likely will not raise interest rates any time soon  Low rates entice businesses to borrow for expansion  hiring  and stock buybacks  and they support higher equity valuation multiples when low bond yields  and a low discount rate  are compared with future earnings in equities discounted back to a present value 
The CBOE Market Volatility Index  VIX   a k a  fear gauge  closed Friday at 13 15  During the recent market pullback  VIX had spiked above 17  but soon fell back to as low as 12 on Friday morning during the early continuation of the market rebound  However  the Friday rumor regarding a direct Ukraine Russia military confrontation gave the VIX an intraday spike near 15 before settling back down  I said last week that if the VIX can stay below 15  bulls should be able to make a good upside run  and indeed they have  certainly aided by some option expiration week short covering 
Corporate earnings reports have been quite strong  and about two thirds of the S P 500 companies have beaten analyst estimates  which is a greater beat rate than normal  And rather than relying on cost cutting and productivity gains  top line revenue growth for 2Q 2014 was up  4 4  versus 2Q 2013 for the S P 500 large caps and  2 7  for the 30 Dow Jones Industrials blue chips  while small caps overall have reported revenue growth of over  11  
By the way  Sabrient s Baker s Dozen top stocks for 2014 appear to be making a move to pull away from the benchmark performance  Former laggard NetApp Inc   NASDAQ NTAP  certainly helped the cause with a strong earnings report  and others among the laggards are starting to show some juice  including Huntington Ingalls Industries  NYSE HII   Marathon Petroleum  NYSE MPC   Jazz Pharmaceuticals  NASDAQ JAZZ   and Express Scripts   NASDAQ ESRX   The notable exception is Ternium S A   NYSE TX   But the top performers since January 13 inception  7 months  are NXP Semiconductors  NASDAQ NXPI   Southwest Airlines  NYSE LUV   Arris Group  NASDAQ ARRS   Actavis plc  NYSE ACT   and Archer Daniels Midland  NYSE ADM  
Yes  the U S  economy has a lot going for it right now  but it is not immune to the global unrest  Between global central banks injecting liquidity and global investors seeking safe havens for those monies  the U S  has been the prime beneficiary 
However  I can t help but observe the similarities between what is going on with  for example  the Israeli Palestinian conflict  and what we are seeing right here on U S  soil in Ferguson  MO  I won t go into all the details on my mind  but in both cases  one of the fundamental problems is the widening income and opportunity gap between the haves and have nots    including legions of young men with more testosterone than education and productive skills  Whether they turn to gangs  crime  or extremism  the end result is inevitably violence  anarchy  police actions  and racial or religious conflict  This drains precious resources  dissuades local investment  and hinders economic progress everywhere 
Social programs that seek only to alleviate the suffering of the disenfranchised usually carry the by products of dependency  an entitlement mentality  breakdown of the family unit  and further disenfranchisement    in other words  an endless cycle of poverty and exclusion  I certainly don t have the answers  but creating real hope and opportunity for all is the only long term solution  And at least here at home  this starts with each of us taking personal responsibility for the actions and welfare of ourselves  our families  and our communities  What happens in Gaza or in Ferguson or outside your front door is not just a problem for President Obama or the local police chief  It is everyone s problem 
SPY chart review 
The SPDR S P 500 Trust  ARCA SPY  closed last Friday at 195 72  which is up nicely from the prior Friday  After the 100 day simple moving average held during the prior week and the oscillators turned up  I predicted last week that we could see a nice rally  and indeed we did  SPY now sits smack dab in the middle of the long standing bullish rising channel and right on the confluence of the 50 day SMA with prior support turned resistance at 196  So  we will see early this week whether there is yet enough bullish conviction  and volume  to push the market higher at this point  Additional support levels are nearby  including resistance turned support lines at 190 and 187 5  and the lower line of the bullish rising channel at 188  followed by the critical 200 day SMA around 187  Oscillators RSI and MACD look like they could run further to the upside  whereas the Slow Stochastic might be signaling a brief consolidation is in order first 

The Russell 2000 small cap index closed Friday at 1141 65 and appeared to have been turned back at what I expected would be tough resistance from the convergence of both its 100  and 200 day SMAs  As I said last week  how it behaves at this test of resistance might be a tell tale sign for the market overall  Thus  the SPY might struggle around the 50 day SMA for a while  But I doubt there is anything short of a major Black Swan event that can send this market into a deep correction  So  if and when bulls can get it in gear and rally back toward the top of the bullish rising channel  the 200 level for the SPY will be extremely tough resistance 
Latest sector rankings  
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  NYSE IYF   Technology  NYSE IYW   Industrial  NYSE IYJ   Healthcare  NYSE IYH   Consumer Goods  NYSE IYK   Consumer Services  NYSE IYC   Energy  NYSE IYE   Basic Materials  NYSE IYM   Telecommunications  NYSE IYZ   and Utilities  NYSE IDU   Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 
   Here are some of my observations on this week s scores 
1   Technology still holds the top spot with an Outlook score of 81  The sector displays solid scores across most factors in the model  including solid Wall Street analyst sentiment  net upward revisions to earnings estimates   a good forward long term growth rate  and strong return ratios  The forward P E is below average  Financial has the lowest   as well as insider sentiment  open market buying   Healthcare remains in the second spot this week with a score of 76 as the sector continues to display the strongest  and still improving  sell side analyst sentiment  upward revisions   a good forward long term growth rate  and reasonable return ratios  Utilities fell back in the pack this week just as suddenly as it jumped up last week  Last week s strong price performance coupled with a low forward long term growth rate made the forward valuation for Utilities a little less attractive this week  Instead  Energy has returned to the third spot  largely due to an improvement in sell side sentiment  Financial and Consumer Goods Staples round out the top five 
2   Telecom stays in the cellar this week with an Outlook score of 9  as the sector has low scores on most factors in the model  Consumer Services Discretionary stays in the bottom two with a score of 14  despite a strong forward long term growth rate  Telecom  Basic Materials  and Consumer Services Discretionary continue to take the brunt of the downward earnings revisions from sell side analysts 
3   Looking at the Bull scores  Healthcare again displays the strongest score of 59  while Utilities remains the clear laggard at 39  The top bottom spread has widened to 20 points  reflecting low sector correlations on particularly strong market days  It is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold  rather than the all boats lifted in a rising tide mentality that dominated 2013 
4   Looking at the Bear scores  Utilities is the clear leader again with a score of 64  which means that stocks within this sector have been the preferred safe havens on weak market days  Telecom also has shown good relative strength during market weakness  Energy continues to display the lowest score of 41  The top bottom spread is 23 points  reflecting low sector correlations on particularly weak market days  Again  it is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points 
5   Healthcare displays the best all weather combination of Outlook Bull Bear scores  while Telecom is clearly the worst  Looking at just the Bull Bear combination  Healthcare is the clear leader  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   Energy  which at times has displayed the best Bull Bear combo score  shows the worst one now  indicating general investor avoidance during extreme conditions 
6   Overall  this week s fundamentals based Outlook rankings continue to look neutral to me  although there are some signs of bullishness  Utilities has fallen back down the rankings while Energy has risen  but for the most part  defensive and economically sensitive sectors are mixed about in the rankings with no clear direction emerging  and the leadership of Healthcare is not highly inspiring 
These Outlook scores represent the view that the Technology and Healthcare sectors are relatively undervalued  while Telecom and Consumer Services Discretionary may be relatively overvalued based on our 1 3 month forward look 
Stock and ETF Ideas 
Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or bearish   suggests holding Technology  Healthcare  and Energy  in that order  in the prevailing neutral climate   Note  In this model  we consider the bias to be neutral from a rules based standpoint when SPY is below its 50 day simple moving average while staying above its 200 day SMA  At the moment  SPY is sitting right on its 50 day but hasn t yet confirmed a breakout back above it   
Other highly ranked ETFs from the Technology  Healthcare  and Energy sectors include First Trust NASDAQ Technology Dividend Index Fund  NASDAQ TDIV   iShares US Healthcare Providers ETF  NYSE IHF   and Market Vectors Oil Services ETF  ARCA OIH  
For an enhanced sector portfolio that enlists top ranked stocks  instead of ETFs  from within Technology  Healthcare  and Energy  some long ideas include Open Text Corp  NASDAQ OTEX   Intuit Inc  NASDAQ INTU   Centene Corp  NYSE CNC   HCA Holdings  NYSE HCA   Cameron International  NYSE CAM   and National Oilwell Varco  NYSE NOV   All are highly ranked in the Sabrient Ratings Algorithm and also score within the top two quintiles  lowest accounting related risk  of our   a pure accounting based risk assessment signal based on the forensic accounting expertise of our subsidiary Gradient Analytics  We have found EQR quite valuable for helping to avoid performance offsetting meltdowns in our model portfolios 
However  if you think the market will continue to strengthen and you prefer to maintain a bullish bias  the Sector Rotation model suggests holding Healthcare  Technology  and Energy  in that order   But if you have a bearish outlook on the market  the model suggests holding Utilities  Healthcare  and Technology  in that order  
Disclosure  Author has no positions in stocks or ETFs mentioned   Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2014-08-18,Scott Martindale,https://www.investing.com/analysis/bullish-investors-jockey-for-position-as-if-correction-is-over-222972,222972
106385,327900,AGN,Stock Market Breakout  Not So Fast,opinion,"Was that really a breakout  With the S P 500 struggling around the 2 000 level for the past two weeks  Friday s strong finish might seem like a bullish breakout  But the market has already given us a couple of false breakouts at this level  and although I see higher prices ahead  I m still not convinced that we have seen all the near term downside that Mr  Market has in store  particularly given we are now in the historically weak month of September  Also  the improving economy is a double edged sword from an equity investor s perspective as they are concerned that the Fed might feel the need to raise rates sooner than currently planned 
In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 
Market overview 
Yes  we are entering the historically weakest month of September  at least according to Stock Trader s Almanac  However  the reality is that the average monthly loss is only  0 5   and nearly half of the time the market finishes positive  Moreover  recent performances have bucked the averages  with solid gains in September the past two years and a robust  8 8  in 2010 
There is no doubt that the U S  economy is strengthening while central banks flood world markets with liquidity  and global investors look to U S  stocks and Treasuries for the unusual combination of more safety and higher returns  Hiring has surged starting with lower wage jobs but also with the expectation that higher wage jobs will soon follow  Corporate profits are at record highs and stock buybacks are raging  Also  oil prices have fallen as domestic production continues to rise  The European Central Bank has joined the other major central banks in lowering interest rates and launching its own version of quantitative easing  and much of that new liquidity should find its way into the relative safety of U S  stocks and Treasuries 
And don t forget  hedge funds are finding themselves way underweight in equities  After the ECB announced its stimulus program  David Tepper of hedge fund Appaloosa Management predicted that this signals the official end of the bond market rally  driving even more capital into equities  Although elevated  valuation multiples are not out of line given low interest rates and strong earnings growth expectations 
However  that doesn t mean that the stock market is destined to go straight up  There hasn t been a real 10  correction in nearly three years  which is twice as long as the typical interval between corrections  We are way overdue  Notably  leading sectors last week were defensive oriented Utilities and Telecom  which is not particularly encouraging to the bulls  And of course  ECB liquidity programs have little chance of making much difference in an EU in desperate need of major structural reform  although U S  equities will welcome the capital inflows  
The yield on the U S  10 Year Treasury fell to less than 2 4  during the summer and closed Friday at 2 46   so a significant weakening in Treasuries hasn t happened yet  In fact  Jeff Gundlach of DoubleLine Funds  who predicted this year s rally in bonds   has predicted the 10 year yield to remain between 2 2 2 8  for the foreseeable future  with the main risk being to the downside  So  there is still no consensus on the near term direction of Treasury bonds 
The CBOE Market Volatility Index  VIX   a k a  fear gauge  closed Friday at 12 09 after taking a few stabs above 13 during the week and challenging its 50 day simple moving average  It has been gradually creeping higher over the past couple of weeks  Investors seem to be quite cognizant of historical market behavior during the month of September 
So  is VIX being kept artificially low to prevent it from reverting to its low term mean of 20  According to a  by Brian Stutland of Equity Armor Investments  a Sabrient strategic partner   monetary policy coupled with a strengthening U S  dollar has pushed money flow into both U S  bonds and stocks  and this enhanced liquidity has tamed realized volatility and equity movements  Nevertheless  he believes that the VIX has nowhere to go from here but up  although it could be a matter of days or months before it happens    VIX is not a timing signal 
Although we remain well overdue for a  10  cleansing correction  we also know that Q4 is traditionally strong for equities  particularly given the strengthening economy and global liquidity  So  whether or not we finally get a correction in the near term  buy the dips remains the mantra until proven otherwise 
By the way  Sabrient s annual Baker s Dozen portfolio of 13 top picks for the year is really starting to kick into gear  Because this portfolio represents a sector diversified group of our favorite Growth At a Reasonable Price  GARP  stocks without regard to timing signals  they usually take a few months to get going  and this year has been no different  Nevertheless  as of last Friday  the portfolio was up nearly  17  since its January 13 launch versus the SPDR S P 500  ARCA SPY  performance of  11 7  over the same timeframe  Top performers include NXP Semiconductors  NASDAQ NXPI  and Southwest Airlines  NYSE LUV   and Jazz Pharmaceuticals  NASDAQ JAZZ  had a big  7  day on Friday  Portfolio performance is quite strong versus many other firms that publish annual Top Picks lists  as shown in  third party tracking site 
Also  there was an  on ETF com last week comparing the performance of the Guggenheim Defensive Equity ETF  NYSE DEF   which tracks our Defensive Equity Index  against the PowerShares S P 500 Low Volatility ETF  NYSE SPLV  as low volatility defensive oriented investments  DEF has been quite impressive 
SPY chart review 
The SPDR S P 500 Trust  SPY  closed last Friday at 201 11  while the underlying S P 500 closed at 2 007 71   and seems to be showing the launch of a bullish breakout  Or is it 
Yes  it is above 200  but it has spent some time intraday below the 200 level virtually every day since it initially breached this psychological level  So  this is still within a consolidation range  The challenge remains recruiting enough new bullish conviction  and fresh capital  to break out in earnest  and that has not happened yet  I am certainly not convinced that a breakout has started  particularly as we just get started with the historically weak month of September  Moreover  the top line of the bullish rising channel is once again providing strong resistance  Like the price action  oscillators RSI  MACD  and Slow Stochastic are all looking neutral and could go either way from here 
 
Latest sector rankings 
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  iShares US Financials  NYSE IYF    Technology  iShares Dow Jones US Technology  NYSE IYW    Industrials  iShares US Industrials  NYSE IYJ    Healthcare  iShares US Healthcare  NYSE IYH    Consumer Goods  iShares US Consumer Goods  NYSE IYK    Consumer Services  iShares US Consumer Services  NYSE IYC    Energy  iShares DJ US Energy Sector Fund  NYSE IYE    Basic Materials  iShares US Basic Materials  NYSE IYM    Telecommunications  iShares US Telecommunications  NYSE IYZ    and Utilities  iShares US Utilities  NYSE IDU    Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 
  Here are some of my observations on this week s scores 
1   Technology still holds the top spot with an Outlook score of 92  The sector displays relatively solid scores across most factors in the model  including the best Wall Street analyst sentiment  net upward revisions to earnings estimates   a good forward long term growth rate  and strong return ratios  The forward P E is below average  Financial and Energy sport the lowest   but insider sentiment  open market buying  is now among the highest  Consumer Goods has taken the second spot this week with a score of 68 as the sector displays strong sell side analyst sentiment  upward revisions  and insider sentiment  as well as strong return ratios  Financial has risen to the third spot  followed by Healthcare and Industrial rounding out the top five 
2   Telecom stays in the cellar this week with an Outlook score of 2  as the sector has low scores on most factors in the model  Consumer Services Discretionary stays in the bottom two with a score of 20  despite a strong forward long term growth rate  Telecom and Energy have been hit recently with the most Wall Street downward earnings revisions 
3   Looking at the Bull scores  Healthcare displays the strongest score of 60  Telecom is the only sector scoring below 50  with a score of 43  The top bottom spread is 17 points  reflecting fairly low sector correlations on particularly strong market days  It is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold  rather than the all boats lifted in a rising tide mentality that dominated 2013 
4   Looking at the Bear scores  Utilities is the leader again  but its score is only 54  which is lower than the 60 70 range it has been showing  Stocks within this sector have been the preferred safe havens on weak market days  Telecom also has shown good relative strength during market weakness  Energy continues to display the lowest score of 40  The top bottom spread has dropped to 14 points  reflecting higher sector correlations on particularly weak market days  Again  it is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points 
5   Technology displays the best all weather combination of Outlook Bull Bear scores  while Telecom is clearly the worst  Looking at just the Bull Bear combination  Healthcare is the leader  followed by Utilities  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   Energy and Telecom score the worst  indicating general investor avoidance during extreme conditions 
6   Overall  this week s fundamentals based Outlook rankings continue to look neutral as defensive and economically sensitive sectors are mixed about in the rankings with no clear direction emerging  Also  all weather sector Healthcare displays the highest Bull score  which is not particularly exciting for a bullish investor 
These Outlook scores represent the view that the Technology and Consumer Goods Staples sectors remain relatively undervalued  while Telecom and Consumer Services Discretionary may be relatively overvalued based on our 1 3 month forward look 
Stock and ETF Ideas 
Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or bearish   suggests holding Healthcare  Technology  and Industrials  in that order  in the prevailing bullish climate   Note  In this model  we consider the bias to be bullish from a rules based standpoint because SPY is above both its 50 day simple moving average and its 200 day SMA  
Other highly ranked ETFs from the Healthcare  Technology  and Industrial sectors include PowerShares DWA Healthcare Momentum Portfolio  NYSE PTH   PowerShares Dynamic Semiconductors Portfolio  NYSE PSI   Market Vectors Semiconductor ETF  NYSE SMH   and PowerShares Dynamic Building   Construction ETF  NYSE PKB  
For an enhanced sector portfolio that enlists top ranked stocks  instead of ETFs  from within Healthcare  Technology  and Industrial  some long ideas include Edwards Lifesciences  NYSE EW   Actavis plc  NYSE ACT   Skyworks Solutions  NASDAQ SWKS   Lam Research  NASDAQ LRCX   AECOM Technology  NYSE ACM   and Lowe s Companies  NYSE LOW   All are highly ranked in the Sabrient Ratings Algorithm and also score within the top two quintiles  lowest accounting related risk  of our    EQR    a pure accounting based risk assessment signal based on the forensic accounting expertise of our subsidiary Gradient Analytics  We have found EQR quite valuable for helping to avoid performance offsetting meltdowns in our model portfolios 
However  if you think the market has come too far and you prefer to maintain a neutral bias  the Sector Rotation model suggests holding Technology  Consumer Goods Staples  and Financial  in that order   But if you have a bearish outlook on the market  the model suggests holding Utilities  Technology  and Consumer Goods Staples  in that order  
Disclosure  Author has no positions in stocks or ETFs mentioned   Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2014-09-08,Scott Martindale,https://www.investing.com/analysis/stock-market-breakout-not-so-fast-225052,225052
106386,327901,AGN,Foamix IPO  Large Market  Good Trial Results  Neutral Rating,opinion,"Foamix Ltd   FOMX     new IPO scheduled for Thursday  Sept  18  2014   The full IPO calendar is available at IPOpremium    Overview FOMX is a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne  impetigo and other skin conditions  Based on clinical trials  FOMX believes that FMX101 has the potential to become the new standard of care for the moderate to severe acne market  The P E ratio is  62  which indicates a low cash burn rate relative to the market cap    Based in Rehovot  Israel  Foamix Ltd   FOMX  scheduled a  65 million IPO on the NASDAQ with a market capitalization of  234 million at a price range midpoint of  11 for Thursday September 18  2014       Manager  Co Managers  Barclays  Cowen   Company Joint Managers  Oppenheimer   Co   Maxim Group LLC   Conclusion 
The rating on FOMX is neutral
Large acne market  Encouraging clinical trial results
License agreements with Bayer AG  Intendis   Merz Pharmaceuticals  LLC and Actavis
Low cash burn rate relative to market cap 
  Valuation    Valuation Ratios Mrkt Cap   mm    220Price  Sls  366 7Price  Erngs   62 1Price  BkVlue  3 3Price  TanBV  3 2  offered in IPO  5   To put the conclusions and observations in context  the following is reorganized  edited and summarized from the full S 1 referenced above    Business FOMX is a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne  impetigo and other skin conditions    Market According to the American Academy of Dermatology  acne affects approximately 40 to 50 million people in the U S  alone  approximately 10 million of whom suffer from moderate to severe acne according to the Journal of Investigative Dermatology    The U S  market for branded prescription drugs for acne was estimated to be approximately  2 6 billion for the 12 months ended March 31  2014  of which  1 0 billion was attributed to oral antibiotics such as Solodyn  the current standard of care for moderate to severe acne  and the remaining  1 6 billion was attributed to topical drugs such as Epiduo and Aczone  which are used to treat mild acne    Technology platform FOMX developed FMX101 and FMX102 using its proprietary technology  which includes its foam based platforms    This technology enables FOMX to formulate and stabilize a wide variety of drugs and deliver them directly to their target site    FOMX s foam platforms have significant advantages over alternative delivery options and are suitable for multiple application sites  creating a potential pipeline of products across a range of conditions to drive future growth    Lead product candidates   clinical trials FOMX s lead product candidates  FMX101 for moderate to severe acne and FMX102 for impetigo  are novel topical foam formulations of the antibiotic minocycline  FOMX s clinically and statistically significant Phase II clinical trial results demonstrate that FOMX s minocycline foam  FMX101  provides a faster  more effective treatment than the reported results for oral minocycline  the current standard of care for moderate to severe acne  and does so with fewer side effects    Based on these results  FOMX believes that FMX101 has the potential to become the new standard of care for the moderate to severe acne market    FMX101 for moderate to severe acne     FMX101  a 4  minocycline foam formulation for moderate to severe acne  is its lead product candidate    In 2013  FOMX completed a dose ranging Phase II clinical trial of FMX101 in Israel  involving 150 patients aged 12 to 25 with moderate to severe acne    This trial demonstrated both clinically and statistically significant efficacy versus the control placebo group  with FMX101 reducing inflammatory acne lesions by 71  in only six weeks and non inflammatory lesions by 73  in 12 weeks  In addition  no drug related systemic side effects were observed    Phase II clinical trial for FMX102 FOMX has also completed a Phase II clinical trial for FMX102  and based on its efficacy and safety profile  FOMX believes it will present an attractive option for the treatment of impetigo  including impetigo caused by methicillin resistant staphylococcus aureus  or MRSA    FOMX expects to commence pivotal Phase III clinical trials for both product candidates in 2015    License agreements In addition  FOMX has entered into development and license agreements relating to its technology with various pharmaceutical companies such as Bayer AG NA  XETRA BAYGN   Intendis   Merz Pharmaceuticals  LLC and Actavis Inc  NYSE ACT   which  from FOMX s inception to June 30  2014  have generated approximately  14 7 million in revenues    The agreements may entitle FOMX to an additional aggregate amount of up to approximately  30 million in contingent payments if certain conditions are met    FOMX is further entitled to royalties from net sales of the licensed products  or  in certain cases  from net profits generated by them  if they are approved for marketing by the relevant regulatory authorities and commercialized by the licensees    Dividend Policy No dividends are planned    Intellectual Property FOMX s most important patent is its U S  patent relating to its lead product candidates  FMX101  FMX102 and FDX104  which is expected to remain in effect until 2030    This patent comprises a claim to a formulation of a tetracycline antibiotic which can include minocycline or doxycycline    FOMX s other patents granted in the U S  have claims relating to certain formulations of its foam platforms and other technology  including emulsion foams  hydrophobic foams and aqueous foams    As of August 31  2014  FOMX s continuous effort in protecting and fortifying its unique intellectual property has yielded a patent portfolio of 70 granted patents in certain countries worldwide  including 31 granted patents in the U S    Additionally  as of August 31  2014  FOMX had 114 pending patent applications worldwide  of which 60 are pending in the U S  describing and claiming its multiple foam based platforms and other technology    FOMX has several composition of matter patent applications pending in relation to FMX101  FMX102 and FDX104 in the U S  as well as one pending in each of the following international markets  Australia  Brazil  Canada  China  the European Union  India  Israel and Mexico  FOMX s other pending applications relate to various foam platforms such as emulsion foam  hydrophobic foam  hydro alcoholic foam and water free foams  as well as specialty foams  such as potent solvent foams  and FOMX s recently developed  metered dose dispenser  for controllable dosing    Competition As more companies develop new intellectual property in FOMX s markets  the possibility of a competitor acquiring patent or other rights that may limit FOMX s products or potential products increases  which could lead to litigation    In addition  FOMX faces competition from the current standard of care    The current standard of care for moderate to severe acne includes oral antibiotic drugs such as Solodyn  Doryx  Dynacin and Minocin  in which minocycline or doxycycline are the active ingredients  occasionally in combination with topical anti acne drugs such as Acanya  Aczone  Ziana  Epiduo  Benzaclin and Differin    The current standard of care for impetigo is the topical agent Bactroban  with Altabax being the most recently approved topical agent for such indication    The active ingredients in Bactroban and Altabax are the antibiotics mupirocin and retapamulin  respectively    The standard of care for moderate to severe rosacea are oral minocycline and doxycycline drugs such as Oracea  the most recently approved oral doxycycline drug for rosacea    The standard of care for milder cases of rosacea are topical drugs such as MetroGel and Finacea    However  based on its clinical trials  FOMX believes that FMX101 and FMX102 have competitive advantages over the current alternatives and have significantly less adverse side effects    5  stockholders Tamarkin Medical Innovation Ltd  21 1  Meir Eini Holdings Ltd  21 5  Amos and Daughters Investments and Properties Ltd  12 1  Benny Shabtai  9 4  Rosa Alba Commerce   Investments Ltd  7 4  Amiram Bornstein 6 7  Doron Freidman 5 7                          Use of proceeds FOMX intends to use the  58 million in proceeds from its IPO as follows     20  ",2014-09-18,Francis Gaskins,"https://www.investing.com/analysis/foamix-ipo:-large-market,-good-trial-results,-neutral-rating-226224",226224
106387,327902,AGN,Dow Jones  Stocks Rose Tuesday After News Of Major Pharmaceutical Merger,opinion,"Dow Jones
An upbeat European economic sentiment  boosted broader U S  equities indices  U S  pharmaceutical Allergan Inc   which makes Botox  agreed to be acquired by Ireland s Actavis Inc  in a  66 billion deal  a move that sent healthcare stocks gaining and taking up broader stock indices up with them  Meanwhile in Europe  improving economic sentiment boosted U S  stocks as well as did upbeat data back home ",2014-11-19,ICM Brokers,https://www.investing.com/analysis/dow-jones:-stocks-rose-tuesday-after-news-of-major-pharmaceutical-merger-233009,233009
106388,327903,AGN,Bulls Expect Further Equity Gains  Looking For Strong 2015 ,opinion,"Another solid year for U S  equities came to a close  But it s not like everyone is jumping up and down with enthusiasm  which is a good thing  With plenty of bogeymen in the closet and under the bed  there is little in the way of irrational exuberance  Although some commentators noted that 2014 finished up much the same as 2013  there was really quite a bit of difference between the past two years  primarily in the way of lower correlations in 2014 as opposed to the all boats lifted environment of 2013 
Looking ahead  2015 looks promising for further gains  but not without bouts of volatility  In fact  it might look a lot like 2014  In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 
Market overview 
As we see the close to yet another successful year for the U S  stock market  we can look back on 2014 and recall the many bogeymen that caused investor consternation  There was the end of the Fed s tapering of QE3  although maturing securities are still being reinvested rather than retired   There was the huge collapse in Crude Oil prices  and still falling today   causing major disruptions in global markets  Then of course we had the slowdowns in China  Japan  and Europe    and Greece is again in crisis mode 
There was major turmoil in Russia and the Ukraine  We witnessed the sudden emergence of ISIS as a terrorist organization with its own army  and social media savvy   There was the fear of Ebola spreading into a global epidemic  And here at home  we had the uncertainty surrounding implementation of Obamacare  as well as the mid term elections putting the GOP in control of both houses of congress  Did I miss anything 
The Dow Jones Industrials blue chips  the S P 500 large cap index  and the NASDAQ ended the year up about  7 5    11 3   and  17 4  respectively  while the S P Midcap 400 gained about  8  and the Russell 2000 small cap index gained only  3 7   The Russell 2000 made an attempt to break out above strong resistance at 1200  but ultimately failed  The NASDAQ at one point looked ready to challenge the 5 000 level for the first time in nearly 15 years  but couldn t gather enough bullish conviction before the year ended  The MSCI emerging markets index finished down  6   Defensive strategies like low volatility and dividend yield outperformed in a general flight to quality 
Still  with leadership from large caps and defensive strategies  total capital in U S  ETFs surpassed the  2 trillion mark  In addition  fixed income indexes rose in 2014 as long dated yields continued to decline despite the Fed s tapering of its quantitative easing  bond buying  
Among the ten U S  business sectors  the top performers for the year were Utilities   25    Healthcare   24    and Technology   19    and all spent a lot of time during the year near the top of Sabrient s forward looking fundamentals based SectorCast rankings  The worst performer by far was Energy  which is not surprising given the 50  haircut in oil prices  Also showing lackluster performance were Telecom and Basic Materials  which both spent a lot of time at the bottom of our sector rankings  Consumer Discretionary and Financial both showed good late year outperformance to make up some ground 
Economic reports continue to impress  at least domestically  Redbook weekly retail sales report showed a robust  5 4  year over year increase  Consumer confidence rose from 88 7 to 92 6  which is quite strong  Also  U S  manufacturing activity continues to expand despite the struggles of overseas economies 
Leading economic indicators are strong  job growth is the strongest since the  90s  and corporate profits sit at all time highs  Strong GDP growth is expected to continue into 2015 and beyond  which should propel equities to new heights  although the future for long term bond prices is not as clear  Although the near term will likely provide further flattening in the yield curve  eventually economic health will demand higher long term rates and a steeper yield curve 
The IPO market last year was the busiest since 2000  and the Healthcare sector was buoyed by FDA approval of the most new drugs in 18 years  including many high priced drugs that address rare conditions and orphan diseases 
For several years  oil production has been climbing in the U S  and Canada  and there has been a lot of recovery among oil fields in Iraq and elsewhere  In addition  rising demand in China and India and other developing nations have kept supply demand in balance  But North American production kept climbing far beyond expert predictions  while slowing growth and or recession in China  Japan  and Europe along with rising fuel efficiencies in the U S  led to reduced demand 
With traders and speculators no longer willing to keep the price artificially high due to geopolitical concerns  oil prices plummeted quickly  plunging much further than anyone thought possible  Sell side analysts covering the Energy sector began slashing earnings projections once it became clear that lower prices were likely here to stay 
But asset classes tend to overshoot in both directions  and I believe we will see oil stabilizing soon  Energy stocks are highly dependent on oil prices and might be dead money for the foreseeable future  but it is not a bad idea to begin accumulating them in long term accounts  particularly those stocks paying a reasonable dividend with hedges in place 
And the toll taker type companies with locked in pricing  including pipeline MLPs   which were the proverbial babies thrown out with the bathwater  might be the best long term accumulation targets of all  Although oil prices may decline further in the near term  they likely will return to a more normal trading range  And in any case  the overall impact is positive for virtually all other segments of the economy 
It is said that bull markets don t die of old age but rather from euphoria  in which valuations get totally out of whack  or when the economy falls into recession  And there seems to be nothing that can prevent a strong 2015  However  there is no denying the cautious and often defensive behavior of investors    as the little voice in the back of their heads tells them that something just doesn t feel right about it all  Bu this is healthy skepticism that is helping to prevent an unhealthy euphoria  a k a   irrational exuberance  
The CBOE Market Volatility Index  VIX   a k a  fear gauge  closed Friday at 17 79  which is still well above the line of complacency at 15  but below the important 20 threshold that suggests real fear  It is indicating heightened volatility and some lingering investor worry going into the New Year 
The U S  10 Year Treasury yield closed at 2 11   which is still quite low  indicating a continued flight to quality among global investors in spite of the Fed s desire for a normalization of interest rates  i e   higher fed funds rate and a steeper yield curve   Its 52 week range is 1 86 3 06  In addition  the US dollar continues to strengthen while the euro sinks to its lowest level since 2006 due to speculation that the ECB will soon begin a quantitative easing program by purchasing sovereign debt 
Any increase in interest rates here at home will serve to attract even more global capital into U S  Treasuries  This keeps lending rates down here at home  helping boost the housing market  but it also further strengthens the dollar  which makes it harder for those countries with the weaker currencies to pay down their debt 
While many are expecting the Fed to begin raising rates nominally sometime in the middle of 2015  the FOMC has taken a more dovish turn with its latest voter rotation  so some observers actually are speculating that we won t see a boost in rates until 2016  I think this scenario is entirely possible  But in any case  rates will not rise rapidly 
Of course  persistently low bond yields also serve to support higher P E multiples in equities  The forward P E on the S P 500 is only about 16  and the spread between the S P 500 earnings yield and the U S  10 Year yield is about 4  versus the historical norm of about 3   Also  robust stock buybacks are likely to continue for a while at the prevailing ultra low borrowing rates  which lowers the denominator in EPS and offsets new stock offerings and IPOs that typically serve to increase the denominator and dilute the overall profit pool  So  the market s forward valuation is still quite reasonable    particularly as corporate earnings continue to grow 
And with Q3 earnings season behind us and Q4 reports starting soon  sell side analysts are anticipating EPS of  29 92 for the S P 500 companies  which is an increase of  5 5  from Q4 2013  and total 2014 EPS growth is expected to come in at  7 5   compared with  4 5  for 2013  This would be the best earnings growth since 2011 s  14 3   Companies that generate real rising sales and earnings should outperform the speculative names  particularly in a global economy characterized by subdued demand and pricing pressures 
Yes  the U S  is the main driver of global growth  while Europe slogs along  Japan slides into recession  and the BRIC countries appear to be destined for their slowest pace since emerging from the Great Recession  This performance gap between the U S  and the rest of the world shows just how insulated we really are  Exports are just 14  of output  and big exporting countries like China  Germany  and Japan will be depending on us to help ignite their economies 
The New Year appears to be set to continue the path it set in 2014  The end of QE3 is allowing asset classes to perform according to their fundamentals rather than rewarding highly correlated risk on risk off behavior  Lower equity correlations  higher volatility  and a modest increase in U S  equity prices are likely in 2015  As a result  some market experts are suggesting greater exposure to long short  long hedged  and market neutral equity strategies 
One choice in this regard is a recently launched actively managed ETF    the First Trust Long Short ETF  FTLS   which employs as an input factor Sabrient s   a pure accounting based risk assessment signal based on the forensic accounting expertise of our subsidiary Gradient Analytics  We have found EQR quite valuable both for identifying short candidates and for helping to avoid higher risk long positions 
As I predicted one year ago  2014 ended up displaying a general flight to quality among investors in which the best companies with the most sustainable earnings growth and reasonable valuations got the most attention  while the speculative high flyers that had been coat tailing on bullish exuberance lost their luster  Sounds like rational investing  But this apparently made life for a lot of portfolio managers difficult  In fact  the Financial Times reported that only about 10  of stock pickers beat their benchmarks  and Morningstar reported that only about 13  of actively managed large company mutual funds beat the S P 500 
However  Sabrient s annual Baker s Dozen portfolio of 13 top picks finished its sixth straight strong year  since 2009 inception   It was up about  22  since its January 13 launch while the S P 500 was up about  15  over the same timeframe  Top performers include Southwest Airlines  NYSE LUV   NXP Semiconductors  NASDAQ NXPI  NV  and Actavis plc  NYSE ACT  
And going into 2015  as we finalize our new portfolio  the top of our forward looking quantitative rankings once again reveals strength in airlines  semiconductors  and biopharma  Baker s Dozen represents a sector diversified group of stocks based on our Growth at a Reasonable Price  GARP  quant model and confirmed by a rigorous forensic accounting review by our subsidiary Gradient Analytics to help us avoid stocks at higher risk of issues that could result in a underperformance  It is packaged as a unit investment trust  UIT  by First Trust Portfolios  note  the new 2015 Baker s Dozen portfolio will launch on January 14  
Looking ahead  companies that generate increasing sales and earnings will outperform  particularly in a global economy characterized by subdued demand and pricing pressures  Moreover  removing the Fed s manipulation will eventually enable normalization to wider yield spreads  more profitable bank lending  increasing money supply  and robust economic growth 
SPY chart review 
The SPDR S P 500 Trust  ARCA SPY  closed last Friday at 205 43 after hitting a new 52 week high at the beginning of the week  I am still hopeful that the December technical pullback down to the lower trend line of the long standing bullish rising channel was all the market needed in the way of a correction to avoid a more dramatic downside event in January  like the one we saw in Jan Feb last year 
Oscillators RSI  MACD  and Slow Stochastic are all in a neutral position and could either cycle a bit further down to oversold territory or turn upward from here  The 50 day simple moving average  100 day SMA  and lower trend line have each provided reliable support levels over the past year  and should continue to do so 
Only the October news driven sell off violated all of these support levels before recovering quickly in a V bottom  Price closed Friday right at the 20 day SMA  and support follows at the 50 day near 204  the 100 day SMA near 201  and the lower trend line that is now approaching 200  There is a mid December gap acting as a bit of a magnet that could take price down to about 201 to fill the gap  which would correspond with the 100 day SMA  Overhead resistance could arise at the 52 week highs and then the upper trend line that is now approaching 211 


Latest sector rankings  
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs are used  We use the iShares that represent the ten major U S  business sectors  Financial  NYSE IYF   Technology  NYSE IYW   Industrial  NYSE IYJ   Healthcare  NYSE IYH   Consumer Goods  NYSE IYK   Consumer Services  NYSE IYC   Energy  NYSE IYE   Basic Materials  iShares US Basic Materials  NYSE IYM   Telecommunications  NYSE IYZ   and Utilities  NYSE IDU   Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each ",2015-01-06,David Brown,"https://www.investing.com/analysis/bulls-expect-further-equity-gains,-looking-for-strong-2015-237510",237510
106389,327904,AGN,New Year Kicks Off With New Fears Keeping Investors On Edge,opinion,"As widely expected  the New Year has begun with plenty of volatility on high trading volume  as investors fear more than just a mild correction to start out the year  Despite the strong fundamentals here in the U S   there are plenty of dangers around the rest of the world  and many fear that our cozy comfort at home simply cannot remain insulated for much longer 
In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 
Market overview 
I would like to start by saying that I have been traveling a lot lately  speaking with and presenting to financial advisors to promote our annual Baker s Dozen portfolio  which is packaged as a unit investment trust by our strategic partner First Trust Portfolios  Many of these advisors are readers of this weekly article  and I want to take this opportunity to say that I have been humbled and gratified by your tremendous interest  enthusiastic reception  and warm hospitality  We are doing our best to sustain your loyalty and respect  and of course  to continue our record of outstanding performance 
Anyway  just when we all had grown accustomed to the old Wall of Worry and the scary bogeymen under the bed  there are new bogeymen peeking out from the bedroom closet  The new sources of worry are really bigger and scarier versions of existing ones  including the continued slide in oil prices  far further than hardly anyone believed possible   worsening recession and deflation in the Eurozone  leading to drastic actions   and the global metastasis of radical Islam  despite our successes in foiling their plots and destroying their infrastructure   News headlines seem to getting worse for both issues 
First  radical Islam has been with us for a long time  and of course it jumped to the forefront with 9 11  Today  splintered organizational infrastructures and terrorist training facilities have suffered highly publicized defeats by the skilled efforts of the civilized world  but each of these successes consumes an incredible amount of time and resources  while the hateful ideology continues to spread like wildfire around the world  with the helpful assistance of social media   I liken it to trying to fight a mosquito problem with a fly swatter  Sure you can swat a whole bunch of them  but the number you eradicate pales in comparison to the numbers that are proliferating in all those innumerable pools of stagnant water  Obviously  any long term solution will need to come from education rather than police action  But in the meantime  the impact on business investment  productivity  and consumer confidence is vast 
Oil prices have fallen beneath  50 barrel  and some observers see more pain ahead before finding a bottom and settling later this year into the  50 60 range   40 is generally considered to be the economic threshold for enhanced extraction techniques  This plunge in prices also has impacted the high yield bond market  which has lent heavily to oil projects  Nominal yields for junk bonds have reached 6 7  versus 5 3  just six months ago  which compared with the U S  10 Year Treasury yield of 1 8  is a wide  and enticing  credit spread 
The impact on petroleum exporting countries has been like a sledgehammer to their budgets but a boon to businesses and consumers everywhere else  Another bright spot from the fall in oil prices is that almost all of terrorist funding comes from oil revenues 
This sudden bear market in oil was created by a supply shock brought on by the tremendous success of enhanced extraction techniques like hydraulic fracking here in North America  coupled with the unwillingness of oil producers around the world to reduce production  The catch 22 is that as prices fall  they are compelled to make up the shortfall by producing and selling more  not less  thus worsening the situation  Scott Minerd of Guggenheim sees a lot of similarities between the current situation and the 1985 86 marketplace in which oil prices launched a recovery leading to tighter credit spreads  i e   rising junk bond prices  and a 20  rally in stocks within a year 
Indeed  the U S  economy seems to be firing on all cylinders  with improving consumer confidence  non existent inflation  further aided by falling oil prices   nominal GDP growth approaching 5   job growth the strongest since the 1990s  unemployment below 6   and corporate profits at all time highs  As Q4 earnings reports continue  the forward P E of the S P 500 is back down to a modest 16x  So far this earnings season  55  of the S P 500 companies that have reported have beaten analyst revenue expectations  and 77  have beaten earnings expectations  although projections have been largely revised downward  
GDP growth and falling unemployment should start to bring about wage growth  which will further propel consumer buying  Beneficiaries of lower oil prices include consumers  airlines  travel  hotels and fast food producers  In addition  although oil producers will struggle with lower revenues tied to energy prices  those involved in marketing refined products should do well  as demand remains steady for lower priced products that garner higher margins at the pump 
So  U S  equities appear to be a likely beneficiary  Nevertheless  volatility is likely to remain with us  as well demonstrated so far this year   so thoughtful stock selection is paramount rather than simply relying on a risk on  all boats lifted mentality of years past  Of course  stock selection becomes more critical as a bull market matures 
A continued flight to quality will favor companies generating strong free cash flow  increasing U S  sourced sales  displaying operational excellence and innovation  making shrewd capital investments  and using conservative accounting with solid earnings quality  This generally should favor Technology  Healthcare  and Consumer sectors  as well as larger  more established companies versus smaller companies with narrow business models  In other words  it looks a lot like 2014    with the exception that bond like Utilities will likely not be a top performer this time around 
The CBOE Market Volatility Index  VIX   a k a  fear gauge  closed Friday at 20 95  which is above the important 20 threshold that suggests real fear  However from a technical perspective  it is displaying a series of lower highs in its series of spikes in mid October  mid December  and now mid January 
Also notable last week was the move by the Swiss National Bank to end its 3 year currency cap  which has sent the Swiss franc soaring versus the euro  while the dollar rose to an 11 year high against the euro  The ECB is widely expected to announce a massive bond purchase  quant easing  program this week in a desperate attempt to steer the Eurozone away from deflation  With oil prices falling so far  Europe s inflation rate has officially fallen below zero  Moreover  with the exception of Greece  sovereign debt yields are collapsing throughout the Eurozone  For example  10 year bond yields in Italy and Spain have declined below 1 9  and 1 7   respectively  and the mighty German bund is at 0 41   Thus  global capital continues to pour into the U S   making a strong dollar even stronger and further flattening the yield curve 
Despite the fact that only a small percentage of active managers beat their benchmarks last year  Sabrient s annual Baker s Dozen portfolio of 13 top picks finished its sixth straight strong year  since 2009 inception   It was up about  22  from its January 13 launch through year end  while the S P 500 was up about  15  over the same timeframe 
Top performers included Southwest Airlines  NYSE LUV   NXP Semiconductors NV  NASDAQ NXPI   and Actavis plc  NYSE ACT   and all three still rank highly in our models  The new portfolio officially launched last week as a unit investment trust  UIT  issued through First Trust Portfolios  and it looks very similar to last year s portfolio in its sector and industry composition  although only two stocks from the prior portfolio repeated into the 2015 portfolio  
Stocks from airlines  semiconductors  and biopharma continue to score among the top  along with a number of consumer names  Notably  few financial stocks  e g   banks  brokers  insurance  REITs  score near the top of our rankings  and so this sector is not represented in the portfolio this year  Baker s Dozen represents a sector diversified group of 13 stocks based on our Growth at a Reasonable Price  GARP  quant model and confirmed by a rigorous forensic accounting review by our subsidiary Gradient Analytics to help us avoid stocks at higher risk of issues that could result in a underperformance 
SPY chart review 
The SPDR S P 500 Trust  ARCA SPY  closed last Friday at 201 63  which is down about  3 5  from its recent high in December  I had been hopeful that the December technical pullback down to the lower trend line of the long standing bullish rising channel was all the market needed in the way of a correction to avoid a more dramatic downside event in January  like the one we saw in January February last year 
We still haven t had an official 10  correction in three years  although the October pullback came close on an intraday basis   Oscillators RSI  MACD  and Slow Stochastic are all in a slightly oversold position and could either cycle a bit further down to oversold territory or turn upward from here  The 50 day simple moving average gave up support  but price is now desperately clinging to the 100 day SMA and lower trend line  both have provided reliable support levels over the past year  
Shown on the chart below is the possible formation of a bearish head and shoulders pattern  with a head around 209 and a neckline at the lower trend line  which would project downside potential to 190  which would fill a previous upside gap in October  If current support fails  the next notable support level comes from the important 200 day SMA near 195  followed by the gap fill at 190  If instead price rallies from here  overhead resistance will come from the 50 day SMA around 204  the highs near 209  and then the upper trend line that is now near 212 
Latest sector rankings 
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
The outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  iShares US Financials  NYSE IYF    Technology  iShares Dow Jones US Technology  NYSE IYW    Industrial  iShares US Industrials  NYSE IYJ    Healthcare  iShares US Healthcare  NYSE IYH    Consumer Goods  iShares US Consumer Goods  NYSE IYK    Consumer Services  iShares US Consumer Services  NYSE IYC    Energy  iShares DJ US Energy Sector Fund  NYSE IYE    Basic Materials  iShares US Basic Materials  NYSE IYM    Telecommunications  iShares US Telecommunications  NYSE IYZ    and Utilities  iShares US Utilities  NYSE IDU    Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 
  Here are some of my observations on this week s scores 
1  Notably  all sectors recently have endured net downward revisions to Wall Street s earnings estimates  Technology ranks first with an Outlook score of 87  It displays the best return ratios  a good forward long term growth rate and forward P E  and relatively good sell side analyst sentiment  only slight downward revisions to earnings estimates   Healthcare is back in second place with a score of 75  displaying a strong forward long term growth rate  relatively good sell side analyst sentiment  slight downward revisions   solid insider sentiment  buying activity   and good return ratios  Financial is close behind in third place with a 72  followed by Industrial and Consumer Services Discretionary  This remains a bullish top five 
2  Energy continues to hold the bottom spot after the plunge in oil prices  Joining Energy in the bottom two is Basic Materials  as these two sectors have taken the brunt of Wall Street s downward revision to forward earnings estimates  and also display the lowest insider buying activity  Notably  Telecom has moved up to sixth place primarily on improving sentiment among both Wall Street analysts and insiders 
3  Looking at the Bull scores  Energy displays the top score of 60  followed by Basic Materials  Telecom scores the lowest at 49  The top bottom spread is only 11 points  which still reflects fairly high sector correlations during particularly strong market days  i e   highly correlated risk on action  It is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold  rather than the all boats lifted in a rising tide  risk on  mentality 
4  Looking at the Bear scores  Utilities displays the highest score of 58 this week  which means that stocks within this sector have been the preferred safe havens on weak market days  Energy has the lowest score of 41  The top bottom spread is 17 points  reflecting fairly low sector correlations on particularly weak market days  In other words  certain sectors are holding up relatively well while others are selling off  Again  it is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points 
5  Technology and Healthcare share the best all around combination of Outlook Bull Bear scores  while Energy is clearly the worst  Looking at just the Bull Bear combination  Healthcare is the leader  followed by Utilities  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   Technology is the worst  somewhat surprisingly  indicating general investor avoidance  at least for the moment  
6  Overall  this week s fundamentals based Outlook rankings look bullish to me  with the top five sectors all economically sensitive and growth oriented  or in the case of Healthcare  all weather   Keep in mind  the Outlook Rank does not include timing or momentum factors  but rather is a reflection of the fundamental expectations of individual stocks aggregated by sector 
Stock and ETF Ideas 
Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or defensive   moved to a neutral bias earlier in the year when the SPY confirmed a loss of support from its 50 day simple moving average  and it suggests holding Technology  Healthcare  and Financial  in that order   Note  In this model  we consider the bias to be neutral from a rules based trend following standpoint because on Friday  SPY remained between its 50 day and 200 day simple moving averages  
Other highly ranked ETFs from the Technology  Healthcare  and Financial sectors include Market Vectors Semiconductor ETF  NYSE SMH   Market Vectors Pharmaceuticals ETF  NYSE PPH   and iShares Mortgage Real Estate Capped  NYSE REM  
For an enhanced sector portfolio that enlists some top ranked stocks  instead of ETFs  from within the top ranked sectors  some long ideas from Technology  Healthcare  and Financial sectors include Tyler Technologies  NYSE TYL   Gartner Inc  Gartner Inc  NYSE IT   IDEXX Laboratories  NASDAQ IDXX   UnitedHealth Group  NYSE UNH   Jones Lang LaSalle  NYSE JLL   and Public Storage  NYSE PSA   All are highly ranked in the Sabrient Ratings Algorithm and also score within the top two quintiles  lowest accounting related risk  of our Earnings Quality Rank  a k a   EQR   a pure accounting based risk assessment signal based on the forensic accounting expertise of our subsidiary Gradient Analytics  We have found EQR quite valuable for helping to avoid performance offsetting meltdowns in our model portfolios 
However  if you prefer to maintain a bullish bias  the Sector Rotation model suggests holding Healthcare  Technology  and Financial  in that order  And if you prefer a defensive stance on the market  the model suggests holding Healthcare  Utilities  and Consumer Services Discretionary  in that order 
IMPORTANT NOTE  I post this information each week as a free look inside some of our institutional research and as a source of some trading ideas for your own further investigation  It is not intended to be traded directly as a rules based strategy in a real money portfolio  I am simply showing what a sector rotation model might suggest if a given portfolio was due for a rebalance  and I may or may not update the information each week  There are many ways for a client to trade such a strategy  including monthly or quarterly rebalancing  perhaps with interim adjustments to the bullish neutral defensive bias when warranted    but not necessarily on the days that I happen to post this weekly article  The enhanced strategy seeks higher returns by employing individual stocks  or stock options  that are also highly ranked  but this introduces greater risks and volatility  I do not track performance of the ETF and stock ideas mentioned here as a managed portfolio 
Disclosure  Author has no positions in stocks or ETFs mentioned  Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2015-01-20,Scott Martindale,https://www.investing.com/analysis/new-year-kicks-off-with-new-fears-keeping-investors-on-edge-239008,239008
106390,327905,AGN,Intellectual Property Company Boasts Strong Dividend,opinion,"The U S  economy is changing  Indeed  it already boasts far fewer brick and mortar stores and packaged goods than in days past 

And if we project this trend forward  we see the potential for companies whose entire rationale is the ownership of ideas  These companies would have a small staff and manufacture nothing  yet they d boast profits that are well worth an investment 

This is important for   because we need to focus on where the economy is going   not where it s been 

Accordingly  this week s opportunity is a company with trivial tangible assets beyond cash  In fact  it has just 10 employees  but it boasts an excellent dividend that s fully covered by earnings 

PDL BioPharma Inc  NASDAQ PDLI  was founded in 1986 to produce monoclonal antibodies  but in 2009  it changed its name and began managing a portfolio of patents and royalty assets 

With just 10 full time employees  as of late 2013   PDLI neither manufactures nor markets  Instead  it uses the expertise of its management to profit from intellectual property  IP   And the company has been profitable  indeed  In both 2012 and 2013  it made over  200 million in net income   and in the first three quarters of 2014  it had already brought in  267 million 

Best of all  the company s trailing four quarters P E ratio is a minuscule 3 6x  and it pays a generous dividend of  0 15 per quarter that equates to an 8 2  yield  Based on trailing earnings  that dividend is covered 3 3 times over 

Of course  there s a catch   as there always is when the numbers look that good 

You see  most of PDLI s income is derived from a collection of  Queen  patents relating to humanized antibodies that expired at the end of 2014 

And even though PDLI won a lawsuit against Glaxosmithkline  NYSE GSK  that will keep Queen patent income flowing until early 2016  PDLI needs to find replacement sources of income as soon as possible 

A Glimpse Into the Future

Luckily  the firm has a cash pile of about  280 million at the last balance sheet date  and it can use that cash to pursue new income opportunities  Plus  it s already invested around  780 million in new revenue producing assets  including deals with drug developers that effectively act as financing transactions 

For example  in 2013  PDLI invested  240 million for the right to receive royalty and milestone payments for sales of diabetes products licensed by Depomed Inc  NASDAQ DEPO   Under this agreement  PDLI will get all royalties until it has received twice the amount of money invested  after which it will split receipts 50 50 with DepoMed 

Another recent debt financing agreement with Durata Therapeutics  DRTX  had an interest rate of 14  for a five year term  And when Durata was acquired by Actavis Inc  NYSE ACT  in November 2014  PDLI received full repayment  accrued interest  prepayment penalty  and change of control fees 

Most recently  PDLI invested  66 million to purchase 75  of the University of Michigan s royalty interest in Cerdelga until the expiry of the licensed patents  The first payments under this deal are expected to arrive in the first quarter of 2015 

Ultimately  investors are relying on the skills of PDLI s very lean management to find and structure deals that make sense  And though there s little chance that future net income will equal the stellar levels of 2012 to 2014  I believe PDLI management will prove that they can find intellectual property deals that enhance shareholder value  allowing PDLI s substantial dividend to continue 

Over the longer term  PDLI appears to have a viable business model  After all  large companies   in pharma or elsewhere   aren t very good at innovating  Instead  this task is often carried out by smaller outfits with entrepreneurial management and little or no bureaucracy 

Of course  the smaller outfits need resources to get their innovations to market   and one way they can obtain these resources is by selling out to the big guys  But in the long run  this may doom their innovations  especially because management will have to deal with big company bureaucracy  

Alternately  they can license innovations to IP management companies like PDLI  which allows the innovators to remain small while giving PDLI returns from IP assets that far outstrip what s available in other financing businesses 

I believe this model for virtual business should become more common in the future  And in the meantime  PDLI s 8 2  yield and decent track record are worth looking at closely 

Good investing ",2015-02-15,Wall Street Daily,https://www.investing.com/analysis/intellectual-property-company-boasts-strong-dividend-241932,241932
106408,327923,AGN,Actavis  Takeover Rumors Start The Fever  Vol Explodes 100 ,opinion,Actavis Inc   ACT   formerly Watson Pharmaceuticals  Inc   is an integrated global pharmaceutical company engaged in the development  manufacturing  marketing  sale and distribution of generic and brand pharmaceutical products   I found this stock using a real time custom scan  This one hunts for elevated vols   What s interesting is that this firm has earnings due out on 5 2 2013 BMO  but the vol explosion and price move have nothing to do with the earnings vol event  This is takeover fever  in a major way  The prior annual high in IV30  was 31     as I m writing this article the implied is trading just under 42   now  The prior 52 wk high in stock price was   101  and the stock is trading well above that level right now as well   Custom Scan Details Stock Price GTE  5  IV30  GTE 30 IV30  Percentile GTE 80 Average Option Volume GTE 1 200  The one year ACT Charts Tab is included  below   The top portion is the stock price the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side  even before today  we can see a nice appreciation over the last year  One year ago this was a  75 36 stock  so it s up a lot even before the pop today  I also note the HV180   pink curve on the bottom portion of the chart    that represents the realized historical volatility of the stock over the last 180 trading days  or about nine months  The stock moves at  20  annualized clip   quite low for a pharma company   although this is a generic pharma company so  it s not quite as spicy as the normal guys in this industry Of course  the real stock story is the pop yesterday on news that over the weekend there may have been discussions about a takeover from Valeant Pharmaceuticals  VRX  Couple that with a raised price target from an analyst and you get  yesterday  My source for this news snippet was Investors com Let s turn to the one year IV30  chart to see the incredible vol rise yesterday That spike is just vertical  Rumor   100  pop in IV30   that s the equation we re looking at today  Wow Finally  let s look to the Options Tab  below  Across the top we can see the monthly vols are priced to 42 08  in May and 32 32  in Jun  That elevated vol in May is due both to earnings and this takeover news  I do note the rise in vol for Jun and Aug as well  look at the little green numbers in parenthesis under the vol number   Those vol pops are not earnings related  but rather takeover related Disclosure  This is trade analysis  not a recommendation Images provided by Livevol ,2013-04-30,Ophir Gottlieb,https://www.investing.com/analysis/actavis:-takeover-rumors-start-the-fever;-vol-explodes-100-165021,165021
106409,327924,AGN,EUR USD Moves To One Month Low Near 1 29,opinion,In the last 24 hours the Euro has reversed again and resumed its downwards move from the last week moving down towards 1 29  and in the process a one month low  It has also become evident over the last couple of days  especially on the 4 hourly chart below  that the 1 30 level is now providing some resistance and placing pressure on price  The Euro finished last week moving back down through the long term key level of 1 30  It did spend the last couple of weeks trading right around the 1 31 level and finding support and resistance at 1 30 and 1 32 respectively  however the former level has now been broken  In finishing last week below 1 30  it moved to levels not seen in over a month  Over the last month the 1 32 level has become quite significant and has been an obstacle to the Euro moving higher  evident in the right half of the daily chart below   During this time  it has had some periods of little movement followed by sharp bursts A couple of weeks ago  the Euro exhibited a classic pin bar reversal candlestick pattern which was indicating the significant selling pressure it experienced at any price above the 1 32 level and likely lower prices to follow  This reinforced the significance of the 1 32 level and how it was going to take considerable effort to move through there  On this pin bar  it moved to near 1 325 and to its highest level in more than two months  since the end of February when it was falling heavily from up near 1 34  Just as quickly  it has fallen away and now moved down to the one month low below 1 30  Prior to that  it was quiet and spent the most part of two weeks ago trading within a narrow range between 1 30 and 1 31  which reinforced how significant this two cent range was  In the middle of April the Euro surged up towards 1 32 and ran into a wall of resistance at that level  to then be followed by a sharp fall back towards the then support level at 1 30 Over the last month the Euro has done well to weather the storm through February and March which saw it fall sharply from around 1 37  although its decline over the last few days may be reversing this good fortune  Despite its strong rally in the first half of April  it was only a few weeks ago that the Euro dropped to its lowest level since the middle of November around 1 2750  so it did very well of late to move back strongly above 1 30  despite its recent lapse  The Euro has spent the best part of the last month consolidating above the key 1 30 and 1 29 levels after its decline throughout February  Over the last couple of weeks  the 1 30 level has been called upon again to prop up price  although it may have reversed roles now as it is providing some resistance to movement higher  Sentiment has completely changed with the Euro and the last couple of months has seen a rollercoaster ride for the Euro as it continued to move strongly towards levels not seen in over 12 months above 1 37 before falling very sharply to below 1 28 and setting a 14 week low a month ago The Euro moved lower after the release of disappointing German data  particularly ZEW Economic Sentiment  which was way below the estimate  Today s Eurozone numbers looked better  as Industrial Production climbed up and ZEW Economic Sentiment was within expectations  German releases have improved in recent readings  but any expectations that we would see the positive trend continue on Tuesday were dashed  Inflation numbers looked weak  as Final CPI declined by 0 5   matching the forecast  WPI also lost ground  dropping by 0 2   but this bettered the forecast of  0 3   The disappointment of the day was German ZEW Economic Sentiment  one of the most important German economic indicators  It posted a reading of 36 4 points  well below the estimate of 39 5 points  Today s Eurozone releases were stronger  as Industrial Production climbed to 1 0   beating the estimate of 0 6   Eurozone ZEW Economic Sentiment came in at 27 6 points  edging out the forecast of 27 3 points  The euro lost ground after the weak German numbers  and was trading in the 1 2980 range in the European  May 15 at 00 30 GMT 1 2933 H  1 3029 L  1 2914EUR USD Technical  title  EUR USD Technical  width  597  height  80    During the early hours of the Asian trading session on Wednesday  the Euro is consolidating in a narrow trading range right around 1 2930 after having recently moved down towards 1 2900 and bounced off  Since the start of February  it has fallen sharply from new highs above 1 37  although it has experienced some strong rallies in that time trying to claw back lost ground  Current range  trading right around 1 2930 Further levels in both directions   Below  1 2900 and 1 2800   Above  1 3000  1 32000 and 1 3300  Shows the ratio of long vs  short positions held for the EUR USD among all OANDA clients  The left percentage  blue  shows long positions  the right percentage  orange  shows short positions   The EUR USD long position ratio has risen sharply in the last couple of days as the Euro has fallen back down below 1 30  The trader sentiment has shifted and is now in favour of long positions  Economic Releases01 30 AU New motor vehicle sales  Apr 01 30 AU Wage Price Index  WPI   Q1 05 00 JP Consumer Confidence  Apr 08 30 UK Average Earnings  incl  bonus   Mar 08 30 UK Claimant Count Change  Apr 08 30 UK Claimant Count Rate  Apr 08 30 UK ILO Unemployment Rate  Mar 09 00 EU GDP  1st Est    Q1 09 30 UK BoE Releases Quarterly Inflation Report12 30 CA Manufacturing sales  Mar 12 30 US Empire State Survey  May 12 30 US PPI  Apr 13 00 US Net Long term TICS Flows  Mar 13 15 US Capacity utilisation  Apr 13 15 US Industrial production  Apr 14 00 US NAHB Builders survey  May ,2013-05-15,Stuart McPhee,https://www.investing.com/analysis/eur-usd-moves-to-one-month-low-near-1.29-166970,166970
106412,327927,AGN,AUD USD Lower Again To Below 0 99,opinion,The AUD USD has experienced its worst week in a long time which has seen it continue to move to new lows below 0 99  from highs above 1 0250  24 hours ago it did halt the slide a little as it consolidated and traded within a narrow range roughly between 0 9940 and 0 9960 however it has since moved to new 11 month lows below 0 99  It is likely the 1 00 level may now provide some resistance to higher prices as the AUD USD tried to claw back some lost ground  At the end of last week  it experienced its largest 24 hour drop in a long time falling strongly down through 1 02 and 1 01  It had an ordinary week last week as it wasn t so long ago it was moving up above 1 03  Up until recently  the 1 02 level was one of significance and presented as a long term support level however this has now clearly been broken  It had been showing some bearish signs over the last few weeks as it continued to place selling pressure on the 1 0220 and 1 02 levels and the RBA rate cut earlier last week was the catalyst for a strong push lower The last couple of weeks have seen the AUD USD establish a strong medium term down trend with lower peaks and lower troughs  as it has moved from near 1 04 down to below 1 in that time  In the previous few weeks  the AUD USD spent most of its time trading between 1 02 and 1 0360  During that time  it moved up to a two week high and back towards 1 04 however it has quickly handed back all of those gains and then some  A couple of times in that same period it received solid support around 1 0220  just above the key long term level at 1 02  All of this just gave way last week as the AUD USD was heavily sold down  and now the 1 02 level is poised to provide resistance and thwart attempts to push higher  although it seems distance away presently Over the course of the last month  the Australian dollar has fallen very sharply from near 1 06 to its lows around 0 9880  and in doing so  it also completely ignored any likely support at either 1 04 or 1 0360  In contrast  the week prior  it enjoyed a solid week moving strongly off the key level of 1 0360 towards 1 06 and to its highest levels since January  Up until mid April  the Australian dollar was enjoying its best move higher since October and November last year  Up until earlier this week  the AUD USD spent the best part of a month trading between the two key levels of 1 0220 and 1 0360 and it will take some effort to return it to this range  with the resistance being offered at the 1 02 level  A couple of months ago  it did well to push back up off the support level at 1 02 and start the move that it was enjoying getting close to  lost more ground on Tuesday after the Australian annual budget pointed to a record deficit  The slumping Australian dollar got no help from the release of the Australian budget earlier on Tuesday  The government  which faces elections later this year  shied away from deep spending cuts but also was forced to revise an earlier forecast of a surplus  In October  the government stated that it would post a modest surplus of A 2 2 billion for 2013 2014   but was forced to revise this to a record deficit of A 19 4 billion  The government blamed the high Australian dollar and weak commodity prices for a dramatic loss in revenue  Meanwhile  both the Standard   Poor s and Moody rating agencies maintained Australia s AAA rating  despite the bleak  May 15 at 02 00 GMT 0 9911 H  1 0003 L  0 9877AUD USD Technical  title  AUD USD Technical  width  599  height  77    During the early hours of the Asian trading session on Wednesday  the AUD USD is rallying a little to back above 0 9900 after having recently dropped back down to 0 9880  Up until a few weeks ago  the AUD USD was spending a fair amount of time within a trading range roughly between the key levels of 1 04 and 1 05  however that range seems a distant memory as it has fallen down to a 11 month low around 0 9940  In moving through to 1 0580 only a few weeks ago  it moved to its highest level since January  Current range  trading right around 0 9960 Further levels in both directions   Below  0 9880   Above  1 0000  1 0360 and 1 0550  Shows the ratio of long vs  short positions held for the AUD USD among all OANDA clients  The left percentage  blue  shows long positions  the right percentage  orange  shows short positions  The long position ratio for the AUD USD remains above 70  which is it highest level in a long time  as the Australian dollar has moved back down below parity  The trader sentiment remains strongly in favour of long positions Economic Releases01 30 AU New motor vehicle sales  Apr 01 30 AU Wage Price Index  WPI   Q1 05 00 JP Consumer Confidence  Apr 08 30 UK Average Earnings  incl  bonus   Mar 08 30 UK Claimant Count Change  Apr 08 30 UK Claimant Count Rate  Apr 08 30 UK ILO Unemployment Rate  Mar 09 00 EU GDP  1st Est    Q1 09 30 UK BoE Releases Quarterly Inflation Report12 30 CA Manufacturing sales  Mar 12 30 US Empire State Survey  May 12 30 US PPI  Apr 13 00 US Net Long term TICS Flows  Mar 13 15 US Capacity utilisation  Apr 13 15 US Industrial production  Apr 14 00 US NAHB Builders survey  May ,2013-05-15,Stuart McPhee,https://www.investing.com/analysis/aud-usd-lower-again-to-below-0.99-166976,166976
106414,327929,AGN,GBP USD  Falls Back Sharply To Support At 1 52,opinion,In the last few hours  the GBP USD is rallying a little higher having recently fallen strongly to a three week low at 1 52  This just continues the slide from last week  almost touching 1 52  a level that proved itself to be one of significance last month  Prior to last week  the pound has enjoyed a strong couple of weeks and moved to new highs above 1 56  It experienced all sorts of bother at 1 56 as it made several pushes to this significant level however it was turned away with excessive supply  For about a week it ran into a wall of resistance right around the 1 56 level  which is very evident in the four hourl chart below  This showed how much buying pressure there was on the 1 56 level but equally how well that level provided resistance to any movement higher  The pound had enjoyed a very solid couple of weeks moving from the support level at 1 52 to reach new highs at 1 56  a new 10 week high It was only a few weeks ago  it found solid support at 1 52 for about a week  which greatly assisted the recent surge higher  and now this level is being called upon again to offer some support and a soft landing  The last week has seen the pound fall strongly and return almost all of its gains from the last few weeks  About a month ago the 1 54 level provided a little piece of resistance and this level has since been broken as it offered limited support  Now that the pound has drifted back down below 1 54  it may provide some resistance again  During its push to 1 56  the pound was able to find some support at 1 55  although this level has also been broken last week  Over the last month or so  the GBP USD has been experiencing a variety of different levels  which have played a role on the price action Toward the end of March the GBP USD was trading within a range roughly between 1 51 and 1 5250 and now on a couple of occasions it has been able to move outside that range and push higher  A few weeks ago  the 1 5350 level was one of significance as it offered resistance before the GBP USD was able to move higher through to 1 56  In early March the pound moved to new lows around 1 4830 from a starting point near 1 64 at the beginning of the year  With the surge higher over the last couple of months  the GBP USD had completely turned around its fortunes from earlier in the year  however it is starting to ease off and return most of the good work  Toward the end of March the GBP USD was trading within a range roughly between 1 51 and 1 5250 and now on a couple of occasions it has been able to move outside that range and push higher  A few weeks ago  the 1 5350 level was one of significance as it offered resistance before the GBP USD was able to move higher through to 1 56  In early March the pound moved to new lows around 1 4830 from a starting point near 1 64 at the beginning of the year  With the surge higher over the last couple of months  the GBP USD had completely turned around its fortunes from earlier in the year  however it is starting to ease off and return most of the good work   The UK has plunged down an economic wellbeing league  falling from fifth place to 12th over six years  according to a new report that underlines the pressure on Britons  finances amid rising unemployment  The Office for National Statistics ranked OECD countries in terms of disposable household income from 2005 to 2011  but on a separate ONS labour market ranking Britain dropped even further  falling 12 places over the six years  The ONS looked at various economic factors that might affect wellbeing across the OECD club of mostly rich nations as part of its scheme to measure national wellbeing  It ranked the United States top in terms of disposable household income  followed by Luxembourg  Chile was ranked bottom out of 30 countries   The UK has plunged down an economic wellbeing league  falling from fifth place to 12th over six years  according to a new report that underlines the pressure on Britons  finances amid rising unemployment  The Office for National Statistics ranked OECD countries in terms of disposable household income from 2005 to 2011  but on a separate ONS labour market ranking Britain dropped even further  falling 12 places over the six years  The ONS looked at various economic factors that might affect wellbeing across the OECD club of mostly rich nations as part of its scheme to measure national wellbeing  It ranked the United States top in terms of disposable household income  followed by Luxembourg  Chile was ranked bottom out of 30 countries  GBP USD  Four Hour Chart  title  Daily 4 Hours Chart  width  568  height  571    GBP USD May 15 at 02 30 GMT 1 52285 H  1 5326 L  1 5207GBP USD Technicals  title  GBP USD Technical  width  599  height  81    During the early hours of the Asian trading session on Wednesday  the GBP USD is rallying a little higher moving up away from 1 52  after having recently fallen strongly down to a three week low at 1 52 in the last few hours  Throughout the first part of this year  the Cable fell very strongly from the key resistance level at 1 63 level down to levels not seen in two and a half years and has done well the last month to rally well and move back up above 1 56  Current range  Right around 1 5350 Further levels in both directions Below  1 5200 and 1 5100 Above  1 5600  Shows the ratio of long vs  short positions held for the GBP USD among all OANDA clients  The left percentage  blue  shows long positions  the right percentage  orange  shows short positions   The GBP USD long positions ratio has moved back up above 50  after the GBP USD has fallen down to the three week low near 1 52  Trader sentiment has shifted to in favour of long positions  Economic Releases01 30 AU New motor vehicle sales  Apr 01 30 AU Wage Price Index  WPI   Q1 05 00 JP Consumer Confidence  Apr 08 30 UK Average Earnings  incl  bonus   Mar 08 30 UK Claimant Count Change  Apr 08 30 UK Claimant Count Rate  Apr 08 30 UK ILO Unemployment Rate  Mar 09 00 EU GDP  1st Est    Q1 09 30 UK BoE Releases Quarterly Inflation Report12 30 CA Manufacturing sales  Mar 12 30 US Empire State Survey  May 12 30 US PPI  Apr 13 00 US Net Long term TICS Flows  Mar 13 15 US Capacity utilisation  Apr 13 15 US Industrial production  Apr 14 00 US NAHB Builders survey  May ,2013-05-15,Stuart McPhee,https://www.investing.com/analysis/gbp-usd:-falls-back-sharply-to-support-at-1.52-167055,167055
106415,327930,AGN,Pharma And Biotech Stock Outlook   March 2014,opinion,"The pharmaceutical sector has been slowly but steadily recovering from the impact of the patent cliff being faced by several companies over the past few years  The worst of the patent cliff is over and the NYSE ARCA Pharmaceutical Index   DRG  is up 21 4  over the last year  So far in 2014  the index is up 6 9   Several companies which had been struggling to post growth in the face of genericization over the past few years are now on the recovery path  New products should start contributing significantly to results  and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  Products that lost exclusivity recently include Eli Lilly s  NYSE LLY  Cymbalta and Evista  AstraZeneca s  AZN  Nexium could also start facing generics from May 2014 in the U S  where sales were  2 1 billion in 2013 
Collaborations  Acquisitions and Restructuring
The pharma sector witnessed major merger and acquisitions  M A  activity over the last couple of years  Going forward  we expect small bolt on acquisitions to continue  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to in licensing activities and collaborations  Most of these companies find it challenging to raise cash  thereby making it difficult for them to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash  We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics  Therapeutic areas which could see a lot of in licensing activity include immuno oncology  oncology  central nervous system disorders  diabetes and immunology inflammation  The hepatitis C virus  HCV  market is also attracting a lot of attention  Some recent acquisitions deals include Shire s  NASDAQ SHPG  acquisition of ViroPharma  Salix s  NASDAQ SLXP  acquisition of Santarus as well as the acquisition of Optimer Pharmaceuticals and Trius Therapeutics by Cubist  NASDAQ CBST  and that of Elan by Perrigo Company  NYSE PRGO   A major acquisition agreement was announced recently    that of Forest Labs  NYSE FRX  by Actavis  NYSE ACT   This deal shows the intention of generic companies to establish a strong position in the branded market  Another significant deal was the one signed between Celgene  NASDAQ CELG  and OncoMed Pharmaceuticals  NASDAQ OMED  for the joint development and commercialization of up to six anti cancer stem cell candidates from OncoMed s biologics pipeline  Another trend that we are seeing in recent months is the divestment of non core business segments  Pfizer  NYSE PFE  sold its Capsugel unit and its Nutrition business in August 2011 and November 2012  respectively  Pfizer then spun off its animal health business into a new company  Zoetis  ZTS   Meanwhile  GlaxoSmithKline  NYSE GSK  divested certain non core brands from its Consumer Healthcare segment  In Aug 2011  AstraZeneca sold its Astra Tech business to DENTSPLY  NASDAQ XRAY   The monetization of non core assets will allow the pharma biotech companies to focus on their areas of expertise  Abbott Labs  NYSE ABT  split into two separate publicly traded companies  while one company deals in diversified medical products  the other  AbbVie  Arca ABBV   is focusing on research based pharmaceuticals  Johnson   Johnson  NYSE JNJ  is also looking to divest its ortho clinical diagnostics business  Vertex  NASDAQ VRTX  monetized its Incivo related royalties  the company can use the cash generated from this deal for its cystic fibrosis program 
Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations  Most of these companies are re evaluating their pipelines and discontinuing programs which do not have a favorable risk benefit profile  Some of the companies that announced restructuring plans include Merck NYSE MRK   Novartis  NYSE NVS    Eli Lilly  Shire and Sanofi  NYSE SNY  
Destination Ireland
Of late  several companies have been looking towards Ireland for acquisitions  The latest company to join the Irish club is Horizon Pharma  NASDAQ HZNP  which is doing a reverse merger with Dublin based Vidara  Tax benefits are a major attraction for such deals  Other such recent acquisitions include that of Warner Chilcott by Actavis and Elan by Perrigo 
Emerging Markets and Biosimilars
Another trend seen in the pharmaceutical sector is a focus on emerging markets  Companies like Mylan  NASDAQ MYL   Pfizer  Merck  Eli Lilly  Glaxo and Sanofi are all looking to expand their presence in India  China  Brazil and other emerging markets 
Until recently  most of the commercialization efforts were focused on the U S     the largest pharmaceutical market    along with Europe and Japan  Emerging markets are slowly and steadily gaining more importance  and several companies are now shifting their focus to these areas 
However  while higher demand for medicines  government initiatives for healthcare  new patient population and increasing use of generics should help drive demand  we point out that emerging markets are also not immune to genericization  Moreover  investigations into bribery charges in China could put a lid on near term growth  Meanwhile  growth in Europe will continue to be pressurized by austerity and cost containment measures  We are also seeing several companies entering into deals for the development of biosimilars  generic versions of biologics  Companies like Merck  Amgen  Biogen  NASDAQ BIIB  and Actavis are all targeting the highly lucrative biosimilars market 
4Q Earnings
All companies falling under the Medical sector have reported fourth quarter and full year 2013 results  While earnings beat and revenue beat ratios  percentage of companies coming out with positive surprises  were pretty impressive  growth ratios were modest  Fourth quarter results were characterized by currency headwinds as well as the impact of generics  Fourth quarter 2013 earnings  beat ratio  was 74 0  while the revenue  beat ratio  was 76 0   Total earnings for this sector were up 1 1   compared to 0 2  recorded in the third quarter of 2013  Total revenues moved up 5 3  in the quarter versus 5 8  growth in the third quarter of 2013  Looking at the consensus earnings expectations for the first quarter  earnings are expected to decline 3 3   Tough challenges for some companies  negative currency movement and a few patent expirees will affect first quarter growth  However  growth should pick up from the second quarter for which 1 6  earnings growth is expected  Overall  2014 earnings are expected to grow 6 5  
Focus on New Products
2013 saw the FDA approving 27 novel medicines  about one third  33   of which were identified by the FDA as  First in Class   meaning they use a new and unique mechanism of action for treating a medical condition  These include drugs like Invokana  type II diabetes   Kadcyla  HER2 positive late stage breast cancer   Sovaldi  an interferon free oral treatment for some patients with chronic hepatitis C  and Mekinist  metastatic melanoma   Yet another one third of the approved drugs fall under the rare or  orphan  disease category that affects 200 000 or fewer Americans  These include Imbruvica  mantle cell lymphoma   Gazyva  chronic lymphocytic leukemia   Kynamro  homozygous familial hypercholesterolemia  and Adempas and Opsumit  both for pulmonary arterial hypertension   Three of the approved drugs   Gazyva  Imbruvica and Sovaldi   had breakthrough therapy designation  Breakthrough status  a new designation that became effective after Jul 9  2012  is designed to cut short the development time of promising new treatments  Some important products approved in 2013 include Drugs like Tecfidera  Sovaldi and Imbruvica represent strong commercial potential  So far in 2014  drugs that have gained approval include AstraZeneca s Myalept  complications of leptin deficiency  and Farxiga  type II diabetes   Chelsea Therapeutics   NASDAQ CHTP  Northera  to treat neurogenic orthostatic hypotension   BioMarin s  NASDAQ BMRN  Vimizim  Morquio A syndrome  and Vanda Pharma s  NASDAQ VNDA  Hetlioz  non 24  hour sleep wake disorder   Upcoming events include FDA advisory panel review of the regulatory application for MannKind s  NASDAQ MNKD  experimental diabetes treatment  Afrezza  April should be an active month with the agency expected to deliver a response on the approvability of several experimental drugs including Afrezza  Glaxo s Eperzan  type II diabetes  and Arzerra  CLL  
Zacks Industry Rank
Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs  As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative   The Zacks Industry Rank for large cap pharma is  225  med biomed gene is  69  med drugs is  84  while the med generic drugs is  8  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Positive for med drugs  med biomed gene and med generic drugs and Negative for large cap pharma stocks 
OPPORTUNITIES
While several companies will continue to face challenges like EU austerity measures and genericization  the pharma industry is out of the worst of its genericization phase  Many companies which had faced generic headwinds in the last couple of years should continue to see a sustained improvement in results this year  Cost cutting  downsizing  streamlining of the pipeline  growth in emerging markets and new product launches should support growth  Among pharma stocks  Shire  a Zacks Rank  1  Strong Buy  stock  looks well positioned for growth with the company expanding its product portfolio and pipeline through the acquisition of ViroPharma  Horizon Pharma  a Zacks Rank  2  Buy  stock  also seems on the right path with the company announcing its plans to acquire Ireland based Vidara  In the biotech space  we are positive on Biogen  Tecfidera  the company s recently launched oral multiple sclerosis drug  is off to a strong start with the product delivering sales of  876 million  as of Dec 31  2013  since its launch in early April 2013  While Tecfidera has gained the top spot in the oral multiple sclerosis market in the U S   Avonex and Tysabri should continue contributing significantly to sales  Tecfidera gained EU approval recently  Biogen is also progressing with its hemophilia pipeline  We are also positive on Amgen  NASDAQ AMGN   Amgen should be able to deliver on its long term strategy based on expansion in key markets  launch of new manufacturing technologies  and pipeline development  Enbrel should continue performing well  Amgen s late stage pipeline is also moving along  While Amgen is a Zacks Rank  2 stock  Biogen is a Zacks Rank  3  Hold  stock  Gilead  NASDAQ GILD   a Zacks Rank  1 stock  continues to do well in the HIV segment and has a potential blockbuster in its portfolio in the form of HCV treatment  Sovaldi  Among generic companies  Actavis looks well positioned  Actavis is slowly and steadily building its position in the branded market through acquisitions  Actavis Group  Warner Chilcott and the upcoming acquisition of Forest   With fewer major patent expiries slated to occur in the next few years  we are encouraged by Actavis  focus on building its branded and biosimilars pipeline  The company carries a Zacks Rank  2 
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take out  These include companies which are developing drugs that are likely to face regulatory hurdles  Among large cap pharma companies  Eli Lilly is gearing up for another round of patent expiries    Cymbalta in Dec 2013 and Evista this year  We prefer waiting on the sidelines until the company is able to emerge from the impact of genericization    Companies that currently carry a Zacks Rank  4  Sell  include Bayer  BAYRY   Sanofi and Glaxo among others  Sanofi  which is facing currency headwinds  was in the news recently related to the development of its PCSK9 inhibitor  alirocumab  The FDA has asked Sanofi and partner Regeneron  NASDAQ REGN  to evaluate potential neurocognitive adverse events across the global development program for alirocumab  especially in long term studies  While results on PCSK9 inhibitors in development have been encouraging so far  this is the first time that serious safety concerns have been raised ",2014-03-27,Zacks Investment Research,https://www.investing.com/analysis/pharma-and-biotech-stock-outlook---march-2014-207530,207530
106425,327940,AGN,Gold Zooms  Stocks Surge As Open Ended QE3 Is Unleashed,opinion,Gold and Silver surged sharply higher after the FOMC announcement that the Federal Reserve has launched more Quantitative Easing  the much awaited QE3  Comex Gold December shot up from the day s  also the week s  lows close to  1702 to a fresh six month high of  1 775 00 as forecasted a day back  the highest for a most active contract since Feb  29  Given 12 Sep in  Gold Futures may soon enter last Massive Rally Lap   Alerted therein was that Comex Gold Futures remain strong till above the crucial  1702 level   can surge to target upside levels of  1756   1774    1810 also  The longer term Target of  1855 for Gold Futures remains within close reach on fresh US Monetary Easing  Till a few minutes before the FOMC announcement Gold had slumped off on some nervousness   traders preferred to maintain a cautious approach on mixed sentiments towards the crucial   much anticipated FOMC meeting results  but Gold surged happily within minutes to the day s highs after the aggressive announcements  When combining the MBS  Mortgage Backed Securities and the purchases via Operation Twist  the Fed is buying  85 billion each month through the end of the year  Gold  Silver  Metals   Equity Markets welcome QE3   Multiple Stimulus Efforts  Commodities surged to a five month high after the Federal Reserve announced a third round of fiscal measures to bolster the U S  economy  fueling expectations that raw material use will increase  reported   The Fed s QE3 compliments the ECB Bond Buying program   the ratification of the ESM timing as appropriate to add to the Global efforts to contain a crisis spreading wide  Gold and Silver gained the most in 10 weeks  leading the rally  Markets had anyways harbored a bullish outlook for Gold Prices  Market expectations favored the view that Bernanke will announce the QE3 or some sort of fresh stimulus package yesterday  after last week s atrociously dismal U S  jobs report  The FOMC statement was aggressively accommodative  which surprised even those who were already expecting QE3 to be announced Thursday  The Fed will now pump  40 billion a month into the U S  financial system and will keep interest rates very low until at least 2015  That news sunk the U S  Dollar index which extended its losses   hit a fresh four month low and was bullish for the U S  Equity Market which surged to a new 4 year high  The LME   London Metal Exchange index  which includes Aluminum  Copper  Lead  Nickel  Zinc and Tin  rose for the fifth straight session  the longest rally in eight months  The highlight   also the most unusualness about the QE3 is that it has an open ended timeframe which makes it positive for Gold because it heightens the inflation fears and weakens the dollar  The start to a Gold Price Rally   the QE3 timing were almost sealed when Federal Reserve Chairman Bernanke s comments in Jackson Hole that QE could help alleviate the stubbornly high unemployment rate  calling the employment situation in theU S   A grave concern   The final boost for Gold came when the U S  Department of Labor released a lower than expected August employment report  On top of expected stimulus from the Fed  Gold found initial support on fresh stimulus from the European Central Bank and China  Unlimited QE3 is Gold Supportive  The  40 billion of mortgage debt each month will increase liquidity  thereby increasing potential for more Inflation  which in turn is good news for Gold  The Federal Reserve didn t set any limit on the ultimate amount of large scale asset purchases it would buy or the duration of the program  This stimulus will be expanded until the Fed sees  sustained improvement  in the labor market  Comex Gold till above  1742 5 may keep its momentum intact for further rises to  1797 4   1825 3   then to  1855   a major resistance zone  MCX Gold remains vulnerable on the INR valuations against the now declining US Dollar  MCX Gold may keep strength till above Rs  32 140 for further Targets of Rs  32 608   32 896 also  Silver should be the Metal to watch out for as repeatedly alerted since long  A push above  34 75 has the potential to send Silver prices to above  44 20   then close to  50 50 also  Base Metals have already shown a steady rise for the last two weeks   seem to have more steam left for further rises  Other Factors Supportive of Higher Gold Prices  The IMF said yesterday that Greece would need a third round of financial bailout assistance  In South Africa  newspapers report striking Gold miners marched to hostels and mine shafts at the Gold Fields KDC West mine to prevent non strikers from working  Around 15000 workers at KDC West began striking on Sunday  There have been calls for a nationwide mining strike following a series of disturbances of several platinum and gold mining sites  including Lonmin s Marikana platinum mine  where 45 people have died since protests began  including 34 shot dead by police last month  Crude Oil prices advanced to a four month high on the QE3 news   also on concerns that protests in the Middle East andNorth Africamay lead to supply disruptions  The QE3 that influenced a Global Rally in Gold  Equity   Commodity Markets  The unusual QE3 definitely is a significant shift in FOMC policy   a very aggressive commitment to success on its mandates  The Federal Reserve said it will expand its holdings of long term securities with open ended purchases of  40 billion of mortgage debt a month in a third round of quantitative easing as it seeks to boost growth and reduce unemployment   If the outlook for the labor market does not improve substantially  the committee will continue its purchases of agency mortgage backed securities  undertake additional asset purchases and employ its other policy tools as appropriate   the Federal Open Market Committee said  The Fed does not have a defined upside limit to securities purchases  except to say that these will continue until the outlook for the labor market improves  If unemployment stays high  this means asset purchases will continue automatically  The FOMC said it would likely hold the federal funds rate near zero  at least through mid 2015   The Fed said it will continue its program to swap  667 billion of short term debt with longer term securities to lengthen the average maturity of its holdings  an action dubbed Operation Twist  The central bank will also continue reinvesting its portfolio of maturing housing debt into agency mortgage  backed securities  The decision risks provoking a renewed backlash from Republicans  including presidential nominee Mitt Romney  who say Bernanke s policies threaten to ignite inflation while doing little to spur the economy  Representative Paul Ryan of Wisconsin  Romney s vice presidential running mate  yesterday said the Fed is  trying to make up for failed fiscal policy   The U S  economy remains vulnerable to the so called fiscal cliff  the  600 billion of tax increases and spending cuts that will kick in automatically at the end of the year unless Congress acts  Bernanke said  Europe s sovereign debt crisis may also weigh on growth  he said  Influence of QE3 on Gold Prices  INR   Equity Trading in Indian Markets  The much awaited third round of quantitative easing by the Federal Reserve   a fuel price hike decision by the Indian Government helped the Indian Equity benchmarks rise to a massive 7 month high  The government may also clear FDI in aviation and broadcasting soon which may give the necessary boost to the Indian Equity Market  The Indian Rupee has rallied up as expected but is yet trading around 54 60 per US Dollar  from the 58 4 life time low  seen a few months ago   yet has huge potential for corrections  Capital inflows from foreign funds in equity markets also boosted the Indian Rupee  MCX Gold Prices shot up yesterday to a New Record of Rs  32 421 for October contracts from it s the day s low of Rs  31 667  MCX Gold Prices have seen a steady rise even when Gold Prices have been on a decline in the International Markets due to the heavy depreciation of the INR   US   For detailed explanations read more at   Posted 5 Sep   MCX Gold Prices in India seem Vulnerable to Potential INR Volatility  Gold Prices in India seem poised to face a very high volatility period  taking into consideration the expected Monetary Infusions by the ECB   the US Fed any time now  These infusions  be it from the ECB or the US Fed  will potentially weaken the US Dollar   simultaneously strengthen the Euro  Comex Gold Prices will rise sharply on the same but the weakening US Dollar may strengthen the INR at the same time   in return weaken MCX Gold Prices  inIndia   The BSE SENSEX climbed 423 62 points or 2 35  to 18 444 78 and the 50 share NSE Nifty jumped 132 15 points or 2 43  to 5 567 50  in line with strong global markets and the government s move to hike diesel prices by Rs  5 per litre to cut subsidies and reduce fiscal deficit  Nifty can expect a resistance towards a 5626   5671 range  A sustained Breakthrough above this range could lift the Nifty to above 6040 levels also  The Wholesale Price Index  WPI  for the month of August rose to 7 55  compared to 6 87  witnessed in July  August inflation was expected at 7 06   Meanwhile  June inflation has been revised to 7 58   7 25    Food articles inflation fell from 10 06  in July to 9 14  in August ,2012-09-14,Commodity Trade Mantra,"https://www.investing.com/analysis/gold-zooms,-stocks-surge-as-open-ended-qe3-is-unleashed-136450",136450
106428,327943,AGN,Those Pesky Inflation Surprises ,opinion,Inflationary pressures  particularly food inflation  continue to percolate across some emerging markets nations  Central bankers don t like openly discussing the problem  fearing just talking about it could raise inflation expectations  But that does not make the problem any less real India  Even though the wholesale inflation  WPI  remains under 8   it has not declined further in spite of India s economic slowdown  see post   and actually rose last month  At the same time food prices remain elevated  Bloomberg  The Reserve Bank of India may focus on inflation when it meets later  especially after the U S  Federal Reserve s decision to embark on a third round of quantitative easing  Previous rounds of easing have stoked foreign capital inflows and increases in commodity prices  especially oil    Indian  wholesale price inflation accelerated to 7 55 percent in August  the highest level in three months  and remains well above the 4 percent to 4 5 percent range where the RBI intends to anchor inflation expectations  The central bank will also be concerned about potential spillover effects from the spike in global food prices  Russia  The central bank actually had to raise rates due to concerns about inflationary pressure   The Bank of Russia unexpectedly raised interest rates across the board on Thursday for the first time in nine months  as it struggles to contain increases in food prices and inflation while the economy slows  The central bank said its decision to raise rates by a quarter of a percentage point was driven by a sharp rise in the rate of inflation in August and early September that had exceeded the bank s  medium term targets   The benchmark refinancing rate was increased to 8 25  from 8   The decision caught some economists off guard  Eight of 11 economists polled by Dow Jones Newswires before Thursday s announcement had said they expected the central bank to leave rates  Some other nations are seeing a pick up in prices as well    Indonesia s inflation unexpectedly accelerated in August on rising food costs  limiting scope for the central bank to cut interest rates even as exports slumped for a fourth month  Clearly slower global growth and weak manufacturing should keep inflation in check  but as monetary expansion in the US and the Eurozone picks up  these  inflation surprises  may become more commonplace ,2012-09-17,Sober Look,https://www.investing.com/analysis/those-pesky-inflation-surprises-136580,136580
106429,327944,AGN,India s Stubborn Inflation Trend Puts RBI In A Bind,opinion,India continues to struggle with stubbornly high inflation levels  In spite of slower economic growth  the Wholesale Price Index  WPI  clocked at 7 81  in September  putting the RBI in a real bind  The central bank needs to cut rates as growth has moderated  but it is difficult to do with inflationary pressures unresolved    The Wholesale Price Index  WPI  inflation figures are out but those looking for repo rate reductions in the forthcoming October 30 monetary policy announcements by the RBI may be in for some disappointment  According to economists  the WPI figure  though certainly better than the 10  odd inflation numbers that the economy was totting up till recently  is still not good enough for the RBI to cut rates  In other words  things aren t as bad as before but they are not good enough to merit a growth inducing repo rate reduction by the RBI  Part of the issue with India s stubbornly high inflation is that it has been elevated for an unusually prolonged period    India has experienced a sustained period of high headline inflation since late 2009  In this period  inflation  as measured by the Wholesale Price Index  WPI   has averaged 9  and has not fallen below 7   Indeed  the high inflation period can be seen from 2007  with a blip due to the GFC between February and November in 2009  This prolonged period of high inflation has not been witnessed since the early 1990s  The problem that often accompanies long periods of inflation is the establishment of deeply rooted inflation expectations  Households now fully expect double digit near term and longer term inflation  The recent rise in food prices is only going to exacerbate these expectations  And as central banks learned from past experiences  inflation expectations create a feedback loop with the actual inflation that is extremely difficult to break  That s why RBI is likely to be on hold for some time ,2012-10-16,Sober Look,https://www.investing.com/analysis/india's-stubborn-inflation-trend-puts-rbi-in-a-bind-139931,139931
106431,327946,AGN,India Fast Tracks Policy  Powers Remain Watered Down,opinion,India approved changes to a century old land law and set up a panel to fast track infrastructure projects worth 10 billion Rupees or more as Prime Minister Manmohan Singh extends a policy overhaul to revive economic growth The cabinet approved creation of a special panel yesterday  albeit with watered down powers to speed up the notoriously slow implementation of big ticket infrastructure projects  Amendments to the colonial era Land Acquisition Act may help the government curb often violent protests that have stalled projects for industry and highways  The cabinet committee also allowed the establishment of an infrastructure panel and a 30  reduction in the sale of airwaves  The government hopes the new body will help to increase investment in an economy that is likely to slow in fiscal 2012 13 to its worst pace in a decade  Prime Minister Manmohan Singh s chief economic adviser sees full year growth of 5 5  to 6   reports Reuters  The approvals add momentum to Singh s policy agenda by addressing transportation and energy bottlenecks that have handicapped growth in Asia s third largest economy  The prime minister has already won support to open the economy to overseas retailers  the biggest embrace of foreign investment in a decade  as he bids to repair the government s reform credentials before national elections in 2014  Prime Minister Manmohan Singh will head a new panel aimed at speeding up approvals of infrastructure projects  The prime minister is seeking  1 trillion in investments for highways  ports and power plants from 2012 to 2017 to spur development  The cabinet approved a 30  cut in the reserve price of mobile phone airwaves in four telecommunication zones  after carriers shunned last month s auction in those zones saying the prices were too high  The cabinet also approved a ministerial panel s proposal to set the auction reserve price of more efficient 900 megahertz band airwaves at twice that of the basic phone airwaves in the 1800 megahertz band India plans to take more steps in the next few weeks  which combined with the measures taken so far will help turn around the economy  the Finance Minister P  Chidambaram said today  however  did not elaborate on the planned measures  India  Asia s third largest economy is headed for the weakest full year growth in a decade  at about 6   far below the near double digit pace before the global economic downturn   I am confident that the steps we have taken  and some more steps that we will take in the next few weeks  will help turn the Indian Economy around   Mr  Chidambaram said addressing the Delhi Economics Conclave Rating agency Standard   Poor s warned again on Tuesday thatIndia s credit rating faces a one in three chance of being downgraded to junk over next 24 months because of a heavy debt burden and pressure on the fiscal deficit  which is seen overshooting a target of 5 3  in the fiscal year ending in March India Sets up Panel   Powers Watered DownInfrastructure companies have pressed for the creation of such a board to speed up hundreds of delayed projects  Regulatory hurdles  such as delayed land acquisition and environmental clearances  have held up projects worth over 2 trillion rupees in the road  power  coal and mining sectors alone  according to government data  Due to opposition from within the government  the powers of the panel have been diluted and it will not be able to directly clear the projects  It will be up to individual ministries to approve projects  but where there are delays  the new panel will have the authority to intervene  It will not  however  be able to overturn any decisions made by the Environment Ministry  Environment Minister Jayanthi Natarajan had stalled the creation of the panel for months  calling it authoritarian  The watering down of the panel s powers  which will likely disappoint investors  underscore the government s struggle to push a reform agenda aimed at reviving growth  Red tape can delay projects for years or  in the worst cases  scupper them altogether  Bureaucracy and fights between industry and farmers over land have prevented India from plugging huge power shortages and upgrading its decrepit transport network  A typical infrastructure project requires clearances from 19 federal ministries and  on average  56 authorizations on issues ranging from the environment to defense  The whole process takes up to 24 months Reserve Bank Of India Interest RatesThe Reserve Bank of India  RBI  is expected to keep interest rates unchanged on Tuesday  Dec 18  according to a new Reuters poll  with respondents split over whether it will cut the cash reserve ratio  CRR  for banks  The RBI has left rates on hold since a 50 basis point cut in April  and expectations for a further cut have been pushed from December into the first quarter of 2013 following guidance by the central bank in late October  The CRR   a tool the Reserve Bank of India has been using to ease a cash crunch and prod banks to loosen lending rates  At 4 25   CRR is at its lowest since 1976  RBI Gov  Duvvuri Subbarao said in the October policy review there was a  reasonable likelihood  of further easing in the January March quarter  when inflation is expected to trend down  The RBI is expected to review monetary policy in January and again in March New Rules From SEBI To Avoid Market Glitches Flash CrashesIndia Stock Market regulator  SEBI   Securities and Exchange Board of India unveiled a new set of measures  including reducing the trading band for a wide category of stocks and capping single orders at nearly  2 million  to prevent future flash crashes  The new set of rules come after an erroneous trade order of more than  125 million from a broker at Emkay Global Financial Services sent shares sharply lower in October  Read more on  Under new guidelines from SEBI  Stock Exchanges will not be able to accept single orders for stocks  equity derivatives or exchange traded funds of more than 100 million rupees   1 8 million  in value  The restriction applies to orders for stocks  exchange traded funds  index futures and equity futures  In addition  the regulator narrowed the trading band for stocks that also trade on derivatives markets to 10  from 20   although exchanges will be able to adjust the band in increments of 5  depending on market conditions  SEBI also directed brokerages to set internal limits on the cumulative value of un executed orders  while directing them to reduce risk when 90  of the collateral for margin trading is utilized  All un executed orders will be canceled once that threshold is reached  and all new orders will be checked for sufficiency of margins  Exchanges have a month to institute the new rules  and can set  more stringent norms based on their assessment   according to the regulator  The NSE   National Stock Exchange of India Ltd   the nation s largest bourse  controls more than 90  of India s  28 billion equity derivatives market including the Nifty Index and handles 75  of stock trades  The exchange began trading equities electronically in 1994  prompting the 137 year old BSE  which runs the BSE India Sensitive Index BSE Sensex  to follow suit India Inflation Betters ForecastIndia s Inflation unexpectedly cooled in November to its weakest pace in 10 months  The wholesale price index  WPI   India s main Inflation gauge  rose 7 24  from a year earlier  below expectations for a rise of 7 6  and below October s 7 45   An easing in annual fuel and manufacturing inflation helped rein in price pressures  The RBI though may not be impressed enough to cut interest rates next week as price gains still remain above its comfort level  The inflation data comes after a spike in industrial output in October and data indicating that infrastructure output and investment is picking up  raising hopes a long slide in India s economic growth is coming to an end  RBI   Reserve Bank of India Governor Duvvuri Subbarao may wait for more evidence that inflation is on an easing trend before heeding Finance Minister P  Chidambaram s call for cheaper credit to back a government policy overhaul ,2012-12-14,Commodity Trade Mantra,"https://www.investing.com/analysis/india-fast-tracks-policy,-powers-remain-watered-down-147641",147641
106438,327953,AGN,European Market Update,opinion,Major European PMI show improvement but mixed in terms of meeting expectationsNotes ObservationsChina  HSBC PMI Manufacturing hits14 month high as it stays above the 50 level for the 2nd consecutive month  after 12 months of contraction   Shanghai Composite surges 4  over hope of new Govt plan on economyJapan Final Oct Industrial Production revised lower  Q4 Tankan survey falls to 11 quarter lowFar East and European bourses put in mixed performancesWhite House and Republican Aides  Obama and Boehner held frank discussions as Tsy Sec Geithner attended  meeting followed reports that Boehner was to head home for Christmas tomorrowLatest polls show the Japan LDP opposition heading for a landslide victory on SundayS P  Downgrades UK sovereign outlook to negative from stable while maintaining AAA rating  sees 50 50 chance of downgrade within 2 yearsFitch maintains France AAA rating  outlook negativeMajor European advanced PMI readings improve from month ago levels but mixed in terms of beating expectationsEconomic Data RU  Russia Narrow Money Supply w e Dec 10th  RUB   7 21T v 7 16T prior IN  India Nov Wholesale Price Index  WPI  Y Y  7 2  v 7 6 e EU  EU27 Nov New Car Registrations   10 3  v  4 8  prior FI  Finland Nov CPI M M   0 3  v  0 2 e  Y Y  2 2  v 2 5 e FR  France Q3 Final Wages Q Q  0 4  v 0 4  prelim FR  France Dec Advanced PMI Manufacturing  44 6 v 44 9e  PMI Services 46 0 v 46 0e FI  Finland Oct Current Account    40M v   70M prior HU  Hungary Oct Final Industrial Production M M   3 8  v  3 8  prelim  Y Y   3 8  v  3 8  prelim ES  Spain Q3 House Prices ToT Homes Q Q   3 8  v  3 3  prior  Y Y   15 2  v  14 4  prior ES  Spain Q3 Labour Costs Y Y   0 1  v  0 3  prior EU  ECB   1 4B borrowed in overnight loan facility vs   1 4B prior   204 4B parked in deposit facility vs   195 1B prior DE  Germany Dec Advanced PMI Manufacturing  46 3 v 47 3e  PMI Services  52 0 v 50 0e  first expansion in Services since April  EU  Euro Zone Dec Advanced PMI Manufacturing  46 3 v 46 6e  PMI Services  47 8 v 47 0e  PMI Composite  47 3 v 46 9e AT  Austria Nov Consumer Price Index M M  0 1  v 0 2  prior  Y Y  2 8 v 2 8  prior IT  Bank of Italy Oct  Public Finance Supplement  Central Govt Debt   2 015T v  1 995T prior ES  Spain Banks Nov Net ECB Borrowings   340 8B v  341 6B prior  3rd straight decline  EU  Euro zone Q3 Employment Q Q   0 2  v 0 0  prior  Y Y   0 7  v  0 7  prior EU  Euro Zone Nov CPI M M   0 2  v  0 2 e  Y Y  2 2  v 2 2 e  Core CPI  1 5  v 1 5 e BR  Brazil Oct Economic Activity Index M M  0 4  v 0 3 e  Y Y  5 0  v 4 4 eFixed Income ZA  South Africa sold I L 2025  2028  2050 BondsSPEAKERS FIXED INCOME FX COMMODITIES ERRATUMEquitiesIndicesFTSE 100  0 10  at 5 922DAX  0 20  at 7 597CAC 40  0 10  at 3 640IBEX 35  0 25  at 8 034FTSE MIB  0 10  at 15 858SMI  0 10  at 6 912S P 500 Futures  0 25  at 1 415European equity markets are currently mixed  despite the more than 4  rally seen for the Chinese Shanghai Composite index  In terms of fundamentals  euro zone manufacturing PMI data missed market expectations  while the services PMI surprised to the upside  In China  Dec manufacturing PMI expanded for the second straight month  following 12 months of contraction  Despite the Chinese data  European resource related firms are mixed  European banks are mostly lower  led by shares of Credit Agricole and Deutsche bank  In news related to the banking sector  in Nov Spanish banks cut their reliance on ECB funding for the third straight month  a similar trend has been seen with Italian banks  In terms of the peripheral corporate bond markets  as issuance conditions have shown improvement  Telecom Italia is marketing seven year EUR denominated bonds in the area of 295bps midswaps  In Sept  the company marketed five yr EUR denominated bonds near 375bps midswaps ,2012-12-14,Trade The News,https://www.investing.com/analysis/european-market-update-147655,147655
106441,327956,AGN,European Market Update,opinion,SNB maintains policy stanceNorway Central Bank cuts Rate Path OutlookSpain special bond sale come in below analysts  target rangeNotes ObservationsNew Zealand central bank leaves Cash Rate unchanged  as expected  but cuts GDP outlook  says strong Kiwi currency is a significant concernSouth Korea Central Bank  BOK  leaves seven Day Repo Rate unchanged at 2 75   as expected but was not unanimous   Analysts see rate cut ahead as economy stagnatesAustralia Feb Employment data registers highest monthly increase in a decade  CPI hits five month high  Markets respond by re pricing expectations of another RBA easing  sending Australian equities down by 1  Japan lower house lawmakers endorse Kuroda as next BoJ Gov  Also approve Nakaso and Iwata as BoJ Dep Govs  as expected  Upper House vote on FridayChina formally elects Xi as president  3000 delegates and only one no vote EU Summit Draft  EU to endorse plans for a structural assessment of member budgets  ie may allow some countries extra time on deficits SNB leaves both Interest Rates and EUR CHF Cross levels unchanged  as expectedNorway Central Bank lowers outlook for its Deposit Rate Path and sees the next hike out further than previously anticipatedSpain sells bonds in special auction at lower yields and strong bid to cover  but overall amount below analysts  soft target between  1 2BEconomic Data JP  Japan Feb Final Machine Tool Orders Y Y   29 8  v  21 5  v prelim IN  India Feb Monthly Wholesale Prices  WPI   6 8  v 6 6 e RU  Russia Feb YTD Budget Level  RUB    259 5B v  81 3B priorto Budget Level to GDP Ratio   2 7  v  1 8  prior FI  Finland Feb CPI M M  0 6  v 0 5 e  Y Y  1 7  v 1 6  prior FI  Finland Jan Final Retail Sales Volume Y Y   1 5 v  0 3  prelim HU  Hungary Jan Final Industrial Production M M  2 9  v 2 9  prelim  Y Y   1 4  v  1 4  prelim CZ  Czech Jan Retail Sales Y Y   0 5  v  2 2 e ES  Spain Jan Adjusted Real Retail Sales Y Y   10 2  v  11 1 e  Real Retail Sales Y Y   9 0  v  10 2  prior PH  Philippines Central Bank  BSP  leaves Overnight Borrowing Rate unchanged at 3 50   as expected  Cuts Special Deposit Account Rate  SDA  by 50bps to 2 50  EU  ECB   197M borrowed in overnight loan facility vs   16M prior   112 9B parked in deposit facility vs   149 6B prior CH  SNB left the 3 Month Libor Target Rate range unchanged between 0 00 0 25  and maintained the floor in EUR CHF at 1 2000  both as expected NL  Netherlands Jan Trade Balance   4 0B v  3 3B prior NL  Netherlands Jan Retail Sales Y Y   0 5  v  4 1  prior SE  Sweden Feb Unemployment Rate  8 5  v 8 4 e  Unemployment Rate Seasonally Adj  8 2  v 8 1 e HK  Hong Kong Q4 Industrial Production Y Y   1 3  v  0 1  prior HK  Hong Kong Q4 Producer Price Y Y   1 1  v  1 4  prior NO  Norway Central Bank  Norges  left its Deposit Rate unchanged at 1 50   as expected but lowered the Rate Path Outlook CZ  Czech Jan Current Account   CZK   6 0B v 10 0Be ZA  South Africa Jan Gold Production Y Y   8 1  v  21 2  prior  Mining Production Y Y   7 3  v  4 2 e EU  Euro Zone Q4 Employment Q Q   0 3  v  0 1  prior  Y Y   0 8  v  0 6  prior GR  Greece Q4 Unemployment Rate  26 0  v 24 8  priorFixed Income ES  Spain Debt Agency  Tesoro  sold total  803M of 2029  2040 and 2041 bonds in special auctionSold  134M in 6  Jan 2029 bonds  Avg Yield  5 224  v 5 787  prior  bid to cover 4 1x v 2 02x prior  Maximum Yield 5 258  v 5 822  prior  Tail 3 4bps v 3 5bps priorSold  304M in 4 9  2040 Bono bond  Avg yield 5 434  v 5 893  prior  bid to cover 2 4x v 2 09x prior  Max Yield 5 445  v 5 928  prior  Tail 1 1bpsSold  365M in 4 70  July 2041 Bono bond  Avg Yield 5 432  v 5 696  prior  Bid to cover  2 1x v 2 00x prior  Maximum Yield 5 454  v 5 705  prior  Tail 2 2bps v 0 9bps priorSPEAKERS FIXED INCOME FX COMMODITIES ERRATUMEquitiesFTSE 100  0 20  at 6 496  DAX  0 70  at 8 028  CAC 40  0 60  at 3 858  IBEX 35  0 90  at 8 573  FTSE MIB  1  at 15 903  SMI  0 50  at 7 821  S P 500 Futures  0 20  at 1 552European equity markets are mostly higher  tracking the gains in Asian and U S  markets  Today s gains have been led by the Italian FTSE MIB  as the index underperformed on Wednesday s session  Earlier during the session  the DAX index hit a fresh multi year high near 8045  European banks are trading mixed  Outperformers include BNP and Santander  while shares of UK banks and Commerzbank have lagged  Resource related firms are mostly lower  despite the gains in oil and copper prices UK movers  Home Retail  15   SSS above ests   Ocado  12   talks related to agreement with WM Morrison   Aggreoko  2 5   supply agreement   William Morrison  1 5   raised dividend  Germany movers  Lufthansa  3   guided FY13 op profit higher y y   K S  3   Outlook above ests  short covering   HeidelbergCement  2   FY results above ests   Leg Immobilien  1   broker commentary   SGL Carbon  3   FY results below ests   Volkswagen  2 5   reaffirmed FY13 guidance   Wacker Chemie  2   guided FY13 profits lower y y  France movers  Altran  2 5   swung to profit in FY12  Italy movers  Generali  5   guided FY13 op profit higher y y   Eni  1 5   asset sale  Switzerland movers  Bucher  2   FY results above sts   Holcim  1   joint venture agreement   Oerlikon  2   CEO resigned  ,2013-03-14,Trade The News,https://www.investing.com/analysis/european-market-update-159013,159013
106452,327967,AGN,Negative Sentiment Maintains Footing Ahead of IMF Global Economic Update,opinion,Economic Data PH  Philippines May Overseas Workers Remittances   1 8B v  1 7B prior IN  India June Wholesale Prices  WPI   7 3  v 7 6 e v 7 6  prior DK  Denmark June Wholesale Prices M M   0 7  v  0 8  prior  Y Y  1 2  v 2 0  prior TR  Turkey June Consumer Confidence  91 8 v 92 1 prior TR  Turkey April Unemployment Rate  9 0  v 9 9  prior CH  Swiss Q1 Industrial Production Y Y  1 4  v 0 0 e AT  Austria June Consumer Price Index M M   0 1 v  0 1  prior  Y Y  2 2 v 2 1  prior IT  Italy May Total Trade Balance    1 0B v   200M prior  Trade Balance EU   691M v  704M prior NO  Norway June Trade Balance  NOK   29 5B v 35 5B prior IT  Bank of Italy  BOI  May General Govt Debt   1 966T v  1 949T prior   Public Finance Supplement EU  Eurozone Jun CPI M M   0 1  v 0 0 e  Y Y  2 4  v 2 4 e  CPI Core Y Y  1 6  v 1 6 e EU  Eurozone May Trade Balance Seasonally Adj   6 3B v  5 0Be  Overall Trade Balance   6 9B v  4 0BeFixed income NL  Netherlands Debt Agency  DSTA sold total  2 38B vs   2 0 4 0B indicated range in 3 month and 6 month BillsSold  1 25B vs   2 0 indicated in 3 month Bills  Yield  0 041  v  0 013 prior  Bid to cover  3 20x v 4 44x priorSold  1 13B vs   2 0 indicated in 6 month Bills  Yield  0 029  v 0 019  prior  Bid to cover  3 19x v 2 65x priorNotes ObservationsChina Premier Wen  Economic rebound not yet stable  Hardship may continue for a period of time EU as fragmented as ever ahead of Friday s Finance Minister meeting  ECB now advocates losses on holders of senior bonds while Ecofin disagrees  German Chancellor Merkel says liability not yet decided German Constitutional Court to announce ESM and Fiscal Compact decision on Sept 12th EquitiesIndices  FTSE 100  0 25  at 5651  DAX  0 25  at 6540  CAC 40  0 40  at 3169  IBEX 35  0 60  at 6622  FTSE MIB  0 30  at 13 672  SMI  0 10  at 6186  S P 500 Futures  0 30  at 1348European equity indices opened the session broadly lower  led by losses in Spain  Banks have traded mixed  as the credit default swaps  CDS  of some Spanish banks have moved wider  as the ECB declined to comment on reports that it had called for losses for senior bondholders of the weakest banks in Spain  Laggards in the banking sector include Barclays and Santander  Mining shares are broadly weaker  tracking the declines in commodity prices and Chinese equities  Looking ahead  US bank Citigroup is due to report quarterly earnings later today In London shares of G4S  GFS UK  are lower by over 7  as the company said it was facing delays in relation to an Olympic security contract  Sage Group  SGE UK  has lost over 1  as the company made cautious comments about Europe in its trading update  Glaxo  GSK UK   has traded slightly higher  amid speculation that the firm could raise its hostile bid for Human Genome Sciences  HGSI   Heidelberger Druck  HDD DE  is higher by over 1   after the company reported its preliminary sales and orders figures for Q1  Dutch financial company SNS Reaal  SR NL  has traded lower by over 3   after the company s shares dropped over 15  on Friday s session  PostNL  PNL NL  is lower by more than 4  on concerns that the company could have to delay its 2012 dividend if the takeover of TNT Express faces significant delays ,2012-07-16,Trade The News,https://www.investing.com/analysis/negative-sentiment-maintains-footing-ahead-of-imf-global-economic-update-129723,129723
106453,327968,AGN,European Market Update   August 14  2012,opinion,Numerous European quarterly GDP data beats expectations  German ZEW Survey signals economy to cool throughout the coming six monthsEconomic Data FR  France July Consumer Price Index M M   0 4  v  0 4 e  Y Y  1 9  v 2 0 e  CPI Ex Tobacco Index  124 22 v 124 20e FR  France July CPI EU Harmonized M M   0 5  v  0 5 e  Y Y  2 2  v 2 3 e FR  France Q2 Preliminary Gross Domestic Product Q Q  0 0  v  0 1 e  Y Y  0 3  v 0 2 e FI  Finland July CPI M M   0 2  v  0 1  prior  Y Y  2 9  v 2 8  prior FI  Finland Jun GDP Indicator WD   0 7  v  0 3  prior FI  Finland Jun Final Retail Sales Volume Y Y  2 3  v 2 4  prior DE  Germany Q2 Preliminary GDP Q Q  0 3  v 0 2 e  Y Y  0 5  v 0 9 e  GDP wda Y Y  1 0  v 1 1 e IN  India July Monthly Wholesale Prices  WPI  Y Y  6 9  v 7 2 e  2 1 2 year low  FR  France Q2 Preliminary Non Farm Payrolls Q Q   0 1  v  0 1 e  Wages Q Q  0 5  v 0 9  prior AT  Austria Q2 GDP Q Q  0 2  v 0 5  prior  Y Y  0 2 v 2 0  prior CZ  Czech Q2 Preliminary GDP Q Q   0 2  v  0 2 e  Y Y   1 2  v  1 1 e HU  Hungary Q2 Preliminary GDP Q Q   0 2  v  0 4 e  Y Y   1 2  v  1 3 e HU  Hungary July Consumer Prices M M   0 1  v  0 2 e  Y Y  5 8  v 5 6 e ES  Spain July Consumer Price Index M M   0 2  v  0 2 e  Y Y  2 2  v 2 2 e ES  Spain July CPI EU Harmonized M M   0 9  v  0 8 e  Y Y  2 2  v 2 2 e ES  Spain July CPI Core M M   0 7  v 0 0  prior  Y Y  1 4  v 1 3 e CH  Swiss July Producer   Import Prices M M   0 3  v  0 2 e  Y Y   1 8  v  1 7 e NL  Netherlands Q2 Preliminary GDP Q Q   0 2  v  0 3 e  Y Y   0 5  v  1 2 e SE  Sweden Jun Industrial Production M M   0 4  v  1 0 e  Y Y   1 1  v  1 1 e SE  Sweden Jun Industrial Orders M M   0 2  v 4 4  prior  Y Y   1 9  v  3 5  prior SE  Sweden July CPI Headline Rate M M   0 4  v  0 3 e  Y Y  0 7  v 0 8 e  CPI Level  v 313 11e SE  Sweden July CPI Underlying Rate  CPIF  M M   0 4  v  0 3 e  Y Y  0 8  v 0 8 e FR  France July SA Real Retail Sales M M   0 2   Y Y   0 3    Bank of France survey ES  Spanish banks July gross borrowing from ECB at  402 2B v  365B m m UK  Jun ONS House Price Y Y  2 3  v 1 5 e UK  July CPI M M   0 1  v  0 1 e  Y Y  2 6  v 2 3 e  Core CPI Y Y  2 3  v 2 1 e UK  July RPI M M   0 1  v  0 2 e  Y Y  3 2  v 2 8 e  RPI Ex Mortgage Interest Payments Y Y  3 2  v 2 9 e  Retail Price Index  242 1 v 241 4e EU  Euro Zone Q2 Advanced GDP Q Q   0 2  v  0 2 e  Y Y   0 4  v  0 4 e EU  Euro Zone Jun Industrial Production M M   2 1  v  2 1 e  Y Y   2 1  v  2 1 e DE  Germany Aug ZEW Economic Sentiment Survey   25 5 v  19 3e  Current Situation Survey  18 2 v 17 5e EU  Euro Zone Aug ZEW Economic Sentiment Survey   21 2 v  22 3 prior PT  Portugal Q2 Preliminary GDP Q Q   1 2  v  0 7 e  Y Y   3 3  v  3 0 eFixed Income  ZA  South Africa sold total ZAR2 1B vs  ZAR2 1B indicated in 2023  2031 and 2048 bonds CH  Switzerland sold 3 Month Bills  Avg Yield   0 553  v  0 593  prior EU  ECB allotted  131 0B vs   130Be in 7 Day Main Refinancing Tender at fixed 0 75  GR  Greece Debt Agency  PDMA  sold  4 062B vs   3 125B indicated in 13 week Bills to cover bond maturity  Avg Yield 4 43  v 4 31  prior  Bid to cover  1 36x v 2 19x HU  Hungary Debt Agency  AKK  sold HUF45B vs  HUF45B indicated in 3 Month Bills  Avg Yield 6 87  v 6 85  prior  Bid to cover  1 43x v 1 88x prior BE  Belgium Debt Agency sold total  2 751B vs   2 5 3 0B indicated rabge in 3 month and 12 month BillsSold  1 50B vs   1 6B indicated in 3 month Bills  Avg yield  0 012  v  0 003  prior  Bid to cover  x v 2 55x priorSold  1 601B vs   1 6B indicated in 12 month Bills  Avg yield 0 093  v 0 040 prior  Bid to cover  x v 1 99x priorSPEAKERS FIXED INCOME FX COMMODITIES ERRATUMNotes ObservationsBOJ minutes  Reiterates view that it will pursue powerful easing to achieve 1  inflation target with several members stating that the central bank should stand ready to take appropriate actionGerman Constitutional Court reaffirmed the ruling date of Sept 12th for ESM and Fiscal pactNumerous European QoQ GDP readings beat expectationsGerman ZEW Economic Sentiment Survey worse than expectedGreece sell over  4B to cover upcoming bond maturityEquitiesIndices  FTSE 100  0 60  at 5864  DAX  0 90  at 6973  CAC 40  0 60  at 3447  IBEX 35  0 90  at 7134  FTSE MIB  0 60  at 14 619  SMI  0 50  at 6496  S P 500 Futures  0 30  at 1406 25European equity indices opened the session higher  supported by gains in Asian stocks and better than expected quarterly GDP data out of France and Germany  Traders have paid less attention to ZEW data out of Germany  which missed analyst market views  as the expectations index hit the lowest level since Dec 2011  amid 4 straight declines  Europeans banks are trading higher led by gains in Italian and Spanish financials  Resource related firms are mixed  despite the gains being seen for commodity prices In Germany  TUI AG  TUI1 DE  has gained over 4  on better than expected Q3 results  Merck KGaA  MRK DE  is higher by more than 3   as the company reported better than expected results and raised its FY forecast  Merck said its quarterly results were driven by positive fx effects  stronger margins and sales growth at the Serono and performance materials units  Pharmaceutical retailer Celesio  CLS1 DE  has gained over 3  following the release of Q2 results  Sky Deutschland s  SKYD DE  shares have advanced by more than 2   as the company confirmed market speculation by reporting better than expected quarterly results  Utility RWE  RWE DE  is lower on the session  as the company reported weaker than expected H1 revenues and in line recurrent profits  In other German movers  Salzgitter  SZG DE  is higher by over 1   issued Q2 results  reaffirmed FY forecast   copper name Aurubis  NDA DE  has gained over 2   issued Q3 results  and shares of Hochtief  HOT DE  are lower by more than 1   reported H1 results   UK listed United Utilities  UU UK  is higher by over 2  on takeover speculation  Irish construction materials firm CRH  CRH UK  is lower by over 5   following the release of its H1 results  Shares of Standard Life  SL UK  are higher by over 3   as the company reported H1 results and raised its dividend by 6 5  ,2012-08-14,Trade The News,"https://www.investing.com/analysis/european-market-update-:-august-14,-2012-132926",132926
